Torsade	B
de	I
pointes	I
ventricular	B
tachycardia	I
during	O
low	O
dose	O
intermittent	O
dobutamine	O
treatment	O
in	O
a	O
patient	O
with	O
dilated	B
cardiomyopathy	I
and	O
congestive	B
heart	I
failure	I
.	O

The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56-year	O
-	O
old	O
woman	O
with	O
chronic	O
,	O
severe	O
heart	B
failure	I
secondary	O
to	O
dilated	B
cardiomyopathy	I
and	O
absence	O
of	O
significant	O
ventricular	B
arrhythmias	I
who	O
developed	O
QT	B
prolongation	I
and	O
torsade	B
de	I
pointes	I
ventricular	B
tachycardia	I
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(	O
2.5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O
dobutamine	O
.	O

This	O
report	O
of	O
torsade	B
de	I
pointes	I
ventricular	B
tachycardia	I
during	O
intermittent	O
dobutamine	O
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	B
may	O
occur	O
even	O
with	O
low	O
doses	O
and	O
in	O
patients	O
with	O
no	O
history	O
of	O
significant	O
rhythm	O
disturbances	O
.	O

The	O
mechanisms	O
of	O
proarrhythmic	O
effects	O
of	O
Dubutamine	O
are	O
discussed	O
.	O

Positive	O
skin	O
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	O
media	O
.	O

In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	O
materials	O
(	O
PRC	O
)	O
have	O
been	O
described	O
with	O
increasing	O
frequency	O
.	O

The	O
authors	O
report	O
two	O
observations	O
on	O
patients	O
with	O
delayed	O
reactions	O
in	O
whom	O
intradermoreactions	O
(	O
IDR	O
)	O
and	O
patch	O
tests	O
to	O
a	O
series	O
of	O
ionic	O
and	O
non	O
ionic	O
PRC	O
were	O
studied	O
.	O

After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	B
,	O
loss	B
of	I
consciousness	I
)	O
and	O
delayed	O
macro	B
-	I
papular	I
rash	I
appeared	O
,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat	O
,	O
persistent	O
pain	B
at	O
the	O
site	O
of	O
injection	O
immediately	O
and	O
a	O
generalised	O
macro	O
-	O
papular	O
reaction	O
after	O
24	O
hours	O
.	O

The	O
skin	O
tests	O
revealed	O
positive	O
delayed	O
reactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patch	O
tests	O
to	O
only	O
some	O
PRC	O
with	O
common	O
chains	O
in	O
their	O
structures	O
.	O

The	O
positive	O
skin	O
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	B
in	O
the	O
patients	O
.	O

Risk	O
of	O
transient	O
hyperammonemic	B
encephalopathy	B
in	O
cancer	B
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5-fluorouracil	O
with	O
the	O
complication	O
of	O
dehydration	B
and	O
infection	B
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cancer	B
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	B
encephalopathy	B
related	O
to	O
continuous	O
infusion	O
of	O
5-fluorouracil	O
(	O
5-FU	O
)	O
were	O
identified	O
.	O

None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	B
disease	I
.	O

Onset	O
of	O
hyperammonemic	B
encephalopathy	B
varied	O
from	O
0.5	O
to	O
5	O
days	O
(	O
mean	O
:	O
2.6	O
+	O
/-	O

1.3	O
days	O
)	O
after	O
the	O
initiation	O
of	O
chemotherapy	O
.	O

Plasma	O
ammonium	O
level	O
ranged	O
from	O
248	O
to	O
2387	O
microg%	O
(	O
mean	O
:	O
626	O
+	O
/-	O

431	O
microg%	O
)	O
.	O

Among	O
the	O
32	O
episodes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
degrees	O
of	O
azotemia	B
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacterial	B
infections	I
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infection	B
occurred	O
during	O
periods	O
of	O
dehydration	B
.	O

Higher	O
plasma	O
ammonium	O
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	B
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	B
infections	I
(	O
p=0.003	O
and	O
0.0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5-FU	O
(	O
p=0.0001	O
and	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
episodes	O
(	O
78	O
%	O
)	O
,	O
plasma	O
ammonium	O
levels	O
and	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
2	O
days	O
after	O
adequate	O
management	O
.	O

In	O
conclusion	O
,	O
hyperammonemic	B
encephalopathy	B
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	O
.	O

Azotemia	B
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	B
infections	I
were	O
frequently	O
found	O
in	O
these	O
patients	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	O
.	O

The	O
effects	O
of	O
quinine	O
and	O
4-aminopyridine	O
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	O
in	O
rats	O
.	O

1	O
.	O

The	O
effects	O
of	O
two	O
unselective	O
potassium	O
(	O
K	O
(	O
+	O
)	O
-	O
)	O
channel	O
blockers	O
,	O
quinine	O
(	O
12.5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4-aminopyridine	O
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tested	O
in	O
Wistar	O
rats	O
.	O

Quinine	O
is	O
known	O
to	O
block	O
voltage-	O
,	O
calcium-	O
and	O
ATP	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
-channels	O
while	O
4-aminopyridine	O
is	O
known	O
to	O
block	O
voltage	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
-channels	O
.	O

2	O
.	O

In	O
the	O
counterbalanced	O
method	O
,	O
quinine	O
attenuated	O
morphine	O
-	O
induced	O
place	O
preference	O
,	O
whereas	O
4-aminopyridine	O
was	O
ineffective	O
.	O

In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex	O
-	O
activity	O
meter	O
neither	O
of	O
the	O
K	O
(	O
+	O
)	O
-channel	O
blockers	O
affected	O
morphine	O
-	O
induced	O
hypoactivity	B
,	O
but	O
both	O
K	O
(	O
+	O
)	O
-channel	O
blockers	O
prevented	O
morphine	O
-	O
induced	O
secondary	O
hyperactivity	B
.	O

3	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine	O
-	O
sensitive	O
but	O
not	O
4-aminopyridine	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
-channels	O
in	O
morphine	O
reward	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K	O
(	O
+	O
)	O
-channels	O
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine	O
-	O
induced	O
hypoactivity	B
whereas	O
morphine	O
-	O
induced	O
hyperactivity	B
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine-	O
and	O
4-aminopyridine	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
-channels	O
.	O

Nociceptin	O
/	O
orphanin	O
FQ	O
and	O
nocistatin	O
on	O
learning	B
and	I
memory	I
impairment	I
induced	O
by	O
scopolamine	O
in	O
mice	O
.	O

1	O
.	O
Nociceptin	O
,	O
also	O
known	O
as	O
orphanin	O
FQ	O
,	O
is	O
an	O
endogenous	O
ligand	O
for	O
the	O
orphan	O
opioid	O
receptor	O
-	O
like	O
receptor	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functions	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistatin	O
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	O
and	O
blocks	O
nociceptin	O
-	O
induced	O
allodynia	B
and	O
hyperalgesia	B
.	O

2	O
.	O

Although	O
ORL1	O
receptors	O
which	O
display	O
a	O
high	O
degree	O
of	O
sequence	O
homology	O
with	O
classical	O
opioid	O
receptors	O
are	O
abundant	O
in	O
the	O
hippocampus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learning	O
and	O
memory	O
.	O

3	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin	O
/	O
orphanin	O
FQ	O
and	O
nocistatin	O
could	O
modulate	O
impairment	B
of	I
learning	I
and	I
memory	I
induced	O
by	O
scopolamine	O
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
antagonist	O
,	O
using	O
spontaneous	O
alternation	O
of	O
Y	O
-	O
maze	O
and	O
step	O
-	O
down	O
type	O
passive	O
avoidance	O
tasks	O
in	O
mice	O
.	O

4	O
.	O
While	O
nocistatin	O
(	O
0.5	O
-	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O
administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours	O
,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step	O
-	O
down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	O
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v.	O
)	O
-treated	O
normal	O
mice	O
.	O

5	O
.	O
Administration	O
of	O
nocistatin	O
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
attenuated	O
the	O
scopolamine	O
-	O
induced	O
impairment	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
behaviours	O
.	O

6	O
.	O

These	O
results	O
indicated	O
that	O
nocistatin	O
,	O
a	O
new	O
biologically	O
active	O
peptide	O
,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	O
,	O
and	O
suggested	O
that	O
these	O
peptides	O
play	O
opposite	O
roles	O
in	O
learning	O
and	O
memory	O
.	O

Meloxicam	O
-	O
induced	O
liver	B
toxicity	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	B
arthritis	I
who	O
developed	O
acute	O
cytolytic	O
hepatitis	B
due	O
to	O
meloxicam	O
.	O

Recently	O
introduced	O
in	O
Belgium	O
,	O
meloxicam	O
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	O
2	O
.	O

The	O
acute	O
cytolytic	O
hepatitis	B
occurred	O
rapidly	O
after	O
meloxicam	O
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	B
mechanism	O
.	O

This	O
first	O
case	O
of	O
meloxicam	O
related	O
liver	B
toxicity	I
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	B
damage	I
.	O

Induction	O
of	O
apoptosis	O
by	O
remoxipride	O
metabolites	O
in	O
HL60	O
and	O
CD34+	O
/	O
CD19-	O
human	O
bone	O
marrow	O
progenitor	O
cells	O
:	O
potential	O
relevance	O
to	O
remoxipride	O
-	O
induced	O
aplastic	B
anemia	I
.	O

The	O
antipsychotic	O
agent	O
,	O
remoxipride	O
[	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-3-bromo	O
-	O
N-	O
[	O
(	O
1-ethyl-2-pyrrolidinyl	O
)	O
methyl	O
]	O
-2,6-dimethoxybenz	O
amide	O
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	B
anemia	I
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	O
,	O
three	O
pyrrolidine	O
ring	O
metabolites	O
and	O
five	O
aromatic	O
ring	O
metabolites	O
of	O
the	O
parent	O
compound	O
to	O
induce	O
apoptosis	O
in	O
HL60	O
cells	O
and	O
human	O
bone	O
marrow	O
progenitor	O
(	O
HBMP	O
)	O
cells	O
.	O

Cells	O
were	O
treated	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
compound	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	O
33342-	O
and	O
propidium	O
iodide	O
stained	O
cell	O
samples	O
.	O

Results	O
were	O
confirmed	O
by	O
determination	O
of	O
internucleosomal	O
DNA	O
fragmentation	O
using	O
gel	O
electrophoresis	O
for	O
HL60	O
cell	O
samples	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
assay	O
in	O
HBMP	O
cells	O
.	O

The	O
catechol	O
and	O
hydroquinone	O
metabolites	O
,	O
NCQ436	O
and	O
NCQ344	O
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time-	O
and	O
concentration	O
dependent	O
manner	O
,	O
while	O
the	O
phenols	O
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	O
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	O
ring	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
effect	O
.	O

No	O
necrosis	B
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	O
but	O
NCQ344	O
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types	O
,	O
inducing	O
apoptosis	O
at	O
lower	O
concentrations	O
and	O
necrosis	B
at	O
higher	O
concentrations	O
.	O

These	O
data	O
show	O
that	O
the	O
catechol	O
and	O
hydroquinone	O
metabolites	O
of	O
remoxipride	O
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells	O
,	O
leading	O
to	O
apoptosis	O
,	O
while	O
the	O
phenol	O
metabolites	O
were	O
inactive	O
.	O

Similarly	O
,	O
benzene	O
-	O
derived	O
catechol	O
and	O
hydroquinone	O
,	O
but	O
not	O
phenol	O
,	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
[	O
Moran	O
et	O
al.	O
,	O
Mol	O
.	O

Pharmacol	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
remoxipride	O
and	O
benzene	O
may	O
induce	O
aplastic	B
anemia	I
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	O
and	O
NCQ344	O
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B
anemia	I
that	O
has	O
been	O
associated	O
with	O
remoxipride	O
.	O

Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1-	O
(	O
1,2-dihydro-2-acenaphthylenyl	O
)	O
piperazine	O
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	O
agents	O
in	O
mice	O
.	O

In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	O
antipsychotic	O
agents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminergic	O
system	O
can	O
be	O
modulated	O
through	O
manipulation	O
of	O
the	O
serotonergic	O
system	O
.	O

The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	O
agents	O
based	O
on	O
the	O
structure	O
of	O
1-	O
(	O
1,2-dihydro-2-acenaphthylenyl	O
)	O
piperazine	O
(	O
7	O
)	O
is	O
described	O
.	O

Compound	O
7e	O
,	O
5-	O
{	O
2-	O
[	O
4-	O
(	O
1,2-dihydro-2-acenaphthylenyl	O
)	O
piperazinyl	O
]	O
ethyl	O
}	O
-2,3-dihy	O
dro-1H-	O
indol-2-one	O
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5-HT1A	O
and	O
5-HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	O
the	O
D2	O
receptor	O
.	O

7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	B
induced	O
by	O
haloperidol	O
indicating	O
its	O
atypical	O
antipsychotic	O
nature	O
.	O

Sub	O
-	O
chronic	O
inhibition	O
of	O
nitric	O
-	O
oxide	O
synthesis	O
modifies	O
haloperidol	O
-	O
induced	O
catalepsy	B
and	O
the	O
number	O
of	O
NADPH	O
-	O
diaphorase	O
neurons	O
in	O
mice	O
.	O

RATIONALE	O
:	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NOARG	O
)	O
,	O
an	O
inhibitor	O
of	O
nitric	O
-	O
oxide	O
synthase	O
(	O
NOS	O
)	O
,	O
induces	O
catalepsy	B
in	O
mice	O
.	O

This	O
effect	O
undergoes	O
rapid	O
tolerance	O
,	O
showing	O
a	O
significant	O
decrease	O
after	O
2	O
days	O
of	O
sub	O
-	O
chronic	O
L	O
-	O
NOARG	O
treatment	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
has	O
been	O
shown	O
to	O
influence	O
dopaminergic	O
neurotransmission	O
in	O
the	O
striatum	O
.	O

Neuroleptic	O
drugs	O
such	O
as	O
haloperidol	O
,	O
which	O
block	O
dopamine	O
receptors	O
,	O
also	O
cause	O
catalepsy	B
in	O
rodents	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L	O
-	O
NOARG	O
treatment	O
in	O
haloperidol	O
-	O
induced	O
catalepsy	B
and	O
the	O
number	O
of	O
NOS	O
neurons	O
in	O
areas	O
related	O
to	O
motor	O
control	O
.	O

METHODS	O
:	O
Male	O
albino	O
Swiss	O
mice	O
were	O
treated	O
sub	O
-	O
chronically	O
(	O
twice	O
a	O
day	O
for	O
4	O
days	O
)	O
with	O
L	O
-	O
NOARG	O
(	O
40	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
or	O
haloperidol	O
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

Catalepsy	B
was	O
evaluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatments	O
.	O

Reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
-	O
diaphorase	O
(	O
NADPH	O
-	O
d	O
)	O
histochemistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enzyme	O
expression	O
in	O
mice	O
brain	O
regions	O
related	O
to	O
motor	O
control	O
.	O

RESULTS	O
:	O
L	O
-	O
NOARG	O
sub	O
-	O
chronic	O
administration	O
produced	O
tolerance	O
of	O
L	O
-	O
NOARG	O
and	O
of	O
haloperidol	O
-	O
induced	O
catalepsy	B
.	O

It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH	O
-	O
d	O
-	O
positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	O
and	O
in	O
the	O
pedunculopontine	O
tegmental	O
nucleus	O
compared	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH	O
-	O
d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra	O
,	O
pars	O
compacta	O
in	O
both	O
haloperidol	O
-	O
treated	O
and	O
L	O
-	O
NOARG	O
-	O
treated	O
animals	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
give	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
NO	O
plays	O
a	O
role	O
in	O
motor	O
behavior	O
control	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
synaptic	O
changes	O
produced	O
by	O
antipsychotic	O
treatment	O
.	O

Prolonged	O
left	B
ventricular	I
dysfunction	I
occurs	O
in	O
patients	O
with	O
coronary	B
artery	I
disease	I
after	O
both	O
dobutamine	O
and	O
exercise	O
induced	O
myocardial	B
ischaemia	I
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	B
ventricular	I
dysfunction	I
in	O
patients	O
with	O
coronary	B
artery	I
disease	I
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

DESIGN	O
:	O
A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	O
induced	O
ischaemia	B
.	O

SUBJECTS	O
:	O
10	O
patients	O
with	O
stable	B
angina	I
,	O
angiographically	O
proven	O
coronary	B
artery	I
disease	I
,	O
and	O
normal	O
left	O
ventricular	O
function	O
.	O

INTERVENTIONS	O
:	O
Treadmill	O
exercise	O
and	O
dobutamine	O
stress	O
were	O
performed	O
on	O
different	O
days	O
.	O

Quantitative	O
assessment	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
was	O
performed	O
using	O
transthoracic	O
echocardiography	O
at	O
baseline	O
and	O
at	O
regular	O
intervals	O
after	O
each	O
test	O
.	O

RESULTS	O
:	O
Both	O
forms	O
of	O
stress	O
led	O
to	O
prolonged	O
but	O
reversible	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(	O
p	O
=	O
0.53	O
)	O
or	O
ST	O
depression	B
(	O
p	O
=	O
0.63	O
)	O
with	O
either	O
form	O
of	O
stress	O
.	O

After	O
exercise	O
,	O
ejection	O
fraction	O
was	O
reduced	O
at	O
15	O
and	O
30	O
minutes	O
compared	O
with	O
baseline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-5.6	O
(	O
1.5	O
)	O
%	O
,	O
p	O
<	O
0.05	O
;	O
and	O
-6.1	O
(	O
2.2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
minutes	O
after	O
dobutamine	O
(	O
-10.8	O
(	O
1.8	O
)	O
%	O
and	O
-5	O
.	O

5	O
(	O
1.8	O
)	O
%	O
,	O
both	O
p	O
<	O
0.01	O
)	O
.	O

Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(	O
-27.9	O
(	O
7.2	O
)	O
%	O
and	O
-28.6	O
(	O
5.7	O
)	O
%	O
,	O
both	O
p	O
<	O
0.01	O
)	O
,	O
and	O
at	O
30	O
minutes	O
after	O
dobutamine	O
(	O
-32	O
(	O
5.3	O
)	O
%	O
,	O
p	O
<	O
0.01	O
)	O
.	O

The	O
isovolumic	O
relaxation	O
period	O
was	O
prolonged	O
45	O
minutes	O
after	O
each	O
form	O
of	O
stress	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
coronary	B
artery	I
disease	I
,	O
dobutamine	O
induced	O
ischaemia	B
results	O
in	O
prolonged	O
reversible	O
left	B
ventricular	I
dysfunction	I
,	O
presumed	O
to	O
be	O
myocardial	B
stunning	I
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

Dobutamine	O
induced	O
ischaemia	B
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B
artery	I
disease	I
.	O

Anorexigens	O
and	O
pulmonary	B
hypertension	I
in	O
the	O
United	O
States	O
:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	B
hypertension	I
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
appetite	O
suppressants	O
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	B
pulmonary	I
hypertension	I
(	O
PPH	B
)	O
.	O

Recently	O
,	O
fenfluramine	O
appetite	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
United	O
States	O
but	O
were	O
withdrawn	O
in	O
September	O
1997	O
because	O
of	O
concerns	O
over	O
adverse	O
effects	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	B
hypertension	I
at	O
12	O
large	O
referral	O
centers	O
in	O
North	O
America	O
.	O

Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B
hypertension	I
and	O
its	O
severity	O
.	O

Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	B
hypertension	I
were	O
classed	O
as	O
PPH	B
.	O

A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants	O
,	O
anorexigens	O
,	O
and	O
amphetamines	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
patients	O
were	O
studied	O
,	O
205	O
with	O
PPH	B
and	O
374	O
with	O
pulmonary	B
hypertension	I
from	O
other	O
causes	O
(	O
secondary	O
pulmonary	B
hypertension	I
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
anorexigens	O
was	O
common	O
in	O
both	O
groups	O
.	O

However	O
,	O
of	O
the	O
medications	O
surveyed	O
,	O
only	O
the	O
fenfluramines	O
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	B
as	O
compared	O
with	O
SPH	O
(	O
adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months	O
,	O
7.5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.7	O
to	O
32.4	O
)	O
.	O

The	O
association	O
was	O
stronger	O
with	O
longer	O
duration	O
of	O
use	O
when	O
compared	O
to	O
shorter	O
duration	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
users	O
than	O
in	O
remote	O
users	O
.	O

An	O
unexpectedly	O
high	O
(	O
11.4	O
%	O
)	O
number	O
of	O
patients	O
with	O
SPH	O
had	O
used	O
anorexigens	O
.	O

CONCLUSION	O
:	O
The	O
magnitude	O
of	O
the	O
association	O
with	O
PPH	B
,	O
the	O
increase	O
of	O
association	O
with	O
increasing	O
duration	O
of	O
use	O
,	O
and	O
the	O
specificity	O
for	O
fenfluramines	O
are	O
consistent	O
with	O
previous	O
studies	O
indicating	O
that	O
fenfluramines	O
are	O
causally	O
related	O
to	O
PPH	B
.	O

The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	B
hypertension	I
in	O
patients	O
with	O
underlying	O
conditions	O
associated	O
with	O
SPH	O
.	O

Clinical	O
aspects	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
and	O
thrombosis	B
and	O
other	O
side	O
effects	O
of	O
heparin	O
therapy	O
.	O

Heparin	O
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	B
for	O
more	O
than	O
50	O
years	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	O
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	B
episodes	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	O
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Bleeding	B
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	O
.	O

Major	O
bleeding	B
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	O
therapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	O
therapy	O
include	O
heparin	O
-	O
induced	O
thrombocytopenia	B
,	O
heparin	O
-	O
associated	O
osteoporosis	B
,	O
eosinophilia	B
,	O
skin	B
reactions	I
,	O
allergic	B
reactions	I
other	O
than	O
thrombocytopenia	B
,	O
alopecia	B
,	O
transaminasemia	O
,	O
hyperkalemia	B
,	O
hypoaldosteronism	B
,	O
and	O
priapism	B
.	O

These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	O
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	B
and	O
osteoporosis	B
.	O

Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
""""	O
softly	O
""""	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	O
,	O
at	O
present	O
the	O
incidences	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
molecular	O
weight	O
heparins	O
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
experience	O
will	O
more	O
clearly	O
define	O
the	O
incidence	O
of	O
each	O
side	O
effect	O
with	O
low	O
molecular	O
weight	O
preparations	O
.	O

A	O
case	O
of	O
bilateral	O
optic	B
neuropathy	I
in	O
a	O
patient	O
on	O
tacrolimus	O
(	O
FK506	O
)	O
therapy	O
after	O
liver	O
transplantation	O
.	O

PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B
neuropathy	I
in	O
a	O
patient	O
receiving	O
tacrolimus	O
(	O
FK	O
506	O
,	O
Prograf	O
;	O
Fujisawa	O
USA	O
,	O
Inc	O
,	O
Deerfield	O
,	O
Illinois	O
)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	O
transplantation	O
.	O

METHOD	O
:	O
Case	O
report	O
.	O

In	O
a	O
58-year	O
-	O
old	O
man	O
receiving	O
tacrolimus	O
after	O
orthotropic	O
liver	O
transplantation	O
,	O
serial	O
neuro	O
-	O
ophthalmologic	O
examinations	O
and	O
laboratory	O
studies	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	O
in	O
both	O
eyes	O
,	O
with	O
clinical	O
features	O
resembling	O
ischemic	B
optic	I
neuropathies	I
.	O

Deterioration	B
of	I
vision	I
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	O
.	O

CONCLUSION	O
:	O
Tacrolimus	O
and	O
other	O
immunosuppressive	O
agents	O
may	O
be	O
associated	O
with	O
optic	B
nerve	I
toxicity	I
.	O

Hypercalcemia	B
,	O
arrhythmia	B
,	O
and	O
mood	O
stabilizers	O
.	O

Recent	O
findings	O
in	O
a	O
bipolar	B
patient	O
receiving	O
maintenance	O
lithium	O
therapy	O
who	O
developed	O
hypercalcemia	B
and	O
severe	O
bradyarrhythmia	B
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	B
patients	O
with	O
lithium	O
-	O
associated	O
hypercalcemia	B
.	O

A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	B
that	O
presented	O
during	O
a	O
1-year	O
period	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercalcemias	B
or	O
those	O
associated	O
with	O
intravenous	O
fluids	O
,	O
the	O
authors	O
identified	O
18	O
non	O
-	O
lithium	O
-	O
treated	O
patients	O
with	O
hypercalcemias	B
related	O
to	O
malignancies	B
and	O
other	O
medical	O
conditions	O
(	O
group	O
A	O
)	O
and	O
12	O
patients	O
with	O
lithium	O
-	O
associated	O
hypercalcemia	B
(	O
group	O
B	O
)	O
.	O

Patients	O
in	O
group	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
group	O
A	O
,	O
as	O
the	O
latter	O
were	O
medically	O
compromised	O
and	O
were	O
receiving	O
multiple	O
pharmacotherapies	O
.	O

Thus	O
,	O
two	O
control	O
groups	O
were	O
generated	O
:	O
group	O
C1	O
,	O
which	O
included	O
age-	O
and	O
sex	O
-	O
comparable	O
lithium	O
-	O
treated	O
bipolar	B
normocalcemic	O
patients	O
,	O
and	O
group	O
C2	O
,	O
which	O
included	O
bipolar	B
normocalcemic	O
patients	O
treated	O
with	O
anticonvulsant	O
mood	O
stabilizers	O
.	O

The	O
electrocardiographic	O
(	O
ECG	O
)	O
findings	O
for	O
patients	O
in	O
group	O
B	O
were	O
compared	O
with	O
those	O
of	O
patients	O
in	O
groups	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
groups	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequency	O
of	O
ECG	O
abnormalities	O
;	O
however	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
frequency	O
of	O
conduction	O
defects	O
.	O

Patients	O
with	O
hypercalcemia	B
resulting	O
from	O
medical	O
diseases	O
and	O
bipolar	B
patients	O
with	O
lithium	O
-	O
associated	O
hypercalcemia	B
had	O
significantly	O
higher	O
frequencies	O
of	O
conduction	O
defects	O
.	O

Patients	O
in	O
group	O
A	O
had	O
significant	O
mortality	O
at	O
2-year	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
mortality	O
in	O
the	O
other	O
three	O
groups	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Attenuation	O
of	O
nephrotoxicity	B
by	O
a	O
novel	O
lipid	O
nanosphere	O
(	O
NS-718	O
)	O
incorporating	O
amphotericin	O
B.	O
NS-718	O
,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	O
B	O
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	B
.	O

We	O
compared	O
the	O
toxicity	B
of	O
NS-718	O
with	O
that	O
of	O
Fungizone	O
(	O
amphotericin	O
B	O
-	O
sodium	O
deoxycholate	O
;	O
D	O
-	O
AmB	O
)	O
in	O
vitro	O
using	O
renal	O
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis	O
,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	O
B	O
following	O
intravenous	O
infusion	O
of	O
the	O
formulation	O
in	O
rats	O
.	O

Incubation	O
with	O
NS-718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D	O
-	O
AmB.	O
Serum	O
blood	O
urea	O
and	O
creatinine	O
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D	O
-	O
AmB	O
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS-718	O
.	O

Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	B
necrosis	I
in	O
D	O
-	O
AmB	O
-	O
treated	O
rats	O
but	O
no	O
change	O
in	O
NS-718-treated	O
rats	O
.	O

Amphotericin	O
B	O
concentrations	O
in	O
the	O
kidney	O
in	O
NS-718-treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D	O
-	O
AmB	O
-	O
treated	O
rats	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	O
B	O
into	O
lipid	O
nanospheres	O
of	O
NS-718	O
attenuates	O
the	O
nephrotoxicity	B
of	O
amphotericin	O
B.	O

Patterns	O
of	O
sulfadiazine	O
acute	B
nephrotoxicity	I
.	O

Sulfadiazine	O
acute	B
nephrotoxicity	I
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	B
in	O
HIV	O
-	O
positive	O
patients	O
.	O

We	O
report	O
4	O
cases	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healthy	O
person	O
.	O

Under	O
treatment	O
with	O
sulfadiazine	O
they	O
developed	O
oliguria	B
,	O
abdominal	B
pain	I
,	O
renal	B
failure	I
and	O
showed	O
multiple	O
radiolucent	O
renal	B
calculi	I
in	O
echography	O
.	O

All	O
patients	O
recovered	O
their	O
previous	O
normal	O
renal	O
function	O
after	O
adequate	O
hydration	O
and	O
alcalinization	O
.	O

A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	B
lithiasis	I
in	O
a	O
single	O
functional	O
kidney	O
.	O

None	O
of	O
them	O
needed	O
dialysis	O
or	O
a	O
renal	O
biopsy	O
because	O
of	O
a	O
typical	O
benign	O
course	O
.	O

Treatment	O
with	O
sulfadiazine	O
requires	O
exquisite	O
control	O
of	O
renal	O
function	O
,	O
an	O
increase	O
in	O
water	O
ingestion	O
and	O
possibly	O
the	O
alcalinization	O
of	O
the	O
urine	O
.	O

We	O
communicate	O
a	O
case	O
in	O
a	O
previously	O
healthy	O
person	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
literature	O
.	O

Probably	O
many	O
more	O
cases	O
are	O
not	O
detected	O
.	O

We	O
think	O
that	O
a	O
prospective	O
study	O
would	O
be	O
useful	O
.	O

Downbeat	B
nystagmus	I
associated	O
with	O
intravenous	O
patient	O
-	O
controlled	O
administration	O
of	O
morphine	O
.	O

IMPLICATIONS	O
:	O
This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	B
with	O
downbeating	B
nystagmus	I
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient	O
-	O
controlled	O
analgesia	O
morphine	O
.	O

Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	O
with	O
these	O
symptoms	O
and	O
signs	O
,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient	O
-	O
controlled	O
analgesia	O
morphine	O
.	O

Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	O
and	O
amiodarone	O
in	O
animals	O
with	O
a	O
healed	O
myocardial	B
infarction	I
.	O

The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	O
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	O
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	O
after	O
prolonged	O
oral	O
administration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	B
infarction	I
.	O

All	O
dogs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
dronedarone	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amiodarone	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
placebo	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
a	O
3-week	O
washout	O
between	O
consecutive	O
treatments	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
MBP	O
)	O
,	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(	O
+	O
LVdP	O
/	O
dt	O
)	O
,	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
and	O
fractional	O
shortening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	O
and	O
exercise	O
-	O
induced	O
sympathetic	O
stimulation	O
were	O
evaluated	O
under	O
baseline	O
and	O
posttreatment	O
conditions	O
.	O

Resting	O
values	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen	O
,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose	O
-	O
dependently	O
lowered	O
after	O
dronedarone	O
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	O
.	O

Both	O
dronedarone	O
and	O
amiodarone	O
significantly	O
reduced	O
the	O
exercise	O
-	O
induced	O
tachycardia	B
and	O
,	O
at	O
the	O
highest	O
dose	O
,	O
decreased	O
the	O
isoproterenol	O
-	O
induced	O
tachycardia	B
.	O

Thus	O
,	O
dronedarone	O
and	O
amiodarone	O
displayed	O
a	O
similar	O
level	O
of	O
antiadrenergic	O
effect	O
and	O
did	O
not	O
impair	O
the	O
resting	O
left	O
ventricular	O
function	O
.	O

Consequently	O
,	O
dronedarone	O
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	B
,	O
without	O
compromising	O
the	O
left	O
ventricular	O
function	O
.	O

Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	O
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
platinum	O
/	O
paclitaxel	O
-	O
refractory	O
ovarian	B
and	I
fallopian	I
tube	I
cancers	I
and	O
primary	O
carcinoma	B
of	I
the	I
peritoneum	I
.	O

BACKGROUND	O
:	O
Several	O
studies	O
have	O
demonstrated	O
liposomal	O
doxorubicin	O
(	O
Doxil	O
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum	O
-	O
resistant	O
ovarian	B
cancer	I
,	O
with	O
dose	O
limiting	O
toxicity	B
of	O
the	O
standard	O
dosing	O
regimen	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
)	O
being	O
severe	O
erythrodysesthesia	B
(	O
""""	O
hand	B
-	I
foot	I
syndrome	I
""""	O
)	O
and	O
stomatitis	B
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	O
doxorubicin	O
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well	O
-	O
defined	O
patient	O
population	O
with	O
platinum	O
/	O
paclitaxel	O
-	O
refractory	O
disease	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Patients	O
with	O
ovarian	B
or	I
fallopian	I
tube	I
cancers	I
or	O
primary	O
peritoneal	B
carcinoma	I
with	O
platinum	O
/	O
paclitaxel	O
-	O
refractory	O
disease	O
(	O
stable	O
or	O
progressive	O
disease	O
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<3	O
months	O
in	O
duration	O
)	O
were	O
treated	O
with	O
liposomal	O
doxorubicin	O
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
49	O
patients	O
(	O
median	O
age	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
phase	O
2	O
trial	O
.	O

The	O
median	O
number	O
of	O
prior	O
regimens	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
patients	O
experienced	O
grade	O
2	O
hand	B
-	I
foot	I
syndrome	I
and	O
stomatitis	B
,	O
respectively	O
(	O
no	O
episodes	O
of	O
grade	O
3	O
)	O
.	O

One	O
patient	O
developed	O
grade	O
3	O
diarrhea	B
requiring	O
hospitalization	O
for	O
hydration	O
.	O

Six	O
(	O
12	O
%	O
)	O
individuals	O
required	O
dose	O
reductions	O
.	O

The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	O
doxorubicin	O
administered	O
on	O
this	O
protocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
patients	O
(	O
9	O
%	O
)	O
evaluable	O
for	O
response	O
exhibited	O
objective	O
and	O
subjective	O
evidence	O
of	O
an	O
antineoplastic	O
effect	O
of	O
therapy	O
.	O

CONCLUSION	O
:	O
This	O
modified	O
liposomal	O
doxorubicin	O
regimen	O
results	O
in	O
less	O
toxicity	B
(	O
stomatitis	B
,	O
hand	B
-	I
foot	I
syndrome	I
)	O
than	O
the	O
standard	O
FDA	O
-	O
approved	O
dose	O
schedule	O
.	O

Definite	O
,	O
although	O
limited	O
,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well	O
-	O
defined	O
platinum-	O
and	O
paclitaxel	O
-	O
refractory	O
ovarian	B
cancer	I
.	O

Efficacy	O
of	O
olanzapine	O
in	O
acute	O
bipolar	B
mania	I
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

The	O
Olanzipine	O
HGGW	O
Study	O
Group	O
.	O

BACKGROUND	O
:	O
We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	O
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	B
mania	I
.	O

METHODS	O
:	O
Four	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
study	O
.	O

A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
bipolar	B
disorder	I
,	O
manic	B
or	O
mixed	O
,	O
were	O
randomized	O
to	O
olanzapine	O
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young	O
-	O
Mania	B
Rating	O
Scale	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
score	O
.	O

Response	O
and	O
euthymia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
improvement	O
from	O
baseline	O
to	O
end	O
point	O
and	O
as	O
a	O
score	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
score	O
,	O
respectively	O
.	O

Safety	O
was	O
assessed	O
using	O
adverse	O
events	O
,	O
Extrapyramidal	B
Symptom	I
(	O
EPS	B
)	O
rating	O
scales	O
,	O
laboratory	O
values	O
,	O
electrocardiograms	O
,	O
vital	O
signs	O
,	O
and	O
weight	O
change	O
.	O

RESULTS	O
:	O
Olanzapine	O
-	O
treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O

SD	O
)	O
improvement	O
in	O
Y	O
-	O
MRS	O
total	O
score	O
than	O
placebo	O
-	O
treated	O
patients	O
(	O
-14.8	O
+	O
/-	O

12.5	O
and	O
-8.1	O
+	O
/-	O

12.7	O
,	O
respectively	O
;	O
P<.001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbaseline	O
observation	O
1	O
week	O
after	O
randomization	O
and	O
was	O
maintained	O
throughout	O
the	O
study	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
.	O

Olanzapine	O
-	O
treated	O
patients	O
demonstrated	O
a	O
higher	O
rate	O
of	O
response	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.02	O
)	O
and	O
euthymia	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
placebo	O
-	O
treated	O
patients	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
EPSs	B
between	O
groups	O
.	O

However	O
,	O
olanzapine	O
-	O
treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O

SD	O
)	O
weight	B
gain	I
than	O
placebo	O
-	O
treated	O
patients	O
(	O
2.1	O
+	O
/-	O
2.8	O
vs	O
0.45	O
+	O
/-	O

2.3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatment	O
-	O
emergent	O
somnolence	B
(	O
21	O
patients	O
[	O
38.2	O
%	O
]	O
vs	O
5	O
[	O
8.3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
Olanzapine	O
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	B
mania	I
and	O
was	O
generally	O
well	O
tolerated	O
.	O

The	O
effect	O
of	O
pupil	B
dilation	I
with	O
tropicamide	O
on	O
vision	O
and	O
driving	O
simulator	O
performance	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
effect	O
of	O
pupil	B
dilation	I
on	O
vision	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers	O
,	O
before	O
and	O
after	O
pupil	B
dilation	I
using	O
guttae	O
tropicamide	O
1	O
%	O
.	O

A	O
driving	O
simulator	O
(	O
Transport	O
Research	O
Laboratory	O
)	O
was	O
used	O
to	O
measure	O
reaction	O
time	O
(	O
RT	O
)	O
,	O
speed	O
maintenance	O
and	O
steering	O
accuracy	O
.	O

Tests	O
of	O
basic	O
visual	O
function	O
included	O
high-	O
and	O
low	O
-	O
contrast	O
visual	O
acuity	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pelli	O
-	O
Robson	O
contrast	O
threshold	O
(	O
CT	O
)	O
and	O
Goldmann	O
perimetry	O
(	O
FIELDS	O
)	O
.	O

Useful	O
Field	O
of	O
View	O
(	O
UFOV	O
--	O
a	O
test	O
of	O
visual	O
attention	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
differences	O
in	O
the	O
pre-	O
and	O
post	O
-	O
dilatation	O
measurements	O
were	O
tested	O
for	O
statistical	O
significance	O
at	O
the	O
95	O
%	O
level	O
using	O
one	O
-	O
tail	O
paired	O
t	O
-	O
tests	O
.	O

RESULTS	O
:	O
Pupillary	B
dilation	I
resulted	O
in	O
a	O
statistically	O
significant	O
deterioration	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O

Five	O
of	O
12	O
drivers	O
also	O
exhibited	O
deterioration	O
in	O
LCVA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
evidence	O
emerged	O
for	O
deterioration	O
in	O
FIELDS	O
and	O
UFOV	O
.	O

Also	O
,	O
7	O
of	O
12	O
drivers	O
appeared	O
to	O
adjust	O
their	O
driving	O
behaviour	O
by	O
reducing	O
their	O
speed	O
on	O
the	O
driving	O
simulator	O
,	O
leading	O
to	O
improved	O
steering	O
accuracy	O
.	O

CONCLUSIONS	O
:	O
Pupillary	B
dilation	I
may	O
lead	O
to	O
a	O
decrease	O
in	O
vision	O
and	O
daylight	O
driving	O
performance	O
in	O
young	O
people	O
.	O

A	O
larger	O
study	O
,	O
including	O
a	O
broader	O
spectrum	O
of	O
subjects	O
,	O
is	O
warranted	O
before	O
guidelines	O
can	O
be	O
recommended	O
.	O

A	O
case	O
of	O
isotretinoin	B
embryopathy	I
with	O
bilateral	O
anotia	B
and	O
Taussig	B
-	I
Bing	I
malformation	I
.	O

We	O
report	O
a	O
newborn	O
infant	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
anotia	B
and	O
Taussig	B
-	I
Bing	I
malformation	I
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	O
within	O
the	O
first	O
trimester	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	O
A	O
-	O
containing	O
drugs	O
to	O
women	O
of	O
childbearing	O
years	O
.	O

Effect	O
of	O
methoxamine	O
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	B
incontinence	I
:	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
study	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1-adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	B
stress	I
incontinence	I
.	O

A	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
design	O
was	O
employed	O
.	O

Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	O
or	O
placebo	O
(	O
saline	O
)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	B
incontinence	I
while	O
measuring	O
maximum	O
urethral	O
pressure	O
(	O
MUP	O
)	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
symptomatic	O
side	O
effects	O
.	O

Methoxamine	O
evoked	O
non	O
-	O
significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	B
significant	I
rise	I
in	I
systolic	I
blood	I
pressure	I
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	O
maximum	O
dosage	O
.	O

Systemic	O
side	O
effects	O
including	O
piloerection	O
,	O
headache	B
,	O
and	O
cold	O
extremities	O
were	O
experienced	O
in	O
all	O
subjects	O
.	O

The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub	O
-	O
type	O
-	O
selective	O
alpha1-adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	B
incontinence	I
may	O
be	O
limited	O
by	O
associated	O
piloerection	O
and	O
cardiovascular	O
side	O
effects	O
.	O

Hyperglycemic	B
effect	O
of	O
amino	O
compounds	O
structurally	O
related	O
to	O
caproate	O
in	O
rats	O
.	O

The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(	O
0.3	O
-	O
3	O
%	O
of	O
diet	O
weight	O
)	O
of	O
certain	O
amino	O
derivatives	O
of	O
caproate	O
resulted	O
in	O
hyperglycemia	B
,	O
an	O
elevated	O
glucose	O
tolerance	O
curve	O
and	O
,	O
occasionally	O
,	O
glucosuria	B
.	O

Effective	O
compounds	O
included	O
norleucine	O
,	O
norvaline	O
,	O
glutamate	O
,	O
epsilon	O
-	O
aminocaproate	O
,	O
methionine	O
,	O
and	O
leucine	O
.	O

Toleration	O
of	O
high	O
doses	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
in	O
patients	O
with	O
chronic	O
heart	B
failure	I
:	O
results	O
from	O
the	O
ATLAS	O
trial	O
.	O

The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	O
and	O
Survival	O
.	O

BACKGROUND	O
:	O
Treatment	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	B
failure	I
(	O
CHF	B
)	O
,	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials	O
,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents	O
,	O
especially	O
at	O
the	O
recommended	O
doses	O
.	O

The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high-	O
compared	O
with	O
low	O
-	O
dose	O
lisinopril	O
in	O
CHF	B
.	O

METHODS	O
:	O
The	O
Assessment	O
of	O
Lisinopril	O
and	O
Survival	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	O
inhibitor	O
treatment	O
were	O
stabilized	O
receiving	O
medium	O
-	O
dose	O
lisinopril	O
(	O
12.5	O
or	O
15.0	O
mg	O
once	O
daily	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomized	O
to	O
high-	O
(	O
35.0	O
or	O
32.5	O
mg	O
OD	O
)	O
or	O
low	O
-	O
dose	O
(	O
5.0	O
or	O
2.5	O
mg	O
OD	O
)	O
groups	O
.	O

Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	B
and	O
left	O
ventricular	O
ejection	O
fractions	O
of	O
no	O
greater	O
than	O
0.30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
a	O
median	O
of	O
46	O
months	O
.	O

We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment	O
,	O
with	O
a	O
focus	O
on	O
hypotension	B
and	O
renal	B
dysfunction	I
.	O

RESULTS	O
:	O
Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	O
inhibitor	O
,	O
doses	O
in	O
only	O
4.2	O
%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	B
(	O
2.0	O
%	O
)	O
or	O
because	O
of	O
renal	B
dysfunction	I
or	O
hyperkalemia	B
(	O
2.3	O
%	O
)	O
.	O

Doses	O
in	O
more	O
than	O
90	O
%	O
of	O
randomized	O
patients	O
in	O
the	O
high-	O
and	O
low	O
-	O
dose	O
groups	O
were	O
titrated	O
to	O
their	O
assigned	O
target	O
,	O
and	O
the	O
mean	O
doses	O
of	O
blinded	O
medication	O
in	O
both	O
groups	O
remained	O
similar	O
throughout	O
the	O
study	O
.	O

Withdrawals	O
occurred	O
in	O
27.1	O
%	O
of	O
the	O
high-	O
and	O
30.7	O
%	O
of	O
the	O
low	O
-	O
dose	O
groups	O
.	O

Subgroups	O
presumed	O
to	O
be	O
at	O
higher	O
risk	O
for	O
ACE	O
inhibitor	O
intolerance	O
(	O
blood	O
pressure	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatinine	O
,	O
>	O
or	O
=	O
132.6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1.5	O
mg	O
/	O
dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
years	O
;	O
and	O
patients	O
with	O
diabetes	B
)	O
generally	O
tolerated	O
the	O
high	O
-	O
dose	O
strategy	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
ACE	O
inhibitor	O
therapy	O
in	O
most	O
patients	O
with	O
CHF	B
can	O
be	O
successfully	O
titrated	O
to	O
and	O
maintained	O
at	O
high	O
doses	O
,	O
and	O
that	O
more	O
aggressive	O
use	O
of	O
these	O
agents	O
is	O
warranted	O
.	O

Cocaine	O
,	O
ethanol	O
,	O
and	O
cocaethylene	O
cardiotoxity	B
in	O
an	O
animal	O
model	O
of	O
cocaine	B
and	I
ethanol	I
abuse	I
.	O

OBJECTIVES	O
:	O
Simultaneous	O
abuse	B
of	I
cocaine	I
and	B
ethanol	I
affects	O
12	O
million	O
Americans	O
annually	O
.	O

In	O
combination	O
,	O
these	O
substances	O
are	O
substantially	O
more	O
toxic	O
than	O
either	O
drug	O
alone	O
.	O

Their	O
combined	O
cardiac	B
toxicity	I
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	O
(	O
CE	O
)	O
,	O
a	O
cocaine	O
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	O
in	O
the	O
combined	O
cardiotoxicity	B
of	O
cocaine	O
and	O
ethanol	O
in	O
a	O
model	O
simulating	O
their	O
abuse	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	O
7.5	O
mg	O
/	O
kg	O
with	O
ethanol	O
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C+E	O
,	O
n	O
=	O
8)	O
,	O
2	O
)	O
three	O
cocaine	O
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethanol	O
infusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebo	O
boluses	O
and	O
infusion	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemodynamic	O
measurements	O
,	O
electrocardiograms	O
,	O
and	O
serum	O
drug	O
concentrations	O
were	O
obtained	O
at	O
baseline	O
,	O
and	O
then	O
at	O
fixed	O
time	O
intervals	O
after	O
each	O
drug	O
was	O
administered	O
.	O

RESULTS	O
:	O
Two	O
of	O
eight	O
dogs	O
in	O
the	O
C+E	O
group	O
experienced	O
cardiovascular	B
collapse	I
.	O

The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	O
bolus	O
in	O
the	O
C+E	O
and	O
C	O
only	O
groups	O
;	O
however	O
,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C+E	O
group	O
.	O

Peak	O
CE	O
levels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/-	O

22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decrease	B
in	I
cardiac	I
output	I
(	O
p	O
<	O
0.05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/-	O

23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
decrease	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/-	O

15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decrease	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0.025	O
)	O
.	O

Ventricular	B
arrhythmias	I
were	O
primarily	O
observed	O
in	O
the	O
C+E	O
group	O
,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	B
tachycardia	I
.	O

CONCLUSIONS	O
:	O
Cocaine	O
and	O
ethanol	O
in	O
combination	O
were	O
more	O
toxic	O
than	O
either	O
substance	O
alone	O
.	O

Co	O
-	O
administration	O
resulted	O
in	O
prolonged	O
cardiac	B
toxicity	I
and	O
was	O
dysrhythmogenic	O
.	O

Peak	O
serum	O
cocaethylene	O
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	B
depression	I
.	O

Worsening	O
of	O
Parkinsonism	B
after	O
the	O
use	O
of	O
veralipride	O
for	O
treatment	O
of	O
menopause	O
:	O
case	O
report	O
.	O

We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson	B
's	I
disease	I
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	O
related	O
symptoms	O
with	O
veralipride	O
,	O
as	O
well	O
as	O
the	O
improvement	O
of	O
her	O
symptoms	O
back	O
to	O
baseline	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

We	O
emphasize	O
the	O
anti	O
-	O
dopaminergic	O
effect	O
of	O
veralipride	O
.	O

Viracept	O
and	O
irregular	B
heartbeat	I
warning	O
.	O

A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	O
inhibitor	O
Viracept	O
may	O
cause	O
an	O
irregular	B
heart	I
beat	I
,	O
known	O
as	O
bradycardia	B
,	O
in	O
people	O
with	O
HIV	O
.	O

Bradycardia	B
occurred	O
in	O
a	O
45-year	O
-	O
old	O
male	O
patient	O
who	O
was	O
Viracept	O
in	O
combination	O
with	O
other	O
anti	O
-	O
HIV	O
drugs	O
.	O

The	O
symptoms	O
ceased	O
after	O
switching	O
to	O
another	O
drug	O
combination	O
.	O

Frequency	O
of	O
appearance	O
of	O
myeloperoxidase	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Graves	B
'	I
disease	I
patients	O
treated	O
with	O
propylthiouracil	O
and	O
the	O
relationship	O
between	O
MPO	O
-	O
ANCA	O
and	O
clinical	O
manifestations	O
.	O

OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
-positive	O
vasculitis	B
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves	B
'	I
disease	I
who	O
were	O
treated	O
with	O
propylthiouracil	O
(	O
PTU	O
)	O
.	O

The	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
in	O
these	O
cases	O
was	O
suspected	O
of	O
being	O
related	O
to	O
PTU	O
because	O
the	O
titres	O
of	O
MPO	O
-	O
ANCA	O
decreased	O
when	O
PTU	O
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasculitis	B
during	O
PTU	O
therapy	O
,	O
or	O
on	O
the	O
incidence	O
of	O
MPO	O
-	O
ANCA	O
in	O
untreated	O
Graves	B
'	I
disease	I
patients	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves	B
'	I
disease	I
.	O

PATIENTS	O
:	O
We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	B
due	O
to	O
Graves	B
'	I
disease	I
for	O
the	O
presence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
development	O
vasculitis	B
after	O
starting	O
PTU	O
therapy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
adverse	O
effects	O
of	O
PTU	O
or	O
because	O
the	O
observation	O
period	O
was	O
less	O
than	O
3	O
months	O
.	O

The	O
remaining	O
73	O
patients	O
(	O
55	O
women	O
and	O
18	O
men	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
months	O
,	O
were	O
adopted	O
as	O
the	O
subjects	O
of	O
the	O
investigation	O
.	O

The	O
median	O
observation	O
period	O
was	O
23.6	O
months	O
(	O
range	O
:	O
3	O
-	O
37	O
months	O
)	O
.	O

MEASUREMENTS	O
:	O
MPO	O
-	O
ANCA	O
was	O
measured	O
at	O
intervals	O
of	O
2	O
-	O
6	O
months	O
.	O

RESULTS	O
:	O
Before	O
treatment	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves	B
'	I
disease	I
patients	O
were	O
within	O
the	O
reference	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4.1	O
%	O
)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO	O
-	O
ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	O
therapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
transiently	O
increased	O
to	O
12.8	O
and	O
15.0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	O
therapy	O
,	O
but	O
no	O
vasculitic	B
disorders	I
developed	O
.	O

In	O
the	O
third	O
patient	O
,	O
the	O
MPO	O
-	O
ANCA	O
titre	O
increased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	B
,	O
oral	B
ulcers	I
and	O
polyarthralgia	B
,	O
but	O
the	O
symptoms	O
resolved	O
2	O
weeks	O
after	O
stopping	O
PTU	O
therapy	O
,	O
and	O
the	O
MPO	O
-	O
ANCA	O
titre	O
decreased	O
to	O
20.7	O
U	O
/	O
ml	O
by	O
4	O
months	O
after	O
discontinuing	O
PTU	O
.	O

CONCLUSIONS	O
:	O
PTU	O
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	B
.	O

Prevalence	O
of	O
heart	B
disease	I
in	O
asymptomatic	O
chronic	O
cocaine	O
users	O
.	O

To	O
determine	O
the	O
prevalence	O
of	O
heart	B
disease	I
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	O
users	O
,	O
35	O
cocaine	O
users	O
and	O
32	O
age	O
-	O
matched	O
controls	O
underwent	O
resting	O
and	O
exercise	O
electrocardiography	O
(	O
ECG	O
)	O
and	O
Doppler	O
echocardiography	O
.	O

Findings	O
consistent	O
with	O
coronary	B
artery	I
disease	I
were	O
detected	O
in	O
12	O
(	O
34	O
%	O
)	O
patients	O
and	O
3	O
(	O
9	O
%	O
)	O
controls	O
(	O
p	O
=	O
0.01	O
)	O
.	O

Decreased	O
left	O
ventricular	O
systolic	O
function	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patients	O
,	O
but	O
in	O
none	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.055	O
)	O
.	O

Finally	O
,	O
resting	O
and	O
peak	O
exercise	O
abnormal	B
left	I
ventricular	I
filling	I
was	O
detected	O
in	O
38	O
and	O
35	O
%	O
of	O
patients	O
as	O
compared	O
to	O
19	O
and	O
9	O
%	O
of	O
controls	O
,	O
respectively	O
(	O
p	O
=	O
0.11	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronary	B
artery	I
or	I
myocardial	I
disease	I
is	O
common	O
(	O
38	O
%	O
)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	O
users	O
.	O

Therefore	O
,	O
screening	O
ECG	O
and	O
echocardiography	O
may	O
be	O
warranted	O
in	O
these	O
patients	O
.	O

Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	O
-	O
induced	O
myocardial	O
stress	O
in	O
rats	O
.	O

The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	O
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
with	O
respect	O
to	O
lipid	O
metabolism	O
in	O
serum	O
and	O
heart	O
tissue	O
has	O
been	O
investigated	O
.	O

Oral	O
pre	O
-	O
treatment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
for	O
15	O
days	O
)	O
significantly	O
prevented	O
the	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
and	O
maintained	O
the	O
rats	O
at	O
near	O
normal	O
status	O
.	O

Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	B
tachycardia	I
in	O
acquired	O
long	B
-	I
QT	I
syndrome	I
:	O
direct	O
evidence	O
from	O
intracellular	O
recordings	O
in	O
the	O
intact	O
left	O
ventricular	O
wall	O
.	O

BACKGROUND	O
:	O
This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	B
de	I
pointes	I
(	O
TdP	B
)	O
with	O
QT	B
prolongation	I
induced	O
by	O
dl	O
-	O
sotalol	O
and	O
azimilide	O
.	O

The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	B
was	O
also	O
evaluated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transmembrane	O
action	O
potentials	O
from	O
epicardium	O
,	O
midmyocardium	O
,	O
and	O
endocardium	O
were	O
recorded	O
simultaneously	O
,	O
together	O
with	O
a	O
transmural	O
ECG	O
,	O
in	O
arterially	O
perfused	O
canine	O
and	O
rabbit	O
left	O
ventricular	O
preparations	O
.	O

dl	O
-	O
Sotalol	O
preferentially	O
prolonged	O
action	O
potential	O
duration	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dose	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	B
prolongation	I
and	O
an	O
increase	O
in	O
TDR	O
.	O

Azimilide	O
,	O
however	O
,	O
significantly	O
prolonged	O
APD	O
and	O
QT	O
interval	O
at	O
concentrations	O
from	O
0.1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shortened	O
them	O
at	O
30	O
micromol	O
/	O
L.	O
Unlike	O
dl	O
-	O
sotalol	O
,	O
azimilide	O
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
increased	O
epicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
sotalol	O
and	O
azimilide	O
rarely	O
induced	O
EADs	O
in	O
canine	O
left	O
ventricles	O
,	O
they	O
produced	O
frequent	O
EADs	O
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B
prolongation	I
was	O
seen	O
.	O

An	O
increase	O
in	O
TDR	O
by	O
dl	O
-	O
sotalol	O
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	B
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles	O
.	O

Of	O
note	O
,	O
although	O
azimilide	O
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
increased	O
APD	O
more	O
than	O
dl	O
-	O
sotalol	O
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagate	O
transmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	B
under	O
QT	B
prolongation	I
.	O

A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	O
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine	O
-	O
associated	O
chest	B
pain	I
.	O

STUDY	O
OBJECTIVE	O
:	O
Chest	B
pain	I
in	O
the	O
setting	O
of	O
cocaine	O
use	O
poses	O
a	O
diagnostic	O
dilemma	O
.	O

Dobutamine	O
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	O
ischemia	B
.	O

Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	O
in	O
the	O
setting	O
of	O
cocaine	O
use	O
,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
.	O

METHODS	O
:	O
A	O
prospective	O
case	O
series	O
was	O
conducted	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urban	O
tertiary	O
-	O
care	O
teaching	O
hospital	O
.	O

Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	O
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	B
pain	I
and	O
had	O
a	O
normal	O
ECG	O
and	O
tropinin	O
I	O
level	O
.	O

Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	O
toxicity	B
were	O
excluded	O
from	O
the	O
study	O
.	O

All	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
serial	O
testing	O
after	O
the	O
DSE	O
testing	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
patients	O
were	O
enrolled	O
.	O

Two	O
patients	O
had	O
inadequate	O
resting	O
images	O
,	O
one	O
DSE	O
was	O
terminated	O
because	O
of	O
inferior	O
hypokinesis	B
,	O
another	O
DSE	O
was	O
terminated	O
because	O
of	O
a	O
rate	O
-	O
related	O
atrial	O
conduction	O
deficit	O
,	O
and	O
1	O
patient	O
did	O
not	O
reach	O
the	O
target	O
heart	O
rate	O
.	O

Thus	O
,	O
19	O
patients	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
target	O
heart	O
rates	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	B
(	O
excluding	O
sinus	B
tachycardia	I
)	O
.	O

Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	O
to	O
reach	O
their	O
target	O
heart	O
rates	O
.	O

CONCLUSION	O
:	O
No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	O
was	O
administered	O
to	O
patients	O
with	O
cocaine	O
-	O
related	O
chest	B
pain	I
.	O

Prenatal	O
cocaine	O
exposure	O
and	O
cranial	O
sonographic	O
findings	O
in	O
preterm	B
infants	I
.	O

PURPOSE	O
:	O
Prenatal	O
cocaine	O
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	B
and	O
the	O
formation	O
of	O
cysts	B
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	O
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	B
cysts	I
in	O
preterm	B
infants	I
.	O

METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
and	O
cranial	O
sonograms	O
obtained	O
during	O
a	O
1-year	O
period	O
on	O
122	O
premature	B
(	I
<	I
36	I
weeks	I
of	I
gestation	I
)	I
infants	I
.	O

Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups	O
:	O
those	O
exposed	O
to	O
cocaine	O
and	O
those	O
not	O
exposed	O
to	O
cocaine	O
.	O

Infants	O
were	O
assigned	O
to	O
the	O
cocaine	O
-	O
exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	B
abuse	I
during	O
pregnancy	O
or	O
if	O
maternal	O
or	O
neonatal	O
urine	O
toxicology	O
results	O
were	O
positive	O
at	O
the	O
time	O
of	O
delivery	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
122	O
infants	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
insufficient	O
medical	O
and	O
drug	O
histories	O
.	O

The	O
incidence	O
of	O
subependymal	B
cysts	I
in	O
the	O
117	O
remaining	O
infants	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
incidence	O
of	O
subependymal	B
cysts	I
in	O
infants	O
exposed	O
to	O
cocaine	O
prenatally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
compared	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexposed	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	B
cyst	I
formation	O
in	O
preterm	B
infants	I
who	O
were	O
exposed	O
to	O
cocaine	O
prenatally	O
.	O

This	O
result	O
is	O
consistent	O
with	O
results	O
of	O
similar	O
studies	O
in	O
term	O
infants	O
.	O

Thalidomide	O
neuropathy	B
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	B
cancer	I
.	O

We	O
prospectively	O
evaluated	O
thalidomide	O
-	O
induced	O
neuropathy	B
using	O
electrodiagnostic	O
studies	O
.	O

Sixty	O
-	O
seven	O
men	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
in	O
an	O
open	O
-	O
label	O
trial	O
of	O
oral	O
thalidomide	O
underwent	O
neurologic	O
examinations	O
and	O
nerve	O
conduction	O
studies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3-month	O
intervals	O
during	O
treatment	O
.	O

NCS	O
included	O
recording	O
of	O
sensory	O
nerve	O
action	O
potentials	O
(	O
SNAPs	O
)	O
from	O
median	O
,	O
radial	O
,	O
ulnar	O
,	O
and	O
sural	O
nerves	O
.	O

SNAP	O
amplitudes	O
for	O
each	O
nerve	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
its	O
baseline	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index	O
.	O

A	O
40	O
%	O
decline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinically	O
significant	O
.	O

Thalidomide	O
was	O
discontinued	O
in	O
55	O
patients	O
for	O
lack	O
of	O
therapeutic	O
response	O
.	O

Of	O
67	O
patients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidomide	O
for	O
3	O
months	O
,	O
8	O
remained	O
at	O
6	O
months	O
,	O
and	O
3	O
remained	O
at	O
9	O
months	O
.	O

Six	O
patients	O
developed	O
neuropathy	B
.	O

Clinical	O
symptoms	O
and	O
a	O
decline	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently	O
.	O

Older	O
age	O
and	O
cumulative	O
dose	O
were	O
possible	O
contributing	O
factors	O
.	O

Neuropathy	B
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	O
in	O
older	O
patients	O
.	O

The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	B
neuropathy	I
,	O
but	O
not	O
for	O
early	O
detection	O
.	O

Overexpression	O
of	O
copper	O
/	O
zinc	O
-	O
superoxide	O
dismutase	O
protects	O
from	O
kanamycin	O
-	O
induced	O
hearing	B
loss	I
.	O

The	O
participation	O
of	O
reactive	O
oxygen	O
species	O
in	O
aminoglycoside	O
-	O
induced	O
ototoxicity	B
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside	O
-	O
iron	O
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	O
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	O
attenuate	O
ototoxicity	B
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu	O
/	O
Zn	O
-	O
superoxide	O
dismutase	O
(	O
h	O
-	O
SOD1	O
)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	B
.	O

Immunocytochemistry	O
confirmed	O
expression	O
of	O
h	O
-	O
SOD1	O
in	O
inner	O
ear	O
tissues	O
of	O
transgenic	O
C57BL	O
/	O
6-TgN	O
[	O
SOD1	O
]	O
3Cje	O
mice	O
.	O

Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	O
(	O
400	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
for	O
10	O
days	O
beginning	O
on	O
day	O
10	O
after	O
birth	O
.	O

Auditory	O
thresholds	O
were	O
tested	O
by	O
evoked	O
auditory	O
brain	O
stem	O
responses	O
at	O
1	O
month	O
after	O
birth	O
.	O

In	O
nontransgenic	O
animals	O
,	O
the	O
threshold	O
in	O
the	O
kanamycin	O
-	O
treated	O
group	O
was	O
45	O
-	O
50	O
dB	O
higher	O
than	O
in	O
saline	O
-	O
injected	O
controls	O
.	O

In	O
the	O
transgenic	O
group	O
,	O
kanamycin	O
increased	O
the	O
threshold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
controls	O
.	O

The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
protection	O
by	O
overexpression	O
of	O
superoxide	O
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	O
-	O
induced	O
ototoxicity	B
.	O

The	O
results	O
also	O
suggest	O
transgenic	O
animals	O
as	O
suitable	O
models	O
to	O
investigate	O
the	O
underlying	O
mechanisms	O
and	O
possible	O
strategies	O
for	O
prevention	O
.	O

Fatty	B
liver	I
induced	O
by	O
tetracycline	O
in	O
the	O
rat	O
.	O

Dose	O
-	O
response	O
relationships	O
and	O
effect	O
of	O
sex	O
.	O

Dose	O
-	O
response	O
relationships	O
,	O
biochemical	O
mechanisms	O
,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	B
liver	I
induced	O
by	O
tetracycline	O
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	O
in	O
vitro	O
.	O

In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	O
and	O
hepatic	O
accumulation	O
of	O
triglyceride	O
.	O

With	O
provision	O
of	O
adequate	O
oleic	O
acid	O
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver	O
,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	O
and	O
both	O
accumulation	O
of	O
triglyceride	O
in	O
the	O
liver	O
and	O
depression	B
of	O
output	O
of	O
triglyceride	O
by	O
livers	O
from	O
male	O
and	O
female	O
rats	O
.	O

Marked	O
differences	O
were	O
observed	O
between	O
female	O
and	O
male	O
rats	O
with	O
regard	O
to	O
base	O
line	O
(	O
control	O
)	O
hepatic	O
concentration	O
of	O
triglyceride	O
and	O
output	O
of	O
triglyceride	O
.	O

Accumulation	O
of	O
hepatic	O
triglyceride	O
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values	O
,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	O
,	O
did	O
not	O
differ	O
significantly	O
between	O
male	O
,	O
female	O
and	O
pregnant	O
rat	O
livers	O
.	O

However	O
,	O
livers	O
from	O
female	O
,	O
and	O
especially	O
pregnant	O
female	O
rats	O
,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	O
on	O
depression	B
of	O
output	O
of	O
triglyceride	O
under	O
these	O
experimental	O
conditions	O
.	O

These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	O
or	O
altered	O
uptake	O
of	O
oleic	O
acid	O
.	O

Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	O
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepatic	O
triglyceride	O
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	O
-	O
rich	O
fatty	B
liver	I
in	O
response	O
to	O
tetracycline	O
.	O

Prednisone	O
induces	O
anxiety	B
and	O
glial	O
cerebral	O
changes	O
in	O
rats	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisone	O
(	O
PDN	O
)	O
produces	O
anxiety	B
and/or	O
cerebral	O
glial	O
changes	O
in	O
rats	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
were	O
studied	O
and	O
3	O
groups	O
were	O
formed	O
(	O
8	O
rats	O
per	O
group	O
)	O
.	O

The	O
moderate	O
-	O
dose	O
group	O
received	O
5	O
mg	O
/	O
kg	O
/	O
day	O
PDN	O
released	O
from	O
a	O
subcutaneous	O
implant	O
.	O

In	O
the	O
high	O
-	O
dose	O
group	O
,	O
implants	O
containing	O
PDN	O
equivalent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
day	O
were	O
applied	O
.	O

In	O
the	O
control	O
group	O
implants	O
contained	O
no	O
PDN	O
.	O

Anxiety	B
was	O
assessed	O
using	O
an	O
open	O
field	O
and	O
elevated	O
plus	O
-	O
maze	O
devices	O
.	O

The	O
number	O
of	O
cells	O
and	O
cytoplasmic	O
transformation	O
of	O
astrocytes	O
and	O
microglia	O
cells	O
were	O
assessed	O
by	O
immunohistochemical	O
analyses	O
.	O

RESULTS	O
:	O
Anxiety	B
was	O
documented	O
in	O
both	O
groups	O
of	O
PDN	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O

The	O
magnitude	O
of	O
transformation	O
of	O
the	O
microglia	O
assessed	O
by	O
the	O
number	O
of	O
intersections	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	O
groups	O
than	O
in	O
controls	O
in	O
the	O
prefrontal	O
cortex	O
(	O
moderate	O
-	O
dose	O
,	O
24.1	O
;	O
high	O
-	O
dose	O
,	O
23.6	O
;	O
controls	O
18.7	O
;	O
p	O
<	O
0.01	O
)	O
and	O
striatum	O
(	O
moderate	O
-	O
dose	O
25.6	O
;	O
high	O
-	O
dose	O
26.3	O
;	O
controls	O
18.9	O
;	O
p	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
hippocampus	O
.	O

The	O
number	O
of	O
stained	O
microglia	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	O
treated	O
groups	O
in	O
the	O
prefrontal	O
cortex	O
than	O
in	O
controls	O
(	O
moderate	O
-	O
dose	O
,	O
29.1	O
;	O
high	O
-	O
dose	O
,	O
28.4	O
;	O
control	O
,	O
17.7	O
cells	O
per	O
field	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Stained	O
microglia	O
cells	O
were	O
significantly	O
more	O
numerous	O
striatum	O
and	O
hippocampus	O
in	O
the	O
high	O
-	O
dose	O
group	O
compared	O
to	O
controls	O
.	O

CONCLUSION	O
:	O
Subacute	O
exposure	O
to	O
PDN	O
induced	O
anxiety	B
and	O
reactivity	O
of	O
microglia	O
.	O

The	O
relevance	O
of	O
these	O
features	O
for	O
patients	O
using	O
PDN	O
remains	O
to	O
be	O
elucidated	O
.	O

Phase	O
II	O
study	O
of	O
carboplatin	O
and	O
liposomal	O
doxorubicin	O
in	O
patients	O
with	O
recurrent	O
squamous	B
cell	I
carcinoma	I
of	B
the	I
cervix	I
.	O

BACKGROUND	O
:	O
The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	O
and	O
liposomal	O
doxorubicin	O
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	B
carcinoma	I
.	O

METHODS	O
:	O
The	O
combination	O
of	O
carboplatin	O
(	O
area	O
under	O
the	O
concentration	O
curve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
liposomal	O
doxorubicin	O
(	O
Doxil	O
;	O
starting	O
dose	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	B
cell	I
cervical	I
carcinoma	I
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	B
profile	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
nine	O
patients	O
were	O
assessable	O
for	O
response	O
,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	B
.	O

The	O
overall	O
response	O
rate	O
was	O
38	O
%	O
,	O
the	O
median	O
time	O
to	O
response	O
was	O
10	O
weeks	O
,	O
the	O
median	O
duration	O
of	O
response	O
was	O
26	O
weeks	O
,	O
and	O
the	O
median	O
survival	O
was	O
37	O
weeks	O
.	O

The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	B
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	B
in	O
16	O
patients	O
,	O
anemia	B
in	O
12	O
patients	O
,	O
thrombocytopenia	B
in	O
11	O
patients	O
,	O
and	O
neutropenic	B
fever	B
in	O
3	O
patients	O
.	O

Four	O
patients	O
had	O
five	O
infusion	O
-	O
related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	O
doxorubicin	O
,	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
three	O
patients	O
.	O

Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	B
included	O
nausea	B
in	O
17	O
patients	O
,	O
emesis	B
in	O
14	O
patients	O
,	O
fatigue	B
in	O
9	O
patients	O
,	O
mucositis	B
and/or	O
stomatitis	B
in	O
8	O
patients	O
,	O
constipation	B
in	O
6	O
patients	O
,	O
weight	B
loss	I
in	O
5	O
patients	O
,	O
hand	B
-	I
foot	I
syndrome	I
in	O
2	O
patients	O
,	O
and	O
skin	B
reactions	I
in	O
3	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
carboplatin	O
and	O
liposomal	O
doxorubicin	O
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	B
carcinoma	I
.	O

Antimicrobial	O
-	O
induced	O
mania	B
(	O
antibiomania	B
)	O
:	O
a	O
review	O
of	O
spontaneous	O
reports	O
.	O

The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic	O
-	O
induced	O
manic	B
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic	O
-	O
induced	O
mania	B
.	O

Unpublished	O
reports	O
were	O
requested	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
.	O

Twenty	O
-	O
one	O
reports	O
of	O
antimicrobial	O
-	O
induced	O
mania	B
were	O
found	O
in	O
the	O
literature	O
.	O

There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	O
,	O
13	O
implicating	O
isoniazid	O
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	O
and	O
amoxicillin	O
.	O

The	O
WHO	O
reported	O
82	O
cases	O
.	O

Of	O
these	O
,	O
clarithromycin	O
was	O
implicated	O
in	O
23	O
(	O
27.6	O
%	O
)	O
cases	O
,	O
ciprofloxacin	O
in	O
12	O
(	O
14.4	O
%	O
)	O
cases	O
,	O
and	O
ofloxacin	O
in	O
10	O
(	O
12	O
%	O
)	O
cases	O
.	O

Cotrimoxazole	O
,	O
metronidazole	O
,	O
and	O
erythromycin	O
were	O
involved	O
in	O
15	O
reported	O
manic	B
episodes	O
.	O

Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	O
and	O
ciprofloxacin	O
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	B
.	O

Statistical	O
analysis	O
of	O
the	O
data	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statistical	O
correlative	O
risk	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	B
while	O
being	O
treated	O
with	O
antimicrobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
statistically	O
significant	O
risk	O
,	O
physicians	O
must	O
be	O
aware	O
of	O
the	O
effect	O
and	O
reversibility	O
.	O

Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial	O
-	O
induced	O
mania	B
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial	O
-	O
induced	O
manic	B
episode	O
among	O
various	O
demographic	O
populations	O
,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	O
disorders	O
once	O
the	O
initial	O
episode	O
,	O
which	O
occurs	O
while	O
the	O
patient	O
is	O
taking	O
antibiotics	O
,	O
subsides	O
.	O

The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	O
""""	O
antibiomania	B
.	O
""""	O

Levodopa	O
-	O
induced	O
ocular	B
dyskinesias	I
in	O
Parkinson	B
's	I
disease	I
.	O

Levodopa	O
-	O
induced	O
ocular	B
dyskinesias	I
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak	O
-	O
dose	O
choreatic	B
dyskinesias	I
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	O
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa	O
-	O
induce	O
ocular	B
dyskinesias	I
.	O

A	O
comparison	O
of	O
glyceryl	O
trinitrate	O
with	O
diclofenac	O
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B
:	O
an	O
open	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
.	O

Primary	O
dysmenorrhea	B
is	O
a	O
syndrome	O
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	O
;	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatment	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	O
trinitrate	O
(	O
GTN	O
)	O
,	O
an	O
NO	O
donor	O
,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	B
in	O
comparison	O
with	O
diclofenac	O
(	O
DCF	O
)	O
.	O

A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	B
were	O
studied	O
during	O
two	O
consecutive	O
menstrual	O
cycles	O
.	O

In	O
an	O
open	O
,	O
cross	O
-	O
over	O
,	O
controlled	O
design	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	O
per	O
os	O
or	O
GTN	O
patches	O
the	O
first	O
days	O
of	O
menses	O
,	O
when	O
menstrual	O
cramps	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
cycle	O
the	O
other	O
treatment	O
was	O
used	O
.	O

Patients	O
received	O
up	O
to	O
3	O
doses	O
/	O
day	O
of	O
50	O
mg	O
DCF	O
or	O
2.5	O
mg	O
/	O
24	O
h	O
transdermal	O
GTN	O
for	O
the	O
first	O
3	O
days	O
of	O
the	O
cycle	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
participants	O
recorded	O
menstrual	O
symptoms	O
and	O
possible	O
side	O
-	O
effects	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
minutes	O
)	O
after	O
the	O
first	O
dose	O
of	O
medication	O
on	O
the	O
first	O
day	O
of	O
the	O
cycle	O
,	O
with	O
both	O
drugs	O
.	O

The	O
difference	O
in	O
pain	B
intensity	O
score	O
(	O
DPI	O
)	O
was	O
the	O
main	O
outcome	O
variable	O
.	O

Both	O
treatments	O
significantly	O
reduced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	O
,	O
-12.8	O
+	O
/-	O

17.9	O
;	O
DCF	O
,	O
-18.9	O
+	O
/-	O

16.6	O
)	O
.	O

However	O
,	O
DCF	O
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	B
pain	I
for	O
two	O
hours	O
,	O
whereas	O
GTN	O
scores	O
remained	O
more	O
or	O
less	O
stable	O
after	O
30	O
min	O
and	O
significantly	O
higher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	O
,	O
-12.8	O
+	O
/-	O

17.9	O
;	O
DFC	O
,	O
-18.9	O
+	O
/-	O

16.6	O
and	O
after	O
two	O
hours	O
:	O
GTN	O
,	O
-23.7	O
+	O
/-	O

20.5	O
;	O
DFC	O
,	O
-59.7	O
+	O
/-	O

17.9	O
,	O
p	O
=	O
0.0001	O
)	O
.	O

Low	B
back	I
pain	I
was	O
also	O
relieved	O
by	O
both	O
drugs	O
.	O

Headache	B
was	O
significantly	O
increased	O
by	O
GTN	O
but	O
not	O
by	O
DCF	O
.	O

Eight	O
patients	O
stopped	O
using	O
GTN	O
because	O
headache	B
--	O
attributed	O
to	O
its	O
use	O
--	O
became	O
intolerable	O
.	O

These	O
findings	O
indicate	O
that	O
GTN	O
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	O
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B
.	O

Temocapril	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
modulates	O
glomerular	B
injury	I
in	O
chronic	O
puromycin	O
aminonucleoside	O
nephrosis	B
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
reduced	O
proteinuria	B
,	O
inhibited	O
glomerular	O
hypertrophy	B
and	O
prevented	O
glomerulosclerosis	B
in	O
chronic	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
-	O
induced	O
nephrotic	B
rats	O
.	O

Nephrosis	B
was	O
induced	O
by	O
injection	O
of	O
PAN	O
(	O
15mg	O
/	O
100	O
g	O
body	O
weight	O
)	O
in	O
male	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

Four	O
groups	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	O
group	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	O
/	O
temocapril	O
(	O
13	O
)	O
,	O
iii	O
)	O
temocapril	O
(	O
14	O
)	O
and	O
iv	O
)	O
untreated	O
controls	O
(	O
15	O
)	O
.	O

Temocapril	O
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
time	O
point	O
,	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
urinary	O
protein	O
excretion	O
and	O
renal	O
histopathological	O
findings	O
were	O
evaluated	O
,	O
and	O
morphometric	O
image	O
analysis	O
was	O
done	O
.	O

Systolic	O
BP	O
in	O
the	O
PAN	O
group	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN	O
/	O
temocapril	O
group	O
.	O

Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	O
group	O
increased	O
significantly	O
,	O
peaking	O
at	O
8	O
days	O
,	O
then	O
decreased	O
at	O
4	O
weeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weeks	O
.	O

Temocapril	O
did	O
not	O
attenuate	O
proteinuria	B
at	O
8	O
days	O
,	O
but	O
it	O
did	O
markedly	O
lower	O
it	O
from	O
weeks	O
4	O
to	O
20	O
.	O

The	O
glomerulosclerosis	B
index	O
(	O
GSI	O
)	O
was	O
6.21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25.35	O
%	O
and	O
30.49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	O
group	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
urinary	O
protein	O
excretion	O
and	O
GSI	O
(	O
r	O
=	O
0.808	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
's	O
capsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	O
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	O
/	O
temocapril	O
group	O
.	O

It	O
appears	O
that	O
temocapril	O
was	O
effective	O
in	O
retarding	O
renal	O
progression	O
and	O
protected	O
renal	O
function	O
in	O
PAN	O
neprotic	B
rats	O
.	O

Pulmonary	B
hypertension	I
after	O
ibuprofen	O
prophylaxis	O
in	O
very	O
preterm	O
infants	O
.	O

We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	B
after	O
ibuprofen	O
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	B
ductus	I
arteriosus	I
with	O
ibuprofen	O
in	O
premature	O
infants	O
born	O
at	O
less	O
than	O
28	O
weeks	O
of	O
gestation	O
.	O

Echocardiography	O
showed	O
severely	O
decreased	O
pulmonary	O
blood	O
flow	O
.	O

Hypoxaemia	B
resolved	O
quickly	O
on	O
inhaled	O
nitric	O
oxide	O
therapy	O
.	O

We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	B
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	O
.	O

Hyponatremia	B
and	O
syndrome	B
of	I
inappropriate	I
anti	I
-	I
diuretic	I
hormone	I
reported	O
with	O
the	O
use	O
of	O
Vincristine	O
:	O
an	O
over	O
-	O
representation	O
of	O
Asians	O
?	O

PURPOSE	O
:	O
This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company	O
's	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	B
and/or	O
syndrome	B
of	I
inappropriate	I
secretion	I
of	I
anti	I
-	I
diuretic	I
hormone	I
(	O
SIADH	B
)	O
among	O
vincristine	O
-	O
treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
risk	O
population	O
subgroups	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
's	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	B
and/or	O
SIADH	B
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	B
and/or	O
SIADH	B
associated	O
with	O
vincristine	O
use	O
were	O
identified	O
.	O

The	O
overall	O
reporting	O
rate	O
was	O
estimated	O
to	O
be	O
1.3	O
/	O
100,000	O
treated	O
patients	O
.	O

The	O
average	O
age	O
of	O
patients	O
was	O
35.6	O
+	O
/-	O

28.3	O
years	O
,	O
and	O
62	O
%	O
were	O
males	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	B
or	O
lymphoma	B
.	O

Among	O
the	O
39	O
reports	O
that	O
included	O
information	O
on	O
race	O
,	O
the	O
racial	O
distribution	O
was	O
:	O
1	O
Black	O
,	O
3	O
Caucasian	O
,	O
and	O
35	O
Asian	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
hyponatremia	B
and/or	O
SIADH	B
associated	O
with	O
vincristine	O
use	O
.	O

Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	B
associated	O
with	O
vincristine	O
is	O
very	O
low	O
,	O
physicians	O
caring	O
for	O
Asian	O
oncology	O
patients	O
should	O
be	O
aware	O
of	O
this	O
potential	O
serious	O
but	O
reversible	O
adverse	O
event	O
.	O

Delayed	O
toxicity	B
of	O
cyclophosphamide	O
on	O
the	O
bladder	O
of	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
female	O
mouse	O
.	O

The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dose	O
of	O
cyclophosphamide	O
(	O
CY	O
)	O
.	O

Inbred	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
female	O
mice	O
were	O
injected	O
with	O
CY	O
,	O
and	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
bladder	O
was	O
assessed	O
during	O
100	O
days	O
by	O
light	O
microscopy	O
using	O
different	O
staining	O
procedures	O
,	O
and	O
after	O
30	O
days	O
by	O
conventional	O
electron	O
microscopy	O
.	O

Early	O
CY	O
toxicity	B
caused	O
a	O
typical	O
haemorrhagic	B
cystitis	B
in	O
both	O
strains	O
that	O
was	O
completely	O
repaired	O
in	O
about	O
7	O
-	O
10	O
days	O
.	O

After	O
30	O
days	O
of	O
CY	O
injection	O
ulcerous	O
and	O
non	O
-	O
ulcerous	O
forms	O
of	O
chronic	O
cystitis	B
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
mice	O
but	O
only	O
in	O
4	O
%	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

Delayed	O
cystitis	B
was	O
characterized	O
by	O
infiltration	O
and	O
transepithelial	O
passage	O
into	O
the	O
lumen	O
of	O
inflammatory	O
cells	O
and	O
by	O
frequent	O
exfoliation	O
of	O
the	O
urothelium	O
.	O

Mast	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
muscular	O
layers	O
of	O
the	O
bladder	O
at	O
a	O
much	O
higher	O
number	O
in	O
DBA	O
/	O
2	O
mice	O
than	O
in	O
C57BL	O
/	O
6	O
mice	O
or	O
untreated	O
controls	O
.	O

Electron	O
microscopy	O
disclosed	O
the	O
absence	O
of	O
the	O
typical	O
discoidal	O
vesicles	O
normally	O
present	O
in	O
the	O
cytoplasm	O
of	O
surface	O
cells	O
.	O

Instead	O
,	O
numerous	O
abnormal	O
vesicles	O
containing	O
one	O
or	O
several	O
dark	O
granules	O
were	O
observed	O
in	O
the	O
cytoplasm	O
of	O
cells	O
from	O
all	O
the	O
epithelial	O
layers	O
.	O

Delayed	O
cystitis	B
still	O
persisted	O
in	O
DBA	O
/	O
2	O
mice	O
100	O
days	O
after	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
delayed	O
toxicity	B
of	O
CY	O
in	O
female	O
DBA	O
/	O
2	O
mice	O
causes	O
a	O
bladder	O
pathology	O
that	O
is	O
not	O
observed	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

This	O
pathology	O
resembles	O
interstitial	B
cystitis	I
in	O
humans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animal	O
model	O
for	O
studies	O
on	O
the	O
disease	O
.	O

High	O
-	O
dose	O
5-fluorouracil	O
/	O
folinic	O
acid	O
in	O
combination	O
with	O
three	O
-	O
weekly	O
mitomycin	O
C	O
in	O
the	O
treatment	O
of	O
advanced	O
gastric	B
cancer	I
.	O

A	O
phase	O
II	O
study	O
.	O

BACKGROUND	O
:	O
The	O
24-hour	O
continuous	O
infusion	O
of	O
5-fluorouracil	O
(	O
5-FU	O
)	O
and	O
folinic	O
acid	O
(	O
FA	O
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	B
cancer	I
(	O
AGC	B
)	O
has	O
shown	O
to	O
be	O
effective	O
,	O
with	O
low	O
toxicity	B
.	O

In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3-weekly	O
bolus	O
5-FU	O
,	O
FA	O
and	O
mitomycin	O
C	O
(	O
MMC	O
)	O
we	O
found	O
a	O
low	O
toxicity	B
rate	O
and	O
response	O
rates	O
comparable	O
to	O
those	O
of	O
regimens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
median	O
overall	O
survival	O
.	O

In	O
order	O
to	O
improve	O
this	O
MMC	O
-	O
dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high	O
-	O
dose	O
5-FU	O
/	O
FA	O
and	O
3-weekly	O
bolus	O
MMC	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
February	O
,	O
1998	O
to	O
September	O
,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	B
to	O
receive	O
weekly	O
24-hour	O
5-FU	O
2,600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2-hour	O
FA	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
.	O

Bolus	O
MMC	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3-weekly	O
intervals	O
.	O

Treatment	O
given	O
on	O
an	O
outpatient	O
basis	O
,	O
using	O
portable	O
pump	O
systems	O
,	O
was	O
repeated	O
on	O
day	O
57	O
.	O

Patients	O
'	O
characteristics	O
were	O
:	O
male	O
/	O
female	O
ratio	O
20	O
/	O
13	O
;	O
median	O
age	O
57	O
(	O
27	O
-	O
75	O
)	O
years	O
;	O
median	O
WHO	O
status	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
patients	O
had	O
a	O
primary	O
AGC	B
,	O
and	O
15	O
showed	O
a	O
relapsed	O
AGC	B
.	O

Median	O
follow	O
-	O
up	O
was	O
11.8	O
months	O
(	O
range	O
of	O
those	O
surviving	O
:	O
2.7	O
-	O
11.8	O
months	O
)	O
.	O

RESULTS	O
:	O
32	O
patients	O
were	O
evaluable	O
for	O
response	O
-	O
complete	O
remission	O
9.1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
partial	O
remission	O
45.5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27.3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progressive	O
disease	O
15.1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Median	O
overall	O
survival	O
time	O
was	O
10.2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
8.7	O
-	O
11.6	O
]	O
,	O
and	O
median	O
progression	O
-	O
free	O
survival	O
time	O
was	O
7.6	O
months	O
(	O
95	O
%	O
CI	O
:	O
4.4	O
-	O
10.9	O
)	O
.	O

The	O
worst	O
toxicities	B
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukopenia	B
45.5	O
/	O
18.2	O
/	O
6.1	O
,	O
thrombocytopenia	B
33.3	O
/	O
9.1	O
/	O
6.1	O
,	O
vomitus	B
24.2	O
/	O
9.1	O
/	O
0	O
,	O
diarrhea	B
36.4	O
/	O
6.1	O
/	O
3.0	O
,	O
stomatitis	B
18.2	O
/	O
9.1	O
/	O
0	O
,	O
hand	B
-	I
foot	I
syndrome	I
12.1	O
/	O
0	O
/	O
0	O
.	O

Two	O
patients	O
developed	O
hemolytic	B
-	I
uremic	I
syndrome	I
(	O
HUS	B
)	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
dose	O
5-FU	O
/	O
FA	O
/	O
MMC	O
is	O
an	O
effective	O
and	O
well	O
-	O
tolerated	O
outpatient	O
regimen	O
for	O
AGC	B
(	O
objective	O
response	O
rate	O
54.6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	O
-	O
containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B
may	O
occur	O
.	O

Persistent	O
sterile	O
leukocyturia	B
is	O
associated	O
with	O
impaired	B
renal	I
function	I
in	O
human	B
immunodeficiency	I
virus	I
type	I
1-infected	I
children	O
treated	O
with	O
indinavir	O
.	O

BACKGROUND	O
:	O
Prolonged	O
administration	O
of	O
indinavir	O
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	O
complications	O
in	O
adults	O
.	O

These	O
well	O
-	O
documented	O
side	O
effects	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
protease	O
inhibitor	O
in	O
children	O
.	O

DESIGN	O
:	O
A	O
prospective	O
study	O
to	O
monitor	O
indinavir	O
-	O
related	O
nephrotoxicity	B
in	O
a	O
cohort	O
of	O
30	O
human	B
immunodeficiency	I
virus	I
type	I
1-infected	I
children	O
treated	O
with	O
indinavir	O
.	O

METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	O
,	O
the	O
presence	O
of	O
erythrocytes	O
,	O
leukocytes	O
,	O
bacteria	O
and	O
crystals	O
,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks	O
.	O

Serum	O
creatinine	O
levels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
time	O
points	O
.	O

Steady	O
-	O
state	O
pharmacokinetics	O
of	O
indinavir	O
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	O
.	O

RESULTS	O
:	O
The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B
(	O
>	O
or	O
=	O
75	O
cells	O
/	O
micro	O
L	O
in	O
at	O
least	O
2	O
consecutive	O
visits	O
)	O
after	O
96	O
weeks	O
was	O
53	O
%	O
.	O

Persistent	O
sterile	O
leukocyturia	B
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	O
albumin	O
/	O
creatinine	O
ratio	O
and	O
by	O
microscopic	O
hematuria	B
.	O

The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	O
levels	O
>	O
50	O
%	O
above	O
normal	O
was	O
33	O
%	O
after	O
96	O
weeks	O
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	B
more	O
frequently	O
had	O
serum	O
creatinine	O
levels	O
of	O
50	O
%	O
above	O
normal	O
than	O
those	O
children	O
without	O
persistent	O
sterile	O
leukocyturia	B
.	O

In	O
children	O
younger	O
than	O
5.6	O
years	O
,	O
persistent	O
sterile	O
leukocyturia	B
was	O
significantly	O
more	O
frequent	O
than	O
in	O
older	O
children	O
.	O

A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	B
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	O
>	O
12	O
mg	O
/	O
L.	O
In	O
4	O
children	O
,	O
indinavir	O
was	O
discontinued	O
because	O
of	O
nephrotoxicity	B
.	O

Subsequently	O
,	O
the	O
serum	O
creatinine	O
levels	O
decreased	O
,	O
the	O
urine	O
albumin	O
/	O
creatinine	O
ratios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyturia	B
disappeared	O
within	O
3	O
months	O
.	O

CONCLUSIONS	O
:	O
Children	O
treated	O
with	O
indinavir	O
have	O
a	O
high	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	B
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	O
levels	O
of	O
>	O
50	O
%	O
above	O
normal	O
.	O

Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	O
complications	O
.	O

The	O
impairment	B
of	I
the	I
renal	I
function	I
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	B
.	O

Indinavir	O
-	O
associated	O
nephrotoxicity	B
must	O
be	O
monitored	O
closely	O
,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	B
,	O
age	O
<	O
5.6	O
years	O
,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L.	O

Utility	O
of	O
troponin	O
I	O
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
.	O

Baseline	O
electrocardiogram	O
abnormalities	O
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	B
necrosis	I
make	O
accurate	O
diagnosis	O
of	O
myocardial	B
infarction	I
(	O
MI	B
)	O
difficult	O
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
.	O

Troponin	O
sampling	O
may	O
offer	O
greater	O
diagnostic	O
utility	O
in	O
these	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	O
chest	B
pain	I
admitted	O
for	O
exclusion	O
of	O
MI	B
.	O

METHODS	O
:	O
Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	B
after	O
cocaine	O
use	O
.	O

All	O
patients	O
underwent	O
a	O
rapid	O
rule	O
-	O
in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	O
kinase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O

Outcomes	O
included	O
CK	O
-	O
MB	O
MI	B
(	O
CK	O
-	O
MB	O
>	O
or=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or=	O
4	O
,	O
cardiac	B
death	I
,	O
and	O
significant	O
coronary	B
disease	I
(	O
>	O
or=50	O
%	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
246	O
admitted	O
patients	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B
and	O
38	O
(	O
16	O
%	O
)	O
had	O
cTnI	O
elevations	O
.	O

Angiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patients	O
who	O
were	O
cTnI	O
-	O
positive	O
,	O
with	O
significant	O
disease	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	O
who	O
had	O
cTnI	O
elevations	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
level	O
of	O
13	O
ng	O
/	O
mL.	O
Sensitivities	O
,	O
specificities	O
,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	B
death	I
or	O
significant	O
disease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	B
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease	O
.	O

Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK	O
-	O
MB	O
for	O
diagnosing	O
necrosis	B
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
and	O
suspected	O
MI	B
.	O

Acute	O
interstitial	B
nephritis	I
due	O
to	O
nicergoline	O
(	O
Sermion	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	B
nephritis	I
(	O
AIN	B
)	O
due	O
to	O
nicergoline	O
(	O
Sermion	O
)	O
.	O

A	O
50-year	O
-	O
old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	B
and	O
acute	B
renal	I
failure	I
.	O

Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	O
and	O
bendazac	O
lysine	O
due	O
to	O
retinal	B
vein	I
occlusion	I
at	O
ophthalmologic	O
department	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fever	B
and	O
skin	B
rash	I
.	O

On	O
admission	O
,	O
clinical	O
symptoms	O
(	O
i.e.	O
arthralgia	B
and	O
fever	B
)	O
and	O
laboratory	O
findings	O
(	O
i.e.	O
eosinophilia	B
and	O
renal	B
failure	I
)	O
suggested	O
AIN	B
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy	O
.	O

A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	O
.	O

Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	O
and	O
intravenous	O
methylprednisolone	O
,	O
and	O
his	O
renal	O
function	O
was	O
completely	O
recovered	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline	O
-	O
associated	O
AIN	B
.	O

Neuroleptic	B
malignant	I
syndrome	I
complicated	O
by	O
massive	O
intestinal	O
bleeding	B
in	O
a	O
patient	O
with	O
chronic	B
renal	I
failure	I
.	O

A	O
patient	O
with	O
chronic	B
renal	I
failure	I
(	O
CRF	B
)	O
developed	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
after	O
administration	O
of	O
risperidone	O
and	O
levomepromazine	O
.	O

In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	B
,	O
massive	O
intestinal	O
bleeding	B
was	O
observed	O
during	O
the	O
episode	O
.	O

This	O
report	O
suggests	O
that	O
NMS	B
in	O
a	O
patient	O
with	O
CRF	B
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	B
and	O
needs	O
special	O
caution	O
for	O
this	O
complication	O
.	O

Blood	O
brain	O
barrier	O
in	O
right-	O
and	O
left	O
-	O
pawed	O
female	O
rats	O
assessed	O
by	O
a	O
new	O
staining	O
method	O
.	O

The	O
asymmetrical	O
breakdown	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
female	O
rats	O
.	O

Paw	O
preference	O
was	O
assessed	O
by	O
a	O
food	O
reaching	O
test	O
.	O

Adrenaline	O
-	O
induced	O
hypertension	B
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	O
(	O
TTC	O
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	O
for	O
30	O
s.	O
In	O
normal	O
rats	O
,	O
the	O
whole	O
brain	O
sections	O
exhibited	O
complete	O
staining	O
with	O
TTC	O
.	O

After	O
adrenaline	O
infusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstained	O
areas	O
in	O
the	O
left	O
brain	O
in	O
right	O
-	O
pawed	O
animals	O
,	O
and	O
vice	O
versa	O
in	O
left	O
-	O
pawed	O
animals	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
seizure	B
-	O
induced	O
breakdown	O
of	O
BBB	O
.	O

These	O
results	O
were	O
explained	O
by	O
an	O
asymmetric	O
cerebral	O
blood	O
flow	O
depending	O
upon	O
the	O
paw	O
preference	O
in	O
rats	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
method	O
and	O
the	O
results	O
are	O
consistent	O
with	O
contralateral	O
motor	O
control	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
dominant	O
cerebral	O
hemisphere	O
in	O
animals	O
.	O

Carvedilol	O
protects	O
against	O
doxorubicin	O
-	O
induced	O
mitochondrial	O
cardiomyopathy	B
.	O

Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose	O
-	O
limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	B
caused	O
by	O
doxorubicin	O
.	O

Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	B
dysfunction	I
are	O
key	O
factors	O
in	O
the	O
pathogenic	O
process	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	O
,	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties	O
,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	O
toxicity	B
.	O

Heart	O
and	O
liver	O
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	O
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
)	O
,	O
carvedilol	O
(	O
1	O
mg	O
/	O
kg	O
ip	O
/	O
week	O
)	O
,	O
or	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
.	O

Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin	O
-	O
treated	O
rats	O
exhibited	O
depressed	O
rates	O
for	O
state	O
3	O
respiration	O
(	O
336	O
+	O
/-	O

26	O
versus	O
425	O
+	O
/-	O

53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
protein	O
)	O
and	O
a	O
lower	O
respiratory	O
control	O
ratio	O
(	O
RCR	O
)	O
(	O
4.3	O
+	O
/-	O

0.6	O
versus	O
5.8	O
+	O
/-	O

0.4	O
)	O
compared	O
with	O
cardiac	O
mitochondria	O
isolated	O
from	O
saline	O
-	O
treated	O
rats	O
.	O

Mitochondrial	O
calcium	O
-	O
loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH	O
-	O
dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin	O
-	O
treated	O
rats	O
.	O

Doxorubicin	O
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	O
mitochondria	O
(	O
3.9	O
+	O
/-	O

0.9	O
versus	O
5.6	O
+	O
/-	O

0.7	O
for	O
control	O
rats	O
)	O
and	O
inhibition	O
of	O
hepatic	O
cytochrome	O
oxidase	O
activity	O
.	O

Coadministration	O
of	O
carvedilol	O
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	O
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Carvedilol	O
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca	O
(	O
2	O
+	O
)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	O
.	O

Carvedilol	O
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	O
mitochondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	O
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose	O
-	O
limiting	O
mitochondrial	B
dysfunction	I
and	O
cardiomyopathy	B
that	O
accompanies	O
long	O
-	O
term	O
doxorubicin	O
therapy	O
in	O
cancer	B
patients	O
.	O

Cocaine	O
-	O
induced	O
hyperactivity	B
is	O
more	O
influenced	O
by	O
adenosine	O
receptor	O
agonists	O
than	O
amphetamine	O
-	O
induced	O
hyperactivity	B
.	O

The	O
influence	O
of	O
adenosine	O
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine	O
-	O
and	O
amphetamine	O
-	O
induced	O
hyperactivity	B
was	O
examined	O
in	O
mice	O
.	O

All	O
adenosine	O
receptor	O
agonists	O
significantly	O
decreased	B
the	I
locomotor	I
activity	I
in	O
mice	O
,	O
and	O
the	O
effects	O
were	O
dose	O
-	O
dependent	O
.	O

It	O
seems	O
that	O
adenosine	O
A1	O
and	O
A2	O
receptors	O
might	O
be	O
involved	O
in	O
this	O
reaction	O
.	O

Moreover	O
,	O
all	O
adenosine	O
receptor	O
agonists	O
:	O
2-p-	O
(	O
2-carboxyethyl	O
)	O
phenethylamino-5'-N	O
-	O
ethylcarboxamidoadenosine	O
(	O
CGS	O
21680	O
)	O
,	O
A2A	O
receptor	O
agonist	O
,	O
N6-cyclopentyladenosine	O
(	O
CPA	O
)	O
,	O
A1	O
receptor	O
agonist	O
,	O
and	O
5'-N	O
-	O
ethylcarboxamidoadenosine	O
(	O
NECA	O
)	O
,	O
A2	O
/	O
A1	O
receptor	O
agonist	O
significantly	O
and	O
dose	O
-	O
dependently	O
decreased	O
cocaine	O
-	O
induced	O
locomotor	O
activity	O
.	O

CPA	O
reduced	O
cocaine	O
action	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	O
21680	O
and	O
NECA	O
decreased	O
the	O
action	O
of	O
cocaine	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
decreased	O
locomotor	O
activity	O
in	O
animals	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	O
receptors	O
in	O
the	O
action	O
of	O
cocaine	O
although	O
agonists	O
of	O
A1	O
receptors	O
seem	O
to	O
have	O
stronger	O
influence	O
on	O
it	O
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	O
receptor	O
by	O
DMPX	O
(	O
3,7-dimethyl-1-propargylxanthine	O
)	O
significantly	O
enhanced	O
cocaine	O
-	O
induced	O
locomotor	O
activity	O
of	O
animals	O
.	O

Caffeine	O
had	O
similar	O
action	O
but	O
the	O
effect	O
was	O
not	O
significant	O
.	O

CPT	O
(	O
8-cyclopentyltheophylline	O
)	O
--A1	O
receptor	O
antagonist	O
,	O
did	O
not	O
show	O
any	O
influence	O
in	O
this	O
test	O
.	O

Similarly	O
,	O
all	O
adenosine	O
receptor	O
agonists	O
decreased	O
amphetamine	O
-	O
induced	O
hyperactivity	B
,	O
but	O
at	O
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine	O
-	O
induced	O
hyperactivity	B
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	O
receptors	O
(	O
DMPX	O
)	O
and	O
non	O
-	O
selective	O
blockade	O
of	O
adenosine	O
receptors	O
(	O
caffeine	O
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	O
in	O
the	O
locomotor	O
activity	O
test	O
.	O

Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	O
receptor	O
agonists	O
(	O
A1	O
and	O
A2	O
)	O
reduce	O
cocaine-	O
and	O
amphetamine	O
-	O
induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine	O
-	O
induced	O
hyperactivity	B
is	O
more	O
influenced	O
by	O
adenosine	O
receptor	O
agonists	O
(	O
particularly	O
A1	O
receptors	O
)	O
than	O
amphetamine	O
-	O
induced	O
hyperactivity	B
.	O

Amiodarone	O
and	O
the	O
risk	O
of	O
bradyarrhythmia	B
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	B
fibrillation	I
and	O
prior	O
myocardial	B
infarction	I
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	O
in	O
patients	O
with	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B
requiring	O
a	O
permanent	O
pacemaker	O
.	O

BACKGROUND	O
:	O
Reports	O
of	O
severe	O
bradyarrhythmia	B
during	O
amiodarone	O
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy	O
's	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	B
arrhythmias	I
.	O

METHODS	O
:	O
A	O
study	O
cohort	O
of	O
8,770	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	B
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	B
infarction	I
(	O
MI	B
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
nested	O
case	O
-	O
control	O
design	O
,	O
477	O
cases	O
of	O
bradyarrhythmia	B
requiring	O
a	O
permanent	O
pacemaker	O
were	O
matched	O
(	O
1:4	O
)	O
to	O
1,908	O
controls	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	O
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	O
,	O
Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	O
channel	O
blockers	O
,	O
and	O
digoxin	O
.	O

RESULTS	O
:	O
amiodarone	O
use	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
2.14	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.30	O
to	O
3.54	O
)	O
.	O

This	O
effect	O
was	O
modified	O
by	O
gender	O
,	O
with	O
a	O
greater	O
risk	O
in	O
women	O
versus	O
men	O
(	O
OR	O
:	O
3.86	O
,	O
95	O
%	O
CI	O
:	O
1.70	O
to	O
8.75	O
vs.	O
OR	O
:	O
1.52	O
,	O
95	O
%	O
CI	O
:	O
0.80	O
to	O
2.89	O
)	O
.	O

Digoxin	O
was	O
the	O
only	O
other	O
medication	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
1.78	O
,	O
95	O
%	O
CI	O
:	O
1.37	O
to	O
2.31	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	O
in	O
elderly	O
patients	O
with	O
AF	B
and	O
a	O
previous	O
MI	B
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B
requiring	O
a	O
permanent	O
pacemaker	O
.	O

The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	O
requires	O
further	O
investigation	O
.	O

Indomethacin	O
-	O
induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	O
bladder	O
epithelium	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
condition	O
.	O

In	O
addition	O
to	O
tiaprofenic	O
acid	O
,	O
indomethacin	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
condition	O
.	O

METHODS	O
:	O
Three	O
groups	O
were	O
established	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	O
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oral	O
indomethacin	O
was	O
administered	O
3.25	O
mg	O
/	O
kg	O
body	O
weight	O
daily	O
for	O
3	O
weeks	O
.	O

The	O
animals	O
were	O
then	O
killed	O
and	O
the	O
bladders	O
removed	O
for	O
light	O
and	O
electron	O
microscopic	O
studies	O
.	O

RESULTS	O
:	O
The	O
light	O
microscopic	O
findings	O
showed	O
some	O
focal	O
epithelial	O
degeneration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
dose	O
group	O
.	O

When	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
indomethacin	O
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
penetration	O
of	O
lanthanum	O
nitrate	O
through	O
intercellular	O
areas	O
of	O
the	O
epithelium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
mast	O
cell	O
counts	O
between	O
the	O
high	O
and	O
therapeutic	O
dose	O
groups	O
was	O
also	O
statistically	O
significant	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Indomethacin	O
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	B
cystitis	I
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	B
.	O

The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B
in	O
humans	O
must	O
be	O
clarified	O
by	O
prospective	O
clinical	O
trials	O
.	O

An	O
open	O
-	O
label	O
phase	O
II	O
study	O
of	O
low	O
-	O
dose	O
thalidomide	O
in	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
.	O

The	O
antiangiogenic	O
effects	O
of	O
thalidomide	O
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	B
malignancies	I
.	O

Thalidomide	O
blocks	O
the	O
activity	O
of	O
angiogenic	O
agents	O
including	O
bFGF	O
,	O
VEGF	O
and	O
IL-6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
label	O
study	O
using	O
thalidomide	O
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
.	O

The	O
mean	O
time	O
of	O
study	O
was	O
109	O
days	O
(	O
median	O
107	O
,	O
range	O
4	O
-	O
184	O
days	O
)	O
.	O

Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
,	O
urea	O
and	O
electrolytes	O
,	O
serum	O
bFGF	O
and	O
VEGF	O
.	O

Three	O
men	O
(	O
15	O
%	O
)	O
showed	O
a	O
decline	O
in	O
serum	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustained	O
throughout	O
treatment	O
.	O

Of	O
16	O
men	O
treated	O
for	O
at	O
least	O
2	O
months	O
,	O
six	O
(	O
37.5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
absolute	O
PSA	O
by	O
a	O
median	O
of	O
48	O
%	O
.	O

Increasing	O
levels	O
of	O
serum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressive	O
disease	O
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decline	O
in	O
bFGF	O
and	O
VEGF	O
levels	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increase	O
in	O
both	O
growth	O
factors	O
.	O

Adverse	O
effects	O
included	O
constipation	B
,	O
morning	O
drowsiness	B
,	O
dizziness	B
and	O
rash	B
,	O
and	O
resulted	O
in	O
withdrawal	O
from	O
the	O
study	O
by	O
three	O
men	O
.	O

Evidence	O
of	O
peripheral	B
sensory	I
neuropathy	I
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treatment	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	O
,	O
subclinical	O
evidence	O
of	O
peripheral	B
neuropathy	I
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing	O
.	O

The	O
findings	O
indicate	O
that	O
thalidomide	O
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	B
neuropathy	I
.	O

Central	B
nervous	I
system	I
toxicity	I
following	O
the	O
administration	O
of	O
levobupivacaine	O
for	O
lumbar	O
plexus	O
block	O
:	O
A	O
report	O
of	O
two	O
cases	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Central	B
nervous	I
system	I
and	I
cardiac	I
toxicity	I
following	O
the	O
administration	O
of	O
local	O
anesthetics	O
is	O
a	O
recognized	O
complication	O
of	O
regional	O
anesthesia	O
.	O

Levobupivacaine	O
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
enantiomer	O
of	O
bupivacaine	O
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	O
.	O

We	O
describe	O
2	O
cases	O
of	O
grand	B
mal	I
seizures	I
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	O
.	O

CASE	O
REPORT	O
:	O
Two	O
patients	O
presenting	O
for	O
elective	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limb	O
underwent	O
blockade	O
of	O
the	O
lumbar	O
plexus	O
via	O
the	O
posterior	O
approach	O
.	O

Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	O
0.5	O
%	O
with	O
epinephrine	O
2.5	O
microgram	O
/	O
mL	O
,	O
the	O
patients	O
developed	O
grand	B
mal	I
seizures	I
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	O
administration	O
.	O

The	O
seizures	B
were	O
successfully	O
treated	O
with	O
sodium	O
thiopental	O
in	O
addition	O
to	O
succinylcholine	O
in	O
1	O
patient	O
.	O

Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	B
toxicity	I
.	O

Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta	O
-	O
adrenergic	O
antagonist	O
medications	O
,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	O
with	O
epinephrine	O
.	O

CONCLUSIONS	O
:	O
Although	O
levobupivacaine	O
may	O
have	O
a	O
safer	O
cardiac	B
toxicity	I
profile	O
than	O
racemic	O
bupivacaine	O
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	O
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	B
.	O

Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	B
nervous	I
system	I
toxicity	I
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	B
toxicity	I
in	O
these	O
2	O
patients	O
.	O

Amiodarone	O
-	O
induced	O
torsade	B
de	I
pointes	I
during	O
bladder	O
irrigation	O
:	O
an	O
unusual	O
presentation	O
--	O
a	O
case	O
report	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(	O
within	O
4	O
days	O
)	O
development	O
of	O
torsade	B
de	I
pointes	I
(	O
TdP	B
)	O
associated	O
with	O
oral	O
amiodarone	O
therapy	O
.	O

Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	B
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	B
and	O
digoxin	O
excess	O
.	O

Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP.	B
It	O
is	O
well	O
known	O
that	O
bradycardia	B
exacerbates	O
acquired	O
TdP.	B
The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	O
therapy	O
resulted	O
in	O
amiodarone	O
-	O
induced	O
proarrhythmia	B
.	O

In	O
the	O
absence	O
of	O
amiodarone	O
therapy	O
,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	B
despite	O
hypokalemia	B
and	O
hypomagnesemia	B
.	O

Anaesthetic	O
complications	O
associated	O
with	O
myotonia	B
congenita	I
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	B
disorders	I
.	O

Myotonia	B
congenita	I
(	O
MC	B
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	O
channel	O
function	O
,	O
which	O
may	O
cause	O
sustained	B
membrane	I
depolarisation	I
.	O

We	O
describe	O
a	O
previously	O
healthy	O
32-year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
life	O
-	O
threatening	O
muscle	B
spasm	I
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	O
.	O

The	O
muscle	B
spasms	I
disappeared	O
spontaneously	O
and	O
the	O
surgery	O
proceeded	O
without	O
further	O
problems	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symptoms	O
suggesting	O
a	O
myotonic	B
condition	I
.	O

Myotonia	B
was	O
found	O
on	O
clinical	O
examination	O
and	O
EMG	O
.	O

The	O
diagnosis	O
MC	B
was	O
confirmed	O
genetically	O
.	O

Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
were	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overview	O
of	O
ion	B
channel	I
disorders	I
including	O
malignant	B
hyperthermia	I
and	O
their	O
anaesthetic	O
considerations	O
.	O

Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	B
.	O

PURPOSE	O
:	O
Apnea	B
is	O
known	O
to	O
occur	O
during	O
seizures	B
,	O
but	O
systematic	O
studies	O
of	O
ictal	O
respiratory	O
changes	O
in	O
adults	O
are	O
few	O
.	O

Data	O
regarding	O
respiratory	O
pattern	O
defects	O
during	O
interictal	O
periods	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine	O
-	O
induced	O
epilepsy	B
.	O

METHODS	O
:	O
Twelve	O
rats	O
(	O
six	O
chronically	O
epileptic	B
animals	O
and	O
six	O
controls	O
)	O
were	O
anesthetized	O
,	O
given	O
tracheotomies	O
,	O
and	O
subjected	O
to	O
hyperventilation	B
or	O
hypoventilation	O
conditions	O
.	O

Breathing	O
movements	O
caused	O
changes	O
in	O
thoracic	O
volume	O
and	O
forced	O
air	O
to	O
flow	O
tidally	O
through	O
a	O
pneumotachograph	O
.	O

This	O
flow	O
was	O
measured	O
by	O
using	O
a	O
differential	O
pressure	O
transducer	O
,	O
passed	O
through	O
a	O
polygraph	O
,	O
and	O
from	O
this	O
to	O
a	O
computer	O
with	O
custom	O
software	O
that	O
derived	O
ventilation	O
(	O
VE	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
inspiratory	O
time	O
(	O
TI	O
)	O
,	O
expiratory	O
time	O
(	O
TE	O
)	O
,	O
breathing	O
frequency	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspiratory	O
flow	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
breath	O
-	O
by	O
-	O
breath	O
basis	O
.	O

RESULTS	O
:	O
The	O
hyperventilation	B
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine	O
-	O
treated	O
and	O
control	O
rats	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups	O
,	O
in	O
the	O
epileptic	B
group	O
,	O
the	O
decrease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
increase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
control	O
animals	O
.	O

The	O
hypoventilation	O
maneuver	O
led	O
to	O
an	O
increase	O
in	O
the	O
arterial	O
Paco2	O
,	O
followed	O
by	O
an	O
increase	O
in	O
VE	O
.	O

In	O
the	O
epileptic	B
group	O
,	O
the	O
increase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decrease	O
in	O
TE	O
peak	O
compared	O
with	O
the	O
control	O
group	O
.	O

Systemic	O
application	O
of	O
KCN	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
peripheral	O
chemoreception	O
activation	O
on	O
ventilation	O
,	O
led	O
to	O
a	O
similar	O
increase	O
in	O
VE	O
for	O
both	O
groups	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
indicate	O
that	O
pilocarpine	O
-	O
treated	O
animals	O
have	O
an	O
altered	O
ability	O
to	O
react	O
to	O
(	O
or	O
compensate	O
for	O
)	O
blood	O
gas	O
changes	O
with	O
changes	O
in	O
ventilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy	B
-	O
associated	O
conditions	O
.	O

Fatal	O
myeloencephalopathy	B
due	O
to	O
intrathecal	O
vincristine	O
administration	O
.	O

Vincristine	O
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	B
,	O
producing	O
sensory	B
and	I
motor	I
dysfunction	I
followed	O
by	O
encephalopathy	B
and	O
death	O
.	O

Separate	O
times	O
for	O
administering	O
vincristine	O
and	O
intrathecal	O
therapy	O
is	O
recommended	O
.	O

Progesterone	O
potentiation	O
of	O
bupivacaine	O
arrhythmogenicity	O
in	O
pentobarbital	O
-	O
anesthetized	O
rats	O
and	O
beating	O
rat	O
heart	O
cell	O
cultures	O
.	O

The	O
effects	O
of	O
progesterone	O
treatment	O
on	O
bupivacaine	O
arrhythmogenicity	O
in	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
and	O
on	O
anesthetized	O
rats	O
were	O
determined	O
.	O

After	O
determining	O
the	O
bupivacaine	O
AD50	O
(	O
the	O
concentration	O
of	O
bupivacaine	O
that	O
caused	O
50	O
%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	B
)	O
,	O
we	O
determined	O
the	O
effect	O
of	O
1-hour	O
progesterone	O
HCl	O
exposure	O
on	O
myocyte	O
contractile	O
rhythm	O
.	O

Each	O
concentration	O
of	O
progesterone	O
(	O
6.25	O
,	O
12.5	O
,	O
25	O
,	O
and	O
50	O
micrograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
concentration	O
-	O
dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	O
.	O

Estradiol	O
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	O
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	O
.	O

Neither	O
progesterone	O
nor	O
estradiol	O
effects	O
on	O
bupivacaine	O
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	O
.	O

Chronic	O
progesterone	O
pretreatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
days	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	O
arrhythmogenicity	O
in	O
intact	O
pentobarbital	O
-	O
anesthetized	O
rats	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	B
as	O
compared	O
with	O
control	O
nonprogesterone	O
-	O
treated	O
rats	O
(	O
6.2	O
+	O
/-	O

1.3	O
vs.	O
30.8	O
+	O
/-	O

2.5	O
min	O
,	O
mean	O
+	O
/-	O

SE	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	O
can	O
potentiate	O
bupivacaine	O
arrhythmogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potentiation	O
of	O
bupivacaine	O
arrhythmia	B
in	O
myocyte	O
cultures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myocyte	O
level	O
.	O

Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
due	O
to	O
paracetamol	O
overdose	B
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas	O
/	O
Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B
liver	I
failure	I
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
.	O

METHODOLOGY	O
:	O
Serum	O
levels	O
of	O
sFas	O
(	O
soluble	O
Fas	O
)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	B
liver	I
failure	I
and	O
10	O
normal	O
control	O
subjects	O
.	O

Serum	O
levels	O
of	O
tumor	B
necrosis	B
factor	O
-	O
alpha	O
and	O
interferon	O
-	O
gamma	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
(	O
median	O
,	O
26.8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.9	O
-	O
52.7	O
U	O
/	O
mL	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
median	O
,	O
8.6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.5	O
-	O
12.0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
due	O
to	O
paracetamol	O
overdose	B
(	O
median	O
,	O
28.7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12.8	O
-	O
52.7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepatitis	B
(	O
median	O
,	O
12.5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.9	O
-	O
46.0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0.01	O
)	O
.	O

There	O
was	O
no	O
relationship	O
of	O
sFas	O
to	O
eventual	O
outcome	O
in	O
the	O
patients	O
.	O

A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	O
aminotransferase	O
(	O
r	O
=	O
0.613	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	B
liver	I
failure	I
may	O
reflect	O
activation	O
of	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
liver	O
and	O
this	O
together	O
with	O
increased	O
tumor	B
necrosis	B
factor	O
-	O
alpha	O
may	O
be	O
an	O
important	O
factor	O
in	O
liver	O
cell	O
loss	O
.	O

Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson	B
's	I
disease	I
.	O

High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	O
and	O
symptoms	O
of	O
advanced	O
Parkinson	B
's	I
disease	I
.	O

AIM	O
:	O
We	O
studied	O
the	O
effect	O
of	O
high	O
frequency	O
STN	O
stimulation	O
in	O
23	O
patients	O
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
patients	O
suffering	O
from	O
severe	O
Parkinson	B
's	I
disease	I
(	O
Stages	O
III	O
-	O
V	O
on	O
Hoehn	O
and	O
Yahr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinesia	B
,	O
rigidity	B
,	O
and	O
levodopa	O
-	O
induced	O
dyskinesias	B
underwent	O
bilateral	O
implantation	O
of	O
electrodes	O
in	O
the	O
STN	O
.	O

Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
follow	O
-	O
up	O
,	O
in	O
""""	O
on	O
""""	O
and	O
""""	O
off	O
""""	O
drug	O
conditions	O
,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson	B
's	I
Disease	I
Rating	O
Scale	O
,	O
Hoehn	O
and	O
Yahr	O
staging	O
,	O
England	O
activities	O
of	O
daily	O
living	O
score	O
and	O
video	O
recordings	O
.	O

RESULTS	O
:	O
After	O
one	O
year	O
of	O
electrical	O
stimulation	O
of	O
the	O
STN	O
,	O
the	O
patients	O
'	O
scores	O
for	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
examination	O
scores	O
(	O
Unified	O
Parkinson	B
's	I
Disease	I
Rating	O
Scale	O
parts	O
II	O
and	O
III	O
)	O
off	O
medication	O
improved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p<0.0005	O
)	O
.	O

The	O
subscores	O
for	O
the	O
akinesia	B
,	O
rigidity	B
,	O
tremor	B
and	O
gait	O
also	O
improved	O
.	O

(	O
p<0.0005	O
)	O
.	O

The	O
average	O
levodopa	O
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cognitive	O
functions	O
remained	O
unchanged	O
.	O

Two	O
patients	O
developed	O
device	O
-	O
related	O
complications	O
and	O
two	O
patients	O
experienced	O
abnormal	O
weight	O
gain	O
.	O

CONCLUSION	O
:	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson	B
's	I
disease	I
.	O

It	O
reduces	O
the	O
severity	O
of	O
""""	O
off	O
""""	O
phase	O
symptoms	O
,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	O
requirements	O
.	O

The	O
reduction	O
in	O
the	O
levodopa	O
dose	O
is	O
useful	O
in	O
controlling	O
drug	B
-	I
induced	I
dyskinesias	I
.	O

Acute	B
renal	I
failure	I
occurring	O
during	O
intravenous	O
desferrioxamine	O
therapy	O
:	O
recovery	O
after	O
haemodialysis	O
.	O

A	O
patient	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	B
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	O
(	O
DFX	O
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy	O
.	O

Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump	O
,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	B
insufficiency	I
.	O

Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values	O
,	O
despite	O
adequate	O
medical	O
treatment	O
,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	B
.	O

From	O
the	O
results	O
obtained	O
,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	B
renal	I
failure	I
caused	O
by	O
desferrioxamine	O
.	O

Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	O
chemotherapy	O
for	O
retinoblastoma	B
.	O

BACKGROUND	O
:	O
Focal	O
subtenon	O
carboplatin	O
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity	B
-	O
free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	B
.	O

OBJECTIVE	O
:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	B
ocular	I
motility	I
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	O
chemotherapy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnormal	B
ocular	I
motility	I
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	B
who	O
had	O
received	O
subtenon	O
carboplatin	O
.	O

During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia	O
,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing	O
,	O
comparing	O
ocular	O
motility	O
after	O
tumor	B
control	O
with	O
ocular	O
motility	O
at	O
diagnosis	O
.	O

Eyes	O
subsequently	O
enucleated	O
because	O
of	O
treatment	O
failure	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histologically	O
.	O

RESULTS	O
:	O
Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	B
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	O
as	O
part	O
of	O
multimodality	O
therapy	O
.	O

Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye	O
,	O
indicative	O
of	O
phagocytosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necrosis	B
.	O

The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	B
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	O
adhesions	O
.	O

CONCLUSIONS	O
:	O
Subtenon	O
carboplatin	O
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	B
of	O
orbital	O
soft	O
tissues	O
,	O
leading	O
to	O
mechanical	O
restriction	O
of	O
eye	O
movements	O
and	O
making	O
subsequent	O
enucleation	O
difficult	O
.	O

Subtenon	O
carboplatin	O
is	O
not	O
free	O
of	O
toxicity	B
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indications	O
.	O

Ethambutol	O
and	O
optic	B
neuropathy	I
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	O
and	O
optic	B
neuropathy	I
.	O

METHOD	O
:	O
Thirteen	O
patients	O
who	O
developed	O
optic	B
neuropathy	I
after	O
being	O
treated	O
with	O
ethambutol	O
for	O
tuberculosis	B
of	I
the	I
lung	I
or	B
lymph	I
node	I
at	O
Siriraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospectively	O
reviewed	O
.	O

The	O
clinical	O
characteristics	O
and	O
initial	O
and	O
final	O
visual	O
acuity	O
were	O
analyzed	O
to	O
determine	O
visual	O
outcome	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
optic	B
neuropathy	I
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2.9	O
months	O
)	O
after	O
starting	O
ethambutol	O
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
patients	O
experienced	O
visual	O
recovery	O
after	O
stopping	O
the	O
drug	O
.	O

Of	O
6	O
patients	O
with	O
irreversible	O
visual	B
impairment	I
,	O
4	O
patients	O
had	O
diabetes	B
mellitus	I
,	O
glaucoma	B
and	O
a	O
history	O
of	O
heavy	O
smoking	O
.	O

CONCLUSION	O
:	O
Early	O
recognition	O
of	O
optic	B
neuropathy	I
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	O
therapy	O
.	O

A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B
mellitus	I
,	O
glaucoma	B
or	O
who	O
are	O
heavy	O
smokers	O
.	O

Treatment	O
of	O
compensatory	O
gustatory	B
hyperhidrosis	I
with	O
topical	O
glycopyrrolate	O
.	O

Gustatory	B
hyperhidrosis	I
is	O
facial	O
sweating	B
usually	O
associated	O
with	O
the	O
eating	O
of	O
hot	O
spicy	O
food	O
or	O
even	O
smelling	O
this	O
food	O
.	O

Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	O
chloride	O
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin	O
.	O

Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1.5	O
%	O
or	O
2	O
%	O
topical	O
glycopyrrolate	O
.	O

All	O
patients	O
had	O
gustatory	B
hyperhidrosis	I
,	O
which	O
interfered	O
with	O
their	O
social	O
activities	O
,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	B
.	O

After	O
applying	O
topical	O
glycopyrrolate	O
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	B
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	B
)	O
in	O
3	O
patients	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
incidents	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eating	O
hot	O
spicy	O
foods	O
.	O

Adverse	O
effects	O
included	O
a	O
mildly	O
dry	B
mouth	I
and	O
a	O
sore	B
throat	I
in	O
2	O
patients	O
(	O
2	O
%	O
glycopyrrolate	O
)	O
,	O
a	O
light	O
headache	B
in	O
1	O
patient	O
(	O
1.5	O
%	O
glycopyrrolate	O
)	O
.	O

The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	O
pad	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
well	O
tolerated	O
,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	B
hyperhidrosis	I
in	O
post	O
transthoracic	O
endoscopic	O
sympathectomy	O
or	O
sympathicotomy	O
patients	O
,	O
with	O
few	O
side	O
effects	O
.	O

Neuroleptic	O
-	O
associated	O
hyperprolactinemia	B
.	O

Can	O
it	O
be	O
treated	O
with	O
bromocriptine	O
?	O

Six	O
stable	O
psychiatric	O
outpatients	O
with	O
hyperprolactinemia	B
and	O
amenorrhea	B
/	O
oligomenorrhea	B
associated	O
with	O
their	O
neuroleptic	O
medications	O
were	O
treated	O
with	O
bromocriptine	O
.	O

Daily	O
dosages	O
of	O
5	O
-	O
10	O
mg	O
corrected	O
the	O
hyperprolactinemia	B
and	O
restored	O
menstruation	O
in	O
four	O
of	O
the	O
six	O
patients	O
.	O

One	O
woman	O
,	O
however	O
,	O
developed	O
worsened	O
psychiatric	B
symptoms	I
while	O
taking	O
bromocriptine	O
,	O
and	O
it	O
was	O
discontinued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	O
.	O

This	O
suggests	O
that	O
bromocriptine	O
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic	O
-	O
associated	O
hyperprolactinemia	B
and	O
amenorrhea	B
/	O
galactorrhea	B
.	O

Ethacrynic	O
acid	O
-	O
induced	O
convulsions	B
and	O
brain	O
neurotransmitters	O
in	O
mice	O
.	O

Intracerebroventricular	O
injection	O
of	O
ethacrynic	O
acid	O
(	O
50	O
%	O
convulsive	B
dose	O
;	O
50	O
micrograms	O
/	O
mouse	O
)	O
accelerated	O
the	O
synthesis	O
/	O
turnover	O
of	O
5-hydroxytryptamine	O
(	O
5-HT	O
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma	O
-	O
aminobutyric	O
acid	O
and	O
acetylcholine	O
in	O
mouse	O
brain	O
.	O

These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate	O
/	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
antagonist	O
,	O
aminophosphonovaleric	O
acid	O
.	O

In	O
ethacrynic	O
acid	O
-	O
induced	O
convulsions	B
,	O
these	O
neurotransmitter	O
systems	O
may	O
be	O
differentially	O
modulated	O
,	O
probably	O
through	O
activation	O
of	O
glutaminergic	O
neurons	O
in	O
the	O
brain	O
.	O

Pharmacology	O
of	O
gamma	O
-	O
aminobutyric	O
acidA	O
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta	O
-	O
carboline	O
derivative	O
abecarnil	O
.	O

In	O
rodents	O
,	O
the	O
effect	O
of	O
the	O
beta	O
-	O
carboline	O
derivative	O
isopropyl-6-	O
benzyloxy-4-methoxymethyl	O
-	O
beta	O
-	O
carboline-3-carboxylate	O
(	O
abecarrnil	O
)	O
,	O
a	O
new	O
ligand	O
for	O
benzodiazepine	O
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties	O
,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
A	O
receptor	O
complex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation	O
,	O
abecarnil	O
increased	O
[	O
3H	O
]	O
GABA	O
binding	O
,	O
enhanced	O
muscimol	O
-	O
stimulated	O
36Cl-	O
uptake	O
and	O
reduced	O
the	O
binding	O
of	O
t-	O
[	O
35S	O
]	O
butylbicyclophosphorothionate	O
(	O
[	O
35S	O
]	O
TBPS	O
)	O
.	O

These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	O
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	O
16	O
-	O
6028	O
(	O
tert	O
-	O
butyl-	O
(	O
S	O
)	O
-8-bromo-11,12,13,13a	O
-	O
tetrahydro-9-oxo-9H-	O
imidazo	O
[	O
1,5-a	O
]	O
-pyrrolo-	O
[	O
2,1-c	O
]	O
[	O
1,4	O
]	O
benzodiazepine-1-carboxylate	O
)	O
showed	O
very	O
weak	O
efficacy	O
in	O
these	O
biochemical	O
tests	O
.	O

After	O
i.p	O
.	O

injection	O
to	O
rats	O
,	O
abecarnil	O
and	O
diazepam	O
decreased	O
in	O
a	O
time	O
-	O
dependent	O
and	O
dose	O
-	O
related	O
(	O
0.25	O
-	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
manner	O
[	O
35S	O
]	O
TBPS	O
binding	O
measured	O
ex	O
vivo	O
in	O
the	O
cerebral	O
cortex	O
.	O

Moreover	O
,	O
both	O
drugs	O
at	O
the	O
dose	O
of	O
0.5	O
mg	O
/	O
kg	O
antagonized	O
completely	O
the	O
convulsant	O
activity	O
and	O
the	O
increase	O
of	O
[	O
35S	O
]	O
TBPS	O
binding	O
induced	O
by	O
isoniazide	O
(	O
350	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
as	O
well	O
as	O
the	O
increase	O
of	O
[	O
35S	O
]	O
TBPS	O
binding	O
induced	O
by	O
foot	O
-	O
shock	O
stress	O
.	O

To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects	O
,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	O
on	O
[	O
35S	O
]	O
TBPS	O
binding	O
,	O
exploratory	O
motility	O
and	O
on	O
isoniazid	O
-	O
induced	O
biochemical	O
and	O
pharmacological	O
effects	O
in	O
mice	O
.	O

In	O
these	O
animals	O
,	O
abecarnil	O
produced	O
a	O
paralleled	O
dose	O
-	O
dependent	O
(	O
0.05	O
-	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
reduction	O
of	O
both	O
motor	O
behavior	O
and	O
cortical	O
[	O
35S	O
]	O
TBPS	O
binding	O
.	O

Moreover	O
,	O
0.05	O
mg	O
/	O
kg	O
of	O
this	O
beta	O
-	O
carboline	O
reduced	O
markedly	O
the	O
increase	O
of	O
[	O
35S	O
]	O
TBPS	O
binding	O
and	O
the	O
convulsions	B
induced	O
by	O
isoniazid	O
(	O
200	O
mg	O
/	O
kg	O
s.c.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Recurrent	O
myocardial	B
infarction	I
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	O
.	O

Myocardial	B
infarction	I
in	O
puerperium	O
is	O
infrequently	O
reported	O
.	O

Spasm	B
,	O
coronary	O
dissection	O
,	O
or	O
atheromatous	O
etiology	O
has	O
been	O
described	O
.	O

Bromocriptine	O
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	B
infarction	I
in	O
the	O
puerperium	O
.	O

Our	O
case	O
(	O
including	O
an	O
inadvertent	O
rechallenge	O
)	O
suggests	O
such	O
a	O
relationship	O
.	O

Although	O
generally	O
regarded	O
as	O
""""	O
safe	O
,	O
""""	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	O
should	O
be	O
acknowledged	O
.	O

Asterixis	B
induced	O
by	O
carbamazepine	O
therapy	O
.	O

There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	B
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
psychopharmacologic	O
agents	O
.	O

In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	B
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	O
(	O
CBZ	O
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O

Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	O
were	O
in	O
a	O
higher	O
range	O
.	O

We	O
consider	O
asterixis	B
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	O
or	O
clozapine	O
are	O
used	O
in	O
combination	O
with	O
CBZ	O
.	O

Pharmacodynamics	O
of	O
the	O
hypotensive	B
effect	O
of	O
levodopa	O
in	O
parkinsonian	B
patients	O
.	O

Blood	O
pressure	O
effects	O
of	O
i.v	O
.	O

levodopa	O
were	O
examined	O
in	O
parkinsonian	B
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	O
.	O

The	O
magnitude	O
of	O
the	O
hypotensive	B
effect	O
of	O
levodopa	O
was	O
concentration	O
dependent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
model	O
in	O
fluctuating	O
responders	O
.	O

Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	B
response	O
.	O

Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients	O
;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	B
effects	O
.	O

Antiparkinsonian	O
effects	O
of	O
levodopa	O
temporally	O
correlated	O
with	O
blood	O
pressure	O
changes	O
.	O

Phenylalanine	O
,	O
a	O
large	O
neutral	O
amino	O
acid	O
(	O
LNAA	O
)	O
competing	O
with	O
levodopa	O
for	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
reduced	O
the	O
hypotensive	B
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	O
.	O

We	O
conclude	O
that	O
levodopa	O
has	O
a	O
central	O
hypotensive	B
action	O
that	O
parallels	O
the	O
motor	O
effects	O
in	O
fluctuating	O
patients	O
.	O

The	O
hypotensive	B
effect	O
appears	O
to	O
be	O
related	O
to	O
the	O
higher	O
baseline	O
blood	O
pressure	O
we	O
observed	O
in	O
fluctuating	O
patients	O
relative	O
to	O
stable	O
patients	O
.	O

Syndrome	B
of	I
inappropriate	I
secretion	I
of	I
antidiuretic	I
hormone	I
after	O
infusional	O
vincristine	O
.	O

A	O
77-year	O
-	O
old	O
woman	O
with	O
refractory	O
multiple	B
myeloma	I
was	O
treated	O
with	O
a	O
4-day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	O
and	O
doxorubicin	O
and	O
4	O
days	O
of	O
oral	O
dexamethasone	O
.	O

Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	B
and	O
weakness	B
associated	O
with	O
hyponatremia	B
.	O

Evaluation	O
revealed	O
the	O
syndrome	B
of	I
inappropriate	I
secretion	I
of	I
antidiuretic	I
hormone	I
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	O
infusion	O
.	O

After	O
normal	O
serum	O
sodium	O
levels	O
returned	O
,	O
further	O
doxorubicin	O
and	O
dexamethasone	O
chemotherapy	O
without	O
vincristine	O
did	O
not	O
produce	O
this	O
complication	O
.	O

Heart	B
failure	I
:	O
to	O
digitalise	O
or	O
not	O
?	O

The	O
view	O
against	O
.	O

Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	O
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
patients	O
with	O
atrial	B
fibrillation	I
digoxin	O
is	O
beneficial	O
for	O
ventricular	O
rate	O
control	O
.	O

For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	B
failure	I
the	O
situation	O
is	O
less	O
clear	O
.	O

Digoxin	O
has	O
a	O
narrow	O
therapeutic	O
:	O
toxic	O
ratio	O
and	O
concentrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
drugs	O
.	O

Also	O
,	O
digoxin	O
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands	O
,	O
and	O
causing	O
arrhythmias	B
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
from	O
well	O
-	O
designed	O
trials	O
.	O

The	O
trials	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitations	O
in	O
design	O
and	O
these	O
show	O
variation	O
in	O
patient	O
benefit	O
.	O

More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	O
improves	O
symptoms	O
or	O
exercise	O
capacity	O
.	O

Furthermore	O
,	O
no	O
trial	O
has	O
had	O
sufficient	O
power	O
to	O
evaluate	O
mortality	O
.	O

Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	O
may	O
increase	O
mortality	O
after	O
myocardial	B
infarction	I
(	O
MI	B
)	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
level	O
monitoring	O
,	O
modify	O
progression	O
of	O
disease	O
,	O
relieve	O
symptoms	O
,	O
improve	O
exercise	O
tolerance	O
and	O
reduce	O
mortality	O
.	O

Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	O
until	O
large	O
mortality	O
trials	O
are	O
completed	O
showing	O
either	O
benefit	O
or	O
harm	O
.	O

Until	O
then	O
digoxin	O
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
therapy	O
.	O

Isradipine	O
treatment	O
for	O
hypertension	B
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

A	O
6-week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	O
treatment	O
was	O
conducted	O
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	B
entered	O
the	O
study	O
.	O

Side	O
effects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patients	O
and	O
caused	O
withdrawal	O
from	O
the	O
study	O
in	O
3	O
patients	O
.	O

The	O
main	O
side	O
-	O
effects	O
were	O
headache	B
,	O
dizziness	B
,	O
palpitation	B
and	O
flushing	B
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	O
or	O
with	O
placebo	O
.	O

Supine	O
blood	O
pressure	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0.01	O
)	O
from	O
170	O
+	O
/-	O

20	O
/	O
102	O
+	O
/-	O

6	O
mmHg	O
to	O
153	O
+	O
/-	O

19	O
/	O
92	O
+	O
/-	O

8	O
,	O
147	O
+	O
/-	O

18	O
/	O
88	O
+	O
/-	O

7	O
and	O
144	O
+	O
/-	O

14	O
/	O
87	O
+	O
/-	O

6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evaluable	O
patients	O
.	O

Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	B
hypotension	I
.	O

Normalization	O
and	O
responder	O
rates	O
at	O
6	O
weeks	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Dosage	O
was	O
increased	O
from	O
2.5	O
mg	O
b.d	O
.	O

to	O
5	O
mg	O
b.d	O
.	O

at	O
4	O
weeks	O
in	O
patients	O
with	O
diastolic	O
blood	O
pressure	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
response	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2.5	O
mg	O
b.d	O
.	O

Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	O
without	O
soyabean	O
oil	O
.	O

We	O
compared	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	O
(	O
AM149	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soyabean	O
oil	O
,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	O
(	O
Disoprivan	O
1	O
%	O
)	O
.	O

In	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg.kg-1	O
propofol	O
.	O

Plasma	O
propofol	O
levels	O
were	O
measured	O
for	O
48	O
h	O
following	O
drug	O
administration	O
and	O
evaluated	O
according	O
to	O
a	O
three	O
-	O
compartment	O
model	O
.	O

The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
effects	O
,	O
and	O
pain	B
on	O
injection	O
.	O

Patients	O
were	O
monitored	O
for	O
side	O
effects	O
over	O
48	O
h.	O
Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	B
,	O
the	O
study	O
was	O
terminated	O
prematurely	O
and	O
only	O
the	O
data	O
of	O
the	O
two	O
parallel	O
treatment	O
groups	O
(	O
15	O
patients	O
in	O
each	O
group	O
)	O
were	O
analysed	O
.	O

Plasma	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulations	O
.	O

Anaesthesia	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
variables	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

Pain	B
on	O
injection	O
(	O
80	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.01	O
)	O
and	O
thrombophlebitis	B
(	O
93.3	O
vs.	O
6.6	O
%	O
,	O
p	O
<	O
0.001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	O
.	O

Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	B
produced	O
.	O

Pure	B
red	I
cell	I
aplasia	I
,	O
toxic	B
dermatitis	I
and	O
lymphadenopathy	B
in	O
a	O
patient	O
taking	O
diphenylhydantoin	O
.	O

A	O
patient	O
taking	O
diphenylhydantoin	O
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	B
rash	I
,	O
lymphadenopathy	B
and	O
pure	B
red	I
cell	I
aplasia	I
.	O

After	O
withdrawal	O
of	O
the	O
pharmacon	O
all	O
symptoms	O
disappeared	O
spontaneously	O
.	O

Skin	B
rash	I
is	O
a	O
well	O
-	O
known	O
complication	O
of	O
diphenylhydantoin	O
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	B
.	O

Pure	B
red	I
cell	I
aplasia	I
associated	O
with	O
diphenylhydantoin	O
medication	O
has	O
been	O
reported	O
in	O
3	O
patients	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	O
exerts	O
its	O
toxic	O
effects	O
is	O
not	O
known	O
.	O

In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	O
and	O
the	O
occurrence	O
of	O
the	O
skin	B
rash	I
,	O
lymphadenopathy	B
and	O
pure	B
red	I
cell	I
aplasia	I
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connection	O
.	O

Vinorelbine	O
-	O
related	O
cardiac	O
events	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
clinical	O
trials	O
.	O

Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	O
(	O
VNR	O
)	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	B
.	O

Randomized	O
clinical	O
trials	O
comparing	O
VNR	O
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	B
were	O
searched	O
in	O
Medline	O
,	O
Embase	O
,	O
Evidence	O
-	O
based	O
Medicine	O
Reviews	O
databases	O
and	O
the	O
Cochrane	O
library	O
from	O
1987	O
to	O
2002	O
.	O

Outcomes	O
of	O
interest	O
were	O
severe	O
cardiac	O
events	O
,	O
toxic	O
deaths	O
and	O
cardiac	O
event	O
-	O
related	O
deaths	O
reported	O
in	O
each	O
publication	O
.	O

We	O
found	O
19	O
trials	O
,	O
involving	O
2441	O
patients	O
treated	O
by	O
VNR	O
and	O
2050	O
control	O
patients	O
.	O

The	O
incidence	O
of	O
cardiac	O
events	O
with	O
VNR	O
was	O
1.19	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0.75	O
;	O
1.67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	O
events	O
between	O
VNR	O
and	O
other	O
drugs	O
[	O
odds	O
ratio	O
:	O
0.92	O
,	O
95	O
%	O
CI	O
(	O
0.54	O
;	O
1.55	O
)	O
]	O
.	O

The	O
risk	O
of	O
VNR	O
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	O
(	O
VDS	O
)	O
and	O
other	O
cardiotoxic	B
drugs	O
[	O
fluorouracil	O
,	O
anthracyclines	O
,	O
gemcitabine	O
(	O
GEM	O
)	O
em	O
leader	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases	O
,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history	O
,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre	O
-	O
existing	O
cardiac	B
diseases	I
.	O

Vinorelbine	O
-	O
related	O
cardiac	O
events	O
concern	O
about	O
1	O
%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
risk	O
associated	O
with	O
VNR	O
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
same	O
indications	O
.	O

MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	B
in	O
a	O
child	O
with	O
hemolytic	B
anemia	I
crisis	O
.	O

We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	B
anemia	I
crisis	O
induced	O
by	O
trimethoprim	O
-	O
sulfomethoxazole	O
,	O
resulting	O
in	O
cerebral	B
anoxia	I
leading	O
to	O
permanent	O
damage	O
.	O

Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	B
in	O
arterial	O
border	O
zones	O
in	O
both	O
cerebral	O
hemispheres	O
,	O
ischemic	O
changes	O
in	O
subcortical	O
white	O
matter	O
of	O
left	O
cerebral	O
hemisphere	O
,	O
and	O
in	O
the	O
left	O
putamen	O
.	O

Although	O
cortical	O
laminar	O
necrosis	B
is	O
a	O
classic	O
entity	O
in	O
adulthood	O
related	O
to	O
conditions	O
of	O
energy	O
depletions	O
,	O
there	O
are	O
few	O
reports	O
available	O
in	O
children	O
.	O

A	O
wide	O
review	O
of	O
the	O
literature	O
is	O
also	O
presented	O
.	O

The	O
natural	O
history	O
of	O
Vigabatrin	O
associated	O
visual	B
field	I
defects	I
in	O
patients	O
electing	O
to	O
continue	O
their	O
medication	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	B
field	I
defects	I
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin	O
-	O
associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	B
control	O
.	O

METHODS	O
:	O
All	O
patients	O
taking	O
Vigabatrin	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(	O
range	O
5	O
-	O
12	O
years	O
)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme	O
.	O

Patients	O
were	O
followed	O
up	O
at	O
6-monthly	O
intervals	O
for	O
not	O
less	O
than	O
18	O
months	O
(	O
range	O
18	O
-	O
43	O
months	O
)	O
.	O

In	O
all	O
,	O
16	O
patients	O
with	O
unequivocal	O
defects	O
continued	O
the	O
medication	O
.	O

Following	O
already	O
published	O
methodology	O
(	O
Eye	O
2002	O
;	O
16;567	O
-	O
571	O
)	O
monocular	O
mean	O
radial	O
degrees	O
(	O
MRDs	O
)	O
to	O
the	O
I	O
/	O
4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	O
the	O
time	O
of	O
discovery	O
of	O
a	O
visual	B
field	I
defect	I
and	O
again	O
after	O
not	O
less	O
than	O
18	O
months	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Mean	O
right	O
eye	O
MRD	O
at	O
presentation	O
was	O
36.98	O
degrees	O
(	O
range	O
22.25	O
-	O
51.0	O
)	O
,	O
compared	O
to	O
38.40	O
degrees	O
(	O
range	O
22.5	O
-	O
49.75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P=0.338	O
unpaired	O
t	O
-	O
test	O
.	O

Only	O
one	O
patient	O
demonstrated	O
a	O
deterioration	B
in	I
visual	I
field	I
during	O
the	O
study	O
period	O
and	O
discontinued	O
treatment	O
.	O

CONCLUSION	O
:	O
Established	O
visual	B
field	I
defects	I
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	O
therapy	O
did	O
not	O
usually	O
progress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medication	O
.	O

These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin	O
-	O
associated	O
visual	B
field	I
defects	I
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose	O
-	O
dependent	O
toxicity	B
.	O

Induction	O
of	O
rosaceiform	O
dermatitis	B
during	O
treatment	O
of	O
facial	B
inflammatory	I
dermatoses	I
with	O
tacrolimus	O
ointment	O
.	O

BACKGROUND	O
:	O
Tacrolimus	O
ointment	O
is	O
increasingly	O
used	O
for	O
anti	O
-	O
inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face	O
,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid	O
-	O
aggravated	O
rosacea	B
and	O
perioral	B
dermatitis	I
.	O

We	O
report	O
on	O
rosaceiform	O
dermatitis	B
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	O
ointment	O
.	O

OBSERVATIONS	O
:	O
Six	O
adult	O
patients	O
with	O
inflammatory	B
facial	I
dermatoses	I
were	O
treated	O
with	O
tacrolimus	O
ointment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
standard	O
treatments	O
.	O

Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well	O
-	O
tolerated	O
treatment	O
,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	B
and	O
1	O
with	O
a	O
history	O
of	O
acne	B
experienced	O
sudden	O
worsening	O
with	O
pustular	O
rosaceiform	O
lesions	O
.	O

Biopsy	O
revealed	O
an	O
abundance	O
of	O
Demodex	O
mites	O
in	O
2	O
of	O
these	O
patients	O
.	O

In	O
1	O
patient	O
with	O
eyelid	O
eczema	B
,	O
rosaceiform	O
periocular	B
dermatitis	I
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

In	O
1	O
patient	O
with	O
atopic	B
dermatitis	I
,	O
telangiectatic	O
and	O
papular	B
rosacea	I
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment	O
.	O

CONCLUSIONS	O
:	O
Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	B
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	O
ointment	O
is	O
heterogeneous	O
.	O

A	O
variety	O
of	O
factors	O
,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	O
,	O
proliferation	O
of	O
Demodex	O
due	O
to	O
local	O
immunosuppression	O
,	O
and	O
the	O
occlusive	O
properties	O
of	O
the	O
ointment	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomena	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
identify	O
individual	O
risk	O
factors	O
.	O

Intravascular	O
hemolysis	B
and	O
acute	B
renal	I
failure	I
following	O
intermittent	O
rifampin	O
therapy	O
.	O

Renal	B
failure	I
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	O
.	O

Intravascular	O
hemolysis	B
leading	O
to	O
acute	B
renal	I
failure	I
following	O
rifampin	O
therapy	O
is	O
extremely	O
rare	O
.	O

Two	O
patients	O
with	O
leprosy	B
who	O
developed	O
hemolysis	B
and	O
acute	B
renal	I
failure	I
following	O
rifampin	O
are	O
reported	O
.	O

Structural	O
abnormalities	O
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	O
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
profile	O
of	O
structural	B
deficits	I
in	I
the	I
human	I
brain	I
associated	O
with	O
chronic	O
methamphetamine	O
(	O
MA	O
)	O
abuse	O
.	O

Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	O
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	B
abnormalities	I
.	O

Using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
new	O
computational	O
brain	O
-	O
mapping	O
techniques	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	O
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	B
impairment	I
.	O

We	O
used	O
high	O
-	O
resolution	O
MRI	O
and	O
surface	O
-	O
based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	B
in	I
the	I
cortex	I
,	I
hippocampus	I
,	I
white	I
matter	I
,	I
and	I
ventricles	I
in	O
22	O
human	O
subjects	O
who	O
used	O
MA	O
and	O
21	O
age	O
-	O
matched	O
,	O
healthy	O
controls	O
.	O

Cortical	O
maps	O
revealed	O
severe	O
gray	O
-	O
matter	O
deficits	O
in	O
the	O
cingulate	O
,	O
limbic	O
,	O
and	O
paralimbic	O
cortices	O
of	O
MA	O
abusers	O
(	O
averaging	O
11.3	O
%	O
below	O
control	O
;	O
p	O
<	O
0.05	O
)	O
.	O

On	O
average	O
,	O
MA	O
abusers	O
had	O
7.8	O
%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(	O
p	O
<	O
0.01	O
;	O
left	O
,	O
p	O
=	O
0.01	O
;	O
right	O
,	O
p	O
<	O
0.05	O
)	O
and	O
significant	O
white	O
-	O
matter	O
hypertrophy	B
(	O
7.0	O
%	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Hippocampal	O
deficits	O
were	O
mapped	O
and	O
correlated	O
with	O
memory	O
performance	O
on	O
a	O
word	O
-	O
recall	O
test	O
(	O
p	O
<	O
0.05	O
)	O
.	O

MRI	O
-	O
based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	O
abuse	O
causes	O
a	O
selective	O
pattern	O
of	O
cerebral	O
deterioration	O
that	O
contributes	O
to	O
impaired	B
memory	I
performance	I
.	O

MA	O
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and	O
,	O
consistent	O
with	O
metabolic	O
studies	O
,	O
the	O
cingulate	O
-	O
limbic	O
cortex	O
,	O
inducing	O
neuroadaptation	O
,	O
neuropil	O
reduction	O
,	O
or	O
cell	O
death	O
.	O

Prominent	O
white	O
-	O
matter	O
hypertrophy	B
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes	O
,	O
including	O
gliosis	B
secondary	O
to	O
neuronal	B
damage	I
.	O

These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	O
abuse	O
,	O
providing	O
therapeutic	O
targets	O
for	O
drug	O
-	O
induced	O
brain	B
injury	I
.	O

Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	O
treatment	O
is	O
associated	O
with	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
target	O
gene	O
activation	O
.	O

Amiodarone	O
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	B
in	O
some	O
patients	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	O
and	O
examined	O
for	O
changes	O
in	O
hepatic	O
histology	O
and	O
gene	O
regulation	O
.	O

Amiodarone	O
induced	O
hepatomegaly	B
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	O
and	O
glucose	O
.	O

Northern	O
blot	O
analysis	O
of	O
hepatic	O
RNA	O
revealed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
critical	O
for	O
fatty	O
acid	O
oxidation	O
,	O
lipoprotein	O
assembly	O
,	O
and	O
lipid	O
transport	O
.	O

Many	O
of	O
these	O
genes	O
are	O
regulated	O
by	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
ligand	O
-	O
activated	O
nuclear	O
hormone	O
receptor	O
transcription	O
factor	O
.	O

The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	B
in	O
PPARalpha	O
knockout	O
[	O
PPARalpha-	O
/	O
-	O
]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	O
were	O
dependent	O
upon	O
the	O
presence	O
of	O
a	O
functional	O
PPARalpha	O
gene	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
treatment	O
of	O
PPARalpha-	O
/	O
-	O
mice	O
with	O
amiodarone	O
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	O
weight	B
loss	I
.	O

The	O
inability	O
of	O
amiodarone	O
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	B
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	O
on	O
the	O
function	O
of	O
this	O
receptor	O
were	O
indirect	O
.	O

Based	O
upon	O
these	O
results	O
,	O
we	O
conclude	O
that	O
amiodarone	O
disrupts	O
hepatic	O
lipid	O
homeostasis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
PPARalpha	O
target	O
genes	O
is	O
secondary	O
to	O
this	O
toxic	O
effect	O
.	O

These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	B
effects	O
of	O
amiodarone	O
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone	O
-	O
induced	O
hepatotoxicity	B
.	O

Safety	O
and	O
compliance	O
with	O
once	O
-	O
daily	O
niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
as	O
initial	O
therapy	O
in	O
the	O
Impact	O
of	O
Medical	O
Subspecialty	O
on	O
Patient	O
Compliance	O
to	O
Treatment	O
(	O
IMPACT	O
)	O
study	O
.	O

Niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	B
and	O
mixed	O
dyslipidemia	B
.	O

This	O
open	O
-	O
labeled	O
,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
when	O
dosed	O
as	O
initial	O
therapy	O
and	O
patient	O
compliance	O
to	O
treatment	O
in	O
various	O
clinical	O
practice	O
settings	O
.	O

A	O
total	O
of	O
4,499	O
patients	O
with	O
dyslipidemia	B
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	O
1,081	O
sites	O
.	O

Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(	O
500	O
mg	O
of	O
niacin	O
extended	O
-	O
release	O
/	O
20	O
mg	O
of	O
lovastatin	O
)	O
once	O
nightly	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tablets	O
for	O
8	O
weeks	O
.	O

Patients	O
also	O
received	O
dietary	O
counseling	O
,	O
educational	O
materials	O
,	O
and	O
reminders	O
to	O
call	O
a	O
toll	O
-	O
free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	B
and	O
niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
.	O

Primary	O
end	O
points	O
were	O
study	O
compliance	O
,	O
increases	O
in	O
liver	O
transaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
clinical	O
myopathy	B
.	O

Final	O
study	O
status	O
was	O
available	O
for	O
4,217	O
patients	O
(	O
94	O
%	O
)	O
.	O

Compliance	O
to	O
niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
was	O
77	O
%	O
,	O
with	O
3,245	O
patients	O
completing	O
the	O
study	O
.	O

Patients	O
in	O
the	O
southeast	O
and	O
those	O
enrolled	O
by	O
endocrinologists	O
had	O
the	O
lowest	O
compliance	O
and	O
highest	O
adverse	O
event	O
rates	O
.	O

Flushing	B
was	O
the	O
most	O
common	O
adverse	O
event	O
,	O
reported	O
by	O
18	O
%	O
of	O
patients	O
and	O
leading	O
to	O
discontinuation	O
by	O
6	O
%	O
.	O

Incidence	O
of	O
increased	O
aspartate	O
aminotransferase	O
and/or	O
alanine	O
aminotransferase	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
was	O
<	O
0.3	O
%	O
.	O

An	O
increase	O
of	O
creatine	O
phosphokinase	O
to	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.24	O
%	O
of	O
patients	O
,	O
and	O
no	O
cases	O
of	O
drug	O
-	O
induced	O
myopathy	B
were	O
observed	O
.	O

Niacin	O
extended	O
-	O
release	O
/	O
lovastatin	O
1,000	O
/	O
40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	O
and	O
muscle	O
enzymes	O
.	O

Protective	O
effect	O
of	O
Terminalia	O
chebula	O
against	O
experimental	O
myocardial	B
injury	I
induced	O
by	O
isoproterenol	O
.	O

Cardioprotective	O
effect	O
of	O
ethanolic	O
extract	O
of	O
Terminalia	O
chebula	O
fruits	O
(	O
500	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
was	O
examined	O
in	O
isoproterenol	O
(	O
200	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
induced	O
myocardial	B
damage	I
in	O
rats	O
.	O

In	O
isoproterenol	O
administered	O
rats	O
,	O
the	O
level	O
of	O
lipid	O
peroxides	O
increased	O
significantly	O
in	O
the	O
serum	O
and	O
heart	O
.	O

A	O
significant	O
decrease	O
was	O
observed	O
in	O
the	O
activity	O
of	O
the	O
myocardial	O
marker	O
enzymes	O
with	O
a	O
concomitant	O
increase	O
in	O
their	O
activity	O
in	O
serum	O
.	O

Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	B
.	O

T.	O
chebula	O
extract	O
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	O
on	O
lipid	O
peroxide	O
formation	O
and	O
retained	O
the	O
activities	O
of	O
the	O
diagnostic	O
marker	O
enzymes	O
.	O

A	O
case	O
of	O
postoperative	O
anxiety	B
due	O
to	O
low	O
dose	O
droperidol	O
used	O
with	O
patient	O
-	O
controlled	O
analgesia	O
.	O

A	O
multiparous	O
woman	O
in	O
good	O
psychological	O
health	O
underwent	O
urgent	O
caesarean	O
section	O
in	O
labour	O
.	O

Postoperatively	O
,	O
she	O
was	O
given	O
a	O
patient	O
-	O
controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	O
0.5	O
mg	O
and	O
droperidol	O
0.025	O
mg	O
.	O

Whilst	O
using	O
the	O
device	O
she	O
gradually	O
became	O
anxious	O
,	O
the	O
feeling	O
worsening	O
after	O
each	O
bolus	O
.	O

The	O
diagnosis	O
of	O
droperidol	O
-	O
induced	O
psychological	B
disturbance	I
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questioning	O
the	O
patient	O
gave	O
a	O
very	O
clear	O
history	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0.9	O
mg	O
droperidol	O
,	O
a	O
syringe	O
containing	O
diamorphine	O
only	O
was	O
substituted	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
dramatic	O
extrapyramidal	O
side	O
effects	O
of	O
dopaminergic	O
antiemetics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifestations	O
may	O
easily	O
be	O
overlooked	O
.	O

Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	B
insipidus	I
:	O
a	O
case	O
study	O
.	O

This	O
case	O
study	O
highlights	O
the	O
important	O
contribution	O
of	O
nursing	O
in	O
obtaining	O
an	O
accurate	O
health	O
history	O
.	O

The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	B
diabetes	I
insipidus	I
(	O
DI	B
)	O
secondary	O
to	O
a	O
traumatic	B
brain	I
injury	I
.	O

The	O
nursing	O
staff	O
,	O
by	O
reviewing	O
the	O
patient	O
's	O
health	O
history	O
with	O
his	O
family	O
,	O
discovered	O
a	O
history	O
of	O
polydipsia	B
and	O
long	O
-	O
standing	O
lithium	O
use	O
.	O

Lithium	O
is	O
implicated	O
in	O
drug	O
-	O
induced	O
nephrogenic	B
DI	I
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	O
since	O
being	O
admitted	O
to	O
the	O
hospital	O
,	O
his	O
treatment	O
changed	O
to	O
focus	O
on	O
nephrogenic	B
DI	I
.	O

By	O
combining	O
information	O
from	O
the	O
patient	O
history	O
,	O
the	O
physical	O
examination	O
,	O
and	O
radiologic	O
and	O
laboratory	O
studies	O
,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self	O
-	O
treating	O
his	O
lithium	O
-	O
induced	O
nephrogenic	B
DI	I
and	O
developed	O
neurogenic	B
DI	I
secondary	O
to	O
brain	B
trauma	I
.	O

Thus	O
successful	O
treatment	O
required	O
that	O
nephrogenic	O
and	O
neurogenic	B
DI	I
be	O
treated	O
concomitantly	O
.	O

Factors	O
contributing	O
to	O
ribavirin	O
-	O
induced	O
anemia	B
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Interferon	O
and	O
ribavirin	O
combination	O
therapy	O
for	O
chronic	B
hepatitis	I
C	I
produces	O
hemolytic	B
anemia	I
.	O

This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin	O
-	O
induced	O
anemia	B
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
patients	O
with	O
chronic	B
hepatitis	I
C	I
who	O
received	O
interferon	O
-	O
alpha-2b	O
at	O
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	O
administered	O
orally	O
at	O
a	O
dose	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
study	O
.	O

A	O
hemoglobin	O
concentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribavirin	O
-	O
induced	O
anemia	B
.	O

RESULTS	O
:	O
Ribavirin	O
-	O
induced	O
anemia	B
occurred	O
in	O
18	O
(	O
20.5	O
%	O
)	O
patients	O
during	O
treatment	O
.	O

A	O
2	O
g	O
/	O
dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	B
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
.	O

The	O
hemoglobin	O
concentration	O
in	O
patients	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decrease	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lower	O
even	O
after	O
week	O
2	O
than	O
in	O
patients	O
with	O
<	O
2	O
g	O
/	O
dL	O
decrease	O
(	O
P	O
<	O
0.01	O
)	O
.	O

A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	O
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	B
(	O
P	O
<	O
0.01	O
)	O
.	O

Such	O
factors	O
as	O
sex	O
(	O
female	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
years	O
old	O
)	O
,	O
and	O
the	O
ribavirin	O
dose	O
by	O
body	O
weight	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univariate	O
analysis	O
.	O

CONCLUSIONS	O
:	O
Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=	O
60	O
years	O
old	O
,	O
in	O
female	O
patients	O
,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O

Patients	O
who	O
experience	O
a	O
fall	O
in	O
hemoglobin	O
concentrations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
should	O
be	O
monitored	O
with	O
particular	O
care	O
.	O

Zidovudine	O
-	O
induced	O
hepatitis	B
.	O

A	O
case	O
of	O
acute	O
hepatitis	B
induced	O
by	O
zidovudine	O
in	O
a	O
38-year	O
-	O
old	O
patient	O
with	O
AIDS	B
is	O
presented	O
.	O

The	O
mechanism	O
whereby	O
the	O
hepatitis	B
was	O
induced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
patient	O
tolerated	O
well	O
an	O
alternative	O
reverse	O
transcriptase	O
inhibitor	O
,	O
2'3	O
'	O
dideoxyinosine	O
.	O

Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	B
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complication	O
.	O

Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin	O
-	O
induced	O
cardiac	O
mitochondrial	B
injury	I
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	O
(	O
ROS	O
)	O
/	O
nitrogen	O
species	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	O
(	O
ADR	O
)	O
-induced	O
cardiotoxicity	B
actually	O
resulted	O
in	O
cardiomyocyte	O
oxidative	O
/	O
nitrative	O
damage	O
,	O
and	O
to	O
quantitatively	O
determine	O
the	O
time	O
course	O
and	O
subcellular	O
localization	O
of	O
these	O
postulated	O
damage	O
products	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg	O
/	O
kg	O
ADR	O
.	O

Ultrastructural	O
damage	O
and	O
levels	O
of	O
4-hydroxy-2-nonenal	O
(	O
4HNE	O
)	O
-protein	O
adducts	O
and	O
3-nitrotyrosine	O
(	O
3NT	O
)	O
were	O
analyzed	O
.	O

Quantitative	O
ultrastructural	O
damage	O
using	O
computerized	O
image	O
techniques	O
showed	O
cardiomyocyte	O
injury	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
mitochondria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
injured	O
subcellular	O
organelle	O
.	O

Analysis	O
of	O
4HNE	O
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	O
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
decline	O
at	O
24	O
hours	O
.	O

3NT	O
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	O
6	O
hours	O
and	O
subsequently	O
declined	O
at	O
24	O
hours	O
.	O

Our	O
data	O
showed	O
ADR	O
induced	O
4HNE	O
-	O
protein	O
adducts	O
in	O
mitochondria	O
at	O
the	O
same	O
time	O
point	O
as	O
when	O
mitochondrial	B
injury	I
initially	O
appeared	O
.	O

These	O
results	O
document	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
mitochondrial	B
oxidative	I
damage	I
precedes	O
nitrative	O
damage	O
.	O

The	O
progressive	O
nature	O
of	O
mitochondrial	B
injury	I
suggests	O
that	O
mitochondria	O
,	O
not	O
other	O
subcellular	O
organelles	O
,	O
are	O
the	O
major	O
site	O
of	O
intracellular	O
injury	O
.	O

Sotalol	O
-	O
induced	O
coronary	B
spasm	I
in	O
a	O
patient	O
with	O
dilated	B
cardiomyopathy	I
associated	O
with	O
sustained	O
ventricular	B
tachycardia	I
.	O

A	O
54-year	O
-	O
old	O
man	O
with	O
severe	O
left	O
ventricular	B
dysfunction	I
due	O
to	O
dilated	B
cardiomyopathy	I
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	B
tachycardia	I
(	O
VT	B
)	O
.	O

After	O
the	O
administration	O
of	O
nifekalant	O
hydrochloride	O
,	O
sustained	O
VT	B
was	O
terminated	O
.	O

An	O
alternate	O
class	O
III	O
agent	O
,	O
sotalol	O
,	O
was	O
also	O
effective	O
for	O
the	O
prevention	O
of	O
VT	B
.	O

However	O
,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	O
to	O
sotalol	O
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	O
almost	O
the	O
same	O
time	O
for	O
three	O
consecutive	O
days	O
.	O

ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiazem	O
.	O

Coronary	B
vasospasm	I
may	O
be	O
induced	O
by	O
the	O
non	O
-	O
selective	O
beta	O
-	O
blocking	O
properties	O
of	O
sotalol	O
.	O

Effects	O
of	O
the	O
antidepressant	O
trazodone	O
,	O
a	O
5-HT	O
2A	O
/	O
2C	O
receptor	O
antagonist	O
,	O
on	O
dopamine	O
-	O
dependent	O
behaviors	O
in	O
rats	O
.	O

RATIONALE	O
:	O
5-Hydroxytryptamine	O
,	O
via	O
stimulation	O
of	O
5-HT	O
2C	O
receptors	O
,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5-HT	O
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O

The	O
antidepressant	O
trazodone	O
is	O
a	O
5-HT	O
2A	O
/	O
2C	O
receptor	O
antagonist	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	O
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O

METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	O
on	O
dexamphetamine-	O
and	O
apomorphine	O
-	O
induced	O
oral	B
stereotypies	I
,	O
on	O
catalepsy	B
induced	O
by	O
haloperidol	O
and	O
apomorphine	O
(	O
0.05	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
on	O
ergometrine	O
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	O
-	O
induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	O
.	O

We	O
also	O
investigated	O
whether	O
trazodone	O
induces	O
catalepsy	B
in	O
rats	O
.	O

RESULTS	O
:	O
Trazodone	O
at	O
2.5	O
-	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
did	O
not	O
induce	O
catalepsy	B
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	O
(	O
1.5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotypy	O
and	O
apomorphine	O
(	O
0.05	O
mg	O
/	O
kg	O
)	O
-induced	O
catalepsy	B
.	O

However	O
,	O
pretreatment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O

trazodone	O
enhanced	O
dexamphetamine	O
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	O
catalepsy	B
,	O
ergometrine	O
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	O
-	O
induced	O
penile	O
erections	O
.	O

Trazodone	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i.p	O
.	O

induced	O
catalepsy	B
and	O
antagonized	O
apomorphine	O
and	O
dexamphetamine	O
stereotypies	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	O
at	O
2.5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodone	O
blocks	O
5-HT	O
2A	O
and	O
5-HT	O
2C	O
receptors	O
.	O

We	O
suggest	O
that	O
trazodone	O
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blocking	O
the	O
5-HT	O
2C	O
receptors	O
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5-HT	O
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	O
stereotypy	O
and	O
antagonizes	O
haloperidol	O
catalepsy	B
.	O

Swallowing	B
abnormalities	I
and	O
dyskinesia	B
in	O
Parkinson	B
's	I
disease	I
.	O

Gastrointestinal	B
abnormalities	I
in	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	B
patients	O
with	O
and	O
without	O
levodopa	O
-	O
induced	O
dyskinesia	B
.	O

Fifteen	O
dyskinetic	B
,	O
12	O
nondyskinetic	O
patients	O
,	O
and	O
a	O
control	O
group	O
were	O
included	O
.	O

Patients	O
were	O
asked	O
about	O
dysphagia	B
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson	B
's	I
Disease	I
Rating	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehn	O
and	O
Yahr	O
scale	O
.	O

Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	O
swallow	O
with	O
videofluoroscopy	O
.	O

Nondyskinetic	O
patients	O
,	O
but	O
not	O
the	O
dyskinetic	B
ones	O
,	O
showed	O
less	O
oropharyngeal	O
swallowing	O
efficiency	O
(	O
OPSE	O
)	O
for	O
liquid	O
food	O
than	O
controls	O
(	O
Dunnett	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Dyskinetic	B
patients	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondyskinetic	O
(	O
Dunnett	O
,	O
P	O
=	O
0.06	O
)	O
.	O

Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	O
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oral	O
transit	O
time	O
(	O
Pearson	O
's	O
correlation	O
,	O
P	O
=	O
0.01	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
report	O
of	O
dysphagia	B
nor	O
any	O
of	O
the	O
PD	B
severity	O
parameters	O
correlated	O
to	O
the	O
videofluoroscopic	O
variables	O
.	O

In	O
the	O
current	O
study	O
,	O
dyskinetic	B
patients	O
performed	O
better	O
in	O
swallowing	O
function	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	O
dose	O
.	O

Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	O
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	B
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	B
.	O

Inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B
nephritis	I
induced	O
by	O
gentamicin	O
.	O

BACKGROUND	O
:	O
Animals	O
treated	O
with	O
gentamicin	O
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	B
in	O
the	O
renal	O
cortex	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	O
or	O
gentamicin	O
+	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
an	O
NF	O
-	O
kappaB	O
inhibitor	O
.	O

METHODS	O
:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	O
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
days	O
,	O
38	O
with	O
gentamicin	O
+	O
PDTC	O
,	O
and	O
28	O
with	O
0.15	O
M	O
NaCl	O
solution	O
.	O

The	O
animals	O
were	O
killed	O
5	O
and	O
30	O
days	O
after	O
these	O
injections	O
and	O
the	O
kidneys	O
were	O
removed	O
for	O
histological	O
and	O
immunohistochemical	O
studies	O
.	O

The	O
results	O
of	O
the	O
immunohistochemical	O
studies	O
were	O
scored	O
according	O
to	O
the	O
extent	O
of	O
staining	O
.	O

The	O
fractional	O
interstitial	O
area	O
was	O
determined	O
by	O
morphometry	O
.	O

RESULTS	O
:	O
Gentamicin	O
-	O
treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	O
levels	O
.	O

Increased	O
ED-1	O
,	O
MAP	O
kinases	O
and	O
NF	O
-	O
kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	O
cortex	O
from	O
all	O
gentamicin	O
-	O
treated	O
rats	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	B
in	O
the	O
renal	O
cortex	O
despite	O
the	O
recovery	O
of	O
renal	O
function	O
.	O

Treatment	O
with	O
PDTC	O
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
show	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B
nephritis	I
induced	O
by	O
gentamicin	O
.	O

Glucose	O
metabolism	O
in	O
patients	O
with	O
schizophrenia	B
treated	O
with	O
atypical	O
antipsychotic	O
agents	O
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B
mellitus	I
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B
treated	O
with	O
certain	O
atypical	O
antipsychotic	O
agents	O
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	O
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	O
and	O
olanzapine	O
)	O
and	O
risperidone	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
.	O

DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O

Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
.	O

Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B
or	O
schizoaffective	B
disorder	I
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	O
,	O
olanzapine	O
,	O
or	O
risperidone	O
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	O
and	O
fasting	O
serum	O
insulin	O
levels	O
,	O
insulin	B
sensitivity	I
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B
resistance	I
,	O
and	O
glucose	O
effectiveness	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/-	O

SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	O
agent	O
was	O
68.3	O
+	O
/-	O

28.9	O
months	O
(	O
clozapine	O
)	O
,	O
29.5	O
+	O
/-	O

17.5	O
months	O
(	O
olanzapine	O
)	O
,	O
and	O
40.9	O
+	O
/-	O

33.7	O
(	O
risperidone	O
)	O
.	O

Fasting	O
serum	O
insulin	O
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3.35	O
;	O
P	O
=	O
.047	O
)	O
(	O
clozapine	O
>	O
olanzapine	O
>	O
risperidone	O
)	O
with	O
significant	O
differences	O
between	O
clozapine	O
and	O
risperidone	O
(	O
t	O
(	O
33	O
)	O
=	O
2.32	O
;	O
P	O
=	O
.03	O
)	O
and	O
olanzapine	O
and	O
risperidone	O
(	O
t	O
(	O
33	O
)	O
=	O
2.15	O
;	O
P	O
=	O
.04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	B
sensitivity	I
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10.66	O
;	O
P<.001	O
)	O
(	O
clozapine	O
<	O
olanzapine	O
<	O
risperidone	O
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	O
and	O
olanzapine	O
exhibiting	O
significant	O
insulin	B
resistance	I
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	O
(	O
clozapine	O
vs	O
risperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
-4.29	O
;	O
P<.001	O
;	O
olanzapine	O
vs	O
risperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
-3.62	O
;	O
P	O
=	O
.001	O
[	O
P<.001	O
]	O
)	O
.	O

The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B
resistance	I
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4.92	O
;	O
P	O
=	O
.01	O
)	O
(	O
clozapine	O
>	O
olanzapine	O
>	O
risperidone	O
)	O
(	O
clozapine	O
vs	O
risperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
2.94	O
;	O
P	O
=	O
.006	O
;	O
olanzapine	O
vs	O
risperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
2.42	O
;	O
P	O
=	O
.02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	O
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4.18	O
;	O
P	O
=	O
.02	O
)	O
(	O
clozapine	O
<	O
olanzapine	O
<	O
risperidone	O
)	O
with	O
significant	O
differences	O
between	O
clozapine	O
and	O
risperidone	O
(	O
t	O
(	O
30	O
)	O
=	O
-2.59	O
;	O
P	O
=	O
.02	O
)	O
and	O
olanzapine	O
and	O
risperidone	O
(	O
t	O
(	O
30	O
)	O
=	O
-2.34	O
,	O
P	O
=	O
.03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine-	O
and	O
olanzapine	O
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B
resistance	I
and	O
impairment	O
of	O
glucose	O
effectiveness	O
compared	O
with	O
risperidone	O
-	O
treated	O
subjects	O
.	O

Patients	O
taking	O
clozapine	O
and	O
olanzapine	O
must	O
be	O
examined	O
for	O
insulin	B
resistance	I
and	O
its	O
consequences	O
.	O

Thoracic	B
hematomyelia	I
secondary	O
to	O
coumadin	O
anticoagulant	O
therapy	O
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
thoracic	B
hematomyelia	I
secondary	O
to	O
anticoagulant	O
therapy	O
is	O
presented	O
.	O

Clinical	O
features	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
cases	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
suspicion	O
may	O
lead	O
to	O
a	O
quick	O
diagnostic	O
procedure	O
and	O
successful	O
decompressive	O
surgery	O
.	O

Mania	B
associated	O
with	O
fluoxetine	O
treatment	O
in	O
adolescents	O
.	O

Fluoxetine	O
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	B
.	O

Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults	O
,	O
fluoxetine	O
has	O
been	O
reported	O
to	O
induce	O
mania	B
.	O

The	O
cases	O
of	O
five	O
depressed	B
adolescents	O
,	O
14	O
-	O
16	O
years	O
of	O
age	O
,	O
who	O
developed	O
mania	B
during	O
pharmacotherapy	O
with	O
fluoxetine	O
,	O
are	O
reported	O
here	O
.	O

Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	B
or	O
hypomania	B
during	O
fluoxetine	O
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
and	O
affective	O
instability	O
;	O
major	O
depression	B
with	O
psychotic	B
features	O
;	O
a	O
family	O
history	O
of	O
affective	B
disorder	I
,	O
especially	O
bipolar	B
disorder	I
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	B
disorder	I
.	O

Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	O
induced	O
mania	B
in	O
adolescents	O
.	O

Acute	B
renal	I
insufficiency	I
after	O
high	O
-	O
dose	O
melphalan	O
in	O
patients	O
with	O
primary	B
systemic	I
amyloidosis	I
during	O
stem	O
cell	O
transplantation	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
primary	B
systemic	I
amyloidosis	I
(	O
AL	B
)	O
have	O
a	O
poor	O
prognosis	O
.	O

Median	O
survival	O
time	O
from	O
standard	O
treatments	O
is	O
only	O
17	O
months	O
.	O

High	O
-	O
dose	O
intravenous	O
melphalan	O
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy	O
,	O
but	O
treatment	O
mortality	O
can	O
be	O
high	O
.	O

The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	B
renal	I
insufficiency	I
immediately	O
after	O
melphalan	O
conditioning	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
risk	O
factors	O
and	O
impact	O
on	O
posttransplant	O
mortality	O
.	O

METHODS	O
:	O
Consecutive	O
AL	B
patients	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrospectively	O
.	O

Acute	B
renal	I
insufficiency	I
(	O
ARI	B
)	O
after	O
high	O
-	O
dose	O
melphalan	O
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0.5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
serum	O
creatinine	O
level	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
baseline	O
immediately	O
after	O
conditioning	O
.	O

Urine	O
sediment	O
score	O
was	O
the	O
sum	O
of	O
the	O
individual	O
types	O
of	O
sediment	O
identified	O
on	O
urine	O
microscopy	O
.	O

RESULTS	O
:	O
Of	O
the	O
80	O
patients	O
studied	O
,	O
ARI	B
developed	O
in	O
18.8	O
%	O
of	O
the	O
patients	O
after	O
high	O
-	O
dose	O
melphalan	O
.	O

Univariate	O
analysis	O
identified	O
age	O
,	O
hypoalbuminemia	B
,	O
heavy	O
proteinuria	B
,	O
diuretic	O
use	O
,	O
and	O
urine	O
sediment	O
score	O
(	O
>	O
3	O
)	O
as	O
risk	O
factors	O
.	O

Age	O
and	O
urine	O
sediment	O
score	O
remained	O
independently	O
significant	O
risk	O
factors	O
in	O
the	O
multivariate	O
analysis	O
.	O

Patients	O
who	O
had	O
ARI	B
after	O
high	O
-	O
dose	O
melphalan	O
underwent	O
dialysis	O
more	O
often	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
had	O
a	O
worse	O
1-year	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSION	O
:	O
The	O
timing	O
of	O
renal	B
injury	I
strongly	O
suggests	O
melphalan	O
as	O
the	O
causative	O
agent	O
.	O

Ongoing	O
tubular	B
injury	I
may	O
be	O
a	O
prerequisite	O
for	O
renal	B
injury	I
by	O
melphalan	O
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment	O
.	O

Development	O
of	O
ARI	B
adversely	O
affected	O
the	O
outcome	O
after	O
PBSCT	O
.	O

Effective	O
preventive	O
measures	O
may	O
help	O
decrease	O
the	O
treatment	O
mortality	O
of	O
PBSCT	O
in	O
AL	B
patients	O
.	O

Focal	O
cerebral	B
ischemia	I
in	O
rats	O
:	O
effect	O
of	O
phenylephrine	O
-	O
induced	O
hypertension	B
during	O
reperfusion	O
.	O

After	O
180	O
min	O
of	O
temporary	O
middle	B
cerebral	I
artery	I
occlusion	I
in	O
spontaneously	O
hypertensive	B
rats	O
,	O
the	O
effect	O
of	O
phenylephrine	O
-	O
induced	O
hypertension	B
on	O
ischemic	B
brain	I
injury	I
and	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
determined	O
.	O

Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion	O
:	O
Control	O
,	O
normotensive	O
reperfusion	O
;	O
90	O
/	O
hypertension	B
(	O
90	O
/	O
HTN	B
)	O
,	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only	O
;	O
15	O
/	O
hypertension	B
(	O
15	O
/	O
HTN	B
)	O
,	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	B
and	O
75	O
min	O
of	O
normotension	O
.	O

Part	O
A	O
,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	B
injury	I
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2,3,5-triphenyltetrazolium	O
chloride	O
and	O
edema	B
was	O
evaluated	O
by	O
microgravimetry	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
rats	O
in	O
each	O
group	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
evaluated	O
by	O
measuring	O
the	O
amount	O
and	O
extent	O
of	O
extravasation	O
of	O
Evans	O
Blue	O
dye	O
.	O

Brain	B
injury	I
(	O
percentage	O
of	O
the	O
ischemic	B
hemisphere	I
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	B
group	O
(	O
16	O
+	O
/-	O

6	O
,	O
mean	O
+	O
/-	O

SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	B
group	O
(	O
30	O
+	O
/-	O

6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
control	O
group	O
(	O
42	O
+	O
/-	O

5	O
)	O
.	O

Specific	O
gravity	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	B
group	O
(	O
1.043	O
+	O
/-	O
0.002	O
)	O
versus	O
the	O
90	O
/	O
HTN	B
(	O
1.036	O
+	O
/-	O

0.003	O
)	O
and	O
control	O
(	O
1.037	O
+	O
/-	O

0.003	O
)	O
groups	O
.	O

Evans	O
Blue	O
(	O
mug	O
g-1	O
of	O
brain	O
tissue	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	B
group	O
(	O
24.4	O
+	O
/-	O

6.0	O
)	O
versus	O
the	O
control	O
group	O
(	O
12.3	O
+	O
/-	O

4.1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	B
group	O
(	O
7.3	O
+	O
/-	O

3.2	O
)	O
.	O

This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion	O
,	O
a	O
short	O
interval	O
of	O
hypertension	B
decreases	O
brain	B
injury	I
and	O
edema	B
;	O
and	O
that	O
sustained	O
hypertension	B
increases	O
the	O
risk	O
of	O
vasogenic	B
edema	I
.	O

People	O
aged	O
over	O
75	O
in	O
atrial	B
fibrillation	I
on	O
warfarin	O
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B
and	O
stroke	B
in	O
more	O
than	O
500	O
patient	O
-	O
years	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B
and	O
stroke	B
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B
fibrillation	I
on	O
adjusted	O
-	O
dose	O
warfarin	O
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O

SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B
fibrillation	I
on	O
warfarin	O
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B
episodes	O
,	O
strokes	B
,	O
and	O
warfarin	O
use	O
was	O
obtained	O
from	O
patients	O
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81.1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfarin	O
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhages	B
,	O
for	O
an	O
annual	O
rate	O
of	O
10.0	O
%	O
,	O
including	O
24	O
(	O
45.3	O
%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9.4	O
%	O
)	O
fatal	O
bleeds	O
.	O

The	O
annual	O
stroke	B
rate	O
after	O
initiation	O
of	O
warfarin	O
was	O
2.6	O
%	O
.	O

CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	B
rate	O
on	O
warfarin	O
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	O
treatment	O
is	O
.	O

Safety	O
of	O
celecoxib	O
in	O
patients	O
with	O
adverse	O
skin	B
reactions	I
to	O
acetaminophen	O
(	O
paracetamol	O
)	O
and	O
nimesulide	O
associated	O
or	O
not	O
with	O
common	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

BACKGROUND	O
:	O
Acetaminophen	O
(	O
paracetamol	O
--	O
P	O
)	O
and	O
Nimesulide	O
(	O
N	O
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	O
/	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

The	O
rate	O
of	O
adverse	O
hypersensitivity	B
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O

On	O
the	O
contrary	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O

Celecoxib	O
(	O
CE	O
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX-2	O
enzyme	O
.	O

OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	O
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B
reactions	I
to	O
P	O
and	O
N	O
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B
to	O
P	O
and	O
N	O
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	O
.	O

The	O
diagnosis	O
of	O
P	O
and	O
N	O
-	O
induced	O
skin	B
reactions	I
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	O
in	O
refracted	O
doses	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
days	O
,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O

All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O

The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B
,	O
rush	O
or	O
urticaria	B
-	O
angioedema	B
.	O

RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88.8	O
%	O
)	O
tolerated	O
CE	O
.	O

Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B
of	O
the	O
lips	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B
reaction	O
to	O
CE	O
was	O
documented	O
among	O
9	O
P	O
and	O
N	O
-	O
highly	O
NSAIDs	O
intolerant	O
patients	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	O
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	O
and	O
N.	O

Case	O
-	O
control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
use	O
and	O
end	B
-	I
stage	I
renal	I
disease	I
.	O

BACKGROUND	O
:	O
Studies	O
on	O
the	O
association	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
aspirin	O
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
end	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
have	O
given	O
conflicting	O
results	O
.	O

In	O
order	O
to	O
examine	O
this	O
association	O
,	O
a	O
case	O
-	O
control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	B
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	B
in	O
the	O
study	O
area	O
between	O
June	O
1	O
,	O
1995	O
and	O
November	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	B
.	O

Controls	O
were	O
patients	O
admitted	O
to	O
the	O
same	O
hospitals	O
from	O
where	O
the	O
cases	O
arose	O
,	O
also	O
matched	O
by	O
age	O
and	O
sex	O
.	O

Odds	O
ratios	O
were	O
calculated	O
using	O
a	O
conditional	O
logistic	O
model	O
,	O
including	O
potential	O
confounding	O
factors	O
,	O
both	O
for	O
the	O
whole	O
study	O
population	O
and	O
for	O
the	O
various	O
underlying	O
diseases	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
cases	O
and	O
1190	O
controls	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Long	O
-	O
term	O
use	O
of	O
any	O
analgesic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
ratio	O
of	O
1.22	O
(	O
95	O
%	O
CI	O
,	O
0.89	O
-	O
1.66	O
)	O
.	O

For	O
specific	O
groups	O
of	O
drugs	O
,	O
the	O
risks	O
were	O
1.56	O
(	O
1.05	O
-	O
2.30	O
)	O
for	O
aspirin	O
,	O
1.03	O
(	O
0.60	O
-	O
1.76	O
)	O
for	O
pyrazolones	O
,	O
0.80	O
(	O
0.39	O
-	O
1.63	O
)	O
for	O
paracetamol	O
,	O
and	O
0.94	O
(	O
0.57	O
-	O
1.56	O
)	O
for	O
nonaspirin	O
NSAIDs	O
.	O

The	O
risk	O
of	O
ESRD	B
associated	O
with	O
aspirin	O
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	B
as	O
underlying	O
disease	O
[	O
2.35	O
(	O
1.17	O
-	O
4.72	O
)	O
]	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	B
.	O

However	O
,	O
the	O
chronic	O
use	O
of	O
aspirin	O
may	O
increase	O
the	O
risk	O
of	O
ESRD	B
.	O

Two	O
cases	O
of	O
amisulpride	O
overdose	B
:	O
a	O
cause	O
for	O
prolonged	B
QT	I
syndrome	I
.	O

Two	O
cases	O
of	O
deliberate	O
self	O
-	O
poisoning	B
with	O
5	O
g	O
and	O
3.6	O
g	O
of	O
amisulpride	O
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
cases	O
,	O
QT	B
prolongation	I
and	O
hypocalcaemia	B
were	O
noted	O
.	O

The	O
QT	B
prolongation	I
appeared	O
to	O
respond	O
to	O
administration	O
of	O
i.v	O
.	O

calcium	O
gluconate	O
.	O

Growth	O
-	O
associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	B
rats	O
treated	O
with	O
cycloheximide	O
.	O

PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	B
.	O

To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43-ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43-ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B
epilepticus	I
induced	O
by	O
pilocarpine	O
(	O
Pilo	O
)	O
,	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	O
(	O
CHX	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	O
was	O
injected	O
before	O
the	O
Pilo	O
injection	O
in	O
adult	O
Wistar	O
rats	O
.	O

The	O
Pilo	O
group	O
was	O
injected	O
with	O
the	O
same	O
drugs	O
,	O
except	O
for	O
CHX	O
.	O

Animals	O
were	O
killed	O
between	O
30	O
and	O
60	O
days	O
later	O
,	O
and	O
brain	O
sections	O
were	O
processed	O
for	O
GAP43	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43-ir	O
in	O
the	O
IML	O
between	O
Pilo	O
,	O
CHX+Pilo	O
,	O
and	O
control	O
groups	O
.	O

However	O
,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX+Pilo	O
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(	O
p	O
=	O
0.03	O
)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	O
group	O
.	O

CONCLUSIONS	O
:	O
Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX+Pilo	O
group	O
have	O
a	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
controls	O
,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals	O
.	O

The	O
change	O
in	O
GAP43-ir	O
present	O
in	O
Pilo	O
-	O
treated	O
animals	O
was	O
a	O
thinning	O
of	O
the	O
band	O
to	O
a	O
very	O
narrow	O
layer	O
just	O
above	O
the	O
granule	O
cell	O
layer	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
loss	O
of	O
hilar	O
cell	O
projections	O
that	O
express	O
GAP-43	O
.	O

Nicotine	O
antagonizes	O
caffeine-	O
but	O
not	O
pentylenetetrazole	O
-	O
induced	O
anxiogenic	O
effect	O
in	O
mice	O
.	O

RATIONALE	O
:	O
Nicotine	O
and	O
caffeine	O
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide	O
.	O

Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B
responses	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	O
on	O
anxiety	B
induced	O
by	O
caffeine	O
and	O
another	O
anxiogenic	O
drug	O
,	O
pentylenetetrazole	O
,	O
in	O
mice	O
.	O

The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B
.	O

METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	O
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	O
(	O
70	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
or	O
pentylenetetrazole	O
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
injections	O
.	O

After	O
15	O
min	O
,	O
mice	O
were	O
evaluated	O
for	O
their	O
open-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10-min	O
session	O
.	O

Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O

RESULTS	O
:	O
Nicotine	O
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	O
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	O
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	O
effect	O
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O

Nicotine	O
(	O
0.25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine-	O
but	O
not	O
pentylenetetrazole	O
-	O
induced	O
anxiety	B
.	O

Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	O
on	O
caffeine	O
-	O
induced	O
anxiety	B
is	O
specific	O
to	O
caffeine	O
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	O
and	O
caffeine	O
.	O

Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women	O
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	B
symptoms	I
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B
disease	I
,	O
osteoporosis	B
and	O
dementia	B
in	O
older	O
women	O
but	O
the	O
evidence	O
supporting	O
its	O
use	O
for	O
these	O
indications	O
is	O
largely	O
observational	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
heart	B
disease	I
,	O
venous	B
thromboembolism	I
,	O
stroke	B
,	O
transient	B
ischaemic	I
attacks	I
,	O
breast	B
cancer	I
,	O
colorectal	B
cancer	I
,	O
ovarian	B
cancer	I
,	O
endometrial	B
cancer	I
,	O
gallbladder	B
disease	I
,	O
cognitive	O
function	O
,	O
dementia	B
,	O
fractures	B
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
up	O
to	O
November	O
2004	O
:	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	O
Group	O
Trials	O
Register	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O

Relevant	O
non	O
-	O
indexed	O
journals	O
and	O
conference	O
abstracts	O
were	O
also	O
searched	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
double	O
-	O
blind	O
trials	O
of	O
HT	O
(	O
oestrogens	O
with	O
or	O
without	O
progestogens	O
)	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O

Fifteen	O
RCTs	O
were	O
included	O
.	O

Trials	O
were	O
assessed	O
for	O
quality	O
and	O
two	O
review	O
authors	O
extracted	O
data	O
independently	O
.	O

They	O
calculated	O
risk	O
ratios	O
for	O
dichotomous	O
outcomes	O
and	O
weighted	O
mean	O
differences	O
for	O
continuous	O
outcomes	O
.	O

Clinical	O
heterogeneity	O
precluded	O
meta	O
-	O
analysis	O
for	O
most	O
outcomes	O
.	O

MAIN	O
RESULTS	O
:	O
All	O
the	O
statistically	O
significant	O
results	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trials	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
's	O
use	O
)	O
,	O
stroke	B
(	O
after	O
3	O
years	O
)	O
,	O
breast	B
cancer	I
(	O
after	O
5	O
years	O
)	O
and	O
gallbladder	B
disease	I
.	O

Long	O
-	O
term	O
oestrogen	O
-	O
only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	B
and	O
gallbladder	B
disease	I
.	O

Overall	O
,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B
and	O
colon	B
cancer	I
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B
.	O

Among	O
women	O
with	O
cardiovascular	B
disease	I
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
.	O

No	O
trials	O
focussed	O
specifically	O
on	O
younger	O
women	O
.	O

However	O
,	O
one	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
-	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	O
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B
thromboembolism	I
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
;	O
their	O
absolute	O
risk	O
remained	O
very	O
low	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	B
disease	I
.	O

We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	O
for	O
menopausal	O
symptom	O
control	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O

Drug	B
-	I
induced	I
liver	I
injury	I
:	O
an	O
analysis	O
of	O
461	O
incidences	O
submitted	O
to	O
the	O
Spanish	O
registry	O
over	O
a	O
10-year	O
period	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug	B
-	I
induced	I
liver	I
injury	I
(	O
DILI	B
)	O
and	O
outcome	O
predictability	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
systematic	O
programs	O
to	O
detect	O
bona	O
fide	O
cases	O
.	O

METHODS	O
:	O
A	O
cooperative	O
network	O
was	O
created	O
in	O
1994	O
in	O
Spain	O
to	O
identify	O
all	O
suspicions	O
of	O
DILI	B
following	O
a	O
prospective	O
structured	O
report	O
form	O
.	O

The	O
liver	B
damage	I
was	O
characterized	O
according	O
to	O
hepatocellular	O
,	O
cholestatic	B
,	O
and	O
mixed	O
laboratory	O
criteria	O
and	O
to	O
histologic	O
criteria	O
when	O
available	O
.	O

Further	O
evaluation	O
of	O
causality	O
assessment	O
was	O
centrally	O
performed	O
.	O

RESULTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
cases	O
,	O
involving	O
505	O
drugs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	B
.	O

The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin	O
-	O
clavulanate	O
accounting	O
for	O
the	O
12.8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hepatocellular	O
pattern	O
of	O
damage	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inversely	O
correlated	O
with	O
age	O
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
outcome	O
(	O
Cox	O
regression	O
,	O
P	O
<	O
.034	O
)	O
.	O

Indeed	O
,	O
the	O
incidence	O
of	O
liver	O
transplantation	O
and	O
death	O
in	O
this	O
group	O
was	O
11.7	O
%	O
if	O
patients	O
had	O
jaundice	B
at	O
presentation	O
,	O
whereas	O
the	O
corresponding	O
figure	O
was	O
3.8	O
%	O
in	O
nonjaundiced	O
patients	O
(	O
P	O
<	O
.04	O
)	O
.	O

Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	B
hepatic	I
failure	I
were	O
female	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4.1	O
-	O
151	O
;	O
P	O
<	O
.0001	O
)	O
,	O
hepatocellular	O
damage	O
(	O
OR	O
=	O
7.9	O
;	O
95	O
%	O
CI	O
:	O
1.6	O
-	O
37	O
;	O
P	O
<	O
.009	O
)	O
,	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	O
value	O
(	O
OR	O
=	O
1.15	O
;	O
95	O
%	O
CI	O
:	O
1.09	O
-	O
1.22	O
;	O
P	O
<	O
.0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
drug	O
-	O
induced	O
hepatocellular	O
jaundice	B
have	O
11.7	O
%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation	O
.	O

Amoxicillin	O
-	O
clavulanate	O
stands	O
out	O
as	O
the	O
most	O
common	O
drug	O
related	O
to	O
DILI	B
.	O

Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d	O
-	O
ribose	O
on	O
adriamycin	O
-	O
evoked	O
cardiotoxicity	B
in	O
rats	O
.	O

The	O
influence	O
of	O
d	O
-	O
ribose	O
on	O
adriamycin	O
-	O
induced	O
myocardiopathy	B
in	O
rats	O
was	O
studied	O
.	O

Adriamycin	O
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
evoked	O
fully	O
developed	O
cardiac	B
toxicity	I
.	O

D	O
-	O
ribose	O
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
influence	O
ADR	O
cardiotoxicity	B
.	O

In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	O
-	O
induced	O
nephrotoxicity	B
:	O
protection	O
by	O
erdosteine	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	O
(	O
VCM	O
)	O
-induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	O
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	O
-	O
induced	O
renal	B
impairment	I
in	O
rats	O
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	O
and	O
VCM	O
plus	O
erdosteine	O
.	O

VCM	O
was	O
administrated	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
with	O
200mgkg	O
(	O
-1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O

Erdosteine	O
was	O
administered	O
orally	O
.	O

VCM	O
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
d	O
-	O
glucosaminidase	O
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B
tubular	I
injury	I
)	O
excretion	O
but	O
decreased	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O

Erdosteine	O
administration	O
with	O
VCM	O
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	O
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	O
alone	O
.	O

Erdosteine	O
showed	O
histopathological	O
protection	O
against	O
VCM	O
-	O
induced	O
nephrotoxicity	B
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B
,	O
desquamation	B
,	O
and	O
necrosis	B
in	O
VCM	O
-	O
treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	O
groups	O
.	O

Erdosteine	O
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	O
-	O
induced	O
nephrotoxicity	B
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	O
reduces	O
the	O
VCM	O
-	O
induced	O
kidney	B
damage	I
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O

Gemfibrozil	O
-	O
lovastatin	O
therapy	O
for	O
primary	O
hyperlipoproteinemias	B
.	O

The	O
specific	O
aim	O
of	O
this	O
retrospective	O
,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long	O
-	O
term	O
(	O
21	O
months	O
/	O
patient	O
)	O
,	O
open	O
-	O
label	O
,	O
gemfibrozil	O
-	O
lovastatin	O
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	B
(	O
68	O
%	O
of	O
whom	O
had	O
atherosclerotic	B
vascular	I
disease	I
)	O
.	O

Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cholesterol	O
/	O
HDL	O
cholesterol	O
less	O
than	O
4.5	O
mg	O
/	O
dl	O
)	O
with	O
diet	O
plus	O
a	O
single	O
drug	O
,	O
gemfibrozil	O
(	O
1.2	O
g	O
/	O
day	O
)	O
-lovastatin	O
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
treatment	O
was	O
given	O
.	O

Follow	O
-	O
up	O
visits	O
were	O
scheduled	O
with	O
2-drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
average	O
of	O
10.3	O
visits	O
per	O
patient	O
,	O
with	O
741	O
batteries	O
of	O
6	O
liver	O
function	O
tests	O
and	O
714	O
creatine	O
phosphokinase	O
levels	O
measured	O
.	O

Only	O
1	O
of	O
the	O
4,446	O
liver	O
function	O
tests	O
(	O
0.02	O
%	O
)	O
,	O
a	O
gamma	O
glutamyl	O
transferase	O
,	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

Of	O
the	O
714	O
creatine	O
phosphokinase	O
levels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0.1	O
%	O
)	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

With	O
2-drug	O
therapy	O
,	O
mean	O
total	O
cholesterol	O
decreased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyceride	O
levels	O
decreased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesterol	O
decreased	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesterol	O
/	O
HDL	O
cholesterol	O
ratio	O
decreased	O
24	O
%	O
from	O
7.1	O
to	O
5.4	O
,	O
all	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.0001	O
.	O

Myositis	B
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
in	O
1	O
%	O
with	O
concurrent	O
high	O
creatine	O
phosphokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patients	O
had	O
rhabdomyolysis	B
or	O
myoglobinuria.	B
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Does	O
domperidone	O
potentiate	O
mirtazapine	O
-	O
associated	O
restless	B
legs	I
syndrome	I
?	O

There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B
legs	I
syndrome	I
(	O
RLS	B
)	O
.	O

For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	O
and	O
dopamine	O
agonists	O
,	O
whereas	O
central	O
dopamine	O
D2	O
receptor	O
antagonists	O
can	O
induce	O
or	O
aggravate	O
RLS	B
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	O
,	O
a	O
peripheral	O
dopamine	O
D2	O
receptor	O
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B
.	O

Mirtazapine	O
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B
in	O
several	O
recent	O
publications	O
.	O

The	O
authors	O
report	O
here	O
a	O
depressed	O
patient	O
comorbid	O
with	O
postprandial	B
dyspepsia	I
who	O
developed	O
RLS	B
after	O
mirtazapine	O
had	O
been	O
added	O
to	O
his	O
domperidone	O
therapy	O
.	O

Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	B
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	O
,	O
and	O
his	O
RLS	B
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	O
.	O

Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	O
and	O
the	O
symptoms	O
of	O
RLS	B
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	O
on	O
mirtazapine	O
-	O
associated	O
RLS	B
.	O

However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	O
can	O
be	O
associated	O
with	O
RLS	B
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	O
D2	O
receptor	O
antagonists	O
.	O

Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	B
arterial	I
disease	I
.	O

AIM	O
:	O
To	O
study	O
the	O
change	O
of	O
lipid	O
metabolism	O
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	B
cancer	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2.5	O
years	O
follow	O
-	O
up	O
the	O
changes	O
in	O
plasma	O
cholesterols	O
(	O
C	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
,	O
lipoproteins	O
(	O
LP	O
)	O
,	O
and	O
apolipoproteins	O
(	O
Apo	O
)	O
B-100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	B
cancer	I
(	O
stage	O
:	O
T1cN0M0	O
,	O
Gleason	O
score	O
:	O
2	O
-	O
5	O
)	O
during	O
treatment	O
with	O
cyproterone	O
acetate	O
(	O
CPA	O
)	O
without	O
surgical	O
management	O
or	O
radiation	O
therapy	O
.	O

RESULTS	O
:	O
Significant	O
decreases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
increase	O
of	O
triglyceride	O
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	O
.	O

After	O
a	O
period	O
of	O
2.5	O
years	O
on	O
CPA	O
treatment	O
,	O
four	O
patients	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	B
heart	I
disease	I
.	O

CONCLUSIONS	O
:	O
Ischaemic	O
coronary	B
arteriosclerosis	I
with	O
an	O
incidence	O
rate	O
of	O
16.6	O
%	O
as	O
caused	O
by	O
prolonged	O
CPA	O
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglyceridemic	B
effect	I
caused	O
by	O
estrogen	O
.	O

5-Fluorouracil	O
cardiotoxicity	B
induced	O
by	O
alpha	O
-	O
fluoro	O
-	O
beta	O
-	O
alanine	O
.	O

Cardiotoxicity	B
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5-fluorouracil	O
(	O
5-FU	O
)	O
treatment	O
for	O
malignancies	B
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70-year	O
-	O
old	O
man	O
with	O
5-FU	O
-	O
induced	O
cardiotoxicity	B
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	O
-	O
fluoro	O
-	O
beta	O
-	O
alanine	O
(	O
FBAL	O
)	O
was	O
observed	O
.	O

The	O
patient	O
,	O
who	O
had	O
unresectable	O
colon	B
cancer	I
metastases	O
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O

After	O
admission	O
,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	O
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	B
pain	I
with	O
right	B
bundle	I
branch	I
block	I
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	O
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precordial	B
pain	I
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5-FU	O
.	O

As	O
the	O
precordial	B
pain	I
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5-FU	O
-	O
induced	O
cardiotoxicity	B
,	O
the	O
administration	O
of	O
5-FU	O
was	O
abandoned	O
.	O

Instead	O
,	O
oral	O
administration	O
of	O
S-1	O
(	O
a	O
derivative	O
of	O
5-FU	O
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S-1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	O
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5-FU	O
into	O
FBAL	O
.	O

The	O
serum	O
FBAL	O
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S-1	O
administration	O
.	O

Thereafter	O
,	O
no	O
cardiac	B
symptoms	I
were	O
observed	O
.	O

The	O
patient	O
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S-1	O
treatment	O
.	O

The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	O
is	O
related	O
to	O
5-FU	O
-	O
induced	O
cardiotoxicity	B
.	O

S-1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5-FU	O
-	O
induced	O
cardiotoxicity	B
.	O

Hepatocellular	B
carcinoma	I
in	O
Fanconi	B
's	I
anemia	I
treated	O
with	O
androgen	O
and	O
corticosteroid	O
.	O

The	O
case	O
of	O
an	O
11-year	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi	B
's	I
anemia	I
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	O
,	O
corticosteroids	O
and	O
transfusions	O
.	O

Two	O
weeks	O
before	O
his	O
death	O
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	B
and	O
marked	O
abnormalities	O
in	O
liver	O
function	O
and	O
died	O
of	O
hemorrhagic	B
bronchopneumonia	I
.	O

At	O
autopsy	O
peliosis	B
and	O
multiple	O
hepatic	B
tumors	I
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well	O
-	O
differentiated	O
hepatocellular	B
carcinoma	I
.	O

This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non	O
-	O
metastasizing	O
hepatic	B
neoplasms	I
and	O
peliosis	B
can	O
develop	O
in	O
patients	O
with	O
androgen-	O
and	O
corticosteroid	O
-	O
treated	O
Fanconi	B
's	I
anemia	I
.	O

The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
doxorubicin	O
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
in	O
mice	O
.	O

PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	B
,	O
the	O
anthracyclin	O
doxorubicin	O
(	O
DOX	O
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O

DOX	O
-	O
induced	O
cardiac	B
damage	I
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	O
.	O

Reactive	O
oxygen	O
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O

The	O
semisynthetic	O
flavonoid	O
monohydroxyethylrutoside	O
(	O
monoHER	O
)	O
showed	O
cardioprotection	O
against	O
DOX	O
-	O
induced	O
cardiotoxicity	B
through	O
its	O
radical	O
scavenging	O
and	O
iron	O
chelating	O
properties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	O
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	O
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect	O
.	O

METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	O
were	O
treated	O
with	O
saline	O
,	O
DOX	O
alone	O
or	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
preceded	O
by	O
monoHER	O
(	O
500	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
with	O
an	O
interval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6-week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks	O
,	O
the	O
mice	O
were	O
sacrificed	O
.	O

Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	B
damage	I
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	B
Treat	O
Rep	O
62	O
(	O
6	O
)	O
:865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	O
alone	O
induced	O
significant	O
cardiac	B
damage	I
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P<0.001	O
)	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9.6-fold	O
(	O
95	O
%	O
CI	O
4.4	O
-	O
21.0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	O
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O

The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	O
preceded	O
by	O
monoHER	O
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1.6	O
to	O
2.8	O
(	O
mean	O
2.2	O
,	O
95	O
%	O
CI	O
1.2	O
-	O
4.1	O
,	O
P=0.019	O
)	O
.	O

The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	O
before	O
DOX	O
led	O
to	O
a	O
significant	O
4.4-fold	O
reduction	O
(	O
P<0.001	O
,	O
95	O
%	O
CI	O
2.3	O
-	O
8.2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O

This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	O
administration	O
(	O
P=0.345	O
)	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	O
may	O
be	O
administered	O
shortly	O
before	O
DOX	O
.	O

Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	O
administration	O
for	O
atrial	B
fibrillation	I
and	B
flutter	I
.	O

BACKGROUND	O
:	O
Bepridil	O
hydrochloride	O
(	O
Bpd	O
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
and	O
atrial	B
flutter	I
(	O
AFL	B
)	O
.	O

However	O
,	O
serious	O
adverse	O
effects	O
,	O
including	O
torsade	B
de	I
pointes	I
(	O
Tdp	B
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Adverse	O
effects	O
of	O
Bpd	O
requiring	O
discontinuation	O
of	O
treatment	O
were	O
evaluated	O
.	O

Bpd	O
was	O
administered	O
to	O
459	O
patients	O
(	O
361	O
males	O
,	O
63+	O
/	O
-12	O
years	O
old	O
)	O
comprising	O
378	O
AF	B
and	O
81	O
AFL	B
cases	O
.	O

Mean	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
atrial	O
dimension	O
(	O
LAD	O
)	O
were	O
66+	O
/	O
-11	O
%	O
and	O
40+	O
/	O
-6	O
mm	O
,	O
respectively	O
.	O

Adverse	O
effects	O
were	O
observed	O
in	O
19	O
patients	O
(	O
4	O
%	O
)	O
during	O
an	O
average	O
follow	O
-	O
up	O
of	O
20	O
months	O
.	O

There	O
was	O
marked	O
QT	B
prolongation	I
greater	O
than	O
0.55	O
s	O
in	O
13	O
patients	O
,	O
bradycardia	B
less	O
than	O
40	O
beats	O
/	O
min	O
in	O
6	O
patients	O
,	O
dizziness	B
and	O
general	O
fatigue	B
in	O
1	O
patient	O
each	O
.	O

In	O
4	O
of	O
13	O
patients	O
with	O
QT	B
prolongation	I
,	O
Tdp	B
occurred	O
.	O

The	O
major	O
triggering	O
factors	O
of	O
Tdp	B
were	O
hypokalemia	B
and	O
sudden	O
decrease	O
in	O
heart	O
rate	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	B
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	B
.	O

CONCLUSION	O
:	O
Careful	O
observation	O
of	O
serum	O
potassium	O
concentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	O
administration	O
,	O
particularly	O
in	O
elderly	O
patients	O
.	O

Enhanced	O
isoproterenol	O
-	O
induced	O
cardiac	B
hypertrophy	I
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate	O
.	O

In	O
this	O
study	O
we	O
aimed	O
at	O
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta	O
-	O
adrenoceptor	O
(	O
beta	O
-	O
AR	O
)	O
agonist	O
isoproterenol	O
(	O
Iso	O
)	O
.	O

Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isolated	O
hearts	O
,	O
Iso	O
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
and	O
maximal	O
contraction	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

LV	B
hypertrophy	I
induced	O
by	O
Iso	O
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
body	O
wt	O
,	O
0.28	O
+	O
/-	O

0.004	O
vs.	O
0.24	O
+	O
/-	O

0.004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	B
hypertrophy	I
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta	O
-	O
AR	O
and	O
upregulation	O
of	O
LV	O
beta	O
-	O
AR	O
kinase-1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats	O
.	O

The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta	O
-	O
AR	O
antagonist	O
metoprolol	O
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(	O
-9.9	O
+	O
/-	O

1.7	O
%	O
vs.	O
-18.1	O
+	O
/-	O

1.5	O
%	O
)	O
,	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	O
on	O
HR	O
was	O
similar	O
in	O
both	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta	O
-	O
AR	O
agonist	O
-	O
induced	O
cardiac	B
inotropic	I
response	O
and	O
hypertrophy	B
,	O
possibly	O
due	O
to	O
chronically	O
low	O
sympathetic	O
outflow	O
directed	O
to	O
the	O
heart	O
.	O

Drug	O
-	O
induced	O
long	B
QT	I
syndrome	I
in	O
injection	O
drug	O
users	O
receiving	O
methadone	O
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B
QT	I
syndrome	I
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O

Methadone	O
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
the	O
inpatient	O
setting	O
,	O
the	O
frequency	O
of	O
QT	B
interval	I
prolongation	I
with	O
methadone	O
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	O
and	O
those	O
not	O
receiving	O
methadone	O
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5-year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	O
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	O
.	O

In	O
addition	O
to	O
methadone	O
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B
prolongation	I
.	O

RESULTS	O
:	O
Among	O
167	O
methadone	O
maintenance	O
patients	O
,	O
the	O
prevalence	O
of	O
QTc	O
prolongation	O
to	O
0.50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16.2	O
%	O
compared	O
with	O
0	O
%	O
in	O
80	O
control	O
subjects	O
.	O

Six	O
patients	O
(	O
3.6	O
%	O
)	O
in	O
the	O
methadone	O
group	O
presented	O
torsades	B
de	I
pointes	I
.	O

QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	O
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0.20	O
;	O
P<.01	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31.8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	O
dose	O
,	O
cytochrome	O
P-450	O
3A4	O
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	B
,	O
and	O
altered	O
liver	O
function	O
.	O

CONCLUSIONS	O
:	O
QT	B
interval	I
prolongation	I
in	O
methadone	O
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O

Methadone	O
dose	O
,	O
presence	O
of	O
cytochrome	O
P-450	O
3A4	O
inhibitors	O
,	O
potassium	O
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B
prolongation	I
.	O

Long	B
QT	I
syndrome	I
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	O
.	O

Mechanisms	O
of	O
hypertension	B
induced	O
by	O
nitric	O
oxide	O
(	O
NO	O
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O

Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
hypertension	B
is	O
a	O
hallmark	O
of	O
arterial	B
dysfunction	I
.	O

Experimental	O
hypertension	B
created	O
by	O
the	O
removal	O
of	O
NO	O
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O

These	O
include	O
augmented	O
endothelin-1	O
(	O
ET-1	O
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O

We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
LNNA	O
)	O
hypertension	B
through	O
these	O
mechanisms	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
NO	O
synthase	O
inhibitor	O
LNNA	O
(	O
0.5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O

Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	O
was	O
119	O
+	O
/-	O

2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/-	O

5	O
mm	O
Hg	O
in	O
LNNA	O
rats	O
(	O
P<0.05	O
)	O
.	O

Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O

Maximal	O
contraction	O
to	O
norepinephrine	O
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	O
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET-1	O
was	O
significantly	O
reduced	O
(	O
54	O
%	O
control	O
)	O
.	O

Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	O
(	O
37	O
%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET-1	O
was	O
observed	O
.	O

Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	O
hypertension	B
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	O
.	O

The	O
superoxide	O
scavenger	O
tempol	O
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	O
rats	O
(	O
-18	O
+	O
/-	O

8	O
,	O
-26	O
+	O
/-	O

15	O
,	O
and	O
-54	O
+	O
/-	O

11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	O
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	O
hypertensive	B
rats	O
(	O
76	O
+	O
/-	O

9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	O
(	O
35	O
+	O
/-	O

10	O
mm	O
Hg	O
)	O
.	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	O
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	O
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O

These	O
data	O
suggest	O
that	O
while	O
NO	O
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B
.	O

Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	O
-	O
induced	O
extrapyramidal	B
syndrome	I
in	O
Chinese	O
schizophrenic	B
patients	O
.	O

AIM	O
:	O
Extrapyramidal	B
syndrome	I
(	O
EPS	B
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor	O
.	O

Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	O
-	O
induced	O
EPS	B
in	O
schizophrenic	B
patients	O
.	O

METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	B
inpatients	O
(	O
59	O
with	O
EPS	B
and	O
87	O
without	O
EPS	B
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	O
after	O
8	O
weeks	O
.	O

The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O

RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O

No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	O
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	B
.	O

Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	B
in	O
Caucasians	O
.	O

Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine	O
-	O
induced	O
seizures	B
in	O
the	O
rat	O
.	O

Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	B
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
problem	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long	O
-	O
term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	B
.	O

Male	O
Wistar	O
rats	O
were	O
subjected	O
to	O
repeated	O
training	O
sessions	O
in	O
a	O
treadmill	O
and	O
swimming	O
pool	O
.	O

Thereafter	O
,	O
seizures	B
were	O
induced	O
by	O
pilocarpine	O
injections	O
in	O
trained	O
and	O
non	O
-	O
trained	O
control	O
groups	O
.	O

During	O
the	O
acute	O
period	O
of	O
status	B
epilepticus	I
,	O
we	O
measured	O
:	O
(	O
1	O
)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensity	O
of	O
seizures	B
,	O
(	O
3	O
)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6-h	O
observation	O
period	O
,	O
and	O
(	O
4	O
)	O
the	O
time	O
when	O
the	O
acute	O
period	O
ended	O
.	O

All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	B
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	B
epilepticus	I
.	O

Tonic	O
dopaminergic	O
stimulation	O
impairs	B
associative	I
learning	I
in	O
healthy	O
subjects	O
.	O

Endogenous	O
dopamine	O
plays	O
a	O
central	O
role	O
in	O
salience	O
coding	O
during	O
associative	O
learning	O
.	O

Administration	O
of	O
the	O
dopamine	O
precursor	O
levodopa	O
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B
patients	O
.	O

Because	O
levodopa	O
increases	O
both	O
phasic	O
and	O
tonic	O
dopaminergic	O
neurotransmission	O
,	O
the	O
critical	O
mechanism	O
mediating	O
the	O
enhancement	O
of	O
learning	O
is	O
unresolved	O
.	O

We	O
here	O
probed	O
how	O
selective	O
tonic	O
dopaminergic	O
stimulation	O
affects	O
associative	O
learning	O
.	O

Forty	O
healthy	O
subjects	O
were	O
trained	O
in	O
a	O
novel	O
vocabulary	O
of	O
45	O
concrete	O
nouns	O
over	O
the	O
course	O
of	O
5	O
consecutive	O
training	O
days	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
design	O
.	O

Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine	O
-	O
receptor	O
agonist	O
pergolide	O
(	O
0.1	O
mg	O
)	O
vs	O
placebo	O
120	O
min	O
before	O
training	O
on	O
each	O
training	O
day	O
.	O

The	O
dopamine	O
agonist	O
significantly	O
impaired	B
novel	I
word	I
learning	I
compared	O
to	O
placebo	O
.	O

This	O
learning	O
decrement	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
weeks	O
post	O
-	O
training	O
.	O

Subjects	O
treated	O
with	O
pergolide	O
also	O
showed	O
restricted	O
emotional	O
responses	O
compared	O
to	O
the	O
PLACEBO	O
group	O
.	O

The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergolide	O
was	O
related	O
to	O
the	O
degree	O
of	O
learning	O
inhibition	O
.	O

These	O
findings	O
suggest	O
that	O
tonic	O
occupation	O
of	O
dopamine	O
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	O
signals	O
.	O

Thus	O
,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	O
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B
patients	O
.	O

Minocycline	O
-	O
induced	O
vasculitis	B
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	B
nodosa	I
.	O

A	O
47-year	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	O
for	O
palmoplantar	B
pustulosis	I
developed	O
fever	B
,	O
myalgias	B
,	O
polyneuropathy	B
,	O
and	O
testicular	B
pain	I
,	O
with	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
.	O

Neither	O
myeloperoxidase-	O
nor	O
proteinase-3-antineutrophil	O
cytoplasmic	O
antibody	O
was	O
positive	O
.	O

These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	B
nodosa	I
.	O

Stopping	O
minocycline	O
led	O
to	O
amelioration	O
of	O
symptoms	O
and	O
normalization	O
of	O
CRP	O
level	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline	O
-	O
induced	O
vasculitis	B
satisfying	O
the	O
criteria	O
.	O

Differential	O
diagnosis	O
for	O
drug	O
-	O
induced	O
disease	O
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	B
nodosa	I
.	O

Intramuscular	O
hepatitis	B
B	I
immune	O
globulin	O
combined	O
with	O
lamivudine	O
in	O
prevention	O
of	O
hepatitis	B
B	I
recurrence	O
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Combined	O
hepatitis	B
B	I
immune	O
globulin	O
(	O
HBIg	O
)	O
and	O
lamivudine	O
in	O
prophylaxis	O
of	O
the	O
recurrence	O
of	O
hepatitis	B
B	I
after	O
liver	O
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	O
positive	O
patients	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	O
transplantation	O
for	O
patients	O
with	O
hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV	O
-	O
related	O
cirrhotic	B
diseases	I
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months	O
.	O

HBIg	O
was	O
administered	O
intravenously	O
during	O
the	O
first	O
week	O
and	O
intramuscularly	O
thereafter	O
.	O

RESULTS	O
:	O
At	O
a	O
median	O
follow	O
-	O
up	O
of	O
14.1	O
months	O
,	O
the	O
overall	O
recurrence	O
rate	O
in	O
the	O
51	O
patients	O
was	O
3.9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O

The	O
overall	O
patient	O
survival	O
was	O
88.3	O
%	O
,	O
and	O
82.4	O
%	O
after	O
1	O
and	O
2	O
years	O
,	O
respectively	O
.	O

A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	O
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57.1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62.5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	O
positive	O
patients	O
respectively	O
to	O
convert	O
to	O
be	O
negative	O
.	O

Intramuscular	O
HBIg	O
was	O
well	O
tolerated	O
in	O
all	O
patients	O
.	O

CONCLUSION	O
:	O
Lamivudine	O
combined	O
with	O
intramuscular	O
HBIg	O
can	O
effectively	O
prevent	O
allograft	O
from	O
the	O
recurrence	O
of	O
HBV	O
after	O
liver	O
transplantation	O
.	O

Anticonvulsant	O
effect	O
of	O
eslicarbazepine	O
acetate	O
(	O
BIA	O
2	O
-	O
093	O
)	O
on	O
seizures	B
induced	O
by	O
microperfusion	O
of	O
picrotoxin	O
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	O
.	O

Eslicarbazepine	O
acetate	O
(	O
BIA	O
2	O
-	O
093	O
,	O
S-	O
(	O
-	O
)	O
-10-acetoxy-10,11-dihydro-5H	O
-	O
dibenzo	O
/	O
b	O
,	O
f	O
/	O
azepine-5-carboxamide	O
)	O
is	O
a	O
novel	O
antiepileptic	O
drug	O
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	O
(	O
CBZ	O
)	O
and	O
oxcarbazepine	O
(	O
OXC	O
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	O
acetate	O
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B
patterns	O
.	O

In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	O
,	O
the	O
average	O
number	O
of	O
seizures	B
was	O
2.3+	O
/	O
-1.2	O
,	O
and	O
average	O
seizure	B
duration	O
was	O
39.5+	O
/	O
-8.4s	O
.	O

Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	O
microperfusion	O
prevented	O
seizures	B
in	O
the	O
75	O
%	O
of	O
the	O
rats	O
.	O

Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	B
duration	O
(	O
24.3+	O
/	O
-6.8s	O
)	O
and	O
seizure	B
number	O
(	O
1.6+	O
/	O
-0.34	O
)	O
were	O
found	O
.	O

No	O
adverse	O
effects	O
of	O
eslicarbazepine	O
acetate	O
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O

Acute	B
renal	I
failure	I
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	O
.	O

Chinese	O
herbal	O
medicine	O
preparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
public	O
as	O
natural	O
and	O
safe	O
remedies	O
for	O
a	O
variety	O
of	O
medical	O
conditions	O
.	O

Nephropathy	B
caused	O
by	O
Chinese	O
herbs	O
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	O
acids	O
.	O

We	O
report	O
a	O
23-year	O
-	O
old	O
woman	O
who	O
developed	O
acute	B
renal	I
failure	I
following	O
prolonged	O
use	O
of	O
a	O
proprietary	O
Chinese	O
herbal	O
slimming	O
pill	O
that	O
contained	O
anthraquinone	O
derivatives	O
,	O
extracted	O
from	O
Rhizoma	O
Rhei	O
(	O
rhubarb	O
)	O
.	O

The	O
renal	B
injury	I
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
diclofenac	O
.	O

Renal	O
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	B
.	O

Spontaneous	O
renal	O
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills	O
,	O
but	O
mild	O
interstitial	O
fibrosis	B
and	O
tubular	O
atrophy	B
was	O
still	O
evident	O
histologically	O
4	O
months	O
later	O
.	O

Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone	O
-	O
containing	O
herbal	O
agent	O
and	O
renal	B
injury	I
remains	O
to	O
be	O
proven	O
,	O
phytotherapy	O
-	O
associated	O
interstitial	O
nephropathy	B
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	B
failure	I
.	O

Chloroacetaldehyde	O
as	O
a	O
sulfhydryl	O
reagent	O
:	O
the	O
role	O
of	O
critical	O
thiol	O
groups	O
in	O
ifosfamide	O
nephropathy	B
.	O

Chloroacetaldehyde	O
(	O
CAA	O
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	O
(	O
IFO	O
)	O
and	O
putatively	O
responsible	O
for	O
renal	B
damage	I
following	O
anti	O
-	O
tumor	B
therapy	O
with	O
IFO	O
.	O

Depletion	O
of	O
sulfhydryl	O
(	O
SH	O
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
work	O
the	O
effect	O
of	O
CAA	O
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	O
)	O
was	O
investigated	O
.	O

Toxicity	B
of	O
CAA	O
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	O
release	O
,	O
trypan	O
blue	O
exclusion	O
assay	O
and	O
caspase-3	O
activity	O
.	O

Free	O
thiols	O
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O

CAA	O
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	O
and	O
an	O
increase	O
in	O
necrosis	B
markers	O
.	O

CAA	O
but	O
not	O
acrolein	O
inhibited	O
the	O
cysteine	O
proteases	O
caspase-3	O
,	O
caspase-8	O
and	O
cathepsin	O
B.	O
Caspase	O
activation	O
by	O
cisplatin	O
was	O
inhibited	O
by	O
CAA	O
.	O

In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	O
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O

The	O
effects	O
of	O
CAA	O
on	O
cysteine	O
protease	O
activities	O
and	O
thiols	O
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	O
with	O
thiol	O
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	O
on	O
necrosis	B
markers	O
,	O
thiol	O
depletion	O
and	O
cysteine	O
protease	O
inhibition	O
in	O
living	O
cells	O
.	O

Thus	O
,	O
CAA	O
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	O
,	O
mediating	O
its	O
toxicity	B
on	O
hRPTEC	O
.	O

This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O

Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	O
nephropathy	B
in	O
patients	O
.	O

Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
in	O
the	O
adult	O
rat	O
.	O

Following	O
status	B
epilepticus	I
in	O
the	O
rat	O
,	O
dentate	O
granule	O
cell	O
neurogenesis	O
increases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
neurons	O
appear	O
to	O
develop	O
ectopically	O
,	O
in	O
the	O
hilar	O
region	O
of	O
the	O
hippocampal	O
formation	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	B
that	O
ultimately	O
develop	O
after	O
status	B
epilepticus	I
.	O

However	O
,	O
the	O
population	O
has	O
never	O
been	O
quantified	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influence	O
on	O
epileptogenesis	O
.	O

To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
.	O

The	O
number	O
of	O
hilar	O
neurons	O
immunoreactive	O
for	O
Prox-1	O
,	O
a	O
granule	O
-	O
cell	O
-	O
specific	O
marker	O
,	O
was	O
estimated	O
using	O
the	O
optical	O
fractionator	O
method	O
.	O

The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	B
epilepticus	I
is	O
substantial	O
,	O
and	O
stable	O
over	O
time	O
.	O

Interestingly	O
,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	B
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	B
.	O

The	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
does	O
not	O
appear	O
to	O
vary	O
systematically	O
across	O
the	O
septotemporal	O
axis	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
increase	O
in	O
volume	O
of	O
the	O
hilus	O
.	O

The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	O
model	O
of	O
temporal	B
lobe	I
epilepsy	I
.	O

A	O
prospective	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	O
in	O
autistic	B
disorder	I
.	O

OBJECTIVE	O
:	O
Post	O
-	O
mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	B
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	O
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator	O
,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B
.	O

METHODS	O
:	O
Thirteen	O
medication	O
-	O
free	O
children	O
with	O
autism	B
(	O
mean	O
age	O
,	O
8.8	O
+	O
/-	O

3.5	O
years	O
)	O
participated	O
in	O
a	O
12-week	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	O
.	O

Patients	O
were	O
rated	O
monthly	O
by	O
parents	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
and	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
,	O
and	O
by	O
a	O
physician	O
using	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
and	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O

RESULTS	O
:	O
Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent	O
-	O
rated	O
irritability	B
and	O
social	O
withdrawal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvements	O
in	O
emotional	O
lability	O
and	O
inattention	O
on	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
--	O
Revised	O
.	O

Similarly	O
,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
.	O

Eight	O
of	O
13	O
participants	O
were	O
rated	O
as	O
responders	O
on	O
the	O
basis	O
of	O
their	O
improvement	O
scores	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O

Overall	O
,	O
galantamine	O
was	O
well	O
-	O
tolerated	O
,	O
with	O
no	O
significant	O
adverse	O
effects	O
apart	O
from	O
headaches	B
in	O
one	O
patient	O
.	O

CONCLUSION	O
:	O
In	O
this	O
open	O
trial	O
,	O
galantamine	O
was	O
well	O
-	O
tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B
,	O
particularly	O
aggression	B
,	O
behavioral	B
dyscontrol	I
,	O
and	O
inattention	B
.	O

Further	O
controlled	O
trials	O
are	O
warranted	O
.	O

Randomized	O
comparison	O
of	O
olanzapine	O
versus	O
risperidone	O
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B
:	O
4-month	O
outcomes	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4-month	O
treatment	O
outcomes	O
for	O
olanzapine	O
versus	O
risperidone	O
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	B
spectrum	O
disorders	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age=23.3	O
years	O
[	O
SD	O
=	O
5.1	O
]	O
)	O
with	O
first	O
-	O
episode	O
schizophrenia	B
(	O
75	O
%	O
)	O
,	O
schizophreniform	B
disorder	I
(	O
17	O
%	O
)	O
,	O
or	O
schizoaffective	B
disorder	I
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	O
(	O
2.5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	O
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O

RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	O
(	O
43.7	O
%	O
,	O
95	O
%	O
CI=28.8%-58.6	O
%	O
)	O
and	O
risperidone	O
(	O
54.3	O
%	O
,	O
95	O
%	O
CI=39.9%-68.7	O
%	O
)	O
.	O

Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	O
group	O
(	O
40.9	O
%	O
,	O
95	O
%	O
CI=16.8%-65.0	O
%	O
)	O
than	O
in	O
the	O
risperidone	O
group	O
(	O
18.9	O
%	O
,	O
95	O
%	O
CI=0%-39.2	O
%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O

Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B
and	O
akathisia	B
did	O
not	O
differ	O
between	O
medications	O
.	O

Extrapyramidal	B
symptom	I
severity	O
scores	O
were	O
1.4	O
(	O
95	O
%	O
CI=1.2	O
-	O
1.6	O
)	O
with	O
risperidone	O
and	O
1.2	O
(	O
95	O
%	O
CI=1.0	O
-	O
1.4	O
)	O
with	O
olanzapine	O
.	O

Significantly	O
more	O
weight	B
gain	I
occurred	O
with	O
olanzapine	O
than	O
with	O
risperidone	O
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17.3	O
%	O
(	O
95	O
%	O
CI=14.2%-20.5	O
%	O
)	O
with	O
olanzapine	O
and	O
11.3	O
%	O
(	O
95	O
%	O
CI=8.4%-14.3	O
%	O
)	O
with	O
risperidone	O
.	O

Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24.3	O
(	O
95	O
%	O
CI=22.8	O
-	O
25.7	O
)	O
versus	O
28.2	O
(	O
95	O
%	O
CI=26.7	O
-	O
29.7	O
)	O
with	O
olanzapine	O
and	O
23.9	O
(	O
95	O
%	O
CI=22.5	O
-	O
25.3	O
)	O
versus	O
26.7	O
(	O
95	O
%	O
CI=25.2	O
-	O
28.2	O
)	O
with	O
risperidone	O
.	O

CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	O
were	O
equal	O
to	O
those	O
with	O
olanzapine	O
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O

Olanzapine	O
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O

Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B
gain	I
,	O
but	O
weight	B
gain	I
was	O
greater	O
with	O
olanzapine	O
.	O

Early	O
paracentral	O
visual	B
field	I
loss	I
in	O
patients	O
taking	O
hydroxychloroquine	O
.	O

OBJECTIVE	O
:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	O
sulfate	O
who	O
attended	O
an	O
ophthalmic	O
screening	O
program	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
.	O

RESULTS	O
:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	O
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmology	O
were	O
reviewed	O
.	O

Of	O
the	O
262	O
patients	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treatment	O
at	O
the	O
time	O
of	O
the	O
study	O
experienced	O
documented	O
adverse	O
effects	O
.	O

Systemic	O
adverse	O
effects	O
occurred	O
in	O
8	O
patients	O
(	O
10.5	O
%	O
)	O
and	O
ocular	O
adverse	O
effects	O
,	O
in	O
5	O
(	O
6.5	O
%	O
)	O
.	O

Thirty	O
-	O
five	O
patients	O
(	O
13.4	O
%	O
)	O
had	O
visual	B
field	I
abnormalities	I
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	O
treatment	O
in	O
4	O
patients	O
(	O
1.5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
patients	O
were	O
taking	O
less	O
than	O
6.5	O
mg	O
/	O
kg	O
per	O
day	O
and	O
all	O
patients	O
had	O
normal	O
renal	O
and	O
liver	O
function	O
test	O
results	O
.	O

CONCLUSIONS	O
:	O
The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	O
assessment	O
,	O
funduscopy	O
,	O
and	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	B
field	I
defects	I
appeared	O
before	O
any	O
corresponding	O
changes	O
in	O
any	O
other	O
tested	O
clinical	O
parameters	O
;	O
the	O
defects	O
were	O
reproducible	O
and	O
the	O
test	O
parameters	O
were	O
reliable	O
.	O

Patients	O
taking	O
hydroxychloroquine	O
can	O
demonstrate	O
a	O
toxic	O
reaction	O
in	O
the	O
retina	O
despite	O
the	O
absence	O
of	O
known	O
risk	O
factors	O
.	O

Screening	O
,	O
including	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
assessment	O
,	O
is	O
recommended	O
2	O
years	O
after	O
the	O
initial	O
baseline	O
and	O
yearly	O
thereafter	O
.	O

Peri	O
-	O
operative	O
atrioventricular	B
block	I
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	O
and	O
paclitaxel	O
.	O

A	O
47-year	O
-	O
old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	B
of	I
the	I
breast	I
6	O
months	O
previously	O
.	O

In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
epirubicin	O
,	O
paclitaxel	O
(	O
Taxol	O
)	O
and	O
cyclophosphamide	O
.	O

This	O
had	O
been	O
apparently	O
uncomplicated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
level	O
of	O
physical	O
activity	O
.	O

She	O
was	O
found	O
to	O
be	O
bradycardic	B
at	O
pre	O
-	O
operative	O
assessment	O
but	O
had	O
no	O
cardiac	O
symptoms	O
.	O

Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	B
block	I
was	O
diagnosed	O
on	O
electrocardiogram	O
,	O
and	O
temporary	O
transvenous	O
ventricular	O
pacing	O
instituted	O
in	O
the	O
peri	O
-	O
operative	O
period	O
.	O

We	O
discuss	O
how	O
evidence	O
-	O
based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case	O
,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	B
that	O
may	O
develop	O
over	O
many	O
years	O
.	O

We	O
suggest	O
that	O
patients	O
who	O
have	O
received	O
chemotherapy	O
at	O
any	O
time	O
should	O
have	O
a	O
pre	O
-	O
operative	O
electrocardiogram	O
even	O
if	O
they	O
are	O
asymptomatic	O
.	O

Risks	O
and	O
benefits	O
of	O
COX-2	O
inhibitors	O
vs	O
non	O
-	O
selective	O
NSAIDs	O
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O

A	O
retrospective	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B
myocardial	I
infarction	I
(	O
AMI	B
)	O
with	O
COX-2	O
inhibitors	O
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B
and	O
GI	B
bleeding	I
among	O
elderly	O
patients	O
using	O
COX-2	O
inhibitors	O
,	O
NS	O
-	O
NSAIDs	O
and	O
acetaminophen	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	O
during	O
1999	O
-	O
2002	O
.	O

Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O

RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	O
were	O
:	O
75,761	O
to	O
acetaminophen	O
,	O
42,671	O
to	O
rofecoxib	O
65,860	O
to	O
celecoxib	O
,	O
and	O
37,495	O
to	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	O
,	O
they	O
were	O
:	O
14,671	O
to	O
rofecoxib	O
,	O
22,875	O
to	O
celecoxib	O
,	O
9,832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38,048	O
to	O
acetaminophen	O
.	O

Among	O
non	O
-	O
users	O
of	O
aspirin	O
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B
/	O
GI	O
vs	O
the	O
acetaminophen	O
(	O
with	O
no	O
aspirin	O
)	O
group	O
were	O
:	O
rofecoxib	O
1.27	O
(	O
1.13	O
,	O
1.42	O
)	O
,	O
celecoxib	O
0.93	O
(	O
0.83	O
,	O
1.03	O
)	O
,	O
naproxen	O
1.59	O
(	O
1.31	O
,	O
1.93	O
)	O
,	O
diclofenac	O
1.17	O
(	O
0.99	O
,	O
1.38	O
)	O
and	O
ibuprofen	O
1.05	O
(	O
0.74	O
,	O
1.51	O
)	O
.	O

Among	O
users	O
of	O
aspirin	O
,	O
they	O
were	O
:	O
rofecoxib	O
1.73	O
(	O
1.52	O
,	O
1.98	O
)	O
,	O
celecoxib	O
1.34	O
(	O
1.19	O
,	O
1.52	O
)	O
,	O
ibuprofen	O
1.51	O
(	O
0.95	O
,	O
2.41	O
)	O
,	O
diclofenac	O
1.69	O
(	O
1.35	O
,	O
2.10	O
)	O
,	O
naproxen	O
1.35	O
(	O
0.97	O
,	O
1.88	O
)	O
and	O
acetaminophen	O
1.29	O
(	O
1.17	O
,	O
1.42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	O
,	O
naproxen	O
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B
/	O
GI	B
bleeding	I
.	O

The	O
AMI	B
/	O
GI	O
toxicity	B
of	O
celecoxib	O
was	O
similar	O
to	O
that	O
of	O
acetaminophen	O
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	O
and	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	O
,	O
both	O
celecoxib	O
and	O
naproxen	O
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O

Quinine	O
-	O
induced	O
arrhythmia	B
in	O
a	O
patient	O
with	O
severe	B
malaria	I
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B
malaria	I
patient	O
with	O
jaundice	B
who	O
presented	O
with	O
arrhythmia	B
(	O
premature	B
ventricular	I
contraction	I
)	O
while	O
getting	O
quinine	O
infusion	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B
,	O
chill	B
,	O
vomiting	B
,	O
jaundice	B
.	O

The	O
patient	O
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	O
8.25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	O
4.36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	O
3.89	O
mg	O
/	O
dL	O
,	O
potassium	O
3.52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B
malaria	I
with	O
jaundice	B
and	O
got	O
quinine	O
infusion	O
in	O
dextrose	O
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B
,	O
diarrhea	B
,	O
tinnitus	B
,	O
loss	B
of	I
hearing	I
.	O

After	O
30	O
hours	O
of	O
quinine	O
infusion	O
the	O
patient	O
felt	O
palpitation	B
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B
ventricular	I
contraction	I
(	O
PVC	B
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
--	O
sinoatrial	B
block	I
,	O
positive	O
U	O
wave	O
.	O

He	O
was	O
treated	O
with	O
lidocaine	O
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	O
5%	O
/	O
24	O
hour	O
and	O
potassium	O
aspartate	O
tablet	O
.	O

Quinine	O
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	O
tablets	O
.	O

Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	B
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	O
level	O
was	O
3.34	O
meq	O
/	O
L.	O
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O

Quinine	O
,	O
like	O
quinidine	O
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti	O
-	O
arrhythmic	B
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	B
that	O
can	O
cause	O
various	O
arrhythmias	B
,	O
including	O
severe	O
arrhythmia	B
such	O
as	O
multiple	O
PVC	B
.	O

Administration	O
of	O
parenteral	O
quinine	O
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	B
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B
diseases	I
or	O
patients	O
with	O
electrolyte	B
disorder	I
(	O
hypokalemia	B
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B
and	O
or	O
diarrhea	B
in	O
malaria	B
cases	O
.	O

Penicillamine	O
-	O
related	O
lichenoid	B
dermatitis	I
and	O
utility	O
of	O
zinc	O
acetate	O
in	O
a	O
Wilson	B
disease	I
patient	O
with	O
hepatic	O
presentation	O
,	O
anxiety	B
and	O
SPECT	O
abnormalities	O
.	O

Wilson	B
's	I
disease	I
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	O
metabolism	O
with	O
consequent	O
copper	O
accumulation	O
and	O
toxicity	B
in	O
many	O
tissues	O
and	O
consequent	O
hepatic	B
,	I
neurologic	I
and	I
psychiatric	I
disorders	I
.	O

We	O
report	O
a	O
case	O
of	O
Wilson	B
's	I
disease	I
with	O
chronic	B
liver	I
disease	I
;	O
moreover	O
,	O
in	O
our	O
patient	O
,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	B
without	O
depression	B
,	O
99mTc	O
-	O
ECD	O
-	O
SPECT	O
showed	O
cortical	O
hypoperfusion	O
in	O
frontal	O
lobes	O
,	O
more	O
marked	O
on	O
the	O
left	O
frontal	O
lobe	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patient	O
,	O
penicillamine	O
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	B
dermatitis	I
,	O
and	O
zinc	O
acetate	O
permitted	O
to	O
continue	O
the	O
successful	O
treatment	O
of	O
the	O
patient	O
without	O
side	O
-	O
effects	O
.	O

In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	O
acetate	O
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson	B
's	I
disease	I
patient	O
in	O
which	O
penicillamine	O
-	O
related	O
side	O
effects	O
appeared	O
.	O

The	O
safety	O
of	O
the	O
zinc	O
acetate	O
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs	O
;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson	B
's	I
disease	I
.	O

Since	O
most	O
of	O
Wilson	B
's	I
disease	I
penicillamine	O
-	O
treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	B
lesion	I
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genetic	O
factor	O
is	O
involved	O
in	O
drug	O
response	O
.	O

Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson	B
's	I
disease	I
therapy	O
,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson	B
's	I
disease	I
phenotypes	O
.	O

A	O
dramatic	O
drop	B
in	I
blood	I
pressure	I
following	O
prehospital	O
GTN	O
administration	O
.	O

A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B
pain	I
awoke	O
with	O
chest	B
pain	I
following	O
an	O
afternoon	O
sleep	O
.	O

The	O
patient	O
did	O
not	O
self	O
medicate	O
.	O

The	O
patient	O
's	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	O
via	O
a	O
face	O
mask	O
and	O
glyceryl	O
trinitrate	O
(	O
GTN	O
)	O
.	O

Several	O
minutes	O
after	O
the	O
GTN	O
the	O
patient	O
experienced	O
a	O
sudden	O
drop	B
in	I
blood	I
pressure	I
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	O
sulphate	O
and	O
a	O
fluid	O
challenge	O
.	O

There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient	O
's	O
condition	O
during	O
transport	O
to	O
hospital	O
.	O

There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold	O
-	O
Jarish	O
reflex	O
,	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre	O
.	O

Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	B
episode	I
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	O
accordingly	O
.	O

Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	B
rats	O
.	O

We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
neurogenic	O
tone	O
in	O
conscious	O
,	O
unrestrained	O
spontaneously	O
hypertensive	B
rats	O
.	O

The	O
lesions	O
were	O
placed	O
via	O
bilateral	O
microinjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartic	O
acid	O
.	O

The	O
restimulation	O
of	O
this	O
area	O
with	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartic	O
acid	O
15	O
days	O
postlesion	O
failed	O
to	O
produce	O
a	O
pressor	O
response	O
.	O

One	O
day	O
postlesion	O
,	O
the	O
resting	O
mean	O
arterial	O
pressure	O
was	O
significantly	O
decreased	O
in	O
lesioned	O
rats	O
when	O
compared	O
with	O
sham	O
rats	O
(	O
100	O
+	O
/-	O

7	O
versus	O
173	O
+	O
/-	O

4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Fifteen	O
days	O
later	O
,	O
the	O
lesioned	O
group	O
still	O
showed	O
values	O
significantly	O
lower	O
than	O
the	O
sham	O
group	O
(	O
150	O
+	O
/-	O

6	O
versus	O
167	O
+	O
/-	O

5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

No	O
significant	O
heart	O
rate	O
differences	O
were	O
observed	O
between	O
the	O
sham	O
and	O
lesioned	O
groups	O
.	O

The	O
ganglionic	O
blocker	O
trimethaphan	O
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
caused	O
similar	O
reductions	O
in	O
mean	O
arterial	O
pressure	O
in	O
both	O
lesioned	O
and	O
sham	O
groups	O
.	O

The	O
trimethaphan	O
-	O
induced	O
hypotension	B
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	B
in	O
lesioned	O
rats	O
(	O
-32	O
+	O
/-	O

13	O
beats	O
per	O
minute	O
)	O
but	O
a	O
tachycardia	B
in	O
sham	O
rats	O
(	O
+	O
33	O
+	O
/-	O

12	O
beats	O
per	O
minute	O
)	O
1	O
day	O
postlesion	O
.	O

Therefore	O
,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	B
in	O
conscious	O
spontaneously	O
hypertensive	B
rats	O
.	O

Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	B
in	O
the	O
lesioned	O
rats	O
.	O

Acute	B
encephalopathy	I
and	O
cerebral	B
vasospasm	I
after	O
multiagent	O
chemotherapy	O
including	O
PEG	O
-	O
asparaginase	O
and	O
intrathecal	O
cytarabine	O
for	O
the	O
treatment	O
of	O
acute	B
lymphoblastic	I
leukemia	I
.	O

A	O
7-year	O
-	O
old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B	O
-	O
cell	O
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O
is	O
described	O
.	O

The	O
patient	O
developed	O
acute	B
encephalopathy	I
evidenced	O
by	O
behavioral	O
changes	O
,	O
aphasia	B
,	O
incontinence	B
,	O
visual	B
hallucinations	I
,	O
and	O
right	O
-	O
sided	O
weakness	B
with	O
diffuse	O
cerebral	B
vasospasm	I
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	O
.	O

Vincristine	O
,	O
dexamethasone	O
,	O
and	O
polyethylene	O
glycol	O
-	O
asparaginase	O
were	O
also	O
administered	O
before	O
the	O
episode	O
as	O
part	O
of	O
induction	O
therapy	O
.	O

Neurologic	O
status	O
returned	O
to	O
baseline	O
within	O
10	O
days	O
of	O
the	O
acute	O
event	O
,	O
and	O
magnetic	O
resonance	O
angiography	O
findings	O
returned	O
to	O
normal	O
4	O
months	O
later	O
.	O

Comparison	O
of	O
valsartan	O
/	O
hydrochlorothiazide	O
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	B
adults	O
.	O

BACKGROUND	O
:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	B
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O

Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	B
therapies	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	O
(	O
VAL	O
)	O
or	O
hydrochlorothiazide	O
(	O
HCTZ	O
)	O
-monotherapy	O
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	O
with	O
essential	B
hypertension	I
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8-week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
.	O

Patients	O
with	O
essential	B
hypertension	I
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	O
160	O
or	O
320	O
mg	O
;	O
HCTZ	O
12.5	O
or	O
25	O
mg	O
;	O
VAL	O
/	O
HCTZ	O
160	O
/	O
12.5	O
,	O
320	O
/	O
12.5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
placebo	O
.	O

Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	O
the	O
8-week	O
core	O
study	O
end	O
point	O
.	O

VAL	O
/	O
HCTZ	O
320	O
/	O
12.5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54-week	O
,	O
open	O
-	O
label	O
extension	O
.	O

Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline	O
.	O

Control	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
compared	O
with	O
baseline	O
.	O

Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1346	O
patients	O
were	O
randomized	O
into	O
the	O
8-week	O
core	O
study	O
(	O
734	O
men	O
,	O
612	O
women	O
;	O
924	O
white	O
,	O
291	O
black	O
,	O
23	O
Asian	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52.7	O
years	O
;	O
mean	O
weight	O
,	O
92.6	O
kg	O
)	O
.	O

All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8-week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	O
and	O
HCTZ	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
mean	O
reduction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	O
/	O
HCTZ	O
320	O
/	O
25	O
mg	O
was	O
24.7	O
/	O
16.6	O
mm	O
Hg	O
,	O
compared	O
with	O
5.9	O
/	O
7.0	O
mm	O
Hg	O
with	O
placebo	O
.	O

The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	O
/	O
HCTZ	O
320	O
/	O
25	O
mg	O
compared	O
with	O
VAL	O
/	O
HCTZ	O
160	O
/	O
12.5	O
mg	O
(	O
P	O
<	O
0.002	O
)	O
.	O

Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy	O
.	O

The	O
incidence	O
of	O
hypokalemia	B
was	O
lower	O
with	O
VAL	O
/	O
HCTZ	O
combinations	O
(	O
1.8%-6.1	O
%	O
)	O
than	O
with	O
HCTZ	O
monotherapies	O
(	O
7.1%-13.3	O
%	O
)	O
.	O

The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O

The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	O
/	O
HCTZ	O
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL	O
/	O
HCTZ	O
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B
than	O
HCTZ	O
alone	O
.	O

Succimer	O
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead	O
-	O
exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B
impairment	I
in	O
the	O
absence	O
of	O
lead	O
exposure	O
.	O

BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	O
levels	O
.	O

However	O
,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	O
-	O
exposed	O
children	O
,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	O
exposure	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	O
exposure	O
and	O
treatment	O
with	O
succimer	O
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B
poisoning	I
.	O

RESULTS	O
:	O
Pb	O
exposure	O
produced	O
lasting	O
impairments	B
in	I
learning	I
,	B
attention	I
,	I
inhibitory	I
control	I
,	I
and	I
arousal	I
regulation	I
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	O
-	O
exposed	O
children	O
.	O

Succimer	O
treatment	O
of	O
the	O
Pb	O
-	O
exposed	O
rats	O
significantly	O
improved	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	O
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O

In	O
contrast	O
,	O
succimer	O
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	O
produced	O
lasting	O
and	O
pervasive	O
cognitive	B
and	I
affective	I
dysfunction	I
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	O
exposure	O
regimen	O
.	O

CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B
deficits	I
due	O
to	O
Pb	O
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	O
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	O
-	O
exposed	O
children	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	O
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	O
or	O
other	O
heavy	O
metals	O
.	O

Caffeine	O
challenge	O
test	O
in	O
panic	B
disorder	I
and	O
depression	B
with	O
panic	B
attacks	I
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B
disorder	I
(	O
PD	B
)	O
and	O
patients	O
with	O
major	B
depression	I
with	O
panic	B
attacks	I
(	O
MDP	B
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B
Disorders	I
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B
attacks	I
by	O
an	O
oral	O
caffeine	O
challenge	O
test	O
.	O

We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	B
,	O
27	O
with	O
MDP	B
,	O
25	O
with	O
major	B
depression	I
without	O
panic	B
attacks	I
(	O
MD	B
)	O
,	O
and	O
28	O
healthy	O
volunteers	O
.	O

The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4-week	O
period	O
.	O

In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	O
and	O
a	O
caffeine	O
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	B
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O

A	O
total	O
of	O
58.6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	B
,	O
44.4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	B
,	O
12.0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	B
,	O
and	O
7.1	O
%	O
(	O
n=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B
attack	I
after	O
the	O
480-mg	O
caffeine	O
challenge	O
test	O
(	O
chi	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16.22	O
,	O
P	O
=	O
.001	O
)	O
.	O

The	O
patients	O
with	O
PD	B
and	O
MDP	B
were	O
more	O
sensitive	O
to	O
caffeine	O
than	O
were	O
patients	O
with	O
MD	B
and	O
healthy	O
volunteers	O
.	O

No	O
panic	B
attack	I
was	O
observed	O
after	O
the	O
caffeine	O
-	O
free	O
solution	O
intake	O
.	O

The	O
patients	O
with	O
MD	B
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2-way	O
analysis	O
of	O
variance	O
,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse	O
-	O
Geisser	O
correction	O
:	O
F	O
(	O
3,762	O
)	O
=	O
2.85	O
,	O
P	O
=	O
.026	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B
attacks	I
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B
or	O
MDP	B
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	O
challenge	O
test	O
.	O

Mitral	O
annuloplasty	O
as	O
a	O
ventricular	O
restoration	O
method	O
for	O
the	O
failing	B
left	I
ventricle	I
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
mitral	O
annuloplasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	B
cardiomyopathy	I
and	O
functional	O
mitral	B
regurgitation	I
(	O
MR	B
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilated	O
left	O
ventricular	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	B
remain	O
incompletely	O
understood	O
.	O

The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	B
failure	I
.	O

METHODS	O
:	O
Six	O
dogs	O
underwent	O
MAP	O
with	O
a	O
prosthetic	O
band	O
on	O
the	O
posterior	O
mitral	O
annulus	O
,	O
using	O
four	O
mattress	O
sutures	O
.	O

The	O
sutures	O
were	O
passed	O
individually	O
through	O
four	O
tourniquets	O
and	O
exteriorized	O
untied	O
via	O
the	O
left	O
atriotomy	O
.	O

Sonomicrometry	O
crystals	O
were	O
implanted	O
around	O
the	O
mitral	O
annulus	O
and	O
left	O
ventricle	O
to	O
measure	O
geometry	O
and	O
regional	O
function	O
.	O

Acute	O
heart	B
failure	I
was	O
induced	O
by	O
propranolol	O
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
;	O
an	O
absence	O
of	O
MR	B
was	O
confirmed	O
by	O
echocardiography	O
.	O

MAP	O
was	O
accomplished	O
by	O
cinching	O
the	O
tourniquets	O
.	O

Data	O
were	O
acquired	O
at	O
baseline	O
,	O
after	O
induction	O
of	O
acute	O
heart	B
failure	I
,	O
and	O
after	O
MAP	O
.	O

RESULTS	O
:	O
MAP	O
decreased	O
mitral	O
annular	O
dimensions	O
in	O
both	O
commissure	O
-	O
commissure	O
and	O
septal	O
-	O
lateral	O
directions	O
.	O

Concomitantly	O
,	O
the	O
diastolic	O
diameter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphericity	O
decreased	O
(	O
i.e.	O
,	O
improved	O
)	O
from	O
37.4	O
+	O
/-	O

9.3	O
to	O
35.9	O
+	O
/-	O

10	O
mm	O
(	O
p	O
=	O
0.063	O
)	O
,	O
and	O
from	O
67.9	O
+	O
/-	O

18.6	O
%	O
to	O
65.3	O
+	O
/-	O

18.9	O
%	O
(	O
p	O
=	O
0.016	O
)	O
,	O
respectively	O
.	O

Decreases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastolic	O
pressure	O
(	O
from	O
17	O
+	O
/-	O

7	O
to	O
15	O
+	O
/-	O

6	O
mmHg	O
,	O
p	O
=	O
0.0480	O
and	O
Tau	O
(	O
from	O
48	O
+	O
/-	O

8	O
to	O
45	O
+	O
/-	O

8	O
ms	O
,	O
p	O
<	O
0.01	O
)	O
,	O
while	O
fractional	O
shortening	O
at	O
the	O
LV	O
base	O
increased	O
from	O
7.7	O
+	O
/-	O

4.5	O
%	O
to	O
9.4	O
+	O
/-	O

4.5	O
%	O
(	O
p	O
=	O
0.045	O
)	O
.	O

After	O
MAP	O
,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	O
output	O
(	O
from	O
1.54	O
+	O
/-	O

0.57	O
to	O
1.65	O
+	O
/-	O

0.57	O
1	O
/	O
min	O
)	O
and	O
Emax	O
(	O
from	O
1.86	O
+	O
/-	O

0.9	O
to	O
2.41	O
+	O
/-	O

1.31	O
mmHg	O
/	O
ml	O
)	O
.	O

CONCLUSION	O
:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension	O
/	O
function	O
in	O
acute	O
heart	B
failure	I
,	O
even	O
in	O
the	O
absence	O
of	O
MR	B
.	O

However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B
failure	I
.	O

Piperacillin	O
/	O
tazobactam	O
-	O
induced	O
seizure	B
rapidly	O
reversed	O
by	O
high	O
flux	O
hemodialysis	O
in	O
a	O
patient	O
on	O
peritoneal	O
dialysis	O
.	O

Despite	O
popular	O
use	O
of	O
piperacillin	O
,	O
the	O
dire	O
neurotoxicity	B
associated	O
with	O
piperacillin	O
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
delay	O
in	O
appropriate	O
management	O
.	O

We	O
report	O
a	O
57-year	O
-	O
old	O
woman	O
with	O
end	B
-	I
stage	I
renal	I
disease	I
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
slurred	O
speech	O
,	O
tremor	B
,	O
bizarre	O
behavior	O
,	O
progressive	O
mental	O
confusion	B
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic	B
-	I
clonic	I
seizure	I
(	O
GTCS	B
)	O
after	O
5	O
doses	O
of	O
piperacillin	O
/	O
tazobactam	O
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectasis	B
with	O
secondary	B
infection	I
.	O

The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	O
levels	O
but	O
leukocytosis	B
.	O

Neurologic	O
examinations	O
showed	O
dysarthria	B
and	O
bilateral	O
Babinski	O
sign	O
.	O

Computed	O
tomography	O
of	O
brain	O
and	O
electroencephalogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	B
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin	O
/	O
tazobactam	O
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	B
and	O
organic	B
brain	I
lesions	I
.	O

Initiation	O
of	O
high	O
-	O
flux	O
hemodialysis	O
rapidly	O
reversed	O
the	O
neurologic	O
symptoms	O
within	O
4	O
hours	O
.	O

Piperacillin	O
-	O
induced	O
encephalopathy	B
should	O
be	O
considered	O
in	O
any	O
uremic	B
patients	O
with	O
unexplained	O
neurological	O
manifestations	O
.	O

CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	O
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin	O
-	O
induced	O
encephalopathy	B
.	O

Frequency	O
of	O
transient	O
ipsilateral	O
vocal	B
cord	I
paralysis	I
in	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O

BACKGROUND	O
:	O
Especially	O
because	O
of	O
improvements	O
in	O
clinical	O
neurologic	O
monitoring	O
,	O
carotid	O
endarterectomy	O
done	O
under	O
local	O
anesthesia	O
has	O
become	O
the	O
technique	O
of	O
choice	O
in	O
several	O
centers	O
.	O

Temporary	O
ipsilateral	O
vocal	B
nerve	I
palsies	I
due	O
to	O
local	O
anesthetics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
contralateral	O
paralysis	B
.	O

We	O
therefore	O
examined	O
the	O
effect	O
of	O
local	O
anesthesia	O
on	O
vocal	O
cord	O
function	O
to	O
better	O
understand	O
its	O
possible	O
consequences	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
included	O
28	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O

Vocal	O
cord	O
function	O
was	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
surgery	O
(	O
postoperative	O
day	O
1	O
)	O
using	O
flexible	O
laryngoscopy	O
.	O

Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ropivacaine	O
)	O
and	O
short	O
-	O
acting	O
(	O
prilocaine	O
)	O
anesthetic	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
normal	O
vocal	O
cord	O
function	O
preoperatively	O
.	O

Twelve	O
patients	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	B
cord	I
paralysis	I
.	O

It	O
resolved	O
in	O
all	O
cases	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	B
cord	I
paralysis	I
compared	O
with	O
those	O
without	O
.	O

CONCLUSION	O
:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	B
cord	I
paralysis	I
in	O
almost	O
half	O
of	O
these	O
patients	O
.	O

Because	O
pre	O
-	O
existing	O
paralysis	B
is	O
of	O
a	O
relevant	O
frequency	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	B
.	O

In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	B
cord	I
paralysis	I
,	O
surgery	O
under	O
general	O
anesthesia	O
should	O
be	O
considered	O
.	O

Impaired	B
fear	I
recognition	I
in	O
regular	O
recreational	O
cocaine	O
users	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
read	O
facial	O
expressions	O
is	O
essential	O
for	O
normal	O
human	O
social	O
interaction	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	O
users	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
groups	O
,	O
comprised	O
of	O
21	O
cocaine	O
naive	O
participants	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
cocaine	O
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recreational	O
cocaine	O
(	O
RC	O
)	O
users	O
,	O
were	O
compared	O
.	O

An	O
emotional	O
facial	O
expression	O
(	O
EFE	O
)	O
task	O
consisting	O
of	O
a	O
male	O
and	O
female	O
face	O
expressing	O
six	O
basic	O
emotions	O
(	O
happiness	O
,	O
surprise	O
,	O
sadness	O
,	O
anger	O
,	O
fear	O
,	O
and	O
disgust	O
)	O
was	O
administered	O
.	O

Mean	O
percent	O
accuracy	O
and	O
latencies	O
for	O
correct	O
responses	O
across	O
eight	O
presentations	O
of	O
each	O
basic	O
emotion	O
were	O
derived	O
.	O

Participants	O
were	O
also	O
assessed	O
with	O
the	O
""""	O
Eyes	O
task	O
""""	O
to	O
investigate	O
their	O
ability	O
to	O
recognize	O
more	O
complex	O
emotional	O
states	O
and	O
the	O
Symptom	O
CheckList-90-Revised	O
to	O
measure	O
psychopathology	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
""""	O
eyes	O
task	O
""""	O
performance	O
,	O
but	O
the	O
RC	O
group	O
,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	O
group	O
,	O
exhibited	O
impaired	B
fear	I
recognition	I
accuracy	O
compared	O
to	O
the	O
OC	O
and	O
CN	O
groups	O
.	O

The	O
RC	O
group	O
also	O
correctly	O
identified	O
anger	O
,	O
fear	O
,	O
happiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
participants	O
.	O

The	O
OC	O
group	O
was	O
slower	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgust	O
.	O

The	O
selective	O
deficit	B
in	I
fear	I
recognition	I
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
can	O
not	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	O
,	O
or	O
ecstasy	O
,	O
because	O
recent	O
and	O
less	O
recent	O
users	O
of	O
these	O
drugs	O
within	O
this	O
group	O
were	O
similarly	O
impaired	O
.	O

Possible	O
parallels	O
between	O
RC	O
users	O
and	O
psychopaths	B
with	O
respect	O
to	O
impaired	B
fear	I
recognition	I
,	O
amygdala	B
dysfunction	I
,	O
and	O
etiology	O
are	O
discussed	O
.	O

Damage	B
of	I
substantia	I
nigra	I
pars	I
reticulata	I
during	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
in	O
the	O
rat	O
:	O
immunohistochemical	O
study	O
of	O
neurons	O
,	O
astrocytes	O
and	O
serum	O
-	O
protein	O
extravasation	O
.	O

The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	B
seizure	I
activity	O
.	O

Additionally	O
,	O
in	O
models	O
of	O
prolonged	B
status	I
epilepticus	I
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	B
derangement	I
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR	O
.	O

In	O
this	O
study	O
,	O
status	B
epilepticus	I
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	O
in	O
rats	O
.	O

The	O
neuropathology	O
of	O
SNR	O
was	O
investigated	O
using	O
immunohistochemical	O
techniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
time	O
-	O
course	O
of	O
changes	O
in	O
neurons	O
and	O
astrocytes	O
.	O

Animals	O
surviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	B
epilepticus	I
were	O
perfusion	O
-	O
fixed	O
,	O
and	O
brains	O
processed	O
for	O
immunohistochemical	O
staining	O
of	O
SNR	O
.	O

Nissl	O
-	O
staining	O
and	O
antibodies	O
against	O
the	O
neuron	O
-	O
specific	O
calcium	O
-	O
binding	O
protein	O
,	O
parvalbumin	O
,	O
served	O
to	O
detect	O
neuronal	B
damage	I
in	O
SNR	O
.	O

Antibodies	O
against	O
the	O
astroglia	O
-	O
specific	O
cytoskeletal	O
protein	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
glial	O
calcium	O
-	O
binding	O
protein	O
,	O
S-100	O
protein	O
,	O
were	O
used	O
to	O
assess	O
the	O
status	O
of	O
astrocytes	O
.	O

Immunohistochemical	O
staining	O
for	O
serum	O
-	O
albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood	O
-	O
brain	O
barrier	O
disturbances	O
and	O
vasogenic	B
edema	I
formation	O
.	O

Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP	O
-	O
staining	O
already	O
at	O
30	O
min	O
after	O
induction	O
of	O
seizures	B
in	O
an	O
oval	O
focus	O
situated	O
in	O
the	O
center	O
of	O
SNR	O
while	O
sparing	O
medial	O
and	O
lateral	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuolation	O
in	O
S-100	O
protein	O
staining	O
.	O

By	O
2	O
hours	O
,	O
parvalbumin	O
-	O
staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	B
damage	I
,	O
and	O
Nissl	O
-	O
staining	O
visualized	O
some	O
neuronal	O
distortion	O
.	O

Staining	O
for	O
serum	O
-	O
proteins	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebrain	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vasogenic	B
edema	I
covered	O
the	O
lesioned	B
SNR	I
.	O

By	O
24	O
h	O
,	O
glial	O
and	O
neuronal	O
markers	O
indicated	O
a	O
massive	O
lesion	O
in	O
the	O
center	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
astrocytes	O
surrounding	O
the	O
lesion	O
increased	O
in	O
size	O
,	O
and	O
polymorphic	O
phagocytotic	O
cells	O
invaded	O
the	O
damaged	O
area	O
.	O

In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days	O
,	O
conventional	O
paraffin	O
-	O
sections	O
confirmed	O
the	O
neuronal	O
and	O
glial	O
damage	B
of	I
SNR	I
.	O

Additional	O
pathology	O
of	O
similar	O
quality	O
was	O
found	O
in	O
the	O
globus	O
pallidus	O
.	O

Since	O
astrocytes	O
were	O
always	O
damaged	O
in	O
parallel	O
with	O
neurons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatomical	O
and	O
functional	O
interrelationship	O
between	O
neurons	O
and	O
astrocytes	O
is	O
particularly	O
tight	O
in	O
SNR	O
.	O

Both	O
cell	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	B
dysfunction	I
as	O
occur	O
during	O
massive	O
status	B
epilepticus	I
.	O

Neuroprotective	O
effects	O
of	O
melatonin	O
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	O
-	O
induced	O
cortical	B
dysplasia	I
.	O

Cortical	B
dysplasia	I
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
,	O
migration	O
and	O
maturation	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine-	O
[	O
1,3-bis	O
(	O
2-chloroethyl	O
)	O
-1-nitrosoure	O
]	O
(	O
BCNU	O
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	O
upon	O
cerebellar	O
BCNU	O
-	O
induced	O
cortical	B
dysplasia	I
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O

Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
,	O
saline	O
-	O
control	O
,	O
melatonin	O
-	O
treated	O
,	O
BCNU	O
-	O
exposed	O
and	O
BCNU	O
-	O
exposed	O
plus	O
melatonin	O
.	O

Rats	O
were	O
exposed	O
to	O
BCNU	O
on	O
embryonic	O
day	O
15	O
and	O
melatonin	O
was	O
given	O
until	O
delivery	O
.	O

Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	O
and	O
superoxide	O
dismutase	O
were	O
determined	O
.	O

Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	O
-	O
exposed	O
cortical	B
dysplasia	I
group	O
.	O

There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	O
-	O
exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	O
significantly	O
reversed	O
these	O
changes	O
.	O

Malondialdehyde	O
level	O
in	O
BCNU	O
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	O
decreased	O
malondialdehyde	O
levels	O
in	O
BCNU	O
group	O
(	O
P<0.01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	O
dismutase	O
levels	O
between	O
these	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	O
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	O
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	O
.	O

Reduced	O
cardiotoxicity	B
of	O
doxorubicin	O
given	O
in	O
the	O
form	O
of	O
N-	O
(	O
2-hydroxypropyl	O
)	O
methacrylamide	O
conjugates	O
:	O
and	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	B
and	O
the	O
late	O
cardiotoxicity	B
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	O
(	O
DOX	O
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N-	O
(	O
2-hydroxypropyl	O
)	O
methacrylamide	O
(	O
HPMA	O
)	O
copolymer	O
conjugates	O
.	O

In	O
these	O
HPMA	O
copolymers	O
,	O
DOX	O
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non	O
-	O
biodegradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly	O
-	O
Phe	O
-	O
Leu	O
-	O
Gly	O
)	O
.	O

In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	O
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	O
.	O

Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i.v	O
.	O

administration	O
of	O
free	O
and	O
polymer	O
-	O
bound	O
DOX	O
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	O
weight	O
.	O

However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer	O
-	O
bound	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	O
copolymer	O
and	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Throughout	O
the	O
study	O
(	O
20	O
weeks	O
)	O
,	O
deaths	O
related	O
to	O
cardiotoxicity	B
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HPMA	O
copolymer	O
and	O
free	O
DOX	O
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	O
-	O
induced	O
cardiotoxicity	B
.	O

Sequential	O
measurements	O
of	O
cardiac	O
output	O
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HPMA	O
copolymer	O
and	O
free	O
DOX	O
showed	O
a	O
reduction	O
of	O
approximately	O
30	O
%	O
in	O
function	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
drug	O
administration	O
.	O

The	O
heart	O
rate	O
in	O
these	O
animals	O
was	O
approximately	O
12	O
%	O
lower	O
than	O
that	O
measured	O
in	O
age	O
-	O
matched	O
control	O
rats	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Animals	O
that	O
were	O
given	O
the	O
HPMA	O
copolymer	O
conjugates	O
containing	O
DOX	O
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	O
output	O
throughout	O
the	O
study	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	O
in	O
the	O
form	O
of	O
HPMA	O
copolymer	O
conjugates	O
and	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

However	O
,	O
these	O
animals	O
had	O
shown	O
a	O
significant	O
increase	O
in	O
heart	O
rate	O
beginning	O
at	O
8	O
weeks	O
after	O
drug	O
administration	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Corneal	B
ulcers	I
associated	O
with	O
aerosolized	O
crack	O
cocaine	O
use	O
.	O

PURPOSE	O
:	O
We	O
report	O
4	O
cases	O
of	O
corneal	B
ulcers	I
associated	O
with	O
drug	B
abuse	I
.	O

The	O
pathogenesis	O
of	O
these	O
ulcers	B
and	O
management	O
of	O
these	O
patients	O
are	O
also	O
reviewed	O
.	O

METHODS	O
:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	B
ulcers	I
associated	O
with	O
drug	B
abuse	I
seen	O
at	O
our	O
institution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESULTS	O
:	O
Four	O
patients	O
with	O
corneal	B
ulcers	I
associated	O
with	O
crack	O
cocaine	O
use	O
were	O
reviewed	O
.	O

All	O
corneal	B
ulcers	I
were	O
cultured	O
,	O
and	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
intensive	O
topical	O
antibiotic	O
treatment	O
.	O

Each	O
patient	O
received	O
comprehensive	O
health	O
care	O
,	O
including	O
medical	O
and	O
substance	B
abuse	I
consultations	O
.	O

Streptococcal	O
organisms	O
were	O
found	O
in	O
3	O
cases	O
and	O
Capnocytophaga	O
and	O
Brevibacterium	O
casei	O
in	O
1	O
patient	O
.	O

The	O
infections	B
responded	O
to	O
antibiotic	O
treatment	O
.	O

Two	O
patients	O
needed	O
a	O
lateral	O
tarsorrhaphy	O
for	O
persistent	O
epithelial	B
defects	I
.	O

CONCLUSIONS	O
:	O
Aerosolized	O
crack	O
cocaine	O
use	O
can	O
be	O
associated	O
with	O
the	O
development	O
of	O
corneal	B
ulcers	I
.	O

Drug	B
abuse	I
provides	O
additional	O
challenges	O
for	O
management	O
.	O

Not	O
only	O
treatment	O
of	O
their	O
infections	B
but	O
also	O
the	O
overall	O
poor	O
health	O
of	O
the	O
patients	O
and	O
increased	O
risk	O
of	O
noncompliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	B
abuse	I
,	O
improve	O
their	O
overall	O
health	O
,	O
and	O
prevent	O
future	O
corneal	O
complications	O
.	O

Topical	O
0.025	O
%	O
capsaicin	O
in	O
chronic	O
post	B
-	I
herpetic	I
neuralgia	I
:	O
efficacy	O
,	O
predictors	O
of	O
response	O
and	O
long	O
-	O
term	O
course	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
efficacy	O
,	O
time	O
-	O
course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	O
,	O
39	O
patients	O
with	O
chronic	O
post	B
-	I
herpetic	I
neuralgia	I
(	O
PHN	B
)	O
,	O
median	O
duration	O
24	O
months	O
,	O
were	O
treated	O
with	O
0.025	O
%	O
capsaicin	O
cream	O
for	O
8	O
weeks	O
.	O

During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	B
on	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verbal	O
outcome	O
scale	O
.	O

A	O
follow	O
-	O
up	O
investigation	O
was	O
performed	O
10	O
-	O
12	O
months	O
after	O
study	O
onset	O
on	O
the	O
patients	O
who	O
had	O
improved	O
.	O

Nineteen	O
patients	O
(	O
48.7	O
%	O
)	O
substantially	O
improved	O
after	O
the	O
8-week	O
trial	O
;	O
5	O
(	O
12.8	O
%	O
)	O
discontinued	O
therapy	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
intolerable	O
capsaicin	O
-	O
induced	O
burning	O
sensations	O
(	O
4	O
)	O
or	O
mastitis	B
(	O
1	O
)	O
;	O
15	O
(	O
38.5	O
%	O
)	O
reported	O
no	O
benefit	O
.	O

The	O
decrease	O
in	O
VAS	O
ratings	O
was	O
significant	O
after	O
2	O
weeks	O
of	O
continuous	O
application	O
.	O

Of	O
the	O
responders	O
72.2	O
%	O
were	O
still	O
improved	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
application	O
irregularly	O
.	O

Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient	O
's	O
age	O
,	O
duration	O
or	O
localization	O
of	O
PHN	B
(	O
trigeminal	O
involvement	O
was	O
excluded	O
)	O
,	O
sensory	B
disturbance	I
or	O
pain	B
character	O
.	O

Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence	O
,	O
time	O
-	O
course	O
or	O
severity	O
of	O
capsaicin	O
-	O
induced	O
burning	O
.	O

If	O
confirmed	O
in	O
controlled	O
trials	O
,	O
the	O
long	O
-	O
term	O
results	O
of	O
this	O
open	O
,	O
non	O
-	O
randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	O
in	O
PHN	B
is	O
mediated	O
by	O
both	O
interference	O
with	O
neuropeptide	O
metabolism	O
and	O
morphological	O
changes	O
(	O
perhaps	O
degeneration	O
)	O
of	O
nociceptive	O
afferents	O
.	O

Myo	O
-	O
inositol-1-phosphate	O
(	O
MIP	O
)	O
synthase	O
inhibition	O
:	O
in	O
-	O
vivo	O
study	O
in	O
rats	O
.	O

Lithium	O
and	O
valproate	O
are	O
the	O
prototypic	O
mood	O
stabilizers	O
and	O
have	O
diverse	O
structures	O
and	O
targets	O
.	O

Both	O
drugs	O
influence	O
inositol	O
metabolism	O
.	O

Lithium	O
inhibits	O
IMPase	O
and	O
valproate	O
inhibits	O
MIP	O
synthase	O
.	O

This	O
study	O
shows	O
that	O
MIP	O
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	O
in	O
the	O
inositol	O
sensitive	O
pilocarpine	O
-	O
induced	O
seizures	B
model	O
.	O

This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
synthesis	O
to	O
cellular	O
inositol	O
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de	O
-	O
novo	O
synthesis	O
by	O
lithium	O
itself	O
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
-	O
associated	O
acute	O
interstitial	B
nephritis	I
with	O
granular	O
tubular	O
basement	O
membrane	O
deposits	O
.	O

Acute	B
tubulo	I
-	I
interstitial	I
nephritis	I
(	O
ATIN	B
)	O
is	O
an	O
important	O
cause	O
of	O
acute	B
renal	I
failure	I
resulting	O
from	O
a	O
variety	O
of	O
insults	O
,	O
including	O
immune	O
complex	O
-	O
mediated	O
tubulo	B
-	I
interstitial	I
injury	I
,	O
but	O
drugs	O
such	O
as	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
frequent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	B
remains	O
under	O
-	O
diagnosed	O
,	O
as	O
symptoms	O
resolve	O
spontaneously	O
if	O
the	O
medication	O
is	O
stopped	O
.	O

We	O
report	O
on	O
a	O
14-year	O
-	O
old	O
boy	O
who	O
developed	O
acute	B
renal	I
failure	I
2	O
weeks	O
after	O
aortic	O
valve	O
surgery	O
.	O

He	O
was	O
put	O
on	O
aspirin	O
following	O
surgery	O
and	O
took	O
ibuprofen	O
for	O
fever	B
for	O
nearly	O
a	O
week	O
prior	O
to	O
presentation	O
.	O

He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
concentration	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatinine	O
of	O
15.3	O
mg	O
/	O
dl	O
and	O
serum	O
potassium	O
of	O
8.7	O
mEq	O
/	O
l	O
.	O

Dialysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kidney	O
biopsy	O
showed	O
inflammatory	O
infiltrate	O
consistent	O
with	O
ATIN	B
.	O

However	O
,	O
in	O
the	O
tubular	O
basement	O
membrane	O
(	O
TBM	O
)	O
,	O
very	O
intense	O
granular	O
deposits	O
of	O
polyclonal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	O
for	O
6	O
months	O
.	O

His	O
renal	O
recovery	O
and	O
disappearance	O
of	O
proteinuria	B
took	O
a	O
year	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
report	O
of	O
NSAIDs	O
-	O
associated	O
ATIN	B
,	O
showing	O
deposits	O
of	O
granular	O
immune	O
complex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glomeruli	O
.	O

Rifampicin	O
-	O
associated	O
segmental	O
necrotizing	O
glomerulonephritis	B
in	O
staphylococcal	B
endocarditis	B
.	O

Segmental	O
necrotising	O
glomerulonephritis	B
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	O
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	B
.	O

Changing	O
epidemiology	O
of	O
infections	B
such	O
as	O
infective	B
endocarditis	I
(	O
IE	B
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	O
for	O
Staphylococcal	B
infections	I
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	B
IE	B
who	O
developed	O
acute	B
renal	I
failure	I
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	B
while	O
being	O
treated	O
with	O
rifampicin	O
,	O
and	O
review	O
the	O
literature	O
regarding	O
this	O
complication	O
of	O
rifampicin	O
therapy	O
.	O

Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	O
-	O
untreated	O
Iranian	O
patients	O
with	O
chronic	B
hepatitis	I
B	I
virus	I
infection	I
.	O

BACKGROUND	O
:	O
Lamivudine	O
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	B
hepatitis	I
B	I
patients	O
.	O

Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(	O
resistant	O
hepatitis	B
B	I
virus	O
)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine	O
-	O
untreated	O
chronic	B
hepatitis	I
B	I
patients	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	O
-	O
untreated	O
chronic	B
hepatitis	I
B	I
patients	O
in	O
Iran	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chronic	B
hepatitis	I
B	I
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	O
were	O
included	O
in	O
the	O
study	O
.	O

Serum	O
samples	O
from	O
patients	O
were	O
tested	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
detection	O
of	O
YMDD	O
motif	O
mutants	O
.	O

All	O
patients	O
were	O
also	O
tested	O
for	O
liver	O
enzymes	O
,	O
anti	O
-	O
HCV	O
,	O
HBeAg	O
,	O
and	O
anti	O
-	O
HBe	O
.	O

RESULTS	O
:	O
Of	O
the	O
77	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
73	O
%	O
were	O
male	O
and	O
27	O
%	O
were	O
female	O
.	O

Mean	O
ALT	O
and	O
AST	O
levels	O
were	O
124.4+	O
/	O
-73.4	O
and	O
103.1+	O
/	O
-81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O

HBeAg	O
was	O
positive	O
in	O
40	O
%	O
and	O
anti	O
-	O
HBe	O
in	O
60	O
%	O
of	O
the	O
patients	O
.	O

Anti	O
-	O
HCV	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O

YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	O
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	O
or	O
anti	O
-	O
HBe	O
.	O

CONCLUSION	O
:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	O
-	O
untreated	O
patients	O
with	O
chronic	B
hepatitis	I
B	I
has	O
been	O
reported	O
,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine	O
-	O
untreated	O
chronic	B
hepatitis	I
B	I
patients	O
.	O

Branch	O
retinal	B
vein	I
occlusion	I
and	O
fluoxetine	O
.	O

A	O
case	O
of	O
branch	O
retinal	B
vein	I
occlusion	I
associated	O
with	O
fluoxetine	O
-	O
induced	O
secondary	O
hypertension	B
is	O
described	O
.	O

Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
therapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	B
because	O
this	O
class	O
of	O
drugs	O
is	O
widely	O
prescribed	O
.	O

The	O
differential	O
effects	O
of	O
bupivacaine	O
and	O
lidocaine	O
on	O
prostaglandin	O
E2	O
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	B
in	O
a	O
clinical	O
pain	B
model	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	O
on	O
local	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B
pain	I
in	O
human	O
subjects	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	O
or	O
0.5	O
%	O
bupivacaine	O
before	O
surgery	O
and	O
either	O
rofecoxib	O
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	O
and	O
thromboxane	O
B2	O
(	O
TXB2	O
)	O
measurements	O
.	O

RESULTS	O
:	O
The	O
bupivacaine	O
/	O
rofecoxib	O
group	O
reported	O
significantly	O
less	O
pain	B
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h.	O
However	O
,	O
the	O
bupivacaine	O
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B
at	O
24	O
h	O
and	O
PGE2	O
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O

Moreover	O
,	O
bupivacaine	O
significantly	O
increased	O
COX-2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	O
/	O
placebo	O
group	O
.	O

Thromboxane	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX-2	O
,	O
but	O
not	O
COX-1	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	O
stimulates	O
COX-2	O
gene	O
expression	O
after	O
tissue	B
injury	I
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	O
production	O
and	O
pain	B
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O

p75NTR	O
expression	O
in	O
rat	O
urinary	O
bladder	O
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
.	O

A	O
role	O
for	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
increased	O
voiding	O
frequency	O
and	O
altered	O
sensation	O
from	O
the	O
urinary	O
bladder	O
has	O
been	O
suggested	O
.	O

Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	O
kinase	O
receptors	O
(	O
Trks	O
)	O
in	O
micturition	O
reflexes	O
with	O
urinary	B
bladder	I
inflammation	I
.	O

The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
durations	O
of	O
bladder	B
inflammation	I
induced	O
by	O
cyclophosphamide	O
(	O
CYP	O
)	O
.	O

CYP	O
-	O
induced	O
cystitis	B
increased	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
the	O
superficial	O
lateral	O
and	O
medial	O
dorsal	O
horn	O
in	O
L1-L2	O
and	O
L6-S1	O
spinal	O
segments	O
.	O

The	O
number	O
of	O
p75	O
(	O
NTR	O
)	O
-immunoreactive	O
(	O
-IR	O
)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
with	O
CYP	O
-	O
induced	O
cystitis	B
(	O
acute	O
,	O
intermediate	O
,	O
and	O
chronic	O
)	O
.	O

Quantitative	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP	O
-	O
induced	O
cystitis	B
.	O

Retrograde	O
dye	O
-	O
tracing	O
techniques	O
with	O
Fastblue	O
were	O
used	O
to	O
identify	O
presumptive	O
bladder	O
afferent	O
cells	O
in	O
the	O
lumbosacral	O
DRG	O
.	O

In	O
bladder	O
afferent	O
cells	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-IR	O
was	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
with	O
cystitis	B
.	O

In	O
addition	O
to	O
increases	O
in	O
p75	O
(	O
NTR	O
)	O
-IR	O
in	O
DRG	O
cell	O
bodies	O
,	O
increases	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O
in	O
pericellular	O
(	O
encircling	O
DRG	O
cells	O
)	O
p75	O
(	O
NTR	O
)	O
-IR	O
in	O
DRG	O
also	O
increased	O
.	O

Confocal	O
analyses	O
demonstrated	O
that	O
pericellular	O
p75	O
(	O
NTR	O
)	O
-IR	O
was	O
not	O
colocalized	O
with	O
the	O
glial	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	B
inflammation	I
.	O

The	O
functional	O
significance	O
of	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
remains	O
to	O
be	O
determined	O
.	O

Azathioprine	O
-	O
induced	O
suicidal	O
erythrocyte	O
death	O
.	O

BACKGROUND	O
:	O
Azathioprine	O
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O

The	O
side	O
effects	O
of	O
azathioprine	O
include	O
anemia	B
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	O
marrow	O
suppression	O
.	O

Alternatively	O
,	O
anemia	B
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	O
(	O
PS	O
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O

METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	O
influences	O
eryptosis	O
.	O

According	O
to	O
annexin	O
V	O
binding	O
,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	O
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	O
.	O

In	O
a	O
second	O
series	O
,	O
cytosolic	O
Ca2	O
+	O
activity	O
(	O
Fluo3	O
fluorescence	O
)	O
,	O
cell	O
volume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS	O
-	O
exposure	O
(	O
annexin	O
V	O
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O

RESULTS	O
:	O
Exposure	O
to	O
azathioprine	O
(	O
>	O
or	O
=	O
2	O
microg	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	O
+	O
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O

The	O
effect	O
of	O
azathioprine	O
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	O
+	O
.	O

CONCLUSIONS	O
:	O
Azathioprine	O
triggers	O
suicidal	O
erythrocyte	O
death	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	O
-	O
induced	O
anemia	B
.	O

Levetiracetam	O
as	O
an	O
adjunct	O
to	O
phenobarbital	O
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	B
epilepsy	I
.	O

OBJECTIVE	O
:	O
To	O
assess	O
pharmacokinetics	O
,	O
efficacy	O
,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	O
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	O
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	B
epilepsy	I
.	O

DESIGN	O
-	O
Open	O
-	O
label	O
,	O
noncomparative	O
clinical	O
trial	O
.	O

ANIMALS	O
:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	B
epilepsy	I
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	O
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	O
.	O

PROCEDURES	O
:	O
Cats	O
were	O
treated	O
with	O
levetiracetam	O
(	O
20	O
mg	O
/	O
kg	O
[	O
9.1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment	O
,	O
serum	O
levetiracetam	O
concentrations	O
were	O
measured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
drug	O
administration	O
,	O
and	O
maximum	O
and	O
minimum	O
serum	O
concentrations	O
and	O
elimination	O
half	O
-	O
life	O
were	O
calculated	O
.	O

Seizure	B
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	O
treatment	O
were	O
compared	O
,	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O

RESULTS	O
:	O
Median	O
maximum	O
serum	O
levetiracetam	O
concentration	O
was	O
25.5	O
microg	O
/	O
mL	O
,	O
median	O
minimum	O
serum	O
levetiracetam	O
concentration	O
was	O
8.3	O
microg	O
/	O
mL	O
,	O
and	O
median	O
elimination	O
half	O
-	O
life	O
was	O
2.9	O
hours	O
.	O

Median	O
seizure	B
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	O
(	O
2.1	O
seizures	B
/	O
mo	O
)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	B
frequency	O
after	O
initiation	O
of	O
levetiracetam	O
treatment	O
(	O
0.42	O
seizures	B
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	O
treatment	O
(	O
ie	O
,	O
reduction	O
in	O
seizure	B
frequency	O
of	O
>	O
or=50	O
%	O
)	O
.	O

Two	O
cats	O
had	O
transient	O
lethargy	B
and	O
inappetence	B
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Results	O
suggested	O
that	O
levetiracetam	O
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	O
treatment	O
in	O
cats	O
with	O
idiopathic	B
epilepsy	I
.	O

Serotonin	O
reuptake	O
inhibitors	O
,	O
paranoia	B
,	O
and	O
the	O
ventral	O
basal	O
ganglia	O
.	O

Antidepressants	O
have	O
previously	O
been	O
associated	O
with	O
paranoid	B
reactions	O
in	O
psychiatric	O
patients	O
.	O

Five	O
cases	O
of	O
paranoid	B
exacerbation	O
with	O
the	O
serotonin	O
reuptake	O
inhibitors	O
fluoxetine	O
and	O
amitriptyline	O
are	O
reported	O
here	O
.	O

Elements	O
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	B
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	B
and	I
psychotic	I
symptoms	I
.	O

Complicated	O
depressive	B
disorders	I
(	O
including	O
atypicality	O
of	O
course	O
and	O
symptomatology	O
,	O
chronicity	O
,	O
psychosis	B
,	O
bipolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	B
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	B
exacerbations	O
associated	O
with	O
serotonin	O
reuptake	O
inhibitors	O
.	O

Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	B
remain	O
cryptic	O
,	O
several	O
mechanisms	O
,	O
including	O
5HT3	O
receptor	O
-	O
mediated	O
dopamine	O
release	O
,	O
beta	O
-	O
noradrenergic	O
receptor	O
downregulation	O
,	O
or	O
GABAB	O
receptor	O
upregulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
ventral	O
basal	O
ganglia	O
(	O
possibly	O
in	O
lateral	O
orbitofrontal	O
or	O
anterior	O
cingulate	O
circuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomenon	O
.	O

These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	B
exacerbations	O
with	O
serotonin	O
reuptake	O
blockers	O
in	O
select	O
patients	O
and	O
raise	O
neurobiological	O
considerations	O
regarding	O
paranoia	B
.	O

Clinical	O
comparison	O
of	O
cardiorespiratory	O
effects	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	O
-	O
spinal	O
block	O
hypotension	B
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setback	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
cardiovascular	O
and	O
respiratory	O
changes	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	O
)	O
,	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	O
surgery	O
.	O

Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
groups	O
:	O
lateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
groups	O
.	O

In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0.5	O
%	O
hyperbaric	O
bupivacaine	O
through	O
a	O
25-gauge	O
spinal	O
needle	O
.	O

Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	O
saturation	O
were	O
monitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
patients	O
(	O
8.1	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13.5	O
%	O
)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	B
,	O
P=	O
0.71	O
.	O

Four	O
(	O
10.8	O
%	O
)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2.7	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
,	O
P=	O
0.17	O
required	O
epinephrine	O
infusion	O
to	O
treat	O
hypotension	B
.	O

Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	O
15	O
,	O
30	O
and	O
45	O
minutes	O
when	O
compared	O
to	O
the	O
baseline	O
(	O
P=	O
0.003	O
,	O
0.001	O
and	O
0.004	O
)	O
.	O

The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	O
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Compared	O
to	O
conventional	O
spinal	O
anaesthesia	O
,	O
unilateral	O
spinal	O
anaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovascular	O
perturbations	O
.	O

Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	O
saturation	O
.	O

Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B
-	I
infected	I
patients	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B
-	I
infected	I
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B
-	I
infected	I
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O

The	O
most	O
common	O
regimens	O
were	O
3TC	O
+	O
d4	O
T	O
+	O
nevirapine	O
(	O
NVP	O
)	O
(	O
54.8	O
%	O
)	O
,	O
zidovudine	O
(	O
AZT	O
)	O
+	O
3TC	O
+	O
NVP	O
(	O
14.5	O
%	O
)	O
,	O
3TC	O
+	O
d4	O
T	O
+	O
efavirenz	O
(	O
EFV	O
)	O
(	O
20.1	O
%	O
)	O
,	O
and	O
AZT	O
+	O
3TC	O
+	O
EFV	O
(	O
5.4	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	B
(	O
15.2	O
%	O
;	O
CD4	O
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B
neuropathy	I
(	O
9.0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O

Clinically	O
significant	O
anemia	B
(	O
hemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5.4	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B
(	O
clinical	O
jaundice	B
with	O
alanine	O
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3.5	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
260	O
cells	O
/	O
microL	O
)	O
.	O

Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B
acidosis	I
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B
reconstitution	I
syndrome	I
(	O
p	O
<	O
0.05	O
)	O
.	O

Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
,	O
NVP	O
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B
and	O
d4	O
T	O
therapy	O
with	O
developing	O
peripheral	B
neuropathy	I
(	O
p	O
<	O
0.05	O
)	O
.	O

Anemia	B
and	O
hepatitis	B
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O

Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O

Thalidomide	O
and	O
sensory	B
neurotoxicity	I
:	O
a	O
neurophysiological	O
study	O
.	O

BACKGROUND	O
:	O
Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	B
axonal	I
neuropathy	I
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	O
.	O

The	O
study	O
's	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(	O
SAP	O
)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	B
lupus	I
erythematosus	I
(	O
CLE	B
)	O
treated	O
with	O
thalidomide	O
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	B
potential	O
of	O
thalidomide	O
and	O
the	O
recovery	O
capacity	O
of	O
sensory	O
fibres	O
after	O
discontinuation	O
of	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	B
during	O
treatment	O
with	O
thalidomide	O
and	O
up	O
to	O
47	O
months	O
after	O
discontinuation	O
of	O
treatment	O
were	O
analysed	O
.	O

Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
criteria	O
for	O
discontinuing	O
therapy	O
.	O

RESULTS	O
:	O
During	O
treatment	O
,	O
11	O
patients	O
showed	O
a	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
compared	O
to	O
baseline	O
values	O
(	O
9	O
with	O
a	O
reduction	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
patient	O
showed	O
no	O
changes	O
in	O
SAP	O
amplitude	O
.	O

Five	O
patients	O
complained	O
of	O
paresthesias	B
and	O
leg	O
cramps	B
.	O

After	O
thalidomide	O
treatment	O
,	O
sural	O
SAP	O
amplitude	O
recovered	O
in	O
3	O
patients	O
.	O

At	O
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
,	O
the	O
median	O
thalidomide	O
cumulative	O
dose	O
was	O
21.4	O
g.	O
The	O
threshold	O
neurotoxic	B
dosage	O
is	O
lower	O
than	O
previously	O
reported	O
.	O

CONCLUSIONS	O
:	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
is	O
a	O
reliable	O
and	O
sensitive	O
marker	O
of	O
degeneration	O
and	O
recovery	O
of	O
sensory	O
fibres	O
.	O

This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	B
potential	O
of	O
thalidomide	O
but	O
is	O
not	O
helpful	O
in	O
predicting	O
the	O
appearance	O
of	O
sensory	O
symptoms	O
.	O

Five	O
cases	O
of	O
encephalitis	B
during	O
treatment	O
of	O
loiasis	B
with	O
diethylcarbamazine	O
.	O

Five	O
cases	O
of	O
encephalitis	B
following	O
treatment	O
with	O
diethylcarbamazine	O
(	O
DEC	O
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	B
.	O

Two	O
cases	O
had	O
a	O
fatal	O
outcome	O
and	O
one	O
resulted	O
in	O
severe	O
sequelae	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
complication	O
occurred	O
in	O
three	O
patients	O
hospitalized	O
before	O
treatment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therapeutic	O
precautions	O
were	O
taken	O
,	O
i.e.	O
,	O
initial	O
dose	O
less	O
than	O
10	O
mg	O
of	O
DEC	O
,	O
very	O
gradual	O
dose	O
increases	O
,	O
and	O
associated	O
anti	O
-	O
allergic	O
treatment	O
.	O

This	O
type	O
of	O
drug	O
-	O
induced	O
complication	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endemic	O
regions	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjects	O
presenting	O
with	O
a	O
high	O
microfilarial	O
load	O
.	O

The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	B
and	O
the	O
decrease	O
in	O
microfilaremia	B
is	O
evident	O
.	O

The	O
pathophysiological	O
mechanisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observations	O
and	O
the	O
few	O
other	O
comments	O
on	O
this	O
subject	O
published	O
in	O
the	O
literature	O
.	O

Amiodarone	O
-	O
related	O
pulmonary	B
mass	I
and	O
unique	O
membranous	B
glomerulonephritis	I
in	O
a	O
patient	O
with	O
valvular	B
heart	I
disease	I
:	O
Diagnostic	O
pitfall	O
and	O
new	O
findings	O
.	O

Amiodarone	O
is	O
an	O
anti	O
-	O
arrhythmic	B
drug	O
for	O
life	O
-	O
threatening	O
tachycardia	B
,	O
but	O
various	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	B
heart	I
disease	I
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	B
mass	I
(	O
1.5	O
cm	O
in	O
diameter	O
)	O
and	O
proteinuria	B
(	O
2.76	O
g	O
/	O
day	O
)	O
after	O
treatment	O
with	O
amiodarone	O
for	O
a	O
long	O
time	O
.	O

The	O
lung	B
mass	I
was	O
highly	O
suspected	O
to	O
be	O
lung	B
cancer	I
on	O
CT	O
and	O
positron	O
emission	O
tomography	O
,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra	O
-	O
alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone	O
-	O
related	O
lesion	O
.	O

In	O
addition	O
,	O
the	O
lung	O
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	B
deposition	O
,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	B
lung	O
portions	O
outside	O
the	O
mass	O
.	O

In	O
the	O
kidneys	O
,	O
glomeruli	O
had	O
membrane	O
spikes	O
,	O
prominent	O
swelling	O
of	O
podocytes	O
and	O
subepithelial	O
deposits	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hump	O
-	O
like	O
.	O

Autoimmune	B
diseases	I
,	O
viral	B
hepatitis	I
,	O
malignant	O
neoplasms	B
or	O
other	O
diseases	O
with	O
a	O
known	O
relationship	O
to	O
membranous	B
glomerulonephritis	I
were	O
not	O
found	O
.	O

The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone	O
-	O
related	O
pulmonary	B
lesion	I
and	O
a	O
neoplasm	B
can	O
be	O
very	O
difficult	O
radiologically	O
,	O
and	O
suggests	O
that	O
membranous	B
glomerulonephritis	I
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	O
treatment	O
.	O

Risk	O
of	O
coronary	B
artery	I
disease	I
associated	O
with	O
initial	O
sulphonylurea	O
treatment	O
of	O
patients	O
with	O
type	B
2	I
diabetes	I
:	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O

AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B
artery	I
disease	I
(	O
CAD	B
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B
2	I
diabetes	I
with	O
different	O
sulphonylureas	O
.	O

METHODS	O
:	O
In	O
type	B
2	I
diabetic	I
patients	O
,	O
cases	O
who	O
developed	O
CAD	B
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O

The	O
20-year	O
risk	O
of	O
CAD	B
at	O
diagnosis	O
of	O
diabetes	B
,	O
using	O
the	O
UKPDS	O
risk	O
engine	O
,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O

RESULTS	O
:	O
The	O
76	O
cases	O
of	O
CAD	B
were	O
compared	O
with	O
152	O
controls	O
.	O

The	O
hazard	O
of	O
developing	O
CAD	B
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2.4-fold	O
(	O
1.3	O
-	O
4.3	O
,	O
P=0.004	O
)	O
with	O
glibenclamide	O
;	O
2-fold	O
(	O
0.9	O
-	O
4.6	O
,	O
P=0.099	O
)	O
with	O
glipizide	O
;	O
2.9-fold	O
(	O
1.6	O
-	O
5.1	O
,	O
P=0.000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	O
.	O

The	O
hazard	O
decreased	O
0.3-fold	O
(	O
0.7	O
-	O
1.7	O
,	O
P=0.385	O
)	O
with	O
glimepiride	O
,	O
0.4-fold	O
(	O
0.7	O
-	O
1.3	O
,	O
P=0.192	O
)	O
with	O
gliclazide	O
,	O
and	O
0.4-fold	O
(	O
0.7	O
-	O
1.1	O
,	O
P=0.09	O
)	O
with	O
either	O
.	O

CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B
2	I
diabetes	I
with	O
glibenclamide	O
or	O
glipizide	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	B
in	O
comparison	O
to	O
gliclazide	O
or	O
glimepiride	O
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	O
,	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O

Reduced	O
progression	O
of	O
adriamycin	O
nephropathy	B
in	O
spontaneously	O
hypertensive	B
rats	O
treated	O
by	O
losartan	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	O
II	O
type-1	O
receptor	O
blocker	O
,	O
losartan	O
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B
disease	I
progression	O
in	O
spontaneously	O
hypertensive	B
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	O
(	O
ADR	O
)	O
nephropathy	B
.	O

METHODS	O
:	O
Six	O
-	O
month	O
-	O
old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups	O
.	O

Two	O
control	O
groups	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehicle	O
.	O

Groups	O
ADR	O
(	O
6	O
)	O
,	O
ADR+LOS	O
(	O
6	O
)	O
and	O
ADR	O
(	O
12	O
)	O
,	O
and	O
ADR+LOS	O
(	O
12	O
)	O
received	O
ADR	O
(	O
2	O
mg	O
/	O
kg	O
/	O
b.w	O
.	O

i.v	O
.	O
)	O
twice	O
in	O
a	O
3-week	O
interval	O
.	O

Group	O
ADR+LOS	O
(	O
6	O
)	O
received	O
losartan	O
(	O
10	O
mg	O
/	O
kg	O
/	O
b.w.	O
/	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR+LOS	O
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	O
.	O

Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks	O
,	O
respectively	O
.	O

Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O

RESULTS	O
:	O
Short	O
-	O
term	O
losartan	O
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B
resulting	O
in	O
decreased	O
proteinuria	B
.	O

Prolonged	O
treatment	O
with	O
losartan	O
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B
and	O
interstitial	B
fibrosis	I
,	O
thus	O
preventing	O
heavy	O
proteinuria	B
and	O
chronic	B
renal	I
failure	I
.	O

Losartan	O
reduced	O
uraemia	B
and	O
increased	O
urea	O
clearance	O
in	O
advanced	O
ADR	O
nephropathy	B
in	O
SHR	O
.	O

Histological	O
examination	O
showed	O
that	O
losartan	O
could	O
prevent	O
tubular	O
atrophy	B
,	O
interstitial	O
infiltration	O
and	O
fibrosis	B
in	O
ADR	O
nephropathy	B
.	O

CONCLUSION	O
:	O
Losartan	O
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	O
-	O
induced	O
focal	B
segmental	I
glomerulosclerosis	I
to	O
end	B
-	I
stage	I
renal	I
disease	I
in	O
SHR	O
.	O

The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	O
acid	O
in	O
cardiac	O
surgery	O
:	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
of	O
1188	O
consecutive	O
patients	O
.	O

BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	O
complications	O
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	O
acid	O
in	O
an	O
unselected	O
,	O
consecutive	O
cohort	O
.	O

METHODS	O
:	O
Perioperative	O
data	O
from	O
consecutive	O
cardiac	O
surgery	O
patients	O
were	O
prospectively	O
collected	O
between	O
September	O
2005	O
and	O
June	O
2006	O
in	O
a	O
university	O
-	O
affiliated	O
clinic	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patients	O
received	O
aprotinin	O
(	O
Group	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	O
acid	O
(	O
Group	O
T	O
)	O
.	O

Except	O
for	O
antifibrinolytic	O
therapy	O
,	O
the	O
anesthetic	O
and	O
surgical	O
protocols	O
remained	O
unchanged	O
.	O

RESULTS	O
:	O
The	O
pre-	O
and	O
intraoperative	O
variables	O
were	O
comparable	O
between	O
the	O
treatment	O
groups	O
.	O

Postoperatively	O
,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	B
was	O
found	O
in	O
Group	O
T	O
(	O
4.6	O
%	O
vs	O
1.2	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
primary	O
valve	O
surgery	O
and	O
the	O
high	O
risk	O
surgery	O
subgroups	O
(	O
7.9	O
%	O
vs	O
1.2	O
%	O
,	O
P	O
=	O
0.003	O
;	O
7.3	O
%	O
vs	O
2.4	O
%	O
,	O
P	O
=	O
0.035	O
,	O
respectively	O
)	O
.	O

Persistent	O
atrial	O
fibrillation	O
(	O
7.9	O
%	O
vs	O
2.3	O
%	O
,	O
P	O
=	O
0.020	O
)	O
and	O
renal	B
failure	I
(	O
9.7	O
%	O
vs	O
1.7	O
%	O
,	O
P	O
=	O
0.002	O
)	O
were	O
also	O
more	O
common	O
in	O
Group	O
T	O
,	O
in	O
the	O
primary	O
valve	O
surgery	O
subgroup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients	O
,	O
there	O
were	O
more	O
acute	O
myocardial	B
infarctions	I
and	O
renal	B
dysfunction	I
in	O
Group	O
A	O
(	O
5.8	O
%	O
vs	O
2.0	O
%	O
,	O
P	O
=	O
0.027	O
;	O
22.5	O
%	O
vs	O
15.2	O
%	O
,	O
P	O
=	O
0.036	O
,	O
respectively	O
)	O
.	O

The	O
1-yr	O
mortality	O
was	O
significantly	O
higher	O
after	O
aprotinin	O
treatment	O
in	O
the	O
high	O
risk	O
surgery	O
group	O
(	O
17.7	O
%	O
vs	O
9.8	O
%	O
,	O
P	O
=	O
0.034	O
)	O
.	O

CONCLUSION	O
:	O
Both	O
antifibrinolytic	O
drugs	O
bear	O
the	O
risk	O
of	O
adverse	O
outcome	O
depending	O
on	O
the	O
type	O
of	O
cardiac	O
surgery	O
.	O

Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients	O
,	O
whereas	O
administration	O
of	O
tranexamic	O
acid	O
is	O
not	O
recommended	O
in	O
valve	O
surgery	O
.	O

Delirium	B
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	O
.	O

Misoprostol	O
has	O
been	O
associated	O
with	O
adverse	O
reactions	O
,	O
including	O
gastrointestinal	O
symptoms	O
,	O
gynecologic	O
problems	O
,	O
and	O
headache	B
.	O

Changes	O
in	O
mental	O
status	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
case	O
in	O
which	O
an	O
89-year	O
-	O
old	O
woman	O
in	O
a	O
long	O
-	O
term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	O
therapy	O
.	O

The	O
patient	O
's	O
change	O
in	O
mental	O
status	O
was	O
first	O
reported	O
nine	O
days	O
after	O
the	O
initiation	O
of	O
therapy	O
.	O

Her	O
delirium	B
significantly	O
improved	O
after	O
misoprostol	O
was	O
discontinued	O
and	O
her	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
a	O
week	O
.	O

Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly	O
,	O
the	O
delirium	B
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	O
therapy	O
.	O

The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	O
and	O
their	O
effects	O
on	O
cardiac	B
arrhythmias	I
.	O

1	O
.	O

The	O
optical	O
isomers	O
of	O
propranolol	O
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities.2	O
.	O

In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	O
,	O
(	O
+	O
)	O
-propranolol	O
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(	O
-	O
)	O
-propranolol	O
.	O

At	O
dose	O
levels	O
of	O
(	O
+	O
)	O
-propranolol	O
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	O
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.3	O
.	O

The	O
metabolic	O
responses	O
to	O
isoprenaline	O
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	O
,	O
lactate	O
and	O
free	O
fatty	O
acids	O
)	O
were	O
all	O
blocked	O
by	O
(	O
-	O
)	O
-propranolol	O
.	O

(	O
+	O
)	O
-Propranolol	O
had	O
no	O
effect	O
on	O
fatty	O
acid	O
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	O
and	O
glucose.4	O
.	O

Both	O
isomers	O
of	O
propranolol	O
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	O
-	O
pigs.5	O
.	O

The	O
isomers	O
of	O
propranolol	O
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	O
.	O

The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer.6	O
.	O

Both	O
isomers	O
of	O
propranolol	O
were	O
capable	O
of	O
preventing	O
adrenaline	O
-	O
induced	O
cardiac	B
arrhythmias	I
in	O
cats	O
anaesthetized	O
with	O
halothane	O
,	O
but	O
the	O
mean	O
dose	O
of	O
(	O
-	O
)	O
-propranolol	O
was	O
0.09+	O
/	O
-0.02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-propranolol	O
was	O
4.2+	O
/	O
-1.2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effective	O
dose	O
level	O
of	O
(	O
+	O
)	O
-propranolol	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O

Blockade	O
of	O
arrhythmias	B
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline.7	O
.	O

Both	O
isomers	O
of	O
propranolol	O
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B
tachycardia	I
caused	O
by	O
ouabain	O
in	O
anaesthetized	O
cats	O
and	O
dogs	O
.	O

The	O
dose	O
of	O
(	O
-	O
)	O
-propranolol	O
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-propranolol	O
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade.8	O
.	O

The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Topotecan	O
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	B
:	O
a	O
phase	O
2	O
study	O
.	O

Improving	O
glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
treatment	O
with	O
radio	O
-	O
chemotherapy	O
remains	O
a	O
challenge	O
.	O

Topotecan	O
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	B
as	O
well	O
as	O
brain	O
penetration	O
.	O

The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(	O
60	O
Gy	O
/	O
30	O
fractions	O
/	O
40	O
days	O
)	O
and	O
topotecan	O
(	O
0.9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
days	O
1	O
-	O
5	O
on	O
weeks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
adults	O
with	O
histologically	O
proven	O
and	O
untreated	O
GBM	B
.	O

The	O
incidence	O
of	O
non	O
-	O
hematological	O
toxicities	B
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	B
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	B
and	O
neutropenia	B
)	O
.	O

Partial	O
response	O
and	O
stabilization	O
rates	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
time	O
to	O
progression	O
of	O
12	O
weeks	O
.	O

One	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
was	O
42	O
%	O
,	O
with	O
a	O
median	O
OS	O
of	O
40	O
weeks	O
.	O

Topotecan	O
in	O
combination	O
with	O
radiotherapy	O
was	O
well	O
tolerated	O
.	O

However	O
,	O
while	O
response	O
and	O
stabilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patients	O
,	O
the	O
study	O
did	O
not	O
show	O
increased	O
benefits	O
in	O
terms	O
of	O
survival	O
in	O
patients	O
with	O
unresectable	O
GBM	B
.	O

Long	O
-	O
term	O
lithium	O
therapy	O
leading	O
to	O
hyperparathyroidism	B
:	O
a	O
case	O
report	O
.	O

PURPOSE	O
:	O
This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	O
therapy	O
on	O
serum	O
calcium	O
level	O
and	O
parathyroid	O
glands	O
,	O
its	O
pathogenesis	O
,	O
and	O
treatment	O
options	O
.	O

We	O
examined	O
the	O
case	O
of	O
a	O
lithium	O
-	O
treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	B
to	O
better	O
understand	O
the	O
disease	O
process	O
.	O

CONCLUSION	O
:	O
Primary	B
hyperparathyroidism	I
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
long	O
-	O
term	O
lithium	O
therapy	O
.	O

Careful	O
patient	O
selection	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
reduce	O
morbidity	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithium	O
-	O
treated	O
patients	O
become	O
hypercalcemic	B
.	O

By	O
routinely	O
monitoring	O
serum	O
calcium	O
levels	O
,	O
healthcare	O
providers	O
can	O
improve	O
the	O
quality	O
of	O
life	O
of	O
this	O
patient	O
group	O
.	O

Comparison	O
of	O
laryngeal	O
mask	O
with	O
endotracheal	O
tube	O
for	O
anesthesia	O
in	O
endoscopic	O
sinus	O
surgery	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions	O
,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	B
as	O
well	O
as	O
intraoperative	O
blood	O
pressure	O
,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(	O
FESS	O
)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(	O
FRLMA	O
)	O
versus	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
in	O
maintaining	O
controlled	O
hypotension	B
anesthesia	O
induced	O
by	O
propofol	O
-	O
remifentanil	O
total	O
i.v	O
.	O

anesthesia	O
(	O
TIVA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I	O
-	O
II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	B
anesthesia	O
caused	O
by	O
propofol	O
-	O
remifentanil	O
-	O
TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
:	O
group	O
I	O
,	O
FRLMA	O
;	O
group	O
II	O
,	O
ETT	O
.	O

Hemorrhage	B
was	O
measured	O
and	O
the	O
visibility	O
of	O
the	O
operative	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

RESULTS	O
:	O
Controlled	O
hypotension	B
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	O
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	O
.	O

CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	B
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	O
loss	O
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	B
with	O
low	O
doses	O
of	O
remifentanil	O
during	O
TIVA	O
in	O
patients	O
undergoing	O
FESS	O
.	O

Nonalcoholic	B
fatty	I
liver	I
disease	I
during	O
valproate	O
therapy	O
.	O

Valproic	O
acid	O
(	O
VPA	O
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	B
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	O
weight	O
.	O

We	O
report	O
a	O
case	O
of	O
nonalcoholic	B
fatty	I
liver	I
disease	I
(	O
NAFLD	B
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	B
during	O
VPA	O
treatment	O
.	O

Laboratory	O
data	O
revealed	O
hyperinsulinemia	B
with	O
insulin	B
resistance	I
.	O

After	O
the	O
withdrawal	O
of	O
VPA	O
therapy	O
,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	B
loss	I
,	O
a	O
decrease	O
of	O
body	O
mass	O
index	O
,	O
and	O
normalization	O
of	O
metabolic	O
and	O
endocrine	O
parameters	O
;	O
moreover	O
,	O
ultrasound	O
measurements	O
showed	O
a	O
complete	O
normalization	O
.	O

The	O
present	O
case	O
suggests	O
that	O
obesity	B
,	O
hyperinsulinemia	B
,	O
insulin	B
resistance	I
,	O
and	O
long	O
-	O
term	O
treatment	O
with	O
VPA	O
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	B
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	O
withdrawal	O
.	O

Carbimazole	O
induced	O
ANCA	B
positive	I
vasculitis	I
.	O

Anti	O
-	O
thyroid	O
drugs	O
,	O
like	O
carbimazole	O
and	O
propylthiouracil	O
(	O
PTU	O
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	B
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effects	O
of	O
antithyroid	O
medications	O
.	O

Antineutrophil	B
cytoplasmic	I
antibody	I
(	I
ANCA	I
)	I
--associated	I
vasculitis	I
is	O
a	O
potentially	O
life	O
-	O
threatening	O
adverse	O
effect	O
of	O
antithyroidmedications	O
.	O

We	O
report	O
a	O
patient	O
with	O
Graves	B
'	I
disease	I
who	O
developed	O
ANCA	O
positive	O
carbimazole	O
induced	O
vasculitis	B
.	O

The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	B
skin	B
rash	I
associated	O
with	O
large	O
joint	O
arthritis	B
,	O
pyrexia	B
and	O
parotiditis	B
but	O
no	O
renal	O
or	O
pulmonary	O
involvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	B
.	O

Carbimazole	O
and	O
methimazole	O
have	O
a	O
lower	O
incidence	O
of	O
reported	O
ANCA	O
positive	O
side	O
effects	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	O
induced	O
vasculitis	B
case	O
reported	O
from	O
India	O
.	O

Aspirin	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	O
events	O
:	O
an	O
update	O
of	O
the	O
evidence	O
for	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
.	O

BACKGROUND	O
:	O
Coronary	B
heart	I
disease	I
and	O
cerebrovascular	B
disease	I
are	O
leading	O
causes	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

In	O
2002	O
,	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	O
with	O
adults	O
who	O
are	O
at	O
increased	O
risk	O
for	O
coronary	B
heart	I
disease	I
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	O
for	O
the	O
primary	O
prevention	O
of	O
myocardial	B
infarctions	I
,	O
strokes	B
,	O
and	O
death	O
.	O

DATA	O
SOURCES	O
:	O
MEDLINE	O
and	O
Cochrane	O
Library	O
(	O
search	O
dates	O
,	O
1	O
January	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
systematic	O
reviews	O
,	O
reference	O
lists	O
of	O
retrieved	O
articles	O
,	O
and	O
suggestions	O
from	O
experts	O
.	O

STUDY	O
SELECTION	O
:	O
English	O
-	O
language	O
randomized	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
;	O
case	O
-	O
control	O
studies	O
;	O
meta	O
-	O
analyses	O
;	O
and	O
systematic	O
reviews	O
of	O
aspirin	O
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	B
disease	I
(	O
CVD	B
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions	O
:	O
Does	O
aspirin	O
decrease	O
coronary	O
heart	O
events	O
,	O
strokes	B
,	O
death	O
from	O
coronary	O
heart	O
events	O
or	O
stroke	B
,	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
adults	O
without	O
known	O
CVD	B
?	O

Does	O
aspirin	O
increase	O
gastrointestinal	B
bleeding	I
or	O
hemorrhagic	B
strokes	B
?	O

DATA	O
EXTRACTION	O
:	O
All	O
studies	O
were	O
reviewed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
quality	O
by	O
using	O
predefined	O
USPSTF	O
criteria	O
.	O

DATA	O
SYNTHESIS	O
:	O
New	O
evidence	O
from	O
1	O
good	O
-	O
quality	O
RCT	O
,	O
1	O
good	O
-	O
quality	O
meta	O
-	O
analysis	O
,	O
and	O
2	O
fair	O
-	O
quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	O
use	O
reduces	O
the	O
number	O
of	O
CVD	B
events	O
in	O
patients	O
without	O
known	O
CVD	B
.	O

Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	B
infarctions	I
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	B
.	O

Aspirin	O
does	O
not	O
seem	O
to	O
affect	O
CVD	B
mortality	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
either	O
men	O
or	O
women	O
.	O

The	O
use	O
of	O
aspirin	O
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	B
events	O
,	O
primarily	O
gastrointestinal	B
bleeding	I
events	O
,	O
in	O
both	O
men	O
and	O
women	O
.	O

Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	B
strokes	B
with	O
aspirin	O
use	O
.	O

A	O
new	O
RCT	O
and	O
meta	O
-	O
analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	B
strokes	B
in	O
women	O
is	O
not	O
statistically	O
significantly	O
increased	O
.	O

LIMITATIONS	O
:	O
New	O
evidence	O
on	O
aspirin	O
for	O
the	O
primary	O
prevention	O
of	O
CVD	B
is	O
limited	O
.	O

The	O
dose	O
of	O
aspirin	O
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
estimation	O
of	O
the	O
most	O
appropriate	O
dose	O
for	O
primary	O
prevention	O
.	O

Several	O
of	O
the	O
RCTs	O
were	O
conducted	O
within	O
populations	O
of	O
health	O
professionals	O
,	O
which	O
potentially	O
limits	O
generalizability	O
.	O

CONCLUSION	O
:	O
Aspirin	O
reduces	O
the	O
risk	O
for	O
myocardial	B
infarction	I
in	O
men	O
and	O
strokes	B
in	O
women	O
.	O

Aspirin	O
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	B
events	O
.	O

Reducing	O
harm	O
associated	O
with	O
anticoagulation	O
:	O
practical	O
considerations	O
of	O
argatroban	O
therapy	O
in	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

Argatroban	O
is	O
a	O
hepatically	O
metabolized	O
,	O
direct	O
thrombin	O
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	B
in	O
heparin	O
-	O
induced	O
thrombocytopenia	B
(	O
HIT	B
)	O
and	O
for	O
patients	O
with	O
or	O
at	O
risk	O
of	O
HIT	B
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	O
therapy	O
in	O
HIT	B
.	O

The	O
US	O
FDA	O
-	O
recommended	O
argatroban	O
dose	O
in	O
HIT	B
is	O
2	O
microg	O
/	O
kg	O
/	O
min	O
(	O
reduced	O
in	O
patients	O
with	O
hepatic	B
impairment	I
and	O
in	O
paediatric	O
patients	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	O
times	O
(	O
aPTTs	O
)	O
1.5	O
-	O
3	O
times	O
baseline	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experiences	O
indicate	O
that	O
reduced	O
doses	O
are	O
also	O
needed	O
in	O
patients	O
with	O
conditions	O
associated	O
with	O
hepatic	O
hypoperfusion	O
,	O
e.g.	O
heart	B
failure	I
,	O
yet	O
are	O
unnecessary	O
for	O
renal	B
dysfunction	I
,	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B
.	O

Argatroban	O
0.5	O
-	O
1.2	O
microg	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
therapeutic	O
aPTTs	O
.	O

The	O
FDA	O
-	O
recommended	O
dose	O
during	O
PCI	O
is	O
25	O
microg	O
/	O
kg	O
/	O
min	O
(	O
350	O
microg	O
/	O
kg	O
initial	O
bolus	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
clotting	O
times	O
(	O
ACTs	O
)	O
of	O
300	O
-	O
450	O
sec.	O
For	O
PCI	O
,	O
argatroban	O
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients	O
;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B
,	O
and	O
lesser	O
doses	O
may	O
be	O
adequate	O
with	O
concurrent	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibition	O
.	O

Argatroban	O
prolongs	O
the	O
International	O
Normalized	O
Ratio	O
,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban	O
-	O
to	O
-	O
warfarin	O
transition	O
should	O
be	O
followed	O
.	O

Major	O
bleeding	B
with	O
argatroban	O
is	O
0	O
-	O
10	O
%	O
in	O
the	O
non	O
-	O
interventional	O
setting	O
and	O
0	O
-	O
5.8	O
%	O
periprocedurally	O
.	O

Argatroban	O
has	O
no	O
specific	O
antidote	O
,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs	O
,	O
argatroban	O
infusion	O
should	O
be	O
stopped	O
or	O
reduced	O
.	O

Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	O
therapy	O
in	O
HIT	B
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	B
(	O
e.g.	O
fewer	O
thromboses	O
)	O
or	O
its	O
treatment	O
(	O
e.g.	O
fewer	O
argatroban	O
medication	O
errors	O
)	O
.	O

Rhabdomyolysis	B
and	O
brain	O
ischemic	B
stroke	I
in	O
a	O
heroin	O
-	O
dependent	O
male	O
under	O
methadone	O
maintenance	O
therapy	O
.	O

OBJECTIVE	O
:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	B
abuse	I
,	O
some	O
of	O
which	O
are	O
life	O
-	O
threatening	O
.	O

Methadone	O
may	O
aggravate	O
this	O
problem	O
.	O

METHOD	O
:	O
A	O
clinical	O
case	O
description	O
.	O

RESULTS	O
:	O
A	O
33-year	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyolysis	B
and	O
cerebral	O
ischemic	B
stroke	I
after	O
intravenous	O
heroin	O
.	O

He	O
had	O
used	O
heroin	O
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadone	O
daily	O
for	O
6	O
months	O
.	O

He	O
was	O
found	O
unconsciousness	B
at	O
home	O
and	O
was	O
sent	O
to	O
our	O
hospital	O
.	O

In	O
the	O
ER	O
,	O
his	O
opiate	O
level	O
was	O
4497	O
ng	O
/	O
ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolysis	B
,	O
acute	B
renal	I
failure	I
and	O
acute	O
respiratory	B
failure	I
.	O

After	O
transfer	O
to	O
an	O
internal	O
ward	O
,	O
we	O
noted	O
aphasia	B
and	O
weakness	B
of	O
his	O
left	O
limbs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cerebral	B
ischemic	I
infarction	I
.	O

CONCLUSION	O
:	O
Those	O
using	O
methadone	O
and	O
heroin	O
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	B
and	O
ischemic	B
stroke	I
.	O

Patients	O
under	O
methadone	O
maintenance	O
therapy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adverse	O
events	O
.	O

Hypotheses	O
of	O
heroin	O
-	O
related	O
rhabdomyolysis	B
and	O
stroke	B
in	O
heroin	O
abusers	O
are	O
discussed	O
.	O

Increased	O
vulnerability	O
to	O
6-hydroxydopamine	O
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	B
in	O
mice	O
lacking	O
CB1	O
cannabinoid	O
receptors	O
.	O

Motor	O
impairment	O
,	O
dopamine	O
(	O
DA	O
)	O
neuronal	O
activity	O
and	O
proenkephalin	O
(	O
PENK	O
)	O
gene	O
expression	O
in	O
the	O
caudate	O
-	O
putamen	O
(	O
CPu	O
)	O
were	O
measured	O
in	O
6-OHDA	O
-	O
lesioned	O
and	O
treated	O
(	O
L	O
-	O
DOPA+benserazide	O
)	O
CB1	O
KO	O
and	O
WT	O
mice	O
.	O

A	O
lesion	O
induced	O
by	O
6-OHDA	O
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	O
neurons	O
and	O
increased	O
PENK	O
gene	O
expression	O
in	O
the	O
CPu	O
.	O

Oxidative	O
/	O
nitrosative	O
and	O
neuroinflammatory	O
parameters	O
were	O
estimated	O
in	O
the	O
CPu	O
and	O
cingulate	O
cortex	O
(	O
Cg	O
)	O
.	O

CB1	O
KO	O
mice	O
exhibited	O
higher	O
MDA	O
levels	O
and	O
iNOS	O
protein	O
expression	O
in	O
the	O
CPu	O
and	O
Cg	O
compared	O
to	O
WT	O
mice	O
.	O

Treatment	O
with	O
L	O
-	O
DOPA+benserazide	O
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	B
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mice	O
.	O

The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	O
lesion	O
,	O
and	O
reduced	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesias	B
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesias	B
.	O

Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	O
ischemia	B
-	O
reperfusion	B
injury	I
.	O

Reperfusion	O
of	O
ischemic	B
intestine	O
results	O
in	O
acute	O
liver	B
dysfunction	I
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma	O
,	O
reduction	O
in	O
bile	O
flow	O
rate	O
,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver	O
.	O

The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	B
injury	I
is	O
unknown	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	O
are	O
associated	O
with	O
the	O
hepatic	B
injury	I
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirect	O
methods	O
of	O
assessing	O
oxidant	O
exposure	O
in	O
vivo	O
.	O

Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	O
ischemia	B
-	O
reperfusion	B
injury	I
.	O

Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	O
and	O
reduced	O
glutathione	O
.	O

There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	O
following	O
intestinal	O
ischemia	B
-	O
reperfusion	B
injury	I
.	O

Oxidized	O
glutathione	O
(	O
GSSG	O
)	O
increased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfusion	O
.	O

There	O
was	O
no	O
increase	O
in	O
any	O
of	O
the	O
products	O
of	O
lipid	O
peroxidation	O
associated	O
with	O
this	O
injury	O
.	O

An	O
increase	O
in	O
GSSG	O
within	O
hepatic	O
tissue	O
during	O
intestinal	O
reperfusion	O
suggests	O
exposure	O
of	O
hepatocytes	O
to	O
an	O
oxidant	O
stress	O
.	O

The	O
lack	O
of	O
a	O
significant	O
increase	O
in	O
products	O
of	O
lipid	O
peroxidation	O
suggests	O
that	O
the	O
oxidant	O
stress	O
is	O
of	O
insufficient	O
magnitude	O
to	O
result	O
in	O
irreversible	O
injury	O
to	O
hepatocyte	O
cell	O
membranes	O
.	O

These	O
data	O
also	O
suggest	O
that	O
the	O
measurement	O
of	O
tissue	O
GSSG	O
may	O
be	O
a	O
more	O
sensitive	O
indicator	O
of	O
oxidant	O
stress	O
than	O
measurement	O
of	O
products	O
of	O
lipid	O
peroxidation	O
.	O

Animal	O
model	O
of	O
mania	B
induced	O
by	O
ouabain	O
:	O
Evidence	O
of	O
oxidative	O
stress	O
in	O
submitochondrial	O
particles	O
of	O
the	O
rat	O
brain	O
.	O

The	O
intracerebroventricular	O
(	O
ICV	O
)	O
administration	O
of	O
ouabain	O
(	O
a	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-ATPase	O
inhibitor	O
)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	B
mania	I
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	B
disorder	I
may	O
be	O
related	O
to	O
mitochondrial	B
dysfunction	I
.	O

Herein	O
,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	O
in	O
rats	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effects	O
of	O
ouabain	O
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(	O
at	O
concentrations	O
of	O
10	O
(	O
-2	O
)	O
and	O
10	O
(	O
-3	O
)	O
M	O
)	O
on	O
locomotion	O
was	O
measured	O
using	O
the	O
open	O
-	O
field	O
test	O
.	O

Additionally	O
,	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
TBARSs	O
)	O
and	O
superoxide	O
production	O
were	O
measured	O
in	O
submitochondrial	O
particles	O
of	O
the	O
prefrontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
amygdala	O
.	O

Our	O
findings	O
demonstrated	O
that	O
ouabain	O
at	O
10	O
(	O
-2	O
)	O
and	O
10	O
(	O
-3	O
)	O
M	O
induced	O
hyperlocomotion	B
in	O
rats	O
,	O
and	O
this	O
response	O
remained	O
up	O
to	O
7	O
days	O
following	O
a	O
single	O
ICV	O
injection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	O
levels	O
and	O
superoxide	O
generation	O
in	O
submitochondrial	O
particles	O
in	O
the	O
prefrontal	O
cortex	O
,	O
striatum	O
and	O
amygdala	O
.	O

In	O
conclusion	O
,	O
ouabain	O
-	O
induced	O
mania	B
-	O
like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	B
disorder	I
.	O

Intraoperative	O
dialysis	O
during	O
liver	O
transplantation	O
with	O
citrate	O
dialysate	O
.	O

Liver	O
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	B
liver	I
failure	I
carries	O
high	O
intraoperative	O
and	O
immediate	O
postoperative	O
risks	O
.	O

These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	B
kidney	I
injury	I
(	O
AKI	B
)	O
and	O
intraoperative	O
dialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplant	O
to	O
proceed	O
.	O

The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	B
liver	I
failure	I
can	O
lead	O
to	O
difficulties	O
with	O
anticoagulation	O
during	O
dialysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operating	O
room	O
.	O

Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	O
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	O
carries	O
the	O
risk	O
of	O
citrate	O
toxicity	B
.	O

Citrate	O
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	O
acid	O
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
can	O
not	O
tolerate	O
heparin	O
or	O
regional	O
citrate	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
40-year	O
-	O
old	O
female	O
with	O
acetaminophen	O
-	O
induced	O
fulminant	B
liver	I
failure	I
with	O
associated	O
AKI	B
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	O
transplantation	O
anticoagulated	O
with	O
citrate	O
dialysate	O
during	O
the	O
entire	O
procedure	O
.	O

The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	O
toxicity	B
and	O
maintained	O
adequate	O
anticoagulation	O
for	O
patency	O
of	O
the	O
dialysis	O
circuit	O
.	O

Citrate	O
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	O
transplantation	O
in	O
fulminant	B
liver	I
failure	I
.	O

Delirium	B
in	O
a	O
patient	O
with	O
toxic	O
flecainide	O
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	O
-	O
induced	O
delirium	B
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
69-year	O
-	O
old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	B
and	O
paranoia	B
over	O
the	O
past	O
several	O
days	O
.	O

On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	O
12	O
mg	O
twice	O
daily	O
,	O
warfarin	O
2	O
mg	O
/	O
day	O
,	O
folic	O
acid	O
1	O
mg	O
/	O
day	O
,	O
levothyroxine	O
100	O
microg	O
/	O
day	O
,	O
pantoprazole	O
40	O
mg	O
/	O
day	O
,	O
paroxetine	O
40	O
mg	O
/	O
day	O
,	O
and	O
flecainide	O
100	O
mg	O
twice	O
daily	O
.	O

Flecainide	O
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B
fibrillation	I
.	O

Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	O
plasma	O
concentration	O
of	O
1360	O
microg	O
/	O
L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	O
and	O
paroxetine	O
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O

Paroxetine	O
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	O
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily	O
.	O

Her	O
delirium	B
resolved	O
3	O
days	O
later	O
.	O

DISCUSSION	O
:	O
Flecainide	O
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	O
channels	O
may	O
cause	O
delirium	B
in	O
susceptible	O
patients	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966-January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	O
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	O
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	O
-	O
induced	O
delirium	B
.	O

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	O
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
's	O
delirium	B
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	O
and	O
paroxetine	O
.	O

CONCLUSIONS	O
:	O
Supratherapeutic	O
flecainide	O
plasma	O
concentrations	O
may	O
cause	O
delirium	B
.	O

Because	O
toxicity	B
may	O
occur	O
when	O
flecainide	O
is	O
prescribed	O
with	O
paroxetine	O
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	O
plasma	O
concentrations	O
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
CYP2D6	O
inhibitors	O
.	O

Efficacy	O
of	O
everolimus	O
(	O
RAD001	O
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	B
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors	O
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B
-	I
small	I
-	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
patients	O
.	O

RAD001	O
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B
.	O

METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B
patients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	O
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	O
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B
.	O

Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O

ORR	O
was	O
4.7	O
%	O
(	O
7.1	O
%	O
stratum	O
1	O
;	O
2.3	O
%	O
stratum	O
2	O
)	O
.	O

Overall	O
disease	O
control	O
rate	O
was	O
47.1	O
%	O
.	O

Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2.6	O
(	O
stratum	O
1	O
)	O
and	O
2.7	O
months	O
(	O
stratum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B
,	O
dyspnea	B
,	O
stomatitis	B
,	O
anemia	B
,	O
and	O
thrombocytopenia	B
.	O

Pneumonitis	B
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	O
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B
.	O

Evaluation	O
of	O
RAD001	O
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B
continues	O
.	O

Posttransplant	O
anemia	B
:	O
the	O
role	O
of	O
sirolimus	O
.	O

Posttransplant	O
anemia	B
is	O
a	O
common	O
problem	O
that	O
may	O
hinder	O
patients	O
'	O
quality	O
of	O
life	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
patients	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttransplant	O
period	O
.	O

A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	B
,	O
of	O
which	O
the	O
level	O
of	O
renal	O
function	O
is	O
most	O
important	O
.	O

Sirolimus	O
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	B
.	O

This	O
review	O
considers	O
anemia	B
associated	O
with	O
sirolimus	O
,	O
including	O
its	O
presentation	O
,	O
mechanisms	O
,	O
and	O
management	O
.	O

Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low	O
-	O
risk	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
.	O

BACKGROUND	O
:	O
Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
are	O
admitted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
""""	O
rule	O
out	O
acute	B
coronary	I
syndrome	I
""""	O
protocol	O
,	O
often	O
with	O
noninvasive	O
testing	O
prior	O
to	O
discharge	O
.	O

In	O
patients	O
without	O
cocaine	O
use	O
,	O
coronary	O
computerized	O
tomography	O
angiography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	O
low	O
risk	O
for	O
cardiac	O
events	O
who	O
can	O
be	O
safely	O
discharged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine	O
-	O
associated	O
chest	B
pain	I
,	O
as	O
coronary	B
vasospasm	I
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	B
.	O

We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
could	O
identify	O
a	O
subset	O
safe	O
for	O
discharge	O
.	O

METHODS	O
:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low	O
-	O
risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassociated	O
chest	B
pain	I
(	O
self	O
-	O
reported	O
or	O
positive	O
urine	O
test	O
)	O
.	O

Consecutive	O
patients	O
received	O
either	O
immediate	O
coronary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
serial	O
markers	O
)	O
or	O
underwent	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
with	O
serial	O
cardiac	O
marker	O
measurements	O
.	O

Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	B
less	O
than	O
50	O
%	O
)	O
were	O
discharged	O
.	O

The	O
main	O
outcome	O
was	O
30-day	O
cardiovascular	O
death	O
or	O
myocardial	B
infarction	I
.	O

RESULTS	O
:	O
A	O
total	O
of	O
59	O
patients	O
with	O
cocaine	O
-	O
associated	O
chest	B
pain	I
were	O
evaluated	O
.	O

Patients	O
had	O
a	O
mean	O
age	O
of	O
45.6	O
+	O
/-	O

6.6	O
yrs	O
and	O
were	O
86	O
%	O
black	O
,	O
66	O
%	O
male	O
.	O

Seventy	O
-	O
nine	O
percent	O
had	O
a	O
normal	O
or	O
nonspecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TIMI	O
score	O
<	O
2	O
.	O

Twenty	O
patients	O
received	O
coronary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
discharged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty	O
-	O
nine	O
received	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
,	O
with	O
37	O
discharged	O
home	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
patients	O
had	O
coronary	B
stenosis	I
>	O
or=50	O
%	O
.	O

During	O
the	O
30-day	O
follow	O
-	O
up	O
period	O
,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6.1	O
%	O
)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	B
infarction	I
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6.1	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
Although	O
cocaine	O
-	O
associated	O
myocardial	B
ischemia	I
can	O
result	O
from	O
coronary	O
vasoconstriction	O
,	O
patients	O
with	O
cocaine	O
associated	O
chest	B
pain	I
,	O
a	O
non	O
-	O
ischemic	B
ECG	O
,	O
and	O
a	O
TIMI	O
risk	O
score	O
<	O
2	O
may	O
be	O
safely	O
discharged	O
from	O
the	O
ED	O
after	O
a	O
negative	O
coronary	O
CTA	O
with	O
a	O
low	O
risk	O
of	O
30-day	O
adverse	O
events	O
.	O

Bilateral	O
haemorrhagic	B
infarction	B
of	I
the	I
globus	I
pallidus	I
after	O
cocaine	O
and	O
alcohol	O
intoxication	O
.	O

Cocaine	O
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B
and	I
haemorrhagic	I
stroke	I
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31-year	O
-	O
old	O
man	O
with	O
bilateral	O
ischemia	B
of	I
the	I
globus	I
pallidus	I
after	O
excessive	O
alcohol	O
and	O
intranasal	O
cocaine	O
use	O
.	O

Drug	O
-	O
related	O
globus	B
pallidus	I
infarctions	I
are	O
most	O
often	O
associated	O
with	O
heroin	O
.	O

Bilateral	O
basal	B
ganglia	I
infarcts	I
after	O
the	O
use	O
of	O
cocaine	O
,	O
without	O
concurrent	O
heroin	O
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	O
,	O
transient	O
cardiac	B
arrhythmia	I
or	O
respiratory	B
dysfunction	I
related	O
to	O
cocaine	O
and/or	O
ethanol	O
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B
hypoperfusion	I
.	O

Late	O
fulminant	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
after	O
liver	O
transplant	O
.	O

OBJECTIVES	O
:	O
Posterior	B
leukoencephalopathy	I
due	O
to	O
calcineurin	O
-	O
inhibitor	O
-	O
related	O
neurotoxicity	B
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	O
agents	O
(	O
primarily	O
those	O
administered	O
after	O
a	O
liver	O
or	O
kidney	O
transplant	O
)	O
.	O

The	O
pathophysiologic	O
mechanisms	O
of	O
that	O
disorder	O
remain	O
unknown	O
.	O

CASE	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
46-year	O
-	O
old	O
woman	O
who	O
received	O
a	O
liver	O
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	B
cirrhosis	I
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	B
leukoencephalopathy	I
or	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
developed	O
110	O
days	O
after	O
transplant	O
.	O

After	O
an	O
initially	O
uneventful	O
course	O
after	O
the	O
transplant	O
,	O
the	O
patient	O
rapidly	O
fell	O
into	O
deep	O
coma	O
.	O

RESULTS	O
:	O
Cerebral	O
MRI	O
scan	O
showed	O
typical	O
signs	O
of	O
enhancement	O
in	O
the	O
pontine	O
and	O
posterior	O
regions	O
.	O

Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	O
to	O
cyclosporine	O
did	O
not	O
improve	O
the	O
clinical	O
situation	O
.	O

The	O
termination	O
of	O
treatment	O
with	O
any	O
calcineurin	O
inhibitor	O
resulted	O
in	O
a	O
complete	O
resolution	O
of	O
that	O
complication	O
.	O

CONCLUSIONS	O
:	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
after	O
liver	O
transplant	O
is	O
rare	O
.	O

We	O
recommend	O
a	O
complete	O
cessation	O
of	O
any	O
calcineurin	O
inhibitor	O
rather	O
than	O
a	O
dose	O
reduction	O
.	O

Prolonged	O
hypothermia	B
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B
edema	I
and	O
intracranial	B
hypertension	I
associated	O
with	O
fulminant	B
hepatic	I
failure	I
.	O

BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B
edema	I
complicating	O
fulminant	B
hepatic	I
failure	I
(	O
FHF	B
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B
.	O

METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27-year	O
-	O
old	O
female	O
with	O
FHF	B
from	O
acetaminophen	O
and	O
resultant	O
cerebral	B
edema	I
.	O

RESULTS	O
:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B
from	O
acetaminophen	O
which	O
was	O
ingested	O
over	O
a	O
2-day	O
period	O
.	O

The	O
patient	O
had	O
depressed	O
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission	O
.	O

Initial	O
evaluation	O
confirmed	O
FHF	B
from	O
acetaminophen	O
and	O
cerebral	B
edema	I
.	O

The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	B
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	B
.	O

Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy	O
.	O

We	O
then	O
initiated	O
therapeutic	O
hypothermia	B
which	O
was	O
continued	O
for	O
5	O
days	O
.	O

At	O
re	O
-	O
warming	O
,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B
edema	I
and	O
intracranial	B
hypertension	I
.	O

At	O
discharge	O
,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
FHF	B
and	O
cerebral	B
edema	I
from	O
acetaminophen	O
overdose	B
,	O
prolonged	O
therapeutic	O
hypothermia	B
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O

A	O
clinical	O
trial	O
of	O
hypothermia	B
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O

Binasal	B
visual	I
field	I
defects	I
are	O
not	O
specific	O
to	O
vigabatrin	O
.	O

This	O
study	O
investigated	O
the	O
visual	B
defects	I
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	O
(	O
VGB	O
)	O
.	O

Two	O
hundred	O
four	O
people	O
with	O
epilepsy	B
were	O
grouped	O
on	O
the	O
basis	O
of	O
antiepileptic	O
drug	O
therapy	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
exposure	O
to	O
VGB	O
)	O
.	O

Groups	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
,	O
and	O
seizure	B
frequency	O
.	O

All	O
patients	O
underwent	O
objective	O
assessment	O
of	O
electrophysiological	O
function	O
(	O
wide	O
-	O
field	O
multifocal	O
electroretinography	O
)	O
and	O
conventional	O
visual	O
field	O
testing	O
(	O
static	O
perimetry	O
)	O
.	O

Bilateral	O
visual	O
field	O
constriction	O
was	O
observed	O
in	O
59	O
%	O
of	O
patients	O
currently	O
taking	O
VGB	O
,	O
43	O
%	O
of	O
patients	O
who	O
previously	O
took	O
VGB	O
,	O
and	O
24	O
%	O
of	O
patients	O
with	O
no	O
exposure	O
to	O
VGB	O
.	O

Assessment	O
of	O
retinal	O
function	O
revealed	O
abnormal	O
responses	O
in	O
48	O
%	O
of	O
current	O
VGB	O
users	O
and	O
22	O
%	O
of	O
prior	O
VGB	O
users	O
,	O
but	O
in	O
none	O
of	O
the	O
patients	O
without	O
previous	O
exposure	O
to	O
VGB	O
.	O

Bilateral	B
visual	I
field	I
abnormalities	I
are	O
common	O
in	O
the	O
treated	O
epilepsy	B
population	O
,	O
irrespective	O
of	O
drug	O
history	O
.	O

Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	B
toxicity	I
associated	O
with	O
VGB	O
.	O

Smoking	O
of	O
crack	O
cocaine	O
as	O
a	O
risk	O
factor	O
for	O
HIV	B
infection	I
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	O
cocaine	O
has	O
on	O
the	O
incidence	O
of	O
HIV	B
infection	I
.	O

Given	O
the	O
increasing	O
use	O
of	O
crack	O
cocaine	O
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B
infection	I
.	O

METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	O
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O

To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B
seroconversion	I
among	O
daily	O
smokers	O
of	O
crack	O
cocaine	O
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996-Nov	O
.	O
30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec.	O
1	O
,	O
1999-Nov	O
.	O
30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec.	O
1	O
,	O
2002-Dec	O
.	O
30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B
infection	I
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	O
cocaine	O
increased	O
from	O
11.6	O
%	O
in	O
period	O
1	O
to	O
39.7	O
%	O
in	O
period	O
3	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B
seroconversion	I
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	O
cocaine	O
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.03	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.57	O
-	O
1.85	O
;	O
period	O
2	O
:	O
HR	O
1.68	O
,	O
95	O
%	O
CI	O
1.01	O
-	O
2.80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2.74	O
,	O
95	O
%	O
CI	O
1.06	O
-	O
7.11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoking	O
of	O
crack	O
cocaine	O
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B
seroconversion	I
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O

This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	O
cocaine	O
.	O

Fluoxetine	O
improves	O
the	O
memory	B
deficits	I
caused	O
by	O
the	O
chemotherapy	O
agent	O
5-fluorouracil	O
.	O

Cancer	B
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O

A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5-fluorouracil	O
(	O
5-FU	O
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O

In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O

In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	O
antidepressant	O
Fluoxetine	O
.	O

In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5-FU	O
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	O
either	O
separately	O
or	O
in	O
combination	O
with	O
5-FU	O
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	O
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5-FU	O
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O

Animals	O
treated	O
only	O
with	O
5-FU	O
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	O
improved	O
their	O
performance	O
.	O

5-FU	O
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	O
was	O
co	O
administered	O
with	O
5-FU	O
.	O

Fluoxetine	O
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O

These	O
findings	O
suggest	O
that	O
5-FU	O
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	O
.	O

Liver	O
-	O
specific	O
ablation	O
of	O
integrin	O
-	O
linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	B
after	O
phenobarbital	O
administration	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
disruption	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
integrin	O
signaling	O
via	O
elimination	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
in	O
hepatocytes	O
interferes	O
with	O
signals	O
leading	O
to	O
termination	O
of	O
liver	O
regeneration	O
.	O

This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	O
enlargement	O
induced	O
by	O
phenobarbital	O
(	O
PB	O
)	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
liver-	O
/	O
-	O
mice	O
were	O
given	O
PB	O
(	O
0.1	O
%	O
in	O
drinking	O
water	O
)	O
for	O
10	O
days	O
.	O

Livers	O
were	O
harvested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
days	O
during	O
PB	O
administration	O
.	O

In	O
the	O
hepatocyte	O
-	O
specific	O
ILK	O
/	O
liver-	O
/	O
-	O
mice	O
,	O
the	O
liver	O
:	O
body	O
weight	O
ratio	O
was	O
more	O
than	O
double	O
as	O
compared	O
to	O
0	O
h	O
at	O
day	O
2	O
(	O
2.5	O
times	O
)	O
,	O
while	O
at	O
days	O
5	O
and	O
10	O
,	O
it	O
was	O
enlarged	O
three	O
times	O
.	O

In	O
the	O
WT	O
mice	O
,	O
the	O
increase	O
was	O
as	O
expected	O
from	O
previous	O
literature	O
(	O
1.8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2	O
.	O

There	O
were	O
slightly	O
increased	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
cells	O
in	O
the	O
ILK	O
/	O
liver-	O
/	O
-	O
animals	O
at	O
day	O
2	O
as	O
compared	O
to	O
WT	O
after	O
PB	O
administration	O
.	O

In	O
the	O
WT	O
animals	O
,	O
the	O
proliferative	O
response	O
had	O
come	O
back	O
to	O
normal	O
by	O
days	O
5	O
and	O
10	O
.	O

Hepatocytes	O
of	O
the	O
ILK	O
/	O
liver-	O
/	O
-	O
mice	O
continued	O
to	O
proliferate	O
up	O
until	O
day	O
10	O
.	O

ILK	O
/	O
liver-	O
/	O
-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	O
different	O
time	O
points	O
during	O
PB	O
administration	O
.	O

In	O
summary	O
,	O
ECM	O
proteins	O
communicate	O
with	O
the	O
signaling	O
machinery	O
of	O
dividing	O
cells	O
via	O
ILK	O
to	O
regulate	O
hepatocyte	O
proliferation	O
and	O
termination	O
of	O
the	O
proliferative	O
response	O
.	O

Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	O
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens	O
,	O
such	O
as	O
PB	O
.	O

Decreased	O
Expression	O
of	O
Na	O
/	O
K	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin	O
-	O
induced	O
Nephropathy	B
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin	O
-	O
induced	O
nephropathy	B
.	O

Sprague	O
-	O
Dawley	O
male	O
rats	O
(	O
200~250	O
g	O
)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	O
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
)	O
for	O
7	O
days	O
,	O
and	O
the	O
expression	O
of	O
tubular	O
transporters	O
was	O
determined	O
by	O
immunoblotting	O
and	O
immunohistochemistry	O
.	O

The	O
mRNA	O
and	O
protein	O
expression	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Gentamicin	O
-	O
treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	O
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	O
levels	O
.	O

Accordingly	O
,	O
the	O
fractional	O
excretion	O
of	O
sodium	O
increased	O
.	O

Urine	O
volume	O
was	O
increased	O
,	O
while	O
urine	O
osmolality	O
and	O
free	O
water	O
reabsorption	O
were	O
decreased	O
.	O

Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin	O
-	O
treated	O
rats	O
.	O

The	O
expression	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
decreased	O
.	O

Gentamicin	O
-	O
induced	O
nephropathy	B
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O

Acute	B
renal	I
failure	I
after	O
high	O
-	O
dose	O
methotrexate	O
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
.	O

High	O
-	O
dose	O
methotrexate	O
(	O
HD	O
-	O
MTX	O
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	B
lymphoma	I
,	O
but	O
can	O
cause	O
hepatic	B
and	I
renal	I
toxicity	I
when	O
its	O
clearance	O
is	O
delayed	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B
renal	I
failure	I
after	O
HD	O
-	O
MTX	O
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
,	O
The	O
patient	O
was	O
a	O
3-year	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
living	O
-	O
related	O
liver	O
transplantation	O
for	O
congenital	O
biliary	B
atresia	I
.	O

At	O
day	O
833	O
after	O
the	O
transplantation	O
,	O
he	O
was	O
diagnosed	O
with	O
PTLD	B
(	O
post	B
-	I
transplantation	I
lymphoproliferative	I
disorder	I
,	O
Burkitt	B
-	I
type	I
malignant	I
lymphoma	I
)	O
.	O

During	O
induction	O
therapy	O
,	O
he	O
suffered	O
ileal	O
perforation	O
and	O
ileostomy	O
was	O
performed	O
.	O

Subsequent	O
HD	O
-	O
MTX	O
therapy	O
caused	O
acute	B
renal	I
failure	I
that	O
required	O
continuous	O
hemodialysis	O
.	O

We	O
supposed	O
that	O
intravascular	O
hypovolemia	B
due	O
to	O
substantial	O
drainage	O
from	O
the	O
ileostoma	O
caused	O
acute	B
prerenal	I
failure	I
.	O

After	O
recovery	O
of	O
his	O
renal	O
function	O
,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD	O
-	O
MTX	O
therapy	O
by	O
controlling	O
drainage	O
from	O
ileostoma	O
with	O
total	O
parenteral	O
nutrition	O
.	O

Longitudinal	O
association	O
of	O
alcohol	O
use	O
with	O
HIV	B
disease	I
progression	O
and	O
psychological	O
health	O
of	O
women	O
with	O
HIV	O
.	O

We	O
evaluated	O
the	O
association	O
of	O
alcohol	O
consumption	O
and	O
depression	B
,	O
and	O
their	O
effects	O
on	O
HIV	B
disease	I
progression	O
among	O
women	O
with	O
HIV	O
.	O

The	O
study	O
included	O
871	O
women	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
cities	O
.	O

The	O
participants	O
had	O
physical	O
examination	O
,	O
medical	O
record	O
extraction	O
,	O
and	O
venipuncture	O
,	O
CD4+T	O
-	O
cell	O
counts	O
determination	O
,	O
measurement	O
of	O
depression	B
symptoms	O
(	O
using	O
the	O
self	O
-	O
report	O
Center	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	B
Scale	O
)	O
,	O
and	O
alcohol	O
use	O
assessment	O
at	O
enrollment	O
,	O
and	O
semiannually	O
until	O
March	O
2000	O
.	O

Multilevel	O
random	O
coefficient	O
ordinal	O
models	O
as	O
well	O
as	O
multilevel	O
models	O
with	O
joint	O
responses	O
were	O
used	O
in	O
the	O
analysis	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	O
use	O
and	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
.	O

When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
association	O
between	O
alcohol	O
and	O
CD4	O
+	O
T	O
-	O
cell	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
association	O
between	O
alcohol	O
consumption	O
and	O
depression	B
was	O
significant	O
(	O
p<0.001	O
)	O
.	O

Depression	B
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findings	O
suggest	O
that	O
alcohol	O
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	B
.	O

Moreover	O
,	O
depression	B
is	O
associated	O
with	O
HIV	B
disease	I
progression	O
.	O

Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	O
use	O
interventions	O
and	O
psychological	O
resources	O
to	O
improve	O
the	O
health	O
of	O
women	O
with	O
HIV	O
.	O

Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
.	O

BACKGROUND	O
:	O
Neuroinflammation	B
occurs	O
after	O
seizures	B
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O

CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O

In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B
epilepticus	I
(	O
SE	B
)	O
induced	O
by	O
pilocarpine	O
injection	O
.	O

METHODS	O
:	O
SE	B
was	O
induced	O
by	O
pilocarpine	O
injection	O
.	O

Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	O
.	O

Five	O
days	O
after	O
SE	B
,	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O

The	O
number	O
of	O
CCR2	O
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O

CCL2	O
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O

RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B
.	O

Seizures	B
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	O
.	O

Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	B
.	O

Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2-labeled	O
cells	O
in	O
SE	B
rats	O
.	O

In	O
addition	O
,	O
rats	O
that	O
experienced	O
SE	B
exhibited	O
CCR2-labeling	O
in	O
populations	O
of	O
hypertrophied	B
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O

These	O
CCR2	O
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	O
.	O

Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B
.	O

CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	O
-	O
induced	O
SE	B
.	O

Seizures	B
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O

These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B
changes	O
that	O
occur	O
following	O
seizures	B
.	O

Metallothionein	O
induction	O
reduces	O
caspase-3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	O
-	O
treated	O
rats	O
.	O

Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O

On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	O
(	O
MT	O
)	O
by	O
ZnSO	O
(	O
4	O
)	O
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	O
induction	O
on	O
carmustine	O
(	O
BCNU	O
)	O
-induced	O
hippocampal	O
cognitive	B
dysfunction	I
in	O
rats	O
.	O

A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
)	O
:	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i.c.v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	O
solvent	O
(	O
i.v	O
)	O
.	O

The	O
second	O
group	O
administered	O
ZnSO	O
(	O
4	O
)	O
(	O
0.1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
,	O
once	O
)	O
then	O
BCNU	O
solvent	O
(	O
i.v	O
)	O
after	O
24	O
h.	O
Third	O
group	O
received	O
BCNU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i.c.v	O
)	O
.	O

Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	O
(	O
4	O
)	O
(	O
0.1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
)	O
then	O
BCNU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O
after	O
24	O
h.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	O
administration	O
resulted	O
in	O
deterioration	B
of	I
learning	I
and	B
short	I
-	I
term	I
memory	I
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	O
reductase	O
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
content	O
.	O

Also	O
,	O
BCNU	O
administration	O
increased	O
serum	O
tumor	B
necrosis	B
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
,	O
hippocampal	O
MT	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
contents	O
as	O
well	O
as	O
caspase-3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O

ZnSO	O
(	O
4	O
)	O
pretreatment	O
counteracted	O
BCNU	O
-	O
induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	O
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	O
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase-3	O
.	O

The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO	O
(	O
4	O
)	O
+	O
BCNU	O
compared	O
to	O
only	O
BCNU	O
-	O
treated	O
animals	O
.	O

In	O
conclusion	O
,	O
MT	O
induction	O
halts	O
BCNU	O
-	O
induced	O
hippocampal	O
toxicity	B
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	O
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	O
,	O
MDA	O
and	O
caspase-3	O
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O

Fatal	O
carbamazepine	O
induced	O
fulminant	B
eosinophilic	I
(	O
hypersensitivity	B
)	O
myocarditis	B
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B
hypersensitivity	I
and	O
differential	O
diagnosis	O
.	O

The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	O
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O

A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	O
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B
)	O
myocarditis	B
.	O

We	O
report	O
a	O
case	O
of	O
hypersensitivity	B
myocarditis	B
secondary	O
to	O
administration	O
of	O
carbamazepine	O
.	O

Acute	O
hypersensitivity	B
myocarditis	B
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O

Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O

Clinically	O
,	O
death	O
was	O
due	O
to	O
cardiogenic	B
shock	I
.	O

To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	O
induced	O
myocarditis	B
reported	O
in	O
English	O
literature	O
.	O

Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	O
marmoset	O
model	O
of	O
Parkinson	B
's	I
disease	I
.	O

OBJECTIVES	O
:	O
Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
.	O

These	O
symptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisation	O
'	O
following	O
repeated	O
levodopa	O
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	O
on	O
the	O
disease	O
state	O
.	O

The	O
levodopa	O
-	O
treated	O
MPTP	O
-	O
lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	B
symptoms	I
in	O
PD	B
patients	O
.	O

Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa	O
-	O
induced	O
motor	O
fluctuations	O
and	O
neuropsychiatric	B
-	I
like	I
behaviors	I
to	O
determine	O
the	O
relationship	O
between	O
duration	O
of	O
treatment	O
and	O
onset	O
of	O
symptoms	O
.	O

METHODS	O
:	O
Marmosets	O
were	O
administered	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	O
(	O
2.0	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
for	O
five	O
days	O
,	O
resulting	O
in	O
stable	O
parkinsonism	B
.	O

Levodopa	O
(	O
15	O
mg	O
/	O
kg	O
and	O
benserazide	O
,	O
3.75	O
mg	O
/	O
kg	O
)	O
p.o	O
.	O

b.i.d	O
,	O
was	O
administered	O
for	O
30	O
days	O
.	O

Animals	O
were	O
evaluated	O
for	O
parkinsonian	B
disability	I
,	O
dyskinesia	B
and	O
on	O
-	O
time	O
(	O
motor	O
fluctuations	O
)	O
and	O
neuropsychiatric	B
-	I
like	I
behaviors	I
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	O
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater	O
,	O
blind	O
to	O
the	O
treatment	O
day	O
.	O

RESULTS	O
:	O
The	O
neuropsychiatric	B
-	I
like	I
behavior	I
rating	O
scale	O
demonstrated	O
high	O
interrater	O
reliability	O
between	O
three	O
trained	O
raters	O
of	O
differing	O
professional	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	O
-	O
induced	O
motor	O
fluctuations	O
,	O
dyskinesia	B
and	O
wearing	O
-	O
off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	O
therapy	O
.	O

In	O
contrast	O
,	O
levodopa	O
-	O
induced	O
neuropsychiatric	B
-	I
like	I
behaviors	I
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	O
treatment	O
and	O
their	O
severity	O
did	O
not	O
correlate	O
with	O
duration	O
of	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
neuropsychiatric	B
disorders	I
in	O
PD	B
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	O
and	O
the	O
disease	O
state	O
than	O
a	O
consequence	O
of	O
sensitisation	O
to	O
repeated	O
dopaminergic	O
therapy	O
.	O

Contrast	O
medium	O
nephrotoxicity	B
after	O
renal	O
artery	O
and	O
coronary	O
angioplasty	O
.	O

BACKGROUND	O
:	O
Renal	B
dysfunction	I
induced	O
by	O
iodinated	O
contrast	O
medium	O
(	O
CM	O
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	O
angioplasty	O
(	O
PTRA	O
)	O
.	O

PURPOSE	O
:	O
To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	B
effect	O
of	O
CM	O
in	O
patients	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patients	O
submitted	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(	O
PTRA	O
group	O
,	O
mean	O
age	O
70+	O
/	O
-12	O
years	O
,	O
23	O
female	O
,	O
basal	O
creatinine	O
1.46+	O
/	O
-0.79	O
,	O
range	O
0.7	O
-	O
4.9	O
mg	O
/	O
dl	O
)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
group	O
)	O
,	O
matched	O
for	O
basal	O
creatinine	O
(	O
1.44+	O
/	O
-0.6	O
,	O
range	O
0.7	O
-	O
3.4	O
mg	O
/	O
dl	O
)	O
,	O
gender	O
,	O
and	O
age	O
.	O

In	O
both	O
groups	O
postprocedural	O
(	O
48	O
h	O
)	O
serum	O
creatinine	O
was	O
measured	O
.	O

RESULTS	O
:	O
Postprocedural	O
creatinine	O
level	O
decreased	O
nonsignificantly	O
in	O
the	O
PTRA	O
group	O
(	O
1.46+	O
/	O
-0.8	O
vs.	O
1.34+	O
/	O
-0.5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
increased	O
significantly	O
in	O
the	O
PCI	O
group	O
(	O
1.44+	O
/	O
-0.6	O
vs.	O
1.57+	O
/	O
-0.7	O
mg	O
/	O
dl	O
,	O
P<0.02	O
)	O
.	O

Changes	O
in	O
serum	O
creatinine	O
after	O
intervention	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
groups	O
(	O
-0.12+	O
/	O
-0.5	O
vs.	O
0.13+	O
/	O
-0.3	O
,	O
P=0.014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	O
administered	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	B
damage	I
induced	O
by	O
CM	O
administration	O
than	O
PCI	O
patients	O
.	O

The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	O
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	O
toxicity	B
.	O

Diphenhydramine	O
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	O
in	O
ICU	O
patients	O
.	O

Cimetidine	O
,	O
a	O
histamine	O
2	O
(	O
H2	O
)	O
antagonist	O
,	O
produces	O
a	O
decrease	O
in	O
arterial	O
pressure	O
due	O
to	O
vasodilatation	O
,	O
especially	O
in	O
critically	O
ill	O
patients	O
.	O

This	O
may	O
be	O
because	O
cimetidine	O
acts	O
as	O
a	O
histamine	O
agonist	O
.	O

We	O
,	O
therefore	O
,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	O
1	O
(	O
H1	O
)	O
receptor	O
antagonist	O
,	O
diphenhydramine	O
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	O
in	O
ICU	O
patients	O
.	O

Each	O
patient	O
was	O
studied	O
on	O
two	O
separate	O
days	O
.	O

In	O
a	O
random	O
fashion	O
,	O
they	O
received	O
cimetidine	O
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatment	O
of	O
diphenhydramine	O
40	O
mg	O
iv	O
with	O
cimetidine	O
200	O
mg	O
iv	O
.	O

In	O
the	O
non	O
-	O
pretreatment	O
group	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
decreased	O
from	O
107.4	O
+	O
/-	O

8.4	O
mmHg	O
to	O
86.7	O
+	O
/-	O

11.4	O
mmHg	O
(	O
P	O
less	O
than	O
0.01	O
)	O
two	O
minutes	O
after	O
cimetidine	O
.	O

Also	O
,	O
systemic	O
vascular	O
resistance	O
(	O
SVR	O
)	O
decreased	O
during	O
the	O
eight	O
-	O
minute	O
observation	O
period	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
pretreatment	O
group	O
,	O
little	O
haemodynamic	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	B
caused	O
by	O
iv	O
cimetidine	O
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
receptor	O
.	O

Medical	O
and	O
psychiatric	O
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen	O
-	O
induced	O
acute	B
liver	I
failure	I
:	O
a	O
case	O
-	O
control	O
study	O
.	O

BACKGROUND	O
:	O
Acetaminophen	O
-	O
induced	O
hepatotoxicity	B
is	O
the	O
most	O
common	O
cause	O
of	O
acute	B
liver	I
failure	I
(	O
ALF	B
)	O
in	O
the	O
UK	O
.	O

Patients	O
often	O
consume	O
the	O
drug	O
with	O
suicidal	O
intent	O
or	O
with	O
a	O
background	O
of	O
substance	O
dependence	O
.	O

AIMS	O
AND	O
METHODS	O
:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness	O
,	O
psychiatric	O
co	O
-	O
morbidity	O
,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	O
transplantation	O
(	O
LT	O
)	O
emergently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminophen	O
-	O
induced	O
ALF	B
(	O
n=36	O
)	O
with	O
age-	O
and	O
sex	O
-	O
matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non	O
-	O
acetaminophen	O
-	O
induced	O
ALF	B
(	O
n=35	O
)	O
and	O
elective	O
LT	O
for	O
chronic	B
liver	I
disease	I
(	O
CLD	B
,	O
n=34	O
)	O
.	O

RESULTS	O
:	O
Acetaminophen	O
-	O
induced	O
ALF	B
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre	O
-	O
LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
requirement	O
for	O
organ	O
support	O
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acetaminophen	O
-	O
induced	O
ALF	B
patients	O
had	O
a	O
formal	O
psychiatric	O
diagnosis	O
before	O
LT	O
(	O
non	O
-	O
acetaminophen	O
-	O
induced	O
ALF=0	B
/	O
35	O
,	O
CLD=2	B
/	O
34	O
;	O
P<0.01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicide	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
median	O
5	O
years	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
)	O
,	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	O
-	O
induced	O
ALF	B
1	O
year	O
87	O
%	O
,	O
5	O
years	O
75	O
%	O
;	O
non	O
-	O
acetaminophen	O
-	O
induced	O
ALF	B
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B
93	O
%	O
,	O
82	O
%	O
:	O
P>0.6	O
log	O
rank	O
)	O
.	O

Two	O
acetaminophen	O
-	O
induced	O
ALF	B
patients	O
reattempted	O
suicide	O
post	O
-	O
LT	O
(	O
one	O
died	O
8	O
years	O
post	O
-	O
LT	O
)	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	O
disturbance	O
,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen	O
-	O
induced	O
ALF	B
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non	O
-	O
acetaminophen	O
-	O
induced	O
ALF	B
and	O
electively	O
for	O
CLD	B
.	O

Multidisciplinary	O
approaches	O
with	O
long	O
-	O
term	O
psychiatric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
low	O
post	O
-	O
transplant	O
suicide	O
rates	O
seen	O
and	O
low	O
rates	O
of	O
graft	O
loss	O
because	O
of	O
non	O
-	O
compliance	O
.	O

Antithrombotic	O
drug	O
use	O
,	O
cerebral	B
microbleeds	I
,	O
and	O
intracerebral	B
hemorrhage	I
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B
microbleeds	I
(	O
MB	B
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B
hemorrhage	I
(	O
ICH	B
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	O
drugs	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B
and	O
ischemic	B
stroke	I
(	O
IS	B
)	O
/	O
transient	B
ischemic	I
attack	I
(	O
TIA	B
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B
or	O
TIA	B
to	O
compare	O
the	O
presence	O
of	O
MB	B
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	B
/	O
TIA	B
;	O
and	O
(	O
3	O
)	O
ICH	B
vs	O
ischemic	B
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O

We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B
in	O
antithrombotic	O
users	O
with	O
MB	B
.	O

RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B
and	O
3817	O
IS	B
/	O
TIA	B
,	O
MB	B
were	O
more	O
frequent	O
in	O
ICH	B
vs	O
IS	B
/	O
TIA	B
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2.8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2.3	O
-	O
3.5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5.7	O
(	O
range	O
,	O
3.4	O
-	O
9.7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8.0	O
(	O
range	O
,	O
3.5	O
-	O
17.8	O
)	O
in	O
warfarin	O
users	O
(	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
also	O
an	O
excess	O
of	O
MB	B
in	O
warfarin	O
users	O
vs	O
nonusers	O
with	O
ICH	B
(	O
OR	O
,	O
2.7	O
;	O
95	O
%	O
CI	O
,	O
1.6	O
-	O
4.4	O
;	O
P<0.001	O
)	O
but	O
none	O
in	O
warfarin	O
users	O
with	O
IS	B
/	O
TIA	B
(	O
OR	O
,	O
1.3	O
;	O
95	O
%	O
CI	O
,	O
0.9	O
-	O
1.7	O
;	O
P=0.33	O
;	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B
(	O
OR	O
,	O
1.7	O
;	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
2.3	O
;	O
P<0.001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	B
/	O
TIA	B
(	O
OR	O
,	O
1.4	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
1.7	O
;	O
P<0.001	O
;	O
P	O
difference=0.25	O
)	O
.	O

In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	B
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B
(	O
OR	O
,	O
12.1	O
;	O
95	O
%	O
CI	O
,	O
3.4	O
-	O
42.5	O
;	O
P<0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B
in	O
warfarin	O
users	O
with	O
ICH	B
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B
increase	O
the	O
risk	O
of	O
warfarin	O
-	O
associated	O
ICH	B
.	O

Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O

Studies	O
of	O
synergy	O
between	O
morphine	O
and	O
a	O
novel	O
sodium	O
channel	O
blocker	O
,	O
CNSB002	O
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B
pain	I
.	O

OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	O
,	O
a	O
sodium	O
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B
pain	I
.	O

DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	O
and	O
CNSB002	O
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	B
models	O
:	O
carrageenan	O
-	O
induced	O
paw	O
inflammation	B
and	O
streptozotocin	O
(	O
STZ	O
)	O
-induced	O
diabetic	B
neuropathy	I
.	O

RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	O
,	O
3.2	O
mg	O
/	O
kg	O
;	O
CNSB002	O
10.0	O
mg	O
/	O
kg	O
;	O
5.0	O
mg	O
/	O
kg	O
CNSB002	O
with	O
morphine	O
3.2	O
mg	O
/	O
kg	O
in	O
combination	O
.	O

The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B
(	O
ED50	O
)	O
were	O
7.54	O
(	O
1.81	O
)	O
and	O
4.83	O
(	O
1.54	O
)	O
in	O
the	O
carrageenan	O
model	O
and	O
44.18	O
(	O
1.37	O
)	O
and	O
9.14	O
(	O
1.24	O
)	O
in	O
the	O
STZ	O
-	O
induced	O
neuropathy	B
model	O
for	O
CNSB002	O
and	O
morphine	O
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses	O
.	O

The	O
ED50	O
values	O
for	O
morphine	O
when	O
given	O
in	O
combination	O
with	O
CNSB002	O
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0.56	O
(	O
1.55	O
)	O
in	O
the	O
carrageenan	O
model	O
and	O
1.37	O
(	O
1.23	O
)	O
in	O
the	O
neuropathy	B
model	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antinociception	O
after	O
morphine	O
(	O
3.2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	O
-	O
administration	O
with	O
CNSB002	O
from	O
28.0	O
and	O
31.7	O
%	O
to	O
114.6	O
and	O
56.9	O
%	O
reversal	O
of	O
hyperalgesia	B
in	O
the	O
inflammatory	O
and	O
neuropathic	B
models	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
;	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
-	O
significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	O
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	O
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
:	O
a	O
practical	O
review	O
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
(	O
HIT	B
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devastating	O
outcomes	O
.	O

It	O
begins	O
when	O
heparin	O
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin	O
-	O
platelet	O
factor	O
4	O
antibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
release	O
of	O
procoagulant	O
platelet	O
particles	O
.	O

Thrombosis	B
and	O
thrombocytopenia	B
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	B
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascular	O
complications	O
.	O

The	O
prevalence	O
of	O
HIT	B
varies	O
among	O
several	O
subgroups	O
,	O
with	O
greater	O
incidence	O
in	O
surgical	O
as	O
compared	O
with	O
medical	O
populations	O
.	O

HIT	B
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	B
and	O
suspected	O
whenever	O
thrombosis	B
occurs	O
after	O
heparin	O
exposure	O
.	O

Early	O
recognition	O
that	O
incorporates	O
the	O
clinical	O
and	O
serologic	O
clues	O
is	O
paramount	O
to	O
timely	O
institution	O
of	O
treatment	O
,	O
as	O
its	O
delay	O
may	O
result	O
in	O
catastrophic	O
outcomes	O
.	O

The	O
treatment	O
of	O
HIT	B
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	O
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	O
thrombin	O
inhibitor	O
.	O

Current	O
""""	O
diagnostic	O
""""	O
tests	O
,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	B
.	O

Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	O
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment	O
.	O

Direct	O
thrombin	O
inhibitors	O
are	O
appropriate	O
,	O
evidence	O
-	O
based	O
alternatives	O
to	O
heparin	O
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	B
,	O
who	O
need	O
to	O
undergo	O
percutaneous	O
coronary	O
intervention	O
.	O

As	O
heparin	O
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	B
with	O
every	O
heparin	O
exposure	O
,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	O
is	O
initiated	O
.	O

Abductor	O
paralysis	B
after	O
botox	O
injection	O
for	O
adductor	B
spasmodic	I
dysphonia	I
.	O

OBJECTIVES	O
/	O
HYPOTHESIS	O
:	O
Botulinum	O
toxin	O
(	O
Botox	O
)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	B
spasmodic	I
dysphonia	I
(	O
ADSD	B
)	O
.	O

Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness	O
,	O
throat	B
pain	I
,	O
and	O
difficulty	O
with	O
swallowing	O
liquids	O
.	O

Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	B
following	O
Botox	O
injections	O
for	O
ADSD	B
,	O
a	O
complication	O
previously	O
unreported	O
.	O

STUDY	O
DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

METHODS	O
:	O
Patients	O
that	O
received	O
Botox	O
injections	O
for	O
spasmodic	B
dysphonia	I
between	O
January	O
2000	O
and	O
October	O
2009	O
were	O
evaluated	O
.	O

Patients	O
with	O
ADSD	B
were	O
identified	O
.	O

The	O
number	O
of	O
treatments	O
received	O
and	O
adverse	O
effects	O
were	O
noted	O
.	O

For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	B
,	O
age	O
,	O
sex	O
,	O
paralytic	O
Botox	O
dose	O
,	O
prior	O
Botox	O
dose	O
,	O
and	O
course	O
following	O
paralysis	B
were	O
noted	O
.	O

RESULTS	O
:	O
From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	O
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	B
.	O

Of	O
these	O
352	O
patients	O
,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	B
,	O
and	O
two	O
suffered	O
this	O
complication	O
twice	O
.	O

All	O
affected	O
patients	O
were	O
females	O
over	O
the	O
age	O
of	O
50	O
years	O
.	O

Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	B
and	O
continued	O
receiving	O
after	O
paralysis	B
.	O

Seven	O
patients	O
recovered	O
after	O
a	O
brief	O
period	O
of	O
activity	O
restrictions	O
,	O
and	O
one	O
underwent	O
a	O
tracheotomy	O
.	O

The	O
incidence	O
of	O
abductor	O
paralysis	B
after	O
Botox	O
injection	O
for	O
ADSD	B
was	O
0.34	O
%	O
.	O

CONCLUSIONS	O
:	O
Bilateral	O
abductor	O
paralysis	B
is	O
a	O
rare	O
complication	O
of	O
Botox	O
injections	O
for	O
ADSD	B
,	O
causing	O
difficulty	O
with	O
breathing	O
upon	O
exertion	O
.	O

The	O
likely	O
mechanism	O
of	O
paralysis	B
is	O
diffusion	O
of	O
Botox	O
around	O
the	O
muscular	O
process	O
of	O
the	O
arytenoid	O
to	O
the	O
posterior	O
cricoarytenoid	O
muscles	O
.	O

The	O
paralysis	B
is	O
temporary	O
,	O
and	O
watchful	O
waiting	O
with	O
restriction	O
of	O
activity	O
is	O
the	O
recommended	O
management	O
.	O

Mitochondrial	B
impairment	I
contributes	O
to	O
cocaine	O
-	O
induced	O
cardiac	B
dysfunction	I
:	O
Prevention	O
by	O
the	O
targeted	O
antioxidant	O
MitoQ.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	O
-	O
induced	O
cardiac	B
dysfunction	I
.	O

We	O
hypothesized	O
that	O
cocaine	B
abuse	I
may	O
lead	O
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	B
ventricular	I
dysfunction	I
.	O

Seven	O
days	O
of	O
cocaine	O
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	O
consumption	O
detected	O
in	O
cardiac	O
fibers	O
,	O
specifically	O
through	O
complex	O
I	O
and	O
complex	O
III	O
.	O

ROS	O
levels	O
were	O
increased	O
,	O
specifically	O
in	O
interfibrillar	O
mitochondria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	O
synthesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemmal	O
mitochondria	O
.	O

This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short	O
-	O
term	O
exposure	O
to	O
cocaine	O
,	O
suggesting	O
that	O
these	O
mitochondrial	B
abnormalities	I
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	O
.	O

MitoQ	O
,	O
a	O
mitochondrial	O
-	O
targeted	O
antioxidant	O
,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	B
abnormalities	I
as	O
well	O
as	O
cardiac	B
dysfunction	I
characterized	O
here	O
by	O
a	O
diastolic	B
dysfunction	I
studied	O
with	O
a	O
conductance	O
catheter	O
to	O
obtain	O
pressure	O
-	O
volume	O
data	O
.	O

Taken	O
together	O
,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine	O
-	O
induced	O
cardiac	B
dysfunction	I
may	O
be	O
due	O
to	O
a	O
mitochondrial	B
defect	I
.	O

Trimethoprim	O
-	O
induced	O
immune	O
hemolytic	B
anemia	I
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	O
hemolytic	O
transfusion	O
reaction	O
.	O

A	O
10-year	O
-	O
old	O
male	O
with	O
acute	B
leukemia	I
presented	O
with	O
post	O
-	O
chemotherapy	O
anemia	B
.	O

During	O
red	O
cell	O
transfusion	O
,	O
he	O
developed	O
hemoglobinuria	B
.	O

Transfusion	O
reaction	O
workup	O
was	O
negative	O
.	O

Drug	O
-	O
induced	O
immune	O
hemolytic	B
anemia	I
was	O
suspected	O
because	O
of	O
positive	O
direct	O
antiglobulin	O
test	O
,	O
negative	O
eluate	O
,	O
and	O
microspherocytes	O
on	O
smear	O
pre-	O
and	O
post	O
-	O
transfusion	O
.	O

Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	O
and	O
trimethoprim	O
-	O
sulfamethoxazole	O
but	O
negative	O
with	O
sulfamethoxazole	O
.	O

The	O
patient	O
recovered	O
after	O
discontinuing	O
the	O
drug	O
,	O
with	O
no	O
recurrence	O
in	O
2	O
years	O
.	O

Other	O
causes	O
of	O
anemia	B
should	O
be	O
considered	O
in	O
patients	O
with	O
worse	O
-	O
than	O
-	O
expected	O
anemia	B
after	O
chemotherapy	O
.	O

Furthermore	O
,	O
hemolysis	B
during	O
transfusion	O
is	O
not	O
always	O
a	O
transfusion	O
reaction	O
.	O

Verapamil	O
stimulation	O
test	O
in	O
hyperprolactinemia	B
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect	O
.	O

AIM	O
:	O
Verapamil	O
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B
,	O
but	O
with	O
conflicting	O
results	O
.	O

Macroprolactinemia	B
was	O
never	O
considered	O
in	O
those	O
previous	O
studies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	O
in	O
a	O
population	O
who	O
were	O
all	O
screened	O
for	O
macroprolactinemia	B
.	O

Prolactin	O
responses	O
to	O
verapamil	O
in	O
65	O
female	O
patients	O
(	O
age	O
:	O
29.9	O
+	O
/-	O
8.1	O
years	O
)	O
with	O
hyperprolactinemia	B
were	O
tested	O
in	O
a	O
descriptive	O
,	O
matched	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
Verapamil	O
80	O
mg	O
,	O
p.o	O
.	O
was	O
administered	O
,	O
and	O
then	O
PRL	O
levels	O
were	O
measured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immunometric	O
chemiluminescence	O
.	O

Verapamil	O
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	O
levels	O
(	O
PRL	O
)	O
.	O

RESULTS	O
:	O
Verapamil	O
significantly	O
increased	O
PRL	O
levels	O
in	O
healthy	O
controls	O
(	O
N.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactinoma	B
(	O
N.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microprolactinoma	B
(	O
N.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macroprolactinemia	B
(	O
N.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolactinoma	B
(	O
N.	O
8	O
,	O
PRL	O
:	O
0.8	O
%	O
)	O
,	O
and	O
risperidone	O
-	O
induced	O
hyperprolactinemia	B
(	O
N.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	O
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminated	O
anatomical	O
or	O
functional	O
stalk	O
effect	O
(	O
sensitivity	O
:	O
74	O
%	O
,	O
specificity	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0.855+	O
/	O
-0.04	O
,	O
P	O
<	O
0.001	O
,	O
CI	O
:	O
0.768	O
-	O
0.942	O
)	O
associated	O
with	O
pseudoprolactinoma	B
or	O
risperidone	O
-	O
induced	O
hyperprolactinemia	B
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Verapamil	O
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B
.	O

However	O
,	O
verapamil	O
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(	O
i.e.	O
,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	B
with	O
varying	O
degrees	O
of	O
responsiveness	O
.	O

Blockade	O
of	O
endothelial	O
-	O
mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	O
-	O
induced	O
diabetic	B
nephropathy	I
.	O

OBJECTIVE	O
:	O
A	O
multicenter	O
,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
in	O
patients	O
with	O
type	B
1	I
diabetes	I
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	B
,	O
suggesting	O
that	O
other	O
mechanism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	B
nephropathy	I
(	O
diabetic	B
nephropathy	I
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
endothelial	O
-	O
mesenchymal	O
-	O
transition	O
(	O
EndoMT	O
)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	O
interstitial	O
fibrosis	B
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	O
(	O
STZ	O
)	O
-induced	O
diabetes	B
.	O

In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	B
nephropathy	I
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EndoMT	O
was	O
induced	O
in	O
a	O
mouse	O
pancreatic	O
microvascular	O
endothelial	O
cell	O
line	O
(	O
MMEC	O
)	O
in	O
the	O
presence	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
and	O
in	O
the	O
endothelial	O
lineage	O
-	O
traceble	O
mouse	O
line	O
Tie2-Cre;Loxp	O
-	O
EGFP	O
by	O
administration	O
of	O
AGEs	O
,	O
with	O
nonglycated	O
mouse	O
albumin	O
serving	O
as	O
a	O
control	O
.	O

Phosphorylated	O
Smad3	O
was	O
detected	O
by	O
immunoprecipitation	O
/	O
Western	O
blotting	O
and	O
confocal	O
microscopy	O
.	O

Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
induced	O
diabetic	B
nephropathy	I
in	O
Tie2-Cre;Loxp	O
-	O
EGFP	O
mice	O
.	O

RESULTS	O
:	O
Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
demonstrated	O
that	O
AGEs	O
induced	O
EndoMT	O
in	O
MMECs	O
and	O
in	O
Tie2-Cre;Loxp	O
-	O
EGFP	O
mice	O
.	O

Immunoprecipitation	O
/	O
Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
induced	O
diabetic	B
nephropathy	I
.	O

Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT	O
,	O
reduced	O
renal	O
fibrosis	B
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	B
.	O

CONCLUSIONS	O
:	O
EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	B
nephropathy	I
.	O

Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	B
nephropathy	I
and	O
other	O
diabetes	B
complications	I
.	O

Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	O
in	O
refractory	O
mantle	B
cell	I
lymphoma	I
.	O

Mantle	B
cell	I
lymphoma	I
(	O
MCL	B
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B
-	I
cell	I
non	I
-	I
Hodgkin	I
's	I
lymphoma	I
.	O

Patients	O
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

However	O
,	O
a	O
38	O
%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B
treated	O
with	O
temsirolimus	O
,	O
a	O
mTOR	O
inhibitor	O
.	O

Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B
who	O
had	O
tumor	B
regression	O
two	O
months	O
after	O
temsirolimus	O
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	O
therapy	O
.	O

Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	O
inhibited	O
tumor	B
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B
cells	O
.	O

Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	O
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B
microvessel	O
density	O
and	O
of	O
VEGF	O
expression	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	B
tissue	O
repair	O
,	O
were	O
found	O
after	O
6-month	O
temsirolimus	O
therapy	O
.	O

Thus	O
,	O
temsirolimus	O
reduced	O
tumor	B
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O

This	O
dual	O
effect	O
of	O
temsirolimus	O
on	O
tumor	B
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B
resistant	O
to	O
conventional	O
chemotherapy	O
.	O

Acute	B
renal	I
failure	I
due	O
to	O
rifampicin	O
.	O

A	O
23-year	O
-	O
old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	B
tuberculosis	I
was	O
treated	O
with	O
the	O
various	O
regimens	O
of	O
antituberculosis	O
drugs	O
for	O
nearly	O
15	O
months	O
.	O

Rifampicin	O
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	B
,	O
vomiting	B
and	O
fever	B
with	O
chills	O
and	O
rigors	O
.	O

The	O
last	O
such	O
episode	O
was	O
of	O
acute	O
renal	O
failure	O
at	O
which	O
stage	O
the	O
patient	O
was	O
seen	O
by	O
the	O
authors	O
of	O
this	O
report	O
.	O

The	O
patient	O
,	O
however	O
,	O
made	O
a	O
full	O
recovery	O
.	O

Syncope	B
caused	O
by	O
hyperkalemia	B
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	O
.	O

A	O
76	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B
infarction	I
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B
of	I
consciousness	I
due	O
to	O
marked	O
bradycardia	B
caused	O
by	O
hyperkalemia	B
.	O

The	O
concentration	O
of	O
serum	O
potassium	O
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	O
level	O
.	O

The	O
cause	O
of	O
hyperkalemia	B
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	O
,	O
an	O
aldosterone	O
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	O
,	O
an	O
ACE	O
inhibitor	O
.	O

This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life	O
-	O
threatening	O
cardiac	O
events	O
.	O

Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE	O
/	O
ARB	O
in	O
combination	O
with	O
potassium	O
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B
disturbance	I
.	O

Diffuse	O
skeletal	O
pain	B
after	O
administration	O
of	O
alendronate	O
.	O

BACKGROUND	O
:	O
Osteoporosis	B
is	O
caused	O
by	O
bone	O
resorption	O
in	O
excess	O
of	O
bone	O
formation	O
,	O
and	O
bisphosphonates	O
,	O
are	O
used	O
to	O
inhibit	O
bone	O
resorption	O
.	O

Alendronate	O
,	O
a	O
biphosphonate	O
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	B
in	O
postmenopausal	O
women	O
.	O

Side	O
effects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestinal	O
.	O

Musculoskeletal	B
pain	I
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patients	O
.	O

We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out	O
-	O
patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	B
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	O
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	B
can	O
report	O
pain	B
,	O
and	O
bisphosphonate	O
-	O
related	O
pain	B
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	B
.	O

Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	O
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	B
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	O
-	O
sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	B
with	O
suspected	O
MSSA	O
meningitis	B
treated	O
with	O
high	O
-	O
dose	O
daptomycin	O
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
54-year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B
shown	O
on	O
chest	O
radiograph	O
.	O

Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	O
,	O
levofloxacin	O
,	O
and	O
piperacillin	O
/	O
tazobactam	O
.	O

Blood	O
cultures	O
revealed	O
S.	O
aureus	O
susceptible	O
to	O
oxacillin	O
.	O

Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	O
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
patient	O
developed	O
acute	B
renal	I
failure	I
(	O
serum	O
creatinine	O
1.9	O
mg	O
/	O
dL	O
,	O
increased	O
from	O
1.2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0.8	O
mg	O
/	O
dL	O
on	O
admission	O
)	O
.	O

The	O
patient	O
's	O
Glasgow	O
Coma	O
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B
arrest	I
on	O
day	O
10	O
.	O

The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	B
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	B
.	O

Nafcillin	O
was	O
discontinued	O
and	O
daptomycin	O
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B
and	O
was	O
continued	O
until	O
the	O
patient	O
's	O
death	O
on	O
day	O
16	O
.	O

Daptomycin	O
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11.21	O
ug	O
/	O
mL	O
and	O
0.52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dose	O
.	O

Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O

Creatine	O
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	O
therapy	O
and	O
were	O
not	O
reassessed	O
.	O

DISCUSSION	O
:	O
Daptomycin	O
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	O
-	O
induced	O
acute	O
interstitial	B
nephritis	I
and	O
relapsing	O
bacteremia	B
.	O

At	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
,	O
resultant	O
penetration	O
of	O
5	O
%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
,	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	O
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
can	O
not	O
tolerate	O
standard	O
therapy	O
.	O

Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	B
is	O
warranted	O
.	O

The	O
role	O
of	O
nitric	O
oxide	O
in	O
convulsions	B
induced	O
by	O
lindane	O
in	O
rats	O
.	O

Lindane	O
is	O
an	O
organochloride	O
pesticide	O
and	O
scabicide	O
.	O

It	O
evokes	O
convulsions	B
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	O
(	O
A	O
)	O
receptors	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
,	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	O
-	O
arginine	O
,	O
precursor	O
of	O
NO	O
syntheses	O
(	O
NOS	O
)	O
,	O
and	O
L	O
-	O
NAME	O
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B
models	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	O
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	O
-	O
induced	O
epilepsy	B
in	O
male	O
Wistar	O
albino	O
rats	O
.	O

The	O
administration	O
of	O
L	O
-	O
arginine	O
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	B
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B
elicited	O
by	O
lower	O
lindane	O
dose	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L	O
-	O
NAME	O
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
decreased	O
convulsion	B
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B
following	O
injection	O
with	O
a	O
convulsive	B
dose	O
of	O
lindane	O
(	O
8	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l	O
-	O
arginine	O
prior	O
to	O
lindane	O
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L	O
-	O
NAME	O
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	O
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	O
seizures	B
.	O

Severe	O
polyneuropathy	B
and	O
motor	O
loss	O
after	O
intrathecal	O
thiotepa	O
combination	O
chemotherapy	O
:	O
description	O
of	O
two	O
cases	O
.	O

Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	B
toxicity	I
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(	O
IT	O
)	O
combination	O
chemotherapy	O
including	O
thiotepa	O
(	O
TSPA	O
)	O
are	O
presented	O
.	O

Both	O
cases	O
developed	O
axonal	B
neuropathy	I
with	O
motor	O
predominance	O
in	O
the	O
lower	O
extremities	O
1	O
and	O
6	O
months	O
after	O
IT	O
chemotherapy	O
was	O
administered	O
.	O

Neurologic	B
toxicities	I
have	O
been	O
described	O
with	O
IT	O
-	O
methotrexate	O
,	O
IT	O
-	O
cytosine	O
arabinoside	O
and	O
IT	O
-	O
TSPA	O
.	O

To	O
our	O
knowledge	O
,	O
however	O
,	O
axonal	B
neuropathy	I
following	O
administration	O
of	O
these	O
three	O
agents	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	O
is	O
a	O
useful	O
IT	O
agent	O
,	O
its	O
combination	O
with	O
MTX	O
,	O
ara	O
-	O
C	O
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	B
.	O

This	O
unexpected	O
complication	O
indicates	O
the	O
need	O
for	O
further	O
toxicology	O
research	O
on	O
IT	O
-	O
TSPA	O
.	O

Effects	O
of	O
cromakalim	O
and	O
pinacidil	O
on	O
large	O
epicardial	O
and	O
small	O
coronary	O
arteries	O
in	O
conscious	O
dogs	O
.	O

The	O
effects	O
of	O
i.v	O
.	O

bolus	O
administration	O
of	O
cromakalim	O
(	O
1	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
and	O
pinacidil	O
(	O
3	O
-	O
100	O
micrograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumflex	O
artery	O
)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	O
(	O
0.03	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
.	O

Nitroglycerin	O
,	O
up	O
to	O
0.3	O
micrograms	O
/	O
kg	O
,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(	O
CxAD	O
)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter	O
.	O

In	O
contrast	O
,	O
cromakalim	O
and	O
pinacidil	O
at	O
all	O
doses	O
and	O
nitroglycerin	O
at	O
doses	O
higher	O
than	O
0.3	O
micrograms	O
/	O
kg	O
simultaneously	O
and	O
dose	O
-	O
dependently	O
increased	O
CxAD	O
,	O
coronary	O
blood	O
flow	O
and	O
heart	O
rate	O
and	O
decreased	O
coronary	O
vascular	O
resistance	O
and	O
aortic	O
pressure	O
.	O

Cromakalim	O
was	O
approximately	O
8-	O
to	O
9.5-fold	O
more	O
potent	O
than	O
pinacidil	O
in	O
increasing	O
CxAD	O
.	O

Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	B
induced	O
by	O
cromakalim	O
and	O
pinacidil	O
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	O
adrenergic	O
and	O
muscarinic	O
receptors	O
blockade	O
but	O
drug	O
-	O
induced	O
tachycardia	B
was	O
abolished	O
.	O

When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant	O
,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	O
(	O
10	O
micrograms	O
/	O
kg	O
)	O
,	O
pinacidil	O
(	O
30	O
micrograms	O
/	O
kg	O
)	O
and	O
nitroglycerin	O
(	O
10	O
micrograms	O
/	O
kg	O
)	O
were	O
reduced	O
by	O
68	O
+	O
/-	O

7	O
,	O
54	O
+	O
/-	O

9	O
and	O
1	O
+	O
/-	O

1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
nitroglycerin	O
preferentially	O
and	O
flow	O
-	O
independently	O
dilates	O
large	O
coronary	O
arteries	O
,	O
cromakalim	O
and	O
pinacidil	O
dilate	O
both	O
large	O
and	O
small	O
coronary	O
arteries	O
and	O
this	O
effect	O
is	O
not	O
dependent	O
upon	O
the	O
simultaneous	O
beta	O
adrenoceptors	O
-	O
mediated	O
rise	O
in	O
myocardial	O
metabolic	O
demand	O
.	O

Finally	O
,	O
two	O
mechanisms	O
at	O
least	O
,	O
direct	O
vasodilation	O
and	O
flow	O
dependency	O
,	O
are	O
involved	O
in	O
the	O
cromakalim-	O
and	O
pinacidil	O
-	O
induced	O
increase	O
in	O
CxAD	O
.	O

Mefenamic	O
acid	O
-	O
induced	O
neutropenia	B
and	O
renal	B
failure	I
in	O
elderly	O
females	O
with	O
hypothyroidism	B
.	O

We	O
report	O
mefenamic	O
acid	O
-	O
induced	O
non	O
-	O
oliguric	O
renal	B
failure	I
and	O
severe	O
neutropenia	B
occurring	O
simultaneously	O
in	O
two	O
elderly	O
females	O
.	O

The	O
neutropenia	B
was	O
due	O
to	O
maturation	O
arrest	O
of	O
the	O
myeloid	O
series	O
in	O
one	O
patient	O
.	O

Both	O
patients	O
were	O
also	O
hypothyroid	B
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposing	O
factor	O
to	O
the	O
development	O
of	O
these	O
adverse	O
reactions	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	O
acid	O
in	O
hypothyroid	B
patients	O
until	O
the	O
hypothyroidism	B
has	O
been	O
corrected	O
.	O

Etiology	O
of	O
hypercalcemia	B
in	O
hemodialysis	O
patients	O
on	O
calcium	O
carbonate	O
therapy	O
.	O

Fourteen	O
of	O
39	O
dialysis	O
patients	O
(	O
36	O
%	O
)	O
became	O
hypercalcemic	B
after	O
switching	O
to	O
calcium	O
carbonate	O
as	O
their	O
principal	O
phosphate	O
binder	O
.	O

In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	B
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	O
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
length	O
of	O
time	O
on	O
dialysis	O
,	O
and	O
etiology	O
of	O
renal	B
disease	I
.	O

In	O
addition	O
to	O
experiencing	O
hypercalcemic	B
episodes	O
with	O
peak	O
calcium	O
values	O
of	O
2.7	O
to	O
3.8	O
mmol	O
/	O
L	O
(	O
10.7	O
to	O
15.0	O
mg	O
/	O
dL	O
)	O
,	O
patients	O
in	O
the	O
hypercalcemic	B
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	O
concentration	O
obtained	O
during	O
6	O
months	O
before	O
the	O
switch	O
,	O
compared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
months	O
of	O
observation	O
after	O
the	O
switch	O
(	O
2.4	O
+	O
/-	O

0.03	O
to	O
2.5	O
+	O
/-	O

0.03	O
mmol	O
/	O
L	O
[	O
9.7	O
+	O
/-	O

0.2	O
to	O
10.2	O
+	O
/-	O

0.1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0.006	O
)	O
.	O

In	O
contrast	O
,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	O
values	O
over	O
the	O
same	O
time	O
period	O
(	O
2.3	O
+	O
/-	O

0.05	O
to	O
2.3	O
+	O
/-	O

0.05	O
mmol	O
/	O
L	O
[	O
9.2	O
+	O
/-	O

0.2	O
to	O
9.2	O
+	O
/-	O

0.2	O
mg	O
/	O
dL	O
]	O
)	O
.	O

CaCO3	O
dosage	O
,	O
calculated	O
dietary	O
calcium	O
intake	O
,	O
and	O
circulating	O
levels	O
of	O
vitamin	O
D	O
metabolites	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Physical	O
activity	O
index	O
and	O
predialysis	O
serum	O
bicarbonate	O
levels	O
also	O
were	O
similar	O
in	O
both	O
groups	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
parameters	O
reflecting	O
bone	O
turnover	O
rates	O
between	O
groups.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Methyldopa	O
-	O
induced	O
hemolytic	B
anemia	I
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near	O
-	O
syncope	B
.	O

Methyldopa	O
is	O
an	O
antihypertensive	O
medication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trade	O
name	O
Aldomet	O
that	O
is	O
widely	O
prescribed	O
in	O
the	O
adult	O
population	O
and	O
infrequently	O
used	O
in	O
children	O
.	O

Methyldopa	O
causes	O
an	O
autoimmune	B
hemolytic	I
anemia	I
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug	O
.	O

We	O
report	O
a	O
case	O
of	O
methyldopa	O
-	O
induced	O
hemolytic	B
anemia	I
in	O
a	O
15-year	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	B
department	I
with	O
near	O
-	O
syncope	B
.	O

The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	O
during	O
a	O
trauma	B
admission	O
seven	O
weeks	O
prior	O
to	O
presentation	O
.	O

Evaluation	O
revealed	O
a	O
hemoglobin	O
of	O
three	O
grams	O
,	O
3	O
+	O
Coombs	O
'	O
test	O
with	O
polyspecific	O
anti	O
-	O
human	O
globulin	O
and	O
monospecific	O
IgG	O
reagents	O
,	O
and	O
a	O
warm	O
reacting	O
autoantibody	O
.	O

Transfusion	O
and	O
corticosteroid	O
therapy	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
the	O
patient	O
.	O

Emergency	O
physicians	O
treating	O
children	O
must	O
be	O
aware	O
of	O
this	O
syndrome	O
in	O
order	O
to	O
diagnose	O
and	O
treat	O
it	O
correctly	O
.	O

A	O
brief	O
review	O
of	O
autoimmune	O
and	O
drug	O
-	O
induced	O
hemolytic	B
anemias	I
is	O
provided	O
.	O

The	O
long	O
-	O
term	O
safety	O
of	O
danazol	O
in	O
women	O
with	O
hereditary	B
angioedema	I
.	O

Although	O
the	O
short	O
-	O
term	O
safety	O
(	O
less	O
than	O
or	O
equal	O
to	O
6	O
months	O
)	O
of	O
danazol	O
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
information	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
safety	O
.	O

We	O
therefore	O
investigated	O
the	O
long	O
-	O
term	O
safety	O
of	O
danazol	O
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	B
angioedema	I
treated	O
with	O
danazol	O
for	O
a	O
continuous	O
period	O
of	O
6	O
months	O
or	O
longer	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
35.2	O
years	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
was	O
59.7	O
months	O
.	O

Virtually	O
all	O
patients	O
experienced	O
one	O
or	O
more	O
adverse	O
reactions	O
.	O

Menstrual	B
abnormalities	I
(	O
79	O
%	O
)	O
,	O
weight	B
gain	I
(	O
60	O
%	O
)	O
,	O
muscle	B
cramps	I
/	O
myalgias	B
(	O
40	O
%	O
)	O
,	O
and	O
transaminase	O
elevations	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
adverse	O
reactions	O
.	O

The	O
drug	O
was	O
discontinued	O
due	O
to	O
adverse	O
reactions	O
in	O
8	O
patients	O
.	O

No	O
patient	O
has	O
died	O
or	O
suffered	O
any	O
apparent	O
long	O
-	O
term	O
sequelae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
drug	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions	O
,	O
danazol	O
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
group	O
of	O
patients	O
.	O

Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	O
diphosphanilate	O
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	B
.	O

Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	B
and	O
mortality	O
in	O
burn	B
patients	O
.	O

Chlorhexidine	O
phosphanilate	O
(	O
CHP	O
)	O
,	O
a	O
new	O
broad	O
-	O
spectrum	O
antimicrobial	O
agent	O
,	O
has	O
been	O
evaluated	O
as	O
a	O
topical	O
burn	B
wound	O
dressing	O
in	O
cream	O
form	O
,	O
but	O
preliminary	O
clinical	O
trials	O
reported	O
that	O
it	O
was	O
painful	O
upon	O
application	O
.	O

This	O
study	O
compared	O
various	O
concentrations	O
of	O
CHP	O
to	O
determine	O
if	O
a	O
tolerable	O
concentration	O
could	O
be	O
identified	O
with	O
retention	O
of	O
antimicrobial	O
efficacy	O
.	O

Twenty	O
-	O
nine	O
burn	B
patients	O
,	O
each	O
with	O
two	O
similar	O
burns	B
which	O
could	O
be	O
separately	O
treated	O
,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	O
successive	O
12-h	O
intervals	O
over	O
a	O
3-day	O
period	O
.	O

One	O
burn	B
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	O
concentrations	O
,	O
from	O
0.25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicle	O
,	O
and	O
1	O
per	O
cent	O
silver	O
sulphadiazine	O
(	O
AgSD	O
)	O
cream	O
,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	B
wounds	O
.	O

The	O
other	O
site	O
was	O
always	O
treated	O
with	O
AgSD	O
cream	O
.	O

There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	O
concentration	O
and	O
patients	O
'	O
ratings	O
of	O
pain	B
on	O
an	O
analogue	O
scale	O
.	O

The	O
0.25	O
per	O
cent	O
CHP	O
cream	O
was	O
closest	O
to	O
AgSD	O
in	O
pain	B
tolerance	O
;	O
however	O
,	O
none	O
of	O
the	O
treatments	O
differed	O
statistically	O
from	O
AgSD	O
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
ease	O
of	O
application	O
of	O
CHP	O
creams	O
was	O
less	O
satisfactory	O
than	O
that	O
of	O
AgSD	O
.	O

It	O
was	O
concluded	O
that	O
formulations	O
at	O
or	O
below	O
0.5	O
per	O
cent	O
CHP	O
may	O
prove	O
acceptable	O
for	O
wound	O
care	O
,	O
but	O
the	O
vehicle	O
system	O
needs	O
pharmaceutical	O
improvement	O
to	O
render	O
it	O
more	O
tolerable	O
and	O
easier	O
to	O
use	O
.	O

Dose	O
-	O
dependent	O
neurotoxicity	B
of	O
high	O
-	O
dose	O
busulfan	O
in	O
children	O
:	O
a	O
clinical	O
and	O
pharmacological	O
study	O
.	O

Busulfan	O
is	O
known	O
to	O
be	O
neurotoxic	B
in	O
animals	O
and	O
humans	O
,	O
but	O
its	O
acute	O
neurotoxicity	B
remains	O
poorly	O
characterized	O
in	O
children	O
.	O

We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(	O
median	O
age	O
,	O
6.5	O
years	O
)	O
receiving	O
high	O
-	O
dose	O
busulfan	O
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	B
,	O
brain	B
tumors	I
excluded	O
.	O

Busulfan	O
was	O
given	O
p.o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
doses	O
over	O
4	O
days	O
.	O

Two	O
total	O
doses	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O

The	O
dose	O
calculation	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
results	O
in	O
higher	O
doses	O
in	O
young	O
children	O
than	O
in	O
older	O
patients	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O

Ninety	O
-	O
six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis	O
;	O
7	O
(	O
7.5	O
%	O
)	O
developed	O
seizures	B
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	O
course	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosing	O
.	O

When	O
the	O
total	O
busulfan	O
dose	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	B
incidence	O
among	O
patients	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1.7	O
%	O
)	O
and	O
patients	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15.4	O
%	O
)	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Twenty	O
-	O
seven	O
patients	O
were	O
given	O
a	O
600-mg	O
/	O
m2	O
busulfan	O
total	O
dose	O
with	O
continuous	O
i.v	O
.	O

infusion	O
of	O
clonazepam	O
;	O
none	O
had	O
any	O
neurological	B
symptoms	I
.	O

Busulfan	O
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	B
nervous	I
system	I
disease	I
under	O
600	O
mg	O
/	O
m2	O
busulfan	O
with	O
clonazepam	O
:	O
busulfan	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
was	O
1.39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0.02	O
)	O
from	O
the	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16-mg	O
/	O
kg	O
total	O
dose	O
of	O
busulfan	O
.	O

This	O
study	O
shows	O
that	O
busulfan	O
neurotoxicity	B
is	O
dose	O
-	O
dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	O
.	O

A	O
busulfan	O
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children	O
,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	B
,	O
close	O
to	O
neurotoxicity	B
incidence	O
observed	O
in	O
adults	O
.	O

Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	O
clearance	O
in	O
children	O
than	O
in	O
adults	O
,	O
this	O
new	O
dose	O
may	O
approximate	O
more	O
closely	O
the	O
adult	O
systemic	O
exposure	O
obtained	O
after	O
the	O
usual	O
16-mg	O
/	O
kg	O
total	O
dose	O
,	O
with	O
potential	O
inferences	O
in	O
terms	O
of	O
anticancer	O
or	O
myeloablative	O
effects	O
.	O

The	O
busulfan	O
dose	O
in	O
children	O
and	O
infants	O
undergoing	O
bone	O
marrow	O
transplantation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pharmacokinetic	O
studies	O
.	O

Long	O
-	O
term	O
oral	O
galactose	O
treatment	O
prevents	O
cognitive	B
deficits	I
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	O
.	O

Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B
of	O
sporadic	O
Alzheimer	B
's	I
disease	I
(	O
sAD	O
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	O
-	O
receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	O
transport	O
via	O
glucose	O
transporter	O
GLUT4	O
and	O
decreased	O
glucose	O
metabolism	O
in	O
brain	O
cells	O
.	O

An	O
alternative	O
source	O
of	O
energy	O
is	O
d	O
-	O
galactose	O
(	O
the	O
C-4-epimer	O
of	O
d	O
-	O
glucose	O
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	O
-	O
independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	O
via	O
the	O
Leloir	O
pathway	O
.	O

Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	O
induce	O
memory	B
deterioration	I
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	O
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	O
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B
deficits	I
in	O
streptozotocin	O
-	O
induced	O
(	O
STZ	O
-	O
icv	O
)	O
rat	O
model	O
of	O
sAD	O
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O

One	O
month	O
of	O
oral	O
galactose	O
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	O
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	O
-	O
icv	O
-	O
induced	O
cognitive	B
deficits	I
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	O
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	O
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Additionally	O
,	O
oral	O
galactose	O
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	O
in	O
the	O
blood	O
.	O

The	O
increase	O
of	O
galactose	O
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	O
dose	O
.	O

Oral	O
galactose	O
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B
deficits	I
associated	O
with	O
glucose	B
hypometabolism	I
in	O
AD	B
.	O

Histamine	O
antagonists	O
and	O
d	O
-	O
tubocurarine	O
-	O
induced	O
hypotension	B
in	O
cardiac	O
surgical	O
patients	O
.	O

Hemodynamic	O
effects	O
and	O
histamine	O
release	O
by	O
bolus	O
injection	O
of	O
0.35	O
mg	O
/	O
kg	O
of	O
d	O
-	O
tubocurarine	O
were	O
studied	O
in	O
24	O
patients	O
.	O

H1-	O
and	O
H2-histamine	O
antagonists	O
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d	O
-	O
tubocurarine	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
fashion	O
to	O
four	O
groups	O
:	O
group	O
1	O
-	O
-placebo	O
;	O
group	O
2	O
-	O
-cimetidine	O
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
group	O
3	O
-	O
-chlorpheniramine	O
,	O
0.1	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
and	O
group	O
4	O
-	O
-cimetidine	O
plus	O
chlorpheniramine	O
.	O

Histamine	O
release	O
occurred	O
in	O
most	O
patients	O
,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d	O
-	O
tubocurarine	O
dosing	O
.	O

Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	O
change	O
and	O
systemic	O
vascular	O
resistance	O
(	O
r	O
=	O
0.58	O
;	O
P	O
less	O
than	O
0.05	O
)	O
not	O
present	O
in	O
group	O
4	O
.	O

Prior	O
dosing	O
with	O
antagonists	O
partially	O
prevented	O
the	O
fall	O
in	O
systemic	O
vascular	O
resistance	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d	O
-	O
tubocurarine	O
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	O
release	O
.	O

Thus	O
prior	O
dosing	O
with	O
H1-	O
and	O
H2-antagonists	O
provides	O
only	O
partial	O
protection	O
.	O

Convulsant	O
effect	O
of	O
lindane	O
and	O
regional	O
brain	O
concentration	O
of	O
GABA	O
and	O
dopamine	O
.	O

Lindane	O
(	O
gamma	O
-	O
hexachlorocyclohexane	O
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	B
effects	O
.	O

Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	O
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagonist	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
-A	O
receptor	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lindane	O
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	O
,	O
dopamine	O
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	O
the	O
onset	O
of	O
seizures	B
.	O

All	O
animals	O
suffered	O
tonic	O
convulsions	B
at	O
18.3	O
+	O
/-	O

1.4	O
min	O
after	O
lindane	O
administration	O
.	O

The	O
concentration	O
of	O
GABA	O
was	O
only	O
slightly	O
but	O
significantly	O
decreased	O
in	O
the	O
colliculi	O
without	O
modifications	O
in	O
the	O
other	O
areas	O
.	O

The	O
concentration	O
of	O
dopamine	O
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	O
was	O
also	O
increased	O
in	O
the	O
mesencephalon	O
and	O
the	O
striatum	O
.	O

Baboon	B
syndrome	I
induced	O
by	O
ketoconazole	O
.	O

A	O
27-year	O
-	O
old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	B
eruption	I
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
drug	O
-	O
induced	O
baboon	B
syndrome	I
based	O
on	O
his	O
history	O
,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	O
,	O
a	O
physical	O
examination	O
,	O
and	O
histopathological	O
findings	O
.	O

Baboon	B
syndrome	I
is	O
a	O
drug-	O
or	O
contact	O
allergen	O
-	O
related	O
maculopapular	B
eruption	I
that	O
typically	O
involves	O
the	O
flexural	O
and	O
gluteal	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole	O
-	O
induced	O
baboon	B
syndrome	I
in	O
the	O
English	O
literature	O
.	O

A	O
Case	O
of	O
Sudden	B
Cardiac	I
Death	I
due	O
to	O
Pilsicainide	O
-	O
Induced	O
Torsades	B
de	I
Pointes	I
.	O

An	O
84-year	O
-	O
old	O
male	O
received	O
oral	O
pilsicainide	O
,	O
a	O
pure	O
sodium	O
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
his	O
paroxysmal	O
atrial	B
fibrillation	I
to	O
a	O
sinus	O
rhythm	O
;	O
the	O
patient	O
developed	O
sudden	B
cardiac	I
death	I
two	O
days	O
later	O
.	O

The	O
Holter	O
electrocardiogram	O
,	O
which	O
was	O
worn	O
by	O
chance	O
,	O
revealed	O
torsade	B
de	I
pointes	I
with	O
gradually	O
prolonged	O
QT	O
intervals	O
.	O

This	O
drug	O
is	O
rapidly	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
most	O
of	O
it	O
is	O
excreted	O
from	O
the	O
kidney	O
.	O

Although	O
the	O
patient	O
's	O
renal	O
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	O
was	O
low	O
,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	O
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsades	B
de	I
pointes	I
in	O
the	O
octogenarian	O
.	O

Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs	O
,	O
including	O
pilsicainide	O
,	O
is	O
effective	O
to	O
terminate	O
atrial	B
fibrillation	I
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drugs	O
to	O
octogenarians	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
-	O
induced	O
inflammatory	O
myositis	B
in	O
a	O
patient	O
with	O
acute	B
promyelocytic	I
leukemia	I
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	B
promyelocytic	I
leukemia	I
(	O
APL	B
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treatable	O
adverse	O
effects	O
involving	O
numerous	O
organ	O
systems	O
,	O
including	O
rare	O
skeletal	O
muscle	O
involvement	O
.	O

Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA	O
-	O
induced	O
myositis	B
in	O
children	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiology	O
literature	O
.	O

We	O
present	O
such	O
a	O
case	O
in	O
a	O
15-year	O
-	O
old	O
boy	O
with	O
APL	B
,	O
where	O
recognition	O
of	O
imaging	O
findings	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnosis	O
and	O
facilitated	O
prompt	O
,	O
effective	O
treatment	O
.	O

Tolerability	O
of	O
lomustine	O
in	O
combination	O
with	O
cyclophosphamide	O
in	O
dogs	O
with	O
lymphoma	B
.	O

This	O
retrospective	O
study	O
describes	O
toxicity	B
associated	O
with	O
a	O
protocol	O
of	O
lomustine	O
(	O
CCNU	O
)	O
and	O
cyclophosphamide	O
(	O
CTX	O
)	O
in	O
dogs	O
with	O
lymphoma	B
.	O

CCNU	O
was	O
administered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
targeted	O
dosage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
body	O
surface	O
area	O
on	O
day	O
0	O
,	O
CTX	O
was	O
administered	O
PO	O
at	O
a	O
targeted	O
dosage	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
days	O
0	O
through	O
4	O
,	O
and	O
all	O
dogs	O
received	O
prophylactic	O
antibiotics	O
.	O

Ninety	O
treatments	O
were	O
given	O
to	O
the	O
57	O
dogs	O
included	O
in	O
the	O
study	O
.	O

Neutropenia	B
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	B
after	O
the	O
first	O
treatment	O
of	O
CCNU	O
/	O
CTX	O
was	O
30	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
body	O
weight	O
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	B
(	O
19.7	O
kg	O
+	O
13.4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	O
weight	O
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	B
(	O
31.7	O
kg	O
+	O
12.4	O
kg	O
;	O
P	O
=	O
.005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	B
.	O

No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	B
toxicity	I
or	O
hemorrhagic	B
cystitis	B
.	O

Adverse	O
gastrointestinal	O
effects	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein	O
,	O
a	O
dose	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CCNU	O
combined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	O
(	O
divided	O
over	O
5	O
days	O
)	O
q	O
4	O
wk	O
is	O
tolerable	O
in	O
tumor	B
-	O
bearing	O
dogs	O
.	O

Nelarabine	O
neurotoxicity	B
with	O
concurrent	O
intrathecal	O
chemotherapy	O
:	O

Case	O
report	O
and	O
review	O
of	O
literature	O
.	O

Severe	O
nelarabine	O
neurotoxicity	B
in	O
a	O
patient	O
who	O
received	O
concurrent	O
intrathecal	O
(	O
IT	O
)	O
chemotherapy	O
is	O
reported	O
.	O

A	O
37-year	O
-	O
old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T	B
-	I
cell	I
lymphoblastic	I
lymphoma	I
was	O
admitted	O
for	O
relapsed	O
disease	O
.	O

She	O
was	O
originally	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
an	O
autologous	O
transplant	O
.	O

She	O
developed	O
relapsed	O
disease	O
10	O
months	O
later	O
with	O
leukemic	B
involvement	O
.	O

She	O
was	O
re	O
-	O
induced	O
with	O
nelarabine	O
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	O
100	O
mg	O
on	O
day	O
2	O
as	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
prophylaxis	O
.	O

At	O
the	O
time	O
of	O
treatment	O
,	O
she	O
was	O
on	O
continuous	O
renal	O
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	B
lysis	I
syndrome	I
(	O
TLS	B
)	O
.	O

She	O
tolerated	O
therapy	O
well	O
,	O
entered	O
a	O
complete	O
remission	O
,	O
and	O
recovered	O
her	O
renal	O
function	O
.	O

She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	O
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later	O
.	O

A	O
week	O
after	O
this	O
second	O
cycle	O
,	O
she	O
noted	O
numbness	O
in	O
her	O
lower	O
extremities	O
.	O

Predominantly	O
sensory	O
,	O
though	O
also	O
motor	O
and	O
autonomic	O
,	O
peripheral	B
neuropathy	I
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximally	O
to	O
the	O
mid	O
-	O
thoracic	O
region	O
,	O
and	O
eventually	O
included	O
her	O
distal	O
upper	O
extremities	O
.	O

A	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
her	O
spine	O
demonstrated	O
changes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacute	O
combined	O
degeneration	O
.	O

Nelarabine	O
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symptoms	O
.	O

Her	O
neuropathy	B
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
reduced	O
-	O
intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission	O
,	O
but	O
relapsed	O
disease	O
10	O
weeks	O
later	O
.	O

She	O
is	O
currently	O
being	O
treated	O
with	O
best	O
supportive	O
care	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	B
caused	O
by	O
nelarabine	O
in	O
a	O
patient	O
who	O
received	O
concurrent	O
IT	O
chemotherapy	O
.	O

Valproate	O
-	O
induced	O
hyperammonemic	B
encephalopathy	B
in	O
a	O
renal	O
transplanted	O
patient	O
.	O

Neurological	B
complications	I
after	O
renal	O
transplantation	O
constitute	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Their	O
differential	O
diagnosis	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
patient	O
's	O
management	O
.	O

Valproate	O
-	O
induced	O
hyperammonemic	B
encephalopathy	B
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	O
treatment	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15-year	O
-	O
old	O
girl	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
therapy	O
with	O
valproate	O
due	O
to	O
epilepsy	B
and	O
revealed	O
impaired	B
consciousness	I
with	O
hyperammonemia	B
12	O
days	O
after	O
renal	O
transplantation	O
.	O

After	O
withdraw	O
of	O
valproate	O
,	O
patients	O
'	O
symptoms	O
resolved	O
within	O
24	O
h.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	O
,	O
especially	O
in	O
transplanted	O
patients	O
.	O

Necrotising	B
fasciitis	I
after	O
bortezomib	O
and	O
dexamethasone	O
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B
macroglobulinaemia	I
.	O

Bortezomib	O
and	O
high	O
-	O
dose	O
dexamethasone	O
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B
infections	I
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	B
.	O

However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76-year	O
-	O
old	O
man	O
with	O
Waldenstrom	B
macroglobulinaemia	I
who	O
suffered	O
necrotising	B
fasciitis	I
without	O
neutropenia	B
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	O
,	O
high	O
-	O
dose	O
dexamethasone	O
and	O
rituximab	O
.	O

Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B
infections	I
related	O
to	O
bortezomib	O
plus	O
high	O
-	O
dose	O
dexamethasone	O
in	O
elderly	O
patients	O
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O

An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
.	O

Many	O
efficacious	O
cancer	B
treatments	O
cause	O
significant	O
cardiac	O
morbidity	O
,	O
yet	O
biomarkers	O
or	O
functional	O
indices	O
of	O
early	O
damage	O
,	O
which	O
would	O
allow	O
monitoring	O
and	O
intervention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	O
(	O
DOX	O
)	O
-induced	O
cardiomyopathy	B
,	O
applying	O
multiple	O
approaches	O
,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	B
.	O

Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1.25	O
mg	O
/	O
kg	O
DOX	O
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
dosing	O
""""	O
recovery	O
""""	O
period	O
.	O

Electron	O
microscopy	O
of	O
the	O
myocardium	O
revealed	O
subcellular	B
degeneration	I
and	O
marked	O
mitochondrial	O
changes	O
after	O
a	O
single	O
dose	O
.	O

Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	B
degeneration	I
,	O
hypertrophy	B
/	O
cytomegaly	O
,	O
and	O
extensive	O
vacuolation	O
after	O
two	O
doses	O
.	O

Extensive	O
replacement	O
fibrosis	B
(	O
quantified	O
by	O
Sirius	O
red	O
staining	O
)	O
developed	O
during	O
the	O
off	O
-	O
dosing	O
period	O
.	O

Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(	O
including	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
cardiac	O
output	O
,	O
and	O
E	O
/	O
A	O
ratio	O
)	O
declined	O
progressively	O
,	O
reaching	O
statistical	O
significance	O
after	O
two	O
doses	O
and	O
culminating	O
in	O
""""	O
clinical	O
""""	O
LV	B
dysfunction	I
by	O
12	O
weeks	O
.	O

Significant	O
increases	O
in	O
peak	O
myocardial	O
contrast	O
enhancement	O
and	O
serological	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
emerged	O
after	O
eight	O
doses	O
,	O
importantly	O
preceding	O
the	O
LVEF	O
decline	O
to	O
<	O
50	O
%	O
.	O

Troponin	O
I	O
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	O
contrast	O
enhancement	O
,	O
histopathological	O
grading	O
,	O
and	O
diastolic	B
dysfunction	I
.	O

In	O
summary	O
,	O
subcellular	O
cardiomyocyte	B
degeneration	I
was	O
the	O
earliest	O
marker	O
,	O
followed	O
by	O
progressive	O
functional	O
decline	O
and	O
histopathological	O
manifestations	O
.	O

Myocardial	O
contrast	O
enhancement	O
and	O
elevations	O
in	O
cTnI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
indices	O
predated	O
""""	O
clinical	O
""""	O
LV	B
dysfunction	I
and	O
thus	O
warrant	O
further	O
evaluation	O
as	O
predictive	O
biomarkers	O
.	O

Intradermal	O
glutamate	O
and	O
capsaicin	O
injections	O
:	O
intra-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	B
and	O
allodynia	B
.	O

Intradermal	O
injections	O
of	O
glutamate	O
and	O
capsaicin	O
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	B
models	O
because	O
hyperalgesia	B
and	O
allodynia	B
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	B
disorders	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
reproducibility	O
of	O
these	O
models	O
.	O

Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	O
and	O
capsaicin	O
in	O
the	O
volar	O
forearm	O
.	O

Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	B
and	O
brush	O
-	O
evoked	O
allodynia	B
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(	O
gauges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brush	O
strokes	O
.	O

Areas	O
of	O
secondary	B
hyperalgesia	I
and	O
allodynia	B
were	O
quantified	O
immediately	O
after	O
injection	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
identical	O
experiments	O
separated	O
by	O
at	O
least	O
7	O
days	O
were	O
performed	O
.	O

Reproducibility	O
across	O
and	O
within	O
volunteers	O
(	O
inter-	O
and	O
intra	O
-	O
individual	O
variation	O
,	O
respectively	O
)	O
was	O
assessed	O
using	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O

Secondary	O
pinprick	O
hyperalgesia	B
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0.001	O
)	O
after	O
glutamate	O
injection	O
.	O

For	O
capsaicin	O
,	O
secondary	O
pinprick	O
hyperalgesia	B
was	O
detected	O
with	O
all	O
von	O
Frey	O
gauges	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Glutamate	O
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0.60	O
)	O
and	O
brush	O
strokes	O
(	O
ICC	O
>	O
0.83	O
)	O
.	O

Capsaicin	O
injection	O
was	O
reproducible	O
for	O
secondary	B
hyperalgesia	I
(	O
ICC	O
>	O
0.70	O
)	O
and	O
allodynia	B
(	O
ICC	O
>	O
0.71	O
)	O
.	O

Intra	O
-	O
individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	B
hyperalgesia	I
and	O
allodynia	B
.	O

In	O
conclusion	O
,	O
glutamate	O
and	O
capsaicin	O
yield	O
reproducible	O
hyperalgesic	B
and	O
allodynic	B
responses	O
,	O
and	O
the	O
present	O
model	O
is	O
well	O
suited	O
for	O
basic	O
research	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulation	O
of	O
central	O
phenomena	O
.	O

Ocular	O
-	O
specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	B
in	O
murine	O
glucocorticoid	O
-	O
induced	O
glaucoma	B
.	O

Administration	O
of	O
glucocorticoids	O
induces	O
ocular	B
hypertension	I
in	O
some	O
patients	O
.	O

If	O
untreated	O
,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	B
that	O
resembles	O
primary	B
open	I
-	I
angle	I
glaucoma	I
(	O
POAG	B
)	O
.	O

The	O
underlying	O
pathology	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O

Here	O
,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B
that	O
exhibits	O
glaucoma	B
features	O
that	O
are	O
observed	O
in	O
patients	O
.	O

Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0.1	O
%	O
dexamethasone	O
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	B
ganglion	I
cells	O
,	O
and	O
axonal	B
degeneration	I
,	O
resembling	O
glucocorticoid	O
-	O
induced	O
glaucoma	B
in	O
human	O
patients	O
.	O

Furthermore	O
,	O
dexamethasone	O
-	O
induced	O
ocular	B
hypertension	I
was	O
associated	O
with	O
chronic	O
ER	O
stress	O
of	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patients	O
,	O
withdrawal	O
of	O
dexamethasone	O
treatment	O
reduced	O
elevated	O
IOP	O
and	O
ER	O
stress	O
in	O
this	O
animal	O
model	O
.	O

Dexamethasone	O
induced	O
the	O
transcriptional	O
factor	O
CHOP	O
,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress	O
,	O
in	O
the	O
anterior	O
segment	O
tissues	O
,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone	O
-	O
induced	O
ocular	B
hypertension	I
.	O

Furthermore	O
,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	O
4-phenylbutyrate	O
prevented	O
dexamethasone	O
-	O
induced	O
ocular	B
hypertension	I
in	O
WT	O
mice	O
.	O

Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid	O
-	O
induced	O
ocular	B
hypertension	I
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid	O
-	O
induced	O
glaucoma	B
.	O

Effects	O
of	O
ginsenosides	O
on	O
opioid	O
-	O
induced	O
hyperalgesia	B
in	O
mice	O
.	O

Opioid	O
-	O
induced	O
hyperalgesia	B
(	O
OIH	B
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	O
use	O
.	O

OIH	B
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B
addiction	I
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	O
,	O
Rg1	O
,	O
and	O
Rb1	O
ginsenosides	O
,	O
the	O
bioactive	O
components	O
of	O
ginseng	O
,	O
on	O
OIH	B
.	O

OIH	B
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	O
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O

During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	O
were	O
administered	O
Re	O
,	O
Rg1	O
,	O
or	O
Rb1	O
intragastrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	O
acid	O
-	O
induced	O
writhing	O
test	O
.	O

Re	O
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	B
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	O
acid	O
-	O
induced	O
writhing	O
test	O
.	O

However	O
,	O
the	O
Rg1	O
and	O
Rb1	O
ginsenosides	O
failed	O
to	O
prevent	O
OIH	B
in	O
either	O
test	O
.	O

Furthermore	O
,	O
Rg1	O
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B
in	O
the	O
acetic	O
acid	O
-	O
induced	O
writhing	O
test	O
.	O

Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	O
Re	O
,	O
but	O
not	O
Rg1	O
or	O
Rb1	O
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B
.	O

A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	O
and	O
propofol	O
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O

OBJECTIVE	O
:	O
Dexmedetomidine	O
and	O
propofol	O
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations	O
.	O

However	O
,	O
both	O
agents	O
are	O
associated	O
with	O
significant	O
hemodynamic	O
side	O
effects	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	O
and	O
propofol	O
.	O

DESIGN	O
:	O
Multicenter	O
,	O
retrospective	O
,	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

SETTING	O
:	O
Neurocritical	O
care	O
units	O
at	O
two	O
academic	O
medical	O
centers	O
with	O
dedicated	O
neurocritical	O
care	O
teams	O
and	O
board	O
-	O
certified	O
neurointensivists	O
.	O

PATIENTS	O
:	O
Neurocritical	O
care	O
patients	O
admitted	O
between	O
July	O
2009	O
and	O
September	O
2012	O
were	O
evaluated	O
and	O
then	O
matched	O
1:1	O
based	O
on	O
propensity	O
scoring	O
of	O
baseline	O
characteristics	O
.	O

INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	O
or	O
propofol	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	O
and	O
237	O
propofol	O
)	O
were	O
included	O
in	O
the	O
analysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
group	O
)	O
by	O
propensity	O
score	O
.	O

The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	B
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	B
(	O
heart	O
rate	O
<	O
50	O
beats	O
/	O
min	O
)	O
during	O
sedative	O
infusion	O
.	O

No	O
difference	O
in	O
the	O
primary	O
composite	O
outcome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0.94	O
)	O
or	O
matched	O
cohorts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0.35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	B
or	O
bradycardia	B
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts	O
.	O

CONCLUSIONS	O
:	O
Severe	O
hypotension	B
and	O
bradycardia	B
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	O
or	O
propofol	O
.	O

Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	B
or	O
bradycardia	B
before	O
starting	O
either	O
sedative	O
.	O

Hydroxytyrosol	O
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B
dysfunction	I
in	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
in	O
rats	O
with	O
breast	B
cancer	I
.	O

Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	B
,	O
aging	O
and	O
cardiovascular	B
disease	I
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	O
.	O

Doxorubicin	O
causes	O
significant	O
cardiotoxicity	B
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	B
dysfunction	I
.	O

Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin	O
-	O
associated	O
chronic	O
cardiac	B
toxicity	I
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	O
in	O
rats	O
with	O
breast	B
cancer	I
.	O

Thirty	O
-	O
six	O
rats	O
bearing	O
breast	B
tumors	I
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	O
(	O
0.5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
doxorubicin	O
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxorubicin	O
plus	O
hydroxytyrosol	O
.	O

Cardiac	B
disturbances	I
at	O
the	O
cellular	O
and	O
mitochondrial	O
level	O
,	O
mitochondrial	O
electron	O
transport	O
chain	O
complexes	O
I	O
-	O
IV	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
and	O
oxidative	O
stress	O
markers	O
have	O
been	O
analyzed	O
.	O

Hydroxytyrosol	O
improved	O
the	O
cardiac	B
disturbances	I
enhanced	O
by	O
doxorubicin	O
by	O
significantly	O
reducing	O
the	O
percentage	O
of	O
altered	O
mitochondria	O
and	O
oxidative	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
hydroxytyrosol	O
improve	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
.	O

This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	O
protect	O
rat	O
heart	B
damage	I
provoked	O
by	O
doxorubicin	O
decreasing	O
oxidative	O
damage	O
and	O
mitochondrial	O
alterations	O
.	O

Amiodarone	O
-	O
induced	O
myxoedema	B
coma	B
.	O

A	O
62-year	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	B
,	O
hypothermia	B
and	O
respiratory	B
failure	I
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	O
therapy	O
for	O
atrial	B
fibrillation	I
.	O

Thyroid	O
-	O
stimulating	O
hormone	O
was	O
found	O
to	O
be	O
168	O
uIU	O
/	O
mL	O
(	O
nl	O
.	O

0.3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
thyroxine	O
(	O
FT4	O
)	O
was	O
<	O
0.2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0.8	O
-	O
1.8	O
ng	O
/	O
dL	O
)	O
.	O

He	O
received	O
intravenous	O
fluids	O
,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	O
;	O
he	O
was	O
intubated	O
and	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	O
in	O
the	O
first	O
18	O
h	O
of	O
therapy	O
,	O
and	O
150	O
ug	O
intravenous	O
daily	O
thereafter	O
.	O

Haemodynamic	O
improvement	O
,	O
along	O
with	O
complete	O
recovery	O
of	O
mental	O
status	O
,	O
occurred	O
after	O
48	O
h.	O
Twelve	O
hours	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
FT4	O
was	O
0.96	O
ng	O
/	O
dL.	O
The	O
patient	O
was	O
maintained	O
on	O
levothyroxine	O
175	O
(	O
g	O
POorally	O
daily	O
.	O

A	O
thyroid	O
ultrasound	O
showed	O
diffuse	O
heterogeneity	O
.	O

The	O
24	O
hour	O
excretion	O
of	O
iodine	O
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

The	O
only	O
two	O
cases	O
of	O
amiodarone	O
-	O
induced	O
myxoedema	B
coma	B
in	O
the	O
literature	O
report	O
patient	O
death	O
despite	O
supportive	O
therapy	O
and	O
thyroid	O
hormone	O
replacement	O
.	O

This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone	O
-	O
induced	O
myxoedema	B
coma	B
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	B
disease	I
.	O

Use	O
of	O
argatroban	O
and	O
catheter	O
-	O
directed	O
thrombolysis	B
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin	O
-	O
induced	O
thrombocytopenia	B
with	O
thrombosis	B
.	O

PURPOSE	O
:	O
The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin	O
-	O
induced	O
thrombocytopenia	B
with	O
thrombosis	B
(	O
HITT	B
)	O
and	O
was	O
treated	O
with	O
argatroban	O
plus	O
catheter	O
-	O
directed	O
thrombolysis	B
(	O
CDT	O
)	O
with	O
alteplase	O
is	O
presented	O
.	O

SUMMARY	O
:	O
A	O
63-year	O
-	O
old	O
Caucasian	O
man	O
with	O
renal	O
amyloidosis	B
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper	B
-	I
extremity	I
deep	I
venous	I
thrombosis	I
(	O
DVT	B
)	O
and	O
pulmonary	B
embolism	I
secondary	O
to	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

A	O
continuous	O
i.v	O
.	O

infusion	O
of	O
argatroban	O
was	O
initiated	O
,	O
and	O
the	O
patient	O
was	O
managed	O
on	O
the	O
general	O
medical	O
floor	O
.	O

After	O
one	O
week	O
of	O
therapy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	B
vena	I
cava	I
(	I
SVC	I
)	I
syndrome	I
.	O

A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted	O
,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	B
.	O

The	O
epistaxis	B
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	O
.	O

A	O
second	O
percutaneous	O
mechanical	O
thrombectomy	O
was	O
performed	O
six	O
days	O
later	O
and	O
resulted	O
in	O
partial	O
revascularization	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
.	O

Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	O
was	O
withheld	O
,	O
and	O
complete	O
patency	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
was	O
achieved	O
after	O
three	O
days	O
of	O
therapy	O
.	O

Alteplase	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	O
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfarin	O
for	O
long	O
-	O
term	O
anticoagulation	O
.	O

Although	O
the	O
patient	O
recovered	O
,	O
he	O
experienced	O
permanent	O
vision	B
and	I
hearing	I
loss	I
,	O
as	O
well	O
as	O
end	B
-	I
stage	I
renal	I
disease	I
.	O

CONCLUSION	O
:	O
A	O
63-year	O
-	O
old	O
man	O
with	O
renal	O
amyloidosis	B
and	O
SVC	B
syndrome	I
secondary	O
to	O
HITT	B
was	O
successfully	O
treated	O
with	O
argatroban	O
and	O
CDT	O
with	O
alteplase	O
.	O

Effects	O
of	O
dehydroepiandrosterone	O
in	O
amphetamine	O
-	O
induced	O
schizophrenia	B
models	O
in	O
mice	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
on	O
animal	O
models	O
of	O
schizophrenia	B
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	O
-	O
free	O
(	O
control	O
)	O
,	O
amphetamine	O
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	O
.	O

The	O
DHEA	O
was	O
administered	O
intraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
days	O
.	O

Amphetamine	O
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
hyper	B
locomotion	O
,	O
apomorphine	O
(	O
1.5	O
mg	O
/	O
kg	O
subcutaneously	O
[	O
sc	O
]	O
)	O
induced	O
climbing	O
,	O
and	O
haloperidol	O
(	O
1.5	O
mg	O
/	O
kg	O
sc	O
)	O
induced	O
catalepsy	B
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	B
.	O

The	O
study	O
was	O
conducted	O
at	O
the	O
Animal	O
Experiment	O
Laboratories	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Medical	O
School	O
,	O
Eskisehir	O
Osmangazi	O
University	O
,	O
Eskisehir	O
,	O
Turkey	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
hyper	B
locomotion	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	B
tests	O
.	O

RESULTS	O
:	O
In	O
the	O
amphetamine	O
-	O
induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	O
-	O
free	O
group	O
.	O

Both	O
DHEA	O
50	O
mg	O
/	O
kg	O
(	O
p<0.05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p<0.01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	O
-	O
induced	O
locomotion	O
group	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	O
-	O
induced	O
catalepsy	B
test	O
(	O
p<0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	O
-	O
induced	O
climbing	O
test	O
(	O
p>0.05	O
)	O
.	O

CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	O
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	B
at	O
both	O
doses	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior	O
.	O

We	O
suggest	O
that	O
DHEA	O
displays	O
typical	O
neuroleptic	O
-	O
like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	B
.	O

Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B
prolongation	I
.	O

Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	O
(	O
+	O
)	O
channel	O
and	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
blocker	O
effects	O
on	O
QT	O
interval	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B
prolongation	I
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B
prolongation	I
induced	O
by	O
multichannel	O
blockers	O
.	O

hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O

IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
blockers	O
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O

Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	O
,	O
Paroxetine	O
,	O
Terfenadine	O
and	O
Citalopram	O
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	O
and	O
Citalopram	O
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B
de	I
Pointes	I
(	O
TdP	B
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O

hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B
potential	O
.	O

Dermal	O
developmental	O
toxicity	B
of	O
N	O
-	O
phenylimide	O
herbicides	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
S-53482	O
and	O
S-23121	O
are	O
N	O
-	O
phenylimide	O
herbicides	O
and	O
produced	O
embryolethality	B
,	O
teratogenicity	B
(	O
mainly	O
ventricular	B
septal	I
defects	I
and	O
wavy	O
ribs	O
)	O
,	O
and	O
growth	B
retardation	I
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	B
studies	O
.	O

Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	B
via	O
the	O
dermal	O
route	O
,	O
which	O
is	O
more	O
relevant	O
to	O
occupational	O
exposure	O
,	O
hence	O
better	O
addressing	O
human	O
health	O
risks	O
.	O

METHODS	O
:	O
S-53482	O
was	O
administered	O
dermally	O
to	O
rats	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organogenesis	O
,	O
and	O
S-23121	O
was	O
administered	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maximum	O
applicable	O
dose	O
level	O
)	O
.	O

Fetuses	O
were	O
obtained	O
by	O
a	O
Cesarean	O
section	O
and	O
examined	O
for	O
external	O
,	O
visceral	O
,	O
and	O
skeletal	O
alterations	O
.	O

RESULTS	O
:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S-53482	O
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	B
similar	O
to	O
those	O
resulting	O
from	O
oral	O
exposure	O
.	O

Toxicity	B
included	O
embryolethality	B
,	O
teratogenicity	B
,	O
and	O
growth	B
retardation	I
.	O

Dermal	O
administration	O
of	O
S-23121	O
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	B
death	I
and	O
ventricular	B
septal	I
defect	I
,	O
but	O
retarded	O
fetal	O
growth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oral	O
exposure	O
to	O
S-23121	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
results	O
,	O
S-53482	O
and	O
S-23121	O
were	O
teratogenic	B
when	O
administered	O
dermally	O
to	O
pregnant	O
rats	O
as	O
were	O
the	O
compounds	O
administered	O
orally	O
.	O

Thus	O
,	O
investigation	O
of	O
the	O
mechanism	O
and	O
its	O
human	O
relevancy	O
become	O
more	O
important	O
.	O

Rates	O
of	O
Renal	B
Toxicity	I
in	O
Cancer	B
Patients	O
Receiving	O
Cisplatin	O
With	O
and	O
Without	O
Mannitol	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
is	O
a	O
widely	O
used	O
antineoplastic	O
.	O

One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	O
use	O
is	O
dose	O
-	O
limiting	O
nephrotoxicity	B
.	O

There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	B
,	O
including	O
the	O
use	O
of	O
mannitol	O
as	O
a	O
nephroprotectant	O
in	O
combination	O
with	O
hydration	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	B
in	O
cancer	B
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	O
with	O
and	O
without	O
mannitol	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	O
shortage	O
.	O

Data	O
were	O
collected	O
on	O
adult	O
cancer	B
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	O
as	O
an	O
outpatient	O
from	O
January	O
2011	O
to	O
September	O
2012	O
.	O

The	O
primary	O
outcome	O
was	O
acute	B
kidney	I
injury	I
(	O
AKI	B
)	O
.	O

RESULTS	O
:	O
We	O
evaluated	O
143	O
patients	O
who	O
received	O
single	O
-	O
agent	O
cisplatin	O
;	O
97.2	O
%	O
of	O
patients	O
had	O
head	B
and	I
neck	I
cancer	I
as	O
their	O
primary	O
malignancy	B
.	O

Patients	O
who	O
did	O
not	O
receive	O
mannitol	O
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	B
:	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.646	O
(	O
95	O
%	O
CI	O
=	O
1.008	O
,	O
6.944	O
;	O
P	O
=	O
0.048	O
)	O
.	O

Patients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	B
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	B
:	O
OR	O
=	O
11.494	O
(	O
95	O
%	O
CI	O
=	O
4.149	O
,	O
32.258	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
OR	O
=	O
3.219	O
(	O
95	O
%	O
CI	O
=	O
1.228	O
,	O
8.439	O
;	O
P	O
=	O
0.017	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
When	O
limited	O
quantities	O
of	O
mannitol	O
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	O
particularly	O
high	O
risk	O
of	O
nephrotoxicity	B
.	O

Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	O
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	B
are	O
at	O
the	O
greatest	O
risk	O
of	O
nephrotoxicity	B
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	O
.	O

Metformin	O
protects	O
against	O
seizures	B
,	O
learning	B
and	I
memory	I
impairments	I
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole	O
-	O
induced	O
kindling	O
in	O
mice	O
.	O

Cognitive	B
impairment	I
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	B
,	O
greatly	O
diminishes	O
the	O
quality	O
of	O
life	O
.	O

However	O
,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	B
can	O
also	O
cause	O
untoward	O
cognitive	O
effects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	B
and	O
cognition	B
deficits	I
.	O

Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B
deficits	I
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential	O
.	O

Metformin	O
,	O
the	O
most	O
commonly	O
prescribed	O
antidiabetic	O
oral	O
drug	O
,	O
has	O
antioxidant	O
properties	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	O
on	O
seizures	B
,	O
cognitive	B
impairment	I
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole	O
-	O
induced	O
kindling	O
animals	O
.	O

Male	O
C57BL	O
/	O
6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	O
(	O
37	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injections	O
.	O

Metformin	O
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	O
.	O

We	O
found	O
that	O
metformin	O
suppressed	O
the	O
progression	O
of	O
kindling	O
,	O
ameliorated	O
the	O
cognitive	B
impairment	I
and	O
decreased	O
brain	O
oxidative	O
stress	O
.	O

Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	O
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	B
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	B
impairment	I
induced	O
by	O
seizures	B
.	O

P53	O
inhibition	O
exacerbates	O
late	O
-	O
stage	O
anthracycline	O
cardiotoxicity	B
.	O

AIMS	O
:	O
Doxorubicin	O
(	O
DOX	O
)	O
is	O
an	O
effective	O
anti	O
-	O
cancer	B
therapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late	O
-	O
stage	O
cardiotoxicity	B
.	O

Children	O
are	O
particularly	O
sensitive	O
to	O
DOX	O
-	O
induced	O
heart	B
failure	I
.	O

Here	O
,	O
the	O
impact	O
of	O
p53	O
inhibition	O
on	O
acute	O
vs.	O
late	O
-	O
stage	O
DOX	O
cardiotoxicity	B
was	O
examined	O
in	O
a	O
juvenile	O
model	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Two	O
-	O
week	O
-	O
old	O
MHC	O
-	O
CB7	O
mice	O
(	O
which	O
express	O
dominant	O
-	O
interfering	O
p53	O
in	O
cardiomyocytes	O
)	O
and	O
their	O
non	O
-	O
transgenic	O
(	O
NON	O
-	O
TXG	O
)	O
littermates	O
received	O
weekly	O
DOX	O
injections	O
for	O
5	O
weeks	O
(	O
25	O
mg	O
/	O
kg	O
cumulative	O
dose	O
)	O
.	O

One	O
week	O
after	O
the	O
last	O
DOX	O
treatment	O
(	O
acute	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
mice	O
exhibited	O
improved	O
cardiac	O
function	O
and	O
lower	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
the	O
NON	O
-	O
TXG	O
mice	O
.	O

Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	O
treatment	O
(	O
late	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
progressive	O
decrease	O
in	O
cardiac	O
function	O
and	O
higher	O
rates	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
NON	O
-	O
TXG	O
mice	O
.	O

p53	O
inhibition	O
blocked	O
transient	O
DOX	O
-	O
induced	O
STAT3	O
activation	O
in	O
MHC	O
-	O
CB7	O
mice	O
,	O
which	O
was	O
associated	O
with	O
enhanced	O
induction	O
of	O
the	O
DNA	O
repair	O
proteins	O
Ku70	O
and	O
Ku80	O
.	O

Mice	O
with	O
cardiomyocyte	O
-	O
restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function	O
,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	O
treatment	O
during	O
the	O
acute	O
stage	O
when	O
compared	O
with	O
control	O
animals	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53-dependent	O
cardioprotective	O
pathway	O
,	O
mediated	O
via	O
STAT3	O
activation	O
,	O
mitigates	O
DOX	O
-	O
induced	O
myocardial	O
stress	O
during	O
drug	O
delivery	O
.	O

Furthermore	O
,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and	O
,	O
paradoxically	O
,	O
enhanced	O
cardiotoxicity	B
long	O
after	O
the	O
cessation	O
of	O
drug	O
treatment	O
.	O

Metronidazole	O
-	O
induced	O
encephalopathy	B
:	O
an	O
uncommon	O
scenario	O
.	O

Metronidazole	O
can	O
produce	O
neurological	O
complications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	B
following	O
prolonged	O
metronidazole	O
intake	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	O
showed	O
abnormal	O
signal	O
intensity	O
involving	O
both	O
dentate	O
nuclei	O
of	O
cerebellum	O
and	O
splenium	O
of	O
corpus	O
callosum	O
.	O

The	O
diagnosis	O
of	O
metronidazole	O
toxicity	B
was	O
made	O
by	O
the	O
MRI	O
findings	O
and	O
supported	O
clinically	O
.	O

Aconitine	O
-	O
induced	O
Ca2	O
+	O
overload	O
causes	O
arrhythmia	B
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats	O
.	O

Aconitine	O
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	O
(	O
+	O
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B
of	O
aconitine	O
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	O
(	O
2	O
+	O
)	O
in	O
aconitine	O
poisoning	B
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	O
(	O
2	O
+	O
)	O
signaling	O
in	O
aconitine	O
poisoning	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	O
(	O
2	O
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B
in	O
conscious	O
freely	O
moving	O
rats	O
.	O

To	O
investigate	O
effects	O
of	O
aconitine	O
on	O
myocardial	B
injury	I
,	O
we	O
performed	O
cytotoxicity	B
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	O
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	O
.	O

The	O
results	O
showed	O
that	O
aconitine	O
resulted	O
in	O
myocardial	B
injury	I
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	O
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca	O
(	O
2	O
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	O
promoted	O
Ca	O
(	O
2	O
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
handling	O
proteins	O
.	O

The	O
expression	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
revealed	O
that	O
pro	O
-	O
apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
BCL-2	O
expression	O
was	O
downregulated	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	O
family	O
members	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	O
significantly	O
aggravates	O
Ca	O
(	O
2	O
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	B
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Chronic	O
treatment	O
with	O
metformin	O
suppresses	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	B
ventricular	I
dysfunction	I
following	O
myocardial	B
infarction	I
.	O

Acute	O
treatment	O
with	O
metformin	O
has	O
a	O
protective	O
effect	O
in	O
myocardial	B
infarction	I
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	O
on	O
cardiac	B
dysfunction	I
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B
infarction	I
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed	O
.	O

Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n=6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	O
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	O
twice	O
daily	O
for	O
14	O
days	O
.	O

Isoproterenol	O
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B
myocardial	I
infarction	I
.	O

Isoproterenol	O
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O

The	O
left	B
ventricular	I
dysfunction	I
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	O
.	O

Metfromin	O
markedly	O
lowered	O
isoproterenol	O
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
,	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
)	O
,	O
tumor	B
necrosis	B
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleukin	O
6	O
(	O
IL-6	O
)	O
in	O
the	O
heart	O
tissues	O
.	O

Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	O
-	O
a	O
and	O
IL-6	O
.	O

However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O

Phosphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	O
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	O
reduces	O
post	O
-	O
myocardial	B
infarction	I
cardiac	O
dysfunction	O
and	O
suppresses	O
inflammatory	O
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	O
activities	O
.	O

This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	O
myocardium	O
.	O

Unusual	O
complications	O
of	O
antithyroid	O
drug	O
therapy	O
:	O
four	O
case	O
reports	O
and	O
review	O
of	O
literature	O
.	O

Two	O
cases	O
of	O
propylthiouracil	O
-	O
associated	O
acute	O
hepatitis	B
,	O
one	O
case	O
of	O
fatal	O
methimazole	O
-	O
associated	O
hepatocellular	B
necrosis	I
and	O
one	O
case	O
of	O
propylthiouracil	O
-	O
associated	O
lupus	B
-	I
like	I
syndrome	I
are	O
described	O
.	O

The	O
literature	O
related	O
to	O
antithyroid	O
drug	O
side	O
effects	O
and	O
the	O
mechanisms	O
for	O
their	O
occurrence	O
are	O
reviewed	O
and	O
the	O
efficacy	O
and	O
complications	O
of	O
thyroidectomy	O
and	O
radioiodine	O
compared	O
to	O
those	O
of	O
antithyroid	O
drugs	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	B
.	O

Neuroleptic	B
malignant	I
syndrome	I
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	O
and	O
tiapride	O
in	O
a	O
Japanese	O
patient	O
with	O
Huntington	B
's	I
disease	I
at	O
the	O
terminal	O
stage	O
of	O
recurrent	O
breast	B
cancer	I
.	O

We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81-year	O
-	O
old	O
Japanese	O
woman	O
with	O
neuroleptic	B
malignant	I
syndrome	I
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	O
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabenazine	O
(	O
12.5	O
mg	O
/	O
day	O
)	O
for	O
Huntington	B
's	I
disease	I
.	O

The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	O
or	O
tetrabenazine	O
alone	O
without	O
any	O
adverse	O
effects	O
before	O
the	O
administration	O
of	O
the	O
combination	O
therapy	O
.	O

She	O
also	O
had	O
advanced	O
breast	B
cancer	I
when	O
the	O
combination	O
therapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
occurrence	O
of	O
neuroleptic	B
malignant	I
syndrome	I
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	O
and	O
tiapride	O
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrabenazine	O
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	O
drugs	O
,	O
particularly	O
in	O
patients	O
with	O
a	O
worsening	O
general	O
condition	O
.	O

A	O
metoprolol	O
-	O
terbinafine	O
combination	O
induced	O
bradycardia	B
.	O

To	O
report	O
a	O
sinus	B
bradycardia	I
induced	O
by	O
metoprolol	O
and	O
terbinafine	O
drug	O
-	O
drug	O
interaction	O
and	O
its	O
management	O
.	O

A	O
63	O
year	O
-	O
old	O
Caucasian	O
man	O
on	O
metoprolol	O
200	O
mg	O
/	O
day	O
for	O
stable	O
coronary	B
artery	I
disease	I
was	O
prescribed	O
a	O
90-day	O
course	O
of	O
oral	O
terbinafine	O
250	O
mg	O
/	O
day	O
for	O
onychomycosis	B
.	O

On	O
the	O
49th	O
day	O
of	O
terbinafine	O
therapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status	O
,	O
confusion	B
and	O
falls	O
.	O

The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats	O
/	O
min	O
sinus	B
bradycardia	I
.	O

A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	B
drug	I
reaction	I
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
's	O
sinus	B
bradycardia	I
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	O
and	O
terbinafine	O
.	O

The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	O
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	O
and	O
the	O
heart	O
rate	O
remained	O
normal	O
.	O

By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6	O
,	O
terbinafine	O
had	O
decreased	O
metoprolol	O
's	O
clearance	O
,	O
leading	O
in	O
metoprolol	O
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	B
bradycardia	I
.	O

Optochiasmatic	O
and	O
peripheral	B
neuropathy	I
due	O
to	O
ethambutol	O
overtreatment	O
.	O

Ethambutol	O
is	O
known	O
to	O
cause	O
optic	B
neuropathy	I
and	O
,	O
more	O
rarely	O
,	O
axonal	O
polyneuropathy	B
.	O

We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72-year	O
-	O
old	O
man	O
who	O
developed	O
visual	B
loss	I
and	O
paresthesias	B
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	O
.	O

This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	O
toxicity	B
.	O

Testosterone	O
ameliorates	O
streptozotocin	O
-	O
induced	O
memory	B
impairment	I
in	O
male	O
rats	O
.	O

AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	O
on	O
streptozotocin	O
(	O
STZ	O
)	O
-induced	O
memory	B
impairment	I
in	O
male	O
rats	O
.	O

METHODS	O
:	O
Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	O
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	O
.	O

Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats	O
,	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation	O
.	O

Testosterone	O
(	O
1	O
mg.kg	O
(	O
-1	O
)	O
.d	O
(	O
-1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgen	O
receptor	O
antagonist	O
flutamide	O
(	O
10	O
mg.kg	O
(	O
-1	O
)	O
.d	O
(	O
-1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrogen	O
receptor	O
antagonist	O
tamoxifen	O
(	O
1	O
mg.kg	O
(	O
-1	O
)	O
.d	O
(	O
-1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	O
(	O
4	O
mg.kg	O
(	O
-1	O
)	O
.d	O
(	O
-1	O
)	O
,	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	O
.	O

RESULTS	O
:	O
STZ	O
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O

Testosterone	O
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats	O
,	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	O
-	O
treated	O
rats	O
.	O

Administration	O
of	O
flutamide	O
,	O
letrozole	O
or	O
tamoxifen	O
significantly	O
impaired	B
the	I
memory	I
in	O
intact	O
rats	O
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	O
replacement	O
in	O
improving	O
STZ-	O
and	O
castration	O
-	O
induced	O
memory	B
impairment	I
.	O

CONCLUSION	O
:	O
Testosterone	O
administration	O
ameliorates	O
STZ-	O
and	O
castration	O
-	O
induced	O
memory	B
impairment	I
in	O
male	O
Wistar	O
rats	O
.	O

Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	O
FC	O
in	O
pilocarpine	O
-	O
induced	O
seizures	B
.	O

Garcinielliptone	O
FC	O
(	O
GFC	O
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart	O
.	O

It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B
diseases	I
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B
and	O
inflammatory	B
diseases	I
.	O

However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	O
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	O
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	O
acid	O
(	O
r	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
,	O
glutamine	O
,	O
aspartate	O
and	O
glutathione	O
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	B
.	O

GFC	O
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B
,	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20.12	O
+	O
2.20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20.95	O
+	O
2.21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23.43	O
+	O
1.99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
addition	O
,	O
GABA	O
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
of	O
46.90	O
%	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
aspartate	O
,	O
glutamine	O
and	O
glutamate	O
levels	O
detected	O
a	O
decrease	O
of	O
5.21	O
%	O
,	O
13.55	O
%	O
and	O
21.80	O
%	O
,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

Hippocampus	O
mice	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
in	O
AChE	O
activity	O
(	O
63.30	O
%	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

The	O
results	O
indicate	O
that	O
GFC	O
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	O
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	O
model	O
by	O
modulating	O
the	O
GABA	O
and	O
glutamate	O
contents	O
and	O
of	O
AChE	O
activity	O
in	O
seized	O
mice	O
hippocampus	O
.	O

This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O

Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	B
kidney	I
injury	I
:	O
a	O
prospective	O
,	O
clinical	O
,	O
non	O
-	O
interventional	O
,	O
observational	O
study	O
.	O

INTRODUCTION	O
:	O
Acute	B
kidney	I
injury	I
(	O
AKI	B
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitalized	O
and	O
66	O
%	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
patients	O
.	O

It	O
increases	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
and	O
costs	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(	O
standard	O
operating	O
procedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoxic	B
antibiotics	O
and	O
the	O
occurrence	O
of	O
AKI	B
.	O

METHODS	O
:	O
This	O
study	O
was	O
carried	O
out	O
as	O
a	O
prospective	O
,	O
clinical	O
,	O
non	O
-	O
interventional	O
,	O
observational	O
study	O
.	O

Data	O
collection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
days	O
in	O
three	O
ICUs	O
at	O
Charite	O
-	O
Universitaetsmedizin	O
Berlin	O
.	O

A	O
total	O
of	O
675	O
patients	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	O
,	O
gentamicin	O
,	O
or	O
tobramycin	O
;	O
were	O
>	O
18	O
years	O
;	O
and	O
treated	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Patients	O
with	O
an	O
adherence	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adherence	O
group	O
(	O
HAG	O
)	O
and	O
patients	O
with	O
an	O
adherence	O
of	O
<	O
70	O
%	O
into	O
the	O
low	O
adherence	O
group	O
(	O
LAG	O
)	O
.	O

AKI	B
was	O
defined	O
according	O
to	O
RIFLE	O
criteria	O
.	O

Adherence	O
to	O
SOPs	O
was	O
evaluated	O
by	O
retrospective	O
expert	O
audit	O
.	O

Development	O
of	O
AKI	B
was	O
compared	O
between	O
groups	O
with	O
exact	O
Chi2-test	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0.05	O
)	O
.	O

RESULTS	O
:	O
LAG	O
consisted	O
of	O
75	O
patients	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
patients	O
(	O
54	O
%	O
)	O
.	O

AKI	B
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0.035	O
)	O
.	O

Basic	O
characteristics	O
were	O
comparable	O
,	O
except	O
an	O
increased	O
rate	O
of	O
soft	O
tissue	O
infections	B
in	O
LAG	O
.	O

Multivariate	O
analysis	O
revealed	O
an	O
odds	O
ratio	O
of	O
2.5-fold	O
for	O
LAG	O
to	O
develop	O
AKI	B
compared	O
with	O
HAG	O
(	O
95	O
%	O
confidence	O
interval	O
1.195	O
to	O
5.124	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	B
antibiotics	O
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
AKI	B
.	O

TRIAL	O
REGISTRATION	O
:	O
Current	O
Controlled	O
Trials	O
ISRCTN54598675	O
.	O

Registered	O
17	O
August	O
2007	O
.	O

Rhabdomyolysis	B
in	O
a	O
hepatitis	B
C	I
virus	I
infected	I
patient	O
treated	O
with	O
telaprevir	O
and	O
simvastatin	O
.	O

A	O
46-year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B
C	I
virus	I
infection	I
received	O
triple	O
therapy	O
with	O
ribavirin	O
,	O
pegylated	O
interferon	O
and	O
telaprevir	O
.	O

The	O
patient	O
also	O
received	O
simvastatin	O
.	O

One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B
.	O

At	O
admission	O
simvastatin	O
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	B
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O

The	O
creatine	O
kinase	O
peaked	O
at	O
62,246	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O

The	O
patient	O
's	O
renal	O
function	O
remained	O
unaffected	O
.	O

Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	O
kinase	O
level	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
discharged	O
.	O

Telaprevir	O
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	O
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O

The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4-mediated	O
simvastatin	O
clearance	O
.	O

Simvastatin	O
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	O
induced	O
muscle	B
toxicity	I
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	O
in	O
blood	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	O
as	O
well	O
as	O
statins	O
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug	O
-	O
drug	O
interactions	O
.	O

Combination	O
of	O
bortezomib	O
,	O
thalidomide	O
,	O
and	O
dexamethasone	O
(	O
VTD	O
)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	B
myeloma	I
in	O
Japanese	O
patients	O
.	O

Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	B
myeloma	I
(	O
MM	B
)	O
has	O
been	O
widely	O
adopted	O
to	O
improve	O
treatment	O
response	O
following	O
autologous	O
stem	O
cell	O
transplantation	O
.	O

In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	O
,	O
thalidomide	O
,	O
and	O
dexamethasone	O
(	O
VTD	O
)	O
as	O
consolidation	O
therapy	O
in	O
24	O
Japanese	O
patients	O
with	O
newly	O
diagnosed	O
MM	B
.	O

VTD	O
consisted	O
of	O
bortezomib	O
at	O
a	O
dose	O
of	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	O
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
day	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35-day	O
cycle	O
,	O
with	O
daily	O
oral	O
thalidomide	O
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
day	O
.	O

Grade	O
3	O
-	O
4	O
neutropenia	B
and	O
thrombocytopenia	B
were	O
documented	O
in	O
four	O
and	O
three	O
patients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
drug	O
dose	O
reduction	O
due	O
to	O
cytopenia	B
was	O
not	O
required	O
in	O
any	O
case	O
.	O

Peripheral	B
neuropathy	I
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
severe	O
grade	O
3	O
-	O
4	O
peripheral	B
neuropathy	I
was	O
not	O
observed	O
.	O

Very	O
good	O
partial	O
response	O
or	O
better	O
response	O
(	O
>	O
VGPR	O
)	O
rates	O
before	O
and	O
after	O
consolidation	O
therapy	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Patients	O
had	O
a	O
significant	O
probability	O
of	O
improving	O
from	O
<	O
VGPR	O
before	O
consolidation	O
therapy	O
to	O
>	O
VGPR	O
after	O
consolidation	O
therapy	O
(	O
p	O
=	O
0.041	O
)	O
.	O

The	O
VTD	O
regimen	O
may	O
be	O
safe	O
and	O
effective	O
as	O
a	O
consolidation	O
therapy	O
in	O
the	O
treatment	O
of	O
MM	O
in	O
Japanese	O
population	O
.	O

Conversion	O
to	O
sirolimus	O
ameliorates	O
cyclosporine	O
-	O
induced	O
nephropathy	B
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
,	O
urine	O
,	O
gene	O
,	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O

Protocols	O
of	O
conversion	O
from	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
to	O
sirolimus	O
(	O
SRL	O
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	O
-	O
induced	O
nephropathy	B
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	O
-	O
to	O
-	O
SRL	O
conversion	O
in	O
a	O
rat	O
model	O
.	O

Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	O
,	O
SRL	O
,	O
and	O
conversion	O
(	O
CsA	O
for	O
3	O
weeks	O
followed	O
by	O
SRL	O
for	O
6	O
weeks	O
)	O
.	O

Classical	O
and	O
emergent	O
serum	O
,	O
urinary	O
,	O
and	O
kidney	O
tissue	O
(	O
gene	O
and	O
protein	O
expression	O
)	O
markers	O
were	O
assessed	O
.	O

Renal	B
lesions	I
were	O
analyzed	O
in	O
hematoxylin	O
and	O
eosin	O
,	O
periodic	O
acid	O
-	O
Schiff	O
,	O
and	O
Masson	O
's	O
trichrome	O
stains	O
.	O

SRL	O
-	O
treated	O
rats	O
presented	O
proteinuria	B
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B
impairment	I
.	O

Short	O
CsA	O
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B
lesions	I
and	O
TGF	O
-	O
b	O
,	O
NF-	O
kb	O
,	O
mTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM-1	O
,	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O

Prolonged	O
CsA	O
exposure	O
aggravated	O
renal	B
damage	I
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF-	O
b	O
and	O
IL-7	O
,	O
TBARs	O
clearance	O
,	O
and	O
kidney	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O

Conversion	O
to	O
SRL	O
prevented	O
CsA	O
-	O
induced	O
renal	B
damage	I
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
)	O
,	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	O
replacement	O
to	O
SRL	O
.	O

Kinin	O
B2	O
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin	O
-	O
induced	O
acute	B
renal	I
injury	I
.	O

Cisplatin	O
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies	O
;	O
however	O
,	O
this	O
drug	O
can	O
induce	O
acute	B
kidney	I
injury	I
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	O
function	O
,	O
augment	O
serum	O
levels	O
of	O
creatinine	O
and	O
urea	O
,	O
increase	O
the	O
acute	B
tubular	I
necrosis	I
score	O
and	O
up	O
-	O
regulate	O
cytokines	O
(	O
e.g.	O
,	O
IL-1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	B
process	O
,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression	O
,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	B
nephropathy	I
status	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin	O
-	O
induced	O
acute	B
kidney	I
injury	I
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	O
.	O

Additionally	O
,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	O
administration	O
.	O

B2	O
receptor	O
-	O
deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice	O
,	O
as	O
shown	O
by	O
reduced	O
weight	B
loss	I
,	O
better	O
preservation	O
of	O
kidney	O
function	O
,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	O
and	O
less	O
acute	B
tubular	I
necrosis	I
.	O

Moreover	O
,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	O
and	O
blood	O
urea	O
after	O
cisplatin	O
administration	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin	O
-	O
induced	O
acute	B
kidney	I
injury	I
by	O
mediating	O
the	O
necrotic	B
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
,	O
thus	O
resulting	O
in	O
declined	O
renal	O
function	O
.	O

These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	B
induced	O
by	O
cisplatin	O
therapy	O
.	O

Safety	O
and	O
efficacy	O
of	O
fluocinolone	O
acetonide	O
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
birdshot	B
retinochoroidopathy	I
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	O
acetonide	O
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
patients	O
with	O
birdshot	B
retinochoroidopathy	I
whose	O
disease	O
is	O
refractory	O
or	O
intolerant	O
to	O
conventional	O
immunomodulatory	O
therapy	O
.	O

METHODS	O
:	O
A	O
retrospective	O
case	O
series	O
involving	O
11	O
birdshot	B
retinochoroidopathy	I
patients	O
(	O
11	O
eyes	O
)	O
.	O

Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
underwent	O
surgery	O
for	O
fluocinolone	O
acetonide	O
implant	O
(	O
0.59	O
mg	O
)	O
.	O

Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	O
baseline	O
,	O
before	O
fluocinolone	O
acetonide	O
implant	O
,	O
and	O
then	O
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
.	O

Disease	O
activity	O
markers	O
,	O
including	O
signs	O
of	O
ocular	O
inflammation	B
,	O
evidence	O
of	O
retinal	B
vasculitis	I
,	O
Swedish	O
interactive	O
threshold	O
algorithm	O
-	O
short	O
wavelength	O
automated	O
perimetry	O
Humphrey	O
visual	O
field	O
analysis	O
,	O
electroretinographic	O
parameters	O
,	O
and	O
optical	O
coherence	O
tomography	O
were	O
recorded	O
.	O

Data	O
on	O
occurrence	O
of	O
cataract	B
and	O
raised	B
intraocular	I
pressure	I
were	O
collected	O
in	O
all	O
eyes	O
.	O

RESULTS	O
:	O
Intraocular	O
inflammation	B
was	O
present	O
in	O
54.5	O
,	O
9.9	O
,	O
11.1	O
,	O
and	O
0	O
%	O
of	O
patients	O
at	O
baseline	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
after	O
receiving	O
the	O
implant	O
,	O
respectively	O
.	O

Active	O
vasculitis	B
was	O
noted	O
in	O
36.3	O
%	O
patients	O
at	O
baseline	O
and	O
0	O
%	O
at	O
3	O
years	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20	O
%	O
(	O
47.61	O
-	O
67.2	O
%	O
)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	B
macular	I
edema	I
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
.	O

At	O
baseline	O
,	O
54.5	O
%	O
patients	O
were	O
on	O
immunomodulatory	O
agents	O
.	O

This	O
percentage	O
decreased	O
to	O
45.45	O
,	O
44.4	O
,	O
and	O
14.28	O
%	O
at	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
,	O
respectively	O
.	O

Adverse	O
events	O
included	O
increased	B
intraocular	I
pressure	I
(	O
54.5	O
%	O
)	O
and	O
cataract	B
formation	O
(	O
100	O
%	O
)	O
.	O

CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
fluocinolone	O
acetonide	O
implant	O
(	O
0.59	O
mg	O
)	O
helps	O
to	O
control	O
inflammation	B
in	O
otherwise	O
treatment	O
-	O
refractory	O
cases	O
of	O
birdshot	B
retinochoroidopathy	I
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	B
and	O
ocular	B
hypertension	I
requiring	O
treatment	O
.	O

Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	O
to	O
decrease	O
fasciculation	B
and	O
myalgia	B
following	O
succinylcholine	O
administration	O
.	O

BACKGROUND	O
:	O
Succinylcholine	O
commonly	O
produces	O
frequent	O
adverse	O
effects	O
,	O
including	O
muscle	B
fasciculation	I
and	O
myalgia	B
.	O

The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	O
to	O
prevent	O
succinylcholine	O
-	O
induced	O
fasciculation	B
and	O
myalgia	B
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	O
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blinded	O
study	O
was	O
conducted	O
in	O
100	O
patients	O
randomly	O
allocated	O
into	O
five	O
groups	O
of	O
20	O
patients	O
each	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
0.02	O
,	O
0.03	O
,	O
0.04	O
,	O
0.05	O
and	O
0.06	O
mg	O
/	O
kg	O
rocuronium	O
as	O
a	O
precurarizing	O
dose	O
.	O

Neuromuscular	O
monitoring	O
after	O
each	O
precurarizing	O
dose	O
was	O
recorded	O
from	O
the	O
adductor	O
pollicis	O
muscle	O
using	O
acceleromyography	O
with	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
of	O
the	O
ulnar	O
nerve	O
.	O

All	O
patients	O
received	O
succinylcholine	O
1.5	O
mg	O
/	O
kg	O
at	O
2	O
minutes	O
after	O
the	O
precurarization	O
,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	B
,	O
while	O
myalgia	B
was	O
assessed	O
at	O
24	O
hours	O
after	O
surgery	O
.	O

RESULTS	O
:	O
The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	B
fasciculation	I
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Those	O
of	O
myalgia	B
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	O
,	O
but	O
there	O
was	O
no	O
significance	O
(	O
P	O
=	O
0.072	O
)	O
.	O

The	O
onset	O
time	O
of	O
succinylcholine	O
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Precurarization	O
with	O
0.04	O
mg	O
/	O
kg	O
rocuronium	O
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	B
and	O
myalgia	B
with	O
acceptable	O
onset	O
time	O
,	O
and	O
the	O
safe	O
and	O
effective	O
precurarization	O
.	O

Absence	O
of	O
PKC	O
-	O
alpha	O
attenuates	O
lithium	O
-	O
induced	O
nephrogenic	B
diabetes	I
insipidus	I
.	O

Lithium	O
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B
diabetes	I
insipidus	I
(	O
NDI	B
)	O
in	O
40	O
%	O
of	O
patients	O
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	O
acutely	O
disrupting	O
the	O
cAMP	O
pathway	O
and	O
chronically	O
reducing	O
urea	O
transporter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
water	O
channel	O
(	O
AQP2	O
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	O
-	O
induced	O
polyuria	B
.	O

PKC	O
-	O
alpha	O
null	O
mice	O
(	O
PKCa	O
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	O
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

WT	O
mice	O
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	O
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	O
;	O
however	O
,	O
AQP2	O
was	O
unchanged	O
in	O
PKCa	O
KO	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
expression	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	O
for	O
6	O
weeks	O
.	O

Lithium	O
-	O
treated	O
WT	O
mice	O
had	O
19-fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4-fold	O
increase	O
in	O
output	O
.	O

AQP2	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	O
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice	O
,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2-fold	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	O
,	O
potassium	O
and	O
calcium	O
were	O
elevated	O
in	O
lithium	O
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	O
-	O
fed	O
PKCa	O
KO	O
mice	O
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	O
-	O
induced	O
NDI	B
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B
associated	O
with	O
lithium	O
therapy	O
.	O

Is	O
Dysguesia	B
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side	O
-	O
effect	O
of	O
Amlodipine	O
?	O

A	O
very	O
rare	O
side	O
-	O
effect	O
of	O
amlodipine	O
is	O
dysguesia	B
.	O

A	O
review	O
of	O
the	O
literature	O
produced	O
only	O
one	O
case	O
.	O

We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	O
hypertension	B
on	O
drug	O
treatment	O
with	O
amlodipine	O
developed	O
loss	B
of	I
taste	I
sensation	I
.	O

Condition	O
moderately	O
improved	O
on	O
stoppage	O
of	O
the	O
drug	O
for	O
25	O
days	O
.	O

We	O
conclude	O
that	O
amlodipine	O
can	O
cause	O
dysguesia	B
.	O

Here	O
,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	O
and	O
dysguesia	B
.	O

Rhabdomyolysis	B
in	O
association	O
with	O
simvastatin	O
and	O
dosage	O
increment	O
in	O
clarithromycin	O
.	O

Clarithromycin	O
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	O
.	O

This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	B
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	O
.	O

The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	O
without	O
any	O
obvious	O
cardiac	O
issues	O
,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	B
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	B
on	O
the	O
structure	O
and	O
function	O
of	O
cardiac	O
muscle	O
.	O

Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	B
or	O
inhibit	O
the	O
CYP3A4	O
enzyme	O
.	O

Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	O
induced	O
rhabdomyolysis	B
,	O
which	O
may	O
warrant	O
further	O
studies	O
.	O

Characterization	O
of	O
a	O
novel	O
BCHE	O
""""	O
silent	O
""""	O
allele	O
:	O
point	O
mutation	O
(	O
p.	O

Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B
with	O
suxamethonium	O
.	O

Butyrylcholinesterase	B
deficiency	I
is	O
characterized	O
by	O
prolonged	O
apnea	B
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	O
or	O
mivacurium	O
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	O
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(	O
c.695T	O
>	O
A	O
,	O
p.	O

Val204Asp	O
)	O
.	O

Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
""""	O
silent	O
""""	O
phenotype	O
.	O

Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	O
(	O
BTC	O
)	O
and	O
benzoylcholine	O
,	O
and	O
values	O
of	O
dibucaine	O
and	O
fluoride	O
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O

Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	O
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	O
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	O
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
p.	O

Val204Asp	O
/	O
p	O
.	O

Asp70Gly	O
-	O
p	O
.	O

Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	O
as	O
the	O
substrate	O
.	O

Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	O
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	O
.	O

Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p.	O

Val204Asp	O
is	O
disruption	O
of	O
hydrogen	O
bonding	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p.	O

Ala204Asp	O
/	O
p	O
.	O

Asp70Gly	O
-	O
p	O
.	O

Ala539Thr	O
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O

Delayed	O
anemia	B
after	O
treatment	O
with	O
injectable	O
artesunate	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
:	O
a	O
manageable	O
issue	O
.	O

Cases	O
of	O
delayed	O
hemolytic	B
anemia	I
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	O
,	O
the	O
current	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
-recommended	O
first	O
-	O
line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	B
.	O

A	O
total	O
of	O
350	O
patients	O
(	O
215	O
[	O
61.4	O
%	O
]	O
<	O
5	O
years	O
of	O
age	O
and	O
135	O
[	O
38.6	O
%	O
]	O
>	O
5	O
years	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatment	O
with	O
injectable	O
artesunate	O
for	O
severe	O
malaria	B
in	O
hospitals	O
and	O
health	O
centers	O
of	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

Complete	O
series	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
measurements	O
were	O
available	O
for	O
201	O
patients	O
.	O

A	O
decrease	O
in	O
Hb	O
levels	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detected	O
in	O
23	O
(	O
11.4	O
%	O
)	O
patients	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

For	O
five	O
patients	O
,	O
Hb	O
levels	O
decreased	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
visit	O
.	O

All	O
cases	O
of	O
delayed	O
anemia	B
were	O
clinically	O
manageable	O
and	O
resolved	O
within	O
one	O
month	O
.	O

Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	O
attenuates	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	B
injury	I
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	O
on	O
acute	O
myocardial	B
ischemia	I
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O

Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	O
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
days	O
.	O

Acute	O
myocardial	B
ischemic	I
injury	I
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	O
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consecutive	O
days	O
.	O

Serum	O
cardiac	O
marker	O
enzyme	O
,	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed	O
.	O

Oral	O
administration	O
of	O
betaine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B
remodeling	I
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	O
-	O
induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	O
treatment	O
in	O
myocardium	O
.	O

Furthermore	O
,	O
betaine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl-2	O
and	O
reduced	O
the	O
level	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl-2	O
/	O
Bax	O
.	O

The	O
protective	O
role	O
of	O
betaine	O
on	O
myocardial	B
damage	I
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	O
pretreatment	O
attenuated	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	B
ischemia	I
via	O
the	O
regulation	O
of	O
STAT3	O
and	O
apoptotic	O
pathways	O
.	O

Quetiapine	O
-	O
induced	O
neutropenia	B
in	O
a	O
bipolar	B
patient	O
with	O
hepatocellular	B
carcinoma	I
.	O

OBJECTIVE	O
:	O
Quetiapine	O
is	O
a	O
dibenzothiazepine	O
derivative	O
,	O
similar	O
to	O
clozapine	O
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	B
dyscrasias	I
,	O
especially	O
neutropenia	B
.	O

There	O
are	O
some	O
case	O
reports	O
about	O
this	O
side	O
effect	O
of	O
quetiapine	O
,	O
but	O
possible	O
risk	O
factors	O
are	O
seldom	O
discussed	O
and	O
identified	O
.	O

A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	B
carcinoma	I
that	O
developed	O
neutropenia	B
after	O
treatment	O
with	O
quetiapine	O
is	O
described	O
here	O
.	O

CASE	O
REPORT	O
:	O
A	O
62-year	O
-	O
old	O
Taiwanese	O
widow	O
with	O
bipolar	B
disorder	I
was	O
diagnosed	O
with	O
hepatocellular	B
carcinoma	I
at	O
age	O
60	O
.	O

She	O
developed	O
leucopenia	B
after	O
being	O
treated	O
with	O
quetiapine	O
.	O

After	O
quetiapine	O
was	O
discontinued	O
,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal	O
.	O

CONCLUSIONS	O
:	O
Although	O
neutropenia	B
is	O
not	O
a	O
common	O
side	O
effect	O
of	O
quetiapine	O
,	O
physicians	O
should	O
be	O
cautious	O
about	O
its	O
presentation	O
and	O
associated	O
risk	O
factors	O
.	O

Hepatic	B
dysfunction	I
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors	O
,	O
and	O
concomitant	O
fever	B
may	O
be	O
a	O
diagnostic	O
marker	O
for	O
adverse	O
reaction	O
to	O
quetiapine	O
.	O

Lateral	O
antebrachial	O
cutaneous	O
neuropathy	B
after	O
steroid	O
injection	O
at	O
lateral	O
epicondyle	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	B
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
steroid	O
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	B
epicondylitis	I
in	O
a	O
40-year	O
-	O
old	O
woman	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40-year	O
-	O
old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	B
over	O
her	O
right	O
lateral	O
forearm	O
;	O
the	O
paresthesia	B
had	O
occurred	O
after	O
a	O
steroid	O
injection	O
in	O
the	O
right	O
lateral	O
epicondyle	O
3	O
months	O
before	O
.	O

Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	B
was	O
diminished	O
over	O
the	O
lateral	O
side	O
of	O
the	O
right	O
forearm	O
and	O
wrist	O
area	O
.	O

RESULTS	O
:	O
The	O
sensory	O
action	O
potential	O
amplitude	O
of	O
the	O
right	O
lateral	O
antebrachial	O
cutaneous	O
nerve	O
(	O
LACN	O
)	O
(	O
6.2	O
uV	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
left	O
(	O
13.1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
amplitude	O
between	O
both	O
sides	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reduction	O
.	O

She	O
was	O
diagnosed	O
with	O
right	O
LACNP	O
(	O
mainly	O
axonal	O
involvement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
manifestation	O
and	O
the	O
electrodiagnostic	O
findings	O
.	O

Her	O
symptoms	O
improved	O
through	O
physical	O
therapy	O
but	O
persisted	O
to	O
some	O
degree	O
.	O

CONCLUSION	O
:	O
This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	O
injection	O
for	O
the	O
treatment	O
of	O
lateral	B
epicondylitis	I
.	O

An	O
electrodiagnostic	O
study	O
,	O
including	O
a	O
nerve	O
conduction	O
study	O
of	O
the	O
LACN	O
,	O
was	O
helpful	O
to	O
diagnose	O
right	O
LACNP	O
and	O
to	O
find	O
the	O
passage	O
of	O
the	O
LACN	O
on	O
the	O
lateral	O
epicondyle	O
.	O

Curcumin	O
prevents	O
maleate	O
-	O
induced	O
nephrotoxicity	B
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	O
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I.	O
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	O
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B
injury	I
induced	O
by	O
maleate	O
was	O
evaluated	O
.	O

Tubular	O
proteinuria	B
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	O
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O

Maleate	O
-	O
induced	O
renal	B
injury	I
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	O
,	O
sodium	O
,	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acetyl	O
b	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
,	O
upregulation	O
of	O
kidney	B
injury	I
molecule	O
(	O
KIM	O
)	O
-1	O
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin-2	O
expression	O
besides	O
of	O
necrosis	B
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels	O
.	O

Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O

Maleate	O
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
in	O
LLC	O
-	O
PK1	O
cells	O
in	O
culture	O
.	O

In	O
addition	O
,	O
maleate	O
treatment	O
reduced	O
oxygen	O
consumption	O
in	O
ADP	O
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	O
/	O
glutamate	O
as	O
substrate	O
.	O

The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	O
.	O

It	O
is	O
concluded	O
that	O
curcumin	O
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	O
-	O
induced	O
nephropathy	B
and	O
in	O
vitro	O
cell	O
damage	O
.	O

The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	O
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	O
production	O
.	O

Anticonvulsant	O
actions	O
of	O
MK-801	O
on	O
the	O
lithium	O
-	O
pilocarpine	O
model	O
of	O
status	B
epilepticus	I
in	O
rats	O
.	O

MK-801	O
,	O
a	O
noncompetitive	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	B
models	O
,	O
coadministration	O
of	O
lithium	O
and	O
pilocarpine	O
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	O
alone	O
.	O

Three	O
major	O
results	O
are	O
reported	O
.	O

First	O
,	O
pretreatment	O
with	O
MK-801	O
produced	O
an	O
effective	O
and	O
dose	O
-	O
dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium	O
-	O
pilocarpine	O
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	O
alone	O
,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	B
in	O
these	O
two	O
models	O
.	O

Second	O
,	O
the	O
anticonvulsant	O
effect	O
of	O
MK-801	O
in	O
the	O
lithium	O
-	O
pilocarpine	O
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	B
activity	O
.	O

This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK-801	O
binding	O
requires	O
agonist	O
-	O
induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	O
receptor	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	B
induced	O
by	O
lithium	O
and	O
pilocarpine	O
by	O
administration	O
of	O
anticonvulsants	O
prior	O
to	O
pilocarpine	O
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	B
epilepticus	I
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	B
.	O

Administration	O
of	O
MK-801	O
30	O
or	O
60	O
min	O
after	O
pilocarpine	O
,	O
i.e.	O
,	O
during	O
status	B
epilepticus	I
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	B
activity	O
and	O
greatly	O
enhanced	O
the	O
survival	O
rate	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	O
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	B
epilepticus	I
and	O
brain	B
damage	I
in	O
the	O
lithium	O
-	O
pilocarpine	O
model	O
.	O

This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	O
and	O
pilocarpine	O
were	O
synergistic	O
,	O
resulting	O
in	O
status	B
epilepticus	I
and	O
subsequent	O
mortality	O
.	O

Continuous	O
infusion	O
tobramycin	O
combined	O
with	O
carbenicillin	O
for	O
infections	B
in	O
cancer	B
patients	O
.	O

The	O
cure	O
rate	O
of	O
infections	B
in	O
cancer	B
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	B
(	O
less	O
than	O
1,000	O
/	O
mm3	O
)	O
.	O

In	O
particular	O
,	O
patients	O
with	O
severe	O
neutropenia	B
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
poor	O
response	O
to	O
antibiotics	O
.	O

To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	B
,	O
tobramycin	O
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	O
.	O

Tobramycin	O
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenicillin	O
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	B
patients	O
receiving	O
myelosuppressive	O
chemotherapy	O
.	O

The	O
overall	O
cure	O
rate	O
was	O
70	O
%	O
.	O

Pneumonia	B
was	O
the	O
most	O
common	O
infection	B
and	O
61	O
%	O
of	O
59	O
episodes	O
were	O
cured	O
.	O

Gram	O
-	O
negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69	O
%	O
of	O
these	O
infections	B
were	O
cured	O
.	O

The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	B
and	O
this	O
,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
gram	B
-	I
negative	I
bacillary	I
infections	I
.	O

Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62	O
%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	B
.	O

However	O
,	O
failure	O
of	O
the	O
neutrophil	O
count	O
to	O
increase	O
during	O
therapy	O
adversely	O
affected	O
response	O
.	O

Azotemia	B
was	O
the	O
major	O
side	O
effect	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
episodes	O
.	O

Major	O
azotemia	B
(	O
serum	O
creatinine	O
greater	O
than	O
2.5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azotemia	B
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	O
concentration	O
.	O

This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	B
toxicity	I
for	O
these	O
patients	O
.	O

Incidence	O
of	O
solid	O
tumours	B
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	O
insecticide	O
diazinon	O
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
an	O
updated	O
analysis	O
.	O

OBJECTIVE	O
:	O
Diazinon	O
,	O
a	O
common	O
organophosphate	O
insecticide	O
with	O
genotoxic	O
properties	O
,	O
was	O
previously	O
associated	O
with	O
lung	B
cancer	I
in	O
the	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
cohort	O
,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon	O
-	O
associated	O
cancer	B
risk	O
.	O

We	O
used	O
updated	O
diazinon	O
exposure	O
and	O
cancer	B
incidence	O
information	O
to	O
evaluate	O
solid	O
tumour	B
risk	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	O
use	O
at	O
enrolment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cancer	B
incidence	O
was	O
assessed	O
through	O
2010	O
(	O
North	O
Carolina	O
)	O
/	O
2011	O
(	O
Iowa	O
)	O
.	O

Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure	O
-	O
response	O
patterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cancer	B
sites	O
with	O
>	O
10	O
exposed	O
cases	O
for	O
both	O
lifetime	O
(	O
LT	O
)	O
exposure	O
days	O
and	O
intensity	O
-	O
weighted	O
(	O
IW	O
)	O
lifetime	O
exposure	O
days	O
(	O
accounting	O
for	O
factors	O
impacting	O
exposure	O
)	O
.	O

RESULTS	O
:	O
We	O
observed	O
elevated	O
lung	B
cancer	I
risks	O
(	O
N=283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR=1.60	O
;	O
95	O
%	O
CI	O
1.11	O
to	O
2.31	O
;	O
Ptrend=0.02	O
)	O
and	O
IW	O
days	O
of	O
diazinon	O
use	O
(	O
RR=1.41	O
;	O
95	O
%	O
CI	O
0.98	O
to	O
2.04	O
;	O
Ptrend=0.08	O
)	O
.	O

Kidney	B
cancer	I
(	O
N=94	O
)	O
risks	O
were	O
non	O
-	O
significantly	O
elevated	O
(	O
RRLT	O
days=1.77	O
;	O
95	O
%	O
CI	O
0.90	O
to	O
3.51	O
;	O
Ptrend=0.09	O
;	O
RRIW	O
days	O
1.37	O
;	O
95	O
%	O
CI	O
0.64	O
to	O
2.92	O
;	O
Ptrend=0.50	O
)	O
,	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	B
cancer	I
(	O
N=656	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
updated	O
evaluation	O
of	O
diazinon	O
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	B
cancer	I
risk	O
.	O

Newly	O
identified	O
links	O
to	O
kidney	B
cancer	I
and	O
associations	O
with	O
aggressive	O
prostate	B
cancer	I
require	O
further	O
evaluation	O
.	O

Associations	O
of	O
Ozone	O
and	O
PM2.5	O
Concentrations	O
With	O
Parkinson	B
's	I
Disease	I
Among	O
Participants	O
in	O
the	O
Agricultural	O
Health	O
Study	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
describes	O
associations	O
of	O
ozone	O
and	O
fine	O
particulate	O
matter	O
with	O
Parkinson	B
's	I
disease	I
observed	O
among	O
farmers	O
in	O
North	O
Carolina	O
and	O
Iowa	O
.	O

METHODS	O
:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self	O
-	O
reported	O
,	O
doctor	O
-	O
diagnosed	O
Parkinson	B
's	I
disease	I
.	O

Daily	O
predicted	O
pollutant	O
concentrations	O
were	O
used	O
to	O
derive	O
surrogates	O
of	O
long	O
-	O
term	O
exposure	O
and	O
link	O
them	O
to	O
study	O
participants	O
'	O
geocoded	O
addresses	O
.	O

RESULTS	O
:	O
We	O
observed	O
positive	O
associations	O
of	O
Parkinson	B
's	I
disease	I
with	O
ozone	O
(	O
odds	O
ratio	O
=	O
1.39	O
;	O
95	O
%	O
CI	O
:	O
0.98	O
to	O
1.98	O
)	O
and	O
fine	O
particulate	O
matter	O
(	O
odds	O
ratio	O
=	O
1.34	O
;	O
95	O
%	O
CI	O
:	O
0.93	O
to	O
1.93	O
)	O
in	O
North	O
Carolina	O
but	O
not	O
in	O
Iowa	O
.	O

CONCLUSIONS	O
:	O
The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson	B
's	I
disease	I
risk	O
is	O
supported	O
by	O
experimental	O
data	O
demonstrating	O
damage	O
to	O
dopaminergic	O
neurons	O
at	O
relevant	O
concentrations	O
.	O

Additional	O
studies	O
are	O
needed	O
to	O
address	O
uncertainties	O
related	O
to	O
confounding	O
and	O
to	O
examine	O
temporal	O
aspects	O
of	O
the	O
associations	O
we	O
observed	O
.	O

Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	O
exposure	O
.	O

UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	O
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B
growth	I
retardation	I
(	O
IUGR	B
)	O
of	O
offspring	O
.	O

Recent	O
research	O
suggested	O
that	O
IUGR	B
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B
.	O

However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O

A	O
rat	O
model	O
of	O
IUGR	B
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O

The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B
as	O
well	O
as	O
interstitial	B
fibrosis	I
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	O
and	O
urine	O
protein	O
.	O

Renal	O
angiotensin	O
II	O
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	O
angiotensin	O
II	O
receptor	O
type	O
1a	O
(	O
AT1aR	O
)	O
/	O
AT2R	O
expression	O
ratio	O
was	O
increased	O
.	O

The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman	O
's	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft	O
,	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone	O
/	O
cortical	O
zone	O
ratio	O
.	O

Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes	O
;	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes	O
,	O
nephrin	O
and	O
podocin	O
,	O
was	O
also	O
detected	O
by	O
q	O
-	O
PCR	O
.	O

Moreover	O
,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	O
-	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
/	O
tyrosine	O
kinase	O
receptor	O
(	O
c	O
-	O
Ret	O
)	O
signaling	O
pathway	O
.	O

These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B
of	I
fetal	I
kidneys	I
as	O
well	O
as	O
glomerulosclerosis	B
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B
.	O

1,3-Butadiene	O
,	O
CML	B
and	O
the	O
t	O
(	O
9:22	O
)	O
translocation	O
:	O
A	O
reality	O
check	O
.	O

UNASSIGNED	O
:	O
Epidemiological	O
studies	O
of	O
1,3-butadiene	O
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	B
myeloid	I
leukemia	I
(	O
CML	B
)	O
.	O

CML	B
has	O
a	O
well	O
-	O
documented	O
association	O
with	O
ionizing	O
radiation	O
,	O
but	O
reports	O
of	O
associations	O
with	O
chemical	O
exposures	O
have	O
been	O
questioned	O
.	O

Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML	B
-	O
associated	O
t	O
(	O
9:22	O
)	O
translocation	O
(	O
Philadelphia	B
chromosome	I
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemicals	O
have	O
not	O
shown	O
this	O
capacity	O
.	O

We	O
have	O
proposed	O
that	O
1,3-butadiene	O
metabolites	O
be	O
so	O
tested	O
as	O
a	O
reality	O
check	O
on	O
the	O
epidemiological	O
reports	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
testing	O
in	O
this	O
regard	O
,	O
it	O
is	O
essential	O
that	O
a	O
positive	O
control	O
for	O
induction	O
be	O
available	O
.	O

We	O
have	O
used	O
ionizing	O
radiation	O
to	O
develop	O
such	O
a	O
control	O
.	O

Results	O
described	O
here	O
demonstrate	O
that	O
this	O
agent	O
does	O
in	O
fact	O
induce	O
pathogenic	O
t	O
(	O
9:22	O
)	O
translocations	O
in	O
a	O
human	O
myeloid	O
cell	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
low	O
frequencies	O
.	O

Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1,3-butadiene	O
are	O
discussed	O
.	O

Cancer	B
incidence	O
and	O
metolachlor	O
use	O
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
An	O
update	O
.	O

UNASSIGNED	O
:	O
Metolachlor	O
,	O
a	O
widely	O
used	O
herbicide	O
,	O
is	O
classified	O
as	O
a	O
Group	O
C	O
carcinogen	O
by	O
the	O
U.S.	O
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	B
neoplasms	I
in	O
female	O
rats	O
.	O

Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	O
have	O
been	O
limited	O
.	O

The	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
is	O
a	O
prospective	O
cohort	O
study	O
including	O
licensed	O
private	O
and	O
commercial	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evaluated	O
cancer	B
incidence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49,616	O
applicators	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	O
.	O

We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	O
use	O
(	O
lifetime	O
days	O
,	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
)	O
and	O
cancer	B
incidence	O
.	O

We	O
saw	O
no	O
association	O
between	O
metolachlor	O
use	O
and	O
incidence	O
of	O
all	O
cancers	B
combined	O
(	O
n	O
=	O
5,701	O
with	O
a	O
5-year	O
lag	O
)	O
or	O
most	O
site	O
-	O
specific	O
cancers	B
.	O

For	O
liver	B
cancer	I
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers	O
,	O
elevations	O
observed	O
at	O
higher	O
categories	O
of	O
use	O
were	O
not	O
statistically	O
significant	O
.	O

However	O
,	O
trends	O
for	O
both	O
lifetime	O
and	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
of	O
metolachor	O
use	O
were	O
positive	O
and	O
statistically	O
significant	O
with	O
an	O
unexposed	O
reference	O
group	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	B
cell	I
lymphoma	I
,	O
but	O
no	O
other	O
lymphoma	B
subtypes	O
.	O

An	O
earlier	O
suggestion	O
of	O
increased	O
lung	B
cancer	I
risk	O
at	O
high	O
levels	O
of	O
metolachlor	O
use	O
in	O
this	O
cohort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	O
and	O
liver	B
cancer	I
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	B
neoplasms	I
in	O
some	O
animal	O
studies	O
.	O

However	O
,	O
our	O
findings	O
for	O
both	O
liver	B
cancer	I
and	O
follicular	O
cell	O
lymphoma	B
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	O
use	O
from	O
other	O
factors	O
.	O

Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	O
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O

BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	O
arsenic	O
(	O
iAs	O
)	O
in	O
their	O
drinking	O
water	O
.	O

Inorganic	O
As	O
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	O
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	O
exposure	O
.	O

DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	O
exposure	O
elicits	O
latent	O
carcinogenic	O
effects	O
.	O

CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	O
exposure	O
and	O
cancer	B
development	O
later	O
in	O
life	O
.	O

Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	O
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O

Nifedipine	O
induced	O
bradycardia	B
in	O
a	O
patient	O
with	O
autonomic	B
neuropathy	I
.	O

An	O
80	O
year	O
old	O
diabetic	B
male	O
with	O
evidence	O
of	O
peripheral	B
and	I
autonomic	I
neuropathy	I
was	O
admitted	O
with	O
chest	B
pain	I
.	O

He	O
was	O
found	O
to	O
have	O
atrial	B
flutter	I
at	O
a	O
ventricular	O
rate	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifedipine	O
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doses	O
,	O
during	O
which	O
he	O
was	O
paced	O
at	O
a	O
rate	O
of	O
70	O
/	O
min	O
.	O

This	O
is	O
inconsistent	O
with	O
the	O
well	O
-	O
established	O
finding	O
that	O
nifedipine	O
induces	O
tachycardia	B
in	O
normally	O
innervated	O
hearts	O
.	O

However	O
,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycardia	B
.	O

The	O
effect	O
of	O
haloperidol	O
in	O
cocaine	O
and	O
amphetamine	O
intoxication	O
.	O

The	O
effectiveness	O
of	O
haloperidol	O
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	O
and	O
cocaine	O
was	O
studied	O
in	O
rats	O
.	O

In	O
this	O
model	O
,	O
toxic	O
effects	O
were	O
induced	O
by	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
of	O
amphetamine	O
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
death	O
rate	O
)	O
or	O
cocaine	O
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
death	O
rate	O
)	O
.	O

Haloperidol	O
failed	O
to	O
prevent	O
amphetamine	O
-	O
induced	O
seizures	B
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	O
most	O
doses	O
tested	O
.	O

Haloperidol	O
decreased	O
the	O
incidence	O
of	O
cocaine	O
-	O
induced	O
seizures	B
at	O
the	O
two	O
highest	O
doses	O
,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	O
any	O
dose	O
.	O

These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	O
blocker	O
haloperidol	O
against	O
death	O
from	O
high	O
-	O
dose	O
amphetamine	O
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	B
.	O

In	O
contrast	O
,	O
haloperidol	O
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine	O
-	O
induced	O
seizures	B
without	O
significantly	O
reducing	O
mortality	O
.	O

Autoradiographic	O
evidence	O
of	O
estrogen	O
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	O
induced	O
hamster	O
renal	B
carcinomas	I
.	O

Estrogen	O
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	O
induced	O
renal	B
carcinomas	I
in	O
three	O
hamsters	O
.	O

Radiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H-17	O
beta	O
estradiol	O
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	B
cells	O
;	O
stereologic	O
analysis	O
revealed	O
a	O
4.5-	O
to	O
6.7-times	O
higher	O
concentration	O
of	O
reduced	O
silver	O
grains	O
over	O
nuclei	O
than	O
cytoplasm	O
of	O
these	O
cells	O
.	O

Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	O
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
normal	O
cells	O
did	O
not	O
appear	O
to	O
bind	O
the	O
ligand	O
.	O

This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	O
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	O
induced	O
hamster	O
renal	B
carcinomas	I
.	O

Bradycardia	B
due	O
to	O
biperiden	O
.	O

In	O
a	O
38-year	O
-	O
old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	B
trigeminal	B
neuralgia	I
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	O
lactate	O
led	O
to	O
a	O
long	O
-	O
lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	B
,	O
dysarthria	B
,	O
and	O
dysphagia	B
.	O

The	O
heart	O
rate	O
was	O
back	O
to	O
normal	O
within	O
12	O
hours	O
upon	O
administration	O
of	O
orciprenaline	O
under	O
cardiac	O
monitoring	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

Bradycardia	B
induced	O
by	O
biperiden	O
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose	O
-	O
related	O
dual	O
effect	O
of	O
atropine	O
-	O
like	O
drugs	O
on	O
muscarine	O
receptors	O
.	O

Deliberate	O
hypotension	B
induced	O
by	O
labetalol	O
with	O
halothane	O
,	O
enflurane	O
or	O
isoflurane	O
for	O
middle	O
-	O
ear	O
surgery	O
.	O

The	O
feasibility	O
of	O
using	O
labetalol	O
,	O
an	O
alpha-	O
and	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
as	O
a	O
hypotensive	B
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	O
,	O
enflurane	O
or	O
isoflurane	O
)	O
was	O
studied	O
in	O
23	O
adult	O
patients	O
undergoing	O
middle	O
-	O
ear	O
surgery	O
.	O

The	O
mean	O
arterial	O
pressure	O
was	O
decreased	O
from	O
86	O
+	O
/-	O

5	O
(	O
s.e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/-	O

1	O
mmHg	O
(	O
11.5	O
+	O
/-	O

0.7	O
to	O
6.9	O
+	O
/-	O

0.1	O
kPa	O
)	O
for	O
98	O
+	O
/-	O

10	O
min	O
in	O
the	O
halothane	O
(	O
H	O
)	O
group	O
,	O
from	O
79	O
+	O
/-	O

5	O
to	O
53	O
+	O
/-	O

1	O
mmHg	O
(	O
10.5	O
+	O
/-	O

0.7	O
to	O
7.1	O
+	O
/-	O

0.1	O
kPa	O
)	O
for	O
129	O
+	O
/-	O

11	O
min	O
in	O
the	O
enflurane	O
(	O
E	O
)	O
group	O
,	O
and	O
from	O
80	O
+	O
/-	O

4	O
to	O
49	O
+	O
/-	O

1	O
mmHg	O
(	O
10.7	O
+	O
/-	O

0.5	O
to	O
6.5	O
+	O
/-	O

0.1	O
kPa	O
)	O
for	O
135	O
+	O
/-	O

15	O
min	O
in	O
the	O
isoflurane	O
(	O
I	O
)	O
group	O
.	O

The	O
mean	O
H	O
concentration	O
during	O
hypotension	B
in	O
the	O
inspiratory	O
gas	O
was	O
0.7	O
+	O
/-	O

0.1	O
vol%	O
,	O
the	O
mean	O
E	O
concentration	O
1.6	O
+	O
/-	O

0.2	O
vol%	O
,	O
and	O
the	O
mean	O
I	O
concentration	O
1.0	O
+	O
/-	O

0.1	O
vol%	O
.	O

In	O
addition	O
,	O
the	O
patients	O
received	O
fentanyl	O
and	O
d	O
-	O
tubocurarine	O
.	O

The	O
initial	O
dose	O
of	O
labetalol	O
for	O
lowering	O
blood	O
pressure	O
was	O
similar	O
,	O
0.52	O
-	O
0.59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
groups	O
.	O

During	O
hypotension	B
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy-	B
or	I
bradycardia	I
.	O

The	O
operating	O
conditions	O
regarding	O
bleeding	B
were	O
estimated	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

During	O
hypotension	B
,	O
the	O
serum	O
creatinine	O
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	B
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups	O
,	O
except	O
the	O
isoflurane	O
group	O
.	O

After	O
hypotension	B
there	O
was	O
no	O
rebound	O
phenomenon	O
in	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

These	O
results	O
indicate	O
that	O
labetalol	O
induces	O
easily	O
adjustable	O
hypotension	B
without	O
compensatory	O
tachycardia	B
and	O
rebound	O
hypertension	B
.	O

Convulsion	B
following	O
intravenous	O
fluorescein	O
angiography	O
.	O

Tonic	B
-	I
clonic	I
seizures	I
followed	O
intravenous	O
fluorescein	O
injection	O
for	O
fundus	O
angiography	O
in	O
a	O
47-year	O
-	O
old	O
male	O
.	O

Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re	O
-	O
exposure	O
to	O
intravenous	O
fluorescein	O
.	O

Pharmacology	O
of	O
ACC-9653	O
(	O
phenytoin	O
prodrug	O
)	O
.	O

ACC-9653	O
,	O
the	O
disodium	O
phosphate	O
ester	O
of	O
3-hydroxymethyl-5,5-diphenylhydantoin	O
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	O
with	O
advantageous	O
physicochemical	O
properties	O
.	O

ACC-9653	O
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	O
in	O
vivo	O
.	O

ACC-9653	O
and	O
phenytoin	O
sodium	O
have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	B
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
in	O
mice	O
following	O
i.p	O
.	O
,	O
oral	O
,	O
or	O
i.v	O
.	O

administration	O
.	O

The	O
ED50	O
doses	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i.v	O
.	O

ACC-9653	O
and	O
8	O
mg	O
/	O
kg	O
for	O
i.v	O
.	O

phenytoin	O
sodium	O
.	O

ACC-9653	O
and	O
phenytoin	O
sodium	O
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	O
-	O
induced	O
ventricular	B
tachycardia	I
in	O
anesthetized	O
dogs	O
.	O

The	O
total	O
doses	O
of	O
ACC-9653	O
or	O
phenytoin	O
sodium	O
necessary	O
to	O
convert	O
the	O
arrhythmia	B
to	O
a	O
normal	O
sinus	O
rhythm	O
were	O
24	O
+	O
/-	O

6	O
and	O
14	O
+	O
/-	O

3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Only	O
phenytoin	O
sodium	O
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin	O
-	O
induced	O
arrhythmias	B
in	O
guinea	O
pig	O
right	O
atria	O
.	O

In	O
anesthetized	O
dogs	O
,	O
a	O
high	O
dose	O
of	O
ACC-9653	O
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	O
sodium	O
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC-9653	O
and	O
phenytoin	O
sodium	O
treatments	O
produced	O
similar	O
marked	O
reductions	O
in	O
diastolic	O
blood	O
pressure	O
and	O
contractile	O
force	O
(	O
LVdP	O
/	O
dt	O
)	O
.	O

The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	O
the	O
time	O
of	O
maximum	O
phenytoin	O
sodium	O
levels	O
.	O

Acute	O
toxicity	B
studies	O
of	O
ACC-9653	O
and	O
phenytoin	O
sodium	O
were	O
carried	O
out	O
in	O
mice	O
,	O
rats	O
,	O
rabbits	O
,	O
and	O
dogs	O
by	O
i.v	O
.	O
,	O
i.m	O
.	O
,	O
and	O
i.p	O
.	O

routes	O
of	O
administration	O
.	O

The	O
systemic	O
toxic	O
signs	O
of	O
both	O
agents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalent	O
doses	O
.	O

Importantly	O
,	O
the	O
local	O
irritation	O
of	O
ACC-9653	O
was	O
markedly	O
less	O
than	O
phenytoin	O
sodium	O
following	O
i.m	O
.	O

administration.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	O
in	O
asthmatics	B
.	O

High	O
doses	O
of	O
inhaled	O
salbutamol	O
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	B
,	O
and	O
are	O
associated	O
with	O
dose	O
-	O
dependent	O
systemic	O
beta	O
-	O
adrenoceptor	O
responses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	O
.	O

Twelve	O
asthmatic	B
patients	O
(	O
FEV1	O
,	O
81	O
+	O
/-	O

4	O
%	O
predicted	O
)	O
,	O
requiring	O
only	O
occasional	O
inhaled	O
beta	O
-	O
agonists	O
as	O
their	O
sole	O
therapy	O
,	O
were	O
given	O
a	O
14-day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	O
(	O
HDS	O
)	O
,	O
4,000	O
micrograms	O
daily	O
,	O
low	O
dose	O
inhaled	O
salbutamol	O
(	O
LDS	O
)	O
,	O
800	O
micrograms	O
daily	O
,	O
or	O
placebo	O
(	O
PI	O
)	O
by	O
metered	O
-	O
dose	O
inhaler	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
crossover	O
design	O
.	O

During	O
the	O
14-day	O
run	O
-	O
in	O
and	O
during	O
washout	O
periods	O
,	O
inhaled	O
beta	O
-	O
agonists	O
were	O
withheld	O
and	O
ipratropium	O
bromide	O
was	O
substituted	O
for	O
rescue	O
purposes	O
.	O

At	O
the	O
end	O
of	O
each	O
14-day	O
treatment	O
,	O
a	O
dose	O
-	O
response	O
curve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
airway	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chronotropic	O
(	O
HR	O
)	O
,	O
tremor	B
,	O
and	O
metabolic	O
(	O
K	O
,	O
Glu	O
)	O
responses	O
were	O
measured	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4,000	O
micrograms	O
)	O
.	O

Treatment	O
had	O
no	O
significant	O
effect	O
on	O
baseline	O
values	O
.	O

There	O
were	O
dose	O
-	O
dependent	O
increases	O
in	O
FEV1	O
and	O
FEF25	O
-	O
75	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
pretreatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
right	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
K	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
Glu	O
(	O
p	O
less	O
than	O
0.005	O
)	O
were	O
attenuated	O
after	O
treatment	O
with	O
HDS	O
compared	O
with	O
PI	O
.	O

There	O
were	O
also	O
differences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
Glu	O
(	O
p	O
less	O
than	O
0.05	O
)	O
responses	O
.	O

Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS	O
:	O
tremor	B
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
palpitations	B
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phenytoin	O
induced	O
fatal	O
hepatic	B
injury	I
.	O

A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	B
failure	I
after	O
phenytoin	O
administration	O
.	O

A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	B
injury	I
.	O

The	O
hematologic	O
,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	B
damage	I
due	O
to	O
drug	B
hypersensitivity	I
.	O

In	O
a	O
patient	O
receiving	O
phenytoin	O
who	O
presents	O
a	O
viral	O
-	O
like	O
illness	O
,	O
early	O
recognition	O
and	O
discontinuation	O
of	O
the	O
drug	O
are	O
mandatory	O
.	O

Treatment	O
of	O
lethal	O
pertussis	O
vaccine	O
reaction	O
with	O
histamine	O
H1	O
antagonists	O
.	O

We	O
studied	O
mortality	O
after	O
pertussis	B
immunization	O
in	O
the	O
mouse	O
.	O

Without	O
treatment	O
,	O
73	O
of	O
92	O
animals	O
(	O
80	O
%	O
)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	B
immunization	O
.	O

After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	O
,	O
2	O
mg	O
mianserin	O
,	O
or	O
2	O
mg	O
chlorpheniramine	O
,	O
only	O
5	O
of	O
105	O
animals	O
(	O
5	O
%	O
)	O
died	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Blockade	O
of	O
histamine	O
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	B
immunization	O
-	O
induced	O
encephalopathy	B
in	O
mice	O
.	O

Support	O
for	O
adrenaline	O
-	O
hypertension	B
hypothesis	O
:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	O
infusion	O
.	O

In	O
a	O
double	O
blind	O
,	O
crossover	O
study	O
6	O
h	O
infusions	O
of	O
adrenaline	O
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5.458	O
pmol	O
)	O
,	O
noradrenaline	O
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5.911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
dextrose	O
solution	O
(	O
5.4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healthy	O
volunteers	O
in	O
random	O
order	O
2	O
weeks	O
apart	O
.	O

By	O
means	O
of	O
intra	O
-	O
arterial	O
ambulatory	O
monitoring	O
the	O
haemodynamic	O
effects	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusions	O
were	O
stopped	O
.	O

Adrenaline	O
,	O
but	O
not	O
noradrenaline	O
,	O
caused	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

Over	O
the	O
total	O
postinfusion	O
period	O
systolic	O
and	O
diastolic	O
arterial	O
pressure	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
higher	O
than	O
after	O
dextrose	O
infusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Thus	O
,	O
""""	O
stress	O
""""	O
levels	O
of	O
adrenaline	O
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline	O
-	O
hypertension	B
hypothesis	O
in	O
man	O
.	O

Effect	O
of	O
alkylxanthines	O
on	O
gentamicin	O
-	O
induced	O
acute	B
renal	I
failure	I
in	O
the	O
rat	O
.	O

Adenosine	O
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	B
and	O
nephrotoxic	B
models	O
of	O
acute	B
renal	I
failure	I
(	O
ARF	B
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	O
with	O
different	O
potencies	O
as	O
adenosine	O
antagonists	O
8-phenyltheophylline	O
,	O
theophylline	O
and	O
enprofylline	O
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	B
renal	I
failure	I
after	O
4	O
daily	O
injections	O
of	O
gentamicin	O
(	O
200	O
mg	O
kg-1	O
)	O
.	O

Renal	O
function	O
was	O
assessed	O
by	O
biochemical	O
(	O
plasma	O
urea	O
and	O
creatinine	O
)	O
,	O
functional	O
(	O
urine	O
analysis	O
and	O
[	O
3H	O
]	O
inulin	O
and	O
[	O
14C	O
]	O
p	O
-	O
aminohippuric	O
acid	O
clearances	O
)	O
and	O
morphological	O
(	O
degree	O
of	O
necrosis	B
)	O
indices	O
.	O

The	O
various	O
drug	O
treatments	O
produced	O
improvements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measurements	O
of	O
renal	O
function	O
.	O

However	O
,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	O
glycol	O
and	O
NaOH	O
)	O
.	O

The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	O
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	O
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiological	O
role	O
in	O
gentamicin	O
-	O
induced	O
ARF	B
.	O

Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	O
.	O

A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	O
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	B
.	O

Blepharoconjunctivitis	B
,	O
subjective	O
complaints	O
of	O
dry	B
eyes	I
,	O
blurred	B
vision	I
,	O
contact	O
lens	O
intolerance	O
,	O
and	O
photodermatitis	B
are	O
reversible	O
side	O
effects	O
.	O

More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	B
,	O
pseudotumor	B
cerebri	I
,	O
and	O
white	O
or	O
gray	O
subepithelial	O
corneal	B
opacities	I
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drug	O
is	O
discontinued	O
.	O

Reported	O
cases	O
of	O
decreased	O
dark	O
adaptation	O
are	O
under	O
investigation	O
.	O

Isotretinoin	O
is	O
contraindicated	O
in	O
pregnancy	O
because	O
of	O
the	O
many	O
reported	O
congenital	B
abnormalities	I
after	O
maternal	O
use	O
(	O
including	O
microphthalmos	B
,	O
orbital	O
hypertelorism	B
,	O
and	O
optic	B
nerve	I
hypoplasia	I
)	O
.	O

Procaterol	O
and	O
terbutaline	O
in	O
bronchial	B
asthma	I
.	O

A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
study	O
.	O

Procaterol	O
,	O
a	O
new	O
beta-2	O
adrenoceptor	O
stimulant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
trial	O
in	O
patients	O
with	O
bronchial	B
asthma	I
.	O

Oral	O
procaterol	O
50	O
micrograms	O
b.d	O
.	O
,	O
procaterol	O
100	O
micrograms	O
b.d	O
.	O
,	O
and	O
terbutaline	O
5	O
mg	O
t.i.d	O
.	O
,	O
were	O
compared	O
when	O
given	O
randomly	O
in	O
1-week	O
treatment	O
periods	O
.	O

The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	O
.	O

Both	O
anti	O
-	O
asthmatic	B
and	O
tremorgenic	B
effects	O
of	O
procaterol	O
were	O
dose	O
-	O
related	O
.	O

Procaterol	O
appeared	O
effective	O
in	O
the	O
doses	O
tested	O
,	O
and	O
a	O
twice	O
daily	O
regimen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
drug	O
.	O

Subacute	O
effects	O
of	O
propranolol	O
and	O
B	O
24	O
/	O
76	O
on	O
isoproterenol	O
-	O
induced	O
rat	O
heart	B
hypertrophy	I
in	O
correlation	O
with	O
blood	O
pressure	O
.	O

We	O
compared	O
the	O
potential	O
beta	O
-	O
receptor	O
blocker	O
,	O
B	O
24	O
/	O
76	O
i.e.	O
1-	O
(	O
2,4-dichlorophenoxy	O
)	O
-3	O
[	O
2	O
-	O
3,4-dimethoxyphenyl	O
)	O
ethanolamino	O
]	O
-prop	O
an-2-ol	O
,	O
which	O
is	O
characterized	O
by	O
beta	O
1-adrenoceptor	O
blocking	O
and	O
beta	O
2-adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	O
.	O

The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol	O
-	O
induced	O
heart	B
hypertrophy	I
in	O
rats	O
.	O

A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	B
hypertrophy	I
with	O
the	O
two	O
beta	O
-	O
receptor	O
blockers	O
.	O

Both	O
beta	O
-	O
blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	B
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	O
decarboxylase	O
activity	O
with	O
both	O
beta	O
-	O
blockers	O
in	O
hypertrophied	B
hearts	I
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
heart	O
mass	O
.	O

Neither	O
propranolol	O
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
changes	O
in	O
the	O
characteristic	O
myosin	O
isoenzyme	O
pattern	O
of	O
the	O
hypertrophied	B
rat	O
heart	O
.	O

Thus	O
,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta	O
-	O
receptor	O
blockers	O
propranolol	O
and	O
B	O
24	O
/	O
76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	O
from	O
producing	O
heart	B
hypertrophy	I
.	O

Increased	O
anxiogenic	O
effects	O
of	O
caffeine	O
in	O
panic	B
disorders	I
.	O

The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavioral	O
ratings	O
,	O
somatic	O
symptoms	O
,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3-methoxy-4-hydroxyphenethyleneglycol	O
(	O
MHPG	O
)	O
and	O
cortisol	O
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM	O
-	O
III	O
criteria	O
for	O
agoraphobia	B
with	O
panic	B
attacks	I
or	O
panic	B
disorder	I
.	O

Caffeine	O
produced	O
significantly	O
greater	O
increases	O
in	O
subject	O
-	O
rated	O
anxiety	B
,	O
nervousness	O
,	O
fear	O
,	O
nausea	B
,	O
palpitations	B
,	O
restlessness	B
,	O
and	O
tremors	B
in	O
the	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O

In	O
the	O
patients	O
,	O
but	O
not	O
the	O
healthy	O
subjects	O
,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	O
levels	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	O
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	B
attacks	I
.	O

Caffeine	O
did	O
not	O
alter	O
plasma	O
MHPG	O
levels	O
in	O
either	O
the	O
healthy	O
subjects	O
or	O
patients	O
.	O

Caffeine	O
increased	O
plasma	O
cortisol	O
levels	O
equally	O
in	O
the	O
patient	O
and	O
healthy	O
groups	O
.	O

Because	O
caffeine	O
is	O
an	O
adenosine	O
receptor	O
antagonist	O
,	O
these	O
results	O
suggest	O
that	O
some	O
panic	B
disorder	I
patients	O
may	O
have	O
abnormalities	B
in	I
neuronal	I
systems	I
involving	O
adenosine	O
.	O

Patients	O
with	O
anxiety	B
disorders	I
may	O
benefit	O
by	O
avoiding	O
caffeine	O
-	O
containing	O
foods	O
and	O
beverages	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	O
bromide	O
and	O
of	O
slow	O
-	O
release	O
theophylline	O
on	O
nocturnal	O
asthma	B
.	O

The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug	O
,	O
oxitropium	O
bromide	O
,	O
and	O
of	O
a	O
slow	O
-	O
release	O
theophylline	O
preparation	O
upon	O
nocturnal	O
asthma	B
were	O
compared	O
in	O
a	O
placebo	O
-	O
controlled	O
double	O
-	O
blind	O
study	O
.	O

Two	O
samples	O
were	O
studied	O
:	O
12	O
patients	O
received	O
oxitropium	O
at	O
600	O
micrograms	O
(	O
6	O
subjects	O
)	O
or	O
at	O
400	O
micrograms	O
t.i.d	O
.	O

(	O
6	O
subjects	O
)	O
whereas	O
11	O
received	O
theophylline	O
at	O
300	O
mg	O
b.i.d	O
.	O

Morning	O
dipping	O
,	O
assessed	O
by	O
the	O
fall	O
in	O
peak	O
flow	O
overnight	O
,	O
was	O
significantly	O
reduced	O
in	O
the	O
periods	O
when	O
either	O
active	O
drug	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
placebo	O
administration	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug	O
,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	O
.	O

No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	O
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	B
,	O
vomiting	B
and	O
tremors	B
after	O
theophylline	O
.	O

Oxitropium	O
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	O
in	O
nocturnal	O
asthma	B
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titration	O
of	O
dosage	O
.	O

Penicillin	O
anaphylaxis	B
.	O

A	O
case	O
of	O
oral	O
penicillin	O
anaphylaxis	B
is	O
described	O
,	O
and	O
the	O
terminology	O
,	O
occurrence	O
,	O
clinical	O
manifestations	O
,	O
pathogenesis	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
anaphylaxis	B
are	O
reviewed	O
.	O

Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	O
anaphylaxis	B
in	O
order	O
to	O
prevent	O
its	O
occurrence	O
by	O
prescribing	O
the	O
antibiotic	O
judiciously	O
and	O
knowledgeably	O
and	O
to	O
offer	O
optimal	O
medical	O
therapy	O
once	O
this	O
life	O
-	O
threatening	O
reaction	O
has	O
begun	O
.	O

Reversible	O
valproic	O
acid	O
-	O
induced	O
dementia	B
:	O
a	O
case	O
report	O
.	O

Reversible	O
valproic	O
acid	O
-	O
induced	O
dementia	B
was	O
documented	O
in	O
a	O
21-year	O
-	O
old	O
man	O
with	O
epilepsy	B
who	O
had	O
a	O
3-year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
abilities	O
documented	O
by	O
serial	O
neuropsychological	O
studies	O
.	O

Repeat	O
neuropsychological	O
testing	O
7	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
revealed	O
dramatic	O
improvement	O
in	O
IQ	O
,	O
memory	O
,	O
naming	O
,	O
and	O
other	O
tasks	O
commensurate	O
with	O
clinical	O
recovery	O
in	O
his	O
intellectual	O
capacity	O
.	O

Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxic	O
effect	O
of	O
valproic	O
acid	O
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	O
acid	O
-	O
induced	O
hyperammonemia	B
.	O

Reversal	O
of	O
scopolamine	O
-	O
induced	O
amnesia	B
of	O
passive	O
avoidance	O
by	O
pre-	O
and	O
post	O
-	O
training	O
naloxone	O
.	O

In	O
a	O
series	O
of	O
five	O
experiments	O
,	O
the	O
modulating	O
role	O
of	O
naloxone	O
on	O
a	O
scopolamine	O
-	O
induced	O
retention	B
deficit	I
in	O
a	O
passive	O
avoidance	O
paradigm	O
was	O
investigated	O
in	O
mice	O
.	O

Scopolamine	O
,	O
but	O
not	O
methyl	O
scopolamine	O
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induced	O
an	O
amnesia	B
as	O
measured	O
by	O
latency	O
and	O
duration	O
parameters	O
.	O

Naloxone	O
(	O
0.3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	B
deficit	I
with	O
a	O
peak	O
of	O
activity	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
effect	O
of	O
naloxone	O
could	O
be	O
antagonized	O
with	O
morphine	O
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	O
effect	O
.	O

Post	O
-	O
training	O
administration	O
of	O
naloxone	O
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine	O
-	O
induced	O
amnesia	B
.	O

Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	B
sensitivity	O
(	O
pre	O
-	O
training	O
naloxone	O
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(	O
post	O
-	O
training	O
naloxone	O
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	O
on	O
the	O
scopolamine	O
-	O
induced	O
retention	B
deficit	I
.	O

These	O
results	O
extend	O
previous	O
findings	O
implicating	O
a	O
cholinergic	O
-	O
opioid	O
interaction	O
in	O
memory	O
processes	O
.	O

A	O
possible	O
mechanism	O
for	O
this	O
interaction	O
involving	O
the	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
is	O
discussed	O
.	O

Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide	O
-	O
induced	O
lesions	B
of	I
the	I
urinary	I
bladder	I
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	O
.	O

Fully	O
developed	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium	O
,	O
severe	O
submucosal	O
edema	B
owing	O
to	O
damage	O
to	O
the	O
microvascular	O
bed	O
and	O
focal	O
muscle	O
necroses	B
.	O

The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	O
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	O
membrane	O
.	O

This	O
damages	O
the	O
cellular	O
barrier	O
against	O
the	O
hypertonic	O
urine	O
.	O

Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells	O
,	O
intercellular	O
and	O
intracellular	O
edema	B
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	O
to	O
progressive	O
degeneration	O
and	O
detachment	O
of	O
the	O
epithelial	O
cells	O
with	O
exposure	O
and	O
splitting	O
of	O
the	O
basal	O
membrane	O
.	O

The	O
morphological	O
changes	O
of	O
the	O
endothelial	O
cells	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stages	O
of	O
the	O
experiment	O
,	O
the	O
involvement	O
of	O
blood	O
vessels	O
regardless	O
of	O
their	O
diameter	O
and	O
the	O
location	O
-	O
dependent	O
extent	O
of	O
the	O
damage	O
indicate	O
a	O
direct	O
type	O
of	O
damage	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
induced	O
increase	O
in	O
permeability	O
,	O
the	O
morphological	O
correlate	O
of	O
which	O
is	O
the	O
formation	O
of	O
gaps	O
in	O
the	O
interendothelial	O
cell	O
connections	O
on	O
the	O
venules	O
.	O

These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	O
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
involvement	O
is	O
the	O
increase	O
in	O
the	O
number	O
of	O
specific	O
granules	O
with	O
a	O
presumed	O
lysosomal	O
function	O
in	O
the	O
superficial	O
cells	O
.	O

Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium	O
-	O
induced	O
muscle	B
fasciculations	I
in	O
children	O
:	O
inhibition	O
by	O
alfentanil	O
.	O

Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	O
1.5	O
mg	O
kg-1	O
i.v	O
.	O
were	O
studied	O
in	O
32	O
children	O
(	O
mean	O
age	O
6.9	O
yr	O
)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	O
50	O
micrograms	O
kg-1	O
.	O

Anaesthesia	O
was	O
induced	O
with	O
thiopentone	O
5	O
mg	O
kg-1	O
.	O

The	O
incidence	O
and	O
intensity	O
of	O
muscle	B
fasciculations	I
caused	O
by	O
suxamethonium	O
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	O
group	O
.	O

The	O
intragastric	O
pressure	O
during	O
muscle	B
fasciculations	I
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(	O
16	O
+	O
/-	O

0.7	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
than	O
in	O
the	O
alfentanil	O
group	O
(	O
7.7	O
+	O
/-	O

1.5	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
.	O

The	O
increase	O
in	O
intragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
intensity	O
of	O
muscle	B
fasciculations	I
(	O
regression	O
line	O
:	O
y	O
=	O
0.5	O
+	O
4.78x	O
with	O
r	O
of	O
0.78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	B
fasciculations	I
caused	O
by	O
suxamethonium	O
in	O
healthy	O
children	O
.	O

Alfentanil	O
50	O
micrograms	O
kg-1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium	O
-	O
induced	O
muscle	B
fasciculations	I
;	O
moreover	O
,	O
intragastric	O
pressure	O
remains	O
at	O
its	O
control	O
value	O
.	O

Acute	O
insulin	O
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	B
effect	O
of	O
isoproterenol	O
in	O
streptozotocin	O
diabetic	B
rats	O
.	O

A	O
morphometric	O
study	O
of	O
isoproterenol	O
induced	O
myocardial	O
fibrosis	B
.	O

The	O
acute	O
effect	O
of	O
insulin	O
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	O
diabetes	B
against	O
the	O
cardiotoxic	B
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	O
(	O
ISO	O
)	O
was	O
investigated	O
in	O
rats	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	O
,	O
ISO	O
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	O
induced	O
fibrosis	B
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0.83	O
,	O
2	O
p	O
=	O
0.006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	O
after	O
insulin	O
treatment	O
appeared	O
.	O

The	O
myocardial	O
content	O
of	O
catecholamines	O
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	B
rats	O
.	O

The	O
norepinephrine	O
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	O
remained	O
unchanged	O
.	O

An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta	O
-	O
adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	O
resistance	O
.	O

The	O
rapid	O
reversion	O
after	O
insulin	O
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	O
in	O
itself	O
causes	O
the	O
ISO	O
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	O
effect	O
on	O
myocardial	O
catecholamine	O
sensitivity	O
in	O
diabetic	B
rats	O
.	O

The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	B
patients	O
.	O

Differential	O
effects	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
seizures	B
produced	O
by	O
pilocarpine	O
in	O
rats	O
.	O

The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	O
induces	O
in	O
rats	O
seizures	B
and	O
status	B
epilepticus	I
followed	O
by	O
widespread	O
damage	O
to	O
the	O
forebrain	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
sodium	O
salicylate	O
,	O
phenylbutazone	O
,	O
indomethacin	O
,	O
ibuprofen	O
and	O
mefenamic	O
acid	O
,	O
on	O
seizures	B
produced	O
by	O
pilocarpine	O
.	O

Pretreatment	O
of	O
rats	O
with	O
sodium	O
salicylate	O
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutazone	O
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
convulsant	O
dose	O
of	O
pilocarpine	O
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsant	O
one	O
.	O

Indomethacin	O
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuprofen	O
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modulate	O
seizures	B
produced	O
by	O
pilocarpine	O
.	O

Mefenamic	O
acid	O
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seizures	B
and	O
protected	O
rats	O
from	O
seizure	B
-	O
related	O
brain	B
damage	I
induced	O
by	O
pilocarpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine	O
-	O
induced	O
seizures	B
.	O

Acute	B
neurologic	I
dysfunction	I
after	O
high	O
-	O
dose	O
etoposide	O
therapy	O
for	O
malignant	B
glioma	I
.	O

Etoposide	O
(	O
VP-16	O
-	O
213	O
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	B
and	O
hematologic	B
malignancies	I
.	O

When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment	O
-	O
resistant	O
cancers	B
including	O
malignant	B
glioma	I
.	O

In	O
six	O
of	O
eight	O
patients	O
(	O
75	O
%	O
)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	B
,	O
sudden	O
severe	O
neurologic	B
deterioration	I
occurred	O
.	O

This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
etoposide	O
therapy	O
.	O

Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	B
,	O
papilledema	B
,	O
somnolence	B
,	O
exacerbation	O
of	O
motor	B
deficits	I
,	O
and	O
sharp	O
increase	O
in	O
seizure	B
activity	O
.	O

These	O
abnormalities	O
resolved	O
rapidly	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
intravenous	O
dexamethasone	O
therapy	O
.	O

In	O
all	O
patients	O
,	O
computerized	O
tomographic	O
(	O
CT	O
)	O
brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	B
size	O
and	O
peritumor	O
edema	B
when	O
compared	O
with	O
pretransplant	O
scans	O
.	O

This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	B
of	O
high	O
-	O
dose	O
etoposide	O
therapy	O
for	O
malignant	B
glioma	I
.	O

Progressive	O
bile	B
duct	I
injury	I
after	O
thiabendazole	O
administration	O
.	O

A	O
27-yr	O
-	O
old	O
man	O
developed	O
jaundice	B
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	O
.	O

Cholestasis	B
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
time	O
a	O
liver	O
transplant	O
was	O
performed	O
.	O

Two	O
liver	O
biopsy	O
specimens	O
and	O
the	O
hepatectomy	O
specimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearance	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Prominent	O
fibrosis	B
and	O
hepatocellular	O
regeneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobular	O
architecture	O
was	O
preserved	O
.	O

This	O
case	O
represents	O
an	O
example	O
of	O
""""	O
idiosyncratic	O
""""	O
drug	B
-	I
induced	I
liver	I
damage	I
in	O
which	O
the	O
primary	O
target	O
of	O
injury	O
is	O
the	O
bile	O
duct	O
.	O

An	O
autoimmune	O
pathogenesis	O
of	O
the	O
bile	B
duct	I
destruction	I
is	O
suggested	O
.	O

Differential	O
effects	O
of	O
1,4-dihydropyridine	O
calcium	O
channel	O
blockers	O
:	O
therapeutic	O
implications	O
.	O

Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	O
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B
disease	I
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	O
channel	O
blocking	O
agents	O
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	B
diseases	I
.	O

The	O
favorable	O
efficacy	O
and	O
tolerability	O
profiles	O
of	O
these	O
agents	O
make	O
them	O
attractive	O
therapeutic	O
modalities	O
.	O

Clinical	O
applications	O
of	O
calcium	O
channel	O
blockers	O
parallel	O
their	O
tissue	O
selectivity	O
.	O

In	O
contrast	O
to	O
verapamil	O
and	O
diltiazem	O
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle	O
,	O
the	O
dihydropyridine	O
calcium	O
channel	O
blockers	O
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	O
agents	O
that	O
exert	O
minimal	O
electrophysiologic	O
effects	O
on	O
cardiac	O
nodal	O
or	O
conduction	O
tissue	O
.	O

As	O
the	O
first	O
dihydropyridine	O
available	O
for	O
use	O
in	O
the	O
United	O
States	O
,	O
nifedipine	O
controls	O
angina	B
and	O
hypertension	B
with	O
minimal	O
depression	O
of	O
cardiac	O
function	O
.	O

Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	O
channel	O
blockers	O
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indications	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therapy	O
.	O

Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	O
and	O
nisoldipine	O
offers	O
a	O
convenient	O
administration	O
schedule	O
,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long	O
-	O
term	O
therapy	O
of	O
hypertension	B
.	O

The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	O
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	B
.	O

Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	O
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	B
hemorrhage	I
,	O
migraine	B
headache	I
,	O
dementia	B
,	O
and	O
stroke	B
.	O

In	O
general	O
,	O
the	O
dihydropyridine	O
calcium	O
channel	O
blockers	O
are	O
usually	O
well	O
tolerated	O
,	O
with	O
headache	B
,	O
facial	O
flushing	B
,	O
palpitations	B
,	O
edema	B
,	O
nausea	B
,	O
anorexia	B
,	O
and	O
dizziness	B
being	O
the	O
more	O
common	O
adverse	O
effects	O
.	O

The	O
enhancement	O
of	O
aminonucleoside	O
nephrosis	B
by	O
the	O
co	O
-	O
administration	O
of	O
protamine	O
.	O

An	O
experimental	O
model	O
of	O
focal	B
segmental	I
glomerular	I
sclerosis	I
(	O
FSGS	B
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin	O
-	O
aminonucleoside	O
(	O
AMNS	O
)	O
and	O
protamine	O
sulfate	O
(	O
PS	O
)	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
uninephrectomized	O
three	O
weeks	O
before	O
,	O
received	O
daily	O
injections	O
of	O
subcutaneous	O
AMNS	O
(	O
1	O
mg	O
/	O
100	O
g	O
body	O
wt	O
)	O
and	O
intravenous	O
PS	O
(	O
2	O
separated	O
doses	O
of	O
2.5	O
mg	O
/	O
100	O
g	O
body	O
wt	O
)	O
for	O
four	O
days	O
.	O

The	O
series	O
of	O
injections	O
were	O
repeated	O
another	O
three	O
times	O
at	O
10	O
day	O
intervals	O
.	O

The	O
animals	O
were	O
sacrificed	O
on	O
days	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
nephrotic	B
syndrome	I
and	O
finally	O
renal	B
failure	I
.	O

The	O
time	O
-	O
course	O
curve	O
of	O
creatinine	O
clearance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.01	O
)	O
from	O
that	O
of	O
each	O
control	O
group	O
,	O
such	O
as	O
,	O
AMNS	O
alone	O
,	O
PS	O
alone	O
or	O
saline	O
injected	O
.	O

Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	B
.	O

The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	O
red	O
on	O
the	O
lamina	O
rara	O
externa	O
and	O
marked	O
changes	O
in	O
epithelial	O
cell	O
cytoplasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	O
enhances	O
the	O
toxicity	B
of	O
AMNS	O
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	B
in	O
rats	O
resulting	O
in	O
the	O
end	B
-	I
stage	I
renal	I
disease	I
.	O

Theophylline	O
neurotoxicity	B
in	O
pregnant	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	B
of	O
theophylline	O
is	O
altered	O
in	O
advanced	O
pregnancy	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	O
until	O
onset	O
of	O
maximal	O
seizures	B
which	O
occurred	O
after	O
28	O
and	O
30	O
minutes	O
respectively	O
.	O

Theophylline	O
concentrations	O
at	O
this	O
endpoint	O
in	O
serum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
serum	O
(	O
free	O
)	O
and	O
brain	O
concentrations	O
were	O
slightly	O
different	O
in	O
pregnant	O
rats	O
.	O

Theophylline	O
serum	O
protein	O
binding	O
determined	O
by	O
equilibrium	O
dialysis	O
was	O
lower	O
in	O
pregnant	O
rats	O
.	O

Fetal	O
serum	O
concentrations	O
at	O
onset	O
of	O
seizures	B
in	O
the	O
mother	O
were	O
similar	O
to	O
maternal	O
brain	O
and	O
CSF	O
concentrations	O
and	O
correlated	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	O
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	B
response	O
to	O
theophylline	O
in	O
rats	O
.	O

Hyperkalemia	B
induced	O
by	O
indomethacin	O
and	O
naproxen	O
and	O
reversed	O
by	O
fludrocortisone	O
.	O

We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	B
arthritis	I
and	O
a	O
history	O
of	O
mefenamic	O
acid	O
nephropathy	B
in	O
whom	O
hyperkalemia	B
and	O
inappropriate	O
hypoaldosteronism	B
were	O
caused	O
by	O
both	O
indomethacin	O
and	O
naproxen	O
,	O
without	O
major	O
decline	O
in	O
renal	O
function	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
renal	B
disease	I
predisposed	O
this	O
patient	O
to	O
type	B
IV	I
renal	I
tubular	I
acidosis	I
with	O
prostaglandin	O
synthetase	O
inhibitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
,	O
fludrocortisone	O
was	O
added	O
,	O
correcting	O
the	O
hyperkalemia	B
and	O
allowing	O
indomethacin	O
therapy	O
to	O
be	O
continued	O
safely	O
.	O

Hypotension	B
as	O
a	O
manifestation	O
of	O
cardiotoxicity	B
in	O
three	O
patients	O
receiving	O
cisplatin	O
and	O
5-fluorouracil	O
.	O

Cardiac	O
symptoms	O
,	O
including	O
hypotension	B
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	B
carcinoma	I
while	O
being	O
treated	O
with	O
cisplatin	O
(	O
CDDP	O
)	O
and	O
5-fluorouracil	O
(	O
5-FU	O
)	O
.	O

In	O
two	O
patients	O
,	O
hypotension	B
was	O
associated	O
with	O
severe	O
left	B
ventricular	I
dysfunction	I
.	O

All	O
three	O
patients	O
required	O
therapy	O
discontinuation	O
.	O

Cardiac	O
enzymes	O
remained	O
normal	O
despite	O
transient	O
electrocardiographic	O
(	O
EKG	O
)	O
changes	O
.	O

The	O
presentation	O
and	O
cardiac	O
evaluation	O
(	O
hemodynamic	O
,	O
echocardiographic	O
,	O
and	O
scintigraphic	O
)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5-FU	O
cardiotoxicity	B
that	O
may	O
be	O
influenced	O
by	O
CDDP	O
.	O

The	O
possible	O
pathophysiologic	O
mechanisms	O
are	O
discussed	O
.	O

Fatal	O
aplastic	B
anemia	I
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	B
anemia	I
due	O
to	O
carbamazepine	O
treatment	O
in	O
an	O
epileptic	B
woman	O
is	O
reported	O
.	O

Despite	O
concerns	O
of	O
fatal	O
bone	B
marrow	I
toxicity	I
due	O
to	O
carbamazepine	O
,	O
this	O
is	O
only	O
the	O
fourth	O
documented	O
and	O
published	O
report	O
.	O

Carbamazepine	O
is	O
a	O
safe	O
drug	O
,	O
but	O
physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rare	O
but	O
potentially	O
fatal	O
side	O
effects	O
,	O
better	O
prevented	O
by	O
clinical	O
than	O
by	O
laboratory	O
monitoring	O
.	O

Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine	O
-	O
induced	O
hypotension	B
and	O
bradycardia	B
.	O

The	O
effects	O
of	O
microinjection	O
of	O
clonidine	O
(	O
1	O
-	O
10	O
micrograms	O
in	O
1	O
microliter	O
)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane	O
-	O
anesthetized	O
rats	O
.	O

Intramedullary	O
administration	O
of	O
clonidine	O
,	O
but	O
not	O
saline	O
vehicle	O
,	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

The	O
clonidine	O
-	O
induced	O
hypotension	B
was	O
antagonized	O
by	O
prior	O
spinal	O
transection	O
,	O
but	O
not	O
bilateral	O
vagotomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clonidine	O
-	O
induced	O
bradycardia	B
was	O
antagonized	O
by	O
prior	O
bilateral	O
vagotomy	O
,	O
but	O
not	O
spinal	O
transection	O
.	O

Furthermore	O
,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5-HT	O
nerves	O
,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5,7-dihydroxytryptamine	O
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	B
responses	O
to	O
clonidine	O
microinjected	O
into	O
the	O
area	O
near	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
in	O
rats	O
.	O

The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine	O
-	O
induced	O
hypotension	B
and	O
bradycardia	B
.	O

The	O
induced	O
hypotension	B
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity	O
,	O
whereas	O
the	O
induced	O
bradycardia	B
was	O
due	O
to	O
an	O
increase	O
in	O
vagal	O
efferent	O
activity	O
.	O

Hypertension	B
in	O
neuroblastoma	B
induced	O
by	O
imipramine	O
.	O

Hypertension	B
is	O
a	O
well	O
-	O
known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	B
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	O
.	O

We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	B
(	O
blood	O
pressure	O
190	O
/	O
160	O
)	O
in	O
a	O
4-year	O
-	O
old	O
girl	O
with	O
neuroblastoma	B
who	O
was	O
given	O
Imipramine	O
to	O
control	O
a	O
behavior	B
disorder	I
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patient	O
's	O
tumor	B
was	O
recurring	O
at	O
the	O
time	O
of	O
her	O
hypertensive	B
episode	O
.	O

Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	O
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
)	O
,	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	B
.	O

The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	O
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	O
.	O

From	O
this	O
experience	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	O
in	O
children	O
with	O
active	O
neuroblastoma	B
.	O

Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	B
candidiasis	I
or	O
hoarseness	B
with	O
beclomethasone	O
dipropionate	O
.	O

Of	O
158	O
asthmatic	B
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	O
,	O
15	O
(	O
9.5	O
%	O
)	O
developed	O
either	O
hoarseness	B
(	O
8)	O
,	O
oral	O
thrush	B
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
adverse	O
reactions	O
subsided	O
,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	O
.	O

These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	B
and	O
three	O
who	O
developed	O
Candidiasis	B
.	O

One	O
patient	O
had	O
both	O
.	O

Oral	O
thrush	B
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
patients	O
with	O
hoarseness	B
had	O
recurrence	O
.	O

We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	O
when	O
clinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	O
rate	O
,	O
patients	O
who	O
develop	O
hoarseness	B
should	O
not	O
be	O
re	O
-	O
challenged	O
.	O

Concomitant	O
use	O
of	O
oral	O
prednisone	O
and	O
topical	O
beclomethasone	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	B
or	O
candidiasis	B
.	O

Cyclophosphamide	O
cardiotoxicity	B
:	O
an	O
analysis	O
of	O
dosing	O
as	O
a	O
risk	O
factor	O
.	O

Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	O
(	O
CYA	O
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patient	O
's	O
weight	O
.	O

At	O
these	O
high	O
doses	O
of	O
CYA	O
,	O
serious	O
cardiotoxicity	B
may	O
occur	O
,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	B
have	O
not	O
been	O
described	O
.	O

Since	O
chemotherapeutic	O
agent	O
toxicity	B
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	O
in	O
patients	O
transplanted	O
at	O
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	O
cardiotoxicity	B
correlated	O
with	O
the	O
dose	O
per	O
body	O
surface	O
area	O
.	O

Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	O
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	B
anemia	I
,	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
or	O
severe	B
combined	I
immunodeficiency	I
syndrome	I
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
patients	O
had	O
symptoms	O
and	O
signs	O
consistent	O
with	O
CYA	O
cardiotoxicity	B
within	O
ten	O
days	O
of	O
receiving	O
1	O
to	O
4	O
doses	O
of	O
CYA	O
.	O

Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	B
heart	I
failure	I
.	O

The	O
dose	O
of	O
CYA	O
per	O
body	O
surface	O
area	O
was	O
calculated	O
for	O
all	O
patients	O
and	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
daily	O
CYA	O
dose	O
:	O
Group	O
1	O
,	O
CYA	O
less	O
than	O
or	O
equal	O
to	O
1.55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Group	O
2	O
,	O
CYA	O
greater	O
than	O
1.55	O
g	O
/	O
m2	O
/	O
d	O
.	O

Cardiotoxicity	B
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	O
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
patients	O
in	O
Group	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Congestive	B
heart	I
failure	I
caused	O
or	O
contributed	O
to	O
death	O
in	O
0	O
/	O
32	O
patients	O
in	O
Group	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
engraftment	O
of	O
evaluable	O
patients	O
in	O
the	O
two	O
groups	O
(	O
P	O
greater	O
than	O
0.5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	O
cardiotoxicity	B
correlates	O
with	O
CYA	O
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area	O
,	O
and	O
that	O
patients	O
with	O
aplastic	B
anemia	I
and	O
immunodeficiencies	B
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	O
a	O
CYA	O
dose	O
of	O
1.55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	B
than	O
patients	O
whose	O
CYA	O
dosage	O
is	O
calculated	O
based	O
on	O
weight	O
.	O

This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	B
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
.	O

Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	O
nephrotoxicity	B
.	O

The	O
epidemiology	O
of	O
aminoglycoside	O
-	O
induced	O
nephrotoxicity	B
is	O
not	O
fully	O
understood	O
.	O

Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	O
cause	O
proximal	O
tubular	O
damage	O
in	O
most	O
patients	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glomerular	B
or	I
tubular	I
dysfunction	I
.	O

Clinical	O
trials	O
of	O
aminoglycosides	O
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	B
renal	I
failure	I
during	O
therapy	O
ranges	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
risk	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy	O
,	O
plasma	O
aminoglycoside	O
levels	O
,	O
liver	B
disease	I
,	O
advanced	O
age	O
,	O
high	O
initial	O
estimated	O
creatinine	O
clearance	O
and	O
,	O
possibly	O
,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	B
.	O

Other	O
causes	O
of	O
acute	B
renal	I
failure	I
,	O
such	O
as	O
shock	B
,	O
appear	O
to	O
have	O
an	O
additive	O
effect	O
.	O

Predictive	O
models	O
have	O
been	O
developed	O
from	O
these	O
analyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk	O
.	O

These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside	O
-	O
induced	O
nephrotoxicity	B
.	O

Central	O
action	O
of	O
narcotic	O
analgesics	O
.	O

Part	O
IV	O
.	O

Noradrenergic	O
influences	O
on	O
the	O
activity	O
of	O
analgesics	O
in	O
rats	O
.	O

The	O
effect	O
of	O
clonidine	O
,	O
naphazoline	O
and	O
xylometazoline	O
on	O
analgesia	O
induced	O
by	O
morphine	O
,	O
codeine	O
,	O
fentanyl	O
and	O
pentazocine	O
,	O
and	O
on	O
cataleptic	B
effect	O
of	O
morphine	O
,	O
codine	O
and	O
fentanyl	O
was	O
studied	O
in	O
rats	O
.	O

The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	O
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	O
(	O
NA	O
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
NA	O
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	B
induced	O
by	O
morphine	O
and	O
fentanyl	O
.	O

Codeine	O
catalepsy	B
was	O
increased	O
by	O
clonidine	O
and	O
decreased	O
by	O
naphazoline	O
and	O
xylometazoline	O
.	O

The	O
brain	O
concentration	O
of	O
NA	O
was	O
not	O
changed	O
by	O
morphine	O
and	O
fentanyl	O
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	O
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enhanced	O
it	O
.	O

Pentazocine	O
dose	O
-	O
dependently	O
decreased	O
the	O
brain	O
level	O
of	O
NA	O
.	O

The	O
rate	O
of	O
NA	O
turnover	O
was	O
not	O
altered	O
by	O
analgesics	O
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	O
(	O
0.2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearance	O
of	O
NA	O
from	O
the	O
brain	O
was	O
diminished	O
.	O

The	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non	O
-	O
uniform	O
data	O
from	O
the	O
literature	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
NA	O
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	O
in	O
the	O
behavioural	O
activity	O
of	O
potent	O
analgesics	O
.	O

Flurothyl	O
seizure	B
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	O
glutamate	O
(	O
MSG	O
)	O
:	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	O
seizure	B
testing	O
.	O

Monosodium	O
glutamate	O
(	O
MSG	O
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	B
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits	O
.	O

These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	O
produced	O
permanent	O
alterations	O
in	O
seizure	B
susceptibility	O
,	O
since	O
previous	O
investigations	O
were	O
inconclusive	O
.	O

A	O
flurothyl	O
ether	O
seizure	B
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	B
susceptibility	O
in	O
adult	O
mice	O
that	O
received	O
neonatal	O
injections	O
of	O
MSG	O
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	O
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	B
threshold	O
.	O

A	O
naloxone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	B
thresholds	O
of	O
either	O
control	O
of	O
MSG	O
-	O
treated	O
mice	O
.	O

Flurothyl	O
ether	O
produced	O
hypothermia	B
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	O
exposure	O
;	O
however	O
,	O
the	O
relationship	O
of	O
hypothermia	B
to	O
seizure	B
induction	O
was	O
unclear	O
.	O

Flurothyl	O
seizure	B
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	B
susceptibility	O
.	O

Susceptibility	O
to	O
seizures	B
produced	O
by	O
pilocarpine	O
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	O
or	O
gamma	O
-	O
vinyl	O
-	O
GABA	O
into	O
the	O
substantia	O
nigra	O
.	O

Pilocarpine	O
,	O
given	O
intraperitoneally	O
to	O
rats	O
,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	B
lobe	I
epilepsy	I
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	B
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	B
within	O
the	O
forebrain	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
-mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	B
produced	O
by	O
pilocarpine	O
in	O
rats	O
,	O
were	O
investigated	O
.	O

In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	O
,	O
150	O
micrograms	O
,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA	O
-	O
synthesizing	O
enzyme	O
,	O
L	O
-	O
glutamic	O
acid	O
decarboxylase	O
,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(	O
SNR	O
)	O
,	O
bilaterally	O
,	O
non	O
-	O
convulsant	O
doses	O
of	O
pilocarpine	O
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	B
and	O
status	B
epilepticus	I
.	O

Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	O
-	O
induced	O
convulsions	B
.	O

Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure	B
-	O
related	O
damage	O
to	O
the	O
hippocampal	O
formation	O
,	O
thalamus	O
,	O
amygdala	O
,	O
olfactory	O
cortex	O
,	O
substantia	O
nigra	O
and	O
neocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	O
in	O
doses	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	O
did	O
not	O
augment	O
seizures	B
produced	O
by	O
pilocarpine	O
,	O
200	O
mg	O
/	O
kg	O
.	O

Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	O
transaminase	O
,	O
gamma	O
-	O
vinyl	O
-	O
GABA	O
(	O
D	O
,	O
L-4-amino	O
-	O
hex-5-enoic	O
acid	O
)	O
,	O
5	O
micrograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	B
produced	O
by	O
pilocarpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	B
damage	I
.	O

Microinjections	O
of	O
gamma	O
-	O
vinyl	O
-	O
GABA	O
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	B
produced	O
by	O
pilocarpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine	O
-	O
induced	O
seizures	B
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA	O
-	O
mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
.	O

Human	O
and	O
canine	O
ventricular	O
vasoactive	O
intestinal	O
polypeptide	O
:	O
decrease	O
with	O
heart	B
failure	I
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
a	O
systemic	O
and	O
coronary	O
vasodilator	O
that	O
may	O
have	O
positive	O
inotropic	O
properties	O
.	O

Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	B
failure	I
in	O
two	O
canine	O
models	O
.	O

In	O
the	O
first	O
,	O
cobalt	O
cardiomyopathy	B
was	O
induced	O
in	O
eight	O
dogs	O
;	O
VIP	O
(	O
by	O
radioimmunoassay	O
)	O
decreased	O
from	O
35	O
+	O
/-	O

11	O
pg	O
/	O
mg	O
protein	O
(	O
mean	O
+	O
/-	O
SD	O
)	O
to	O
5	O
+	O
/-	O

4	O
pg	O
/	O
mg	O
protein	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
six	O
dogs	O
with	O
doxorubicin	O
-	O
induced	O
heart	B
failure	I
,	O
VIP	O
decreased	O
from	O
31	O
+	O
/-	O

7	O
to	O
11	O
+	O
/-	O

4	O
pg	O
/	O
mg	O
protein	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(	O
five	O
with	O
rheumatic	B
disease	I
,	O
nine	O
with	O
myxomatous	B
degeneration	I
)	O
receiving	O
mitral	O
valve	O
prostheses	O
.	O

The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	B
disease	I
(	O
one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses	O
)	O
(	O
6.3	O
+	O
/-	O

1.9	O
pg	O
/	O
mg	O
protein	O
)	O
.	O

The	O
other	O
patients	O
undergoing	O
transplantation	O
had	O
an	O
average	O
ejection	O
fraction	O
of	O
17	O
%	O
+	O
/-	O

6	O
%	O
and	O
a	O
VIP	O
level	O
of	O
8.8	O
+	O
/-	O

3.9	O
pg	O
/	O
mg	O
protein	O
.	O

The	O
hearts	O
without	O
coronary	B
artery	I
disease	I
(	O
average	O
ejection	O
fraction	O
of	O
this	O
group	O
62	O
%	O
+	O
/-	O

10	O
%	O
)	O
had	O
a	O
VIP	O
concentration	O
of	O
14.1	O
+	O
/-	O

7.9	O
pg	O
/	O
mg	O
protein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	B
disease	I
and	O
the	O
hearts	O
of	O
patients	O
receiving	O
a	O
transplant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Myocardial	O
catecholamines	O
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0.57	O
,	O
P	O
less	O
than	O
0.05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	O
was	O
noted.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Non	O
-	O
invasive	O
detection	O
of	O
coronary	B
artery	I
disease	I
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	O
infusion	O
.	O

Electrocardiographic	O
changes	O
after	O
dipyridamole	O
infusion	O
(	O
0.568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B
artery	I
disease	I
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
;	O
19	O
patients	O
without	O
myocardial	B
infarction	I
(	O
non	O
-	O
MI	B
group	O
)	O
,	O
14	O
with	O
anterior	B
infarction	I
(	O
ANT	B
-	I
MI	I
)	O
and	O
eight	O
with	O
inferior	B
infarction	I
(	O
INF	B
-	I
MI	I
)	O
.	O

Eighty	O
-	O
seven	O
unipolar	O
electrocardiograms	O
(	O
ECGs	O
)	O
distributed	O
over	O
the	O
entire	O
thoracic	O
surface	O
were	O
simultaneously	O
recorded	O
.	O

After	O
dipyridamole	O
,	O
ischemic	B
ST	O
-	O
segment	O
depression	B
(	O
0.05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B
group	O
,	O
29	O
%	O
of	O
the	O
ANT	B
-	I
MI	I
group	O
,	O
63	O
%	O
of	O
the	O
INF	B
-	I
MI	I
group	O
and	O
61	O
%	O
of	O
the	O
total	O
population	O
.	O

Exercise	O
-	O
induced	O
ST	O
depression	B
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B
group	O
,	O
43	O
%	O
of	O
the	O
ANT	B
-	I
MI	I
group	O
,	O
38	O
%	O
of	O
the	O
INF	B
-	I
MI	I
group	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
individual	O
patients	O
,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	B
in	O
both	O
tests	O
.	O

The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	O
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmill	O
exercise	O
.	O

The	O
data	O
suggest	O
that	O
the	O
dipyridamole	O
-	O
induced	O
myocardial	B
ischemia	I
is	O
caused	O
by	O
the	O
inhomogenous	O
distribution	O
of	O
myocardial	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
the	O
dipyridamole	O
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	B
artery	I
disease	I
.	O

Bradycardia	B
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	O
therapy	O
.	O

In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	B
arthritis	I
who	O
received	O
intravenous	O
high	O
-	O
dose	O
methylprednisolone	O
(	O
MP	O
)	O
therapy	O
(	O
1	O
g	O
daily	O
for	O
2	O
or	O
3	O
consecutive	O
days	O
)	O
,	O
a	O
decline	O
in	O
pulse	O
rate	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	B
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure	O
.	O

Reversal	O
to	O
normal	O
heart	O
rate	O
was	O
found	O
on	O
day	O
7	O
.	O

Electrocardiographic	O
registrations	O
showed	O
sinus	B
bradycardia	I
in	O
all	O
cases	O
.	O

No	O
significant	O
changes	O
in	O
plasma	O
concentrations	O
of	O
electrolytes	O
were	O
found	O
.	O

Careful	O
observation	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
MP	O
is	O
recommended	O
.	O

High	O
-	O
dose	O
MP	O
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	B
disease	I
.	O

Two	O
cases	O
of	O
downbeat	B
nystagmus	I
and	O
oscillopsia	B
associated	O
with	O
carbamazepine	O
.	O

Downbeat	B
nystagmus	I
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	O
the	O
craniocervical	O
junction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestation	O
of	O
metabolic	O
imbalance	O
or	O
drug	O
intoxication	O
.	O

We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	B
nystagmus	I
related	O
to	O
carbamazepine	O
therapy	O
.	O

The	O
nystagmus	B
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	O
levels	O
.	O

Neuroradiologic	O
investigations	O
including	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
both	O
patients	O
showed	O
no	O
evidence	O
of	O
intracranial	O
abnormality	O
.	O

In	O
patients	O
with	O
downbeat	B
nystagmus	I
who	O
are	O
taking	O
anticonvulsant	O
medications	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
in	O
dose	O
before	O
further	O
investigation	O
is	O
undertaken	O
.	O

Improvement	O
by	O
denopamine	O
(	O
TA-064	O
)	O
of	O
pentobarbital	O
-	O
induced	O
cardiac	B
failure	I
in	O
the	O
dog	O
heart	O
-	O
lung	O
preparation	O
.	O

The	O
efficacy	O
of	O
denopamine	O
,	O
an	O
orally	O
active	O
beta	O
1-adrenoceptor	O
agonist	O
,	O
in	O
improving	O
cardiac	B
failure	I
was	O
assessed	O
in	O
dog	O
heart	O
-	O
lung	O
preparations	O
.	O

Cardiac	O
functions	O
depressed	O
by	O
pentobarbital	O
(	O
118	O
+	O
/-	O

28	O
mg	O
;	O
mean	O
value	O
+	O
/-	O

SD	O
)	O
such	O
that	O
cardiac	O
output	O
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
reduced	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	O
(	O
10	O
-	O
300	O
micrograms	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

With	O
100	O
micrograms	O
denopamine	O
,	O
almost	O
complete	O
restoration	O
of	O
cardiac	O
performance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
increase	O
in	O
heart	O
rate	O
.	O

No	O
arrhythmias	B
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	O
.	O

The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	O
in	O
the	O
treatment	O
of	O
cardiac	B
failure	I
.	O

Clonazepam	O
monotherapy	O
for	O
epilepsy	B
in	O
childhood	O
.	O

Sixty	O
patients	O
(	O
age	O
-	O
range	O
one	O
month	O
to	O
14	O
years	O
)	O
with	O
other	O
types	O
of	O
epilepsy	B
than	O
infantile	B
spasms	I
were	O
treated	O
with	O
clonazepam	O
.	O

Disappearance	O
of	O
seizures	B
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	B
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Seizures	B
disappeared	O
in	O
71	O
%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	B
and	O
89	O
%	O
of	O
partial	O
seizures	B
.	O

Improvement	O
of	O
abnormal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diffuse	O
paroxysms	O
and	O
in	O
67	O
%	O
of	O
focal	O
paroxysms	O
.	O

In	O
excellent	O
cases	O
,	O
mean	O
effective	O
dosages	O
were	O
0.086	O
+	O
/-	O

0.021	O
mg	O
/	O
kg	O
/	O
day	O
in	O
infants	O
and	O
0.057	O
+	O
/-	O

0.022	O
mg	O
/	O
kg	O
/	O
day	O
in	O
schoolchildren	O
,	O
this	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	B
and	O
ataxia	B
was	O
only	O
5	O
%	O
.	O

Postmarketing	O
study	O
of	O
timolol	O
-	O
hydrochlorothiazide	O
antihypertensive	O
therapy	O
.	O

A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed	O
-	O
ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	O
maleate	O
and	O
25	O
mg	O
of	O
hydrochlorothiazide	O
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	B
patients	O
.	O

Data	O
on	O
9,037	O
patients	O
were	O
collected	O
by	O
1,455	O
participating	O
physicians	O
.	O

Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	O
-	O
hydrochlorothiazide	O
therapy	O
(	O
P	O
less	O
than	O
0.01	O
,	O
both	O
comparisons	O
)	O
.	O

Age	O
,	O
race	O
,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
decrease	O
in	O
blood	O
pressure	O
.	O

The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	B
.	O

Overall	O
,	O
1,453	O
patients	O
experienced	O
a	O
total	O
of	O
2,658	O
adverse	O
events	O
,	O
the	O
most	O
common	O
being	O
fatigue	B
,	O
dizziness	B
,	O
and	O
weakness	B
.	O

Treatment	O
in	O
590	O
patients	O
was	O
discontinued	O
because	O
of	O
adverse	O
events	O
.	O

Salicylate	O
nephropathy	B
in	O
the	O
Gunn	O
rat	O
:	O
potential	O
role	O
of	O
prostaglandins	O
.	O

We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	O
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	B
in	O
the	O
Gunn	O
strain	O
of	O
rat	O
.	O

The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	B
due	O
to	O
the	O
absence	O
of	O
glucuronyl	O
transferase	O
,	O
leading	O
to	O
marked	O
bilirubin	O
deposition	O
in	O
renal	O
medulla	O
and	O
papilla	O
.	O

These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	B
necrosis	I
with	O
analgesic	O
administration	O
.	O

We	O
used	O
homozygous	O
(	O
jj	O
)	O
and	O
phenotypically	O
normal	O
heterozygous	O
(	O
jJ	O
)	O
animals	O
.	O

Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	O
300	O
mg	O
/	O
kg	O
every	O
other	O
day	O
or	O
sham	O
-	O
treated	O
.	O

After	O
one	O
week	O
,	O
slices	O
of	O
cortex	O
,	O
outer	O
and	O
inner	O
medulla	O
from	O
one	O
kidney	O
were	O
incubated	O
in	O
buffer	O
and	O
prostaglandin	O
synthesis	O
was	O
determined	O
by	O
radioimmunoassay	O
.	O

The	O
other	O
kidney	O
was	O
examined	O
histologically	O
.	O

A	O
marked	O
corticomedullary	O
gradient	O
of	O
prostaglandin	O
synthesis	O
was	O
observed	O
in	O
all	O
groups	O
.	O

PGE2	O
synthesis	O
was	O
significantly	O
higher	O
in	O
outer	O
medulla	O
,	O
but	O
not	O
cortex	O
or	O
inner	O
medulla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/-	O

6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
rats	O
(	O
15	O
+	O
/-	O

3	O
)	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Aspirin	O
treatment	O
reduced	O
PGE2	O
synthesis	O
in	O
all	O
regions	O
,	O
but	O
outer	O
medullary	O
PGE2	O
remained	O
higher	O
in	O
jj	O
(	O
18	O
+	O
/-	O

3	O
)	O
than	O
jJ	O
rats	O
(	O
9	O
+	O
/-	O

2	O
)	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

PGF2	O
alpha	O
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	O
administration	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
changes	O
in	O
renal	O
prostaglandin	O
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	B
damage	I
in	O
aspirin	O
-	O
treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by	O
:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	B
(	O
p	O
less	O
than	O
0.01	O
)	O
;	O
increased	O
serum	O
creatinine	O
(	O
p	O
less	O
than	O
0.05	O
)	O
;	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(	O
p	O
less	O
than	O
0.005	O
compared	O
to	O
either	O
sham	O
-	O
treated	O
jj	O
or	O
aspirin	O
-	O
treated	O
jJ	O
)	O
.	O

These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	O
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	O
function	O
and	O
morphological	O
integrity	O
,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
may	O
lead	O
to	O
pathological	B
renal	I
medullary	I
lesions	I
and	O
deterioration	B
of	I
renal	I
function	I
.	O

Prophylactic	O
lidocaine	O
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	B
infarction	I
.	O

Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	B
infarction	I
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double	O
-	O
blind	O
randomized	O
trial	O
of	O
lidocaine	O
vs	O
placebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	B
fibrillation	I
or	O
sustained	O
ventricular	B
tachycardia	I
among	O
the	O
204	O
patients	O
with	O
acute	O
myocardial	B
infarction	I
was	O
low	O
,	O
1.5	O
%	O
.	O

Lidocaine	O
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously	O
,	O
did	O
not	O
prevent	O
sustained	O
ventricular	B
tachycardia	I
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	B
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
average	O
plasma	O
lidocaine	O
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	B
infarction	I
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	B
.	O

The	O
mean	O
plasma	O
lidocaine	O
level	O
of	O
patients	O
on	O
beta	O
-	O
blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents	O
.	O

During	O
the	O
1-hour	O
study	O
period	O
,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	O
group	O
,	O
hypotension	B
occurred	O
in	O
11	O
patients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	O
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	B
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	O
.	O

We	O
can	O
not	O
advocate	O
the	O
administration	O
of	O
lidocaine	O
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	B
infarction	I
.	O

Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol	O
-	O
induced	O
catalepsy	B
.	O

Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	B
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	O
-	O
induced	O
catalepsy	B
.	O

Large	O
doses	O
of	O
the	O
cholinomimetic	O
,	O
pilocarpine	O
,	O
could	O
induce	O
catalepsy	B
when	O
peripheral	O
cholinergic	O
receptors	O
were	O
blocked	O
.	O

Low	O
doses	O
of	O
pilocarpine	O
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	B
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker	O
,	O
haloperidol	O
.	O

A	O
muscarinic	O
receptor	O
blocker	O
,	O
atropine	O
,	O
disrupted	O
haloperidol	O
-	O
induced	O
catalepsy	B
.	O

Intracranial	O
injection	O
of	O
an	O
acetylcholine	O
-	O
synthesis	O
inhibitor	O
,	O
hemicholinium	O
,	O
prevented	O
the	O
catalepsy	B
that	O
is	O
usually	O
induced	O
by	O
haloperidol	O
.	O

These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	B
that	O
is	O
produced	O
by	O
neuroleptics	O
such	O
as	O
haloperidol	O
is	O
actually	O
mediated	O
by	O
intrinsic	O
central	O
cholinergic	O
systems	O
.	O

Alternatively	O
,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	B
by	O
suppression	O
of	O
dopaminergic	O
systems	O
.	O

Cardiovascular	B
dysfunction	I
and	O
hypersensitivity	B
to	O
sodium	O
pentobarbital	O
induced	O
by	O
chronic	O
barium	O
chloride	O
ingestion	O
.	O

Barium	O
-	O
supplemented	O
Long	O
-	O
Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	B
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	O
(	O
100	O
micrograms	O
/	O
ml	O
mineral	O
fortified	O
water	O
)	O
treatment	O
.	O

Analysis	O
of	O
in	O
vivo	O
myocardial	O
excitability	O
,	O
contractility	O
,	O
and	O
metabolic	O
characteristics	O
at	O
16	O
months	O
revealed	O
other	O
significant	O
barium	O
-	O
induced	O
disturbances	B
within	I
the	I
cardiovascular	I
system	I
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	O
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	B
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	O
pentobarbital	O
.	O

Under	O
barbiturate	O
anesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	O
significantly	O
in	O
barium	O
-	O
exposed	O
rats	O
relative	O
to	O
the	O
corresponding	O
control	O
-	O
fed	O
rats	O
.	O

The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	O
and	O
xylazine	O
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	O
pentobarbital	O
in	O
barium	O
-	O
treated	O
rats	O
were	O
linked	O
specifically	O
to	O
this	O
anesthetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalized	O
anesthetic	O
response	O
.	O

Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	O
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
employed	O
.	O

The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium	O
-	O
treated	O
rats	O
relative	O
to	O
the	O
control	O
groups	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
regimen	O
.	O

Similarly	O
,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	O
were	O
detected	O
in	O
the	O
barium	O
-	O
exposed	O
rats	O
which	O
were	O
consistent	O
with	O
the	O
reduced	O
contractile	O
element	O
shortening	O
velocity	O
.	O

In	O
addition	O
,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	O
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium	O
-	O
exposed	O
rats	O
.	O

Overall	O
,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics	O
,	O
the	O
myocardial	O
metabolic	B
disturbances	I
,	O
and	O
the	O
hypersensitivity	B
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	O
pentobarbital	O
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	B
disorder	I
induced	O
by	O
chronic	O
barium	O
exposure	O
.	O

These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life	O
-	O
long	O
barium	O
ingestion	O
may	O
have	O
significant	O
adverse	O
effects	O
on	O
the	O
mammalian	O
cardiovascular	O
system	O
.	O

Propranolol	O
antagonism	O
of	O
phenylpropanolamine	O
-	O
induced	O
hypertension	B
.	O

Phenylpropanolamine	O
(	O
PPA	O
)	O
overdose	B
can	O
cause	O
severe	O
hypertension	B
,	O
intracerebral	B
hemorrhage	I
,	O
and	O
death	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	O
in	O
the	O
treatment	O
of	O
PPA	O
-	O
induced	O
hypertension	B
.	O

Subjects	O
received	O
propranolol	O
either	O
by	O
mouth	O
for	O
48	O
hours	O
before	O
PPA	O
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	O
.	O

PPA	O
,	O
75	O
mg	O
alone	O
,	O
increased	O
blood	O
pressure	O
(	O
31	O
+	O
/-	O

14	O
mm	O
Hg	O
systolic	O
,	O
20	O
+	O
/-	O

5	O
mm	O
Hg	O
diastolic	O
)	O
,	O
and	O
propranolol	O
pretreatment	O
antagonized	O
this	O
increase	O
(	O
12	O
+	O
/-	O

10	O
mm	O
Hg	O
systolic	O
,	O
10	O
+	O
/-	O

7	O
mm	O
Hg	O
diastolic	O
)	O
.	O

Intravenous	O
propranolol	O
after	O
PPA	O
also	O
decreased	O
blood	O
pressure	O
.	O

Left	O
ventricular	O
function	O
(	O
assessed	O
by	O
echocardiography	O
)	O
showed	O
that	O
PPA	O
increased	O
the	O
stroke	B
volume	O
30	O
%	O
(	O
from	O
62.5	O
+	O
/-	O

20.9	O
to	O
80.8	O
+	O
/-	O

22.4	O
ml	O
)	O
,	O
the	O
ejection	O
fraction	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/-	O

10	O
%	O
to	O
70	O
%	O
+	O
/-	O

7	O
%	O
)	O
,	O
and	O
cardiac	O
output	O
14	O
%	O
(	O
from	O
3.6	O
+	O
/-	O

0.6	O
to	O
4.1	O
+	O
/-	O

1.0	O
L	O
/	O
min	O
)	O
.	O

Intravenous	O
propranolol	O
reversed	O
these	O
effects	O
.	O

Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	O
28	O
%	O
(	O
from	O
1710	O
+	O
/-	O

200	O
to	O
2190	O
+	O
/-	O

700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	O
22	O
%	O
(	O
to	O
2660	O
+	O
/-	O

1200	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	O
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
,	O
and	O
that	O
propranolol	O
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	O
on	O
cardiac	O
output	O
.	O

That	O
propranolol	O
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	O
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	O
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	O
.	O

This	O
is	O
probably	O
because	O
PPA	O
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	O
.	O

Mesangial	O
function	O
and	O
glomerular	B
sclerosis	I
in	O
rats	O
with	O
aminonucleoside	O
nephrosis	B
.	O

The	O
possible	O
relationship	O
between	O
mesangial	B
dysfunction	I
and	O
development	O
of	O
glomerular	B
sclerosis	I
was	O
studied	O
in	O
the	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
model	O
.	O

Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	O
injections	O
;	O
five	O
controls	O
received	O
saline	O
only	O
.	O

After	O
4	O
weeks	O
the	O
PAN	O
rats	O
were	O
severely	O
proteinuric	B
(	O
190	O
+	O
/-	O

80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	O
(	O
CC	O
)	O
intravenously	O
.	O

At	O
5	O
months	O
glomerular	B
sclerosis	I
was	O
found	O
in	O
7.6	O
+	O
/-	O

3.4	O
%	O
of	O
the	O
glomeruli	O
of	O
PAN	O
rats	O
;	O
glomeruli	O
of	O
the	O
controls	O
were	O
normal	O
.	O

Glomeruli	O
of	O
PAN	O
rats	O
contained	O
significantly	O
more	O
CC	O
than	O
glomeruli	O
of	O
controls	O
.	O

Glomeruli	O
with	O
sclerosis	B
contained	O
significantly	O
more	O
CC	O
than	O
non	O
-	O
sclerotic	O
glomeruli	O
in	O
the	O
same	O
kidneys	O
.	O

CC	O
was	O
preferentially	O
localized	O
within	O
the	O
sclerotic	O
areas	O
of	O
the	O
affected	O
glomeruli	O
.	O

Since	O
mesangial	O
CC	O
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	O
treatment	O
,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	O
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	O
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	B
will	O
develop	O
subsequently	O
.	O

Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	O
glomeruli	O
in	O
concordance	O
with	O
the	O
random	O
localization	O
of	O
mesangial	O
areas	O
with	O
dysfunction	O
in	O
this	O
model	O
.	O

Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	O
nephrosis	B
the	O
development	O
of	O
glomerular	B
sclerosis	I
may	O
be	O
related	O
to	O
""""	O
mesangial	O
overloading	O
.	O
""""	O

Relationship	O
between	O
nicotine	O
-	O
induced	O
seizures	B
and	O
hippocampal	O
nicotinic	O
receptors	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
years	O
concerning	O
the	O
physiological	O
relevance	O
of	O
the	O
nicotinic	O
receptor	O
measured	O
by	O
alpha	O
-	O
bungarotoxin	O
binding	O
.	O

Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design	O
,	O
a	O
relationship	O
between	O
nicotine	O
-	O
induced	O
seizures	B
and	O
alpha	O
-	O
bungarotoxin	O
nicotinic	O
receptor	O
concentration	O
was	O
found	O
.	O

Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	O
had	O
greater	O
alpha	O
-	O
bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	B
insensitive	O
mice	O
.	O

The	O
binding	O
sites	O
from	O
seizure	B
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	O
,	O
trypsin	O
or	O
heat	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	B
sensitive	O
and	O
insensitive	O
animals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocampal	O
nicotinic	O
receptor	O
concentration	O
as	O
measured	O
with	O
alpha	O
-	O
bungarotoxin	O
binding	O
.	O

The	O
role	O
of	O
p	O
-	O
aminophenol	O
in	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	B
:	O
effect	O
of	O
bis	O
(	O
p	O
-	O
nitrophenyl	O
)	O
phosphate	O
on	O
acetaminophen	O
and	O
p	O
-	O
aminophenol	O
nephrotoxicity	B
and	O
metabolism	O
in	O
Fischer	O
344	O
rats	O
.	O

Acetaminophen	O
(	O
APAP	O
)	O
produces	O
proximal	O
tubular	B
necrosis	I
in	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
.	O

Recently	O
,	O
p	O
-	O
aminophenol	O
(	O
PAP	O
)	O
,	O
a	O
known	O
potent	O
nephrotoxicant	O
,	O
was	O
identified	O
as	O
a	O
metabolite	O
of	O
APAP	O
in	O
F344	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	O
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	O
-	O
induced	O
nephrotoxicity	B
.	O

Therefore	O
,	O
the	O
effect	O
of	O
bis	O
(	O
p	O
-	O
nitrophenyl	O
)	O
phosphate	O
(	O
BNPP	O
)	O
,	O
an	O
acylamidase	O
inhibitor	O
,	O
on	O
APAP	O
and	O
PAP	O
nephrotoxicity	B
and	O
metabolism	O
was	O
determined	O
.	O

BNPP	O
(	O
1	O
to	O
8	O
mM	O
)	O
reduced	O
APAP	O
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	O
cortical	O
homogenates	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Pretreatment	O
of	O
animals	O
with	O
BNPP	O
prior	O
to	O
APAP	O
or	O
PAP	O
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	O
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxicity	B
but	O
not	O
PAP	O
nephrotoxicity	B
.	O

This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	O
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	O
cortical	O
and	O
hepatic	O
tissue	O
.	O

Rather	O
,	O
BNPP	O
pretreatment	O
reduced	O
the	O
fraction	O
of	O
APAP	O
excreted	O
as	O
PAP	O
by	O
64	O
and	O
75	O
%	O
after	O
APAP	O
doses	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BNPP	O
did	O
not	O
alter	O
the	O
excretion	O
of	O
APAP	O
or	O
any	O
of	O
its	O
non	O
-	O
deacetylated	O
metabolites	O
nor	O
did	O
BNPP	O
alter	O
excretion	O
of	O
PAP	O
or	O
its	O
metabolites	O
after	O
PAP	O
doses	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BNPP	O
-	O
induced	O
reduction	O
in	O
APAP	O
-	O
induced	O
nephrotoxicity	B
appears	O
to	O
be	O
due	O
to	O
inhibition	O
of	O
APAP	O
deacetylation	O
.	O

It	O
is	O
concluded	O
that	O
PAP	O
formation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP	O
-	O
induced	O
renal	B
tubular	I
necrosis	I
.	O

Morphine	O
-	O
induced	O
seizures	B
in	O
newborn	O
infants	O
.	O

Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	B
during	O
the	O
course	O
of	O
intravenous	O
morphine	O
sulfate	O
for	O
post	O
-	O
operative	O
analgesia	O
.	O

They	O
received	O
morphine	O
in	O
doses	O
of	O
32	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micrograms	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6	O
-	O
24	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizures	B
.	O

Plasma	O
concentrations	O
of	O
morphine	O
in	O
these	O
neonates	O
was	O
excessive	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
reasons	O
for	O
seizures	B
were	O
ruled	O
out	O
and	O
the	O
convulsions	B
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	O
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months	O
.	O

It	O
is	O
suggested	O
that	O
post	O
-	O
operative	O
intravenous	O
morphine	O
should	O
not	O
exceed	O
20	O
micrograms	O
/	O
kg	O
/	O
ml	O
in	O
neonates	O
.	O

On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N	O
-	O
substituted	O
piperazine	O
derivative	O
of	O
trans-2-amino-3-hydroxy-1	O
,	O
2	O
,	O
3	O
,	O
4-tetrahydroanaphthalene	O
.	O

The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N-	O
(	O
trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl	O
)	O
-N-	O
(	O
3-oxo-3-phenyl-2-methylpropyl	O
)	O
-piperazine	O
hydrochloride	O
,	O
referred	O
to	O
as	O
P11	O
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
anaesthesized	O
rabbits	O
.	O

Four	O
types	O
of	O
experimental	O
arrhythmia	B
are	O
used	O
--	O
with	O
BaCl2	O
,	O
with	O
chloroform	O
-	O
adrenaline	O
,	O
with	O
strophantine	O
G	O
and	O
with	O
aconitine	O
.	O

The	O
compound	O
P11	O
is	O
introduced	O
in	O
doses	O
of	O
0.25	O
and	O
0.50	O
mg	O
/	O
kg	O
intravenously	O
and	O
10	O
mg	O
/	O
kg	O
orally	O
.	O

The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	B
used	O
,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	B
induced	O
by	O
chloroform	O
-	O
adrenaline	O
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	O
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
results	O
obtained	O
are	O
associated	O
with	O
the	O
beta	O
-	O
adrenoblocking	O
and	O
with	O
the	O
membrane	O
-	O
stabilizing	O
action	O
of	O
the	O
compound	O
.	O

Recurrent	O
subarachnoid	B
hemorrhage	I
associated	O
with	O
aminocaproic	O
acid	O
therapy	O
and	O
acute	B
renal	I
artery	I
thrombosis	I
.	O

Case	O
report	O
.	O

Epsilon	O
aminocaproic	O
acid	O
(	O
EACA	O
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	B
hemorrhage	I
(	O
SAH	B
)	O
.	O

Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding	O
,	O
several	O
reports	O
have	O
described	O
thrombotic	B
complications	O
of	O
EACA	O
therapy	O
.	O

These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	B
vascular	I
thrombosis	I
in	O
patients	O
with	O
SAH	B
,	O
arteriolar	O
and	O
capillary	O
fibrin	O
thrombi	B
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	O
,	O
or	O
other	O
thromboembolic	B
phenomena	I
.	O

Since	O
intravascular	O
fibrin	O
thrombi	B
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders	O
,	O
EACA	O
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	B
in	O
patients	O
with	O
disseminated	B
intravascular	I
coagulation	I
or	O
other	O
""""	O
consumption	B
coagulopathies	I
.	O
""""	O

This	O
report	O
describes	O
subtotal	O
infarction	B
of	O
the	O
kidney	O
due	O
to	O
thrombosis	B
of	I
a	I
normal	I
renal	I
artery	I
.	O

This	O
occlusion	O
occurred	O
after	O
EACA	O
therapy	O
in	O
a	O
patient	O
with	O
SAH	B
and	O
histopathological	O
documentation	O
of	O
recurrent	O
SAH	B
.	O

The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	B
and	O
abrupt	O
neurological	O
deterioration	O
.	O

Effect	O
of	O
vincristine	O
sulfate	O
on	O
Pseudomonas	B
infections	I
in	O
monkeys	O
.	O

In	O
rhesus	O
monkeys	O
,	O
intravenous	O
challenge	O
with	O
0.6	O
x	O
10	O
(	O
10	O
)	O
to	O
2.2	O
x	O
10	O
(	O
10	O
)	O
Pseudomonas	O
aeruginosa	O
organisms	O
caused	O
acute	O
illness	O
of	O
4	O
to	O
5	O
days	O
'	O
duration	O
with	O
spontaneous	O
recovery	O
in	O
13	O
of	O
15	O
monkeys	O
;	O
blood	O
cultures	O
became	O
negative	O
3	O
to	O
17	O
days	O
after	O
challenge	O
.	O

Leukocytosis	B
was	O
observed	O
in	O
all	O
monkeys	O
.	O

Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2.0	O
to	O
2.5	O
mg	O
of	O
vincristine	O
sulfate	O
was	O
followed	O
by	O
leukopenia	B
in	O
4	O
to	O
5	O
days	O
.	O

Intravenous	O
inoculation	O
of	O
4.2	O
x	O
10	O
(	O
10	O
)	O
to	O
7.8	O
x	O
10	O
(	O
10	O
)	O
pyocin	O
type	O
6	O
Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	O
sulfate	O
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	B
in	O
11	O
of	O
14	O
monkeys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseudomonas	O
alone	O
died	O
.	O

These	O
studies	O
suggest	O
that	O
an	O
antimetabolite	O
-	O
induced	O
leukopenia	B
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	B
and	O
that	O
such	O
monkeys	O
may	O
serve	O
as	O
a	O
biological	O
model	O
for	O
study	O
of	O
comparative	O
efficacy	O
of	O
antimicrobial	O
agents	O
.	O

Modification	O
by	O
propranolol	O
of	O
cardiovascular	O
effects	O
of	O
induced	O
hypoglycaemia	B
.	O

The	O
cardiovascular	O
effects	O
of	O
hypoglycaemia	B
,	O
with	O
and	O
without	O
beta	O
-	O
blockade	O
,	O
were	O
compared	O
in	O
fourteen	O
healthy	O
men	O
.	O

Eight	O
received	O
insulin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulin	O
-	O
only	O
group	O
,	O
were	O
given	O
propranolol	O
and	O
insulin	O
.	O

In	O
the	O
insulin	O
-	O
group	O
the	O
period	O
of	O
hypoglycaemia	B
was	O
associated	O
with	O
an	O
increase	O
in	O
heart	O
-	O
rate	O
and	O
a	O
fall	O
in	O
diastolic	O
blood	O
-	O
pressure	O
.	O

In	O
the	O
propranolol	O
-	O
insulin	O
group	O
there	O
was	O
a	O
significant	O
fall	O
in	O
heart	O
-	O
rate	O
in	O
most	O
subjects	O
and	O
an	O
increase	O
in	O
diastolic	O
pressure	O
.	O

Typical	O
S	O
-	O
T	O
/	O
T	O
changes	O
occurred	O
in	O
the	O
insulin	O
-	O
group	O
but	O
in	O
none	O
of	O
the	O
propranolol	O
-	O
insulin	O
group	O
.	O

Hypertension	B
in	O
diabetics	B
prone	O
to	O
hypoglycaemia	B
attacks	O
should	O
not	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
because	O
these	O
drugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blood	O
-	O
pressure	O
in	O
such	O
patients	O
.	O

Long	O
-	O
term	O
propranolol	O
therapy	O
in	O
pregnancy	O
:	O
maternal	O
and	O
fetal	O
outcome	O
.	O

Propranolol	O
,	O
a	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
has	O
found	O
an	O
important	O
position	O
in	O
the	O
practice	O
of	O
medicine	O
.	O

Its	O
use	O
in	O
pregnancy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detrimental	O
side	O
effects	O
have	O
been	O
reported	O
in	O
the	O
fetus	O
and	O
neonate	O
.	O

Ten	O
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	O
has	O
been	O
administered	O
.	O

Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	O
therapy	O
are	O
also	O
examined	O
.	O

Maternal	O
,	O
fetal	O
,	O
and	O
neonatal	O
complications	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differentiate	O
drug	O
-	O
related	O
complications	O
from	O
maternal	O
disease	O
--	O
related	O
complications	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	B
,	O
hyperbilirubinemia	B
,	O
polycythemia	B
,	O
neonatal	B
apnea	I
,	O
and	O
bradycardia	B
are	O
not	O
invariable	O
and	O
can	O
not	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	O
therapy	O
.	O

Growth	B
retardation	I
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

Central	O
excitatory	O
actions	O
of	O
flurazepam	O
.	O

Toxic	O
actions	O
of	O
flurazepam	O
(	O
FZP	O
)	O
were	O
studied	O
in	O
cats	O
,	O
mice	O
and	O
rats	O
.	O

High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	B
,	O
superimposed	O
on	O
general	O
depression	B
.	O

Following	O
a	O
lethal	O
dose	O
,	O
death	O
was	O
always	O
associated	O
with	O
convulsions	B
.	O

Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	B
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	B
at	O
doses	O
that	O
did	O
not	O
first	O
cause	O
loss	B
of	I
consciousness	I
,	O
while	O
cats	O
most	O
clearly	O
showed	O
marked	O
central	O
excitatory	O
actions	O
.	O

Signs	O
of	O
FZP	O
toxocity	B
in	O
cats	O
included	O
excessive	O
salivation	B
,	O
extreme	O
apprehensive	O
behavior	O
,	O
retching	O
,	O
muscle	B
tremors	I
and	O
convulsions	B
.	O

An	O
interaction	O
between	O
FZP	O
and	O
pentylenetetrazol	O
(	O
PTZ	O
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	O
before	O
PTZ	O
challenge	O
.	O

As	O
a	O
function	O
of	O
dose	O
,	O
FZP	O
first	O
protected	O
against	O
convulsions	B
and	O
death	O
.	O

At	O
higher	O
doses	O
,	O
however	O
,	O
convulsions	B
again	O
emerged	O
.	O

These	O
doses	O
of	O
FZP	O
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	B
.	O

These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	O
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability	O
,	O
such	O
as	O
epilepsy	B
or	O
sedative	O
-	O
hypnotic	O
drug	O
withdrawal	O
.	O

Use	O
of	O
propranolol	O
in	O
the	O
treatment	O
of	O
idiopathic	B
orthostatic	I
hypotension	I
.	O

Five	O
patients	O
with	O
idiopathic	B
orthostatic	I
hypotension	I
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	O
dysfunction	O
were	O
included	O
in	O
the	O
study	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	O
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	B
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	O
.	O

Treatment	O
with	O
propanolol	O
administered	O
intravenously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
increases	O
in	O
supine	O
and	O
upright	O
blood	O
pressure	O
in	O
4	O
of	O
the	O
5	O
individuals	O
with	O
rises	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O

Chronic	O
oral	O
administration	O
of	O
propranolol	O
(	O
40	O
-	O
160	O
mg	O
/	O
day	O
)	O
also	O
elevated	O
the	O
blood	O
pressures	O
of	O
these	O
individuals	O
with	O
increases	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
patient	O
,	O
marked	O
hypertension	B
was	O
induced	O
by	O
propranolol	O
and	O
the	O
drug	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
tolerated	O
and	O
no	O
important	O
side	O
effects	O
were	O
observed	O
.	O

Treatment	O
has	O
been	O
continued	O
in	O
3	O
individuals	O
for	O
6	O
-	O
13	O
months	O
with	O
persistence	O
of	O
the	O
pressor	O
effect	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decrease	O
in	O
the	O
degree	O
of	O
response	O
with	O
time	O
.	O

Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	O
therapy	O
.	O

The	O
studies	O
suggest	O
that	O
propranolol	O
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	B
orthostatic	I
hypotension	I
.	O

Total	O
intravenous	O
anesthesia	O
with	O
etomidate	O
.	O

III	O
.	O

Some	O
observations	O
in	O
adults	O
.	O

An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	O
required	O
to	O
maintain	O
sleep	O
in	O
adults	O
undergoing	O
surgery	O
under	O
regional	O
local	O
anesthesia	O
.	O

Premedication	O
of	O
diazepam	O
10	O
mg	O
and	O
atropine	O
0.5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	O
0.1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patient	O
would	O
open	O
his	O
eyes	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dose	O
of	O
etomidate	O
17.4	O
microgram	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
sleep	O
,	O
but	O
great	O
individual	O
variation	O
occurred	O
,	O
with	O
older	O
patients	O
requiring	O
less	O
drug	O
.	O

The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side	O
-	O
effects	O
,	O
particularly	O
pain	B
and	O
myoclonia	B
,	O
which	O
caused	O
the	O
technique	O
to	O
be	O
abandoned	O
in	O
two	O
cases	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etomidate	O
will	O
prove	O
to	O
be	O
the	O
hypnotic	O
of	O
choice	O
for	O
a	O
totally	O
intravenous	O
anesthetic	O
technique	O
in	O
adults	O
because	O
of	O
the	O
high	O
incidence	O
of	O
myoclonia	B
after	O
prolonged	O
administration	O
.	O

In	O
several	O
patients	O
uncontrollable	O
muscle	O
movements	O
persisted	O
for	O
many	O
minutes	O
after	O
complete	O
recovery	O
of	O
consciousness	O
.	O

Evidence	O
for	O
cardiac	O
beta	O
2-adrenoceptors	O
in	O
man	O
.	O

We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	O
(	O
cardioselective	O
)	O
,	O
40	O
mg	O
propranolol	O
(	O
nonselective	O
)	O
,	O
and	O
placebo	O
on	O
both	O
exercise-	O
and	O
isoproterenol	O
-	O
induced	O
tachycardia	B
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects	O
.	O

Maximal	O
exercise	O
heart	O
rate	O
was	O
reduced	O
from	O
187	O
+	O
/-	O

4	O
(	O
SEM	O
)	O
after	O
placebo	O
to	O
146	O
+	O
/-	O

7	O
bpm	O
after	O
atenolol	O
and	O
138	O
+	O
/-	O

6	O
bpm	O
after	O
propranolol	O
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
the	O
drugs	O
.	O

The	O
effects	O
on	O
isoproterenol	O
tachycardia	B
were	O
determined	O
before	O
and	O
after	O
atropine	O
(	O
0.04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Isoproterenol	O
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
increased	O
from	O
1.8	O
+	O
/-	O

0.3	O
micrograms	O
after	O
placebo	O
to	O
38.9	O
+	O
/-	O

8.3	O
micrograms	O
after	O
propranolol	O
and	O
8.3	O
+	O
/-	O

1.7	O
micrograms	O
after	O
atenolol	O
.	O

The	O
difference	O
in	O
the	O
effects	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
atropine	O
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(	O
2.3	O
+	O
/-	O

0.3	O
micrograms	O
)	O
and	O
atenolol	O
(	O
7.7	O
+	O
/-	O

1.3	O
micrograms	O
)	O
;	O
it	O
was	O
reduced	O
after	O
propranolol	O
(	O
24.8	O
+	O
/-	O

5.0	O
micrograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenolol	O
.	O

This	O
change	O
with	O
propranolol	O
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka	O
,	O
this	O
was	O
unchanged	O
by	O
atropine	O
(	O
11.7	O
+	O
/-	O

2.1	O
and	O
10.1	O
+	O
/-	O

2.5	O
ml	O
/	O
ng	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise	O
-	O
induced	O
tachycardia	B
results	O
largely	O
from	O
beta	O
1-receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	O
activates	O
both	O
beta	O
1-	O
and	O
beta	O
2-receptors	O
so	O
that	O
after	O
cardioselective	O
blockade	O
there	O
remains	O
a	O
beta	O
2-component	O
that	O
can	O
be	O
blocked	O
with	O
a	O
nonselective	O
drug	O
.	O

While	O
there	O
appear	O
to	O
be	O
beta	O
2-receptors	O
in	O
the	O
human	O
heart	O
,	O
their	O
physiologic	O
or	O
pathologic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

Hormones	O
and	O
risk	O
of	O
breast	B
cancer	I
.	O

This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
study	O
of	O
50	O
menopausal	O
women	O
receiving	O
hormonal	O
replacement	O
therapy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
surgical	O
menopause	O
;	O
their	O
mean	O
age	O
was	O
45.7	O
years	O
.	O

It	O
was	O
hypothesized	O
that	O
progestins	O
could	O
equilibrate	O
the	O
effects	O
of	O
the	O
estrogenic	O
stimulation	O
on	O
the	O
mammary	O
and	O
endometrial	O
target	O
tissues	O
of	O
women	O
on	O
hormonal	O
replacement	O
therapy	O
.	O

The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	O
estrogens	O
(	O
Premarin	O
)	O
1.25	O
mg	O
/	O
day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	O
acetate	O
10	O
mg	O
/	O
day	O
for	O
10	O
days	O
in	O
each	O
month	O
.	O

The	O
mean	O
treatment	O
period	O
was	O
18	O
months	O
.	O

During	O
the	O
follow	O
-	O
up	O
period	O
,	O
attention	O
was	O
paid	O
to	O
breast	O
modifications	O
as	O
evidenced	O
by	O
symptomatology	O
,	O
physical	O
examination	O
,	O
and	O
plate	O
thermography	O
.	O

Mastodynia	B
was	O
reported	O
by	O
21	O
patients	O
,	O
and	O
physical	O
examination	O
revealed	O
a	O
light	O
increase	O
in	O
breast	O
firmness	O
in	O
12	O
women	O
and	O
a	O
moderate	O
increase	O
in	O
breast	O
nodularity	O
in	O
2	O
women	O
.	O

Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	B
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	B
.	O

Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	O
dose	O
.	O

These	O
results	O
suggest	O
that	O
hormonal	O
replacement	O
therapy	O
can	O
be	O
safely	O
prescribed	O
if	O
the	O
following	O
criteria	O
are	O
satisfied	O
:	O
1	O
)	O
preliminary	O
evaluation	O
of	O
patients	O
from	O
a	O
clinical	O
,	O
metabolic	O
,	O
cytologic	O
,	O
and	O
mammographic	O
perspective	O
;	O
2	O
)	O
cyclic	O
treatment	O
schedule	O
,	O
with	O
a	O
progestative	O
phase	O
of	O
10	O
days	O
;	O
and	O
3	O
)	O
periodic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
accurate	O
thermographic	O
evaluation	O
of	O
the	O
breast	O
target	O
tissues	O
.	O

Early	O
infections	B
in	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
transplant	O
recipients	O
on	O
cyclosporine	O
.	O

Eighty	O
-	O
one	O
renal	O
,	O
seventeen	O
heart	O
,	O
and	O
twenty	O
-	O
four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	B
.	O

Seventeen	O
renal	O
patients	O
received	O
azathioprine	O
(	O
Aza	O
)	O
and	O
prednisone	O
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine	O
-	O
and	O
-	O
prednisone	O
-	O
treated	O
renal	O
transplant	O
patients	O
.	O

All	O
others	O
received	O
cyclosporine	O
and	O
prednisone	O
.	O

The	O
randomized	O
Aza	O
patients	O
had	O
more	O
overall	O
infections	B
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
more	O
nonviral	O
infections	B
(	O
P	O
less	O
than	O
0.02	O
)	O
than	O
the	O
randomized	O
cyclosporine	O
patients	O
.	O

Heart	O
and	O
liver	O
patients	O
had	O
more	O
infections	B
than	O
cyclosporine	O
renal	O
patients	O
but	O
fewer	O
infections	B
than	O
the	O
Aza	O
renal	O
patients	O
.	O

There	O
were	O
no	O
infectious	O
deaths	O
in	O
renal	O
transplant	O
patients	O
on	O
cyclosporine	O
or	O
Aza	O
,	O
but	O
infection	B
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	O
and	O
in	O
8	O
out	O
of	O
9	O
liver	O
transplant	O
deaths	O
.	O

Renal	O
patients	O
on	O
cyclosporine	O
had	O
the	O
fewest	O
bacteremias	B
.	O

Analysis	O
of	O
site	O
of	O
infection	B
showed	O
a	O
preponderance	O
of	O
abdominal	B
infections	I
in	O
liver	O
patients	O
,	O
intrathoracic	O
infections	B
in	O
heart	O
patients	O
,	O
and	O
urinary	B
tract	I
infections	I
in	O
renal	O
patients	O
.	O

Pulmonary	O
infections	B
were	O
less	O
common	O
in	O
cyclosporine	O
-	O
treated	O
renal	O
patients	O
than	O
in	O
Aza	O
-	O
treated	O
patients	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Aza	O
patients	O
had	O
significantly	O
more	O
staphylococcal	B
infections	I
than	O
all	O
other	O
transplant	O
groups	O
(	O
P	O
less	O
than	O
0.005	O
)	O
,	O
and	O
systemic	O
fungal	B
infections	I
occurred	O
only	O
in	O
the	O
liver	O
transplant	O
group	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cyclosporine	O
patients	O
and	O
76	O
%	O
of	O
Aza	O
patients	O
.	O

Of	O
the	O
cyclosporine	O
patients	O
,	O
15	O
%	O
had	O
symptoms	O
related	O
to	O
CMV	B
infection	I
.	O

Serological	O
evidence	O
for	O
Epstein	B
Barr	I
Virus	I
infection	I
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporine	O
patients	O
studied	O
.	O

Three	O
had	O
associated	O
symptoms	O
,	O
and	O
one	O
developed	O
a	O
lymphoma	B
.	O

Structure	O
-	O
activity	O
and	O
dose	O
-	O
effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin	O
-	O
induced	O
seizures	B
by	O
cholecystokinin	O
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	O
in	O
mice	O
.	O

Intraperitoneal	O
administration	O
of	O
cholecystokinin	O
octapeptide	O
sulphate	O
ester	O
(	O
CCK-8-SE	O
)	O
and	O
nonsulphated	O
cholecystokinin	O
octapeptide	O
(	O
CCK-8-NS	O
)	O
enhanced	O
the	O
latency	O
of	O
seizures	B
induced	O
by	O
picrotoxin	O
in	O
mice	O
.	O

Experiments	O
with	O
N-	O
and	O
C	O
-	O
terminal	O
fragments	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
tetrapeptide	O
(	O
CCK-5	O
-	O
8	O
)	O
was	O
the	O
active	O
centre	O
of	O
the	O
CCK	O
octapeptide	O
molecule	O
.	O

The	O
analogues	O
CCK-8-SE	O
and	O
CCK-8-NS	O
(	O
dose	O
range	O
0.2	O
-	O
6.4	O
mumol	O
/	O
kg	O
)	O
and	O
caerulein	O
dose	O
range	O
0.1	O
-	O
0.8	O
mumol	O
/	O
kg	O
)	O
showed	O
bell	O
-	O
shaped	O
dose	O
-	O
effect	O
curves	O
,	O
with	O
the	O
greatest	O
maximum	O
inhibition	O
for	O
CCK-8-NS	O
.	O

The	O
peptide	O
CCK-5	O
-	O
8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides	O
,	O
3.2	O
mumol	O
/	O
kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug	O
,	O
diazepam	O
,	O
totally	O
prevented	O
picrotoxin	O
-	O
induced	O
seizures	B
and	O
mortality	O
.	O

The	O
maximum	O
effect	O
of	O
the	O
peptides	O
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	O
.	O

Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta	O
-	O
alanyl	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK-8-SE	O
.	O

Of	O
the	O
CCK-2	O
-	O
8	O
analogues	O
,	O
Ser	O
(	O
SO3H	O
)	O
7-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
and	O
Thr	O
(	O
SO3H	O
)	O
7-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
and	O
Hyp	O
(	O
SO3H	O
)	O
-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
were	O
slightly	O
more	O
active	O
than	O
CCK-8-SE	O
.	O

Vasopressin	O
as	O
a	O
possible	O
contributor	O
to	O
hypertension	B
.	O

The	O
role	O
of	O
vasopressin	O
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	B
process	O
was	O
examined	O
.	O

Vasopressin	O
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA	O
-	O
salt	O
hypertension	B
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium	O
-	O
treated	O
diabetes	B
insipidus	I
after	O
DOCA	O
-	O
salt	O
treatment	O
.	O

Administration	O
of	O
DDAVP	O
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
pressor	O
action	O
of	O
vasopressin	O
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	B
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	B
.	O

Increased	O
secretion	O
of	O
vasopressin	O
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	B
.	O

An	O
unproportional	O
release	O
of	O
vasopressin	O
compared	O
to	O
plasma	O
osmolality	O
may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	O
II	O
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	O
balance	O
in	O
the	O
brain	O
.	O

However	O
,	O
the	O
role	O
of	O
vasopressin	O
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	O
hypertension	B
.	O

Toxic	B
hepatitis	I
induced	O
by	O
disulfiram	O
in	O
a	O
non	O
-	O
alcoholic	O
.	O

A	O
reversible	O
toxic	B
liver	I
damage	I
was	O
observed	O
in	O
a	O
non	O
-	O
alcoholic	O
woman	O
treated	O
with	O
disulfiram	O
.	O

The	O
causative	O
relationship	O
was	O
proven	O
by	O
challenge	O
.	O

Atrial	B
thrombosis	I
involving	O
the	O
heart	O
of	O
F-344	O
rats	O
ingesting	O
quinacrine	O
hydrochloride	O
.	O

Quinacrine	O
hydrochloride	O
is	O
toxic	O
for	O
the	O
heart	O
of	O
F-344	O
rats	O
.	O

Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	O
hydrochloride	O
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	B
thrombosis	I
.	O

The	O
lesion	O
was	O
associated	O
with	O
cardiac	B
hypertrophy	I
and	O
dilatation	O
and	O
focal	O
myocardial	B
degeneration	I
.	O

Rats	O
died	O
from	O
cardiac	B
hypertrophy	I
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs	O
,	O
liver	O
,	O
and	O
other	O
organs	O
.	O

Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	O
hydrochloride	O
and	O
1,000	O
ppm	O
sodium	O
nitrite	O
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	B
of	O
the	O
atria	O
of	O
the	O
heart	O
,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	B
thrombosis	I
.	O

Sodium	O
nitrite	O
in	O
combination	O
with	O
quinacrine	O
hydrochloride	O
appeared	O
to	O
have	O
no	O
additional	O
effect	O
.	O

Alternating	B
sinus	I
rhythm	I
and	O
intermittent	O
sinoatrial	B
block	I
induced	O
by	O
propranolol	O
.	O

Alternating	B
sinus	I
rhythm	I
and	O
intermittent	O
sinoatrial	B
(	I
S	I
-	I
A	I
)	I
block	I
was	O
observed	O
in	O
a	O
57-year	O
-	O
old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	B
with	O
80	O
mg	O
propranolol	O
daily	O
.	O

The	O
electrocardiogram	O
showed	O
alternation	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
intervals	O
and	O
occasional	O
pauses	O
.	O

These	O
pauses	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
intervals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
intervals	O
of	O
0.92	O
-	O
0.95	O
s	O
representing	O
the	O
basic	O
sinus	O
cycle	O
.	O

Following	O
these	O
basic	O
sinus	O
cycles	O
,	O
alternating	B
rhythm	I
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
interval	O
.	O

The	O
long	O
P	O
-	O
P	O
intervals	O
ranged	O
between	O
1.04	O
-	O
1.12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
intervals	O
between	O
0.80	O
-	O
0.84	O
s	O
,	O
respectively	O
.	O

The	O
duration	O
of	O
the	O
pauses	O
were	O
equal	O
or	O
almost	O
equal	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
interval	O
or	O
to	O
twice	O
the	O
basic	O
sinus	O
cycle	O
.	O

In	O
one	O
recording	O
a	O
short	O
period	O
of	O
regular	O
sinus	O
rhythm	O
with	O
intermittent	O
2	O
/	O
1	O
S	B
-	I
A	I
block	I
was	O
observed	O
.	O

This	O
short	O
period	O
of	O
sinus	O
rhythm	O
was	O
interrupted	O
by	O
sudden	O
prolongation	O
of	O
the	O
P	O
-	O
P	O
interval	O
starting	O
the	O
alternative	O
rhythm	O
.	O

There	O
were	O
small	O
changes	O
in	O
the	O
shape	O
of	O
the	O
P	O
waves	O
and	O
P	O
-	O
R	O
intervals	O
.	O

S	O
-	O
A	O
conduction	O
through	O
two	O
pathways	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
block	O
the	O
second	O
having	O
0.12	O
-	O
0.14	O
s	O
longer	O
conduction	O
time	O
and	O
with	O
occasional	O
2	O
/	O
1	O
block	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
interval	O
and	O
other	O
electrocardiographic	O
features	O
seen	O
.	O

Atropine	O
1	O
mg	O
given	O
intravenously	O
resulted	O
in	O
shortening	O
of	O
all	O
P	O
-	O
P	O
intervals	O
without	O
changing	O
the	O
rhythm	O
.	O

The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	O
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2	O
/	O
1	O
S	B
-	I
A	I
block	I
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	O
being	O
the	O
cause	O
of	O
this	O
conduction	B
disorder	I
.	O

Antitumor	O
effect	O
,	O
cardiotoxicity	B
,	O
and	O
nephrotoxicity	B
of	O
doxorubicin	O
in	O
the	O
IgM	O
solid	O
immunocytoma	B
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Antitumor	O
activity	O
,	O
cardiotoxicity	B
,	O
and	O
nephrotoxicity	B
induced	O
by	O
doxorubicin	O
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inbred	O
rats	O
each	O
bearing	O
a	O
transplantable	O
solid	O
IgM	O
immunocytoma	B
.	O

Animals	O
with	O
a	O
tumor	B
(	O
diameter	O
,	O
15.8	O
+	O
/-	O

3.3	O
mm	O
)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	O
on	O
5	O
consecutive	O
days	O
,	O
followed	O
by	O
1	O
weekly	O
injection	O
for	O
7	O
weeks	O
(	O
dose	O
range	O
,	O
0.015	O
-	O
4.0	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
.	O

Tumor	B
regression	O
was	O
observed	O
with	O
0.5	O
mg	O
doxorubicin	O
/	O
kg	O
.	O

Complete	O
disappearance	O
of	O
the	O
tumor	B
was	O
induced	O
with	O
1.0	O
mg	O
doxorubicin	O
/	O
kg	O
.	O

Histologic	O
evidence	O
of	O
cardiotoxicity	B
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dose	O
of	O
1.0	O
mg	O
doxorubicin	O
/	O
kg	O
.	O

Light	O
microscopic	O
evidence	O
of	O
renal	B
damage	I
was	O
seen	O
above	O
a	O
dose	O
of	O
0.5	O
mg	O
doxorubicin	O
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuria	B
and	O
very	O
low	O
serum	O
albumin	O
levels	O
.	O

In	O
the	O
group	O
that	O
received	O
1.0	O
mg	O
doxorubicin	O
/	O
kg	O
,	O
the	O
serum	O
albumin	O
level	O
decreased	O
from	O
33.6	O
+	O
/-	O

4.1	O
to	O
1.5	O
+	O
/-	O

0.5	O
g	O
/	O
liter	O
.	O

Ascites	B
and	O
hydrothorax	B
were	O
observed	O
simultaneously	O
.	O

The	O
same	O
experiments	O
were	O
performed	O
with	O
non	O
-	O
tumor	B
-	O
bearing	O
rats	O
,	O
in	O
which	O
no	O
major	O
differences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	B
,	O
and	O
nephrotoxicity	B
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Albuminuria	B
due	O
to	O
renal	B
damage	I
led	O
to	O
extremely	O
low	O
serum	O
albumin	O
levels	O
,	O
so	O
ascites	B
and	O
hydrothorax	B
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	B
.	O

Intraoperative	O
bradycardia	B
and	O
hypotension	B
associated	O
with	O
timolol	O
and	O
pilocarpine	O
eye	O
drops	O
.	O

A	O
69-yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	O
nitrate	O
and	O
timolol	O
maleate	O
eye	O
drops	O
,	O
developed	O
a	O
bradycardia	B
and	O
became	O
hypotensive	B
during	O
halothane	O
anaesthesia	O
.	O

Both	O
timolol	O
and	O
pilocarpine	O
were	O
subsequently	O
identified	O
in	O
a	O
24-h	O
collection	O
of	O
urine	O
.	O

Timolol	O
(	O
but	O
not	O
pilocarpine	O
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery	O
;	O
the	O
plasma	O
concentration	O
of	O
timolol	O
(	O
2.6	O
ng	O
ml-1	O
)	O
was	O
consistent	O
with	O
partial	O
beta	O
-	O
adrenoceptor	O
blockade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	O
anaesthesia	O
with	O
resultant	O
bradycardia	B
and	O
hypotension	B
.	O

Pilocarpine	O
may	O
have	O
had	O
a	O
contributory	O
effect	O
.	O

Succinylcholine	O
apnoea	B
:	O
attempted	O
reversal	O
with	O
anticholinesterases	O
.	O

Anticholinesterases	O
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	B
blockade	I
following	O
the	O
administration	O
of	O
succinylcholine	O
in	O
a	O
patient	O
later	O
found	O
to	O
be	O
homozygous	O
for	O
atypical	O
plasma	O
cholinesterase	O
.	O

Edrophonium	O
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcholine	O
,	O
when	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
was	O
characteristic	O
of	O
phase	O
II	O
block	O
,	O
produced	O
partial	O
antagonism	O
which	O
was	O
not	O
sustained	O
.	O

Repeated	O
doses	O
of	O
edrophonium	O
to	O
70	O
mg	O
and	O
neostigmine	O
to	O
2.5	O
mg	O
did	O
not	O
antagonize	O
or	O
augment	O
the	O
block	O
.	O

Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	O
administration	O
.	O

It	O
is	O
concluded	O
that	O
anticholinesterases	O
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	O
apnoea	B
despite	O
muscle	O
twitch	O
activity	O
typical	O
of	O
phase	O
II	O
block	O
.	O

Effect	O
of	O
doxorubicin	O
on	O
[	O
omega	O
-	O
I-131	O
]	O
heptadecanoic	O
acid	O
myocardial	O
scintigraphy	O
and	O
echocardiography	O
in	O
dogs	O
.	O

The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	O
on	O
dynamic	O
myocardial	O
scintigraphy	O
with	O
[	O
omega	O
-	O
I-131	O
]	O
heptadecanoic	O
acid	O
(	O
I-131	O
HA	O
)	O
,	O
and	O
on	O
global	O
left	O
-	O
ventricular	O
function	O
determined	O
echocardiographically	O
,	O
were	O
studied	O
in	O
a	O
group	O
of	O
nine	O
mongrel	O
dogs	O
.	O

Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin	O
-	O
treated	O
dogs	O
.	O

A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	O
a	O
cumulative	O
doxorubicin	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1	O
/	O
2	O
of	O
the	O
I-131	O
HA	O
was	O
observed	O
only	O
at	O
a	O
higher	O
cumulative	O
dose	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	O
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I-131	O
HA	O
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	O
cardiotoxicity	B
.	O

Hemodynamics	O
and	O
myocardial	O
metabolism	O
under	O
deliberate	O
hypotension	B
.	O

An	O
experimental	O
study	O
in	O
dogs	O
.	O

Coronary	O
blood	O
flow	O
,	O
cardiac	O
work	O
and	O
metabolism	O
were	O
studied	O
in	O
dogs	O
under	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
and	O
trimetaphan	O
(	O
TMP	O
)	O
deliberate	O
hypotension	B
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
pressure	O
decrease	O
from	O
baseline	O
)	O
.	O

Regarding	O
the	O
effects	O
of	O
drug	O
-	O
induced	O
hypotension	B
on	O
coronary	O
blood	O
flow	O
,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusside	O
hypotension	B
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control	O
,	O
trimetaphan	O
hypotension	B
to	O
20	O
%	O
mean	O
blood	O
pressure	O
decrease	O
.	O

Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	O
hypotension	B
.	O

Myocardial	O
O2	O
consumption	O
and	O
O2	O
availability	O
were	O
directly	O
dependent	O
on	O
the	O
coronary	O
perfusion	O
.	O

Careful	O
invasive	O
monitoring	O
of	O
the	O
blood	O
pressure	O
,	O
blood	O
gases	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
segment	O
is	O
mandatory	O
.	O

Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	O
in	O
the	O
rat	O
.	O

Male	O
rats	O
received	O
the	O
noradrenaline	O
neurotoxin	O
DSP4	O
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D	O
-	O
amphetamine	O
(	O
10	O
or	O
40	O
mumol	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

The	O
hyperactivity	B
induced	O
by	O
D	O
-	O
amphetamine	O
(	O
10	O
mumol	O
/	O
kg	O
)	O
was	O
significantly	O
reduced	O
by	O
DSP4	O
pretreatment	O
.	O

However	O
,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine	O
-	O
induced	O
stereotypies	B
were	O
not	O
blocked	O
by	O
pretreatment	O
with	O
DSP4	O
.	O

The	O
reduction	O
of	O
amphetamine	O
hyperactivity	B
induced	O
by	O
DSP4	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline	O
-	O
uptake	O
blocking	O
agent	O
,	O
desipramine	O
,	O
which	O
prevents	O
the	O
neurotoxic	B
action	O
of	O
DSP4	O
.	O

The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	O
in	O
the	O
rat	O
.	O

Accelerated	B
junctional	I
rhythms	I
during	O
oral	O
verapamil	O
therapy	O
.	O

This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	B
junctional	I
rhythms	I
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	O
.	O

Accelerated	B
junctional	I
rhythms	I
and	O
AV	O
dissociation	O
were	O
frequent	O
in	O
patients	O
with	O
supraventricular	B
tachyarrhythmias	I
,	O
particularly	O
AV	O
nodal	O
reentry	O
.	O

Verapamil	O
administration	O
to	O
these	O
patients	O
led	O
to	O
an	O
asymptomatic	O
increase	O
in	O
activity	O
of	O
these	O
junctional	O
pacemakers	O
.	O

In	O
patients	O
with	O
various	O
chest	B
pain	I
syndromes	O
,	O
verapamil	O
neither	O
increased	O
the	O
frequency	O
of	O
junctional	O
rhythms	O
nor	O
suppressed	O
their	O
role	O
as	O
escape	O
rhythms	O
under	O
physiologically	O
appropriate	O
circumstances	O
.	O

Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	O
among	O
inbred	O
mice	O
.	O

Acute	O
toxic	O
dosage	O
-	O
dependent	O
behavioral	O
effects	O
of	O
caffeine	O
were	O
compared	O
in	O
adult	O
males	O
from	O
seven	O
inbred	O
mouse	O
strains	O
(	O
A	O
/	O
J	O
,	O
BALB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C57BL	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C57BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
""""	O
prototypic	O
""""	O
mouse	O
strain	O
,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffeine	O
doses	O
.	O

Five	O
phenotypic	O
characteristics	O
--	O
locomotor	O
activity	O
,	O
righting	O
ability	O
,	O
clonic	B
seizure	I
induction	O
,	O
stress	O
-	O
induced	O
lethality	O
,	O
death	O
without	O
external	O
stress	O
--	O
were	O
scored	O
at	O
various	O
caffeine	O
doses	O
in	O
drug	O
-	O
naive	O
animals	O
under	O
empirically	O
optimized	O
,	O
rigidly	O
constant	O
experimental	O
conditions	O
.	O

Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume	O
/	O
g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	O
in	O
doses	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

Loss	O
of	O
righting	O
ability	O
was	O
scored	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
post	O
dosing	O
and	O
at	O
5	O
min	O
intervals	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	B
seizures	I
was	O
scored	O
as	O
to	O
time	O
of	O
onset	O
and	O
severity	O
for	O
20	O
min	O
after	O
drug	O
administration	O
.	O

When	O
these	O
proceeded	O
to	O
tonic	B
seizures	I
,	O
death	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water	O
,	O
and	O
death	O
-	O
producing	O
tonic	B
seizures	I
were	O
scored	O
for	O
2	O
min	O
.	O

In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	O
administration	O
.	O

By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria	O
,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	O
doses	O
were	O
observed	O
between	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	B
testing	O
of	O
alkylxanthines	O
in	O
a	O
single	O
mouse	O
strain	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toxic	O
responses	O
of	O
the	O
central	O
nervous	O
system	O
to	O
this	O
class	O
of	O
compounds	O
are	O
genetically	O
influenced	O
in	O
mammals	O
.	O

Treatment	O
of	O
ovarian	B
cancer	I
with	O
a	O
combination	O
of	O
cis	O
-	O
platinum	O
,	O
adriamycin	O
,	O
cyclophosphamide	O
and	O
hexamethylmelamine	O
.	O

During	O
the	O
last	O
2	O
1	O
/	O
2	O
years	O
,	O
38	O
patients	O
with	O
ovarian	B
cancer	I
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	O
(	O
CPDD	O
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adriamycin	O
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphamide	O
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hexamethylmelamine	O
(	O
HMM	O
)	O
,	O
6	O
mg	O
/	O
kg	O
daily	O
,	O
for	O
14	O
days	O
.	O

Each	O
course	O
was	O
repeated	O
monthly	O
.	O

2	O
patients	O
had	O
stage	O
II	O
,	O
14	O
stage	O
III	O
and	O
22	O
stage	O
IV	O
disease	O
.	O

14	O
of	O
the	O
38	O
patients	O
were	O
previously	O
treated	O
with	O
chemotherapy	O
,	O
1	O
with	O
radiation	O
,	O
6	O
with	O
both	O
chemotherapy	O
and	O
radiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatment	O
before	O
CPDD	O
combination	O
.	O

31	O
of	O
the	O
38	O
cases	O
(	O
81.5	O
%	O
)	O
demonstrated	O
objective	O
responses	O
lasting	O
for	O
2	O
months	O
or	O
more	O
.	O

These	O
responses	O
were	O
partial	O
in	O
19	O
and	O
complete	O
in	O
12	O
cases	O
.	O

Hematologic	B
toxicity	I
was	O
moderate	O
and	O
with	O
reversible	O
anemia	B
developing	O
in	O
71	O
%	O
of	O
patients	O
.	O

Gastrointestinal	O
side	O
effects	O
from	O
CPDD	O
were	O
universal	O
.	O

HMM	O
gastrointestinal	B
toxicity	I
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients	O
.	O

Severe	O
nephrotoxicity	B
was	O
observed	O
in	O
2	O
patients	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
drug	O
-	O
related	O
deaths	O
.	O

Nontraumatic	O
dissecting	B
aneurysm	I
of	O
the	O
basilar	O
artery	O
.	O

A	O
case	O
of	O
nontraumatic	O
dissecting	B
aneurysm	I
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	B
,	O
smoke	O
,	O
and	O
oral	O
contraceptives	O
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked	B
-	I
in	I
syndrome	I
.	O

A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	B
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta	O
-	O
mimetics	O
.	O

A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	B
as	O
a	O
displacement	O
-	O
time	O
curve	O
is	O
described	O
,	O
using	O
a	O
test	O
system	O
with	O
simple	O
amplitude	O
calibration	O
.	O

The	O
coordinates	O
of	O
the	O
inversion	O
points	O
of	O
the	O
displacement	O
-	O
time	O
curves	O
were	O
transferred	O
through	O
graphical	O
input	O
equipment	O
to	O
punched	O
tape	O
.	O

By	O
means	O
of	O
a	O
computer	O
program	O
,	O
periods	O
and	O
amplitudes	O
of	O
tremor	B
oscillations	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
event	O
frequency	O
for	O
each	O
class	O
of	O
periods	O
and	O
amplitudes	O
was	O
determined	O
.	O

The	O
actions	O
of	O
fenoterol	O
-	O
hydrobromide	O
,	O
ritodrin	O
-	O
HCl	O
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double	O
-	O
blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method	O
.	O

At	O
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	B
amplitude	O
to	O
about	O
three	O
times	O
the	O
control	O
level	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
mean	O
period	O
within	O
each	O
class	O
of	O
amplitudes	O
shortened	O
by	O
10	O
-	O
-20	O
ms	O
,	O
whereas	O
the	O
mean	O
periods	O
calculated	O
from	O
all	O
oscillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
fenoterol	O
-	O
hydrobromide	O
infusion	O
,	O
tremor	B
amplitudes	O
decreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodrin	O
-	O
HCl	O
infusion	O
.	O

Propylthiouracil	O
-	O
induced	O
hepatic	B
damage	I
.	O

Two	O
cases	O
of	O
propylthiouracil	O
-	O
induced	O
liver	B
damage	I
have	O
been	O
observed	O
.	O

The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	B
active	I
hepatitis	I
,	O
with	O
spontaneous	O
remission	O
.	O

Studies	O
on	O
the	O
bradycardia	B
induced	O
by	O
bepridil	O
.	O

Bepridil	O
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	B
attacks	I
,	O
induced	O
persistent	O
bradycardia	B
and	O
a	O
non	O
-	O
specific	O
anti	O
-	O
tachycardial	B
effect	O
,	O
the	O
mechanisms	O
of	O
which	O
were	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perfusion	O
of	O
bepridil	O
in	O
the	O
life	O
-	O
support	O
medium	O
for	O
isolated	O
sino	O
-	O
atrial	O
tissue	O
from	O
rabbit	O
heart	O
,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(	O
AP	O
)	O
spike	O
frequency	O
(	O
recorded	O
by	O
KCl	O
microelectrodes	O
)	O
starting	O
at	O
doses	O
of	O
5	O
X	O
10	O
(	O
-6	O
)	O
M.	O
This	O
effect	O
was	O
dose	O
-	O
dependent	O
up	O
to	O
concentrations	O
of	O
5	O
X	O
10	O
(	O
-5	O
)	O
M	O
,	O
whereupon	O
blockade	O
of	O
sinus	O
activity	O
set	O
in	O
.	O

Bepridil	O
at	O
a	O
dose	O
of	O
5	O
X	O
10	O
(	O
-6	O
)	O
M	O
,	O
induced	O
a	O
concomitant	O
reduction	O
in	O
AP	O
amplitude	O
(	O
falling	O
from	O
71	O
+	O
/-	O

8	O
mV	O
to	O
47	O
+	O
/-	O

6	O
mV	O
)	O
,	O
maximum	O
systolic	O
depolarization	O
velocity	O
(	O
phase	O
0	O
)	O
which	O
fell	O
from	O
1.85	O
+	O
/-	O

0.35	O
V	O
/	O
s	O
to	O
0.84	O
+	O
/-	O

0.28	O
V	O
/	O
s	O
,	O
together	O
with	O
maximum	O
diastolic	O
depolarization	O
velocity	O
(	O
phase	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/-	O

3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/-	O

5	O
mV	O
/	O
s	O
.	O

In	O
vivo	O
injection	O
of	O
bepridil	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i.v	O
.	O
)	O
into	O
6	O
anaesthetized	O
dogs	O
which	O
had	O
undergone	O
ablation	O
of	O
all	O
the	O
extrinsic	O
cardiac	O
afferent	O
nerve	O
supply	O
,	O
together	O
with	O
a	O
bilateral	O
medullo	O
-	O
adrenalectomy	O
,	O
caused	O
a	O
marked	O
reduction	O
in	O
heart	O
rate	O
which	O
fell	O
from	O
98.7	O
+	O
/-	O

4.2	O
beats	O
/	O
min	O
to	O
76	O
+	O
/-	O

5.3	O
beats	O
/	O
min	O
sustained	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
bepridil	O
reduces	O
heart	O
rate	O
by	O
acting	O
directly	O
on	O
the	O
sinus	O
node	O
.	O

This	O
effect	O
,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
duration	O
,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	O
current	O
(	O
Ip	O
)	O
.	O

Hepatitis	B
and	O
renal	B
tubular	I
acidosis	I
after	O
anesthesia	O
with	O
methoxyflurane	O
.	O

A	O
69-year	O
-	O
old	O
man	O
operated	O
for	O
acute	B
cholecystitis	I
under	O
methoxyflurane	O
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	B
insufficiency	I
syndrome	I
and	O
renal	B
tubular	I
acidosis	I
.	O

Massive	O
bleeding	B
appeared	O
during	O
surgery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Postoperative	O
evolution	O
under	O
supportive	O
therapy	O
was	O
favourable	O
.	O

Complete	O
recovery	O
was	O
confirmed	O
by	O
repeated	O
controls	O
performed	O
over	O
a	O
period	O
of	O
one	O
year	O
after	O
surgery	O
.	O

Pituitary	O
response	O
to	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
during	O
haloperidol	O
-	O
induced	O
hyperprolactinemia	B
.	O

The	O
effects	O
of	O
a	O
6-hour	O
infusion	O
with	O
haloperidol	O
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infusions	O
,	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH	O
-	O
releasing	O
hormone	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O

Control	O
patients	O
received	O
infusions	O
of	O
0.9	O
%	O
NaCl	O
solution	O
.	O

During	O
the	O
course	O
of	O
haloperidol	O
infusions	O
,	O
significant	O
hyperprolactinemia	B
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O

Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin	O
-	O
associated	O
renal	B
failure	I
.	O

5	O
patients	O
with	O
acute	B
renal	I
failure	I
(	O
3	O
with	O
thrombopenia	B
and	O
hemolysis	B
)	O
induced	O
by	O
the	O
reintroduction	O
of	O
rifampicin	O
are	O
described	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
severity	O
of	O
clinical	O
manifestations	O
and	O
the	O
total	O
dose	O
taken	O
by	O
the	O
patients	O
.	O

In	O
all	O
but	O
1	O
patient	O
,	O
antirifampicin	O
antibodies	O
were	O
detected	O
.	O

Antibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
class	O
were	O
detected	O
in	O
all	O
3	O
patients	O
with	O
hematological	B
disorders	I
.	O

The	O
pattern	O
of	O
non	O
-	O
specific	O
acute	B
tubular	I
necrosis	I
found	O
in	O
the	O
2	O
biopsied	O
patients	O
,	O
indistinguishable	O
from	O
that	O
of	O
ischemic	O
origin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascular	O
-	O
mediated	O
damage	O
.	O

In	O
3	O
patients	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoallergic	O
mechanism	O
is	O
discussed	O
.	O

Cardiovascular	O
effects	O
of	O
hypotension	B
induced	O
by	O
adenosine	O
triphosphate	O
and	O
sodium	O
nitroprusside	O
on	O
dogs	O
with	O
denervated	O
hearts	O
.	O

Adenosine	O
triphosphate	O
(	O
ATP	O
)	O
and	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	B
during	O
anesthesia	O
.	O

SNP	O
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	O
is	O
clinically	O
used	O
in	O
other	O
countries	O
such	O
as	O
Japan	O
.	O

We	O
investigated	O
how	O
these	O
two	O
drugs	O
act	O
on	O
the	O
cardiovascular	O
systems	O
of	O
20	O
dogs	O
whose	O
hearts	O
had	O
been	O
denervated	O
by	O
a	O
procedure	O
we	O
had	O
devised	O
.	O

ATP	O
(	O
10	O
dogs	O
)	O
or	O
SNP	O
(	O
10	O
dogs	O
)	O
was	O
administered	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
control	O
.	O

Before	O
,	O
during	O
and	O
after	O
induced	O
hypotension	B
,	O
we	O
measured	O
major	O
cardiovascular	O
parameters	O
.	O

Hypotension	B
induced	O
by	O
ATP	O
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
body	O
oxygen	O
consumption	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
;	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	O
was	O
stopped	O
.	O

Cardiac	O
output	O
did	O
not	O
change	O
.	O

During	O
hypotension	B
produced	O
by	O
SNP	O
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
oxygen	O
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
cardiac	O
output	O
(	O
p	O
less	O
than	O
0.05	O
)	O
were	O
increased	O
.	O

Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	O
had	O
been	O
stopped	O
.	O

Both	O
ATP	O
and	O
SNP	O
should	O
act	O
on	O
the	O
pacemaker	O
tissue	O
of	O
the	O
heart	O
.	O

Comparative	O
study	O
:	O
Endografine	O
(	O
diatrizoate	O
)	O
,	O
Vasurix	O
polyvidone	O
(	O
acetrizoate	O
)	O
,	O
Dimer	O
-	O
X	O
(	O
iocarmate	O
)	O
and	O
Hexabrix	O
(	O
ioxaglate	O
)	O
in	O
hysterosalpingography	O
.	O

Side	O
effects	O
of	O
hysterosalpingography	O
with	O
Dimer	O
-	O
X	O
,	O
Hexabrix	O
,	O
Vasurix	O
polyvidone	O
and	O
Endografine	O
in	O
142	O
consecutive	O
patients	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tested	O
media	O
were	O
evaluated	O
from	O
replies	O
to	O
postal	O
questionnaires	O
.	O

The	O
Dimer	O
-	O
X	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	B
and	O
dizziness	B
.	O

The	O
Endografine	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	B
pain	I
.	O

These	O
differences	O
occur	O
especially	O
in	O
the	O
age	O
groups	O
under	O
30	O
years	O
.	O

Hexabrix	O
and	O
Vasurix	O
polyvidone	O
are	O
considered	O
the	O
best	O
contrast	O
media	O
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	B
Hexabrix	O
should	O
be	O
preferred	O
.	O

Post	O
-	O
suxamethonium	O
pains	B
in	O
Nigerian	O
surgical	O
patients	O
.	O

Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon	O
,	O
scoline	O
pain	B
occurs	O
in	O
African	O
negroes	O
.	O

Its	O
incidence	O
was	O
determined	O
in	O
a	O
prospective	O
study	O
involving	O
a	O
total	O
of	O
100	O
Nigerian	O
patients	O
(	O
50	O
out	O
-	O
patients	O
and	O
50	O
in	O
-	O
patients	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out	O
-	O
patients	O
developed	O
scoline	O
pain	B
as	O
compared	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
patients	O
.	O

The	O
abolition	O
of	O
muscle	O
fasciculations	B
(	O
by	O
0.075mg	O
/	O
kg	O
dose	O
of	O
Fazadinium	O
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	O
pain	B
.	O

Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	O
or	O
Thiopentone	O
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	O
used	O
(	O
chloride	O
or	O
bromide	O
)	O
,	O
affected	O
the	O
incidence	O
of	O
scoline	O
pain	B
.	O

Invasive	O
carcinoma	B
of	I
the	I
renal	I
pelvis	I
following	O
cyclophosphamide	O
therapy	O
for	O
nonmalignant	O
disease	O
.	O

A	O
47-year	O
-	O
old	O
woman	O
with	O
right	O
hydroureteronephrosis	B
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	O
hematuria	B
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	O
for	O
cerebral	B
vasculitis	I
.	O

A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	B
.	O

The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	B
of	I
the	I
renal	I
pelvis	I
.	O

Although	O
the	O
ability	O
of	O
cyclophosphamide	O
to	O
cause	O
hemorrhagic	B
cystitis	B
and	O
urine	O
cytologic	O
abnormalities	O
indistinguishable	O
from	O
high	O
grade	O
carcinoma	B
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	B
of	I
the	I
urinary	I
tract	I
.	O

Twenty	O
carcinomas	B
of	I
the	I
urinary	I
bladder	I
and	O
one	O
carcinoma	B
of	I
the	I
prostate	I
have	O
been	O
reported	O
in	O
association	O
with	O
its	O
use	O
.	O

The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	B
of	I
the	I
renal	I
pelvis	I
reported	O
in	O
association	O
with	O
cyclophosphamide	O
treatment	O
.	O

It	O
is	O
the	O
third	O
urinary	B
tract	I
cancer	I
reported	O
in	O
association	O
with	O
cyclophosphamide	O
treatment	O
for	O
nonmalignant	O
disease	O
.	O

The	O
association	O
of	O
the	O
tumor	B
with	O
preexisting	O
hydroureteronephrosis	B
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	O
.	O

Patients	O
who	O
are	O
candidates	O
for	O
long	O
-	O
term	O
cyclophosphamide	O
treatment	O
should	O
be	O
routinely	O
evaluated	O
for	O
obstructive	B
uropathy	I
.	O

Medial	O
changes	O
in	O
arterial	O
spasm	B
induced	O
by	O
L	O
-	O
norepinephrine	O
.	O

In	O
normal	O
rats	O
,	O
the	O
media	O
of	O
small	O
arteries	O
(	O
0.4	O
-	O
-0.2	O
mm	O
in	O
diameter	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intracellular	O
vacuoles	O
,	O
identified	O
ultrastructurally	O
as	O
herniations	O
of	O
one	O
smooth	O
muscle	O
cell	O
into	O
another	O
.	O

The	O
hypothesis	O
that	O
intense	O
vasoconstriction	O
would	O
increase	O
the	O
number	O
of	O
such	O
vacuoles	O
has	O
been	O
tested	O
.	O

In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch	O
,	O
vasoconstriction	O
induced	O
by	O
L	O
-	O
norepinephrine	O
produced	O
many	O
cell	O
-	O
to	O
-	O
cell	O
hernias	B
within	O
15	O
minutes	O
.	O

At	O
1	O
day	O
their	O
number	O
was	O
reduced	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
days	O
the	O
vessel	O
was	O
almost	O
restored	O
to	O
normal	O
.	O

Triple	O
stimulation	O
over	O
1	O
day	O
induced	O
more	O
severe	O
changes	O
in	O
the	O
media	O
.	O

These	O
findings	O
suggest	O
that	O
smooth	O
muscle	O
cells	O
are	O
susceptible	O
to	O
damage	O
in	O
the	O
course	O
of	O
their	O
specific	O
function	O
.	O

The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	B
.	O

Endothelial	O
changes	O
that	O
developed	O
in	O
the	O
same	O
experimental	O
model	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

Bilateral	O
retinal	B
artery	I
and	I
choriocapillaris	I
occlusion	I
following	O
the	O
injection	O
of	O
long	O
-	O
acting	O
corticosteroid	O
suspensions	O
in	O
combination	O
with	O
other	O
drugs	O
:	O
I.	O
Clinical	O
studies	O
.	O

Two	O
well	O
-	O
documented	O
cases	O
of	O
bilateral	O
retinal	B
artery	I
and	I
choriocapillaris	I
occlusions	I
with	O
blindness	B
following	O
head	O
and	O
neck	O
soft	O
-	O
tissue	O
injection	O
with	O
methylprednisolone	O
acetate	O
in	O
combination	O
with	O
lidocaine	O
,	O
epinephrine	O
,	O
or	O
penicillin	O
are	O
reported	O
.	O

One	O
case	O
had	O
only	O
a	O
unilateral	O
injection	O
.	O

The	O
acute	O
observations	O
included	O
hazy	O
sensorium	O
,	O
superior	O
gaze	O
palsy	B
,	O
pupillary	B
abnormalities	I
,	O
and	O
conjunctival	O
hemorrhages	B
with	O
edema	B
.	O

Follow	O
-	O
up	O
changes	O
showed	O
marked	O
visual	B
loss	I
,	O
constricted	O
visual	O
fields	O
,	O
optic	O
nerve	O
pallor	O
,	O
vascular	O
attenuation	O
,	O
and	O
chorioretinal	B
atrophy	I
.	O

The	O
literature	O
is	O
reviewed	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormalities	O
of	O
the	O
pupil	O
and	O
visual	O
-	O
evoked	O
potential	O
in	O
quinine	O
amblyopia	B
.	O

Total	O
blindness	B
with	O
a	O
transient	O
tonic	B
pupillary	I
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
developed	O
in	O
a	O
54-year	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
quinine	O
sulfate	O
for	O
leg	B
cramps	I
.	O

He	O
later	O
recovered	O
normal	O
visual	O
acuity	O
.	O

A	O
transient	O
tonic	B
pupillary	I
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
in	O
quinine	O
toxicity	B
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxamethonium	O
-	O
induced	O
jaw	B
stiffness	I
and	O
myalgia	B
associated	O
with	O
atypical	O
cholinesterase	O
:	O
case	O
report	O
.	O

An	O
11-year	O
-	O
old	O
boy	O
was	O
given	O
halothane	O
,	O
nitrous	O
oxide	O
and	O
oxygen	O
,	O
pancuronium	O
0.4	O
mg	O
and	O
suxamethonium	O
100	O
mg	O
for	O
induction	O
of	O
anaesthesia	O
.	O

In	O
response	O
to	O
this	O
a	O
marked	O
jaw	B
stiffness	I
occurred	O
which	O
lasted	O
for	O
two	O
minutes	O
and	O
the	O
anaesthesia	O
were	O
terminated	O
.	O

Four	O
hours	O
of	O
apnoea	B
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	B
lasting	O
for	O
one	O
week	O
.	O

He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	O
number	O
of	O
12	O
,	O
indicating	O
homozygocity	O
.	O

This	O
was	O
verified	O
by	O
study	O
of	O
the	O
family	O
.	O

The	O
case	O
shows	O
that	O
prolonged	B
jaw	I
rigidity	I
and	O
myalgia	B
may	O
occur	O
after	O
suxamethonium	O
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	O
.	O

Indomethacin	O
-	O
induced	O
hyperkalemia	B
in	O
three	O
patients	O
with	O
gouty	B
arthritis	I
.	O

We	O
describe	O
three	O
patients	O
in	O
whom	O
severe	O
,	O
life	O
-	O
threatening	O
hyperkalemia	B
and	O
renal	B
insufficiency	I
developed	O
after	O
treatment	O
of	O
acute	O
gouty	B
arthritis	I
with	O
indomethacin	O
.	O

This	O
complication	O
may	O
result	O
from	O
an	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
and	O
consequent	O
hyporeninemic	B
hypoaidosteronism	I
.	O

Careful	O
attention	O
to	O
renal	O
function	O
and	O
potassium	O
balance	O
in	O
patients	O
receiving	O
indomethacin	O
or	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	B
mellitus	I
or	O
preexisting	O
renal	B
disease	I
,	O
will	O
help	O
prevent	O
this	O
potentially	O
serious	O
complication	O
.	O

Etomidate	O
:	O
a	O
foreshortened	O
clinical	O
trial	O
.	O

A	O
clinical	O
evaluation	O
of	O
etomidate	O
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon	O
.	O

Unpremedicated	O
patients	O
were	O
given	O
fentanyl	O
1	O
microgram	O
/	O
kg	O
followed	O
by	O
etomidate	O
0.3	O
mg	O
/	O
kg	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	O
in	O
2	O
-	O
4	O
mg	O
doses	O
.	O

Patients	O
were	O
interviewed	O
personally	O
later	O
the	O
same	O
day	O
,	O
and	O
by	O
questionnaire	O
three	O
to	O
four	O
weeks	O
later	O
.	O

The	O
trial	O
was	O
discontinued	O
after	O
20	O
cases	O
because	O
of	O
an	O
unacceptable	O
incidence	O
of	O
side	O
effects	O
.	O

Venous	O
pain	B
occurred	O
in	O
68	O
%	O
of	O
patients	O
and	O
50	O
%	O
had	O
redness	O
,	O
pain	B
or	O
swelling	B
related	O
to	O
the	O
injection	O
site	O
,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia	O
.	O

Skeletal	O
movements	O
occurred	O
in	O
50	O
%	O
of	O
patients	O
;	O
30	O
%	O
experienced	O
respiratory	B
upset	I
,	O
one	O
sufficiently	O
severe	O
to	O
necessitate	O
abandoning	O
the	O
technique	O
.	O

Nausea	B
and	O
vomiting	B
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergence	O
psychoses	B
.	O

Levodopa	O
-	O
induced	O
dyskinesias	B
are	O
improved	O
by	O
fluoxetine	O
.	O

We	O
evaluated	O
the	O
severity	O
of	O
motor	B
disability	I
and	O
dyskinesias	B
in	O
seven	O
levodopa	O
-	O
responsive	O
patients	O
with	O
Parkinson	B
's	I
disease	I
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	O
agonist	O
,	O
apomorphine	O
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	O
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/-	O

1	O
days	O
.	O

After	O
fluoxetine	O
treatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvement	O
(	O
p	O
<	O
0.05	O
)	O
of	O
apomorphine	O
-	O
induced	O
dyskinesias	B
without	O
modification	O
of	O
parkinsonian	B
motor	B
disability	I
.	O

The	O
dyskinesias	B
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	B
dyskinesias	B
(	O
onset-	O
and	O
end	O
-	O
of	O
-	O
dose	O
dyskinesias	B
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	B
mid	B
-	I
dose	I
dyskinesias	I
.	O

The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	O
may	O
reduce	O
levodopa-	O
or	O
dopamine	O
agonist	O
-	O
induced	O
dyskinesias	B
without	O
aggravating	O
parkinsonian	B
motor	B
disability	I
.	O

A	O
large	O
population	O
-	O
based	O
follow	O
-	O
up	O
study	O
of	O
trimethoprim	O
-	O
sulfamethoxazole	O
,	O
trimethoprim	O
,	O
and	O
cephalexin	O
for	O
uncommon	O
serious	O
drug	B
toxicity	I
.	O

We	O
conducted	O
a	O
population	O
-	O
based	O
45-day	O
follow	O
-	O
up	O
study	O
of	O
232,390	O
people	O
who	O
were	O
prescribed	O
trimethoprim	O
-	O
sulfamethoxazole	O
(	O
TMP	O
-	O
SMZ	O
)	O
,	O
266,951	O
prescribed	O
trimethoprim	O
alone	O
,	O
and	O
196,397	O
prescribed	O
cephalexin	O
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver	B
,	I
blood	I
,	I
skin	I
,	I
and	I
renal	I
disorders	I
resulting	O
in	O
referral	O
or	O
hospitalization	O
associated	O
with	O
these	O
drugs	O
.	O

The	O
results	O
were	O
based	O
on	O
information	O
recorded	O
on	O
office	O
computers	O
by	O
selected	O
general	O
practitioners	O
in	O
the	O
United	O
Kingdom	O
,	O
together	O
with	O
a	O
review	O
of	O
clinical	O
records	O
.	O

The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	B
disease	I
was	O
similar	O
for	O
persons	O
prescribed	O
TMP	O
-	O
SMZ	O
(	O
5.2	O
/	O
100,000	O
)	O
and	O
those	O
prescribed	O
trimethoprim	O
alone	O
(	O
3.8	O
/	O
100,000	O
)	O
.	O

The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	O
was	O
somewhat	O
lower	O
(	O
2.0	O
/	O
100,000	O
)	O
.	O

Only	O
five	O
patients	O
experienced	O
blood	O
disorders	O
,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP	O
-	O
SMZ	O
;	O
of	O
seven	O
with	O
erythema	B
multiforme	I
and	O
Stevens	B
-	I
Johnson	I
syndrome	I
,	O
four	O
were	O
exposed	O
to	O
TMP	O
-	O
SMZ	O
.	O

The	O
one	O
case	O
of	O
toxic	B
epidermal	I
necrolysis	I
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	O
.	O

Finally	O
,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	B
disease	I
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
study	O
drug	O
.	O

We	O
conclude	O
that	O
the	O
risk	O
of	O
the	O
serious	O
diseases	O
studied	O
is	O
small	O
for	O
the	O
three	O
agents	O
,	O
and	O
compares	O
reasonably	O
with	O
the	O
risk	O
for	O
many	O
other	O
antibiotics	O
.	O

Clinical	O
safety	O
of	O
lidocaine	O
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
myocardial	B
infarction	I
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	O
in	O
the	O
setting	O
of	O
cocaine	O
-	O
induced	O
myocardial	B
infarction	I
(	O
MI	B
)	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
,	O
multicenter	O
study	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
university	O
,	O
university	O
-	O
affiliated	O
,	O
or	O
community	O
hospitals	O
during	O
a	O
6-year	O
period	O
(	O
total	O
of	O
117	O
cumulative	O
hospital	O
-	O
years	O
)	O
.	O

PARTICIPANTS	O
:	O
Patients	O
with	O
cocaine	O
-	O
associated	O
MI	B
who	O
received	O
lidocaine	O
in	O
the	O
emergency	O
department	O
.	O

RESULTS	O
:	O
Of	O
29	O
patients	O
who	O
received	O
lidocaine	O
in	O
the	O
setting	O
of	O
cocaine	O
-	O
associated	O
MI	B
,	O
no	O
patient	O
died	O
;	O
exhibited	O
bradydysrhythmias	B
,	O
ventricular	B
tachycardia	I
,	O
or	O
ventricular	B
fibrillation	I
;	O
or	O
experienced	O
seizures	B
after	O
administration	O
of	O
lidocaine	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	O
may	O
enhance	O
cocaine	O
toxicity	B
,	O
the	O
use	O
of	O
lidocaine	O
in	O
patients	O
with	O
cocaine	O
-	O
associated	O
MI	B
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	B
or	I
central	I
nervous	I
system	I
toxicity	I
.	O

Experimental	O
progressive	O
muscular	B
dystrophy	I
and	O
its	O
treatment	O
with	O
high	O
doses	O
anabolizing	O
agents	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	B
dystrophy	I
in	O
man	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimental	O
field	O
;	O
a	O
recessive	O
autosomic	O
form	O
found	O
in	O
the	O
mouse	O
seems	O
to	O
bear	O
the	O
closest	O
resemblance	O
to	O
the	O
human	O
form	O
from	O
the	O
genetic	O
point	O
of	O
view	O
.	O

Myopathy	B
due	O
to	O
lack	O
of	O
vitamin	O
E	O
and	O
myopathy	B
induced	O
by	O
certain	O
viruses	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
pathologically	O
with	O
the	O
human	O
form	O
.	O

The	O
authors	O
induced	O
myodystrophy	B
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	O
E.	O
The	O
pharmacological	O
characteristics	O
of	O
vitamin	O
E	O
and	O
the	O
degenerative	O
changes	O
brought	O
about	O
by	O
its	O
deficiency	O
,	O
especially	O
in	O
the	O
muscles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	B
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	B
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre	O
,	O
Florence	O
.	O

The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	B
patients	O
by	O
using	O
anabolizing	O
steroids	O
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	O
,	O
CIBA	O
)	O
at	O
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	B
by	O
a	O
diet	O
deficient	O
in	O
vitamin	O
E.	O
In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	O
weight	O
(	O
increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	O
a	O
dose	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolizing	O
agent	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histological	O
changes	O
due	O
to	O
""""	O
regenerative	O
""""	O
changes	O
in	O
the	O
muscle	O
tissue	O
,	O
which	O
however	O
maintained	O
its	O
myopathic	B
characteristics	O
in	O
the	O
control	O
animals	O
that	O
were	O
not	O
treated	O
with	O
the	O
anabolizing	O
agent	O
.	O

The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	O
in	O
experimental	O
myopathic	B
disease	I
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field	O
,	O
where	O
high	O
dosage	O
can	O
not	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility	O
;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
stage	O
vis	O
-	O
a	O
-	O
vis	O
the	O
""""	O
regeneration	O
""""	O
of	O
the	O
muscle	O
tissue	O
;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	O
E	O
but	O
something	O
as	O
yet	O
unknown	O
.	O

Paclitaxel	O
3-hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	O
:	O
preliminary	O
results	O
of	O
dose	O
-	O
escalation	O
trials	O
.	O

Paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
by	O
3-hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	O
in	O
a	O
phase	O
I	O
/	O
II	O
study	O
directed	O
to	O
patients	O
with	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

Carboplatin	O
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
of	O
6.0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	O
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	B
(	O
arthralgia	B
and	O
sensory	B
neuropathy	I
)	O
.	O

Therapeutic	O
effects	O
were	O
noted	O
at	O
all	O
dose	O
levels	O
,	O
with	O
objective	O
responses	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
partial	O
regressions	O
)	O
of	O
41	O
previously	O
untreated	O
patients	O
.	O

Toxicities	B
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	O
alone	O
at	O
identical	O
dose	O
levels	O
.	O

Carboplatin	O
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	B
toxicities	I
observed	O
,	O
and	O
the	O
paclitaxel	O
/	O
carboplatin	O
combination	O
could	O
be	O
dosed	O
every	O
3	O
weeks	O
.	O

The	O
dose	O
-	O
dependent	O
effect	O
of	O
misoprostol	O
on	O
indomethacin	O
-	O
induced	O
renal	B
dysfunction	I
in	O
well	O
compensated	O
cirrhosis	B
.	O

Misoprostol	O
(	O
200	O
micrograms	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin	O
-	O
induced	O
renal	B
dysfunction	I
in	O
well	O
compensated	O
cirrhotic	B
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	O
was	O
dose	O
-	O
dependent	O
.	O

Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	O
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	B
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	O
and	O
various	O
doses	O
of	O
misoprostol	O
.	O

The	O
200-micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	O
effects	O
of	O
indomethacin	O
,	O
whereas	O
the	O
800-micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	O
hemodynamics	O
and	O
sodium	O
retention	O
.	O

These	O
changes	O
were	O
maximal	O
in	O
the	O
hour	O
immediately	O
after	O
medications	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
levels	O
thereafter	O
.	O

These	O
results	O
suggest	O
that	O
the	O
renal	O
protective	O
effects	O
of	O
misoprostol	O
is	O
dose	O
-	O
dependent	O
.	O

However	O
,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	O
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	O
on	O
renal	O
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	B
.	O

Increased	O
frequency	O
and	O
severity	O
of	O
angio	B
-	I
oedema	I
related	O
to	O
long	O
-	O
term	O
therapy	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
in	O
two	O
patients	O
.	O

Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	O
urticaria	B
,	O
and	O
angio	B
-	I
oedema	I
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
,	O
used	O
to	O
treat	O
hypertension	B
and	O
congestive	B
heart	I
failure	I
,	O
were	O
introduced	O
in	O
Europe	O
in	O
the	O
middle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
drugs	O
has	O
increased	O
progressively	O
.	O

Soon	O
after	O
the	O
introduction	O
of	O
ACE	O
inhibitors	O
,	O
acute	O
bouts	O
of	O
angio	B
-	I
oedema	I
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs	O
.	O

We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
adverse	O
reactions	O
to	O
ACE	O
inhibitors	O
after	O
long	O
-	O
term	O
use	O
and	O
in	O
patients	O
with	O
pre	O
-	O
existing	O
angio	B
-	I
oedema	I
.	O

Myoclonus	B
associated	O
with	O
lorazepam	O
therapy	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
infants	O
.	O

Lorazepam	O
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant	O
.	O

Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	O
in	O
this	O
age	O
group	O
,	O
especially	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
(	O
VLBW	O
;	O
<	O
1,500	O
g	O
)	O
infants	O
.	O

Three	O
young	O
infants	O
,	O
all	O
of	O
birth	O
weight	O
<	O
1,500	O
g	O
,	O
experienced	O
myoclonus	B
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	O
.	O

The	O
potential	O
neurotoxic	B
effects	O
of	O
the	O
drug	O
(	O
and	O
its	O
vehicle	O
)	O
in	O
this	O
population	O
are	O
discussed	O
.	O

Injectable	O
lorazepam	O
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infants	O
.	O

Transvenous	O
right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	B
.	O

We	O
describe	O
the	O
cardiopulmonary	O
resuscitation	O
efforts	O
on	O
five	O
patients	O
who	O
presented	O
in	O
acute	O
circulatory	B
failure	I
from	O
myocardial	B
dysfunction	I
.	O

Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	B
,	O
one	O
had	O
a	O
carbamazepine	O
-	O
induced	O
acute	O
eosinophilic	B
myocarditis	B
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	O
resulting	O
in	O
acute	O
cardiogenic	B
shock	I
.	O

All	O
patients	O
were	O
continuously	O
monitored	O
with	O
central	O
venous	O
and	O
arterial	O
catheters	O
in	O
addition	O
to	O
routine	O
noninvasive	O
monitoring	O
.	O

An	O
introducer	O
sheath	O
,	O
a	O
pacemaker	O
,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	B
.	O

All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	B
and	O
dysrhythmias	B
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admission	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
.	O

Right	O
ventricular	O
pacemaker	O
wires	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
.	O

In	O
four	O
patients	O
,	O
cardiac	O
pacing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
temporary	O
captured	O
rhythm	O
and	O
restoration	O
of	O
their	O
cardiac	O
output	O
.	O

These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	B
arrest	I
,	O
resulting	O
in	O
death	O
,	O
within	O
10	O
to	O
60	O
minutes	O
.	O

In	O
one	O
patient	O
,	O
cardiac	O
pacing	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
normal	O
sinus	O
rhythm	O
by	O
electrical	O
defibrillation	O
within	O
three	O
minutes	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
cardiac	O
pacing	O
during	O
resuscitative	O
efforts	O
in	O
pediatric	O
patients	O
suffering	O
from	O
acute	O
myocardial	B
dysfunction	I
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temporary	O
hemodynamic	O
stability	O
is	O
achieved	O
by	O
this	O
procedure	O
,	O
it	O
may	O
provide	O
additional	O
time	O
needed	O
to	O
institute	O
other	O
therapeutic	O
modalities	O
.	O

Efficacy	O
and	O
safety	O
of	O
granisetron	O
,	O
a	O
selective	O
5-hydroxytryptamine-3	O
receptor	O
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	B
and	O
vomiting	B
induced	O
by	O
high	O
-	O
dose	O
cisplatin	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	O
(	O
Kytril	O
;	O
SmithKline	O
Beecham	O
Pharmaceuticals	O
,	O
Philadelphia	O
,	O
PA	O
)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin	O
-	O
induced	O
nausea	B
and	O
vomiting	B
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	O
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
signs	O
,	O
nausea	B
,	O
vomiting	B
,	O
retching	O
,	O
and	O
appetite	O
were	O
assessed	O
.	O

Safety	O
analyses	O
included	O
incidence	O
of	O
adverse	O
experiences	O
and	O
laboratory	O
parameter	O
changes	O
.	O

RESULTS	O
:	O
After	O
granisetron	O
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrograms	O
/	O
kg	O
,	O
a	O
major	O
response	O
(	O
<	O
or	O
=	O
two	O
vomiting	B
or	O
retching	O
episodes	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
response	O
(	O
no	O
vomiting	B
or	O
retching	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	B
(	O
P	O
=	O
.0015	O
)	O
and	O
vomiting	B
(	O
P	O
=	O
.0001	O
)	O
,	O
and	O
fewer	O
patients	O
were	O
administered	O
additional	O
antiemetic	O
medication	O
in	O
the	O
10-micrograms	O
/	O
kg	O
dosing	O
groups	O
than	O
in	O
the	O
5-micrograms	O
/	O
kg	O
dosing	O
group	O
.	O

As	O
granisetron	O
dose	O
increased	O
,	O
appetite	O
return	O
increased	O
(	O
P	O
=	O
.040	O
)	O
.	O

Headache	B
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
(	O
20	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
single	O
10-	O
,	O
20-	O
,	O
or	O
40-micrograms	O
/	O
kg	O
dose	O
of	O
granisetron	O
was	O
effective	O
in	O
controlling	O
vomiting	B
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patients	O
who	O
received	O
cisplatin	O
at	O
doses	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomiting	B
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patients	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
efficacy	O
between	O
the	O
10-micrograms	O
/	O
kg	O
dose	O
and	O
the	O
20-	O
and	O
40-micrograms	O
/	O
kg	O
doses	O
.	O

Granisetron	O
was	O
well	O
tolerated	O
at	O
all	O
doses	O
.	O

Adverse	O
interaction	O
between	O
clonidine	O
and	O
verapamil	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	O
and	O
verapamil	O
resulting	O
in	O
atrioventricular	B
(	I
AV	I
)	I
block	I
in	O
both	O
patients	O
and	O
severe	O
hypotension	B
in	O
one	O
patient	O
.	O

CASE	O
SUMMARIES	O
:	O
A	O
54-year	O
-	O
old	O
woman	O
with	O
hyperaldosteronism	B
was	O
treated	O
with	O
verapamil	O
480	O
mg	O
/	O
d	O
and	O
spironolactone	O
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	O
(	O
0.15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	B
block	I
and	O
severe	O
hypotension	B
,	O
which	O
resolved	O
upon	O
cessation	O
of	O
all	O
medications	O
.	O

A	O
65-year	O
-	O
old	O
woman	O
was	O
treated	O
with	O
extended	O
-	O
release	O
verapamil	O
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clonidine	O
0.15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B
block	I
,	O
which	O
resolved	O
after	O
all	O
therapy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
adverse	O
interaction	O
between	O
clonidine	O
and	O
verapamil	O
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
cases	O
and	O
discuss	O
the	O
various	O
mechanisms	O
that	O
might	O
cause	O
such	O
an	O
interaction	O
.	O

Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	O
drugs	O
.	O

CONCLUSIONS	O
:	O
Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	O
and	O
verapamil	O
therapy	O
,	O
even	O
in	O
patients	O
who	O
do	O
not	O
have	O
sinus	O
or	O
AV	O
node	O
dysfunction	O
.	O

The	O
two	O
drugs	O
may	O
act	O
synergistically	O
on	O
both	O
the	O
AV	O
node	O
and	O
the	O
peripheral	O
circulation	O
.	O

Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	O
calcium	O
antagonist	O
,	O
S-312-d	O
.	O

5th	O
communication	O
:	O
anticonvulsant	O
effects	O
in	O
mice	O
.	O

S-312	O
,	O
S-312-d	O
,	O
but	O
not	O
S-312-l	O
,	O
L	O
-	O
type	O
calcium	O
channel	O
antagonists	O
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	B
tonic	I
convulsions	I
in	O
DBA	O
/	O
2	O
mice	O
;	O
and	O
their	O
ED50	O
values	O
were	O
18.4	O
(	O
12.8	O
-	O
27.1	O
)	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
and	O
15.0	O
(	O
10.2	O
-	O
23.7	O
)	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	O
was	O
34.0	O
(	O
26.0	O
-	O
44.8	O
)	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O

Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S-312-d	O
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	B
induced	O
by	O
pentylenetetrazole	O
(	O
85	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
or	O
bemegride	O
(	O
40	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
,	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	B
induced	O
by	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
,	O
picrotoxin	O
,	O
or	O
electroshock	O
in	O
Slc	O
:	O
ddY	O
mice	O
.	O

S-312-d	O
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	B
.	O

Transmural	O
myocardial	B
infarction	I
with	O
sumatriptan	O
.	O

For	O
sumatriptan	O
,	O
tightness	O
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
users	O
.	O

We	O
describe	O
a	O
47-year	O
-	O
old	O
woman	O
with	O
an	O
acute	O
myocardial	B
infarction	I
after	O
administration	O
of	O
sumatriptan	O
6	O
mg	O
subcutaneously	O
for	O
cluster	B
headache	I
.	O

The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	B
heart	I
disease	I
or	O
Prinzmetal	B
's	I
angina	I
.	O

She	O
recovered	O
without	O
complications	O
.	O

Flumazenil	O
induces	O
seizures	B
and	O
death	O
in	O
mixed	O
cocaine	O
-	O
diazepam	O
intoxications	O
.	O

STUDY	O
HYPOTHESIS	O
:	O
Administration	O
of	O
the	O
benzodiazepine	O
antagonist	O
flumazenil	O
may	O
unmask	O
seizures	B
in	O
mixed	O
cocaine	O
-	O
benzodiazepine	O
intoxication	O
.	O

DESIGN	O
:	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
100	O
mg	O
/	O
kg	O
cocaine	O
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazepam	O
alone	O
,	O
or	O
a	O
combination	O
of	O
diazepam	O
and	O
cocaine	O
.	O

Three	O
minutes	O
later	O
,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	O
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Animal	O
behavior	O
,	O
seizures	B
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
death	O
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
and	O
cortical	O
EEG	O
tracings	O
were	O
recorded	O
.	O

INTERVENTIONS	O
:	O
Administration	O
of	O
flumazenil	O
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	O
and	O
diazepam	O
.	O

RESULTS	O
:	O
In	O
group	O
1	O
,	O
animals	O
received	O
cocaine	O
followed	O
by	O
vehicle	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
seizures	B
and	O
death	O
.	O

Group	O
2	O
received	O
diazepam	O
alone	O
followed	O
by	O
vehicle	O
.	O

Animals	O
became	O
somnolent	O
and	O
none	O
died	O
.	O

Group	O
3	O
received	O
diazepam	O
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	O
.	O

Animals	O
became	O
somnolent	O
after	O
diazepam	O
and	O
then	O
active	O
after	O
flumazenil	O
administration	O
.	O

In	O
group	O
4	O
,	O
a	O
combination	O
of	O
cocaine	O
and	O
diazepam	O
was	O
administered	O
simultaneously	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectable	O
seizures	B
and	O
a	O
50	O
%	O
incidence	O
of	O
death	O
.	O

Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	O
and	O
diazepam	O
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	O
.	O

This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B
,	O
90	O
%	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
death	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.01	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O

Group	O
6	O
received	O
cocaine	O
and	O
diazepam	O
followed	O
by	O
10	O
mg	O
/	O
kg	O
flumazenil	O
.	O

This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.01	O
)	O
,	O
and	O
death	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O

CONCLUSION	O
:	O
Flumazenil	O
can	O
unmask	O
seizures	B
and	O
increase	O
the	O
incidence	O
of	O
death	O
in	O
a	O
model	O
of	O
combined	O
cocaine	O
-	O
diazepam	O
intoxications	O
.	O

Mechanisms	O
for	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	O
-	O
mediated	O
nephropathy	B
in	O
rats	O
.	O

Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	O
(	O
GM	O
)	O
-mediated	O
nephropathy	B
.	O

Administration	O
of	O
GM	O
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
inulin	O
clearance	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tubular	B
damage	I
.	O

A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	O
3',5'-cyclic	O
monophosphate	O
(	O
cGMP	O
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin-1	O
contents	O
were	O
also	O
observed	O
in	O
GM	O
-	O
mediated	O
nephropathy	B
.	O

Superoxide	O
dismutase	O
(	O
SOD	O
)	O
or	O
dimethylthiourea	O
(	O
DMTU	O
)	O
significantly	O
lessened	O
the	O
GM	O
-	O
induced	O
decrement	O
in	O
CIn	O
.	O

The	O
SOD	O
-	O
induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF	O
,	O
an	O
increase	O
in	O
urinary	O
cGMP	O
excretion	O
,	O
and	O
a	O
decrease	O
in	O
renal	O
renin	O
and	O
endothelin-1	O
content	O
.	O

SOD	O
did	O
not	O
attenuate	O
the	O
tubular	B
damage	I
.	O

In	O
contrast	O
,	O
DMTU	O
significantly	O
reduced	O
the	O
tubular	B
damage	I
and	O
lipid	O
peroxidation	O
,	O
but	O
it	O
did	O
not	O
affect	O
renal	O
hemodynamics	O
and	O
vasoactive	O
substances	O
.	O

Neither	O
SOD	O
nor	O
DMTU	O
affected	O
the	O
renal	O
cortical	O
GM	O
content	O
in	O
GM	O
-	O
treated	O
rats	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	O
have	O
protective	O
effects	O
on	O
GM	O
-	O
mediated	O
nephropathy	B
,	O
2	O
)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	O
,	O
and	O
3	O
)	O
superoxide	O
anions	O
play	O
a	O
critical	O
role	O
in	O
GM	O
-	O
induced	O
renal	O
vasoconstriction	O
.	O

Cephalothin	O
-	O
induced	O
immune	O
hemolytic	B
anemia	I
.	O

A	O
patient	O
with	O
renal	B
disease	I
developed	O
Coombs	O
-	O
positive	O
hemolytic	B
anemia	I
while	O
receiving	O
cephalothin	O
therapy	O
.	O

An	O
anti	O
-	O
cephalothin	O
IgG	O
antibody	O
was	O
detected	O
in	O
the	O
patient	O
's	O
serum	O
and	O
in	O
the	O
eluates	O
from	O
her	O
erythrocytes	O
.	O

In	O
addition	O
,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient	O
's	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin	O
-	O
coated	O
normal	O
red	O
cells	O
was	O
demonstrated	O
.	O

Skin	O
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	O
and	O
also	O
to	O
ampicillin	O
.	O

Careful	O
investigation	O
of	O
drug	O
-	O
induced	O
hemolytic	B
anemias	I
reveals	O
the	O
complexity	O
of	O
the	O
immune	O
mechanisms	O
involved	O
.	O

Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	B
in	O
adult	O
mice	O
.	O

The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	B
hypertrophy	I
was	O
assessed	O
in	O
adult	O
mice	O
.	O

Isoproterenol	O
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb	O
/	O
FeJ	O
mice	O
resulted	O
in	O
a	O
46	O
%	O
increase	O
in	O
heart	O
weight	O
and	O
a	O
19.3	O
%	O
increase	O
in	O
cardiomyocyte	O
area	O
.	O

No	O
DNA	O
synthesis	O
,	O
as	O
assessed	O
by	O
autoradiographic	O
analysis	O
of	O
isolated	O
cardiomyocytes	O
,	O
was	O
observed	O
in	O
control	O
or	O
hypertrophic	B
hearts	I
.	O

A	O
survey	O
of	O
15	O
independent	O
inbred	O
strains	O
of	O
mice	O
revealed	O
that	O
ventricular	O
cardiomyocyte	O
nuclear	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
mononucleate	O
,	O
suggesting	O
that	O
cardiomyocyte	O
terminal	O
differentiation	O
is	O
influenced	O
directly	O
or	O
indirectly	O
by	O
genetic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B
hypertrophy	I
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey	O
.	O

These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol	O
-	O
induced	O
cardiac	B
hypertrophy	I
.	O

Central	O
cardiovascular	O
effects	O
of	O
AVP	O
and	O
ANP	O
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	B
rats	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
in	O
normotensive	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	B
(	O
SHR	O
)	O
rats	O
.	O

Three	O
series	O
of	O
experiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chronically	O
instrumented	O
with	O
guide	O
tubes	O
in	O
the	O
lateral	O
ventricle	O
(	O
LV	O
)	O
and	O
arterial	O
and	O
venous	O
catheters	O
.	O

MAP	O
and	O
HR	O
were	O
monitored	O
before	O
and	O
after	O
i.v	O
.	O

injections	O
of	O
either	O
vehicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(	O
CCB	O
)	O
,	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
period	O
(	O
HRp	O
)	O
during	O
phenylephrine	O
(	O
Phe	O
)	O
-induced	O
hypertension	B
and	O
sodium	O
nitroprusside	O
(	O
SN	O
)	O
-induced	O
hypotension	B
.	O

CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle	O
,	O
AVP	O
,	O
ANP	O
,	O
or	O
both	O
peptides	O
together	O
.	O

Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle	O
,	O
but	O
it	O
abolished	O
AVP	O
-	O
induced	O
MAP	O
increase	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	O
during	O
SN	O
-	O
induced	O
hypotension	B
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP	O
,	O
AVP	O
and	O
ANP	O
+	O
AVP	O
decreased	O
CCB	O
during	O
Phe	O
-	O
induced	O
MAP	O
elevation	O
.	O

The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	O
and	O
ANP	O
exert	O
differential	O
effects	O
on	O
blood	O
pressure	O
and	O
baroreflex	O
control	O
of	O
heart	O
rate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interaction	O
of	O
these	O
two	O
peptides	O
in	O
blood	O
pressure	O
regulation	O
at	O
the	O
level	O
of	O
central	O
nervous	O
system	O
.	O

Cutaneous	O
exposure	O
to	O
warfarin	O
-	O
like	O
anticoagulant	O
causing	O
an	O
intracerebral	B
hemorrhage	I
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
intercerebral	O
hematoma	B
due	O
to	O
warfarin	O
-	O
induced	O
coagulopathy	B
is	O
presented	O
.	O

The	O
39-year	O
-	O
old	O
woman	O
had	O
spread	O
a	O
warfarin	O
-	O
type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands	O
,	O
with	O
no	O
washing	O
post	O
application	O
.	O

Percutaneous	O
absorption	O
of	O
warfarin	O
causing	O
coagulopathy	B
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
risk	O
if	O
protective	O
measures	O
,	O
such	O
as	O
gloves	O
,	O
are	O
not	O
used	O
.	O

An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	O
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	B
.	O

Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	O
.	O

From	O
1986	O
to	O
February	O
1993	O
,	O
40	O
children	O
aged	O
2	O
months	O
to	O
18	O
years	O
(	O
average	O
age	O
10.4	O
+	O
/-	O

5.8	O
years	O
)	O
underwent	O
heart	O
transplantation	O
.	O

Indications	O
for	O
transplantation	O
were	O
idiopathic	B
cardiomyopathy	I
(	O
52	O
%	O
)	O
,	O
congenital	B
heart	I
disease	I
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
repair	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hypertrophic	B
cardiomyopathy	I
(	O
5	O
%	O
)	O
,	O
valvular	B
heart	I
disease	I
(	O
3	O
%	O
)	O
,	O
and	O
doxorubicin	O
cardiomyopathy	B
(	O
5	O
%	O
)	O
.	O

Patients	O
were	O
managed	O
with	O
cyclosporine	O
and	O
azathioprine	O
.	O

No	O
prophylaxis	O
with	O
antilymphocyte	O
globulin	O
was	O
used	O
.	O

Steroids	O
were	O
given	O
to	O
39	O
%	O
of	O
patients	O
for	O
refractory	O
rejection	O
,	O
but	O
weaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
patients	O
(	O
14	O
%	O
)	O
received	O
maintenance	O
steroids	O
.	O

Four	O
patients	O
died	O
in	O
the	O
perioperative	O
period	O
and	O
one	O
died	O
4	O
months	O
later	O
.	O

There	O
have	O
been	O
no	O
deaths	O
related	O
to	O
rejection	O
or	O
infection	B
.	O

Average	O
follow	O
-	O
up	O
was	O
36	O
+	O
/-	O

19	O
months	O
(	O
range	O
1	O
to	O
65	O
months	O
)	O
.	O

Cumulative	O
survival	O
is	O
88	O
%	O
at	O
5	O
years	O
.	O

In	O
patients	O
less	O
than	O
7	O
years	O
of	O
age	O
,	O
rejection	O
was	O
monitored	O
noninvasively	O
.	O

In	O
the	O
first	O
postoperative	O
month	O
,	O
89	O
%	O
of	O
patients	O
were	O
treated	O
for	O
rejection	O
.	O

Freedom	O
from	O
serious	O
infections	B
was	O
83	O
%	O
at	O
1	O
month	O
and	O
65	O
%	O
at	O
1	O
year	O
.	O

Cytomegalovirus	B
infections	I
were	O
treated	O
successfully	O
with	O
ganciclovir	O
in	O
11	O
patients	O
.	O

No	O
impairment	O
of	O
growth	O
was	O
observed	O
in	O
children	O
who	O
underwent	O
transplantation	O
compared	O
with	O
a	O
control	O
population	O
.	O

Twenty	O
-	O
one	O
patients	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	B
has	O
been	O
observed	O
.	O

Seizures	B
occurred	O
in	O
five	O
patients	O
(	O
14	O
%	O
)	O
and	O
hypertension	B
was	O
treated	O
in	O
10	O
patients	O
(	O
28	O
%	O
)	O
.	O

No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	B
disorder	I
was	O
observed.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Delirium	B
during	O
fluoxetine	O
treatment	O
.	O

A	O
case	O
report	O
.	O

The	O
correlation	O
between	O
high	O
serum	O
tricyclic	O
antidepressant	O
concentrations	O
and	O
central	O
nervous	O
system	O
side	O
effects	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
reports	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
toxic	O
effects	O
.	O

In	O
some	O
cases	O
,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	O
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	B
and	O
movement	B
difficulties	I
.	O

Widespread	O
cognitive	B
disorders	I
,	O
such	O
as	O
delirium	B
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
blood	O
levels	O
of	O
SSRIs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	B
delirium	B
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	O
(	O
fluoxetine	O
plus	O
desmethylfluoxetine	O
)	O
concentration	O
.	O

Pulmonary	B
edema	I
and	O
shock	B
after	O
high	O
-	O
dose	O
aracytine	O
-	O
C	O
for	O
lymphoma	B
;	O
possible	O
role	O
of	O
TNF	O
-	O
alpha	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
Ara	O
-	O
C	O
for	O
lymphomas	B
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	O
during	O
the	O
perfusion	O
.	O

It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	B
,	O
diarrhea	B
,	O
shock	B
,	O
pulmonary	B
edema	I
,	O
acute	B
renal	I
failure	I
,	O
metabolic	B
acidosis	I
,	O
weight	B
gain	I
and	O
leukocytosis	B
.	O

Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	B
.	O

Sequential	O
biological	O
assays	O
of	O
IL-1	O
,	O
IL-2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	O
-	O
C	O
infusion	O
to	O
ten	O
patients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome	O
.	O

TNF	O
and	O
PAF	O
activity	O
was	O
found	O
in	O
the	O
serum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
cases	O
,	O
but	O
not	O
in	O
the	O
six	O
controls	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	B
and	O
adult	B
respiratory	I
distress	I
syndrome	I
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dose	O
Ara	O
-	O
C	O
may	O
be	O
associated	O
with	O
cytokine	O
release	O
.	O

Protective	O
effect	O
of	O
clentiazem	O
against	O
epinephrine	O
-	O
induced	O
cardiac	B
injury	I
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
clentiazem	O
,	O
a	O
1,5-benzothiazepine	O
calcium	O
antagonist	O
,	O
on	O
epinephrine	O
-	O
induced	O
cardiomyopathy	B
in	O
rats	O
.	O

With	O
2-week	O
chronic	O
epinephrine	O
infusion	O
,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days	O
,	O
and	O
severe	O
ischemic	B
lesions	I
and	O
fibrosis	B
of	O
the	O
left	O
ventricles	O
were	O
observed	O
.	O

In	O
epinephrine	O
-	O
treated	O
rats	O
,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	O
were	O
reduced	O
,	O
but	O
responses	O
to	O
calcium	O
were	O
normal	O
or	O
enhanced	O
compared	O
to	O
controls	O
.	O

Left	O
ventricular	O
alpha	O
and	O
beta	O
adrenoceptor	O
densities	O
were	O
also	O
reduced	O
compared	O
to	O
controls	O
.	O

Treatment	O
with	O
clentiazem	O
prevented	O
epinephrine	O
-	O
induced	O
death	O
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	B
lesions	I
and	O
fibrosis	B
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	O
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	O
alone	O
,	O
but	O
combined	O
with	O
epinephrine	O
,	O
clentiazem	O
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	O
.	O

On	O
the	O
other	O
hand	O
clentiazem	O
did	O
not	O
prevent	O
epinephrine	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
alpha	O
and	O
beta	O
adrenoceptors	O
.	O

Interestingly	O
,	O
clentiazem	O
,	O
infused	O
alone	O
,	O
resulted	O
in	O
decreased	O
adrenergic	O
receptor	O
densities	O
in	O
the	O
left	O
ventricle	O
.	O

Clentiazem	O
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	O
seen	O
in	O
the	O
epinephrine	O
-	O
treated	O
animals	O
,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	O
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	O
compared	O
to	O
epinephrine	O
-	O
treated	O
animals	O
.	O

In	O
conclusion	O
,	O
clentiazem	O
attenuated	O
epinephrine	O
-	O
induced	O
cardiac	B
injury	I
,	O
possibly	O
through	O
its	O
effect	O
on	O
the	O
adrenergic	O
pathway	O
.	O

Kaliuretic	O
effect	O
of	O
L	O
-	O
dopa	O
treatment	O
in	O
parkinsonian	B
patients	O
.	O

Hypokalemia	B
,	O
sometimes	O
severe	O
,	O
was	O
observed	O
in	O
some	O
L	O
-	O
dopa	O
-	O
treated	O
parkinsonian	B
patients	O
.	O

The	O
influence	O
of	O
L	O
-	O
dopa	O
on	O
the	O
renal	O
excretion	O
of	O
potassium	O
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	B
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
,	O
plasma	O
concentration	O
of	O
potassium	O
and	O
sodium	O
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	O
,	O
sodium	O
and	O
aldosterone	O
.	O

L	O
-	O
Dopa	O
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	O
,	O
and	O
sometimes	O
also	O
of	O
sodium	O
,	O
in	O
the	O
hypokalemic	O
but	O
not	O
in	O
the	O
normokalemic	O
patients	O
.	O

This	O
effect	O
on	O
the	O
renal	O
function	O
could	O
be	O
prohibited	O
by	O
the	O
administration	O
of	O
a	O
peripheral	O
dopa	O
decarbodylase	O
inhibitor	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	O
production	O
and	O
this	O
renal	O
effect	O
of	O
L	O
-	O
dopa	O
.	O

Cocaine	O
induced	O
myocardial	B
ischemia	I
.	O

We	O
report	O
a	O
case	O
of	O
myocardial	B
ischemia	I
induced	O
by	O
cocaine	O
.	O

The	O
ischemia	B
probably	O
induced	O
by	O
coronary	B
artery	I
spasm	I
was	O
reversed	O
by	O
nitroglycerin	O
and	O
calcium	O
blocking	O
agents	O
.	O

Doxorubicin	O
-	O
induced	O
cardiotoxicity	B
monitored	O
by	O
ECG	O
in	O
freely	O
moving	O
mice	O
.	O

A	O
new	O
model	O
to	O
test	O
potential	O
protectors	O
.	O

In	O
laboratory	O
animals	O
,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
.	O

However	O
,	O
for	O
monitoring	O
during	O
treatment	O
,	O
large	O
numbers	O
of	O
animals	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
method	O
to	O
measure	O
ECG	O
values	O
in	O
freely	O
moving	O
mice	O
by	O
telemetry	O
.	O

With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	O
administration	O
on	O
the	O
ECG	O
of	O
freely	O
moving	O
BALB	O
/	O
c	O
mice	O
and	O
the	O
efficacy	O
of	O
ICRF-187	O
as	O
a	O
protective	O
agent	O
.	O

The	O
ST	O
interval	O
significantly	O
widened	O
from	O
15.0	O
+	O
/-	O

1.5	O
to	O
56.8	O
+	O
/-	O

11.8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	O
given	O
i.v	O
.	O

plus	O
3	O
weeks	O
of	O
observation	O
)	O
.	O

The	O
ECG	O
of	O
the	O
control	O
animals	O
did	O
not	O
change	O
during	O
the	O
entire	O
study	O
.	O

After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin	O
-	O
treated	O
animals	O
were	O
enlarged	O
and	O
the	O
atria	O
were	O
hypertrophic	B
.	O

As	O
this	O
schedule	O
exerted	O
more	O
toxicity	B
than	O
needed	O
to	O
investigate	O
protective	O
agents	O
,	O
the	O
protection	O
of	O
ICRF-187	O
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	B
(	O
6	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	O
given	O
i.v	O
.	O
plus	O
2	O
weeks	O
of	O
observation	O
)	O
.	O

On	O
this	O
schedule	O
,	O
the	O
animals	O
'	O
hearts	O
appeared	O
normal	O
after	O
sacrifice	O
and	O
ICRF-187	O
(	O
50	O
mg	O
/	O
kg	O
given	O
i.p	O
.	O

1	O
h	O
before	O
doxorubicin	O
)	O
provided	O
almost	O
full	O
protection	O
.	O

These	O
data	O
were	O
confirmed	O
by	O
histology	O
.	O

The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	B
with	O
time	O
.	O

These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
as	O
demonstrated	O
by	O
the	O
protection	O
provided	O
by	O
ICRF-187	O
.	O

Epinephrine	O
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	O
in	O
dogs	O
.	O

Since	O
bupivacaine	O
and	O
epinephrine	O
may	O
both	O
precipitate	O
dysrhythmias	B
,	O
circulating	O
bupivacaine	O
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	O
.	O

We	O
therefore	O
examined	O
whether	O
bupivacaine	O
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	O
in	O
conscious	O
,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	B
infarction	I
.	O

Forty	O
-	O
one	O
conscious	O
dogs	O
received	O
10	O
micrograms.kg-1.min-1	O
epinephrine	O
.	O

Seventeen	O
animals	O
responded	O
with	O
ventricular	B
tachycardia	I
(	O
VT	B
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupivacaine	O
or	O
saline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micrograms.kg-1.min-1	O
epinephrine	O
.	O

In	O
the	O
bupivacaine	O
groups	O
,	O
epinephrine	O
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	O
.	O

VT	B
appeared	O
in	O
fewer	O
dogs	O
and	O
at	O
a	O
later	O
time	O
,	O
and	O
there	O
were	O
more	O
sinoatrial	O
beats	O
and	O
less	O
ectopies	O
.	O

Epinephrine	O
shortened	O
QT	O
less	O
after	O
bupivacaine	O
than	O
in	O
control	O
animals	O
.	O

One	O
day	O
after	O
experimental	O
myocardial	B
infarction	I
,	O
six	O
additional	O
halothane	O
-	O
anesthetized	O
dogs	O
received	O
4	O
micrograms.kg-1.min-1	O
epinephrine	O
until	O
VT	B
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivacaine	O
was	O
injected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
micrograms.kg-1.min-1	O
epinephrine	O
.	O

In	O
these	O
dogs	O
,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	O
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	O
.	O

Bupivacaine	O
antagonizes	O
epinephrine	O
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	B
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	B
.	O

There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	O
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	O
.	O

Milk	B
-	I
alkali	I
syndrome	I
induced	O
by	O
1,25	O
(	O
OH	O
)	O
2D	O
in	O
a	O
patient	O
with	O
hypoparathyroidism	B
.	O

Milk	B
-	I
alkali	I
syndrome	I
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	B
ulcer	I
disease	I
with	O
large	O
amounts	O
of	O
calcium	O
and	O
alkali	O
.	O

Although	O
with	O
current	O
ulcer	B
therapy	O
(	O
H-2	O
blockers	O
,	O
omeprazole	O
,	O
and	O
sucralfate	O
)	O
,	O
the	O
frequency	O
of	O
milk	B
-	I
alkali	I
syndrome	I
has	O
decreased	O
significantly	O
,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	B
,	O
alkalosis	B
,	O
and	O
renal	B
impairment	I
remains	O
the	O
hallmark	O
of	O
the	O
syndrome	O
.	O

Milk	B
-	I
alkali	I
syndrome	I
can	O
present	O
serious	O
and	O
occasionally	O
life	O
-	O
threatening	O
illness	O
unless	O
diagnosed	O
and	O
treated	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	B
who	O
was	O
treated	O
with	O
calcium	O
carbonate	O
and	O
calcitriol	O
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk	B
-	I
alkali	I
syndrome	I
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	O
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	O
on	O
the	O
second	O
.	O

This	O
illustrates	O
intravenous	O
pamidronate	O
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk	B
-	I
alkali	I
syndrome	I
presents	O
as	O
hypercalcemic	B
emergency	I
.	O

Encephalopathy	B
during	O
amitriptyline	O
therapy	O
:	O
are	O
neuroleptic	B
malignant	I
syndrome	I
and	O
serotonin	B
syndrome	I
spectrum	O
disorders	O
?	O

This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	B
developed	O
in	O
the	O
course	O
of	O
amitriptyline	O
therapy	O
,	O
during	O
a	O
remission	O
of	O
unipolar	B
depression	I
.	O

This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
or	O
serotonin	B
syndrome	I
(	O
SS	B
)	O
.	O

The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine	O
/	O
serotonin	O
imbalance	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
NMS	B
-	O
like	O
encephalopathy	B
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	O
indicates	O
that	O
NMS	B
and	O
SS	B
are	O
spectrum	O
disorders	O
induced	O
by	O
drugs	O
with	O
both	O
antidopaminergic	O
and	O
serotonergic	O
effects	O
.	O

Genetic	O
separation	O
of	O
tumor	B
growth	O
and	O
hemorrhagic	B
phenotypes	O
in	O
an	O
estrogen	O
-	O
induced	O
tumor	B
.	O

Chronic	O
administration	O
of	O
estrogen	O
to	O
the	O
Fischer	O
344	O
(	O
F344	O
)	O
rat	O
induces	O
growth	O
of	O
large	O
,	O
hemorrhagic	B
pituitary	B
tumors	I
.	O

Ten	O
weeks	O
of	O
diethylstilbestrol	O
(	O
DES	O
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109.2	O
+	O
/-	O

6.3	O
mg	O
(	O
mean	O
+	O
/-	O
SE	O
)	O
versus	O
11.3	O
+	O
/-	O

1.4	O
mg	O
for	O
untreated	O
rats	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagic	B
.	O

The	O
same	O
DES	O
treatment	O
produced	O
no	O
significant	O
growth	O
(	O
8.9	O
+	O
/-	O

0.5	O
mg	O
for	O
treated	O
females	O
versus	O
8.7	O
+	O
/-	O

1.1	O
for	O
untreated	O
females	O
)	O
or	O
morphological	O
changes	O
in	O
Brown	O
Norway	O
(	O
BN	O
)	O
rat	O
pituitaries	O
.	O

An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	O
treatment	O
with	O
an	O
average	O
mass	O
of	O
26.3	O
+	O
/-	O

0.7	O
mg	O
compared	O
with	O
8.6	O
+	O
/-	O

0.9	O
mg	O
for	O
untreated	O
rats	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hybrid	O
tumors	B
were	O
not	O
hemorrhagic	B
and	O
had	O
hemoglobin	O
content	O
and	O
outward	O
appearance	O
identical	O
to	O
that	O
of	O
BN	O
.	O

Expression	O
of	O
both	O
growth	O
and	O
morphological	O
changes	O
is	O
due	O
to	O
multiple	O
genes	O
.	O

However	O
,	O
while	O
DES	O
-	O
induced	O
pituitary	O
growth	O
exhibited	O
quantitative	O
,	O
additive	O
inheritance	O
,	O
the	O
hemorrhagic	B
phenotype	O
exhibited	O
recessive	O
,	O
epistatic	O
inheritance	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	B
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	B
,	O
indicating	O
that	O
the	O
hemorrhagic	B
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth	O
.	O

The	O
hemorrhagic	B
F2	O
pituitaries	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
genes	O
regulate	O
both	O
phenotypes	O
.	O

Increased	O
expression	O
of	O
neuronal	O
nitric	O
oxide	O
synthase	O
in	O
bladder	O
afferent	O
pathways	O
following	O
chronic	O
bladder	B
irritation	I
.	O

Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
in	O
bladder	O
pathways	O
following	O
acute	O
and	O
chronic	O
irritation	B
of	I
the	I
urinary	I
tract	I
of	O
the	O
rat	O
.	O

Chemical	O
cystitis	B
was	O
induced	O
by	O
cyclophosphamide	O
(	O
CYP	O
)	O
which	O
is	O
metabolized	O
to	O
acrolein	O
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine	O
.	O

Injection	O
of	O
CYP	O
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
perfusion	O
(	O
acute	O
treatment	O
)	O
of	O
the	O
animals	O
increased	O
Fos	O
-	O
immunoreactivity	O
(	O
IR	O
)	O
in	O
neurons	O
in	O
the	O
dorsal	O
commissure	O
,	O
dorsal	O
horn	O
,	O
and	O
autonomic	O
regions	O
of	O
spinal	O
segments	O
(	O
L1-L2	O
and	O
L6-S1	O
)	O
which	O
receive	O
afferent	O
inputs	O
from	O
the	O
bladder	O
,	O
urethra	O
,	O
and	O
ureter	O
.	O

Fos	O
-	O
IR	O
in	O
the	O
spinal	O
cord	O
was	O
not	O
changed	O
in	O
rats	O
receiving	O
chronic	O
CYP	O
treatment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
every	O
3rd	O
day	O
for	O
2	O
weeks	O
)	O
.	O

In	O
control	O
animals	O
and	O
in	O
animals	O
treated	O
acutely	O
with	O
CYP	O
,	O
only	O
small	O
numbers	O
of	O
NOS	O
-	O
IR	O
cells	O
(	O
0.5	O
-	O
0.7	O
cell	O
profiles	O
/	O
sections	O
)	O
were	O
detected	O
in	O
the	O
L6-S1	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O

Chronic	O
CYP	O
administration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.002	O
)	O
increased	O
bladder	O
weight	O
by	O
60	O
%	O
and	O
increased	O
(	O
7-	O
to	O
11-fold	O
)	O
the	O
numbers	O
of	O
NOS	O
-	O
immunoreactive	O
(	O
IR	O
)	O
afferent	O
neurons	O
in	O
the	O
L6-S1	O
DRG	O
.	O

A	O
small	O
increase	O
(	O
1.5-fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
detected	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bladder	O
afferent	O
cells	O
in	O
the	O
L6-S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(	O
40	O
microliters	O
)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
control	O
animals	O
;	O
however	O
,	O
following	O
chronic	O
CYP	O
administration	O
,	O
a	O
significant	O
percentage	O
of	O
bladder	O
afferent	O
neurons	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19.8	O
+	O
/-	O

4.6	O
%	O
)	O
and	O
S1	O
(	O
25.3	O
+	O
/-	O

2.9	O
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
neuronal	O
gene	O
expression	O
in	O
visceral	O
sensory	O
pathways	O
can	O
be	O
upregulated	O
by	O
chemical	O
irritation	O
of	O
afferent	O
receptors	O
in	O
the	O
urinary	O
tract	O
and/or	O
that	O
pathological	O
changes	O
in	O
the	O
urinary	O
tract	O
can	O
initiate	O
chemical	O
signals	O
that	O
alter	O
the	O
chemical	O
properties	O
of	O
visceral	O
afferent	O
neurons	O
.	O

Effects	O
of	O
a	O
new	O
calcium	O
antagonist	O
,	O
CD-832	O
,	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B
ischemia	I
in	O
dogs	O
with	O
partial	O
coronary	B
stenosis	I
.	O

Effects	O
of	O
CD-832	O
on	O
isoproterenol	O
(	O
ISO	O
)	O
-induced	O
myocardial	B
ischemia	I
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	B
stenosis	I
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	O
or	O
diltiazem	O
.	O

In	O
the	O
presence	O
of	O
coronary	B
artery	I
stenosis	I
,	O
3-min	O
periods	O
of	O
intracoronary	O
ISO	O
infusion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
increased	O
heart	O
rate	O
and	O
maximal	O
rate	O
of	O
left	O
ventricular	O
pressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
and	O
ST	O
-	O
segment	O
elevation	O
of	O
the	O
epicardial	O
electrocardiogram	O
.	O

After	O
the	O
control	O
ISO	O
infusion	O
with	O
stenosis	B
was	O
performed	O
,	O
equihypotensive	O
doses	O
of	O
CD-832	O
(	O
3	O
and	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifedipine	O
(	O
1	O
and	O
3	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiazem	O
(	O
10	O
and	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	O
infusion	O
.	O

Both	O
CD-832	O
and	O
diltiazem	O
,	O
but	O
not	O
nifedipine	O
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	O
infusion	O
.	O

In	O
contrast	O
to	O
nifedipine	O
,	O
CD-832	O
(	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
32	O
+	O
/-	O

12	O
%	O
to	O
115	O
+	O
/-	O

26	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.01	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
5.6	O
+	O
/-	O

1.0	O
mV	O
to	O
1.6	O
+	O
/-	O

1.3	O
mV	O
(	O
P	O
<	O
.01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
infusion	O
with	O
stenosis	B
.	O

Diltiazem	O
(	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+	O
/-	O

14	O
%	O
to	O
63	O
+	O
/-	O

18	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.05	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
4.7	O
+	O
/-	O

0.7	O
mV	O
to	O
2.1	O
+	O
/-	O

0.7	O
mV	O
(	O
P	O
<	O
.01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
infusion	O
with	O
stenosis	B
.	O

These	O
data	O
show	O
that	O
CD-832	O
improves	O
myocardial	B
ischemia	I
during	O
ISO	O
infusion	O
with	O
stenosis	B
and	O
suggest	O
that	O
the	O
negative	O
chronotropic	O
property	O
of	O
CD-832	O
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD-832	O
.	O

The	O
effect	O
of	O
recombinant	O
human	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
on	O
chronic	O
puromycin	O
aminonucleoside	O
nephropathy	B
in	O
rats	O
.	O

We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
nephropathy	B
,	O
an	O
experimental	O
model	O
of	O
glomerular	B
disease	I
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recombinant	O
human	O
(	O
rh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	B
failure	I
in	O
rats	O
with	O
chronic	O
PAN	O
nephropathy	B
.	O

The	O
glomerulopathy	B
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	O
over	O
12	O
wk	O
.	O

Experimental	O
animals	O
(	O
n	O
=	O
6	O
)	O
received	O
rhIGF	O
-	O
I	O
,	O
400	O
micrograms	O
/	O
d	O
,	O
whereas	O
control	O
rats	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vehicle	O
.	O

rhIGF	O
-	O
I	O
improved	O
weight	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0.05	O
)	O
,	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	B
disease	I
.	O

Urinary	O
protein	O
excretion	O
was	O
unaltered	O
by	O
rhIGF	O
-	O
I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	O
nephropathy	B
.	O

After	O
12	O
wk	O
,	O
the	O
inulin	O
clearance	O
was	O
higher	O
in	O
rhIGF	O
-	O
I	O
-	O
treated	O
rats	O
,	O
0.48	O
+	O
/-	O

0.08	O
versus	O
0.24	O
+	O
/-	O

0.06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
body	O
weight	O
in	O
untreated	O
PAN	O
nephropathy	B
animals	O
,	O
p	O
<	O
0.05	O
.	O

The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	B
hypertrophy	I
or	O
increased	O
segmental	O
glomerulosclerosis	B
,	O
tubulointerstitial	B
injury	I
,	O
or	O
renal	O
cortical	O
malondialdehyde	O
content	O
.	O

In	O
rats	O
with	O
PAN	O
nephropathy	B
,	O
administration	O
of	O
rhIGF	O
-	O
I	O
increased	O
IGF	O
-	O
I	O
and	O
GH	O
receptor	O
gene	O
expression	O
,	O
without	O
altering	O
the	O
steady	O
state	O
level	O
of	O
IGF	O
-	O
I	O
receptor	O
mRNA	O
.	O

In	O
normal	O
rats	O
with	O
intact	O
kidneys	O
,	O
rhIGF	O
-	O
I	O
administration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
weight	O
gain	O
,	O
blood	O
pressure	O
,	O
proteinuria	B
,	O
GFR	O
,	O
glomerular	O
planar	O
area	O
,	O
renal	O
cortical	O
malondialdehyde	O
content	O
,	O
or	O
glomerular	O
or	O
tubulointerstitial	B
damage	I
,	O
compared	O
with	O
untreated	O
animals	O
(	O
n	O
=	O
4	O
)	O
.	O

rhIGF	O
-	O
I	O
treatment	O
reduced	O
the	O
steady	O
state	O
renal	O
IGF	O
-	O
I	O
mRNA	O
level	O
but	O
did	O
not	O
modify	O
gene	O
expression	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
receptors	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF	O
-	O
I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	O
nephropathy	B
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worsen	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	O
model	O
.	O

Nefiracetam	O
(	O
DM-9384	O
)	O
reverses	O
apomorphine	O
-	O
induced	O
amnesia	B
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O

Nefiracetam	O
is	O
a	O
novel	O
pyrrolidone	O
derivative	O
which	O
attenuates	O
scopolamine	O
-	O
induced	O
learning	B
and	I
post	I
-	I
training	I
consolidation	I
deficits	I
.	O

Given	O
that	O
apomorphine	O
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	O
to	O
attenuate	O
amnesia	B
induced	O
by	O
dopaminergic	O
agonism	O
.	O

A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	O
(	O
0.5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O

Co	O
-	O
administration	O
of	O
nefiracetam	O
and	O
apomorphine	O
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	O
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	O
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B
induced	O
by	O
apomorphine	O
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	O
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	O
23390	O
or	O
[	O
3H	O
]	O
spiperone	O
binding	O
from	O
D1	O
or	O
D2	O
dopamine	O
receptor	O
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	O
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O

Phenytoin	O
encephalopathy	B
as	O
probable	O
idiosyncratic	O
reaction	O
:	O
case	O
report	O
.	O

A	O
case	O
of	O
phenytoin	O
(	O
DPH	O
)	O
encephalopathy	B
with	O
increasing	O
seizures	B
and	O
EEG	O
and	O
mental	O
changes	O
is	O
described	O
.	O

Despite	O
adequate	O
oral	O
dosage	O
of	O
DPH	O
(	O
5	O
mg	O
/	O
kg	O
/	O
daily	O
)	O
the	O
plasma	O
level	O
was	O
very	O
low	O
(	O
2.8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
encephalopathy	B
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	O
reaction	O
.	O

In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	O
was	O
normal	O
,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	B
during	O
DPH	O
treatment	O
,	O
the	O
protidogram	O
was	O
normal	O
,	O
and	O
an	O
intradermic	O
DPH	O
injection	O
had	O
no	O
local	O
effect	O
.	O

The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	O
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	B
,	O
with	O
EEG	O
and	O
mental	O
changes	O
occurring	O
simultaneously	O
,	O
should	O
alert	O
the	O
physician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	O
from	O
the	O
therapeutic	O
regimen	O
,	O
even	O
if	O
plasma	O
concentrations	O
are	O
low	O
.	O

Prevention	O
and	O
treatment	O
of	O
endometrial	B
disease	I
in	O
climacteric	O
women	O
receiving	O
oestrogen	O
therapy	O
.	O

The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	B
disease	I
among	O
850	O
climacteric	O
women	O
receiving	O
oestrogen	O
therapy	O
.	O

Cystic	O
hyperplasia	B
was	O
associated	O
with	O
unopposed	O
oestrogen	O
therapy	O
without	O
progestagen	O
.	O

Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	O
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	B
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	B
.	O

4	O
cases	O
of	O
endometrial	B
carcinoma	I
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	O
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	B
from	O
malignancy	B
.	O

Cyclical	O
low	O
-	O
dose	O
oestrogen	O
therapy	O
with	O
7	O
-	O
-13	O
days	O
of	O
progestagen	O
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	B
hyperplasia	I
or	O
carcinoma	B
.	O

Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
.	O

The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
was	O
studied	O
in	O
male	O
rats	O
.	O

Ninety	O
-	O
three	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

The	O
exercise	O
-	O
isoproterenol	O
(	O
E-1	O
)	O
and	O
exercise	O
control	O
(	O
EC	O
)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	O
1	O
mph	O
,	O
2	O
%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary	O
-	O
isoproterenol	O
(	O
S	O
-	O
I	O
)	O
group	O
remained	O
sedentary	O
.	O

Eight	O
animals	O
were	O
assigned	O
to	O
the	O
sedentary	O
control	O
(	O
SC	O
)	O
group	O
which	O
remained	O
sedentary	O
throughout	O
the	O
experimental	O
period	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exercise	O
period	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	O
(	O
250	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Animals	O
of	O
the	O
S	O
-	O
I	O
group	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0.05	O
)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	O
than	O
animals	O
of	O
the	O
E	O
-	O
I	O
group	O
.	O

Serum	O
CPK	O
activity	O
for	O
E	O
-	O
I	O
animals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	O
injection	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	O
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions	O
,	O
changes	O
in	O
heart	O
weight	O
,	O
or	O
heart	O
weight	O
to	O
body	O
weight	O
ratios	O
.	O

The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	O
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	B
.	O

Human	O
corticotropin	O
-	O
releasing	O
hormone	O
and	O
thyrotropin	O
-	O
releasing	O
hormone	O
modulate	O
the	O
hypercapnic	B
ventilatory	O
response	O
in	O
humans	O
.	O

Human	O
corticotropin	O
-	O
releasing	O
hormone	O
(	O
hCRH	O
)	O
and	O
thyrotropin	O
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stimulate	O
ventilation	O
after	O
i.v	O
.	O

administration	O
in	O
humans	O
.	O

In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blind	O
study	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptides	O
act	O
by	O
altering	O
central	O
chemosensitivity	O
.	O

Two	O
subsequent	O
CO2-rebreathing	O
tests	O
were	O
performed	O
in	O
healthy	O
young	O
volunteers	O
.	O

During	O
the	O
first	O
test	O
0.9	O
%	O
NaCl	O
was	O
given	O
i.v	O
.	O
;	O
during	O
the	O
second	O
test	O
200	O
micrograms	O
of	O
hCRH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
micrograms	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
administered	O
i.v	O
.	O

Nine	O
subjects	O
received	O
0.9	O
%	O
NaCl	O
i.v	O
.	O

during	O
both	O
rebreathing	O
manoeuvres	O
.	O

The	O
CO2-response	O
curves	O
for	O
the	O
two	O
tests	O
were	O
compared	O
within	O
the	O
same	O
subject	O
.	O

In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2-response	O
curve	O
to	O
the	O
left	O
was	O
observed	O
after	O
hCRH	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
same	O
effect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0.05	O
)	O
.	O

hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	O
threshold	O
.	O

The	O
CO2-response	O
curves	O
in	O
the	O
control	O
group	O
were	O
nearly	O
identical	O
.	O

The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	O
on	O
the	O
hypercapnic	B
ventilatory	O
response	O
in	O
humans	O
,	O
presumably	O
independent	O
of	O
central	O
chemosensitivity	O
.	O

Lamivudine	O
is	O
effective	O
in	O
suppressing	O
hepatitis	B
B	I
virus	O
DNA	O
in	O
Chinese	O
hepatitis	O
B	O
surface	O
antigen	O
carriers	O
:	O
a	O
placebo	O
-	O
controlled	O
trial	O
.	O

Lamivudine	O
is	O
a	O
novel	O
2',3'-dideoxy	O
cytosine	O
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	B
B	I
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
carriers	O
.	O

Forty	O
-	O
two	O
Chinese	O
HBsAg	O
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
6	O
patients	O
)	O
or	O
lamivudine	O
orally	O
in	O
dosages	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
daily	O
(	O
12	O
patients	O
for	O
each	O
dosage	O
)	O
.	O

The	O
drug	O
was	O
given	O
for	O
4	O
weeks	O
.	O

The	O
patients	O
were	O
closely	O
monitored	O
clinically	O
,	O
biochemically	O
,	O
and	O
serologically	O
up	O
to	O
4	O
weeks	O
after	O
drug	O
treatment	O
.	O

All	O
36	O
patients	O
receiving	O
lamivudine	O
had	O
a	O
decrease	O
in	O
hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
DNA	O
values	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.001	O
compared	O
with	O
placebo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lamivudine	O
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(	O
P	O
=	O
.011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.005	O
)	O
,	O
it	O
still	O
induced	O
94	O
%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
therapy	O
.	O

HBV	O
DNA	O
values	O
returned	O
to	O
pretreatment	O
levels	O
within	O
4	O
weeks	O
of	O
cessation	O
of	O
therapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	B
B	I
e	O
antigen	O
status	O
or	O
in	O
aminotransferase	O
levels	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4-week	O
course	O
of	O
lamivudine	O
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	O
carriers	O
.	O

The	O
suppression	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Studies	O
with	O
long	O
-	O
term	O
lamivudine	O
administration	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prolonged	O
suppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Population	O
-	O
based	O
study	O
of	O
risk	O
of	O
venous	B
thromboembolism	I
associated	O
with	O
various	O
oral	O
contraceptives	O
.	O

BACKGROUND	O
:	O
Four	O
studies	O
published	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	B
thromboembolism	I
(	O
VTE	B
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	O
contraceptives	O
(	O
OCs	O
)	O
containing	O
the	O
third	O
-	O
generation	O
progestagens	O
gestodene	O
or	O
desogestrel	O
than	O
in	O
users	O
of	O
OCs	O
containing	O
second	O
-	O
generation	O
progestagens	O
.	O

However	O
,	O
confounding	O
and	O
bias	O
in	O
the	O
design	O
of	O
these	O
studies	O
may	O
have	O
affected	O
the	O
findings	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re	O
-	O
examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	B
and	O
OC	O
use	O
with	O
a	O
different	O
study	O
design	O
and	O
analysis	O
to	O
avoid	O
some	O
of	O
the	O
bias	O
and	O
confounding	O
of	O
the	O
earlier	O
studies	O
.	O

METHODS	O
:	O
We	O
used	O
computer	O
records	O
of	O
patients	O
from	O
143	O
general	O
practices	O
in	O
the	O
UK	O
.	O

The	O
study	O
was	O
based	O
on	O
the	O
medical	O
records	O
of	O
about	O
540,000	O
women	O
born	O
between	O
1941	O
and	O
1981	O
.	O

All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep	B
-	I
vein	I
thrombosis	I
,	O
venous	B
thrombosis	I
not	O
otherwise	O
specified	O
,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period	O
,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	B
.	O

We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	B
in	O
users	O
of	O
the	O
main	O
OC	O
preparations	O
,	O
and	O
a	O
nested	O
case	O
-	O
control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	B
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	O
,	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
.	O

In	O
the	O
case	O
-	O
control	O
study	O
,	O
we	O
matched	O
cases	O
to	O
controls	O
by	O
exact	O
year	O
of	O
birth	O
,	O
practice	O
,	O
and	O
current	O
use	O
of	O
OCs	O
.	O

We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body	O
-	O
mass	O
index	O
,	O
number	O
of	O
cycles	O
,	O
change	O
in	O
type	O
of	O
OC	O
prescribed	O
within	O
3	O
months	O
of	O
the	O
event	O
,	O
previous	O
pregnancy	O
,	O
and	O
concurrent	O
disease	O
.	O

FINDINGS	O
:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	B
,	O
two	O
of	O
whom	O
were	O
users	O
of	O
progestagen	O
-	O
only	O
OCs	O
.	O

Of	O
the	O
83	O
cases	O
of	O
VTE	B
associated	O
with	O
use	O
of	O
combined	O
OCs	O
,	O
43	O
were	O
recorded	O
as	O
deep	B
-	I
vein	I
thrombosis	I
,	O
35	O
as	O
pulmonary	O
thrombosis	B
,	O
and	O
five	O
as	O
venous	B
thrombosis	I
not	O
otherwise	O
specified	O
.	O

The	O
crude	O
rate	O
of	O
VTE	B
per	O
10,000	O
woman	O
-	O
years	O
was	O
4.10	O
in	O
current	O
users	O
of	O
any	O
OC	O
,	O
3.10	O
in	O
users	O
of	O
second	O
-	O
generation	O
OCs	O
,	O
and	O
4.96	O
in	O
users	O
of	O
third	O
-	O
generation	O
preparations	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
the	O
rate	O
ratio	O
of	O
VTE	B
in	O
users	O
of	O
third	O
-	O
generation	O
relative	O
to	O
second	O
-	O
generation	O
OCs	O
was	O
1.68	O
(	O
95	O
%	O
CI	O
1.04	O
-	O
2.75	O
)	O
.	O

Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	B
between	O
users	O
of	O
third	O
-	O
generation	O
and	O
second	O
-	O
generation	O
OCs	O
.	O

Among	O
users	O
of	O
third	O
-	O
generation	O
progestagens	O
,	O
the	O
risk	O
of	O
VTE	B
was	O
higher	O
in	O
users	O
of	O
desogestrel	O
with	O
20	O
g	O
ethinyloestradiol	O
than	O
in	O
users	O
of	O
gestodene	O
or	O
desogestrel	O
with	O
30	O
g	O
ethinyloestradiol	O
.	O

With	O
all	O
second	O
-	O
generation	O
OCs	O
as	O
the	O
reference	O
,	O
the	O
odds	O
ratios	O
for	O
VTE	B
were	O
3.49	O
(	O
1.21	O
-	O
10.12	O
)	O
for	O
desogestrel	O
plus	O
20	O
g	O
ethinyloestradiol	O
and	O
1.18	O
(	O
0.66	O
-	O
2.17	O
)	O
for	O
the	O
other	O
third	O
-	O
generation	O
progestagens	O
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
increase	O
in	O
odds	O
ratio	O
associated	O
with	O
third	O
-	O
generation	O
OCs	O
when	O
compared	O
with	O
second	O
-	O
generation	O
products	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residual	O
confounding	O
by	O
age	O
.	O

The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	O
and	O
desogestrel	O
compared	O
with	O
the	O
30	O
micrograms	O
product	O
is	O
biologically	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferential	O
prescribing	O
and	O
,	O
thus	O
,	O
confounding	O
.	O

MK-801	O
augments	O
pilocarpine	O
-	O
induced	O
electrographic	O
seizure	B
but	O
protects	O
against	O
brain	B
damage	I
in	O
rats	O
.	O

1	O
.	O

The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK-801	O
on	O
the	O
pilocarpine	O
-	O
induced	O
seizure	B
model	O
.	O

Intraperitoneal	O
injection	O
of	O
pilocarpine	O
(	O
400	O
mg	O
/	O
kg	O
)	O
induced	O
tonic	B
and	I
clonic	I
seizure	I
.	O

Scopolamine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pentobarbital	O
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
development	O
of	O
pilocarpine	O
-	O
induced	O
behavioral	O
seizure	B
but	O
MK-801	O
(	O
0.5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

2	O
.	O

An	O
electrical	O
seizure	B
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine	O
-	O
treated	O
group	O
.	O

Scopolamine	O
and	O
pentobarbital	O
blocked	O
the	O
pilocarpine	O
-	O
induced	O
electrographic	O
seizure	B
,	O
MK-801	O
treatment	O
augmented	O
the	O
electrographic	O
seizure	B
induced	O
by	O
pilocarpine	O
.	O

3	O
.	O

Brain	B
damage	I
was	O
assessed	O
by	O
examining	O
the	O
hippocampus	O
microscopically	O
.	O

Pilocarpine	O
produced	O
neuronal	B
death	I
in	O
the	O
hippocampus	O
,	O
which	O
showed	O
pyknotic	O
changes	O
.	O

Pentobarbital	O
,	O
scopolamine	O
and	O
MK-801	O
protected	O
the	O
brain	B
damage	I
by	O
pilocarpine	O
,	O
though	O
in	O
the	O
MK-801-treated	O
group	O
,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal	O
.	O

In	O
all	O
treatments	O
,	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
not	O
affected	O
.	O

4	O
.	O

These	O
results	O
indicate	O
that	O
status	B
epilepticus	I
induced	O
by	O
pilocarpine	O
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission	O
,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	B
damage	I
through	O
an	O
excitatory	O
NMDA	O
receptor	O
-	O
mediated	O
mechanism	O
.	O

Paclitaxel	O
,	O
5-fluorouracil	O
,	O
and	O
folinic	O
acid	O
in	O
metastatic	O
breast	B
cancer	I
:	O
BRE-26	O
,	O
a	O
phase	O
II	O
trial	O
.	O

5-Fluorouracil	O
plus	O
folinic	O
acid	O
and	O
paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	B
cancer	I
patients	O
.	O

Paclitaxel	O
and	O
5-fluorouracil	O
have	O
additive	O
cytotoxicity	B
in	O
MCF-7	O
cell	O
lines	O
.	O

We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	O
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	O
acid	O
300	O
mg	O
over	O
1	O
hour	O
before	O
5-fluorouracil	O
350	O
mg	O
/	O
m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(	O
TFL	O
)	O
in	O
women	O
with	O
metastatic	O
breast	B
cancer	I
.	O

Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL	O
:	O
nine	O
cycles	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
grade	O
3	O
/	O
4	O
neutropenia	B
requiring	O
hospitalization	O
;	O
seven	O
(	O
4	O
%	O
)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
due	O
to	O
neutropenia	B
;	O
no	O
patient	O
required	O
platelet	O
transfusions	O
.	O

Grade	O
3	O
/	O
4	O
nonhematologic	O
toxicities	B
were	O
uncommon	O
.	O

Among	O
the	O
34	O
patients	O
evaluable	O
for	O
response	O
,	O
there	O
were	O
three	O
complete	O
responses	O
(	O
9	O
%	O
)	O
and	O
18	O
partial	O
responses	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
response	O
rate	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	O
exposure	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxorubicin	O
.	O

Plasma	O
paclitaxel	O
concentrations	O
were	O
measured	O
at	O
the	O
completion	O
of	O
paclitaxel	O
infusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patients	O
.	O

TFL	O
is	O
an	O
active	O
,	O
well	O
-	O
tolerated	O
regimen	O
in	O
metastatic	O
breast	B
cancer	I
.	O

Efficacy	O
and	O
proarrhythmia	B
with	O
the	O
use	O
of	O
d	O
,	O
l	O
-	O
sotalol	O
for	O
sustained	O
ventricular	B
tachyarrhythmias	I
.	O

This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy	O
,	O
the	O
incidence	O
of	O
torsades	B
de	I
pointes	I
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	B
de	I
pointes	I
in	O
patients	O
treated	O
with	O
d	O
,	O
l	O
-	O
sotalol	O
for	O
sustained	O
ventricular	B
tachyarrhythmias	I
.	O

Eighty	O
-	O
one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B
artery	I
disease	I
,	O
and	O
20	O
with	O
dilated	B
cardiomyopathy	I
)	O
with	O
inducible	O
sustained	O
ventricular	B
tachycardia	I
or	O
ventricular	B
fibrillation	I
received	O
oral	O
d	O
,	O
l	O
-	O
sotalol	O
to	O
prevent	O
induction	O
of	O
the	O
ventricular	B
tachyarrhythmia	I
.	O

During	O
oral	O
loading	O
with	O
d	O
,	O
l	O
-	O
sotalol	O
,	O
continuous	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
was	O
performed	O
.	O

Those	O
patients	O
in	O
whom	O
d	O
,	O
l	O
-	O
sotalol	O
prevented	O
induction	O
of	O
ventricular	B
tachycardia	I
or	O
ventricular	B
fibrillation	I
were	O
discharged	O
with	O
the	O
drug	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
for	O
21	O
+	O
/-	O

18	O
months	O
.	O

Induction	O
of	O
the	O
ventricular	B
tachyarrhythmia	I
was	O
prevented	O
by	O
oral	O
d	O
,	O
l	O
-	O
sotalol	O
in	O
35	O
(	O
43	O
%	O
)	O
patients	O
;	O
the	O
ventricular	B
tachyarrhythmia	I
remained	O
inducible	O
in	O
40	O
(	O
49	O
%	O
)	O
patients	O
;	O
and	O
two	O
(	O
2.5	O
%	O
)	O
patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	O
,	O
l	O
-	O
sotalol	O
once	O
daily	O
.	O

Four	O
(	O
5	O
%	O
)	O
patients	O
had	O
from	O
torsades	B
de	I
pointes	I
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d	O
,	O
l	O
-	O
sotalol	O
.	O

Neither	O
ECG	O
[	O
sinus	O
-	O
cycle	O
length	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	B
de	I
pointes	I
.	O

However	O
,	O
the	O
oral	O
dose	O
of	O
d	O
,	O
l	O
-	O
sotalol	O
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	B
de	I
pointes	I
(	O
200	O
+	O
/-	O
46	O
vs.	O
328	O
+	O
/-	O

53	O
mg	O
/	O
day	O
;	O
p	O
=	O
0.0017	O
)	O
.	O

Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	B
de	I
pointes	I
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(	O
p	O
=	O
0.049	O
)	O
,	O
female	O
gender	O
(	O
p	O
=	O
0.015	O
)	O
,	O
and	O
significant	O
dose	O
-	O
corrected	O
changes	O
of	O
SCL	O
,	O
QT	O
interval	O
,	O
and	O
QTc	O
interval	O
(	O
p	O
<	O
0.05	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	B
tachycardia	I
recurrence	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
patients	O
died	O
suddenly	O
.	O

One	O
female	O
patient	O
with	O
stable	O
cardiac	B
disease	I
had	O
recurrent	O
torsades	B
de	I
pointes	I
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d	O
,	O
l	O
-	O
sotalol	O
.	O

Torsades	B
de	I
pointes	I
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d	O
,	O
l	O
-	O
sotalol	O
.	O

Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(	O
cycle	O
length	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d	O
,	O
l	O
-	O
sotalol	O
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	B
de	I
pointes	I
.	O

Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d	O
,	O
l	O
-	O
sotalol	O
did	O
not	O
identify	O
patients	O
at	O
increased	O
risk	O
for	O
torsades	B
de	I
pointes	I
.	O

Recurrence	O
rates	O
of	O
ventricular	B
tachyarrhythmias	I
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	B
during	O
programmed	O
stimulation	O
.	O

Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d	O
,	O
l	O
-	O
sotalol	O
seems	O
to	O
be	O
of	O
limited	O
prognostic	O
value	O
.	O

Chronic	O
hyperprolactinemia	B
and	O
changes	O
in	O
dopamine	O
neurons	O
.	O

The	O
tuberoinfundibular	O
dopaminergic	O
(	O
TIDA	O
)	O
system	O
is	O
known	O
to	O
inhibit	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
.	O

In	O
young	O
animals	O
this	O
system	O
responds	O
to	O
acute	O
elevations	O
in	O
serum	O
PRL	O
by	O
increasing	O
its	O
activity	O
.	O

However	O
,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	O
rats	O
with	O
chronically	O
high	O
serum	O
PRL	O
levels	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	B
in	O
rats	O
for	O
extended	O
periods	O
of	O
time	O
and	O
examine	O
its	O
effects	O
on	O
dopaminergic	O
systems	O
in	O
the	O
brain	O
.	O

Hyperprolactinemia	B
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	O
,	O
a	O
dopamine	O
receptor	O
antagonist	O
,	O
and	O
Palkovits	O
'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain	O
.	O

After	O
6	O
months	O
of	O
hyperprolactinemia	B
,	O
dopamine	O
(	O
DA	O
)	O
concentrations	O
in	O
the	O
median	O
eminence	O
(	O
ME	O
)	O
increased	O
by	O
84	O
%	O
over	O
the	O
control	O
group	O
.	O

Nine	O
months	O
of	O
hyperprolactinemia	B
produced	O
a	O
50	O
%	O
increase	O
in	O
DA	O
concentrations	O
in	O
the	O
ME	O
over	O
the	O
control	O
group	O
.	O

However	O
,	O
DA	O
response	O
was	O
lost	O
if	O
a	O
9-month	O
long	O
haloperidol	O
-	O
induced	O
hyperprolactinemia	B
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
month	O
-	O
long	O
extremely	O
high	O
increase	O
in	O
serum	O
PRL	O
levels	O
produced	O
by	O
implantation	O
of	O
MMQ	O
cells	O
under	O
the	O
kidney	O
capsule	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	O
,	O
norepinephrine	O
(	O
NE	O
)	O
,	O
serotonin	O
(	O
5-HT	O
)	O
,	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(	O
AN	O
)	O
,	O
medial	O
preoptic	O
area	O
(	O
MPA	O
)	O
,	O
caudate	O
putamen	O
(	O
CP	O
)	O
,	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
and	O
zona	O
incerta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrease	O
in	O
5-hydroxyindoleacetic	O
acid	O
(	O
5-HIAA	O
)	O
in	O
the	O
AN	O
after	O
6-months	O
of	O
hyperprolactinemia	B
and	O
an	O
increase	O
in	O
DA	O
concentrations	O
in	O
the	O
AN	O
after	O
9-months	O
of	O
hyperprolactinemia	B
.	O

These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	B
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary	O
,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	B
.	O

The	O
age	O
-	O
related	O
decrease	O
in	O
hypothalamic	O
dopamine	O
function	O
may	O
be	O
associated	O
with	O
increases	O
in	O
PRL	O
secretion	O
.	O

Treatment	O
-	O
related	O
disseminated	O
necrotizing	O
leukoencephalopathy	B
with	O
characteristic	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
.	O

This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1-weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	B
,	O
which	O
developed	O
from	O
acute	B
lymphoblastic	I
leukemia	I
treated	O
with	O
high	O
-	O
dose	O
methotrexate	O
.	O

In	O
both	O
patients	O
,	O
the	O
enhancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
brain	O
than	O
at	O
the	O
vertex	O
.	O

Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	B
of	I
myelination	I
and	O
necrosis	B
of	O
the	O
white	O
matter	O
.	O

Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	B
are	O
discussed	O
.	O

Thrombotic	B
complications	O
in	O
acute	B
promyelocytic	I
leukemia	I
during	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
therapy	O
.	O

A	O
case	O
of	O
acute	B
renal	I
failure	I
,	O
due	O
to	O
occlusion	B
of	I
renal	I
vessels	I
in	O
a	O
patient	O
with	O
acute	B
promyelocytic	I
leukemia	I
(	O
APL	B
)	O
treated	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
tranexamic	O
acid	O
has	O
been	O
described	O
recently	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B
renal	I
failure	I
in	O
an	O
APL	B
patient	O
treated	O
with	O
ATRA	O
alone	O
.	O

This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	B
complications	O
associated	O
with	O
ATRA	O
therapy	O
in	O
APL	B
patients	O
.	O

The	O
patients	O
,	O
a	O
43-year	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
signs	O
and	O
symptoms	O
of	O
APL	B
and	O
was	O
included	O
in	O
a	O
treatment	O
protocol	O
with	O
ATRA	O
.	O

After	O
10	O
days	O
of	O
treatment	O
,	O
he	O
developed	O
acute	B
renal	I
failure	I
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	O
of	O
APL	B
was	O
achieved	O
and	O
therapy	O
discontinued	O
.	O

We	O
conclude	O
that	O
ATRA	O
is	O
a	O
valid	O
therapeutic	O
choice	O
for	O
patients	O
with	O
APL	B
,	O
although	O
the	O
procoagulant	O
tendency	O
is	O
not	O
completely	O
corrected	O
.	O

Thrombotic	B
events	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dose	O
heparin	O
.	O

Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant	O
-	O
induced	O
mania	B
:	O
a	O
case	O
report	O
.	O

A	O
30-year	O
-	O
old	O
cocaine	O
-	O
dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	O
(	O
DEP	O
)	O
became	O
manic	B
during	O
his	O
second	O
week	O
on	O
the	O
study	O
drug	O
.	O

Pupillometric	O
changes	O
while	O
on	O
DEP	O
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B
oscillation	I
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	B
.	O

The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	B
oscillation	I
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	B
.	O

Such	O
medication	O
-	O
associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B
oscillation	I
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	O
risk	O
for	O
manic	B
-	O
like	O
adverse	O
effects	O
during	O
the	O
medical	O
use	O
of	O
psychomotor	O
stimulants	O
or	O
sympathomimetic	O
agents	O
.	O

Fetal	O
risks	O
due	O
to	O
warfarin	O
therapy	O
during	O
pregnancy	O
.	O

Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	O
during	O
pregnancy	O
.	O

In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	O
with	O
heparin	O
.	O

The	O
baby	O
died	O
of	O
cerebral	B
and	I
pulmonary	I
hemorrhage	I
.	O

The	O
second	O
mother	O
had	O
a	O
male	O
infant	O
by	O
caesarean	O
section	O
.	O

The	O
baby	O
showed	O
warfarin	O
-	O
induced	O
embryopathy	B
with	O
nasal	B
hypoplasia	I
and	O
stippled	B
epiphyses	I
(	O
chondrodysplasia	B
punctata	I
)	O
.	O

Nasal	B
hypoplasia	I
with	O
or	O
without	O
stippled	B
epiphyses	I
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	O
during	O
the	O
first	O
trimester	O
,	O
and	O
a	O
causal	O
association	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
risks	O
to	O
both	O
mother	O
and	O
fetus	O
in	O
women	O
with	O
prosthetic	O
cardiac	O
valves	O
it	O
is	O
recommended	O
that	O
therapeutic	O
abortion	O
be	O
advised	O
as	O
the	O
first	O
alternative	O
.	O

The	O
negative	O
mucosal	O
potential	O
:	O
separating	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
in	O
man	O
.	O

OBJECTIVE	O
:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain	B
-	O
related	O
signal	O
(	O
chemo	O
-	O
somatosensory	O
evoked	O
potential	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripheral	O
signal	O
(	O
negative	O
mucosal	O
potential	O
,	O
NMP	O
)	O
allows	O
for	O
separation	O
of	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
.	O

For	O
this	O
purpose	O
,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	O
pain	B
by	O
either	O
central	O
or	O
peripheral	O
mechanisms	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
controlled	O
,	O
threefold	O
cross	O
-	O
over	O
design	O
,	O
18	O
healthy	O
subjects	O
(	O
11	O
males	O
,	O
7	O
females	O
;	O
mean	O
age	O
26	O
years	O
)	O
received	O
either	O
placebo	O
,	O
400	O
mg	O
ibuprofen	O
,	O
or	O
800	O
mg	O
ibuprofen	O
.	O

Phasic	O
pain	B
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	O
to	O
the	O
nasal	O
mucosa	O
(	O
stimulus	O
duration	O
500	O
ms	O
,	O
interval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
tonic	O
pain	B
was	O
induced	O
in	O
the	O
nasal	O
cavity	O
by	O
means	O
of	O
dry	O
air	O
of	O
controlled	O
temperature	O
,	O
humidity	O
and	O
flow	O
rate	O
(	O
22	O
degrees	O
C	O
,	O
0	O
%	O
relative	O
humidity	O
,	O
145	O
ml.s-1	O
)	O
.	O

Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	B
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	O
stimuli	O
.	O

Additionally	O
,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	O
pain	B
by	O
means	O
of	O
visual	O
analogue	O
scales	O
.	O

RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
administration	O
of	O
ibuprofen	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	O
pain	B
but	O
-	O
relative	O
to	O
placebo	O
-	O
an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	B
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	O
on	O
the	O
interaction	O
between	O
the	O
pain	B
stimuli	O
under	O
these	O
special	O
experimental	O
conditions	O
.	O

Based	O
on	O
the	O
similar	O
behaviour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
pharmacological	O
process	O
underlying	O
this	O
phenomenon	O
was	O
localised	O
in	O
the	O
periphery	O
.	O

By	O
means	O
of	O
the	O
simultaneous	O
recording	O
of	O
interrelated	O
peripheral	O
and	O
central	O
electrophysiologic	O
correlates	O
of	O
nociception	O
,	O
it	O
was	O
possible	O
to	O
separate	O
central	O
and	O
peripheral	O
effects	O
of	O
an	O
NSAID	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pain	B
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain	B
-	O
related	O
activity	O
directly	O
using	O
a	O
non	O
-	O
invasive	O
technique	O
in	O
humans	O
.	O

Effect	O
of	O
D	O
-	O
Glucarates	O
on	O
basic	O
antibiotic	O
-	O
induced	O
renal	B
damage	I
in	O
rats	O
.	O

Dehydrated	B
rats	O
regularly	O
develop	O
acute	B
renal	I
failure	I
following	O
single	O
injection	O
of	O
aminoglycoside	O
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only	O
.	O

Oral	O
administration	O
of	O
2,5-di	O
-	O
O	O
-	O
acetyl	O
-	O
D	O
-	O
glucaro-1,4	O
-	O
6,3-dilactone	O
protected	O
rats	O
against	O
renal	B
failure	I
induced	O
by	O
kanamycin	O
-	O
dextran	O
.	O

The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D	O
-	O
glucarates	O
,	O
and	O
also	O
to	O
other	O
saccharic	O
acid	O
,	O
hexauronic	O
acids	O
and	O
hexaaldonic	O
acids	O
,	O
although	O
to	O
a	O
lesser	O
degree	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
sugar	O
alcohols	O
,	O
substances	O
inthe	O
TCA	O
cycle	O
and	O
other	O
acidic	O
compounds	O
.	O

D	O
-	O
Glucarates	O
were	O
effective	O
against	O
renal	B
damage	I
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	O
antibitocis	O
.	O

Dose	O
-	O
responses	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D	O
-	O
Glucarates	O
.	O

With	O
a	O
D	O
-	O
glucarate	O
of	O
a	O
fixed	O
size	O
of	O
dose	O
,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	B
damages	I
induced	O
by	O
different	O
basic	O
antibiotics	O
despite	O
large	O
disparities	O
in	O
administration	O
doses	O
of	O
different	O
antibiotics	O
.	O

D	O
-	O
Glucarates	O
had	O
the	O
ability	O
to	O
prevent	O
renal	B
damage	I
but	O
not	O
to	O
cure	O
it	O
.	O

Rats	O
excreted	O
acidic	O
urine	O
when	O
they	O
were	O
spared	O
from	O
renal	B
lesions	I
by	O
monosaccharides	O
.	O

The	O
reduction	O
effect	O
of	O
D	O
-	O
glucarates	O
against	O
nephrotoxicity	B
of	O
basic	O
antibiotics	O
was	O
discussed	O
.	O

Acute	O
severe	O
depression	B
following	O
peri	O
-	O
operative	O
ondansetron	O
.	O

A	O
41-year	O
-	O
old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	B
nausea	I
and	I
vomiting	I
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	O
prophylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
severe	O
acute	O
major	B
depression	I
disorder	I
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	O
antagonist	O
.	O

Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self	O
-	O
limited	O
puerperal	O
depressive	B
episode	I
.	O

Anaesthesia	O
with	O
a	O
propofol	O
infusion	O
and	O
avoidance	O
of	O
serotonin	O
antagonists	O
provided	O
a	O
nausea	B
-	O
free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	B
disorder	I
.	O

Hypertensive	B
response	O
during	O
dobutamine	O
stress	O
echocardiography	O
.	O

Among	O
3,129	O
dobutamine	O
stress	O
echocardiographic	O
studies	O
,	O
a	O
hypertensive	B
response	O
,	O
defined	O
as	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patients	O
(	O
1	O
%	O
)	O
.	O

Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	B
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O
BP	O
before	O
dobutamine	O
infusion	O
.	O

Continuously	O
nebulized	O
albuterol	O
in	O
severe	O
exacerbations	O
of	O
asthma	B
in	O
adults	O
:	O
a	O
case	O
-	O
controlled	O
study	O
.	O

A	O
retrospective	O
,	O
case	O
-	O
controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	B
who	O
received	O
continuously	O
nebulized	O
albuterol	O
(	O
CNA	O
)	O
versus	O
intermittent	O
albuterol	O
(	O
INA	O
)	O
treatments	O
is	O
reported	O
.	O

Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	B
are	O
compared	O
.	O

CNA	O
was	O
administered	O
for	O
a	O
mean	O
of	O
11	O
+	O
/-	O

10	O
hr	O
.	O

The	O
incidence	O
of	O
cardiac	B
dysrhythmias	I
was	O
similar	O
between	O
groups	O
.	O

Symptomatic	O
hypokalemia	B
did	O
not	O
occur	O
.	O

CNA	O
patients	O
had	O
higher	O
heart	O
rates	O
during	O
treatment	O
,	O
which	O
may	O
reflect	O
severity	O
of	O
illness	O
.	O

The	O
incidence	O
of	O
intubation	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
profiles	O
with	O
regard	O
to	O
safety	O
,	O
morbidity	O
,	O
and	O
mortality	O
.	O

Paraplegia	B
following	O
intrathecal	O
methotrexate	O
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

A	O
patient	O
who	O
developed	O
paraplegia	B
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	O
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
cases	O
of	O
this	O
unusual	O
complication	O
are	O
reviewed	O
.	O

The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication	O
:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	B
nervous	I
system	I
leukemia	I
,	O
and	O
epidural	O
cerebrospinal	O
leakage	O
;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	O
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	O
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults	O
;	O
the	O
presence	O
of	O
neurotoxic	B
preservatives	O
in	O
commercially	O
available	O
methotrexate	O
preparations	O
and	O
diluents	O
;	O
and	O
the	O
use	O
of	O
methotrexate	O
diluents	O
of	O
unphysiologic	O
pH	O
,	O
ionic	O
content	O
and	O
osmolarity	O
.	O

The	O
role	O
of	O
methotrexate	O
contaminants	O
,	O
local	O
folate	B
deficiency	I
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	O
toxicity	B
is	O
unclear	O
.	O

The	O
incidence	O
of	O
neurotoxicity	B
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	O
in	O
the	O
presence	O
of	O
central	B
nervous	I
system	I
leukemia	I
,	O
in	O
older	O
children	O
and	O
adults	O
,	O
and	O
in	O
the	O
presence	O
of	O
epidural	O
leakage	O
.	O

Only	O
preservative	O
-	O
free	O
methotrexate	O
in	O
Elliott	O
's	O
B	O
Solution	O
at	O
a	O
concentration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
intrathecal	O
administration	O
.	O

Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	O
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	B
.	O

Hyperosmolar	B
nonketotic	I
coma	I
precipitated	O
by	O
lithium	O
-	O
induced	O
nephrogenic	B
diabetes	I
insipidus	I
.	O

A	O
45-year	O
-	O
old	O
man	O
,	O
with	O
a	O
10-year	O
history	O
of	O
manic	B
depression	I
treated	O
with	O
lithium	O
,	O
was	O
admitted	O
with	O
hyperosmolar	B
,	I
nonketotic	I
coma	I
.	O

He	O
gave	O
a	O
five	O
-	O
year	O
history	O
of	O
polyuria	B
and	O
polydipsia	B
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	O
.	O

After	O
recovery	O
from	O
hyperglycaemia	B
,	O
he	O
remained	O
polyuric	B
despite	O
normal	O
blood	O
glucose	O
concentrations	O
;	O
water	O
deprivation	O
testing	O
indicated	O
nephrogenic	B
diabetes	I
insipidus	I
,	O
likely	O
to	O
be	O
lithium	O
-	O
induced	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	B
2	I
diabetes	I
,	O
chronic	O
polyuria	B
due	O
to	O
nephrogenic	B
diabetes	I
insipidus	I
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	B
.	O

Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	O
on	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	O
causes	O
a	O
profound	O
deterioration	B
of	I
left	I
ventricular	I
(	I
LV	I
)	I
systolic	I
function	I
and	O
an	O
increase	O
in	O
LV	O
end	O
-	O
diastolic	O
pressure	O
.	O

This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	O
concentration	O
on	O
LV	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patients	O
(	O
14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years	O
)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	B
pain	I
,	O
we	O
measured	O
heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15-minute	O
intracoronary	O
infusion	O
of	O
saline	O
(	O
n=10	O
,	O
control	O
subjects	O
)	O
or	O
cocaine	O
hydrochloride	O
1	O
mg	O
/	O
min	O
(	O
n=10	O
)	O
.	O

No	O
variable	O
changed	O
with	O
saline	O
.	O

With	O
cocaine	O
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3.0+	O
/	O
-0.4	O
(	O
mean+	O
/	O
-SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	O
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	O
intoxication	O
.	O

Cocaine	O
induced	O
no	O
significant	O
change	O
in	O
heart	O
rate	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
positive	O
or	O
negative	O
)	O
,	O
or	O
LV	O
end	O
-	O
diastolic	O
volume	O
,	O
but	O
it	O
caused	O
an	O
increase	O
in	O
systolic	O
and	O
mean	O
arterial	O
pressures	O
,	O
LV	O
end	O
-	O
diastolic	O
pressure	O
,	O
and	O
LV	O
end	O
-	O
systolic	O
volume	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LV	O
ejection	O
fraction	O
.	O

CONCLUSIONS	O
:	O
In	O
humans	O
,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	O
sufficient	O
in	O
amount	O
to	O
achieve	O
a	O
high	O
drug	O
concentration	O
in	O
coronary	O
sinus	O
blood	O
causes	O
a	O
deterioration	B
of	I
LV	I
systolic	I
and	I
diastolic	I
performance	I
.	O

Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	O
administered	O
after	O
normal	O
vaginal	O
birth	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carbetocin	O
(	O
a	O
long	O
-	O
acting	O
synthetic	O
analogue	O
of	O
oxytocin	O
)	O
,	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Carbetocin	O
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	O
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	O
term	O
.	O

Dosage	O
groups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
microg	O
carbetocin	O
were	O
assigned	O
to	O
blocks	O
of	O
three	O
women	O
according	O
to	O
the	O
continual	O
reassessment	O
method	O
(	O
CRM	O
)	O
.	O

RESULTS	O
:	O
All	O
dosage	O
groups	O
consisted	O
of	O
three	O
women	O
,	O
except	O
those	O
with	O
100	O
microg	O
(	O
n=6	O
)	O
and	O
200	O
microg	O
(	O
n=18	O
)	O
.	O

Recorded	O
were	O
dose	O
-	O
limiting	O
adverse	O
events	O
:	O
hyper-	B
or	I
hypotension	I
(	O
three	O
)	O
,	O
severe	O
abdominal	B
pain	I
(	O
0	O
)	O
,	O
vomiting	B
(	O
0	O
)	O
and	O
retained	B
placenta	I
(	O
four	O
)	O
.	O

Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B
loss	I
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion	O
.	O

Maximum	O
blood	B
loss	I
was	O
greatest	O
at	O
the	O
upper	O
and	O
lower	O
dose	O
levels	O
,	O
and	O
lowest	O
in	O
the	O
70	O
-	O
125	O
microg	O
dose	O
range	O
.	O

Four	O
out	O
of	O
six	O
cases	O
with	O
blood	B
loss	I
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
microg	O
group	O
.	O

The	O
majority	O
of	O
additional	O
administration	O
of	O
oxytocics	O
(	O
4	O
/	O
5	O
)	O
and	O
blood	O
transfusion	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
dose	O
groups	O
of	O
200	O
microg	O
.	O

All	O
retained	O
placentae	O
were	O
found	O
in	O
the	O
group	O
of	O
200	O
microg	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
microg	O
carbetocin	O
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
,	O
paradoxical	O
thromboembolism	B
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	O
therapy	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	O
remains	O
the	O
drug	O
of	O
choice	O
for	O
most	O
anticoagulation	O
needs	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	O
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Important	O
untoward	O
effects	O
of	O
heparin	O
therapy	O
including	O
heparin	O
-	O
induced	O
thrombocytopenia	B
,	O
heparin	O
-	O
associated	O
osteoporosis	B
,	O
eosinophilia	B
,	O
skin	B
reactions	I
,	O
allergic	B
reactions	I
other	O
than	O
thrombocytopenia	B
and	O
alopecia	B
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	B
obstruction	I
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	O
therapy	O
.	O

OBJECTIVE	O
:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	B
calculi	I
in	O
six	O
HIV	B
-	I
infected	I
patients	O
receiving	O
indinavir	O
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	B
.	O

CONCLUSION	O
:	O
Ureteric	B
obstruction	I
caused	O
by	O
precipitated	O
indinavir	O
crystals	O
may	O
be	O
difficult	O
to	O
diagnose	O
with	O
unenhanced	O
CT	O
.	O

The	O
calculi	O
are	O
not	O
opaque	O
,	O
and	O
secondary	O
signs	O
of	O
obstruction	O
may	O
be	O
absent	O
or	O
minimal	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Images	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i.v	O
.	O

contrast	O
material	O
to	O
enable	O
diagnosis	O
of	O
ureteric	B
stones	I
or	B
obstruction	I
in	O
patients	O
with	O
HIV	B
infection	I
who	O
receive	O
indinavir	O
therapy	O
.	O

Ischemic	B
colitis	I
and	O
sumatriptan	O
use	O
.	O

Sumatriptan	O
succinate	O
,	O
a	O
serotonin-1	O
(	O
5-hydroxytryptamine-1	O
)	O
receptor	O
agonist	O
,	O
is	O
an	O
antimigraine	O
drug	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constricting	O
intracranial	O
arteries	O
.	O

Recently	O
,	O
vasopressor	O
responses	O
that	O
are	O
distinct	O
from	O
the	O
cranial	O
circulation	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systemic	O
,	O
pulmonary	O
,	O
and	O
coronary	O
circulations	O
.	O

Cases	O
have	O
been	O
published	O
of	O
coronary	B
vasospasm	I
,	O
myocardial	B
ischemia	I
,	O
and	O
myocardial	B
infarction	I
occurring	O
after	O
sumatriptan	O
use	O
.	O

We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	B
colitis	I
in	O
patients	O
with	O
migraine	B
treated	O
with	O
sumatriptan	O
.	O

Pallidotomy	O
with	O
the	O
gamma	O
knife	O
:	O
a	O
positive	O
experience	O
.	O

51	O
patients	O
with	O
medically	O
refractory	O
Parkinson	B
's	I
disease	I
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	B
,	O
rigidity	B
,	O
and	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesias	B
.	O

In	O
29	O
patients	O
,	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Leksell	O
Gamma	O
Knife	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
standard	O
radiofrequency	O
(	O
RF	O
)	O
method	O
.	O

Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson	B
's	I
Disease	I
Rating	O
Scale	O
(	O
UPDRS	O
)	O
scores	O
were	O
carried	O
out	O
pre-	O
and	O
postoperatively	O
.	O

Mean	O
follow	O
-	O
up	O
time	O
is	O
20.6	O
months	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
patients	O
have	O
been	O
followed	O
more	O
than	O
one	O
year	O
.	O

85	O
percent	O
of	O
patients	O
with	O
dyskinesias	B
were	O
relieved	O
of	O
symptoms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Gamma	O
Knife	O
or	O
radiofrequency	O
methods	O
.	O

About	O
2	O
/	O
3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	B
and	O
rigidity	B
,	O
although	O
when	O
considered	O
as	O
a	O
group	O
neither	O
the	O
Gamma	O
Knife	O
nor	O
the	O
radiofrequency	O
group	O
showed	O
statistically	O
significant	O
improvements	O
in	O
UPDRS	O
scores	O
.	O

One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(	O
3.4	O
%	O
)	O
developed	O
a	O
homonymous	B
hemianopsia	I
9	O
months	O
following	O
treatment	O
and	O
5	O
patients	O
(	O
27.7	O
%	O
)	O
in	O
the	O
radiofrequency	O
group	O
became	O
transiently	O
confused	O
postoperatively	O
.	O

No	O
other	O
complications	O
were	O
seen	O
.	O

Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson	B
's	I
disease	I
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants	O
,	O
have	O
bleeding	B
diatheses	O
or	O
serious	O
systemic	O
medical	O
illnesses	O
.	O

It	O
is	O
a	O
viable	O
option	O
for	O
other	O
patients	O
as	O
well	O
.	O

Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	O
in	O
anesthetized	O
rats	O
.	O

The	O
pressor	O
response	O
to	O
the	O
intracisternal	O
(	O
i.c	O
.	O
)	O
injection	O
of	O
carbachol	O
(	O
1	O
mug	O
)	O
in	O
anesthetized	O
rats	O
was	O
analyzed	O
.	O

This	O
response	O
was	O
significantly	O
reduced	O
by	O
the	O
intravenous	O
(	O
i.v	O
.	O
)	O
injection	O
of	O
guanethidine	O
(	O
5	O
mg	O
)	O
,	O
hexamethonium	O
(	O
10	O
mg	O
)	O
or	O
phentolamine	O
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentiated	O
by	O
i.v	O
.	O

desmethylimipramine	O
(	O
0.3	O
mg	O
)	O
,	O
while	O
propranolol	O
(	O
0.5	O
mg	O
)	O
i.v	O
.	O
selectively	O
inhibited	O
the	O
enlargement	B
of	I
pulse	I
pressure	I
and	O
the	O
tachycardia	B
following	O
i.c	O
.	O

carbachol	O
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
response	O
to	O
i.c	O
.	O

carbachol	O
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
blocked	O
by	O
i.c	O
.	O

atropine	O
(	O
3	O
mug	O
)	O
or	O
hexamethonium	O
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
reduced	O
by	O
i.c	O
.	O

chlorpromazine	O
(	O
50	O
mug	O
)	O
but	O
significantly	O
potentiated	O
by	O
i.c	O
.	O

desmethylimipramine	O
(	O
30	O
mug	O
)	O
.	O

The	O
pressor	O
response	O
to	O
i.c	O
.	O

carbachol	O
(	O
1	O
mug	O
)	O
remained	O
unchanged	O
after	O
sectioning	O
of	O
the	O
bilateral	O
cervical	O
vagal	O
nerves	O
but	O
disappeared	O
after	O
sectioning	O
of	O
the	O
spinal	O
cord	O
(	O
C7-C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
pressor	O
response	O
to	O
i.c	O
.	O

carbachol	O
ortral	O
and	O
peripheral	O
adrenergic	O
mechanisms	O
,	O
and	O
that	O
the	O
sympathetic	O
trunk	O
is	O
the	O
main	O
pathway	O
.	O

Neuroleptic	B
malignant	I
syndrome	I
and	O
methylphenidate	O
.	O

A	O
1-year	O
-	O
old	O
female	O
presented	O
with	O
neuroleptic	B
malignant	I
syndrome	I
probably	O
caused	O
by	O
methylphenidate	O
.	O

She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	B
encephalomalacia	I
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic	B
-	I
ischemic	I
encephalopathy	I
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B
malignant	I
syndrome	I
.	O

A	O
dopaminergic	O
blockade	O
mechanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesis	O
of	O
this	O
syndrome	O
.	O

However	O
,	O
methylphenidate	O
is	O
a	O
dopamine	O
agonist	O
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	O
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(	O
mainly	O
the	O
midbrain	O
)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome	O
.	O

A	O
relative	O
gamma	O
-	O
aminobutyric	O
acid	O
-	O
ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	O
,	O
a	O
gamma	O
-	O
aminobutyric	O
acid	O
-	O
mimetic	O
agent	O
,	O
was	O
strikingly	O
effective	O
.	O

This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	B
malignant	I
syndrome	I
probably	O
caused	O
by	O
methylphenidate	O
.	O

Differential	O
effects	O
of	O
17alpha	O
-	O
ethinylestradiol	O
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	O
salt	O
synthesis	O
in	O
the	O
rat	O
.	O

Effects	O
of	O
17alpha	O
-	O
ethinylestradiol	O
(	O
EE	O
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	O
salt	O
(	O
BS	O
)	O
synthesis	O
were	O
evaluated	O
in	O
rats	O
with	O
an	O
intact	O
enterohepatic	O
circulation	O
and	O
in	O
rats	O
with	O
long	O
-	O
term	O
bile	O
diversion	O
to	O
induce	O
BS	O
synthesis	O
.	O

For	O
this	O
purpose	O
,	O
bile	O
salt	O
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	O
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	O
7alpha	O
-	O
hydroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
sterol	O
27-hydroxylase	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	O
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	O
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
days	O
)	O
or	O
its	O
vehicle	O
.	O

BS	O
pool	O
size	O
was	O
decreased	O
by	O
27	O
%	O
but	O
total	O
BS	O
synthesis	O
was	O
not	O
affected	O
by	O
EE	O
in	O
intact	O
rats	O
.	O

Synthesis	O
of	O
cholate	O
was	O
reduced	O
by	O
68	O
%	O
in	O
EE	O
-	O
treated	O
rats	O
,	O
while	O
that	O
of	O
chenodeoxycholate	O
was	O
increased	O
by	O
60	O
%	O
.	O

The	O
recently	O
identified	O
Delta22-isomer	O
of	O
beta	O
-	O
muricholate	O
contributed	O
for	O
5.4	O
%	O
and	O
18.3	O
%	O
(	O
P	O
<	O
0.01	O
)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE	O
-	O
treated	O
rats	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detected	O
in	O
bile	O
after	O
exhaustion	O
of	O
the	O
pool	O
.	O

A	O
clear	O
reduction	O
of	O
BS	O
synthesis	O
was	O
found	O
in	O
bile	O
-	O
diverted	O
rats	O
treated	O
with	O
EE	O
,	O
yet	O
biliary	O
BS	O
composition	O
was	O
only	O
minimally	O
affected	O
.	O

Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	O
in	O
both	O
intact	O
and	O
bile	O
-	O
diverted	O
rats	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
CYP27	O
was	O
not	O
affected	O
.	O

Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	O
in	O
bile	O
-	O
diverted	O
rats	O
only	O
;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	O
.	O

In	O
addition	O
,	O
mRNA	O
levels	O
of	O
sterol	O
12alpha	O
-	O
hydroxylase	O
and	O
lithocholate	O
6beta	O
-	O
hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	O
.	O

This	O
study	O
shows	O
that	O
17alpha	O
-	O
ethinylestradiol	O
(	O
EE	O
)	O
-induced	O
intrahepatic	B
cholestasis	I
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	O
salt	O
(	O
BS	O
)	O
synthesis	O
.	O

Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	O
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	O
on	O
BS	O
synthesis	O
.	O

Glibenclamide	O
-	O
sensitive	O
hypotension	B
produced	O
by	O
helodermin	O
assessed	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
helodermin	O
,	O
a	O
basic	O
35-amino	O
acid	O
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland	O
,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	O
sensitive	O
K+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channels	O
is	O
involved	O
in	O
the	O
responses	O
.	O

The	O
results	O
were	O
also	O
compared	O
with	O
those	O
of	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
.	O

Helodermin	O
produced	O
hypotension	B
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
approximately	O
similar	O
potency	O
and	O
duration	O
to	O
VIP	O
.	O

Hypotension	B
induced	O
by	O
both	O
peptides	O
was	O
significantly	O
attenuated	O
by	O
glibenclamide	O
,	O
which	O
abolished	O
a	O
levcromakalim	O
-	O
produced	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
.	O

Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin	O
-	O
induced	O
hypotension	B
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	O
(	O
ACh	O
)	O
-produced	O
hypotension	B
.	O

These	O
findings	O
suggest	O
that	O
helodermin	O
-	O
produced	O
hypotension	B
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide	O
-	O
sensitive	O
K+	O
channels	O
(	O
K	O
(	O
ATP	O
)	O
channels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
arterial	O
smooth	O
muscle	O
cells	O
.	O

EDRF	O
(	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
)	O
/	O
nitric	O
oxide	O
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide	O
-	O
produced	O
hypotension	B
.	O

Long	O
-	O
term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	O
sustained	O
-	O
release	O
tablets	O
for	O
cyclosporin	O
A	O
-	O
induced	O
hypertension	B
in	O
patients	O
with	O
psoriasis	B
.	O

Thirteen	O
psoriatic	B
patients	O
with	O
hypertension	B
during	O
the	O
course	O
of	O
cyclosporin	O
A	O
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	O
channel	O
blocker	O
,	O
sustained	O
-	O
release	O
nifedipine	O
,	O
to	O
study	O
the	O
clinical	O
antihypertensive	O
effects	O
and	O
adverse	O
events	O
during	O
treatment	O
with	O
both	O
drugs	O
.	O

Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	B
state	O
before	O
cyclosporin	O
A	O
therapy	O
.	O

Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	O
therapy	O
,	O
and	O
blood	O
pressure	O
was	O
maintained	O
within	O
the	O
normal	O
range	O
thereafter	O
for	O
25	O
months	O
.	O

The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	O
A	O
and	O
nifedipine	O
included	O
an	O
increase	O
in	O
blood	O
urea	O
nitrogen	O
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	B
hyperplasia	I
in	O
2	O
of	O
the	O
13	O
patients	O
.	O

Our	O
findings	O
indicate	O
that	O
sustained	O
-	O
release	O
nifedipine	O
is	O
useful	O
for	O
hypertensive	B
psoriatic	B
patients	O
under	O
long	O
-	O
term	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	B
hyperplasia	I
.	O

This	O
can	O
translate	O
into	O
global	O
effects	O
on	O
cellular	O
health	O
and	O
differentiation	O
state	O
.	O

Recently	O
,	O
several	O
reports	O
have	O
identified	O
crucial	O
roles	O
for	O
miRNAs	O
in	O
controlling	O
the	O
production	O
,	O
differentiation	O
,	O
and	O
health	O
of	O
myelinating	O
cells	O
of	O
the	O
mammalian	O
nervous	O
system	O
.	O

As	O
single	O
miRNAs	O
are	O
often	O
predicted	O
to	O
target	O
up	O
to	O
hundreds	O
of	O
individual	O
transcripts	O
,	O
miRNAs	O
are	O
able	O
to	O
broadly	O
affect	O
the	O
overall	O
protein	O
expression	O
state	O
of	O
the	O
cell	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
how	O
individual	O
miRNAs	O
regulate	O
these	O
various	O
processes	O
,	O
and	O
also	O
how	O
miRNA	O
production	O
in	O
general	O
is	O
required	O
for	O
several	O
stages	O
of	O
myelin	O
generation	O
and	O
maintenance	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
small	O
(	O
approx	O
.	O
22	O
nt	O
)	O
noncoding	O
RNAs	O
that	O
are	O
capable	O
of	O
post	O
-	O
transcriptionally	O
silencing	O
mRNAs	O
that	O
contain	O
sequences	O
complementary	O
to	O
the	O
miRNAs	O
'	O
7-	O
to	O
8-bp	O
'	O
seed	O
'	O
sequence	O
.	O

MicroRNAs	O
in	O
oligodendrocyte	O
and	O
Schwann	O
cell	O
differentiation	O
.	O

Identification	O
of	O
blood	O
microRNAs	O
associated	O
to	O
Parkinsońs	B
disease	I
.	I

While	O
miR-1	O
,	O
miR-22	O
*	O
and	O
miR-29	O
expression	O
levels	O
allowed	O
to	O
distinguish	O
non	O
-	O
treated	O
PD	O
from	O
healthy	O
subjects	O
,	O
miR-16	O
-	O
2	O
*	O
,	O
miR-26a2	O
*	O
and	O
miR30a	O
differentiated	O
treated	O
from	O
untreated	O
patients	O
.	O

They	O
form	O
two	O
groups	O
according	O
to	O
their	O
expression	O
profile	O
in	O
control	O
,	O
non	O
-	O
treated	O
,	O
early	O
-	O
onset	O
and	O
treated	O
Parkinson	O
's	B
disease	I
subjects	O
.	O

A	O
set	O
of	O
six	O
differentially	O
expressed	O
microRNAs	O
were	O
identified	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
blood	O
samples	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
miRNA	O
identification	O
associated	O
to	O
Parkinson	O
's	B
disease	I
(	O
PD	O
)	B
.	O

This	O
study	O
is	O
innovative	O
in	O
contributing	O
to	O
the	O
development	O
of	O
effective	O
PD	O
biomarkers	O
.	O

Our	O
data	O
suggests	O
that	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
may	O
contribute	O
to	O
glioma	B
and	O
GBM	B
,	O
in	O
part	O
,	O
by	O
coordinately	O
up	O
-	O
regulating	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
,	O
resulting	O
in	O
the	O
proliferation	O
of	O
undifferentiated	O
GBM	B
cells	O
.	O

Addition	O
of	O
exogenous	O
miRNA-128	O
to	O
CRL-1690	O
and	O
CRL-2610	O
GBM	O
cell	O
lines	O
(	O
a	O
)	O
restored	O
'	O
homeostatic	O
'	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
expression	O
,	O
and	O
(	O
b	O
)	O
significantly	O
decreased	O
the	O
proliferation	O
of	O
CRL-1690	O
and	O
CRL-2610	O
cell	O
lines	O
.	O

Three	O
bioinformatics	O
-	O
verified	O
miRNA-128	O
targets	O
,	O
angiopoietin	O
-	O
related	O
growth	O
factor	O
protein	O
5	O
(	O
ARP5	O
;	O
ANGPTL6	O
)	O
,	O
a	O
transcription	O
suppressor	O
that	O
promotes	O
stem	O
cell	O
renewal	O
and	O
inhibits	O
the	O
expression	O
of	O
known	O
tumor	O
suppressor	O
genes	O
involved	O
in	O
senescence	O
and	O
differentiation	O
,	O
Bmi-1	O
,	O
and	O
a	O
transcription	O
factor	O
critical	O
for	O
the	O
control	O
of	O
cell	O
-	O
cycle	O
progression	O
,	O
E2F-3a	O
,	O
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
.	O

The	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
was	O
found	O
to	O
inversely	O
correlate	O
with	O
WHO	O
tumor	B
grade	O
.	O

High	O
density	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
arrays	O
,	O
fluorescent	O
-	O
reporter	O
miRNA	O
assay	O
and	O
Northern	O
miRNA	O
dot	O
-	O
blot	O
analysis	O
show	O
that	O
a	O
brain	O
-	O
enriched	O
miRNA-128	O
is	O
significantly	O
down	O
-	O
regulated	O
in	O
glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
and	O
in	O
GBM	B
cell	O
lines	O
when	O
compared	O
to	O
age	O
-	O
matched	O
controls	O
.	O

Micro	O
-	O
RNA-128	O
(	O
miRNA-128	O
)	O
down	O
-	O
regulation	O
in	O
glioblastoma	B
targets	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
,	O
key	O
regulators	O
of	O
brain	O
cell	O
proliferation	O
.	O

This	O
reveals	O
a	O
previously	O
unrecognized	O
signaling	O
cascade	O
involved	O
in	O
meningioma	B
tumor	I
development	O
and	O
highlights	O
a	O
novel	O
molecular	O
interaction	O
between	O
miR-200a	O
and	O
Wnt	O
signaling	O
,	O
thereby	O
providing	O
insights	O
into	O
novel	O
therapies	O
for	O
meningiomas	B
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
downregulation	O
of	O
miR-200a	O
and	O
the	O
upregulation	O
of	O
beta	O
-	O
catenin	O
in	O
human	O
meningioma	B
samples	O
.	O

Thus	O
,	O
miR-200a	O
appears	O
to	O
act	O
as	O
a	O
multifunctional	O
tumor	O
suppressor	O
miRNA	O
in	O
meningiomas	B
through	O
effects	O
on	O
the	O
E	O
-	O
cadherin	O
and	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
pathways	O
.	O

miR-200a	O
was	O
found	O
to	O
directly	O
target	O
beta	O
-	O
catenin	O
mRNA	O
,	O
thereby	O
inhibiting	O
its	O
translation	O
and	O
blocking	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
,	O
which	O
is	O
frequently	O
involved	O
in	O
cancer	B
.	O

Downregulation	O
of	O
miR-200a	O
in	O
meningiomas	B
and	O
arachnoidal	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
beta	O
-	O
catenin	O
and	O
cyclin	O
D1	O
involved	O
in	O
cell	O
proliferation	O
.	O

Upregulation	O
of	O
miR-200a	O
decreased	O
the	O
expression	O
of	O
transcription	O
factors	O
ZEB1	O
and	O
SIP1	O
,	O
with	O
consequent	O
increased	O
expression	O
of	O
E	O
-	O
cadherin	O
,	O
an	O
adhesion	O
protein	O
associated	O
with	O
cell	O
differentiation	O
.	O

Elevated	O
levels	O
of	O
miR-200a	O
inhibited	O
meningioma	B
cell	O
growth	O
in	O
culture	O
and	O
in	O
a	O
tumor	B
model	O
in	O
vivo	O
.	O

Meningiomas	B
,	O
one	O
of	O
the	O
most	O
common	O
human	O
brain	B
tumors	I
,	O
are	O
derived	O
from	O
arachnoidal	O
cells	O
associated	O
with	O
brain	O
meninges	O
,	O
are	O
usually	O
benign	O
,	O
and	O
are	O
frequently	O
associated	O
with	O
neurofibromatosis	B
type	I
2	I
.	O
Here	O
,	O
we	O
define	O
a	O
typical	O
human	O
meningioma	B
microRNA	O
(	O
miRNA	O
)	O
profile	O
and	O
characterize	O
the	O
effects	O
of	O
one	O
downregulated	O
miRNA	O
,	O
miR-200a	O
,	O
on	O
tumor	B
growth	O
.	O

Downregulated	O
microRNA-200a	O
in	O
meningiomas	B
promotes	O
tumor	B
growth	O
by	O
reducing	O
E	O
-	O
cadherin	O
and	O
activating	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
pathway	O
.	O

In	O
neurodegenerative	B
disorders	I
such	O
as	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
,	O
brain	O
miRNA	O
profiles	O
are	O
altered	O
;	O
thus	O
miRNA	O
dysfunction	O
could	O
be	O
both	O
a	O
cause	O
and	O
a	O
consequence	O
of	O
disease	O
.	O

These	O
small	O
non	O
-	O
coding	O
RNA	O
regulators	O
are	O
highly	O
enriched	O
in	O
brain	O
where	O
they	O
play	O
key	O
roles	O
in	O
neuronal	O
development	O
,	O
plasticity	O
and	O
disease	O
.	O

Normal	O
brain	O
development	O
and	O
function	O
depends	O
on	O
microRNA	O
(	O
miRNA	O
)	O
networks	O
to	O
fine	O
tune	O
the	O
balance	O
between	O
the	O
transcriptome	O
and	O
proteome	O
of	O
the	O
cell	O
.	O

Neuronal	O
microRNA	O
deregulation	O
in	O
response	O
to	O
Alzheimer	B
's	I
disease	I
amyloid	O
-	O
beta	O
.	O

Bioinformatic	O
analysis	O
predicts	O
that	O
the	O
deregulated	O
miRNAs	O
are	O
likely	O
to	O
affect	O
target	O
genes	O
present	O
in	O
prominent	O
neuronal	O
pathways	O
known	O
to	O
be	O
disrupted	O
in	O
AD	B
.	O
Remarkably	O
,	O
we	O
also	O
found	O
that	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
was	O
paralleled	O
in	O
vivo	O
by	O
a	O
deregulation	O
in	O
the	O
hippocampus	O
of	O
Abeta42-depositing	O
APP23	O
mice	O
,	O
at	O
the	O
onset	O
of	O
Abeta	O
plaque	O
formation	O
.	O

Time	O
-	O
course	O
assays	O
of	O
neuronal	O
Abeta	O
treatments	O
show	O
that	O
Abeta	O
is	O
in	O
fact	O
a	O
powerful	O
regulator	O
of	O
miRNA	O
levels	O
as	O
the	O
response	O
of	O
certain	O
mature	O
miRNAs	O
is	O
extremely	O
rapid	O
.	O

We	O
used	O
sensitive	O
TaqMan	O
low	O
density	O
miRNA	O
arrays	O
(	O
TLDA	O
)	O
on	O
murine	O
primary	O
hippocampal	O
cultures	O
to	O
show	O
that	O
about	O
half	O
of	O
all	O
miRNAs	O
tested	O
were	O
down	O
-	O
regulated	O
in	O
response	O
to	O
Abeta	O
peptides	O
.	O

Our	O
study	O
dissects	O
the	O
complexity	O
of	O
human	O
AD	B
pathology	O
,	O
and	O
addresses	O
the	O
hypothesis	O
that	O
amyloid	O
-	O
beta	O
(	O
Abeta	O
)	O
itself	O
,	O
a	O
known	O
causative	O
factor	O
of	O
AD	B
,	O
causes	O
neuronal	O
miRNA	O
deregulation	O
,	O
which	O
could	O
contribute	O
to	O
the	O
pathomechanisms	O
of	O
AD	B
.	O

In	O
addition	O
,	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
and	O
APP23	O
hippocampus	O
overlaps	O
with	O
those	O
obtained	O
in	O
human	O
AD	B
studies	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
neuronal	O
miRNA	O
deregulation	O
in	O
response	O
to	O
an	O
insult	O
by	O
Abeta	O
may	O
be	O
an	O
important	O
factor	O
contributing	O
to	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
AD	B
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
pituitary	O
tumor	O
apoptosis	O
gene	O
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
novel	O
differentially	O
methylated	O
chromosome	O
22	O
CpG	O
island	O
-	O
associated	O
gene	O
(	O
C22orf3	O
)	O
.	O

To	O
determine	O
mechanisms	O
for	O
pituitary	O
neoplasia	O
we	O
used	O
methylation	O
-	O
sensitive	O
arbitrarily	O
primed	O
-	O
PCR	O
to	O
isolate	O
novel	O
genes	O
that	O
are	O
differentially	O
methylated	O
relative	O
to	O
normal	O
pituitary	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
individual	O
adenomas	B
showed	O
that	O
6	O
of	O
30	O
(	O
20	O
%	O
)	O
that	O
failed	O
to	O
express	O
pituitary	O
tumor	O
apoptosis	O
gene	O
(	O
PTAG	O
)	O
were	O
methylated	O
;	O
however	O
,	O
genetic	O
change	O
as	O
determined	O
by	O
loss	O
of	O
heterozygosity	O
and	O
sequence	O
analysis	O
was	O
not	O
apparent	O
in	O
the	O
remaining	O
tumors	B
that	O
failed	O
to	O
express	O
this	O
gene	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
pooled	O
tumor	B
cohorts	O
,	O
used	O
in	O
the	O
isolation	O
of	O
this	O
gene	O
,	O
showed	O
that	O
only	O
a	O
proportion	O
of	O
the	O
adenomas	B
within	O
the	O
pools	O
were	O
methylated	O
;	O
however	O
,	O
expression	O
analysis	O
by	O
quantitative	O
RT	O
-	O
PCR	O
of	O
individual	O
adenoma	B
irrespective	O
of	O
subtype	O
showed	O
the	O
majority	O
(	O
30	O
of	O
38	O
;	O
79	O
%	O
)	O
failed	O
to	O
express	O
this	O
gene	O
relative	O
to	O
normal	O
pituitary	O
.	O

Enforced	O
expression	O
of	O
C22orf3	O
in	O
AtT20	O
cells	O
had	O
no	O
measurable	O
effects	O
on	O
cell	O
proliferation	O
or	O
viability	O
;	O
however	O
,	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
(	O
10	O
-	O
40	O
microm	O
)	O
cells	O
expressing	O
this	O
gene	O
showed	O
a	O
significantly	O
augmented	O
apoptotic	O
response	O
as	O
determined	O
by	O
both	O
acridine	O
orange	O
staining	O
and	O
TUNEL	O
labeling	O
.	O

In	O
those	O
cases	O
where	O
the	O
CpG	O
island	O
of	O
these	O
genes	O
was	O
methylated	O
it	O
was	O
invariably	O
associated	O
with	O
loss	O
of	O
transcript	O
expression	O
.	O

In	O
addition	O
,	O
in	O
time	O
course	O
experiments	O
,	O
direct	O
measurement	O
of	O
active	O
caspases	O
by	O
fluorochrome	O
-	O
labeled	O
inhibition	O
of	O
caspases	O
,	O
showed	O
an	O
augmented	O
increase	O
(	O
approximately	O
2.4	O
fold	O
)	O
in	O
active	O
caspases	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
in	O
cells	O
expressing	O
C22orf3	O
relative	O
to	O
those	O
harboring	O
an	O
empty	O
vector	O
control	O
.	O

The	O
apoptotic	O
response	O
to	O
bromocriptine	O
challenge	O
was	O
inhibited	O
in	O
coincubation	O
experiments	O
with	O
the	O
general	O
caspase	O
inhibitor	O
z	O
-	O
VAD	O
-	O
fmk	O
.	O

The	O
pituitary	B
tumor	I
derivation	O
and	O
its	O
role	O
in	O
apoptosis	O
of	O
this	O
gene	O
led	O
us	O
to	O
assign	O
the	O
acronym	O
PTAG	O
to	O
this	O
gene	O
and	O
its	O
protein	O
product	O
.	O

The	O
ability	O
of	O
cells	O
,	O
showing	O
reduced	O
expression	O
of	O
PTAG	O
,	O
to	O
evade	O
or	O
show	O
a	O
blunted	O
apoptotic	O
response	O
may	O
underlie	O
oncogenic	O
transformation	O
in	O
both	O
the	O
pituitary	O
and	O
other	O
tumor	B
types	O
.	O

It	O
has	O
been	O
recently	O
demonstrated	O
that	O
herpesviruses	O
encode	O
miRNAs	O
to	O
control	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
expression	O
from	O
their	O
own	O
genomes	O
and	O
possibly	O
that	O
of	O
their	O
host	O
,	O
thus	O
adding	O
an	O
additional	O
layer	O
of	O
complexity	O
to	O
the	O
physiological	O
cross	O
-	O
talk	O
between	O
host	O
and	O
pathogen	O
.	O

MicroRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
approximately	O
22	O
nt	O
long	O
that	O
modulate	O
gene	O
expression	O
in	O
animals	O
and	O
plants	O
.	O

Co	O
-	O
expression	O
of	O
host	O
and	O
viral	O
microRNAs	O
in	O
porcine	O
dendritic	O
cells	O
infected	O
by	O
the	O
pseudorabies	O
virus	O
.	O

Almost	O
95	O
%	O
of	O
reads	O
mapped	O
to	O
the	O
draft	O
pig	O
genome	O
sequence	O
and	O
pig	O
miRNAs	O
previously	O
annotated	O
in	O
dedicated	O
databases	O
were	O
detected	O
by	O
sequence	O
alignment	O
.	O

An	O
average	O
of	O
2	O
million	O
reads	O
per	O
sample	O
with	O
a	O
size	O
of	O
21	O
-	O
24	O
nucleotides	O
was	O
obtained	O
from	O
six	O
libraries	O
representing	O
three	O
biological	O
replicates	O
of	O
infected	O
and	O
mock	O
-	O
infected	O
DCs	O
.	O

A	O
catalogue	O
of	O
porcine	O
and	O
viral	O
miRNAs	O
,	O
expressed	O
eight	O
hours	O
post	O
-	O
infection	B
,	O
was	O
established	O
by	O
deep	O
sequencing	O
.	O

The	O
present	O
study	O
focussed	O
on	O
the	O
interactions	O
between	O
porcine	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
the	O
Pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
an	O
alpha	O
-	O
herpesvirus	O
causing	O
Aujeszky	B
's	I
disease	I
in	O
pigs	O
.	O

In	O
silico	O
prediction	O
allowed	O
the	O
identification	O
of	O
unknown	O
porcine	O
as	O
well	O
as	O
of	O
five	O
miRNAs	O
transcribed	O
by	O
the	O
Large	O
Latency	O
Transcript	O
(	O
LLT	O
)	O
of	O
PRV	O
.	O

The	O
gene	O
target	O
prediction	O
of	O
the	O
viral	O
miRNAs	O
and	O
the	O
Ingenuity	O
Pathway	O
Analysis	O
of	O
differentially	O
expressed	O
pig	O
miRNAs	O
were	O
conducted	O
to	O
contextualize	O
the	O
identified	O
small	O
RNA	O
molecules	O
and	O
functionally	O
characterize	O
their	O
involvement	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
.	O

The	O
results	O
support	O
a	O
role	O
for	O
PRV	O
miRNAs	O
in	O
the	O
maintenance	O
of	O
the	O
host	O
cell	O
latency	O
state	O
through	O
the	O
down	O
-	O
regulation	O
of	O
immediate	O
-	O
early	O
viral	O
genes	O
which	O
is	O
similar	O
to	O
other	O
herpesviruses	O
.	O

The	O
differentially	O
expressed	O
swine	O
miRNAs	O
identified	O
a	O
unique	O
network	O
of	O
target	O
genes	O
with	O
highly	O
significant	O
functions	O
in	O
the	O
development	O
and	O
function	O
of	O
the	O
nervous	O
system	O
and	O
in	O
infectious	O
mechanisms	O
,	O
suggesting	O
that	O
the	O
modulation	O
of	O
both	O
host	O
and	O
viral	O
miRNAs	O
is	O
necessary	O
for	O
the	O
establishment	O
of	O
PRV	O
latency	O
.	O

The	O
RAKE	O
assay	O
is	O
theoretically	O
versatile	O
and	O
may	O
be	O
used	O
for	O
other	O
applications	O
,	O
such	O
as	O
viral	O
gene	O
profiling	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
can	O
be	O
isolated	O
and	O
profiled	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
which	O
opens	O
up	O
new	O
opportunities	O
for	O
analyses	O
of	O
small	O
RNAs	O
from	O
archival	O
human	O
tissue	O
.	O

RAKE	O
offers	O
unique	O
advantages	O
for	O
specificity	O
over	O
northern	O
blots	O
or	O
other	O
microarray	O
-	O
based	O
expression	O
profiling	O
platforms	O
.	O

We	O
show	O
that	O
the	O
RAKE	O
assay	O
is	O
sensitive	O
and	O
specific	O
for	O
miRNAs	O
and	O
is	O
ideally	O
suited	O
for	O
rapid	O
expression	O
profiling	O
of	O
all	O
known	O
miRNAs	O
.	O

We	O
used	O
RAKE	O
to	O
study	O
human	O
cell	O
lines	O
and	O
brain	B
tumors	I
.	O

The	O
technique	O
is	O
termed	O
the	O
RNA	O
-	O
primed	O
,	O
array	O
-	O
based	O
Klenow	O
enzyme	O
(	O
RAKE	O
)	O
assay	O
,	O
because	O
it	O
involves	O
on	O
-	O
slide	O
application	O
of	O
the	O
Klenow	O
fragment	O
of	O
DNA	O
polymerase	O
I	O
to	O
extend	O
unmodified	O
miRNAs	O
hybridized	O
to	O
immobilized	O
DNA	O
probes	O
.	O

We	O
describe	O
a	O
new	O
method	O
for	O
high	O
-	O
throughput	O
miRNA	O
detection	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
RNAs	O
that	O
serve	O
fundamental	O
biological	O
roles	O
across	O
eukaryotic	O
species	O
.	O

Microarray	O
-	O
based	O
,	O
high	O
-	O
throughput	O
gene	O
expression	O
profiling	O
of	O
microRNAs	O
.	O

Brain	O
cells	O
maintain	O
distinct	O
populations	O
of	O
miRNAs	O
that	O
support	O
physiologically	O
normal	O
patterns	O
of	O
expression	O
,	O
however	O
,	O
certain	O
miRNA	O
abundances	O
are	O
significantly	O
altered	O
in	O
neurodegenerative	B
disorders	I
such	O
as	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Here	O
we	O
provide	O
evidence	O
in	O
human	O
neural	O
(	O
HN	O
)	O
cells	O
of	O
an	O
aluminum	O
-	O
sulfate-	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
-mediated	O
up	O
-	O
regulation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
miRNA-146a	O
that	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
complement	O
factor	O
H	O
(	O
CFH	O
)	O
,	O
an	O
important	O
repressor	O
of	O
inflammation	O
.	O

Characterization	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
regulated	O
,	O
miRNA-146a	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
complement	O
factor	O
H	O
(	O
CFH	O
)	O
in	O
metal	O
-	O
sulfate	O
-	O
stressed	O
human	O
brain	O
cells	O
.	O

Micro	O
RNAs	O
(	O
miRNAs	O
)	O
represent	O
a	O
family	O
of	O
small	O
ribonucleic	O
acids	O
(	O
RNAs	O
)	O
that	O
are	O
post	O
-	O
transcriptional	O
regulators	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
.	O

An	O
NF	O
-	O
kappaB	O
-	O
containing	O
miRNA-146a	O
-	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
transfected	O
into	O
HN	O
cells	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-146a	O
after	O
aluminum	O
-	O
sulfate	O
treatment	O
that	O
corresponded	O
to	O
decreased	O
CFH	O
gene	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
(	O
1	O
)	O
as	O
in	O
AD	B
brain	O
,	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
,	O
miRNA-146a	O
-	O
mediated	O
,	O
modulation	O
of	O
CFH	O
gene	O
expression	O
may	O
contribute	O
to	O
inflammatory	O
responses	O
in	O
aluminum	O
-	O
stressed	O
HN	O
cells	O
,	O
and	O
(	O
2	O
)	O
underscores	O
the	O
potential	O
of	O
nanomolar	O
aluminum	O
to	O
drive	O
genotoxic	O
mechanisms	O
characteristic	O
of	O
neurodegenerative	B
disease	I
processes	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
miRNA-146a	O
-	O
CFH	O
signaling	O
circuit	O
is	O
known	O
to	O
be	O
similarly	O
affected	O
by	O
Abeta42	O
peptides	O
and	O
in	O
AD	B
brain	O
.	O

These	O
aluminum	O
-	O
sulfate	O
-	O
inducible	O
events	O
were	O
not	O
observed	O
in	O
parallel	O
experiments	O
using	O
iron-	O
,	O
magnesium-	O
,	O
or	O
zinc	O
-	O
sulfate	O
-	O
stressed	O
HN	O
cells	O
.	O

A	O
specific	O
subset	O
of	O
five	O
miRNAs	O
revealed	O
by	O
in	O
silico	O
target	O
prediction	O
was	O
significantly	O
overexpressed	O
in	O
NFA	O
samples	O
;	O
three	O
miRs	O
(	O
miR-128a	O
,	O
miR-155	O
,	O
and	O
miR-516a-3p	O
)	O
targeted	O
the	O
3'-untranslated	O
region	O
of	O
the	O
Wee1	O
transcript	O
,	O
and	O
exogenous	O
overexpression	O
of	O
these	O
miRs	O
inhibited	O
Wee1	O
protein	O
expression	O
and	O
HeLa	O
cell	O
proliferation	O
.	O

RESULTS	O
:	O
Wee1	O
protein	O
expression	O
was	O
decreased	O
in	O
NFAs	O
and	O
GH	O
-	O
producing	O
tumors	B
with	O
or	O
without	O
prolactin	O
production	O
,	O
but	O
no	O
change	O
in	O
mRNA	O
expression	O
was	O
observed	O
with	O
qRT	O
-	O
PCR	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
suggesting	O
that	O
regulation	O
of	O
Wee1	O
kinase	O
by	O
miRs	O
may	O
be	O
linked	O
to	O
pituitary	O
tumorigenesis	O
.	O

CONTEXT	O
:	O
The	O
tumorigenic	O
mechanisms	O
involved	O
in	O
pituitary	B
adenomas	I
,	O
especially	O
of	O
nonfunctional	O
pituitary	O
adenomas	O
(	O
NFAs	O
)	O
,	O
remains	O
unclear	O
.	O

Down	O
-	O
regulation	O
of	O
Wee1	O
kinase	O
by	O
a	O
specific	O
subset	O
of	O
microRNA	O
in	O
human	O
sporadic	O
pituitary	B
adenomas	I
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
expression	O
of	O
Wee1	O
in	O
pituitary	B
tumors	I
and	O
to	O
identify	O
microRNAs	O
(	O
miRs	O
)	O
that	O
can	O
regulate	O
its	O
expression	O
.	O

Various	O
cell	O
cycle	O
inhibitors	O
have	O
been	O
found	O
to	O
be	O
underexpressed	O
in	O
pituitary	B
tumors	I
;	O
however	O
,	O
Wee1	O
kinase	O
,	O
a	O
nuclear	O
protein	O
that	O
delays	O
mitosis	O
and	O
was	O
recently	O
recognized	O
as	O
a	O
tumor	O
suppressor	O
gene	O
,	O
has	O
not	O
been	O
previously	O
investigated	O
in	O
pituitary	B
tumors	I
.	O

Identification	O
of	O
miRs	O
targeting	O
the	O
Wee1	O
3'-untranslated	O
region	O
was	O
performed	O
by	O
miR	O
array	O
followed	O
by	O
expression	O
analysis	O
of	O
identified	O
miRs	O
using	O
qRT	O
-	O
PCR	O
.	O

DESIGN	O
:	O
Expression	O
of	O
Wee1	O
was	O
examined	O
by	O
immunohistochemistry	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

PATIENTS	O
:	O
A	O
total	O
of	O
57	O
pituitary	O
tissue	O
samples	O
including	O
27	O
NFAs	O
,	O
15	O
GH	O
-	O
producing	O
adenomas	B
with	O
or	O
without	O
prolactin	O
overproduction	O
,	O
and	O
15	O
normal	O
pituitary	O
glands	O
were	O
analyzed	O
.	O

Dual	O
-	O
luciferase	O
assay	O
and	O
transient	O
transfection	O
of	O
miRs	O
into	O
Hela	O
cells	O
followed	O
by	O
immunoblot	O
analysis	O
of	O
Wee1	O
protein	O
and	O
cell	O
proliferation	O
analysis	O
were	O
carried	O
out	O
.	O

In	O
this	O
review	O
article	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
role	O
and	O
function	O
of	O
miRNAs	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
neurological	O
and	O
neurodegenerative	B
diseases	I
will	O
be	O
discussed	O
,	O
with	O
a	O
focus	O
on	O
the	O
fragile	B
X	I
syndrome	I
,	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
and	O
prion	B
disease	I
.	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

MicroRNAs	O
as	O
a	O
molecular	O
basis	O
for	O
mental	B
retardation	I
,	O
Alzheimer	B
's	I
and	O
prion	B
diseases	I
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
approximately	O
21-	O
to	O
23-nucleotide	O
(	O
nt	O
)	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
act	O
as	O
key	O
regulators	O
of	O
gene	O
expression	O
along	O
a	O
central	O
and	O
well	O
-	O
defined	O
cellular	O
process	O
known	O
as	O
RNA	O
silencing	O
,	O
and	O
involving	O
the	O
recognition	O
and	O
translational	O
control	O
of	O
specific	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
.	O

Generated	O
through	O
the	O
well	O
-	O
orchestrated	O
and	O
sequential	O
processing	O
of	O
miRNA	O
precursor	O
molecules	O
,	O
mature	O
miRNAs	O
are	O
subsequently	O
incorporated	O
into	O
miRNA	O
-	O
containing	O
ribonucleoprotein	O
effector	O
complexes	O
to	O
regulate	O
mRNA	O
translation	O
through	O
the	O
recognition	O
of	O
specific	O
binding	O
sites	O
of	O
imperfect	O
complementarity	O
located	O
mainly	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
.	O

Predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	O
,	O
miRNAs	O
may	O
thus	O
control	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	O
body	O
.	O

High	O
levels	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
also	O
significantly	O
correlated	O
with	O
the	O
proliferation	O
marker	O
Ki-67	O
(	O
P<0.0001	O
)	O
.	O

High	O
levels	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
were	O
more	O
frequently	O
observed	O
in	O
macroadenomas	O
than	O
in	O
microadenomas	O
(	O
P<0.05	O
)	O
.	O

Overexpression	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
was	O
observed	O
in	O
39	O
%	O
(	O
38	O
/	O
98	O
)	O
of	O
pituitary	B
adenomas	I
compared	O
with	O
normal	O
adenohypophysial	O
tissue	O
and	O
was	O
frequently	O
found	O
in	O
adenomas	B
including	O
prolactin	O
(	O
PRL	O
)	O
,	O
adrenocorticotrophic	O
hormone	O
,	O
or	O
follicle	O
-	O
stimulating	O
hormone	O
/	O
luteinizing	O
hormone	O
and	O
in	O
null	O
cell	O
adenomas	B
,	O
but	O
relatively	O
rare	O
in	O
growth	O
hormone	O
(	O
GH	O
)	O
and	O
mixed	O
GH	O
/	O
PRL	O
adenomas	B
.	O

High	O
-	O
mobility	O
group	O
A2	O
expression	O
was	O
significantly	O
associated	O
with	O
tumor	B
invasion	O
(	O
P<0.05	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
grade	O
IV	O
than	O
in	O
grades	O
I	O
,	O
II	O
,	O
and	O
III	O
adenomas	B
(	O
P<0.05	O
)	O
.	O

However	O
,	O
no	O
studies	O
have	O
investigated	O
the	O
clinical	O
significance	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
and	O
its	O
relationship	O
to	O
the	O
let-7	O
miRNA	O
family	O
in	O
human	O
pituitary	B
adenomas	I
.	O

Using	O
immunohistochemistry	O
,	O
we	O
analyzed	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
with	O
respect	O
to	O
various	O
clinicopathologic	O
factors	O
in	O
98	O
pituitary	B
adenomas	I
.	O

Recent	O
studies	O
report	O
that	O
high	O
-	O
mobility	O
group	O
A2	O
is	O
negatively	O
regulated	O
by	O
the	O
let-7	O
microRNAs	O
(	O
miRNAs	O
)	O
family	O
in	O
vitro	O
.	O

The	O
development	O
of	O
pituitary	B
adenomas	I
in	O
high	O
-	O
mobility	O
group	O
A2	O
transgenic	O
mice	O
showed	O
that	O
high	O
-	O
mobility	O
group	O
A2	O
may	O
be	O
involved	O
in	O
pituitary	O
tumorigenesis	O
.	O

Overexpression	O
of	O
HMGA2	O
relates	O
to	O
reduction	O
of	O
the	O
let-7	O
and	O
its	O
relationship	O
to	O
clinicopathological	O
features	O
in	O
pituitary	B
adenomas	I
.	O

High	O
-	O
mobility	O
group	O
A2	O
is	O
highly	O
expressed	O
during	O
embryogenesis	O
and	O
in	O
various	O
benign	O
and	O
malignant	B
tumors	I
.	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
expression	O
of	O
let-7	O
in	O
55	O
pituitary	B
adenomas	I
.	O

Subsequently	O
,	O
decreased	O
expression	O
of	O
let-7	O
was	O
confirmed	O
in	O
23	O
of	O
55	O
(	O
42	O
%	O
)	O
adenomas	B
and	O
was	O
correlated	O
with	O
high	B
-	I
grade	I
tumors	I
(	O
P<0.05	O
)	O
.	O

An	O
inverse	O
correlation	O
between	O
let-7	O
and	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
was	O
evident	O
(	O
R=-0.33	O
,	O
P<0.05	O
)	O
.	O

These	O
findings	O
support	O
a	O
causal	O
link	O
between	O
let-7	O
and	O
high	O
-	O
mobility	O
group	O
A2	O
whereby	O
loss	O
of	O
let-7	O
expression	O
induces	O
high	O
-	O
mobility	O
group	O
A2	O
upregulation	O
that	O
represents	O
an	O
important	O
mechanism	O
in	O
pituitary	O
tumorigenesis	O
and	O
progression	O
.	O

The	O
proliferation	O
inhibition	O
and	O
induced	O
apoptosis	O
by	O
this	O
recombinant	O
with	O
an	O
apoptosis	O
ratio	O
of	O
21.89	O
%	O
in	O
U87	O
cell	O
were	O
also	O
observed	O
.	O

The	O
results	O
of	O
Western	O
blot	O
indicated	O
the	O
expression	O
of	O
Flag	O
of	O
No	O
1	O
recombinant	O
plasmid	O
group	O
was	O
inhibited	O
heavily	O
with	O
a	O
34.3	O
%	O
expression	O
level	O
by	O
compared	O
with	O
control	O
group	O
.	O

The	O
expressed	O
Flag	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
to	O
evaluate	O
the	O
inhibition	O
effect	O
of	O
targeting	O
sequences	O
.	O

The	O
confirmed	O
pGCSIL	O
-	O
GFP	O
recombinants	O
by	O
combining	O
with	O
pEGFP	O
-	O
miR-221	O
were	O
transfected	O
into	O
293	O
T	O
cells	O
seperately	O
.	O

RESULTS	O
:	O
The	O
resulting	O
recombinants	O
were	O
confirmed	O
by	O
sequencing	O
which	O
demonstrated	O
that	O
the	O
recombinant	O
plasmids	O
contained	O
the	O
correct	O
sequences	O
of	O
designed	O
transcript	O
templates	O
.	O

Then	O
a	O
recombinant	O
with	O
the	O
highest	O
anti	O
-	O
miR-221	O
effect	O
was	O
screened	O
and	O
transfected	O
into	O
U87	O
glioma	B
cell	O
,	O
and	O
its	O
anti	O
-	O
tumor	O
effect	O
was	O
evaluated	O
by	O
MTT	O
and	O
FCM	O
.	O

[	O
Construction	O
and	O
screening	O
an	O
effective	O
anti	O
-	O
miR-221	O
RNAi	O
vector	O
in	O
vitro	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
construct	O
and	O
screen	O
an	O
effective	O
anti	O
-	O
miR-221	O
vector	O
of	O
siRNA	O
.	O

METHODS	O
:	O
Four	O
hairpin	O
structure	O
of	O
siRNA	O
transcript	O
templates	O
targeting	O
miR-221	O
and	O
a	O
negative	O
control	O
were	O
synthesized	O
,	O
then	O
ligated	O
with	O
pGCSIL	O
-	O
GFP	O
vector	O
and	O
a	O
pEGFP	O
-	O
miR-221	O
which	O
express	O
pre	O
-	O
miR-221	O
was	O
also	O
constructed	O
.	O

All	O
the	O
recombinants	O
were	O
sequenced	O
.	O

CONCLUSION	O
:	O
The	O
anti	O
-	O
miR-221	O
expression	O
siRNA	O
espression	O
recombinants	O
were	O
constructed	O
successfully	O
,	O
and	O
one	O
sequence	O
with	O
the	O
highest	O
inhibition	O
efficiency	O
was	O
screened	O
out	O
,	O
which	O
could	O
inhibit	O
U87	O
cell	O
proliferation	O
and	O
induce	O
cell	O
apoptosis	O
,	O
and	O
could	O
be	O
used	O
to	O
suppress	O
target	O
gene	O
for	O
further	O
study	O
in	O
tumor	B
biology	O
.	O

Expression	O
profiling	O
showed	O
strong	O
miRNA	O
and	O
isomiR	O
expression	O
deregulation	O
in	O
HD	B
,	O
most	O
being	O
common	O
to	O
both	O
FC	O
and	O
ST	O
.	O

Around	O
80	O
-	O
90	O
%	O
of	O
the	O
miRNAs	O
presented	O
modifications	O
in	O
the	O
3'-terminus	O
mainly	O
in	O
the	O
form	O
of	O
trimming	O
and/or	O
as	O
nucleotide	O
addition	O
variants	O
,	O
while	O
the	O
5'-terminus	O
of	O
the	O
miRNAs	O
was	O
specially	O
protected	O
from	O
changes	O
.	O

Deep	O
sequencing	O
revealed	O
length	O
and	O
sequence	O
heterogeneity	O
(	O
IsomiRs	O
)	O
for	O
the	O
vast	O
majority	O
of	O
miRNAs	O
.	O

More	O
than	O
80	O
%	O
of	O
the	O
small	O
-	O
RNAs	O
were	O
annotated	O
as	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
all	O
samples	O
.	O

We	O
have	O
applied	O
the	O
Illumina	O
massively	O
parallel	O
sequencing	O
to	O
deeply	O
analyze	O
the	O
small	O
RNA	O
populations	O
of	O
two	O
different	O
forebrain	O
areas	O
,	O
the	O
frontal	O
cortex	O
(	O
FC	O
)	O
and	O
the	O
striatum	O
(	O
ST	O
)	O
of	O
healthy	O
individuals	O
and	O
individuals	O
with	O
HD	B
.	O

Huntington	B
disease	I
(	O
HD	B
)	O
is	O
a	O
neurodegenerative	B
disorder	I
that	O
predominantly	O
affects	O
neurons	O
of	O
the	O
forebrain	O
.	O

A	O
myriad	O
of	O
miRNA	O
variants	O
in	O
control	O
and	O
Huntington	B
's	I
disease	I
brain	O
regions	O
detected	O
by	O
massively	O
parallel	O
sequencing	O
.	O

Our	O
results	O
show	O
that	O
miRNA	O
variability	O
is	O
a	O
ubiquitous	O
phenomenon	O
in	O
the	O
adult	O
human	O
brain	O
,	O
which	O
may	O
influence	O
gene	O
expression	O
in	O
physiological	O
and	O
pathological	O
conditions	O
.	O

The	O
putative	O
targets	O
of	O
deregulated	O
miRNAs	O
and	O
seed	O
-	O
region	O
IsomiRs	O
strongly	O
suggest	O
that	O
their	O
altered	O
expression	O
contributes	O
to	O
the	O
aberrant	O
gene	O
expression	O
in	O
HD	B
.	O

The	O
analysis	O
of	O
the	O
upstream	O
regulatory	O
regions	O
in	O
co	O
-	O
regulated	O
miRNAs	O
suggests	O
a	O
role	O
for	O
RE1-Silencing	O
Transcription	O
Factor	O
(	O
REST	O
)	O
and	O
P53	O
in	O
miRNAs	O
downregulation	O
in	O
HD	B
.	O

Moreover	O
,	O
LPS	O
stimulation	O
decreased	O
expression	O
of	O
microRNAs	O
(	O
miRNA	O
)	O
--miR-17	O
-	O
5	O
,	O
miR-20a	O
,	O
and	O
miR-93	O
-	O
-which	O
target	O
MICA	O
,	O
implicating	O
a	O
novel	O
role	O
for	O
miRNAs	O
in	O
NKG2D	O
ligand	O
expression	O
.	O

However	O
,	O
it	O
was	O
not	O
sufficient	O
for	O
surface	O
protein	O
expression	O
,	O
which	O
was	O
controlled	O
posttranscriptionally	O
via	O
a	O
separate	O
pathway	O
involving	O
the	O
ataxia	O
telangiectasia	O
mutated	O
/	O
ataxia	O
telangiectasia	O
and	O
Rad3	O
related	O
kinases	O
.	O

Thus	O
,	O
TLR	O
stimulation	O
allows	O
expression	O
of	O
NKG2D	O
ligands	O
through	O
multiple	O
pathways	O
,	O
including	O
downmodulation	O
of	O
specific	O
miRNAs	O
.	O

In	O
this	O
paper	O
,	O
we	O
clarify	O
that	O
LPS	O
,	O
which	O
ligates	O
TLR-4	O
,	O
preferentially	O
upregulated	O
MICA	O
and	O
not	O
MICB	O
;	O
CL097	O
,	O
which	O
ligates	O
TLR-7	O
/	O
8	O
,	O
upregulated	O
both	O
MICA	O
and	O
MICB	O
;	O
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
,	O
which	O
ligates	O
TLR-3	O
,	O
upregulated	O
neither	O
.	O

However	O
,	O
NKG2D	O
ligands	O
can	O
also	O
be	O
induced	O
on	O
human	O
macrophages	O
by	O
TLR	O
stimulation	O
,	O
which	O
has	O
been	O
far	O
less	O
studied	O
.	O

This	O
finding	O
suggests	O
that	O
increased	O
levels	O
of	O
MICA	O
mRNA	O
following	O
LPS	O
stimulation	O
resulted	O
from	O
increased	O
transcription	O
.	O

To	O
probe	O
how	O
LPS	O
stimulation	O
triggers	O
MICA	O
expression	O
,	O
we	O
determined	O
that	O
the	O
stability	O
of	O
MICA	O
mRNA	O
was	O
much	O
longer	O
than	O
that	O
of	O
MICB	O
mRNA	O
,	O
but	O
neither	O
was	O
changed	O
by	O
LPS	O
stimulation	O
.	O

Multiple	O
mechanisms	O
downstream	O
of	O
TLR-4	O
stimulation	O
allow	O
expression	O
of	O
NKG2D	O
ligands	O
to	O
facilitate	O
macrophage	O
/	O
NK	O
cell	O
crosstalk	O
.	O

This	O
establishes	O
recognition	O
of	O
""""	O
induced	O
self	O
""""	O
as	O
an	O
important	O
strategy	O
for	O
surveillance	O
of	O
infections	B
or	O
tumor	B
transformation	O
.	O

The	O
activating	O
receptor	O
NKG2D	O
recognizes	O
proteins	O
that	O
are	O
not	O
normally	O
expressed	O
at	O
the	O
surface	O
of	O
most	O
cells	O
but	O
are	O
expressed	O
during	O
a	O
cellular	O
""""	O
stress	O
""""	O
response	O
(	O
e.g.	O
,	O
upon	O
induction	O
of	O
the	O
DNA	B
damage	I
pathway	O
)	O
.	O

MicroRNA	O
in	O
Situ	O
Hybridization	O
in	O
the	O
Human	O
Entorhinal	O
and	O
Transentorhinal	O
Cortex	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
key	O
roles	O
in	O
gene	O
expression	O
regulation	O
in	O
both	O
healthy	O
and	O
disease	O
brains	O
.	O

To	O
better	O
understand	O
those	O
roles	O
,	O
it	O
is	O
necessary	O
to	O
characterize	O
the	O
miRNAs	O
that	O
are	O
expressed	O
in	O
particular	O
cell	O
types	O
under	O
a	O
range	O
of	O
conditions	O
.	O

In	O
situ	O
hybridization	O
(	O
ISH	O
)	O
can	O
demonstrate	O
cell-	O
and	O
lamina	O
-	O
specific	O
patterns	O
of	O
miRNA	O
expression	O
that	O
would	O
be	O
lost	O
in	O
tissue	O
-	O
level	O
expression	O
profiling	O
.	O

In	O
the	O
present	O
study	O
,	O
ISH	O
was	O
performed	O
with	O
special	O
focus	O
on	O
the	O
human	O
entorhinal	O
cortex	O
(	O
EC	O
)	O
and	O
transentorhinal	O
cortex	O
(	O
TEC	O
)	O
.	O

The	O
TEC	O
is	O
the	O
area	O
of	O
the	O
cerebral	O
cortex	O
that	O
first	O
develops	O
neurofibrillary	O
tangles	O
in	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

However	O
,	O
the	O
reason	O
for	O
TEC	O
's	O
special	O
vulnerability	O
to	O
AD	B
-	O
type	O
pathology	O
is	O
unknown	O
.	O

MiRNA	O
ISH	O
was	O
performed	O
on	O
three	O
human	O
brains	O
with	O
well	O
-	O
characterized	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Locked	O
nucleic	O
acid	O
ISH	O
probes	O
were	O
used	O
referent	O
to	O
miR-107	O
,	O
miR-124	O
,	O
miR-125b	O
,	O
and	O
miR-320	O
.	O

In	O
order	O
to	O
correlate	O
the	O
ISH	O
data	O
with	O
AD	B
pathology	O
,	O
the	O
ISH	O
staining	O
was	O
compared	O
with	O
near	O
-	O
adjacent	O
slides	O
processed	O
using	O
Thioflavine	O
stains	O
.	O

MiRNA	O
ISH	O
is	O
among	O
the	O
first	O
methods	O
to	O
show	O
special	O
staining	O
characteristics	O
of	O
cells	O
and	O
laminae	O
of	O
the	O
human	O
TEC	O
.	O

As	O
with	O
other	O
areas	O
of	O
brain	O
,	O
the	O
TEC	O
and	O
EC	O
have	O
characteristic	O
miRNA	O
expression	O
patterns	O
.	O

Not	O
all	O
neurons	O
or	O
cortical	O
lamina	O
stain	O
with	O
equal	O
intensity	O
for	O
individual	O
miRNAs	O
.	O

Our	O
in	O
vitro	O
results	O
suggested	O
that	O
Aβ42	O
oligomer	O
-	O
induced	O
miR-106b	O
leads	O
to	O
impairment	O
in	O
TGF	O
-	O
β	O
signaling	O
through	O
TβR	O
II	O
,	O
concomitant	O
with	O
retinoic	O
acid	O
-	O
induced	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

These	O
results	O
show	O
that	O
TβR	O
II	O
is	O
a	O
functional	O
target	O
of	O
miR-106b	O
and	O
that	O
miR-106b	O
may	O
influence	O
TGF	O
-	O
β	O
signaling	O
,	O
thereby	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
AD	B
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
abundantly	O
expressed	O
in	O
the	O
brain	O
and	O
play	O
an	O
important	O
role	O
in	O
disorders	O
of	O
the	O
brain	O
,	O
including	O
Alzheimer	B
's	I
diseases	I
(	O
AD	B
)	O
.	O

miR-106b	O
aberrantly	O
expressed	O
in	O
a	O
double	O
transgenic	O
mouse	O
model	O
for	O
Alzheimer	B
's	I
disease	I
targets	O
TGF	O
-	O
β	O
type	O
II	O
receptor	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
miRNAs	O
involved	O
in	O
AD	B
pathogenesis	O
by	O
regulating	O
TGF	O
-	O
β	O
signaling	O
.	O

Growing	O
body	O
of	O
evidence	O
suggests	O
that	O
the	O
TGF	O
-	O
β	O
signaling	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
AD	B
.	O

Sequence	O
analysis	O
revealed	O
two	O
putative	O
binding	O
sites	O
for	O
miR-106b	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
TβR	O
II	O
mRNA	O
.	O

Here	O
we	O
found	O
that	O
miR-106b	O
and	O
TGF	O
-	O
β	O
type	O
II	O
receptor	O
(	O
TβR	O
II	O
)	O
were	O
aberrantly	O
expressed	O
in	O
APPswe	O
/	O
PS∆E9	O
mice	O
(	O
a	O
double	O
transgenic	O
mouse	O
model	O
for	O
AD	B
)	O
.	O

After	O
induced	O
neurodifferentiation	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
,	O
we	O
observed	O
significant	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
stably	O
transfected	O
with	O
miR-106b	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
miR-106b	O
was	O
inversely	O
correlated	O
with	O
TβR	O
II	O
protein	O
levels	O
and	O
miR-106b	O
can	O
directly	O
inhibit	O
the	O
TβR	O
II	O
translation	O
in	O
vitro	O
.	O

Exposure	O
of	O
SH	O
-	O
SY5Y	O
cells	O
to	O
Aβ42	O
oligomers	O
led	O
to	O
the	O
expression	O
of	O
miR-106b	O
was	O
first	O
increased	O
and	O
then	O
decreased	O
and	O
TβR	O
II	O
levels	O
reduced	O
.	O

Western	O
blot	O
analysis	O
revealed	O
unchanged	O
total	O
Smad2	O
/	O
3	O
protein	O
levels	O
,	O
but	O
reduced	O
phospho	O
-	O
Smad2	O
/	O
3	O
(	O
p	O
-	O
Smad2	O
/	O
3	O
)	O
and	O
increased	O
Smad6	O
/	O
7	O
protein	O
levels	O
in	O
the	O
miR-106b	O
stably	O
transfected	O
cell	O
line	O
.	O

Nuclear	O
factor	O
TDP-43	O
can	O
affect	O
selected	O
microRNA	O
levels	O
.	O

TDP-43	O
has	O
recently	O
been	O
described	O
as	O
the	O
major	O
component	O
of	O
the	O
inclusions	O
found	O
in	O
the	O
brain	O
of	O
patients	O
with	O
a	O
variety	O
of	O
neurodegenerative	B
diseases	I
,	O
such	O
as	O
frontotemporal	B
lobar	I
degeneration	I
and	O
amyotrophic	B
lateral	I
sclerosis	I
.	O

Apart	O
from	O
its	O
involvement	O
in	O
transcription	O
,	O
splicing	O
and	O
mRNA	O
stability	O
,	O
TDP-43	O
has	O
also	O
been	O
described	O
as	O
a	O
Drosha	O
-	O
associated	O
protein	O
.	O

TDP-43	O
is	O
a	O
ubiquitous	O
protein	O
whose	O
specific	O
functions	O
are	O
probably	O
crucial	O
to	O
establishing	O
its	O
pathogenic	O
role	O
.	O

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
which	O
changes	O
occur	O
in	O
the	O
total	O
miRNA	O
population	O
following	O
TDP-43	O
knockdown	O
in	O
culture	O
cells	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
the	O
role	O
of	O
TDP-43	O
in	O
the	O
microRNA	O
(	O
miRNA	O
)	O
synthesis	O
pathway	O
is	O
limited	O
to	O
the	O
association	O
mentioned	O
above	O
.	O

Interestingly	O
,	O
both	O
miRNAs	O
are	O
capable	O
of	O
binding	O
directly	O
to	O
TDP-43	O
in	O
different	O
positions	O
:	O
within	O
the	O
miRNA	O
sequence	O
itself	O
(	O
let-7b	O
)	O
or	O
in	O
the	O
hairpin	O
precursor	O
(	O
miR-663	O
)	O
.	O

In	O
particular	O
,	O
we	O
have	O
observed	O
that	O
let-7b	O
and	O
miR-663	O
expression	O
levels	O
are	O
down-	O
and	O
upregulated	O
,	O
respectively	O
.	O

Using	O
microarray	O
data	O
and	O
real	O
-	O
time	O
PCR	O
we	O
have	O
also	O
identified	O
several	O
candidate	O
transcripts	O
whose	O
expression	O
levels	O
are	O
selectively	O
affected	O
by	O
these	O
TDP-43-miRNA	O
interactions	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
tissue	O
-	O
specific	O
miRNAs	O
may	O
serve	O
as	O
diagnostically	O
sensitive	O
plasma	O
biomarkers	O
of	O
tissue	B
injury	I
.	O

The	O
miR-124	O
concentration	O
increased	O
in	O
the	O
plasma	O
of	O
rats	O
8	O
h	O
after	O
surgery	O
to	O
produce	O
brain	B
injury	I
and	O
peaked	O
at	O
24	O
h	O
,	O
while	O
the	O
miR-122	O
and	O
miR-133a	O
concentrations	O
remained	O
at	O
baseline	O
values	O
.	O

Furthermore	O
,	O
miR-122	O
exhibited	O
a	O
diagnostic	O
sensitivity	O
superior	O
to	O
that	O
of	O
ALT	O
when	O
the	O
results	O
were	O
correlated	O
to	O
the	O
liver	O
histopathologic	O
results	O
.	O

Plasma	O
MicroRNAs	O
as	O
sensitive	O
and	O
specific	O
biomarkers	O
of	O
tissue	B
injury	I
.	O

BACKGROUND	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
,	O
small	O
noncoding	O
RNAs	O
.	O

Because	O
of	O
their	O
size	O
,	O
abundance	O
,	O
tissue	O
specificity	O
,	O
and	O
relative	O
stability	O
in	O
plasma	O
,	O
miRNAs	O
hold	O
promise	O
as	O
unique	O
accessible	O
biomarkers	O
to	O
monitor	O
tissue	B
injury	I
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
use	O
of	O
liver-	O
,	O
muscle-	O
and	O
brain	O
-	O
specific	O
miRNAs	O
as	O
circulating	O
biomarkers	O
of	O
tissue	B
injury	I
.	O

We	O
used	O
a	O
highly	O
sensitive	O
quantitative	O
PCR	O
assay	O
to	O
measure	O
specific	O
miRNAs	O
(	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
)	O
in	O
plasma	O
samples	O
from	O
rats	O
treated	O
with	O
liver	O
or	O
muscle	O
toxicants	O
and	O
from	O
a	O
rat	O
surgical	O
model	O
of	O
stroke	B
.	O

RESULTS	O
:	O
We	O
observed	O
increases	O
in	O
plasma	O
concentrations	O
of	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
corresponding	O
to	O
injuries	B
in	I
liver	I
,	O
muscle	O
,	O
and	O
brain	O
,	O
respectively	O
.	O

miR-122	O
and	O
miR-133a	O
illustrated	O
specificity	O
for	O
liver	O
and	O
muscle	O
toxicity	O
,	O
respectively	O
,	O
because	O
they	O
were	O
not	O
detectable	O
in	O
the	O
plasma	O
of	O
animals	O
with	O
toxicity	O
to	O
the	O
other	O
organ	O
.	O

This	O
result	O
contrasted	O
with	O
the	O
results	O
for	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
,	O
which	O
were	O
both	O
increased	O
with	O
either	O
organ	O
toxicity	O
.	O

Meanwhile	O
,	O
3NP	O
rats	O
showed	O
dynamic	O
changes	O
in	O
the	O
miRNA	O
profiles	O
during	O
disease	O
development	O
and	O
a	O
few	O
miRNAs	O
with	O
altered	O
expression	O
.	O

In	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	O
,	O
downregulation	O
was	O
dominant	O
in	O
the	O
miRNA	O
expressions	O
and	O
the	O
level	O
of	O
Drosha	O
decreased	O
concomitantly	O
.	O

Nine	O
miRNAs	O
(	O
miR-22	O
,	O
miR-29c	O
,	O
miR-128	O
,	O
miR-132	O
,	O
miR-138	O
,	O
miR-218	O
,	O
miR-222	O
,	O
miR-344	O
,	O
and	O
miR-674	O
*	O
)	O
were	O
commonly	O
down	O
-	O
regulated	O
in	O
both	O
the	O
12-month	O
-	O
old	O
YAC128	O
and	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	O
.	O

Concomitantly	O
,	O
the	O
expressions	O
of	O
Drosha	O
-	O
DGCR8	O
,	O
Exportin-5	O
,	O
and	O
Dcp1	O
were	O
increased	O
at	O
5months	O
,	O
and	O
the	O
expression	O
of	O
Dicer	O
was	O
decreased	O
at	O
12	O
months	O
.	O

YAC128	O
mice	O
showed	O
upregulation	O
-	O
dominant	O
miRNA	O
expressions	O
at	O
5	O
months	O
and	O
downregulation	O
-	O
dominant	O
expressions	O
at	O
12	O
months	O
.	O

After	O
characterizing	O
the	O
phenotypes	O
by	O
behavioral	O
tests	O
and	O
histological	O
analyses	O
,	O
we	O
profiled	O
striatal	O
miRNAs	O
using	O
a	O
miRNA	O
microarray	O
and	O
we	O
measured	O
the	O
key	O
molecules	O
involved	O
in	O
miRNA	O
biogenesis	O
and	O
function	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
miRNA	O
expression	O
and	O
miRNA	O
regulators	O
in	O
two	O
transgenic	O
models	O
of	O
HD	B
,	O
YAC128	O
and	O
R6	O
/	O
2	O
mice	O
,	O
and	O
in	O
a	O
3-nitropropionic	O
acid	O
(	O
3NP	O
)	O
-induced	O
striatal	O
degeneration	O
rat	O
model	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
RNA	O
molecules	O
regulating	O
gene	O
expression	O
,	O
and	O
are	O
implicated	O
in	O
a	O
variety	O
of	O
diseases	O
including	O
HD	B
.	O
However	O
,	O
the	O
profiles	O
and	O
regulation	O
of	O
miRNAs	O
in	O
HD	B
are	O
not	O
fully	O
understood	O
.	O

Huntington	B
's	I
disease	I
(	O
HD	B
)	O
is	O
a	O
genetic	O
neurodegenerative	B
disease	I
caused	O
by	O
abnormal	O
CAG	O
expansion	O
.	O

Altered	O
microRNA	O
regulation	O
in	O
Huntington	B
's	I
disease	I
models	O
.	O

This	O
information	O
should	O
aid	O
in	O
future	O
studies	O
on	O
therapeutic	O
application	O
of	O
miRNAs	O
in	O
HD	B
.	O

Our	O
results	O
show	O
that	O
transgenic	O
HD	B
mice	O
have	O
abnormal	O
miRNA	O
biogenesis	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
miRNA	O
profiles	O
in	O
A.	O
cantonensis	O
,	O
which	O
may	O
represent	O
a	O
new	O
platform	O
for	O
studying	O
regulation	O
of	O
genes	O
and	O
their	O
networks	O
in	O
A.	O
cantonensis	O
.	O

Nucleotide	O
bias	O
analysis	O
showed	O
that	O
uracil	O
was	O
the	O
prominent	O
nucleotide	O
,	O
particularly	O
at	O
positions	O
of	O
1	O
,	O
10	O
,	O
14	O
,	O
17	O
and	O
22	O
,	O
approximately	O
at	O
the	O
beginning	O
,	O
middle	O
and	O
the	O
end	O
of	O
the	O
conserved	O
miRNAs	O
.	O

No	O
new	O
miRNA	O
sequence	O
was	O
found	O
.	O

A	O
total	O
of	O
8861,260	O
and	O
10,957,957	O
high	O
quality	O
reads	O
with	O
20	O
and	O
23	O
conserved	O
miRNAs	O
were	O
obtained	O
in	O
females	O
and	O
males	O
,	O
respectively	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
and	O
characterize	O
miRNAs	O
of	O
female	O
and	O
male	O
adults	O
of	O
A.	O
cantonensis	O
by	O
Solexa	O
deep	O
sequencing	O
.	O

They	O
have	O
been	O
identified	O
in	O
a	O
diverse	O
range	O
of	O
organisms	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
play	O
crucial	O
roles	O
in	O
gene	O
expression	O
regulation	O
,	O
cellular	O
function	O
and	O
defense	O
,	O
homeostasis	O
and	O
pathogenesis	O
.	O

Angiostrongylus	O
cantonensis	O
causes	O
eosinophilic	B
meningitis	I
and	O
eosinophilic	B
pleocytosis	I
in	O
humans	O
and	O
is	O
of	O
significant	O
socio	O
-	O
economic	O
importance	O
globally	O
.	O

Angiostrongylus	O
cantonensis	O
:	O
Identification	O
and	O
characterization	O
of	O
microRNAs	O
in	O
male	O
and	O
female	O
adults	O
.	O

However	O
,	O
none	O
of	O
these	O
individuals	O
reported	O
here	O
have	O
epilepsy	B
,	O
although	O
two	O
have	O
an	O
abnormal	O
EEG	O
.	O

CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
chromosome	O
15q13.2q13.3	O
BP4-BP5	O
microdeletion	O
/	O
duplication	O
syndrome	O
may	O
include	O
features	O
of	O
autism	B
spectrum	I
disorder	I
,	O
a	O
variety	O
of	O
neuropsychiatric	B
disorders	I
,	O
and	O
cognitive	B
impairment	I
.	O

Recognition	O
of	O
this	O
broader	O
phenotype	O
has	O
implications	O
for	O
clinical	O
diagnostic	O
testing	O
and	O
efforts	O
to	O
understand	O
the	O
underlying	O
aetiology	O
of	O
this	O
syndrome	O
.	O

PATIENTS	O
:	O
DNA	O
samples	O
from	O
1445	O
unrelated	O
patients	O
submitted	O
consecutively	O
for	O
clinical	O
array	O
comparative	O
genomic	O
hybridisation	O
(	O
CGH	O
)	O
testing	O
at	O
Children	O
's	O
Hospital	O
Boston	O
and	O
DNA	O
samples	O
from	O
1441	O
individuals	O
with	O
autism	B
from	O
751	O
families	O
in	O
the	O
Autism	B
Genetic	O
Resource	O
Exchange	O
(	O
AGRE	O
)	O
repository	O
.	O

RESULTS	O
:	O
We	O
report	O
the	O
clinical	O
features	O
of	O
five	O
patients	O
with	O
a	O
BP4-BP5	O
deletion	O
,	O
three	O
with	O
a	O
BP4-BP5	O
duplication	O
,	O
and	O
two	O
with	O
an	O
overlapping	O
but	O
smaller	O
duplication	O
identified	O
by	O
whole	O
genome	O
high	O
resolution	O
oligonucleotide	O
array	O
CGH	O
.	O

Microdeletion	O
/	O
duplication	O
at	O
15q13.2q13.3	O
among	O
individuals	O
with	O
features	O
of	O
autism	B
and	O
other	O
neuropsychiatric	B
disorders	I
.	O

BACKGROUND	O
:	O
Segmental	O
duplications	O
at	O
breakpoints	O
(	O
BP4-BP5	O
)	O
of	O
chromosome	O
15q13.2q13.3	O
mediate	O
a	O
recurrent	O
genomic	O
imbalance	O
syndrome	O
associated	O
with	O
mental	B
retardation	I
,	O
epilepsy	B
,	O
and/or	O
electroencephalogram	B
(	I
EEG	I
)	I
abnormalities	I
.	O

BP4-BP5	O
covers	O
approximately	O
1.5	O
Mb	O
(	O
chr15:28.719	O
-	O
30.298	O
Mb	O
)	O
and	O
includes	O
six	O
reference	O
genes	O
and	O
1	O
miRNA	O
gene	O
,	O
while	O
the	O
smaller	O
duplications	O
cover	O
approximately	O
500	O
kb	O
(	O
chr15:28.902	O
-	O
29.404	O
Mb	O
)	O
and	O
contain	O
three	O
reference	O
genes	O
and	O
one	O
miRNA	O
gene	O
.	O

Cognitive	B
impairment	I
varied	O
from	O
moderate	O
mental	B
retardation	I
to	O
normal	O
IQ	O
with	O
learning	B
disability	I
.	O

These	O
BP4-BP5	O
deletion	O
cases	O
exhibit	O
minor	O
dysmorphic	O
features	O
,	O
significant	O
expressive	O
language	O
deficits	O
,	O
and	O
a	O
spectrum	O
of	O
neuropsychiatric	B
impairments	I
that	O
include	O
autism	B
spectrum	I
disorder	I
,	O
attention	B
deficit	I
hyperactivity	I
disorder	I
,	O
anxiety	B
disorder	I
,	O
and	O
mood	B
disorder	I
.	O

The	O
BP4-BP5	O
deletion	O
and	O
duplication	O
events	O
span	O
CHRNA7	O
,	O
a	O
candidate	O
gene	O
for	O
seizures	B
.	O

The	O
KIAA0226	O
gene	O
encodes	O
a	O
protein	O
that	O
we	O
named	O
rundataxin	O
,	O
with	O
two	O
conserved	O
domains	O
:	O
an	O
N	O
-	O
terminal	O
RUN	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
containing	O
a	O
diacylglycerol	O
binding	O
-	O
like	O
motif	O
.	O

Mutation	O
screening	O
of	O
all	O
coding	O
sequences	O
revealed	O
a	O
single	O
nucleotide	O
deletion	O
,	O
2927delC	O
,	O
in	O
exon	O
19	O
of	O
the	O
KIAA0226	O
gene	O
,	O
which	O
results	O
in	O
a	O
frame	O
shift	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
p	O
.	O
Ala943ValfsX146	O
)	O
.	O

The	O
rundataxin	O
pathway	O
appears	O
therefore	O
distinct	O
from	O
the	O
ataxia	B
pathways	O
involving	O
deficiency	O
in	O
mitochondrial	O
or	O
nuclear	O
proteins	O
and	O
broadens	O
the	O
range	O
of	O
mechanisms	O
leading	O
to	O
recessive	O
ataxias	B
.	O

The	O
closest	O
paralogue	O
of	O
rundataxin	O
,	O
the	O
plekstrin	O
homology	O
domain	O
family	O
member	O
M1	O
,	O
has	O
been	O
shown	O
to	O
colocalize	O
with	O
Rab7	O
,	O
a	O
small	O
GTPase	O
associated	O
with	O
late	O
endosomes	O
/	O
lysosomes	O
,	O
suggesting	O
that	O
rundataxin	O
may	O
also	O
be	O
associated	O
with	O
vesicular	O
trafficking	O
and	O
signalling	O
pathways	O
through	O
its	O
RUN	O
and	O
diacylglycerol	O
binding	O
-	O
like	O
domains	O
.	O

The	O
three	O
patients	O
presented	O
with	O
childhood	O
onset	O
gait	O
and	O
limb	O
ataxia	B
,	O
dysarthria	B
and	O
had	O
limited	O
walking	O
without	O
aid	O
into	O
their	O
teenage	O
years	O
.	O

We	O
have	O
identified	O
a	O
novel	O
form	O
of	O
recessive	O
ataxia	B
that	O
segregates	O
in	O
three	O
children	O
of	O
a	O
large	O
consanguineous	O
Saudi	O
Arabian	O
family	O
.	O

Linkage	O
studies	O
allowed	O
us	O
to	O
identify	O
a	O
single	O
locus	O
that	O
segregated	O
with	O
the	O
disease	O
on	O
chromosome	O
3q28-qter	O
.	O

Two	O
patients	O
developed	O
epilepsy	B
at	O
7	O
months	O
without	O
relapse	O
after	O
treatment	O
,	O
and	O
mental	B
retardation	I
.	O

Rundataxin	O
,	O
a	O
novel	O
protein	O
with	O
RUN	O
and	O
diacylglycerol	O
binding	O
domains	O
,	O
is	O
mutant	O
in	O
a	O
new	O
recessive	O
ataxia	B
.	O

A	O
novel	O
microRNA	O
and	O
transcription	O
factor	O
mediated	O
regulatory	O
network	O
in	O
schizophrenia	B
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
changes	O
in	O
gene	O
expression	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
schizophrenia	B
,	O
and	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
are	O
primary	O
regulators	O
of	O
this	O
gene	O
expression	O
.	O

BACKGROUND	O
:	O
Schizophrenia	B
is	O
a	O
complex	O
brain	B
disorder	I
with	O
molecular	O
mechanisms	O
that	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

We	O
hypothesized	O
that	O
miRNAs	O
and	O
TFs	O
might	O
play	O
combinatory	O
regulatory	O
roles	O
for	O
schizophrenia	B
genes	O
and	O
,	O
thus	O
,	O
explored	O
miRNA	O
-	O
TF	O
regulatory	O
networks	O
in	O
schizophrenia	B
.	O

So	O
far	O
,	O
several	O
miRNA	O
-	O
TF	O
mediated	O
regulatory	O
modules	O
have	O
been	O
verified	O
.	O

Our	O
evaluation	O
revealed	O
that	O
these	O
observed	O
FFLs	O
were	O
significantly	O
enriched	O
in	O
schizophrenia	B
genes	O
.	O

RESULTS	O
:	O
We	O
identified	O
32	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
among	O
our	O
compiled	O
schizophrenia	B
-	O
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
.	O

By	O
converging	O
the	O
FFLs	O
and	O
mutual	O
feedback	O
loops	O
,	O
we	O
constructed	O
a	O
novel	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
schizophrenia	B
.	O

Our	O
analysis	O
revealed	O
EGR3	O
and	O
hsa	O
-	O
miR-195	O
were	O
core	O
regulators	O
in	O
this	O
regulatory	O
network	O
.	O

We	O
next	O
proposed	O
a	O
model	O
highlighting	O
EGR3	O
and	O
miRNAs	O
involved	O
in	O
signaling	O
pathways	O
and	O
regulatory	O
networks	O
in	O
the	O
nervous	O
system	O
.	O

It	O
represents	O
the	O
first	O
investigation	O
of	O
a	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
a	O
complex	O
disease	O
,	O
as	O
demonstrated	O
in	O
schizophrenia	B
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
many	O
insights	O
on	O
the	O
regulatory	O
mechanisms	O
of	O
genes	O
involved	O
in	O
schizophrenia	B
.	O

Finally	O
,	O
we	O
suggested	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
located	O
on	O
miRNAs	O
,	O
their	O
target	O
sites	O
,	O
and	O
TFBSs	O
,	O
which	O
may	O
have	O
an	O
effect	O
in	O
schizophrenia	B
gene	O
regulation	O
.	O

MicroRNA	O
expression	O
in	O
ACTH	O
-	O
producing	O
pituitary	B
tumors	I
:	O
up	O
-	O
regulation	O
of	O
microRNA-122	O
and	O
-493	O
in	O
pituitary	B
carcinomas	I
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
were	O
used	O
to	O
confirm	O
and	O
independently	O
validate	O
miRNAs	O
that	O
were	O
significantly	O
up	O
-	O
regulated	O
or	O
down	O
-	O
regulated	O
between	O
the	O
pituitary	O
tissues	O
.	O

We	O
used	O
miRNA	O
profiling	O
with	O
1,145	O
probes	O
to	O
study	O
miRNA	O
expression	O
in	O
normal	O
anterior	O
pituitary	O
(	O
6	O
cases	O
)	O
,	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
-producing	O
adenomas	B
(	O
8	O
cases	O
)	O
,	O
and	O
ACTH	O
-	O
producing	O
pituitary	B
carcinomas	I
(	O
two	O
cases	O
)	O
.	O

The	O
expression	O
of	O
miRNAs	O
in	O
pituitary	B
carcinomas	I
has	O
not	O
been	O
previously	O
examined	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
,	O
and	O
can	O
function	O
as	O
tumor	O
suppressor	O
genes	O
or	O
oncogenes	O
.	O

MiRNA-493	O
was	O
also	O
up	O
-	O
regulated	O
in	O
carcinomas	B
compared	O
to	O
ACTH	O
adenomas	B
.	O

Analysis	O
of	O
genes	O
that	O
miRNA-493	O
interacts	O
with	O
included	O
LGALS3	O
and	O
RUNX2	O
(	O
http://microrna.sanger.ac.uk	O
)	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
have	O
roles	O
in	O
pituitary	B
tumor	I
cell	O
growth	O
.	O

There	O
were	O
more	O
miRNAs	O
up-	O
(	O
188	O
)	O
or	O
down	O
-	O
regulated	O
(	O
160	O
)	O
between	O
adenomas	B
and	O
normal	O
pituitaries	O
compared	O
to	O
carcinomas	B
and	O
normal	O
pituitaries	O
(	O
92	O
up-	O
and	O
91	O
down	O
-	O
regulated	O
)	O
or	O
between	O
carcinomas	B
and	O
adenomas	B
(	O
46	O
up-	O
and	O
52	O
down	O
-	O
regulated	O
)	O
.	O

Both	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-122	O
between	O
pituitary	B
carcinomas	I
and	O
adenomas	B
.	O

These	O
results	O
provide	O
information	O
about	O
marker	O
miRNAs	O
that	O
may	O
lead	O
to	O
further	O
insights	O
into	O
the	O
regulation	O
of	O
pituitary	B
tumor	I
growth	O
and	O
development	O
.	O

Vascular	B
injury	I
triggers	O
dedifferentiation	O
and	O
cytoskeletal	O
remodeling	O
of	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
,	O
culminating	O
in	O
vessel	B
occlusion	I
.	O

MicroRNAs	O
miR-143	O
and	O
miR-145	O
modulate	O
cytoskeletal	O
dynamics	O
and	O
responsiveness	O
of	O
smooth	O
muscle	O
cells	O
to	O
injury	B
.	O

Serum	O
response	O
factor	O
(	O
SRF	O
)	O
and	O
its	O
coactivator	O
,	O
myocardin	O
,	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
smooth	O
muscle	O
phenotypes	O
by	O
regulating	O
the	O
expression	O
of	O
cytoskeletal	O
genes	O
.	O

We	O
show	O
that	O
SRF	O
and	O
myocardin	O
regulate	O
a	O
cardiovascular	O
-	O
specific	O
microRNA	O
(	O
miRNA	O
)	O
cluster	O
encoding	O
miR-143	O
and	O
miR-145	O
.	O

To	O
assess	O
the	O
functions	O
of	O
these	O
miRNAs	O
in	O
vivo	O
,	O
we	O
systematically	O
deleted	O
them	O
singly	O
and	O
in	O
combination	O
in	O
mice	O
.	O

Mice	O
lacking	O
both	O
miR-143	O
and	O
miR-145	O
are	O
viable	O
and	O
do	O
not	O
display	O
overt	O
abnormalities	O
in	O
smooth	O
muscle	O
differentiation	O
,	O
although	O
they	O
show	O
a	O
significant	O
reduction	O
in	O
blood	O
pressure	O
due	O
to	O
reduced	O
vascular	O
tone	O
.	O

Remarkably	O
,	O
however	O
,	O
neointima	B
formation	I
in	O
response	O
to	O
vascular	B
injury	I
is	O
profoundly	O
impeded	O
in	O
mice	O
lacking	O
these	O
miRNAs	O
,	O
due	O
to	O
disarray	O
of	O
actin	O
stress	O
fibers	O
and	O
diminished	O
migratory	O
activity	O
of	O
SMCs	O
.	O

These	O
abnormalities	O
reflect	O
the	O
regulation	O
of	O
a	O
cadre	O
of	O
modulators	O
of	O
SRF	O
activity	O
and	O
actin	O
dynamics	O
by	O
miR-143	O
and	O
miR-145	O
.	O

Thus	O
,	O
miR-143	O
and	O
miR-145	O
act	O
as	O
integral	O
components	O
of	O
the	O
regulatory	O
network	O
whereby	O
SRF	O
controls	O
cytoskeletal	O
remodeling	O
and	O
phenotypic	O
switching	O
of	O
SMCs	O
during	O
vascular	B
disease	I
.	O

Plasma	O
concentrations	O
of	O
miR-124	O
were	O
significantly	O
elevated	O
at	O
6	O
h	O
,	O
and	O
remained	O
elevated	O
at	O
48	O
h	O
after	O
MCAO	B
introduction	O
.	O

Thus	O
,	O
plasma	O
concentration	O
of	O
miR-124	O
provides	O
a	O
promising	O
candidate	O
biomarker	O
for	O
early	O
detection	O
of	O
cerebral	B
infarction	I
.	O

In	O
this	O
study	O
,	O
miRNA	O
array	O
analysis	O
in	O
various	O
tissues	O
showed	O
that	O
miR-124	O
is	O
almost	O
exclusively	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
neuronal	O
cells	O
,	O
suggesting	O
that	O
it	O
might	O
be	O
useful	O
as	O
a	O
potential	O
biomarker	O
for	O
neurological	B
diseases	I
.	O

We	O
examined	O
whether	O
plasma	O
concentrations	O
of	O
brain	O
-	O
specific	O
miRNA	O
can	O
serve	O
as	O
a	O
biomarker	O
for	O
cerebral	B
infarction	I
,	O
where	O
the	O
cerebral	B
infarction	I
was	O
modeled	O
by	O
middle	B
cerebral	I
artery	I
occlusion	I
(	O
MCAO	B
)	O
in	O
the	O
rat	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
RNAs	O
that	O
play	O
an	O
important	O
role	O
in	O
various	O
physiological	O
processes	O
by	O
downregulating	O
target	O
genes	O
.	O

Recently	O
,	O
plasma	O
miRNAs	O
have	O
been	O
investigated	O
as	O
biomarkers	O
for	O
various	O
diseases	O
.	O

Plasma	O
miR-124	O
as	O
a	O
biomarker	O
for	O
cerebral	B
infarction	I
.	O

METHODS	O
:	O
Surgical	O
outcome	O
data	O
were	O
prospectively	O
collected	O
for	O
2	O
to	O
11	O
years	O
in	O
161	O
consecutive	O
patients	O
with	O
MTLE	B
/	O
HS	B
.	O
Eighty	O
patients	O
underwent	O
an	O
ATL	O
and	O
81	O
an	O
SA	O
.	O
Seizure	B
control	O
achieved	O
with	O
each	O
technique	O
was	O
compared	O
using	O
the	O
Engel	O
classification	O
scheme	O
.	O

Postoperative	O
memory	O
testing	O
was	O
performed	O
in	O
86	O
patients	O
(	O
53	O
%	O
)	O
.	O

At	O
the	O
last	O
follow	O
up	O
,	O
72	O
%	O
of	O
the	O
patients	O
who	O
had	O
undergone	O
an	O
ATL	O
(	O
mean	O
follow	O
up	O
6.7	O
years	O
)	O
and	O
71	O
%	O
of	O
those	O
who	O
had	O
undergone	O
an	O
SA	O
(	O
mean	O
follow	O
up	O
4.5	O
years	O
)	O
were	O
seizure	B
free	O
(	O
Engle	O
Class	O
IA	O
)	O
.	O

Estimated	O
survival	O
in	O
patients	O
in	O
Engel	O
Classes	O
I	O
,	O
IA	O
,	O
and	O
I	O
and	O
II	O
combined	O
did	O
not	O
differ	O
between	O
the	O
two	O
surgical	O
techniques	O
.	O

Preoperatively	O
,	O
58	O
%	O
of	O
the	O
patients	O
had	O
verbal	O
memory	O
scores	O
one	O
standard	O
deviation	O
(	O
SD	O
)	O
below	O
the	O
normal	O
mean	O
.	O

One	O
third	O
of	O
the	O
patients	O
with	O
preoperative	O
scores	O
in	O
the	O
normal	O
range	O
worsened	O
after	O
surgery	O
,	O
although	O
this	O
outcome	O
was	O
not	O
related	O
to	O
the	O
surgical	O
technique	O
.	O

In	O
contrast	O
,	O
one	O
third	O
of	O
those	O
whose	O
preoperative	O
scores	O
were	O
less	O
than	O
-1	O
SD	O
experienced	O
improvement	O
after	O
surgery	O
.	O

Nine	O
(	O
18	O
%	O
)	O
of	O
the	O
50	O
patients	O
whose	O
left	O
side	O
had	O
been	O
surgically	O
treated	O
improved	O
their	O
verbal	O
memory	O
scores	O
by	O
more	O
than	O
one	O
SD	O
.	O
Seven	O
(	O
78	O
%	O
)	O
of	O
these	O
nine	O
underwent	O
an	O
SA	O
(	O
p	O
=	O
0.05	O
)	O
.	O

OBJECT	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
seizure	B
and	O
memory	O
outcome	O
in	O
patients	O
with	O
medically	O
refractory	O
mesial	B
temporal	I
lobe	I
epilepsy	I
due	O
to	O
hippocampal	B
sclerosis	I
(	O
MTLE	B
/	O
HS	B
)	O
treated	O
using	O
an	O
anterior	O
temporal	O
lobectomy	O
(	O
ATL	O
)	O
or	O
a	O
selective	O
amygdalohippocampectomy	O
(	O
SA	O
)	O
.	O

Seizure	B
and	O
memory	O
outcome	O
following	O
temporal	O
lobe	O
surgery	O
:	O
selective	O
compared	O
with	O
nonselective	O
approaches	O
for	O
hippocampal	B
sclerosis	I
.	O

Preliminary	O
data	O
suggest	O
that	O
postoperative	O
verbal	O
memory	O
scores	O
may	O
improve	O
in	O
patients	O
who	O
undergo	O
selective	O
resection	O
of	O
a	O
sclerotic	O
hippocampus	O
in	O
the	O
dominant	O
temporal	O
lobe	O
.	O

CONCLUSIONS	O
:	O
Both	O
ATL	O
and	O
SA	O
can	O
lead	O
to	O
similar	O
favorable	O
seizure	B
control	O
in	O
patients	O
with	O
MTLE	B
/	O
HS	B
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSV-1-induced	O
miRNA-146a	O
in	O
the	O
evasion	O
of	O
HSV-1	O
from	O
the	O
complement	O
system	O
,	O
and	O
the	O
activation	O
of	O
key	O
elements	O
of	O
the	O
arachidonic	O
acid	O
cascade	O
known	O
to	O
contribute	O
to	O
Alzheimer	B
-	O
type	O
neuropathological	O
change	O
.	O

A	O
known	O
miRNA-146a	O
target	O
in	O
the	O
brain	O
,	O
complement	O
factor	O
H	O
,	O
was	O
downregulated	O
.	O

Expression	O
of	O
cytoplasmic	O
phospholipase	O
A2	O
,	O
the	O
inducible	O
prostaglandin	O
synthase	O
cyclooxygenase-2	O
,	O
and	O
the	O
neuroinflammatory	O
cytokine	O
interleukin-1beta	O
were	O
each	O
upregulated	O
.	O

We	O
report	O
that	O
infection	B
of	O
human	O
primary	O
neural	O
cells	O
with	O
a	O
high	O
phenotypic	O
reactivator	O
HSV-1	O
(	O
17syn+	O
)	O
induces	O
upregulation	O
of	O
a	O
brain	O
-	O
enriched	O
microRNA	O
(	O
miRNA	O
)	O
-146a	O
that	O
is	O
associated	O
with	O
proinflammatory	O
signaling	O
in	O
stressed	O
brain	O
cells	O
and	O
Alzheimer	B
's	I
disease	I
.	O

Herpes	B
simplex	I
virus	I
type-1	I
(	I
HSV-1	I
)	I
infection	I
of	O
human	O
brain	O
cells	O
induces	O
changes	O
in	O
gene	O
expression	O
favorable	O
to	O
the	O
propagation	O
of	O
the	O
infecting	O
agent	O
and	O
detrimental	O
to	O
the	O
function	O
of	O
the	O
host	O
cells	O
.	O

HSV-1	B
infection	I
of	O
human	O
brain	O
cells	O
induces	O
miRNA-146a	O
and	O
Alzheimer	B
-	O
type	O
inflammatory	O
signaling	O
.	O

This	O
study	O
reveals	O
the	O
occurrence	O
of	O
novel	O
mechanisms	O
of	O
HIF	O
regulation	O
,	O
which	O
might	O
contribute	O
to	O
developing	O
novel	O
strategies	O
for	O
therapeutic	O
intervention	O
of	O
HIF	O
-	O
related	O
pathologies	O
,	O
including	O
heart	B
attack	I
,	O
cancer	B
,	O
and	O
stroke	B
.	O

One	O
remarkable	O
hit	O
was	O
the	O
argonaute	O
1	O
(	O
ago1	O
)	O
gene	O
,	O
a	O
central	O
element	O
of	O
the	O
microRNA	O
(	O
miRNA	O
)	O
translational	O
silencing	O
machinery	O
.	O

Further	O
studies	O
confirmed	O
the	O
physiological	O
role	O
of	O
the	O
miRNA	O
machinery	O
in	O
HIF	O
-	O
dependent	O
transcription	O
.	O

After	O
3	O
rounds	O
of	O
selection	O
,	O
30	O
genes	O
emerged	O
as	O
critical	O
HIF	O
regulators	O
in	O
hypoxia	B
,	O
most	O
of	O
which	O
had	O
not	O
been	O
previously	O
associated	O
with	O
HIF	O
biology	O
.	O

The	O
list	O
of	O
genes	O
includes	O
components	O
of	O
chromatin	O
remodeling	O
complexes	O
,	O
transcription	O
elongation	O
factors	O
,	O
and	O
translational	O
regulators	O
.	O

Molecular	O
mechanisms	O
that	O
mediate	O
oxygen	O
-	O
dependent	O
HIF	O
regulation	O
operate	O
at	O
the	O
level	O
of	O
the	O
alpha	O
subunit	O
,	O
controlling	O
protein	O
stability	O
,	O
subcellular	O
localization	O
,	O
and	O
transcriptional	O
coactivator	O
recruitment	O
.	O

We	O
have	O
conducted	O
an	O
unbiased	O
genome	O
-	O
wide	O
RNA	O
interference	O
(	O
RNAi	O
)	O
screen	O
in	O
Drosophila	O
cells	O
aimed	O
to	O
the	O
identification	O
of	O
genes	O
required	O
for	O
HIF	O
activity	O
.	O

Drosophila	O
genome	O
-	O
wide	O
RNAi	O
screen	O
identifies	O
multiple	O
regulators	O
of	O
HIF	O
-	O
dependent	O
transcription	O
in	O
hypoxia	B
.	O

Hypoxia	O
-	O
inducible	O
factors	O
(	O
HIFs	O
)	O
are	O
a	O
family	O
of	O
evolutionary	O
conserved	O
alpha	O
-	O
beta	O
heterodimeric	O
transcription	O
factors	O
that	O
induce	O
a	O
wide	O
range	O
of	O
genes	O
in	O
response	O
to	O
low	O
oxygen	O
tension	O
.	O

Follow	O
up	O
functional	O
enrichment	O
analysis	O
of	O
these	O
FFLs	O
uncovered	O
some	O
functions	O
important	O
to	O
carcinogenesis	O
but	O
also	O
some	O
unique	O
functions	O
specific	O
to	O
the	O
FFLs	O
we	O
identified	O
.	O

Transcriptional	O
aberrations	O
may	O
play	O
a	O
vital	O
role	O
in	O
the	O
etiology	O
of	O
glioblastoma	B
,	O
which	O
might	O
be	O
caused	O
by	O
both	O
genomic	O
alterations	O
and	O
other	O
regulation	O
molecules	O
.	O

Illustrating	O
the	O
functions	O
being	O
disturbed	O
during	O
carcinogenesis	O
and	O
how	O
they	O
are	O
deregulated	O
is	O
very	O
important	O
for	O
us	O
to	O
understand	O
its	O
underlying	O
mechanism	O
.	O

We	O
searched	O
glioblastoma	B
-	O
specific	O
regulatory	O
networks	O
by	O
integrating	O
glioblastoma	B
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
,	O
and	O
identified	O
54	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
cooperative	O
deregulation	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
in	O
glioblastoma	B
,	O
under	O
the	O
hypothesis	O
that	O
miRNAs	O
and	O
TFs	O
might	O
have	O
a	O
combinational	O
regulatory	O
effect	O
on	O
glioblastoma	B
genes	O
.	O

Glioblastoma	B
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
brain	B
tumour	I
in	O
humans	O
.	O

Gene	O
regulation	O
in	O
glioblastoma	B
:	O
a	O
combinatorial	O
analysis	O
of	O
microRNAs	O
and	O
transcription	O
factors	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
patterns	O
of	O
miRNA	O
expression	O
in	O
cortical	O
GM	O
may	O
contribute	O
to	O
AD	B
pathogenetically	O
,	O
because	O
the	O
aggregate	O
change	O
in	O
miRNA	O
expression	O
observed	O
early	O
in	O
the	O
disease	O
would	O
be	O
predicted	O
to	O
cause	O
profound	O
changes	O
in	O
gene	O
expression	O
.	O

Patterns	O
of	O
microRNA	O
expression	O
in	O
normal	O
and	O
early	O
Alzheimer	B
's	I
disease	I
human	O
temporal	O
cortex	O
:	O
white	O
matter	O
versus	O
gray	O
matter	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
assessed	O
in	O
human	O
cerebral	O
cortical	O
gray	O
matter	O
(	O
GM	O
)	O
and	O
white	O
matter	O
(	O
WM	O
)	O
in	O
order	O
to	O
provide	O
the	O
first	O
insights	O
into	O
the	O
difference	O
between	O
GM	O
and	O
WM	O
miRNA	O
repertoires	O
across	O
a	O
range	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
pathology	O
.	O

RNA	O
was	O
isolated	O
separately	O
from	O
GM	O
and	O
WM	O
portions	O
of	O
superior	O
and	O
middle	O
temporal	O
cerebral	O
cortex	O
(	O
N	O
=	O
10	O
elderly	O
females	O
,	O
postmortem	O
interval	O
<	O
4	O
h	O
)	O
.	O

miRNA	O
profiling	O
experiments	O
were	O
performed	O
using	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
Exiqon	O
(	O
©	O
)	O
LNA	O
-	O
microarrays	O
.	O

A	O
subset	O
of	O
miRNAs	O
that	O
appeared	O
to	O
be	O
strongly	O
expressed	O
according	O
to	O
the	O
microarrays	O
did	O
not	O
appear	O
to	O
be	O
conventional	O
miRNAs	O
according	O
to	O
Northern	O
blot	O
analyses	O
.	O

Some	O
well	O
-	O
characterized	O
miRNAs	O
were	O
substantially	O
enriched	O
in	O
WM	O
as	O
expected	O
.	O

However	O
,	O
most	O
of	O
the	O
miRNA	O
expression	O
variability	O
that	O
correlated	O
with	O
the	O
presence	O
of	O
early	O
AD	B
-	O
related	O
pathology	O
was	O
seen	O
in	O
GM	O
.	O

We	O
confirm	O
that	O
downregulation	O
of	O
a	O
set	O
of	O
miRNAs	O
in	O
GM	O
(	O
including	O
several	O
miR-15	O
/	O
107	O
genes	O
and	O
miR-29	O
paralogs	O
)	O
correlated	O
strongly	O
with	O
the	O
density	O
of	O
diffuse	O
amyloid	B
plaques	I
detected	O
in	O
adjacent	O
tissue	O
.	O

A	O
few	O
miRNAs	O
were	O
differentially	O
expressed	O
in	O
WM	O
,	O
including	O
miR-212	O
that	O
is	O
downregulated	O
in	O
AD	B
and	O
miR-424	O
which	O
is	O
upregulated	O
in	O
AD	B
.	O

The	O
expression	O
of	O
certain	O
miRNAs	O
correlates	O
with	O
other	O
miRNAs	O
across	O
different	O
cases	O
,	O
and	O
particular	O
subsets	O
of	O
miRNAs	O
are	O
coordinately	O
expressed	O
in	O
relation	O
to	O
AD	B
-	O
related	O
pathology	O
.	O

Leukodystrophy	B
and	O
gene	O
therapy	O
with	O
a	O
dimmer	O
switch	O
.	O

The	O
authors	O
reviewed	O
the	O
records	O
of	O
nineteen	O
consecutive	O
children	O
with	O
newly	O
diagnosed	O
IIH	O
in	O
order	O
to	O
compare	O
demographic	O
characteristics	O
,	O
clinical	O
pictures	O
and	O
ophthalmologic	O
aspects	O
as	O
optic	O
disc	O
evaluation	O
and	O
visual	O
field	O
evaluation	O
,	O
as	O
well	O
as	O
treatment	O
modalities	O
and	O
follow	O
up	O
.	O

Beside	O
obesity	B
and	O
female	O
gender	O
,	O
potential	O
alternative	O
risk	O
factors	O
remains	O
to	O
be	O
investigated	O
,	O
which	O
need	O
a	O
good	O
collaboration	O
between	O
neuro	O
-	O
ophthalmologists	O
and	O
pediatric	O
neurologists	O
.	O

Idiopathic	B
intracranial	I
hypertension	I
(	O
IIH	B
)	O
is	O
a	O
clinical	O
condition	O
characterized	O
by	O
elevated	B
intracranial	I
pressure	I
and	O
absence	O
of	O
clinical	O
,	O
laboratory	O
or	O
radiographic	O
evidence	O
of	O
central	B
nervous	I
system	I
infection	I
,	O
vascular	B
malformation	I
,	O
intracranial	O
space	O
occupying	O
lesion	B
or	O
hydrocephalus	B
.	O

In	O
the	O
last	O
years	O
the	O
raising	O
understanding	O
of	O
pediatric	O
IIH	O
,	O
especially	O
concerning	O
its	O
demographics	O
and	O
epidemiology	O
,	O
has	O
brought	O
up	O
to	O
a	O
redefinition	O
of	O
diagnostic	O
criteria	O
and	O
reevaluation	O
of	O
pathogenesis	O
and	O
treatment	O
.	O

Pediatric	O
idiopathic	B
intracranial	I
hypertension	I
:	O
clinical	O
and	O
demographic	O
features	O
.	O

Although	O
microRNAs	O
are	O
expressed	O
extensively	O
in	O
the	O
central	O
nervous	O
system	O
in	O
physiological	O
and	O
pathological	O
conditions	O
,	O
their	O
expression	O
in	O
neurological	B
disorder	I
of	O
epilepsy	B
has	O
not	O
been	O
well	O
characterized	O
.	O

Expression	O
profile	O
of	O
microRNAs	O
in	O
rat	O
hippocampus	O
following	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
.	O

Rat	O
MicroRNA	O
array	O
and	O
differential	O
analysis	O
had	O
detected	O
19	O
up	O
-	O
regulated	O
microRNAs	O
and	O
7	O
down	O
-	O
regulated	O
microRNAs	O
in	O
rat	O
hippocampus	O
,	O
and	O
four	O
randomly	O
selected	O
deregulated	O
microRNAs	O
(	O
microRNA-34a	O
,	O
microRNA-22	O
,	O
microRNA-125a	O
,	O
microRNA-21	O
)	O
were	O
confirmed	O
by	O
qRT	O
-	O
PCR	O
,	O
then	O
their	O
expression	O
alterations	O
in	O
rat	O
peripheral	O
blood	O
were	O
analyzed	O
.	O

Here	O
we	O
investigated	O
microRNA	O
expression	O
pattern	O
in	O
post	O
status	B
epilepticus	I
rats	O
(	O
24h	O
after	O
status	O
)	O
.	O

Thus	O
,	O
our	O
results	O
have	O
not	O
only	O
characterized	O
the	O
microRNA	O
expression	O
profile	O
in	O
post	O
status	B
epilepticus	I
rat	O
hippocampus	O
but	O
also	O
demonstrated	O
that	O
some	O
rat	O
hippocampal	O
microRNAs	O
were	O
probably	O
associated	O
with	O
rat	O
peripheral	O
blood	O
microRNAs	O
.	O

We	O
found	O
that	O
these	O
four	O
deregulated	O
microRNAs	O
were	O
also	O
differentially	O
expressed	O
in	O
rat	O
peripheral	O
blood	O
,	O
and	O
trends	O
for	O
their	O
blood	O
expression	O
alterations	O
were	O
just	O
the	O
same	O
as	O
their	O
counterparts	O
in	O
rat	O
hippocampus	O
.	O

Moreover	O
,	O
targets	O
of	O
these	O
deregulated	O
microRNAs	O
were	O
analyzed	O
using	O
bioinformatics	O
and	O
the	O
identified	O
enriched	O
MAPK	O
pathway	O
and	O
long	O
-	O
term	O
potentiation	O
pathway	O
might	O
have	O
been	O
involved	O
in	O
molecular	O
mechanisms	O
concerning	O
neuronal	B
death	I
,	O
inflammation	B
and	O
epileptogenesis	B
.	O

Remarks	O
are	O
also	O
provided	O
to	O
point	O
out	O
the	O
unanswered	O
questions	O
and	O
to	O
outline	O
the	O
new	O
directions	O
for	O
the	O
future	O
research	O
of	O
the	O
field	O
.	O

Speculations	O
on	O
the	O
development	O
of	O
miRNAs	O
as	O
potential	O
therapeutic	O
targets	O
are	O
also	O
presented	O
.	O

These	O
small	O
molecules	O
act	O
by	O
repressing	O
the	O
expression	O
of	O
either	O
the	O
proapoptotic	O
or	O
antiapoptotic	O
genes	O
to	O
produce	O
antiapoptotic	O
or	O
proapoptotic	O
effects	O
.	O

Appealing	O
evidence	O
has	O
been	O
accumulating	O
for	O
the	O
involvement	O
of	O
miRNAs	O
in	O
human	O
diseases	O
associated	O
with	O
apoptotic	O
cell	O
death	O
and	O
the	O
potential	O
of	O
miRNAs	O
as	O
novel	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
the	O
diseases	O
.	O

The	O
importance	O
of	O
miRNAs	O
has	O
steadily	O
gained	O
appreciation	O
and	O
miRNA	O
biology	O
has	O
exploded	O
into	O
a	O
massive	O
swell	O
of	O
interest	O
with	O
enormous	O
range	O
and	O
potential	O
in	O
almost	O
every	O
biological	O
discipline	O
because	O
of	O
their	O
widespread	O
expression	O
and	O
diverse	O
functions	O
in	O
both	O
animals	O
and	O
humans	O
.	O

It	O
has	O
been	O
established	O
that	O
miRNAs	O
are	O
critical	O
regulators	O
of	O
apoptosis	O
of	O
various	O
cell	O
types	O
.	O

Tremendous	O
efforts	O
have	O
been	O
made	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
involved	O
in	O
apoptosistic	O
cell	O
death	O
.	O

Once	O
ignored	O
completely	O
or	O
overlooked	O
as	O
cellular	O
detritus	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
that	O
were	O
discovered	O
only	O
a	O
decade	O
ago	O
,	O
have	O
recently	O
taken	O
many	O
by	O
surprise	O
.	O

MicroRNA	O
:	O
A	O
matter	O
of	O
life	O
or	O
death	O
.	O

Progressive	O
cell	O
loss	O
due	O
to	O
apoptosis	O
is	O
a	O
pathological	O
hallmark	O
implicated	O
in	O
a	O
wide	O
spectrum	O
of	O
degenerative	O
diseases	O
such	O
as	O
heart	B
disease	I
,	O
atherosclerotic	O
arteries	O
and	O
hypertensive	B
vessels	O
,	O
Alzheimer	B
's	I
disease	I
and	O
other	O
neurodegenerative	B
disorders	I
.	O

This	O
editorial	O
aims	O
to	O
convey	O
this	O
message	O
and	O
to	O
boost	O
up	O
the	O
research	O
interest	O
by	O
providing	O
a	O
timely	O
,	O
comprehensive	O
overview	O
on	O
regulation	O
of	O
apoptosis	O
by	O
miRNAs	O
and	O
a	O
synopsis	O
on	O
the	O
pathophysiologic	O
implications	O
of	O
this	O
novel	O
regulatory	O
network	O
based	O
on	O
the	O
currently	O
available	O
data	O
in	O
the	O
literature	O
.	O

It	O
begins	O
with	O
a	O
brief	O
introduction	O
to	O
apoptosis	O
and	O
miRNAs	O
,	O
followed	O
by	O
the	O
description	O
of	O
the	O
fundamental	O
aspects	O
of	O
miRNA	O
biogenesis	O
and	O
action	O
,	O
and	O
the	O
role	O
of	O
miRNAs	O
in	O
regulating	O
apoptosis	O
of	O
cancer	B
cells	O
and	O
cardiovascular	O
cells	O
.	O

The	O
accurate	O
diagnosis	O
of	O
brain	O
malignancies	O
is	O
essential	O
for	O
selection	O
of	O
proper	O
treatment	O
.	O

A	O
recurring	O
challenge	O
for	O
brain	O
pathologists	O
is	O
to	O
diagnose	O
whether	O
a	O
brain	O
malignancy	O
is	O
a	O
primary	B
tumor	I
or	O
a	O
metastasis	O
from	O
some	O
other	O
tissue	O
.	O

MiR-92b	O
and	O
miR-9	O
/	O
9	O
*	O
are	O
specifically	O
expressed	O
in	O
brain	O
primary	B
tumors	I
and	O
can	O
be	O
used	O
to	O
differentiate	O
primary	O
from	O
metastatic	B
brain	I
tumors	I
.	O

These	O
microRNAs	O
thus	O
represent	O
excellent	O
biomarkers	O
for	O
brain	B
primary	I
tumors	I
.	O

By	O
considering	O
the	O
expression	O
of	O
only	O
these	O
two	O
microRNAs	O
,	O
it	O
is	O
possible	O
to	O
distinguish	O
between	O
primary	O
and	O
metastatic	B
brain	I
tumors	I
with	O
very	O
high	O
accuracy	O
.	O

Using	O
microRNA	O
expression	O
profiling	O
,	O
we	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
over	O
-	O
expressed	O
,	O
specifically	O
in	O
brain	B
primary	I
tumors	I
,	O
as	O
compared	O
to	O
primary	B
tumors	I
from	O
other	O
tissues	O
and	O
their	O
metastases	O
to	O
the	O
brain	O
.	O

MicroRNAs	O
are	O
a	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
regulate	O
gene	O
expression	O
;	O
many	O
exhibit	O
tissue	O
-	O
specific	O
expression	O
and	O
are	O
misregulated	O
in	O
cancer	B
.	O

Previous	O
reports	O
have	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
expressed	O
more	O
strongly	O
in	O
developing	O
neurons	O
and	O
brain	O
than	O
in	O
adult	O
brain	O
.	O

Thus	O
,	O
their	O
specific	O
over	O
-	O
expression	O
in	O
brain	B
primary	I
tumors	I
supports	O
a	O
functional	O
role	O
for	O
these	O
microRNAs	O
or	O
a	O
link	O
between	O
neuronal	O
stem	O
cells	O
and	O
brain	O
tumorigenesis	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
levels	O
of	O
human	O
APP	O
can	O
be	O
regulated	O
by	O
miRNAs	O
.	O

Over	O
-	O
expression	O
of	O
these	O
miRNAs	O
,	O
but	O
not	O
control	O
miRNAs	O
,	O
results	O
in	O
translational	O
repression	O
of	O
APP	O
mRNA	O
and	O
significantly	O
reduces	O
APP	O
protein	O
levels	O
.	O

Here	O
we	O
test	O
the	O
hypothesis	O
that	O
APP	O
protein	O
levels	O
can	O
be	O
regulated	O
by	O
miRNAs	O
,	O
evolutionarily	O
conserved	O
small	O
noncoding	O
RNA	O
molecules	O
that	O
play	O
an	O
important	O
role	O
in	O
regulating	O
gene	O
expression	O
.	O

Utilizing	O
human	O
cell	O
lines	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
hsa	O
-	O
mir-106a	O
and	O
hsa	O
-	O
mir-520c	O
bind	O
to	O
their	O
predicted	O
target	O
sequences	O
in	O
the	O
APP	O
3'UTR	O
and	O
negatively	O
regulate	O
reporter	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
increased	O
APP	O
levels	O
,	O
resulting	O
from	O
either	O
a	O
genomic	O
locus	O
duplication	O
or	O
alteration	O
in	O
APP	O
regulatory	O
sequences	O
,	O
can	O
lead	O
to	O
development	O
of	O
early	O
-	O
onset	O
dementias	B
,	O
including	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Therefore	O
,	O
understanding	O
how	O
APP	O
levels	O
are	O
regulated	O
could	O
provide	O
valuable	O
insight	O
into	O
the	O
genetic	O
basis	O
of	O
AD	B
and	O
illuminate	O
novel	O
therapeutic	O
avenues	O
for	O
AD	B
.	O

MicroRNAs	O
can	O
regulate	O
human	O
APP	O
levels	O
.	O

MicroRNA	O
expression	O
profiling	O
for	O
molecular	O
classification	O
of	O
pediatric	B
brain	I
tumors	I
.	O

The	O
transcription	O
factor	O
REST	O
silences	O
neuronal	O
gene	O
expression	O
in	O
non	O
-	O
neuronal	O
cells	O
.	O

The	O
bifunctional	O
microRNA	O
miR-9	O
/	O
miR-9	O
*	O
regulates	O
REST	O
and	O
CoREST	O
and	O
is	O
downregulated	O
in	O
Huntington	B
's	I
disease	I
.	O

Polyglutamine	O
expansions	O
in	O
huntingtin	O
,	O
which	O
causes	O
Huntington	B
's	I
disease	I
(	O
HD	B
)	O
,	O
abrogates	O
REST	O
-	O
huntingtin	O
binding	O
.	O

In	O
neurons	O
,	O
the	O
protein	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
in	O
part	O
through	O
binding	O
to	O
huntingtin	O
.	O

In	O
this	O
work	O
,	O
we	O
found	O
that	O
levels	O
of	O
several	O
microRNAs	O
(	O
miRNAs	O
)	O
with	O
upstream	O
RE1	O
sites	O
are	O
decreased	O
in	O
HD	B
patient	O
cortices	O
relative	O
to	O
healthy	O
controls	O
.	O

Consequently	O
,	O
REST	O
translocates	O
to	O
the	O
nucleus	O
,	O
occupies	O
RE1	O
repressor	O
sequences	O
and	O
decreases	O
neuronal	O
gene	O
expression	O
.	O

Interestingly	O
,	O
one	O
of	O
these	O
,	O
the	O
bifunctional	O
brain	O
enriched	O
miR-9	O
/	O
miR-9	O
*	O
,	O
targets	O
two	O
components	O
of	O
the	O
REST	O
complex	O
:	O
miR-9	O
targets	O
REST	O
and	O
miR-9	O
*	O
targets	O
CoREST	O
.	O

These	O
data	O
provide	O
evidence	O
for	O
a	O
double	O
negative	O
feedback	O
loop	O
between	O
the	O
REST	O
silencing	O
complex	O
and	O
the	O
miRNAs	O
it	O
regulates	O
.	O

Specificity	O
,	O
duplex	O
degradation	O
and	O
subcellular	O
localization	O
of	O
antagomirs	O
.	O

Finally	O
,	O
we	O
show	O
that	O
antagomirs	O
,	O
although	O
incapable	O
of	O
silencing	O
miRNAs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
when	O
injected	O
systemically	O
,	O
efficiently	O
target	O
miRNAs	O
when	O
injected	O
locally	O
into	O
the	O
mouse	O
cortex	O
.	O

Our	O
data	O
further	O
validate	O
the	O
effectiveness	O
of	O
antagomirs	O
in	O
vivo	O
and	O
should	O
facilitate	O
future	O
studies	O
to	O
silence	O
miRNAs	O
for	O
functional	O
analysis	O
and	O
in	O
clinically	O
relevant	O
settings	O
.	O

We	O
demonstrate	O
that	O
antagomirs	O
harbor	O
optimized	O
phosphorothioate	O
modifications	O
,	O
require	O
>	O
19-nt	O
length	O
for	O
highest	O
efficiency	O
and	O
can	O
discriminate	O
between	O
single	O
nucleotide	O
mismatches	O
of	O
the	O
targeted	O
miRNA	O
.	O

Degradation	O
of	O
different	O
chemically	O
protected	O
miRNA	O
/	O
antagomir	O
duplexes	O
in	O
mouse	O
livers	O
and	O
localization	O
of	O
antagomirs	O
in	O
a	O
cytosolic	O
compartment	O
that	O
is	O
distinct	O
from	O
processing	O
(	O
P	O
)	O
-bodies	O
indicates	O
a	O
degradation	O
mechanism	O
independent	O
of	O
the	O
RNA	O
interference	O
(	O
RNAi	O
)	O
pathway	O
.	O

We	O
recently	O
demonstrated	O
silencing	O
miRNA	O
function	O
in	O
mice	O
using	O
chemically	O
modified	O
and	O
cholesterol	O
-	O
conjugated	O
RNAs	O
termed	O
'	O
antagomirs	O
'	O
.	O

Here	O
,	O
we	O
further	O
characterize	O
the	O
properties	O
and	O
function	O
of	O
antagomirs	O
in	O
mice	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
an	O
abundant	O
class	O
of	O
20	O
-	O
23-nt	O
long	O
regulators	O
of	O
gene	O
expression	O
.	O

The	O
study	O
of	O
miRNA	O
function	O
in	O
mice	O
and	O
potential	O
therapeutic	O
approaches	O
largely	O
depend	O
on	O
modified	O
oligonucleotides	O
.	O

Altered	O
microRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
:	O
miR-146a	O
targets	O
TBP	O
.	O

We	O
studied	O
expression	O
of	O
90	O
miRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
,	O
a	O
model	O
for	O
Huntington	B
's	I
disease	I
and	O
compared	O
with	O
that	O
obtained	O
in	O
STHdh	O
(	O
Q7	O
)	O
/	O
Hdh	O
(	O
Q7	O
)	O
cells	O
.	O

Fifteen	O
miRNAs	O
were	O
down	O
regulated	O
and	O
12	O
miRNAs	O
were	O
up	O
regulated	O
more	O
than	O
2-fold	O
.	O

Such	O
changes	O
were	O
statistically	O
significant	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
two	O
genes	O
are	O
experimentally	O
known	O
targets	O
of	O
these	O
altered	O
miRNAs	O
.	O

Using	O
luciferase	O
reporter	O
assays	O
with	O
3'-UTRs	O
of	O
TBP	O
,	O
over	O
-	O
expression	O
and	O
inhibition	O
of	O
miR-146a	O
,	O
we	O
showed	O
that	O
miR-146a	O
targets	O
TBP	O
.	O

It	O
has	O
been	O
predicted	O
that	O
miR-146a	O
may	O
target	O
Tata	O
Binding	O
Protein	O
(	O
TBP	O
)	O
.	O

Regulation	O
of	O
TBP	O
by	O
miR-146a	O
may	O
contribute	O
to	O
HD	B
pathogenesis	O
.	O

Many	O
of	O
these	O
pathways	O
were	O
first	O
identified	O
in	O
genetic	O
screens	O
in	O
Drosophila	O
and	O
other	O
lower	O
organisms	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
it	O
has	O
become	O
clear	O
that	O
developmental	O
genes	O
and	O
their	O
regulators	O
,	O
noncoding	O
RNAs	O
including	O
microRNAs	O
and	O
long	O
-	O
noncoding	O
RNAs	O
,	O
within	O
signaling	O
pathways	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	B
.	O

Genes	O
and	O
pathways	O
expressed	O
during	O
embryonic	O
development	O
,	O
including	O
the	O
Notch	O
,	O
Wnt	O
/	O
β	O
-	O
Catenin	O
,	O
TGF	O
-	O
β	O
/	O
BMP	O
,	O
Shh	O
/	O
Patched	O
,	O
and	O
Hippo	O
pathways	O
are	O
mutated	O
,	O
lost	O
,	O
or	O
aberrantly	O
regulated	O
in	O
a	O
wide	O
variety	O
of	O
human	B
cancers	I
,	O
including	O
skin	O
,	O
breast	O
,	O
blood	O
,	O
and	O
brain	B
cancers	I
,	O
including	O
medulloblastoma	B
.	O

Mammalian	O
orthologs	O
were	O
subsequently	O
identified	O
and	O
genes	O
within	O
the	O
pathways	O
cloned	O
and	O
found	O
to	O
regulate	O
cell	O
growth	O
.	O

Cerebellum	O
development	O
and	O
medulloblastoma	B
.	O

Medulloblastoma	B
,	O
the	O
most	O
common	O
malignant	O
nervous	O
system	O
tumor	B
in	O
childhood	O
,	O
are	O
thought	O
to	O
arise	O
from	O
disruptions	O
in	O
cerebellar	O
development	O
[	O
reviewed	O
by	O
Marino	O
,	O
S.	O
(	O
2005	O
)	O
]	O
.	O

These	O
biochemical	O
pathways	O
affect	O
cell	O
fate	O
determination	O
,	O
axis	O
formation	O
,	O
and	O
patterning	O
during	O
development	O
and	O
regulate	O
tissue	O
homeostasis	O
and	O
regeneration	O
in	O
adults	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
review	O
the	O
development	O
of	O
the	O
cerebellar	O
cortex	O
,	O
highlighting	O
signaling	O
pathways	O
of	O
potential	O
relevance	O
to	O
tumorigenesis	O
.	O

Defining	O
the	O
extracellular	O
cues	O
and	O
intracellular	O
signaling	O
pathways	O
that	O
control	O
cerebellar	O
neurogenesis	O
,	O
especially	O
granule	O
cell	O
progenitor	O
(	O
GCP	O
)	O
proliferation	O
and	O
differentiation	O
has	O
been	O
useful	O
for	O
developing	O
models	O
to	O
unravel	O
the	O
mechanisms	O
underlying	O
medulloblastoma	B
formation	O
and	O
growth	O
.	O

This	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
case	O
of	O
this	O
kind	O
found	O
in	O
Argentina	O
and	O
is	O
additional	O
evidence	O
that	O
HAM	B
/	O
TSP	B
solely	O
related	O
to	O
HTLV	B
-	I
II	I
infection	I
occurs	O
in	O
HTLV	O
-	O
I	O
-	O
negative	O
subjects	O
.	O

A	O
case	O
of	O
neurological	B
disease	I
featuring	O
human	B
T	I
lymphocyte	I
virus	I
-	I
associated	I
myelopathy	I
/	O
tropical	B
spastic	I
paraparesis	I
(	O
HAM	B
/	O
TSP	B
)	O
was	O
diagnosed	O
by	O
serological	O
(	O
Western	O
blot	O
)	O
and	O
molecular	O
(	O
polymerase	O
chain	O
reaction	O
)	O
criteria	O
as	O
related	O
to	O
human	B
T	I
lymphocyte	I
virus	I
(	I
HTLV	I
)	I
-II	I
infection	I
.	O

A	O
possible	O
case	O
of	O
myelopathy	B
/	O
tropical	B
spastic	I
paraparesis	I
in	O
an	O
Argentinian	O
woman	O
with	O
human	O
T	O
lymphocyte	O
virus	O
type	O
II	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
directly	O
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	O
in	O
the	O
tested	O
cells	O
,	O
consequently	O
,	O
affects	O
their	O
growth	O
potential	O
by	O
reducing	O
a	O
G1	O
to	O
S	O
shift	O
in	O
the	O
cell	O
cycle	O
.	O

Consistently	O
,	O
miR-221	O
/	O
222	O
knocked	O
-	O
down	O
through	O
antisense	O
2'-OME	O
-	O
oligonucleotides	O
increased	O
p27Kip1	O
in	O
U251	O
glioma	B
subcutaneous	O
mice	O
and	O
strongly	O
reduced	O
tumor	B
growth	O
in	O
vivo	O
through	O
up	O
regulation	O
of	O
p27Kip1	O
.	O

Our	O
results	O
suggest	O
that	O
miR-221	O
/	O
222	O
is	O
a	O
regulator	O
of	O
the	O
tumor	O
suppressor	O
gene	O
p27Kip1	O
,	O
and	O
co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
expression	O
in	O
advanced	O
gliomas	B
may	O
inhibit	O
glioma	B
cell	O
proliferation	O
by	O
a	O
mechanism	O
involving	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
cluster	O
suppresses	O
human	B
glioma	I
cell	O
growth	O
by	O
targeting	O
p27kip1	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
are	O
short	O
regulatory	O
RNAs	O
that	O
negatively	O
modulate	O
protein	O
expression	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
altered	O
regulation	O
of	O
miRNA	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
types	O
of	O
cancers	B
.	O

In	O
the	O
current	O
study	O
,	O
an	O
inverse	O
relationship	O
between	O
the	O
expression	O
of	O
miR-221	O
/	O
miR-222	O
and	O
the	O
cell	O
cycle	O
inhibitor	O
p27Kip1	O
was	O
identified	O
in	O
U251	O
glioma	B
cells	O
.	O

The	O
mRNA	O
expression	O
of	O
the	O
RNases	O
Drosha	O
and	O
Dicer	O
,	O
cofactor	O
Pasha	O
,	O
and	O
the	O
pre	O
-	O
miRNA	O
transporter	O
exportin-5	O
,	O
which	O
modulate	O
miRNA	O
biogenesis	O
,	O
were	O
not	O
altered	O
after	O
transient	O
middle	O
cerebral	B
artery	I
occlusion	I
.	O

Thus	O
,	O
the	O
present	O
studies	O
indicate	O
a	O
critical	O
role	O
of	O
miRNAs	O
in	O
controlling	O
mRNA	O
transcription	O
and	O
translation	O
in	O
the	O
postischemic	O
brain	O
.	O

Bioinformatics	O
analysis	O
indicated	O
a	O
correlation	O
between	O
miRNAs	O
altered	O
to	O
several	O
mRNAs	O
known	O
to	O
mediate	O
inflammation	B
,	O
transcription	O
,	O
neuroprotection	O
,	O
receptors	O
function	O
,	O
and	O
ionic	O
homeostasis	O
.	O

Of	O
those	O
,	O
17	O
showed	O
>	O
5	O
fold	O
change	O
.	O

In	O
silico	O
analysis	O
showed	O
sequence	O
complementarity	O
of	O
eight	O
miRNAs	O
induced	O
after	O
focal	B
ischemia	I
to	O
877	O
promoters	O
indicating	O
the	O
possibility	O
of	O
noncoding	O
RNA	O
-	O
induced	O
activation	O
of	O
gene	O
expression	O
.	O

Antagomir	O
-	O
mediated	O
prevention	O
of	O
mir-145	O
expression	O
led	O
to	O
an	O
increased	O
protein	O
expression	O
of	O
its	O
downstream	O
target	O
superoxide	O
dismutase-2	O
in	O
the	O
postischemic	O
brain	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
approximately	O
22	O
nucleotides	O
long	O
,	O
noncoding	O
RNAs	O
that	O
control	O
cellular	O
function	O
by	O
either	O
degrading	O
mRNAs	O
or	O
arresting	O
their	O
translation	O
.	O

Transient	B
focal	I
ischemia	I
induces	O
extensive	O
temporal	O
changes	O
in	O
rat	O
cerebral	O
microRNAome	O
.	O

Of	O
the	O
238	O
miRNAs	O
evaluated	O
,	O
8	O
showed	O
increased	O
and	O
12	O
showed	O
decreased	O
expression	O
at	O
least	O
at	O
4	O
out	O
of	O
5	O
reperfusion	O
time	O
points	O
studied	O
between	O
3	O
h	O
and	O
3	O
days	O
compared	O
with	O
sham	O
.	O

To	O
understand	O
their	O
functional	O
significance	O
in	O
ischemic	O
pathophysiology	O
,	O
we	O
profiled	O
miRNAs	O
in	O
adult	O
rat	O
brain	O
as	O
a	O
function	O
of	O
reperfusion	O
time	O
after	O
transient	O
middle	B
cerebral	I
artery	I
occlusion	I
.	O

The	O
therapy	O
employed	O
,	O
in	O
a	O
single	O
baculoviral	O
vector	O
,	O
a	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
gene	O
promoter	O
and	O
the	O
repeated	O
target	O
sequences	O
of	O
three	O
miRNAs	O
that	O
are	O
enriched	O
in	O
astrocytes	O
but	O
downregulated	O
in	O
glioblastoma	B
cells	O
to	O
control	O
the	O
expression	O
of	O
the	O
herpes	O
simplex	O
virus	O
thymidine	O
kinase	O
(	O
HSVtk	O
)	O
gene	O
.	O

This	O
resulted	O
in	O
significantly	O
improved	O
in	O
vivo	O
selectivity	O
over	O
the	O
use	O
of	O
a	O
control	O
vector	O
without	O
miRNA	O
regulation	O
,	O
enabling	O
effective	O
elimination	O
of	O
human	B
glioma	I
xenografts	O
while	O
producing	O
negligible	O
toxic	O
effects	O
on	O
normal	O
astrocytes	O
.	O

In	O
the	O
context	O
of	O
cancer	B
suicide	O
gene	O
therapy	O
,	O
this	O
approach	O
may	O
lead	O
to	O
cytotoxic	O
effects	O
in	O
both	O
cancer	B
and	O
nontarget	O
normal	O
cells	O
.	O

Considering	O
microRNA	O
(	O
miRNA	O
)	O
function	O
in	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
,	O
we	O
have	O
developed	O
a	O
viral	O
vector	O
platform	O
combining	O
cellular	O
promoter	O
-	O
based	O
transcriptional	O
targeting	O
with	O
miRNA	O
regulation	O
for	O
a	O
glioma	B
suicide	O
gene	O
therapy	O
in	O
the	O
mouse	O
brain	O
.	O

Thus	O
,	O
incorporating	O
miRNA	O
regulation	O
into	O
a	O
transcriptional	O
targeting	O
vector	O
adds	O
an	O
extra	O
layer	O
of	O
security	O
to	O
prevent	O
off	O
-	O
target	O
transgene	O
expression	O
and	O
should	O
be	O
useful	O
for	O
the	O
development	O
of	O
gene	O
delivery	O
vectors	O
with	O
high	O
targeting	O
specificity	O
for	O
cancer	B
therapy	O
.	O

Transcriptional	O
targeting	O
using	O
a	O
tissue	O
-	O
specific	O
cellular	O
promoter	O
is	O
proving	O
to	O
be	O
a	O
powerful	O
means	O
for	O
restricting	O
transgene	O
expression	O
in	O
targeted	O
tissues	O
.	O

Combinatorial	O
control	O
of	O
suicide	O
gene	O
expression	O
by	O
tissue	O
-	O
specific	O
promoter	O
and	O
microRNA	O
regulation	O
for	O
cancer	B
therapy	O
.	O

The	O
possible	O
use	O
of	O
RNAi	O
in	O
the	O
treatment	O
of	O
spinocerebellar	B
ataxia	I
or	O
amyotrophic	B
lateral	I
sclerosis	I
,	O
with	O
its	O
advantages	O
and	O
pitfalls	O
and	O
possible	O
extensions	O
to	O
other	O
diseases	O
are	O
discussed	O
.	O

RNAi	O
has	O
moved	O
from	O
a	O
purely	O
experimental	O
technique	O
to	O
the	O
stage	O
of	O
potential	O
clinical	O
applications	O
.	O

RNAi	O
utilises	O
cellular	O
machinery	O
associated	O
with	O
the	O
processing	O
of	O
naturally	O
occurring	O
micro	O
RNA	O
(	O
miRNAs	O
)	O
.	O

RNAi	O
has	O
both	O
admirers	O
and	O
detractors	O
,	O
but	O
is	O
undeniably	O
a	O
technique	O
with	O
great	O
potential	O
,	O
which	O
has	O
come	O
a	O
long	O
way	O
in	O
the	O
short	O
time	O
since	O
its	O
discovery	O
.	O

RNA	O
interference	O
has	O
become	O
the	O
tool	O
of	O
choice	O
to	O
analyse	O
the	O
loss	O
-	O
of	O
-	O
function	O
of	O
individual	O
genes	O
and	O
has	O
been	O
exploited	O
to	O
identify	O
complex	O
regulatory	O
pathways	O
following	O
genomic	O
screening	O
.	O

Design	O
of	O
shRNAs	O
for	O
RNAi	O
-	O
A	O
lesson	O
from	O
pre	O
-	O
miRNA	O
processing	O
:	O
possible	O
clinical	O
applications	O
.	O

The	O
cellular	O
processing	O
of	O
shRNAs	O
shares	O
common	O
features	O
with	O
the	O
biogenesis	O
of	O
naturally	O
occurring	O
miRNA	O
such	O
as	O
cleavage	O
by	O
nuclear	O
RNase	O
Drosha	O
,	O
export	O
from	O
the	O
nucleus	O
,	O
processing	O
by	O
a	O
cytoplasmic	O
RNase	O
Dicer	O
,	O
and	O
incorporation	O
into	O
the	O
RNA	O
-	O
induced	O
silencing	O
complex	O
(	O
RISC	O
)	O
.	O

Each	O
step	O
has	O
a	O
crucial	O
influence	O
on	O
the	O
efficiency	O
of	O
RNAi	O
and	O
their	O
consideration	O
should	O
be	O
a	O
part	O
of	O
a	O
standard	O
experimental	O
design	O
.	O

More	O
recently	O
an	O
introduction	O
of	O
short	O
approximately	O
22	O
nucleotide	O
RNA	O
duplexes	O
has	O
become	O
the	O
standard	O
in	O
short	O
-	O
term	O
experiments	O
,	O
but	O
is	O
insufficient	O
for	O
long	O
-	O
term	O
knock	O
-	O
down	O
assays	O
.	O

Long	O
-	O
term	O
expression	O
of	O
siRNAs	O
has	O
been	O
achieved	O
by	O
in	O
vivo	O
transcription	O
from	O
plasmids	O
coding	O
for	O
short	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
.	O

Effective	O
use	O
of	O
RNAi	O
requires	O
detailed	O
knowledge	O
of	O
the	O
individual	O
steps	O
and	O
the	O
proteins	O
involved	O
,	O
as	O
well	O
as	O
the	O
similarities	O
and	O
distinctions	O
between	O
miRNA	O
and	O
siRNA	O
pathways	O
.	O

RNAi	O
was	O
originally	O
induced	O
by	O
the	O
introduction	O
of	O
long	O
double	O
stranded	O
RNAs	O
(	O
dsRNAs	O
)	O
into	O
cells	O
in	O
which	O
the	O
RNA	O
was	O
cleaved	O
into	O
short	O
RNAs	O
which	O
effectively	O
interfered	O
with	O
a	O
transcription	O
of	O
cognate	O
mRNA	O
.	O

[	O
AD	O
-	O
FTLD	O
spectrum	O
--	O
new	O
findings	O
on	O
risk	O
genes	O
in	O
neurodegenerative	B
diseases	I
]	O
.	O

Our	O
microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	B
brain	I
injury	I
has	O
shown	O
that	O
some	O
microRNA	O
such	O
as	O
miR-21	O
could	O
be	O
involved	O
in	O
the	O
intricate	O
process	O
of	O
TBI	B
course	O
.	O

Furthermore	O
,	O
we	O
revealed	O
global	O
up	O
-	O
regulation	O
of	O
miR-21	O
expression	O
within	O
all	O
the	O
four	O
time	O
points	O
post	O
injury	B
.	O

Our	O
research	O
revealed	O
that	O
136	O
miRNAs	O
were	O
expressing	O
at	O
6	O
h	O
post	O
injury	B
,	O
in	O
which	O
13	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
14	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
118	O
miRNAs	O
were	O
expressing	O
at	O
24	O
h	O
post	O
injury	B
,	O
in	O
which	O
4	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
23	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
149	O
miRNAs	O
were	O
expressing	O
at	O
48	O
h	O
post	O
injury	B
,	O
in	O
which	O
16	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
11	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
and	O
203	O
miRNAs	O
were	O
expressing	O
at	O
72	O
h	O
post	O
injury	B
,	O
in	O
which	O
19	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
5	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
.	O

The	O
qRT	O
-	O
PCR	O
results	O
indicated	O
good	O
consistency	O
with	O
the	O
results	O
of	O
the	O
microarray	O
method	O
.	O

Finally	O
,	O
we	O
utilized	O
qRT	O
-	O
PCR	O
methods	O
to	O
verify	O
the	O
microarray	O
results	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
very	O
important	O
regulators	O
of	O
biological	O
processes	O
such	O
as	O
development	O
,	O
cellular	O
differentiation	O
,	O
and	O
tumor	B
generation	O
.	O

MiRNA	O
microarray	O
has	O
been	O
found	O
to	O
be	O
a	O
high	O
throughput	O
global	O
analysis	O
tool	O
for	O
detecting	O
miRNA	O
expression	O
profiling	O
,	O
and	O
miRNA	O
expression	O
profiling	O
will	O
facilitate	O
the	O
study	O
of	O
the	O
biological	O
function	O
of	O
miRNAs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
miRNA	O
expression	O
level	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	B
brain	I
injury	I
using	O
microarray	O
method	O
.	O

We	O
choose	O
several	O
time	O
points	O
post	O
brain	B
injury	I
:	O
6	O
h	O
,	O
24	O
h	O
,	O
48	O
h	O
and	O
72	O
h	O
,	O
respectively	O
,	O
to	O
reveal	O
differential	O
expression	O
of	O
miRNAs	O
in	O
rat	O
brain	O
cortex	O
compared	O
with	O
control	O
groups	O
.	O

Microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	B
brain	I
injury	I
.	O

Ectopic	O
expression	O
of	O
miR-29b	O
decreased	O
hPGRN	O
expression	O
at	O
the	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

To	O
examine	O
the	O
direct	O
effect	O
of	O
manipulating	O
endogenous	O
miR-29b	O
on	O
hPGRN	O
expression	O
,	O
we	O
established	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
expresses	O
hPGRN	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
.	O

Endogenous	O
hPGRN	O
in	O
HEK	O
293	O
cells	O
was	O
also	O
regulated	O
by	O
miR-29b	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
miR-29b	O
with	O
locked	O
nucleic	O
acid	O
increased	O
the	O
production	O
and	O
secretion	O
of	O
hPGRN	O
in	O
NIH3T3	O
cells	O
.	O

How	O
progranulin	O
(	O
PGRN	O
)	O
expression	O
is	O
regulated	O
is	O
largely	O
unknown	O
.	O

Progranulin	O
deficiency	O
is	O
thought	O
to	O
cause	O
some	O
forms	O
of	O
frontotemporal	B
dementia	I
(	O
FTD	B
)	O
,	O
a	O
major	O
early	O
-	O
onset	O
age	O
-	O
dependent	O
neurodegenerative	B
disease	I
.	O

miR-29b	O
downregulates	O
the	O
expression	O
of	O
luciferase	O
through	O
hPGRN	O
or	O
mouse	O
PGRN	O
(	O
mPGRN	O
)	O
3'UTRs	O
,	O
and	O
the	O
regulation	O
was	O
abolished	O
by	O
mutations	O
in	O
the	O
miR-29b	O
binding	O
site	O
.	O

We	O
identified	O
an	O
evolutionarily	O
conserved	O
binding	O
site	O
for	O
microRNA-29b	O
(	O
miR-29b	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
of	O
the	O
human	O
PGRN	O
(	O
hPGRN	O
)	O
mRNA	O
.	O

MicroRNA-29b	O
regulates	O
the	O
expression	O
level	O
of	O
human	O
progranulin	O
,	O
a	O
secreted	O
glycoprotein	O
implicated	O
in	O
frontotemporal	B
dementia	I
.	O

These	O
findings	O
identify	O
miR-29b	O
as	O
a	O
novel	O
posttranscriptional	O
regulator	O
of	O
PGRN	O
expression	O
,	O
raising	O
the	O
possibility	O
that	O
miR-29b	O
or	O
other	O
miRNAs	O
might	O
be	O
targeted	O
therapeutically	O
to	O
increase	O
hPGRN	O
levels	O
in	O
some	O
FTD	B
patients	O
.	O

We	O
studied	O
the	O
expression	O
of	O
selected	O
miRNAs	O
following	O
infection	B
of	O
CBA	O
mice	O
with	O
Plasmodium	O
berghei	O
ANKA	O
(	O
PbA	O
)	O
,	O
which	O
causes	O
cerebral	B
malaria	I
(	O
CM	B
)	O
,	O
or	O
Plasmodium	O
berghei	O
K173	O
(	O
PbK	O
)	O
,	O
which	O
causes	O
severe	O
malaria	B
but	O
without	O
cerebral	O
complications	O
,	O
termed	O
non	O
-	O
CM	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
posttranscriptional	O
regulatory	O
molecules	O
that	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
immune	O
responses	O
,	O
but	O
their	O
role	O
in	O
the	O
immune	O
response	O
to	O
Plasmodium	B
infection	I
is	O
unknown	O
.	O

Differential	O
MicroRNA	O
Expression	O
in	O
Experimental	O
Cerebral	O
and	O
Noncerebral	O
Malaria	B
.	O

To	O
investigate	O
the	O
involvement	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
in	O
CM	B
-	O
resistant	O
mice	O
,	O
we	O
assessed	O
the	O
expression	O
levels	O
in	O
gamma	O
interferon	O
knockout	O
(	O
IFN	O
-	O
γ	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
on	O
a	O
C57BL	O
/	O
6	O
genetic	O
background	O
.	O

In	O
contrast	O
,	O
no	O
miRNA	O
changes	O
were	O
detected	O
in	O
the	O
heart	O
,	O
an	O
organ	O
with	O
no	O
known	O
pathology	O
during	O
acute	B
malaria	I
.	O

We	O
identified	O
three	O
miRNAs	O
that	O
were	O
differentially	O
expressed	O
in	O
the	O
brain	O
of	O
PbA	O
-	O
infected	O
CBA	O
mice	O
:	O
let7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
.	O

The	O
differential	O
expression	O
profiles	O
of	O
selected	O
miRNAs	O
(	O
let-7i	O
,	O
miR-27a	O
,	O
miR-150	O
,	O
miR-126	O
,	O
miR-210	O
,	O
and	O
miR-155	O
)	O
were	O
analyzed	O
in	O
mouse	O
brain	O
and	O
heart	O
tissue	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
the	O
CBA	O
mouse	O
at	O
least	O
,	O
miRNA	O
may	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	B
.	O

Overexpression	O
of	O
these	O
three	O
miRNAs	O
during	O
PbA	O
,	O
but	O
not	O
PbK	O
,	O
infection	B
in	O
WT	O
mice	O
may	O
be	O
critical	O
for	O
the	O
triggering	O
of	O
the	O
neurological	B
syndrome	I
via	O
regulation	O
of	O
their	O
potential	O
downstream	O
targets	O
.	O

The	O
expression	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
was	O
unchanged	O
in	O
both	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
IFN	O
-	O
γ	O
(	O
-	O
/	O
-	O
)	O
mice	O
following	O
infection	B
.	O

[	O
Genetic	O
and	O
molecular	O
abnormalities	O
of	O
glioblastomas	B
(	O
GBM	B
)	O
]	O
.	O

This	O
presentation	O
reports	O
a	O
series	O
of	O
data	O
dealing	O
with	O
recurrent	O
genetic	O
abnormalities	O
and	O
gene	O
expression	O
profiles	O
that	O
characterize	O
primary	B
glioblastomas	I
and	O
secondary	B
glioblastomas	I
resulting	O
from	O
the	O
transformation	O
of	O
low	B
grade	I
tumors	I
(	O
grade	O
II	O
and	O
III	O
astrocytomas	B
and	O
oligodendrogliomas	B
)	O
.	O

Finally	O
,	O
a	O
short	O
description	O
of	O
exosomes	O
as	O
vectors	O
of	O
tumor	B
information	O
will	O
be	O
presented	O
.	O

The	O
most	O
recent	O
aspects	O
of	O
the	O
concept	O
of	O
tumor	B
stem	O
cells	O
that	O
may	O
explain	O
the	O
relentless	O
growth	O
of	O
GBM	B
will	O
be	O
reported	O
.	O

Molecular	O
features	O
of	O
tumor	B
neoangiogenesis	O
will	O
be	O
described	O
.	O

Epigenetic	O
alterations	O
and	O
deregulation	O
of	O
gene	O
expression	O
by	O
microRNAs	O
(	O
miRs	O
)	O
will	O
be	O
also	O
included	O
.	O

Some	O
aspects	O
of	O
tumor	B
predisposition	O
will	O
be	O
also	O
discussed	O
.	O

In	O
an	O
effort	O
to	O
shed	O
light	O
on	O
consequences	O
mediated	O
by	O
p53	O
inactivation	O
in	O
gliomas	B
,	O
we	O
established	O
the	O
Tet	O
-	O
On	O
system	O
for	O
p53	O
in	O
the	O
LN	O
-	O
Z308	O
glioblastoma	B
cell	O
line	O
.	O

p53	O
is	O
activated	O
upon	O
various	O
kinds	O
of	O
cellular	O
stress	O
leading	O
to	O
apoptosis	O
or	O
cell	O
cycle	O
arrest	O
,	O
but	O
is	O
also	O
implicated	O
in	O
complex	O
biological	O
processes	O
such	O
as	O
inhibition	O
of	O
angiogenesis	O
and	O
metastasis	O
.	O

Oxygen	O
deprivation	O
,	O
an	O
important	O
cellular	O
stress	O
,	O
revealed	O
MIC-1	O
as	O
an	O
anoxia	B
responsive	O
gene	O
in	O
glioblastoma	B
cell	O
lines	O
.	O

The	O
macrophage	O
inhibitory	O
cytokine-1	O
(	O
MIC-1	O
)	O
gene	O
was	O
identified	O
as	O
a	O
most	O
prominent	O
p53	O
target	O
gene	O
upon	O
gene	O
expression	O
profiling	O
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
MIC-1	O
in	O
LN	O
-	O
Z308	O
cell	O
line	O
completely	O
abolished	O
its	O
inherent	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
while	O
proliferation	O
in	O
vitro	O
was	O
not	O
affected	O
.	O

MIC-1	O
up	O
-	O
regulation	O
by	O
anoxia	B
is	O
mediated	O
through	O
an	O
alternative	O
,	O
p53	O
and	O
hypoxia	O
inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
independent	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
MIC-1	O
is	O
an	O
important	O
downstream	O
mediator	O
of	O
p53	O
function	O
,	O
while	O
acting	O
itself	O
as	O
an	O
intercessor	O
of	O
cellular	O
stress	O
signaling	O
and	O
exerting	O
anti	O
-	O
tumorigenic	O
activities	O
.	O

In	O
the	O
present	O
experimental	O
model	O
MIC-1	O
may	O
exert	O
its	O
anti	O
-	O
tumorigenic	O
properties	O
via	O
a	O
paracrine	O
mechanism	O
mediated	O
by	O
host	O
cells	O
in	O
vivo	O
.	O

Human	O
astrocytic	B
brain	I
tumors	I
select	O
for	O
mutations	O
in	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
early	O
in	O
malignant	O
progression	O
.	O

Anoxia	B
induces	O
macrophage	O
inhibitory	O
cytokine-1	O
(	O
MIC-1	O
)	O
in	O
glioblastoma	B
cells	O
independently	O
of	O
p53	O
and	O
HIF-1	O
.	O

Reduction	O
of	O
miR-21	O
induces	O
glioma	B
cell	O
apoptosis	O
via	O
activating	O
caspase	O
9	O
and	O
3	O
.	O
Extensive	O
data	O
indicate	O
that	O
miR-21	O
plays	O
a	O
critical	O
role	O
in	O
gliomagenesis	O
,	O
however	O
,	O
knowledge	O
is	O
limited	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miR-21	O
,	O
including	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
migration	O
.	O

Moreover	O
,	O
reduction	O
of	O
miR-21	O
activated	O
caspase	O
9	O
and	O
3	O
,	O
which	O
may	O
be	O
mediated	O
by	O
modulating	O
multiple	O
potential	O
target	O
genes	O
,	O
such	O
as	O
TIMP3	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
miR-21	O
expression	O
by	O
antisense	O
oligonucleotides	O
inhibited	O
glioma	B
cell	O
proliferation	O
and	O
induced	O
cell	O
apoptosis	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
miR-21	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
cell	O
apoptosis	O
in	O
gliomas	B
and	O
may	O
serve	O
as	O
a	O
target	O
for	O
effective	O
therapies	O
.	O

Membership	O
in	O
this	O
group	O
is	O
defined	O
based	O
on	O
sequence	O
similarity	O
near	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
end	O
:	O
all	O
include	O
the	O
sequence	O
AGCAGC	O
.	O

Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
the	O
evolution	O
of	O
miR-15	O
/	O
107	O
group	O
member	O
genes	O
;	O
(	O
2	O
)	O
the	O
expression	O
levels	O
of	O
miRNAs	O
in	O
mammalian	O
tissues	O
;	O
(	O
3	O
)	O
evidence	O
for	O
overlapping	O
gene	O
-	O
regulatory	O
functions	O
by	O
different	O
miRNAs	O
;	O
(	O
4	O
)	O
the	O
normal	O
biochemical	O
pathways	O
regulated	O
by	O
miR-15	O
/	O
107	O
group	O
miRNAs	O
;	O
and	O
(	O
5	O
)	O
the	O
roles	O
played	O
by	O
these	O
miRNAs	O
in	O
human	O
diseases	O
.	O

While	O
all	O
vertebrates	O
studied	O
to	O
date	O
express	O
miR-15a	O
,	O
miR-15b	O
,	O
miR-16	O
,	O
miR-103	O
,	O
and	O
miR-107	O
,	O
mammals	O
alone	O
are	O
known	O
to	O
express	O
miR-195	O
,	O
miR-424	O
,	O
miR-497	O
,	O
miR-503	O
,	O
and	O
miR-646	O
.	O

Phylogeny	O
of	O
this	O
group	O
of	O
miRNAs	O
is	O
incomplete	O
;	O
thus	O
,	O
a	O
definitive	O
taxonomic	O
classification	O
(	O
e.g.	O
,	O
designation	O
as	O
a	O
""""	O
superfamily	O
""""	O
)	O
is	O
currently	O
not	O
possible	O
.	O

We	O
present	O
data	O
on	O
the	O
expression	O
of	O
all	O
known	O
miR-15	O
/	O
107	O
group	O
members	O
in	O
human	O
cerebral	O
cortical	O
gray	O
matter	O
and	O
white	O
matter	O
using	O
new	O
miRNA	O
profiling	O
microarrays	O
.	O

Multiple	O
different	O
miRNAs	O
in	O
the	O
miR-15	O
/	O
107	O
group	O
are	O
expressed	O
at	O
moderate	O
to	O
high	O
levels	O
in	O
human	O
tissues	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
genes	O
:	O
evolutionary	O
biology	O
,	O
cellular	O
functions	O
,	O
and	O
roles	O
in	O
human	O
diseases	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
is	O
increasingly	O
appreciated	O
to	O
serve	O
key	O
functions	O
in	O
humans	O
.	O

These	O
miRNAs	O
regulate	O
gene	O
expression	O
involved	O
in	O
cell	O
division	O
,	O
metabolism	O
,	O
stress	O
response	O
,	O
and	O
angiogenesis	O
in	O
vertebrate	O
species	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
has	O
also	O
been	O
implicated	O
in	O
human	O
cancers	B
,	O
cardiovascular	B
disease	I
and	O
neurodegenerative	B
disease	I
,	O
including	O
Alzheimer	B
's	I
disease	I
.	O

In	O
conclusion	O
,	O
the	O
miR-15	O
/	O
107	O
group	O
of	O
miRNA	O
genes	O
is	O
a	O
fascinating	O
topic	O
of	O
study	O
for	O
evolutionary	O
biologists	O
,	O
miRNA	O
biochemists	O
,	O
and	O
clinically	O
oriented	O
translational	O
researchers	O
alike	O
.	O

We	O
show	O
new	O
data	O
from	O
cultured	O
H4	O
cancer	B
cells	O
that	O
demonstrate	O
similarities	O
in	O
mRNAs	O
targeted	O
by	O
miR-16	O
and	O
miR-103	O
and	O
also	O
support	O
the	O
importance	O
of	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
seed	O
region	O
in	O
mRNA	O
target	O
recognition	O
.	O

There	O
is	O
extensive	O
overlap	O
in	O
the	O
mRNAs	O
targeted	O
by	O
miR-15	O
/	O
107	O
group	O
members	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
comprising	O
21	O
-	O
23	O
nucleotides	O
that	O
regulate	O
gene	O
expression	O
by	O
transcriptionally	O
repressing	O
their	O
complementary	O
mRNAs	O
.	O

Let-7	O
microRNA	O
inhibits	O
the	O
proliferation	O
of	O
human	B
glioblastoma	I
cells	O
.	O

Transfection	O
of	O
let-7	O
miRNA	O
reduced	O
expression	O
of	O
pan	O
-	O
RAS	O
,	O
N	O
-	O
RAS	O
,	O
and	O
K	O
-	O
RAS	O
in	O
the	O
glioblastoma	B
cells	O
.	O

Human	B
glioblastoma	I
cells	O
(	O
U251	O
or	O
U87	O
cells	O
)	O
were	O
transfected	O
with	O
let-7	O
miRNA	O
and	O
assayed	O
for	O
in	O
-	O
vitro	O
proliferation	O
,	O
migration	O
,	O
and	O
in	O
-	O
vivo	O
tumor	B
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
tumorigenic	O
effect	O
of	O
let-7	O
miRNA	O
in	O
glioblastoma	B
cells	O
.	O

In	O
particular	O
,	O
let-7	O
miRNA	O
has	O
been	O
postulated	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
in	O
various	O
cancer	B
cells	O
,	O
but	O
not	O
yet	O
in	O
glioblastoma	B
.	O

These	O
results	O
indicate	O
that	O
let-7	O
miRNA	O
has	O
an	O
anti	O
-	O
tumorigenic	O
effect	O
on	O
glioblastoma	B
cells	O
,	O
and	O
suggest	O
possible	O
use	O
of	O
let-7	O
miRNA	O
for	O
treating	O
glioblastoma	B
.	O

However	O
,	O
let-7	O
miRNA	O
exerted	O
no	O
effect	O
on	O
the	O
proliferation	O
of	O
normal	O
human	O
astrocytes	O
.	O

Let-7	O
miRNA	O
also	O
reduced	O
the	O
in	O
-	O
vitro	O
proliferation	O
and	O
migration	O
of	O
the	O
cells	O
,	O
and	O
reduced	O
the	O
sizes	O
of	O
the	O
tumors	B
produced	O
after	O
transplantation	O
into	O
nude	O
mice	O
.	O

MiRNAs	O
microarray	O
analysis	O
results	O
showed	O
that	O
125	O
miRNAs	O
were	O
detected	O
in	O
the	O
hippocampus	O
of	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
TLE	B
rats	O
and	O
normal	O
rats	O
.	O

To	O
understand	O
the	O
role	O
of	O
miRNAs	O
in	O
the	O
molecular	O
mechanisms	O
of	O
temporal	B
lobe	I
epilepsy	I
(	O
TLE	B
)	O
,	O
we	O
investigated	O
the	O
changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiles	O
of	O
chronic	O
TLE	B
rat	O
models	O
.	O

Temporal	B
lobe	I
epilepsy	I
induces	O
differential	O
expression	O
of	O
hippocampal	O
miRNAs	O
including	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
.	O

let-7e	O
was	O
detected	O
down	O
-	O
regulated	O
expression	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
2days	O
,	O
7days	O
,	O
50days	O
after	O
SE	B
and	O
up	O
-	O
regulated	O
expression	O
at	O
12h	O
,	O
24h	O
,	O
10days	O
,	O
30days	O
after	O
SE	B
,	O
which	O
was	O
significantly	O
up	O
-	O
regulated	O
expression	O
at	O
24h	O
after	O
SE	B
(	O
10.49	O
folds	O
,	O
P<0.01	O
)	O
.	O

miR-23a	O
/	O
b	O
was	O
detected	O
down	O
-	O
regulated	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
2days	O
,	O
7days	O
,	O
10days	O
,	O
30days	O
after	O
SE	B
and	O
significantly	O
up	O
-	O
regulated	O
at	O
24h	O
(	O
4.49	O
folds	O
P<0.01	O
)	O
,	O
50d	O
(	O
2.4	O
folds	O
,	O
P<0.01	O
)	O
after	O
SE	B
.	O
TLE	B
alters	O
the	O
expression	O
levels	O
of	O
a	O
subset	O
of	O
miRNAs	O
in	O
the	O
hippocampus	O
and	O
these	O
deregulated	O
miRNAs	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
epilepsy	B
directly	O
or	O
indirectly	O
.	O

Compared	O
with	O
normal	O
rats	O
(	O
control	O
group	O
)	O
,	O
23	O
of	O
the	O
125	O
miRNAs	O
were	O
expressed	O
differentially	O
in	O
TLE	B
rats	O
including	O
5	O
down	O
-	O
regulated	O
miRNAs	O
(	O
let-7e	O
included	O
)	O
and	O
18	O
up	O
-	O
regulated	O
miRNAs	O
(	O
miR-23a	O
/	O
b	O
included	O
)	O
.	O

Furthermore	O
,	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
analysis	O
in	O
rat	O
hippocampus	O
were	O
performed	O
by	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
24h	O
,	O
2days	O
,	O
7days,10days	O
,	O
30days,50days	O
after	O
induction	O
of	O
status	B
epilepticus	I
(	O
SE	B
)	O
.	O

Also	O
the	O
temporal	O
change	O
of	O
the	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
expression	O
in	O
the	O
epileptogenesis	O
indicated	O
their	O
underlying	O
functions	O
on	O
TLE	B
.	O

The	O
findings	O
also	O
indicate	O
that	O
allopregnanolone	O
and	O
perhaps	O
other	O
neurosteroid	O
-	O
like	O
compounds	O
might	O
represent	O
potential	O
biomarkers	O
or	O
therapies	O
for	O
multiple	B
sclerosis	I
.	O

These	O
multi	O
-	O
platform	O
studies	O
point	O
to	O
impaired	O
neurosteroidogenesis	O
in	O
both	O
multiple	B
sclerosis	I
and	O
experimental	O
autoimmune	B
encephalomyelitis	I
.	O

Allopregnanolone	O
treatment	O
of	O
the	O
experimental	O
autoimmune	B
encephalomyelitis	I
mouse	O
model	O
limited	O
the	O
associated	O
neuropathology	O
,	O
including	O
neuroinflammation	B
,	O
myelin	O
and	O
axonal	B
injury	I
and	O
reduced	O
neurobehavioral	O
deficits	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Levels	O
of	O
important	O
neurosteroids	O
,	O
including	O
allopregnanolone	O
,	O
were	O
suppressed	O
in	O
the	O
white	O
matter	O
of	O
patients	O
with	O
multiple	B
sclerosis	I
(	O
P	O
<	O
0.05	O
)	O
.	O

Induction	O
of	O
the	O
murine	O
micro	O
-	O
RNAs	O
,	O
miR-338	O
and	O
miR-155	O
,	O
accompanied	O
by	O
diminished	O
expression	O
of	O
neurosteroidogenic	O
enzymes	O
and	O
allopregnanolone	O
,	O
was	O
also	O
observed	O
in	O
the	O
brains	O
of	O
mice	O
with	O
experimental	O
autoimmune	B
encephalomyelitis	I
(	O
P	O
<	O
0.05	O
)	O
.	O

Analysis	O
of	O
the	O
neurosteroidogenic	O
pathways	O
targeted	O
by	O
micro	O
-	O
RNAs	O
revealed	O
suppression	O
of	O
enzyme	O
transcript	O
and	O
protein	O
levels	O
in	O
the	O
white	O
matter	O
of	O
patients	O
with	O
multiple	B
sclerosis	I
(	O
P	O
<	O
0.05	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
firefly	O
/	O
Renilla	O
luciferase	O
micro	O
-	O
RNA	O
target	O
knockdown	O
experiments	O
(	O
P	O
<	O
0.05	O
)	O
and	O
detection	O
of	O
specific	O
micro	O
-	O
RNAs	O
by	O
in	O
situ	O
hybridization	O
in	O
the	O
brains	O
of	O
patients	O
with	O
or	O
without	O
multiple	B
sclerosis	I
.	O

These	O
observations	O
were	O
verified	O
using	O
the	O
in	O
vivo	O
multiple	B
sclerosis	I
model	O
,	O
experimental	O
autoimmune	B
encephalomyelitis	I
.	O

Brains	O
of	O
patients	O
with	O
or	O
without	O
multiple	B
sclerosis	I
demonstrated	O
differential	O
expression	O
of	O
multiple	O
micro	O
-	O
RNAs	O
,	O
but	O
expression	O
of	O
three	O
neurosteroid	O
synthesis	O
enzyme	O
-	O
specific	O
micro	O
-	O
RNAs	O
(	O
miR-338	O
,	O
miR-155	O
and	O
miR-491	O
)	O
showed	O
a	O
bias	O
towards	O
induction	O
in	O
patients	O
with	O
multiple	B
sclerosis	I
(	O
P	O
<	O
0.05	O
)	O
.	O

High	O
-	O
throughput	O
technologies	O
have	O
led	O
to	O
advances	O
in	O
the	O
recognition	O
of	O
disease	O
pathways	O
and	O
their	O
underlying	O
mechanisms	O
.	O

To	O
investigate	O
the	O
impact	O
of	O
micro	O
-	O
RNAs	O
on	O
the	O
disease	O
process	O
in	O
multiple	B
sclerosis	I
,	O
a	O
prototypic	B
inflammatory	I
neurological	I
disorder	I
,	O
we	O
examined	O
cerebral	O
white	O
matter	O
from	O
patients	O
with	O
or	O
without	O
the	O
disease	O
by	O
micro	O
-	O
RNA	O
profiling	O
,	O
together	O
with	O
confirmatory	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
immunoblotting	O
and	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Impaired	O
neurosteroid	O
synthesis	O
in	O
multiple	B
sclerosis	I
.	O

This	O
review	O
reports	O
the	O
current	O
knowledge	O
of	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
in	O
pituitary	B
adenomas	I
,	O
focusing	O
on	O
recent	O
microarray	O
data	O
.	O

Moreover	O
,	O
a	O
discussion	O
is	O
provided	O
concerning	O
the	O
possible	O
role	O
of	O
validated	O
and	O
putative	O
targets	O
of	O
the	O
most	O
dysregulated	O
miRNA	O
in	O
pituitary	B
adenoma	I
pathogenesis	O
.	O

MicroRNAs	O
and	O
possible	O
role	O
in	O
pituitary	B
adenoma	I
.	O

These	O
findings	O
indicate	O
that	O
miR-107	O
contributes	O
to	O
GRN	O
expression	O
regulation	O
with	O
implications	O
for	O
brain	B
disorders	I
.	O

In	O
brain	O
tissue	O
subjacent	O
to	O
1.0	O
mm	O
depth	O
controlled	O
cortical	O
impact	O
,	O
surviving	O
hippocampal	O
neurons	O
show	O
decreased	O
miR-107	O
with	O
augmentation	O
of	O
neuronal	O
GRN	O
expression	O
.	O

We	O
also	O
tested	O
a	O
mouse	O
model	O
where	O
miR-107	O
has	O
been	O
shown	O
to	O
be	O
down	O
-	O
regulated	O
.	O

However	O
,	O
GRN	O
regulation	O
expression	O
is	O
poorly	O
understood	O
.	O

A	O
high	O
-	O
throughput	O
experimental	O
microRNA	O
assay	O
showed	O
that	O
GRN	O
is	O
the	O
strongest	O
target	O
for	O
miR-107	O
in	O
human	O
H4	O
neuroglioma	B
cells	O
.	O

miR-107	O
has	O
been	O
implicated	O
in	O
Alzheimer	B
's	I
disease	I
pathogenesis	O
,	O
and	O
sequence	O
elements	O
in	O
the	O
open	O
reading	O
frame	O
-	O
rather	O
than	O
the	O
3	O
'	O
untranslated	O
region	O
-	O
of	O
GRN	O
mRNA	O
are	O
recognized	O
by	O
miR-107	O
and	O
are	O
highly	O
conserved	O
among	O
vertebrate	O
species	O
.	O

To	O
better	O
understand	O
the	O
mechanism	O
of	O
this	O
interaction	O
,	O
FLAG	O
-	O
tagged	O
Argonaute	O
constructs	O
were	O
used	O
following	O
miR-107	O
transfection	O
.	O

miR-107	O
regulates	O
granulin	O
/	O
progranulin	O
with	O
implications	O
for	O
traumatic	B
brain	I
injury	I
and	O
neurodegenerative	B
disease	I
.	O

Granulin	O
(	O
GRN	O
,	O
or	O
progranulin	O
)	O
is	O
a	O
protein	O
involved	O
in	O
wound	B
repair	O
,	O
inflammation	B
,	O
and	O
neoplasia	B
.	O

GRN	O
has	O
also	O
been	O
directly	O
implicated	O
in	O
frontotemporal	B
dementia	I
and	O
may	O
contribute	O
to	O
Alzheimer	B
's	I
disease	I
pathogenesis	O
.	O

GRN	O
mRNA	O
interacts	O
preferentially	O
with	O
Argonaute	O
2	O
.	O
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
indicate	O
that	O
regulation	O
of	O
GRN	O
by	O
miR-107	O
may	O
be	O
functionally	O
important	O
.	O

Glucose	O
supplementation	O
in	O
cultured	O
cells	O
that	O
leads	O
to	O
increased	O
miR-107	O
levels	O
also	O
results	O
in	O
decreased	O
GRN	O
expression	O
,	O
including	O
changes	O
in	O
cell	O
compartmentation	O
and	O
decreased	O
secretion	O
of	O
GRN	O
protein	O
.	O

This	O
effect	O
was	O
eliminated	O
following	O
miR-107	O
transfection	O
.	O

Many	O
miRNA	O
targets	O
have	O
been	O
computationally	O
predicted	O
but	O
only	O
a	O
limited	O
number	O
of	O
these	O
were	O
experimentally	O
validated	O
.	O

However	O
,	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
are	O
complex	O
and	O
very	O
often	O
there	O
are	O
numerous	O
putative	O
miRNA	O
recognition	O
sites	O
in	O
mRNAs	O
.	O

Therefore	O
,	O
it	O
is	O
of	O
particular	O
interest	O
to	O
reliably	O
predict	O
potential	O
miRNA	O
targets	O
which	O
might	O
be	O
involved	O
in	O
these	O
diseases	O
.	O

Both	O
the	O
deregulation	O
of	O
genes	O
controlled	O
by	O
miRNAs	O
and	O
the	O
altered	O
miRNA	O
expression	O
have	O
been	O
linked	O
to	O
many	O
disorders	O
,	O
including	O
cancer	B
,	O
cardiovascular	O
,	O
metabolic	O
and	O
neurodegenerative	B
diseases	I
.	O

In	O
this	O
review	O
,	O
currently	O
available	O
and	O
frequently	O
used	O
computational	O
tools	O
for	O
miRNA	O
target	O
prediction	O
,	O
i.e.	O
,	O
PicTar	O
,	O
TargetScan	O
,	O
DIANA	O
-	O
microT	O
,	O
miRanda	O
,	O
rna22	O
and	O
PITA	O
are	O
outlined	O
and	O
various	O
practical	O
aspects	O
of	O
miRNA	O
target	O
analysis	O
are	O
extensively	O
discussed	O
.	O

Hence	O
,	O
finding	O
a	O
functional	O
miRNA	O
target	O
is	O
still	O
a	O
challenging	O
task	O
.	O

Although	O
a	O
variety	O
of	O
miRNA	O
target	O
prediction	O
algorithms	O
are	O
available	O
,	O
results	O
of	O
their	O
application	O
are	O
often	O
inconsistent	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
non	O
-	O
coding	O
RNAs	O
that	O
control	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
.	O

These	O
small	O
regulatory	O
molecules	O
play	O
a	O
key	O
role	O
in	O
the	O
majority	O
of	O
biological	O
processes	O
and	O
their	O
expression	O
is	O
also	O
tightly	O
regulated	O
.	O

Practical	O
Aspects	O
of	O
microRNA	O
Target	O
Prediction	O
.	O

Moreover	O
,	O
the	O
performance	O
of	O
three	O
algorithms	O
(	O
PicTar	O
,	O
TargetScan	O
and	O
DIANA	O
-	O
microT	O
)	O
is	O
both	O
demonstrated	O
and	O
evaluated	O
by	O
performing	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
miRNA	O
interactions	O
with	O
mRNAs	O
derived	O
from	O
genes	O
triggering	O
hereditary	O
neurological	B
disorders	I
known	O
as	O
trinucleotide	B
repeat	I
expansion	I
diseases	I
(	O
TREDs	B
)	O
,	O
such	O
as	O
Huntington	B
's	I
disease	I
(	O
HD	B
)	O
,	O
a	O
number	O
of	O
spinocerebellar	B
ataxias	I
(	O
SCAs	B
)	O
,	O
and	O
myotonic	B
dystrophy	I
type	I
1	I
(	O
DM1	B
)	O
.	O

Our	O
study	O
shows	O
that	O
one	O
aspect	O
of	O
miR-155	O
function	O
is	O
the	O
promotion	O
of	O
T	O
cell	O
-	O
dependent	O
tissue	O
inflammation	B
,	O
suggesting	O
that	O
miR-155	O
might	O
be	O
a	O
promising	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmune	B
disorders	I
.	O

miR-155	O
functions	O
in	O
the	O
hematopoietic	O
compartment	O
to	O
promote	O
the	O
development	O
of	O
inflammatory	O
T	O
cells	O
including	O
the	O
T	O
helper	O
17	O
(	O
Th17	O
)	O
cell	O
and	O
Th1	O
cell	O
subsets	O
.	O

Furthermore	O
,	O
the	O
major	O
contribution	O
of	O
miR-155	O
to	O
EAE	B
was	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
intrinsic	O
,	O
whereas	O
miR-155	O
was	O
also	O
required	O
for	O
optimum	O
dendritic	O
cell	O
production	O
of	O
cytokines	O
that	O
promoted	O
Th17	O
cell	O
formation	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
miR-155	O
during	O
an	O
autoimmune	B
inflammatory	I
disease	I
.	O

Consistent	O
with	O
a	O
positive	O
role	O
for	O
miR-155	O
in	O
mediating	O
inflammatory	O
responses	O
,	O
Mir155	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
highly	O
resistant	O
to	O
experimental	B
autoimmune	I
encephalomyelitis	I
(	O
EAE	B
)	O
.	O

MicroRNA-155	O
promotes	O
autoimmune	B
inflammation	I
by	O
enhancing	O
inflammatory	O
T	O
cell	O
development	O
.	O

Mammalian	O
noncoding	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
gene	O
regulators	O
that	O
have	O
been	O
linked	O
to	O
immune	O
system	O
function	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
in	O
cancer	B
:	O
discovery	O
,	O
function	O
and	O
future	O
perspectives	O
.	O

Expression	O
of	O
these	O
miRNAs	O
inhibits	O
cell	O
proliferation	O
,	O
promotes	O
apoptosis	O
of	O
cancer	B
cells	O
,	O
and	O
suppresses	O
tumorigenicity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
encoded	O
by	O
the	O
miR-15	O
/	O
16	O
cluster	O
are	O
known	O
to	O
act	O
as	O
tumor	O
suppressors	O
.	O

Down	O
-	O
regulation	O
of	O
these	O
miRNAs	O
has	O
been	O
reported	O
in	O
chronic	B
lymphocytic	I
lymphoma	I
(	O
CLL	B
)	O
,	O
pituitary	B
adenomas	I
,	O
and	O
prostate	B
carcinoma	I
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
function	O
by	O
targeting	O
multiple	O
oncogenes	O
,	O
including	O
BCL2	O
,	O
MCL1	O
,	O
CCND1	O
,	O
and	O
WNT3A	O
.	O

This	O
review	O
summarizes	O
the	O
discovery	O
,	O
functions	O
,	O
and	O
clinical	O
relevance	O
of	O
these	O
miRNAs	O
in	O
cancer	B
,	O
particularly	O
CLL	B
.	O

During	O
experimental	B
autoimmune	I
encephalomyelitis	I
(	O
EAE	B
)	O
,	O
miR-124	O
was	O
downregulated	O
in	O
activated	O
microglia	O
.	O

Peripheral	O
administration	O
of	O
miR-124	O
in	O
EAE	B
caused	O
systemic	O
deactivation	O
of	O
macrophages	O
,	O
reduced	O
activation	O
of	O
myelin	O
-	O
specific	O
T	O
cells	O
and	O
marked	O
suppression	O
of	O
disease	O
.	O

Conversely	O
,	O
knockdown	O
of	O
miR-124	O
in	O
microglia	O
and	O
macrophages	O
resulted	O
in	O
activation	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

These	O
findings	O
identify	O
miR-124	O
both	O
as	O
a	O
key	O
regulator	O
of	O
microglia	O
quiescence	O
in	O
the	O
central	O
nervous	O
system	O
and	O
as	O
a	O
previously	O
unknown	O
modulator	O
of	O
monocyte	O
and	O
macrophage	O
activation	O
.	O

MicroRNA-124	O
promotes	O
microglia	O
quiescence	O
and	O
suppresses	O
EAE	B
by	O
deactivating	O
macrophages	O
via	O
the	O
C	O
/	O
EBP	O
-	O
α	O
-	O
PU.1	O
pathway	O
.	O

MicroRNAs	O
are	O
a	O
family	O
of	O
regulatory	O
molecules	O
involved	O
in	O
many	O
physiological	O
processes	O
,	O
including	O
differentiation	O
and	O
activation	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
found	O
that	O
brain	O
-	O
specific	O
miR-124	O
is	O
expressed	O
in	O
microglia	O
but	O
not	O
in	O
peripheral	O
monocytes	O
or	O
macrophages	O
.	O

When	O
overexpressed	O
in	O
macrophages	O
,	O
miR-124	O
directly	O
inhibited	O
the	O
transcription	O
factor	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
-	O
α	O
(	O
C	O
/	O
EBP	O
-	O
α	O
)	O
and	O
its	O
downstream	O
target	O
PU.1	O
,	O
resulting	O
in	O
transformation	O
of	O
these	O
cells	O
from	O
an	O
activated	O
phenotype	O
into	O
a	O
quiescent	O
CD45	O
(	O
low	O
)	O
,	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
(	O
low	O
)	O
phenotype	O
resembling	O
resting	O
microglia	O
.	O

Molecular	O
and	O
cellular	O
neurobiological	O
studies	O
of	O
the	O
miRNAs	O
in	O
neurodegeneration	O
represent	O
the	O
exploration	O
of	O
a	O
new	O
Frontier	O
of	O
miRNAs	O
biology	O
and	O
the	O
potential	O
development	O
of	O
new	O
diagnostic	O
tests	O
and	O
genetic	O
therapies	O
for	O
neurodegenerative	B
diseases	I
.	O

MiRNA	O
studies	O
in	O
neurobiology	O
showed	O
their	O
involvement	O
in	O
synaptic	O
plasticity	O
and	O
brain	B
diseases	I
.	O

In	O
this	O
review	O
,	O
correlations	O
between	O
miRNA	O
-	O
mediated	O
gene	O
silencing	O
and	O
Alzheimer	B
's	I
,	O
Parkinson	B
's	I
,	O
and	O
other	O
neurodegenerative	B
diseases	I
will	O
be	O
discussed	O
.	O

In	O
few	O
years	O
our	O
understanding	O
of	O
microRNA	O
(	O
miRNA	O
)	O
biogenesis	O
,	O
molecular	O
mechanisms	O
by	O
which	O
miRNAs	O
regulate	O
gene	O
expression	O
,	O
and	O
the	O
functional	O
roles	O
of	O
miRNAs	O
has	O
been	O
expanded	O
.	O

Interestingly	O
,	O
numerous	O
miRNAs	O
are	O
expressed	O
in	O
a	O
spatially	O
and	O
temporally	O
controlled	O
manner	O
in	O
the	O
nervous	O
system	O
,	O
suggesting	O
that	O
their	O
posttrascriptional	O
regulation	O
may	O
be	O
particularly	O
relevant	O
in	O
neural	O
development	O
and	O
function	O
.	O

Searching	O
for	O
MIND	O
:	O
microRNAs	O
in	O
neurodegenerative	B
diseases	I
.	O

In	O
gliomas	B
,	O
microRNA-21	O
(	O
miR-21	O
)	O
levels	O
have	O
been	O
reported	O
to	O
be	O
elevated	O
and	O
their	O
knockdown	O
is	O
associated	O
with	O
increased	O
apoptotic	O
activity	O
.	O

We	O
hypothesized	O
that	O
suppression	O
of	O
miR-21	O
might	O
sensitize	O
gliomas	B
for	O
cytotoxic	O
tumor	O
therapy	O
.	O

With	O
the	O
use	O
of	O
locked	O
nucleic	O
acid	O
(	O
LNA	O
)	O
-antimiR-21	O
oligonucleotides	O
,	O
bimodal	O
imaging	O
vectors	O
,	O
and	O
neural	O
precursor	O
cells	O
(	O
NPC	O
)	O
expressing	O
a	O
secretable	O
variant	O
of	O
the	O
cytotoxic	O
agent	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
S	O
-	O
TRAIL	O
)	O
,	O
we	O
show	O
that	O
the	O
combined	O
suppression	O
of	O
miR-21	O
and	O
NPC	O
-	O
S	O
-	O
TRAIL	O
leads	O
to	O
a	O
synergistic	O
increase	O
in	O
caspase	O
activity	O
and	O
significantly	O
decreased	O
cell	O
viability	O
in	O
human	B
glioma	I
cells	O
in	O
vitro	O
.	O

This	O
phenomenon	O
persists	O
in	O
vivo	O
,	O
as	O
we	O
observed	O
complete	O
eradication	O
of	O
LNA	O
-	O
antimiR-21-treated	O
gliomas	B
subjected	O
to	O
the	O
presence	O
of	O
NPC	O
-	O
S	O
-	O
TRAIL	O
in	O
the	O
murine	O
brain	O
.	O

Our	O
results	O
reveal	O
the	O
efficacy	O
of	O
miR-21	O
antagonism	O
in	O
murine	O
glioma	B
models	O
and	O
implicate	O
miR-21	O
as	O
a	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Furthermore	O
,	O
our	O
findings	O
provide	O
the	O
basis	O
for	O
developing	O
combination	O
therapies	O
using	O
miRNA	O
modulation	O
and	O
cytotoxic	O
tumor	O
therapies	O
.	O

MicroRNA-21	O
knockdown	O
disrupts	O
glioma	B
growth	O
in	O
vivo	O
and	O
displays	O
synergistic	O
cytotoxicity	O
with	O
neural	O
precursor	O
cell	O
delivered	O
S	O
-	O
TRAIL	O
in	O
human	B
gliomas	I
.	O

Mounting	O
evidence	O
indicates	O
that	O
microRNAs	O
(	O
miRNA	O
)	O
might	O
play	O
a	O
fundamental	O
role	O
in	O
tumorigenesis	O
,	O
controlling	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Despite	O
the	O
development	O
of	O
new	O
glioma	B
therapies	O
that	O
allow	O
for	O
tumor	B
-	O
targeted	O
in	O
situ	O
delivery	O
of	O
cytotoxic	O
drugs	O
,	O
tumor	O
resistance	O
to	O
apoptosis	O
remains	O
a	O
key	O
impediment	O
to	O
effective	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
irregularity	O
of	O
prolactin	O
secretion	O
in	O
patients	O
with	O
NPG	B
is	O
not	O
dependant	O
on	O
the	O
presence	O
of	O
a	O
pituitary	B
tumour	I
which	O
suggests	O
that	O
a	O
hypothalamic	B
dysfunction	I
underlies	O
this	O
condition	O
.	O

An	O
irregular	O
secretion	O
and	O
a	O
higher	O
daily	O
mass	O
production	O
of	O
prolactin	O
in	O
patients	O
with	O
NPG	B
could	O
explain	O
both	O
galactorrhea	B
and	O
infertility	B
.	O

BACKGROUND	O
:	O
Abnormal	O
frequency	O
and	O
pulse	O
amplitud	O
of	O
prolactin	O
secretion	O
in	O
micro	O
and	O
macroprolactinomas	B
has	O
been	O
atributed	O
to	O
a	O
dysfunctional	O
tumoral	O
lactotrope	O
.	O

[	O
Irregular	O
secretion	O
of	O
prolactin	O
in	O
infertile	O
women	O
with	O
normoprolactinemic	B
galactorrhea	I
]	O
.	O

The	O
regularity	O
of	O
prolactin	O
secretion	O
has	O
not	O
been	O
studied	O
with	O
cuantitative	O
methods	O
in	O
patients	O
with	O
normoprolactinemic	B
galactorrhea	I
(	O
NPG	B
)	O
which	O
could	O
be	O
considered	O
an	O
entity	O
that	O
precedes	O
non	O
tumoral	O
and	O
tumoral	B
hyperprolactinemia	I
.	O

Previous	O
evidence	O
suggests	O
that	O
non	B
tumoral	I
hyperprolactinemia	I
is	O
caused	O
by	O
a	O
hypothalamic	B
dysfunction	I
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
transversal	O
-	O
comparative	O
study	O
was	O
carried	O
out	O
in	O
6	O
infertile	O
women	O
with	O
normoprolactinemic	B
galactorrhea	I
and	O
4	O
healthy	O
women	O
as	O
controls	O
.	O

Objective	O
:	O
To	O
analyze	O
the	O
24-hour	O
prolactin	O
secretion	O
pattern	O
and	O
its	O
secretion	O
regularity	O
in	O
a	O
group	O
of	O
infertile	O
women	O
with	O
normoprolactinemic	O
galatorea	O
.	O

RESULTS	O
:	O
Blunting	O
of	O
the	O
nyctohemeral	O
rythm	O
and	O
nocturn	B
hyperprolactinaemia	I
occurred	O
in	O
patients	O
with	O
normoprolactinemic	B
galactorrhea	I
(	O
NPG	B
)	O
.	O

The	O
24	O
hour	O
prolactin	O
profile	O
,	O
the	O
ratio	O
night	O
time	O
mean	O
concentration	O
/	O
daytime	O
mean	O
concentrattion	O
(	O
NM	O
/	O
DM	O
ratio	O
)	O
and	O
apparent	O
entropy	O
(	O
Ap	O
En	O
,	O
Ap	O
En	O
ratio	O
)	O
were	O
compared	O
in	O
the	O
two	O
groups	O
.	O

Higher	O
irregularity	O
of	O
prolactin	O
secretion	O
was	O
found	O
in	O
patients	O
with	O
NPG	B
(	O
ApEn	O
:	O
0.853	O
+	O
/-	O
0.158	O
vs	O
0.608	O
+	O
/-	O
0.171	O
,	O
p=0.04	O
;	O
Ap	O
En	O
ratio	O
:	O
0.839	O
+	O
/-	O
0.11	O
vs	O
0.661	O
+	O
/-	O
0.14	O
;	O
p=0.04	O
)	O
.	O

NM	O
/	O
DM	O
ratio	O
was	O
lower	O
in	O
patients	O
with	O
NPG	B
than	O
in	O
controls	O
(	O
1.28	O
+	O
/-	O
0.25	O
vs.	O
1.75	O
+	O
/-	O
0.05	O
;	O
p=	O
0.01	O
)	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
whether	O
microRNA	O
targets	O
could	O
be	O
engineered	O
into	O
VSV	O
to	O
ameliorate	O
its	O
neuropathogenicity	O
.	O

Using	O
a	O
panel	O
of	O
recombinant	O
VSVs	O
incorporating	O
microRNA	O
target	O
sequences	O
corresponding	O
to	O
neuron	O
-	O
specific	O
or	O
control	O
microRNAs	O
(	O
in	O
forward	O
and	O
reverse	O
orientations	O
)	O
,	O
we	O
tested	O
viral	O
replication	O
kinetics	O
in	O
cell	O
lines	O
treated	O
with	O
microRNA	O
mimics	O
,	O
neurotoxicity	B
after	O
direct	O
intracerebral	O
inoculation	O
in	O
mice	O
,	O
and	O
antitumor	O
efficacy	O
.	O

Compared	O
to	O
picornaviruses	O
and	O
adenoviruses	O
,	O
the	O
engineered	O
VSVs	O
were	O
relatively	O
resistant	O
to	O
microRNA	O
-	O
mediated	O
inhibition	O
,	O
but	O
neurotoxicity	B
could	O
nevertheless	O
be	O
ameliorated	O
significantly	O
using	O
this	O
approach	O
,	O
without	O
compromise	O
to	O
antitumor	O
efficacy	O
.	O

Neurotoxicity	B
was	O
most	O
profoundly	O
reduced	O
in	O
a	O
virus	O
carrying	O
four	O
tandem	O
copies	O
of	O
a	O
neuronal	O
mir125	O
target	O
sequence	O
inserted	O
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
viral	O
polymerase	O
(	O
L	O
)	O
gene	O
.	O

Attenuation	O
of	O
vesicular	B
stomatitis	I
virus	I
encephalitis	I
through	O
microRNA	O
targeting	O
.	O

Vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
has	O
long	O
been	O
regarded	O
as	O
a	O
promising	O
recombinant	O
vaccine	O
platform	O
and	O
oncolytic	O
agent	O
but	O
has	O
not	O
yet	O
been	O
tested	O
in	O
humans	O
because	O
it	O
causes	O
encephalomyelitis	B
in	O
rodents	O
and	O
primates	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
specific	O
tropisms	O
of	O
several	O
viruses	O
could	O
be	O
eliminated	O
by	O
engineering	O
microRNA	O
target	O
sequences	O
into	O
their	O
genomes	O
,	O
thereby	O
inhibiting	O
spread	O
in	O
tissues	O
expressing	O
cognate	O
microRNAs	O
.	O

Alteration	O
of	O
miRNA	O
expression	O
by	O
disease	O
and	O
insult	O
also	O
holds	O
the	O
potential	O
for	O
improved	O
diagnostic	O
tools	O
.	O

Finally	O
,	O
miRNAs	O
have	O
been	O
shown	O
to	O
control	O
cellular	O
proliferation	O
and	O
specification	O
,	O
suggesting	O
that	O
manipulation	O
of	O
miRNAs	O
in	O
cultured	O
cells	O
could	O
result	O
in	O
more	O
convenient	O
generation	O
of	O
pure	O
cell	O
populations	O
for	O
transplantation	O
.	O

miRNAs	O
appear	O
to	O
be	O
dysregulated	O
in	O
a	O
number	O
of	O
neurodegenerative	B
diseases	I
,	O
developmental	B
disorders	I
,	O
and	O
as	O
a	O
result	O
of	O
stroke	B
.	O

MicroRNAS	O
(	O
miRNAs	O
)	O
have	O
been	O
suggested	O
to	O
play	O
important	O
roles	O
in	O
the	O
central	O
nervous	O
system	O
during	O
development	O
as	O
well	O
as	O
disease	O
.	O

The	O
therapeutic	O
potential	O
of	O
microRNAs	O
in	O
nervous	O
system	O
damage	O
,	O
degeneration	O
,	O
and	O
repair	O
.	O

Artificial	O
miRNAs	O
have	O
also	O
been	O
generated	O
for	O
the	O
repression	O
of	O
specific	O
transcripts	O
.	O

Both	O
viral	O
delivery	O
and	O
administration	O
of	O
modified	O
oligonucleotides	O
mimicking	O
or	O
inhibiting	O
specific	O
miRNAs	O
have	O
been	O
effective	O
in	O
model	O
systems	O
.	O

Recent	O
findings	O
suggest	O
that	O
it	O
may	O
eventually	O
be	O
possible	O
to	O
treat	O
some	O
neurological	B
disorders	I
by	O
restoring	O
or	O
inhibiting	O
miRNAs	O
altered	O
by	O
disease	O
pathology	O
.	O

Each	O
miRNA	O
has	O
the	O
ability	O
to	O
regulate	O
hundreds	O
of	O
messenger	O
RNA	O
transcripts	O
,	O
both	O
by	O
causing	O
degradation	O
of	O
the	O
mRNA	O
and	O
by	O
inhibition	O
of	O
protein	O
translation	O
.	O

MicroRNA-210	O
as	O
a	O
novel	O
blood	O
biomarker	O
in	O
acute	O
cerebral	B
ischemia	I
.	O

MicroRNA-210	O
(	O
miR-210	O
)	O
,	O
a	O
master	O
and	O
pleiotropic	O
hypoxia	B
-	O
microRNA	O
,	O
plays	O
multiple	O
roles	O
in	O
brain	B
ischemia	I
.	O

However	O
,	O
miR-210	O
expression	O
and	O
its	O
function	O
in	O
humans	O
have	O
not	O
been	O
explored	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
correlation	O
of	O
blood	O
miR-210	O
with	O
clinical	O
findings	O
in	O
acute	B
ischemic	I
stroke	I
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
stroke	B
patients	O
(	O
n=112	O
)	O
and	O
healthy	O
controls	O
(	O
n=	O
60	O
)	O
.	O

MiR-210	O
was	O
measured	O
at	O
within	O
3	O
,	O
7	O
and	O
14	O
days	O
after	O
stroke	B
using	O
a	O
quantitative	O
PCR	O
technique	O
.	O

Stroke	B
severity	O
and	O
clinical	O
outcome	O
were	O
evaluated	O
by	O
NIHSS	O
and	O
modified	O
Rankin	O
Score	O
.	O

Both	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	O
was	O
examined	O
and	O
the	O
correlation	O
was	O
investigated	O
.	O

Compared	O
to	O
healthy	O
controls	O
,	O
blood	O
miRNA-210	O
was	O
significantly	O
decreased	O
in	O
stroke	B
patients	O
(	O
0.93	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
,	O
especially	O
at	O
7	O
days	O
(	O
0.56	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
and	O
14	O
days	O
of	O
stroke	B
onset	O
(	O
0.50	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
.	O

The	O
cut	O
off	O
point	O
of	O
miR-210	O
in	O
diagnosis	O
was	O
0.505	O
with	O
88.3	O
per	O
cent	O
sensitivity	O
.	O

MiR-210	O
level	O
in	O
stroke	B
patients	O
with	O
good	O
outcome	O
was	O
significantly	O
higher	O
than	O
patients	O
with	O
poor	O
outcome	O
(	O
1.2	O
vs.	O
0.44	O
;	O
P=0.012	O
)	O
.	O

The	O
correlation	O
between	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	O
was	O
positive	O
(	O
R2=0.57	O
,	O
P=0.001	O
)	O
.	O

Blood	O
miR-210	O
is	O
a	O
novel	O
sensitive	O
biomarker	O
for	O
clinical	O
diagnosis	O
and	O
prognosis	O
in	O
acute	B
cerebral	I
ischemia	I
.	O

Out	O
of	O
the	O
5	O
positive	O
samples	O
,	O
one	O
was	O
an	O
HTLV	O
,	O
three	O
HTLV-1	O
and	O
one	O
HTLV-2	O
.	O

These	O
blood	O
donors	O
were	O
residents	O
of	O
Posadas	O
,	O
Eldorado	O
and	O
Oberá	O
,	O
with	O
no	O
risk	O
antecedents	O
.	O

This	O
study	O
demonstrates	O
the	O
presence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
population	O
of	O
Misiones	O
with	O
a	O
prevalence	O
rate	O
similar	O
to	O
those	O
reported	O
among	O
blood	O
donors	O
from	O
non	O
-	O
endemic	O
areas	O
.	O

[	O
Seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
blood	O
donors	O
from	O
Misiones	O
Province	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
blood	O
donor	O
population	O
from	O
Misiones	O
province	O
.	O

They	O
are	O
transmitted	O
through	O
sex	O
contact	O
,	O
parenterally	O
and	O
from	O
mother	O
to	O
child	O
.	O

HTLV-1	O
/	O
2	O
screening	O
was	O
performed	O
with	O
ELISA	O
and	O
particle	O
agglutination	O
,	O
and	O
reactive	O
samples	O
were	O
confirmed	O
by	O
Western	O
Blot	O
.	O

A	O
total	O
of	O
6912	O
accepted	O
blood	O
donations	O
in	O
2008	O
were	O
analyzed	O
.	O

It	O
is	O
endemic	O
worldwide	O
,	O
including	O
the	O
North	O
of	O
Argentina	O
where	O
both	O
associated	O
diseases	O
have	O
also	O
been	O
detected	O
.	O

Human	O
T	O
-	O
cell	O
Lymphotropic	O
viruses	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
the	O
first	O
human	O
oncoretrovirus	O
to	O
be	O
discovered	O
,	O
is	O
the	O
etiologic	O
agent	O
of	O
Adult	B
T	I
-	I
cell	I
Leukemia	I
(	O
ATL	B
)	O
and	O
HTLV-1	B
Associated	I
Mielopathy	I
or	O
Tropical	B
Spastic	I
Paraparesis	I
(	O
HAM	B
/	O
TSP	B
)	O
.	O

Both	O
retroviruses	O
are	O
endemic	O
in	O
native	O
populations	O
of	O
The	O
Americas	O
,	O
Africa	O
and	O
at	O
-	O
risk	O
populations	O
.	O

No	O
etiologic	O
role	O
has	O
been	O
described	O
for	O
HTLV-2	O
,	O
although	O
it	O
has	O
been	O
associated	O
with	O
HAM	B
/	O
TSP	B
-	O
like	O
neurologic	B
syndromes	I
.	O

From	O
the	O
total	O
,	O
5	O
samples	O
resulted	O
seropositive	O
with	O
a	O
final	O
prevalence	O
of	O
0.00072	O
.	O

Furthermore	O
,	O
in	O
patient	O
samples	O
expression	O
of	O
miR	O
124a	O
is	O
significantly	O
decreased	O
.	O

Our	O
data	O
strongly	O
indicate	O
that	O
CDK6	O
is	O
regulated	O
by	O
microRNA	O
124	O
in	O
medulloblastoma	B
and	O
that	O
miR	O
124	O
modulates	O
medulloblastoma	B
cell	O
growth	O
.	O

We	O
hypothesized	O
that	O
CDK6	O
expression	O
is	O
also	O
regulated	O
by	O
microRNAs	O
in	O
medulloblastoma	B
.	O

Genomic	O
amplification	O
accounts	O
for	O
some	O
,	O
but	O
not	O
all	O
of	O
the	O
CDK6	O
over	O
-	O
expression	O
.	O

Expression	O
of	O
miR	O
124a	O
was	O
significantly	O
decreased	O
in	O
medulloblastoma	B
cells	O
compared	O
to	O
normal	O
adult	O
cerebellum	O
.	O

We	O
identified	O
putative	O
miR	O
sites	O
in	O
the	O
CDK6	O
including	O
microRNA	O
124a	O
,	O
a	O
brain	O
enriched	O
microRNA	O
.	O

Additionally	O
,	O
re	O
-	O
expression	O
of	O
miR	O
124a	O
in	O
medulloblastoma	B
cells	O
decreased	O
expression	O
of	O
CDK6	O
protein	O
.	O

Functional	O
association	O
between	O
miR	O
124a	O
and	O
CDK6	O
in	O
medulloblastoma	B
was	O
established	O
using	O
luciferase	O
assays	O
.	O

Transfection	O
of	O
miR	O
124	O
significantly	O
decreases	O
medulloblastoma	B
cell	O
growth	O
but	O
does	O
not	O
alter	O
apoptosis	O
.	O

Regulation	O
of	O
cyclin	O
dependent	O
kinase	O
6	O
by	O
microRNA	O
124	O
in	O
medulloblastoma	B
.	O

Despite	O
recent	O
advances	O
in	O
treatment	O
medulloblastoma	B
continues	O
to	O
remain	O
a	O
vexing	O
problem	O
.	O

Recently	O
increased	O
expression	O
of	O
cyclin	O
dependent	O
kinase	O
6	O
(	O
CDK6	O
)	O
was	O
identified	O
as	O
an	O
adverse	O
prognostic	O
marker	O
in	O
medulloblastoma	B
.	O

CONCLUSIONS	O
:	O
The	O
study	O
suggests	O
that	O
spatial	O
orientation	O
memory	O
relies	O
on	O
the	O
integrity	O
of	O
the	O
right	O
hippocampus	O
.	O

Nevertheless	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
confirm	O
this	O
hypothesis	O
.	O

The	O
subjects	O
were	O
submitted	O
to	O
a	O
neuropsychologic	O
evaluation	O
through	O
the	O
Route	O
Learning	O
Test	O
and	O
the	O
Childhood	O
Home	O
Test	O
in	O
the	O
preoperative	O
period	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
,	O
analysis	O
of	O
variance	O
,	O
χ	O
,	O
and	O
Mann	O
-	O
Whitney	O
U	O
tests	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
performance	O
in	O
the	O
remote	O
visuospatial	O
memory	O
(	O
as	O
measured	O
by	O
the	O
Childhood	O
Home	O
Test	O
)	O
across	O
the	O
groups	O
(	O
LTLE	O
,	O
RTLE	O
,	O
and	O
control	O
)	O
.	O

Concerning	O
the	O
spatial	O
orientation	O
memory	O
,	O
however	O
,	O
there	O
was	O
a	O
significant	O
difference	O
between	O
the	O
LTLE	O
and	O
controls	O
as	O
compared	O
with	O
the	O
RTLE	O
group	O
(	O
P<0.001	O
)	O
,	O
the	O
latter	O
showing	O
a	O
poorer	O
performance	O
.	O

However	O
,	O
evaluations	O
of	O
the	O
right	O
hippocampal	O
functions	O
have	O
not	O
been	O
consistent	O
.	O

In	O
ablative	O
interventions	O
,	O
neuropsychologic	O
testing	O
of	O
memory	O
is	O
a	O
crucial	O
step	O
.	O

METHODS	O
:	O
A	O
controlled	O
study	O
of	O
patients	O
with	O
left	O
(	O
LTLE	O
)	O
or	O
right	O
(	O
RTLE	O
)	O
TLE	B
.	O

AIM	O
:	O
To	O
assess	O
the	O
hippocampal	O
function	O
in	O
remote	O
orientation	O
and	O
visuospatial	O
memory	O
in	O
patients	O
with	O
refractory	B
temporal	I
epilepsy	I
.	O

INTRODUCTION	O
:	O
In	O
temporal	B
lobe	I
epilepsy	I
(	O
TLE	B
)	O
,	O
about	O
30	O
%	O
of	O
the	O
patients	O
do	O
not	O
achieve	O
adequate	O
pharmacologic	O
control	O
of	O
refractory	O
crises	O
,	O
and	O
surgery	O
becomes	O
an	O
alternative	O
.	O

Route	O
Learning	O
Performance	O
:	O
Is	O
it	O
a	O
Hippocampus	O
Function	O
?	O

Thrombolytic	O
therapy	O
involving	O
recombinant	O
tissue	O
plasminogen	O
activator	O
(	O
rtPA	O
)	O
has	O
been	O
shown	O
to	O
be	O
beneficial	O
only	O
when	O
used	O
within	O
4.5	O
hours	O
of	O
onset	O
of	O
acute	B
ischemic	I
stroke	I
.	O

There	O
are	O
two	O
major	O
types	O
of	O
stroke	B
:	O
cerebral	B
ischemia	I
caused	O
by	O
obstruction	O
of	O
blood	O
vessels	O
in	O
the	O
brain	O
and	O
haemorrhagic	B
stroke	I
that	O
is	O
triggered	O
by	O
the	O
disruption	O
of	O
blood	O
vessels	O
.	O

Stroke	B
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
and	O
disability	O
worldwide	O
.	O

microRNAs	O
in	O
stroke	B
pathogenesis	O
.	O

Although	O
the	O
biochemistry	O
of	O
stroke	B
and	O
related	O
diseases	O
is	O
quite	O
well	O
understood	O
,	O
the	O
knowledge	O
on	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
diseases	O
is	O
still	O
at	O
its	O
infancy	O
.	O

microRNAs	O
that	O
form	O
a	O
unique	O
class	O
of	O
endogenous	O
riboregulators	O
of	O
gene	O
function	O
,	O
offer	O
tremendous	O
potential	O
in	O
unraveling	O
the	O
mechanisms	O
underlying	O
stroke	B
pathogenesis	O
.	O

rtPA	O
treatment	O
beyond	O
this	O
time	O
window	O
has	O
been	O
found	O
to	O
be	O
unsuitable	O
and	O
usually	O
resulting	O
in	O
haemorrhagic	O
transformation	O
.	O

Stroke	B
is	O
a	O
multifactorial	O
disease	O
that	O
forms	O
a	O
possible	O
end	O
state	O
for	O
majority	O
of	O
patients	O
suffering	O
from	O
diabetes	B
,	O
atherosclerosis	B
and	O
hypertension	B
which	O
are	O
known	O
risk	O
factors	O
.	O

microRNA	O
expression	O
also	O
reflects	O
the	O
response	O
of	O
individuals	O
to	O
drugs	O
and	O
therapy	O
.	O

Several	O
microRNAs	O
and	O
their	O
target	O
genes	O
,	O
known	O
to	O
be	O
involved	O
in	O
endothelial	B
dysfunction	I
,	O
dysregulation	O
of	O
neurovascular	O
integrity	O
,	O
edema	B
formation	I
,	O
pro	O
-	O
apoptosis	O
,	O
inflammation	B
and	O
extra	O
-	O
cellular	O
matrix	O
remodeling	O
contribute	O
to	O
the	O
critical	O
processes	O
in	O
the	O
pathogenesis	O
of	O
stroke	B
.	O

In	O
this	O
review	O
,	O
we	O
will	O
also	O
be	O
discussing	O
the	O
role	O
of	O
microRNAs	O
as	O
possible	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
as	O
well	O
as	O
potential	O
therapeutic	O
targets	O
in	O
stroke	B
pathogenesis	O
.	O

Mutations	O
in	O
ABHD12	O
cause	O
the	O
neurodegenerative	B
disease	I
PHARC	B
:	O
An	O
inborn	O
error	O
of	O
endocannabinoid	O
metabolism	O
.	O

Previously	O
,	O
we	O
mapped	O
this	O
Refsum	O
-	O
like	O
disorder	O
to	O
a	O
16	O
Mb	O
region	O
on	O
chromosome	O
20	O
.	O

Polyneuropathy	B
,	O
hearing	B
loss	I
,	O
ataxia	B
,	O
retinitis	B
pigmentosa	I
,	O
and	O
cataract	B
(	O
PHARC	B
)	O
is	O
a	O
neurodegenerative	B
disease	I
marked	O
by	O
early	O
-	O
onset	O
cataract	B
and	O
hearing	B
loss	I
,	O
retinitis	B
pigmentosa	I
,	O
and	O
involvement	O
of	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
,	O
including	O
demyelinating	O
sensorimotor	O
polyneuropathy	B
and	O
cerebellar	B
ataxia	I
.	O

Our	O
findings	O
show	O
that	O
ABHD12	O
performs	O
essential	O
functions	O
in	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
and	O
the	O
eye	O
.	O

Any	O
future	O
drug	O
-	O
mediated	O
interference	O
with	O
this	O
enzyme	O
should	O
consider	O
the	O
potential	O
risk	O
of	O
long	O
-	O
term	O
adverse	O
effects	O
.	O

Here	O
we	O
report	O
that	O
mutations	O
in	O
the	O
ABHD12	O
gene	O
cause	O
PHARC	B
disease	O
and	O
we	O
describe	O
the	O
clinical	O
manifestations	O
in	O
a	O
total	O
of	O
19	O
patients	O
from	O
four	O
different	O
countries	O
.	O

The	O
ABHD12	O
enzyme	O
was	O
recently	O
shown	O
to	O
hydrolyze	O
2-arachidonoyl	O
glycerol	O
(	O
2-AG	O
)	O
,	O
the	O
main	O
endocannabinoid	O
lipid	O
transmitter	O
that	O
acts	O
on	O
cannabinoid	O
receptors	O
CB1	O
and	O
CB2	O
.	O

Our	O
data	O
therefore	O
represent	O
an	O
example	O
of	O
an	O
inherited	O
disorder	O
related	O
to	O
endocannabinoid	O
metabolism	O
.	O

The	O
endocannabinoid	O
system	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
physiological	O
processes	O
including	O
neurotransmission	O
,	O
mood	O
,	O
appetite	O
,	O
pain	B
appreciation	O
,	O
addiction	O
behavior	O
,	O
and	O
inflammation	B
,	O
and	O
several	O
potential	O
drugs	O
targeting	O
these	O
pathways	O
are	O
in	O
development	O
for	O
clinical	O
applications	O
.	O

These	O
cellular	O
responses	O
are	O
mediated	O
by	O
augmented	O
expression	O
of	O
the	O
direct	O
targets	O
of	O
miR-10b	O
,	O
including	O
BCL2L11	O
/	O
Bim	O
,	O
TFAP2C	O
/	O
AP-2γ	O
,	O
CDKN1A	O
/	O
p21	O
,	O
and	O
CDKN2A	O
/	O
p16	O
,	O
which	O
normally	O
protect	O
cells	O
from	O
uncontrolled	O
growth	O
.	O

Analysis	O
of	O
The	O
Cancer	O
Genome	O
Atlas	O
expression	O
data	O
set	O
reveals	O
a	O
strong	O
positive	O
correlation	O
between	O
numerous	O
genes	O
sustaining	O
cellular	O
growth	O
and	O
miR-10b	O
levels	O
in	O
human	B
glioblastomas	I
,	O
while	O
proapoptotic	O
genes	O
anticorrelate	O
with	O
the	O
expression	O
of	O
miR-10b	O
.	O

Molecular	O
functions	O
of	O
these	O
miRNAs	O
in	O
gliomagenesis	O
are	O
mainly	O
unknown	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
miR-10b	O
,	O
a	O
miRNA	O
not	O
expressed	O
in	O
human	O
brain	O
and	O
strongly	O
upregulated	O
in	O
both	O
low	O
-	O
grade	O
and	O
high	B
-	I
grade	I
gliomas	I
,	O
reduces	O
glioma	B
cell	O
growth	O
by	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Human	B
glioma	I
growth	O
is	O
controlled	O
by	O
microRNA-10b	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
profiling	O
studies	O
revealed	O
a	O
number	O
of	O
miRNAs	O
dysregulated	O
in	O
the	O
malignant	B
brain	I
tumor	I
glioblastoma	I
.	O

Altogether	O
,	O
our	O
experiments	O
validate	O
an	O
important	O
role	O
of	O
miR-10b	O
in	O
gliomagenesis	O
,	O
reveal	O
a	O
novel	O
mechanism	O
of	O
miR-10b	O
-	O
mediated	O
regulation	O
,	O
and	O
suggest	O
the	O
possibility	O
of	O
its	O
future	O
use	O
as	O
a	O
therapeutic	O
target	O
in	O
gliomas	B
.	O

Furthermore	O
,	O
survival	O
of	O
glioblastoma	B
patients	O
expressing	O
high	O
levels	O
of	O
miR-10	O
family	O
members	O
is	O
significantly	O
reduced	O
in	O
comparison	O
to	O
patients	O
with	O
low	O
miR-10	O
levels	O
,	O
indicating	O
that	O
miR-10	O
may	O
contribute	O
to	O
glioma	B
growth	O
in	O
vivo	O
.	O

Finally	O
,	O
inhibition	O
of	O
miR-10b	O
in	O
a	O
mouse	O
model	O
of	O
human	B
glioma	I
results	O
in	O
significant	O
reduction	O
of	O
tumor	B
growth	O
.	O

MRI	O
scan	O
showed	O
an	O
area	O
of	O
encephalomalacia	B
in	O
the	O
left	O
temporal	O
lobe	O
,	O
as	O
well	O
as	O
post	O
-	O
surgical	O
changes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

He	O
presented	O
with	O
status	B
epilepticus	I
every	O
two	O
or	O
three	O
months	O
,	O
and	O
required	O
long	O
periods	O
of	O
hospitalization	O
on	O
each	O
occasion	O
for	O
post	B
-	I
ictal	I
confusion	I
and	O
aphasia	B
.	O

He	O
continued	O
to	O
have	O
frequent	O
seizures	B
despite	O
treatment	O
with	O
multiple	O
combinations	O
of	O
antiepileptic	O
medications	O
.	O

EEG	O
telemetry	O
recorded	O
multiple	B
seizures	I
,	O
all	O
with	O
a	O
clear	O
focus	O
in	O
the	O
left	O
temporal	O
area	O
.	O

Scalp	O
EEG	O
showed	O
continuous	O
spikes	O
and	O
polyspikes	O
and	O
persistent	O
slowing	O
in	O
the	O
left	O
temporal	O
area	O
,	O
as	O
well	O
as	O
spikes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

CASE	O
REPORT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
75-year	O
-	O
old	O
right	O
-	O
handed	O
man	O
who	O
underwent	O
a	O
left	O
fronto	O
-	O
temporal	O
craniotomy	O
for	O
resection	O
of	O
a	O
suprasellar	B
meningioma	I
in	O
2002	O
.	O

Immediately	O
following	O
hospital	O
discharge	O
,	O
he	O
began	O
to	O
experience	O
complex	O
partial	O
seizures	B
.	O

BACKGROUND	O
:	O
Epilepsy	B
surgery	O
is	O
increasingly	O
well	O
-	O
supported	O
as	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
intractable	O
epilepsy	B
.	O

It	O
is	O
most	O
often	O
performed	O
on	O
younger	O
patients	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
epilepsy	B
surgery	O
in	O
elderly	O
patients	O
are	O
not	O
frequently	O
described	O
.	O

Epilepsy	B
surgery	O
in	O
the	O
elderly	O
:	O
an	O
unusual	O
case	O
of	O
a	O
75-year	O
-	O
old	O
man	O
with	O
recurrent	O
status	B
epilepticus	I
.	O

In	O
addition	O
,	O
few	O
cases	O
with	O
such	O
a	O
malignant	O
evolution	O
of	O
temporal	B
lobe	I
epilepsy	I
have	O
been	O
described	O
in	O
this	O
age	O
group	O
.	O

A	O
left	O
anteromesial	O
temporal	O
lobectomy	O
was	O
performed	O
with	O
intraoperative	O
electrocorticography	O
.	O

Neuropsychological	O
testing	O
showed	O
bilateral	B
memory	I
impairment	I
with	O
no	O
significant	O
cognitive	O
decline	O
expected	O
after	O
unilateral	O
temporal	O
lobe	O
resection	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
one	O
of	O
the	O
oldest	O
patients	O
reported	O
in	O
the	O
literature	O
with	O
epilepsy	B
surgery	O
and	O
supports	O
the	O
possibility	O
of	O
epilepsy	B
surgery	O
in	O
elderly	O
patients	O
for	O
particular	O
cases	O
.	O

Since	O
surgery	O
,	O
the	O
patient	O
was	O
not	O
seizure	B
-	O
free	O
(	O
Engel	O
class	O
II	O
-	O
b	O
)	O
,	O
but	O
had	O
no	O
further	O
episodes	O
of	O
status	B
epilepticus	I
in	O
one	O
year	O
and	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Adult	O
-	O
onset	O
autosomal	O
dominant	O
leukodystrophy	B
:	O
linking	O
nuclear	O
envelope	O
to	O
myelin	O
.	O

Aberrant	O
expression	O
of	O
miRNAs	O
can	O
lead	O
to	O
diseases	O
,	O
including	O
cancer	B
.	O

Expression	O
of	O
many	O
miRNAs	O
in	O
the	O
de	B
-	I
differentiated	I
brain	I
tumor	I
cancer	B
stem	O
cells	O
resembles	O
that	O
of	O
neural	O
stem	O
cells	O
.	O

MicroRNAs	O
:	O
regulators	O
of	O
oncogenesis	O
and	O
stemness	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
essential	O
post	O
-	O
transcriptional	O
regulators	O
that	O
determine	O
cell	O
identity	O
and	O
fate	O
.	O

In	O
this	O
issue	O
of	O
BMC	O
Medicine	O
,	O
Silber	O
et	O
al	O
provide	O
evidence	O
of	O
the	O
expression	O
of	O
such	O
miRNAs	O
and	O
their	O
potential	O
to	O
mediate	O
differentiation	O
in	O
both	O
stem	O
cell	O
populations	O
.	O

In	O
this	O
commentary	O
,	O
we	O
discuss	O
the	O
known	O
functions	O
of	O
miRNAs	O
in	O
cancer	B
and	O
stem	O
cells	O
,	O
their	O
therapeutic	O
potential	O
and	O
how	O
the	O
findings	O
of	O
Silber	O
et	O
al	O
provide	O
insight	O
into	O
the	O
role	O
of	O
miR-124	O
/	O
miR-137	O
dysregulation	O
in	O
glioblastomas	B
.	O

The	O
emerging	O
role	O
of	O
epigenetics	O
in	O
stroke	B
:	O
II	O
.	O
RNA	O
regulatory	O
circuitry	O
.	O

These	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
include	O
subclasses	O
that	O
are	O
well	O
known	O
,	O
such	O
as	O
transfer	O
RNAs	O
and	O
ribosomal	O
RNAs	O
,	O
as	O
well	O
as	O
those	O
that	O
have	O
more	O
recently	O
been	O
characterized	O
,	O
such	O
as	O
microRNAs	O
,	O
small	O
nucleolar	O
RNAs	O
,	O
and	O
long	O
ncRNAs	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
role	O
of	O
these	O
novel	O
ncRNAs	O
in	O
the	O
nervous	O
system	O
and	O
highlight	O
emerging	O
evidence	O
that	O
implicates	O
RNA	O
-	O
based	O
networks	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
stroke	B
.	O

Recent	O
scientific	O
advances	O
have	O
demonstrated	O
the	O
existence	O
of	O
extensive	O
RNA	O
-	O
based	O
regulatory	O
networks	O
involved	O
in	O
orchestrating	O
nearly	O
every	O
cellular	O
process	O
in	O
health	O
and	O
various	O
disease	O
states	O
.	O

This	O
previously	O
hidden	O
layer	O
of	O
functional	O
RNAs	O
is	O
derived	O
largely	O
from	O
non	O
-	O
protein	O
-	O
coding	O
DNA	O
sequences	O
that	O
constitute	O
more	O
than	O
98	O
%	O
of	O
the	O
genome	O
in	O
humans	O
.	O

These	O
novel	O
approaches	O
for	O
neural	O
cell-	O
and	O
tissue	O
-	O
selective	O
reprogramming	O
of	O
epigenetic	O
regulatory	O
mechanisms	O
are	O
likely	O
to	O
promote	O
more	O
effective	O
neuroprotective	O
and	O
neural	O
regenerative	O
responses	O
for	O
safeguarding	O
and	O
even	O
restoring	O
central	O
nervous	O
system	O
function	O
.	O

We	O
also	O
describe	O
RNA	O
editing	O
,	O
a	O
related	O
epigenetic	O
mechanism	O
that	O
is	O
partly	O
responsible	O
for	O
generating	O
the	O
exquisite	O
degrees	O
of	O
environmental	O
responsiveness	O
and	O
molecular	O
diversity	O
that	O
characterize	O
ncRNAs	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
development	O
of	O
future	O
therapeutic	O
strategies	O
for	O
locus	O
-	O
specific	O
and	O
genome	O
-	O
wide	O
regulation	O
of	O
genes	O
and	O
functional	O
gene	O
networks	O
through	O
the	O
modulation	O
of	O
RNA	O
transcription	O
,	O
posttranscriptional	O
RNA	O
processing	O
(	O
eg	O
,	O
RNA	O
modifications	O
,	O
quality	O
control	O
,	O
intracellular	O
trafficking	O
,	O
and	O
local	O
and	O
long	O
-	O
distance	O
intercellular	O
transport	O
)	O
,	O
and	O
RNA	O
translation	O
.	O

These	O
results	O
indicate	O
that	O
miRNAs	O
are	O
differentially	O
expressed	O
in	O
C.	O
elegans	O
PD	B
models	O
and	O
suggest	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
pathogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
12	O
specific	O
miRNAs	O
are	O
differentially	O
regulated	O
in	O
the	O
animals	O
overexpressing	O
alpha	O
-	O
synuclein	O
,	O
five	O
in	O
cat-1	O
,	O
and	O
three	O
in	O
the	O
pdr-1	O
mutants	O
.	O

The	O
family	O
of	O
miR-64	O
and	O
miR-65	O
are	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	O
-	O
synuclein	O
transgenic	O
and	O
cat-1	O
strains	O
,	O
and	O
members	O
of	O
let-7	O
family	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	O
-	O
synuclein	O
and	O
pdr-1	O
strains	O
;	O
mdl-1	O
and	O
ptc-1	O
genes	O
are	O
target	O
candidates	O
for	O
miR-64	O
and	O
miR-65	O
and	O
are	O
overexpressed	O
in	O
alpha	O
-	O
synuclein	O
transgenic	O
as	O
well	O
as	O
miR-64	O
/	O
65	O
(	O
tm3711	O
)	O
knockout	O
animals	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
an	O
important	O
role	O
in	O
human	O
brain	O
development	O
and	O
maintenance	O
.	O

To	O
search	O
for	O
miRNAs	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinsons	B
disease	I
(	O
PD	B
)	O
,	O
we	O
utilized	O
miRNA	O
microarrays	O
to	O
identify	O
potential	O
gene	O
expression	O
changes	O
in	O
115	O
annotated	O
miRNAs	O
in	O
PD	B
-	O
associated	O
Caenorhabditis	O
elegans	O
models	O
that	O
either	O
overexpress	O
human	O
A53	O
T	O
alpha	O
-	O
synuclein	O
or	O
have	O
mutations	O
within	O
the	O
vesicular	O
catecholamine	O
transporter	O
(	O
cat-1	O
)	O
or	O
parkin	O
(	O
pdr-1	O
)	O
ortholog	O
.	O

Global	O
microRNA	O
expression	O
profiling	O
of	O
Caenorhabditis	O
elegans	O
Parkinson	B
's	I
disease	I
models	O
.	O

A	O
series	O
of	O
novel	O
and	O
established	O
medulloblastoma	B
defects	O
were	O
detected	O
(	O
MYC	O
amplification	O
(	O
n	O
=	O
4	O
)	O
,	O
17q21.31	O
high	O
-	O
level	O
gain	O
(	O
n	O
=	O
1	O
)	O
;	O
9p21.1-p21.3	O
(	O
n	O
=	O
1	O
)	O
and	O
6q23.1	O
(	O
n	O
=	O
1	O
)	O
homozygous	O
deletion	O
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
performed	O
a	O
SNP	O
-	O
array	O
based	O
genome	O
-	O
wide	O
copy	O
number	O
analysis	O
in	O
medulloblastoma	B
cell	O
lines	O
,	O
to	O
identify	O
regions	O
of	O
genomic	O
amplification	O
and	O
homozygous	O
deletion	O
,	O
which	O
may	O
harbour	O
critical	O
disease	O
genes	O
.	O

Most	O
notably	O
,	O
a	O
novel	O
recurrent	O
region	O
of	O
genomic	O
amplification	O
at	O
8q24.22-q24.23	O
was	O
identified	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
selected	O
for	O
further	O
investigation	O
.	O

Amplification	O
and	O
overexpression	O
of	O
Hsa	O
-	O
miR-30b	O
,	O
Hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
at	O
8q24.22-q24.23	O
in	O
medulloblastoma	B
.	O

The	O
identification	O
of	O
critical	O
genes	O
involved	O
in	O
its	O
pathogenesis	O
will	O
be	O
central	O
to	O
advances	O
in	O
our	O
understanding	O
of	O
its	O
molecular	O
basis	O
,	O
and	O
the	O
development	O
of	O
improved	O
therapeutic	O
approaches	O
.	O

BACKGROUND	O
:	O
Medulloblastoma	B
is	O
the	O
most	O
common	O
malignant	B
brain	I
tumour	I
of	O
childhood	O
.	O

Of	O
these	O
,	O
only	O
expression	O
of	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
correlated	O
with	O
copy	O
number	O
status	O
,	O
and	O
all	O
three	O
of	O
these	O
transcripts	O
also	O
displayed	O
evidence	O
of	O
elevated	O
expression	O
in	O
sub	O
-	O
sets	O
of	O
primary	O
medulloblastomas	B
,	O
measured	O
relative	O
to	O
the	O
normal	O
cerebellum	O
.	O

Additional	O
analysis	O
by	O
interphase	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
iFISH	O
)	O
,	O
PCR	O
-	O
based	O
mapping	O
and	O
SNP	O
-	O
array	O
revealed	O
this	O
novel	O
amplification	O
at	O
8q24.22-q24.23	O
is	O
independent	O
of	O
MYC	O
amplification	O
at	O
8q24.21	O
,	O
and	O
is	O
unique	O
to	O
medulloblastoma	B
in	O
over	O
800	O
cancer	B
cell	O
lines	O
assessed	O
from	O
different	O
tumour	B
types	O
,	O
suggesting	O
it	O
contains	O
key	O
genes	O
specifically	O
involved	O
in	O
medulloblastoma	B
development	O
.	O

Detailed	O
mapping	O
identified	O
a	O
3Mb	O
common	O
minimal	O
region	O
of	O
amplification	O
harbouring	O
3	O
coding	O
genes	O
(	O
ZFAT1	O
,	O
LOC286094	O
,	O
KHDRBS3	O
)	O
and	O
two	O
genes	O
encoding	O
micro	O
-	O
RNAs	O
(	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
)	O
.	O

Our	O
findings	O
suggest	O
critical	O
roles	O
for	O
these	O
genes	O
in	O
medulloblastoma	B
development	O
,	O
and	O
further	O
support	O
the	O
contribution	O
of	O
micro	O
-	O
RNA	O
species	O
to	O
medulloblastoma	B
pathogenesis	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
data	O
implicate	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
as	O
putative	O
oncogenic	O
target	O
(	O
s	O
)	O
of	O
a	O
novel	O
recurrent	O
medulloblastoma	B
amplicon	O
at	O
8q24.22-q24.23	O
.	O

PURPOSE	O
Medulloblastomas	B
are	O
heterogeneous	O
tumors	B
that	O
collectively	O
represent	O
the	O
most	O
common	O
malignant	O
brain	B
tumor	I
in	O
children	O
.	O

Integrative	O
genomic	O
analysis	O
of	O
medulloblastoma	B
identifies	O
a	O
molecular	O
subgroup	O
that	O
drives	O
poor	O
clinical	O
outcome	O
.	O

We	O
reveal	O
the	O
relative	O
contribution	O
of	O
each	O
subgroup	O
to	O
clinical	O
outcome	O
as	O
a	O
whole	O
and	O
show	O
that	O
a	O
previously	O
unidentified	O
molecular	O
subgroup	O
,	O
characterized	O
genetically	O
by	O
c	O
-	O
MYC	O
copy	O
number	O
gains	O
and	O
transcriptionally	O
by	O
enrichment	O
of	O
photoreceptor	O
pathways	O
and	O
increased	O
miR-183∼96∼182	O
expression	O
,	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
event	O
-	O
free	O
and	O
overall	O
survivals	O
.	O

Results	O
Identified	O
are	O
six	O
molecular	O
subgroups	O
of	O
medulloblastoma	B
,	O
each	O
with	O
a	O
unique	O
combination	O
of	O
numerical	O
and	O
structural	O
chromosomal	B
aberrations	I
that	O
globally	O
influence	O
mRNA	O
and	O
miRNA	O
expression	O
.	O

CONCLUSION	O
Our	O
results	O
detail	O
the	O
complex	O
genomic	O
heterogeneity	O
of	O
medulloblastomas	B
and	O
identify	O
a	O
previously	O
unrecognized	O
molecular	O
subgroup	O
with	O
poor	O
clinical	O
outcome	O
for	O
which	O
more	O
effective	O
therapeutic	O
strategies	O
should	O
be	O
developed	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
profiled	O
the	O
mRNA	O
transcriptome	O
of	O
194	O
medulloblastomas	B
and	O
performed	O
high	O
-	O
density	O
single	O
nucleotide	O
polymorphism	O
array	O
and	O
miRNA	O
analysis	O
on	O
115	O
and	O
98	O
of	O
these	O
,	O
respectively	O
.	O

To	O
understand	O
the	O
molecular	O
characteristics	O
underlying	O
their	O
heterogeneity	O
and	O
to	O
identify	O
whether	O
such	O
characteristics	O
represent	O
risk	O
factors	O
for	O
patients	O
with	O
this	O
disease	O
,	O
we	O
performed	O
an	O
integrated	O
genomic	O
analysis	O
of	O
a	O
large	O
series	O
of	O
primary	O
tumors	B
.	O

We	O
additionally	O
validated	O
our	O
findings	O
in	O
three	O
previously	O
published	O
independent	O
medulloblastoma	B
data	O
sets	O
.	O

Non	O
-	O
negative	O
matrix	O
factorization	O
-	O
based	O
clustering	O
of	O
mRNA	O
expression	O
data	O
was	O
used	O
to	O
identify	O
molecular	O
subgroups	O
of	O
medulloblastoma	B
;	O
DNA	O
copy	O
number	O
,	O
miRNA	O
profiles	O
,	O
and	O
clinical	O
outcomes	O
were	O
analyzed	O
for	O
each	O
.	O

The	O
reason	O
why	O
a	O
mild	B
TBI	I
results	O
in	O
varying	O
clinical	O
symptoms	O
is	O
currently	O
unknown	O
.	O

Based	O
on	O
evidence	O
that	O
microRNA	O
species	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
may	O
reflect	O
molecular	O
alterations	O
in	O
neurodegenerative	B
disorders	I
,	O
it	O
can	O
be	O
hypothesized	O
that	O
at	O
early	O
,	O
preclinical	O
phases	O
of	O
the	O
disease	O
,	O
PBMC	O
may	O
provide	O
an	O
ideal	O
and	O
clinically	O
assessable	O
""""	O
window	O
""""	O
into	O
the	O
brain	O
.	O

Patients	O
who	O
have	O
sustained	O
a	O
mild	B
traumatic	I
brain	I
injury	I
(	O
TBI	B
)	O
from	O
both	O
civilian	O
and	O
military	O
populations	O
exhibit	O
clinical	O
symptoms	O
of	O
varying	O
severity	O
with	O
minimal	O
to	O
profound	O
impact	O
on	O
their	O
daily	O
functioning	O
.	O

Although	O
most	O
patients	O
make	O
a	O
full	O
recovery	O
,	O
a	O
subgroup	O
of	O
mild	B
TBI	I
patients	O
develop	O
cognitive	O
,	O
somatic	O
,	O
and	O
neurobehavioral	O
sequelae	O
that	O
generally	O
resolve	O
over	O
3	O
to	O
6	O
months	O
;	O
a	O
smaller	O
subgroup	O
develop	O
persisting	O
symptoms	O
.	O

Personalized	O
medicine	O
in	O
traumatic	B
brain	I
injury	I
.	O

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
changes	O
in	O
the	O
expression	O
profile	O
of	O
clinically	O
accessible	O
biological	O
indices	O
(	O
biomarkers	O
)	O
,	O
such	O
as	O
microRNA	O
in	O
PBMC	O
,	O
may	O
reflect	O
molecular	O
alterations	O
following	O
TBI	B
that	O
contribute	O
to	O
the	O
onset	O
and	O
progression	O
of	O
TBI	B
phenotypes	O
including	O
chronic	B
traumatic	I
encephalopathy	I
.	O

It	O
is	O
possible	O
that	O
the	O
availability	O
of	O
TBI	B
biomarkers	O
may	O
provide	O
potential	O
elements	O
with	O
clinical	O
relevance	O
to	O
prevention	O
,	O
prognosis	O
,	O
and	O
treatment	O
of	O
postconcussive	B
disorders	I
.	O

This	O
opportunistic	O
mycosis	B
infection	I
presented	O
with	O
clinically	O
totally	O
nonspecific	O
signs	O
and	O
symptoms	O
of	O
CNS	O
affection	O
.	O

Therefore	O
,	O
we	O
suspected	O
affection	O
of	O
CNS	O
with	O
SLE	B
.	O

Even	O
though	O
all	O
diagnostic	O
procedures	O
were	O
made	O
on	O
time	O
and	O
that	O
adequate	O
antifungal	O
and	O
supportive	O
agents	O
were	O
applied	O
very	O
early	O
after	O
the	O
infection	B
onset	O
,	O
the	O
outcome	O
was	O
fatal	O
.	O

Because	O
of	O
infective	O
diathesis	O
in	O
patients	O
with	O
SLE	B
,	O
which	O
present	O
with	O
common	O
and	O
opportunistic	B
infections	I
,	O
and	O
due	O
to	O
high	O
mortality	O
rates	O
caused	O
by	O
these	O
infections	B
,	O
we	O
have	O
tried	O
to	O
emphasise	O
the	O
importance	O
of	O
taking	O
adequate	O
specimens	O
early	O
after	O
infection	B
outcome	O
for	O
these	O
rare	O
infective	O
agents	O
like	O
C.	O
neophormans	O
.	O

It	O
was	O
meningitis	B
caused	O
by	O
C.	O
neoformans	O
.	O

Reports	O
from	O
Europe	O
are	O
very	O
rare	O
,	O
and	O
this	O
case	O
is	O
the	O
one	O
of	O
that	O
kind	O
in	O
Croatia	O
.	O

In	O
recent	O
medical	O
literature	O
are	O
dominant	O
cases	O
reported	O
in	O
Asia	O
.	O

Systemic	B
erythematosus	I
lupus	I
(	O
SLE	B
)	O
is	O
a	O
disease	O
with	O
wide	O
range	O
of	O
clinical	O
manifestations	O
,	O
signs	O
and	O
symptoms	O
.	O

[	O
Cryptococcal	B
meningitis	I
as	O
a	O
diagnostic	O
problem	O
in	O
a	O
patient	O
with	O
SLE	B
--	O
case	O
report	O
]	O
.	O

Very	O
important	O
cause	O
of	O
death	O
in	O
patients	O
with	O
SLE	B
is	O
infection	B
.	O

Disease	O
outcome	O
depends	O
mostly	O
on	O
the	O
affection	O
of	O
kidneys	O
and	O
central	O
nervous	O
system	O
by	O
the	O
disease	O
.	O

During	O
one	O
of	O
the	O
disease	O
flares	O
the	O
patient	O
was	O
hospitalized	O
an	O
opportunistic	O
infection	B
developed	O
.	O

As	O
an	O
outcome	O
of	O
the	O
combined	O
effect	O
of	O
disease	O
and	O
immunosuppressive	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
,	O
the	O
patient	O
had	O
increased	O
infective	O
diathesis	O
(	O
repeated	O
infections	B
caused	O
by	O
S.	O
enteritidis	O
--	O
urinary	B
infections	I
and	O
sepsis	B
)	O
.	O

In	O
this	O
case	O
report	O
we	O
have	O
presented	O
a	O
patient	O
with	O
SLE	B
who	O
initially	O
had	O
severe	O
renal	O
affection	O
,	O
but	O
also	O
complications	O
of	O
immunosuppressive	O
therapy	O
that	O
was	O
administered	O
.	O

Infections	B
are	O
very	O
common	O
among	O
these	O
patients	O
due	O
to	O
aggressive	O
immunosuppressive	O
treatment	O
that	O
is	O
needed	O
for	O
the	O
disease	O
inflammatory	O
activity	O
control	O
.	O

Because	O
of	O
lupus	B
nephropathy	I
,	O
in	O
the	O
early	O
phase	O
of	O
the	O
disease	O
we	O
administered	O
aggressive	O
immunosuppressive	O
therapy	O
(	O
combined	O
parenteral	O
therapy	O
of	O
glucocorticoides	O
and	O
cyclophosphamide	O
)	O
.	O

Even	O
though	O
the	O
disease	O
was	O
accidentally	O
diagnosed	O
,	O
it	O
had	O
a	O
severe	O
clinical	O
progress	O
.	O

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B
adenomatous	I
polyposis	I
.	O

Inactivation	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O

Patients	O
with	O
familial	B
APC	I
(	O
FAP	B
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B
gene	O
and	O
develop	O
multiple	O
colorectal	B
adenomas	I
and	O
subsequent	O
carcinomas	B
early	O
in	O
life	O
.	O

The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B
mutants	O
.	O

Loss	O
of	O
APC	B
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta	O
-	O
catenin-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B
.	O

Wild	O
-	O
type	O
APC	B
activity	O
in	O
beta	O
-	O
catenin-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

In	O
contrast	O
,	O
mutant	O
APC	B
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B
polyposis	I
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
APC	B
activity	O
.	O

These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
FAP	B
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B
tumor	I
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
..	O

Overgrowth	B
of	I
oral	I
mucosa	I
and	I
facial	I
skin	I
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
lysosomal	B
storage	I
disorder	I
caused	O
by	O
deficiency	B
of	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

The	O
main	O
symptom	O
is	O
progressive	O
mental	B
retardation	I
.	O

A	O
spectrum	O
of	O
different	O
mutations	O
has	O
been	O
reported	O
in	O
this	O
disease	O
,	O
one	O
missense	O
mutation	O
(	O
Cys163Ser	O
)	O
being	O
responsible	O
for	O
the	O
majority	O
of	O
Finnish	O
cases	O
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Biopsy	O
specimens	O
of	O
16	O
oral	O
lesions	O
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B
lesions	I
were	O
studied	O
histologically	O
.	O

Immunohistochemical	O
staining	O
for	O
AGA	O
was	O
performed	O
on	O
15	O
oral	O
specimens	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B
of	I
the	I
facial	I
skin	I
already	O
common	O
in	O
childhood	O
.	O

Of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B
angiofibromas	I
,	O
tumours	B
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B
sclerosis	I
.	O

Oedemic	B
buccal	I
mucosa	I
(	O
leucoedema	B
)	O
and	O
gingival	B
overgrowths	I
were	O
more	O
frequent	O
in	O
AGU	B
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Of	O
16	O
oral	B
mucosal	I
lesions	I
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	B
or	I
epithelial	I
hyperplasias	I
and	O
were	O
reactive	O
in	O
nature	O
.	O

Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four	O
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B
patients	O
mucosal	B
lesions	I
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Thus	O
,	O
the	O
high	O
frequency	O
of	O
mucosal	B
overgrowth	I
in	O
AGU	B
patients	O
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	O
storage	O
or	O
with	O
alterations	O
in	O
the	O
level	O
of	O
AGA	O
expression	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B
syndrome	I
thyrocytes	O
.	O

Pendred	B
syndrome	I
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B
deafness	I
,	O
characterized	O
by	O
dyshormonogenic	B
goiter	I
associated	O
with	O
sensory	B
-	I
neural	I
deafness	I
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B
goiter	I
and	O
sensory	B
-	I
neural	I
deafness	I
remains	O
an	O
enigma	O
.	O

PDS	O
codes	O
for	O
a	O
novel	O
protein	O
,	O
pendrin	O
,	O
which	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
sufate	O
transporters	O
.	O

Mechanisms	O
by	O
which	O
abnormal	O
sulfate	O
transport	O
could	O
deleteriously	O
affect	O
iodide	O
organification	O
have	O
been	O
proposed	O
.	O

We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	B
syndrome	I
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

This	O
suggests	O
that	O
pendrin	O
in	O
fact	O
may	O
not	O
be	O
a	O
sulfate	O
transporter	O
,	O
and	O
emphasizes	O
the	O
importance	O
of	O
functional	O
studies	O
on	O
this	O
novel	O
protein	O
..	O

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	B
patients	O
.	O

Alkaptonuria	B
(	O
AKU	B
)	O
,	O
the	O
prototypic	O
inborn	B
error	I
of	I
metabolism	I
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate-1	O
,	O
2-dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	B
patients	O
of	O
different	O
ethnic	O
origin	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
(	O
R58fs	O
,	O
R330S	O
,	O
and	O
H371R	O
)	O
and	O
one	O
common	O
AKU	B
mutation	O
(	O
M368V	O
)	O
,	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
five	O
Finnish	O
AKU	B
pedigrees	O
.	O

The	O
three	O
novel	O
AKU	B
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
Finnish	O
population	O
and	O
have	O
originated	O
recently	O
..	O

Genetic	O
analysis	O
,	O
phenotypic	O
diagnosis	O
,	O
and	O
risk	O
of	O
venous	B
thrombosis	I
in	O
families	O
with	O
inherited	O
deficiencies	B
of	I
protein	I
S.	I
Protein	B
S	I
deficiency	I
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B
thrombosis	I
.	O

Of	O
all	O
the	O
inherited	O
thrombophilic	B
conditions	I
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability	O
,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results	O
.	O

We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	O
of	O
patients	O
from	O
a	O
single	O
center	O
where	O
the	O
diagnosis	O
was	O
confirmed	O
at	O
the	O
genetic	O
level	O
.	O

Twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B
S	I
deficiency	I
and	O
a	O
PROS1	B
gene	I
defect	I
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O

To	O
avoid	O
selection	O
bias	O
,	O
we	O
confined	O
analysis	O
of	O
total	O
and	O
free	O
protein	O
S	O
levels	O
and	O
thrombotic	O
risk	O
to	O
the	O
patients	O
relatives	O
.	O

In	O
this	O
group	O
of	O
relatives	O
,	O
a	O
low	O
free	O
protein	O
S	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	B
gene	I
defect	I
(	O
sensitivity	O
97	O
.	O
7	O
%	O
,	O
specificity	O
100	O
%	O
)	O
.	O

First	O
-	O
degree	O
relatives	O
with	O
a	O
PROS1	B
gene	I
defect	I
had	O
a	O
5	O
.	O

0-fold	O
higher	O
risk	O
of	O
thrombosis	B
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
-	O
16	O
.	O

8)	O
than	O
those	O
with	O
a	O
normal	O
PROS1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	B
defect	I
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O

Relatives	O
with	O
splice	O
-	O
site	O
or	O
major	O
structural	O
defects	B
in	I
the	I
PROS1	I
gene	I
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
S	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations	O
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	B
gene	I
defects	I
and	O
protein	B
S	I
deficiency	I
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B
and	O
that	O
free	O
protein	O
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O

(	O
Blood	O
.	O

2000	O
;	O
95	O
1935	O
-	O
1941	O
)	O
.	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	O
domain	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
WASP	O
proteins	O
.	O

Here	O
we	O
report	O
the	O
autoinhibited	O
structure	O
of	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	O
region	O
or	O
by	O
organic	O
co	O
-	O
solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	O
domain	O
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2	O
/	O
3	O
actin	O
-	O
nucleating	O
complex	O
.	O

Binding	O
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	O
domain	O
causes	O
a	O
dramatic	O
conformational	O
change	O
,	O
resulting	O
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	O
regulatory	O
machinery	O
.	O

These	O
data	O
show	O
that	O
intrinsically	O
unstructured	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
can	O
be	O
induced	O
into	O
distinct	O
structural	O
and	O
functional	O
states	O
depending	O
on	O
context	O
..	O

Locus	O
heterogeneity	O
in	O
Friedreich	B
ataxia	I
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B
recessive	I
ataxia	I
.	O

The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene	O
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	O
.	O

To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	B
.	O

We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B
locus	O
.	O

Studying	O
two	O
siblings	O
with	O
FRDA	B
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7	O
/	O
X25	O
.	O

Haplotype	O
analysis	O
of	O
the	O
STM7	O
/	O
X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients	O
.	O

Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
FRDA	B
caused	O
by	O
the	O
second	O
locus	O
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	O
FRDA	B
patient	O
with	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B
can	O
not	O
be	O
distinguished	O
clinically	O
..	O

Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B
degeneration	I
slow	O
mice	O
by	O
gene	O
therapy	O
.	O

The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor	O
-	O
specific	O
membrane	O
glycoprotein	O
,	O
peripherin-2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	O
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom-1	O
(	O
ref	O
.	O

2	O
)	O
.	O

The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	O
,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O

Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B
dystrophies	I
,	O
including	O
autosomal	B
dominant	I
retinitis	I
pigmentosa	I
and	O
macular	B
dystrophy	I
.	O

A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B
degeneration	I
slow	O
(	O
rds	O
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
null	O
mutation	O
in	O
Prph2	O
.	O

It	O
is	O
characterized	O
by	O
a	O
complete	O
failure	O
to	O
develop	O
photoreceptor	O
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	O
of	O
photoreceptor	O
cells	O
.	O

The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	O
have	O
greatly	O
diminished	O
a	O
-	O
wave	O
and	O
b	O
-	O
wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O

Subretinal	O
injection	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
encoding	O
a	O
Prph2	O
transgene	O
results	O
in	O
stable	O
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	O
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin-2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	O
are	O
morphologically	O
similar	O
to	O
normal	O
outer	O
segments	O
.	O

Moreover	O
,	O
the	O
re	O
-	O
establishment	O
of	O
the	O
structural	O
integrity	O
of	O
the	O
photoreceptor	O
layer	O
also	O
results	O
in	O
electrophysiological	O
correction	O
.	O

These	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	O
defect	O
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	O
gene	O
transfer	O
..	O

Function	O
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity	O
.	O

The	O
axonal	O
chemoattractant	O
netrin-1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
DCC	O
(	O
Deleted	O
in	O
Colorectal	B
Cancer	I
)	O
.	O

We	O
have	O
found	O
that	O
chemical	O
inhibitors	O
of	O
metalloproteases	O
potentiate	O
netrin	O
-	O
mediated	O
axon	O
outgrowth	O
in	O
vitro	O
.	O

We	O
have	O
also	O
found	O
that	O
DCC	O
is	O
a	O
substrate	O
for	O
metalloprotease	O
-	O
dependent	O
ectodomain	O
shedding	O
,	O
and	O
that	O
the	O
inhibitors	O
block	O
proteolytic	O
processing	O
of	O
DCC	O
and	O
cause	O
an	O
increase	O
in	O
DCC	O
protein	O
levels	O
on	O
axons	O
within	O
spinal	O
cord	O
explants	O
.	O

Thus	O
,	O
potentiation	O
of	O
netrin	O
activity	O
by	O
inhibitors	O
may	O
result	O
from	O
stabilization	O
of	O
DCC	O
on	O
the	O
axons	O
,	O
and	O
proteolytic	O
activity	O
may	O
regulate	O
axon	O
migration	O
by	O
controlling	O
the	O
number	O
of	O
functional	O
extracellular	O
axon	O
guidance	O
receptors	O
..	O

Myotonic	B
dystrophy	I
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B
dystrophy	I
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene	O
.	O

The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O

We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice	O
.	O

Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	B
and	O
myopathy	B
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O

Thus	O
,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	B
phenotype	O
.	O

This	O
result	O
supports	O
a	O
role	O
for	O
RNA	O
gain	O
of	O
function	O
in	O
disease	O
pathogenesis	O
..	O

Malignant	B
neoplasms	I
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia	B
-	I
telangiectasia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
an	O
autosomal	B
recessive	I
syndrome	I
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	B
neoplasms	I
in	O
homozygous	O
affected	O
individuals	O
.	O

Heterozygotes	O
for	O
the	O
gene	O
for	O
A	B
-	I
T	I
are	O
thought	O
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	B
.	O

Heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
A	B
-	I
T	I
,	O
although	O
individual	O
carriers	O
can	O
not	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	B
neoplasms	I
in	O
2	O
families	O
of	O
patients	O
with	O
A	B
-	I
T	I
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population	O
.	O

There	O
were	O
59	O
deaths	O
from	O
malignant	B
neoplasms	I
in	O
relatives	O
dying	O
before	O
age	O
75	O
,	O
compared	O
to	O
42	O
.	O

6	O
expected	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

For	O
A	B
-	I
T	I
heterozygotes	O
younger	O
than	O
age	O
45	O
,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	B
neoplasm	I
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population	O
.	O

A	B
-	I
T	I
heterozygotes	O
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B
before	O
age	O
45	O
.	O

The	O
incidence	O
of	O
ovarian	B
,	I
gastric	I
,	I
and	I
biliary	I
system	I
carcinomas	I
and	O
of	O
leukemia	B
and	O
lymphoma	B
was	O
increased	O
in	O
these	O
A	B
-	I
T	I
families	O
.	O

Other	O
neoplasms	B
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic	B
,	I
basal	I
cell	I
,	I
colonic	I
,	I
breast	I
,	I
and	I
cervical	I
carcinomas	I
.	O

Analbuminemia	B
in	O
an	O
American	O
Indian	O
girl	O
.	O

Analbuminemia	B
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12-year	O
-	O
old	O
American	O
Indian	O
girl	O
with	O
atopic	B
dermatitis	I
,	O
mild	O
bronchial	B
asthma	I
,	O
a	O
mild	O
seizure	B
disorder	I
,	O
and	O
hyperlipoproteinemia	B
with	O
a	O
corneal	B
arcus	I
.	O

Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(	O
17	O
mg	O
/	O
100	O
ml	O
)	O
of	O
apparently	O
normal	O
serum	O
albumin	O
.	O

The	O
patients	O
parents	O
were	O
remotely	O
related	O
.	O

The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B
.	O

Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin	O
.	O

The	O
Gc	O
-	O
locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus	O
.	O

Gc	O
-	O
protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B
.	O

Gc	O
-	O
types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B
to	O
the	O
Gc	O
-	O
locus	O
.	O

These	O
findings	O
suggest	O
a	O
""""	O
thalassemia	B
""""	O
-like	O
mutation	O
for	O
this	O
disorder	O
..	O

Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP	O
.	O

A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene	O
.	O

Co	O
-	O
amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
/	O
BMD	B
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	B
patient	O
identified	O
by	O
this	O
approach	O
.	O

The	O
mutation	O
introduces	O
a	O
termination	O
codon	O
within	O
exon	O
8	O
of	O
the	O
dystrophin	O
gene	O
.	O

It	O
is	O
predicted	O
to	O
cause	O
a	O
very	O
premature	O
translational	O
termination	O
accounting	O
for	O
the	O
severe	O
phenotype	O
observed	O
.	O

The	O
patient	O
inherited	O
this	O
mutation	O
from	O
his	O
mother	O
.	O

In	O
addition	O
the	O
analysis	O
revealed	O
5	O
polymorphisms	O
useful	O
for	O
internal	O
control	O
..	O

Linkage	O
of	O
gene	O
for	O
C2	B
deficiency	I
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man	O
.	O

Family	O
study	O
of	O
a	O
further	O
case	O
.	O

Close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
was	O
first	O
reported	O
by	O
FU	O
and	O
co	O
-	O
workers	O
in	O
1974	O
.	O

We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31-year	O
-	O
old	O
C2-deficient	B
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	B
disease	I
.	O

The	O
following	O
markers	O
were	O
tested	O
C2	O
levels	O
,	O
factor	O
B	O
polymorphism	O
,	O
blood	O
groups	O
,	O
and	O
enzyme	O
typing	O
.	O

In	O
addition	O
to	O
close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(	O
HL	O
-	O
A	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
B	O
)	O
.	O

The	O
two	O
HL	O
-	O
A	O
haplotypes	O
closely	O
linked	O
to	O
C2	B
deficiency	I
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O

They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	O
7a	O
..	O

Late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

In	O
that	O
allele	O
arginine84	O
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	O
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	B
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B
..	O

Trisomy	B
15	I
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
due	O
to	O
maternal	B
disomy	I
.	O

Uniparental	B
disomy	I
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B
disomy	I
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B
disomy	I
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B
15	I
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O

Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O

The	O
child	O
was	O
hypotonic	B
at	O
birth	O
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-70	O
%	O
of	O
patients	O
with	O
PWS	B
.	O

Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	B
developed	O
.	O

Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B
disomy	I
in	O
this	O
case	O
of	O
PWS	B
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
..	O

Genetic	O
heterogeneity	O
in	O
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
.	O

The	O
AMELX	O
gene	O
located	O
at	O
Xp22	O
.	O

1-p22	O
.	O

3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	B
dental	I
abnormality	I
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
(	O
XAI	B
)	O
.	O

Three	O
families	O
with	O
XAI	B
have	O
been	O
investigated	O
using	O
polymorphic	O
DNA	O
markers	O
flanking	O
the	O
position	O
of	O
AMELX	O
.	O

Using	O
two	O
-	O
point	O
linkage	O
analysis	O
,	O
linkage	O
was	O
established	O
between	O
XAI	B
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families	O
,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6	O
.	O

05	O
for	O
DXS16	O
at	O
theta	O
=	O
0	O
.	O
04	O
04	O
.	O

This	O
supports	O
the	O
involvement	O
of	O
AMELX	O
,	O
located	O
close	O
to	O
DXS16	O
,	O
in	O
the	O
XAI	B
disease	I
process	O
(	O
AIH1	O
)	O
in	O
those	O
families	O
.	O

Using	O
multipoint	O
linkage	O
analysis	O
,	O
the	O
combined	O
maximum	O
lod	O
score	O
for	O
these	O
two	O
families	O
was	O
7	O
.	O
30	O
for	O
a	O
location	O
of	O
AIH1	O
at	O
2	O
cM	O
distal	O
to	O
DXS16	O
.	O

The	O
support	O
interval	O
around	O
this	O
location	O
extended	O
about	O
8	O
cM	O
proximal	O
to	O
DXS92	O
,	O
and	O
the	O
AIH1	O
location	O
could	O
not	O
be	O
precisely	O
defined	O
by	O
multipoint	O
mapping	O
.	O

Study	O
of	O
recombination	O
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	O
between	O
DXS143	O
and	O
DXS85	O
.	O

There	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family	O
,	O
indicating	O
locus	O
heterogeneity	O
in	O
XAI	B
.	O

Further	O
analysis	O
with	O
markers	O
on	O
the	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
showed	O
evidence	O
of	O
linkage	O
to	O
DXS144E	O
and	O
F9	O
with	O
no	O
recombination	O
with	O
either	O
of	O
these	O
markers	O
.	O

Two	O
-	O
point	O
analysis	O
gave	O
a	O
peak	O
lod	O
score	O
at	O
DXS144E	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
2	O
.	O

83	O
at	O
theta	O
=	O
0	O
,	O
with	O
a	O
peak	O
lod	O
score	O
in	O
multipoint	O
linkage	O
analysis	O
of	O
2	O
.	O
84	O
at	O
theta	O
=	O
0	O
.	O

The	O
support	O
interval	O
extended	O
9	O
cM	O
proximal	O
to	O
DXS144E	O
and	O
14	O
cM	O
distal	O
to	O
F9	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Typical	O
and	O
partial	O
cat	B
eye	I
syndrome	I
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH	O
.	O

Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B
eye	I
syndrome	I
(	O
CES	B
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	B
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH	O
.	O

Using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B
was	O
shown	O
in	O
all	O
cases	O
..	O

Linkage	O
analysis	O
in	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
and	O
application	O
in	O
post-	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(	O
F8C	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
.	O

The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22	O
.	O

5	O
at	O
1	O
cM.	O
F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	B
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7	O
.	O
8	O
without	O
recombination	O
.	O

Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	B
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52	O
.	O

In	O
four	O
patients	O
with	O
ALD	B
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B
in	I
the	I
vision	I
blindness	I
genes	I
.	O

DNA	O
analysis	O
appeared	O
to	O
be	O
of	O
use	O
in	O
determination	O
of	O
the	O
carrier	O
status	O
of	O
females	O
at	O
risk	O
,	O
for	O
the	O
determination	O
of	O
the	O
origin	O
of	O
the	O
mutation	O
in	O
a	O
particular	O
family	O
,	O
and	O
for	O
prenatal	O
diagnosis	O
.	O

Huntington	B
disease	I
and	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
.	O

A	O
40-year	O
-	O
old	O
man	O
with	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
developed	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood	O
-	O
onset	O
TS	B
with	O
adult	O
onset	O
HD	B
.	O

Discovery	O
of	O
other	O
cases	O
with	O
both	O
disorders	O
may	O
provide	O
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
..	O

Linkage	O
of	O
aspartylglucosaminuria	B
(	O
AGU	B
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
AGA	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21-qter	O
of	O
chromosome	O
4	O
.	O

We	O
have	O
studied	O
the	O
map	O
position	O
of	O
the	O
AGU	O
locus	O
in	O
relation	O
to	O
other	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
using	O
linkage	O
analyses	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
ADH2	O
,	O
ADH3	O
,	O
EGF	O
,	O
FG	O
alpha	O
and	O
FG	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
MNS	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
Finnish	O
AGU	B
families	O
.	O

The	O
heterozygous	O
family	O
members	O
were	O
identified	O
by	O
reduced	O
activity	O
of	O
AGA	O
in	O
lymphocytes	O
.	O

Linkage	O
studies	O
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	O
analyses	O
.	O

Loose	O
linkage	O
of	O
the	O
AGU	B
locus	O
to	O
the	O
FG	O
and	O
MNS	O
loci	O
was	O
observed	O
(	O
z	O
=	O
1	O
.	O
16	O
,	O
z	O
=	O
1	O
.	O
39	O
,	O
respectively	O
)	O
.	O

Multipoint	O
analysis	O
to	O
the	O
fixed	O
map	O
[	O
ADH-	O
(	O
0	O
.	O
03	O
)	O
-EGF-	O
(	O
0	O
.	O
35	O
)	O
-FG-	O
(	O
0	O
.	O
11	O
)	O
-MNS	O
]	O
suggests	O
that	O
the	O
location	O
of	O
the	O
AGU	O
locus	O
is	O
0	O
.	O
05	O
-	O
0	O
.	O
30	O
recombination	O
units	O
distal	O
to	O
MNS	O
(	O
z	O
=	O
3	O
.	O
03	O
)	O
.	O

The	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
FG	O
-	O
MNS	O
-	O
AGU	O
is	O
35	O
times	O
more	O
likely	O
than	O
the	O
next	O
best	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
AGU	O
-	O
FG	O
-	O
MNS	O
.	O

Detection	O
of	O
98	O
%	O
of	O
DMD	B
/	O
BMD	B
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
.	O

We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	O
promoter	O
of	O
the	O
dystrophin	O
gene	O
in	O
a	O
single	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	O
,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	O
with	O
Duchenne	B
or	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
,	O
BMD	B
)	O
.	O

Furthermore	O
,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	O
prone	O
""""	O
hot	O
spot	O
""""	O
region	O
around	O
exons	O
44	O
to	O
53	O
,	O
allowing	O
determination	O
of	O
deletion	O
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	O
on	O
the	O
translational	O
reading	O
frame	O
.	O

Thus	O
,	O
use	O
of	O
these	O
PCR	O
-	O
based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
DMD	B
/	O
BMD	B
patients	O
in	O
a	O
fraction	O
of	O
the	O
time	O
required	O
for	O
Southern	O
blot	O
analysis	O
..	O

Statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
,	O
and	O
in	O
sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
renal	B
cell	I
carcinoma	I
.	O

Analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	B
and	I
bilateral	I
retinoblastoma	I
led	O
Knudson	O
to	O
propose	O
that	O
hereditary	B
tumours	I
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	B
tumours	I
by	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B
renal	I
cell	I
carcinoma	I
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

We	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	B
cell	I
carcinoma	I
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B
haemangioblastoma	I
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	O
with	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
43	O
patients	O
with	O
sporadic	B
cerebellar	I
haemangioblastoma	I
.	O

The	O
age	O
incidence	O
curves	O
for	O
renal	B
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
in	O
VHL	B
disease	I
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model	O
,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
suggested	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

These	O
data	O
are	O
compatible	O
with	O
the	O
VHL	B
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	B
suppressor	O
gene	O
.	O

Sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
some	O
renal	B
cell	I
carcinoma	I
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
VHL	B
locus	O
..	O

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
or	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	B
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b-7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B
,	O
BMD	B
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al.	O
and	O
Koenig	O
et	O
al.	O
but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al.	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

X	B
-	I
linked	I
glucose-6-phosphate	I
dehydrogenase	I
deficiency	I
in	O
Mus	O
musculus	O
.	O

A	O
mouse	O
with	O
X	B
-	I
linked	I
glucose-6-phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1-ethyl-1-nitrosourea	O
-	O
treated	O
male	O
mice	O
.	O

The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts	O
.	O

Hemizygous	O
,	O
heterozygous	O
,	O
and	O
homozygous	O
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types	O
.	O

The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration	O
,	O
the	O
isoelectric	O
point	O
,	O
or	O
the	O
thermal	O
stability	O
.	O

Kinetic	O
properties	O
,	O
such	O
as	O
the	O
Km	O
for	O
glucose-6-phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino	O
-	O
NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O

This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X	B
-	I
linked	I
G6PD	I
deficiency	I
in	O
humans	O
..	O

Genetic	O
analysis	O
in	O
families	O
with	O
van	B
der	I
Woude	I
syndrome	I
.	O

We	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
.	O

Both	O
types	O
of	O
oral	B
cleft	I
,	O
cleft	B
palate	I
(	O
CP	B
)	O
and	O
cleft	B
lip	I
with	O
or	O
without	O
CP	B
(	O
CLP	B
)	O
,	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	B
pits	I
or	O
fistulae	B
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
K	O
=	O
.	O

89	O
and	O
.	O
99	O
by	O
different	O
methods	O
.	O

Cleft	O
types	O
(	O
CLP	B
and	O
CP	B
)	O
occur	O
in	O
VWS	B
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non	O
-	O
VWS	O
population	O
,	O
ie	O
,	O
about	O
twice	O
as	O
many	O
cleft	O
-	O
bearing	O
individuals	O
have	O
CLP	B
as	O
have	O
CP	B
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
CP	B
and	O
excess	O
of	O
males	O
with	O
CLP	B
;	O
in	O
VWS	B
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal	O
.	O

Lip	B
pits	I
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O

Affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	B
.	O

However	O
,	O
there	O
is	O
an	O
excess	O
of	O
less	O
severely	O
affected	O
individuals	O
among	O
transmitters	O
and	O
a	O
deficiency	O
of	O
more	O
severely	O
affected	O
,	O
brought	O
about	O
by	O
a	O
proband	O
bias	O
and	O
differential	O
fecundity	O
.	O

The	O
expression	O
of	O
VWS	B
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children	O
.	O

For	O
a	O
VWS	B
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26	O
.	O
45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B
pits	I
is	O
23	O
.	O
55	O
%	O
.	O

Three	O
pedigrees	O
of	O
lip	B
pits	I
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals	O
.	O

Control	O
of	O
gene	O
expression	O
in	O
VWS	B
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O

Mutation	O
rate	O
of	O
the	O
VWS	B
gene	O
is	O
calculated	O
to	O
be	O
1	O
.	O
8	O
X	O
10	O
(	O
-5	O
)	O

Familial	B
discoid	I
lupus	I
erythematosus	I
associated	O
with	O
heterozygote	O
C2	B
deficiency	I
.	O

Two	O
siblings	O
with	O
chronic	B
discoid	I
lupus	I
erythematosus	I
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	B
deficiency	I
.	O

An	O
association	O
with	O
histocompatibility	O
markers	O
HLA	O
-	O
B18	O
and	O
HLA	O
-	O
Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
genes	O
coding	O
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O

One	O
HLA	O
-	O
ACB	O
/	O
DBf	O
recombinant	O
was	O
observed	O
showing	O
closer	O
linkage	O
between	O
HLA	O
-	O
D	O
and	O
Bf	O
than	O
between	O
HLA	O
-	O
B	O
and	O
Bf	O
..	O

New	O
genetic	O
variants	O
of	O
glucose	O
6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Italy	O
.	O

Six	O
new	O
variants	O
of	O
human	O
erythrocyte	O
G6PD	O
have	O
been	O
characterized	O
.	O

All	O
of	O
them	O
were	O
found	O
in	O
Italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	B
deficiency	I
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	B
.	O

These	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	O
,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
Italy	O
where	O
common	O
types	O
of	O
G6PD	B
deficiency	I
are	O
also	O
prevalent	O
..	O

Aberrant	O
subcellular	O
localization	O
of	O
BRCA1	O
in	O
breast	B
cancer	I
.	O

The	O
BRCA1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220-kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells	O
,	O
including	O
breast	O
ductal	O
epithelial	O
cells	O
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary	O
.	O

In	O
16	O
of	O
17	O
breast	B
and	I
ovarian	I
cancer	I
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions	O
,	O
however	O
,	O
BRCA1	O
localized	O
mainly	O
in	O
cytoplasm	O
.	O

Absence	O
of	O
BRCA1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B
cancer	I
biopsies	O
.	O

These	O
findings	O
suggest	O
that	O
BRCA1	B
abnormalities	I
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	B
cancers	I
,	O
sporadic	O
as	O
well	O
as	O
familial	O
..	O

The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
.	O

Since	O
BRCA1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B
breast	I
cancer	I
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B
and	I
ovarian	I
cancer	I
.	O

In	O
high	O
-	O
risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	O
of	O
ovarian	B
cancer	I
.	O

However	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B
or	I
ovarian	I
cancer	I
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B
as	O
in	O
individuals	O
from	O
the	O
high	O
-	O
risk	O
families	O
studied	O
so	O
far	O
.	O

Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O

We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0	O
.	O
9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	O
.	O

Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B
and/or	I
ovarian	I
cancer	I
.	O

The	O
protein	O
deficient	O
in	O
Lowe	B
syndrome	I
is	O
a	O
phosphatidylinositol-4,5-bisphosphate	O
5-phosphatase	O
.	O

Lowe	B
syndrome	I
,	O
also	O
known	O
as	O
oculocerebrorenal	B
syndrome	I
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
chromosome	O
-	O
encoded	O
OCRL	O
gene	O
.	O

The	O
OCRL	O
protein	O
is	O
51	O
%	O
identical	O
to	O
inositol	O
polyphosphate	O
5-phosphatase	O
II	O
(	O
5-phosphatase	O
II	O
)	O
from	O
human	O
platelets	O
over	O
a	O
span	O
of	O
744	O
aa	O
,	O
suggesting	O
that	O
OCRL	O
may	O
be	O
a	O
similar	O
enzyme	O
.	O

We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	O
cDNA	O
that	O
encodes	O
amino	O
acids	O
homologous	O
to	O
the	O
platelet	O
5-phosphatase	O
for	O
expression	O
in	O
baculovirus	O
-	O
infected	O
Sf9	O
insect	O
cells	O
.	O

This	O
cDNA	O
encodes	O
aa	O
264	O
-	O
968	O
of	O
the	O
OCRL	O
protein	O
.	O

The	O
recombinant	O
protein	O
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	O
5-phosphatase	O
II	O
.	O

Thus	O
OCRL	O
converts	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate	O
to	O
inositol	O
1	O
,	O
4-bisphosphate	O
,	O
and	O
it	O
converts	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5-tetrakisphosphate	O
to	O
inositol	O
1	O
,	O
3	O
,	O
4-trisphosphate	O
.	O

Most	O
important	O
,	O
the	O
enzyme	O
converts	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
to	O
phosphatidylinositol	O
4-phosphate	O
.	O

The	O
relative	O
ability	O
of	O
OCRL	O
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5-phosphatase	O
II	O
and	O
from	O
that	O
of	O
another	O
5-phosphatase	O
isoenzyme	O
from	O
platelets	O
,	O
5-phosphatase	O
I.	O
The	O
recombinant	O
OCRL	O
protein	O
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10-	O
to	O
30-fold	O
better	O
than	O
5-phosphatase	O
II	O
,	O
and	O
5-phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all	O
.	O

We	O
also	O
show	O
that	O
OCRL	O
functions	O
as	O
a	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
5-phosphatase	O
in	O
OCRL	O
-	O
expressing	O
Sf9	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
OCRL	O
is	O
mainly	O
a	O
lipid	O
phosphatase	O
that	O
may	O
control	O
cellular	O
levels	O
of	O
a	O
critical	O
metabolite	O
,	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
Lowe	B
syndrome	I
..	O

A	O
single	O
amino	O
acid	O
substitution	O
(	O
G103D	O
)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	B
dysplasia	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen	O
,	O
COL2A1	O
.	O

Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	B
trunk	I
and	I
extremities	I
,	O
mid	B
-	I
face	I
hypoplasia	I
,	O
cleft	B
palate	I
,	O
myopia	B
,	O
retinal	B
detachment	I
,	O
and	O
hearing	B
loss	I
.	O

Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	B
dysplasia	I
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	B
dysplasia	I
phenotype	O
.	O

We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	B
dysplasia	I
.	O

An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient	O
.	O

DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate	O
.	O

The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	O
.	O

Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage	O
.	O

These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	B
dysplasia	I
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
II	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
..	O

Mutation	O
spectrum	O
in	O
the	O
CHM	B
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	B
patients	O
.	O

The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B
(	O
CHM	B
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B
.	O

We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
technique	O
.	O

Causative	O
mutations	O
in	O
the	O
CHM	B
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O

In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O

Thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	B
gene	O
.	O

Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O

In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Interestingly	O
,	O
all	O
CHM	B
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
..	O

X	B
-	I
linked	I
spastic	I
paraplegia	I
and	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
are	O
allelic	B
disorders	I
at	O
the	O
proteolipid	O
protein	O
locus	O
.	O

Three	O
forms	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
have	O
been	O
defined	O
.	O

One	O
locus	O
(	O
SPG	O
1	O
)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O

A	O
rare	O
X	B
-	I
linked	I
dysmyelinating	I
disorder	I
of	O
the	O
central	O
nervous	O
system	O
,	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
Xq21-q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
PLP	O
and	O
DM20	O
.	O

While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree	O
,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus	O
,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene	O
.	O

We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(	O
His139Tyr	O
)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	O
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	O
=	O
0	O
.	O
00	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B
are	O
allelic	B
disorders	I

Huntington	B
disease	I
without	O
CAG	O
expansion	O
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	O
?	O

Huntington	B
disease	I
(	O
HD	B
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
CAG	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16	O
.	O

3	O
(	O
IT15	O
)	O
.	O

A	O
total	O
of	O
30	O
of	O
1	O
,	O
022	O
affected	O
persons	O
(	O
2	O
.	O
9	O
%	O
of	O
our	O
cohort	O
)	O
did	O
not	O
have	O
an	O
expanded	O
CAG	O
in	O
the	O
disease	O
range	O
.	O

The	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
HD	B
.	O

Here	O
we	O
show	O
that	O
the	O
majority	O
(	O
18	O
)	O
of	O
the	O
individuals	O
with	O
normal	O
sized	O
alleles	O
represent	O
misdiagnosis	O
,	O
sample	O
mix	O
-	O
up	O
,	O
or	O
clerical	O
error	O
.	O

The	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
HD	B
.	O

In	O
at	O
least	O
four	O
cases	O
,	O
family	O
studies	O
of	O
these	O
phenocopies	O
excluded	O
4p16	O
.	O

3	O
as	O
the	O
region	O
responsible	O
for	O
the	O
phenotype	O
.	O

Mutations	O
in	O
the	O
HD	B
gene	O
that	O
are	O
other	O
than	O
CAG	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	O
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
HD	B
.	O

This	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
HD	B

Assignment	O
of	O
the	O
human	O
Na+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
to	O
chromosome	O
22q13.1	O
.	O

The	O
Na	O
+	O
/glucose	O
cotransporter	O
gene	O
SGLT1	O
encodes	O
the	O
primary	O
carrier	O
protein	O
responsible	O
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	O
and	O
galactose	O
from	O
the	O
intestinal	O
lumen	O
.	O

SGLT1	O
transport	O
activity	O
is	O
currently	O
exploited	O
in	O
oral	O
rehydration	O
therapy	O
.	O

The	O
75-kDa	O
glycoprotein	O
is	O
localized	O
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	O
to	O
comprise	O
12	O
membrane	O
spans	O
.	O

In	O
two	O
patients	O
with	O
the	O
autosomal	B
recessive	I
disease	I
glucose	I
/	I
galactose	I
malabsorption	I
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
SGLT1	O
,	O
and	O
the	O
Asp28	O
-	O
-	O
>	O
Asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	O
transport	O
activity	O
.	O

The	O
SGLT1	O
gene	O
was	O
previously	O
shown	O
to	O
reside	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
(	O
11	O
.	O
2	O
-	O
-	O
>	O
qter	O
)	O
.	O

We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
which	O
refines	O
the	O
localization	O
to	O
22q13	O
.	O

1	O
,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	B
diseases	I
associated	O
with	O
translocations	O
of	O
chromosome	O
22	O
.	O

Haplotype	O
studies	O
in	O
Wilson	B
disease	I
.	O

In	O
51	O
families	O
with	O
Wilson	B
disease	I
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
CA	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O

3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	B
disease	I
gene	O
(	O
WND	B
)	O
.	O

In	O
addition	O
to	O
a	O
marker	O
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	O
to	O
the	O
WND	B
locus	O
.	O

We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	B
mutation	O
.	O

We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	B
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	B
disease	I
.	O

Brca1	B
deficiency	I
results	O
in	O
early	O
embryonic	B
lethality	I
characterized	O
by	O
neuroepithelial	B
abnormalities	I
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc	O
-	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
,	O
as	O
well	O
as	O
some	O
non	O
-	O
familial	O
sporadic	O
ovarian	B
cancers	I
.	O

The	O
loss	O
of	O
wild	O
-	O
type	O
BRCA1	O
in	O
tumours	B
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	B
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele	O
.	O

Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development	O
,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10-E13	O
)	O
.	O

Abnormalities	O
in	O
Brca1-deficient	B
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B
bifida	I
and	O
anencephaly	B
.	O

In	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
Brca1-deficient	B
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
..	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
elusive	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190-kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
family	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

Both	O
BRCA1	O
and	O
the	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O
hormones	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
suppressor	O
gene	O
products	O
..	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
locus	O
.	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
70	O
(	O
ref	O
.	O

1	O
)	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O

5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
of	O
cancer	B
penetrance	O
.	O

Individuals	O
who	O
have	O
rare	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
including	O
breast	B
cancer	I
(	O
2	O
-	O
4	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
technique	O
.	O

The	O
risk	O
for	O
ovarian	B
cancer	I
was	O
2	O
.	O
11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
.	O

Susceptibility	O
to	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B
cancer	I
syndrome	I

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3-untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O

3	O
.	O
Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
presence	O
of	O
the	O
expansion	O
.	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
of	O
chromatin	O
disruption	O
.	O

We	O
have	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O
5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
significant	O
homology	O
.	O

These	O
correspond	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
heart	O
and	O
brain	O
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

For	O
improvement	O
over	O
previous	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O
.	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
the	O
banding	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

By	O
using	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

The	O
mutations	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
..	O

Type	B
II	I
human	I
complement	I
C2	I
deficiency	I
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
--	O
>	O
Phe	O
;	O
Gly444	O
--	O
>	O
Arg	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

Type	B
II	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	O
common	O
Type	B
I	I
C2	I
deficiency	I
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
L	O
-	O
cells	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
deficiency	I
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
--	O
>	O
T	O
;	O
Ser189	O
--	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
--	O
>	O
A	O
;	O
Gly444	O
--	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
pathway	O
..	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
apparent	O
abnormality	O
.	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

The	O
second	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
.	O

The	O
structural	O
consequences	O
of	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
bond	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

We	O
conclude	O
that	O
CyS2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
..	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

The	O
Rho	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
and	O
Rho	O
.	O

This	O
interaction	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
.	O

This	O
clustering	O
is	O
not	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
.	O

Thus	O
,	O
WASP	O
provides	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O
in	O
WAS	B
.	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
..	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
's	I
disease	I
in	O
young	O
adult	O
male	O
patients	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O
yr	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
is	O
frequently	O
associated	O
with	O
AMN	B
or	O
cerebral	B
ALD	I
and	O
may	O
remain	O
the	O
only	O
clinical	O
expression	O
of	O
ALD	B
(	O
8	O
%	O
of	O
cases	O
)	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
remains	O
unknown	O
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B
insufficiency	I
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

None	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O
.	O

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B
ALD	I
,	O
one	O
had	O
adrenomyeloneuropathy	B
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
AMN	B
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
adults	O
..	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Prostate	B
cancer	I
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O
disease	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
carcinomas	I
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
.	O

We	O
report	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B
adenocarcinoma	I
cells	O
.	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
line	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O
p53	O
.	O

These	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
functionally	O
restored	O
in	O
prostatic	B
adenocarcinoma	I
..	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Inherited	O
mutant	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
.	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O

An	O
exception	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
.	O

This	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
.	O

A	O
second	O
,	O
recently	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B
cancer	I
roughly	O
equal	O
to	O
BRCA1	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B
suppressor	O
gene	O
.	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
breast	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
breast	B
carcinoma	I
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibility	O
to	O
pancreatic	B
cancer	I
..	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O
.	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
direct	O
sequencing	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
.	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
mutations	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B
cancer	I
phenotype	O
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	B
.	O

Other	O
tumor	B
types	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

In	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B
cancer	I
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O

001	O
)	O
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

Rapid	O
detection	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

UKCCCR	O
Familial	O
Ovarian	B
Cancer	I
Study	O
Group	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B
and/or	I
ovarian	I
cancer	I
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
.	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
mutations	O
so	O
far	O
reported	O
in	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
..	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

We	O
report	O
details	O
of	O
a	O
family	O
with	O
classic	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	B
suppressor	O
gene	O
TP53	O
.	O

Codon	O
344	O
is	O
a	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B
tumours	I
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O

The	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
the	O
spectrum	O
of	O
tumours	B
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
tumour	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
..	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
71	O
patients	O
.	O

Four	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

No	O
region	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
in	O
single	O
base	O
substitutions	O
.	O

Recurrent	O
transitions	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
codons	O
within	O
the	O
RB1	O
.	O

No	O
mutation	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
.	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3-terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
.	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

No	O
correlation	O
between	O
the	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
..	O

Phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
reveals	O
HD	B
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
.	O

Abnormal	O
CAG	O
expansions	O
in	O
the	O
IT-15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

Most	O
large	O
analyses	O
that	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
.	O

Many	O
of	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
.	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
.	O

We	O
have	O
optimized	O
methods	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
.	O

Seven	O
HD	B
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
.	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95-year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
HD	B
.	O

The	O
apparently	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
HD	B
mutation	O
may	O
not	O
always	O
be	O
fully	O
penetrant	O
..	O

Identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O
background	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1-	O
and	O
4-bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16	O
T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
Canavan	B
disease	I
.	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

Six	O
single	O
-	O
base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16	O
T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O
.	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
.	O

In	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	B
of	I
ASPA	I
and	O
should	O
therefore	O
result	O
in	O
Canavan	B
disease	I
..	O

Identification	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
has	O
been	O
identified	O
.	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22-q23	O
..	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O

the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
sequence	O
.	O

A	O
distinct	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

The	O
genomic	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
expressed	O
as	O
an	O
approximately	O
2	O
.	O

4-kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
.	O

Chromosomal	O
mapping	O
in	O
an	O
interspecific	O
M.	O
Musculus	O
/	O
M.	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

This	O
localization	O
makes	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	O
fatal	B
lymphoreticular	I
disease	I
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
fever	I
.	O

OBJECTIVE	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
.	O

METHODS	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O
.	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
.	O

RESULTS	O
.	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
.	O

Its	O
levels	O
ranged	O
between	O
1	O
.	O
9	O
and	O
8	O
.	O
6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
curves	O
)	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
factors	O
.	O

CONCLUSION	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
infant	O
is	O
small	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
take	O
colchicine	O
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B
in	O
mice	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
in	O
mice	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
neonatal	O
mortality	O
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

These	O
results	O
strengthen	O
the	O
contention	O
that	O
simple	O
loss-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
..	O

Mice	O
lacking	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	B
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk-	O
/	O
-	O
)	O
mice	O
.	O

Dmpk-	O
/	O
-mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
features	O
with	O
DM	B
.	O

Muscles	O
from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
.	O

Adult	O
Dmpk-	O
/	O
-mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
generation	O
compared	O
to	O
young	O
mice	O
.	O

Our	O
results	O
indicate	O
that	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	O
DM	B
pathology	O
..	O

The	O
tumor	B
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

Mutations	O
of	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/-	O

mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
eleven	O
months	O
.	O

Homozygous	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoderm	O
formation	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm-2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

The	O
expression	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
.	O

Buttressing	O
these	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
.	O

Thus	O
,	O
the	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O
levels	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
mutations	O
(	O
D442	O
G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14	O
G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442	O
G	O
)	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O
43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
,	O
the	O
RR	O
was	O
1	O
.	O
55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O
68	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442	O
G	O
mutation	O
alone	O
.	O

Increased	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	B
prevalence	O
.	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442	O
G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i.	O
e.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

2	O
2	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
WAS	B
and	O
in	O
patients	O
showing	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

Mutation	O
analysis	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
like	O
filaments	O
..	O

Influence	O
of	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
PAX6	O
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
abnormalities	I
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O
.	O

When	O
crossed	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
transgene	O
rescues	O
the	O
mutant	O
phenotype	O
.	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

Thus	O
,	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
defects	I
..	O

Heterodimer	O
formation	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose-1-phosphate	O
uridylyltransferase	O
.	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
true	O
molecular	O
homozygotes	O
.	O

Furthermore	O
,	O
the	O
broad	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
.	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O
?	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
defined	O
heterodimer	O
pools	O
.	O

We	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
activity	O
.	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
..	O

Cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED-3	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
.	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
of	I
inappropriate	I
apoptosis	I
..	O

The	O
5	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
region	O
.	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O
terms	O
.	O

We	O
also	O
show	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
directly	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
believe	O
that	O
these	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
..	O

Deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
in	O
either	O
patient	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
critical	O
region	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
..	O

Expression	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
carcinoma	I
and	O
phaeochromocytoma	B
.	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

Regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
VHL	B
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

Although	O
VHL	B
mRNA	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

Within	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

Two	O
alternatively	O
spliced	O
VHL	B
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
..	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

However	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
is	O
explained	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
ovarian	I
cancer	I
risk	O
.	O

Twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B
cancer	I
research	O
programs	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B
or	I
ovarian	I
cancer	I
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

No	O
families	O
were	O
attributed	O
to	O
BRCA2	O
.	O

Five	O
families	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
five	O
families	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
..	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
fish	B
-	I
eye	I
disease	I
)	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O
structure	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
sequence	O
.	O

Three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B
-	I
eye	I
disease	I
(	O
FED	B
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

Sequencing	O
of	O
the	O
LCAT	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
FED	B
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
IVS4	O
T-22C	O
)	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
intron	O
retention	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
allele	O
in	O
a	O
patient	O
with	O
FED	B
.	O

In	O
addition	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
gene	O
expression	O
..	O

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-15	O
%	O
of	O
A	B
-	I
T	I
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137-bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
second	O
A	B
-	I
T	I
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

The	O
level	O
of	O
the	O
137-bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B
ataxia	I
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
patients	O
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
-	I
T	I
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
..	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and/or	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

Chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

In	O
22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and/or	O
HD	O
analysis	O
.	O

No	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

In	O
addition	O
,	O
15	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
.	O

None	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
patterns	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinoma	I
..	O

The	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
-	O
reacting	O
proteins	O
.	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
detected	O
in	O
some	O
tissues	O
.	O

Immunofluorescence	O
microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
.	O

A	O
muscle	O
biopsy	O
from	O
an	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
EDMD	B
families	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post-100	O
,	O
000	O
g	O
)	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O
..	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O

Many	O
human	O
tumours	B
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O

It	O
is	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
instability	O
.	O

In	O
yeast	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
.	O

Thus	O
,	O
we	O
screened	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

Extracts	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
..	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
.	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
-mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
R	O
-	O
banding	O
FISH	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O
q24	O
.	O

1	O
of	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4-qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
.	O

The	O
regions	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O
2	O
.	O

0	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O
3	O
cM	O
proximal	O
to	O
D9Mit102	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

An	O
animal	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
mice	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

The	O
outer	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
.	O

At	O
the	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
.	O

These	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
..	O

The	O
hybrid	O
PAX3-FKHR	O
fusion	O
protein	O
of	O
alveolar	B
rhabdomyosarcoma	I
transforms	O
fibroblasts	O
in	O
culture	O
.	O

Pediatric	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
.	O

PAX3	O
codes	O
for	O
a	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O
factor	O
.	O

The	O
PAX3-FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3-FKHR	O
protein	O
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3-FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
.	O

Expression	O
of	O
the	O
PAX3-FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3-FKHR	O
-	O
induced	O
oncogenesis	O
..	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose-6-phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B
deficiency	I
.	O

X	O
-	O
chromosome	O
inactivation	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O
.	O

In	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose-6-phosphate	B
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G--	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C--	O
>	O
T	O
)	O
.	O

We	O
found	O
that	O
in	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
severe	O
G6PD	B
deficiency	I
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
..	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
.	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
.	O

To	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
DM	B
locus	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
distortion	O
.	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
difference	O
from	O
.	O

5	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13-q15	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27-q28	O
is	O
preferentially	O
involved	O
.	O

In	O
previous	O
studies	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3-derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
.	O

Using	O
3-RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	B
cell	O
line	O
Li-501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27-q28	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

Upon	O
partial	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
organization	O
of	O
LPP	O
were	O
established	O
.	O

The	O
gene	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kb	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
three	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
lines	O
and	O
primary	B
lipomas	I
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27-q28	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
..	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
disease	I
transcript	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
gene	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

By	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B
abnormalities	I
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

In	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O

Rather	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
97	O
meioses	O
.	O

This	O
suggests	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
..	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7;11	O
)	O
(	O
q31.2;p13	O
)	O
.	O

A	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

This	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
abnormalities	I
with	O
11p13	O
breakpoints	O
..	O

Muscle	O
expression	O
of	O
glucose-6-phosphate	B
dehydrogenase	I
deficiency	I
in	O
different	O
variants	O
.	O

Muscle	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

The	O
type	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
.	O

All	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
=	O
0	O
.	O

390X	O
+	O
0	O
.	O
198	O
198	O
.	O

The	O
results	O
suggest	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

Gene	O
therapy	O
for	O
phenylketonuria	B
.	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O

Three	O
different	O
vector	O
systems	O
have	O
been	O
examined	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
can	O
not	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	B
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
..	O

Exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
low	O
-	O
voltage	O
EEG	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
one	O
extended	O
pedigree	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I
..	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
in	O
carrier	O
females	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
and	O
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B
breast	I
cancer	I
cases	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
majority	O
resulting	O
in	O
protein	O
truncation	O
.	O

A	O
specific	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
.	O
9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O
haplotype	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O

8)	O
,	O
as	O
well	O
as	O
in	O
three	O
Ashkenazi	O
male	B
breast	I
cancer	I
patients	O
.	O

We	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
.	O

BRCA1	O
mutation	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O
09	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
.	O
13	O
%	O
for	O
the	O
5382insC	O
mutation	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O
52	O
%	O
for	O
the	O
6174delT	O
mutation	O
.	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

Dual	O
roles	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O

In	O
addition	O
,	O
ATM-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O
.	O

ATM-	O
/	O
-	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O
culture	O
.	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
cycle	O
progression	O
.	O

ATM	O
+	O
/-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
..	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
thymic	B
lymphoma	I
.	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B
human	I
disease	I
ataxia	B
-	I
telangiectasia	I
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
homologous	O
recombination	O
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

The	O
homozygous	O
mutant	O
(	O
ATM-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

The	O
infertility	B
of	O
ATM-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O

The	O
cerebella	O
of	O
ATM-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B
abnormalities	I
.	O

The	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
..	O

Cloning	O
and	O
characterization	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
the	O
initial	O
step	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
used	O
the	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
these	O
genes	O
are	O
evolutionarily	O
related	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
chromosome	O
17p11	O
.	O

2-p11	O
.	O

13105	O
.	O

Using	O
Northern	O
and	O
Western	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
deficiency	I
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
VLCAD	O
alleles	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
and	I
C7	I
deficiencies	I
.	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

A	O
defect	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O
point	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
,	O
forming	O
a	O
distinct	O
haplotype	O
.	O

The	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
C6	B
or	I
C7	I
deficiency	I
,	O
but	O
with	O
different	O
consequences	O
.	O

Where	O
it	O
is	O
combined	O
with	O
a	O
C6-deficient	B
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

In	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
small	O
amount	O
of	O
C7	O
.	O

Each	O
molecular	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
..	O

Genetic	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
Neisseria	B
meningitidis	I
.	O

We	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
.	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
exon	O
15	O
of	O
case	O
2	O
.	O

The	O
mutation	O
of	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

In	O
case	O
2	O
,	O
a	O
homozygous	O
2-bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
C7D	B
in	O
case	O
1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
components	I
..	O

HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
deficient	I
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B
of	I
APRT	I
in	O
combination	O
with	O
HPRT	B
-	I
deficiency	I
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
C.	O
L.	O
Wu	O
and	O
D.	O
W.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O

3	O
,	O
235	O
-	O
240	O
]	O
.	O

To	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8-dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O

Thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
deficient	I
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
previously	O
suggested	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
cancers	I
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12-base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B
cancers	I
,	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
..	O

Pleiotropic	O
defects	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
mice	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O
.	O

Atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

Atm	O
-	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
..	O

The	O
DCC	O
protein	O
and	O
prognosis	O
in	O
colorectal	B
cancer	I
.	O

BACKGROUND	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
.	O

Although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
cancer	I
)	O
gene	O
is	O
a	O
candidate	O
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
carcinoma	I
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

The	O
Cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	B
site	O
,	O
degree	O
of	O
tumor	B
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O
3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O
6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
patients	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O

3	O
percent	O
and	O
33	O
.	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
group	O
of	O
patients	O

Association	O
of	O
anxiety	B
-	I
related	I
traits	I
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5-hydroxytryptamine	O
or	O
5-HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Human	O
5-HT	O
transporter	O
(	O
5-HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
in	O
its	O
upstream	O
regulatory	O
region	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5-HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5-HTT	O
expression	O
and	O
5-HT	O
uptake	O
in	O
lymphoblasts	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5-HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
..	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO-2	B
,	O
one	O
with	O
DTD	B
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
AO2	B
/	O
DTD	B
)	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
three	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862	O
t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
""""	O
Finnish	O
""""	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
DTDST	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O

This	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
..	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
WASP	O
mutation	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
can	O
not	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O
genotypes	O
..	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	B
.	O

Mutations	O
at	O
the	O
5	O
end	O
of	O
APC	B
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
APC	B
protein	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
AAPC	B
phenotype	O
..	O

Complete	O
genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

The	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143-bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O
specific	O
library	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
span	O
an	O
81-kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
density	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
8	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
to	O
9	O
.	O
2	O
kb	O
and	O
contain	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

Partial	O
sequences	O
of	O
the	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O
the	O
contig	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
intron	O
13	O
.	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere-1FP	O
35-VAT1-Rho7-BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

Identification	O
of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O
.	O

The	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
.	O

This	O
BRCA1-associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O
of	O
BRCA1	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B
cancer	I
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B
suppression	O
by	O
BRCA1	O
..	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O

We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20-nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O

45-kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O

Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21-q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21-q32	O
(	O
HRPT2	O
)	O
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

In	O
the	O
first	O
family	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	B
and	O
JT	B
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

The	O
possibility	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21-q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	B
and	O
MEN2	B
regions	O
was	O
excluded	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
to	O
approximately	O
34	O
centimorgans	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
.	O

All	O
renal	B
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21-q32	O
region	O
.	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

Independent	O
origin	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6-phosphate	O
dehydrogenase	O
gene	O
.	O

The	O
vast	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
.	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A--	O
>	O
G	O
(	O
126	O
Asn--	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O
G6PD	O
A.	O
In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A--	O
>	O
T	O
(	O
181	O
Asp--	O
>	O
Val	O
)	O
mutation	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

G6PD	O
Malaga	O
is	O
associated	O
with	O
enzyme	B
deficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A--	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

These	O
findings	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
..	O

BRCA1	O
R841W	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
.	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C--	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
cases	O
from	O
Orange	O
County	O
,	O
CA	O
.	O

These	O
are	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O
.	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B
incidence	O
with	O
the	O
presence	O
of	O
R841W	O
.	O

The	O
age	O
of	O
cancer	B
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	B
in	O
one	O
parent	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
this	O
population	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
founder	O
effect	O
among	O
north	O
African	O
Jews	O
.	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
characterized	O
by	O
cerebellar	B
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B
predisposition	I
.	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
-	I
prone	I
.	O

A	O
wide	O
variety	O
of	O
A	B
-	I
T	I
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O

However	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	O
A	B
-	I
T	I
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

This	O
mutation	O
,	O
103C--	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
origin	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
a	O
large	O
Jewish	O
community	O
..	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
breast	I
cancer	I
population	O
.	O

A	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B
breast	I
cancer	I
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

Nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O

A	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B
/	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

No	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Only	O
one	O
of	O
the	O
two	O
male	B
breast	I
cancer	I
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B
,	O
with	O
one	O
case	O
of	O
ovarian	B
cancer	I
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B
breast	I
cancer	I
with	O
a	O
family	O
history	O
of	O
breast	B
/	I
ovarian	I
cancer	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
or	O
the	O
BRCA2	O
gene	O
..	O

Molecular	O
basis	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
/	O
N314D	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
""""	O
Los	O
Angeles	O
(	O
LA	O
)	O
phenotype	O
,	O
""""	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
containing	O
alleles	O
.	O

We	O
found	O
seven	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C--	O
>	O
T	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O
.	O

The	O
1721C--	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
L218L	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C--	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
/	O
D	O
)	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
.	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C--	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
..	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O
15	O
.	O
1	O
-	O
15	O
1	O
-	O
15	O
.	O
2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B
cancer	I
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	B
.	O

No	O
TSG101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B
cancer	I

Moderate	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
a	O
55-CTG	O
repeat	O
in	O
transgenic	O
mice	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
.	O

The	O
(	O
CTG	O
)	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
DM	B
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
.	O

To	O
investigate	O
the	O
role	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45-kb	O
genomic	O
segment	O
with	O
a	O
55-CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O
..	O

Missense	O
mutations	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

The	O
Fas	O
/	O
Apo-1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
Fas	O
gene	O
.	O

We	O
describe	O
a	O
novel	O
family	O
with	O
ALPS	B
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
manifestations	I
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4-CD8-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin-2	O
receptor	O
(	O
slL-2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
..	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O

The	O
product	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

ATM	O
protein	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
..	O

Type	O
III	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
of	O
internal	O
organs	O
and	O
skin	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
,	O
a	O
disease	O
leading	O
to	O
aortic	B
rupture	I
in	O
early	O
adult	O
life	O
.	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O
..	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

We	O
report	O
a	O
G--	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
.	O

The	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
.	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O

The	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B
-	I
associated	I
disease	I
in	O
both	O
humans	O
and	O
mice	O
..	O

Common	O
BRCA1	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
general	O
population	O
.	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B
cancer	I
incidence	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

There	O
are	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

We	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
large	O
series	O
of	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
matched	O
controls	O
.	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
.	O
3	O
%	O
.	O

The	O
most	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
.	O
57	O
and	O
0	O
.	O
32	O
respectively	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
ovarian	I
cancer	I
risk	O
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B
cancer	I
.	O

If	O
this	O
finding	O
can	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O
function	O
.	O

Kniest	B
dysplasia	I
:	O
Dr.	O
W.	O
Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
.	O

Kniest	B
dysplasia	I
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
.	O

We	O
report	O
about	O
Dr.	O
Kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
mobility	I
,	O
and	O
blindness	B
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O
..	O

Cloning	O
of	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
mouse	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2-dioxygenase	O
(	O
HGO	O
;	O
E.	O
C.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
mouse	O
liver	O
.	O

After	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
.	O

The	O
deduced	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

By	O
combining	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

One	O
clone	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
.	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
predicted	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

The	O
positions	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
determined	O
by	O
multiple	O
sequence	O
alignment	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
gene	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
different	O
cDNAs	O
.	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
.	O

3-q21	O
.	O

This	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	B
gene	O
(	O
AKU	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
cancer	I
.	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B
cancer	I
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B
glioblastomas	I
.	O

The	O
predicted	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O
adhesions	O
.	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
suppress	O
tumor	B
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	B
cell	O
invasion	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adhesions	O
..	O

Heterogeneity	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
.	O

Genetic	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O
subgroups	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B
dysplasia	I
with	O
myotonia	B
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O
changes	O
.	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B
type	I
1A	I
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B
dysplasia	I
resembling	O
Pyle	B
disease	I
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

CONCLUSIONS	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

The	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
..	O

A	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
WT	I
)	O
carry	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B
granulosa	I
cell	I
tumour	I
,	O
non	B
-	I
asbestos	I
related	I
mesothelioma	I
,	O
desmoplastic	B
small	I
round	I
cell	I
tumour	I
and	O
,	O
most	O
recently	O
,	O
acute	B
myeloid	I
leukemia	I
..	O

A	O
mutation	O
in	O
autosomal	B
dominant	I
myotonia	I
congenita	I
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
inherited	B
disorder	I
of	I
skeletal	I
muscle	I
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
Cl-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl-	O
channel	O
(	O
hCIC-1	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O

I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
the	O
hClC-1	O
conduction	O
pathway	O
.	O

Both	O
binding	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

These	O
findings	O
suggest	O
that	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC-1	O
and	O
that	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
..	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

Twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

Three	O
mutation	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
.	O

The	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
.	O

For	O
RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
.	O

On	O
genomic	O
products	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
.	O

Ten	O
of	O
the	O
possible	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
and	O
12	O
.	O

SSCP	O
analysis	O
of	O
individually	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
the	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O
..	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
Japanese	O
.	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O
region	O
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
with	O
IDDM	B
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
9	O
)	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

These	O
data	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
.	O

The	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	B
in	O
Japanese	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O
complex	O
.	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B
infections	I
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
C9	I
deficiency	I
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
464	O
)	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

Therefore	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
10	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
..	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O
in	O
individual	O
families	O
.	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B
cancer	I
.	O

Conformation	O
-	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

RESULTS	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
BRCA1	O
mutations	O
.	O

The	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
.	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B
cancer	I
,	O
the	O
presence	O
of	O
ovarian	B
cancer	I
,	O
the	O
presence	O
of	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
woman	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
BRCA1	O
mutation	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B
cancer	I
in	O
a	O
family	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
breast	B
cancer	I
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O

These	O
results	O
suggest	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
..	O

Mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
ARP	O
)	O
in	O
pancreatic	B
cancer	I
.	O

The	O
ARP	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

1	O
1	O
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
tumors	I
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B
previously	O
examined	O
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
tumors	I
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B
.	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9-deficient	B
subject	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

One	O
patient	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
absent	O
.	O

The	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
.	O

Western	O
blot	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
detection	O
of	O
this	O
molecule	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
C9	O
.	O

We	O
also	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
..	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B
and	I
ovarian	I
cancer	I
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
ESR	O
)	O
.	O

Three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	B
were	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O
.	O

This	O
alteration	O
was	O
also	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
.	O

However	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B
cancer	I
was	O
carrying	O
the	O
variant	O
allele	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
can	O
not	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
further	O
investigated	O
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
receptor	I
-	I
positive	I
breast	I
carcinomas	I
..	O

Molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
different	O
defects	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O
family	O
.	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
be	O
deleted	O
.	O

Marker	O
haplotype	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

The	O
Israeli	O
C7-deficient	B
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
..	O

Molecular	O
heterogeneity	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
Duarte-1	O
(	O
D-1	O
)	O
and	O
Duarte-2	O
(	O
D-2	O
)	O
,	O
both	O
of	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O
.	O

D-1	O
increases	O
,	O
whereas	O
D-2	O
decreases	O
GALT	O
activity	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D-2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
D-1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B
alleles	O
.	O

Q188R	O
accounted	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Eight	O
novel	O
candidate	O
galactosemia	B
mutations	O
were	O
found	O
.	O

On	O
all	O
D-2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D-1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
mutation	O
in	O
our	O
population	O
..	O

Isolation	O
of	O
full	O
-	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
ATM	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

ATM	O
is	O
a	O
member	O
of	O
the	O
phosphatidylinositol-3-kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
-	I
T	I
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
..	O

Fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

In	O
the	O
pediatric	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
PAX3-FKHR	O
or	O
PAX7-FKHR	O
fusion	O
proteins	O
,	O
respectively	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O
overexpression	O
.	O

Furthermore	O
,	O
PAX3-FKHR	O
and	O
PAX7-FKHR	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O
.	O

Transcription	O
of	O
PAX3-FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
independent	O
process	O
.	O

In	O
contrast	O
,	O
PAX7-FKHR	O
overexpression	O
results	O
from	O
fusion	O
gene	O
amplification	O
.	O

Thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3-FKHR	O
and	O
PAX7-FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
fusions	O
..	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
toxicity	I
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
respectively	O
.	O

The	O
two	O
genes	O
are	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
.	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	O
T	B
-	I
cell	I
lymphomas	I
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O

To	O
study	O
the	O
interactions	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

With	O
respect	O
to	O
their	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

This	O
implies	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B
..	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
expression	O
of	O
DMAHP	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O

3	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

Although	O
the	O
DM	B
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O
gene	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O

Allele	O
-	O
specific	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
DM	B
pathogenesis	O
.	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C--	O
>	O
T	O
transitions	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
of	O
5-methylcytosine	O
within	O
these	O
CpGs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
of	O
RB1	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O
.	O

We	O
found	O
that	O
DNA	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O
..	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
and	I
sporadic	I
RCCs	I
.	O

Recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC-	B
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

We	O
have	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5-	O
to	O
10-fold	O
.	O

Deletion	O
analysis	O
defined	O
a	O
144-bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1-mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
directly	O
interact	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
and	O
RCC	B
..	O

Adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B
GALC	I
activity	I
in	O
their	O
leukocytes	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66	O
M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon-6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66	O
M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
.	O

The	O
fourth	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
in	O
COS-1	O
cells	O
.	O

Three	O
mutations	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon-6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B
GALC	I
activity	I
as	O
expected	O
.	O

The	O
I66	O
M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
low	O
enzymatic	O
activity	O
.	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66	O
M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
central	O
domain	O
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
GLD	B
.	O

Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
system	I
disorder	I
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22-q23	O
(	O
ref	O
.	O

3	O
)	O
.	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
T	I
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B
-	I
PLL	I
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutations	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O

Two	O
of	O
seventeen	O
mutated	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
previously	O
reported	O
A	B
-	I
T	I
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B
.	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	B
DNA	O
from	O
patients	O
with	O
B	B
-	I
cell	I
non	I
-	I
Hodgkins	I
lymphomas	I
(	O
B	B
-	I
NHL	I
)	O
and	O
a	O
B	B
-	I
NHL	I
cell	O
line	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	B
suppressor	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
investigation	O
..	O

Myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
..	O

Constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
predisposition	O
to	O
their	O
offspring	O
.	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B
tissue	O
.	O

The	O
analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B
and	O
the	O
other	O
later	O
developed	O
bilateral	B
retinoblastoma	I
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
..	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
man	O
.	O

I.	O
Clinical	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

The	O
proband	O
,	O
a	O
20-year	O
-	O
old	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components	O
.	O

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B
deficiency	I
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5-deficient	B
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
..	O

Susceptibility	O
to	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
.	O

METHODS	O
Twins	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	B
.	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27-positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
""""	O
BRCA1	O
nuclear	O
dots	O
.	O
""""	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1-	O
and	O
S	O
-	O
phase	O
cells	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1-mediated	O
tumor	B
suppression	O
.	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O
.	O

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A.	O
Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

The	O
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	B
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
->Val	O
in	O
neurophysin	O
II	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	O
NPII	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

A	O
T1-weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
..	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
cancer	I
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
common	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B
remain	O
to	O
be	O
elucidated	O
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
cancer	I
.	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O

A	O
new	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B
cancer	I
cell	O
lines	O
.	O

We	O
screened	O
80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
..	O

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
.	O

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B
.	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

With	O
direct	O
tests	O
for	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
..	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B
IVA	I
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O
4	O
%	O
and	O
10	O
.	O
5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B
cancer	I
families	O
and	O
in	O
one	O
breast	B
-	I
ovarian	I
cancer	I
family	O
.	O

among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
.	O
8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

3	O
and	O
37	O
.	O
4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
.	O

2	O
years	O
.	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B
/	I
ovarian	I
cancer	I
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

Paternal	O
transmission	O
of	O
congenital	B
myotonic	I
dystrophy	I
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B
myotonic	I
dystrophy	I
(	O
DM	B
)	O
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B
.	O

Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
.	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
have	O
been	O
reported	O
recently	O
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B
DM	I
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
30	O
years	O
in	O
the	O
father	O
..	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B
and	I
retinal	I
tumours	I
of	O
the	O
patient	O
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B
and	I
the	I
pineal	I
tumours	I
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O
.	O

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B
..	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O
5	O
%	O
-6	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A.	O
Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
.	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
.	O

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O

Growth	B
retardation	I
of	O
the	O
Smad4-deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B
defect	I
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
.	O

The	O
French	O
Familial	B
Melanoma	I
Study	O
Group	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B
melanoma	I
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B
-	O
predisposing	O
gene	O
..	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

The	O
genetic	O
basis	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
can	O
not	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and/or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
..	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
..	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B
-	I
T	I
but	O
may	O
be	O
cancer	B
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2-phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B
-	I
T	I
patients	O
,	O
13	O
obligate	O
A	B
-	I
T	I
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
that	O
the	O
G2-phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B
-	I
T	I
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B
risk	O
or	O
development	O
..	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
..	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
hemangioblastomas	I
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
..	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796	O
G	O
.	O

Though	O
auditory	B
anomalies	I
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B
syndrome	I
..	O

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O
5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I.	O
All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23-q25	O
near	O
COL17A1	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
..	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
.	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
5	O
side	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/-SD	O
=	O
0	O
.	O
049	O
+	O
/-0	O
.	O

043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/-1	O
.	O

07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O
50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/-0	O
.	O

33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B
remains	O
unknown	O

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B
,	O
lymphoma	B
,	O
and	O
breast	B
cancer	I
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B
-	I
T	I
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T--	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	B
-	I
T	I
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B
degeneration	I
.	O

This	O
mutation	O
(	O
7271T--	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B
-	I
T	I
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
..	O

The	O
hemochromatosis	B
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
.	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys-282	O
--	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2-microglobulin	O
(	O
beta2	O
m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2	O
m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR.	O
Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2	O
m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2	O
m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B
hemochromatosis	I
..	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6-AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6-AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
lack	O
15q11-q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B
disomy	I
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O
6	O
kb	O
and	O
a	O
3-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O
5	O
kb	O
of	O
5-UTR	O
and	O
>	O
2	O
kb	O
of	O
3-UTR	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
mutation	O
.	O

The	O
tumour	B
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B
.	O

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B
breast	I
,	I
brain	I
,	I
prostate	I
and	I
kidney	I
cancer	I
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumours	I
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	B
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutations	O
identified	O
in	O
this	O
exon	O
.	O

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
.	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B
families	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
breast	I
disease	I
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
.	O

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
deficiency	I
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16-year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
neisserial	B
infection	I
.	O

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
..	O

PAX6	O
mutations	O
reviewed	O
.	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
congenital	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Very	O
nearly	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
..	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B
cancer	I
families	O
.	O

The	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B
-	I
ovarian	I
cancer	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B
cancer	I
only	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-77	O
%	O
)	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2-mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
cancer	I
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
corresponding	O
ovarian	B
cancer	I
risks	O
were	O
0	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B
movement	I
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxia	I
type	I
I.	I
We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B
.	O

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	O
.	O

In	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
..	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

Ventricular	B
fibrillation	I
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

A	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
..	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

One	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
..	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B
mesangial	I
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
diffuse	B
mesangial	I
sclerosis	I
(	O
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and/or	O
Wilms	B
tumor	I
(	O
WT	B
)	O
.	O

Most	O
mutations	O
in	O
DDS	B
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
DDS	B
,	O
and	O
4	O
with	O
urogenital	B
abnormalities	I
and/or	O
WT	B
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B
.	O

One	O
male	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

Two	O
mutations	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
described	O
in	O
DDS	B
patients	O
.	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
..	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
population	O
.	O

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I
cancer	I
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
..	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
hemochromatosis	I
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O

The	O
2	O
.	O
6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

Four	O
mutations	O
--	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
--	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
disease	I
.	O

Arg778Leu	O
,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O
5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B
disease	I
.	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B
gene	O
.	O

One	O
model	O
of	O
DM	B
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
..	O

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	B
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
..	O

Genetic	O
heterogeneity	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O
.	O

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B
synostosis	I
,	O
brachycephaly	B
,	O
low	B
frontal	I
hairline	I
,	O
facial	B
asymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
broad	B
great	I
toes	I
,	O
and	O
clinodactyly	B
.	O

Significant	O
intra-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B
condition	I
-	O
such	O
as	O
Saethre	B
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
..	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11-q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
families	O
.	O

Two	O
identical	O
de	O
novo	O
5-bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	B
daughter	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
..	O

The	O
hemochromatosis	B
845	O
G-->A	O
and	O
187	O
C-->G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
and	O
premature	B
death	I
.	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G--	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C--	O
>	O
G	O
(	O
H63D	O
)	O
.	O

Although	O
hemochromatosis	B
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G--	O
>	O
A	O
and	O
187	O
C--	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G--	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G--	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
C--	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O
68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C--	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C--	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G--	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
families	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B
adenomas	I
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
observed	O
.	O

No	O
desmoid	B
tumors	I
were	O
found	O
in	O
these	O
kindreds	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
..	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax-1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF-1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF-1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

In	O
males	O
,	O
SF-1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF-1	O
to	O
promote	O
MIS	O
expression	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
to	O
synergize	O
with	O
SF-1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax-1	O
,	O
antagonizes	O
synergy	O
between	O
SF-1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
SF-1	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax-1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF-1-mediated	O
transactivation	O
..	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
centre	O
mutations	O
.	O

Imprinting	O
in	O
the	O
15q11-q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	B
infants	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
..	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	B
-	I
T	I
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B
-	I
T	I
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

The	O
others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T--	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

We	O
identified	O
a	O
1422	O
G--	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4-bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS-7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
TSD	B
.	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G--	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
deficiency	I
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
this	O
proband	O
..	O

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22-q31	O
.	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	B
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

The	O
identification	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
.	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

The	O
insertion	O
was	O
a	O
5-truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5-untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
..	O

Severe	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B
deficiency	I
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin-4-receptor	O
(	O
MC4-R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	O

Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013	O
T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
..	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
deficiency	I
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
..	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
phenotype	O
.	O

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B
tumors	I
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys--	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
..	O

Maternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3;15	O
)	O
(	O
p25;q11.2	O
)	O
.	O

Maternal	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
for	I
chromosome	I
15	I
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent-1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O

2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
J.	O
B.	O
)	O
,	O
a	O
17-year	O
-	O
old	O
white	O
male	O
with	O
PWS	B
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J.	O
B.	O
Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J.	O
B.	O
Maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O

A	O
niece	O
(	O
B.	O
B.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p.	O
Uniparental	B
disomy	I
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
.	O

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
PWS	B

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
""""	O
lumping	O
""""	O
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
skeletal	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
2	I
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
,	O
which	O
comprises	O
campomelia	B
at	O
birth	O
with	O
skeletal	B
dysplasia	I
,	O
contractures	B
,	O
and	O
early	B
death	I
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
..	O

A	O
mouse	O
model	O
of	O
severe	O
von	B
Willebrand	I
disease	I
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B
.	O

von	B
Willebrand	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
von	B
Willebrand	I
disease	I
in	O
humans	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

vWf	B
-	I
deficient	I
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O

Defective	O
thrombosis	B
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
..	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B
ovarian	I
cancer	I
.	O

Hereditary	B
Ovarian	I
Cancer	I
Clinical	O
Study	O
Group	O
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B
forms	I
of	I
ovarian	I
cancer	I
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	O
.	O

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O

8)	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B
cancer	I
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B
type	O
.	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
AD	B
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B
of	I
the	I
cerebral	I
white	I
matter	I
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B
lesion	I
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B
degeneration	I
in	O
ALD	B
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
..	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
deficiency	I
.	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9-deficient	B
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B
meningitis	I
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA--	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9-deficient	B
individuals	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
..	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
..	O

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-rich	O
transactivation	O
domain	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5-fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
..	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
deficiency	I
.	O

Very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
the	O
outcome	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B
in	O
children	O
..	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
(	O
IDDM	B
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B
.	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
..	O

The	O
APC	B
variants	O
I1307	O
K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
gene	O
.	O

A	O
variant	O
of	O
FAP	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	B
gene	O
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
""""	O
multiple	O
""""	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
.	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
mutations	O
in	O
the	O
APC	B
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307	O
K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B
tumors	I
,	O
including	O
multiple	O
adenomas	B
,	O
in	O
Ashkenazim	O
.	O

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and/or	I
carcinoma	I
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15	O
G	O
)	O
of	O
the	O
APC	B
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O

Three	O
patients	O
with	O
the	O
I1307	O
K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B
cancer	I
risk	O
in	O
the	O
general	O
population	O
..	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
gene	O
.	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39	O
kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H_RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
gene	O
(	O
PDS	B
)	O
..	O

The	O
APCI1307	O
K	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

APC	B
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307	O
K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

The	O
I1307	O
K	O
allele	O
was	O
found	O
in	O
6	O
.	O
1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
(	O
ref	O
.	O

2	O
)	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307	O
K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

Risk	O
of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307	O
K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
gene	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B
gene	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
..	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B
leukodystrophy	I
.	O

Deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
al.	O
,	O
1997	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	B

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
syndrome	I
)	O
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
..	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and/or	O
homologous	O
recombination	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and/or	I
ovarian	I
cancer	I
..	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27-hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS-1	O
cells	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O
5	O
%	O
of	O
the	O
normal	O
level	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-2	O
position	O
of	O
exon	O
6-intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS-1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27-hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
Dutch	O
population	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B
-	I
T	I
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Moreover	O
,	O
a	O
16	O
.	O

7-kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype	O
.	O

All	O
patients	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O
5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B
cancer	I
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
from	O
Quebec	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O

The	O
BRCA1	O
C4446	O
T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B
cancer	I
in	O
the	O
family	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
impairment	I
in	O
Duchenne	B
muscular	I
dystrophy	I
?	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B
impairment	I
observed	O
in	O
most	O
DMD	B
patients	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dysfunction	I
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
..	O

I1307	O
K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

Interestingly	O
,	O
the	O
I1307	O
K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O

The	O
I1307	O
K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307	O
K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B
..	O

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B
coproporphyria	I
family	O
.	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
characterized	O
by	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B
patients	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC-1	O
)	O
,	O
supporting	O
that	O
TIC-1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC-2	O
..	O

Human	B
complement	I
factor	I
H	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
syndrome	I
.	O

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	I
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B
renal	I
disease	I
.	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150-kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42-kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL-1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
with	O
HUS	B
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and/or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
..	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B
chromosomes	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
always	O
haplotype	O
A.	O
To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
ataxia	I
..	O

The	O
molecular	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Deficiency	B
of	I
the	I
sixth	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6-deficient	B
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
..	O

Complement	B
C7	I
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B
deficiency	I
are	O
described	O
.	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B
defects	I
are	O
tabulated	O
..	O

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B
affective	I
disorder	I
among	O
the	O
Old	O
Order	O
Amish	O
.	O

Bipolar	B
affective	I
disorder	I
(	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B
and/or	O
hypomania	B
interspersed	O
with	O
periods	O
of	O
depression	B
.	O

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	B
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	B
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B
disorders	I
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B
disorder	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	B
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
related	O
affective	B
disorders	I
.	O

Segregation	O
distortion	O
in	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
pedigree	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B
in	O
the	O
population	O
.	O

In	O
a	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O
3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O
7	O
%	O
were	O
affected	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	B
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

Diagnosis	O
of	O
hemochromatosis	B
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B
is	O
still	O
being	O
evaluated	O
.	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B
before	O
hepatic	B
cirrhosis	I
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
..	O

Prevalence	O
of	O
the	O
I1307	O
K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i.	O
e.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307	O
K	O
APC	B
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O
1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

We	O
assessed	O
the	O
I1307	O
K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and/or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307	O
K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307	O
K	O
was	O
found	O
in	O
5	O
.	O
0	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O
6	O
%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
.	O
4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B
risk	O
.	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307	O
K	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B
.	O

CONCLUSIONS	O
The	O
I1307	O
K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B
cancer	I
in	O
European	O
Israelis	O
.	O

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
coproporphyria	I
and	O
mutation	O
update	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B
diseases	I
.	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	O
.	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c--	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
..	O

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	B
patients	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0-type	O
mutation	O
459	O
+	O
1	O
G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1	O
G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0-type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
..	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
type	I
1	I
.	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T--	O
>	O
Arg226Stop	O
)	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and/or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
..	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
eye	I
malformations	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B
patients	O
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B
phenotypes	O
.	O

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B
-related	I
disease	I
remains	O
to	O
be	O
uncovered	O
..	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
deficiency	I
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O
035	O
.	O

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
deficiency	I
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O
04	O
.	O
18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
.	O

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O
042	O
.	O

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O
04	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B.	O
These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-B	O
,	O
-D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B
deficiency	I
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B
deficiency	I
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B
deficiency	I
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B
.	O

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
..	O

Genetic	O
mapping	O
of	O
the	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13-p16	O
.	O

Abnormal	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B
disease	I
.	O

We	O
examined	O
whether	O
the	O
WD	B
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
WD	B
can	O
not	O
be	O
homologous	O
to	O
CT	B
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O

2	O
-	O
22	O
.	O
5	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107-containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13-p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
APC	B
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	B
amino	O
acid	O
changes	O
in	O
colorectal	B
cancer	I
predisposition	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
mutations	O
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
.	O

METHODS	O
The	O
APC	B
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I
patients	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B
and	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
..	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
I1307	O
K	O
polymorphism	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

Recently	O
,	O
an	O
isoleucine--	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307	O
K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
APC	O
I1307	O
K	O
polymorphism	O
.	O

The	O
APC	O
I1307	O
K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307	O
K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O

5	O
-	O
1	O
.	O
7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O

01	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307	O
K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
cancers	I
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O

We	O
conclude	O
that	O
the	O
APC	O
I1307	O
K	O
variant	O
leads	O
to	O
increased	O
adenoma	B
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B
cancer	I
.	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B
cancer	I
prevention	O
in	O
this	O
population	O
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
.	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	B
-	O
suppressor	O
gene	O
and	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	B
-	I
familial	I
cancers	I
is	O
unclear	O
.	O

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B
cancers	I
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	I
.	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus	O
.	O

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

These	O
reagents	O
detect	O
a	O
220-kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B
malignancies	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cancers	I
..	O

Prolactin	O
and	O
dopamine	O
:	O
what	O
is	O
the	O
connection	O
?	O

A	O
review	O
article	O
.	O

Dopamine	O
(	O
DA	O
)	O
holds	O
a	O
predominant	O
role	O
in	O
the	O
regulation	O
of	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
.	O

Through	O
a	O
direct	O
effect	O
on	O
anterior	O
pituitary	O
lactotrophs	O
,	O
DA	O
inhibits	O
the	O
basally	O
high	O
-	O
secretory	O
tone	O
of	O
the	O
cell	O
.	O

It	O
accomplishes	O
this	O
by	O
binding	O
to	O
D2	O
receptors	O
expressed	O
on	O
the	O
cell	O
membrane	O
of	O
the	O
lactotroph	O
,	O
activation	O
of	O
which	O
results	O
in	O
a	O
reduction	O
of	O
PRL	O
exocytosis	O
and	O
gene	O
expression	O
by	O
a	O
variety	O
of	O
intracellular	O
signalling	O
mechanisms	O
.	O

The	O
hypothalamic	O
dopaminergic	O
neurons	O
,	O
which	O
provide	O
DA	O
to	O
the	O
anterior	O
pituitary	O
gland	O
,	O
are	O
themselves	O
regulated	O
by	O
feedback	O
from	O
PRL	O
through	O
a	O
's	O
hort	O
-	O
loop	O
feedback	O
mechanism	O
'	O
.	O

A	O
variety	O
of	O
other	O
modulators	O
of	O
prolactin	O
secretion	O
act	O
at	O
the	O
hypothalamic	O
level	O
by	O
either	O
disinhibition	O
of	O
the	O
dopaminergic	O
tone	O
(	O
e.g.	O
serotonin	O
,	O
GABA	O
,	O
oestrogens	O
and	O
opioids	O
)	O
or	O
by	O
reinforcing	O
it	O
(	O
e.g.	O
substance	O
P	O
)	O
.	O

All	O
typical	O
antipsychotic	O
medications	O
are	O
associated	O
with	O
sustained	B
hyperprolactinaemia	I
due	O
to	O
their	O
high	O
affinity	O
for	O
the	O
D2	O
receptor	O
and	O
their	O
slow	O
dissociation	O
from	O
the	O
receptor	O
once	O
bound	O
,	O
but	O
atypicals	O
differ	O
quite	O
dramatically	O
in	O
their	O
propensity	O
to	O
cause	O
prolonged	O
high	O
prolactin	O
levels	O
.	O

Of	O
those	O
atypicals	O
that	O
are	O
associated	O
with	O
prolactin	O
elevation	O
,	O
the	O
main	O
causative	O
factor	O
appears	O
to	O
be	O
a	O
higher	O
peripheral	O
-	O
to	O
-	O
central	O
dopamine	O
receptor	O
potency	O
of	O
either	O
the	O
parent	O
drug	O
or	O
its	O
active	O
metabolite	O
(	O
e.g.	O
risperidone	O
,	O
9	O
-	O
hydroxy	O
-	O
risperidone	O
and	O
amisulpride	O
)	O
.	O

Antipsychotics	O
that	O
easily	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
exhibit	O
fast	O
dissociation	O
from	O
the	O
dopamine	O
receptor	O
once	O
bound	O
do	O
not	O
result	O
in	O
sustained	B
hyperprolactinaemia	I
.	O

Arsenic	O
upregulates	O
MMP	O
-	O
9	O
and	O
inhibits	O
wound	B
repair	O
in	O
human	O
airway	O
epithelial	O
cells	O
.	O

As	O
part	O
of	O
the	O
innate	O
immune	O
defense	O
,	O
the	O
polarized	O
conducting	O
lung	O
epithelium	O
acts	O
as	O
a	O
barrier	O
to	O
keep	O
particulates	O
carried	O
in	O
respiration	O
from	O
underlying	O
tissue	O
.	O

Arsenic	O
is	O
a	O
metalloid	O
toxicant	O
that	O
can	O
affect	O
the	O
lung	O
via	O
inhalation	O
or	O
ingestion	O
.	O

We	O
have	O
recently	O
shown	O
that	O
chronic	O
exposure	O
of	O
mice	O
or	O
humans	O
to	O
arsenic	O
(	O
10	O
-	O
50	O
ppb	O
)	O
in	O
drinking	O
water	O
alters	O
bronchiolar	O
lavage	O
or	O
sputum	O
proteins	O
consistent	O
with	O
reduced	O
epithelial	O
cell	O
migration	O
and	O
wound	B
repair	O
in	O
the	O
airway	O
.	O

In	O
this	O
report	O
,	O
we	O
used	O
an	O
in	O
vitro	O
model	O
to	O
examine	O
effects	O
of	O
acute	O
exposure	O
of	O
arsenic	O
(	O
15	O
-	O
290	O
ppb	O
)	O
on	O
conducting	O
airway	O
lung	O
epithelium	O
.	O

We	O
found	O
that	O
arsenic	O
at	O
concentrations	O
as	O
low	O
as	O
30	O
ppb	O
inhibits	O
reformation	O
of	O
the	O
epithelial	O
monolayer	O
following	O
scrape	O
wounds	O
of	O
monolayer	O
cultures	O
.	O

In	O
an	O
effort	O
to	O
understand	O
functional	O
contributions	O
to	O
epithelial	O
wound	B
repair	O
altered	O
by	O
arsenic	O
,	O
we	O
showed	O
that	O
acute	O
arsenic	O
exposure	O
increases	O
activity	O
and	O
expression	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
9	O
,	O
an	O
important	O
protease	O
in	O
lung	O
function	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
MMP	O
-	O
9	O
in	O
arsenic	O
-	O
treated	O
cells	O
improved	O
wound	B
repair	O
.	O

We	O
propose	O
that	O
arsenic	O
in	O
the	O
airway	O
can	O
alter	O
the	O
airway	O
epithelial	O
barrier	O
by	O
restricting	O
proper	O
wound	B
repair	O
in	O
part	O
through	O
the	O
upregulation	O
of	O
MMP	O
-	O
9	O
by	O
lung	O
epithelial	O
cells	O
.	O

Stem	O
cell	O
mobilization	O
with	O
cyclophosphamide	O
overcomes	O
the	O
suppressive	O
effect	O
of	O
lenalidomide	O
therapy	O
on	O
stem	O
cell	O
collection	O
in	O
multiple	B
myeloma	I
.	O

A	O
total	O
of	O
28	O
treatment	O
-	O
na	O
?	O

ve	O
patients	O
with	O
stage	O
II	O
or	O
III	O
multiple	B
myeloma	I
(	O
MM	B
)	O
were	O
treated	O
with	O
the	O
combination	O
of	O
clarithromycin	O
,	O
lenalidomide	O
,	O
and	O
dexamethasone	O
(	O
BiRD	O
)	O
.	O

Stem	O
cells	O
were	O
collected	O
following	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
or	O
cyclophosphamide	O
(	O
Cy	O
)	O
plus	O
G	O
-	O
CSF	O
mobilization	O
at	O
maximum	O
response	O
.	O

Sufficient	O
stem	O
cells	O
for	O
2	O
autologous	O
stem	O
cell	O
transplants	O
were	O
collected	O
from	O
all	O
patients	O
mobilized	O
with	O
Cy	O
plus	O
G	O
-	O
CSF	O
,	O
versus	O
33	O
%	O
mobilized	O
with	O
G	O
-	O
CSF	O
alone	O
(	O
P	O
<	O
.0001	O
)	O
.	O

The	O
duration	O
of	O
prior	O
lenalidomide	O
therapy	O
did	O
not	O
correlate	O
with	O
success	O
of	O
stem	O
cell	O
harvests	O
(	O
P	O
=	O
.91	O
)	O
.	O

In	O
conclusion	O
,	O
Cy	O
can	O
be	O
added	O
to	O
G	O
-	O
CSF	O
for	O
stem	O
cell	O
mobilization	O
to	O
successfully	O
overcome	O
the	O
suppressive	O
effect	O
of	O
prior	O
treatment	O
with	O
lenalidomide	O
.	O

Fluctuating	O
functions	O
related	O
to	O
quality	O
of	O
life	O
in	O
advanced	O
Parkinson	O
disease	O
:	O
effects	O
of	O
duodenal	O
levodopa	O
infusion	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
fluctuations	O
in	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
and	O
motor	O
performance	O
in	O
patients	O
with	O
advanced	O
Parkinson	O
disease	O
(	O
PD	O
)	O
treated	O
with	O
continuous	O
daytime	O
duodenal	O
levodopa	O
/	O
carbidopa	O
infusion	O
or	O
conventional	O
therapy	O
.	O

METHODS	O
:	O
Of	O
18	O
patients	O
completing	O
a	O
6	O
-	O
week	O
trial	O
(	O
DIREQT	O
)	O
,	O
12	O
were	O
followed	O
for	O
up	O
to	O
6	O
months	O
and	O
assessed	O
using	O
electronic	O
diaries	O
and	O
the	O
PD	O
Questionnaire	O
-	O
39	O
(	O
PDQ	O
-	O
39	O
)	O
.	O

RESULTS	O
:	O
During	O
the	O
trial	O
and	O
follow	O
-	O
up	O
,	O
major	O
diurnal	O
fluctuations	O
were	O
observed	O
,	O
especially	O
for	O
hyperkinesia	B
,	O
'	O
off	O
'	O
time	O
,	O
ability	O
to	O
walk	O
and	O
depression	B
.	O

Duodenal	O
infusion	O
was	O
associated	O
with	O
significantly	O
more	O
favourable	O
outcomes	O
compared	O
with	O
conventional	O
treatment	O
for	O
satisfaction	O
with	O
overall	O
functioning	O
,	O
'	O
off	O
'	O
time	O
and	O
ability	O
to	O
walk	O
,	O
with	O
improved	O
outcomes	O
with	O
PDQ	O
-	O
39	O
.	O

CONCLUSIONS	O
:	O
Relative	O
to	O
conventional	O
treatment	O
,	O
infusion	O
therapy	O
may	O
stabilize	O
and	O
significantly	O
improve	O
motor	O
function	O
and	O
patient	O
's	O
QoL	O
.	O

The	O
potential	O
for	O
daily	O
fluctuation	O
in	O
PD	O
symptoms	O
means	O
single	O
measures	O
of	O
treatment	O
effectiveness	O
can	O
result	O
in	O
bias	O
in	O
effect	O
estimates	O
and	O
hence	O
repeated	O
measures	O
are	O
recommended	O
.	O

Apaziquone	O
for	O
non	B
-	I
muscle	I
invasive	I
bladder	I
cancer	I
:	O
a	O
critical	O
review	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
needs	O
in	O
non	B
-	I
muscle	I
invasive	I
bladder	I
cancer	I
(	O
NMIBC	B
)	O
and	O
review	O
the	O
potential	O
of	O
apaziquone	O
in	O
this	O
respect	O
.	O

METHODS	O
:	O
Epidemiology	O
and	O
clinical	O
practice	O
in	O
NMIBC	B
,	O
as	O
well	O
as	O
new	O
drugs	O
and	O
strategies	O
are	O
reviewed	O
.	O

RESULTS	O
:	O
Bladder	B
cancer	I
is	O
a	O
heterogeneous	O
and	O
frequent	O
disease	O
.	O

Clinical	O
risk	O
factors	O
help	O
in	O
determining	O
additional	O
therapy	O
after	O
initial	O
resection	O
.	O

However	O
,	O
current	O
treatments	O
have	O
clear	O
limitations	O
with	O
regard	O
to	O
efficacy	O
and	O
/	O
or	O
toxicity	O
.	O

New	O
drugs	O
and	O
strategies	O
have	O
been	O
tested	O
recently	O
and	O
are	O
in	O
(	O
pre	O
)	O
clinical	O
use	O
.	O

Intravesical	O
apaziquone	O
(	O
EOquin	O
)	O
is	O
a	O
new	O
drug	O
.	O

It	O
has	O
theoretical	O
advantages	O
for	O
intravesical	O
use	O
,	O
has	O
proven	O
safety	O
and	O
is	O
presently	O
under	O
further	O
clinical	O
evaluation	O
.	O

CONCLUSION	O
:	O
Apaziquone	O
is	O
a	O
promising	O
drug	O
for	O
intravesical	O
use	O
in	O
patients	O
with	O
NMIBC	B
.	O

Allopregnanolone	O
impairs	O
episodic	O
memory	O
in	O
healthy	O
women	O
.	O

OBJECTIVE	O
:	O
Allopregnanolone	O
is	O
an	O
endogenous	O
neuroactive	O
steroid	O
that	O
,	O
through	O
its	O
binding	O
to	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
A	O
receptor	O
,	O
has	O
GABA	O
-	O
active	O
properties	O
.	O

Animal	O
studies	O
indicate	O
that	O
allopregnanolone	O
administration	O
results	O
in	O
diminished	B
learning	I
and	O
memory	B
impairment	I
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
intravenously	O
administered	O
allopregnanolone	O
on	O
episodic	O
memory	O
,	O
semantic	O
memory	O
,	O
and	O
working	O
memory	O
in	O
healthy	O
women	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
eight	O
healthy	O
women	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
participants	O
were	O
scheduled	O
for	O
the	O
memory	O
tests	O
twice	O
in	O
the	O
follicular	O
phase	O
.	O

During	O
the	O
test	O
sessions	O
,	O
an	O
intravenous	O
allopregnanolone	O
and	O
placebo	O
infusion	O
were	O
administered	O
in	O
a	O
double	O
-	O
blinded	O
,	O
randomized	O
order	O
at	O
intervals	O
of	O
48	O
h	O
.	O

Before	O
and	O
10	O
min	O
after	O
the	O
allopregnanolone	O
/	O
placebo	O
injections	O
,	O
memory	O
tasks	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
study	O
demonstrated	O
that	O
allopregnanolone	O
impaired	O
episodic	O
memory	O
in	O
healthy	O
women	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
pre	O
-	O
and	O
postallopregnanolone	O
injection	O
episodic	O
memory	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
no	O
change	O
in	O
episodic	O
memory	O
performance	O
following	O
the	O
placebo	O
injections	O
.	O

There	O
was	O
also	O
a	O
significant	O
difference	O
between	O
allopregnanolone	O
and	O
placebo	O
postinjection	O
episodic	O
memory	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
effects	O
of	O
allopregnanolone	O
on	O
the	O
semantic	O
memory	O
task	O
or	O
working	O
memory	O
task	O
.	O

CONCLUSION	O
:	O
Intravenous	O
allopregnanolone	O
impairs	O
episodic	O
memory	O
in	O
healthy	O
women	O
,	O
but	O
there	O
is	O
a	O
high	O
degree	O
of	O
individual	O
variability	O
.	O

Effect	O
of	O
carbocisteine	O
on	O
acute	O
exacerbation	O
of	O
chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
PEACE	O
Study	O
)	O
:	O
a	O
randomised	O
placebo	O
-	O
controlled	O
study	O
.	O

BACKGROUND	O
:	O
Chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
COPD	B
)	O
is	O
characterised	O
by	O
airflow	O
limitation	O
,	O
and	O
has	O
many	O
components	O
including	O
mucus	O
hypersecretion	O
,	O
oxidative	O
stress	O
,	O
and	O
airway	O
inflammation	O
.	O

We	O
aimed	O
to	O
assess	O
whether	O
carbocisteine	O
,	O
a	O
mucolytic	O
agent	O
with	O
anti	O
-	O
inflammatory	O
and	O
antioxidation	O
activities	O
,	O
could	O
reduce	O
the	O
yearly	O
exacerbation	O
rate	O
in	O
patients	O
with	O
COPD	B
.	O

METHODS	O
:	O
We	O
did	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
709	O
patients	O
from	O
22	O
centres	O
in	O
China	O
.	O

Participants	O
were	O
eligible	O
if	O
they	O
were	O
diagnosed	O
as	O
having	O
COPD	B
with	O
a	O
postbronchodilator	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV	O
(	O
1	O
)	O
)	O
to	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
ratio	O
(	O
FEV	O
(	O
1	O
)	O
/	O
FVC	O
)	O
of	O
less	O
than	O
0.7	O
and	O
an	O
FEV	O
(	O
1	O
)	O
between	O
25	O
%	O
and	O
79	O
%	O
of	O
the	O
predicted	O
value	O
,	O
were	O
aged	O
between	O
40	O
and	O
80	O
years	O
,	O
had	O
a	O
history	O
of	O
at	O
least	O
two	O
COPD	B
exacerbations	O
within	O
the	O
previous	O
2	O
years	O
,	O
and	O
had	O
remained	O
clinically	O
stable	O
for	O
over	O
4	O
weeks	O
before	O
the	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
1500	O
mg	O
carbocisteine	O
or	O
placebo	O
per	O
day	O
for	O
a	O
year	O
.	O

The	O
primary	O
endpoint	O
was	O
exacerbation	O
rate	O
over	O
1	O
year	O
,	O
and	O
analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
trial	O
is	O
registered	O
with	O
the	O
Japan	O
Clinical	O
Trials	O
Registry	O
(	O
http://umin.ac.jp/ctr/index/htm	O
)	O
number	O
UMIN	O
-	O
CRT	O
C000000233	O
.	O

FINDINGS	O
:	O
354	O
patients	O
were	O
assigned	O
to	O
the	O
carbocisteine	O
group	O
and	O
355	O
to	O
the	O
placebo	O
group	O
.	O

Numbers	O
of	O
exacerbations	O
per	O
patient	O
per	O
year	O
declined	O
significantly	O
in	O
the	O
carbocisteine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
1.01	O
[	O
SE	O
0.06	O
]	O
vs	O
1.35	O
[	O
SE	O
0.06	O
]	O
)	O
,	O
risk	O
ratio	O
0.75	O
(	O
95	O
%	O
CI	O
0.62	O
-	O
0.92	O
,	O
p	O
=	O
0.004	O
)	O
.	O

Non	O
-	O
significant	O
interactions	O
were	O
found	O
between	O
the	O
preventive	O
effects	O
and	O
COPD	B
severity	O
,	O
smoking	O
,	O
as	O
well	O
as	O
concomitant	O
use	O
of	O
inhaled	O
corticosteroids	O
.	O

Carbocisteine	O
was	O
well	O
tolerated	O
.	O

INTERPRETATION	O
:	O
Mucolytics	O
,	O
such	O
as	O
carbocisteine	O
,	O
should	O
be	O
recognised	O
as	O
a	O
worthwhile	O
treatment	O
for	O
prevention	O
of	O
exacerbations	O
in	O
Chinese	O
patients	O
with	O
COPD	B
.	O

Induction	O
of	O
the	O
multixenobiotic	O
/	O
multidrug	O
resistance	O
system	O
in	O
various	O
cell	O
lines	O
in	O
response	O
to	O
perfluorinated	O
carboxylic	O
acids	O
.	O

The	O
multixenobiotic	O
resistance	O
(	O
closely	O
related	O
to	O
multidrug	O
resistance	O
)	O
system	O
controls	O
transport	O
across	O
the	O
plasma	O
membrane	O
as	O
a	O
defense	O
against	O
toxic	O
molecules	O
.	O

Multixenobiotic	O
resistance	O
system	O
consists	O
of	O
an	O
efflux	O
pump	O
,	O
ABCB1	O
(	O
also	O
named	O
P	O
-	O
glycoprotein	O
,	O
P	O
-	O
gp	O
)	O
,	O
and	O
/	O
or	O
a	O
molecule	O
of	O
the	O
ABCC	O
family	O
(	O
also	O
named	O
multiple	O
resistance	O
associated	O
protein	O
,	O
MRP	O
)	O
.	O

ABCB1	O
is	O
able	O
to	O
increase	O
efflux	O
of	O
many	O
low	O
-	O
molecular	O
foreign	O
molecules	O
.	O

Measuring	O
system	O
induction	O
may	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
cell	O
/	O
organism	O
exposure	O
to	O
foreign	O
substances	O
.	O

Various	O
established	O
cell	O
lines	O
were	O
tested	O
for	O
constitutive	O
and	O
induced	O
multixenobiotic	O
resistance	O
proteins	O
by	O
Western	O
blotting	O
immunodetection	O
.	O

The	O
pumping	O
function	O
was	O
indirectly	O
assayed	O
with	O
Rhodamine	O
B	O
by	O
visualization	O
of	O
cell	O
fluorescence	O
in	O
the	O
presence	O
of	O
verapamil	O
.	O

Changes	O
in	O
ABC	O
proteins	O
were	O
measured	O
by	O
flow	O
cytometry	O
after	O
exposition	O
to	O
various	O
perfluorinated	O
carboxylic	O
acids	O
.	O

MCF7	O
and	O
HeLa	O
cells	O
were	O
found	O
to	O
contain	O
the	O
highest	O
constitutive	O
level	O
of	O
both	O
ABCB1	O
and	O
ABCC1	O
.	O

HEK293	O
exhibited	O
much	O
less	O
ABCB1	O
and	O
no	O
activity	O
of	O
pumping	O
out	O
Rhodamine	O
B	O
.	O

The	O
pumping	O
activity	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
amount	O
of	O
the	O
cell	O
-	O
type	O
specific	O
170	O
kDa	O
ABCB1	O
protein	O
.	O

An	O
8	O
-	O
day	O
exposure	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
perfluorononanoic	O
acid	O
resulted	O
in	O
about	O
2	O
-	O
2.5	O
-	O
fold	O
increase	O
of	O
ABCB1	O
level	O
.	O

That	O
was	O
confirmed	O
also	O
for	O
short	O
times	O
by	O
flow	O
cytometry	O
of	O
cells	O
exposed	O
to	O
perfluorinated	O
acids	O
and	O
its	O
natural	O
congeners	O
.	O

Both	O
ABCB1	O
-	O
and	O
ABCC1	O
-	O
related	O
fluorescence	O
increased	O
along	O
with	O
the	O
carbon	O
chain	O
in	O
acids	O
from	O
C	O
(	O
6	O
)	O
up	O
to	O
C	O
(	O
9	O
)	O
and	O
decreased	O
for	O
C	O
(	O
10	O
)	O
.	O

Measuring	O
of	O
multixenobiotic	O
resistance	O
changes	O
in	O
vitro	O
induced	O
by	O
chemicals	O
may	O
be	O
a	O
convenient	O
test	O
for	O
screening	O
for	O
their	O
potential	O
toxicity	O
.	O

Phase	O
I	O
/	O
II	O
study	O
of	O
biweekly	O
paclitaxel	O
and	O
radiation	O
in	O
androgen	O
-	O
ablated	O
locally	O
advanced	O
prostate	B
cancer	I
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
concurrent	O
paclitaxel	O
and	O
radiation	O
therapy	O
(	O
RT	O
)	O
in	O
patients	O
with	O
locally	O
advanced	O
prostate	B
cancer	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Eligible	O
patients	O
had	O
T2	O
-	O
4	O
tumors	B
with	O
Gleason	O
scores	O
greater	O
than	O
7	O
and	O
/	O
or	O
PSA	O
levels	O
greater	O
than	O
10	O
ng	O
/	O
mL	O
and	O
/	O
or	O
had	O
tumors	B
with	O
pathologic	O
stage	O
TxN1	O
.	O

Hormonal	O
ablation	O
was	O
initiated	O
3	O
months	O
before	O
RT	O
and	O
was	O
given	O
for	O
9	O
months	O
.	O

RT	O
was	O
delivered	O
daily	O
(	O
1.8	O
Gy	O
)	O
with	O
concurrent	O
twice	O
-	O
weekly	O
paclitaxel	O
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

The	O
whole	O
pelvis	O
was	O
irradiated	O
to	O
39.6	O
Gy	O
.	O

The	O
radiation	O
dose	O
was	O
escalated	O
as	O
follows	O
:	O
63	O
Gy	O
,	O
66.6	O
Gy	O
,	O
70.2	O
Gy	O
,	O
and	O
73.8	O
Gy	O
.	O

The	O
last	O
RT	O
dose	O
level	O
was	O
fixed	O
at	O
73.8	O
Gy	O
.	O

RESULTs	O
:	O
Between	O
January	O
2000	O
and	O
October	O
2006	O
,	O
22	O
patients	O
were	O
enrolled	O
.	O

The	O
median	O
age	O
was	O
59	O
years	O
(	O
range	O
,	O
48	O
to	O
72	O
years	O
)	O
;	O
the	O
median	O
PSA	O
level	O
was	O
22.4	O
ng	O
/	O
mL	O
(	O
range	O
,	O
2.8	O
to	O
113	O
ng	O
/	O
mL	O
)	O
.	O

The	O
number	O
of	O
patients	O
per	O
stage	O
was	O
as	O
follows	O
:	O
three	O
with	O
T1	O
,	O
eight	O
with	O
T2	O
,	O
11	O
with	O
T3	O
,	O
and	O
five	O
with	O
pN1	O
=	O
5	O
.	O

No	O
grade	O
3	O
toxicities	O
occurred	O
at	O
63	O
Gy	O
.	O

Grade	O
3	O
diarrhea	B
occurred	O
in	O
three	O
patients	O
at	O
66.6	O
Gy	O
.	O

The	O
protocol	O
then	O
was	O
amended	O
to	O
treat	O
the	O
prostate	O
volume	O
first	O
followed	O
by	O
the	O
whole	O
pelvis	O
.	O

No	O
grade	O
3	O
toxicities	O
were	O
observed	O
at	O
70.2	O
Gy	O
.	O

One	O
patient	O
experienced	O
grade	O
3	O
diarrhea	B
at	O
73.8	O
Gy	O
.	O

Five	O
additional	O
patients	O
were	O
treated	O
to	O
73.8	O
Gy	O
without	O
grade	O
3	O
toxicity	O
,	O
which	O
established	O
the	O
MTD	O
for	O
combined	O
paclitaxel	O
and	O
RT	O
at	O
73.8	O
Gy	O
.	O

At	O
38	O
months	O
median	O
follow	O
-	O
up	O
(	O
range	O
,	O
9	O
to	O
87	O
months	O
)	O
,	O
21	O
(	O
95	O
%	O
)	O
of	O
22	O
patients	O
are	O
alive	O
.	O

Six	O
(	O
27	O
%	O
)	O
of	O
22	O
experienced	O
recurrence	O
.	O

CONCLUSION	O
:	O
Concurrent	O
biweekly	O
paclitaxel	O
with	O
RT	O
is	O
feasible	O
,	O
with	O
an	O
MTD	O
of	O
73.8	O
Gy	O
.	O

Recovery	O
of	O
gonadal	O
function	O
occurs	O
in	O
the	O
majority	O
of	O
patients	O
.	O

These	O
results	O
encourage	O
testing	O
in	O
a	O
phase	O
III	O
setting	O
.	O

Application	O
of	O
a	O
high	O
-	O
content	O
multiparameter	O
cytotoxicity	B
assay	O
to	O
prioritize	O
compounds	O
based	O
on	O
toxicity	O
potential	O
in	O
humans	O
.	O

Prioritization	O
of	O
compounds	O
based	O
on	O
human	O
hepatotoxicity	B
potential	O
is	O
currently	O
a	O
key	O
unmet	O
need	O
in	O
drug	O
discovery	O
,	O
as	O
it	O
can	O
become	O
a	O
major	O
problem	O
for	O
several	O
lead	O
compounds	O
in	O
later	O
stages	O
of	O
the	O
drug	O
discovery	O
pipeline	O
.	O

The	O
authors	O
report	O
the	O
validation	O
and	O
implementation	O
of	O
a	O
high	O
-	O
content	O
multiparametric	O
cytotoxicity	B
assay	O
based	O
on	O
simultaneous	O
measurement	O
of	O
8	O
key	O
cell	O
health	O
indicators	O
associated	O
with	O
nuclear	O
morphology	O
,	O
plasma	O
membrane	O
integrity	O
,	O
mitochondrial	O
function	O
,	O
and	O
cell	O
proliferation	O
.	O

Compounds	O
are	O
prioritized	O
by	O
(	O
a	O
)	O
computing	O
an	O
in	O
vitro	O
safety	O
margin	O
using	O
the	O
minimum	O
cytotoxic	O
concentration	O
(	O
IC	O
(	O
20	O
)	O
)	O
across	O
all	O
8	O
indicators	O
and	O
cell	O
-	O
based	O
efficacy	O
data	O
and	O
(	O
b	O
)	O
using	O
the	O
minimal	O
cytotoxic	O
concentration	O
alone	O
to	O
take	O
into	O
account	O
concentration	O
of	O
drug	O
in	O
tissues	O
.	O

Feasibility	O
data	O
using	O
selected	O
compounds	O
,	O
including	O
quinolone	O
antibiotics	O
,	O
thiazolidinediones	O
,	O
and	O
statins	O
,	O
suggest	O
the	O
viability	O
of	O
this	O
approach	O
.	O

To	O
increase	O
overall	O
throughput	O
of	O
compound	O
prioritization	O
,	O
the	O
authors	O
have	O
identified	O
the	O
higher	O
throughput	O
,	O
plate	O
reader	O
-	O
based	O
CyQUANT	O
assay	O
that	O
is	O
similar	O
to	O
the	O
high	O
-	O
content	O
screening	O
(	O
HCS	O
)	O
assay	O
in	O
sensitivity	O
of	O
measuring	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

It	O
is	O
expected	O
that	O
the	O
phenotypic	O
output	O
from	O
the	O
multiparametric	O
HCS	O
assay	O
in	O
combination	O
with	O
other	O
highly	O
sensitive	O
approaches	O
,	O
such	O
as	O
microarray	O
-	O
based	O
expression	O
analysis	O
of	O
toxic	O
signatures	O
,	O
will	O
contribute	O
to	O
a	O
better	O
understanding	O
and	O
predictivity	O
of	O
human	O
hepatotoxicity	B
potential	O
.	O

Amended	O
final	O
report	O
of	O
the	O
safety	O
assessment	O
of	O
cocamidopropylamine	O
oxide	O
.	O

Cocamidopropylamine	O
Oxide	O
is	O
a	O
tertiary	O
amine	O
oxide	O
which	O
functions	O
as	O
a	O
hair	O
-	O
conditioning	O
agent	O
and	O
as	O
a	O
surfactant	O
,	O
currently	O
used	O
in	O
60	O
cosmetic	O
formulations	O
at	O
concentrations	O
between	O
0.07	O
%	O
and	O
4.0	O
%	O
.	O

In	O
an	O
earlier	O
safety	O
assessment	O
,	O
the	O
Cosmetic	O
Ingredient	O
Review	O
(	O
CIR	O
)	O
Expert	O
Panel	O
had	O
determined	O
that	O
the	O
available	O
data	O
were	O
insufficient	O
to	O
support	O
the	O
safety	O
of	O
this	O
ingredient	O
in	O
cosmetic	O
products	O
.	O

Additional	O
data	O
have	O
now	O
been	O
provided	O
and	O
reviewed	O
.	O

Cocamidopropylamine	O
Oxide	O
was	O
determined	O
to	O
have	O
an	O
acute	O
oral	O
LD	O
(	O
50	O
)	O
between	O
500	O
and	O
1000	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
using	O
rats	O
.	O

The	O
acute	O
dermal	O
LD	O
(	O
50	O
)	O
in	O
rats	O
was	O
>	O
2174	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
.	O

A	O
28	O
-	O
day	O
repeated	O
oral	O
dose	B
toxicity	I
study	O
in	O
rats	O
found	O
hemolytic	B
anemia	I
at	O
150	O
and	O
1000	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
,	O
with	O
a	O
no	O
observed	O
effect	O
level	O
(	O
NOEL	O
)	O
of	O
15	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
.	O

At	O
5	O
%	O
,	O
Cocamidopropylamine	O
Oxide	O
solution	O
was	O
not	O
a	O
primary	O
dermal	O
irritant	O
.	O

Application	O
of	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
to	O
rabbit	O
skin	O
caused	O
moderate	O
irritation	B
under	O
Draize	O
classification	O
scale	O
,	O
but	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
in	O
rabbit	O
eyes	O
caused	O
severe	O
irritation	B
.	O

A	O
maximization	O
study	O
classified	O
Cocamidopropylamine	O
Oxide	O
as	O
a	O
nonsensitizer	O
to	O
guinea	O
pig	O
skin	O
.	O

Cocamidopropylamine	O
Oxide	O
was	O
not	O
mutagenic	O
in	O
an	O
Ames	O
test	O
,	O
with	O
and	O
without	O
metabolic	O
activation	O
.	O

No	O
evidence	O
of	O
increased	O
chromosomal	O
aberrations	O
were	O
noted	O
in	O
human	O
lymphocytes	O
treated	O
with	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
.	O

In	O
a	O
clinical	O
study	O
,	O
7.5	O
%	O
Cocamidopropylamine	O
Oxide	O
was	O
not	O
a	O
sensitizer	O
,	O
although	O
it	O
did	O
produce	O
some	O
reactions	O
typical	O
of	O
mild	O
irritation	B
.	O

Although	O
the	O
impurities	O
,	O
amidoamine	O
and	O
dimethylaminopropylamine	O
,	O
have	O
been	O
implicated	O
in	O
contact	B
allergy	I
reactions	O
to	O
products	O
containing	O
cocamidopropylamine	O
betaine	O
,	O
clinical	O
testing	O
of	O
a	O
product	O
with	O
cocamidopropylamine	O
betaine	O
containing	O
these	O
impurities	O
,	O
at	O
levels	O
comparable	O
to	O
those	O
found	O
in	O
Cocamidopropylamine	O
Oxide	O
,	O
failed	O
to	O
produce	O
a	O
reaction	O
in	O
10	O
individuals	O
known	O
to	O
be	O
sensitive	O
to	O
cocamidopropylamine	O
betaine	O
.	O

Two	O
repeat	O
-	O
insult	O
patch	O
tests	O
using	O
a	O
facial	O
wash	O
with	O
1	O
%	O
raw	O
material	O
containing	O
35	O
%	O
to	O
36.5	O
%	O
Cocamidopropylamine	O
Oxide	O
did	O
not	O
find	O
evidence	O
of	O
dermal	B
sensitization	I
.	O

Tests	O
for	O
dermal	B
phototoxicity	I
and	O
photoallergenicity	B
with	O
the	O
same	O
facial	O
wash	O
product	O
also	O
did	O
not	O
produce	O
evidence	O
of	O
effect	O
.	O

The	O
CIR	O
Expert	O
Panel	O
recognizes	O
that	O
there	O
are	O
data	O
gaps	O
regarding	O
the	O
use	O
and	O
concentration	O
of	O
this	O
ingredient	O
.	O

However	O
,	O
the	O
overall	O
information	O
available	O
on	O
types	O
of	O
products	O
in	O
which	O
this	O
ingredient	O
is	O
used	O
and	O
at	O
what	O
concentration	O
indicate	O
a	O
pattern	O
of	O
use	O
,	O
which	O
was	O
considered	O
by	O
the	O
Expert	O
Panel	O
in	O
assessing	O
safety	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
Cocamidopropylamine	O
Oxide	O
has	O
low	O
toxicity	O
in	O
animal	O
and	O
in	O
vitro	O
tests	O
.	O

Although	O
there	O
are	O
no	O
available	O
carcinogenicity	B
data	O
,	O
the	O
available	O
genotoxicity	B
data	O
,	O
combined	O
with	O
the	O
absence	O
of	O
any	O
structural	O
alerts	O
,	O
suggest	O
no	O
carcinogenic	O
potential	O
.	O

The	O
Panel	O
noted	O
the	O
absence	O
of	O
reproductive	O
and	O
developmental	B
toxicity	I
data	O
.	O

Because	O
this	O
ingredient	O
has	O
a	O
highly	O
polarized	O
molecular	O
structure	O
,	O
the	O
Panel	O
considered	O
that	O
it	O
would	O
be	O
,	O
at	O
most	O
,	O
slowly	O
absorbed	O
.	O

Given	O
that	O
most	O
of	O
the	O
uses	O
and	O
the	O
highest	O
use	O
concentration	O
of	O
4	O
%	O
is	O
found	O
in	O
rinse	O
-	O
off	O
products	O
,	O
the	O
Panel	O
determined	O
that	O
the	O
available	O
data	O
suggest	O
that	O
Cocamidopropylamine	O
Oxide	O
is	O
safe	O
as	O
used	O
in	O
rinse	O
-	O
off	O
products	O
.	O

Although	O
dermal	O
penetration	O
may	O
be	O
slow	O
,	O
data	O
on	O
the	O
extent	O
of	O
dermal	O
penetration	O
of	O
Cocamidopropylamine	O
Oxide	O
are	O
needed	O
to	O
support	O
the	O
safety	O
of	O
leave	O
-	O
on	O
uses	O
.	O

If	O
there	O
is	O
significant	O
dermal	O
absorption	O
,	O
dermal	O
reproductive	O
and	O
developmental	B
toxicity	I
data	O
may	O
be	O
needed	O
.	O

Intravenous	O
fat	O
emulsion	O
:	O
a	O
potential	O
novel	O
antidote	O
.	O

Intravenous	O
fat	O
emulsions	O
(	O
IFE	O
)	O
are	O
traditionally	O
used	O
as	O
a	O
component	O
of	O
parenteral	O
nutrition	O
therapy	O
.	O

Recently	O
,	O
IFE	O
was	O
used	O
to	O
resuscitate	O
severe	O
local	B
anesthetic	I
drug	I
toxicity	I
.	O

This	O
review	O
focuses	O
on	O
the	O
potential	O
role	O
of	O
IFE	O
in	O
treatment	O
of	O
toxicity	O
due	O
to	O
local	O
anesthetics	O
and	O
other	O
lipid	O
-	O
soluble	O
drugs	O
.	O

The	O
general	O
properties	O
of	O
IFE	O
,	O
metabolic	O
fate	O
,	O
and	O
associated	O
adverse	O
events	O
are	O
described	O
.	O

Cases	O
of	O
local	B
anesthetic	I
toxicity	I
treated	O
with	O
IFE	O
are	O
presented	O
along	O
with	O
a	O
discussion	O
of	O
the	O
possible	O
antidotal	O
mechanisms	O
.	O

Initial	O
investigations	O
into	O
the	O
antidotal	O
use	O
of	O
IFE	O
for	O
lipophilic	O
central	O
nervous	O
and	O
cardiovascular	B
drug	I
toxicity	I
are	O
also	O
reviewed	O
.	O

The	O
use	O
of	O
ultrasound	O
and	O
micelles	O
in	O
cancer	B
treatment	O
.	O

The	O
high	O
toxicity	O
of	O
potent	O
chemotherapeutic	O
drugs	O
like	O
Doxorubicin	O
(	O
Dox	O
)	O
limits	O
the	O
therapeutic	O
window	O
in	O
which	O
they	O
can	O
be	O
applied	O
.	O

This	O
window	O
can	O
be	O
expanded	O
by	O
controlling	O
the	O
drug	O
delivery	O
in	O
both	O
space	O
and	O
time	O
such	O
that	O
non	O
-	O
targeted	O
tissues	O
are	O
not	O
adversely	O
affected	O
.	O

Recent	O
research	O
has	O
shown	O
that	O
ultrasound	O
(	O
US	O
)	O
can	O
be	O
used	O
to	O
control	O
the	O
release	O
of	O
Dox	O
and	O
other	O
hydrophobic	O
drugs	O
from	O
polymeric	O
micelles	O
in	O
both	O
time	O
and	O
space	O
.	O

It	O
has	O
also	O
been	O
shown	O
using	O
an	O
in	O
vivo	O
rat	O
tumor	O
model	O
that	O
Dox	O
activity	O
can	O
be	O
enhanced	O
by	O
ultrasound	O
in	O
one	O
region	O
,	O
while	O
in	O
an	O
adjacent	O
region	O
there	O
is	O
little	O
or	O
no	O
effect	O
of	O
the	O
drug	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
research	O
being	O
conducted	O
in	O
the	O
area	O
of	O
using	O
ultrasound	O
to	O
enhance	O
and	O
target	O
micellar	O
drug	O
delivery	O
to	O
cancerous	O
tissues	O
.	O

Additionally	O
,	O
we	O
summarize	O
our	O
previously	O
published	O
mathematical	O
models	O
that	O
attempt	O
to	O
represent	O
the	O
release	O
and	O
re	O
-	O
encapsulation	O
phenomena	O
of	O
Dox	O
from	O
Pluronic	O
P105	O
micelles	O
upon	O
the	O
application	O
of	O
ultrasound	O
.	O

The	O
potential	O
benefits	O
of	O
such	O
controlled	O
chemotherapy	O
compels	O
a	O
thorough	O
investigation	O
of	O
the	O
role	O
of	O
ultrasound	O
(	O
US	O
)	O
and	O
the	O
mechanisms	O
by	O
which	O
US	O
accomplishes	O
drug	O
release	O
and	O
/	O
or	O
enhances	O
drug	O
potency	O
.	O

Therefore	O
we	O
will	O
summarize	O
our	O
findings	O
related	O
to	O
the	O
mechanism	O
involved	O
in	O
acoustically	O
activated	O
micellar	O
drug	O
delivery	O
to	O
tumors	B
.	O

Drug	O
insight	O
:	O
aggrecanases	O
as	O
therapeutic	O
targets	O
for	O
osteoarthritis	B
.	O

In	O
healthy	O
cartilage	O
,	O
effective	O
weight	O
-	O
bearing	O
requires	O
a	O
high	O
concentration	O
of	O
intact	O
aggrecan	O
.	O

Degradation	O
and	O
loss	O
of	O
aggrecan	O
are	O
features	O
of	O
osteoarthritis	B
(	O
OA	B
)	O
.	O

It	O
is	O
unclear	O
whether	O
ADAMTS	O
-	O
4	O
,	O
ADAMTS	O
-	O
5	O
,	O
or	O
both	O
of	O
these	O
aggrecanases	O
from	O
the	O
ADAMTS	O
(	O
a	O
disintegrin	O
and	O
metalloproteinase	O
with	O
thrombospondin	O
motifs	O
)	O
enzyme	O
family	O
,	O
are	O
responsible	O
for	O
aggrecanolysis	O
in	O
human	O
OA	B
,	O
and	O
at	O
what	O
stage	O
of	O
disease	O
these	O
enzymes	O
are	O
active	O
.	O

Several	O
potential	O
disease	O
-	O
modifying	O
agents	O
for	O
OA	B
include	O
glucosamine	O
and	O
chondroitin	O
sulfate	O
,	O
diacerhein	O
,	O
and	O
pentosan	O
polysulfate	O
;	O
although	O
their	O
mechanisms	O
of	O
action	O
in	O
vivo	O
are	O
unknown	O
,	O
data	O
from	O
in	O
vitro	O
studies	O
and	O
animal	O
models	O
suggest	O
that	O
their	O
efficacy	O
might	O
be	O
partly	O
due	O
to	O
inhibition	O
of	O
proinflammatory	O
pathways	O
that	O
lead	O
to	O
downregulation	O
of	O
ADAMTS	O
enzymes	O
.	O

Some	O
histone	O
deacetylase	O
inhibitors	O
that	O
are	O
successfully	O
used	O
to	O
treat	O
cancer	B
can	O
block	O
ADAMTS	O
-	O
5	O
expression	O
;	O
however	O
,	O
these	O
inhibitors	O
will	O
only	O
be	O
considered	O
as	O
potential	O
therapies	O
for	O
OA	B
if	O
their	O
toxicity	O
is	O
markedly	O
reduced	O
.	O

ADAMTS	O
inhibitors	O
currently	O
in	O
development	O
are	O
expected	O
to	O
show	O
excellent	O
specificity	O
now	O
that	O
crystal	O
structures	O
for	O
several	O
ADAMTS	O
enzymes	O
are	O
available	O
to	O
guide	O
drug	O
design	O
.	O

ADAMTS	O
-	O
4	O
and	O
ADAMTS	O
-	O
5	O
are	O
appropriate	O
targets	O
for	O
OA	B
therapies	O
,	O
but	O
ultimately	O
,	O
inhibitors	O
of	O
these	O
enzymes	O
will	O
form	O
only	O
part	O
of	O
a	O
larger	O
arsenal	O
of	O
therapies	O
.	O

Long	O
-	O
term	O
clinical	O
and	O
surrogate	O
marker	O
effects	O
of	O
subcutaneous	O
intermittent	O
interleukin	O
-	O
2	O
without	O
antiretroviral	O
therapy	O
in	O
HIV	O
-	O
infected	O
patients	O
.	O

OBJECTIVES	O
:	O
Subcutaneous	O
administration	O
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
has	O
been	O
shown	O
to	O
increase	O
CD4	O
counts	O
in	O
HIV	O
-	O
infected	O
patients	O
.	O

It	O
remains	O
unclear	O
whether	O
this	O
effect	O
is	O
associated	O
with	O
a	O
clinical	O
benefit	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
in	O
the	O
cohort	O
of	O
the	O
UK	O
-	O
Vanguard	O
study	O
in	O
which	O
three	O
groups	O
of	O
12	O
antiretroviral	O
-	O
naive	O
subjects	O
with	O
CD4	O
cell	O
counts	O
>	O
350	O
cells	O
/	O
mm	O
(	O
3	O
)	O
received	O
no	O
treatment	O
or	O
IL	O
-	O
2	O
at	O
either	O
4.5	O
or	O
7.5	O
MIU	O
twice	O
daily	O
in	O
5	O
day	O
cycles	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Mean	O
follow	O
-	O
up	O
was	O
376	O
weeks	O
.	O

IL	O
-	O
2	O
therapy	O
was	O
associated	O
with	O
a	O
higher	O
area	O
under	O
the	O
curve	O
of	O
CD4	O
cell	O
count	O
change	O
from	O
baseline	O
at	O
week	O
48	O
but	O
not	O
thereafter	O
.	O

HIV	O
-	O
RNA	O
levels	O
were	O
unaffected	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
was	O
initiated	O
after	O
a	O
mean	O
of	O
172	O
,	O
175	O
and	O
152	O
weeks	O
in	O
the	O
control	O
group	O
,	O
low	O
-	O
dose	O
and	O
high	O
-	O
dose	O
IL	O
-	O
2	O
treatment	O
group	O
,	O
respectively	O
,	O
a	O
statistically	O
non	O
-	O
significant	O
difference	O
.	O

There	O
was	O
a	O
tendency	O
to	O
start	O
HAART	O
soon	O
after	O
discontinuation	O
of	O
IL	O
-	O
2	O
therapy	O
which	O
may	O
have	O
been	O
triggered	O
by	O
the	O
steep	O
decay	O
of	O
CD4	O
counts	O
.	O

There	O
were	O
two	O
serious	O
adverse	O
events	O
in	O
the	O
control	O
group	O
,	O
seven	O
in	O
the	O
low	O
-	O
dose	O
IL	O
-	O
2	O
group	O
and	O
eight	O
in	O
the	O
high	O
-	O
dose	O
IL	O
-	O
2	O
group	O
.	O

No	O
pattern	O
of	O
disease	O
was	O
detected	O
,	O
making	O
an	O
association	O
with	O
IL	O
-	O
2	O
therapy	O
unlikely	O
.	O

CONCLUSIONS	O
:	O
We	O
could	O
detect	O
neither	O
a	O
benefit	O
of	O
IL	O
-	O
2	O
therapy	O
after	O
week	O
48	O
nor	O
delayed	O
initiation	O
of	O
HAART	O
.	O

This	O
is	O
currently	O
the	O
longest	O
follow	O
-	O
up	O
data	O
comparing	O
IL	O
-	O
2	O
therapy	O
with	O
no	O
therapy	O
in	O
antiretroviral	O
-	O
naive	O
HIV	O
-	O
infected	O
patients	O
and	O
does	O
not	O
show	O
a	O
persistent	O
benefit	O
of	O
the	O
intervention	O
.	O

Altered	O
first	O
-	O
pass	O
effects	O
in	O
a	O
liver	O
transplant	O
recipient	O
explained	O
intraindividual	O
variation	O
in	O
calcineurin	O
inhibitor	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
The	O
significant	O
interindividual	O
and	O
intraindividual	O
variability	O
in	O
the	O
blood	O
concentrations	O
of	O
the	O
most	O
commonly	O
used	O
calcineurin	O
inhibitors	O
such	O
as	O
tacrolimus	O
and	O
cyclosporine	O
makes	O
the	O
exact	O
dosing	O
of	O
these	O
agents	O
in	O
transplant	O
recipients	O
very	O
challenging	O
.	O

As	O
both	O
of	O
these	O
drugs	O
have	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
hepatic	O
and	O
intestinal	O
cytochrome	O
P450	O
3A	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
these	O
variations	O
are	O
secondary	O
to	O
varying	O
first	O
-	O
pass	O
effects	O
in	O
the	O
gut	O
and	O
the	O
liver	O
over	O
a	O
period	O
of	O
time	O
.	O

CASE	O
REPORT	O
:	O
A	O
liver	O
transplant	O
recipient	O
,	O
who	O
had	O
previously	O
presented	O
with	O
tacrolimus	B
toxicity	I
on	O
his	O
usual	O
dosing	O
regimen	O
and	O
intolerant	O
to	O
standard	O
doses	O
of	O
cyclosporine	O
,	O
was	O
selected	O
to	O
undergo	O
the	O
study	O
.	O

Oral	O
and	O
intravenous	O
midazolam	O
was	O
used	O
as	O
the	O
probe	O
to	O
measure	O
hepatic	O
and	O
intestinal	O
CYP3A4	O
activities	O
at	O
two	O
different	O
time	O
points	O
(	O
phases	O
one	O
and	O
two	O
)	O
.	O

Small	O
intestinal	O
biopsies	O
were	O
also	O
obtained	O
for	O
measuring	O
CYP3A4	O
activity	O
for	O
in	O
vitro	O
studies	O
.	O

On	O
serially	O
determining	O
the	O
patient	O
's	O
hepatic	O
and	O
intestinal	O
CYP3A	O
activities	O
,	O
we	O
concluded	O
that	O
the	O
variability	O
in	O
the	O
dosing	O
requirements	O
is	O
due	O
to	O
altered	O
first	O
-	O
pass	O
effects	O
in	O
the	O
intestine	O
.	O

DISCUSSION	O
:	O
Transplant	O
recipients	O
receive	O
multiple	O
medications	O
that	O
may	O
inhibit	O
or	O
induce	O
these	O
metabolizing	O
enzymes	O
,	O
which	O
eventually	O
determine	O
the	O
concentrations	O
of	O
these	O
narrow	O
therapeutic	O
agents	O
.	O

If	O
no	O
obvious	O
etiology	O
of	O
intolerance	O
to	O
calcineurin	O
inhibitors	O
in	O
a	O
transplant	O
recipient	O
is	O
identified	O
,	O
one	O
should	O
consider	O
altered	O
first	O
-	O
pass	O
effects	O
in	O
the	O
gut	O
and	O
the	O
liver	O
contributing	O
to	O
intraindividual	O
variations	O
in	O
the	O
blood	O
concentrations	O
.	O

AIDS	B
-	I
related	I
malignancies	I
:	O
state	O
of	O
the	O
art	O
and	O
therapeutic	O
challenges	O
.	O

Despite	O
the	O
impact	O
of	O
combination	O
antiretroviral	O
therapy	O
(	O
cART	O
)	O
on	O
HIV	O
-	O
related	O
mortality	O
,	O
malignancy	O
remains	O
an	O
important	O
cause	O
of	O
death	O
in	O
the	O
current	O
era	O
.	O

Although	O
the	O
advent	O
of	O
cART	O
has	O
resulted	O
in	O
reductions	O
in	O
the	O
incidence	O
of	O
Kaposi	B
's	I
sarcoma	I
and	O
non	B
-	I
Hodgkin	I
's	I
lymphoma	I
,	O
non	B
-	I
AIDS	I
-	I
defining	I
malignancies	I
present	O
an	O
increased	O
risk	O
for	O
HIV	O
-	O
infected	O
patients	O
,	O
characterized	O
by	O
some	O
common	O
clinical	O
features	O
,	O
generally	O
with	O
a	O
more	O
aggressive	B
behavior	I
and	O
a	O
more	O
advanced	O
disease	O
at	O
diagnosis	O
,	O
which	O
is	O
responsible	O
for	O
poorer	O
patient	O
outcomes	O
.	O

Specific	O
therapeutic	O
recommendations	O
are	O
lacking	O
for	O
these	O
new	O
nonopportunistic	O
malignancies	B
,	O
such	O
as	O
Hodgkin	B
's	I
lymphoma	I
,	O
anal	B
cancer	I
,	O
lung	B
cancer	I
,	O
hepatocarcinoma	B
,	O
and	O
many	O
others	O
.	O

Antiretroviral	O
agents	O
have	O
a	O
propensity	O
for	O
causing	O
drug	O
interactions	O
as	O
a	O
result	O
of	O
their	O
ability	O
to	O
either	O
inhibit	O
or	O
induce	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
enzyme	O
system	O
.	O

Because	O
many	O
antineoplastic	O
drugs	O
are	O
also	O
metabolized	O
by	O
the	O
CYP	O
system	O
,	O
coadministration	O
with	O
cART	O
could	O
result	O
in	O
either	O
drug	O
accumulation	O
with	O
increased	O
toxicity	O
,	O
or	O
decreased	O
efficacy	O
of	O
one	O
or	O
both	O
classes	O
of	O
drugs	O
.	O

Further	O
research	O
delineating	O
the	O
combined	O
safety	O
and	O
pharmacokinetics	O
of	O
antiretrovirals	O
and	O
antineoplastic	O
therapy	O
is	O
necessary	O
.	O

Special	O
considerations	O
of	O
these	O
AIDS	O
-	O
related	O
and	O
non	B
-	I
AIDS	I
-	I
related	I
malignancies	I
and	O
their	O
clinical	O
and	O
therapeutic	O
aspects	O
constitute	O
the	O
subject	O
of	O
this	O
review	O
.	O

Doxorubicin	O
,	O
cardiac	O
risk	O
factors	O
,	O
and	O
cardiac	B
toxicity	I
in	O
elderly	O
patients	O
with	O
diffuse	O
B	B
-	I
cell	I
non	I
-	I
Hodgkin	I
's	I
lymphoma	I
.	O

PURPOSE	O
:	O
Anthracycline	O
-	O
based	O
chemotherapy	O
,	O
which	O
improves	O
survival	O
for	O
patients	O
with	O
non	B
-	I
Hodgkin	I
's	I
lymphoma	I
,	O
is	O
often	O
withheld	O
from	O
elderly	O
patients	O
because	O
of	O
its	O
cardiotoxicity	B
.	O

We	O
studied	O
the	O
cardiac	O
effects	O
of	O
doxorubicin	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
older	O
patients	O
with	O
diffuse	B
large	I
B	I
-	I
cell	I
lymphoma	I
(	O
DLBCL	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Among	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
diagnosed	O
with	O
DLBCL	B
from	O
1991	O
to	O
2002	O
in	O
the	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
-	O
Medicare	O
database	O
,	O
we	O
developed	O
logistic	O
regression	O
models	O
of	O
the	O
associations	O
of	O
doxorubicin	O
with	O
demographic	O
,	O
clinical	O
,	O
and	O
cardiac	O
variables	O
.	O

We	O
then	O
developed	O
Cox	O
proportional	O
hazards	O
models	O
of	O
the	O
association	O
between	O
doxorubicin	O
and	O
subsequent	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
,	O
taking	O
predictors	O
of	O
CHF	B
into	O
account	O
.	O

RESULTS	O
:	O
Of	O
9,438	O
patients	O
with	O
DLBCL	B
,	O
3,164	O
(	O
42	O
%	O
)	O
received	O
doxorubicin	O
-	O
based	O
chemotherapy	O
.	O

Any	O
doxorubicin	O
use	O
was	O
associated	O
with	O
a	O
29	O
%	O
increase	O
in	O
risk	O
of	O
CHF	B
(	O
95	O
%	O
CI	O
,	O
1.02	O
to	O
1.62	O
)	O
;	O
CHF	B
risk	O
increased	O
with	O
number	O
of	O
doxorubicin	O
claims	O
,	O
increasing	O
age	O
,	O
prior	B
heart	I
disease	I
,	O
comorbidities	O
,	O
diabetes	B
,	O
and	O
hypertension	B
;	O
hypertension	B
intensified	O
the	O
effect	O
of	O
doxorubicin	O
on	O
risk	O
of	O
CHF	B
(	O
hazard	O
ratio	O
=	O
1.8	O
;	O
P	O
<	O
.01	O
)	O
.	O

In	O
the	O
8	O
years	O
after	O
diagnosis	O
,	O
the	O
adjusted	O
CHF	O
-	O
free	O
survival	O
rate	O
was	O
74	O
%	O
in	O
doxorubicin	O
-	O
treated	O
patients	O
versus	O
79	O
%	O
in	O
patients	O
not	O
treated	O
with	O
doxorubicin	O
.	O

CONCLUSION	O
:	O
Among	O
patients	O
receiving	O
chemotherapy	O
for	O
DLBCL	B
,	O
those	O
with	O
prior	B
heart	I
disease	I
were	O
less	O
likely	O
than	O
others	O
to	O
be	O
treated	O
with	O
doxorubicin	O
,	O
and	O
those	O
who	O
received	O
doxorubicin	O
were	O
more	O
likely	O
than	O
others	O
to	O
develop	O
CHF	B
.	O

Various	O
cardiac	O
risk	O
factors	O
increased	O
CHF	B
risk	O
,	O
but	O
only	O
hypertension	B
was	O
synergistic	O
with	O
doxorubicin	O
.	O

Doxorubicin	O
has	O
dramatically	O
improved	O
survival	O
of	O
DLBCL	B
patients	O
;	O
nonetheless	O
,	O
some	O
subgroups	O
may	O
benefit	O
from	O
efforts	O
to	O
reduce	O
doxorubicin	O
-	O
related	O
CHF	B
risk	O
.	O

A	O
high	O
throughput	O
in	O
vitro	O
analytical	O
approach	O
to	O
screen	O
for	O
oxidative	O
stress	O
potential	O
exerted	O
by	O
nanomaterials	O
using	O
a	O
biologically	O
relevant	O
matrix	O
:	O
human	O
blood	O
serum	O
.	O

Limited	O
studies	O
have	O
shown	O
that	O
selected	O
nanomaterials	O
(	O
NMs	O
)	O
impart	O
various	O
forms	O
of	O
toxicity	O
in	O
biological	O
systems	O
;	O
however	O
,	O
a	O
common	O
metric	O
to	O
screen	O
for	O
potential	O
toxicity	O
is	O
needed	O
.	O

This	O
study	O
optimized	O
and	O
utilized	O
a	O
'	O
Ferric	O
reducing	O
ability	O
of	O
serum	O
(	O
FRAS	O
)	O
'	O
assay	O
as	O
a	O
screening	O
tool	O
to	O
quantitate	O
the	O
degree	O
of	O
oxidative	O
damage	O
induced	O
by	O
NMs	O
on	O
human	O
blood	O
serum	O
.	O

Antioxidants	O
in	O
blood	O
protect	O
against	O
oxidative	O
damage	O
caused	O
by	O
free	O
radicals	O
via	O
chemical	O
quenching	O
and	O
will	O
decrease	O
when	O
exposed	O
to	O
oxidatively	O
stressful	O
materials	O
.	O

Using	O
this	O
approach	O
,	O
the	O
antioxidant	O
capacity	O
of	O
NM	O
treated	O
serum	O
was	O
significantly	O
decreased	O
by	O
nano	O
-	O
silver	O
,	O
a	O
series	O
of	O
nano	O
-	O
carbon	O
blacks	O
,	O
fullerene	O
soot	O
,	O
and	O
nano	O
-	O
TiO	O
(	O
2	O
)	O
(	O
anatase	O
,	O
p	O
<	O
0.05	O
)	O
,	O
but	O
not	O
with	O
nano	O
-	O
alumina	O
,	O
fullerite	O
,	O
purified	O
fullerene	O
,	O
fine	O
TiO	O
(	O
2	O
)	O
(	O
rutile	O
)	O
and	O
Min	O
-	O
U	O
-	O
Sil	O
5	O
.	O

Particle	O
surface	O
area	O
and	O
not	O
biological	O
particle	O
size	O
was	O
highly	O
associated	O
with	O
the	O
degree	O
of	O
oxidative	O
stress	O
observed	O
.	O

This	O
approach	O
appears	O
responsive	O
to	O
multiple	O
determinants	O
of	O
oxidative	O
damage	O
,	O
including	O
particle	O
chemistry	O
,	O
surface	O
area	O
and	O
impurities	O
,	O
and	O
may	O
be	O
a	O
valid	O
screening	O
method	O
to	O
determine	O
oxidative	O
damage	O
imparted	O
by	O
nanomaterials	O
.	O

Efficacy	O
and	O
safety	O
of	O
two	O
doses	O
of	O
pemetrexed	O
supplemented	O
with	O
folic	O
acid	O
and	O
vitamin	O
B12	O
in	O
previously	O
treated	O
patients	O
with	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

PURPOSE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
doses	O
of	O
pemetrexed	O
supplemented	O
with	O
folic	O
acid	O
and	O
vitamin	O
B	O
(	O
12	O
)	O
in	O
pretreated	O
Japanese	O
patients	O
with	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Patients	O
with	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
to	O
2	O
,	O
stage	O
III	O
or	O
IV	O
,	O
and	O
who	O
received	O
previously	O
one	O
or	O
two	O
chemotherapy	O
regimens	O
were	O
randomized	O
to	O
receive	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
pemetrexed	O
(	O
P500	O
)	O
or	O
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
pemetrexed	O
(	O
P1000	O
)	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
response	O
rate	O
.	O

RESULTS	O
:	O
Of	O
the	O
216	O
patients	O
evaluable	O
for	O
efficacy	O
(	O
108	O
in	O
each	O
arm	O
)	O
,	O
response	O
rates	O
were	O
18.5	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
,	O
12.6	O
-	O
25.8	O
%	O
)	O
and	O
14.8	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
,	O
9.5	O
-	O
21.6	O
%	O
)	O
,	O
median	O
survival	O
times	O
were	O
16.0	O
and	O
12.6	O
months	O
,	O
1	O
-	O
year	O
survival	O
rates	O
were	O
59.2	O
%	O
and	O
53.7	O
%	O
,	O
and	O
median	O
progression	O
-	O
free	O
survival	O
were	O
3.0	O
and	O
2.5	O
months	O
for	O
the	O
P500	O
and	O
P1000	O
,	O
respectively	O
.	O

Cox	O
multiple	O
regression	O
analysis	O
indicated	O
that	O
pemetrexed	O
dose	O
was	O
not	O
a	O
significant	O
prognostic	O
factor	O
.	O

Drug	B
-	I
related	I
toxicity	I
was	O
generally	O
tolerable	O
for	O
both	O
doses	O
;	O
however	O
,	O
the	O
safety	O
profile	O
of	O
P500	O
showed	O
generally	O
milder	O
toxicity	O
.	O

Main	O
adverse	O
drug	O
reactions	O
of	O
severity	O
grade	O
3	O
or	O
4	O
were	O
neutrophil	B
count	I
decreased	I
(	O
20.2	O
%	O
)	O
and	O
alanine	B
aminotransferase	I
(	I
glutamine	I
pyruvic	I
transaminase	I
)	I
increased	I
(	O
15.8	O
%	O
)	O
in	O
P500	O
and	O
neutrophil	B
count	I
decreased	I
(	O
24.3	O
%	O
)	O
,	O
WBC	B
count	I
decreased	I
(	O
20.7	O
%	O
)	O
,	O
and	O
lymphocyte	B
count	I
decreased	I
(	O
18.0	O
%	O
)	O
in	O
P1000	O
.	O

One	O
drug	O
-	O
related	O
death	O
from	O
interstitial	B
lung	I
disease	I
occurred	O
in	O
the	O
P500	O
.	O

CONCLUSION	O
:	O
P500	O
and	O
P1000	O
are	O
similarly	O
active	O
with	O
promising	O
efficacy	O
and	O
acceptable	O
safety	O
outcomes	O
in	O
pretreated	O
patients	O
with	O
NSCLC	B
.	O

These	O
results	O
support	O
the	O
use	O
of	O
P500	O
as	O
a	O
second	O
-	O
and	O
third	O
-	O
line	O
treatment	O
of	O
NSCLC	B
.	O

Pharmacogenetics	O
of	O
analgesics	O
:	O
toward	O
the	O
individualization	O
of	O
prescription	O
.	O

The	O
use	O
of	O
analgesics	O
is	O
based	O
on	O
the	O
empiric	O
administration	O
of	O
a	O
given	O
drug	O
with	O
clinical	O
monitoring	O
for	O
efficacy	O
and	O
toxicity	O
.	O

However	O
,	O
individual	O
responses	O
to	O
drugs	O
are	O
influenced	O
by	O
a	O
combination	O
of	O
pharmacokinetic	O
and	O
pharmacodynamic	O
factors	O
that	O
can	O
sometimes	O
be	O
regulated	O
by	O
genetic	O
factors	O
.	O

Whereas	O
polymorphic	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
drug	O
transporters	O
may	O
affect	O
the	O
pharmacokinetics	O
of	O
drugs	O
,	O
polymorphic	O
drug	O
targets	O
and	O
disease	O
-	O
related	O
pathways	O
may	O
influence	O
the	O
pharmacodynamic	O
action	O
of	O
drugs	O
.	O

After	O
a	O
usual	O
dose	O
,	O
variations	O
in	O
drug	B
toxicity	I
and	O
inefficacy	O
can	O
be	O
observed	O
depending	O
on	O
the	O
polymorphism	O
,	O
the	O
analgesic	O
considered	O
and	O
the	O
presence	O
or	O
absence	O
of	O
active	O
metabolites	O
.	O

For	O
opioids	O
,	O
the	O
most	O
studied	O
being	O
morphine	O
,	O
mutations	O
in	O
the	O
ABCB1	O
gene	O
,	O
coding	O
for	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
,	O
and	O
in	O
the	O
micro	O
-	O
opioid	O
receptor	O
reduce	O
morphine	O
potency	O
.	O

Cytochrome	O
P450	O
(	O
CYP	O
)	O
2D6	O
mutations	O
influence	O
the	O
analgesic	O
effect	O
of	O
codeine	O
and	O
tramadol	O
,	O
and	O
polymorphism	O
of	O
CYP2C9	O
is	O
potentially	O
linked	O
to	O
an	O
increase	O
in	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
adverse	O
events	O
.	O

Furthermore	O
,	O
drug	O
interactions	O
can	O
mimic	O
genetic	O
deficiency	O
and	O
contribute	O
to	O
the	O
variability	O
in	O
response	O
to	O
analgesics	O
.	O

This	O
review	O
summarizes	O
the	O
available	O
data	O
on	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
consequences	O
of	O
known	O
polymorphisms	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
drug	O
transporters	O
,	O
drug	O
targets	O
and	O
other	O
nonopioid	O
biological	O
systems	O
on	O
central	O
and	O
peripheral	O
analgesics	O
.	O

Effect	O
of	O
repeated	O
doses	O
of	O
darunavir	O
plus	O
low	O
-	O
dose	O
ritonavir	O
on	O
the	O
pharmacokinetics	O
of	O
sildenafil	O
in	O
healthy	O
male	O
subjects	O
:	O
phase	O
I	O
randomized	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
way	O
crossover	O
study	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Darunavir	O
(	O
DRV	O
,	O
TMC114	O
)	O
is	O
a	O
novel	O
protease	O
inhibitor	O
administered	O
in	O
combination	O
with	O
low	O
-	O
dose	O
ritonavir	O
(	O
DRV	O
/	O
r	O
)	O
and	O
is	O
highly	O
active	O
against	O
both	O
wild	O
-	O
type	O
and	O
multidrug	O
-	O
resistant	O
HIV	O
-	O
1	O
strains	O
.	O

Sildenafil	O
is	O
an	O
oral	O
therapy	O
for	O
erectile	B
dysfunction	I
.	O

Concomitant	O
administration	O
of	O
protease	O
inhibitors	O
and	O
sildenafil	O
increases	O
sildenafil	O
plasma	O
concentrations	O
.	O

The	O
potential	O
for	O
a	O
pharmacokinetic	O
drug	O
interaction	O
exists	O
when	O
sildenafil	O
and	O
DRV	O
/	O
r	O
are	O
co	O
-	O
administered	O
,	O
as	O
these	O
drugs	O
are	O
primarily	O
metabolized	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A	O
,	O
and	O
darunavir	O
and	O
ritonavir	O
are	O
CYP3A	O
inhibitors	O
.	O

The	O
primary	O
objective	O
of	O
this	O
open	O
-	O
label	O
,	O
crossover	O
,	O
phase	O
I	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
multiple	O
doses	O
of	O
DRV	O
/	O
r	O
on	O
the	O
pharmacokinetics	O
of	O
sildenafil	O
and	O
its	O
active	O
metabolite	O
N	O
-	O
desmethyl	O
sildenafil	O
.	O

The	O
secondary	O
objective	O
was	O
to	O
assess	O
the	O
short	O
-	O
term	O
safety	O
and	O
tolerability	O
of	O
co	O
-	O
administration	O
of	O
sildenafil	O
and	O
DRV	O
/	O
r	O
.	O

METHODS	O
:	O
Sixteen	O
HIV	O
-	O
negative	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
sequences	O
.	O

In	O
two	O
sessions	O
each	O
subject	O
received	O
treatments	O
A	O
and	O
B	O
.	O

In	O
treatment	O
A	O
,	O
a	O
single	O
dose	O
of	O
sildenafil	O
100	O
mg	O
was	O
administered	O
.	O

In	O
treatment	O
B	O
,	O
the	O
subjects	O
received	O
DRV	O
/	O
r	O
400	O
/	O
100	O
mg	O
twice	O
daily	O
for	O
8	O
days	O
and	O
on	O
day	O
7	O
a	O
single	O
dose	O
of	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
.	O

Full	O
pharmacokinetic	O
profiles	O
of	O
sildenafil	O
,	O
N	O
-	O
desmethyl	O
sildenafil	O
,	O
darunavir	O
and	O
ritonavir	O
were	O
determined	O
.	O

Safety	O
and	O
tolerability	O
were	O
also	O
assessed	O
.	O

RESULTS	O
:	O
Sildenafil	O
exposure	O
(	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
[	O
AUC	O
]	O
)	O
was	O
comparable	O
between	O
the	O
two	O
treatments	O
despite	O
administration	O
of	O
a	O
lower	O
dose	O
of	O
sildenafil	O
(	O
25	O
mg	O
)	O
with	O
DRV	O
/	O
r	O
than	O
when	O
sildenafil	O
(	O
100	O
mg	O
)	O
was	O
administered	O
alone	O
.	O

When	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
,	O
the	O
sildenafil	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
was	O
38	O
%	O
lower	O
compared	O
with	O
Cmax	O
after	O
administration	O
of	O
sildenafil	O
alone	O
at	O
a	O
dose	O
of	O
100	O
mg	O
.	O

N	O
-	O
desmethyl	O
sildenafil	O
Cmax	O
and	O
AUC	O
from	O
the	O
time	O
of	O
administration	O
until	O
the	O
last	O
time	O
point	O
with	O
a	O
measurable	O
concentration	O
after	O
dosing	O
(	O
calculated	O
by	O
linear	O
trapezoidal	O
summation	O
[	O
AUClast	O
]	O
)	O
values	O
decreased	O
by	O
approximately	O
95	O
%	O
when	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
compared	O
with	O
sildenafil	O
100	O
mg	O
alone	O
.	O

Combined	O
treatment	O
with	O
DRV	O
/	O
r	O
and	O
sildenafil	O
was	O
generally	O
safe	O
and	O
well	O
tolerated	O
.	O

CONCLUSION	O
:	O
Sildenafil	O
exposure	O
is	O
increased	O
in	O
the	O
presence	O
of	O
DRV	O
/	O
r	O
.	O

In	O
this	O
setting	O
,	O
a	O
dose	O
adjustment	O
for	O
sildenafil	O
is	O
warranted	O
;	O
no	O
more	O
than	O
25	O
mg	O
of	O
sildenafil	O
is	O
recommended	O
over	O
a	O
48	O
-	O
hour	O
period	O
when	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
.	O

Paternal	O
exposure	O
and	O
counselling	O
:	O
experience	O
of	O
a	O
Teratology	O
Information	O
Service	O
.	O

We	O
describe	O
paternal	O
exposure	O
and	O
counselling	O
in	O
a	O
selected	O
population	O
calling	O
to	O
an	O
Italian	O
Teratology	O
Information	O
Service	O
(	O
TIS	O
)	O
.	O

The	O
majority	O
of	O
callers	O
asked	O
for	O
paternal	O
drug	O
exposure	O
(	O
76	O
%	O
,	O
drugs	O
except	O
chemotherapy	O
)	O
and	O
treatment	O
for	O
cancer	B
(	O
17	O
%	O
,	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
)	O
.	O

Others	O
asked	O
for	O
exposure	O
to	O
diagnostic	O
radiations	O
(	O
4	O
%	O
)	O
,	O
recreational	O
drugs	O
(	O
2	O
%	O
)	O
and	O
occupational	O
chemicals	O
(	O
1	O
%	O
)	O
.	O

Among	O
paternal	O
drugs	O
neurological	O
compounds	O
,	O
immunosuppressive	O
drugs	O
and	O
antiviral	O
agents	O
were	O
the	O
main	O
reasons	O
for	O
calling	O
.	O

In	O
humans	O
,	O
there	O
are	O
no	O
evidences	O
of	O
birth	B
defects	I
after	O
paternal	O
exposures	O
,	O
but	O
to	O
minimize	O
any	O
possible	O
risk	O
,	O
counselling	O
in	O
men	O
exposed	O
to	O
radio	O
and	O
chemotherapy	O
should	O
recommend	O
delaying	O
conception	O
for	O
at	O
least	O
3	O
months	O
after	O
the	O
end	O
of	O
the	O
therapy	O
.	O

Male	O
patients	O
treated	O
with	O
drugs	O
,	O
whose	O
teratogenic	O
potential	O
has	O
been	O
well	O
assessed	O
or	O
suspected	O
for	O
maternal	O
exposure	O
,	O
should	O
be	O
advised	O
to	O
practice	O
effective	O
birth	O
control	O
during	O
therapy	O
and	O
up	O
to	O
one	O
or	O
two	O
cycles	O
of	O
spermatogenesis	O
and	O
to	O
avoid	O
semen	O
contact	O
with	O
vaginal	O
walls	O
during	O
first	O
trimester	O
of	O
pregnancy	O
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
study	O
of	O
once	O
-	O
daily	O
dexmethylphenidate	O
in	O
children	O
with	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
:	O
rapid	O
onset	O
of	O
effect	O
.	O

BACKGROUND	O
:	O
Long	O
-	O
acting	O
methylphenidate	O
formulations	O
provide	O
control	O
of	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
symptoms	O
for	O
up	O
to	O
12	O
hours	O
;	O
however	O
,	O
not	O
all	O
formulations	O
have	O
rapid	O
onset	O
of	O
therapeutic	O
effect	O
,	O
which	O
is	O
essential	O
for	O
providing	O
symptom	O
control	O
during	O
morning	O
hours	O
.	O

The	O
primary	O
objective	O
of	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
dexmethylphenidate	O
extended	O
release	O
(	O
ER	O
)	O
versus	O
placebo	O
by	O
measuring	O
the	O
change	O
from	O
pre	O
-	O
dose	O
to	O
0.5	O
hours	O
post	O
-	O
dose	O
on	O
the	O
Swanson	O
,	O
Kotkin	O
,	O
Agler	O
,	O
M	O
-	O
Flynn	O
and	O
Pelham	O
(	O
SKAMP	O
)	O
rating	O
scale	O
.	O

METHODS	O
:	O
Eighty	O
-	O
six	O
children	O
(	O
6	O
-	O
12	O
years	O
)	O
with	O
ADHD	B
diagnosed	O
using	O
the	O
DSM	O
-	O
IV	O
criteria	O
were	O
randomized	O
to	O
receive	O
dexmethylphenidate	O
ER	O
20	O
mg	O
/	O
day	O
or	O
placebo	O
,	O
sequentially	O
,	O
for	O
7	O
days	O
,	O
with	O
the	O
final	O
dose	O
administered	O
in	O
a	O
laboratory	O
classroom	O
setting	O
on	O
day	O
7	O
of	O
each	O
treatment	O
period	O
.	O

The	O
primary	O
efficacy	O
comparison	O
was	O
change	O
in	O
the	O
SKAMP	O
-	O
Combined	O
score	O
from	O
pre	O
-	O
dose	O
to	O
0.5	O
hours	O
post	O
-	O
dose	O
,	O
with	O
additional	O
secondary	O
assessments	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
hours	O
post	O
-	O
dose	O
.	O

Secondary	O
efficacy	O
measures	O
included	O
change	O
from	O
pre	O
-	O
dose	O
at	O
all	O
timepoints	O
in	O
the	O
SKAMP	O
-	O
Attention	O
and	O
SKAMP	O
-	O
Deportment	O
,	O
Math	O
Test	O
-	O
Attempted	O
and	O
Math	O
Test	O
-	O
Correct	O
scores	O
,	O
and	O
change	O
from	O
baseline	O
on	O
the	O
Conners	O
'	O
ADHD	B
/	O
DSM	O
-	O
IV	O
Scale	O
for	O
Parents	O
(	O
CADS	O
-	O
P	O
)	O
.	O

In	O
an	O
exploratory	O
analysis	O
,	O
a	O
daily	O
diary	O
card	O
was	O
completed	O
by	O
parents	O
on	O
the	O
children	O
's	O
in	O
-	O
home	O
behaviour	O
before	O
school	O
.	O

Safety	O
was	O
assessed	O
by	O
occurrence	O
of	O
adverse	O
events	O
,	O
monitoring	O
of	O
vital	O
signs	O
and	O
interpretation	O
of	O
ECGs	O
.	O

RESULTS	O
:	O
Significant	O
improvements	O
were	O
noted	O
at	O
0.5	O
hours	O
and	O
at	O
all	O
timepoints	O
post	O
-	O
dose	O
throughout	O
the	O
8	O
-	O
hour	O
laboratory	O
classroom	O
day	O
for	O
dexmethylphenidate	O
ER	O
vs	O
placebo	O
in	O
the	O
primary	O
outcome	O
measure	O
of	O
the	O
SKAMP	O
-	O
Combined	O
scores	O
(	O
p	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
SKAMP	O
-	O
Attention	O
,	O
SKAMP	O
-	O
Deportment	O
,	O
Math	O
Test	O
-	O
Attempted	O
and	O
Math	O
Test	O
-	O
Correct	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
changes	O
from	O
baseline	O
in	O
CADS	O
-	O
P	O
scores	O
were	O
significantly	O
greater	O
with	O
dexmethylphenidate	O
ER	O
than	O
placebo	O
(	O
-	O
16.382	O
vs	O
-	O
4.622	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Responses	O
to	O
all	O
diary	O
questions	O
indicated	O
significant	O
improvement	O
with	O
dexmethylphenidate	O
ER	O
treatment	O
versus	O
placebo	O
(	O
all	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
abdominal	B
pain	I
(	O
dexmethylphenidate	O
ER	O
3.5	O
%	O
;	O
placebo	O
4.7	O
%	O
)	O
,	O
headache	B
(	O
dexmethylphenidate	O
ER	O
3.5	O
%	O
;	O
placebo	O
2.3	O
%	O
)	O
and	O
increased	B
appetite	I
(	O
dexmethylphenidate	O
ER	O
0	O
%	O
;	O
placebo	O
3.5	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Compared	O
with	O
placebo	O
,	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
20	O
mg	O
provided	O
rapid	O
and	O
significant	O
improvement	O
at	O
0.5	O
hours	O
post	O
-	O
dose	O
in	O
attention	O
,	O
deportment	O
and	O
academic	O
performance	O
,	O
which	O
was	O
sustained	O
for	O
8	O
hours	O
post	O
-	O
dose	O
.	O

Overall	O
,	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
20	O
mg	O
was	O
well	O
tolerated	O
.	O

In	O
an	O
analysis	O
of	O
parental	O
assessment	O
of	O
diary	O
responses	O
,	O
children	O
appeared	O
more	O
organized	O
,	O
and	O
morning	O
preparation	O
for	O
school	O
was	O
smoother	O
and	O
less	O
frustrating	O
with	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
compared	O
with	O
placebo	O
.	O

Clostridium	O
perfringens	O
enterotoxin	O
in	O
antibiotic	B
-	I
associated	I
diarrhea	I
.	O

Clostridium	O
perfringens	O
type	O
A	O
is	O
associated	O
with	O
5	O
-	O
20	O
%	O
cases	O
of	O
antibiotic	B
-	I
associated	I
diarrhea	I
(	O
AAD	O
)	O
even	O
though	O
Clostridium	O
difficile	O
is	O
implicated	O
in	O
the	O
most	O
severe	O
cases	O
.	O

Fecal	O
specimens	O
from	O
one	O
hundred	O
hospitalized	O
patients	O
,	O
who	O
developed	O
diarrhea	B
regardless	O
of	O
antibiotic	O
intake	O
and	O
who	O
were	O
negative	O
for	O
C	O
.	O

difficile	O
toxin	O
assay	O
,	O
were	O
investigated	O
for	O
C	O
.	O

perfringens	O
enterotoxin	O
(	O
CPE	O
)	O
.	O

Simultaneously	O
,	O
cultures	O
were	O
set	O
up	O
for	O
other	O
possible	O
aetiological	O
factors	O
.	O

Ten	B
healthy	O
controls	O
were	O
also	O
similarly	O
investigated	O
.	O

CPE	O
was	O
positive	O
in	O
2	O
/	O
100	O
(	O
2	O
%	O
)	O
of	O
the	O
patients	O
and	O
the	O
samples	O
were	O
also	O
positive	O
for	O
the	O
organism	O
in	O
culture	O
.	O

Other	O
organisms	O
isolated	O
were	O
non	O
-	O
toxigenic	O
C	O
.	O

difficile	O
(	O
4	O
%	O
)	O
,	O
staphylococci	O
(	O
6	O
%	O
)	O
,	O
Candida	O
(	O
18	O
%	O
)	O
and	O
Klebsiella	O
pneumoniae	O
(	O
1	O
%	O
)	O
.	O

Stool	O
samples	O
from	O
healthy	O
controls	O
grew	O
mixed	O
growth	O
of	O
no	O
significance	O
and	O
CPE	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O

Detection	O
of	O
CPE	O
is	O
not	O
part	O
of	O
routine	O
laboratory	O
investigation	O
due	O
to	O
resource	O
implication	O
.	O

Criteria	O
for	O
initiating	O
investigations	O
have	O
to	O
be	O
therefore	O
established	O
by	O
understanding	O
the	O
true	O
burden	O
of	O
C	O
.	O

perfringens	O
-	O
associated	O
AAD	O
by	O
further	O
research	O
.	O

Should	O
we	O
abandon	O
corticosteroids	O
during	O
septic	B
shock	I
?	O

No	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
With	O
the	O
publication	O
of	O
the	O
results	O
of	O
the	O
recent	O
CORTICUS	O
trial	O
,	O
stress	O
(	O
'	O
low	O
'	O
)	O
doses	O
of	O
corticosteroids	O
for	O
the	O
treatment	O
of	O
vasopressor	O
-	O
dependent	O
septic	B
shock	I
in	O
adults	O
can	O
still	O
be	O
considered	O
controversial	O
.	O

The	O
purpose	O
of	O
this	O
narrative	O
review	O
is	O
to	O
elaborate	O
the	O
pros	O
and	O
cons	O
of	O
this	O
treatment	O
in	O
clinical	O
practice	O
and	O
to	O
formulate	O
clinical	O
and	O
research	O
directions	O
.	O

RECENT	O
FINDINGS	O
:	O
The	O
recent	O
CORTICUS	O
study	O
only	O
shows	O
a	O
beneficial	O
effect	O
of	O
stress	O
doses	O
of	O
corticosteroids	O
in	O
the	O
time	O
interval	O
to	O
shock	O
reversal	O
and	O
not	O
on	O
mortality	O
,	O
potentially	O
explained	O
by	O
an	O
increased	O
risk	O
for	O
superinfection	B
.	O

The	O
mortality	O
in	O
the	O
placebo	O
arm	O
was	O
relatively	O
low	O
and	O
lower	O
than	O
in	O
earlier	O
randomized	O
studies	O
in	O
which	O
stress	O
doses	O
of	O
corticosteroids	O
had	O
a	O
favorable	O
hemodynamic	O
effect	O
and	O
conferred	O
a	O
survival	O
benefit	O
in	O
septic	B
shock	I
.	O

SUMMARY	O
:	O
Treatment	O
by	O
stress	O
doses	O
of	O
corticosteroids	O
should	O
not	O
be	O
abandoned	O
during	O
septic	B
shock	I
.	O

Additional	O
studies	O
are	O
needed	O
,	O
however	O
,	O
to	O
better	O
delineate	O
the	O
patient	O
group	O
with	O
the	O
highest	O
likelihood	O
to	O
benefit	O
from	O
this	O
therapy	O
,	O
as	O
a	O
function	O
of	O
severity	O
of	O
illness	O
,	O
response	O
to	O
adrenocorticotrophic	O
hormone	O
testing	O
or	O
both	O
.	O

For	O
now	O
,	O
results	O
of	O
the	O
CORTICUS	O
study	O
should	O
not	O
change	O
current	O
clinical	O
practice	O
of	O
administering	O
200	O
-	O
300	O
mg	O
of	O
hydrocortisone	O
daily	O
(	O
in	O
divided	O
doses	O
)	O
in	O
case	O
of	O
fluid	O
and	O
vasopressor	O
-	O
insensitive	O
septic	B
shock	I
and	O
rapid	O
tapering	O
of	O
this	O
treatment	O
on	O
the	O
basis	O
of	O
a	O
hemodynamic	O
response	O
.	O

Inhibition	O
of	O
cell	O
-	O
cycle	O
progression	O
in	O
human	O
colorectal	O
carcinoma	O
Lovo	O
cells	O
by	O
andrographolide	O
.	O

In	O
recent	O
years	O
,	O
attention	O
has	O
been	O
focused	O
on	O
the	O
anti	O
-	O
cancer	O
properties	O
of	O
pure	O
components	O
,	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
disease	O
.	O

Andrographolide	O
(	O
Andro	O
)	O
,	O
the	O
major	O
constituent	O
of	O
Andrographis	O
paniculata	O
(	O
Burm	O
.	O
F	O
.	O
)	O

Nees	O
plant	O
,	O
is	O
implicated	O
towards	O
its	O
pharmacological	O
activity	O
.	O

To	O
investigate	O
the	O
mechanism	O
basis	O
for	O
the	O
anti	O
-	O
tumor	O
properties	O
of	O
Andro	O
,	O
Andro	O
was	O
used	O
to	O
examine	O
its	O
effect	O
on	O
cell	O
-	O
cycle	O
progression	O
in	O
human	O
colorectal	O
carcinoma	O
Lovo	O
cells	O
.	O

The	O
data	O
from	O
cell	O
growth	O
experiment	O
showed	O
that	O
Andro	O
exhibited	O
the	O
anti	O
-	O
proliferation	O
effect	O
on	O
Lovo	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
event	O
was	O
accompanied	O
the	O
arrest	O
of	O
the	O
cells	O
at	O
the	O
G1	O
-	O
S	O
phase	O
by	O
Andro	O
at	O
the	O
tested	O
concentrations	O
of	O
0	O
-	O
30	O
microM	O
.	O

Cellular	O
uptake	O
of	O
Andro	O
and	O
Andro	O
was	O
confirmed	O
by	O
capillary	O
electrophoresis	O
analysis	O
and	O
the	O
intracellular	O
accumulation	O
of	O
Andro	O
(	O
0.61	O
+	O
/	O
-	O
0.07	O
microM	O
/	O
mg	O
protein	O
)	O
was	O
observed	O
when	O
treatment	O
of	O
Lovo	O
cells	O
with	O
Andro	O
for	O
12h	O
.	O

In	O
addition	O
,	O
an	O
accumulation	O
of	O
the	O
cells	O
in	O
G1	O
phase	O
(	O
15	O
%	O
increase	O
for	O
10	O
microM	O
of	O
Andro	O
)	O
was	O
observed	O
as	O
well	O
as	O
by	O
the	O
association	O
with	O
a	O
marked	O
decrease	O
in	O
the	O
protein	O
expression	O
of	O
Cyclin	O
A	O
,	O
Cyclin	O
D1	O
,	O
Cdk2	O
and	O
Cdk4	O
.	O

Andro	O
also	O
inducted	O
the	O
content	O
of	O
Cdk	O
inhibitor	O
p21	O
and	O
p16	O
,	O
and	O
the	O
phosphorylation	O
of	O
p53	O
.	O

Further	O
immunoprecipitation	O
studies	O
found	O
that	O
,	O
in	O
response	O
to	O
the	O
treatment	O
,	O
the	O
formation	O
of	O
Cyclin	O
D1	O
/	O
Cdk4	O
and	O
Cyclin	O
A	O
/	O
Cdk2	O
complexes	O
had	O
declined	O
,	O
preventing	O
the	O
phosphorylation	O
of	O
Rb	O
and	O
the	O
subsequent	O
dissociation	O
of	O
Rb	O
/	O
E2F	O
complex	O
.	O

These	O
results	O
suggested	O
Andro	O
can	O
inhibit	O
Lovo	O
cell	O
growth	O
by	O
G1	O
-	O
S	O
phase	O
arrest	O
,	O
and	O
was	O
exerted	O
by	O
inducing	O
the	O
expression	O
of	O
p53	O
,	O
p21	O
and	O
p16	O
that	O
,	O
in	O
turn	O
,	O
repressed	O
the	O
activity	O
of	O
Cyclin	O
D1	O
/	O
Cdk4	O
and	O
/	O
or	O
Cyclin	O
A	O
/	O
Cdk2	O
,	O
as	O
well	O
as	O
Rb	O
phosphorylation	O
.	O

Impact	O
of	O
antioxidant	O
supplementation	O
on	O
chemotherapeutic	B
toxicity	I
:	O
a	O
systematic	O
review	O
of	O
the	O
evidence	O
from	O
randomized	O
controlled	O
trials	O
.	O

Much	O
debate	O
has	O
focused	O
on	O
whether	O
antioxidants	O
interfere	O
with	O
the	O
efficacy	O
of	O
cancer	B
chemotherapy	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
systematically	O
review	O
the	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
evidence	O
evaluating	O
the	O
effects	O
of	O
concurrent	O
use	O
of	O
antioxidants	O
with	O
chemotherapy	O
on	O
toxic	O
side	O
effects	O
.	O

We	O
performed	O
a	O
search	O
of	O
literature	O
from	O
1966	O
-	O
October	O
2007	O
using	O
MEDLINE	O
,	O
Cochrane	O
,	O
CinAhl	O
,	O
AMED	O
,	O
AltHealthWatch	O
and	O
EMBASE	O
databases	O
.	O

Randomized	O
,	O
controlled	O
clinical	O
trials	O
reporting	O
antioxidant	O
-	O
based	O
mitigation	O
of	O
chemotherapy	B
toxicity	I
were	O
included	O
in	O
the	O
final	O
tally	O
.	O

Searches	O
were	O
performed	O
following	O
a	O
standardized	O
protocol	O
for	O
systematic	O
reviews	O
.	O

Only	O
33	O
of	O
965	O
articles	O
considered	O
,	O
including	O
2,446	O
subjects	O
,	O
met	O
the	O
inclusion	O
criteria	O
.	O

Antioxidants	O
evaluated	O
were	O
:	O
glutathione	O
(	O
11	O
)	O
,	O
melatonin	O
(	O
7	O
)	O
,	O
vitamin	O
A	O
(	O
1	O
)	O
,	O
an	O
antioxidant	O
mixture	O
(	O
2	O
)	O
,	O
N	O
-	O
acetylcysteine	O
(	O
2	O
)	O
,	O
vitamin	O
E	O
(	O
5	O
)	O
,	O
selenium	O
(	O
2	O
)	O
,	O
L	O
-	O
carnitine	O
(	O
1	O
)	O
,	O
Co	O
-	O
Q10	O
(	O
1	O
)	O
and	O
ellagic	O
acid	O
(	O
1	O
)	O
.	O

The	O
majority	O
(	O
24	O
)	O
of	O
the	O
33	O
studies	O
included	O
reported	O
evidence	O
of	O
decreased	O
toxicities	O
from	O
the	O
concurrent	O
use	O
of	O
antioxidants	O
with	O
chemotherapy	O
.	O

Nine	O
studies	O
reported	O
no	O
difference	O
in	O
toxicities	O
between	O
the	O
2	O
groups	O
.	O

Only	O
1	O
study	O
(	O
vitamin	O
A	O
)	O
reported	O
a	O
significant	O
increase	O
in	O
toxicity	O
in	O
the	O
antioxidant	O
group	O
.	O

Five	O
studies	O
reported	O
the	O
antioxidant	O
group	O
completed	O
more	O
full	O
doses	O
of	O
chemotherapy	O
or	O
had	O
less	O
-	O
dose	O
reduction	O
than	O
control	O
groups	O
.	O

Statistical	O
power	O
and	O
poor	O
study	O
quality	O
were	O
concerns	O
with	O
some	O
studies	O
.	O

This	O
review	O
provides	O
the	O
first	O
systematically	O
reviewed	O
evidence	O
that	O
antioxidant	O
supplementation	O
during	O
chemotherapy	O
holds	O
potential	O
for	O
reducing	O
dose	O
-	O
limiting	O
toxicities	O
.	O

However	O
,	O
well	O
-	O
designed	O
studies	O
evaluating	O
larger	O
populations	O
of	O
patients	O
given	O
specific	O
antioxidants	O
defined	O
by	O
dose	O
and	O
schedule	O
relative	O
to	O
chemotherapy	O
are	O
warranted	O
.	O

Optimizing	O
docetaxel	O
chemotherapy	O
in	O
patients	O
with	O
cancer	B
of	I
the	I
gastric	I
and	I
gastroesophageal	I
junction	I
:	O
evolution	O
of	O
the	O
docetaxel	O
,	O
cisplatin	O
,	O
and	O
5	O
-	O
fluorouracil	O
regimen	O
.	O

Advanced	O
gastroesophageal	B
cancer	I
patients	O
are	O
often	O
treated	O
with	O
systemic	O
combination	O
chemotherapy	O
.	O

The	O
V	O
-	O
325	O
study	O
demonstrated	O
that	O
adding	O
docetaxel	O
(	O
D	O
)	O
to	O
a	O
frequently	O
used	O
regimen	O
of	O
cisplatin	O
and	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
provided	O
benefits	O
with	O
regard	O
to	O
overall	O
survival	O
,	O
response	O
rate	O
,	O
time	O
-	O
to	O
-	O
disease	O
progression	O
,	O
clinical	O
benefit	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

Although	O
the	O
DCF	O
regimen	O
provides	O
these	O
advantages	O
,	O
it	O
is	O
accompanied	O
by	O
an	O
increase	O
in	O
toxicity	O
compared	O
with	O
the	O
doublet	O
regimen	O
.	O

The	O
toxicity	O
profile	O
of	O
DCF	O
is	O
acceptable	O
only	O
with	O
appropriately	O
selected	O
patients	O
and	O
comprehensive	O
toxicity	O
management	O
strategies	O
.	O

The	O
objective	O
of	O
the	O
current	O
review	O
was	O
to	O
identify	O
trials	O
that	O
investigated	O
modifications	O
to	O
the	O
original	O
DCF	O
regimen	O
to	O
improve	O
its	O
toxicity	O
profile	O
and	O
summarize	O
response	O
rate	O
and	O
toxicities	O
.	O

An	O
attempt	O
was	O
also	O
made	O
to	O
summarize	O
ongoing	O
modifications	O
of	O
the	O
DCF	O
regimen	O
.	O

MEDLINE	O
,	O
major	O
meeting	O
proceedings	O
,	O
and	O
the	O
government	O
clinical	O
trials	O
website	O
were	O
searched	O
until	O
2007	O
.	O

The	O
modified	O
DCF	O
regimens	O
appear	O
to	O
improve	O
the	O
toxicity	O
profile	O
when	O
compared	O
with	O
the	O
original	O
DCF	O
regimen	O
.	O

The	O
docetaxel	O
-	O
based	O
triplet	O
combinations	O
appear	O
to	O
have	O
a	O
higher	O
response	O
rate	O
than	O
the	O
doublet	O
combinations	O
.	O

Many	O
institutions	O
and	O
cooperative	O
groups	O
continue	O
to	O
study	O
docetaxel	O
-	O
based	O
modifications	O
of	O
the	O
DCF	O
regimen	O
to	O
treat	O
patients	O
with	O
gastroesophageal	B
carcinoma	I
.	O

However	O
,	O
although	O
modified	O
DCF	O
reduces	O
the	O
frequency	O
of	O
severe	O
toxicities	O
previously	O
reported	O
with	O
DCF	O
,	O
considerably	O
more	O
advances	O
are	O
needed	O
to	O
improve	O
the	O
safety	O
,	O
survival	O
,	O
and	O
convenience	O
of	O
patients	O
with	O
advanced	O
gastroesophageal	B
cancer	I
.	O

Pentachlorophenol	O
decreases	O
ATP	O
levels	O
in	O
human	O
natural	O
killer	O
cells	O
.	O

Pentachlorophenol	O
(	O
PCP	O
)	O
is	O
used	O
as	O
a	O
wood	O
preservative	O
and	O
is	O
found	O
in	O
human	O
blood	O
and	O
urine	O
.	O

PCP	O
causes	O
significant	O
decreases	O
in	O
the	O
tumor	O
-	O
killing	O
(	O
lytic	O
)	O
function	O
of	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
a	O
critical	O
immune	O
defense	O
.	O

The	O
current	O
study	O
examined	O
the	O
association	O
between	O
decreased	O
lytic	O
function	O
and	O
decreased	O
ATP	O
levels	O
,	O
as	O
well	O
as	O
the	O
ability	O
of	O
antioxidants	O
(	O
vitamin	O
E	O
and	O
reduced	O
glutathione	O
)	O
to	O
prevent	O
PCP	O
-	O
induced	O
decreases	O
in	O
either	O
ATP	O
levels	O
or	O
lytic	O
function	O
.	O

Exposure	O
of	O
NK	O
cells	O
to	O
10	O
microm	O
PCP	O
decreased	O
ATP	O
levels	O
by	O
15	O
%	O
at	O
24	O
h	O
,	O
and	O
exposure	O
to	O
5	O
microm	O
PCP	O
decreased	O
ATP	O
levels	O
by	O
32	O
%	O
at	O
48	O
h	O
.	O

No	O
effects	O
were	O
seen	O
with	O
0.5	O
microm	O
at	O
48	O
h	O
or	O
with	O
5	O
microm	O
at	O
24	O
h	O
.	O

However	O
,	O
10	O
microm	O
PCP	O
decreased	O
lytic	O
function	O
by	O
69	O
%	O
at	O
24	O
h	O
and	O
5	O
microm	O
decreased	O
it	O
by	O
90	O
%	O
at	O
48	O
h	O
.	O

Even	O
0.5	O
microm	O
PCP	O
decreased	O
lytic	O
function	O
by	O
46	O
%	O
at	O
48	O
h	O
.	O

None	O
of	O
these	O
effects	O
were	O
prevented	O
by	O
pretreatment	O
with	O
1	O
mm	O
vitamin	O
E	O
or	O
reduced	O
glutathione	O
.	O

Using	O
dietary	O
exposure	O
and	O
physiologically	O
based	O
pharmacokinetic	O
/	O
pharmacodynamic	O
modeling	O
in	O
human	O
risk	O
extrapolations	O
for	O
acrylamide	B
toxicity	I
.	O

The	O
discovery	O
of	O
acrylamide	O
(	O
AA	O
)	O
in	O
many	O
common	O
cooked	O
starchy	O
foods	O
has	O
presented	O
significant	O
challenges	O
to	O
toxicologists	O
,	O
food	O
scientists	O
,	O
and	O
national	O
regulatory	O
and	O
public	O
health	O
organizations	O
because	O
of	O
the	O
potential	O
for	O
producing	O
neurotoxicity	B
and	O
cancer	B
.	O

This	O
paper	O
reviews	O
some	O
of	O
the	O
underlying	O
experimental	O
bases	O
for	O
AA	B
toxicity	I
and	O
earlier	O
risk	O
assessments	O
.	O

Then	O
,	O
dietary	O
exposure	O
modeling	O
is	O
used	O
to	O
estimate	O
probable	O
AA	O
intake	O
in	O
the	O
U	O
.	O

S	O
.	O

population	O
,	O
and	O
physiologically	O
based	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PBPK	O
/	O
PD	O
)	O
modeling	O
is	O
used	O
to	O
integrate	O
the	O
findings	O
of	O
rodent	O
neurotoxicity	B
and	O
cancer	B
into	O
estimates	O
of	O
risks	O
from	O
human	O
AA	O
exposure	O
through	O
the	O
diet	O
.	O

The	O
goal	O
of	O
these	O
modeling	O
techniques	O
is	O
to	O
reduce	O
the	O
uncertainty	O
inherent	O
in	O
extrapolating	O
toxicological	O
findings	O
across	O
species	O
and	O
dose	O
by	O
comparing	O
common	O
exposure	O
biomarkers	O
.	O

PBPK	O
/	O
PD	O
modeling	O
estimated	O
population	O
-	O
based	O
lifetime	O
excess	O
cancer	B
risks	O
from	O
average	O
AA	O
consumption	O
in	O
the	O
diet	O
in	O
the	O
range	O
of	O
1	O
-	O
4	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
however	O
,	O
modeling	O
did	O
not	O
support	O
a	O
link	O
between	O
dietary	O
AA	O
exposure	O
and	O
human	O
neurotoxicity	B
because	O
marginal	O
exposure	O
ratios	O
were	O
50	O
-	O
300	O
lower	O
than	O
in	O
rodents	O
.	O

In	O
addition	O
,	O
dietary	O
exposure	O
modeling	O
suggests	O
that	O
because	O
AA	O
is	O
found	O
in	O
so	O
many	O
common	O
foods	O
,	O
even	O
big	O
changes	O
in	O
concentration	O
for	O
single	O
foods	O
or	O
groups	O
of	O
foods	O
would	O
probably	O
have	O
a	O
small	O
impact	O
on	O
overall	O
population	O
-	O
based	O
intake	O
and	O
risk	O
.	O

These	O
results	O
suggest	O
that	O
a	O
more	O
holistic	O
analysis	O
of	O
dietary	B
cancer	I
risks	O
may	O
be	O
appropriate	O
,	O
by	O
which	O
potential	O
risks	O
from	O
AA	O
should	O
be	O
considered	O
in	O
conjunction	O
with	O
other	O
risks	O
and	O
benefits	O
from	O
foods	O
.	O

Review	O
article	O
:	O
new	O
drug	O
formulations	O
,	O
chemical	O
entities	O
and	O
therapeutic	O
approaches	O
for	O
the	O
management	O
of	O
ulcerative	B
colitis	I
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
for	O
ulcerative	B
colitis	I
(	O
UC	B
)	O
are	O
expanding	O
with	O
the	O
development	O
of	O
novel	O
drug	O
formulations	O
and	O
dosing	O
regimens	O
and	O
new	O
chemical	O
entities	O
.	O

Although	O
the	O
goals	O
of	O
medical	O
therapy	O
for	O
UC	B
remain	O
unchanged	O
,	O
that	O
is	O
to	O
induce	O
and	O
to	O
maintain	O
remission	O
,	O
focus	O
has	O
also	O
centred	O
on	O
improving	O
patient	O
compliance	O
,	O
modifying	O
the	O
natural	O
course	O
of	O
disease	O
and	O
healing	O
the	O
mucosa	O
.	O

AIM	O
:	O
To	O
examine	O
novel	O
formulations	O
,	O
new	O
chemical	O
entities	O
and	O
novel	O
therapeutic	O
approaches	O
to	O
the	O
management	O
of	O
UC	B
.	O

METHODS	O
:	O
Searches	O
for	O
all	O
studies	O
related	O
to	O
UC	B
treatment	O
in	O
Medline	O
and	O
abstracts	O
from	O
major	O
national	O
and	O
international	O
meetings	O
published	O
in	O
the	O
last	O
10	O
years	O
.	O

RESULTS	O
:	O
5	O
-	O
Aminosalicylic	O
acids	O
(	O
5	O
-	O
ASA	O
)	O
remain	O
the	O
standard	O
first	O
-	O
line	O
treatment	O
for	O
patients	O
with	O
mild	O
to	O
moderately	O
active	O
UC	B
.	O

New	O
formulations	O
with	O
altered	O
delivery	O
,	O
and	O
new	O
dosing	O
regimens	O
have	O
demonstrated	O
possible	O
improvements	O
in	O
efficacy	O
compared	O
with	O
historically	O
available	O
preparations	O
and	O
dosing	O
patterns	O
.	O

Once	O
-	O
daily	O
dosing	O
,	O
micropellet	O
formulations	O
,	O
and	O
high	O
-	O
dose	O
tablets	O
offer	O
enhanced	O
efficacy	O
and	O
improved	O
compliance	O
.	O

5	O
-	O
ASA	O
is	O
now	O
recognized	O
as	O
a	O
ligand	O
for	O
peroxisome	O
proliferator	O
activated	O
receptor	O
-	O
gamma	O
(	O
PPAR	O
-	O
gamma	O
)	O
and	O
it	O
has	O
a	O
role	O
as	O
a	O
chemo	O
-	O
preventive	O
agent	O
in	O
long	O
-	O
standing	O
UC	B
.	O

New	O
colonic	O
release	O
corticosteroid	O
formulations	O
help	O
to	O
limit	O
systemic	B
toxicity	I
;	O
turmeric	O
,	O
tacrolimus	O
and	O
infliximab	O
have	O
shown	O
promising	O
results	O
.	O

New	O
anti	O
-	O
inflammatory	O
targeted	O
therapies	O
include	O
an	O
anti	O
-	O
CD3	O
antibody	O
,	O
selective	O
integrin	O
blockers	O
,	O
anti	O
-	O
IL	O
-	O
2	O
antibody	O
and	O
PPAR	O
-	O
gamma	O
agonists	O
.	O

CONCLUSION	O
:	O
The	O
evolution	O
of	O
novel	O
oral	O
5	O
-	O
ASA	O
formulations	O
and	O
dosage	O
regimens	O
,	O
and	O
recent	O
development	O
of	O
new	O
molecules	O
have	O
expanded	O
the	O
therapeutic	O
armamentarium	O
of	O
UC	B
.	O

Dietary	O
flavonoids	O
inhibit	O
the	O
anticancer	O
effects	O
of	O
the	O
proteasome	O
inhibitor	O
bortezomib	O
.	O

Dietary	O
flavonoids	O
have	O
many	O
health	O
-	O
promoting	O
actions	O
,	O
including	O
anticancer	O
activity	O
via	O
proteasome	O
inhibition	O
.	O

Bor	O
-	O
tezomib	O
is	O
a	O
dipeptide	O
boronate	O
proteasome	O
inhibitor	O
that	O
has	O
activity	O
in	O
the	O
treatment	O
of	O
multiple	B
myeloma	I
but	O
is	O
not	O
effective	O
in	O
chronic	B
lymphocytic	I
leukemia	I
(	O
CLL	B
)	O
.	O

Although	O
CLL	B
cells	O
are	O
sensitive	O
in	O
vitro	O
to	O
bortezomib	O
-	O
induced	O
apoptosis	B
when	O
cultured	O
in	O
medium	O
,	O
the	O
killing	O
activity	O
was	O
blocked	O
when	O
cultured	O
in	O
50	O
%	O
fresh	O
autologous	O
plasma	O
.	O

Dietary	O
flavonoids	O
,	O
quercetin	O
and	O
myricetin	O
,	O
which	O
are	O
abundant	O
in	O
plasma	O
,	O
inhibited	O
bortezomib	O
-	O
induced	O
apoptosis	B
of	O
primary	O
CLL	B
and	O
malignant	O
B	O
-	O
cell	O
lines	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
inhibitory	O
effect	O
was	O
associated	O
with	O
chemical	O
reactions	O
between	O
quercetin	O
and	O
the	O
boronic	O
acid	O
group	O
,	O
-	O
RB	O
(	O
OH	O
)	O
2	O
,	O
in	O
bortezomib	O
.	O

The	O
addition	O
of	O
boric	O
acid	O
diminished	O
the	O
inhibitory	O
effect	O
of	O
both	O
quercetin	O
and	O
plasma	O
on	O
bortezomib	O
-	O
induced	O
apoptosis	B
.	O

The	O
protective	O
effect	O
was	O
also	O
reduced	O
when	O
myeloma	B
cell	O
lines	O
,	O
but	O
not	O
B	O
-	O
cell	O
lines	O
,	O
were	O
preincubated	O
with	O
quercetin	O
,	O
indicating	O
a	O
direct	O
effect	O
of	O
quercetin	O
on	O
myeloma	B
cells	O
.	O

At	O
high	O
doses	O
,	O
quercetin	O
itself	O
induced	O
tumor	O
cell	B
death	I
.	O

These	O
data	O
indicate	O
that	O
dietary	O
flavonoids	O
limit	O
the	O
efficacy	O
of	O
bortezomib	O
,	O
whereas	O
supplemental	O
inorganic	O
boric	O
acid	O
is	O
able	O
to	O
reverse	O
this	O
.	O

The	O
complex	O
interactions	O
between	O
quercetin	O
,	O
tumor	O
cells	O
,	O
and	O
bortezomib	O
mean	O
caution	O
is	O
required	O
when	O
giving	O
dietary	O
advice	O
to	O
patients	O
.	O

Nitrate	O
-	O
induced	O
toxicity	O
and	O
preconditioning	O
:	O
a	O
rationale	O
for	O
reconsidering	O
the	O
use	O
of	O
these	O
drugs	O
.	O

Although	O
organic	O
nitrates	O
have	O
been	O
clinically	O
used	O
for	O
more	O
than	O
a	O
century	O
,	O
findings	O
in	O
the	O
last	O
decade	O
have	O
radically	O
challenged	O
our	O
traditional	O
view	O
concerning	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
their	O
clinical	O
effects	O
and	O
implications	O
.	O

While	O
their	O
hemodynamic	O
properties	O
are	O
well	O
known	O
,	O
the	O
knowledge	O
that	O
nitrates	O
possess	O
previously	O
unexpected	O
nonhemodynamic	O
effects	O
is	O
a	O
unique	O
opportunity	O
of	O
which	O
clinicians	O
should	O
be	O
aware	O
but	O
,	O
at	O
the	O
same	O
time	O
,	O
it	O
also	O
provides	O
a	O
rationale	O
to	O
worry	O
about	O
previously	O
unanticipated	O
clinical	O
consequences	O
of	O
long	O
-	O
term	O
treatment	O
with	O
these	O
drugs	O
.	O

The	O
effect	O
of	O
QuYuHuaTanTongLuo	O
Decoction	O
on	O
the	O
non	B
-	I
alcoholic	I
steatohepatitis	I
.	O

Non	B
-	I
alcoholic	I
steatohepatitis	I
(	O
NASH	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
cryptogenic	B
cirrhosis	I
,	O
is	O
becoming	O
more	O
prevalent	O
in	O
China	O
.	O

However	O
,	O
there	O
is	O
as	O
yet	O
no	O
clearly	O
established	O
therapy	O
for	O
reversing	O
fatty	B
liver	I
.	O

Our	O
aim	O
is	O
to	O
explore	O
the	O
effect	O
of	O
traditional	O
Chinese	O
herbs	O
QuYuHuaTanTongLuo	O
Decoction	O
(	O
QYHTTLD	O
)	O
on	O
non	B
-	I
alcoholic	I
steatohepatitis	I
.	O

Sixty	O
-	O
nine	O
non	B
-	I
alcoholic	I
steatohepatitis	I
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

One	O
group	O
of	O
35	O
patients	O
were	O
treated	O
by	O
QYHTTLD	O
,	O
another	O
group	O
of	O
34	O
patients	O
were	O
treated	O
by	O
Ursodeoxycholic	O
acid	O
(	O
UDCA	O
)	O
.	O

The	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
,	O
MDA	O
level	O
,	O
SOD	O
activity	O
and	O
liver	O
function	O
,	O
as	O
well	O
as	O
B	O
ultrasonic	O
image	O
were	O
detected	O
before	O
and	O
after	O
being	O
treated	O
.	O

The	O
results	O
showed	O
:	O
after	O
6	O
months	O
treatment	O
,	O
MBI	O
of	O
the	O
treatment	O
group	O
was	O
obviously	O
decreased	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
TC	O
,	O
TG	O
and	O
LDL	O
-	O
C	O
were	O
significantly	O
decreased	O
whereas	O
the	O
level	O
of	O
HDL	O
-	O
C	O
increased	O
(	O
p	O
<	O
0.01	O
,	O
p	O
<	O
0.05	O
,	O
p	O
<	O
0.05	O
,	O
and	O
p	O
<	O
0.05	O
,	O
respectively	O
)	O
in	O
the	O
treatment	O
group	O
,	O
the	O
levels	O
of	O
TC	O
,	O
TG	O
,	O
LDL	O
-	O
C	O
and	O
HDL	O
-	O
C	O
had	O
no	O
significant	O
difference	O
in	O
the	O
control	O
group	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
and	O
MDA	O
were	O
significantly	O
decreased	O
whereas	O
SOD	O
activity	O
was	O
significantly	O
increased	O
(	O
p	O
<	O
0.01	O
,	O
p	O
<	O
0.05	O
,	O
p	O
<	O
0.01	O
,	O
and	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O
in	O
the	O
treatment	O
group	O
,	O
the	O
level	O
of	O
MDA	O
was	O
significantly	O
decreased	O
in	O
the	O
control	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

B	O
ultrasonic	O
images	O
were	O
ameliorated	O
in	O
different	O
degree	O
(	O
p	O
<	O
0.01	O
and	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

Both	O
QYHTTLD	O
and	O
UDCA	O
had	O
the	O
effect	O
in	O
improving	O
the	O
scores	O
of	O
symptoms	O
and	O
signs	O
of	O
patients	O
,	O
however	O
,	O
the	O
difference	O
value	O
of	O
the	O
scores	O
in	O
treatment	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
control	O
group	O
after	O
being	O
treated	O
for	O
6	O
months	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Conclusion	O
:	O
QYHTTLD	O
is	O
effective	O
for	O
treating	O
non	B
-	I
alcoholic	I
steatohepatitis	I
,	O
and	O
its	O
effect	O
seems	O
to	O
relate	O
with	O
the	O
ways	O
of	O
QYHTTL	O
down	O
-	O
regulating	O
inflammation	B
cytokine	O
IL	O
-	O
8	O
level	O
and	O
relieving	O
lipid	O
peroxidation	O
of	O
liver	O
.	O

Fragrance	O
material	O
review	O
on	O
sclareol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
sclareol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
Material	O
Review	O
on	O
isopulegol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
isopulegol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
material	O
review	O
on	O
ocimenol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
ocimenol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Topical	O
pyrethrin	B
toxicity	I
leading	O
to	O
acute	B
-	I
onset	I
stuttering	I
in	O
a	O
toddler	O
.	O

Pyrethrin	O
compounds	O
can	O
cause	O
neurotoxicity	B
when	O
used	O
in	O
an	O
excessive	O
dose	O
.	O

A	O
case	O
of	O
stuttering	B
and	O
general	O
clumsiness	B
in	O
a	O
toddler	O
associated	O
with	O
topical	O
pyrethrin	O
use	O
is	O
described	O
.	O

Antitumor	O
properties	O
of	O
a	O
sulfated	O
polysaccharide	O
from	O
the	O
red	O
seaweed	O
Champia	O
feldmannii	O
(	O
Diaz	O
-	O
Pifferer	O
)	O
.	O

In	O
recent	O
years	O
,	O
much	O
attention	O
has	O
been	O
focused	O
on	O
polysaccharides	O
isolated	O
from	O
natural	O
sources	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
properties	O
of	O
a	O
sulfated	O
polysaccharide	O
isolated	O
from	O
the	O
seaweed	O
C	O
.	O

feldmannii	O
(	O
Cf	O
-	O
PLS	O
)	O
.	O

Hematological	O
,	O
biochemical	O
and	O
histopathological	O
analyses	O
were	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
toxicological	O
aspects	O
related	O
to	O
Cf	O
-	O
PLS	O
treatment	O
.	O

Its	O
effects	O
on	O
the	O
immunological	O
system	O
were	O
also	O
investigated	O
.	O

The	O
Cf	O
-	O
PLS	O
did	O
not	O
show	O
any	O
significant	O
in	O
vitro	O
cytotoxicity	B
at	O
the	O
experimental	O
exposure	O
levels	O
that	O
were	O
used	O
,	O
but	O
showed	O
in	O
vivo	O
antitumor	O
effect	O
.	O

The	O
inhibition	O
rates	O
of	O
sarcoma	B
180	O
tumor	B
development	O
were	O
48.62	O
and	O
48.16	O
%	O
at	O
the	O
doses	O
of	O
10	O
and	O
25	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
Cf	O
-	O
PLS	O
was	O
also	O
able	O
to	O
increase	O
the	O
response	O
elicited	O
by	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
from	O
48.66	O
to	O
68.32	O
%	O
.	O

The	O
histopathological	O
analysis	O
of	O
liver	O
and	O
kidney	O
showed	O
that	O
both	O
organs	O
were	O
moderately	O
affected	O
by	O
Cf	O
-	O
PLS	O
-	O
treatment	O
.	O

Neither	O
enzymatic	O
activity	O
of	O
alanine	O
aminotransferase	O
nor	O
urea	O
or	O
creatinine	O
levels	O
were	O
significantly	O
altered	O
.	O

In	O
hematological	O
analysis	O
,	O
leucopeny	B
was	O
observed	O
after	O
5	O
-	O
FU	O
treatment	O
,	O
but	O
this	O
effect	O
was	O
prevented	O
when	O
the	O
treatment	O
was	O
associated	O
with	O
the	O
Cf	O
-	O
PLS	O
.	O

It	O
was	O
also	O
demonstrated	O
that	O
Cf	O
-	O
PLS	O
acts	O
as	O
an	O
immunomodulatory	O
agent	O
,	O
raising	O
the	O
production	O
of	O
specific	O
antibodies	O
,	O
and	O
increasing	O
the	O
production	O
of	O
OVA	O
-	O
specific	O
antibodies	O
.	O

It	O
also	O
induced	O
a	O
discreet	O
hyperplasia	B
of	I
lymphoid	I
folicules	I
of	O
the	O
white	O
pulp	O
in	O
the	O
spleen	O
of	O
treated	O
mice	O
.	O

In	O
conclusion	O
,	O
Cf	O
-	O
PLS	O
has	O
some	O
interesting	O
anticancer	O
activity	O
that	O
could	O
be	O
associated	O
with	O
its	O
immunostimulating	O
properties	O
.	O

A	O
multi	O
-	O
centre	O
dose	O
-	O
escalation	O
and	O
pharmacokinetic	O
study	O
of	O
diflomotecan	O
in	O
patients	O
with	O
advanced	O
malignancy	B
.	O

PURPOSE	O
:	O
Diflomotecan	O
,	O
a	O
homocamptothecin	O
,	O
targets	O
DNA	O
topoisomerase	O
I	O
.	O

Previous	O
clinical	O
trials	O
have	O
demonstrated	O
a	O
variable	O
degree	O
of	O
dose	B
limiting	I
toxicity	I
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
evaluate	O
the	O
safety	O
and	O
pharmacokinetic	O
profile	O
of	O
a	O
range	O
of	O
diflomotecan	O
doses	O
administered	O
intravenously	O
.	O

METHODS	O
:	O
Patients	O
with	O
advanced	O
solid	O
malignant	B
tumours	I
,	O
refractory	O
to	O
standard	O
therapies	O
,	O
with	O
adequate	O
haematologic	O
,	O
renal	O
and	O
hepatic	O
function	O
,	O
received	O
diflomotecan	O
administered	O
as	O
a	O
20	O
min	O
intravenous	O
infusion	O
every	O
21	O
days	O
.	O

Cohorts	O
of	O
six	O
patients	O
were	O
recruited	O
sequentially	O
to	O
one	O
of	O
three	O
fixed	O
starting	O
dose	O
groups	O
-	O
2	O
,	O
4	O
,	O
or	O
7	O
mg	O
,	O
with	O
drug	O
administered	O
by	O
fixed	O
-	O
dose	O
rather	O
than	O
dosing	O
by	O
body	O
surface	O
area	O
.	O

Pharmacokinetic	O
analyses	O
were	O
performed	O
on	O
serial	O
blood	O
samples	O
taken	O
over	O
the	O
first	O
24	O
h	O
after	O
diflomotecan	O
administration	O
(	O
cycles	O
1	O
and	O
2	O
)	O
.	O

Cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
activity	O
was	O
determined	O
by	O
an	O
erythromycin	O
breath	O
test	O
(	O
EBT	O
)	O
prior	O
to	O
diflomotecan	O
administration	O
in	O
cycles	O
1	O
and	O
2	O
.	O

RESULTS	O
:	O
Thirteen	O
patients	O
,	O
were	O
treated	O
with	O
a	O
starting	O
dose	O
of	O
either	O
2	O
mg	O
(	O
n	O
=	O
8	O
)	O
or	O
4	O
mg	O
(	O
n	O
=	O
5	O
)	O
of	O
diflomotecan	O
.	O

Dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
observed	O
in	O
1	O
patient	O
in	O
the	O
2	O
mg	O
starting	O
dose	O
level	O
(	O
grade	O
4	O
neutropenia	B
which	O
lasted	O
for	O
8	O
days	O
)	O
,	O
and	O
in	O
2	O
of	O
5	O
patients	O
enrolled	O
at	O
the	O
4	O
mg	O
starting	O
dose	O
level	O
(	O
grade	O
4	O
neutropenia	B
for	O
11	O
days	O
;	O
grade	O
4	O
neutropenia	B
leading	O
to	O
withdrawal	O
from	O
the	O
study	O
)	O
,	O
and	O
no	O
further	O
dose	O
escalation	O
was	O
performed	O
.	O

Pharmacokinetic	O
analyses	O
revealed	O
a	O
less	O
than	O
dose	O
-	O
proportional	O
increase	O
in	O
diflomotecan	O
and	O
for	O
the	O
two	O
metabolites	O
BN80942	O
and	O
P	O
-	O
20	O
,	O
with	O
a	O
magnitude	O
of	O
P	O
-	O
20	O
exposure	O
similar	O
to	O
the	O
parent	O
drug	O
.	O

There	O
was	O
a	O
high	O
inter	O
-	O
patient	O
variability	O
in	O
diflomotecan	O
exposure	O
similar	O
to	O
that	O
observed	O
with	O
other	O
camptothecin	O
derivatives	O
.	O

One	O
minor	O
response	O
was	O
observed	O
in	O
a	O
patient	O
with	O
oesophageal	B
cancer	I
.	O

CONCLUSIONS	O
:	O
Diflomotecan	O
administered	O
as	O
a	O
20	O
-	O
min	O
intravenous	O
infusion	O
3	O
-	O
weekly	O
is	O
characterised	O
by	O
a	O
variable	O
pharmacokinetic	O
profile	O
.	O

Alternative	O
oral	O
dosing	O
schedules	O
of	O
diflomotecan	O
have	O
been	O
shown	O
to	O
display	O
a	O
more	O
predictable	O
PK	O
/	O
PD	O
and	O
safety	O
profile	O
and	O
should	O
be	O
selected	O
for	O
further	O
evaluation	O
in	O
Phase	O
II	O
clinical	O
trials	O
.	O

Hepatic	O
protection	O
by	O
noni	O
fruit	O
juice	O
against	O
CCl	O
(	O
4	O
)	O
-	O
induced	O
chronic	B
liver	I
damage	I
in	O
female	O
SD	O
rats	O
.	O

Morinda	O
citrifolia	O
L	O
.	O

(	O
noni	O
)	O
has	O
been	O
used	O
throughout	O
the	O
Pacific	O
,	O
Southeast	O
Asia	O
,	O
Central	O
America	O
,	O
and	O
the	O
Caribbean	O
for	O
a	O
variety	O
of	O
health	O
conditions	O
,	O
including	O
heart	O
and	O
liver	O
ailments	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
hepatoprotective	O
effects	O
of	O
TAHITIAN	O
NONI	O
Juice	O
(	O
TNJ	O
)	O
against	O
CCl	O
(	O
4	O
)	O
-	O
induced	O
chronic	B
liver	I
damage	I
in	O
female	O
Sprague	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

Twelve	O
female	O
SD	O
rats	O
were	O
divided	O
into	O
control	O
,	O
placebo	O
and	O
TNJ	O
(	O
6	O
mL	O
/	O
rat	O
/	O
day	O
)	O
groups	O
.	O

On	O
day	O
15	O
,	O
animals	O
in	O
the	O
placebo	O
and	O
TNJ	O
groups	O
received	O
0.25	O
mL	O
/	O
kg	O
CCl	O
(	O
4	O
)	O
in	O
corn	O
oil	O
once	O
a	O
week	O
for	O
12	O
successive	O
weeks	O
.	O

All	O
animals	O
were	O
sacrificed	O
at	O
week	O
16	O
.	O

Blood	O
and	O
liver	O
were	O
collected	O
for	O
liver	O
function	O
,	O
lipid	O
panel	O
tests	O
,	O
and	O
histological	O
observation	O
.	O

Histopathological	O
examination	O
revealed	O
that	O
liver	O
sections	O
from	O
the	O
TNJ	O
+	O
CCl	O
(	O
4	O
)	O
appeared	O
similar	O
to	O
controls	O
,	O
whereas	O
typical	O
hepatic	B
steatosis	I
was	O
observed	O
in	O
the	O
placebo	O
+	O
CCl	O
(	O
4	O
)	O
group	O
.	O

Serum	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
very	O
low	O
-	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
levels	O
were	O
increased	O
in	O
the	O
placebo	O
group	O
compared	O
with	O
the	O
TNJ	O
group	O
.	O

In	O
contrast	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
was	O
increased	O
in	O
the	O
TNJ	O
group	O
and	O
decreased	O
in	O
the	O
placebo	O
group	O
.	O

Thus	O
,	O
TNJ	O
juice	O
appears	O
to	O
protect	O
the	O
liver	O
from	O
chronic	O
exogenous	O
CCl	O
(	O
4	O
)	O
exposures	O
.	O

Such	O
protective	O
mechanisms	O
are	O
supportive	O
evidence	O
for	O
the	O
utility	O
of	O
noni	O
in	O
traditional	O
medicine	O
for	O
liver	O
ailments	O
.	O

Chronopharmacology	O
and	O
antimicrobial	O
therapeutics	O
.	O

Chronobiology	O
studies	O
the	O
phenomenon	O
of	O
rhythmicity	O
in	O
living	O
organisms	O
.	O

Circadian	O
rhythms	O
are	O
genetically	O
determined	O
and	O
are	O
regulated	O
by	O
external	O
synchronizers	O
(	O
i.e.	O
light	O
/	O
day	O
cycle	O
)	O
.	O

Several	O
biological	O
processes	O
involved	O
in	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
drugs	O
are	O
subject	O
to	O
circadian	O
variations	O
.	O

Chronopharmacology	O
studies	O
how	O
biological	O
rhythms	O
impact	O
on	O
drug	O
pharmacokinetic	O
(	O
chronokinetics	O
)	O
,	O
pharmacodynamics	O
(	O
chronoesthesy	O
)	O
and	O
toxicity	O
and	O
determines	O
whether	O
time	O
of	O
day	O
administration	O
modifies	O
drug	O
's	O
pharmacological	O
characteristics	O
.	O

Chronotherapy	O
applies	O
chronopharmacological	O
studies	O
to	O
clinical	O
treatments	O
,	O
determining	O
the	O
best	O
biological	O
time	O
for	O
its	O
dosing	O
,	O
i.e.	O
when	O
beneficial	O
effects	O
are	O
maximal	O
and	O
incidence	O
and	O
/	O
or	O
intensity	O
of	O
related	O
side	O
-	O
effects	O
and	O
toxicity	O
are	O
minimal	O
.	O

Significant	O
variations	O
in	O
the	O
pharmacokinetics	O
and	O
toxicity	O
of	O
antibiotics	O
(	O
aminoglycosides	O
,	O
beta	O
-	O
lactams	O
and	O
fluoroquinolones	O
)	O
related	O
to	O
administration	O
time	O
are	O
well	O
known	O
.	O

The	O
aims	O
of	O
this	O
review	O
are	O
to	O
discuss	O
,	O
briefly	O
,	O
the	O
currently	O
accepted	O
model	O
of	O
the	O
circadian	O
system	O
that	O
substantiates	O
endogenous	O
rhythmicity	O
and	O
to	O
provide	O
an	O
update	O
on	O
the	O
knowledge	O
of	O
circadian	O
rhythms	O
applied	O
to	O
drugs	O
used	O
as	O
medicines	O
,	O
with	O
a	O
special	O
mention	O
to	O
the	O
possible	O
impact	O
on	O
antimicrobial	O
treatments	O
.	O

It	O
is	O
concluded	O
that	O
the	O
dosing	O
time	O
of	O
an	O
antimicrobial	O
agent	O
might	O
be	O
clinically	O
relevant	O
in	O
some	O
treatments	O
,	O
thus	O
,	O
clinicians	O
should	O
be	O
aware	O
that	O
the	O
dosing	O
time	O
might	O
affect	O
the	O
clinical	O
response	O
of	O
a	O
drug	O
.	O

Chemoimmunotherapy	O
reinduction	O
with	O
epratuzumab	O
in	O
children	O
with	O
acute	B
lymphoblastic	I
leukemia	I
in	O
marrow	O
relapse	O
:	O
a	O
Children	O
's	O
Oncology	O
Group	O
Pilot	O
Study	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
tolerability	O
and	O
serum	O
concentration	O
of	O
epratuzumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
targeting	O
CD22	O
,	O
administered	O
alone	O
and	O
in	O
combination	O
with	O
reinduction	O
chemotherapy	O
in	O
children	O
with	O
relapsed	O
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O
,	O
and	O
to	O
preliminarily	O
assess	O
tumor	O
targeting	O
and	O
efficacy	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Therapy	O
consisted	O
of	O
a	O
single	O
-	O
agent	O
phase	O
(	O
epratuzumab	O
360	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
dose	O
intravenously	O
twice	O
weekly	O
x	O
four	O
doses	O
)	O
,	O
followed	O
by	O
four	O
weekly	O
doses	O
of	O
epratuzumab	O
in	O
combination	O
with	O
standard	O
reinduction	O
chemotherapy	O
.	O

Morphologic	O
and	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
responses	O
were	O
determined	O
at	O
the	O
end	O
of	O
this	O
6	O
-	O
week	O
period	O
.	O

Serum	O
concentrations	O
of	O
epratuzumab	O
were	O
determined	O
before	O
and	O
30	O
minutes	O
after	O
infusions	O
,	O
and	O
CD22	O
targeting	O
efficiency	O
was	O
determined	O
by	O
quantifying	O
changes	O
in	O
CD22	O
expression	O
after	O
epratuzumab	O
administration	O
.	O

RESULTS	O
:	O
Fifteen	O
patients	O
(	O
12	O
fully	O
assessable	O
for	O
toxicity	O
)	O
with	O
first	O
or	O
later	O
CD22	O
-	O
positive	O
ALL	B
marrow	O
relapse	O
enrolled	O
on	O
the	O
feasibility	O
portion	O
of	O
this	O
study	O
from	O
December	O
2005	O
to	O
June	O
2006	O
.	O

Two	O
dose	O
-	O
limiting	O
toxicities	O
occurred	O
:	O
one	O
grade	O
4	O
seizure	B
of	O
unclear	O
etiology	O
and	O
one	O
asymptomatic	O
grade	O
3	O
ALT	O
elevation	O
.	O

In	O
all	O
but	O
one	O
patient	O
,	O
surface	O
CD22	O
was	O
not	O
detected	O
by	O
flow	O
cytometry	O
on	O
peripheral	O
blood	O
leukemic	O
blasts	O
within	O
24	O
hours	O
of	O
drug	O
administration	O
,	O
indicating	O
effective	O
targeting	O
of	O
leukemic	O
cells	O
by	O
epratuzumab	O
.	O

Nine	O
patients	O
achieved	O
a	O
complete	O
remission	O
after	O
chemoimmunotherapy	O
,	O
seven	O
of	O
whom	O
were	O
MRD	O
negative	O
.	O

CONCLUSION	O
:	O
Treatment	O
with	O
epratuzumab	O
plus	O
standard	O
reinduction	O
chemotherapy	O
is	O
feasible	O
and	O
acceptably	O
tolerated	O
in	O
children	O
with	O
relapsed	O
CD22	O
-	O
positive	O
ALL	B
.	O

CD22	O
targeting	O
was	O
efficient	O
,	O
and	O
the	O
majority	O
of	O
patients	O
achieved	O
favorable	O
early	O
responses	O
.	O

Pharmacokinetic	O
interaction	O
between	O
ethinyl	O
estradiol	O
,	O
norethindrone	O
and	O
darunavir	O
with	O
low	O
-	O
dose	O
ritonavir	O
in	O
healthy	O
women	O
.	O

BACKGROUND	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
crossover	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
effect	O
of	O
multiple	O
doses	O
of	O
darunavir	O
co	O
-	O
administered	O
with	O
low	O
-	O
dose	O
ritonavir	O
(	O
DRV	O
/	O
r	O
)	O
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
the	O
oral	O
contraceptives	O
ethinyl	O
estradiol	O
(	O
EE	O
)	O
and	O
norethindrone	O
(	O
NE	O
)	O
(	O
commercial	O
name	O
of	O
the	O
combined	O
drug	O
Ortho	O
-	O
Novum	O
1	O
/	O
35	O
)	O
in	O
19	O
HIV	O
-	O
negative	O
healthy	O
women	O
.	O

METHODS	O
:	O
In	O
session	O
1	O
,	O
participants	O
received	O
35	O
microg	O
EE	O
and	O
1.0	O
mg	O
NE	O
from	O
days	O
1	O
to	O
21	O
.	O

In	O
session	O
2	O
,	O
participants	O
received	O
the	O
same	O
oral	O
contraceptive	O
treatment	O
as	O
in	O
session	O
1	O
on	O
days	O
1	O
to	O
21	O
plus	O
DRV	O
/	O
r	O
(	O
600	O
mg	O
/	O
100	O
mg	O
twice	O
daily	O
)	O
on	O
days	O
1	O
to	O
14	O
.	O

Pharmacokinetic	O
assessments	O
were	O
performed	O
on	O
day	O
14	O
for	O
each	O
session	O
.	O

RESULTS	O
:	O
Steady	O
-	O
state	O
systemic	O
exposure	O
to	O
EE	O
and	O
NE	O
decreased	O
when	O
DRV	O
/	O
r	O
was	O
co	O
-	O
administered	O
,	O
based	O
on	O
the	O
ratio	O
of	O
least	O
square	O
means	O
of	O
the	O
minimum	O
plasma	O
concentration	O
(	O
Cmin	O
)	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
,	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC24h	O
)	O
of	O
EE	O
(	O
which	O
decreased	O
by	O
62	O
%	O
,	O
32	O
%	O
and	O
44	O
%	O
,	O
respectively	O
)	O
and	O
NE	O
(	O
which	O
decreased	O
by	O
30	O
%	O
,	O
10	O
%	O
and	O
14	O
%	O
,	O
respectively	O
)	O
compared	O
with	O
administration	O
of	O
EE	O
and	O
NE	O
alone	O
.	O

Five	O
participants	O
discontinued	O
the	O
study	O
due	O
to	O
grade	O
2	O
cutaneous	O
events	O
,	O
as	O
required	O
per	O
protocol	O
,	O
during	O
treatment	O
with	O
EE	O
and	O
NE	O
in	O
combination	O
with	O
DRV	O
/	O
r	O
.	O

There	O
were	O
no	O
clinically	O
relevant	O
findings	O
for	O
laboratory	O
and	O
cardiovascular	O
parameters	O
.	O

CONCLUSIONS	O
:	O
The	O
pharmacokinetic	O
interaction	O
observed	O
here	O
is	O
considered	O
to	O
be	O
clinically	O
relevant	O
as	O
EE	O
concentrations	O
are	O
considerably	O
reduced	O
when	O
DRV	O
/	O
r	O
is	O
co	O
-	O
administered	O
with	O
EE	O
and	O
NE	O
.	O

Alternative	O
or	O
additional	O
contraceptive	O
measures	O
should	O
be	O
used	O
when	O
oestrogen	O
-	O
based	O
contraceptives	O
are	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
.	O

Eosinophil	O
-	O
derived	O
neurotoxin	O
/	O
RNase	O
2	O
:	O
connecting	O
the	O
past	O
,	O
the	O
present	O
and	O
the	O
future	O
.	O

The	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
,	O
also	O
known	O
as	O
eosinophil	O
protein	O
-	O
X	O
)	O
is	O
best	O
-	O
known	O
as	O
one	O
of	O
the	O
four	O
major	O
proteins	O
found	O
in	O
the	O
large	O
specific	O
granules	O
of	O
human	O
eosinophilic	O
leukocytes	O
.	O

Although	O
it	O
was	O
named	O
for	O
its	O
discovery	O
and	O
initial	O
characterization	O
as	O
a	O
neurotoxin	O
,	O
it	O
is	O
also	O
expressed	O
constitutively	O
in	O
human	O
liver	O
tissue	O
and	O
its	O
expression	O
can	O
be	O
induced	O
in	O
macrophages	O
by	O
proinflammatory	O
stimuli	O
.	O

EDN	O
and	O
its	O
divergent	O
orthologs	O
in	O
rodents	O
have	O
ribonuclease	O
activity	O
,	O
and	O
are	O
members	O
of	O
the	O
extensive	O
RNase	O
A	O
superfamily	O
,	O
although	O
the	O
relationship	O
between	O
the	O
characterized	O
physiologic	O
functions	O
and	O
enzymatic	O
activity	O
remains	O
poorly	O
understood	O
.	O

Recent	O
explorations	O
into	O
potential	O
physiologic	O
functions	O
for	O
EDN	O
have	O
provided	O
us	O
with	O
some	O
insights	O
into	O
its	O
role	O
in	O
antiviral	O
host	O
defense	O
,	O
as	O
a	O
chemoattractant	O
for	O
human	O
dendritic	O
cells	O
,	O
and	O
most	O
recently	O
,	O
as	O
an	O
endogenous	O
ligand	O
for	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
.	O

Endogenous	O
alpha	O
-	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
mitigates	O
liver	B
fibrosis	I
in	O
chronic	B
hepatitis	I
induced	O
by	O
repeated	O
administration	O
of	O
concanavalin	O
A	O
.	O

BACKGROUND	O
:	O
Alpha	O
-	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
alphaCGRP	O
)	O
is	O
a	O
37	O
-	O
amino	O
acid	O
pleiotropic	O
peptide	O
that	O
we	O
previously	O
showed	O
to	O
exert	O
a	O
hepatoprotective	O
effect	O
during	O
concanavalin	O
A	B
(	I
Con	I
A	I
)	I
-	I
induced	I
acute	I
hepatitis	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
further	O
investigate	O
the	O
antifibrogenic	O
and	O
hepatoprotective	O
effects	O
of	O
endogenous	O
alphaCGRP	O
in	O
Con	O
A	O
-	O
induced	O
chronic	B
hepatitis	I
.	O

METHODS	O
:	O
Chronic	B
hepatitis	I
was	O
induced	O
in	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	O
by	O
repeated	O
administration	O
of	O
Con	O
A	O
.	O

Serum	O
transaminases	O
were	O
measured	O
to	O
assess	O
hepatic	O
injury	B
.	O

The	O
severity	O
of	O
fibrosis	B
and	O
the	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
were	O
analysed	O
by	O
Masson	O
trichrome	O
staining	O
and	O
immunohistochemical	O
staining	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
alpha	O
-	O
SMA	O
)	O
respectively	O
.	O

Altered	O
expression	O
of	O
fibrosis	O
-	O
and	O
inflammation	O
-	O
related	O
genes	O
was	O
evaluated	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Activation	O
and	O
proliferation	O
of	O
HSCs	O
were	O
analysed	O
using	O
both	O
primary	O
cultured	O
HSCs	O
from	O
the	O
mice	O
and	O
the	O
LI90	O
HSC	O
cell	O
line	O
.	O

RESULTS	O
:	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
more	O
severe	O
liver	B
fibrosis	I
than	O
wild	O
-	O
type	O
mice	O
in	O
a	O
Con	O
A	O
-	O
induced	O
chronic	B
hepatitis	I
model	O
.	O

In	O
histological	O
and	O
gene	O
expression	O
analyses	O
,	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
greater	O
inflammatory	O
and	O
fibrotic	O
changes	O
,	O
greater	O
HSC	O
activation	O
and	O
a	O
higher	O
incidence	O
of	O
apoptosis	B
among	O
nonparenchymal	O
cells	O
than	O
wild	O
-	O
type	O
mice	O
.	O

CONCLUSIONS	O
:	O
Endogenous	O
alphaCGRP	O
mitigates	O
liver	B
fibrosis	I
in	O
chronic	B
hepatitis	I
induced	O
by	O
repeated	O
administration	O
of	O
Con	O
A	O
.	O

alphaCGRP	O
could	O
be	O
a	O
useful	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
chronic	B
hepatitis	I
.	O

Novel	O
roles	O
for	O
ceramides	O
,	O
calpains	O
and	O
caspases	O
in	O
kidney	O
proximal	O
tubule	O
cell	O
apoptosis	O
:	O
lessons	O
from	O
in	O
vitro	O
cadmium	B
toxicity	I
studies	O
.	O

Apoptosis	O
is	O
a	O
tightly	O
regulated	O
physiological	O
process	O
,	O
which	O
can	O
be	O
initiated	O
by	O
toxic	O
stimuli	O
,	O
such	O
as	O
cadmium	O
(	O
Cd2	O
+	O
)	O
.	O

Cd2	O
+	O
(	O
10	O
-	O
50	O
microM	O
)	O
induces	O
a	O
rapid	O
increase	O
in	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
(	O
>	O
or	O
=	O
30	O
min	O
)	O
in	O
a	O
cell	O
line	O
derived	O
from	O
the	O
S1	O
segment	O
of	O
rat	O
kidney	O
proximal	O
tubule	O
,	O
without	O
any	O
apparent	O
mitochondrial	O
dysfunction	O
.	O

The	O
sphingolipid	O
ceramide	O
is	O
an	O
important	O
second	O
messenger	O
in	O
apoptosis	O
.	O

Short	O
exposure	O
to	O
Cd2	O
+	O
(	O
3h	O
)	O
causes	O
an	O
increase	O
in	O
ceramides	O
,	O
which	O
occurs	O
downstream	O
of	O
ROS	O
formation	O
,	O
and	O
may	O
interact	O
with	O
cellular	O
components	O
,	O
such	O
as	O
endoplasmic	O
reticulum	O
and	O
mitochondria	O
.	O

Following	O
apoptosis	O
initiation	O
,	O
execution	O
must	O
take	O
place	O
.	O

The	O
classical	O
executioners	O
of	O
apoptosis	O
are	O
caspases	O
,	O
a	O
family	O
of	O
cysteine	O
proteases	O
.	O

However	O
,	O
increasing	O
studies	O
report	O
caspase	O
-	O
independent	O
apoptosis	O
,	O
which	O
questions	O
the	O
essentiality	O
of	O
caspases	O
for	O
apoptosis	O
implementation	O
.	O

With	O
low	O
micromolar	O
Cd2	O
+	O
concentrations	O
(	O
<	O
10	O
microM	O
)	O
,	O
caspases	O
are	O
only	O
activated	O
after	O
24h	O
and	O
not	O
at	O
earlier	O
time	O
points	O
,	O
which	O
supports	O
the	O
notion	O
of	O
caspase	O
-	O
independent	O
apoptosis	O
.	O

Due	O
to	O
increased	O
cytosolic	O
Ca	O
(	O
2	O
+	O
)	O
under	O
pathological	O
conditions	O
,	O
a	O
role	O
for	O
the	O
Ca2	O
+	O
-	O
dependent	O
proteases	O
,	O
calpains	O
,	O
has	O
emerged	O
.	O

Calpain	O
activation	O
by	O
Cd2	O
+	O
(	O
3	O
-	O
6	O
h	O
)	O
seems	O
to	O
be	O
regulated	O
by	O
ceramide	O
levels	O
,	O
in	O
order	O
to	O
induce	O
apoptosis	O
.	O

Calpain	O
and	O
caspase	O
substrates	O
overlap	O
but	O
yield	O
different	O
fragments	O
,	O
which	O
may	O
explain	O
their	O
diverse	O
downstream	O
targets	O
.	O

Furthermore	O
,	O
calpains	O
and	O
caspases	O
may	O
interact	O
with	O
one	O
another	O
to	O
enhance	O
,	O
as	O
seen	O
by	O
Cd2	O
+	O
,	O
or	O
diminish	O
apoptosis	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
novel	O
roles	O
for	O
ceramides	O
,	O
calpains	O
and	O
caspases	O
as	O
part	O
of	O
Cd2	O
+	O
-	O
induced	O
apoptotic	O
signalling	O
pathways	O
in	O
the	O
kidney	O
proximal	O
tubule	O
and	O
their	O
in	O
vivo	O
relevance	O
to	O
Cd2	O
+	O
-	O
induced	O
nephrotoxicity	B
.	O

Effect	O
of	O
darbepoetin	O
alfa	O
administered	O
once	O
monthly	O
on	O
maintaining	O
hemoglobin	O
levels	O
in	O
older	O
patients	O
with	O
chronic	B
kidney	I
disease	I
.	O

BACKGROUND	O
:	O
The	O
anemia	B
of	I
chronic	I
kidney	I
disease	I
(	O
CKD	B
)	O
is	O
associated	O
with	O
increased	O
hospitalizations	O
,	O
increased	O
cardiovascular	O
morbidity	O
and	O
mortality	O
,	O
and	O
diminished	O
quality	O
of	O
life	O
in	O
the	O
elderly	O
.	O

Darbepoetin	O
alfa	O
is	O
an	O
erythropoiesis	O
-	O
stimulating	O
agent	O
that	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	O
anemia	B
in	O
patients	O
with	O
CKD	B
(	O
but	O
not	O
on	O
dialysis	O
)	O
when	O
administered	O
using	O
extended	O
-	O
dosing	O
regimens	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
post	O
hoc	O
analysis	O
was	O
to	O
examine	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
once	O
-	O
monthly	O
(	O
QM	O
)	O
darbepoetin	O
alfa	O
in	O
study	O
patients	O
stratified	O
according	O
to	O
age	O
(	O
ie	O
,	O
<	O
65	O
,	O
65	O
-	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
CKD	B
but	O
not	O
on	O
dialysis	O
,	O
receiving	O
darbepoetin	O
alfa	O
every	O
other	O
week	O
(	O
Q2W	O
)	O
,	O
and	O
with	O
stable	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
between	O
11	O
and	O
13	O
g	O
/	O
dL	O
,	O
inclusive	O
,	O
were	O
enrolled	O
in	O
this	O
33	O
-	O
week	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
arm	O
study	O
.	O

The	O
study	O
was	O
carried	O
out	O
at	O
36	O
US	O
centers	O
and	O
consisted	O
of	O
a	O
24	O
-	O
week	O
QM	O
darbepoetin	O
alfa	O
dose	O
-	O
titration	O
period	O
followed	O
by	O
an	O
8	O
-	O
week	O
evaluation	O
period	O
.	O

Hb	O
levels	O
were	O
measured	O
Q2W	O
.	O

Study	O
results	O
were	O
stratified	O
according	O
to	O
patient	O
age	O
(	O
<	O
65	O
,	O
65	O
-	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
)	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
152	O
patients	O
(	O
79	O
women	O
,	O
73	O
men	O
)	O
were	O
enrolled	O
;	O
55	O
patients	O
(	O
36	O
%	O
)	O
were	O
<	O
65	O
years	O
of	O
age	O
,	O
46	O
(	O
30	O
%	O
)	O
were	O
65	O
to	O
74	O
years	O
of	O
age	O
,	O
and	O
51	O
(	O
34	O
%	O
)	O
were	O
>	O
or	O
=	O
75	O
years	O
of	O
age	O
.	O

In	O
patients	O
who	O
received	O
>	O
or	O
=	O
1	O
dose	O
of	O
darbepoetin	O
alfa	O
,	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
were	O
maintained	O
in	O
76	O
%	O
,	O
80	O
%	O
,	O
and	O
71	O
%	O
of	O
patients	O
aged	O
<	O
65	O
,	O
65	O
to	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
,	O
respectively	O
.	O

For	O
patients	O
who	O
completed	O
the	O
study	O
,	O
the	O
proportions	O
who	O
maintained	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
were	O
83	O
%	O
,	O
88	O
%	O
,	O
and	O
85	O
%	O
,	O
respectively	O
,	O
for	O
the	O
3	O
age	O
groups	O
.	O

The	O
safety	O
profile	O
of	O
QM	O
darbepoetin	O
alfa	O
in	O
this	O
study	O
was	O
consistent	O
with	O
that	O
expected	O
in	O
patients	O
with	O
CKD	B
not	O
receiving	O
dialysis	O
.	O

CONCLUSIONS	O
:	O
Darbepoetin	O
alfa	O
administered	O
QM	O
maintained	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
in	O
patients	O
with	O
CKD	B
(	O
not	O
on	O
dialysis	O
)	O
aged	O
<	O
65	O
,	O
65	O
to	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
.	O

This	O
treatment	O
regimen	O
may	O
help	O
optimize	O
anemia	B
management	O
for	O
older	O
community	O
-	O
dwelling	O
and	O
long	O
-	O
term	O
care	O
patients	O
.	O

EF24	O
,	O
a	O
novel	O
curcumin	O
analog	O
,	O
disrupts	O
the	O
microtubule	O
cytoskeleton	O
and	O
inhibits	O
HIF	O
-	O
1	O
.	O

Curcumin	O
,	O
the	O
yellow	O
pigment	O
of	O
the	O
spice	O
turmeric	O
,	O
has	O
emerged	O
as	O
a	O
promising	O
anticancer	O
agent	O
due	O
to	O
its	O
antiproliferative	O
and	O
antiangiogenic	O
properties	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
action	O
of	O
this	O
compound	O
remains	O
a	O
subject	O
of	O
debate	O
.	O

In	O
addition	O
,	O
curcumin	O
's	O
low	O
bioavailability	O
and	O
efficacy	O
profile	O
in	O
vivo	O
further	O
hinders	O
its	O
clinical	O
development	O
.	O

This	O
study	O
focuses	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
EF24	O
,	O
a	O
novel	O
curcumin	O
analog	O
with	O
greater	O
than	O
curcumin	O
biological	O
activity	O
and	O
bioavailability	O
,	O
but	O
no	O
increased	O
toxicity	O
.	O

Treatment	O
of	O
MDA	O
-	O
MB231	O
breast	O
and	O
PC3	O
prostate	B
cancer	I
cells	O
with	O
EF24	O
or	O
curcumin	O
led	O
to	O
inhibition	O
of	O
HIF	O
-	O
1alpha	O
protein	O
levels	O
and	O
,	O
consequently	O
,	O
inhibition	O
of	O
HIF	O
transcriptional	O
activity	O
.	O

This	O
drug	O
-	O
induced	O
HIF	O
inhibition	O
occurred	O
in	O
a	O
VHL	O
-	O
dependent	O
but	O
proteasome	O
-	O
independent	O
manner	O
.	O

We	O
found	O
that	O
,	O
while	O
curcumin	O
inhibited	O
HIF	O
-	O
1alpha	O
gene	O
transcription	O
,	O
EF24	O
exerted	O
its	O
activity	O
by	O
inhibiting	O
HIF	O
-	O
1alpha	O
posttranscriptionally	O
.	O

This	O
result	O
suggested	O
that	O
the	O
two	O
compounds	O
are	O
structurally	O
similar	O
but	O
mechanistically	O
distinct	O
.	O

Another	O
cellular	O
effect	O
that	O
further	O
differentiated	O
the	O
two	O
compounds	O
was	O
the	O
ability	O
of	O
EF24	O
,	O
but	O
not	O
curcumin	O
,	O
to	O
induce	O
microtubule	O
stabilization	O
in	O
cells	O
.	O

EF24	O
had	O
no	O
stabilizing	O
effect	O
on	O
tubulin	O
polymerization	O
in	O
an	O
in	O
vitro	O
assay	O
using	O
purified	O
bovine	O
brain	O
tubulin	O
,	O
suggesting	O
that	O
the	O
EF24	O
-	O
induced	O
cytoskeletal	O
disruption	O
in	O
cells	O
may	O
be	O
the	O
result	O
of	O
upstream	O
signaling	O
events	O
rather	O
than	O
EF24	O
direct	O
binding	O
to	O
tubulin	O
.	O

In	O
summary	O
,	O
our	O
study	O
identifies	O
EF24	O
as	O
a	O
novel	O
curcumin	O
-	O
related	O
compound	O
possessing	O
a	O
distinct	O
mechanism	O
of	O
action	O
,	O
which	O
we	O
believe	O
contributes	O
to	O
the	O
potent	O
anticancer	O
activity	O
of	O
this	O
agent	O
and	O
can	O
be	O
further	O
exploited	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
EF24	O
.	O

How	O
can	O
biologically	O
-	O
based	O
modeling	O
of	O
arsenic	O
kinetics	O
and	O
dynamics	O
inform	O
the	O
risk	O
assessment	O
process	O
?	O

-	O
A	O
workshop	O
review	O
.	O

Quantitative	O
biologically	O
-	O
based	O
models	O
describing	O
key	O
events	O
in	O
the	O
continuum	O
from	O
arsenic	O
exposure	O
to	O
the	O
development	O
of	O
adverse	O
health	O
effects	O
provide	O
a	O
framework	O
to	O
integrate	O
information	O
obtained	O
across	O
diverse	O
research	O
areas	O
.	O

For	O
example	O
,	O
genetic	O
polymorphisms	O
in	O
arsenic	O
metabolizing	O
enzymes	O
can	O
lead	O
to	O
differences	O
in	O
target	O
tissue	O
dosimetry	O
for	O
key	O
metabolites	O
causative	O
in	O
toxic	O
and	O
carcinogenic	B
response	I
.	O

This	O
type	O
of	O
variation	O
can	O
be	O
quantitatively	O
incorporated	O
into	O
pharmacokinetic	O
(	O
PK	O
)	O
models	O
and	O
used	O
together	O
with	O
population	O
-	O
based	O
modeling	O
approaches	O
to	O
evaluate	O
the	O
impact	O
of	O
genetic	O
variation	O
in	O
methylation	O
capacity	O
on	O
dose	O
of	O
key	O
metabolites	O
to	O
target	O
tissue	O
.	O

The	O
PK	O
model	O
is	O
an	O
essential	O
bridge	O
to	O
the	O
pharmacodynamic	O
(	O
PD	O
)	O
models	O
.	O

A	O
particular	O
benefit	O
of	O
PD	O
modeling	O
for	O
arsenic	O
is	O
that	O
alternative	O
models	O
can	O
be	O
constructed	O
for	O
multiple	O
proposed	O
modes	O
of	O
action	O
for	O
arsenicals	O
.	O

Genomics	O
data	O
will	O
prove	O
useful	O
for	O
identifying	O
the	O
key	O
pathways	O
involved	O
in	O
particular	O
responses	O
and	O
aid	O
in	O
determining	O
other	O
types	O
of	O
data	O
needed	O
for	O
quantitative	O
modeling	O
.	O

These	O
models	O
,	O
when	O
linked	O
with	O
PK	O
models	O
,	O
can	O
be	O
used	O
to	O
better	O
understand	O
and	O
explain	O
dose	O
-	O
and	O
time	O
-	O
response	O
behaviors	O
.	O

This	O
in	O
turn	O
assists	O
in	O
prioritizing	O
modes	O
of	O
action	O
with	O
respect	O
to	O
their	O
risk	O
assessment	O
relevance	O
and	O
future	O
research	O
.	O

This	O
type	O
of	O
integrated	O
modeling	O
approach	O
can	O
form	O
the	O
basis	O
for	O
a	O
highly	O
informative	O
mode	O
-	O
of	O
-	O
action	O
directed	O
risk	O
assessment	O
for	O
inorganic	O
arsenic	O
(	O
iAs	O
)	O
.	O

This	O
paper	O
will	O
address	O
both	O
practical	O
and	O
theoretical	O
aspects	O
of	O
integrating	O
PK	O
and	O
PD	O
data	O
in	O
a	O
modeling	O
framework	O
,	O
including	O
practical	O
barriers	O
to	O
its	O
application	O
.	O

Enhanced	O
PDE4B	O
expression	O
augments	O
LPS	O
-	O
inducible	O
TNF	O
expression	O
in	O
ethanol	O
-	O
primed	O
monocytes	O
:	O
relevance	O
to	O
alcoholic	B
liver	I
disease	I
.	O

Increased	O
plasma	O
and	O
hepatic	O
TNF	O
-	O
alpha	O
expression	O
is	O
well	O
documented	O
in	O
patients	O
with	O
alcoholic	B
hepatitis	I
and	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
alcoholic	B
liver	I
disease	I
.	O

We	O
have	O
previously	O
shown	O
that	O
monocytes	O
from	O
patients	O
with	O
alcoholic	B
hepatitis	I
show	O
increased	O
constitutive	O
and	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
production	O
.	O

Our	O
recent	O
studies	O
showed	O
that	O
chronic	O
ethanol	O
exposure	O
significantly	O
decreased	O
cellular	O
cAMP	O
levels	O
in	O
both	O
LPS	O
-	O
stimulated	O
and	O
unstimulated	O
monocytes	O
and	O
Kupffer	O
cells	O
,	O
leading	O
to	O
an	O
increase	O
in	O
LPS	O
-	O
inducible	O
TNF	O
-	O
alpha	O
production	O
by	O
affecting	O
NF	O
-	O
kappaB	O
activation	O
and	O
induction	O
of	O
TNF	O
mRNA	O
expression	O
.	O

Accordingly	O
,	O
the	O
mechanisms	O
underlying	O
this	O
ethanol	O
-	O
induced	O
decrease	O
in	O
cellular	O
cAMP	O
leading	O
to	O
an	O
increase	O
in	O
TNF	O
expression	O
were	O
examined	O
in	O
monocytes	O
/	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
chronic	O
ethanol	O
exposure	O
was	O
observed	O
to	O
significantly	O
increase	O
LPS	O
-	O
inducible	O
expression	O
of	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
(	O
PDE	O
)	O
4B	O
that	O
degrades	O
cellular	O
cAMP	O
.	O

Increased	O
PDE4B	O
expression	O
was	O
associated	O
with	O
enhanced	O
NF	O
-	O
kappaB	O
activation	O
and	O
transcriptional	O
activity	O
and	O
subsequent	O
priming	O
of	O
monocytes	O
/	O
macrophages	O
leading	O
to	O
enhanced	O
LPS	O
-	O
inducible	O
TNF	O
-	O
alpha	O
production	O
.	O

Selective	O
inhibition	O
of	O
PDE4	O
by	O
rolipram	O
abrogated	O
LPS	O
-	O
mediated	O
TNF	O
-	O
alpha	O
expression	O
at	O
both	O
protein	O
and	O
mRNA	O
levels	O
in	O
control	O
and	O
ethanol	O
-	O
treated	O
cells	O
.	O

Notably	O
,	O
PDE4	O
inhibition	O
did	O
not	O
affect	O
LPS	O
-	O
inducible	O
NF	O
-	O
kappaB	O
activation	O
but	O
significantly	O
decreased	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
.	O

These	O
findings	O
strongly	O
support	O
the	O
pathogenic	O
role	O
of	O
PDE4B	O
in	O
the	O
ethanol	O
-	O
mediated	O
priming	O
of	O
monocytes	O
/	O
macrophages	O
and	O
increased	O
LPS	O
-	O
inducible	O
TNF	O
production	O
and	O
the	O
subsequent	O
development	O
of	O
alcoholic	B
liver	I
disease	I
(	O
ALD	B
)	O
.	O

Since	O
enhanced	O
TNF	O
expression	O
plays	O
a	O
significant	O
role	O
in	O
the	O
evolution	O
of	O
clinical	O
and	O
experimental	O
ALD	B
,	O
its	O
downregulation	O
via	O
selective	O
PDE4B	O
inhibitors	O
could	O
constitute	O
a	O
novel	O
therapeutic	O
approach	O
in	O
the	O
treatment	O
of	O
ALD	B
.	O

The	O
molecular	O
basis	O
of	O
class	O
side	O
effects	O
due	O
to	O
treatment	O
with	O
inhibitors	O
of	O
the	O
VEGF	O
/	O
VEGFR	O
pathway	O
.	O

Vascular	O
Endothelial	O
Growth	O
Factor	O
(	O
VEGF	O
)	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
regulators	O
of	O
angiogenesis	O
and	O
a	O
new	O
key	O
target	O
in	O
anti	O
-	O
cancer	O
treatment	O
.	O

Various	O
clinical	O
trials	O
have	O
validated	O
the	O
clinical	O
importance	O
of	O
anti	O
-	O
VEGF	O
or	O
anti	O
-	O
VEGF	O
receptor	O
(	O
VEGFR	O
)	O
therapy	O
.	O

Currently	O
the	O
humanized	O
monoclonal	O
antibody	O
bevacizumab	O
(	O
blocks	O
VEGF	O
-	O
A	O
)	O
,	O
and	O
the	O
tyrosine	O
kinase	O
inhibitors	O
sunitinib	O
and	O
sorafenib	O
(	O
inhibit	O
VEGFRs	O
)	O
are	O
approved	O
for	O
patients	O
with	O
various	O
malignancies	B
and	O
several	O
others	O
are	O
expected	O
in	O
the	O
coming	O
years	O
.	O

Unfortunately	O
,	O
anti	O
-	O
VEGF	O
/	O
VEGFR	O
treatment	O
is	O
not	O
void	O
of	O
side	O
effects	O
.	O

An	O
array	O
of	O
unexpected	O
side	O
effects	O
is	O
now	O
seen	O
in	O
clinical	O
practice	O
.	O

Management	O
of	O
these	O
side	O
effects	O
is	O
extremely	O
important	O
in	O
the	O
development	O
of	O
the	O
various	O
anti	O
-	O
VEGF	O
/	O
VEGFR	O
therapies	O
and	O
their	O
optimal	O
use	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
toxicity	O
profile	O
of	O
this	O
class	O
of	O
agents	O
,	O
the	O
molecular	O
basis	O
behind	O
these	O
side	O
effects	O
and	O
indicates	O
potential	O
options	O
for	O
management	O
.	O

VEGF	O
and	O
its	O
receptors	O
play	O
an	O
important	O
role	O
in	O
normal	O
tissues	O
and	O
are	O
widely	O
expressed	O
.	O

It	O
is	O
likely	O
that	O
interference	O
with	O
this	O
pathway	O
induces	O
an	O
array	O
of	O
side	O
effects	O
due	O
to	O
the	O
lack	O
of	O
normal	O
function	O
of	O
VEGF	O
.	O

A	O
consistent	O
pattern	O
of	O
side	O
effects	O
is	O
now	O
emerging	O
.	O

Hypertension	B
,	O
gastro	B
-	I
intestinal	I
toxicity	I
,	O
hypothyroidism	B
,	O
proteinuria	B
,	O
coagulation	B
disorders	I
and	O
neurotoxicity	B
are	O
side	O
effects	O
observed	O
with	O
both	O
anti	O
-	O
VEGF	O
and	O
anti	O
-	O
VEGFR	O
inhibitors	O
.	O

For	O
these	O
side	O
effects	O
the	O
role	O
of	O
VEGF	O
/	O
VEGFR	O
pathway	O
in	O
normal	O
tissue	O
was	O
reviewed	O
in	O
order	O
to	O
provide	O
a	O
molecular	O
mechanism	O
that	O
linked	O
side	O
effect	O
with	O
physiological	O
activity	O
of	O
VEGF	O
/	O
VEGFR	O
.	O

Insight	O
into	O
the	O
molecular	O
basis	O
may	O
aid	O
specific	O
supportive	O
care	O
measures	O
to	O
ensure	O
optimal	O
use	O
of	O
this	O
class	O
of	O
agents	O
.	O

Conclusion	O
:	O
Inhibiting	O
the	O
VEGF	O
/	O
VEGFR	O
pathway	O
is	O
an	O
effective	O
approach	O
to	O
treat	O
cancer	B
.	O

It	O
has	O
also	O
provided	O
new	O
insight	O
into	O
the	O
physiological	O
role	O
of	O
this	O
pathway	O
in	O
various	O
organs	O
.	O

Integrating	O
the	O
knowledge	O
in	O
daily	O
oncological	O
practice	O
will	O
be	O
a	O
challenge	O
for	O
the	O
future	O
.	O

Safety	O
of	O
drug	O
eluting	O
stents	O
:	O
current	O
concerns	O
and	O
controversies	O
.	O

Coronary	O
artery	O
stenting	O
is	O
currently	O
the	O
most	O
frequently	O
performed	O
percutaneous	O
coronary	O
intervention	O
for	O
the	O
treatment	O
of	O
coronary	B
artery	I
disease	I
.	O

Recently	O
,	O
drug	O
-	O
eluting	O
stents	O
,	O
loaded	O
with	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
migratory	O
,	O
anti	O
-	O
proliferative	O
or	O
pro	O
-	O
healing	O
drugs	O
,	O
have	O
revolutionized	O
the	O
management	O
of	O
coronary	B
artery	I
disease	I
by	O
markedly	O
reducing	O
in	O
-	O
stent	O
restenosis	O
.	O

Despite	O
the	O
excellent	O
short	O
-	O
and	O
mid	O
-	O
term	O
results	O
of	O
randomized	O
controlled	O
trials	O
observed	O
with	O
drug	O
-	O
eluting	O
stents	O
,	O
there	O
remain	O
a	O
number	O
of	O
unresolved	O
issues	O
and	O
valid	O
concerns	O
about	O
long	O
-	O
term	O
safety	O
and	O
efficacy	O
of	O
this	O
revolutionary	O
technology	O
.	O

Important	O
safety	O
issues	O
such	O
as	O
thrombosis	B
,	O
late	O
stent	B
malapposition	I
,	O
aneurysm	B
formation	O
,	O
edge	B
effect	I
,	O
late	O
inflammation	B
due	O
to	O
choice	O
of	O
polymer	O
used	O
to	O
bind	O
the	O
drug	O
,	O
the	O
release	O
of	O
toxins	O
,	O
and	O
potential	O
interactions	O
with	O
brachytherapy	O
and	O
drugs	O
have	O
not	O
been	O
completely	O
addressed	O
.	O

This	O
review	O
article	O
evaluates	O
current	O
available	O
scientific	O
evidence	O
on	O
the	O
various	O
safety	O
issues	O
related	O
to	O
the	O
use	O
of	O
drug	O
-	O
eluting	O
stents	O
.	O

Evidence	O
for	O
altered	O
hippocampal	O
volume	O
and	O
brain	O
metabolites	O
in	O
workers	O
occupationally	O
exposed	O
to	O
lead	O
:	O
a	O
study	O
by	O
magnetic	O
resonance	O
imaging	O
and	O
(	O
1	O
)	O
H	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Environmental	O
and	O
occupational	O
exposure	O
to	O
lead	O
(	O
Pb	O
)	O
remains	O
to	O
be	O
a	O
major	O
public	O
health	O
issue	O
.	O

The	O
purpose	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
was	O
to	O
use	O
non	O
-	O
invasive	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
proton	O
magnetic	O
resonance	O
spectroscopy	O
(	O
(	O
1	O
)	O
H	O
MRS	O
)	O
techniques	O
to	O
investigate	O
whether	O
chronic	O
exposure	O
to	O
Pb	O
in	O
an	O
occupational	O
setting	O
altered	O
brain	O
structure	O
and	O
function	O
of	O
Pb	O
-	O
exposed	O
workers	O
.	O

The	O
Pb	O
-	O
exposed	O
group	O
consisted	O
of	O
15	O
workers	O
recruited	O
from	O
either	O
a	O
Pb	O
-	O
smelting	O
factory	O
or	O
a	O
Pb	O
-	O
battery	O
manufacturer	O
.	O

The	O
control	O
group	O
had	O
19	O
healthy	O
volunteers	O
who	O
had	O
no	O
history	O
of	O
Pb	O
exposure	O
in	O
working	O
environment	O
or	O
at	O
home	O
.	O

The	O
average	O
airborne	O
Pb	O
concentrations	O
in	O
fume	O
and	O
dust	O
were	O
0.43	O
and	O
0.44	O
mg	O
/	O
m	O
(	O
3	O
)	O
,	O
respectively	O
,	O
in	O
the	O
smeltery	O
,	O
and	O
0.10	O
and	O
1.06	O
mg	O
/	O
m	O
(	O
3	O
)	O
,	O
respectively	O
,	O
in	O
the	O
Pb	O
battery	O
workshop	O
.	O

The	O
average	O
blood	O
Pb	O
concentrations	O
(	O
BPb	O
)	O
in	O
Pb	O
-	O
exposed	O
and	O
control	O
workers	O
were	O
63.5	O
and	O
8.7	O
microg	O
/	O
dL	O
,	O
respectively	O
.	O

The	O
MRI	O
examination	O
showed	O
that	O
brain	O
hippocampal	O
volume	O
among	O
Pb	O
-	O
exposed	O
workers	O
was	O
significantly	O
diminished	O
in	O
comparison	O
to	O
age	O
-	O
matched	O
control	O
subjects	O
(	O
p	O
<	O
0.01	O
)	O
,	O
although	O
the	O
extent	O
of	O
this	O
reduction	O
was	O
relatively	O
small	O
(	O
5	O
-	O
6	O
%	O
of	O
the	O
control	O
values	O
)	O
.	O

Linear	O
regression	O
analyses	O
revealed	O
significant	O
inverse	O
associations	O
between	O
BPb	O
and	O
the	O
decreased	O
hippocampal	O
volume	O
on	O
both	O
sides	O
of	O
brain	O
hemisphere	O
.	O

Among	O
five	O
brain	O
metabolites	O
investigated	O
by	O
MRS	O
,	O
i.e.	O
,	O
N	O
-	O
acetyl	O
-	O
aspartate	O
(	O
NAA	O
)	O
,	O
creatine	O
(	O
Cr	O
)	O
,	O
choline	O
(	O
Cho	O
)	O
,	O
inosine	O
(	O
mI	O
)	O
,	O
glutamate	O
/	O
glutamine	O
(	O
Glx	O
)	O
and	O
lipids	O
(	O
Lip	O
)	O
,	O
a	O
significant	O
decrease	O
in	O
NAA	O
/	O
Cr	O
ratio	O
(	O
7	O
%	O
of	O
controls	O
,	O
p	O
<	O
0.05	O
)	O
and	O
a	O
remarkable	O
increase	O
in	O
Lip	O
/	O
Cr	O
ratio	O
(	O
40	O
%	O
,	O
p	O
<	O
0.01	O
)	O
were	O
observed	O
in	O
the	O
brains	O
of	O
Pb	O
-	O
exposed	O
workers	O
as	O
compared	O
to	O
controls	O
.	O

Furthermore	O
,	O
the	O
increased	O
Lip	O
/	O
Cr	O
ratio	O
was	O
significantly	O
associated	O
with	O
BPb	O
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Taken	O
together	O
,	O
this	O
study	O
suggests	O
that	O
occupational	O
exposure	O
to	O
Pb	O
may	O
cause	O
subtle	O
structural	O
and	O
functional	O
alteration	O
in	O
human	O
brains	O
.	O

The	O
MRI	O
and	O
MRS	O
brain	O
imaging	O
techniques	O
can	O
be	O
used	O
as	O
the	O
non	O
-	O
invasive	O
means	O
to	O
evaluate	O
Pb	O
-	O
induced	O
neurotoxicity	B
.	O

Anemia	B
during	O
sequential	O
induction	O
chemotherapy	O
and	O
chemoradiation	O
for	O
head	B
and	I
neck	I
cancer	I
:	O
the	O
impact	O
of	O
blood	O
transfusion	O
on	O
treatment	O
outcome	O
.	O

PURPOSE	O
:	O
Sequential	O
treatment	O
(	O
chemotherapy	O
followed	O
by	O
concomitant	O
chemoradiation	O
;	O
CCRT	O
)	O
is	O
increasingly	O
being	O
used	O
for	O
radical	O
treatment	O
of	O
squamous	B
cell	I
cancer	I
of	I
the	I
head	I
and	I
neck	I
(	O
SCCHN	B
)	O
,	O
which	O
results	O
in	O
increased	O
myelosuppression	B
.	O

In	O
this	O
study	O
,	O
we	O
review	O
the	O
incidence	O
of	O
anemia	B
and	O
the	O
effect	O
of	O
a	O
policy	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
maintenance	O
by	O
blood	O
transfusion	O
on	O
disease	O
outcomes	O
in	O
these	O
patients	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Retrospective	O
review	O
of	O
the	O
records	O
of	O
patients	O
with	O
SCCHN	B
treated	O
with	O
sequential	O
CCRT	O
formed	O
the	O
basis	O
of	O
this	O
study	O
.	O

The	O
incidence	O
of	O
anemia	B
and	O
statistics	O
on	O
blood	O
transfusion	O
were	O
documented	O
.	O

For	O
the	O
purpose	O
of	O
outcome	O
analyses	O
,	O
patients	O
were	O
divided	O
into	O
four	O
categories	O
by	O
(	O
1	O
)	O
transfusion	O
status	O
,	O
(	O
2	O
)	O
nadir	O
Hb	O
concentration	O
,	O
(	O
3	O
)	O
number	O
of	O
transfusion	O
episodes	O
,	O
and	O
(	O
4	O
)	O
number	O
of	O
units	O
of	O
blood	O
transfused	O
(	O
NOUT	O
)	O
.	O

Data	O
on	O
3	O
-	O
year	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
,	O
disease	O
-	O
specific	O
survival	O
(	O
DSS	O
)	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
One	O
hundred	O
and	O
sixty	O
-	O
nine	O
patients	O
were	O
identified	O
.	O

The	O
median	O
follow	O
-	O
up	O
was	O
23.6	O
months	O
.	O

The	O
RFS	O
(	O
52	O
%	O
vs.	O
41	O
%	O
,	O
p	O
=	O
0.03	O
)	O
,	O
DSS	O
(	O
71	O
%	O
vs.	O
66	O
%	O
,	O
p	O
=	O
0.02	O
)	O
,	O
and	O
OS	O
(	O
58	O
%	O
vs.	O
42	O
%	O
p	O
=	O
0.005	O
)	O
were	O
significantly	O
better	O
for	O
patients	O
who	O
did	O
not	O
have	O
a	O
transfusion	O
vs.	O
those	O
who	O
did	O
.	O

The	O
LRC	O
,	O
RFS	O
,	O
DSS	O
,	O
and	O
OS	O
were	O
also	O
significantly	O
better	O
for	O
patients	O
with	O
nadir	O
Hb	O
level	O
>	O
12	O
vs.	O
<	O
12	O
g	O
/	O
dL	O
and	O
NOUT	O
1	O
-	O
4	O
vs.	O
>	O
4	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
seems	O
to	O
suggest	O
that	O
blood	O
transfusion	O
during	O
radical	O
treatment	O
for	O
SCCHN	B
might	O
be	O
detrimental	O
.	O

Further	O
research	O
should	O
be	O
undertaken	O
into	O
the	O
complex	O
interactions	O
among	O
tumor	B
hypoxia	I
,	O
anemia	B
,	O
and	O
the	O
treatment	O
of	O
anemia	B
before	O
making	O
treatment	O
recommendations	O
.	O

Disparities	O
in	O
the	O
use	O
of	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
therapy	O
for	O
elderly	O
advanced	O
colorectal	B
cancer	I
patients	O
in	O
the	O
community	O
oncology	O
setting	O
.	O

BACKGROUND	O
:	O
The	O
clinical	O
trials	O
on	O
which	O
the	O
treatment	O
of	O
advanced	O
colorectal	B
(	O
CRC	B
)	O
is	O
based	O
enroll	O
few	O
elderly	O
patients	O
.	O

Furthermore	O
,	O
few	O
investigations	O
have	O
determined	O
the	O
use	O
and	O
outcomes	O
of	O
the	O
treatment	O
of	O
advanced	O
CRC	B
in	O
practice	O
.	O

This	O
study	O
evaluated	O
the	O
treatment	O
of	O
advanced	O
CRC	B
in	O
community	O
oncology	O
practices	O
,	O
focusing	O
on	O
age	O
-	O
related	O
differences	O
in	O
treatment	O
and	O
outcome	O
.	O

METHODS	O
:	O
A	O
national	O
,	O
retrospective	O
chart	O
review	O
was	O
conducted	O
to	O
evaluate	O
the	O
management	O
of	O
advanced	O
CRC	B
in	O
10	O
community	O
practices	O
across	O
the	O
U	O
.	O

S	O
.	O

All	O
medical	O
records	O
of	O
patients	O
diagnosed	O
with	O
advanced	O
CRC	B
initiating	O
chemotherapy	O
treatment	O
after	O
January	O
1	O
,	O
2003	O
through	O
2006	O
were	O
included	O
.	O

The	O
primary	O
aim	O
was	O
to	O
compare	O
the	O
proportion	O
receiving	O
doublet	O
chemotherapy	O
(	O
irinotecan	O
or	O
oxaliplatin	O
with	O
a	O
fluoropyrimidine	O
)	O
as	O
initial	O
therapy	O
in	O
young	O
(	O
age	O
<	O
or	O
=	O
65	O
years	O
)	O
and	O
elderly	O
(	O
age	O
>	O
65	O
years	O
)	O
patients	O
.	O

Additional	O
aims	O
included	O
age	O
-	O
based	O
comparisons	O
of	O
the	O
addition	O
of	O
bevacizumab	O
to	O
chemotherapy	O
,	O
overall	O
chemotherapy	O
use	O
,	O
all	O
-	O
cause	O
mortality	O
,	O
and	O
toxicity	O
-	O
related	O
events	O
.	O

RESULTS	O
:	O
Overall	O
,	O
520	O
patients	O
(	O
56	O
%	O
elderly	O
)	O
received	O
6,253	O
cycles	O
of	O
chemotherapy	O
.	O

Of	O
the	O
younger	O
patients	O
,	O
84	O
%	O
received	O
doublet	O
chemotherapy	O
first	O
-	O
line	O
,	O
compared	O
with	O
58	O
%	O
of	O
elderly	O
patients	O
(	O
p	O
<	O
.001	O
)	O
.	O

The	O
use	O
of	O
each	O
of	O
the	O
medications	O
-	O
-	O
irinotecan	O
,	O
oxaliplatin	O
,	O
and	O
bevacizumab	O
-	O
-	O
was	O
lower	O
in	O
elderly	O
patients	O
(	O
p	O
<	O
.001	O
)	O
.	O

Independent	O
predictors	O
of	O
a	O
higher	O
risk	O
for	O
mortality	O
were	O
age	O
>	O
65	O
(	O
adjusted	O
hazards	O
ratio	O
[	O
HR	O
]	O
,	O
1.19	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02	O
-	O
1.39	O
)	O
and	O
performance	O
status	O
score	O
>	O
or	O
=	O
2	O
(	O
HR	O
,	O
1.65	O
;	O
95	O
%	O
CI	O
,	O
1.41	O
-	O
1.91	O
)	O
.	O

CONCLUSION	O
:	O
Elderly	O
patients	O
are	O
less	O
likely	O
to	O
receive	O
first	O
-	O
line	O
doublet	O
chemotherapy	O
than	O
younger	O
patients	O
.	O

Age	O
and	O
performance	O
status	O
are	O
independent	O
predictors	O
of	O
treatment	O
and	O
overall	O
survival	O
.	O

Pharmacological	O
profile	O
,	O
efficacy	O
and	O
safety	O
of	O
rupatadine	O
in	O
allergic	B
rhinitis	I
.	O

Allergic	B
rhinitis	I
(	O
AR	B
)	O
is	O
a	O
disease	O
with	O
high	O
prevalence	O
.	O

In	O
AR	B
,	O
exposure	O
to	O
airborne	O
allergens	O
elicits	O
an	O
allergic	O
response	O
which	O
involves	O
epithelial	O
accumulation	O
of	O
effector	O
cells	O
-	O
e.g.	O
mast	O
cells	O
and	O
basophils	O
-	O
and	O
subsequent	O
inflammation	B
.	O

During	O
the	O
early	O
response	O
in	O
AR	B
,	O
histamine	O
has	O
been	O
found	O
to	O
be	O
the	O
most	O
abundant	O
mediator	O
and	O
it	O
is	O
associated	O
with	O
many	O
symptoms	O
of	O
this	O
disease	O
mediated	O
through	O
the	O
histamine	O
H1	O
receptor	O
.	O

Therefore	O
,	O
anti	O
-	O
histamines	O
have	O
a	O
role	O
to	O
play	O
in	O
the	O
management	O
of	O
AR	B
.	O

However	O
,	O
the	O
available	O
antihistamines	O
have	O
certain	O
well	O
-	O
known	O
side	O
effects	O
like	O
sedation	B
and	O
potential	O
pro	B
-	I
arrythmic	I
effects	I
owing	O
to	O
their	O
interactions	O
with	O
other	O
drugs	O
,	O
as	O
well	O
as	O
having	O
poor	O
or	O
no	O
effect	O
on	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
which	O
also	O
plays	O
an	O
important	O
role	O
in	O
AR	B
.	O

This	O
article	O
is	O
a	O
qualitative	O
systematic	O
literature	O
review	O
on	O
the	O
pharmacological	O
profile	O
of	O
rupatadine	O
in	O
order	O
to	O
evaluate	O
its	O
safety	O
and	O
efficacy	O
in	O
AR	B
as	O
compared	O
to	O
other	O
anti	O
-	O
histamines	O
.	O

Rupatadine	O
is	O
a	O
once	O
-	O
daily	O
non	O
-	O
sedative	O
,	O
selective	O
,	O
long	O
-	O
acting	O
H1	O
anti	O
-	O
histamine	O
with	O
antagonistic	O
PAF	O
effects	O
through	O
its	O
interaction	O
with	O
specific	O
receptors	O
.	O

Rupatadine	O
significantly	O
improves	O
nasal	O
symptoms	O
in	O
patients	O
with	O
AR	B
.	O

It	O
has	O
a	O
good	O
safety	O
profile	O
and	O
is	O
devoid	O
of	O
arrythmogenic	B
effects	I
.	O

These	O
properties	O
make	O
rupatadine	O
a	O
suitable	O
first	O
line	O
anti	O
-	O
histamine	O
for	O
the	O
treatment	O
of	O
AR	B
.	O

Variability	O
in	O
platelet	O
response	O
to	O
a	O
single	O
daily	O
dose	O
of	O
150	O
mg	O
enteric	O
coated	O
aspirin	O
in	O
a	O
high	O
risk	O
population	O
.	O

PURPOSE	O
:	O
Previous	O
studies	O
have	O
reported	O
inadequate	O
anti	O
-	O
platelet	O
effect	O
in	O
0.4	O
-	O
35	O
%	O
of	O
patients	O
taking	O
aspirin	O
.	O

Such	O
studies	O
have	O
arbitrarily	O
defined	O
the	O
terms	O
""""	O
semi	O
-	O
responders	O
""""	O
,	O
""""	O
non	O
-	O
responders	O
""""	O
or	O
""""	O
resistant	O
""""	O
to	O
variable	O
doses	O
of	O
aspirin	O
on	O
the	O
basis	O
of	O
absolute	O
values	O
derived	O
from	O
different	O
ex	O
-	O
vivo	O
platelet	O
aggregation	O
(	O
PA	O
)	O
methods	O
.	O

Our	O
objective	O
was	O
to	O
define	O
response	O
to	O
150	O
-	O
mg	O
dose	O
of	O
aspirin	O
in	O
terms	O
of	O
normally	O
distributed	O
values	O
using	O
an	O
ex	O
-	O
vivo	O
measure	O
of	O
PA	O
in	O
a	O
population	O
at	O
high	O
risk	O
for	O
vascular	O
events	O
.	O

METHODS	O
:	O
We	O
prospectively	O
studied	O
high	O
risk	O
patients	O
with	O
either	O
established	O
coronary	B
artery	I
disease	I
(	O
CAD	B
)	O
or	O
stroke	B
or	O
transient	B
ischemic	I
attack	I
(	O
TIA	B
)	O
or	O
peripheral	B
vascular	I
disease	I
or	O
with	O
multiple	O
atherothrombotic	O
risk	O
factors	O
like	O
diabetes	B
plus	O
one	O
of	O
the	O
following	O
-	O
-	O
hypertension	B
,	O
increased	O
total	O
cholesterol	O
,	O
cigarette	O
smoking	O
,	O
micro	O
-	O
albuminuria	O
,	O
low	O
-	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
,	O
family	O
history	O
of	O
CAD	B
and	O
receiving	O
single	O
150	O
mg	O
dose	O
of	O
aspirin	O
daily	O
.	O

PA	O
was	O
assessed	O
by	O
chronolog	O
lumi	O
-	O
aggregometer	O
(	O
490	O
-	O
2	O
D	O
)	O
using	O
arachidonic	O
acid	O
(	O
AA	O
)	O
reagent	O
.	O

RESULTS	O
:	O
130	O
patients	O
were	O
studied	O
.	O

The	O
response	O
of	O
subjects	O
to	O
aspirin	O
followed	O
a	O
normal	O
,	O
bell	O
shaped	O
distribution	O
curve	O
with	O
a	O
mean	O
and	O
standard	O
deviation	O
(	O
S	O
.	O

D	O
.	O
)	O
of	O
13.1	O
+	O
/	O
-	O
4.4	O
%	O
.	O

3.1	O
%	O
patients	O
had	O
PA	O
values	O
more	O
than	O
2	O
S	O
.	O

D	O
.	O
of	O
the	O
mean	O
,	O
hence	O
termed	O
as	O
hypo	O
-	O
responders	O
to	O
aspirin	O
while	O
another	O
3.1	O
%	O
patients	O
had	O
PA	O
values	O
less	O
than	O
2	O
S	O
.	O

D	O
.	O
of	O
the	O
mean	O
,	O
hence	O
termed	O
as	O
hyper	O
-	O
responders	O
to	O
aspirin	O
.	O

CONCLUSION	O
:	O
There	O
is	O
minimal	O
inter	O
-	O
individual	O
variability	O
in	O
the	O
response	O
to	O
aspirin	O
when	O
tested	O
with	O
AA	O
as	O
the	O
reagent	O
.	O

The	O
response	O
to	O
aspirin	O
follows	O
a	O
normal	O
Gaussian	O
distribution	O
.	O

The	O
prevalence	O
of	O
hypo	O
-	O
responders	O
to	O
aspirin	O
in	O
high	O
risk	O
population	O
is	O
only	O
3.1	O
%	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
document	O
""""	O
hypo	O
""""	O
and	O
""""	O
hyper	O
-	O
responders	O
""""	O
to	O
single	O
daily	O
dose	O
of	O
150	O
mg	O
aspirin	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
findings	O
remains	O
to	O
be	O
determined	O
.	O

Effect	O
of	O
2	O
-	O
hydroxyethyl	O
-	O
methacrylate	O
(	O
HEMA	O
)	O
on	O
the	O
phagocytic	O
and	O
respiratory	O
burst	O
activity	O
of	O
human	O
neutrophils	O
and	O
monocytes	O
.	O

Neutrophils	O
and	O
monocytes	O
/	O
macrophages	O
(	O
M	O
?	O
)	O
,	O
found	O
in	O
oral	O
mucosa	O
and	O
gingival	O
sulcus	O
,	O
phagocytose	O
and	O
kill	O
bacteria	O
using	O
products	O
produced	O
during	O
a	O
respiratory	O
burst	O
.	O

2	O
-	O
Hydroxyethyl	O
-	O
methacrylate	O
(	O
HEMA	O
)	O
is	O
a	O
major	O
component	O
released	O
from	O
resin	O
glass	O
ionomer	O
and	O
dental	O
adhesives	O
.	O

Hence	O
,	O
in	O
pulp	O
and	O
gingiva	O
,	O
phagocytes	O
can	O
come	O
into	O
contact	O
with	O
unpolymerized	O
HEMA	O
monomers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
exposure	O
to	O
HEMA	O
on	O
neutrophil	O
and	O
monocyte	O
bactericidal	O
function	O
.	O

Blood	O
collected	O
from	O
five	O
female	O
volunteers	O
was	O
exposed	O
in	O
vitro	O
to	O
HEMA	O
for	O
2	O
h	O
and	O
then	O
phagocytosis	O
,	O
respiratory	O
burst	O
,	O
and	O
cellular	O
integrity	O
were	O
measured	O
using	O
flow	O
cytometry	O
.	O

Respiratory	O
burst	O
was	O
quantified	O
by	O
measuring	O
fluorescent	O
rhodamine	O
123	O
generated	O
via	O
oxidation	O
of	O
dihydrorhodamine	O
123	O
.	O

Cellular	O
membrane	O
integrity	O
was	O
evaluated	O
by	O
staining	O
with	O
propidium	O
iodide	O
.	O

The	O
respiratory	O
burst	O
activity	O
of	O
the	O
neutrophils	O
was	O
significantly	O
decreased	O
by	O
exposure	O
to	O
7.5	O
and	O
15	O
mM	O
HEMA	O
.	O

No	O
significant	O
effect	O
of	O
HEMA	O
was	O
seen	O
on	O
the	O
number	O
of	O
granulocytes	O
or	O
monocytes	O
capable	O
of	O
performing	O
respiratory	O
burst	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
effect	O
of	O
HEMA	O
on	O
the	O
phagocytic	O
activity	O
of	O
the	O
monocytes	O
or	O
the	O
granulocytes	O
.	O

In	O
conclusion	O
,	O
HEMA	O
did	O
not	O
affect	O
the	O
phagocytosis	O
activity	O
of	O
neutrophils	O
;	O
however	O
,	O
the	O
ability	O
of	O
the	O
cells	O
to	O
kill	O
internalized	O
prey	O
was	O
significantly	O
reduced	O
.	O

Methods	O
in	O
safety	O
pharmacology	O
in	O
focus	O
.	O

This	O
focused	O
issue	O
of	O
the	O
Journal	O
of	O
Pharmacological	O
and	O
Toxicological	O
Methods	O
is	O
the	O
fifth	O
to	O
highlight	O
Methods	O
in	O
Safety	O
Pharmacology	O
and	O
includes	O
a	O
number	O
of	O
articles	O
from	O
the	O
7th	O
Annual	O
Safety	O
Pharmacology	O
Society	O
(	O
SPS	O
)	O
meeting	O
that	O
was	O
held	O
in	O
Edinburgh	O
,	O
Scotland	O
,	O
September	O
19	O
-	O
21	O
,	O
2007	O
.	O

However	O
,	O
unlike	O
issues	O
of	O
the	O
past	O
,	O
in	O
which	O
content	O
predominantly	O
focused	O
on	O
cardiovascular	O
issues	O
(	O
specifically	O
QT	O
interval	O
prolongation	O
,	O
QT	O
-	O
HR	O
correction	O
methods	O
and	O
validation	O
of	O
non	O
-	O
clinical	O
cardiovascular	O
models	O
)	O
this	O
issue	O
is	O
composed	O
of	O
a	O
number	O
of	O
non	O
-	O
cardiovascular	O
methods	O
papers	O
and	O
review	O
articles	O
.	O

Of	O
particular	O
interest	O
to	O
readers	O
will	O
be	O
articles	O
related	O
to	O
CNS	O
studies	O
,	O
in	O
particular	O
neurobehavioral	O
assessments	O
in	O
non	O
-	O
human	O
primates	O
and	O
the	O
effects	O
of	O
drugs	O
in	O
juvenile	O
and	O
adult	O
rats	O
(	O
an	O
article	O
that	O
may	O
be	O
relevant	O
in	O
light	O
of	O
recent	O
EU	O
/	O
US	O
pediatric	O
legislation	O
)	O
.	O

While	O
cardiovascular	O
function	O
may	O
not	O
dominate	O
there	O
are	O
several	O
useful	O
methodological	O
papers	O
including	O
an	O
assessment	O
of	O
cardiovascular	O
sensitivity	O
of	O
drugs	O
in	O
conscious	O
and	O
anesthetized	O
non	O
-	O
human	O
primates	O
,	O
and	O
a	O
mathematical	O
model	O
(	O
fractal	O
analysis	O
)	O
applied	O
to	O
canine	O
heartbeat	O
dynamics	O
.	O

A	O
first	O
for	O
the	O
journal	O
is	O
a	O
paper	O
by	O
Vargas	O
et	O
al.	O
,	O
(	O
2008	O
-	O
this	O
issue	O
)	O
in	O
which	O
members	O
of	O
the	O
SPS	O
formed	O
a	O
working	O
group	O
in	O
order	O
to	O
assess	O
and	O
review	O
safety	O
pharmacology	O
testing	O
of	O
biological	O
therapeutic	O
agents	O
(	O
specifically	O
monoclonal	O
antibodies	O
,	O
mAbs	O
)	O
.	O

The	O
group	O
provides	O
recommendations	O
that	O
will	O
likely	O
shape	O
regulatory	O
strategy	O
and	O
discussions	O
in	O
the	O
yet	O
to	O
be	O
fully	O
discussed	O
area	O
of	O
biological	O
safety	O
testing	O
.	O

In	O
the	O
tradition	O
of	O
obtaining	O
a	O
perspective	O
on	O
industry	O
safety	O
pharmacology	O
program	O
practices	O
Lindgren	O
et	O
al.	O
,	O
(	O
2008	O
-	O
this	O
issue	O
)	O
provide	O
the	O
results	O
of	O
a	O
recent	O
SPS	O
survey	O
that	O
examines	O
ICH	O
S7A	O
and	O
S7B	O
trends	O
,	O
aspects	O
of	O
early	O
'	O
frontloading	O
'	O
safety	O
studies	O
,	O
abuse	O
and	O
dependence	O
liability	O
and	O
Contract	O
Research	O
Organization	O
(	O
CRO	O
)	O
tests	O
/	O
assays	O
used	O
in	O
safety	O
assessment	O
of	O
core	O
battery	O
and	O
supplementary	O
organ	O
systems	O
.	O

In	O
keeping	O
with	O
the	O
translation	O
track	O
aspect	O
of	O
the	O
2007	O
meeting	O
is	O
an	O
overview	O
of	O
the	O
Distinguished	O
Service	O
Award	O
lecture	O
to	O
Dr.	O
T	O
.	O

Hammond	O
that	O
discusses	O
many	O
aspects	O
of	O
safety	O
pharmacology	O
including	O
its	O
evolution	O
,	O
impact	O
,	O
value	O
and	O
translation	O
of	O
non	O
-	O
clinical	O
findings	O
to	O
humans	O
.	O

Finally	O
,	O
perspectives	O
are	O
presented	O
on	O
the	O
use	O
of	O
the	O
zebrafish	O
as	O
an	O
early	O
safety	O
pharmacology	O
-	O
screening	O
assay	O
.	O

Intensity	O
-	O
modulated	O
radiotherapy	O
in	O
postoperative	O
treatment	O
of	O
oral	B
cavity	I
cancers	I
.	O

PURPOSE	O
:	O
To	O
present	O
our	O
single	O
-	O
institution	O
experience	O
of	O
intensity	O
-	O
modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
for	O
oral	B
cavity	I
cancer	I
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Between	O
September	O
2000	O
and	O
December	O
2006	O
,	O
35	O
patients	O
with	O
histologically	O
confirmed	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
oral	I
cavity	I
underwent	O
surgery	O
followed	O
by	O
postoperative	O
IMRT	O
.	O

The	O
sites	O
included	O
were	O
buccal	O
mucosa	O
in	O
8	O
,	O
oral	O
tongue	O
in	O
11	O
,	O
floor	O
of	O
the	O
mouth	O
in	O
9	O
,	O
gingiva	O
in	O
4	O
,	O
hard	O
palate	O
in	O
2	O
,	O
and	O
retromolar	O
trigone	O
in	O
1	O
.	O

Most	O
patients	O
had	O
Stage	O
III	O
-	O
IV	O
disease	O
(	O
80	O
%	O
)	O
.	O

Ten	O
patients	O
(	O
29	O
%	O
)	O
also	O
received	O
concurrent	O
postoperative	O
chemotherapy	O
with	O
IMRT	O
.	O

The	O
median	O
prescribed	O
radiation	O
dose	O
was	O
60	O
Gy	O
.	O

RESULTS	O
:	O
The	O
median	O
follow	O
-	O
up	O
for	O
surviving	O
patients	O
was	O
28.1	O
months	O
(	O
range	O
,	O
11.9	O
-	O
85.1	O
)	O
.	O

Treatment	O
failure	O
occurred	O
in	O
11	O
cases	O
as	O
follows	O
:	O
local	O
in	O
4	O
,	O
regional	O
in	O
2	O
,	O
and	O
distant	O
metastases	O
in	O
5	O
.	O

Of	O
the	O
5	O
patients	O
with	O
distant	O
metastases	O
,	O
2	O
presented	O
with	O
dermal	O
metastases	O
.	O

The	O
2	O
-	O
and	O
3	O
-	O
year	O
estimates	O
of	O
locoregional	O
progression	O
-	O
free	O
survival	O
,	O
distant	O
metastasis	O
-	O
free	O
survival	O
,	O
disease	O
-	O
free	O
survival	O
,	O
and	O
overall	O
survival	O
were	O
84	O
%	O
and	O
77	O
%	O
,	O
85	O
%	O
and	O
85	O
%	O
,	O
70	O
%	O
and	O
64	O
%	O
,	O
and	O
74	O
%	O
and	O
74	O
%	O
,	O
respectively	O
.	O

Acute	O
Grade	O
2	O
or	O
greater	O
dermatitis	B
,	O
mucositis	B
,	O
and	O
esophageal	B
reactions	I
were	O
experienced	O
by	O
54	O
%	O
,	O
66	O
%	O
,	O
and	O
40	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Documented	O
late	O
complications	O
included	O
trismus	B
(	O
17	O
%	O
)	O
and	O
osteoradionecrosis	B
(	O
5	O
%	O
)	O
.	O

CONCLUSION	O
:	O
IMRT	O
as	O
an	O
adjuvant	O
treatment	O
after	O
surgical	O
resection	O
for	O
oral	B
cavity	I
tumors	I
is	O
feasible	O
and	O
effective	O
,	O
with	O
promising	O
results	O
and	O
acceptable	O
toxicity	O
.	O

Breakthrough	O
cryptococcosis	B
in	O
a	O
patient	O
with	O
systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
receiving	O
micafungin	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
lupus	B
nephritis	I
.	O

Methylprednisolone	O
minipulse	O
therapy	O
dramatically	O
reduced	O
her	O
proteinuria	B
;	O
however	O
;	O
she	O
then	O
complained	O
of	O
general	O
fatigue	B
with	O
low	O
-	O
grade	O
fever	B
.	O

Radiological	O
and	O
culture	O
studies	O
revealed	O
no	O
infectious	O
focus	O
,	O
but	O
she	O
was	O
treated	O
with	O
meropenem	O
and	O
micafungin	O
,	O
considering	O
her	O
immunosuppressive	O
state	O
.	O

Cytomegalovirus	O
antigenemia	O
was	O
later	O
determined	O
and	O
ganciclovir	O
was	O
added	O
.	O

She	O
became	O
afebrile	O
,	O
but	O
complained	O
of	O
nausea	B
and	O
headache	B
,	O
and	O
disorientation	B
,	O
without	O
meningeal	B
signs	I
.	O

Because	O
a	O
brain	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
showed	O
no	O
abnormality	O
,	O
we	O
initially	O
suspected	O
some	O
kind	O
of	O
drug	O
interaction	O
.	O

Despite	O
the	O
discontinuation	O
of	O
all	O
drugs	O
,	O
however	O
,	O
she	O
still	O
suffered	O
from	O
disturbance	O
of	O
consciousness	O
.	O

A	O
lumbar	O
puncture	O
revealed	O
yeast	O
cells	O
stained	O
by	O
India	O
ink	O
.	O

A	O
diagnosis	O
of	O
cryptococcal	B
meningitis	I
was	O
confirmed	O
.	O

Though	O
fluconazole	O
and	O
meropenem	O
were	O
administered	O
,	O
the	O
patient	O
died	O
.	O

Autopsy	O
findings	O
revealed	O
disseminated	B
cryptococcosis	I
concomitant	O
with	O
pulmonary	B
aspergillosis	I
.	O

Micafungin	O
is	O
a	O
recently	O
approved	O
echinocandin	O
-	O
class	O
antifungal	O
agent	O
that	O
is	O
now	O
widely	O
used	O
in	O
Japan	O
because	O
of	O
its	O
minimal	O
toxicity	O
and	O
broadspectrum	O
activity	O
.	O

However	O
,	O
such	O
echinocandins	O
have	O
limited	O
activity	O
against	O
a	O
number	O
of	O
fungi	O
.	O

Indeed	O
,	O
breakthrough	O
trichosporonosis	O
is	O
becoming	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
hematological	B
malignancies	I
who	O
are	O
receiving	O
echinocandins	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
breakthrough	O
cryptococcosis	B
,	O
as	O
seen	O
in	O
our	O
patient	O
,	O
has	O
not	O
been	O
reported	O
previously	O
in	O
patients	O
who	O
were	O
receiving	O
micafungin	O
as	O
an	O
empiric	O
antifungal	O
therapy	O
.	O

This	O
case	O
highlights	O
that	O
cryptococcosis	B
should	O
be	O
kept	O
in	O
mind	O
as	O
a	O
possible	O
breakthrough	O
infection	B
during	O
the	O
administration	O
of	O
echinocandins	O
,	O
especially	O
in	O
patients	O
with	O
cellular	B
immunodeficiency	I
.	O

Multicenter	O
clinical	O
study	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
inhalable	O
insulin	O
aerosol	O
in	O
the	O
treatment	O
of	O
type	B
2	I
diabetes	I
.	O

BACKGROUND	O
:	O
A	O
new	O
inhalable	O
insulin	O
aerosol	O
(	O
Inh	O
-	O
Ins	O
)	O
was	O
developed	O
in	O
China	O
.	O

The	O
aim	O
of	O
this	O
multicenter	O
clinical	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
this	O
new	O
Inh	O
-	O
Ins	O
as	O
a	O
treatment	O
of	O
type	B
2	I
diabetes	I
.	O

Regular	O
porcine	O
insulin	O
(	O
RI	O
)	O
was	O
used	O
as	O
a	O
control	O
.	O

METHODS	O
:	O
This	O
study	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
multicenter	O
clinical	O
trial	O
in	O
which	O
253	O
qualified	O
patients	O
with	O
type	B
2	I
diabetes	I
received	O
the	O
insulin	O
Glargine	O
daily	O
at	O
bedtime	O
plus	O
either	O
a	O
pre	O
-	O
meal	O
Inh	O
-	O
Ins	O
or	O
a	O
pre	O
-	O
meal	O
subcutaneous	O
RI	O
for	O
12	O
weeks	O
.	O

HbA1c	O
,	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
the	O
1	O
-	O
hour	O
-	O
postprandial	O
blood	O
glucose	O
(	O
1hPBG	O
)	O
and	O
the	O
2	O
-	O
hour	O
-	O
postprandial	O
blood	O
glucose	O
(	O
2hPBG	O
)	O
were	O
measured	O
.	O

Events	O
were	O
monitored	O
for	O
adverse	O
effects	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
,	O
the	O
HbA1c	O
decreased	O
significantly	O
from	O
baseline	O
in	O
both	O
treatment	O
groups	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
regimens	O
.	O

In	O
the	O
Inh	O
-	O
Ins	O
group	O
,	O
FPG	O
,	O
both	O
1hPBG	O
and	O
2hPBG	O
significantly	O
declined	O
from	O
baseline	O
after	O
the	O
8th	O
-	O
and	O
12th	O
-	O
weeks	O
of	O
treatment	O
.	O

The	O
reduced	O
values	O
of	O
FPG	O
or	O
1hPBG	O
between	O
the	O
two	O
groups	O
showed	O
a	O
more	O
significant	O
hypoglycemic	O
effect	O
with	O
the	O
Inh	O
-	O
Ins	O
than	O
the	O
RI	O
.	O

After	O
12	O
weeks	O
,	O
the	O
pulmonary	O
carbon	O
monoxide	O
diffusing	O
capacity	O
(	O
DLco	O
)	O
was	O
significantly	O
lower	O
in	O
Inh	O
-	O
Ins	O
group	O
than	O
in	O
the	O
RI	O
.	O

The	O
main	O
side	O
effects	O
of	O
Inh	O
-	O
Ins	O
were	O
coughing	B
,	O
excessive	B
sputum	I
,	O
and	O
hypoglycemia	B
.	O

CONCLUSIONS	O
:	O
Inh	O
-	O
Ins	O
was	O
effective	O
in	O
decreasing	O
HbA1c	O
like	O
the	O
RI	O
.	O

It	O
was	O
better	O
in	O
lowering	O
the	O
FPG	O
and	O
the	O
1hPBG	O
than	O
the	O
RI	O
.	O

Its	O
main	O
side	O
effects	O
were	O
coughing	B
,	O
excessive	B
sputum	I
,	O
and	O
hypoglycemia	B
.	O

Also	O
,	O
Inh	O
-	O
Ins	O
slightly	O
impaired	O
DLco	O
.	O

Choosing	O
a	O
skeletal	O
muscle	O
relaxant	O
.	O

Skeletal	O
muscle	O
relaxants	O
are	O
widely	O
used	O
in	O
treating	O
musculoskeletal	O
conditions	O
.	O

However	O
,	O
evidence	O
of	O
their	O
effectiveness	O
consists	O
mainly	O
of	O
studies	O
with	O
poor	O
methodologic	O
design	O
.	O

In	O
addition	O
,	O
these	O
drugs	O
have	O
not	O
been	O
proven	O
to	O
be	O
superior	O
to	O
acetaminophen	O
or	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
for	O
low	B
back	I
pain	I
.	O

Systematic	O
reviews	O
and	O
meta	O
-	O
analyses	O
support	O
using	O
skeletal	O
muscle	O
relaxants	O
for	O
short	O
-	O
term	O
relief	O
of	O
acute	B
low	I
back	I
pain	I
when	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
or	O
acetaminophen	O
are	O
not	O
effective	O
or	O
tolerated	O
.	O

Comparison	O
studies	O
have	O
not	O
shown	O
one	O
skeletal	O
muscle	O
relaxant	O
to	O
be	O
superior	O
to	O
another	O
.	O

Cyclobenzaprine	O
is	O
the	O
most	O
heavily	O
studied	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
various	O
musculoskeletal	O
conditions	O
.	O

The	O
sedative	O
properties	O
of	O
tizanidine	O
and	O
cyclobenzaprine	O
may	O
benefit	O
patients	O
with	O
insomnia	B
caused	O
by	O
severe	O
muscle	B
spasms	I
.	O

Methocarbamol	O
and	O
metaxalone	O
are	O
less	O
sedating	O
,	O
although	O
effectiveness	O
evidence	O
is	O
limited	O
.	O

Adverse	O
effects	O
,	O
particularly	O
dizziness	B
and	O
drowsiness	B
,	O
are	O
consistently	O
reported	O
with	O
all	O
skeletal	O
muscle	O
relaxants	O
.	O

The	O
potential	O
adverse	O
effects	O
should	O
be	O
communicated	O
clearly	O
to	O
the	O
patient	O
.	O

Because	O
of	O
limited	O
comparable	O
effectiveness	O
data	O
,	O
choice	O
of	O
agent	O
should	O
be	O
based	O
on	O
side	O
-	O
effect	O
profile	O
,	O
patient	O
preference	O
,	O
abuse	B
potential	O
,	O
and	O
possible	O
drug	O
interactions	O
.	O

Two	O
rare	O
cases	O
of	O
methotrexate	O
-	O
induced	O
pneumonitis	B
and	O
pleurisy	B
in	O
patients	O
with	O
gestational	B
trophoblastic	I
neoplasms	I
.	O

BACKGROUND	O
:	O
Pneumonitis	B
is	O
a	O
serious	O
and	O
unpredictable	O
side	O
-	O
effect	O
of	O
treatment	O
with	O
methotrexate	O
(	O
MTX	O
)	O
that	O
may	O
result	O
in	O
a	O
life	O
-	O
threatening	O
outcome	O
.	O

Pulmonary	B
toxicity	I
of	O
methotrexate	O
in	O
patients	O
with	O
a	O
gestational	B
trophoblastic	I
neoplasm	I
(	O
GTN	B
)	O
has	O
rarely	O
been	O
reported	O
before	O
.	O

CASE	O
REPORTS	O
:	O
For	O
the	O
first	O
time	O
two	O
cases	O
of	O
methotrexate	O
-	O
induced	O
pneumonitis	B
and	O
pleurisy	B
in	O
GTN	B
patients	O
of	O
Chinese	O
ethnicity	O
are	O
presented	O
.	O

Two	O
patients	O
were	O
both	O
categorized	O
as	O
the	O
low	O
-	O
risk	O
group	O
,	O
and	O
underwent	O
a	O
single	O
regimen	O
therapy	O
of	O
methotrexate	O
.	O

Their	O
symptoms	O
,	O
such	O
as	O
fever	B
,	O
chest	B
pain	I
,	O
acute	B
nonproductive	I
cough	I
,	O
dyspnea	B
and	O
hypoxemia	B
did	O
not	O
respond	O
to	O
antibiotics	O
immediately	O
.	O

Treatment	O
with	O
corticosteroids	O
may	O
be	O
helpful	O
.	O

CONCLUSION	O
:	O
Awareness	O
of	O
pneumonitis	B
and	O
pleurisy	B
,	O
potentially	O
life	O
-	O
threatening	O
complications	O
of	O
MTX	O
,	O
is	O
very	O
necessary	O
and	O
important	O
to	O
early	O
recognition	O
and	O
treatment	O
.	O

Reduced	O
weight	O
gain	O
with	O
insulin	O
detemir	O
compared	O
to	O
NPH	O
insulin	O
is	O
not	O
explained	O
by	O
a	O
reduction	O
in	O
hypoglycemia	B
.	O

BACKGROUND	O
:	O
Weight	O
gain	O
often	O
occurs	O
when	O
insulin	O
therapy	O
is	O
initiated	O
.	O

The	O
long	O
-	O
acting	O
insulin	O
analog	O
insulin	O
detemir	O
has	O
been	O
shown	O
to	O
be	O
effective	O
and	O
well	O
tolerated	O
when	O
used	O
in	O
basal	O
-	O
bolus	O
regimens	O
or	O
as	O
an	O
add	O
-	O
on	O
to	O
oral	O
antidiabetic	O
drugs	O
(	O
OADs	O
)	O
and	O
causes	O
less	O
weight	O
gain	O
than	O
other	O
insulins	O
.	O

The	O
aim	O
of	O
this	O
exploratory	O
analysis	O
was	O
to	O
investigate	O
any	O
correlations	O
between	O
weight	O
change	O
and	O
occurrence	O
of	O
hypoglycemia	B
with	O
NPH	O
insulin	O
and	O
insulin	O
detemir	O
.	O

METHODS	O
:	O
The	O
analysis	O
was	O
based	O
on	O
a	O
26	O
-	O
week	O
,	O
randomized	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
trial	O
in	O
which	O
glycemic	O
control	O
,	O
hypoglycemia	B
,	O
and	O
weight	O
change	O
were	O
compared	O
between	O
insulin	O
detemir	O
and	O
NPH	O
insulin	O
.	O

A	O
total	O
of	O
476	O
insulin	O
-	O
naive	O
patients	O
with	O
type	B
2	I
diabetes	I
treated	O
with	O
one	O
or	O
two	O
OADs	O
added	O
insulin	O
detemir	O
(	O
n	O
=	O
237	O
)	O
or	O
NPH	O
insulin	O
(	O
n	O
=	O
239	O
)	O
morning	O
and	O
evening	O
to	O
their	O
current	O
oral	O
treatment	O
.	O

Weight	O
gain	O
data	O
from	O
this	O
study	O
were	O
analyzed	O
as	O
a	O
function	O
of	O
hypoglycemia	B
frequency	O
.	O

RESULTS	O
:	O
Both	O
groups	O
achieved	O
excellent	O
glycosylated	O
hemoglobin	O
control	O
(	O
insulin	O
detemir	O
,	O
6.6	O
%	O
;	O
NPH	O
insulin	O
,	O
6.5	O
%	O
[	O
difference	O
not	O
significant	O
]	O
)	O
.	O

Weight	O
gain	O
with	O
insulin	O
detemir	O
was	O
less	O
than	O
half	O
that	O
of	O
NPH	O
insulin	O
(	O
1.2	O
vs.	O
2.8	O
kg	O
,	O
respectively	O
[	O
P	O
<	O
0.001	O
]	O
)	O
,	O
and	O
the	O
overall	O
risk	O
of	O
hypoglycemia	B
was	O
47	O
%	O
lower	O
with	O
insulin	O
detemir	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
relationship	O
between	O
hypoglycemia	B
and	O
weight	O
gain	O
was	O
seen	O
with	O
insulin	O
detemir	O
(	O
P	O
=	O
0.2	O
)	O
,	O
while	O
a	O
statistically	O
significant	O
correlation	O
was	O
found	O
for	O
NPH	O
insulin	O
(	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
:	O
Hypoglycemia	B
is	O
predictive	O
of	O
weight	O
gain	O
with	O
NPH	O
insulin	O
,	O
but	O
the	O
same	O
relationship	O
is	O
not	O
seen	O
with	O
insulin	O
detemir	O
.	O

It	O
is	O
therefore	O
likely	O
that	O
the	O
weight	O
-	O
sparing	O
effect	O
of	O
insulin	O
detemir	O
involves	O
other	O
mechanisms	O
.	O

Lung	B
fibrosis	I
10	O
years	O
after	O
cessation	O
of	O
bleomycin	O
therapy	O
.	O

Bleomycin	O
(	O
BLM	O
)	O
is	O
a	O
chemotherapeutic	O
agent	O
used	O
for	O
the	O
treatment	O
of	O
several	O
types	O
of	O
malignancy	O
,	O
including	O
germ	B
cell	I
tumors	I
,	O
lymphoma	B
,	O
and	O
certain	O
types	O
of	O
squamous	B
-	I
cell	I
carcinoma	I
.	O

The	O
common	O
adverse	O
effect	O
of	O
BLM	O
is	O
interstitial	B
pneumonitis	I
,	O
followed	O
by	O
pulmonary	B
fibrosis	I
.	O

BLM	O
-	O
induced	O
pneumonitis	B
occurs	O
in	O
up	O
to	O
46	O
%	O
of	O
patients	O
treated	O
with	O
BLM	O
-	O
containing	O
chemotherapy	O
and	O
lung	B
toxicity	I
usually	O
appears	O
during	O
treatment	O
.	O

Here	O
we	O
describe	O
a	O
patient	O
with	O
lung	B
fibrosis	I
,	O
who	O
presented	O
with	O
slow	O
progressive	B
breathlessness	I
and	O
pneumothorax	B
more	O
than	O
10	O
years	O
after	O
cessation	O
of	O
BLM	O
therapy	O
.	O

A	O
15	O
year	O
-	O
old	O
girl	O
presented	O
with	O
abnormal	O
shadows	O
on	O
chest	O
X	O
-	O
ray	O
.	O

The	O
patient	O
had	O
a	O
yolk	B
sac	I
carcinoma	I
in	O
the	O
sacral	O
region	O
at	O
1	O
year	O
of	O
age	O
and	O
obtained	O
complete	O
remission	O
after	O
being	O
treated	O
with	O
tumor	B
resection	O
,	O
radiation	O
,	O
and	O
several	O
anti	O
-	O
cancer	O
drugs	O
including	O
BLM	O
.	O

There	O
were	O
no	O
abnormal	O
findings	O
in	O
chest	O
X	O
-	O
ray	O
until	O
she	O
reached	O
3	O
years	O
of	O
age	O
,	O
when	O
she	O
had	O
developed	O
respiratory	B
distress	I
that	O
worsened	O
with	O
age	O
.	O

The	O
patient	O
had	O
experienced	O
an	O
episode	O
of	O
pneumothorax	B
at	O
13	O
years	O
of	O
age	O
.	O

Chest	O
CT	O
at	O
the	O
time	O
revealed	O
interstitial	O
reticular	O
opacities	O
.	O

Radiological	O
findings	O
and	O
pathological	O
examination	O
of	O
the	O
lung	O
tissue	O
obtained	O
during	O
bullectomy	O
with	O
video	O
-	O
assisted	O
thoracic	O
surgery	O
were	O
compatible	O
with	O
BLM	O
-	O
induced	O
pneumonitis	B
.	O

The	O
present	O
study	O
suggests	O
that	O
lung	B
fibrosis	I
may	O
surface	O
more	O
than	O
10	O
years	O
after	O
cessation	O
of	O
BLM	O
therapy	O
at	O
the	O
age	O
of	O
1	O
year	O
,	O
with	O
no	O
chest	O
radiographic	O
findings	O
1	O
year	O
after	O
completion	O
of	O
chemotherapy	O
.	O

The	O
use	O
of	O
BLM	O
in	O
infants	O
requires	O
strict	O
supervision	O
and	O
observation	O
and	O
careful	O
long	O
-	O
term	O
follow	O
up	O
.	O

Riluzole	O
in	O
psychiatry	O
:	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
.	O

BACKGROUND	O
:	O
The	O
glutamate	O
system	O
seems	O
to	O
be	O
an	O
important	O
contributor	O
to	O
the	O
pathophysiology	O
of	O
mood	O
and	O
anxiety	B
disorders	I
.	O

Thus	O
,	O
glutamatergic	O
modulators	O
are	O
reasonable	O
candidate	O
drugs	O
to	O
test	O
in	O
patients	O
with	O
mood	O
and	O
anxiety	B
disorders	I
.	O

Riluzole	O
,	O
a	O
neuroprotective	O
agent	O
with	O
anticonvulsant	O
properties	O
approved	O
for	O
the	O
treatment	O
of	O
amyotrophic	B
lateral	I
sclerosis	I
(	O
ALS	B
)	O
is	O
one	O
such	O
agent	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
the	O
potential	O
risks	O
and	O
benefits	O
of	O
riluzole	O
treatment	O
in	O
psychiatric	O
patients	O
.	O

METHODS	O
:	O
A	O
PubMed	O
search	O
was	O
performed	O
using	O
the	O
keywords	O
'	O
riluzole	O
'	O
,	O
'	O
inhibitor	O
of	O
glutamate	O
release	O
'	O
and	O
'	O
glutamatergic	O
modulator	O
'	O
to	O
identify	O
all	O
clinical	O
studies	O
and	O
case	O
reports	O
involving	O
riluzole	O
in	O
psychiatric	O
patients	O
.	O

RESULTS	O
/	O
CONCLUSION	O
:	O
Riluzole	O
's	O
side	O
effect	O
profile	O
is	O
favorable	O
and	O
preliminary	O
results	O
regarding	O
riluzole	O
for	O
the	O
treatment	O
of	O
severe	O
mood	O
,	O
anxiety	B
and	O
impulsive	B
disorders	I
are	O
encouraging	O
.	O

Estimates	O
of	O
cancer	B
potency	O
of	O
2,3,4,7,8	O
-	O
pentachlorodibenzofuran	O
using	O
both	O
nonlinear	O
and	O
linear	O
approaches	O
.	O

Cancer	B
potency	O
estimates	O
were	O
derived	O
for	O
2,3,4,7,8	O
-	O
pentachlorodibenzofuran	O
(	O
4	O
-	O
PeCDF	O
)	O
using	O
data	O
collected	O
from	O
the	O
recently	O
published	O
National	O
Toxicology	O
Program	O
bioassay	O
in	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

By	O
using	O
a	O
toxicokinetic	O
model	O
for	O
4	O
-	O
PeCDF	O
,	O
the	O
dose	O
-	O
response	O
relationship	O
for	O
combined	O
liver	B
tumors	I
(	O
hepatocellular	B
adenomas	I
and	O
cholangiocarcinomas	B
)	O
in	O
rats	O
was	O
assessed	O
in	O
terms	O
of	O
lifetime	O
average	O
liver	O
concentration	O
and	O
lifetime	O
average	O
adipose	O
concentration	O
with	O
data	O
from	O
both	O
the	O
lifetime	O
and	O
the	O
stop	O
-	O
exposure	O
components	O
of	O
the	O
bioassay	O
.	O

Benchmark	O
dose	O
modeling	O
was	O
performed	O
to	O
estimate	O
tissue	O
concentrations	O
at	O
two	O
points	O
of	O
departure	O
(	O
EC	O
(	O
10	O
)	O
and	O
EC	O
(	O
01	O
)	O
and	O
their	O
95	O
%	O
upper	O
and	O
lower	O
confidence	O
limits	O
)	O
.	O

The	O
same	O
toxicokinetic	O
model	O
with	O
human	O
input	O
values	O
was	O
then	O
used	O
to	O
back	O
-	O
extrapolate	O
human	O
equivalent	O
doses	O
that	O
corresponded	O
to	O
the	O
internal	O
tissue	O
concentration	O
measures	O
at	O
the	O
points	O
of	O
departure	O
.	O

Information	O
regarding	O
the	O
cancer	B
mode	O
of	O
action	O
was	O
used	O
to	O
support	O
the	O
development	O
of	O
several	O
toxicity	O
criterion	O
values	O
based	O
on	O
a	O
nonlinear	O
method	O
,	O
e.g.	O
,	O
reference	O
dose	O
or	O
tolerable	O
daily	O
intake	O
.	O

Nonlinear	O
estimates	O
of	O
toxicity	O
criteria	O
based	O
on	O
observed	O
noncancer	O
toxic	O
events	O
as	O
possible	O
precursors	O
to	O
tumor	B
formation	O
were	O
also	O
derived	O
and	O
were	O
similar	O
in	O
value	O
to	O
those	O
based	O
on	O
combined	O
liver	B
tumors	I
.	O

For	O
comparison	O
purposes	O
,	O
linear	O
estimates	O
of	O
cancer	B
potency	O
were	O
also	O
derived	O
.	O

Phase	O
II	O
preradiation	O
R115777	O
(	O
tipifarnib	O
)	O
in	O
newly	O
diagnosed	O
GBM	O
with	O
residual	O
enhancing	O
disease	O
.	O

Glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
is	O
a	O
lethal	O
primary	O
malignant	B
brain	I
tumor	I
in	O
adults	O
.	O

R115777	O
(	O
tipifarnib	O
)	O
is	O
an	O
oral	O
agent	O
with	O
antiproliferative	O
effects	O
,	O
being	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
farnesyltransferase	O
.	O

This	O
multicenter	O
,	O
open	O
-	O
label	O
phase	O
II	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
R115777	O
given	O
after	O
surgery	O
and	O
prior	O
to	O
radiation	O
in	O
patients	O
with	O
newly	O
diagnosed	O
and	O
residual	O
enhancing	O
GBM	B
.	O

Following	O
surgery	O
,	O
an	O
MRI	O
confirmed	O
the	O
presence	O
of	O
residual	O
enhancing	O
tumor	O
.	O

Patients	O
on	O
enzyme	O
-	O
inducing	O
antiseizure	O
drugs	O
(	O
EIASDs	O
)	O
received	O
600	O
mg	O
twice	O
per	O
day	O
,	O
and	O
those	O
not	O
on	O
EIASDs	O
received	O
300	O
mg	O
twice	O
per	O
day	O
.	O

One	O
to	O
three	O
monthly	O
cycles	O
of	O
R115777	O
were	O
administered	O
,	O
and	O
radiation	O
was	O
initiated	O
with	O
progression	O
or	O
after	O
three	O
cycles	O
.	O

A	O
cycle	O
consisted	O
of	O
3	O
weeks	O
of	O
continuous	O
R115777	O
followed	O
by	O
a	O
1	O
-	O
week	O
rest	O
.	O

MRI	O
was	O
done	O
monthly	O
.	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
end	O
points	O
were	O
tumor	B
response	O
rate	O
and	O
toxicity	O
.	O

A	O
total	O
of	O
28	O
confirmed	O
GBM	O
patients	O
entered	O
the	O
study	O
;	O
15	O
patients	O
(	O
54	O
%	O
)	O
were	O
on	O
EIASDs	O
.	O

The	O
overall	O
median	O
time	O
of	O
survival	O
was	O
7.7	O
months	O
.	O

There	O
were	O
no	O
tumor	B
responses	O
.	O

Eight	O
patients	O
(	O
29	O
%	O
)	O
had	O
stable	O
disease	O
as	O
the	O
best	O
response	O
.	O

The	O
study	O
was	O
stopped	O
early	O
due	O
to	O
progression	O
of	O
the	O
disease	O
in	O
12	O
patients	O
(	O
48	O
%	O
)	O
.	O

A	O
total	O
of	O
24	O
patients	O
(	O
85	O
%	O
)	O
were	O
off	O
study	O
before	O
the	O
planned	O
treatment	O
schedule	O
for	O
radiation	O
therapy	O
.	O

R115777	O
administered	O
prior	O
to	O
radiation	O
therapy	O
in	O
patients	O
with	O
newly	O
diagnosed	O
GBM	B
and	O
residual	O
enhancing	O
disease	O
did	O
not	O
result	O
in	O
any	O
measurable	O
responses	O
or	O
improvement	O
in	O
survival	O
.	O

R115777	O
administered	O
prior	O
to	O
radiation	O
therapy	O
is	O
not	O
recommended	O
for	O
patients	O
with	O
newly	O
diagnosed	O
GBM	B
.	O

Effect	O
of	O
calpain	O
and	O
proteasome	O
inhibition	O
on	O
Ca2	O
+	O
-	O
dependent	O
proteolysis	O
and	O
muscle	O
histopathology	O
in	O
the	O
mdx	O
mouse	O
.	O

Dystrophin	O
deficiency	O
is	O
the	O
underlying	O
molecular	O
cause	O
of	O
progressive	B
muscle	I
weakness	I
observed	O
in	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Loss	O
of	O
functional	O
dystrophin	O
leads	O
to	O
elevated	O
levels	O
of	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
,	O
a	O
key	O
step	O
in	O
the	O
cellular	O
pathology	O
of	O
DMD	B
.	O

The	O
cysteine	O
protease	O
calpain	O
is	O
activated	O
in	O
dystrophin	O
-	O
deficient	O
muscle	O
,	O
and	O
its	O
inhibition	O
is	O
regarded	O
as	O
a	O
potential	O
therapeutic	O
approach	O
.	O

In	O
addition	O
,	O
previous	O
work	O
has	O
shown	O
that	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
also	O
contributes	O
to	O
muscle	O
protein	O
breakdown	O
in	O
dystrophic	O
muscle	O
and	O
,	O
therefore	O
,	O
also	O
qualifies	O
as	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
DMD	B
.	O

The	O
relative	O
contribution	O
of	O
calpain	O
-	O
and	O
proteasome	O
-	O
mediated	O
proteolysis	O
induced	O
by	O
increased	O
Ca	O
(	O
2	O
+	O
)	O
levels	O
was	O
characterized	O
in	O
cultured	O
muscle	O
cells	O
and	O
revealed	O
initial	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
-	O
dependent	O
calpain	O
activity	O
and	O
subsequent	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
activity	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
.	O

We	O
then	O
set	O
out	O
to	O
optimize	O
novel	O
small	O
-	O
molecule	O
inhibitors	O
that	O
inhibit	O
both	O
calpain	O
as	O
well	O
as	O
the	O
20S	O
proteasome	O
in	O
a	O
cellular	O
system	O
with	O
impaired	O
Ca	O
(	O
2	O
+	O
)	O
homeostasis	O
.	O

On	O
administration	O
of	O
such	O
inhibitors	O
to	O
mdx	O
mice	O
,	O
quantitative	O
histological	O
parameters	O
improved	O
significantly	O
,	O
in	O
particular	O
with	O
compounds	O
strongly	O
inhibiting	O
the	O
20S	O
proteasome	O
.	O

To	O
investigate	O
the	O
role	O
of	O
calpain	O
inhibition	O
without	O
interfering	O
with	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
,	O
we	O
crossed	O
mdx	O
mice	O
with	O
transgenic	O
mice	O
,	O
overexpressing	O
the	O
endogenous	O
calpain	O
inhibitor	O
calpastatin	O
.	O

Although	O
our	O
data	O
show	O
that	O
proteolysis	O
by	O
calpain	O
is	O
strongly	O
inhibited	O
in	O
the	O
transgenic	O
mdx	O
mouse	O
,	O
this	O
calpain	O
inhibition	O
did	O
not	O
ameliorate	O
muscle	O
histology	O
.	O

Our	O
results	O
indicate	O
that	O
inhibition	O
of	O
the	O
proteasome	O
rather	O
than	O
calpain	O
is	O
required	O
for	O
histological	O
improvement	O
of	O
dystrophin	O
-	O
deficient	O
muscle	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
novel	O
proteasome	O
inhibitors	O
that	O
qualify	O
as	O
potential	O
candidates	O
for	O
pharmacological	O
intervention	O
in	O
muscular	B
dystrophy	I
.	O

Effects	O
of	O
in	O
vitro	O
brevetoxin	O
exposure	O
on	O
apoptosis	O
and	O
cellular	O
metabolism	O
in	O
a	O
leukemic	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
.	O

Harmful	O
algal	O
blooms	O
(	O
HABs	O
)	O
of	O
the	O
toxic	O
dinoflagellate	O
,	O
Karenia	O
brevis	O
,	O
produce	O
red	O
tide	O
toxins	O
,	O
or	O
brevetoxins	O
.	O

Significant	O
health	O
effects	O
associated	O
with	O
red	O
tide	O
toxin	O
exposure	O
have	O
been	O
reported	O
in	O
sea	O
life	O
and	O
in	O
humans	O
,	O
with	O
brevetoxins	O
documented	O
within	O
immune	O
cells	O
from	O
many	O
species	O
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
investigate	O
potential	O
immunotoxic	O
effects	O
of	O
brevetoxins	O
using	O
a	O
leukemic	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
as	O
an	O
in	O
vitro	O
model	O
system	O
.	O

Viability	O
,	O
cell	O
proliferation	O
,	O
and	O
apoptosis	O
assays	O
were	O
conducted	O
using	O
brevetoxin	O
congeners	O
PbTx	O
-	O
2	O
,	O
PbTx	O
-	O
3	O
,	O
and	O
PbTx	O
-	O
6	O
.	O

The	O
effects	O
of	O
in	O
vitro	O
brevetoxin	O
exposure	O
on	O
cell	O
viability	O
and	O
cellular	O
metabolism	O
or	O
proliferation	O
were	O
determined	O
using	O
trypan	O
blue	O
and	O
MTT	O
(	O
1	O
-	O
(	O
4,5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
3,5	O
-	O
diphenylformazan	O
)	O
,	O
respectively	O
.	O

Using	O
MTT	O
,	O
cellular	O
metabolic	O
activity	O
was	O
decreased	O
in	O
Jurkat	O
cells	O
exposed	O
to	O
5	O
-	O
10	O
microg	O
/	O
ml	O
PbTx	O
-	O
2	O
or	O
PbTx	O
-	O
6	O
.	O

After	O
3	O
h	O
,	O
no	O
significant	O
effects	O
on	O
cell	O
viability	O
were	O
observed	O
with	O
any	O
toxin	O
congener	O
in	O
concentrations	O
up	O
to	O
10	O
microg	O
/	O
ml	O
.	O

Viability	O
decreased	O
dramatically	O
after	O
24	O
h	O
in	O
cells	O
treated	O
with	O
PbTx	O
-	O
2	O
or	O
-	O
6	O
.	O

Apoptosis	O
,	O
as	O
measured	O
by	O
caspase	O
-	O
3	O
activity	O
,	O
was	O
significantly	O
increased	O
in	O
cells	O
exposed	O
to	O
PbTx	O
-	O
2	O
or	O
PbTx	O
-	O
6	O
.	O

In	O
summary	O
,	O
brevetoxin	O
congeners	O
varied	O
in	O
effects	O
on	O
Jurkat	O
cells	O
,	O
with	O
PbTx	O
-	O
2	O
and	O
PbTx	O
-	O
6	O
eliciting	O
greater	O
cellular	O
effects	O
compared	O
to	O
PbTx	O
-	O
3	O
.	O

Influence	O
of	O
valproic	O
acid	O
on	O
outcome	O
of	O
high	O
-	O
grade	O
gliomas	O
in	O
children	O
.	O

BACKGROUND	O
:	O
Chemotherapy	O
has	O
limited	O
effects	O
in	O
the	O
treatment	O
of	O
high	O
-	O
grade	O
gliomas	B
(	O
HGGs	B
)	O
.	O

Valproic	O
acid	O
(	O
VPA	O
)	O
,	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
,	O
may	O
sensitize	O
HGGs	O
to	O
radiochemotherapy	O
.	O

As	O
the	O
drug	O
has	O
been	O
given	O
frequently	O
as	O
an	O
antiepileptic	O
drug	O
,	O
a	O
retrospective	O
analysis	O
was	O
conducted	O
to	O
ensure	O
relevant	O
information	O
was	O
not	O
missed	O
before	O
a	O
prospective	O
study	O
was	O
launched	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
An	O
analysis	O
of	O
66	O
pediatric	O
patients	O
(	O
range	O
,	O
1	O
-	O
19	O
years	O
of	O
age	O
)	O
with	O
glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
(	O
n	O
=	O
40	O
)	O
or	O
anaplastic	B
astrocytoma	I
(	O
AA	B
)	O
(	O
n	O
=	O
26	O
)	O
was	O
retrospectively	O
conducted	O
for	O
predictors	O
of	O
survival	O
and	O
response	O
and	O
for	O
effects	O
of	O
VPA	O
on	O
outcome	O
or	O
toxicity	O
.	O

RESULTS	O
:	O
The	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
better	O
for	O
AA	B
(	O
p	O
=	O
0.0114	O
)	O
and	O
complete	O
resection	O
(	O
p	O
<	O
0.00005	O
)	O
and	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
was	O
better	O
for	O
complete	O
resection	O
(	O
p	O
=	O
0.0049	O
)	O
.	O

Nine	O
patients	O
received	O
VPA	O
(	O
for	O
seizure	B
)	O
plus	O
further	O
oncological	O
treatment	O
.	O

The	O
most	O
severe	O
adverse	O
effect	O
was	O
a	O
pulmonary	B
embolism	I
(	O
n	O
=	O
1	O
)	O
;	O
no	O
other	O
severe	O
side	O
-	O
effects	O
were	O
noted	O
.	O

The	O
response	O
to	O
nonsurgical	O
treatment	O
after	O
8	O
weeks	O
was	O
:	O
complete	O
response	O
(	O
CR	O
)	O
:	O
0	O
,	O
partial	O
response	O
(	O
PR	O
)	O
:	O
3	O
,	O
stable	O
disease	O
(	O
SD	O
)	O
:	O
4	O
,	O
progressive	O
disease	O
(	O
PD	O
)	O
:	O
2	O
.	O

Some	O
of	O
the	O
patients	O
with	O
SD	O
responded	O
later	O
resulting	O
in	O
best	O
response	O
:	O
CR	O
:	O
0	O
,	O
PR	O
:	O
5	O
,	O
SD	O
:	O
2	O
,	O
PD	O
:	O
2	O
.	O

CONCLUSION	O
:	O
Treatment	O
with	O
VPA	O
plus	O
radiochemotherapy	O
is	O
well	O
tolerated	O
with	O
an	O
encouraging	O
response	O
rate	O
.	O

Tacrolimus	O
for	O
the	O
treatment	O
of	O
systemic	B
lupus	I
erythematosus	I
with	O
pure	O
class	O
V	O
nephritis	B
.	O

OBJECTIVES	O
:	O
The	O
treatment	O
of	O
pure	O
membranous	O
(	O
class	O
V	O
)	O
lupus	B
nephropathy	I
remains	O
unsatisfactory	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
tacrolimus	O
in	O
the	O
treatment	O
of	O
membranous	B
nephritis	I
secondary	O
to	O
SLE	B
.	O

METHODS	O
:	O
We	O
recruited	O
18	O
consecutive	O
SLE	B
patients	O
(	O
tacrolimus	O
group	O
)	O
with	O
recently	O
confirmed	O
biopsy	O
-	O
proven	O
class	O
V	O
lupus	B
nephritis	I
.	O

They	O
were	O
treated	O
with	O
a	O
tailing	O
dose	O
of	O
oral	O
prednisolone	O
and	O
tacrolimus	O
0.1	O
-	O
0.2	O
mg	O
/	O
kg	O
/	O
day	O
for	O
6	O
months	O
,	O
followed	O
by	O
maintenance	O
prednisolone	O
and	O
AZA	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
proteinuria	B
and	O
SLEDAI	O
were	O
compared	O
with	O
19	O
historical	O
controls	O
treated	O
with	O
oral	O
cyclophosphamide	O
or	O
AZA	O
(	O
control	O
group	O
)	O
.	O

All	O
patients	O
were	O
followed	O
for	O
12	O
months	O
.	O

RESULTS	O
:	O
Baseline	O
clinical	O
characteristics	O
were	O
comparable	O
between	O
the	O
groups	O
.	O

For	O
the	O
tacrolimus	O
group	O
,	O
the	O
complete	O
and	O
partial	O
remission	O
rates	O
were	O
27.8	O
and	O
50.0	O
%	O
,	O
respectively	O
at	O
12	O
weeks	O
;	O
for	O
the	O
control	O
group	O
,	O
they	O
were	O
15.8	O
and	O
47.4	O
%	O
,	O
respectively	O
(	O
overall	O
chi	O
-	O
square	O
test	O
,	O
P	O
=	O
0.5	O
)	O
.	O

However	O
,	O
tacrolimus	O
group	O
had	O
faster	O
resolution	O
of	O
proteinuria	B
than	O
the	O
control	O
group	O
by	O
the	O
general	O
linear	O
model	O
with	O
repeated	O
measures	O
(	O
P	O
=	O
0.032	O
)	O
.	O

At	O
12	O
weeks	O
,	O
proteinuria	B
was	O
reduced	O
by	O
76.2	O
+	O
/	O
-	O
17.0	O
%	O
for	O
the	O
tacrolimus	O
group	O
and	O
47.1	O
+	O
/	O
-	O
51.1	O
%	O
for	O
the	O
control	O
group	O
(	O
P	O
=	O
0.028	O
)	O
.	O

Serial	O
change	O
in	O
renal	O
function	O
and	O
SLEDAI	O
score	O
did	O
not	O
differ	O
between	O
the	O
groups	O
.	O

During	O
the	O
study	O
period	O
,	O
four	O
patients	O
of	O
the	O
tacrolimus	O
group	O
,	O
and	O
11	O
of	O
the	O
control	O
group	O
,	O
developed	O
lupus	B
flare	I
(	O
P	O
=	O
0.027	O
)	O
.	O

There	O
was	O
no	O
serious	O
adverse	O
effect	O
in	O
the	O
tacrolimus	O
group	O
.	O

CONCLUSIONS	O
:	O
A	O
6	O
-	O
month	O
course	O
of	O
tacrolimus	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
of	O
pure	O
class	O
V	O
(	O
membranous	O
)	O
lupus	B
nephritis	I
.	O

As	O
compared	O
with	O
conventional	O
cytotoxic	O
treatment	O
,	O
tacrolimus	O
possibly	O
results	O
in	O
a	O
faster	O
resolution	O
of	O
proteinuria	B
,	O
and	O
a	O
lower	O
risk	O
of	O
lupus	B
flare	I
within	O
1	O
yr	O
.	O

The	O
long	O
-	O
term	O
effect	O
and	O
optimal	O
regimen	O
of	O
tacrolimus	O
require	O
further	O
study	O
.	O

7	O
-	O
Deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
as	O
subversive	O
substrate	O
of	O
Toxoplasma	O
gondii	O
adenosine	O
kinase	O
:	O
activities	O
and	O
selective	O
toxicities	O
.	O

Toxoplasma	O
gondii	O
adenosine	O
kinase	O
(	O
EC	O
.2	O
.7	O
.1	O
.20	O
)	O
is	O
the	O
major	O
route	O
of	O
adenosine	O
metabolism	O
in	O
this	O
parasite	O
.	O

The	O
enzyme	O
is	O
significantly	O
more	O
active	O
than	O
any	O
other	O
enzyme	O
of	O
the	O
purine	O
salvage	O
in	O
T	O
.	O

gondii	O
and	O
has	O
been	O
established	O
as	O
a	O
potential	O
chemotherapeutic	O
target	O
for	O
the	O
treatment	O
of	O
toxoplasmosis	B
.	O

Certain	O
6	O
-	O
benzylthioinosines	O
act	O
as	O
subversive	O
substrates	O
of	O
T	O
.	O

gondii	O
,	O
but	O
not	O
human	O
,	O
adenosine	O
kinase	O
.	O

Therefore	O
,	O
these	O
compounds	O
are	O
preferentially	O
metabolized	O
to	O
their	O
respective	O
nucleotides	O
and	O
become	O
selectively	O
toxic	O
against	O
the	O
parasites	O
but	O
not	O
their	O
host	O
.	O

Moreover	O
,	O
7	O
-	O
deazaadenosine	O
(	O
tubercidin	O
)	O
was	O
shown	O
to	O
be	O
an	O
excellent	O
ligand	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

Therefore	O
,	O
we	O
synthesized	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
,	O
and	O
analogues	O
with	O
various	O
substitutions	O
at	O
their	O
phenyl	O
ring	O
,	O
to	O
increase	O
the	O
binding	O
affinity	O
of	O
the	O
6	O
-	O
benzylthioinosines	O
to	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

Indeed	O
,	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
were	O
better	O
ligands	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
than	O
the	O
parent	O
compounds	O
,	O
6	O
-	O
benzylthioinosine	O
and	O
7	O
-	O
deazainosine	O
.	O

Herein	O
,	O
we	O
report	O
the	O
testing	O
of	O
the	O
metabolism	O
of	O
these	O
newly	O
synthesized	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosines	O
,	O
as	O
well	O
as	O
their	O
efficacy	O
as	O
anti	O
-	O
toxoplasmic	O
agents	O
in	O
cell	O
culture	O
.	O

All	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
were	O
metabolized	O
to	O
their	O
5	O
'	O
-	O
monophosphate	O
derivatives	O
,	O
albeit	O
to	O
different	O
degrees	O
.	O

These	O
results	O
indicate	O
that	O
these	O
compounds	O
are	O
not	O
only	O
ligands	O
but	O
also	O
substrates	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

All	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
showed	O
a	O
selective	O
antitoxoplasmic	O
effect	O
against	O
wild	O
type	O
parasites	O
,	O
but	O
not	O
mutants	O
lacking	O
adenosine	O
kinase	O
.	O

The	O
efficacy	O
of	O
these	O
compounds	O
varied	O
with	O
the	O
position	O
and	O
nature	O
of	O
the	O
substitution	O
on	O
their	O
phenyl	O
ring	O
.	O

Moreover	O
,	O
none	O
of	O
these	O
analogues	O
exhibited	O
host	O
toxicity	O
.	O

The	O
best	O
compounds	O
were	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
methoxybenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
4.6	O
microM	O
)	O
,	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
methoxycarbonylbenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
5.0	O
microM	O
)	O
,	O
and	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
cyanobenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
5.3	O
microM	O
)	O
.	O

These	O
results	O
further	O
confirm	O
that	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
is	O
an	O
excellent	O
target	O
for	O
chemotherapy	O
and	O
that	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosines	O
are	O
potential	O
antitoxoplasmic	O
agents	O
.	O

INN	O
-	O
toxin	O
,	O
a	O
highly	O
lethal	O
peptide	O
from	O
the	O
venom	O
of	O
Indian	O
cobra	O
(	O
Naja	O
naja	O
)	O
venom	O
-	O
Isolation	O
,	O
characterization	O
and	O
pharmacological	O
actions	O
.	O

A	O
novel	O
toxic	O
polypeptide	O
,	O
INN	O
-	O
toxin	O
,	O
is	O
purified	O
from	O
the	O
venom	O
of	O
Naja	O
naja	O
using	O
combination	O
of	O
gel	O
-	O
permeation	O
and	O
ion	O
-	O
exchange	O
chromatography	O
.	O

It	O
has	O
a	O
molecular	O
mass	O
of	O
6951.6	O
Da	O
as	O
determined	O
by	O
MALDI	O
-	O
TOF	O
/	O
MS	O
and	O
the	O
N	O
-	O
terminal	O
sequence	O
of	O
LKXNKLVPLF	O
.	O

It	O
showed	O
both	O
neurotoxic	O
as	O
well	O
as	O
cytotoxic	B
activities	I
.	O

INN	O
-	O
toxin	O
is	O
lethal	O
to	O
mice	O
with	O
a	O
LD	O
(	O
50	O
)	O
of	O
1.2	O
mg	O
/	O
kg	O
body	O
weight	O
.	O

IgY	O
raised	O
in	O
chicks	O
against	O
basic	O
peptide	O
pool	O
neutralized	O
the	O
toxicity	O
of	O
INN	O
-	O
toxin	O
.	O

INN	O
-	O
toxin	O
did	O
not	O
inhibit	O
cholinesterase	O
activity	O
.	O

It	O
is	O
toxic	O
to	O
Ehrlich	O
ascites	O
tumor	O
(	O
EAT	O
)	O
cells	O
,	O
but	O
it	O
is	O
not	O
toxic	O
to	O
leukocyte	O
culture	O
.	O

The	O
toxin	O
appears	O
to	O
be	O
specific	O
in	O
its	O
mode	O
of	O
action	O
.	O

Interaction	O
of	O
N	O
-	O
bromosuccinamide	O
(	O
NBS	O
)	O
with	O
the	O
peptide	O
resulted	O
in	O
the	O
modification	O
of	O
tryptophan	O
residues	O
and	O
loss	O
of	O
lethal	O
toxicity	O
of	O
INN	O
-	O
toxin	O
.	O

Role	O
and	O
relevance	O
of	O
PEPT2	O
in	O
drug	O
disposition	O
,	O
dynamics	O
,	O
and	O
toxicity	O
.	O

Pept2	O
knockout	O
mice	O
are	O
an	O
important	O
tool	O
to	O
evaluate	O
the	O
evolving	O
role	O
and	O
relevance	O
of	O
this	O
proton	O
-	O
coupled	O
oligopeptide	O
transporter	O
beyond	O
drug	O
disposition	O
,	O
where	O
the	O
transporter	O
also	O
modulates	O
the	O
pharmacodynamic	O
and	O
toxicodynamic	O
effects	O
of	O
drug	O
substrates	O
.	O

Our	O
in	O
vivo	O
studies	O
with	O
glycylsarcosine	O
in	O
Pept2	O
knockout	O
mice	O
have	O
established	O
""""	O
proof	O
of	O
concept	O
""""	O
that	O
PEPT2	O
can	O
have	O
a	O
significant	O
effect	O
on	O
dipeptide	O
disposition	O
.	O

Subsequent	O
studies	O
with	O
the	O
aminocephalosporin	O
antibiotic	O
cefadroxil	O
have	O
shown	O
relevance	O
to	O
pharmacology	O
and	O
infectious	O
disease	O
.	O

Finally	O
,	O
studies	O
with	O
the	O
endogenous	O
peptidomimetic	O
5	O
-	O
aminolevulinic	O
acid	O
have	O
demonstrated	O
relevance	O
to	O
toxicology	O
in	O
the	O
framework	O
of	O
porphyria	O
-	O
and	O
lead	O
-	O
induced	O
neurotoxicity	B
.	O

These	O
studies	O
have	O
consistently	O
demonstrated	O
the	O
dual	O
action	O
of	O
PEPT2	O
with	O
respect	O
to	O
its	O
apical	O
localization	O
in	O
choroid	O
plexus	O
epithelium	O
and	O
kidney	O
in	O
:	O
1	O
)	O
effluxing	O
substrates	O
from	O
CSF	O
into	O
choroid	O
plexus	O
,	O
thereby	O
affecting	O
regional	O
pharmacokinetics	O
in	O
brain	O
;	O
and	O
2	O
)	O
reabsorbing	O
substrates	O
from	O
renal	O
tubular	O
fluid	O
into	O
proximal	O
tubules	O
,	O
thereby	O
affecting	O
systemic	O
pharmacokinetics	O
and	O
exposure	O
.	O

Moreover	O
,	O
these	O
studies	O
have	O
shown	O
that	O
the	O
regional	O
effect	O
of	O
PEPT2	O
in	O
limiting	O
substrate	O
concentrations	O
in	O
the	O
CSF	O
is	O
more	O
dramatic	O
than	O
its	O
effect	O
in	O
increasing	O
systemic	O
exposure	O
.	O

In	O
the	O
case	O
of	O
5	O
-	O
aminolevulinic	O
acid	O
,	O
such	O
regional	O
modulation	O
of	O
drug	O
disposition	O
translates	O
directly	O
into	O
significant	O
changes	O
in	O
neurotoxicity	B
.	O

Amiodarone	O
pulmonary	B
toxicity	I
after	O
lung	O
transplantation	O
.	O

Atrial	B
fibrillation	I
occurs	O
frequently	O
after	O
lung	O
transplantation	O
and	O
is	O
commonly	O
treated	O
with	O
amiodarone	O
.	O

Pulmonary	B
toxicity	I
may	O
result	O
from	O
amiodarone	O
exposure	O
and	O
is	O
characterized	O
by	O
non	O
-	O
specific	O
respiratory	O
manifestations	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
reports	O
of	O
this	O
complication	O
occurring	O
after	O
lung	O
transplantation	O
.	O

We	O
present	O
a	O
patient	O
who	O
developed	O
radiologic	O
evidence	O
of	O
amiodarone	O
deposition	O
in	O
the	O
lungs	O
after	O
bilateral	O
lung	O
transplantation	O
.	O

The	O
phenomenology	O
of	O
the	O
psychotic	O
break	O
and	O
Huxley	O
's	O
trip	O
:	O
substance	O
use	O
and	O
the	O
onset	O
of	O
psychosis	B
.	O

BACKGROUND	O
:	O
While	O
considerable	O
research	O
attention	O
has	O
been	O
devoted	O
to	O
the	O
causal	O
relationship	O
between	O
substance	O
use	O
and	O
psychosis	B
,	O
the	O
phenomenology	O
of	O
the	O
association	O
between	O
the	O
two	O
has	O
largely	O
been	O
ignored	O
.	O

This	O
is	O
a	O
significant	O
shortcoming	O
,	O
because	O
it	O
blinds	O
researchers	O
to	O
the	O
possibility	O
that	O
there	O
may	O
be	O
elements	O
of	O
the	O
subjective	O
experience	O
of	O
substance	O
use	O
and	O
psychosis	B
that	O
contribute	O
to	O
their	O
apparent	O
relationship	O
in	O
empirical	O
studies	O
.	O

SAMPLING	O
AND	O
METHODS	O
:	O
The	O
current	O
paper	O
examines	O
the	O
phenomenology	O
of	O
the	O
onset	O
of	O
psychosis	B
and	O
the	O
phenomenology	O
of	O
substance	O
intoxication	O
through	O
consideration	O
of	O
two	O
texts	O
:	O
Sass	O
's	O
account	O
of	O
the	O
phenomenology	O
of	O
psychosis	B
onset	O
and	O
Huxley	O
's	O
account	O
of	O
the	O
experience	O
of	O
hallucinogenic	B
intoxication	I
.	O

Sass	O
's	O
account	O
of	O
psychosis	B
onset	O
includes	O
four	O
components	O
:	O
Unreality	O
,	O
Fragmentation	O
,	O
Mere	O
Being	O
,	O
and	O
Apophany	O
.	O

RESULTS	O
:	O
The	O
analysis	O
reveals	O
significant	O
parallels	O
-	O
and	O
also	O
some	O
differences	O
-	O
between	O
this	O
account	O
and	O
the	O
phenomenology	O
of	O
substance	O
intoxication	O
.	O

CONCLUSIONS	O
:	O
We	O
discuss	O
the	O
implications	O
of	O
this	O
for	O
the	O
causal	O
relationship	O
between	O
psychosis	B
and	O
substance	O
use	O
and	O
suggest	O
several	O
ways	O
of	O
understanding	O
the	O
overlapping	O
phenomenologies	O
.	O

This	O
includes	O
the	O
suggestion	O
of	O
a	O
shared	O
factor	O
,	O
perhaps	O
best	O
described	O
as	O
psychotic	O
-	O
like	O
experience	O
,	O
which	O
seems	O
to	O
involve	O
a	O
breakdown	O
of	O
the	O
sign	O
-	O
referent	O
relationship	O
and	O
relationship	O
with	O
the	O
common	O
-	O
sense	O
,	O
practical	O
world	O
.	O

However	O
,	O
in	O
the	O
onset	O
of	O
psychosis	B
,	O
this	O
breakdown	O
is	O
primarily	O
experienced	O
as	O
a	O
sense	O
of	O
alienation	O
from	O
self	O
and	O
world	O
,	O
whereas	O
in	O
the	O
hallucinogenic	O
state	O
a	O
sense	O
of	O
mystical	O
union	O
and	O
revelation	O
seems	O
predominant	O
.	O

Further	O
research	O
may	O
extend	O
this	O
analysis	O
by	O
looking	O
at	O
experiences	O
with	O
other	O
drugs	O
,	O
particularly	O
cannabis	O
,	O
and	O
by	O
examining	O
the	O
phenomenology	O
of	O
psychotic	B
disorder	I
beyond	O
the	O
first	O
episode	O
.	O

Phase	O
I	O
study	O
of	O
capecitabine	O
in	O
combination	O
with	O
cisplatin	O
and	O
irinotecan	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

PURPOSE	O
:	O
This	O
phase	O
I	O
trial	O
assessed	O
the	O
safety	O
and	O
the	O
maximum	O
tolerated	O
dose	O
of	O
capecitabine	O
given	O
for	O
10	O
days	O
prior	O
to	O
a	O
combination	O
of	O
cisplatin	O
and	O
irinotecan	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

It	O
also	O
evaluated	O
the	O
changes	O
in	O
cisplatin	O
DNA	O
adducts	O
induced	O
by	O
capecitabine	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
refractory	O
solid	O
tumors	O
who	O
had	O
not	O
failed	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
analogs	O
or	O
topoisomerase	O
I	O
inhibitors	O
were	O
eligible	O
.	O

All	O
cohorts	O
of	O
patients	O
first	O
received	O
a	O
28	O
-	O
day	O
cycle	O
of	O
cisplatin	O
and	O
irinotecan	O
.	O

Both	O
drugs	O
were	O
given	O
at	O
a	O
dose	O
of	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
day	O
1	O
,	O
followed	O
by	O
irinotecan	O
on	O
days	O
8	O
and	O
15	O
at	O
the	O
same	O
dose	O
.	O

The	O
first	O
cycle	O
served	O
as	O
an	O
internal	O
control	O
.	O

Starting	O
from	O
the	O
second	O
cycle	O
,	O
patients	O
received	O
increasing	O
doses	O
per	O
cohort	O
of	O
capecitabine	O
from	O
day	O
1	O
to	O
10	O
of	O
each	O
cycle	O
,	O
followed	O
by	O
cisplatin	O
on	O
day	O
11	O
and	O
irinotecan	O
on	O
days	O
11	O
,	O
18	O
and	O
25	O
,	O
both	O
at	O
same	O
doses	O
as	O
the	O
first	O
cycle	O
.	O

Cycles	O
were	O
repeated	O
every	O
38	O
days	O
.	O

The	O
starting	O
dose	O
of	O
capecitabine	O
was	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
which	O
was	O
escalated	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
the	O
subsequent	O
cohort	O
of	O
patients	O
to	O
reach	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O

Later	O
,	O
additional	O
patients	O
were	O
treated	O
at	O
the	O
MTD	O
of	O
capecitabine	O
to	O
further	O
evaluate	O
the	O
safety	O
,	O
pharmacodynamics	O
,	O
and	O
tumor	O
response	O
.	O

Patients	O
blood	O
was	O
tested	O
for	O
cisplatin	O
-	O
DNA	O
adducts	O
to	O
determine	O
the	O
impact	O
of	O
capecitabine	O
on	O
cisplatin	O
-	O
based	O
therapy	O
.	O

RESULTS	O
:	O
Fifteen	O
patients	O
received	O
at	O
least	O
2	O
cycles	O
of	O
treatment	O
.	O

At	O
1,250	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
two	O
DLT	O
of	O
prolonged	O
neutropenia	B
of	O
grade	O
>	O
or	O
=	O
3	O
were	O
observed	O
.	O

The	O
MTD	O
for	O
capecitabine	O
was	O
thus	O
determined	O
to	O
be	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O

Fatigue	B
and	O
diarrhea	B
of	O
grade	O
1	O
or	O
2	O
were	O
the	O
most	O
frequent	O
toxicities	O
at	O
this	O
dose	O
level	O
.	O

No	O
significant	O
hematologic	B
toxicity	I
was	O
observed	O
at	O
the	O
MTD	O
.	O

Two	O
complete	O
and	O
three	O
partial	O
remissions	O
were	O
observed	O
.	O

Four	O
of	O
the	O
responders	O
had	O
received	O
a	O
platinum	O
agent	O
and	O
/	O
or	O
5	O
-	O
FU	O
in	O
the	O
past	O
.	O

CONCLUSIONS	O
:	O
A	O
sequential	O
treatment	O
with	O
capecitabine	O
followed	O
by	O
cisplatin	O
and	O
irinotecan	O
is	O
well	O
tolerated	O
and	O
demonstrates	O
clinical	O
activity	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

The	O
influence	O
of	O
capecitabine	O
,	O
if	O
any	O
,	O
on	O
the	O
efficacy	O
of	O
the	O
cisplatin	O
-	O
irinotecan	O
combination	O
is	O
not	O
related	O
to	O
a	O
variation	O
in	O
cisplatin	O
-	O
DNA	O
adducts	O
.	O

The	O
safety	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
among	O
patients	O
with	O
asthma	B
using	O
inhaled	O
corticosteroids	O
:	O
systematic	O
review	O
and	O
metaanalysis	O
.	O

RATIONALE	O
:	O
Inhaled	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
(	O
LABAs	O
)	O
,	O
when	O
used	O
as	O
monotherapy	O
in	O
asthma	B
,	O
may	O
increase	O
asthma	O
-	O
related	O
hospitalizations	O
,	O
life	O
threatening	O
events	O
requiring	O
intubation	O
/	O
mechanical	O
ventilation	O
,	O
and	O
asthma	O
-	O
related	O
deaths	O
,	O
but	O
concomitant	O
use	O
of	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
may	O
modify	O
this	O
effect	O
.	O

Objectives	O
:	O
To	O
determine	O
the	O
safety	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
among	O
patients	O
with	O
asthma	B
using	O
corticosteroids	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
systematic	O
review	O
and	O
metaanalysis	O
of	O
parallel	O
-	O
group	O
,	O
blinded	O
,	O
randomized	O
,	O
controlled	O
trials	O
with	O
at	O
least	O
12	O
weeks	O
of	O
treatment	O
addressing	O
the	O
impact	O
of	O
LABA	O
on	O
asthma	B
-	O
related	O
and	O
total	O
morbidity	O
and	O
mortality	O
in	O
patients	O
concomitantly	O
using	O
ICS	O
.	O

We	O
searched	O
MEDLINE	O
,	O
EMBASE	O
,	O
ACPJC	O
,	O
and	O
Cochrane	O
(	O
Central	O
)	O
databases	O
,	O
and	O
contacted	O
authors	O
and	O
sponsors	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
We	O
used	O
a	O
random	O
effects	O
model	O
to	O
pool	O
results	O
from	O
different	O
studies	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
)	O
(	O
OR	O
<	O
1.0	O
favors	O
LABA	O
)	O
.	O

The	O
search	O
yielded	O
62	O
relevant	O
studies	O
included	O
in	O
this	O
analysis	O
.	O

Among	O
over	O
29,000	O
participants	O
(	O
15,710	O
taking	O
LABA	O
,	O
with	O
over	O
8,000	O
patient	O
-	O
years	O
observed	O
in	O
the	O
LABA	O
groups	O
)	O
,	O
there	O
were	O
three	O
asthma	B
-	O
related	O
deaths	O
and	O
two	O
asthma	B
-	O
related	O
,	O
nonfatal	O
intubations	O
(	O
all	O
in	O
LABA	O
groups	O
;	O
<	O
or	O
=	O
one	O
event	O
per	O
study	O
)	O
.	O

Differences	O
in	O
asthma	O
-	O
related	O
hospitalizations	O
(	O
OR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.53	O
-	O
1.03	O
)	O
and	O
asthma	O
-	O
related	O
serious	O
adverse	O
events	O
(	O
mostly	O
hospitalizations	O
;	O
OR	O
,	O
0.75	O
;	O
95	O
%	O
CI	O
,	O
0.54	O
-	O
1.03	O
)	O
failed	O
to	O
reach	O
statistical	O
significance	O
.	O

The	O
OR	O
for	O
total	O
mortality	O
was	O
1.26	O
(	O
95	O
%	O
CI	O
,	O
0.58	O
-	O
2.74	O
)	O
,	O
reflecting	O
14	O
deaths	O
in	O
LABA	O
groups	O
and	O
eight	O
deaths	O
in	O
control	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
asthma	B
using	O
ICS	O
,	O
LABA	O
did	O
not	O
increase	O
the	O
risk	O
of	O
asthma	O
-	O
related	O
hospitalizations	O
.	O

There	O
were	O
very	O
few	O
asthma	O
-	O
related	O
deaths	O
and	O
intubations	O
,	O
and	O
events	O
were	O
too	O
infrequent	O
to	O
establish	O
LABA	O
's	O
relative	O
effect	O
on	O
these	O
outcomes	O
.	O

Adjuvant	O
treatment	O
with	O
vindesine	O
in	O
comparison	O
to	O
observation	O
alone	O
in	O
patients	O
with	O
metastasized	B
melanoma	I
after	O
complete	O
metastasectomy	O
:	O
a	O
randomized	O
multicenter	O
trial	O
of	O
the	O
German	O
Dermatologic	O
Cooperative	O
Oncology	O
Group	O
.	O

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
vindesine	O
in	O
patients	O
with	O
metastatic	B
melanoma	I
after	O
complete	O
metastasectomy	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
two	O
patients	O
with	O
metastatic	O
spread	O
to	O
regional	O
sites	O
,	O
lymph	O
nodes	O
,	O
and	O
distant	O
sites	O
after	O
complete	O
metastasectomy	O
were	O
randomized	O
to	O
receive	O
either	O
treatment	O
with	O
vindesine	O
for	O
2	O
years	O
or	O
observation	O
alone	O
.	O

Vindesine	O
3	O
mg	O
/	O
m	O
intravenously	O
was	O
administered	O
biweekly	O
for	O
the	O
first	O
26	O
weeks	O
following	O
3	O
-	O
week	O
intervals	O
for	O
an	O
additional	O
26	O
weeks	O
and	O
thereafter	O
every	O
4	O
weeks	O
for	O
52	O
weeks	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
were	O
eligible	O
for	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
46	O
months	O
.	O

Median	O
recurrence	O
free	O
survival	O
was	O
7.9	O
months	O
in	O
the	O
vindesine	O
group	O
and	O
7.6	O
months	O
in	O
the	O
observational	O
group	O
(	O
P	O
=	O
0.40	O
)	O
.	O

Three	O
-	O
year	O
overall	O
survival	O
rate	O
was	O
54.9	O
%	O
(	O
37	O
patients	O
)	O
for	O
patients	O
receiving	O
vindesine	O
in	O
comparison	O
to	O
43.6	O
%	O
(	O
31	O
patients	O
)	O
in	O
the	O
observation	O
arm	O
(	O
P	O
=	O
0.07	O
)	O
.	O

No	O
grade	O
IV	O
toxicity	O
was	O
observed	O
.	O

The	O
two	O
major	O
side	O
effects	O
in	O
the	O
vindesine	O
group	O
were	O
alopecia	B
and	O
peripheral	B
neuropathy	I
.	O

Ten	O
patients	O
went	O
off	O
treatment	O
because	O
of	O
grade	O
III	O
toxicity	O
.	O

Adjuvant	O
treatment	O
with	O
vindesine	O
did	O
not	O
significantly	O
prolong	O
disease	O
free	O
or	O
overall	O
survival	O
in	O
high	O
-	O
risk	O
melanoma	B
patients	O
.	O

Thus	O
,	O
this	O
randomized	O
trial	O
did	O
not	O
confirm	O
earlier	O
reports	O
of	O
beneficial	O
effects	O
of	O
adjuvant	O
vindesine	O
and	O
can	O
therefore	O
not	O
be	O
recommended	O
.	O

Risk	O
assessment	O
of	O
khat	O
use	O
in	O
the	O
Netherlands	O
:	O
a	O
review	O
based	O
on	O
adverse	O
health	O
effects	O
,	O
prevalence	O
,	O
criminal	O
involvement	O
and	O
public	O
order	O
.	O

In	O
preparing	O
a	O
decision	O
about	O
the	O
legal	O
status	O
of	O
khat	O
in	O
the	O
Netherlands	O
,	O
the	O
Dutch	O
Minister	O
of	O
Health	O
requested	O
CAM	O
(	O
Coordination	O
point	O
Assessment	O
and	O
Monitoring	O
new	O
drugs	O
)	O
to	O
assess	O
the	O
overall	O
risk	O
of	O
khat	O
in	O
the	O
Netherlands	O
.	O

The	O
present	O
paper	O
is	O
a	O
redraft	O
of	O
a	O
report	O
which	O
formed	O
the	O
scientific	O
basis	O
of	O
the	O
risk	O
evaluation	O
procedure	O
(	O
October	O
2007	O
)	O
.	O

This	O
report	O
reviews	O
the	O
scientific	O
data	O
about	O
khat	O
available	O
in	O
the	O
international	O
literature	O
.	O

In	O
addition	O
,	O
the	O
report	O
contains	O
some	O
information	O
specific	O
for	O
the	O
Netherlands	O
(	O
prevalence	O
,	O
availability	O
of	O
khat	O
and	O
public	O
order	O
aspects	O
)	O
.	O

The	O
main	O
psychoactive	O
compounds	O
in	O
khat	O
leaves	O
are	O
cathine	O
and	O
cathinone	O
,	O
which	O
are	O
some	O
2	O
-	O
to	O
10	O
-	O
fold	O
less	O
active	O
than	O
amphetamine	O
.	O

Acute	O
health	O
problems	O
are	O
rarely	O
seen	O
,	O
and	O
are	O
usually	O
related	O
with	O
malnutrition	O
,	O
social	O
and	O
financial	O
problems	O
.	O

Khat	O
has	O
a	O
low	O
addictive	O
potential	O
.	O

Chronic	B
toxicity	I
of	O
khat	O
is	O
modest	O
when	O
used	O
in	O
low	O
amounts	O
,	O
whereas	O
at	O
high	O
levels	O
,	O
khat	O
use	O
is	O
associated	O
with	O
adverse	O
effects	O
,	O
like	O
hypertension	B
,	O
heart	B
rhythm	I
disorders	I
,	O
insomnia	B
and	O
loss	B
of	I
appetite	I
.	O

In	O
addition	O
,	O
khat	O
users	O
show	O
a	O
higher	O
prevalence	O
of	O
cancers	B
in	O
the	O
digestive	O
tract	O
.	O

At	O
population	O
level	O
,	O
khat	O
does	O
not	O
lead	O
to	O
specific	O
health	O
risks	O
in	O
the	O
Netherlands	O
,	O
as	O
its	O
use	O
is	O
confined	O
to	O
East	O
-	O
African	O
immigrants	O
.	O

A	O
relationship	O
between	O
khat	O
use	O
and	O
psychiatric	O
disorders	O
has	O
been	O
suggested	O
,	O
but	O
the	O
reports	O
are	O
contradictory	O
,	O
and	O
such	O
studies	O
are	O
presumably	O
heavily	O
confounded	O
by	O
posttraumatic	O
and	O
social	O
stress	O
.	O

In	O
the	O
Netherlands	O
(	O
and	O
other	O
countries	O
)	O
,	O
khat	O
use	O
occasionally	O
leads	O
to	O
minor	O
disturbance	O
of	O
civil	O
order	O
in	O
the	O
public	O
domain	O
(	O
loud	O
talking	O
,	O
spitting	O
)	O
,	O
but	O
is	O
not	O
related	O
to	O
criminal	O
activities	O
.	O

Following	O
the	O
assessment	O
,	O
CAM	O
estimated	O
the	O
overall	O
risk	O
potential	O
of	O
khat	O
use	O
in	O
the	O
Netherlands	O
as	O
very	O
low	O
.	O

A	O
similar	O
conclusion	O
may	O
be	O
drawn	O
for	O
countries	O
with	O
a	O
comparable	O
prevalence	O
of	O
khat	O
use	O
and	O
khat	O
related	O
public	O
order	O
disturbance	O
.	O

High	O
-	O
dose	O
methylprednisolone	O
in	O
a	O
pregnant	O
woman	O
with	O
Crohn	B
's	I
disease	I
and	O
adrenal	B
suppression	I
in	O
her	O
newborn	O
.	O

BACKGROUND	O
:	O
The	O
synthetic	O
corticosteroid	O
methylprednisolone	O
is	O
used	O
for	O
the	O
treatment	O
of	O
acute	O
exacerbations	O
of	O
Crohn	B
's	I
disease	I
,	O
also	O
in	O
pregnancy	O
.	O

Its	O
use	O
is	O
considered	O
to	O
be	O
less	O
harmful	O
than	O
the	O
effect	O
of	O
active	O
disease	O
on	O
the	O
fetus	O
.	O

Adrenal	B
suppression	I
in	O
a	O
fetus	O
due	O
to	O
administration	O
of	O
methylprednisolone	O
has	O
hitherto	O
been	O
rarely	O
published	O
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
neonatal	B
adrenal	I
suppression	I
due	O
to	O
the	O
use	O
of	O
high	O
-	O
dose	O
methylprednisolone	O
in	O
late	O
pregnancy	O
of	O
a	O
woman	O
with	O
Crohn	B
's	I
disease	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Clinical	O
signs	O
of	O
adrenal	B
suppression	I
were	O
observed	O
in	O
the	O
newborn	O
3	O
h	O
after	O
birth	O
.	O

After	O
hydrocortisone	O
supplementation	O
and	O
intensive	O
therapy	O
the	O
baby	O
recovered	O
completely	O
.	O

CONCLUSIONS	O
:	O
Life	O
-	O
threatening	O
adrenal	B
suppression	I
,	O
requiring	O
hydrocortisone	O
supplementation	O
and	O
intensive	O
therapy	O
,	O
was	O
observed	O
and	O
successfully	O
treated	O
in	O
a	O
newborn	O
,	O
whose	O
mother	O
had	O
received	O
high	O
-	O
dose	O
methylprednisolone	O
in	O
late	O
pregnancy	O
.	O

Effect	O
of	O
ranitidine	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
prasugrel	O
and	O
clopidogrel	O
.	O

OBJECTIVE	O
:	O
Clopidogrel	O
is	O
an	O
oral	O
thienopyridine	O
antiplatelet	O
agent	O
indicated	O
for	O
the	O
treatment	O
of	O
atherothrombotic	O
events	O
in	O
patients	O
with	O
acute	B
coronary	I
syndrome	I
(	O
ACS	O
)	O
.	O

Prasugrel	O
,	O
a	O
novel	O
oral	O
thienopyridine	O
,	O
is	O
under	O
investigation	O
for	O
the	O
reduction	O
of	O
atherothrombotic	O
events	O
in	O
patients	O
with	O
ACS	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
.	O

Prasugrel	O
's	O
solubility	O
decreases	O
with	O
increasing	O
pH	O
,	O
suggesting	O
that	O
concomitantly	O
-	O
administered	O
medications	O
that	O
increase	O
gastric	O
pH	O
may	O
lower	O
the	O
rate	O
and	O
/	O
or	O
extent	O
of	O
prasugrel	O
absorption	O
.	O

This	O
study	O
evaluated	O
the	O
influence	O
of	O
ranitidine	O
coadministration	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
the	O
respective	O
active	O
metabolite	O
of	O
prasugrel	O
and	O
clopidogrel	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
In	O
this	O
open	O
-	O
label	O
,	O
two	O
-	O
period	O
,	O
two	O
-	O
treatment	O
,	O
crossover	O
study	O
,	O
47	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
study	O
arms	O
,	O
receiving	O
either	O
prasugrel	O
(	O
60	O
-	O
mg	O
loading	O
dose	O
[	O
LD	O
]	O
,	O
10	O
-	O
mg	O
maintenance	O
dose	O
[	O
MD	O
]	O
for	O
7	O
days	O
;	O
n	O
=	O
23	O
)	O
or	O
clopidogrel	O
(	O
600	O
-	O
mg	O
LD	O
,	O
75	O
-	O
mg	O
MD	O
for	O
7	O
days	O
;	O
n	O
=	O
24	O
)	O
.	O

In	O
one	O
treatment	O
period	O
,	O
subjects	O
received	O
prasugrel	O
or	O
clopidogrel	O
alone	O
,	O
and	O
in	O
the	O
alternate	O
period	O
received	O
the	O
same	O
thienopyridine	O
with	O
ranitidine	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
starting	O
1	O
day	O
before	O
the	O
LD	O
)	O
.	O

Pharmacokinetic	O
parameter	O
estimates	O
(	O
AUC	O
(	O
0	O
-	O
t	O
last	O
)	O
,	O
C	O
(	O
max	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
)	O
and	O
inhibition	O
of	O
platelet	O
aggregation	O
(	O
IPA	O
)	O
by	O
light	O
transmission	O
aggregometry	O
were	O
assessed	O
at	O
multiple	O
time	O
points	O
after	O
the	O
LD	O
and	O
final	O
MD	O
.	O

RESULTS	O
:	O
Ranitidine	O
had	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
area	O
under	O
the	O
plasma	O
-	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
and	O
did	O
not	O
affect	O
the	O
time	O
to	O
C	O
(	O
max	O
)	O
(	O
t	O
(	O
max	O
)	O
)	O
for	O
active	O
metabolites	O
of	O
either	O
prasugrel	O
or	O
clopidogrel	O
.	O

It	O
reduced	O
the	O
geometric	O
mean	O
maximum	O
concentrations	O
of	O
active	O
metabolite	O
(	O
C	O
(	O
max	O
)	O
)	O
after	O
a	O
prasugrel	O
and	O
clopidogrel	O
LD	O
by	O
14	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
but	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

When	O
coadministered	O
with	O
a	O
60	O
-	O
mg	O
prasugrel	O
LD	O
,	O
ranitidine	O
did	O
not	O
affect	O
the	O
time	O
to	O
,	O
or	O
magnitude	O
of	O
,	O
peak	O
IPA	O
,	O
but	O
did	O
result	O
in	O
a	O
modest	O
reduction	O
at	O
0.5	O
h	O
from	O
67.4	O
to	O
55.1	O
%	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Ranitidine	O
did	O
not	O
affect	O
prasugrel	O
IPA	O
during	O
MD	O
.	O

For	O
clopidogrel	O
,	O
IPA	O
was	O
not	O
affected	O
by	O
ranitidine	O
.	O

Prasugrel	O
and	O
clopidogrel	O
were	O
both	O
well	O
-	O
tolerated	O
,	O
with	O
/	O
without	O
ranitidine	O
.	O

CONCLUSIONS	O
:	O
Results	O
from	O
this	O
study	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
drug	O
-	O
drug	O
interaction	B
between	O
oral	O
ranitidine	O
therapy	O
and	O
concomitantly	O
-	O
administered	O
prasugrel	O
or	O
clopidogrel	O
.	O

Dielectrophoretic	O
field	O
-	O
flow	O
fractionation	O
system	O
for	O
detection	O
of	O
aquatic	O
toxicants	O
.	O

Dielectrophoretic	O
field	O
-	O
flow	O
fractionation	O
(	O
dFFF	O
)	O
was	O
applied	O
as	O
a	O
contact	O
-	O
free	O
way	O
to	O
sense	O
changes	O
in	O
the	O
plasma	O
membrane	O
capacitances	O
and	O
conductivities	O
of	O
cultured	O
human	O
HL	O
-	O
60	O
cells	O
in	O
response	O
to	O
toxicant	O
exposure	O
.	O

A	O
micropatterned	O
electrode	O
imposed	O
electric	O
forces	O
on	O
cells	O
in	O
suspension	O
in	O
a	O
parabolic	O
flow	O
profile	O
as	O
they	O
moved	O
through	O
a	O
thin	O
chamber	O
.	O

Relative	O
changes	O
in	O
the	O
dFFF	O
peak	O
elution	O
time	O
,	O
reflecting	O
changes	O
in	O
cell	O
membrane	O
area	O
and	O
ion	O
permeability	O
,	O
were	O
measured	O
as	O
indices	O
of	O
response	O
during	O
the	O
first	O
150	O
min	O
of	O
exposure	O
to	O
eight	O
toxicants	O
having	O
different	O
single	O
or	O
mixed	O
modes	O
of	O
action	O
(	O
acrylonitrile	O
,	O
actinomycin	O
D	O
,	O
carbon	O
tetrachloride	O
,	O
endosulfan	O
,	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
(	O
NMU	O
)	O
,	O
paraquat	O
dichloride	O
,	O
puromycin	O
,	O
and	O
styrene	O
oxide	O
)	O
.	O

The	O
dFFF	O
method	O
was	O
compared	O
with	O
the	O
cell	O
viability	O
assay	O
for	O
all	O
toxicants	O
and	O
with	O
the	O
mitochondrial	O
potentiometric	O
dye	O
assay	O
or	O
DNA	O
alkaline	O
comet	O
assay	O
according	O
to	O
the	O
mode	O
of	O
action	O
of	O
the	O
specific	O
agents	O
.	O

Except	O
for	O
low	O
doses	O
of	O
nucleic	O
acid	O
-	O
targeting	O
agents	O
(	O
actinomycin	O
D	O
and	O
NMU	O
)	O
,	O
the	O
dFFF	O
method	O
detected	O
all	O
toxicants	O
more	O
sensitively	O
than	O
other	O
assays	O
,	O
in	O
some	O
cases	O
up	O
to	O
10	O
(	O
5	O
)	O
times	O
more	O
sensitively	O
than	O
the	O
viability	O
approach	O
.	O

The	O
results	O
suggest	O
the	O
dFFF	O
method	O
merits	O
additional	O
study	O
for	O
possible	O
applicability	O
in	O
toxicology	O
.	O

Hyperthermia	B
adds	O
to	O
chemotherapy	O
.	O

The	O
hallmarks	O
of	O
hyperthermia	B
and	O
its	O
pleotropic	O
effects	O
are	O
in	O
favour	O
of	O
its	O
combined	O
use	O
with	O
chemotherapy	O
.	O

Preclinical	O
research	O
reveals	O
that	O
for	O
heat	O
killing	O
and	O
synergistic	O
effects	O
the	O
thermal	O
dose	O
is	O
most	O
critical	O
.	O

Thermal	O
enhancement	O
of	O
drug	B
cytotoxicity	I
is	O
accompanied	O
by	O
cellular	O
death	O
and	O
necrosis	O
without	O
increasing	O
its	O
oncogenic	O
potential	O
.	O

The	O
induction	O
of	O
genetically	O
defined	O
stress	O
responses	O
can	O
deliver	O
danger	O
signals	O
to	O
activate	O
the	O
host	O
's	O
immune	O
system	O
.	O

The	O
positive	O
results	O
of	O
randomised	O
trials	O
have	O
definitely	O
established	O
hyperthermia	B
in	O
combination	O
with	O
chemotherapy	O
as	O
a	O
novel	O
clinical	O
modality	O
for	O
the	O
treatment	O
of	O
cancer	B
.	O

Hyperthermia	B
targets	O
the	O
action	O
of	O
chemotherapy	O
within	O
the	O
heated	O
tumour	B
region	O
without	O
affecting	O
systemic	B
toxicity	I
.	O

In	O
specific	O
clinical	O
settings	O
regional	B
hyperthermia	I
(	O
RHT	B
)	O
or	O
hyperthermic	O
perfusion	O
has	O
proved	O
its	O
value	O
and	O
deserve	O
a	O
greater	O
focus	O
and	O
investigation	O
in	O
other	O
malignancies	O
.	O

In	O
Europe	O
,	O
more	O
specialised	O
centres	O
should	O
be	O
created	O
and	O
maintained	O
as	O
network	O
of	O
excellence	O
for	O
hyperthermia	B
in	O
the	O
field	O
of	O
oncology	O
.	O

Multiple	O
-	O
pool	O
cell	O
lifespan	O
models	O
for	O
neutropenia	B
to	O
assess	O
the	O
population	O
pharmacodynamics	O
of	O
unbound	O
paclitaxel	O
from	O
two	O
formulations	O
in	O
cancer	B
patients	O
.	O

PURPOSE	O
:	O
Our	O
objective	O
was	O
to	O
build	O
a	O
mechanism	O
-	O
based	O
pharmacodynamic	O
model	O
for	O
the	O
time	O
course	O
of	O
neutropenia	B
in	O
cancer	B
patients	O
following	O
paclitaxel	O
treatment	O
with	O
a	O
tocopherol	O
-	O
based	O
Cremophor	O
-	O
free	O
formulation	O
(	O
Tocosol	O
Paclitaxel	O
)	O
and	O
Cremophor	O
EL	O
-	O
formulated	O
paclitaxel	O
(	O
Taxol	O
)	O
.	O

METHODS	O
:	O
A	O
randomized	O
two	O
-	O
way	O
crossover	O
trial	O
was	O
performed	O
with	O
35	O
adult	O
patients	O
who	O
received	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	O
as	O
either	O
15	O
min	O
(	O
Tocosol	O
Paclitaxel	O
)	O
or	O
3	O
h	O
(	O
Taxol	O
)	O
intravenous	O
infusions	O
.	O

Paclitaxel	O
concentrations	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O

NONMEM	O
VI	O
was	O
used	O
for	O
population	O
pharmacodynamics	O
.	O

RESULTS	O
:	O
The	O
cytotoxic	B
effect	I
on	O
neutrophils	O
was	O
described	O
by	O
four	O
mechanism	O
-	O
based	O
models	O
predicated	O
on	O
known	O
properties	O
of	O
paclitaxel	O
that	O
used	O
unbound	O
concentrations	O
in	O
the	O
central	O
,	O
deep	O
peripheral	O
or	O
an	O
intracellular	O
compartment	O
as	O
forcing	O
functions	O
.	O

Tocosol	O
Paclitaxel	O
was	O
estimated	O
to	O
release	O
9.8	O
%	O
of	O
the	O
dose	O
directly	O
into	O
the	O
deep	O
peripheral	O
compartment	O
(	O
DPC	O
)	O
.	O

All	O
models	O
provided	O
reasonable	O
fitting	O
of	O
neutropenic	O
effects	O
.	O

The	O
model	O
with	O
the	O
best	O
predictive	O
performance	O
assumed	O
that	O
this	O
dose	O
fraction	O
was	O
released	O
into	O
22.5	O
%	O
of	O
the	O
DPC	O
which	O
included	O
the	O
site	O
of	O
toxicity	O
.	O

The	O
second	O
-	O
order	O
cytotoxic	O
rate	O
constant	O
was	O
0.00211	O
mL	O
/	O
ng	O
per	O
hour	O
(	O
variability	O
:	O
52	O
%	O
CV	O
)	O
.	O

The	O
relative	O
exposure	O
at	O
the	O
site	O
of	O
toxicity	O
was	O
2.21	O
+	O
/	O
-	O
0.41	O
times	O
(	O
average	O
+	O
/	O
-	O
SD	O
)	O
larger	O
for	O
Tocosol	O
Paclitaxel	O
compared	O
to	O
Taxol	O
.	O

Lifespan	O
was	O
11.0	O
days	O
for	O
progenitor	O
cells	O
,	O
1.95	O
days	O
for	O
maturating	O
cells	O
,	O
and	O
4.38	O
days	O
for	O
neutrophils	O
.	O

Total	O
drug	O
exposure	O
in	O
blood	O
explained	O
half	O
of	O
the	O
variance	O
in	O
nadir	O
to	O
baseline	O
neutrophil	O
count	O
ratio	O
.	O

CONCLUSIONS	O
:	O
The	O
relative	O
exposure	O
of	O
unbound	O
paclitaxel	O
at	O
the	O
site	O
of	O
toxicity	O
was	O
twice	O
as	O
large	O
for	O
Tocosol	O
Paclitaxel	O
compared	O
to	O
Taxol	O
.	O

The	O
proposed	O
mechanism	O
-	O
based	O
models	O
explained	O
the	O
extent	O
and	O
time	O
course	O
of	O
neutropenia	B
jointly	O
for	O
both	O
formulations	O
.	O

Effect	O
of	O
ABCG2	O
on	O
cytotoxicity	B
of	O
platinum	O
drugs	O
:	O
interference	O
of	O
EGFP	O
.	O

ATP	O
-	O
binding	O
drug	O
efflux	O
transporters	O
decrease	O
intracellular	O
concentrations	O
of	O
cytotoxic	O
drugs	O
,	O
causing	O
multidrug	O
resistance	O
in	O
cancer	B
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
possible	O
interactions	O
of	O
ABCG2	O
transporter	O
with	O
platinum	O
cytotoxic	O
drugs	O
.	O

We	O
demonstrate	O
here	O
an	O
interference	O
of	O
platinum	O
drugs	O
with	O
enhanced	O
green	O
fluorescence	O
protein	O
(	O
EGFP	O
)	O
in	O
the	O
cellular	O
models	O
,	O
where	O
EGFP	O
was	O
employed	O
as	O
a	O
reporter	O
gene	O
.	O

Cytotoxicity	B
of	O
cisplatin	O
(	O
CIP	O
)	O
,	O
carboplatin	O
(	O
CAP	O
)	O
and	O
oxaliplatin	O
(	O
OXP	O
)	O
was	O
significantly	O
lowered	O
in	O
MDCKII	O
cells	O
transfected	O
with	O
ABCG2	O
transporter	O
and	O
EGFP	O
reporter	O
.	O

The	O
IC	O
(	O
50	O
)	O
values	O
in	O
MDCKII	O
-	O
ABCG2	O
were	O
25.7	O
,	O
164	O
and	O
165	O
microM	O
for	O
CIP	O
,	O
CAP	O
and	O
OXP	O
,	O
respectively	O
,	O
whereas	O
IC	O
(	O
50	O
)	O
for	O
the	O
same	O
cytostatics	O
in	O
MDCKII	O
cells	O
were	O
as	O
follows	O
:	O
15.4	O
,	O
133	O
and	O
50.3	O
microM	O
.	O

Addition	O
of	O
fumitremorgin	O
C	O
(	O
FTC	O
)	O
,	O
a	O
potent	O
ABCG2	O
inhibitor	O
,	O
significantly	O
suppressed	O
the	O
resistance	O
of	O
MDCKII	O
-	O
ABCG2	O
to	O
OXP	O
,	O
suggesting	O
that	O
OXP	O
interacts	O
with	O
ABCG2	O
.	O

However	O
,	O
FTC	O
did	O
not	O
change	O
the	O
sensitivity	O
of	O
the	O
cells	O
to	O
CIP	O
and	O
CAP	O
.	O

We	O
assume	O
that	O
EGFP	O
rather	O
than	O
ABCG2	O
causes	O
the	O
diminished	O
toxicity	O
of	O
the	O
platinum	O
cytostatics	O
in	O
the	O
transfected	O
cells	O
.	O

This	O
hypothesis	O
was	O
confirmed	O
in	O
human	O
Hep2	O
cells	O
expressing	O
EGFP	O
:	O
using	O
MTT	O
test	O
,	O
IC	O
(	O
50	O
)	O
of	O
30.0	O
,	O
247	O
and	O
27.9	O
microM	O
were	O
obtained	O
for	O
CIP	O
,	O
CAP	O
and	O
OXP	O
,	O
respectively	O
,	O
while	O
12.3	O
,	O
106	O
and	O
20.5	O
microM	O
were	O
observed	O
in	O
the	O
parent	O
Hep2	O
cells	O
.	O

Employing	O
neutral	O
red	O
cytotoxicity	B
assay	O
,	O
similar	O
data	O
were	O
obtained	O
(	O
IC	O
(	O
50	O
)	O
7.73	O
,	O
685	O
and	O
112	O
microM	O
for	O
CIP	O
,	O
CAP	O
,	O
and	O
OXP	O
,	O
respectively	O
,	O
in	O
the	O
Hep2	O
-	O
EGFP	O
cells	O
and	O
1.65	O
,	O
79.4	O
and	O
24.5	O
microM	O
in	O
the	O
parent	O
Hep2	O
cells	O
)	O
.	O

Caspase	O
-	O
3	O
/	O
7	O
assay	O
revealed	O
lower	O
susceptibility	O
of	O
EGFP	O
expressing	O
Hep2	O
cells	O
to	O
apoptosis	O
induced	O
by	O
CIP	O
when	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
.	O

We	O
therefore	O
conclude	O
that	O
EGFP	O
in	O
transfected	O
cells	O
interferes	O
with	O
cytotoxicity	B
of	O
platinum	O
drugs	O
by	O
hindering	O
the	O
drug	O
induced	O
apoptosis	O
and	O
could	O
cause	O
misinterpretation	O
of	O
results	O
obtained	O
in	O
cytotoxicity	B
studies	O
.	O

Protective	O
effects	O
of	O
asiatic	O
acid	O
on	O
rotenone	O
-	O
or	O
H2O2	O
-	O
induced	O
injury	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
is	O
a	O
progressive	B
neurodegenerative	I
disorder	I
with	O
a	O
prevalence	O
of	O
1	O
-	O
2	O
%	O
in	O
people	O
over	O
the	O
age	O
of	O
50	O
.	O

Mitochondrial	O
dysfunction	O
occurred	O
in	O
PD	B
patients	O
showing	O
a	O
15	O
-	O
30	O
%	O
loss	O
of	O
activity	O
in	O
complex	O
I	O
.	O

Asiatic	O
acid	O
(	O
AA	O
)	O
,	O
a	O
triterpenoid	O
,	O
is	O
an	O
antioxidant	O
and	O
used	O
for	O
depression	B
treatment	O
,	O
but	O
the	O
effect	O
of	O
AA	O
against	O
PD	B
-	O
like	O
damage	O
has	O
never	O
been	O
reported	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
protective	O
effects	O
of	O
AA	O
against	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
or	O
rotenone	O
-	O
induced	O
cellular	B
injury	I
and	O
mitochondrial	O
dysfunction	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
and	O
the	O
expression	O
of	O
voltage	O
-	O
dependent	O
anion	O
channel	O
(	O
VDAC	O
)	O
were	O
detected	O
with	O
or	O
without	O
AA	O
pretreatment	O
following	O
cellular	B
injury	I
to	O
address	O
the	O
possible	O
mechanisms	O
of	O
AA	O
neuroprotection	O
.	O

The	O
results	O
showed	O
that	O
pre	O
-	O
treatment	O
of	O
AA	O
(	O
0.01	O
-	O
100	O
nM	O
)	O
protected	O
cells	O
against	O
the	O
toxicity	O
induced	O
by	O
rotenone	O
or	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

In	O
addition	O
,	O
MMP	O
dissipation	O
occurred	O
following	O
the	O
exposure	O
of	O
rotenone	O
,	O
which	O
could	O
be	O
prevented	O
by	O
AA	O
treatment	O
.	O

More	O
interestingly	O
,	O
pre	O
-	O
administration	O
of	O
AA	O
inhibited	O
the	O
elevation	O
of	O
VDAC	O
mRNA	O
and	O
protein	O
levels	O
induced	O
by	O
rotenone	O
(	O
100	O
nM	O
)	O
or	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
300	O
microM	O
)	O
.	O

These	O
data	O
indicate	O
that	O
AA	O
could	O
protect	O
neuronal	O
cells	O
against	O
mitochondrial	O
dysfunctional	O
injury	O
and	O
suggest	O
that	O
AA	O
might	O
be	O
developed	O
as	O
an	O
agent	O
for	O
PD	O
prevention	O
or	O
therapy	O
.	O

Efficient	O
telomerase	O
inhibition	O
in	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
by	O
liposomal	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
.	O

The	O
antisense	O
oligonucleotide	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
is	O
a	O
selective	O
telomerase	O
inhibitor	O
targeting	O
the	O
telomerase	O
RNA	O
component	O
and	O
represents	O
a	O
potential	O
candidate	O
for	O
anticancer	O
therapy	O
.	O

The	O
poor	O
cellular	O
uptake	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
is	O
a	O
limiting	O
factor	O
that	O
may	O
contribute	O
to	O
the	O
lack	O
of	O
functional	O
efficacy	O
.	O

To	O
improve	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
and	O
consequently	O
antitumoral	O
efficiency	O
in	O
human	O
lung	O
cancer	O
cells	O
,	O
we	O
have	O
investigated	O
several	O
transfection	O
reagents	O
.	O

The	O
transfection	O
reagents	O
DOTAP	O
,	O
MegaFectin	O
60	O
,	O
SuperFect	O
,	O
FuGENE	O
6	O
and	O
MATra	O
-	O
A	O
were	O
tested	O
for	O
intracellular	O
delivery	O
.	O

A	O
FAM	O
-	O
labeled	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
was	O
used	O
to	O
assess	O
the	O
intracellular	O
distribution	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
in	O
A549	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
.	O

Telomerase	O
activity	O
was	O
measured	O
using	O
the	O
telomeric	O
repeat	O
amplification	O
protocol	O
.	O

Cell	O
viability	O
after	O
transfection	O
was	O
quantified	O
by	O
the	O
MTT	O
assay	O
.	O

All	O
transfection	O
reagents	O
enhanced	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
uptake	O
in	O
A549	O
cells	O
but	O
the	O
cationic	O
lipid	O
reagents	O
DOTAP	O
and	O
MegaFectin	O
60	O
were	O
most	O
efficient	O
in	O
the	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
resulting	O
in	O
telomerase	O
inhibition	O
.	O

Among	O
both	O
DOTAP	O
exhibited	O
the	O
lowest	O
cytotoxicity	B
.	O

Our	O
experiments	O
show	O
that	O
DOTAP	O
is	O
the	O
most	O
suitable	O
transfection	O
reagent	O
for	O
the	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
in	O
human	O
lung	O
cancer	O
cells	O
according	O
to	O
its	O
relatively	O
low	O
cytotoxicity	B
and	O
its	O
ability	O
to	O
promote	O
efficient	O
uptake	O
leading	O
to	O
the	O
inhibition	O
of	O
telomerase	O
.	O

Particulate	O
matter	O
inhibits	O
DNA	O
repair	O
and	O
enhances	O
mutagenesis	O
.	O

Exposure	O
to	O
ambient	O
air	O
pollution	O
has	O
been	O
associated	O
with	O
adverse	O
health	O
effects	O
including	O
lung	B
cancer	I
.	O

A	O
recent	O
epidemiology	O
study	O
has	O
established	O
that	O
each	O
10	O
microg	O
/	O
m3	O
elevation	O
in	O
long	O
-	O
term	O
exposure	O
to	O
average	O
PM2	O
.5	O
ambient	O
concentration	O
was	O
associated	O
with	O
approximately	O
8	O
%	O
of	O
lung	B
cancer	I
mortality	O
.	O

The	O
underlying	O
mechanisms	O
of	O
how	O
PM	O
contributes	O
to	O
lung	O
carcinogenesis	O
,	O
however	O
,	O
remain	O
to	O
be	O
elucidated	O
.	O

We	O
have	O
recently	O
found	O
that	O
transition	O
metals	O
such	O
as	O
nickel	O
and	O
chromium	O
and	O
oxidative	O
stress	O
induced	O
lipid	O
peroxidation	O
metabolites	O
such	O
as	O
aldehydes	O
can	O
greatly	O
inhibit	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
enhance	O
carcinogen	O
-	O
induced	O
mutations	O
.	O

Because	O
PM	O
is	O
rich	O
in	O
metal	O
and	O
aldehyde	O
content	O
and	O
can	O
induce	O
oxidative	O
stress	O
,	O
we	O
tested	O
the	O
effect	O
of	O
PM	O
on	O
DNA	O
repair	O
capacity	O
in	O
cultured	O
human	O
lung	O
cells	O
using	O
in	O
vitro	O
DNA	O
repair	O
synthesis	O
and	O
host	O
cell	O
reactivation	O
assays	O
.	O

We	O
found	O
that	O
PM	O
greatly	O
inhibits	O
NER	O
for	O
ultraviolet	O
(	O
UV	O
)	O
light	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
diol	O
epoxide	O
(	O
BPDE	O
)	O
induced	O
DNA	O
damage	O
in	O
human	O
lung	O
cells	O
.	O

We	O
further	O
demonstrated	O
that	O
PM	O
exposure	O
can	O
significantly	O
increase	O
both	O
spontaneous	O
and	O
UV	O
-	O
induced	O
mutagenesis	O
.	O

These	O
results	O
together	O
suggest	O
that	O
the	O
carcinogenicity	B
of	O
PM	O
may	O
act	O
through	O
its	O
combined	O
effect	O
on	O
suppression	O
of	O
DNA	O
repair	O
and	O
enhancement	O
of	O
DNA	O
replication	O
errors	O
.	O

Nicotine	O
and	O
4	O
-	O
(	O
methylnitrosamino	O
)	O
-	O
1	O
-	O
(	O
3	O
-	O
pyridyl	O
)	O
-	O
1	O
-	O
butanone	O
induce	O
cyclooxygenase	O
-	O
2	O
activity	O
in	O
human	O
gastric	O
cancer	O
cells	O
:	O
Involvement	O
of	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAChR	O
)	O
and	O
beta	O
-	O
adrenergic	O
receptor	O
signaling	O
pathways	O
.	O

Induction	O
of	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
associates	O
with	O
cigarette	O
smoke	O
exposure	O
in	O
many	O
malignancies	O
.	O

Nicotine	O
and	O
its	O
derivative	O
,	O
4	O
-	O
(	O
methylnitrosamino	O
)	O
-	O
1	O
-	O
(	O
3	O
-	O
pyridyl	O
)	O
-	O
1	O
-	O
butanone	O
(	O
NNK	O
)	O
,	O
are	O
the	O
two	O
important	O
components	O
in	O
cigarette	O
smoke	O
that	O
contributes	O
to	O
cancer	B
development	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
nicotine	O
or	O
NNK	O
promotes	O
gastric	O
carcinogenesis	O
remains	O
largely	O
unknown	O
.	O

We	O
found	O
that	O
nicotine	O
and	O
NNK	O
significantly	O
enhanced	O
cell	O
proliferation	O
in	O
AGS	O
cells	O
that	O
expressed	O
both	O
alpha7	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
alpha7	O
nAChR	O
)	O
and	O
beta	O
-	O
adrenergic	O
receptors	O
.	O

Treatment	O
of	O
cells	O
with	O
alpha	O
-	O
bungarotoxin	O
(	O
alpha	O
-	O
BTX	O
,	O
alpha7nAChR	O
antagonist	O
)	O
or	O
propranolol	O
(	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
)	O
blocked	O
NNK	O
-	O
induced	O
COX	O
-	O
2	O
/	O
PGE	O
(	O
2	O
)	O
and	O
cell	O
proliferation	O
,	O
while	O
nicotine	O
-	O
mediated	O
cell	O
growth	O
and	O
COX	O
-	O
2	O
/	O
PGE	O
(	O
2	O
)	O
induction	O
can	O
only	O
be	O
suppressed	O
by	O
propranolol	O
,	O
but	O
not	O
alpha	O
-	O
BTX	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
the	O
dependence	O
of	O
growth	O
promoting	O
effect	O
of	O
nicotine	O
on	O
Erk	O
activation	O
,	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
repressed	O
NNK	O
-	O
induced	O
COX	O
-	O
2	O
upregulation	O
and	O
resulted	O
in	O
suppression	O
of	O
cell	O
growth	O
.	O

In	O
addition	O
,	O
nicotine	O
and	O
NNK	O
mediated	O
COX	O
-	O
2	O
induction	O
via	O
different	O
receptors	O
to	O
modulate	O
several	O
G1	O
/	O
S	O
transition	O
regulatory	O
proteins	O
and	O
promote	O
gastric	O
cancer	O
cell	O
growth	O
.	O

Selective	O
COX	O
-	O
2	O
inhibitor	O
(	O
SC	O
-	O
236	O
)	O
caused	O
G1	O
arrest	O
and	O
abrogated	O
nicotine	O
/	O
NNK	O
-	O
induced	O
cell	O
proliferation	O
.	O

Aberrant	O
expression	O
of	O
cyclin	O
D1	O
and	O
other	O
G1	O
regulatory	O
proteins	O
are	O
reversed	O
by	O
blockade	O
of	O
COX	O
-	O
2	O
.	O

These	O
results	O
pointed	O
to	O
the	O
importance	O
of	O
adrenergic	O
and	O
nicotinic	O
receptors	O
in	O
gastric	B
tumor	I
growth	O
through	O
MAPK	O
/	O
COX	O
-	O
2	O
activation	O
,	O
which	O
may	O
perhaps	O
provide	O
a	O
chemoprevention	O
strategy	O
for	O
cigarette	O
smoke	O
-	O
related	O
gastric	B
carcinogenesis	I
.	O

Selenium	O
nanoparticles	O
fabricated	O
in	O
Undaria	O
pinnatifida	O
polysaccharide	O
solutions	O
induce	O
mitochondria	O
-	O
mediated	O
apoptosis	O
in	O
A375	O
human	O
melanoma	O
cells	O
.	O

Selenium	O
nanoparticle	O
(	O
Nano	O
-	O
Se	O
)	O
is	O
a	O
novel	O
Se	O
species	O
with	O
novel	O
biological	O
activities	O
and	O
low	O
toxicity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
a	O
simple	O
method	O
for	O
synthesis	O
of	O
size	O
-	O
controlled	O
Nano	O
-	O
Se	O
by	O
adding	O
Undaria	O
pinnatifida	O
polysaccharides	O
to	O
the	O
redox	O
system	O
of	O
selenite	O
and	O
ascorbic	O
acid	O
.	O

A	O
panel	O
of	O
four	O
human	O
cancer	O
cell	O
lines	O
was	O
shown	O
to	O
be	O
susceptible	O
to	O
Nano	O
-	O
Se	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
3.0	O
to	O
14.1	O
microM	O
.	O

Treatment	O
of	O
A375	O
human	O
melanoma	O
cells	O
with	O
the	O
Nano	O
-	O
Se	O
resulted	O
in	O
dose	O
-	O
dependent	O
cell	O
apoptosis	O
as	O
indicated	O
by	O
DNA	O
fragmentation	O
and	O
phosphatidylserine	O
translocation	O
.	O

Further	O
investigation	O
on	O
intracellular	O
mechanisms	O
found	O
that	O
Nano	O
-	O
Se	O
treatment	O
triggered	O
apoptotic	O
cell	O
death	O
in	O
A375	O
cells	O
with	O
the	O
involvement	O
of	O
oxidative	O
stress	O
and	O
mitochondrial	O
dysfunction	O
.	O

Our	O
results	O
suggest	O
that	O
Nano	O
-	O
Se	O
may	O
be	O
a	O
candidate	O
for	O
further	O
evaluation	O
as	O
a	O
chemopreventive	O
and	O
chemotherapeutic	O
agent	O
for	O
human	O
cancers	O
,	O
especially	O
melanoma	B
cancer	I
.	O

An	O
EORTC	O
phase	O
I	O
study	O
of	O
Bortezomib	O
in	O
combination	O
with	O
oxaliplatin	O
,	O
leucovorin	O
and	O
5	O
-	O
fluorouracil	O
in	O
patients	O
with	O
advanced	O
colorectal	B
cancer	I
.	O

The	O
combination	O
of	O
oxaliplatin	O
,	O
leucovorin	O
and	O
5	O
-	O
fluorouracil	O
(	O
FOLFOX	O
-	O
4	O
)	O
is	O
still	O
a	O
reference	O
regimen	O
in	O
advanced	O
colorectal	B
cancer	I
;	O
however	O
,	O
the	O
addition	O
of	O
new	O
biologic	O
compounds	O
represents	O
a	O
significant	O
way	O
forward	O
.	O

Bortezomib	O
is	O
an	O
inhibitor	O
of	O
proteasome	O
,	O
a	O
multicatalytic	O
enzyme	O
complex	O
that	O
degrades	O
several	O
intracellular	O
proteins	O
.	O

In	O
this	O
study	O
,	O
escalating	O
doses	O
of	O
Bortezomib	O
were	O
administered	O
along	O
with	O
the	O
standard	O
FOLFOX	O
-	O
4	O
doses	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
dose	B
-	I
limiting	I
toxicity	I
(	O
DLT	B
)	O
,	O
toxicity	O
profile	O
and	O
activity	O
of	O
the	O
combination	O
.	O

Patients	O
with	O
advanced	O
colorectal	B
cancer	I
,	O
unpretreated	O
for	O
metastatic	B
disease	I
,	O
were	O
enroled	O
in	O
the	O
study	O
.	O

Bortezomib	O
starting	O
dose	O
was	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
which	O
was	O
to	O
be	O
escalated	O
in	O
the	O
subsequent	O
steps	O
according	O
to	O
the	O
toxicities	O
observed	O
after	O
first	O
cycle	O
.	O

Exploratory	O
pharmacogenetics	O
research	O
was	O
conducted	O
by	O
analysing	O
the	O
association	O
between	O
clinical	O
outcomes	O
and	O
polymorphisms	O
in	O
candidate	O
genes	O
for	O
response	O
to	O
each	O
of	O
the	O
used	O
drugs	O
.	O

Correlation	O
between	O
tumour	O
marker	O
changes	O
and	O
response	O
was	O
also	O
investigated	O
.	O

One	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
DL	O
-	O
1	O
)	O
was	O
defined	O
as	O
being	O
the	O
maximum	O
tolerated	O
dose	O
since	O
only	O
1	O
DLT	O
was	O
observed	O
in	O
6	O
patients	O
.	O

The	O
main	O
toxicities	O
were	O
haematologic	O
,	O
neuropathy	B
,	O
diarrhoea	B
and	O
fatigue	B
.	O

Amongst	O
13	O
evaluable	O
patients	O
,	O
five	O
had	O
a	O
partial	O
response	O
,	O
five	O
had	O
a	O
stable	O
disease	O
and	O
three	O
patients	O
progressed	O
.	O

Two	O
patients	O
are	O
long	O
-	O
term	O
survivors	O
after	O
a	O
combined	O
chemosurgical	O
approach	O
.	O

Further	O
trials	O
of	O
the	O
current	O
combination	O
may	O
be	O
justified	O
.	O

Derivation	O
of	O
a	O
chronic	O
reference	O
dose	O
and	O
reference	O
concentration	O
for	O
trimethylbenzenes	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
.	O

Trimethylbenzenes	O
(	O
TMBs	O
)	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
are	O
structurally	O
similar	O
and	O
have	O
similar	O
toxicity	O
.	O

Based	O
on	O
a	O
review	O
of	O
the	O
entire	O
TMB	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
toxicology	O
database	O
,	O
oral	O
and	O
inhalation	O
studies	O
were	O
identified	O
to	O
serve	O
as	O
the	O
basis	O
for	O
a	O
Reference	O
dose	O
(	O
RfD	O
)	O
and	O
Reference	O
concentrations	O
(	O
RfC	O
)	O
.	O

The	O
RfD	O
and	O
RfC	O
were	O
derived	O
using	O
standard	O
USEPA	O
methods	O
and	O
assumptions	O
.	O

The	O
RfD	O
was	O
calculated	O
to	O
be	O
0.4	O
mg	O
/	O
kg	O
/	O
day	O
using	O
a	O
90	O
-	O
day	O
oral	O
study	O
that	O
resulted	O
in	O
a	O
NOAEL	O
of	O
600	O
mg	O
/	O
kg	O
/	O
day	O
,	O
based	O
on	O
a	O
lack	O
of	O
adverse	O
effects	O
at	O
the	O
highest	O
dose	O
level	O
(	O
reversible	O
effects	O
such	O
as	O
increased	O
serum	O
phosphorus	O
levels	O
and	O
liver	O
and	O
kidney	O
weights	O
)	O
,	O
along	O
with	O
a	O
total	O
uncertainty	O
factor	O
of	O
1000	O
.	O

For	O
the	O
RfC	O
,	O
three	O
studies	O
were	O
considered	O
based	O
on	O
different	O
study	O
designs	O
and	O
toxicological	O
endpoints	O
,	O
including	O
neurotoxicity	B
,	O
systemic	B
toxicity	I
,	O
and	O
potential	O
developmental	O
and	O
reproductive	B
toxicity	I
.	O

For	O
all	O
three	O
studies	O
,	O
as	O
the	O
calculated	O
RfCs	O
were	O
consistent	O
(	O
3	O
-	O
4	O
mg	O
/	O
m3	O
)	O
,	O
the	O
most	O
conservative	O
RfC	O
,	O
3	O
mg	O
/	O
m3	O
,	O
was	O
selected	O
.	O

The	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
referred	O
to	O
herein	O
are	O
based	O
on	O
chemistries	O
assessed	O
as	O
part	O
of	O
the	O
TSCA	O
Section	O
4	O
Test	O
Rule	O
.	O

These	O
solvents	O
contain	O
primarily	O
ethyl	O
toluene	O
and	O
tri	O
-	O
methyl	O
benzene	O
isomers	O
,	O
but	O
the	O
specific	O
compositions	O
can	O
vary	O
based	O
on	O
feedstock	O
and	O
manufacturing	O
process	O
,	O
thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
composition	O
of	O
any	O
specific	O
solvent	O
to	O
assess	O
similarity	O
to	O
that	O
assessed	O
in	O
the	O
TSCA	O
Section	O
4	O
Test	O
Rule	O
program	O
.	O

Fatal	O
toxic	B
epidermal	I
necrolysis	I
and	O
severe	O
granulocytopenia	B
following	O
therapy	O
with	O
cefuroxime	O
.	O

Toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
is	O
one	O
of	O
the	O
most	O
threatening	O
adverse	O
reactions	O
to	O
various	O
drugs	O
.	O

No	O
case	O
of	O
concomitant	O
occurrence	O
TEN	B
and	O
severe	O
granulocytopenia	B
following	O
the	O
treatment	O
with	O
cefuroxime	O
has	O
been	O
reported	O
to	O
date	O
.	O

Herein	O
we	O
present	O
a	O
case	O
of	O
TEN	B
that	O
developed	O
eighteen	O
days	O
of	O
the	O
initiation	O
of	O
cefuroxime	O
axetil	O
therapy	O
for	O
urinary	B
tract	I
infection	I
in	O
a	O
73	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	B
renal	I
failure	I
and	O
no	O
previous	O
history	O
of	O
allergic	B
diathesis	I
.	O

The	O
condition	O
was	O
associated	O
with	O
severe	O
granulocytopenia	B
and	O
followed	O
by	O
gastrointestinal	B
hemorrhage	I
,	O
severe	O
sepsis	B
and	O
multiple	B
organ	I
failure	I
syndrome	I
development	O
.	O

Despite	O
intensive	O
medical	O
treatment	O
the	O
patient	O
died	O
.	O

The	O
present	O
report	O
underlines	O
the	O
potential	O
of	O
cefuroxime	O
to	O
simultaneously	O
induce	O
life	O
threatening	O
adverse	O
effects	O
such	O
as	O
TEN	B
and	O
severe	O
granulocytopenia	B
.	O

Further	O
on	O
,	O
because	O
the	O
patient	O
was	O
also	O
taking	O
furosemide	O
for	O
chronic	B
renal	I
failure	I
,	O
the	O
possible	O
unfavorable	O
interactions	O
between	O
the	O
two	O
drugs	O
could	O
be	O
hypothesized	O
.	O

Therefore	O
,	O
awareness	O
of	O
the	O
possible	O
drug	O
interaction	O
is	O
necessary	O
,	O
especially	O
when	O
given	O
in	O
conditions	O
of	O
their	O
altered	O
pharmacokinetics	O
as	O
in	O
case	O
of	O
chronic	B
renal	I
failure	I
.	O

Spatial	O
and	O
temporal	O
aspects	O
of	O
muscle	B
hyperalgesia	I
induced	O
by	O
nerve	O
growth	O
factor	O
in	O
humans	O
.	O

Intramuscular	O
injection	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
has	O
been	O
shown	O
to	O
induce	O
long	O
-	O
term	O
sensitisation	O
and	O
time	O
-	O
dependent	O
hyperalgesia	B
indicating	O
potential	O
involvement	O
of	O
both	O
central	O
and	O
peripheral	O
pain	B
mechanisms	O
.	O

This	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
was	O
designed	O
to	O
describe	O
the	O
spatial	O
distribution	O
of	O
muscle	B
hyperalgesia	I
over	O
time	O
(	O
immediately	O
after	O
,	O
3	O
h	O
,	O
1	O
,	O
4	O
,	O
7	O
and	O
21	O
days	O
)	O
after	O
injecting	O
NGF	O
(	O
5	O
mug	O
)	O
into	O
the	O
tibialis	O
anterior	O
(	O
TA	O
)	O
muscle	O
,	O
to	O
explore	O
possibly	O
involved	O
central	O
pain	B
mechanisms	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
gender	O
on	O
development	O
of	O
hyperalgesia	B
.	O

Totally	O
20	O
healthy	O
volunteers	O
(	O
10	O
men	O
and	O
10	O
women	O
)	O
participated	O
in	O
the	O
study	O
.	O

An	O
isotonic	O
saline	O
injection	O
into	O
the	O
contralateral	O
TA	O
muscle	O
served	O
as	O
a	O
control	O
condition	O
for	O
the	O
NGF	O
injection	O
.	O

Pressure	O
pain	B
thresholds	O
(	O
PPT	O
)	O
were	O
used	O
to	O
test	O
for	O
muscle	B
hyperalgesia	I
along	O
the	O
TA	O
(	O
seven	O
sites	O
)	O
muscle	O
at	O
the	O
extensor	O
digitorum	O
longus	O
and	O
at	O
the	O
web	O
between	O
1st	O
and	O
2nd	O
metatarsal	O
(	O
central	O
involvement	O
)	O
.	O

One	O
day	O
after	O
the	O
NGF	O
/	O
control	O
injections	O
,	O
hypertonic	O
saline	O
(	O
0.5	O
ml	O
,	O
5.8	O
%	O
)	O
was	O
injected	O
into	O
the	O
left	O
and	O
right	O
TA	O
to	O
study	O
the	O
pain	B
response	O
to	O
chemical	O
stimulation	O
of	O
the	O
hyperalgesic	O
muscle	O
tissue	O
.	O

Scores	O
on	O
a	O
modified	O
Likert	O
scale	O
were	O
used	O
to	O
assess	O
soreness	O
during	O
muscle	O
function	O
.	O

An	O
area	O
of	O
hyperalgesia	B
was	O
observed	O
locally	O
at	O
the	O
injected	O
site	O
3	O
h	O
after	O
injection	O
of	O
NGF	O
,	O
which	O
expanded	O
both	O
proximally	O
and	O
distally	O
on	O
day	O
1	O
;	O
this	O
effect	O
subsided	O
on	O
day	O
4	O
.	O

Decreased	O
PPT	O
was	O
also	O
found	O
between	O
1st	O
and	O
2nd	O
metatarsal	O
on	O
day	O
1	O
.	O

Hypertonic	O
saline	O
evoked	O
more	O
pain	B
in	O
men	O
when	O
injected	O
in	O
the	O
NGF	O
treated	O
TA	O
compared	O
to	O
the	O
control	O
leg	O
.	O

Injection	O
of	O
NGF	O
increased	O
muscle	B
soreness	I
during	O
muscle	O
activity	O
for	O
7	O
days	O
.	O

In	O
this	O
material	O
there	O
was	O
no	O
gender	O
effect	O
of	O
NGF	O
-	O
induced	O
muscle	B
hyperalgesia	I
.	O

The	O
expansion	O
of	O
muscle	B
hyperalgesia	I
to	O
distant	O
areas	O
indicates	O
that	O
central	O
mechanisms	O
are	O
involved	O
.	O

Occupational	O
hazard	O
:	O
treating	O
cocaine	O
body	O
packers	O
in	O
Caribbean	O
countries	O
.	O

Body	O
packing	O
is	O
a	O
common	O
method	O
of	O
smuggling	O
cocaine	O
where	O
individuals	O
ingest	O
several	O
drug	O
-	O
filled	O
parcels	O
for	O
transport	O
.	O

When	O
identified	O
by	O
the	O
authorities	O
,	O
body	O
packers	O
are	O
usually	O
taken	O
to	O
hospital	O
for	O
evaluation	O
.	O

There	O
are	O
several	O
points	O
during	O
management	O
of	O
these	O
patients	O
when	O
the	O
health	O
care	O
team	O
may	O
be	O
placed	O
at	O
risk	O
.	O

We	O
explore	O
the	O
hazards	O
encountered	O
during	O
the	O
management	O
of	O
these	O
patients	O
in	O
developing	O
Caribbean	O
nations	O
.	O

The	O
addition	O
of	O
rituximab	O
to	O
front	O
-	O
line	O
therapy	O
with	O
CHOP	O
(	O
R	O
-	O
CHOP	O
)	O
results	O
in	O
a	O
higher	O
response	O
rate	O
and	O
longer	O
time	O
to	O
treatment	O
failure	O
in	O
patients	O
with	O
lymphoplasmacytic	B
lymphoma	I
:	O
results	O
of	O
a	O
randomized	O
trial	O
of	O
the	O
German	O
Low	O
-	O
Grade	O
Lymphoma	B
Study	O
Group	O
(	O
GLSG	O
)	O
.	O

Lymphoplasmacytic	B
lymphoma	I
(	O
LPL	B
)	O
is	O
an	O
indolent	O
lymphoma	B
with	O
moderate	O
sensitivity	O
to	O
conventional	O
chemotherapy	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
addition	O
of	O
rituximab	O
to	O
standard	O
chemotherapy	O
improves	O
treatment	O
outcome	O
in	O
LPL	B
and	O
the	O
subgroup	O
of	O
LPL	B
patients	O
fulfilling	O
the	O
criteria	O
of	O
Waldenstroem	B
's	I
macroglobulinemia	I
(	O
WM	B
)	O
.	O

A	O
total	O
of	O
69	O
patients	O
with	O
previously	O
untreated	O
LPL	B
were	O
enrolled	O
into	O
the	O
trial	O
;	O
64	O
patients	O
were	O
evaluable	O
for	O
treatment	O
outcome	O
.	O

In	O
all	O
,	O
48	O
of	O
the	O
64	O
LPL	B
patients	O
fulfilled	O
the	O
criteria	O
of	O
WM	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
R	O
-	O
CHOP	O
(	O
rituximab	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
and	O
prednisone	O
,	O
n	O
=	O
34	O
)	O
or	O
CHOP	O
(	O
n	O
=	O
30	O
)	O
.	O

R	O
-	O
CHOP	O
resulted	O
in	O
significantly	O
higher	O
overall	O
response	O
(	O
OR	O
)	O
rate	O
(	O
94	O
vs	O
67	O
%	O
,	O
P	O
=	O
0.0085	O
)	O
in	O
the	O
LPL	B
patients	O
and	O
in	O
the	O
WM	B
subgroup	O
(	O
91	O
vs	O
60	O
%	O
,	O
P	O
=	O
0.0188	O
)	O
.	O

With	O
a	O
median	O
observation	O
time	O
of	O
42	O
months	O
,	O
R	O
-	O
CHOP	O
induced	O
a	O
significantly	O
longer	O
time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
with	O
a	O
median	O
of	O
63	O
months	O
for	O
R	O
-	O
CHOP	O
vs	O
22	O
months	O
in	O
the	O
CHOP	O
arm	O
in	O
the	O
LPL	B
patients	O
(	O
P	O
=	O
0.0033	O
)	O
and	O
in	O
the	O
WM	B
subgroup	O
(	O
P	O
=	O
0.0241	O
)	O
.	O

There	O
was	O
no	O
major	O
difference	O
of	O
treatment	B
-	I
associated	I
toxicity	I
between	O
both	O
treatment	O
groups	O
.	O

These	O
data	O
indicate	O
that	O
the	O
addition	O
of	O
rituximab	O
to	O
front	O
-	O
line	O
chemotherapy	O
improves	O
treatment	O
outcome	O
in	O
patients	O
with	O
LPL	B
or	O
WM	B
.	O

Novel	O
therapeutic	O
agents	O
targeting	O
the	O
glucocorticoid	O
receptor	O
for	O
inflammation	B
and	O
cancer	B
.	O

Glucocorticoids	O
,	O
through	O
their	O
interaction	O
with	O
the	O
ubiquitous	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
,	O
have	O
extensive	O
and	O
disparate	O
effects	O
on	O
different	O
cells	O
and	O
tissues	O
.	O

They	O
have	O
long	O
been	O
used	O
in	O
the	O
treatment	O
of	O
asthma	B
,	O
arthritis	B
and	O
autoimmune	B
diseases	I
based	O
on	O
their	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

For	O
these	O
reasons	O
,	O
as	O
well	O
as	O
for	O
their	O
ability	O
to	O
induce	O
massive	O
apoptosis	O
in	O
hematological	B
malignancies	I
,	O
they	O
are	O
also	O
commonly	O
used	O
as	O
cotreatment	O
in	O
cancers	B
.	O

Despite	O
their	O
wide	O
usage	O
,	O
chronic	O
glucocorticoid	O
therapy	O
has	O
deleterious	O
side	O
effects	O
,	O
including	O
weight	O
gain	O
,	O
osteoporosis	B
and	O
diabetes	B
mellitus	I
,	O
and	O
has	O
been	O
shown	O
to	O
diminish	O
the	O
tumor	B
toxicity	I
of	O
chemotherapy	O
,	O
preventing	O
the	O
full	O
potential	O
of	O
glucocorticoid	O
treatment	O
from	O
being	O
realized	O
.	O

Technological	O
advances	O
have	O
contributed	O
to	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
glucocorticoid	O
action	O
,	O
prompting	O
the	O
development	O
of	O
tailored	O
therapeutics	O
targeting	O
the	O
desired	O
outcomes	O
of	O
GR	O
signaling	O
.	O

This	O
review	O
discusses	O
recent	O
advances	O
in	O
the	O
development	O
of	O
novel	O
therapeutic	O
agents	O
for	O
inflammation	B
and	O
cancer	B
through	O
targeting	O
the	O
GR	O
.	O

Inhibition	O
of	O
hydroxyapatite	O
dissolution	O
by	O
whole	O
casein	O
:	O
the	O
effects	O
of	O
pH	O
,	O
protein	O
concentration	O
,	O
calcium	O
,	O
and	O
ionic	O
strength	O
.	O

Formulating	O
drinks	O
with	O
reduced	O
erosive	O
potential	O
is	O
one	O
approach	O
for	O
reducing	O
dental	O
erosion	O
.	O

In	O
this	O
study	O
,	O
whole	O
casein	O
was	O
added	O
to	O
citric	O
acid	O
solutions	O
representative	O
of	O
soft	O
drinks	O
,	O
and	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
was	O
assessed	O
.	O

Adding	O
0.02	O
%	O
(	O
w	O
/	O
v	O
)	O
casein	O
to	O
acid	O
solutions	O
significantly	O
reduced	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
by	O
51	O
+	O
/	O
-	O
4	O
%	O
at	O
pH	O
values	O
of	O
2.80	O
,	O
3.00	O
,	O
3.20	O
,	O
3.40	O
,	O
and	O
3.60	O
,	O
although	O
the	O
baseline	O
dissolution	O
rates	O
of	O
course	O
varied	O
as	O
a	O
function	O
of	O
pH	O
.	O

The	O
protein	O
concentration	O
[	O
0.002	O
,	O
0.02	O
,	O
and	O
0.2	O
%	O
(	O
w	O
/	O
v	O
)	O
casein	O
]	O
had	O
no	O
significant	O
effect	O
on	O
dissolution	O
inhibition	O
.	O

Adding	O
both	O
casein	O
and	O
calcium	O
to	O
citric	O
acid	O
resulted	O
in	O
a	O
further	O
reduction	O
in	O
the	O
dissolution	O
rate	O
at	O
low	O
and	O
intermediate	O
calcium	O
concentrations	O
(	O
5	O
and	O
10	O
mM	O
)	O
but	O
not	O
at	O
higher	O
calcium	O
concentrations	O
(	O
20	O
and	O
50	O
mM	O
)	O
.	O

Ionic	O
strength	O
had	O
no	O
significant	O
impact	O
on	O
the	O
efficacy	O
of	O
casein	O
.	O

Casein	O
also	O
significantly	O
reduced	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
when	O
the	O
hydroxyapatite	O
was	O
coated	O
with	O
a	O
salivary	O
pellicle	O
.	O

The	O
reduction	O
in	O
dissolution	O
rate	O
is	O
ascribed	O
to	O
firmly	O
adsorbed	O
casein	O
on	O
the	O
hydroxyapatite	O
surface	O
,	O
which	O
stabilizes	O
the	O
crystal	O
surface	O
and	O
inhibits	O
ion	O
detachment	O
.	O

A	O
phase	O
II	O
study	O
of	O
oxaliplatin	O
,	O
pemetrexed	O
,	O
and	O
bevacizumab	O
in	O
previously	O
treated	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

INTRODUCTION	O
:	O
Single	O
agent	O
chemotherapy	O
is	O
standard	O
for	O
second	O
and	O
third	O
line	O
treatment	O
of	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
.	O

Combination	O
therapy	O
to	O
date	O
has	O
not	O
proven	O
to	O
be	O
superior	O
to	O
single	O
agents	O
in	O
this	O
setting	O
,	O
often	O
adding	O
toxicity	O
without	O
any	O
additional	O
efficacy	O
.	O

We	O
investigated	O
the	O
activity	O
and	O
tolerability	O
of	O
the	O
combination	O
of	O
oxaliplatin	O
,	O
pemetrexed	O
,	O
and	O
bevacizumab	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	O
NSCLC	B
.	O

METHODS	O
:	O
This	O
multicenter	O
phase	O
II	O
trial	O
evaluated	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
pemetrexed	O
(	O
500	O
mg	O
/	O
m	O
)	O
,	O
oxaliplatin	O
(	O
120	O
mg	O
/	O
m	O
)	O
,	O
and	O
bevacizumab	O
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
given	O
every	O
21	O
days	O
,	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	O
NSCLC	B
.	O

Eligibility	O
criteria	O
included	O
performance	O
status	O
0	O
to	O
1	O
,	O
nonsquamous	O
histology	O
,	O
and	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen	O
.	O

Patients	O
with	O
treated	O
brain	B
metastases	I
were	O
allowed	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	O
rate	O
,	O
with	O
secondary	O
endpoints	O
of	O
progression	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
six	O
patients	O
were	O
enrolled	O
on	O
this	O
study	O
.	O

Treatment	O
was	O
well	O
tolerated	O
;	O
the	O
most	O
common	O
grade	O
3	O
toxicity	O
was	O
hypertension	B
,	O
which	O
was	O
easily	O
managed	O
with	O
oral	O
medications	O
.	O

The	O
nine	O
(	O
25	O
%	O
)	O
patients	O
with	O
treated	O
brain	B
metastases	I
had	O
no	O
episodes	O
of	O
cerebral	B
hemorrhage	I
.	O

Of	O
the	O
34	O
patients	O
evaluable	O
for	O
tumor	B
response	O
,	O
none	O
had	O
complete	O
response	O
,	O
nine	O
(	O
27	O
%	O
)	O
had	O
partial	O
response	O
,	O
15	O
(	O
44	O
%	O
)	O
had	O
stable	O
disease	O
,	O
and	O
10	O
(	O
29	O
%	O
)	O
had	O
progressive	O
disease	O
.	O

Median	O
progression	O
-	O
free	O
survival	O
was	O
5.8	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
4.1	O
-	O
7.8	O
months	O
)	O
and	O
median	O
overall	O
survival	O
was	O
12.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
7.3	O
-	O
17	O
months	O
)	O
.	O

CONCLUSIONS	O
:	O
Treatment	O
with	O
oxaliplatin	O
and	O
pemetrexed	O
in	O
combination	O
with	O
the	O
targeted	O
antiangiogenic	O
agent	O
bevacizumab	O
yielded	O
promising	O
efficacy	O
with	O
manageable	O
toxicity	O
in	O
the	O
previously	O
treated	O
advanced	O
NSCLC	B
population	O
.	O

Early	O
-	O
onset	O
pancytopenia	B
and	O
skin	B
ulcer	I
following	O
low	O
-	O
dose	O
methotrexate	O
therapy	O
.	O

Pancytopenia	B
is	O
a	O
rare	O
but	O
serious	O
adverse	O
effect	O
of	O
low	O
-	O
dose	O
methotrexate	O
(	O
MTX	O
)	O
sodium	O
therapy	O
,	O
and	O
this	O
case	O
report	O
describes	O
a	O
very	O
early	O
-	O
onset	O
of	O
pancytopenia	B
and	O
cutaneous	B
lesions	I
after	O
three	O
days	O
of	O
ingestion	O
.	O

A	O
64	O
-	O
year	O
-	O
old	O
man	O
was	O
presented	O
to	O
Emergency	O
Department	O
with	O
weakness	B
,	O
fever	B
,	O
poor	B
appetite	I
,	O
nausea	B
,	O
and	O
vomiting	B
after	O
he	O
had	O
had	O
accidentally	O
ingested	O
MTX	O
tablets	O
(	O
2.5	O
mg	O
)	O
twice	O
a	O
day	O
for	O
the	O
last	O
three	O
days	O
.	O

On	O
initial	O
examination	O
,	O
several	O
painful	B
lesions	I
in	O
his	O
oral	O
mucosa	O
and	O
a	O
cutaneous	B
ulceration	I
on	O
his	O
right	O
foot	O
were	O
also	O
observed	O
.	O

He	O
had	O
severe	O
pancytopenia	B
,	O
poor	O
kidney	O
functions	O
,	O
and	O
abnormal	B
coagulation	I
parameters	O
.	O

The	O
blood	O
level	O
of	O
MTX	O
was	O
found	O
to	O
be	O
within	O
therapeutic	O
range	O
.	O

He	O
was	O
treated	O
with	O
leucovorine	O
,	O
intravenous	O
antibiotics	O
,	O
and	O
appropriate	O
blood	O
transfusions	O
;	O
he	O
was	O
discharged	O
from	O
hospital	O
without	O
any	O
sequela	O
.	O

Pancytopenia	B
associated	O
with	O
low	O
-	O
dose	O
(	O
cumulative	O
dose	O
of	O
15	O
mg	O
in	O
3	O
days	O
)	O
MTX	O
therapy	O
had	O
not	O
been	O
reported	O
previously	O
.	O

The	O
Naranjo	O
probability	O
scale	O
showed	O
pancytopenia	B
and	O
skin	B
ulcer	I
associated	O
with	O
low	O
-	O
dose	O
MTX	O
therapy	O
as	O
probable	O
adverse	O
reactions	O
.	O

Risk	O
factors	O
for	O
pancytopenia	B
such	O
as	O
renal	B
insufficiency	I
,	O
hypoalbuminemia	B
,	O
low	O
folate	O
levels	O
,	O
concomitant	B
infections	I
,	O
concomitant	O
use	O
of	O
drugs	O
,	O
and	O
folate	O
supplementation	O
were	O
not	O
identified	O
in	O
our	O
patient	O
.	O

Although	O
pancytopenia	B
associated	O
with	O
low	O
-	O
dose	O
MTX	O
therapy	O
is	O
not	O
expected	O
as	O
early	O
as	O
3	O
days	O
after	O
initiation	O
of	O
the	O
therapy	O
,	O
physicians	O
should	O
also	O
be	O
aware	O
of	O
this	O
life	O
threatening	O
adverse	O
effect	O
during	O
the	O
very	O
first	O
days	O
of	O
MTX	O
therapy	O
for	O
rheumatoid	B
arthritis	I
patients	O
.	O

Limited	O
place	O
for	O
plasma	O
monitoring	O
of	O
new	O
antiepileptic	O
drugs	O
in	O
clinical	O
practice	O
.	O

Therapeutic	O
drug	O
monitoring	O
(	O
TDM	O
)	O
has	O
been	O
recognized	O
as	O
a	O
useful	O
guide	O
in	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
epilepsy	B
,	O
in	O
particular	O
those	O
on	O
therapy	O
with	O
traditional	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
.	O

The	O
demonstration	O
of	O
significant	O
drug	O
interactions	O
and	O
the	O
introduction	O
of	O
the	O
concept	O
""""	O
therapeutic	O
range	O
""""	O
have	O
also	O
contributed	O
to	O
the	O
view	O
that	O
monotherapy	O
should	O
be	O
considered	O
the	O
""""	O
gold	O
standard	O
""""	O
in	O
the	O
treatment	O
of	O
epilepsy	B
.	O

Ten	O
new	O
AEDs	O
have	O
been	O
approved	O
and	O
released	O
to	O
the	O
market	O
in	O
the	O
last	O
fifteen	O
years	O
.	O

The	O
most	O
obvious	O
consequence	O
has	O
been	O
an	O
increased	O
number	O
of	O
patients	O
on	O
polytherapy	O
.	O

In	O
general	O
,	O
newer	O
AEDs	O
have	O
better	O
and	O
more	O
predictable	O
pharmacokinetics	O
than	O
older	O
AEDs	O
and	O
usually	O
show	O
lower	O
risk	O
of	O
interactions	O
leading	O
to	O
toxicity	O
as	O
well	O
as	O
large	O
therapeutic	O
indexes	O
.	O

This	O
pragmatic	O
review	O
focuses	O
on	O
practical	O
suggestions	O
about	O
the	O
potential	O
clinical	O
usefulness	O
of	O
TDM	O
of	O
newer	O
AEDs	O
in	O
relation	O
to	O
their	O
mechanism	O
of	O
action	O
and	O
pharmacokinetic	O
characteristics	O
and	O
in	O
response	O
to	O
patient	O
-	O
specific	O
problems	O
.	O

Overall	O
,	O
the	O
usefulness	O
of	O
TDM	O
of	O
newer	O
AEDs	O
seems	O
to	O
be	O
limited	O
and	O
its	O
indiscriminate	O
use	O
is	O
not	O
justified	O
.	O

However	O
,	O
in	O
selected	O
cases	O
or	O
in	O
response	O
to	O
a	O
specific	O
clinical	O
question	O
,	O
a	O
wise	O
use	O
of	O
TDM	O
of	O
some	O
new	O
AEDs	O
could	O
represent	O
a	O
useful	O
tool	O
in	O
the	O
management	O
of	O
epileptic	O
patients	O
.	O

Exceptions	O
are	O
thus	O
represented	O
by	O
special	O
conditions	O
such	O
as	O
renal	B
failure	I
,	O
dialysis	O
,	O
ascertainment	O
of	O
non	O
-	O
compliance	O
,	O
and	O
pregnancy	O
.	O

For	O
some	O
new	O
AEDs	O
,	O
TDM	O
could	O
be	O
selectively	O
and	O
properly	O
used	O
in	O
response	O
to	O
a	O
single	O
patient	O
-	O
specific	O
pharmacokinetic	O
or	O
pharmacodynamic	O
issue	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
bile	O
acid	O
dimers	O
linked	O
with	O
1,2,3	O
-	O
triazole	O
and	O
bis	O
-	O
beta	O
-	O
lactam	O
.	O

We	O
report	O
herein	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
bile	O
acid	O
dimers	O
linked	O
through	O
1,2,3	O
-	O
triazole	O
and	O
bis	O
-	O
beta	O
-	O
lactam	O
.	O

The	O
dimers	O
were	O
synthesized	O
using	O
1,3	O
-	O
dipolar	O
cycloaddition	O
reaction	O
of	O
diazido	O
bis	O
-	O
beta	O
-	O
lactams	O
,	O
and	O
terminal	O
alkynes	O
derived	O
from	O
cholic	O
acid	O
/	O
deoxycholic	O
acid	O
in	O
the	O
presence	O
of	O
Cu	O
(	O
i	O
)	O
catalyst	O
(	O
click	O
chemistry	O
)	O
.	O

These	O
novel	O
molecules	O
were	O
evaluated	O
in	O
vitro	O
for	O
their	O
antifungal	O
and	O
antibacterial	O
activity	O
.	O

Most	O
of	O
the	O
compounds	O
exhibited	O
significant	O
antifungal	O
as	O
well	O
as	O
antibacterial	O
activity	O
against	O
all	O
the	O
tested	O
fungal	O
and	O
bacterial	O
strains	O
.	O

Moreover	O
,	O
their	O
in	O
vitro	O
cytotoxicities	B
towards	O
HEK	O
-	O
293	O
and	O
MCF	O
-	O
7	O
cells	O
were	O
also	O
established	O
.	O

Platinum	O
versus	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
for	O
small	B
cell	I
lung	I
cancer	I
.	O

BACKGROUND	O
:	O
Small	B
cell	I
lung	I
cancer	I
(	O
SCLC	B
)	O
is	O
a	O
very	O
fast	O
growing	O
form	O
of	O
cancer	B
and	O
is	O
characterised	O
by	O
early	O
metastasis	B
.	O

As	O
a	O
result	O
,	O
chemotherapy	O
is	O
the	O
mainstay	O
of	O
treatment	O
.	O

A	O
number	O
of	O
different	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
and	O
non	O
-	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
SCLC	B
,	O
with	O
varying	O
results	O
.	O

This	O
review	O
was	O
conducted	O
to	O
analyse	O
the	O
data	O
from	O
these	O
trials	O
in	O
order	O
to	O
compare	O
their	O
effectiveness	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
effectiveness	O
of	O
platinum	O
chemotherapy	O
regimens	O
compared	O
with	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
in	O
the	O
treatment	O
of	O
SCLC	B
with	O
respect	O
to	O
survival	O
,	O
tumour	B
response	O
,	O
toxicity	O
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
biomedical	O
literature	O
databases	O
CENTRAL	O
(	O
The	O
Cochrane	O
Library	O
2007	O
,	O
Issue	O
2	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
and	O
CINAHL	O
from	O
1966	O
to	O
April	O
2007	O
.	O

In	O
addition	O
,	O
we	O
handsearched	O
reference	O
lists	O
from	O
relevant	O
resources	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
randomised	O
controlled	O
trials	O
involving	O
patients	O
with	O
pathologically	O
confirmed	O
(	O
cytological	O
or	O
histological	O
)	O
SCLC	B
and	O
the	O
use	O
of	O
a	O
platinum	O
-	O
based	O
chemotherapy	O
regimen	O
in	O
at	O
least	O
one	O
treatment	O
arm	O
and	O
a	O
non	O
-	O
platinum	O
-	O
based	O
chemotherapy	O
regimen	O
in	O
a	O
separate	O
arm	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	O
independently	O
assessed	O
search	O
results	O
.	O

We	O
assessed	O
included	O
studies	O
for	O
methodological	O
quality	O
and	O
recorded	O
the	O
following	O
outcome	O
data	O
:	O
survival	O
,	O
tumour	B
response	O
,	O
toxicity	O
and	O
quality	O
of	O
life	O
.	O

We	O
combined	O
the	O
results	O
of	O
the	O
survival	O
,	O
tumour	B
response	O
and	O
toxicity	O
data	O
in	O
a	O
meta	O
-	O
analysis	O
.	O

MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
29	O
trials	O
involving	O
5530	O
patients	O
were	O
included	O
in	O
this	O
systematic	O
review	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
terms	O
of	O
survival	O
at	O
6	O
months	O
,	O
12	O
months	O
and	O
24	O
months	O
.	O

There	O
was	O
also	O
no	O
statistically	O
significant	O
difference	O
in	O
terms	O
of	O
overall	O
tumour	B
response	O
.	O

However	O
,	O
platinum	O
-	O
based	O
treatment	O
regimens	O
did	O
have	O
a	O
significantly	O
higher	O
rate	O
of	O
complete	O
response	O
.	O

Platinum	O
-	O
based	O
chemotherapy	O
regimens	O
had	O
significantly	O
higher	O
rates	O
of	O
nausea	B
and	O
vomiting	B
,	O
anaemia	B
and	O
thrombocytopenia	B
toxicity	O
.	O

Three	O
trials	O
presented	O
quality	O
of	O
life	O
data	O
but	O
the	O
data	O
presented	O
were	O
not	O
complete	O
and	O
therefore	O
could	O
not	O
be	O
combined	O
in	O
a	O
meta	O
-	O
analysis	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Platinum	O
-	O
based	O
chemotherapy	O
regimens	O
did	O
not	O
offer	O
a	O
statistically	O
significant	O
benefit	O
in	O
survival	O
or	O
overall	O
tumour	B
response	O
compared	O
with	O
non	O
-	O
platinum	O
-	O
based	O
regimens	O
.	O

However	O
,	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
did	O
increase	O
complete	O
response	O
rates	O
,	O
at	O
the	O
cost	O
of	O
higher	O
adverse	O
events	O
including	O
nausea	B
and	O
vomiting	B
,	O
anaemia	B
and	O
thrombocytopenia	B
toxicity	O
.	O

These	O
data	O
suggest	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
have	O
a	O
more	O
advantageous	O
risk	O
-	O
benefit	O
profile	O
.	O

This	O
systematic	O
review	O
highlights	O
the	O
lack	O
of	O
quality	O
of	O
life	O
data	O
in	O
trials	O
involving	O
chemotherapy	O
treatment	O
for	O
SCLC	B
.	O

With	O
poor	O
long	O
-	O
term	O
survival	O
associated	O
with	O
both	O
treatment	O
groups	O
,	O
the	O
issue	O
of	O
the	O
quality	O
of	O
the	O
survival	O
period	O
takes	O
on	O
even	O
more	O
significance	O
.	O

It	O
would	O
be	O
beneficial	O
for	O
future	O
trials	O
in	O
this	O
area	O
to	O
include	O
a	O
quality	O
of	O
life	O
assessment	O
.	O

Blood	O
pressure	B
lowering	O
efficacy	O
of	O
renin	O
inhibitors	O
for	O
primary	B
hypertension	I
.	O

BACKGROUND	O
:	O
Hypertension	B
is	O
a	O
chronic	O
condition	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
mortality	O
and	O
morbidity	O
.	O

The	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
is	O
an	O
important	O
target	O
site	O
for	O
five	O
antihypertensive	O
drug	O
classes	O
:	O
beta	O
blockers	O
,	O
renin	O
inhibitors	O
,	O
ACE	O
inhibitors	O
,	O
angiotensin	O
receptor	O
blockers	O
(	O
ARBs	O
)	O
and	O
aldosterone	O
inhibitors	O
.	O

Renin	O
is	O
the	O
enzyme	O
responsible	O
for	O
converting	O
angiotensinogen	O
to	O
angiotensin	O
I	O
,	O
which	O
is	O
then	O
converted	O
to	O
angiotensin	O
II	O
.	O

Renin	O
inhibitors	O
prevent	O
the	O
formation	O
of	O
both	O
angiotensin	O
I	O
and	O
angiotensin	O
II	O
.	O

Renin	O
inhibitors	O
do	O
not	O
affect	O
kinin	O
metabolism	O
and	O
may	O
produce	O
fewer	O
adverse	O
effects	O
than	O
ACE	O
inhibitors	O
such	O
as	O
dry	B
cough	I
or	O
angioedema	B
.	O

OBJECTIVES	O
:	O
To	O
quantify	O
the	O
dose	O
-	O
related	O
blood	O
pressure	B
lowering	O
efficacy	O
of	O
renin	O
inhibitors	O
versus	O
placebo	O
in	O
the	O
treatment	O
of	O
primary	B
hypertension	I
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
for	O
randomised	O
,	O
double	O
blind	B
,	O
placebo	O
-	O
controlled	O
trials	O
of	O
renin	O
inhibitors	O
:	O
Medline	O
(	O
1966	O
-	O
March	O
2008	O
)	O
,	O
EMBASE	O
(	O
1988	O
-	O
March	O
2008	O
)	O
,	O
Cochrane	O
CENTRAL	O
,	O
and	O
bibliographic	O
citations	O
from	O
retrieved	O
references	O
.	O

No	O
language	O
restrictions	O
were	O
applied	O
.	O

SELECTION	O
CRITERIA	O
:	O
Study	O
design	O
had	O
to	O
meet	O
the	O
following	O
criteria	O
:	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
;	O
random	O
allocation	O
to	O
a	O
specific	O
dose	O
of	O
renin	O
inhibitor	O
group	O
and	O
parallel	O
placebo	O
group	O
;	O
duration	O
of	O
follow	O
-	O
up	O
of	O
at	O
least	O
three	O
weeks	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
reviewers	O
independently	O
extracted	O
data	O
and	O
assessed	O
trial	O
quality	O
using	O
risk	O
of	O
bias	O
tables	O
.	O

Disagreements	O
were	O
resolved	O
by	O
discussion	O
or	O
a	O
third	O
reviewer	O
.	O

Data	O
synthesis	O
and	O
analyses	O
were	O
done	O
using	O
the	O
Cochrane	O
Review	O
Manager	O
software	O
,	O
RevMan	O
5	O
.	O

Data	O
for	O
continuous	O
variables	O
were	O
combined	O
using	O
a	O
weighted	O
mean	O
difference	O
method	O
.	O

Dichotomous	O
variables	O
were	O
analysed	O
using	O
relative	O
risk	O
.	O

MAIN	O
RESULTS	O
:	O
Six	O
trials	O
(	O
N	O
=	O
3694	O
)	O
met	O
the	O
inclusion	O
criteria	O
for	O
this	O
review	O
.	O

Aliskiren	O
was	O
the	O
only	O
renin	O
inhibitor	O
studied	O
in	O
these	O
studies	O
.	O

The	O
meta	O
-	O
analysis	O
shows	O
that	O
aliskiren	O
has	O
a	O
dose	O
-	O
related	O
both	O
systolic	O
/	O
diastolic	O
blood	O
pressure	B
lowering	O
effect	O
as	O
compared	O
to	O
placebo	O
:	O
aliskiren	O
75	O
mg	O
-	O
2.9	O
/	O
-	O
2.3	O
mmHg	O
,	O
aliskiren	O
150	O
mg	O
-	O
5.5	O
/	O
-	O
3.0	O
mmHg	O
,	O
aliskiren	O
300	O
mg	O
-	O
8.7	O
/	O
-	O
5.0	O
,	O
aliskiren	O
600	O
mg	O
-	O
11.4	O
/	O
-	O
6.6	O
mmHg	O
.	O

Aliskiren	O
300	O
mg	O
significantly	O
lowered	O
both	O
SBP	O
and	O
DBP	O
as	O
compared	O
to	O
aliskiren	O
150	O
mg	O
(	O
SBP	O
:	O
-	O
2.97	O
(	O
95	O
%	O
CI	O
-	O
3.99	O
,	O
-	O
1.95	O
)	O
and	O
DBP	O
:	O
-	O
1.66	O
(	O
95	O
%	O
CI	O
-	O
2.32	O
,	O
-	O
1.0	O
)	O
.	O

Aliskiren	O
has	O
no	O
effect	O
on	O
blood	O
pressure	B
variability	O
.	O

No	O
data	O
was	O
available	O
to	O
assess	O
the	O
effect	O
of	O
aliskiren	O
on	O
heart	O
rate	O
and	O
pulse	O
pressure	B
.	O

This	O
review	O
found	O
weak	O
evidence	O
that	O
with	O
short	O
-	O
term	O
use	O
,	O
aliskiren	O
does	O
not	O
increase	O
withdrawals	O
due	O
to	O
adverse	O
effects	O
as	O
compared	O
to	O
placebo	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Aliskiren	O
has	O
a	O
dose	O
-	O
related	O
blood	O
pressure	B
lowering	O
effect	O
better	O
than	O
placebo	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
determined	O
for	O
ACE	O
inhibitors	O
and	O
ARBs	O
.	O

Fragrance	O
material	O
review	O
on	O
tricyclodecanyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
tricyclodecanyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

NRF2	O
as	O
a	O
determinant	O
of	O
cellular	O
resistance	O
in	O
retinoic	O
acid	O
cytotoxicity	B
.	O

Clinical	O
use	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
is	O
hindered	O
by	O
toxicity	O
possibly	O
related	O
to	O
oxidative	O
stress	O
.	O

Recently	O
,	O
RA	O
at	O
relatively	O
low	O
concentrations	O
was	O
shown	O
to	O
inhibit	O
NRF2	O
and	O
the	O
expression	O
of	O
its	O
target	O
antioxidative	O
genes	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
RA	B
toxicity	I
may	O
result	O
from	O
cellular	O
inability	O
to	O
cope	O
with	O
resultant	O
oxidative	O
stress	O
.	O

Using	O
in	O
vitro	O
cell	O
and	O
in	O
vivo	O
mouse	O
models	O
,	O
we	O
report	O
that	O
RA	O
,	O
specifically	O
all	O
-	O
trans	O
-	O
RA	O
(	O
atRA	O
)	O
at	O
concentrations	O
implicated	O
in	O
toxicity	O
,	O
can	O
activate	O
NRF2	O
and	O
induce	O
NRF2	O
target	O
genes	O
,	O
particularly	O
the	O
subunits	O
of	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
glutathione	O
biosynthesis	O
,	O
glutamate	O
cysteine	O
ligase	O
(	O
GCLM	O
/	O
GCLC	O
)	O
.	O

RNA	O
interference	O
-	O
mediated	O
silencing	O
of	O
NRF2	O
,	O
but	O
not	O
of	O
retinoid	O
X	O
receptor	O
-	O
alpha	O
and	O
-	O
beta	O
,	O
reduced	O
basal	O
and	O
atRA	O
-	O
induced	O
GCLM	O
/	O
GCLC	O
gene	O
expression	O
.	O

Moreover	O
,	O
RA	O
increased	O
nuclear	O
accumulation	O
of	O
NRF2	O
,	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
reporter	O
activity	O
,	O
and	O
NRF2	O
occupancy	O
at	O
AREs	O
.	O

4	O
-	O
Hydroxynonenal	O
,	O
a	O
lipid	O
peroxidation	O
product	O
,	O
was	O
increased	O
by	O
RA	O
.	O

Inhibition	O
of	O
MEK1	O
/	O
ERK	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
significantly	O
suppressed	O
atRA	O
-	O
induced	O
NRF2	O
activation	O
and	O
ARE	O
-	O
regulated	O
gene	O
expression	O
,	O
reducing	O
cell	O
resistance	O
against	O
toxic	O
concentrations	O
of	O
RA	O
.	O

NRF2	O
-	O
silenced	O
cells	O
were	O
vulnerable	O
to	O
atRA	O
-	O
induced	O
mitochondrial	B
toxicity	I
and	O
apoptosis	O
.	O

In	O
conclusion	O
,	O
toxic	O
RA	O
activates	O
NRF2	O
,	O
thereby	O
triggering	O
an	O
adaptive	O
response	O
against	O
the	O
resultant	O
oxidative	O
stress	O
.	O

NRF2	O
enhancement	O
as	O
a	O
therapeutic	O
target	O
of	O
retinoid	O
toxicity	O
awaits	O
further	O
investigation	O
.	O

Renin	O
-	O
angiotensin	O
-	O
aldosterone	O
responsiveness	O
to	O
low	O
sodium	O
and	O
blood	O
pressure	O
reactivity	O
to	O
angiotensin	O
-	O
II	O
are	O
unrelated	O
to	O
cholesteryl	O
ester	O
transfer	O
protein	O
mass	O
in	O
healthy	O
subjects	O
.	O

BACKGROUND	O
:	O
The	O
blood	O
pressure	O
increase	O
associated	O
with	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
inhibitor	O
,	O
torcetrapib	O
is	O
probably	O
attributable	O
to	O
an	O
off	O
-	O
target	O
effect	O
but	O
it	O
is	O
unknown	O
whether	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
may	O
be	O
related	O
to	O
variation	O
in	O
the	O
plasma	O
CETP	O
level	O
.	O

We	O
questioned	O
whether	O
the	O
plasma	O
CETP	O
level	O
would	O
affect	O
RAAS	O
responsiveness	O
to	O
low	O
sodium	O
diet	O
and	O
the	O
blood	O
pressure	O
response	O
to	O
angiotensin	O
-	O
II	O
infusion	O
in	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
RAAS	O
parameters	O
and	O
blood	O
pressure	O
were	O
determined	O
during	O
liberal	O
sodium	O
diet	O
(	O
200	O
mmol	O
/	O
24	O
h	O
)	O
and	O
low	O
sodium	O
diet	O
(	O
50	O
mmol	O
/	O
24	O
h	O
)	O
in	O
67	O
healthy	O
men	O
.	O

Blood	O
pressure	O
response	O
to	O
incremental	O
angiotensin	O
-	O
II	O
infusion	O
was	O
assessed	O
in	O
34	O
subjects	O
during	O
liberal	O
sodium	O
diet	O
.	O

Correlation	O
analysis	O
was	O
performed	O
to	O
test	O
whether	O
RAAS	O
responsiveness	O
and	O
blood	O
pressure	O
were	O
related	O
to	O
plasma	O
CETP	O
mass	O
,	O
high	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
and	O
apolipoprotein	O
A	O
-	O
I	O
measured	O
during	O
liberal	O
sodium	O
diet	O
.	O

RESULTS	O
:	O
CETP	O
mass	O
ranged	O
from	O
1.29	O
to	O
2.95	O
mg	O
/	O
l	O
.	O

No	O
significant	O
differences	O
in	O
(	O
changes	O
)	O
in	O
mean	O
arterial	O
pressure	O
,	O
aldosterone	O
and	O
active	O
plasma	O
renin	O
concentration	O
in	O
response	O
to	O
low	O
sodium	O
were	O
observed	O
between	O
the	O
lowest	O
and	O
highest	O
tertiles	O
of	O
CETP	O
mass	O
,	O
HDL	O
-	O
C	O
and	O
apolipoprotein	O
A	O
-	O
I	O
.	O

These	O
outcome	O
variables	O
were	O
also	O
not	O
significantly	O
correlated	O
with	O
CETP	O
,	O
HDL	O
-	O
C	O
and	O
apolipoprotein	O
A	O
-	O
I	O
,	O
except	O
for	O
a	O
modest	O
relation	O
of	O
aldosterone	O
measured	O
during	O
low	O
sodium	O
with	O
apolipoprotein	O
A	O
-	O
I	O
(	O
r	O
=	O
0.28	O
,	O
p	O
=	O
0.022	O
)	O
.	O

Blood	O
pressure	O
response	O
to	O
angiotensin	O
-	O
II	O
was	O
similar	O
between	O
CETP	O
tertiles	O
.	O

CONCLUSIONS	O
:	O
Mineralocorticoid	O
and	O
blood	O
pressure	O
responsiveness	O
to	O
dietary	O
salt	O
intake	O
are	O
not	O
significantly	O
related	O
to	O
physiological	O
interindividual	O
differences	O
in	O
plasma	O
CETP	O
.	O

We	O
suggest	O
that	O
a	O
lower	O
CETP	O
mass	O
does	O
not	O
exert	O
adverse	O
effects	O
on	O
blood	O
pressure	O
regulation	O
.	O

D	O
-	O
chiro	O
-	O
inositol	O
-	O
enriched	O
tartary	O
buckwheat	O
bran	O
extract	O
lowers	O
the	O
blood	O
glucose	O
level	O
in	O
KK	O
-	O
Ay	O
mice	O
.	O

D	O
-	O
chiro	O
-	O
inositol	O
(	O
DCI	O
)	O
is	O
an	O
active	O
compound	O
in	O
tartary	O
buckwheat	O
[	O
Fagopyrum	O
tataricum	O
(	O
L	O
.	O
)	O

Gaench	O
]	O
with	O
an	O
insulin	O
-	O
like	O
bioactivity	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
(	O
i	O
)	O
prepare	O
DCI	O
-	O
enriched	O
tartary	O
buckwheat	O
bran	O
extract	O
(	O
TBBE	O
)	O
,	O
(	O
ii	O
)	O
evaluate	O
its	O
acute	B
toxicity	I
in	O
mice	O
,	O
and	O
(	O
iii	O
)	O
examine	O
its	O
blood	O
glucose	O
lowering	O
activity	O
in	O
diabetic	O
mice	O
.	O

It	O
was	O
found	O
that	O
steaming	O
buckwheat	O
bran	O
in	O
an	O
autoclave	O
at	O
1.6	O
MPa	O
and	O
120	O
degrees	O
C	O
for	O
60	O
min	O
could	O
significantly	O
enrich	O
the	O
DCI	O
level	O
in	O
TBBE	O
from	O
0.03	O
to	O
0.22	O
%	O
and	O
further	O
to	O
22	O
%	O
after	O
passage	O
of	O
the	O
TBBE	O
through	O
activated	O
carbon	O
and	O
ion	O
exchange	O
resins	O
.	O

An	O
acute	B
toxicity	I
test	O
demonstrated	O
that	O
the	O
LD	O
50	O
of	O
TBBE	O
was	O
>	O
20	O
g	O
/	O
kg	O
of	O
body	O
weight	O
in	O
mice	O
,	O
suggesting	O
that	O
TBBE	O
was	O
in	O
general	O
nontoxic	O
and	O
safe	O
in	O
mice	O
.	O

Male	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
(	O
type	B
2	I
diabetic	I
)	O
and	O
C57BL	O
/	O
6	O
mice	O
(	O
the	O
control	O
)	O
were	O
used	O
to	O
investigate	O
the	O
antidiabetic	O
activity	O
of	O
TBBE	O
.	O

In	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
,	O
the	O
blood	O
glucose	O
,	O
plasma	O
C	O
-	O
peptide	O
,	O
glucagon	O
,	O
total	O
cholesterol	O
,	O
triglyceride	O
,	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
levels	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
addition	O
,	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
showed	O
an	O
obvious	O
decrease	O
in	O
insulin	O
immunoreactivity	O
in	O
the	O
pancreas	O
.	O

The	O
present	O
study	O
clearly	O
demonstrated	O
that	O
oral	O
administration	O
of	O
DCI	O
-	O
enriched	O
TBBE	O
could	O
lower	O
plasma	O
glucose	O
,	O
C	O
-	O
peptide	O
,	O
glucagon	O
,	O
triglyceride	O
,	O
and	O
BUN	O
,	O
improve	O
glucose	O
tolerance	B
,	O
and	O
enhance	O
insulin	O
immunoreactivity	O
in	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
.	O

Optimal	O
timing	O
for	O
adjuvant	O
radiation	O
therapy	O
in	O
breast	B
cancer	I
:	O
a	O
comprehensive	O
review	O
and	O
perspectives	O
.	O

PURPOSE	O
:	O
The	O
optimal	O
sequence	O
of	O
modalities	O
involved	O
in	O
breast	B
cancer	I
treatment	O
with	O
respect	O
to	O
radiotherapy	O
and	O
the	O
maximum	O
acceptable	O
interval	O
between	O
radiotherapy	O
and	O
surgery	O
need	O
to	O
be	O
determined	O
.	O

DESIGN	O
:	O
This	O
review	O
attempts	O
a	O
critical	O
reading	O
of	O
the	O
literature	O
.	O

RESULTS	O
:	O
A	O
delay	O
of	O
radiotherapy	O
more	O
than	O
8	O
-	O
12	O
weeks	O
after	O
surgery	O
adversely	O
affects	O
local	O
recurrence	O
.	O

Radiotherapy	O
should	O
be	O
administered	O
within	O
7	O
months	O
after	O
surgery	O
,	O
when	O
chemotherapy	O
is	O
administered	O
first	O
.	O

Several	O
chemotherapy	O
regimens	O
can	O
be	O
safely	O
administered	O
concurrently	O
with	O
radiotherapy	O
.	O

The	O
concurrent	O
use	O
of	O
tamoxifen	O
with	O
chemotherapy	O
should	O
be	O
avoided	O
,	O
but	O
not	O
with	O
radiotherapy	O
.	O

Data	O
is	O
insufficient	O
with	O
regard	O
to	O
concurrent	O
use	O
of	O
aromatase	O
inhibitors	O
with	O
radiotherapy	O
.	O

The	O
use	O
of	O
trastuzumab	O
concomitantly	O
with	O
radiotherapy	O
may	O
enhance	O
toxicities	O
but	O
may	O
also	O
improve	O
its	O
efficacy	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
issue	O
of	O
radiotherapy	O
delay	O
and	O
that	O
of	O
sequence	O
with	O
chemotherapy	O
or	O
tamoxifen	O
are	O
clarified	O
,	O
the	O
sequence	O
of	O
radiotherapy	O
with	O
aromatase	O
inhibitors	O
and	O
trastuzumab	O
needs	O
to	O
be	O
defined	O
.	O

Individual	O
radiosensitivity	O
may	O
influence	O
toxicity	O
.	O

New	O
biologic	O
markers	O
have	O
to	O
be	O
determined	O
in	O
the	O
future	O
for	O
tailoring	O
radiotherapy	O
in	O
breast	B
cancer	I
.	O

Determinants	O
of	O
negative	O
white	O
-	O
coat	O
effect	O
in	O
treated	O
hypertensive	O
patients	O
:	O
the	O
Jichi	O
Morning	O
Hypertension	B
Research	O
(	O
J	O
-	O
MORE	O
)	O
study	O
.	O

BACKGROUND	O
:	O
The	O
negative	O
white	O
-	O
coat	O
effect	O
(	O
WCE	O
)	O
,	O
a	O
phenomenon	O
in	O
which	O
out	O
-	O
of	O
-	O
office	O
blood	O
pressure	O
(	O
BP	O
)	O
is	O
higher	O
than	O
clinic	O
BP	O
,	O
has	O
not	O
been	O
well	O
examined	O
,	O
unlike	O
the	O
WCE	O
.	O

METHODS	O
:	O
As	O
part	O
of	O
the	O
Jichi	O
Morning	O
Hypertension	B
Research	O
study	O
,	O
in	O
which	O
clinic	O
and	O
home	O
BP	O
were	O
measured	O
in	O
969	O
hypertensive	O
outpatients	O
,	O
405	O
patients	O
with	O
normal	O
clinic	O
BP	O
were	O
separately	O
analyzed	O
.	O

Clinic	O
BP	O
was	O
measured	O
on	O
two	O
different	O
occasions	O
,	O
and	O
home	O
BP	O
was	O
measured	O
twice	O
in	O
the	O
morning	O
and	O
twice	O
in	O
the	O
evening	O
for	O
three	O
consecutive	O
days	O
.	O

Clinic	O
and	O
home	O
BP	O
were	O
each	O
averaged	O
from	O
all	O
readings	O
,	O
and	O
negative	O
WCE	O
was	O
defined	O
as	O
clinic	O
systolic	O
BP	O
(	O
SBP	O
)	O
lower	O
than	O
home	O
SBP	O
.	O

RESULTS	O
:	O
Negative	O
WCE	O
was	O
observed	O
in	O
324	O
(	O
33	O
%	O
)	O
of	O
the	O
patients	O
overall	O
and	O
in	O
173	O
(	O
42	O
%	O
)	O
of	O
the	O
patients	O
with	O
controlled	O
BP	O
(	O
clinic	O
BP	O
<	O
140	O
/	O
90	O
mm	O
Hg	O
)	O
.	O

In	O
multiple	O
logistic	O
regression	O
analysis	O
adjusting	O
for	O
covariates	O
including	O
home	O
SBP	O
and	O
pulse	O
rate	O
,	O
negative	O
WCE	O
was	O
correlated	O
with	O
older	O
age	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
1.03	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.01	O
-	O
1.06	O
)	O
and	O
male	O
gender	O
(	O
OR	O
1.08	O
,	O
95	O
%	O
CI	O
1.01	O
-	O
1.14	O
)	O
in	O
overall	O
subjects	O
.	O

Among	O
patients	O
with	O
well	O
-	O
controlled	O
clinic	O
BP	O
,	O
negative	O
WCE	O
was	O
significantly	O
correlated	O
with	O
the	O
presence	O
of	O
ischemic	B
heart	I
disease	I
(	O
OR	O
1.17	O
,	O
95	O
%	O
CI	O
1.04	O
-	O
1.31	O
)	O
.	O

The	O
association	O
of	O
negative	O
WCE	O
with	O
age	O
and	O
male	O
gender	O
remained	O
significant	O
under	O
stringent	O
criteria	O
(	O
negative	O
WCE	O
<	O
-	O
10.2	O
mm	O
Hg	O
(	O
the	O
mean	O
-	O
1	O
s	O
.	O

d	O
.	O
)	O
)	O
.	O

CONCLUSIONS	O
:	O
Negative	O
WCE	O
remaining	O
even	O
after	O
clinic	O
BP	O
is	O
controlled	O
may	O
be	O
related	O
to	O
cardiovascular	O
risk	O
factors	O
such	O
as	O
older	O
age	O
,	O
male	O
gender	O
,	O
and	O
a	O
history	O
of	O
ischemic	B
heart	I
disease	I
.	O

Addition	O
of	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
:	O
Oral	O
sildenafil	O
and	O
intravenous	O
epoprostenol	O
have	O
independently	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adding	O
oral	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
.	O

DESIGN	O
:	O
A	O
16	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
.	O

SETTING	O
:	O
Multinational	O
study	O
at	O
41	O
centers	O
in	O
11	O
countries	O
from	O
3	O
July	O
2003	O
to	O
27	O
January	O
2006	O
.	O

PATIENTS	O
:	O
267	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
(	O
idiopathic	O
,	O
associated	O
anorexigen	O
use	O
or	O
connective	B
tissue	I
disease	I
,	O
or	O
corrected	O
congenital	B
heart	I
disease	I
)	O
who	O
were	O
receiving	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
.	O

INTERVENTION	O
:	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
sildenafil	O
,	O
20	O
mg	O
three	O
times	O
daily	O
,	O
titrated	O
to	O
40	O
mg	O
and	O
80	O
mg	O
three	O
times	O
daily	O
,	O
as	O
tolerated	O
,	O
at	O
4	O
-	O
week	O
intervals	O
.	O

Of	O
265	O
patients	O
who	O
received	O
treatment	O
,	O
256	O
(	O
97	O
%	O
)	O
patients	O
(	O
123	O
in	O
the	O
placebo	O
group	O
and	O
133	O
in	O
the	O
sildenafil	O
group	O
)	O
completed	O
the	O
study	O
.	O

MEASUREMENTS	O
:	O
Change	O
from	O
baseline	O
in	O
exercise	O
capacity	O
measured	O
by	O
6	O
-	O
minute	O
walk	O
distance	O
(	O
primary	O
end	O
point	O
)	O
and	O
hemodynamic	O
measurements	O
,	O
time	O
to	O
clinical	O
worsening	O
,	O
and	O
Borg	O
dyspnea	B
score	O
(	O
secondary	O
end	O
points	O
)	O
.	O

RESULTS	O
:	O
A	O
placebo	O
-	O
adjusted	O
increase	O
of	O
28.8	O
meters	O
(	O
95	O
%	O
CI	O
,	O
13.9	O
to	O
43.8	O
meters	O
)	O
in	O
the	O
6	O
-	O
minute	O
walk	O
distance	O
occurred	O
in	O
patients	O
in	O
the	O
sildenafil	O
group	O
;	O
these	O
improvements	O
were	O
most	O
prominent	O
among	O
patients	O
with	O
baseline	O
distances	O
of	O
325	O
meters	O
or	O
more	O
.	O

Relative	O
to	O
epoprostenol	O
monotherapy	O
,	O
addition	O
of	O
sildenafil	O
resulted	O
in	O
a	O
greater	O
change	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
by	O
-	O
3.8	O
mm	O
Hg	O
(	O
CI	O
,	O
-	O
5.6	O
to	O
-	O
2.1	O
mm	O
Hg	O
)	O
;	O
cardiac	O
output	O
by	O
0.9	O
L	O
/	O
min	O
(	O
CI	O
,	O
0.5	O
to	O
1.2	O
L	O
/	O
min	O
)	O
;	O
and	O
longer	O
time	O
to	O
clinical	O
worsening	O
,	O
with	O
a	O
smaller	O
proportion	O
of	O
patients	O
experiencing	O
a	O
worsening	O
event	O
in	O
the	O
sildenafil	O
group	O
(	O
0.062	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
0.195	O
)	O
by	O
week	O
16	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Health	O
-	O
related	O
quality	O
of	O
life	O
also	O
improved	O
in	O
patients	O
who	O
received	O
combined	O
therapy	O
compared	O
with	O
those	O
who	O
received	O
epoprostenol	O
monotherapy	O
.	O

There	O
was	O
no	O
effect	O
on	O
the	O
Borg	O
dyspnea	O
score	O
.	O

Of	O
the	O
side	O
effects	O
generally	O
associated	O
with	O
sildenafil	O
treatment	O
,	O
the	O
most	O
commonly	O
reported	O
in	O
the	O
placebo	O
and	O
sildenafil	O
groups	O
,	O
respectively	O
,	O
were	O
headache	B
(	O
34	O
%	O
and	O
57	O
%	O
;	O
difference	O
,	O
23	O
percentage	O
points	O
[	O
CI	O
,	O
12	O
to	O
35	O
percentage	O
points	O
]	O
)	O
,	O
dyspepsia	B
(	O
2	O
%	O
and	O
16	O
%	O
;	O
difference	O
,	O
13	O
percentage	O
points	O
[	O
CI	O
,	O
7	O
to	O
20	O
percentage	O
points	O
]	O
)	O
,	O
pain	B
in	O
extremity	O
(	O
18	O
%	O
and	O
25	O
%	O
;	O
difference	O
,	O
8	O
percentage	O
points	O
[	O
CI	O
,	O
-	O
2	O
to	O
18	O
percentage	O
points	O
]	O
)	O
,	O
and	O
nausea	B
(	O
18	O
%	O
and	O
25	O
%	O
;	O
difference	O
,	O
8	O
percentage	O
points	O
[	O
CI	O
,	O
-	O
2	O
to	O
18	O
percentage	O
points	O
]	O
)	O
.	O

LIMITATIONS	O
:	O
The	O
study	O
excluded	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
associated	O
with	O
other	O
causes	O
.	O

There	O
was	O
an	O
imbalance	O
in	O
missing	O
data	O
between	O
groups	O
,	O
with	O
8	O
placebo	O
recipients	O
having	O
no	O
postbaseline	O
walk	O
assessment	O
compared	O
with	O
1	O
sildenafil	O
recipient	O
.	O

These	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

CONCLUSION	O
:	O
In	O
some	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
,	O
the	O
addition	O
of	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
improves	O
exercise	O
capacity	O
,	O
hemodynamic	O
measurements	O
,	O
time	O
to	O
clinical	O
worsening	O
,	O
and	O
quality	O
of	O
life	O
,	O
but	O
not	O
Borg	O
dyspnea	B
score	O
.	O

Increased	O
rates	O
of	O
headache	B
and	O
dyspepsia	B
occurred	O
with	O
the	O
addition	O
of	O
sildenafil	O
.	O

Capecitabine	O
:	O
have	O
we	O
got	O
the	O
dose	O
right	O
?	O

In	O
the	O
past	O
5	O
-	O
10	O
years	O
there	O
has	O
been	O
a	O
growing	O
trend	O
for	O
substituting	O
conventional	O
5	O
-	O
fluorouracil	O
with	O
the	O
oral	O
prodrug	O
of	O
5	O
-	O
fluorouracil	O
,	O
capecitabine	O
,	O
in	O
chemotherapy	O
regimens	O
.	O

This	O
regimen	O
change	O
is	O
based	O
on	O
evidence	O
of	O
the	O
efficacy	O
equivalence	O
of	O
these	O
two	O
drugs	O
and	O
the	O
lack	O
of	O
an	O
increase	O
in	O
overall	O
toxic	O
effects	O
when	O
capecitabine	O
is	O
used	O
.	O

Many	O
investigators	O
in	O
different	O
parts	O
of	O
the	O
world	O
have	O
determined	O
their	O
own	O
starting	O
dose	O
for	O
capecitabine	O
,	O
usually	O
based	O
on	O
their	O
experience	O
of	O
toxic	O
events	O
within	O
the	O
population	O
of	O
patients	O
they	O
treat	O
.	O

This	O
starting	O
dose	O
is	O
usually	O
between	O
1,000	O
-	O
1,250	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
which	O
is	O
generally	O
administered	O
twice	O
daily	O
for	O
14	O
days	O
followed	O
by	O
7	O
days	O
rest	O
.	O

This	O
Review	O
summarizes	O
why	O
there	O
may	O
indeed	O
not	O
be	O
a	O
universally	O
applicable	O
starting	O
dose	O
for	O
capecitabine	O
because	O
of	O
interpatient	O
differences	O
in	O
basic	O
physiology	O
,	O
pharmacogenomics	O
and	O
diet	O
.	O

This	O
article	O
also	O
explores	O
which	O
of	O
these	O
factors	O
contribute	O
to	O
the	O
observed	O
inter	O
-	O
regional	O
geographical	O
variation	O
in	O
capecitabine	O
toxicity	O
,	O
and	O
explains	O
why	O
even	O
within	O
a	O
region	O
various	O
factors	O
should	O
prompt	O
a	O
clinician	O
to	O
modify	O
the	O
starting	O
dose	O
.	O

Predicting	O
and	O
preventing	O
acute	B
kidney	I
injury	I
after	O
cardiac	O
surgery	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
Acute	B
kidney	I
injury	I
(	O
AKI	B
)	O
after	O
cardiac	O
surgery	O
is	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

Despite	O
the	O
proliferation	O
of	O
predictive	O
clinical	O
scoring	O
models	O
of	O
renal	O
risk	O
after	O
cardiac	O
surgery	O
,	O
limitations	O
in	O
preventing	O
AKI	O
through	O
the	O
use	O
of	O
pharmacological	O
agents	O
remain	O
.	O

Here	O
we	O
review	O
the	O
evolution	O
of	O
predictive	O
models	O
of	O
renal	O
risk	O
after	O
cardiac	O
surgery	O
,	O
and	O
highlight	O
the	O
important	O
gains	O
made	O
in	O
preventing	O
its	O
occurrence	O
.	O

RECENT	O
FINDINGS	O
:	O
Simple	O
risk	O
indices	O
predicting	O
AKI	O
after	O
cardiac	O
surgery	O
have	O
been	O
developed	O
and	O
can	O
now	O
be	O
readily	O
applied	O
clinically	O
.	O

However	O
,	O
studies	O
focusing	O
on	O
preventing	O
AKI	O
after	O
surgery	O
have	O
yet	O
to	O
demonstrate	O
any	O
consistent	O
renoprotective	O
effect	O
.	O

SUMMARY	O
:	O
Clinical	O
scoring	O
systems	O
predicting	O
AKI	O
risk	O
after	O
cardiac	O
surgery	O
are	O
available	O
and	O
should	O
be	O
employed	O
in	O
the	O
preoperative	O
assessment	O
.	O

Elucidation	O
of	O
beneficial	O
preventive	O
strategies	O
of	O
AKI	O
after	O
cardiac	O
surgery	O
requires	O
ongoing	O
research	O
.	O

Transient	O
gene	O
delivery	O
for	O
functional	O
enrichment	O
of	O
differentiating	O
embryonic	O
stem	O
cells	O
.	O

There	O
is	O
a	O
critical	O
need	O
for	O
new	O
sources	O
of	O
hepatocytes	O
,	O
both	O
clinically	O
to	O
provide	O
support	O
for	O
patients	O
with	O
liver	B
failure	I
and	O
in	O
drug	O
discovery	O
for	O
toxicity	O
,	O
metabolic	O
and	O
pharmacokinetic	O
screening	O
of	O
new	O
drug	O
entities	O
.	O

We	O
have	O
reported	O
previously	O
a	O
variety	O
of	O
methods	O
for	O
differentiating	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
into	O
hepatocyte	O
-	O
like	O
cells	O
.	O

One	O
major	O
challenge	O
of	O
our	O
work	O
and	O
others	O
in	O
the	O
field	O
has	O
been	O
the	O
ability	O
to	O
selectively	O
purify	O
and	O
enrich	O
these	O
cells	O
from	O
a	O
heterogeneous	O
population	O
.	O

Traditional	O
approaches	O
for	O
inserting	O
new	O
genes	O
(	O
e.g.	O
,	O
stable	O
transfection	O
,	O
knock	O
-	O
in	O
,	O
retroviral	O
transduction	O
)	O
involve	O
permanent	O
alterations	O
in	O
the	O
genome	O
.	O

These	O
approaches	O
can	O
lead	O
to	O
mutations	O
and	O
involve	O
the	O
extra	O
costs	O
and	O
time	O
of	O
developing	O
,	O
validating	O
and	O
maintaining	O
new	O
cell	O
lines	O
.	O

We	O
have	O
developed	O
a	O
transient	O
gene	O
delivery	O
system	O
that	O
uses	O
fluorescent	O
gene	O
reporters	O
for	O
purification	O
of	O
the	O
cells	O
.	O

Following	O
a	O
transient	O
transfection	O
,	O
the	O
cells	O
are	O
purified	O
through	O
a	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
(	O
FACS	O
)	O
,	O
re	O
-	O
plated	O
in	O
secondary	O
culture	O
and	O
subsequent	O
phenotypic	O
analysis	O
is	O
performed	O
.	O

In	O
an	O
effort	O
to	O
test	O
the	O
ability	O
of	O
the	O
reporters	O
to	O
work	O
in	O
a	O
transient	O
environment	O
for	O
our	O
differentiation	O
system	O
,	O
we	O
engineered	O
two	O
non	O
-	O
viral	O
plasmid	O
reporters	O
,	O
the	O
first	O
driven	O
by	O
the	O
mouse	O
albumin	O
enhancer	O
/	O
promoter	O
and	O
the	O
second	O
by	O
the	O
mouse	O
cytochrome	O
P450	O
7A1	O
(	O
Cyp7A1	O
)	O
promoter	O
.	O

We	O
optimized	O
the	O
transfection	O
efficiency	O
of	O
delivering	O
these	O
genes	O
into	O
spontaneously	O
differentiated	O
ES	O
cells	O
and	O
sorted	O
independent	O
fractions	O
positive	O
for	O
each	O
reporter	O
17	O
days	O
after	O
inducing	O
differentiation	O
.	O

We	O
found	O
that	O
cells	O
sorted	O
based	O
on	O
the	O
Cyp7A1	O
promoter	O
showed	O
significant	O
enrichment	O
in	O
terms	O
of	O
albumin	O
secretion	O
,	O
urea	O
secretion	O
and	O
cytochrome	O
P450	O
1A2	O
detoxification	O
activity	O
as	O
compared	O
to	O
enrichment	O
garnered	O
by	O
the	O
albumin	O
promoter	O
-	O
based	O
cell	O
sort	O
.	O

Development	O
of	O
gene	O
reporter	O
systems	O
that	O
allow	O
us	O
to	O
identify	O
,	O
purify	O
and	O
assess	O
homogeneous	O
populations	O
of	O
cells	O
is	O
important	O
in	O
better	O
understanding	O
stem	O
cell	O
differentiation	O
pathways	O
.	O

And	O
engineering	O
cellular	O
systems	O
without	O
making	O
permanent	O
gene	O
changes	O
will	O
be	O
critical	O
for	O
the	O
generation	O
of	O
clinically	O
acceptable	O
cellular	O
material	O
in	O
the	O
future	O
.	O

Two	O
modes	O
of	O
microsatellite	O
instability	O
in	O
human	O
cancer	B
:	O
differential	O
connection	O
of	O
defective	O
DNA	O
mismatch	O
repair	O
to	O
dinucleotide	O
repeat	O
instability	O
Abstract	O
Microsatellite	O
instability	O
(	O
MSI	O
)	O
is	O
associated	O
with	O
defective	O
DNA	O
mismatch	O
repair	O
in	O
various	O
human	O
malignancies	B
.	O

Using	O
a	O
unique	O
fluorescent	O
technique	O
,	O
we	O
have	O
observed	O
two	O
distinct	O
modes	O
of	O
dinucleotide	O
microsatellite	O
alterations	O
in	O
human	O
colorectal	B
cancer	I
.	O

Type	O
A	O
alterations	O
are	O
defined	O
as	O
length	O
changes	O
of	O
≤6	O
bp	O
.	O

Type	O
B	O
changes	O
are	O
more	O
drastic	O
and	O
involve	O
modifications	O
of	O
≥8	O
bp	O
.	O

We	O
show	O
here	O
that	O
defective	O
mismatch	O
repair	O
is	O
necessary	O
and	O
sufficient	O
for	O
Type	O
A	O
changes	O
.	O

These	O
changes	O
were	O
observed	O
in	O
cell	O
lines	O
and	O
in	O
tumours	B
from	O
mismatch	O
repair	O
gene	O
-	O
knockout	O
mice	O
.	O

No	O
Type	O
B	O
instability	O
was	O
seen	O
in	O
these	O
cells	O
or	O
tumours	B
.	O

In	O
a	O
panel	O
of	O
human	O
colorectal	O
tumours	B
,	O
both	O
Type	O
A	O
MSI	O
and	O
Type	O
B	O
instability	O
were	O
observed	O
.	O

Both	O
types	O
of	O
MSI	O
were	O
associated	O
with	O
hMSH2	O
or	O
hMLH1	O
mismatch	O
repair	O
gene	O
alterations	O
.	O

Intriguingly	O
,	O
p53	O
mutations	O
,	O
which	O
are	O
generally	O
regarded	O
as	O
uncommon	O
in	O
human	O
tumours	B
of	O
the	O
MSI+	B
phenotype	O
,	O
were	O
frequently	O
associated	O
with	O
Type	B
A	I
instability	I
,	O
whereas	O
none	O
was	O
found	O
in	O
tumours	B
with	O
Type	B
B	I
instability	I
,	O
reflecting	O
the	O
prevailing	O
viewpoint	O
.	O

Inspection	O
of	O
published	O
data	O
reveals	O
that	O
the	O
microsatellite	O
instability	O
that	O
has	O
been	O
observed	O
in	O
various	O
malignancies	O
,	O
including	O
those	O
associated	O
with	O
Hereditary	B
Non	I
-	I
Polyposis	I
Colorectal	I
Cancer	I
(	O
HNPCC	B
)	O
,	O
is	O
predominantly	O
Type	O
B.	O
Our	O
findings	O
indicate	O
that	O
Type	O
B	O
instability	O
is	O
not	O
a	O
simple	O
reflection	O
of	O
a	O
repair	O
defect	O
.	O

We	O
suggest	O
that	O
there	O
are	O
at	O
least	O
two	O
qualitatively	O
distinct	O
modes	O
of	O
dinucleotide	B
MSI	I
in	O
human	O
colorectal	B
cancer	I
,	O
and	O
that	O
different	O
molecular	O
mechanisms	O
may	O
underlie	O
these	O
modes	O
of	O
MSI	O
.	O

The	O
relationship	O
between	O
MSI	O
and	O
defective	O
mismatch	O
repair	O
may	O
be	O
more	O
complex	O
than	O
hitherto	O
suspected	O
.	O

Analysis	O
of	O
microsatellites	O
in	O
MEFs	O
and	O
tumours	B
from	O
MMR	O
-	O
defective	O
animals	O
therefore	O
indicates	O
that	O
Type	O
A	O
MSI	O
is	O
a	O
direct	O
consequence	O
of	O
defective	O
MMR	O
.	O

The	O
absence	O
of	O
more	O
extensive	O
microsatellite	O
length	O
changes	O
may	O
indicate	O
further	O
that	O
an	O
Msh2	O
or	O
Mlh1	O
defect	O
is	O
insufficient	O
for	O
the	O
development	O
of	O
Type	O
B	O
instability	O
.	O

Mismatch	O
repair	O
gene	O
inactivation	O
is	O
associated	O
with	O
both	O
Type	O
A	O
and	O
Type	O
B	O
MSI	O
in	O
human	O
colorectal	B
cancer	I
HNPCC	B
patients	O
inherit	O
mutations	O
in	O
MMR	O
genes	O
(	O
6,7	O
)	O
.	O

More	O
than	O
90	O
%	O
of	O
HNPCC	B
tumours	B
are	O
MSI+	B
(	O
20	O
)	O
.	O

The	O
MSI+	O
phenotype	O
is	O
also	O
frequent	O
among	O
sporadic	O
colorectal	O
carcinomas	B
(	O
2–4,6,21	O
)	O
.	O

Inspection	O
of	O
published	O
data	O
derived	O
from	O
the	O
conventional	O
microsatellite	O
analysis	O
reveals	O
that	O
microsatellite	O
changes	O
thus	O
far	O
reported	O
in	O
various	O
tumours	B
,	O
including	O
those	O
in	O
HNPCC	B
individuals	O
,	O
are	O
largely	O
Type	O
B	O
(	O
2–4,20–22	O
)	O
.	O

We	O
considered	O
the	O
possibility	O
that	O
the	O
more	O
subtle	O
Type	O
A	O
MSI	O
might	O
have	O
remained	O
undetected	O
in	O
some	O
cases	O
.	O

Using	O
our	O
fluorescent	O
assay	O
with	O
a	O
panel	O
of	O
five	O
dinucleotide	O
repeat	O
microsatellites	O
,	O
we	O
found	O
that	O
the	O
frequencies	O
of	O
Type	O
A	O
and	O
Type	B
B	I
MSI	I
among	O
79	O
colorectal	O
carcinomas	B
were	O
30	O
%	O
and	O
17	O
%	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
that	O
Type	O
B	O
instability	O
is	O
common	O
in	O
HNPCC	B
colon	B
tumours	I
,	O
the	O
IC690	O
tumour	B
and	O
the	O
colorectal	O
carcinoma	B
cell	O
line	O
,	O
NoTa	O
(	O
Table	O
1	O
)	O
,	O
both	O
of	O
which	O
were	O
derived	O
from	O
patients	O
who	O
fulfilled	O
the	O
Amsterdam	O
Criteria	O
II	O
for	O
HNPCC	B
(	O
23	O
)	O
,	O
exhibited	O
Type	O
B	O
instability	O
(	O
Figure	O
1	O
G	O
and	O
H	O
)	O
.	O

Our	O
finding	O
that	O
17	O
%	O
of	O
colorectal	O
tumours	B
display	O
Type	B
B	I
MSI	I
is	O
consistent	O
with	O
the	O
generally	O
reported	O
figure	O
of	O
around	O
20	O
%	O
for	O
MSI	B
among	O
colorectal	O
carcinomas	B
(	O
20,24,25	O
)	O
.	O

The	O
observation	O
that	O
a	O
further	O
30	O
%	O
of	O
tumours	B
displayed	O
Type	B
A	I
MSI	I
suggests	O
that	O
the	O
frequency	O
of	O
MSI	O
,	O
at	O
least	O
in	O
colorectal	O
carcinomas	B
,	O
has	O
previously	O
been	O
underestimated	O
.	O

The	O
relationship	O
between	O
MSI	O
and	O
defective	O
MMR	O
in	O
our	O
set	O
of	O
colorectal	O
tumours	B
was	O
investigated	O
further	O
.	O

hMSH2	O
and	O
hMLH1	O
MMR	O
genes	O
of	O
12	O
tumours	B
with	O
Type	O
A	O
and	O
9	O
with	O
Type	B
B	I
MSI	I
were	O
sequenced	O
.	O

The	O
same	O
genes	O
in	O
the	O
NoTa	O
cell	O
line	O
were	O
also	O
sequenced	O
(	O
Figure	O
3A	O
and	O
Table	O
1	O
)	O
.	O

Sequence	O
alterations	O
causing	O
amino	O
acid	O
substitutions	O
were	O
identified	O
in	O
5	O
of	O
the	O
21	O
tumours	B
.	O

Four	O
of	O
these	O
(	O
80	O
%	O
)	O
were	O
associated	O
with	O
Type	B
A	I
MSI	I
.	O

In	O
addition	O
,	O
one	O
patient	O
with	O
Type	B
A	I
MSI	I
(	O
IC793	O
)	O
in	O
whom	O
no	O
mutation	O
was	O
identified	O
was	O
negative	O
for	O
immunohistochemical	O
staining	O
of	O
hMLH1	O
(	O
Figure	O
3B	O
,	O
panel	O
b	O
)	O
.	O

This	O
is	O
consistent	O
with	O
a	O
possible	O
epigenetic	O
hMLH1	O
gene	O
silencing	O
(	O
26–28	O
)	O
.	O

In	O
one	O
other	O
Type	O
A	O
case	O
(	O
IC669	O
)	O
and	O
one	O
Type	O
B	O
case	O
(	O
IC690	O
)	O
,	O
there	O
was	O
an	O
abnormal	O
intracellular	O
distribution	O
of	O
hMLH1	O
which	O
remained	O
predominantly	O
cytoplasmic	O
(	O
Figure	O
3B	O
,	O
panels	O
c	O
and	O
d	O
)	O
.	O

Among	O
the	O
10	O
tumours	B
displaying	O
Type	B
B	I
MSI	I
,	O
there	O
was	O
an	O
example	O
of	O
base	O
substitutions	O
causing	O
amino	O
acid	O
change	O
in	O
hMLH1	O
.	O

In	O
this	O
case	O
,	O
IC690	O
,	O
the	O
failure	O
of	O
hMLH1	O
to	O
localize	O
to	O
the	O
nucleus	O
was	O
associated	O
with	O
the	O
codon	O
226	O
mutation	O
in	O
exon	O
8	O
(	O
Figure	O
3A	O
,	O
panel	O
c	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
Type	O
A	O
instability	O
,	O
as	O
well	O
as	O
Type	O
B	O
,	O
is	O
indeed	O
associated	O
with	O
MMR	O
defects	O
.	O

DISCUSSION	O
The	O
fluorescent	O
technique	O
we	O
used	O
here	O
allows	O
the	O
unequivocal	O
designation	O
of	O
Type	O
A	O
and	O
Type	O
B	O
MSI	O
,	O
and	O
has	O
revealed	O
a	O
previously	O
unrecognized	O
complexity	O
in	O
the	O
relationship	O
between	O
dinucleotide	O
MSI	O
and	O
defective	O
DNA	O
MMR	O
in	O
human	O
cancer	B
.	O

Type	O
A	O
MSI	O
(	O
changes	O
≤	O
6	O
bp	O
)	O
is	O
clearly	O
linked	O
with	O
MMR	O
inactivation	O
in	O
both	O
mice	O
and	O
humans	O
,	O
which	O
implies	O
that	O
Type	O
A	O
MSI	O
is	O
a	O
direct	O
consequence	O
of	O
defective	O
MMR	O
.	O

Since	O
we	O
found	O
no	O
evidence	O
of	O
Type	O
B	O
instability	O
(	O
changes	O
≥	O
8	O
bp	O
)	O
in	O
MMR	O
-	O
defective	O
animals	O
,	O
it	O
is	O
possible	O
that	O
changes	O
in	O
addition	O
to	O
repair	O
deficiency	O
contribute	O
to	O
,	O
or	O
are	O
responsible	O
for	O
,	O
Type	O
B	O
MSI	O
.	O

One	O
important	O
finding	O
of	O
this	O
study	O
is	O
that	O
Type	O
A	O
instability	O
is	O
frequent	O
among	O
human	O
tumours	B
.	O

Type	O
A	O
MSI	O
predominated	O
in	O
our	O
large	O
panel	O
of	O
colorectal	O
carcinomas	B
.	O

We	O
suggest	O
that	O
,	O
because	O
the	O
changes	O
associated	O
with	O
Type	O
A	O
instability	O
are	O
more	O
subtle	O
,	O
the	O
frequency	O
of	O
MSI	O
among	O
colorectal	O
tumours	B
may	O
have	O
been	O
considerably	O
underestimated	O
.	O

Our	O
findings	O
also	O
reveal	O
a	O
hitherto	O
unrecognized	O
association	O
between	O
defective	O
MMR	O
and	O
p53	O
mutation	O
.	O

Significantly	O
,	O
Type	B
A	I
MSI	I
was	O
strongly	O
associated	O
with	O
p53	O
mutation	O
in	O
human	O
colorectal	O
tumours	B
.	O

Since	O
Type	O
A	O
instability	O
is	O
unequivocally	O
associated	O
with	O
MMR	O
deficiency	O
,	O
this	O
novel	O
finding	O
implies	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
p53	O
mutations	O
are	O
common	O
in	O
MMR	O
-	O
defective	O
tumours	B
,	O
at	O
least	O
in	O
human	O
colorectal	B
cancer	I
.	O

Established	O
guidelines	O
for	O
classification	O
of	O
MSI	O
utilize	O
the	O
frequency	O
of	O
changes	O
in	O
a	O
defined	O
set	O
of	O
microsatellite	O
markers	O
,	O
i.e.	O
MSI	O
-	O
H	O
and	O
-L	O
(	O
10	O
)	O
.	O

However	O
,	O
qualitative	O
differences	O
in	O
microsatellite	O
changes	O
are	O
not	O
widely	O
discussed	O
.	O

In	O
one	O
of	O
the	O
earliest	O
report	O
of	O
the	O
MSI	O
phenomenon	O
,	O
however	O
,	O
Thibodeau	O
et	O
al.	O
divided	O
microsatellite	O
changes	O
into	O
two	O
categories	O
;	O
Type	O
I	O
and	O
II	O
mutations	O
(	O
3	O
)	O
.	O

The	O
former	O
was	O
defined	O
a	O
'	O
significant	O
increase	O
(	O
expansion	O
)	O
or	O
decrease	O
(	O
deletion	O
)	O
in	O
the	O
apparent	O
fragment	O
size	O
'	O
and	O
the	O
latter	O
as	O
a	O
'	O
single	O
2	O
bp	O
change	O
'	O
.	O

This	O
distinction	O
has	O
received	O
little	O
attention	O
since	O
then	O
.	O

Our	O
data	O
indicate	O
that	O
Type	O
A	O
MSI	O
,	O
which	O
appears	O
similar	O
to	O
their	O
Type	O
II	O
mutation	O
,	O
is	O
more	O
frequent	O
than	O
hitherto	O
suspected	O
,	O
and	O
suggest	O
that	O
it	O
represents	O
the	O
bona	O
fide	O
MMR	O
-	O
deficient	O
phenotype	O
.	O

On	O
the	O
other	O
hand	O
,	O
Type	O
I	O
mutations	O
may	O
correspond	O
to	O
our	O
Type	O
B	O
instability	O
.	O

The	O
problem	O
is	O
that	O
mutations	O
in	O
MMR	O
genes	O
have	O
been	O
reported	O
in	O
tumours	B
displaying	O
this	O
type	O
of	O
instability	O
.	O

More	O
than	O
90	O
%	O
of	O
HNPCC	B
tumours	B
are	O
MSI+	B
(	O
20	O
)	O
,	O
and	O
this	O
type	O
of	O
MSI	O
can	O
be	O
categorized	O
as	O
Type	O
B	O
/	O
Type	B
I	I
(	O
2–4,20–22	O
)	O
.	O

However	O
,	O
the	O
frequencies	O
of	O
mutation	O
in	O
the	O
two	O
major	O
MMR	O
genes	O
,	O
hMSH2	O
and	O
hMLH1	O
,	O
in	O
HNPCC	B
kindred	O
are	O
not	O
high	O
in	O
some	O
reports	O
(	O
35–40	O
)	O
.	O

Among	O
the	O
panel	O
of	O
tumours	B
displaying	O
Type	B
B	I
MSI	I
,	O
we	O
found	O
a	O
base	O
substitution	O
mutation	O
in	O
hMLH1	O
and	O
one	O
case	O
with	O
a	O
possible	O
hMLH1	O
silencing	O
.	O

This	O
incidence	O
of	O
MMR	O
gene	O
inactivation	O
in	O
the	O
Type	O
B	O
group	O
is	O
not	O
unduly	O
low	O
,	O
compared	O
with	O
the	O
reported	O
frequencies	O
in	O
the	O
literature	O
(	O
25,36,41–43	O
)	O
.	O

The	O
relationship	O
between	O
Type	O
B	O
MSI	O
and	O
defective	O
MMR	O
is	O
probably	O
more	O
complex	O
than	O
hitherto	O
suspected	O
.	O

Background	O
Cancer	B
is	O
thought	O
to	O
arise	O
through	O
a	O
multistep	O
process	O
involving	O
sequential	O
cycles	O
of	O
mutation	O
and	O
selection	O
[	O
1	O
]	O
.	O

The	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
,	O
but	O
perhaps	O
six	O
general	O
cellular	O
functions	O
are	O
typically	O
altered	O
[	O
2	O
]	O
.	O

Numbers	O
of	O
oncogenic	O
mutations	O
may	O
also	O
be	O
inferred	O
from	O
the	O
age	O
-	O
related	O
increases	O
in	O
frequencies	O
observed	O
with	O
many	O
cancer	B
types	O
.	O

For	O
example	O
,	O
logarithms	O
of	O
cancer	B
frequencies	O
versus	O
age	O
typically	O
yield	O
straight	O
lines	O
,	O
with	O
slopes	O
proportional	O
to	O
numbers	O
of	O
cancer	B
mutations	O
[	O
3	O
]	O
.	O

Colorectal	B
cancer	I
epidemiology	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
before	O
transformation	O
[	O
3	O
-	O
6	O
]	O
.	O

The	O
variability	O
in	O
estimated	O
numbers	O
of	O
mutations	O
may	O
reflect	O
a	O
number	O
of	O
differences	O
.	O

For	O
example	O
,	O
estimates	O
vary	O
between	O
populations	O
,	O
with	O
five	O
to	O
six	O
mutations	O
in	O
England	O
and	O
six	O
to	O
seven	O
mutations	O
in	O
Finland	O
[	O
4	O
]	O
.	O

Recent	O
advances	O
in	O
cancer	B
genetics	O
also	O
reveal	O
biologic	O
colorectal	B
cancer	I
heterogeneity	O
.	O

Approximately	O
5	O
%	O
of	O
all	O
colorectal	B
cancers	I
have	O
strong	O
familial	O
predispositions	O
and	O
arise	O
in	O
individuals	O
with	O
germline	O
mutations	O
in	O
critical	O
susceptibility	O
loci	O
[	O
7	O
]	O
.	O

Such	O
hereditary	O
cancers	B
(	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
and	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
)	O
typically	O
present	O
at	O
younger	O
ages	O
and	O
should	O
require	O
fewer	O
somatic	O
mutations	O
than	O
their	O
sporadic	O
counterparts	O
because	O
one	O
mutation	O
is	O
inherited	O
.	O

Genetic	O
instability	O
also	O
divides	O
colorectal	B
cancers	I
into	O
two	O
groups	O
[	O
8	O
]	O
.	O

Approximately	O
10	O
to	O
15	O
%	O
of	O
sporadic	O
cancers	B
exhibit	O
microsatellite	B
instability	I
(	O
MSI	O
)	O
secondary	O
to	O
somatic	O
loss	O
of	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
.	O

Most	O
other	O
cancers	B
exhibit	O
chromosomal	B
instability	I
(	O
CIN	B
)	O
characterized	O
by	O
aneuploidy	B
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
[	O
7,8	O
]	O
.	O

CIN	B
and	O
MSI+	B
colorectal	B
cancers	I
have	O
different	O
characteristics	O
with	O
respect	O
to	O
mutated	O
loci	O
,	O
tumor	B
location	O
,	O
morphology	O
,	O
and	O
clinical	O
outcomes	O
[	O
7,8	O
]	O
.	O

Numbers	O
of	O
oncogenic	O
mutations	O
may	O
differ	O
between	O
cancer	B
subtypes	O
.	O

Therefore	O
,	O
colorectal	B
cancers	I
arising	O
in	O
a	O
population	O
-	O
based	O
setting	O
were	O
molecularly	O
classified	O
as	O
either	O
sporadic	O
or	O
hereditary	O
,	O
and	O
MSI+	B
or	O
MSI-	B
.	O

Cancers	B
were	O
also	O
classified	O
with	O
respect	O
to	O
clinical	O
stage	O
because	O
additional	O
mutations	O
may	O
be	O
required	O
for	O
invasion	O
or	O
metastasis	O
.	O

Ages	O
at	O
cancer	B
for	O
each	O
subgroup	O
were	O
used	O
to	O
infer	O
numbers	O
of	O
mutations	O
required	O
for	O
each	O
type	O
of	O
colorectal	B
cancer	I
.	O

Conclusion	O

The	O
biology	O
of	O
cancer	B
must	O
underlie	O
the	O
epidemiology	O
of	O
cancer	B
.	O

Here	O
we	O
illustrate	O
that	O
multistage	O
models	O
provide	O
conceptually	O
plausible	O
solutions	O
even	O
when	O
colorectal	B
cancers	I
are	O
divided	O
into	O
biologically	O
relevant	O
and	O
quite	O
different	O
subtypes	O
.	O

Ages	O
at	O
cancer	B
are	O
consistent	O
with	O
five	O
or	O
six	O
somatic	O
oncogenic	O
mutations	O
for	O
hereditary	O
(	O
HNPCC	B
)	O
MSI+	B
cancers	B
and	O
seven	O
or	O
eight	O
mutations	O
for	O
its	O
sporadic	O
counterpart	O
.	O

The	O
apparent	O
requirement	O
for	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
in	O
sporadic	O
MSI+	B
cancers	B
may	O
reflect	O
that	O
MMR	O
inactivation	O
is	O
commonly	O
epigenetic	O
,	O
which	O
may	O
involve	O
multiple	O
steps	O
.	O

Ages	O
at	O
MSI-	B
cancers	B
were	O
consistent	O
with	O
six	O
or	O
seven	O
oncogenic	O
mutations	O
,	O
with	O
similar	O
estimates	O
for	O
all	O
clinical	O
stages	O
,	O
suggesting	O
that	O
mutations	O
acquired	O
very	O
early	O
in	O
life	O
dictate	O
the	O
cancer	B
phenotype	O
at	O
the	O
time	O
of	O
transformation	O
.	O

Better	O
integration	O
of	O
cancer	B
epidemiology	O
with	O
its	O
biology	O
remains	O
a	O
further	O
challenge	O
.	O

Background	O
Carcinogenesis	O
is	O
a	O
multi	O
-	O
step	O
process	O
that	O
involves	O
the	O
accumulation	O
of	O
numerous	O
genetic	O
and	O
epigenetic	O
changes	O
in	O
cells	O
[	O
1	O
]	O
.	O

These	O
genetic	O
aberrations	O
affect	O
a	O
limited	O
number	O
of	O
identified	O
pathways	O
that	O
are	O
involved	O
in	O
(	O
colorectal	O
)	O
carcinogenesis	B
[	O
2	O
]	O
.	O

A	O
genetic	O
model	O
for	O
sporadic	O
colorectal	B
cancer	I
has	O
been	O
proposed	O
,	O
which	O
describes	O
the	O
sequential	O
accumulation	O
of	O
specific	O
genetic	O
alterations	O
in	O
various	O
pathways	O
,	O
involving	O
tumour	B
suppressor	O
genes	O
(	O
e.g.	O
APC	O
,	O
SMAD4	O
,	O
TP53	O
)	O
and	O
oncogenes	O
(	O
e.g.	O
CTNNB1	O
,	O
K	O
-	O
ras	O
)	O
[	O
3,4	O
]	O
.	O

Important	O
molecular	O
pathways	O
that	O
upon	O
activation	O
affect	O
the	O
early	O
and	O
intermediate	O
stages	O
of	O
colorectal	O
carcinogenesis	B
are	O
the	O
Wnt	O
and	O
Ras	O
signalling	O
pathways	O
,	O
whereas	O
TP53	O
inactivation	O
is	O
considered	O
a	O
late	O
event	O
.	O

Activation	O
of	O
the	O
Wnt	O
pathway	O
plays	O
a	O
central	O
role	O
in	O
the	O
aetiology	O
of	O
most	O
colorectal	B
cancers	I
and	O
is	O
often	O
the	O
result	O
of	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
APC	O
gene	O
,	O
that	O
lead	O
to	O
partial	O
or	O
complete	O
loss	O
of	O
this	O
region	O
and	O
thereby	O
to	O
loss	O
of	O
the	O
β	O
-	O
catenin	O
regulating	O
function	O
[	O
5,6	O
]	O
.	O

Conversely	O
,	O
in	O
tumours	B
lacking	O
these	O
APC	O
mutations	O
[	O
7	O
]	O
,	O
activating	O
missense	O
mutations	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
at	O
codons	O
31	O
,	O
33	O
,	O
37	O
and	O
45	O
of	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
(	O
encoding	O
the	O
β	O
-	O
catenin	O
protein	O
)	O
can	O
render	O
it	O
stable	O
as	O
it	O
can	O
no	O
longer	O
be	O
tagged	O
for	O
cellular	O
degradation	O
.	O

Activation	O
of	O
the	O
Ras	O
pathway	O
in	O
cancer	B
is	O
marked	O
by	O
the	O
loss	O
of	O
the	O
intrinsic	O
GTPase	O
activity	O
of	O
the	O
Ras	O
protein	O
,	O
which	O
can	O
be	O
ascribed	O
to	O
missense	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
exon	O
1	O
,	O
which	O
are	O
responsible	O
for	O
90	O
%	O
activating	O
mutations	O
in	O
the	O
of	O
the	O
K	O
-	O
ras	O
gene	O
[	O
8	O
]	O
.	O

According	O
to	O
the	O
paradigm	O
for	O
colorectal	B
cancer	I
development	O
,	O
mutations	O
in	O
the	O
APC	O
and	O
K	O
-	O
ras	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
early	O
developmental	O
stages	O
of	O
colorectal	B
cancer	I
[	O
3	O
]	O
.	O

However	O
,	O
a	O
recent	O
study	O
based	O
on	O
the	O
analysis	O
of	O
APC	O
,	O
K	O
-	O
ras	O
and	O
TP53	O
genes	O
concluded	O
that	O
simultaneous	O
occurrence	O
of	O
all	O
three	O
genetic	O
alterations	O
is	O
rare	O
and	O
that	O
multiple	O
genetic	O
pathways	O
may	O
be	O
relevant	O
to	O
colorectal	B
cancer	I
[	O
9	O
]	O
.	O

Genetic	O
instability	O
is	O
seen	O
in	O
most	O
types	O
of	O
cancer	B
[	O
10	O
]	O
.	O

Two	O
distinct	O
types	O
of	O
genetic	O
instability	O
appear	O
to	O
occur	O
in	O
colorectal	B
cancer	I
[	O
11	O
]	O
:	O
chromosomal	O
and	O
microsatellite	O
instability	O
.	O

Chromosomal	B
instability	I
results	O
in	O
gains	O
or	O
losses	O
of	O
entire	O
chromosomes	O
or	O
parts	O
of	O
them	O
,	O
and	O
gives	O
rise	O
to	O
aneuploid	O
tumours	B
and	O
occurs	O
in	O
the	O
majority	O
of	O
cancers	B
.	O

A	O
smaller	O
proportion	O
of	O
colorectal	B
cancers	I
displays	O
microsatellite	B
instability	I
,	O
represented	O
by	O
diploid	O
cells	O
acquiring	O
high	O
mutation	O
rates	O
,	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
defective	B
mismatch	I
repair	I
[	O
12	O
]	O
.	O

These	O
tumours	B
are	O
less	O
likely	O
to	O
harbour	O
mutations	O
in	O
genes	O
associated	O
with	O
chromosomally	B
instable	I
and	O
generally	O
aneuploid	O
tumours	B
,	O
such	O
as	O
APC	O
,	O
K	O
-	O
ras	O
and	O
TP53	O
[	O
13	O
-	O
21	O
]	O
,	O
suggesting	O
that	O
these	O
tumours	B
form	O
a	O
distinct	O
group	O
.	O

Moreover	O
,	O
microsatellite	B
instable	I
tumours	B
are	O
found	O
predominantly	O
in	O
the	O
proximal	O
colon	O
[	O
22,23	O
]	O
,	O
are	O
more	O
likely	O
to	O
occur	O
in	O
patients	O
with	O
a	O
positive	B
family	I
history	I
of	O
colorectal	B
cancer	I
[	O
22,23	O
]	O
,	O
are	O
often	O
less	O
differentiated	O
than	O
microsatellite	B
stable	I
tumours	B
[	O
22	O
]	O
,	O
and	O
occur	O
more	O
frequently	O
in	O
women	O
[	O
24	O
]	O
and	O
at	O
older	O
age	O
[	O
25	O
]	O
.	O

Moreover	O
,	O
in	O
tumours	B
displaying	O
microsatellite	B
instability	I
,	O
mutations	O
the	O
CTNNB1	O
gene	O
were	O
more	O
frequent	O
[	O
26	O
]	O
.	O

Methods	O
Study	O
population	O
The	O
prospective	O
Netherlands	O
Cohort	O
Study	O
on	O
diet	O
and	O
cancer	B
was	O
initiated	O
in	O
September	O
1986	O
.	O

The	O
study	O
design	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
29	O
]	O
.	O

The	O
study	O
population	O
originated	O
from	O
204	O
municipal	O
population	O
registries	O
throughout	O
the	O
Netherlands	O
,	O
and	O
included	O
a	O
total	O
of	O
58,279	O
men	O
and	O
62,573	O
women	O
between	O
the	O
ages	O
of	O
55	O
and	O
69	O
years	O
at	O
baseline	O
.	O

Incident	O
cancer	B
cases	O
are	O
identified	O
by	O
monitoring	O
of	O
the	O
entire	O
cohort	O
for	O
cancer	B
occurrence	O
through	O
annual	O
record	O
linkage	O
to	O
the	O
Netherlands	O
Cancer	O
Registry	O
,	O
i.e.	O
nine	O
regional	O
cancer	B
registries	O
throughout	O
the	O
Netherlands	O
,	O
and	O
to	O
PALGA	O
,	O
a	O
nationwide	O
network	O
and	O
registry	O
of	O
histo-	O
and	O
cytopathology	O
[	O
30	O
]	O
.	O

Together	O
,	O
the	O
NCR	O
and	O
PALGA	O
provide	O
a	O
near	O
100	O
%	O
coverage	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

The	O
first	O
2.3	O
years	O
of	O
follow	O
up	O
were	O
excluded	O
because	O
of	O
possible	O
pre	O
-	O
clinical	O
disease	O
affecting	O
exposure	O
status	O
and	O
because	O
of	O
incomplete	O
nationwide	O
coverage	O
of	O
PALGA	O
in	O
some	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
in	O
that	O
period	O
.	O

From	O
1989	O
until	O
1994	O
,	O
929	O
incident	O
cases	O
with	O
histologically	O
confirmed	O
colorectal	B
cancer	I
were	O
identified	O
within	O
the	O
cohort	O
,	O
of	O
whom	O
819	O
could	O
also	O
be	O
linked	O
to	O
a	O
PALGA	O
report	O
of	O
the	O
lesion	O
.	O

The	O
PALGA	O
reports	O
were	O
used	O
to	O
identify	O
and	O
locate	O
tumour	B
tissue	O
from	O
eligible	O
colorectal	B
cancer	I
patients	O
in	O
Dutch	O
pathology	O
laboratories	O
.	O

Colon	O
and	O
rectal	B
cancer	I
were	O
classified	O
according	O
to	O
site	O
as	O
follows	O
,	O
colon	O
:	O
cecum	O
through	O
sigmoid	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.0	O
,	O
153.1	O
,	O
153.2	O
,	O
153.3	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
,	O
153.7	O
)	O
,	O
rectosigmoid	O
(	O
ICD	O
-	O
O	O
code	O
154.0	O
)	O
,	O
and	O
rectum	O
(	O
ICD	O
-	O
O	O
code	O
154.1	O
)	O
.	O

Tissue	O
samples	O
Tumour	B
material	O
of	O
colorectal	B
cancer	I
patients	O
was	O
collected	O
after	O
approval	O
by	O
the	O
Ethical	O
Review	O
Board	O
of	O
Maastricht	O
University	O
,	O
PALGA	O
and	O
the	O
NCR	O
.	O

Tissue	O
samples	O
from	O
819	O
colorectal	B
cancer	I
patients	O
were	O
localized	O
in	O
54	O
pathology	O
laboratories	O
throughout	O
the	O
Netherlands	O
.	O

Forty	O
-	O
four	O
(	O
5	O
%	O
)	O
tumour	B
tissue	O
samples	O
could	O
not	O
be	O
retrieved	O
from	O
the	O
pathology	O
archives	O
.	O

Of	O
775	O
available	O
tissue	O
samples	O
,	O
737	O
(	O
95	O
%	O
)	O
contained	O
sufficient	O
tumour	B
material	O
for	O
molecular	O
analyses	O
.	O

Tissue	O
sections	O
were	O
cut	O
from	O
each	O
sample	O
,	O
which	O
were	O
used	O
for	O
DNA	O
isolation	O
and	O
immunohistochemical	O
analysis	O
.	O

DNA	O
isolation	O
DNA	O
isolation	O
was	O
described	O
in	O
detail	O
elsewhere	O
[	O
27	O
]	O
.	O

Briefly	O
,	O
a	O
4	O
μm	O
section	O
,	O
cut	O
from	O
each	O
paraffin	O
-	O
embedded	O
tumour	B
tissue	O
block	O
,	O
was	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
for	O
histopathological	O
examination	O
by	O
a	O
pathologist	O
.	O

Five	O
20	O
μm	O
sections	O
of	O
tumour	B
tissue	O
were	O
cut	O
from	O
each	O
sample	O
for	O
DNA	O
isolation	O
.	O

Tumour	B
tissue	O
was	O
separated	O
from	O
normal	O
colon	O
epithelium	O
using	O
the	O
HE	O
section	O
as	O
a	O
reference	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
macrodissected	O
tumour	B
tissue	O
using	O
proteinase	O
K	O
(	O
Qiagen	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
and	O
the	O
Puregene	O
DNA	O
isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O

DNA	O
concentration	O
and	O
purity	O
was	O
measured	O
at	O
260	O
and	O
280	O
nm	O
.	O

Conclusion	O
In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
mutations	O
in	O
the	O
CTNNB1	O
gene	O
are	O
presumably	O
of	O
minor	O
importance	O
in	O
sporadic	O
colorectal	B
cancer	I
.	O

Although	O
APC	O
and	O
K	O
-	O
ras	O
mutations	O
are	O
often	O
observed	O
seperately	O
in	O
a	O
tumour	B
,	O
these	O
mutations	O
seem	O
to	O
also	O
occur	O
in	O
a	O
co	O
-	O
dependent	O
manner	O
.	O

Tumours	B
that	O
display	O
mismatch	O
repair	O
deficiency	O
,	O
may	O
form	O
a	O
distinct	O
sub	O
-	O
group	O
as	O
they	O
differ	O
from	O
tumours	B
with	O
APC	O
and/or	O
K	O
-	O
ras	O
mutations	O
with	O
regard	O
to	O
age	O
,	O
sex	O
,	O
tumour	B
sub	O
-	O
localisation	O
and	O
differentiation	O
.	O

Background	O
BRAF	O
is	O
a	O
member	O
of	O
the	O
RAF	O
family	O
of	O
kinases	O
that	O
acts	O
upstream	O
of	O
the	O
MEK1	O
/	O
2	O
kinases	O
in	O
response	O
to	O
RAS	O
signals	O
.	O

Activating	O
mutations	O
in	O
BRAF	O
have	O
been	O
reported	O
in	O
5–15	O
%	O
of	O
colorectal	O
carcinomas	B
(	O
CRC	B
)	O
,	O
with	O
by	O
far	O
the	O
most	O
common	O
mutation	O
being	O
a	O
1796	O
T	O
to	O
A	O
transversion	O
leading	O
to	O
a	O
V600E	O
substitution	O
[	O
1	O
-	O
3	O
]	O
.	O

The	O
BRAF	O
V600E	O
hotspot	O
mutation	O
is	O
strongly	O
associated	O
with	O
the	O
microsatellite	O
instability	O
(	O
MSI+	O
)	O
phenotype	O
but	O
is	O
mutually	O
exclusive	O
with	O
KRAS	O
mutations	O
[	O
4	O
-	O
7	O
]	O
.	O

Interestingly	O
,	O
BRAF	O
mutations	O
are	O
found	O
only	O
in	O
MSI+	B
sporadic	O
tumors	B
that	O
result	O
from	O
aberrant	O
MLH1	O
promoter	O
methylation	O
and	O
do	O
not	O
occur	O
in	O
MSI+	B
tumors	B
from	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
patients	O
[	O
5,8	O
-	O
10	O
]	O
,	O
thus	O
providing	O
a	O
convenient	O
discriminator	O
between	O
sporadic	O
and	O
familial	O
cases	O
.	O

The	O
majority	O
of	O
MSI+	B
sporadic	O
tumors	B
belong	O
to	O
a	O
larger	O
CRC	B
group	O
referred	O
to	O
as	O
the	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP+	O
)	O
that	O
is	O
characterised	O
by	O
widespread	O
hypermethylation	O
of	O
CpG	O
islands	O
located	O
with	O
gene	O
promoter	O
regions	O
[	O
11	O
]	O
.	O

Both	O
MSI+	B
and	O
CIMP+	O
tumors	B
are	O
thought	O
to	O
arise	O
from	O
large	B
hyperplastic	I
polyps	B
and	O
serrated	O
adenomas	B
[	O
12,13	O
]	O
and	O
recent	O
work	O
has	O
demonstrated	O
a	O
high	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
these	O
lesions	B
[	O
7,14,15	O
]	O
.	O

Although	O
the	O
positive	O
association	O
with	O
MSI+	O
and	O
inverse	O
association	O
with	O
KRAS	O
mutation	O
have	O
been	O
well	O
documented	O
,	O
little	O
is	O
known	O
about	O
the	O
other	O
properties	O
of	O
tumors	B
with	O
BRAF	O
mutation	O
.	O

In	O
the	O
present	O
study	O
we	O
analysed	O
for	O
BRAF	O
V600E	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
275	O
CRCs	B
that	O
were	O
well	O
characterised	O
for	O
the	O
major	O
pathological	O
and	O
molecular	O
features	O
of	O
this	O
disease	O
.	O

Our	O
results	O
demonstrate	O
that	O
oncogenic	O
BRAF	O
mutation	O
occurs	O
preferentially	O
within	O
a	O
subgroup	O
of	O
CRCs	B
that	O
have	O
distinctive	O
features	O
.	O

It	O
could	O
therefore	O
be	O
used	O
as	O
a	O
convenient	O
marker	O
for	O
the	O
further	O
characterisation	O
of	O
these	O
tumors	B
,	O
particularly	O
in	O
relation	O
to	O
their	O
prognosis	O
and	O
response	O
to	O
adjuvant	O
chemotherapy	O
.	O

Results	O
Figure	O
1A	O
shows	O
representative	O
Fluorescent	O
-	O
SSCP	O
results	O
for	O
the	O
screening	O
of	O
BRAF	O
mutations	O
in	O
this	O
CRC	B
series	O
,	O
while	O
Figure	O
1B	O
shows	O
DNA	O
sequencing	O
confirmation	O
of	O
the	O
1799	O
T	O
to	O
A	O
transversion	O
resulting	O
in	O
the	O
V600E	O
mutation	O
.	O

The	O
overall	O
frequency	O
of	O
BRAF	O
mutation	O
was	O
8.4	O
%	O
(	O
23	O
/	O
275	O
)	O
,	O
comparing	O
favourably	O
with	O
frequencies	O
of	O
9–11	O
%	O
reported	O
for	O
other	O
large	O
studies	O
of	O
this	O
tumor	B
type	O
[	O
6,16,17	O
]	O
.	O

The	O
mean	O
age	O
of	O
patients	O
with	O
and	O
without	O
BRAF	O
mutation	O
was	O
identical	O
(	O
Table	O
1	O
)	O
.	O

Strong	O
associations	O
were	O
observed	O
between	O
BRAF	O
mutation	O
and	O
tumor	B
origin	O
in	O
the	O
proximal	O
side	O
of	O
the	O
large	O
bowel	O
,	O
poor	O
histological	O
grade	O
,	O
mucinous	O
appearance	O
and	O
the	O
presence	O
of	O
infiltrating	O
lymphocytes	O
.	O

Higher	O
frequencies	O
of	O
BRAF	O
mutation	O
were	O
also	O
observed	O
in	O
females	O
and	O
in	O
node	O
negative	O
tumors	B
but	O
these	O
did	O
not	O
reach	O
significance	O
.	O

(	O
A	O
)	O
Representative	O
F	O
-	O
SSCP	O
gel	O
used	O
to	O
detect	O
BRAF	O
mutationsin	O
colorectal	B
cancer	I
.	O

WT	O
,	O
wild	O
-	O
type	O
;	O
M	O
,	O
mutation	O
.	O

(	O
B	O
)	O
DNA	O
sequencing	O
gel	O
resultconfirms	O
the	O
presence	O
of	O
a	O
1799	O
T	O
to	O
A	O
mutation	O
giving	O
rise	O
to	O
the	O
V600E	O
mutation	O
.	O

Associations	O
between	O
BRAF	O
mutation	O
and	O
clinicopathological	O
features	O
of	O
colorectal	B
cancer	I
.	O

a	O
Data	O
was	O
unavailable	O
for	O
gender	O
in	O
43	O
cases	O
,	O
infiltrating	O
lymphocytes	O
in	O
55	O
cases	O
,	O
nodal	O
involvement	O
in	O
77	O
cases	O
,	O
tumor	B
site	O
in	O
56	O
cases	O
,	O
grade	O
in	O
106	O
cases	O
and	O
mucinous	O
appearance	O
in	O
89	O
cases	O
.	O

BRAF	O
mutations	O
showed	O
no	O
association	O
with	O
TP53	O
mutations	O
and	O
were	O
mutually	O
exclusive	O
with	O
the	O
presence	O
of	O
KRAS	O
mutations	O
(	O
Table	O
2	O
)	O
.	O

In	O
contrast	O
,	O
BRAF	O
mutations	O
were	O
approximately	O
10-fold	O
more	O
frequent	O
in	O
MSI+	B
and	O
CIMP+	O
tumors	B
compared	O
to	O
tumors	B
without	O
these	O
phenotypes	O
.	O

A	O
strong	O
association	O
was	O
also	O
seen	O
with	O
methylation	O
of	O
the	O
MLH1	O
gene	O
promoter	O
and	O
in	O
particular	O
with	O
methylation	O
of	O
its	O
proximal	O
region	O
.	O

We	O
have	O
previously	O
examined	O
the	O
methylation	O
status	O
of	O
7	O
different	O
CpG	O
islands	O
in	O
this	O
CRC	B
series	O
[	O
18	O
]	O
.	O

The	O
mean	O
number	O
of	O
these	O
methylated	O
sites	O
was	O
3-fold	O
higher	O
in	O
tumors	B
with	O
BRAF	O
mutation	O
compared	O
to	O
those	O
without	O
(	O
2.6	O
±	O
1.7	O
vs	O
0.8	O
±	O
1.0	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
MSI+	O
was	O
the	O
only	O
significant	O
independent	O
predictor	O
of	O
BRAF	O
mutation	O
(	O
RR	O
=	O
6.3	O
,	O
95%CI	O
[	O
1.2–32.3	O
]	O
;	O
P	O
=	O
0.028	O
)	O
in	O
a	O
model	O
that	O
included	O
CIMP+	O
,	O
tumor	B
site	O
,	O
histological	O
grade	O
,	O
presence	O
of	O
infiltrating	O
lymphocytes	O
and	O
mucinous	O
appearance	O
.	O

Associations	O
between	O
BRAF	O
mutation	O
and	O
molecular	O
features	O
of	O
colorectal	B
cancer	I
.	O

a	O
Data	O
was	O
unavailable	O
for	O
MSI	O
status	O
in	O
40	O
cases	O
,	O
methylation	O
status	O
in	O
83	O
cases	O
,	O
KRAS	O
mutation	O
in	O
26	O
cases	O
and	O
TP53	O
mutation	O
in	O
26	O
cases	O
We	O
next	O
examined	O
whether	O
the	O
characteristic	O
features	O
of	O
tumors	B
with	O
BRAF	O
mutation	O
were	O
still	O
apparent	O
following	O
stratification	O
into	O
MSI	O
and	O
CIMP	O
phenotypes	O
.	O

Although	O
the	O
statistical	O
power	O
of	O
this	O
subgroup	O
analysis	O
was	O
limited	O
,	O
the	O
morphological	O
features	O
of	O
infiltrating	O
lymphocytes	O
,	O
poor	O
histological	O
grade	O
and	O
mucinous	O
appearance	O
were	O
clearly	O
associated	O
with	O
BRAF	O
mutation	O
regardless	O
of	O
tumor	B
MSI	O
status	O
(	O
Table	O
3	O
)	O
.	O

Similarly	O
,	O
these	O
features	O
were	O
each	O
more	O
common	O
in	O
tumors	B
with	O
BRAF	O
mutation	O
in	O
both	O
the	O
CIMP-	O
and	O
CIMP+	O
subgroups	O
(	O
Table	O
4	O
)	O
.	O

Similar	O
to	O
previous	O
observations	O
in	O
a	O
separate	O
CRC	B
cohort	O
[	O
20	O
]	O
,	O
the	O
frequency	O
of	O
KRAS	O
mutation	O
was	O
lower	O
in	O
MSI+	B
compared	O
to	O
MSI-	B
tumors	B
(	O
P	O
=	O
0.034	O
;	O
Table	O
3	O
)	O
,	O
while	O
the	O
frequency	O
of	O
TP53	O
mutation	O
was	O
also	O
considerably	O
lower	O
in	O
MSI+	B
tumors	B
with	O
wildtype	O
BRAF	O
than	O
in	O
MSI-	B
tumors	B
with	O
wildtype	O
BRAF	O
(	O
P	O
=	O
0.014	O
)	O
.	O

Mismatch	O
repair	O
and	O
treatment	O
resistance	O
in	O
ovarian	B
cancer	I
Abstract	O
Background	O
The	O
treatment	O
of	O
ovarian	B
cancer	I
is	O
hindered	O
by	O
intrinsic	O
or	O
acquired	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
frequency	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
inactivation	O
in	O
ovarian	B
cancer	I
and	O
its	O
association	O
with	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
.	O

Methods	O
We	O
determined	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
as	O
a	O
marker	O
for	O
MMR	O
inactivation	O
(	O
analysis	O
of	O
BAT25	O
and	O
BAT26	O
)	O
,	O
MLH1	O
promoter	O
methylation	O
status	O
(	O
methylation	O
specific	O
PCR	O
on	O
bisulfite	O
treated	O
DNA	O
)	O
and	O
mRNA	O
expression	O
of	O
MLH1	O
,	O
MSH2	O
,	O
MSH3	O
,	O
MSH6	O
and	O
PMS2	O
(	O
quantitative	O
RT	O
-	O
PCR	O
)	O
in	O
75	O
ovarian	O
carcinomas	B
and	O
eight	O
ovarian	B
cancer	I
cell	O
lines	O
Results	O
MSI	B
was	O
detected	O
in	O
three	O
of	O
the	O
eight	O
cell	O
lines	O
i.e.	O
A2780	O
(	O
no	O
MLH1	O
mRNA	O
expression	O
due	O
to	O
promoter	O
methylation	O
)	O
,	O
SKOV3	O
(	O
no	O
MLH1	O
mRNA	O
expression	O
)	O
and	O
2774	O
(	O
no	O
altered	O
expression	O
of	O
MMR	O
genes	O
)	O
.	O

Overall	O
,	O
there	O
was	O
no	O
association	O
between	O
cisplatin	O
response	O
and	O
MMR	O
status	O
in	O
these	O
eight	O
cell	O
lines	O
.	O

Seven	O
of	O
the	O
75	O
ovarian	O
carcinomas	B
showed	O
MLH1	O
promoter	O
methylation	O
,	O
however	O
,	O
none	O
of	O
these	O
showed	O
MSI	O
.	O

Forty	O
-	O
six	O
of	O
these	O
patients	O
received	O
platinum	O
-	O
based	O
chemotherapy	O
(	O
11	O
non	O
-	O
responders	O
,	O
34	O
responders	O
,	O
one	O
unknown	O
response	O
)	O
.	O

The	O
resistance	O
seen	O
in	O
the	O
eleven	O
non	O
-	O
responders	O
was	O
not	B
related	I
to	I
MSI	I
and	O
therefore	O
also	O
not	O
to	O
MMR	O
inactivation	O
.	O

Conclusion	O

No	O
MMR	O
inactivation	O
was	O
detected	O
in	O
75	O
ovarian	O
carcinoma	B
specimens	O
and	O
no	O
association	O
was	O
seen	O
between	O
MMR	B
inactivation	I
and	O
resistance	O
in	O
the	O
ovarian	B
cancer	I
cell	O
lines	O
as	O
well	O
as	O
the	O
ovarian	O
carcinomas	B
.	O

In	O
the	O
discussion	O
,	O
the	O
results	O
were	O
compared	O
to	O
that	O
of	O
twenty	O
similar	O
studies	O
in	O
the	O
literature	O
including	O
in	O
total	O
1315	O
ovarian	B
cancer	I
patients	O
.	O

Although	O
no	O
association	O
between	O
response	O
and	O
MMR	O
status	O
was	O
seen	O
in	O
the	O
primary	O
tumor	B
the	O
possible	O
role	O
of	O
MMR	O
inactivation	O
in	O
acquired	O
resistance	O
deserves	O
further	O
investigation	O
.	O

Interestingly	O
,	O
a	O
number	O
of	O
in	O
vitro	O
studies	O
have	O
suggested	O
a	O
relationship	O
between	O
MMR	O
deficiency	O
and	O
platinum	O
-	O
drug	O
resistance	O
.	O

Several	O
resistant	O
sublines	O
of	O
ovarian	O
and	O
melanoma	B
cell	O
lines	O
generated	O
by	O
cisplatin	O
selection	O
,	O
appeared	O
to	O
be	O
MMR	O
deficient	O
[	O
11	O
-	O
15	O
]	O
.	O

In	O
addition	O
,	O
a	O
colon	O
(	O
HCT116	O
)	O
and	O
an	O
endometrioid	O
cell	O
line	O
(	O
HEC59	O
)	O
,	O
deficient	B
for	I
MLH1	I
and	I
MSH2	I
respectively	O
,	O
were	O
2.1	O
and	O
1.8	O
fold	O
resistant	O
to	O
cisplatin	O
compared	O
to	O
cell	O
lines	O
complemented	O
with	O
chromosome	O
3	O
,	O
containing	O
MLH1	O
,	O
or	O
chromosome	O
2	O
,	O
containing	O
MSH2	O
[	O
15	O
-	O
17	O
]	O
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
inactivation	O
of	O
proteins	O
involved	O
in	O
the	O
initiation	O
of	O
MMR	O
might	O
cause	O
cisplatin	O
resistance	O
.	O

It	O
is	O
thought	O
that	O
the	O
DNA	O
damage	O
caused	O
by	O
platin	O
-	O
drugs	O
is	O
recognized	O
by	O
MMR	O
.	O

The	O
cell	O
will	O
then	O
undergo	O
several	O
unsuccessful	O
repair	O
cycles	O
,	O
finally	O
resulting	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O

When	O
MMR	O
is	O
inactive	O
the	O
DNA	O
damage	O
caused	O
by	O
platin	O
-	O
drugs	O
will	O
not	O
be	O
picked	O
up	O
and	O
will	O
therefore	O
not	O
result	O
in	O
apoptosis	O
rendering	O
the	O
cells	O
resistant	O
to	O
platin	O
-	O
drugs	O
.	O

Several	O
studies	O
have	O
determined	O
the	O
frequency	O
of	O
MMR	O
inactivation	O
in	O
ovarian	B
cancer	I
using	O
MSI	O
as	O
a	O
marker	O
[	O
18	O
-	O
37	O
]	O
.	O

However	O
,	O
there	O
was	O
a	O
wide	O
range	O
observed	O
(	O
0%–39	O
%	O
)	O
and	O
so	O
far	O
only	O
a	O
few	O
studies	O
have	O
linked	O
MMR	O
inactivation	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
.	O

Thus	O
,	O
there	O
is	O
still	O
no	O
general	O
agreement	O
about	O
the	O
frequency	O
of	O
MMR	O
inactivation	O
and	O
its	O
possible	O
involvement	O
in	O
the	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
seen	O
in	O
ovarian	B
cancer	I
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
frequency	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
inactivation	O
in	O
ovarian	B
cancer	I
and	O
whether	O
it	O
is	O
associated	O
with	O
platinum	O
-	O
based	O
chemotherapy	O
resistance	O
.	O

To	O
this	O
purpose	O
we	O
analyzed	O
seventy	O
-	O
five	O
ovarian	O
carcinomas	B
and	O
eight	O
ovarian	B
cancer	I
cell	O
lines	O
.	O

In	O
the	O
discussion	O
,	O
the	O
results	O
were	O
compared	O
to	O
that	O
of	O
twenty	O
similar	O
studies	O
in	O
the	O
literature	O
including	O
in	O
total	O
1315	O
ovarian	B
cancer	I
patients	O
.	O

Another	O
difference	O
between	O
the	O
studies	O
is	O
the	O
distribution	O
of	O
the	O
various	O
histological	O
types	O
of	O
the	O
ovarian	O
carcinoma	B
tissues	O
analyzed	O
(	O
Table	O
2	O
)	O
.	O

This	O
difference	O
in	O
the	O
distribution	O
could	O
be	O
a	O
cause	O
for	O
the	O
wide	O
range	O
in	O
the	O
MSI	O
frequency	O
especially	O
since	O
it	O
has	O
been	O
suggested	O
that	O
certain	O
histological	O
types	O
have	O
a	O
higher	O
frequency	O
of	O
MSI	O
.	O

To	O
determine	O
whether	O
there	O
is	O
a	O
relation	O
between	O
histology	O
and	O
MSI	O
within	O
these	O
studies	O
,	O
we	O
looked	O
at	O
the	O
frequency	O
of	O
MSI	O
per	O
histological	O
type	O
for	O
the	O
628	O
patients	O
with	O
known	O
histology	O
(	O
Table	O
2	O
)	O
.	O

The	O
summary	O
of	O
these	O
studies	O
suggests	O
that	O
the	O
frequency	O
of	O
MSI	O
is	O
higher	O
in	O
the	O
mucinous	B
and	O
endometrioid	O
adenocarcinoma	B
compared	O
to	O
clear	O
cell	O
and	O
serous	O
adenocarcinoma	B
(	O
the	O
overall	O
frequencies	O
of	O
MSI	B
were	O
22	O
%	O
,	O
16	O
%	O
,	O
9	O
%	O
and	O
8	O
%	O
,	O
respectively	O
)	O
(	O
Table	O
2	O
)	O
.	O

We	O
hypothesize	O
that	O
mucinous	O
and	O
endometrioid	O
histology	O
might	O
be	O
prone	O
to	O
a	O
higher	O
MSI	O
frequency	O
since	O
sporadic	O
endometrial	O
carcinoma	B
,	O
which	O
is	O
closely	O
related	O
to	O
endometrioid	O
ovarian	B
cancer	I
,	O
has	O
a	O
MSI	O
frequency	O
of	O
20–30	O
%	O
[	O
49	O
-	O
51	O
]	O
and	O
MSI	B
is	O
almost	O
universal	O
present	O
in	O
the	O
colorectal	O
tumors	B
of	O
the	O
hereditary	B
nonpolyposis	I
colon	I
cancer	I
(	O
HNPCC	B
)	O
syndrome	O
which	O
all	O
have	O
a	O
mucinous	B
histological	O
type	O
.	O

Therefore	O
,	O
the	O
different	O
histology	O
's	O
of	O
the	O
ovarian	O
carcinomas	B
included	O
in	O
the	O
several	O
studies	O
seems	O
to	O
be	O
a	O
plausible	O
cause	O
for	O
the	O
wide	O
range	O
in	O
MSI	O
frequency	O
reported	O
in	O
these	O
studies	O
.	O

Next	O
we	O
addressed	O
the	O
second	O
part	O
of	O
the	O
aim	O
of	O
this	O
study	O
,	O
is	O
MMR	O
inactivation	O
associated	O
with	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
in	O
ovarian	B
cancer	I
.	O

Forty	O
-	O
six	O
of	O
the	O
75	O
ovarian	O
carcinomas	B
we	O
analyzed	O
had	O
been	O
treated	O
with	O
platinum	O
-	O
based	O
chemotherapy	O
,	O
eleven	O
did	O
not	O
respond	O
and	O
34	O
did	O
.	O

For	O
one	O
patient	O
the	O
response	O
was	O
not	O
known	O
.	O

Methylation	O
of	O
the	O
MLH1	O
promoter	O
was	O
detected	O
in	O
two	O
of	O
the	O
eleven	O
non	O
-	O
responders	O
(	O
18	O
%	O
)	O
and	O
four	O
of	O
the	O
34	O
responders	O
(	O
12	O
%	O
)	O
and	O
this	O
was	O
not	O
significantly	O
different	O
(	O
p	O
=	O
0.664	O
)	O
.	O

Since	O
we	O
did	O
not	O
detect	O
any	O
MSI	O
,	O
the	O
resistance	O
seen	O
in	O
the	O
eleven	O
patients	O
could	O
not	O
be	O
associated	O
with	O
MSI	O
and	O
MMR	B
inactivation	I
.	O

The	O
relation	O
between	O
MMR	O
deficiency	O
and	O
platinum	O
-	O
drug	O
resistance	O
has	O
been	O
investigated	O
in	O
only	O
a	O
few	O
in	O
vivo	O
studies	O
.	O

Similarly	O
to	O
our	O
result	O
,	O
no	B
MSI	I
was	O
detected	O
by	O
Mesquita	O
et	O
al.	O
[	O
18	O
]	O
who	O
studied	O
34	O
ovarian	O
carcinomas	B
of	O
which	O
seven	O
did	O
not	O
respond	O
to	O
cisplatin	O
/	O
paclitaxel	O
therapy	O
.	O

So	O
the	O
resistance	O
seen	O
in	O
these	O
seven	O
nonresponding	O
patients	O
was	O
also	O
not	O
associated	O
with	O
MMR	B
inactivation	I
.	O

In	O
contrast	O
,	O
Samimi	O
et	O
al.	O
[	O
52	O
]	O
found	O
an	O
inverse	O
relation	O
between	O
MLH1	O
protein	O
expression	O
and	O
the	O
response	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
in	O
54	O
ovarian	O
carcinomas	B
.	O

Again	O
,	O
the	O
number	O
of	O
ovarian	O
carcinomas	B
included	O
in	O
these	O
studies	O
is	O
small	O
and	O
no	O
further	O
conclusion	O
can	O
be	O
drawn	O
from	O
these	O
results	O
.	O

Since	O
platinum	O
-	O
drug	O
resistance	O
is	O
thought	O
to	O
be	O
multifactorial	O
the	O
involvement	O
of	O
other	O
resistance	O
mechanisms	O
could	O
have	O
overruled	O
the	O
possible	O
contribution	O
of	O
MMR	O
status	O
.	O

However	O
,	O
platinum	O
treatment	O
does	O
seem	O
to	O
select	O
for	O
MMR	O
deficient	O
cells	O
since	O
in	O
vitro	O
enrichment	O
for	O
MLH1	B
deficient	I
colon	B
cancer	I
HCT116	O
cells	O
in	O
a	O
mixed	O
cell	O
population	O
was	O
seen	O
after	O
cisplatin	O
treatment	O
[	O
53	O
]	O
.	O

In	O
addition	O
,	O
several	O
in	O
vivo	O
studies	O
found	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
MSI	O
and	O
MLH1	O
methylation	O
after	O
platinum	O
-	O
based	O
chemotherapy	O
as	O
well	O
as	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
cells	O
positive	O
for	O
MLH1	O
and	O
MSH2	O
[	O
14,19,25,52	O
]	O
.	O

Moreover	O
,	O
an	O
increase	O
in	O
MLH1	O
methylation	O
after	O
platinum	O
-	O
based	O
chemotherapy	O
was	O
associated	O
with	O
poor	O
survival	O
in	O
ovarian	B
cancer	I
patients	O
[	O
19	O
]	O
.	O

These	O
results	O
as	O
well	O
as	O
the	O
in	O
vitro	O
studies	O
mentioned	O
in	O
the	O
introduction	O
,	O
suggest	O
that	O
MMR	O
inactivation	O
causes	O
a	O
low	O
level	O
resistance	O
to	O
platinum	O
-	O
based	O
chemotherapy	O
which	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
intrinsic	O
resistance	O
.	O

However	O
,	O
due	O
to	O
selection	O
during	O
chemotherapy	O
MMR	O
inactivation	O
might	O
play	O
a	O
greater	O
role	O
in	O
the	O
acquired	O
resistance	O
.	O

We	O
therefore	O
propose	O
that	O
the	O
role	O
of	O
MMR	O
inactivation	O
in	O
acquired	O
resistance	O
in	O
ovarian	B
cancer	I
should	O
be	O
further	O
investigated	O
.	O

Whole	O
-	O
chromosome	O
plots	O
of	O
running	O
average	O
of	O
fractions	O
of	O
samples	O
showing	O
up-	O
/	O
down	O
-	O
regulation	O
in	O
tumor	B
versus	O
normal	B
samples	O
(	O
Chromosome	O
17,18,19,20,21,22,X	O
,	O
Y	O
)	O
.	O

For	O
each	O
chromosome	O
you	O
see	O
a	O
separate	O
figure	O
.	O

Gray	O
dots	O
denote	O
the	O
number	O
of	O
patients	O
with	O
up-	O
or	O
down	O
-	O
regulation	O
for	O
a	O
single	O
gene	O
.	O

Orange	O
/	O
green	O
lines	O
represent	O
a	O
running	O
average	O
of	O
these	O
values	O
.	O

The	O
plots	O
are	O
made	O
to	O
be	O
easily	O
comparable	O
with	O
whole	O
-	O
genome	O
CGH	O
plots	O
(	O
like	O
e.g.	O
those	O
in	O
Knösel	O
et	O
al.	O
[	O
21	O
]	O
)	O

Further	O
details	O
of	O
plot	O
construction	O
are	O
described	O
in	O
the	O
methods	O
section	O
.	O

Individual	O
chromosomal	O
islands	O
of	O
up-	O
or	O
down	O
-	O
regulation	O
.	O

These	O
are	O
condensed	O
results	O
of	O
the	O
ChARM	O
analyses	O
:	O
overlapping	O
regions	O
with	O
evidence	O
for	O
up-	O
or	O
down	O
-	O
regulation	O
from	O
various	O
analyses	O
of	O
different	O
cross	O
-	O
correlation	O
window	O
sizes	O
have	O
been	O
fused	O
into	O
single	O
regions	O
.	O

The	O
original	O
ChARM	O
output	O
including	O
p	O
values	O
for	O
each	O
region	O
and	O
additional	O
annotation	O
can	O
be	O
found	O
in	O
Additional	O
file	O
1	O
.	O

Hereditary	O
colorectal	B
cancer	I
syndromes	O
are	O
indicated	O
along	O
with	O
their	O
OMIM	O
ID	O
.	O

Gene	O
symbols	O
are	O
official	O
or	O
provisional	O
HUGO	O
symbols	O
if	O
available	O
,	O
otherwise	O
names	O
of	O
Unigene	O
clusters	O
.	O

Information	O
about	O
known	O
tumor	B
genes	O
in	O
misregulated	O
regions	O
were	O
extracted	O
from	O
the	O
literature	O
.	O

Tumor	B
-	O
associated	O
genes	O
are	O
located	O
within	O
expression	O
islands	O
or	O
in	O
near	O
vicinity	O
.	O

Statistics	O
on	O
expression	O
imbalances	O
across	O
human	O
chromosomes	O
.	O

Here	O
,	O
estimates	O
of	O
portions	O
of	O
chromosomes	O
that	O
are	O
affected	O
by	O
regional	O
regulation	O
of	O
expression	O
are	O
given	O
.	O

The	O
second	O
column	O
gives	O
the	O
number	O
of	O
genes	O
on	O
a	O
particular	O
chromosome	O
that	O
were	O
included	O
in	O
our	O
analysis	O
.	O

The	O
following	O
columns	O
contain	O
the	O
numbers	O
of	O
genes	O
that	O
are	O
located	O
in	O
deregulated	O
expression	O
islands	O
(	O
up	O
/	O
down	O
)	O
.	O

Individual	O
chromosomal	O
islands	O
with	O
gain	O
of	O
expression	O
8q11.23-q21.13	O
Gain	O
of	O
expression	O
in	O
region	O
8q11.23-q21.13	O
is	O
strongest	O
in	O
a	O
small	O
interval	O
(	O
8q12.1	O
)	O
that	O
spans	O
genes	O
from	O
TCEA1	O
to	O
PLAG1	O
(	O
see	O
Figures	O
6	O
,	O
7	O
,	O
8)	O
.	O

There	O
have	O
been	O
numerous	O
reports	O
of	O
copy	O
number	O
gains	O
of	O
chromosome	O
8q	O
in	O
CRC	B
[	O
18,21,23,25	O
]	O
which	O
suggests	O
a	O
possible	O
mechanism	O
leading	O
to	O
over	O
-	O
expression	O
in	O
our	O
patients	O
.	O

The	O
known	O
blood	O
cell	O
oncogene	O
LYN	O
is	O
located	O
in	O
this	O
interval	O
and	O
it	O
is	O
up	O
-	O
regulated	O
in	O
several	O
of	O
our	O
tumor	B
samples	O
.	O

It	O
has	O
been	O
reported	O
before	O
that	O
LYN	O
is	O
expressed	O
in	O
colorectal	O
tumors	B
[	O
26	O
]	O
.	O

The	O
concerted	O
up	O
-	O
regulation	O
of	O
LYN	O
along	O
with	O
other	O
genes	O
in	O
this	O
region	O
suggests	O
a	O
role	O
for	O
LYN	O
in	O
CRC	B
.	O

Another	O
interesting	O
gene	O
in	O
this	O
interval	O
is	O
PLAG1	O
(	O
pleomorphic	O
adenoma	B
gene	O
1	O
)	O
for	O
which	O
chromosomal	O
aberrations	O
have	O
been	O
described	O
that	O
lead	O
to	O
over	O
-	O
expression	O
in	O
salivary	O
gland	O
tumors	B
[	O
27,28	O
]	O
.	O

No	O
informative	O
expression	O
measures	O
were	O
obtained	O
for	O
the	O
MOS	O
protein	O
kinase	O
gene	O
which	O
is	O
located	O
between	O
RPS20	O
and	O
PLAG1	O
,	O
although	O
this	O
may	O
be	O
due	O
to	O
technical	O
limitations	O
.	O

Genes	O
encoding	O
components	O
of	O
the	O
translation	O
machinery	O
,	O
the	O
mitochondrial	O
ribosomal	O
protein	O
MRPL15	O
and	O
cytosolic	O
ribosomal	O
proteins	O
RPL7	O
and	O
RPS20	O
,	O
are	O
located	O
in	O
this	O
region	O
,	O
highlighting	O
the	O
need	O
for	O
enhanced	O
translation	O
in	O
cancer	B
cells	O
.	O

The	O
concomitant	O
down	O
-	O
regulation	O
of	O
the	O
TOX	O
and	O
ANKTM1	O
genes	O
in	O
many	O
patients	O
in	O
an	O
environment	O
of	O
transcriptional	O
activation	O
is	O
remarkable	O
,	O
but	O
the	O
functional	O
significance	O
remains	O
unclear	O
.	O

Buffart	O
et	O
al.	O
have	O
reported	O
amplifications	B
of	I
8q11-q24	I
in	O
metastasizing	O
CRC	B
[	O
29	O
]	O
,	O
highlighting	O
a	O
possible	O
mechanism	O
for	O
gain	O
of	O
expression	O
in	O
this	O
region	O
.	O

In	O
summary	O
,	O
our	O
analysis	O
suggests	O
that	O
chromosomal	O
region	O
8q12.1	O
is	O
a	O
candidate	O
target	O
region	O
for	O
genetic	O
alterations	O
that	O
lead	O
to	O
over	O
-	O
expression	O
in	O
CRC	B
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
T	O
/	O
N	O
relative	O
expression	O
heat	O
map	O
)	O
.	O

Heat	O
map	O
of	O
fold	O
change	O
of	O
tumor	B
-	O
versus	O
-	O
normal	O
expression	O
.	O

Genes	O
are	O
given	O
in	O
chromosomal	O
order	O
on	O
the	O
horizontal	O
axis	O
.	O

Patient	O
codes	O
are	O
given	O
on	O
the	O
vertical	O
axis	O
.	O

The	O
legend	O
depicts	O
which	O
colors	O
code	O
for	O
which	O
expression	O
changes	O
on	O
a	O
loge	O
scale	O
(	O
green	O
:	O
down	O
in	O
tumor	O
;	O
red	O
:	O
up	O
in	O
tumor	O
)	O
.	O

View	O
in	O
conjunction	O
with	O
Figures	O
7	O
and	O
8	O
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
patient	O
counts	O
with	O
coordinate	O
up	O
-	O
regulation	O
)	O
.	O

Grayscale	O
plot	O
of	O
cross	O
-	O
comparison	O
of	O
up	O
-	O
regulation	O
patterns	O
across	O
patients	O
for	O
gene	O
pairs	O
in	O
a	O
particular	O
region	O
.	O

Both	O
,	O
horizontal	O
and	O
vertical	O
axes	O
comprise	O
the	O
same	O
genes	O
in	O
chromosomal	O
order	O
.	O

In	O
each	O
square	O
total	O
counts	O
of	O
patients	O
with	O
consistent	O
up	O
-	O
regulation	O
in	O
two	O
genes	O
are	O
coded	O
by	O
different	O
shades	O
of	O
gray	O
.	O

Dark	O
squared	O
regions	O
along	O
the	O
diagonal	O
indicate	O
coordinated	O
regulation	O
in	O
patient	O
subgroups	O
.	O

Note	O
,	O
that	O
many	O
more	O
patients	O
show	O
up	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
this	O
figure	O
than	O
down	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
Figure	O
8	O
.	O

The	O
left	O
region	O
of	O
exceptionally	O
strong	O
up	O
-	O
regulation	O
spans	O
TCEA1	O
,	O
LYPLA1	O
,	O
MRPL15	O
,	O
the	O
known	O
tumor	O
gene	O
LYN	O
,	O
and	O
PLAG1	O
.	O

Note	O
that	O
TOX	O
and	O
ANKTM1	O
are	O
down	O
-	O
regulated	O
in	O
approximately	O
half	O
of	O
the	O
tumor	B
samples	O
.	O

Up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
8q11.23-q21.13	O
(	O
patient	O
counts	O
with	O
coordinate	O
down	O
-	O
regulation	O
)	O
.	O

Grayscale	O
plot	O
of	O
cross	O
-	O
comparison	O
of	O
down	O
-	O
regulation	O
patterns	O
across	O
patients	O
for	O
gene	O
pairs	O
in	O
a	O
particular	O
region	O
.	O

Both	O
,	O
horizontal	O
and	O
vertical	O
axes	O
comprise	O
the	O
same	O
genes	O
in	O
chromosomal	O
order	O
.	O

In	O
each	O
square	O
total	O
counts	O
of	O
patients	O
with	O
consistent	O
down	O
-	O
regulation	O
in	O
two	O
genes	O
are	O
coded	O
by	O
different	O
shades	O
of	O
gray	O
.	O

Dark	O
squared	O
regions	O
along	O
the	O
diagonal	O
indicate	O
coordinated	O
regulation	O
in	O
patient	O
subgroups	O
.	O

View	O
in	O
conjunction	O
with	O
Figures	O
6	O
and	O
7	O
.	O

20q11.22-q11.23	O
The	O
region	O
20q11.22-q11.23	O
was	O
among	O
the	O
most	O
frequently	O
up	O
-	O
regulated	O
regions	O
(	O
see	O
Figures	O
12	O
,	O
13	O
,	O
14	O
)	O
.	O

Amplifications	O
of	O
regions	O
on	O
chromosome	O
20q	O
have	O
been	O
identified	O
independently	O
by	O
several	O
groups	O
in	O
CRCs	B
[	O
19,21,23,24	O
]	O
.	O

The	O
interval	O
comprises	O
the	O
known	O
tumor	B
gene	O
SRC	O
(	O
located	O
between	O
MANBAL	O
and	O
BLCAP	O
in	O
Figures	O
12	O
,	O
13	O
,	O
14	O
)	O
for	O
which	O
no	O
informative	O
expression	O
measures	O
were	O
obtained	O
.	O

We	O
note	O
that	O
it	O
is	O
possible	O
that	O
the	O
SRC	O
gene	O
is	O
the	O
primary	O
target	O
of	O
up	O
-	O
regulation	O
in	O
our	O
CRC	B
patients	O
,	O
the	O
up	O
-	O
regulation	O
of	O
other	O
genes	O
being	O
just	O
piggy	O
-	O
back	O
effects	O
.	O

However	O
,	O
also	O
the	O
up	O
-	O
regulation	O
of	O
the	O
CTNN1L1	O
transcript	O
could	O
be	O
of	O
potential	O
functional	O
significance	O
for	O
CRC	B
development	O
.	O

CTNN1L1	O
shows	O
partial	O
homology	O
to	O
the	O
known	O
colorectal	B
cancer	I
gene	O
beta	O
-	O
catenin	O
in	O
the	O
armadillo	O
repeat	O
region	O
and	O
has	O
a	O
nuclear	O
localization	O
signal	O
,	O
suggesting	O
that	O
it	O
could	O
play	O
an	O
important	O
role	O
in	O
signal	O
transduction	O
to	O
the	O
nucleus	O
in	O
CRC	B
.	O

Also	O
up	O
-	O
regulation	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
Itchy	O
(	O
ITCH	O
)	O
could	O
be	O
of	O
potential	O
importance	O
as	O
selective	O
ubiquitin	O
-	O
tagging	O
of	O
signaling	O
proteins	O
for	O
destruction	O
is	O
an	O
emerging	O
mechanism	O
in	O
cancer	B
biology	O
.	O

The	O
need	O
for	O
accelerated	O
protein	O
synthesis	O
in	O
cancer	B
cells	O
is	O
reflected	O
by	O
the	O
up	O
-	O
regulation	O
of	O
the	O
translation	O
initiation	O
factor	O
EIF2S2	O
.	O

Remarkably	O
,	O
we	O
found	O
dramatic	O
down	O
-	O
regulation	O
against	O
the	O
regional	O
trend	O
of	O
C20orf110	O
alias	O
p53-inducible	O
protein	O
2	O
(	O
TP53INP2	O
)	O
whose	O
expression	O
is	O
usually	O
positively	O
controlled	O
by	O
the	O
p53	O
protein	O
.	O

For	O
unknown	O
reasons	O
p53	O
seems	O
to	O
be	O
unable	O
to	O
induce	O
TP53INP2	O
expression	O
in	O
the	O
majority	O
of	O
CRCs	B
studied	O
here	O
.	O

Down	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
14q24.1	O
-	O
14q24.3	O
–	O
the	O
FOS	O
region	O
(	O
patient	O
counts	O
with	O
coordinate	O
up	O
-	O
regulation	O
)	O
.	O

Grayscale	O
cross	O
-	O
comparison	O
plot	O
of	O
up	O
-	O
regulation	O
patterns	O
across	O
patients	O
(	O
analogous	O
to	O
Figures	O
7	O
,	O
10	O
,	O
13	O
)	O
.	O

View	O
this	O
plot	O
in	O
conjunction	O
with	O
Figures	O
30	O
and	O
32	O
.	O

Down	O
-	O
regulation	O
of	O
mRNA	O
expression	O
in	O
human	O
chromosomal	O
region	O
14q24.1	O
-	O
14q24.3	O
–	O
the	O
FOS	O
region	O
(	O
patient	O
counts	O
with	O
coordinate	O
down	O
-	O
regulation	O
)	O
.	O

Grayscale	O
cross	O
-	O
comparison	O
plot	O
of	O
down	O
-	O
regulation	O
patterns	O
across	O
patients	O
(	O
analogous	O
to	O
Figures	O
8	O
,	O
11	O
,	O
14	O
)	O
.	O

View	O
this	O
plot	O
in	O
conjunction	O
with	O
Figures	O
30	O
and	O
31	O
.	O

Note	O
,	O
that	O
many	O
more	O
patients	O
show	O
down	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
this	O
plot	O
than	O
up	O
-	O
regulation	O
as	O
indicated	O
by	O
dark	O
spots	O
in	O
Figure	O
31	O
.	O

This	O
region	O
has	O
been	O
reported	O
in	O
other	O
studies	O
to	O
be	O
frequently	O
deleted	O
in	O
colon	B
cancer	I
metastases	O
(	O
see	O
Table	O
1	O
)	O
.	O

The	O
FOS	O
oncogene	O
is	O
the	O
5th	O
gene	O
from	O
the	O
right	O
and	O
is	O
one	O
of	O
the	O
most	O
strongly	O
down	O
-	O
regulated	O
genes	O
in	O
this	O
region	O
.	O

Note	O
the	O
expression	O
of	O
MLH3	O
,	O
KIAA0317	O
,	O
KIAA0440	O
/	O
SIPA1L1	O
,	O
NUMB	O
,	O
SYNJ2BP	O
and	O
PSEN1	O
.	O

Discussion	O
Global	O
analysis	O
of	O
chromosomal	O
regions	O
with	O
expression	O
gain	O
or	O
loss	O
We	O
found	O
that	O
25	O
%	O
of	O
the	O
genes	O
lie	O
in	O
regions	O
that	O
are	O
affected	O
by	O
expression	O
imbalance	O
in	O
colon	B
cancer	I
.	O

This	O
does	O
not	O
mean	O
that	O
25	O
%	O
of	O
the	O
genes	O
are	O
misregulated	O
as	O
many	O
genes	O
that	O
fall	O
into	O
these	O
regions	O
are	O
not	O
expressed	O
at	O
all	O
in	O
tumors	B
and	O
in	O
normal	B
epithelium	O
of	O
the	O
colon	O
.	O

Additionally	O
,	O
we	O
note	O
that	O
these	O
numbers	O
are	O
probably	O
an	O
upper	O
limit	O
because	O
the	O
sliding	O
window	O
approach	O
probably	O
included	O
several	O
genes	O
in	O
close	O
proximity	O
to	O
the	O
boundaries	O
of	O
misexpressed	O
regions	O
.	O

Nevertheless	O
,	O
the	O
number	O
of	O
regions	O
of	O
imbalanced	O
expression	O
is	O
remarkable	O
and	O
suggest	O
that	O
there	O
is	O
extensive	O
regulation	O
in	O
CRC	B
at	O
the	O
genomic	O
level	O
.	O

Recently	O
,	O
Nakao	O
et	O
al.	O
estimated	O
from	O
genome	O
-	O
wide	O
array	O
CGH	O
data	O
that	O
~17	O
%	O
of	O
the	O
human	O
genome	O
is	O
affected	O
by	O
DNA	O
copy	O
number	O
changes	O
in	O
CRC	B
[	O
23	O
]	O
.	O

Prior	O
to	O
a	O
more	O
detailed	O
analysis	O
of	O
individual	O
regions	O
in	O
this	O
study	O
,	O
this	O
suggested	O
that	O
not	O
all	O
regional	O
expression	O
changes	O
in	O
CRC	B
will	O
be	O
explainable	O
by	O
DNA	O
copy	O
number	O
aberrations	O
.	O

There	O
are	O
only	O
slightly	O
more	O
genes	O
with	O
expression	O
loss	O
than	O
regions	O
with	O
expression	O
gain	O
.	O

One	O
can	O
argue	O
that	O
a	O
tumor	O
ought	O
to	O
show	O
a	O
higher	O
frequency	O
of	O
expression	O
loss	O
than	O
expression	O
gain	O
.	O

Reasons	O
are	O
that	O
there	O
should	O
be	O
a	O
tendency	O
to	O
lose	O
tumor	O
suppressor	O
genes	O
selectively	O
and	O
to	O
lose	O
non	O
-	O
essential	O
genes	O
(	O
genomic	O
ballast	O
)	O
as	O
a	O
side	O
effect	O
.	O

If	O
transcription	O
would	O
be	O
a	O
process	O
that	O
is	O
predominantly	O
driven	O
by	O
positive	O
regulation	O
of	O
transcriptional	O
activators	O
,	O
one	O
would	O
assume	O
that	O
any	O
partial	O
genome	O
loss	O
results	O
in	O
a	O
slow	O
down	O
of	O
transcription	O
.	O

In	O
the	O
light	O
of	O
these	O
considerations	O
,	O
an	O
equally	O
high	O
number	O
of	O
regions	O
with	O
expression	O
gain	O
can	O
be	O
interpreted	O
in	O
two	O
ways	O
.	O

Either	O
positive	O
selection	O
drives	O
expression	O
gain	O
of	O
some	O
regions	O
in	O
cancer	O
cells	O
,	O
or	O
a	O
default	O
phenotype	O
of	O
transcription	O
suppression	O
dominates	O
in	O
normal	O
cells	O
which	O
is	O
relaxed	O
during	O
tumor	O
cell	O
development	O
.	O

Gene	O
expression	O
in	O
chromosomal	O
regions	O
with	O
frequent	O
DNA	O
copy	O
number	O
changes	O
in	O
CRC	B
Most	O
studies	O
reported	O
frequent	O
gains	O
of	O
chromosome	O
7	O
,	O
8q	O
,	O
13q	O
,	O
20q	O
and	O
losses	O
of	O
4	O
and	O
18q	O
in	O
CRC	B
[	O
18,19,21	O
-	O
25	O
]	O
.	O

These	O
broadly	O
-	O
defined	O
alterations	O
are	O
in	O
perfect	O
agreement	O
with	O
chromosome	O
-	O
specific	O
trends	O
in	O
our	O
expression	O
data	O
,	O
especially	O
the	O
exclusive	O
presence	O
of	O
domains	O
of	O
expression	O
gain	O
on	O
8	O
,	O
13	O
and	O
20	O
and	O
the	O
exclusive	O
presence	O
of	O
domains	O
of	O
expression	O
loss	O
on	O
chromosome	O
4	O
and	O
18	O
(	O
see	O
Table	O
2	O
and	O
Figures	O
21	O
,	O
22	O
,	O
23	O
,	O
24	O
,	O
25	O
,	O
26	O
)	O
.	O

There	O
is	O
a	O
single	O
discrepancy	O
for	O
chromosome	O
7	O
:	O
region	O
7q11	O
-	O
7q12	O
has	O
been	O
reported	O
as	O
amplified	O
in	O
CRC	B
,	O
but	O
its	O
expression	O
is	O
significantly	O
down	O
-	O
regulated	O
in	O
our	O
tumor	O
samples	O
.	O

Conclusion	O
Roughly	O
a	O
quarter	O
of	O
all	O
human	O
genes	O
is	O
located	O
in	O
islands	O
of	O
misregulated	O
gene	O
expression	O
in	O
colorectal	B
cancer	I
.	O

There	O
are	O
only	O
slightly	O
more	O
down	O
-	O
regulated	O
than	O
up	O
-	O
regulated	O
genes	O
.	O

Chromosomal	O
regions	O
that	O
are	O
linked	O
to	O
hereditary	O
colorectal	B
cancer	I
often	O
exhibit	O
deregulated	O
expression	O
,	O
suggesting	O
that	O
they	O
are	O
implicated	O
in	O
spontaneous	O
CRC	B
not	O
only	O
through	O
collection	O
of	O
mutations	O
.	O

Thus	O
,	O
genes	O
in	O
these	O
chromosomal	O
hotspots	O
may	O
be	O
systematically	O
tested	O
in	O
patients	O
with	O
sporadic	O
CRC	B
for	O
molecular	O
lesions	B
and	O
for	O
transcriptional	O
silencing	O
.	O

Chromosomal	O
regions	O
that	O
are	O
frequently	O
deleted	O
in	O
CRC	B
very	O
often	O
comprise	O
islands	O
in	O
which	O
we	O
found	O
reduced	O
expression	O
.	O

Although	O
many	O
regions	O
that	O
are	O
known	O
to	O
be	O
amplified	O
in	O
colorectal	O
tumors	B
show	O
a	O
gain	O
of	O
expression	O
,	O
there	O
are	O
also	O
a	O
considerable	O
number	O
of	O
amplified	O
islands	O
that	O
show	O
no	O
alterations	O
or	O
even	O
down	O
-	O
regulation	O
.	O

Comparison	O
of	O
published	O
CGH	O
studies	O
with	O
our	O
expression	O
data	O
suggests	O
that	O
amplified	O
or	O
deleted	O
chromosomal	O
regions	O
are	O
responsible	O
for	O
many	O
islands	O
with	O
aberrant	O
expression	O
.	O

However	O
,	O
we	O
suggest	O
that	O
it	O
is	O
necessary	O
to	O
invoke	O
other	O
mechanism	O
like	O
epigenetic	O
regulation	O
of	O
chromatin	O
or	O
disruption	O
of	O
enhancer	O
actions	O
to	O
explain	O
the	O
remaining	O
expression	O
imbalances	O
.	O

Non	B
-	I
dysplastic	I
serrated	O
polyps	B
:	O
HP	B
and	O
SSA	B
Non	B
-	I
dysplastic	I
serrated	O
polyps	B
comprise	O
conventional	O
HPs	B
and	O
the	O
variant	O
lesion	B
which	O
has	O
been	O
described	O
as	O
SSA	B
.	O

In	O
this	O
study	O
,	O
SSAs	B
accounted	O
for	O
approximately	O
3	O
%	O
of	O
the	O
overall	O
series	O
of	O
polyps	B
and	O
were	O
more	O
age	O
-	O
related	O
than	O
HPs	B
.	O

Importantly	O
,	O
SSAs	B
have	O
been	O
linked	O
with	O
the	O
subset	O
of	O
colorectal	B
cancer	I
with	O
BRAF	O
mutation	O
,	O
DNA	O
methylation	O
,	O
MSI	B
and	O
serrated	B
architecture.14,18,37	I
In	O
this	O
study	O
there	O
was	O
a	O
high	O
frequency	O
of	O
BRAF	O
mutation	O
in	O
conventional	O
HPs	B
(	O
67	O
%	O
)	O
as	O
well	O
as	O
in	O
SSAs	B
(	O
81	O
%	O
)	O
.	O

Previous	O
reports	O
have	O
shown	O
very	O
similar	O
results	O
for	O
BRAF	O
mutation	O
in	O
SSA,16	B
but	O
higher	O
frequencies	O
of	O
KRAS	O
mutation	O
and	O
lower	O
frequencies	O
of	O
BRAF	O
mutation	O
in	O
HPs.12,16,38	B
As	O
mentioned	O
in	O
Materials	O
and	O
methods	O
,	O
there	O
had	O
been	O
selection	O
of	O
larger	O
HPs	B
in	O
an	O
earlier	O
cell	O
kinetic	O
study	O
involving	O
the	O
same	O
material	O
.	O

Large	O
HPs	B
are	O
more	O
likely	O
to	O
include	O
the	O
subset	O
described	O
as	O
'	O
microvesicular	O
'	O
,	O
in	O
which	O
the	O
columnar	O
cells	O
contain	O
apical	O
mucin	O
droplets	O
within	O
small	O
vesicles	O
while	O
goblet	O
cells	O
are	O
rendered	O
inconspicuous.25BRAF	O
mutation	O
occurs	O
more	O
frequently	O
in	O
the	O
microvesicular	O
variant	O
of	O
HP.16	B
By	O
contrast	O
,	O
KRAS	O
mutation	O
occurs	O
much	O
more	O
commonly	O
in	O
the	O
goblet	O
cell	O
variant	O
of	O
HP	B
,	O
which	O
is	O
usually	O
small	O
,	O
located	O
in	O
the	O
left	O
colon	O
or	O
rectum	O
and	O
deviates	O
minimally	O
from	O
normal	B
colorectal	O
mucosa	O
in	O
terms	O
of	O
differentiation	O
and	O
architecture.16,25	O
The	O
latter	O
were	O
under	O
-	O
represented	O
in	O
this	O
series	O
(	O
details	O
not	O
shown	O
)	O
.	O

dysplastic	B
serrated	O
polyps	B
:	O
MP	B
and	O
SA	B
Serrated	O
polyps	B
with	O
dysplasia	B
,	O
i.e.	O
MPs	B
and	O
SAs	B
,	O
together	O
comprised	O
only	O
2	O
%	O
of	O
the	O
overall	O
consecutive	O
series	O
of	O
1250	O
polyps	B
.	O

While	O
mutation	O
of	O
KRAS	O
and	O
BRAF	O
was	O
associated	O
with	O
conventional	O
adenoma	B
and	O
SSA	B
,	O
respectively	O
(	O
see	O
above	O
)	O
,	O
BRAF	O
and	O
KRAS	O
mutation	O
occurred	O
with	O
similar	O
frequency	O
in	O
both	O
MPs	B
(	O
40	O
%	O
and	O
50	O
%	O
,	O
respectively	O
)	O
and	O
SAs	B
(	O
33	O
%	O
and	O
27	O
%	O
,	O
respectively	O
)	O
.	O

In	O
the	O
literature	O
,	O
the	O
frequency	O
of	O
BRAF	O
and	O
KRAS	O
mutation	O
in	O
MP	B
or	O
SA	B
has	O
ranged	O
from	O
36	O
to	O
100	O
%	O
and	O
from	O
0	O
%	O
to	O
60	O
%	O
,	O
respectively.12,16,39–42	O
These	O
findings	O
indicate	O
that	O
this	O
subset	O
of	O
colorectal	O
polyps	B
is	O
likely	O
to	O
be	O
heterogeneous	O
in	O
terms	O
of	O
its	O
molecular	O
origins	O
.	O

These	O
polyps	B
were	O
therefore	O
reclassified	O
according	O
to	O
their	O
resemblance	O
to	O
HP	B
or	O
SSA	B
(	O
Group	O
A	O
)	O
(	O
Figure	O
1A	O
,	O
B	O
,	O
E	O
,	O
F	O
)	O
or	O
to	O
conventional	O
adenoma	B
(	O
Group	O
B	O
)	O
(	O
Figure	O
1C	O
,	O
D	O
)	O
.	O

Particular	O
histological	O
features	O
among	O
the	O
Group	O
A	O
polyps	B
were	O
:	O
marked	O
serration	O
,	O
a	O
papillary	B
or	I
villous	I
architecture	I
,	O
a	O
relatively	O
abundant	O
eosinophilic	O
cytoplasm	O
,	O
columnar	O
cells	O
with	O
apical	O
mucin	O
droplets	O
,	O
nuclei	O
that	O
were	O
enlarged	O
,	O
ovoid	O
,	O
vesicular	O
and	O
contained	O
a	O
prominent	O
nucleolus	O
,	O
and	O
adjacent	O
non	B
-	I
dysplastic	I
serrated	O
polyp	B
.	O

Particular	O
histological	O
features	O
among	O
the	O
Group	O
B	O
polyps	B
were	O
:	O
some	O
glandular	O
serration	O
,	O
frequent	O
villous	O
change	O
and	O
epithelial	B
dysplasia	I
that	I
appeared	I
adenomatous	I
(	O
cytoplasmic	O
basophilia	O
and	O
nuclei	O
that	O
were	O
elongated	O
,	O
pseudostratified	O
and	O
hyperchromatic	O
without	O
a	O
prominent	O
nucleolus	O
)	O
.	O

Importantly	O
,	O
BRAF	O
mutation	O
occurred	O
more	O
frequently	O
among	O
Group	O
A	O
polyps	B
(	O
P	O
<	O
0.03	O
)	O
,	O
whereas	O
there	O
was	O
a	O
trend	O
for	O
KRAS	O
to	O
be	O
more	O
frequent	O
among	O
Group	O
B	O
polyps	B
(	O
P	O
=	O
0.06	O
)	O
.	O

In	O
summary	O
,	O
MPs	B
and	O
SAs	B
account	O
for	O
only	O
about	O
2	O
%	O
of	O
colorectal	O
polyps	B
.	O

Nevertheless	O
,	O
those	O
serrated	O
polyps	B
with	O
dysplasia	B
show	O
frequent	O
mutation	O
of	O
either	O
KRAS	O
or	O
BRAF	O
and	O
frequent	O
loss	O
of	O
expression	O
of	O
MGMT	O
(	O
particularly	O
MP	B
)	O
.	O

Additionally	O
,	O
four	O
of	O
25	O
(	O
16	O
%	O
)	O
showed	O
high	B
-	I
grade	I
dysplasia	I
and	O
in	O
three	O
of	O
these	O
there	O
was	O
concordant	O
aberrant	O
nuclear	O
expression	O
of	O
p53	O
.	O

Along	O
with	O
SSAs	B
,	O
these	O
rare	O
polyps	B
may	O
serve	O
as	O
the	O
precursors	O
of	O
sporadic	O
CRCs	B
with	O
BRAF	O
mutation	O
and	O
DNA	O
methylation	O
(	O
with	B
and	I
without	I
DNA	I
MSI	I
)	O
and	O
a	O
subset	O
of	O
CRCs	B
with	O
KRAS	O
mutation	O
.	O

Their	O
malignant	O
potential	O
is	O
explained	O
by	O
the	O
accumulation	O
of	O
genetic	O
alterations	O
that	O
may	O
in	O
turn	O
depend	O
upon	O
the	O
inactivation	O
of	O
the	O
DNA	O
repair	O
gene	O
MGMT.28	O
The	O
importance	O
of	O
these	O
'	O
fusion	O
'	O
polyps	B
as	O
cancer	B
precursors	O
may	O
be	O
under	O
-	O
appreciated	O
because	O
critical	O
rate	O
-	O
limiting	O
changes	O
governing	O
malignant	O
transition	O
,	O
particularly	O
in	O
association	O
with	O
loss	O
of	O
function	O
of	O
MLH1	O
of	O
p53	O
,	O
occur	O
rapidly	O
and	O
can	O
rarely	O
be	O
'	O
caught	O
in	O
the	O
act	O
'	O
.	O

Methods	O
Patients	O
A	O
large	O
colorectal	B
cancer	I
family	O
(	O
Figure	O
1	O
)	O
with	O
a	O
recently	O
identified	O
mutation	O
in	O
the	O
MLH1	O
gene	O
(	O
c.1046dupT	O
,	O
p.	O

Pro350fs	O
)	O
was	O
studied	O
.	O

Nine	O
family	O
members	O
are	O
affected	O
with	O
colorectal	B
cancer	I
.	O

Another	O
two	O
family	O
members	O
are	O
affected	B
with	O
polyps	B
and	O
three	O
cases	O
with	O
skin	O
cancer	B
(	O
non	O
-	O
specified	O
)	O
and	O
one	O
case	O
with	O
endometrium	O
cancer	B
(	O
non	O
-	O
specified	O
)	O
are	O
seen	O
as	O
well	O
.	O

Peripheral	O
blood	O
lymphocytes	O
were	O
collected	O
from	O
the	O
family	O
members	O
.	O

DNA	O
was	O
extracted	O
using	O
standard	O
procedures	O
.	O

A	O
total	O
of	O
thirteen	O
family	O
members	O
were	O
genotyped	O
on	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
10	O
K	O
2.0	O
SNP	O
arrays	O
.	O

The	O
arrays	O
were	O
processed	O
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
.	O

The	O
mean	O
SNP	O
call	O
rate	O
was	O
96.3	O
%	O
(	O
89.0%-98.5	O
%	O
)	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Medical	O
Ethical	O
Committee	O
of	O
the	O
LUMC	O
(	O
protocol	O
P01	O
-	O
019	O
)	O
.	O

Workflow	O
We	O
processed	O
the	O
data	O
according	O
to	O
the	O
following	O
workflow	O
:	O
1	O
)	O
First	O
,	O
the	O
genotype	O
data	O
were	O
generated	O
by	O
GeneChip	O
DNA	O
Analysis	O
Software	O
(	O
GDAS	O
)	O
from	O
Affymetrix	O
.	O

2	O
)	O
These	O
genotype	O
data	O
were	O
combined	O
with	O
the	O
pedigree	O
and	O
the	O
marker	O
information	O
in	O
Alohomora	O
.	O

3	O
)	O
In	O
this	O
program	O
the	O
uninformative	O
SNPs	O
were	O
removed	O
as	O
well	O
.	O

4	O
)	O
To	O
be	O
able	O
to	O
perform	O
linkage	O
analysis	O
in	O
the	O
desired	O
program	O
,	O
the	O
output	O
files	O
(	O
in	O
Merlin	O
-	O
format	O
)	O
of	O
Alohomora	O
were	O
by	O
Mega2	O
converted	O
to	O
the	O
proper	O
format	O
.	O

5	O
)	O
Mega2	O
also	O
removed	O
the	O
Mendelian	O
inconsistent	O
errors	O
.	O

6	O
)	O
The	O
files	O
were	O
then	O
ready	O
to	O
perform	O
parametric	O
linkage	O
analysis	O
using	O
2	O
flanking	O
markers	O
in	O
MENDEL	O
;	O
affected	O
-	O
only	O
analysis	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
using	O
liability	O
classes	O
was	O
performed	O
.	O

7	O
)	O
Based	O
on	O
the	O
second	O
analysis	O
,	O
regions	O
of	O
interest	O
were	O
defined	O
that	O
were	O
further	O
tested	O
for	O
Mendelian	O
consistent	O
errors	O
and	O
8)	O
possible	O
linkage	O
disequilibrium	O
was	O
removed	O
in	O
SNPLINK	O
.	O

9	O
)	O
Multipoint	O
parametric	O
linkage	O
analysis	O
using	O
the	O
liability	O
classes	O
was	O
then	O
performed	O
in	O
Simwalk2	O
for	O
the	O
ROIs	O
and	O
10	O
)	O
finally	O
,	O
the	O
haplotypes	O
were	O
inferred	O
in	O
Simwalk2	O
.	O

Data	O
formatting	O
and	O
quality	O
control	O
Genotype	O
data	O
of	O
the	O
individual	O
family	O
members	O
were	O
generated	O
using	O
GeneChip	O
DNA	O
Analysis	O
Software	O
(	O
GDAS	O
)	O
from	O
Affymetrix	O
.	O

In	O
the	O
Alohomora	O
program	O
[	O
32	O
]	O
the	O
pedigree	O
information	O
,	O
allele	O
frequencies	O
and	O
map	O
position	O
of	O
the	O
SNPs	O
were	O
combined	O
with	O
the	O
genotype	O
data	O
generated	O
by	O
GDAS	O
.	O

The	O
uninformative	O
SNPs	O
in	O
this	O
pedigree	O
,	O
that	O
show	O
either	O
only	O
A	O
alleles	O
and	O
No	O
Calls	O
or	O
only	O
B	O
alleles	O
and	O
No	O
Calls	O
,	O
were	O
removed	O
from	O
further	O
analysis	O
by	O
Alohomora	O
.	O

The	O
data	O
files	O
were	O
exported	O
in	O
Merlin	O
format	O
.	O

Subsequently	O
,	O
in	O
Mega2	O
[	O
33	O
]	O
these	O
Alohomora	O
files	O
were	O
converted	O
into	O
the	O
appropriate	O
format	O
for	O
the	O
programs	O
used	O
for	O
linkage	O
analysis	O
,	O
i.e.	O
either	O
the	O
Mendel	O
5	O
format	O
or	O
the	O
SimWalk2	O
format	O
.	O

Mendelian	O
inconsistent	O
errors	O
were	O
removed	O
from	O
analysis	O
with	O
Mega2	O
by	O
setting	O
all	O
genotypes	O
of	O
these	O
SNPs	O
to	O
unknown	O
.	O

Results	O
HLA	O
class	O
I	O
,	O
β2	O
m	O
and	O
APM	O
component	O
expression	O
In	O
order	O
to	O
compare	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
sporadic	O
MSI	B
-	I
H	I
and	O
MSS	B
right	O
sided	O
tumors	B
(	O
RST	B
)	O
and	O
HNPCC	B
MSI	B
-	I
H	I
cases	O
,	O
we	O
used	O
an	O
antibody	O
panel	O
recognizing	O
monomorphic	O
determinants	O
expressed	O
on	O
HLA	O
class	O
I	O
heavy	O
chains	O
,	O
β2	O
m	O
and	O
APM	O
components	O
(	O
Figure	O
1	O
)	O
.	O

In	O
total	O
,	O
we	O
identified	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
about	O
34.6	O
%	O
of	O
the	O
RST	B
and	O
42.7	O
%	O
of	O
the	O
HNPCC	B
cases	O
.	O

The	O
frequency	O
of	O
alterations	O
differed	O
significantly	O
between	O
the	O
sporadic	O
MSS	B
and	O
MSI	B
-	I
H	I
RST	B
.	O

The	O
lack	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
more	O
frequent	O
in	O
MSI	B
-	I
H	I
sporadic	O
cases	O
than	O
in	O
MSS	B
cases	O
(	O
p	O
<	O
0.0001	O
)	O
,	O
as	O
it	O
was	O
16.7	O
%	O
in	O
the	O
latter	O
group	O
,	O
but	O
60.6	O
%	O
in	O
the	O
former	O
(	O
Table	O
2	O
)	O
.	O

Subsequently	O
,	O
we	O
have	O
investigated	O
the	O
frequency	O
of	O
a	O
concomitant	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
with	O
that	O
of	O
either	O
the	O
β2	O
m	O
molecule	O
or	O
of	O
any	O
APM	O
component	O
.	O

In	O
the	O
sporadic	O
subset	O
,	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
more	O
often	O
associated	O
with	O
that	O
of	O
one	O
of	O
the	O
APM	O
components	O
,	O
occurring	O
in	O
about	O
37	O
%	O
of	O
HLA	B
-	I
negative	I
tumors	B
regardless	O
of	O
their	O
mismatch	O
repair	O
status	O
(	O
Table	O
2	O
)	O
.	O

β2	O
m	O
loss	O
was	O
only	O
found	O
in	O
one	O
HLA	B
class	I
I	I
negative	I
MSI	B
-	I
H	I
sporadic	O
tumor	B
(	O
case	O
65	O
)	O
that	O
interestingly	O
also	O
presented	O
loss	O
of	O
the	O
APM	O
molecules	O
TAP2	O
,	O
Calreticulin	O
and	O
Tapasin	O
(	O
Figure	O
2	O
)	O
.	O

In	O
contrast	O
,	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
HNPCC	B
cases	O
was	O
more	O
frequently	O
associated	O
with	O
that	O
of	O
β2	O
m	O
(	O
Table	O
2	O
)	O
,	O
as	O
it	O
was	O
found	O
in	O
46.9	O
%	O
of	O
the	O
HLA	B
class	I
I	I
-	I
negative	I
tumors	B
.	O

In	O
contrast	O
loss	O
of	O
any	O
APM	O
component	O
was	O
observed	O
in	O
only	O
6	O
%	O
of	O
these	O
cases	O
(	O
h38	O
,	O
h49	O
)	O
which	O
also	O
showed	O
loss	O
of	O
β2	O
m	O
expression	O
.	O

In	O
sporadic	O
RST	B
,	O
the	O
simultaneous	O
loss	O
of	O
more	O
than	O
one	O
APM	O
molecule	O
per	O
case	O
was	O
frequent	O
(	O
Figure	O
2	O
)	O
.	O

Only	O
3	O
out	O
of	O
10	O
cases	O
lost	O
a	O
single	O
APM	O
component	O
.	O

The	O
TAP2	O
molecule	O
was	O
most	O
frequently	O
lost	O
(	O
6	O
cases	O
)	O
,	O
followed	O
by	O
TAP1	O
,	O
Tapasin	O
and	O
LMP2	O
(	O
5	O
cases	O
)	O
,	O
Calreticulin	O
(	O
4	O
cases	O
)	O
,	O
LMP7	O
(	O
2	O
cases	O
)	O
,	O
and	O
Calnexin	O
and	O
ERp57	O
(	O
1	O
case	O
)	O
.	O

Loss	O
of	O
the	O
LPM10	O
protein	O
was	O
detected	O
in	O
neither	O
sporadic	O
RST	B
nor	O
HNPCC	B
tumors	B
.	O

The	O
HNPCC	B
cases	O
h38	O
and	O
h49	O
lost	O
the	O
expression	O
of	O
TAP2	O
and	O
LMP7	O
respectively	O
.	O

LOH	O
and	O
frameshift	O
analysis	O
Polymorphic	O
markers	O
around	O
the	O
classical	O
HLA	O
genes	O
(	O
A	O
,	O
B	O
and	O
C	O
)	O
,	O
TAP	O
1	O
and	O
TAP2	O
genes	O
were	O
used	O
to	O
study	O
LOH	O
and	O
reveal	O
possible	O
chromosomal	O
aberrations	O
that	O
could	O
relate	O
to	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
HNPCC	B
cases	O
,	O
LOH	O
analysis	O
was	O
only	O
performed	O
around	O
the	O
HLA	O
genes	O
since	O
loss	O
of	O
the	O
TAP1	O
and	O
TAP2	O
proteins	O
was	O
rarely	O
associated	O
with	O
HLA	O
class	O
I	O
loss	O
.	O

LOH	O
was	O
more	O
frequent	O
in	O
the	O
MSS	B
tumors	B
(	O
50	O
%	O
)	O
than	O
in	O
the	O
MSI	B
-	I
H	I
sporadic	O
(	O
20	O
%	O
)	O
and	O
HNPCC	B
(	O
6	O
%	O
)	O
tumors	B
with	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
(	O
P	O
<	O
0.05	O
)	O
(	O
Figure	O
3	O
,	O
4	O
)	O
.	O

Furthermore	O
,	O
the	O
patterns	O
of	O
LOH	O
in	O
the	O
MSS	B
cases	O
might	O
indicate	O
loss	O
of	O
the	O
entire	O
6p21.3	O
region	O
,	O
in	O
contrast	O
to	O
the	O
MSI	B
-	I
H	I
cases	O
(	O
hereditary	O
and	O
sporadic	O
forms	O
)	O
where	O
LOH	O
seems	O
to	O
be	O
limited	O
.	O

Discussion	O
Abnormalities	B
in	I
HLA	I
class	I
I	I
cell	I
surface	I
expression	I
are	O
commonly	O
observed	O
in	O
tumors	B
and	O
are	O
interpreted	O
as	O
a	O
mechanism	O
by	O
which	O
tumor	B
cells	O
evade	O
the	O
host	O
immune	O
system	O
[	O
1	O
]	O
.	O

In	O
colorectal	B
cancer	I
,	O
especially	O
in	O
MSI	B
-	I
H	I
tumors	B
,	O
the	O
high	O
degree	O
of	O
lymphocytic	O
infiltrate	O
in	O
some	O
cases	O
may	O
suggest	O
an	O
active	O
immune	O
response	O
during	O
tumor	B
development	O
[	O
41,42	O
]	O
.	O

Moreover	O
,	O
MSI	B
-	I
H	I
tumors	B
might	O
cause	O
increased	O
immune	O
reactivity	O
as	O
a	O
consequence	O
of	O
the	O
high	O
amounts	O
of	O
aberrant	O
frameshift	O
peptides	O
they	O
generate	O
[	O
8,18	O
]	O
.	O

A	O
selective	O
pressure	O
by	O
CTLs	O
upon	O
these	O
tumors	B
would	O
favor	O
the	O
outgrowth	O
of	O
tumor	B
cells	O
that	O
lost	O
HLA	O
class	O
I	O
expression	O
at	O
the	O
cell	O
surface	O
allowing	O
them	O
to	O
surpass	O
the	O
action	O
of	O
the	O
immune	O
system	O
.	O

Applying	O
immunohistochemistry	O
on	O
tissue	O
arrays	O
,	O
we	O
compared	O
HLA	O
class	O
I	O
expression	O
in	O
both	O
sporadic	O
RST	B
(	O
MSI	B
-	I
H	I
and	O
MSS	B
sub	O
-	O
groups	O
)	O
and	O
HNPCC	B
tumors	B
.	O

RST	B
were	O
chosen	O
because	O
of	O
the	O
high	O
percentage	O
of	O
MSI	B
-	I
H	I
cases	O
in	O
this	O
specific	O
tumor	B
type	O
[	O
43	O
]	O
.	O

Indeed	O
,	O
immunohistochemical	O
staining	O
with	O
mAb	O
showed	O
that	O
HLA	O
class	O
I	O
loss	O
was	O
frequent	O
in	O
the	O
MSI	B
-	I
H	I
cases	O
analyzed	O
when	O
compared	O
to	O
their	O
MSS	B
counterpart	O
.	O

This	O
finding	O
supports	O
the	O
hypothesis	O
that	O
MSI	B
-	I
H	I
tumors	B
face	O
greater	O
selective	O
pressure	O
to	O
lose	O
HLA	O
class	O
I	O
expression	O
,	O
as	O
described	O
by	O
Kloor	O
et	O
al	O
[	O
8	O
]	O
.	O

However	O
,	O
we	O
have	O
shown	O
for	O
the	O
first	O
time	O
that	O
distinct	O
molecular	O
mechanisms	O
underlie	O
HLA	O
class	O
I	O
loss	O
in	O
sporadic	O
MSI	B
-	I
H	I
and	O
HNPCC	B
colon	B
cancers	I
.	O

In	O
the	O
latter	O
,	O
HLA	O
class	O
I	O
loss	O
was	O
preferentially	O
associated	O
with	O
that	O
of	O
β2	O
m	O
,	O
while	O
in	O
the	O
former	O
HLA	O
class	O
I	O
loss	O
was	O
associated	O
with	O
that	O
of	O
one	O
or	O
more	O
APM	O
components	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

We	O
investigated	O
the	O
genetic	O
abnormalities	O
underlying	O
the	O
HLA	O
class	O
I	O
loss	O
of	O
expression	O
.	O

They	O
included	O
LOH	O
on	O
chromosome	O
region	O
6p21.3	O
(	O
encompassing	O
HLA	O
class	O
I	O
and	O
TAP	O
genes	O
)	O
,	O
mutations	O
in	O
APM	O
components	O
and	O
mutations	O
in	O
β2	O
m	O
.	O

Loss	O
of	O
heterozygosity	O
at	O
6p21.3	O
was	O
most	O
prevalent	O
in	O
MSS	B
tumors	B
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
these	O
tumors	B
frequently	O
possess	O
gross	O
chromosomal	O
aberrations	O
and	O
are	O
often	O
aneuploid	O
[	O
13	O
]	O
.	O

Moreover	O
,	O
since	O
LOH	O
events	O
in	O
MSS	B
tumors	B
normally	O
comprise	O
large	O
areas	O
of	O
a	O
chromosome	O
,	O
LOH	O
on	O
6p21	O
might	O
not	O
be	O
a	O
direct	O
consequence	O
of	O
selective	O
pressure	O
directed	O
to	O
the	O
loss	O
of	O
HLA	O
expression	O
but	O
instead	O
to	O
other	O
genes	O
within	O
the	O
same	O
chromosomal	O
region	O
.	O

The	O
general	O
absence	O
of	O
LOH	O
in	O
MSI	B
-	I
H	I
tumors	B
suggests	O
that	O
this	O
is	O
not	O
the	O
major	O
mechanism	O
by	O
which	O
the	O
cells	O
abrogate	O
HLA	O
class	O
I	O
expression	O
.	O

The	O
genome	O
's	O
coding	O
regions	O
contain	O
multiple	O
microsatellite	O
repeats	O
,	O
which	O
are	O
considered	O
hotspots	O
for	O
mutations	O
in	O
mismatch	B
repair	I
-	I
deficient	I
tumors	B
[	O
43	O
]	O
.	O

Such	O
repeats	O
are	O
also	O
present	O
within	O
the	O
exons	O
of	O
the	O
APM	O
components	O
,	O
β2	O
m	O
,	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
genes	O
.	O

In	O
about	O
half	O
of	O
the	O
MSI	B
-	I
H	I
cases	O
,	O
loss	O
of	O
expression	O
of	O
HLA	O
class	O
I	O
was	O
concordant	O
with	O
the	O
detection	O
of	O
one	O
or	O
more	O
mutations	O
in	O
these	O
genes	O
.	O

We	O
have	O
discovered	O
novel	O
mutations	O
in	O
the	O
antigen	O
presenting	O
machinery	O
genes	O
;	O
Tapasin	O
,	O
Erp57	O
,	O
Calreticulin	O
and	O
Calnexin	O
in	O
colorectal	B
cancer	I
.	O

Previous	O
reports	O
associated	O
the	O
loss	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
MSI	B
-	I
H	I
tumors	B
with	O
defects	O
on	O
β2	O
m	O
molecule	O
[	O
7,9	O
]	O
.	O

However	O
,	O
the	O
authors	O
did	O
not	O
distinguish	O
the	O
sporadic	O
/	O
hereditary	O
nature	O
of	O
the	O
tumors	B
that	O
were	O
studied	O
.	O

We	O
can	O
not	O
exclude	O
that	O
the	O
MSI	B
-	I
H	I
cases	O
included	O
in	O
these	O
studies	O
were	O
mainly	O
HNPCC	B
tumors	B
.	O

Dietary	O
fat	O
and	O
risk	O
of	O
colon	O
and	O
rectal	O
cancer	B
with	O
aberrant	O
MLH1	O
expression	O
,	O
or	O
genes	O
Abstract	O
Objective	O
To	O
investigate	O
baseline	O
fat	O
intake	O
and	O
the	O
risk	O
of	O
colon	O
and	O
rectal	O
tumors	B
lacking	O
MLH1	O
(	O
mutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	O
type	O
2	O
)	O
repair	O
gene	O
expression	O
and	O
harboring	O
mutations	O
in	O
the	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
)	O
tumor	B
suppressor	O
gene	O
and	O
in	O
the	O
KRAS	O
(	O
v	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
)	O
oncogene	O
.	O

Methods	O
After	O
7.3	O
years	O
of	O
follow	O
-	O
up	O
of	O
the	O
Netherlands	O
Cohort	O
Study	O
(	O
n	O
=	O
120,852	O
)	O
,	O
adjusted	O
incidence	O
rate	O
ratios	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
computed	O
,	O
based	O
on	O
401	O
colon	O
and	O
130	O
rectal	O
cancer	B
patients	O
.	O

Results	O
Total	O
,	O
saturated	O
and	O
monounsaturated	O
fat	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
colon	O
or	O
rectal	O
cancer	B
,	O
or	O
different	O
molecular	O
subgroups	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
polyunsaturated	O
fat	O
and	O
the	O
risk	O
of	O
overall	O
or	O
subgroups	O
of	O
rectal	O
cancer	B
.	O

Linoleic	O
acid	O
,	O
the	O
most	O
abundant	O
polyunsaturated	O
fatty	O
acid	O
in	O
the	O
diet	O
,	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
colon	O
tumors	B
with	O
only	O
a	O
KRAS	O
mutation	O
and	O
no	O
additional	O
truncating	O
APC	O
mutation	O
or	O
lack	O
of	O
MLH1	O
expression	O
(	O
RR	O
=	O
1.41	O
,	O
95	O
%	O
CI	O
1.18–1.69	O
for	O
one	O
standard	O
deviation	O
(	O
i.e.	O
,	O
7.5	O
g	O
/	O
day	O
)	O
increase	O
in	O
intake	O
,	O
p	O
-	O
trend	O
over	O
the	O
quartiles	O
of	O
intake	O
<	O
0.001	O
)	O
.	O

Linoleic	O
acid	O
intake	O
was	O
not	O
associated	O
with	O
risk	O
of	O
colon	O
tumors	B
without	O
any	O
of	O
the	O
gene	O
defects	O
,	O
or	O
with	O
tumors	B
harboring	O
aberrations	O
in	O
either	O
MLH1	O
or	O
APC	O
.	O

Conclusion	O
Linoleic	O
acid	O
intake	O
is	O
associated	O
with	O
colon	O
tumors	B
with	O
an	O
aberrant	O
KRAS	O
gene	O
,	O
but	O
an	O
intact	O
APC	O
gene	O
and	O
MLH1	O
expression	O
,	O
suggesting	O
a	O
unique	O
etiology	O
of	O
tumors	B
with	O
specific	O
genetic	O
aberrations	O
.	O

These	O
observations	O
and	O
hypotheses	O
prompted	O
us	O
to	O
investigate	O
the	O
associations	O
between	O
the	O
intake	O
of	O
total	O
fat	O
and	O
different	O
types	O
of	O
fat	O
and	O
the	O
risk	O
of	O
colon	O
and	O
rectal	O
tumors	B
lacking	O
MLH1	O
expression	O
and	O
with	O
and	O
without	O
APC	O
gene	O
mutations	O
,	O
two	O
early	O
events	O
in	O
colorectal	O
tumorigenesis	B
,	O
independent	O
of	O
tumors	B
harboring	O
KRAS	O
gene	O
mutations	O
.	O

Materials	O
and	O
methods	O
Study	O
population	O
The	O
prospective	O
NLCS	O
was	O
initiated	O
in	O
The	O
Netherlands	O
in	O
September	O
1986	O
.	O

The	O
study	O
design	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
23	O
]	O
.	O

Briefly	O
,	O
at	O
baseline	O
a	O
total	O
of	O
58,279	O
men	O
and	O
62,573	O
women	O
,	O
between	O
the	O
ages	O
of	O
55	O
and	O
69	O
years	O
,	O
completed	O
a	O
self	O
-	O
administered	O
food	O
frequency	O
and	O
lifestyle	O
questionnaire	O
.	O

Incident	O
cancer	B
cases	O
are	O
identified	O
by	O
monitoring	O
of	O
the	O
entire	O
cohort	O
for	O
cancer	B
occurrence	O
through	O
annual	O
record	O
linkage	O
to	O
the	O
National	O
Cancer	O
Registry	O
(	O
NCR	O
)	O
,	O
consisting	O
of	O
nine	O
regional	O
cancer	B
registries	O
throughout	O
The	O
Netherlands	O
,	O
and	O
to	O
PALGA	O
,	O
a	O
nationwide	O
network	O
and	O
registry	O
of	O
histo-	O
and	O
cytopathology	O
[	O
24	O
]	O
.	O

The	O
NCR	O
and	O
PALGA	O
together	O
provide	O
a	O
near	O
100	O
%	O
coverage	O
of	O
the	O
204	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

Accumulation	O
of	O
person	O
-	O
time	O
in	O
the	O
cohort	O
was	O
estimated	O
through	O
biennial	O
vital	O
status	O
follow	O
-	O
up	O
of	O
a	O
subcohort	O
of	O
3,500	O
men	O
and	O
women	O
who	O
were	O
randomly	O
selected	O
after	O
baseline	O
exposure	O
measurement	O
[	O
24	O
]	O
.	O

Cases	O
with	O
prevalent	O
cancer	B
other	O
than	O
non	B
-	I
melanoma	I
skin	O
cancer	B
were	O
excluded	O
from	O
the	O
subcohort	O
,	O
which	O
left	O
3,346	O
men	O
and	O
women	O
for	O
analysis	O
next	O
to	O
all	O
colorectal	B
cancer	I
cases	O
from	O
the	O
entire	O
cohort	O
.	O

No	O
subcohort	O
members	O
were	O
lost	O
to	O
follow	O
-	O
up	O
.	O

A	O
flow	O
diagram	O
of	O
subcohort	O
members	O
and	O
patients	O
on	O
whom	O
the	O
analyses	O
are	O
based	O
is	O
given	O
in	O
Fig.	O
1	O
.	O

Fig.	O
1Flow	O
diagram	O
of	O
the	O
number	O
of	O
subjects	O
on	O
whom	O
the	O
final	O
statistical	O
analyses	O
were	O
based	O
.	O

aNetherlands	O
Cancer	O
Registry	O
.	O

bPathologisch	O
Anatomisch	O
Landelijk	O
Geautomatiseerd	O
Archief	O
.	O

cPatients	O
with	O
rectosigmoid	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analyses	O
.	O

dmutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	B
type	I
2	I
.	O

eAdenomatous	O
polyposis	O
coli	O
.	O

fMutation	O
cluster	O
region	O
.	O

gv	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
.	O

hPatients	O
with	O
rectal	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analysis	O
according	O
to	O
MLH1	O
expression	O
Flow	O
diagram	O
of	O
the	O
number	O
of	O
subjects	O
on	O
whom	O
the	O
final	O
statistical	O
analyses	O
were	O
based	O
.	O

aNetherlands	O
Cancer	O
Registry	O
.	O

bPathologisch	O
Anatomisch	O
Landelijk	O
Geautomatiseerd	O
Archief	O
.	O

cPatients	O
with	O
rectosigmoid	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analyses	O
.	O

dmutL	O
homolog	O
1	O
,	O
colon	B
cancer	I
,	O
nonpolyposis	B
type	I
2	I
.	O

eAdenomatous	O
polyposis	O
coli	O
.	O

fMutation	O
cluster	O
region	O
.	O

gv	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
.	O

hPatients	O
with	O
rectal	O
tumors	B
were	O
not	O
included	O
in	O
the	O
analysis	O
according	O
to	O
MLH1	O
expression	O
The	O
first	O
2.3	O
years	O
of	O
follow	O
up	O
were	O
excluded	O
because	O
of	O
possible	O
preclinical	O
disease	B
affecting	O
exposure	O
status	O
and	O
because	O
of	O
incomplete	O
nationwide	O
coverage	O
of	O
PALGA	O
alone	O
(	O
i.e.	O
,	O
not	O
in	O
combination	O
with	O
the	O
NCR	O
)	O
in	O
some	O
of	O
the	O
municipalities	O
included	O
in	O
the	O
NLCS	O
.	O

Within	O
this	O
period	O
,	O
83	O
subcohort	O
members	O
deceased	O
or	O
were	O
diagnosed	O
with	O
cancer	B
other	O
than	O
non	B
-	I
melanoma	I
skin	O
cancer	B
,	O
leaving	O
3,263	O
subcohort	O
members	O
for	O
analysis	O
.	O

From	O
1989	O
to	O
1994	O
,	O
929	O
incident	O
cases	O
with	O
histologically	O
confirmed	O
colorectal	B
cancer	I
were	O
identified	O
within	O
the	O
entire	O
cohort	O
,	O
of	O
whom	O
819	O
could	O
also	O
be	O
linked	O
to	O
a	O
PALGA	O
report	O
of	O
the	O
lesion	B
.	O

The	O
PALGA	O
reports	O
were	O
used	O
to	O
identify	O
and	O
locate	O
tumor	B
tissues	O
from	O
eligible	O
colorectal	B
cancer	I
patients	O
in	O
54	O
pathology	O
laboratories	O
throughout	O
the	O
Netherlands	O
.	O

Cancers	B
were	O
classified	O
according	O
to	O
site	O
as	O
follows	O
,	O
colon	O
:	O
cecum	O
through	O
sigmoid	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153:0	O
,	O
153.1	O
,	O
153.2	O
,	O
153.3	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
,	O
153.7	O
)	O
,	O
proximal	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.0	O
,	O
153.1	O
,	O
153.4	O
,	O
153.5	O
,	O
153.6	O
)	O
,	O
distal	O
colon	O
(	O
ICD	O
-	O
O	O
codes	O
153.2	O
,	O
153,3	O
,	O
`	O
53.7	O
)	O
,	O
rectosigmoid	O
(	O
ICD	O
-	O
O	O
code	O
154.0	O
)	O
,	O
and	O
rectum	O
(	O
ICD	O
-	O
O	O
code	O
154.1	O
)	O
.	O

This	O
still	O
does	O
not	O
satisfy	O
our	O
third	O
query	O
,	O
i.e.	O
,	O
why	O
are	O
the	O
associations	O
specifically	O
confined	O
to	O
this	O
subgroup	O
of	O
colon	B
cancer	I
patients	O
whose	O
tumors	B
are	O
characterized	O
by	O
activating	O
KRAS	O
mutations	O
,	O
and	O
not	O
truncating	O
APC	O
mutations	O
or	O
lack	O
of	O
MLH1	O
expression	O
?	O

It	O
is	O
speculative	O
,	O
but	O
plausible	O
,	O
that	O
when	O
KRAS	O
is	O
the	O
only	O
one	O
of	O
the	O
three	O
genes	O
affected	B
,	O
the	O
mutation	O
may	O
more	O
likely	O
be	O
the	O
result	O
of	O
exogenous	O
exposure	O
,	O
for	O
example	O
a	O
relatively	O
high	O
linoleic	O
acid	O
intake	O
.	O

In	O
contrast	O
,	O
when	O
a	O
KRAS	O
mutation	O
co	O
-	O
occurs	O
with	O
a	O
mutation	O
in	O
APC	O
or	O
,	O
although	O
more	O
rarely	O
,	O
in	O
addition	O
to	O
a	O
defective	O
MLH1	O
,	O
these	O
other	O
early	O
gene	O
defects	O
also	O
had	O
a	O
role	O
in	O
tumor	B
formation	O
and	O
may	O
have	O
resulted	O
in	O
a	O
mutator	O
phenotype	O
leading	O
to	O
mutations	O
in	O
other	O
genes	O
(	O
such	O
as	O
the	O
KRAS	O
gene	O
)	O
irrespective	O
of	O
exogenous	O
factors	O
.	O

Since	O
there	O
is	O
no	O
information	O
on	O
the	O
timing	O
of	O
genetic	O
aberrations	O
in	O
this	O
type	O
of	O
human	O
studies	O
,	O
we	O
can	O
not	O
verify	O
this	O
with	O
our	O
data	O
.	O

Aberrations	O
in	O
other	O
genes	O
,	O
not	O
available	O
for	O
this	O
study	O
,	O
but	O
possibly	O
involved	O
in	O
early	O
tumorigenesis	O
of	O
colorectal	B
cancer	I
,	O
could	O
not	O
be	O
accounted	O
for	O
in	O
analyses	O
and	O
may	O
have	O
influenced	O
results	O
.	O

However	O
,	O
a	O
recent	O
systematic	O
sequence	O
analysis	O
of	O
13,023	O
exons	O
in	O
individual	O
colorectal	B
cancers	I
showed	O
that	O
the	O
prevalence	O
of	O
mutations	O
other	O
than	O
in	O
APC	O
,	O
KRAS	O
and	O
TP53	O
is	O
rather	O
low	O
[	O
44	O
]	O
,	O
and	O
mutations	O
in	O
TP53	O
is	O
not	O
an	O
early	O
event	O
in	O
colorectal	O
carcinogenesis	O
.	O

Finally	O
,	O
results	O
are	O
based	O
on	O
relatively	O
small	O
numbers	O
of	O
patients	O
,	O
especially	O
in	O
the	O
reference	O
group	O
of	O
polyunsaturated	O
fat	O
or	O
linoleic	O
acid	O
intake	O
(	O
four	O
patients	O
,	O
see	O
Table	O
4	O
)	O
,	O
and	O
point	O
estimates	O
of	O
RRs	O
for	O
quartiles	O
of	O
intake	O
of	O
polyunstaturated	O
fat	O
or	O
linoleic	O
acid	O
should	O
therefore	O
,	O
be	O
interpreted	O
cautiously	O
.	O

Nevertheless	O
,	O
as	O
discussed	O
previously	O
,	O
the	O
association	O
appears	O
to	O
be	O
robust	O
when	O
regarding	O
the	O
results	O
for	O
one	O
standard	O
deviation	O
increase	O
in	O
linoleic	O
acid	O
intake	O
(	O
based	O
on	O
a	O
total	O
of	O
65	O
patients	O
)	O
.	O

Therefore	O
,	O
Breivik	O
and	O
Glaudernack	O
's	O
hypothesis	O
for	O
distinct	O
carcinogens	O
to	O
exert	O
their	O
effect	O
on	O
two	O
proposed	O
types	O
of	O
genetic	O
instability	O
,	O
i.e.	O
,	O
microsatellite	O
instability	O
and	O
chromosomal	O
instability	O
[	O
16	O
]	O
,	O
may	O
be	O
extended	O
to	O
the	O
potential	O
effect	O
of	O
carcinogens	O
on	O
more	O
specific	O
genetic	O
pathways	O
to	O
colorectal	O
tumorigenesis	O
,	O
as	O
for	O
example	O
the	O
KRAS	O
mutated	O
pathway	O
.	O

The	O
data	O
from	O
this	O
large	O
prospective	O
cohort	O
study	O
suggest	O
that	O
linoleic	O
acid	O
intake	O
is	O
strongly	O
associated	O
with	O
colon	O
tumors	B
with	O
an	O
aberrant	O
KRAS	O
gene	O
,	O
but	O
an	O
intact	O
APC	O
gene	O
and	O
MLH1	O
expression	O
.	O

Verification	O
in	O
other	O
studies	O
is	O
warranted	O
.	O

Possibly	O
,	O
tumors	B
revealing	O
the	O
involvement	O
of	O
distinct	O
genetic	O
pathways	O
on	O
the	O
basis	O
of	O
specific	O
genetic	O
aberrations	O
,	O
may	O
have	O
a	O
unique	O
etiology	O
.	O

Discussion	O
We	O
report	O
the	O
analysis	O
of	O
the	O
combined	O
miRNA	O
/	O
mRNA	O
expression	O
for	O
the	O
discrimination	O
of	O
MSI	B
-	I
H	I
versus	O
MSS	B
human	O
colon	B
cancer	I
.	O

Because	O
colorectal	O
tumors	B
characterized	O
by	O
MSI	B
are	O
distinct	O
from	O
MSS	B
tumors	B
in	O
many	O
molecular	O
aspects	O
,	O
such	O
the	O
association	O
with	O
the	O
methylator	O
phenotype	O
,	O
which	O
is	O
responsible	O
for	O
MLH1	O
methylation	O
,	O
the	O
higher	O
frequency	O
of	O
BRAF	O
mutations	O
and	O
the	O
lower	O
frequencies	O
of	O
KRAS	O
,	O
APC	O
and	O
TP53	O
mutations	O
,	O
MSI	B
and	O
MSS	B
colon	B
cancers	I
represent	O
tumors	B
with	O
a	O
different	O
molecular	O
background	O
.	O

Thus	O
,	O
it	O
is	O
reasonable	O
that	O
their	O
overall	O
gene	O
expression	O
pattern	O
(	O
including	O
both	O
mRNAs	O
and	O
microRNAs	O
)	O
might	O
be	O
affected	O
by	O
any	O
of	O
the	O
above	O
mentioned	O
mechanisms	O
.	O

Indeed	O
,	O
our	O
analyses	O
identified	O
14	O
miRNAs	O
and	O
451	O
mRNAs	O
differentially	O
expressed	O
between	O
the	O
two	O
genetically	O
distinct	O
colon	B
cancer	I
classes	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
mRNA	O
/	O
miRNA	O
gene	O
expression	O
profile	O
able	O
to	O
distinguish	O
MSS	B
versus	O
MSI	B
colon	B
cancers	I
,	O
but	O
also	O
indicate	O
that	O
the	O
combination	O
of	O
miRNA	O
/	O
mRNA	O
gene	O
expression	O
data	O
can	O
distinguish	O
microsatellite	O
instability	O
status	O
of	O
human	O
colorectal	B
cancers	I
better	O
than	O
each	O
RNA	O
class	O
independently	O
,	O
suggesting	O
that	O
the	O
combination	O
of	O
mRNA	O
and	O
miRNA	O
expression	O
may	O
potentially	O
represent	O
a	O
general	O
approach	O
for	O
improving	O
characterization	O
and	O
classification	O
of	O
bio	O
-	O
molecular	O
and	O
possibly	O
clinical	O
traits	O
associated	O
with	O
human	O
cancer	B
.	O

We	O
also	O
examined	O
the	O
prediction	O
power	O
of	O
published	O
lists	O
of	O
genes	O
differentially	O
expressed	O
between	O
MSI	B
-	I
H	I
and	O
MSS	B
colorectal	B
cancers	I
[	O
34	O
-	O
36	O
]	O
against	O
our	O
data	O
set	O
.	O

Two	O
published	O
lists	O
describe	O
differentially	O
expressed	O
genes	O
(	O
100	O
genes	O
in	O
the	O
report	O
from	O
Di	O
Pietro	O
et	O
al.	O
2005	O
[	O
36	O
]	O
and	O
542	O
genes	O
from	O
Banerjea	O
et	O
al.	O
2004	O
[	O
35	O
]	O
)	O
and	O
one	O
is	O
a	O
short	O
list	O
of	O
predictors	O
(	O
9	O
genes	O
in	O
Kruhoffer	O
et	O
al.	O
2005	O
[	O
34	O
]	O
)	O
.	O

Although	O
these	O
studies	O
were	O
all	O
performed	O
on	O
Affymetrix	O
platforms	O
,	O
they	O
generated	O
only	O
partially	O
overlapping	O
results	O
.	O

The	O
list	O
of	O
genes	O
from	O
Di	O
Pietro	O
et	O
al.	O
[	O
36	O
]	O
was	O
the	O
one	O
that	O
better	O
correlated	O
with	O
our	O
results	O
.	O

Twenty	O
two	O
of	O
their	O
100	O
genes	O
were	O
present	O
in	O
our	O
list	O
of	O
differentially	O
expressed	O
genes	O
and	O
,	O
for	O
all	O
the	O
remaining	O
genes	O
,	O
expression	O
tendency	O
completely	O
matched	O
our	O
data	O
.	O

A	O
cluster	O
analysis	O
of	O
our	O
data	O
set	O
using	O
the	O
100	O
genes	O
from	O
the	O
Di	O
Pietro	O
's	O
paper	O
could	O
generate	O
a	O
good	O
,	O
although	O
not	O
perfect	O
,	O
separation	O
between	O
MSS	B
versus	O
MSI	B
-	I
H	I
tumors	B
and	O
performed	O
well	O
in	O
the	O
prediction	O
of	O
our	O
samples	O
(	O
36	O
of	O
39	O
samples	O
were	O
correctly	O
classified	O
using	O
the	O
SVM	O
prediction	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
that	O
a	O
similar	O
set	O
of	O
genes	O
emerged	O
as	O
differentially	O
expressed	O
between	O
MSS	B
and	O
MSI	B
-	I
H	I
colon	B
cancers	I
in	O
the	O
Di	O
Pietro	O
's	O
and	O
our	O
studies	O
,	O
with	O
discrepancies	O
possibly	O
due	O
to	O
small	O
statistical	O
differences	O
.	O

Discrepancies	O
between	O
results	O
obtained	O
with	O
different	O
microarray	O
platforms	O
are	O
not	O
uncommon	O
and	O
are	O
mainly	O
determined	O
by	O
differences	O
in	O
microarray	O
probe	O
sequences	O
used	O
to	O
detect	O
mRNA	O
transcripts	O
[	O
37	O
]	O
and	O
in	O
algorithms	O
used	O
for	O
predictor	O
genes	O
identification	O
.	O

Hence	O
,	O
the	O
parallel	O
between	O
Di	O
Pietro	O
's	O
and	O
our	O
results	O
is	O
significant	O
given	O
that	O
data	O
were	O
generated	O
using	O
a	O
different	O
set	O
of	O
samples	O
and	O
a	O
different	O
microarray	O
platform	O
,	O
and	O
suggests	O
that	O
the	O
commonly	O
identified	O
set	O
of	O
genes	O
may	O
represent	O
the	O
most	O
significant	O
differences	O
between	O
MSI	B
-	I
H	I
and	O
MSS	B
colon	B
cancers	I
(	O
Additional	O
file	O
6	O
)	O
.	O

Unfortunately	O
,	O
data	O
sets	O
from	O
published	O
reports	O
were	O
not	O
available	O
for	O
cross	O
confirmation	O
of	O
our	O
list	O
of	O
predictive	O
genes	O
on	O
published	O
microarray	O
data	O
.	O

Conclusion	O
This	O
report	O
provides	O
the	O
first	O
study	O
on	O
microRNA	O
expression	O
in	O
MSI	B
versus	O
MSS	B
colon	B
cancer	I
.	O

We	O
identified	O
microRNAs	O
that	O
are	O
differentially	O
expressed	O
between	O
these	O
two	O
classes	O
of	O
tumors	B
;	O
moreover	O
,	O
the	O
addition	O
of	O
microRNAs	O
in	O
the	O
molecular	O
classifier	O
improves	O
the	O
separation	O
between	O
MSI	B
and	O
MSS	B
cancer	B
samples	O
,	O
suggesting	O
that	O
the	O
mRNA	O
/	O
miRNA	O
combination	O
could	O
provide	O
an	O
improved	O
stratification	O
of	O
tumor	O
-	O
associated	O
characters	O
.	O

Interestingly	O
,	O
the	O
most	O
prominent	O
class	O
of	O
differentially	O
expressed	O
miRNAs	O
includes	O
various	O
members	O
of	O
the	O
oncogenic	O
miR-17	O
-	O
92	O
family	O
,	O
suggesting	O
that	O
these	O
microRNAs	O
have	O
a	O
role	O
in	O
bio	O
-	O
pathologic	O
characteristics	O
that	O
distinguish	O
MSS	B
versus	O
MSI	B
colon	B
cancers	I
.	O

Introduction	O
Over	O
the	O
past	O
ten	O
years	O
,	O
aberrant	O
DNA	O
methylation	O
has	O
been	O
recognized	O
as	O
one	O
of	O
the	O
most	O
common	O
molecular	O
abnormalities	O
in	O
breast	B
cancer	I
[	O
1,2	O
]	O
.	O

A	O
large	O
body	O
of	O
evidence	O
implicates	O
potential	O
hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
loss	O
of	O
expression	O
of	O
a	O
variety	O
of	O
crucial	O
genes	O
.	O

Tumor	O
-	O
suppressor	O
genes	O
with	O
aberrant	O
methylation	O
in	O
breast	B
cancers	I
include	O
ARHI	O
[	O
3,4	O
]	O
,	O
RASSF1A	O
[	O
5	O
]	O
,	O
HIN-1	O
[	O
6	O
]	O
,	O
the	O
retinoic	O
acid	O
receptor	O
II	O
gene	O
(	O
RARβ2	O
)	O
[	O
7	O
]	O
,	O
hMLH1	O
[	O
8	O
]	O
,	O
14	O
-	O
3	O
-	O
3	O
σ	O
[	O
9	O
]	O
,	O
RIZ1	O
[	O
10	O
]	O
,	O
p16	O
[	O
11	O
]	O
,	O
the	O
E	O
-	O
cadherin	O
gene	O
[	O
12	O
]	O
,	O
PTEN	O
[	O
13	O
]	O
,	O
and	O
BRCA1	O
[	O
14	O
]	O
.	O

Methylation	O
in	O
breast	B
cancer	I
has	O
been	O
related	O
to	O
clinical	O
and	O
pathologic	O
characteristics	O
evident	O
at	O
presentation	O
and	O
clinical	O
outcomes	O
.	O

A	O
higher	O
prevalence	O
of	O
HIN-1	O
and	O
RAR	O
β2	O
methylation	O
was	O
found	O
in	O
the	O
lymph	O
nodes	O
,	O
bone	O
,	O
brain	O
,	O
and	O
lung	O
metastases	B
than	O
the	O
primary	O
tumor	B
[	O
15	O
]	O
.	O

Widschwendter	O
and	O
colleagues	O
[	O
16	O
]	O
reported	O
that	O
the	O
methylation	O
of	O
certain	O
genes	O
was	O
associated	O
with	O
hormone	O
receptor	O
(	O
HR	O
)	O
status	O
,	O
in	O
addition	O
to	O
the	O
response	O
to	O
treatment	O
with	O
tamoxifen	O
.	O

A	O
high	O
prevalence	O
of	O
PGR	O
,	O
HSD17B4	O
,	O
and	O
CDH13	O
methylation	O
has	O
been	O
associated	O
with	O
HER-2	B
/	I
neu	I
-	I
positive	I
breast	B
cancer	I
[	O
17	O
]	O
.	O

Methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
is	O
a	O
sensitive	O
assay	O
used	O
to	O
detect	O
methylation	O
and	O
analyze	O
the	O
methylation	O
status	O
of	O
genes	O
of	O
interest	O
.	O

However	O
,	O
problems	O
inherent	O
to	O
this	O
assay	O
(	O
such	O
as	O
those	O
caused	O
by	O
the	O
use	O
of	O
different	O
primers	O
for	O
the	O
methylated	O
or	O
unmethylated	O
alleles	O
,	O
the	O
gel	O
-	O
based	O
data	O
analysis	O
system	O
used	O
,	O
and	O
difficulties	O
in	O
quantitation	O
)	O
have	O
caused	O
frequent	O
false	O
-	O
positive	O
results	O
in	O
tissue	O
-	O
sample	O
analyses	O
.	O

A	O
new	O
technique	O
,	O
pyrosequencing	O
,	O
has	O
been	O
adapted	O
for	O
use	O
in	O
highly	O
sensitive	O
and	O
quantitative	O
methylation	O
analyses	O
[	O
18,19	O
]	O
.	O

Pyrosequencing	O
methylation	O
analysis	O
is	O
a	O
modification	O
of	O
the	O
combined	O
bisulfite	O
restriction	O
analysis	O
(	O
COBRA	O
)	O
that	O
compares	O
favorably	O
with	O
COBRA	O
in	O
sensitivity	O
,	O
specificity	O
,	O
and	O
robustness	O
[	O
18	O
]	O
.	O

Tost	O
and	O
colleagues	O
also	O
confirmed	O
that	O
the	O
pyrosequencing	O
technique	O
is	O
quantitative	O
,	O
amenable	O
to	O
the	O
analysis	O
of	O
bisulfite	O
-	O
treated	O
DNA	O
derived	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
samples	O
,	O
highly	O
reproducible	O
,	O
and	O
accurate	O
[	O
19	O
]	O
.	O

Bisulfite	O
pyrosequencing	O
has	O
been	O
used	O
in	O
clinical	O
trials	O
of	O
hypomethylating	O
drug	O
treatment	O
and	O
provides	O
accurate	O
and	O
reliable	O
results	O
[	O
20	O
]	O
.	O

To	O
investigate	O
methylation	O
profiles	O
in	O
breast	B
cancer	I
cells	O
,	O
we	O
used	O
bisulfite	O
pyrosequencing	O
to	O
screen	O
12	O
known	O
tumor	O
-	O
suppressor	O
genes	O
in	O
90	O
pairs	O
of	O
breast	B
cancers	I
and	O
normal	B
tissues	O
.	O

Although	O
all	O
12	O
genes	O
had	O
been	O
reported	O
to	O
exhibit	O
hypermethylation	O
in	O
a	O
fraction	O
of	O
breast	B
cancer	I
cases	O
,	O
our	O
assays	O
provided	O
a	O
comprehensive	O
survey	O
of	O
their	O
methylation	O
status	O
and	O
confirmed	O
that	O
five	O
genes	O
could	O
be	O
useful	O
in	O
defining	O
a	O
methylation	O
profile	O
in	O
breast	B
cancer	I
cells	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
two	O
panels	O
of	O
methylation	O
profiles	O
correlated	O
,	O
either	O
positively	O
or	O
negatively	O
,	O
to	O
HR	O
status	O
.	O

Statistical	O
methods	O
and	O
analysis	O
In	O
the	O
studied	O
cohort	O
,	O
adjacent	O
normal	B
breast	O
tissue	O
was	O
taken	O
from	O
each	O
of	O
90	O
patients	O
during	O
surgery	O
.	O

Taking	O
advantage	O
of	O
paired	O
normal	B
/	O
tumor	B
samples	O
in	O
this	O
study	O
,	O
we	O
chose	O
the	O
value	O
of	O
normal	B
samples	O
as	O
the	O
reference	O
.	O

If	O
using	O
the	O
sample	O
mean	O
plus	O
two	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
pooled	O
normal	B
samples	O
(	O
and	O
a	O
minimum	O
of	O
10	O
%	O
methylation	O
)	O
as	O
a	O
cut	O
-	O
off	O
point	O
,	O
there	O
is	O
>	O
97	O
%	O
probability	O
that	O
the	O
methylation	O
level	O
for	O
a	O
normal	B
tissue	O
will	O
be	O
lower	O
than	O
the	O
cut	O
-	O
off	O
point	O
.	O

It	O
is	O
reasonable	O
to	O
assume	O
that	O
a	O
value	O
larger	O
than	O
the	O
cut	O
-	O
off	O
point	O
is	O
likely	O
to	O
be	O
abnormal	O
(	O
or	O
positive	O
)	O
.	O

Panels	O
of	O
genes	O
,	O
that	O
is	O
to	O
say	O
,	O
HIN-1	O
/	O
RASSF1A	O
and	O
RIL	O
/	O
CDH13	O
were	O
considered	O
positive	O
if	O
both	O
markers	O
in	O
each	O
panel	O
were	O
positive	O
.	O

Descriptive	O
analyses	O
were	O
performed	O
first	O
for	O
exploratory	O
purposes	O
.	O

Pair	O
-	O
wise	O
scatter	O
plots	O
are	O
presented	O
to	O
show	O
the	O
correlations	O
among	O
the	O
genes	O
methylated	O
.	O

Heat	O
maps	O
were	O
plotted	O
to	O
show	O
levels	O
of	O
gene	O
expression	O
or	O
methylation	O
using	O
hierarchical	O
clustering	O
to	O
visually	O
represent	O
the	O
association	O
of	O
different	O
genes	O
or	O
samples	O
by	O
histopathologic	O
tumor	B
characteristics	O
(	O
ERs	O
,	O
PRs	O
,	O
and	O
HER-2	O
/	O
neu	O
)	O
.	O

Chi	O
-	O
square	O
or	O
Fisher	O
's	O
exact	O
test	O
were	O
used	O
to	O
assess	O
the	O
dependence	O
between	O
two	O
categorical	O
variables	O
.	O

Pearson	O
's	O
correlation	O
coefficient	O
was	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
two	O
continuous	O
variables	O
.	O

The	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
was	O
used	O
to	O
compare	O
either	O
continuous	O
or	O
categorical	O
variables	O
between	O
two	O
groups	O
.	O

Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
applied	O
to	O
compare	O
the	O
values	O
of	O
gene	O
methylation	O
with	O
tumor	B
characteristics	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
assess	O
the	O
ability	O
of	O
various	O
levels	O
of	O
gene	O
methylation	O
to	O
predict	O
the	O
ER	O
,	O
PR	O
,	O
HR	O
,	O
or	O
HER-2	O
/	O
neu	O
status	O
.	O

All	O
reported	O
p	O
values	O
are	O
two	O
-	O
sided	O
and	O
considered	O
statistically	O
significant	O
if	O
p	O
<	O
0.05	O
.	O

Analyses	O
were	O
performed	O
using	O
S	O
-	O
PLUS	O
2000	O
software	O
(	O
Insightful	O
Corp.	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
.	O

Discussion	O
Although	O
a	O
large	O
body	O
of	O
evidence	O
has	O
demonstrated	O
that	O
aberrant	O
DNA	O
methylation	O
has	O
an	O
important	O
role	O
in	O
breast	O
carcinogenesis	B
,	O
variation	O
in	O
the	O
data	O
is	O
still	O
a	O
problem	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
bisulfite	O
pyrosequencing	O
to	O
quantitate	O
the	O
methylation	O
of	O
12	O
known	O
tumor	O
-	O
suppressor	O
genes	O
in	O
breast	B
cancers	I
.	O

To	O
avoid	O
contamination	O
with	O
normal	B
tissues	O
,	O
we	O
isolated	O
breast	B
cancer	I
cells	O
by	O
microdissection	O
and	O
compared	O
levels	O
of	O
methylation	O
with	O
those	O
in	O
normal	B
breast	O
epithelial	O
cells	O
from	O
the	O
same	O
patients	O
.	O

Bisulfite	O
pyrosequencing	O
provided	O
sensitive	O
and	O
reproducible	O
measurements	O
.	O

The	O
variation	O
between	O
the	O
different	O
assays	O
was	O
<	O
6	O
%	O
.	O

Our	O
data	O
confirmed	O
that	O
RIL	O
,	O
HIN-1	O
,	O
RASSF1A	O
,	O
CDH13	O
,	O
and	O
RARβ2	O
were	O
frequently	O
methylated	O
in	O
breast	B
cancers	I
but	O
not	O
in	O
normal	B
breast	O
tissues	O
.	O

The	O
other	O
six	O
genes	O
were	O
not	O
highly	O
methylated	O
in	O
breast	B
cancers	I
or	O
methylated	O
in	O
either	O
malignant	B
and	O
normal	B
breast	O
tissues	O
;	O
ARHI	O
,	O
as	O
an	O
imprinted	O
gene	O
,	O
has	O
a	O
different	O
methylation	O
status	O
.	O

All	O
the	O
inconsistencies	O
indicate	O
that	O
these	O
seven	O
genes	O
are	O
unsuitable	O
for	O
methylation	O
profile	O
studies	O
.	O

In	O
the	O
past	O
,	O
methylation	O
data	O
have	O
been	O
correlated	O
to	O
clinical	O
pathologic	O
parameters	O
,	O
to	O
clarify	O
the	O
role	O
of	O
methylation	O
in	O
breast	O
carcinogenesis	B
.	O

Our	O
most	O
interesting	O
finding	O
was	O
a	O
correlation	O
between	O
gene	O
methylation	O
and	O
the	O
HR	O
status	O
.	O

Methylation	O
in	O
breast	B
cancer	I
has	O
already	O
been	O
connected	O
to	O
hormone	O
regulation	O
,	O
but	O
the	O
correlation	O
is	O
not	O
clear	O
yet	O
.	O

Campan	O
and	O
colleagues	O
[	O
26	O
]	O
reviewed	O
the	O
DNA	O
methylation	O
profiles	O
of	O
breast	O
,	O
endometrial	O
,	O
ovarian	O
,	O
and	O
proximal	O
colon	O
cancers	B
but	O
did	O
not	O
find	O
evidence	O
for	O
global	O
hormone	O
-	O
specific	O
DNA	O
methylation	O
alterations	O
.	O

Widschwendter	O
and	O
colleagues	O
[	O
16	O
]	O
reported	O
significant	O
differences	O
in	O
the	O
HR	O
status	O
between	O
clusters	O
of	O
DNA	O
methylation	O
profiles	O
.	O

Their	O
results	O
suggested	O
the	O
existence	O
of	O
an	O
interaction	O
between	O
DNA	O
methylation	O
and	O
HR	O
biology	O
in	O
breast	B
cancer	I
cells	O
.	O

In	O
our	O
own	O
study	O
,	O
we	O
found	O
that	O
the	O
ER	O
status	O
was	O
positively	O
associated	O
with	O
the	O
methylation	O
of	O
HIN-1	O
and	O
RASSF1A	O
but	O
negatively	O
correlated	O
to	O
the	O
methylation	O
of	O
RIL	O
.	O

In	O
addition	O
,	O
the	O
PR	O
status	O
was	O
positively	O
associated	O
with	O
the	O
methylation	O
of	O
HIN-1	O
and	O
negatively	O
associated	O
with	O
the	O
methylation	O
of	O
CDH13	O
.	O

Moreover	O
,	O
if	O
data	O
from	O
the	O
methylation	O
of	O
individual	O
genes	O
were	O
combined	O
into	O
two	O
panels	O
,	O
methylation	O
of	O
the	O
HIN-1	O
/	O
RASSF1A	O
panel	O
strongly	O
predicted	O
the	O
expression	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
and	O
methylation	O
of	O
the	O
RIL	O
/	O
CDH13	O
panel	O
strongly	O
predicted	O
the	O
negative	O
expression	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
.	O

The	O
status	O
of	O
ERs	O
,	O
PRs	O
,	O
and	O
HRs	O
has	O
been	O
recognized	O
as	O
an	O
important	O
prognostic	O
factor	O
in	O
patients	O
with	O
breast	B
cancer	I
,	O
in	O
addition	O
to	O
a	O
predictive	O
marker	O
for	O
the	O
response	O
to	O
treatment	O
with	O
endocrine	O
therapy	O
.	O

The	O
presence	O
of	O
ERs	O
and/or	O
PRs	O
is	O
predictive	O
of	O
the	O
response	O
to	O
treatment	O
with	O
the	O
antiestrogen	O
tamoxifen	O
[	O
27	O
]	O
.	O

ER	O
and	O
PR	O
expression	O
patterns	O
are	O
heavily	O
influenced	O
by	O
changes	O
in	O
the	O
chromatin	O
structure	O
during	O
transcription	O
.	O

Indeed	O
,	O
both	O
the	O
predominant	O
mammalian	O
DNA	O
methyltransferase	O
and	O
histone	O
deacetylases	O
have	O
crucial	O
roles	O
in	O
maintaining	O
transcriptionally	O
repressive	O
chromatin	O
by	O
forming	O
suppressive	O
complexes	O
at	O
replication	O
foci	O
[	O
28	O
]	O
.	O

Our	O
current	O
studies	O
provide	O
evidence	O
that	O
epigenetic	O
changes	O
are	O
tightly	O
connected	O
with	O
HR	O
regulation	O
in	O
breast	B
cancer	I
.	O

Tumors	B
negatively	O
stained	O
for	O
HCA2	O
and/or	O
HC10	O
were	O
stained	O
for	O
mismatch	O
repair	O
proteins	O
MLH1	O
and	O
PMS2	O
.	O

MLH1	B
and	I
PMS2	I
are	I
deficient	I
in	O
sporadic	O
MSI	B
tumors	B
.	O

Therefore	O
,	O
the	O
expression	O
of	O
these	O
proteins	O
was	O
used	O
to	O
differentiate	O
MSI	B
and	O
MSS	B
rectal	B
cancers	I
.	O

Tissue	O
stromal	O
cells	O
,	O
normal	B
epithelium	O
or	O
lymph	O
follicles	O
served	O
as	O
positive	O
internal	O
controls	O
when	O
analyzing	O
MLH1	O
,	O
PMS2	O
expression	O
.	O

The	O
expression	O
of	O
MLH1	O
and	O
PMS2	O
was	O
scored	O
positive	O
if	O
tumor	B
cells	O
showed	O
expression	O
,	O
and	O
negative	O
if	O
tumor	B
cells	O
showed	O
no	O
expression	O
of	O
either	O
MLH1	O
or	O
PMS2	O
,	O
provided	O
that	O
and	O
tissue	O
stromal	O
cells	O
did	O
show	O
expression	O
,	O
indicating	O
microsatellite	B
stable	I
(	O
MSS	B
)	O
and	O
microsatellite	B
instable	I
(	O
MSI	B
)	O
tumors	B
,	O
respectively	O
[	O
7	O
]	O
.	O

Statistical	O
analyses	O
All	O
analyses	O
were	O
performed	O
with	O
SPSS	O
statistical	O
software	O
(	O
version	O
12.0	O
for	O
Windows	O
,	O
SPSS	O
Inc	O
,	O
Chicago	O
,	O
USA	O
)	O
.	O

Mann	O
–	O
Whitney	O
U	O
,	O
t	O
test	O
and	O
χ2-tests	O
were	O
used	O
to	O
compare	O
variables	O
.	O

Kaplan	O
–	O
Meier	O
analyses	O
were	O
performed	O
to	O
analyze	O
patient	O
survival	O
.	O

The	O
entry	O
date	O
for	O
the	O
survival	O
analyses	O
was	O
the	O
time	O
of	O
surgery	O
of	O
the	O
primary	O
tumor	B
.	O

Events	O
for	O
time	O
to	O
local	O
recurrence	O
,	O
distant	O
recurrence	O
,	O
cancer	B
-	O
specific	O
survival	O
,	O
disease	B
-	O
free	O
and	O
overall	O
survival	O
were	O
defined	O
as	O
follows	O
:	O
from	O
time	O
of	O
surgery	O
to	O
time	O
of	O
local	O
disease	B
relapse	O
(	O
for	O
local	O
recurrence	O
)	O
,	O
time	O
of	O
distant	O
disease	B
relapse	O
(	O
for	O
distant	O
recurrence	O
)	O
,	O
time	O
of	O
disease	B
relapse	O
or	O
death	O
by	O
disease	B
(	O
for	O
cancer	B
specific	O
survival	O
)	O
,	O
time	O
of	O
disease	B
relapse	O
or	O
death	O
(	O
for	O
disease	B
free	O
survival	O
)	O
and	O
time	O
of	O
death	O
,	O
respectively	O
(	O
for	O
overall	O
survival	O
)	O
.	O

Non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
were	O
first	O
separately	O
analyzed	O
in	O
univariate	O
analysis	O
and	O
second	O
,	O
variables	O
with	O
a	O
P	O
value	O
of	O
<	O
0.10	O
in	O
the	O
univariate	O
analyses	O
were	O
subjected	O
to	O
a	O
multivariate	O
analysis	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
on	O
the	O
whole	O
group	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
the	O
following	O
variables	O
:	O
HLA	O
class	O
I	O
,	O
randomization	O
for	O
radiotherapy	O
,	O
TNM	O
and	O
circumferential	O
margin	O
.	O

Cox	O
'	O
regression	O
analyses	O
were	O
used	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

Most	O
rectal	O
tumors	B
have	O
high	O
numbers	O
of	O
tumor	B
cells	O
positive	O
for	O
HCA2	O
or	O
HC10	O
Numbers	O
(	O
N	O
)	O
of	O
patients	O
are	O
indicated	O
with	O
percentages	O
shown	O
in	O
parentheses	O
,	O
showing	O
:	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
,	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
and	O
total	O
absence	O
(	O
absence	O
)	O
Examples	O
of	O
HCA2	O
and	O
HC10	O
immunohistochemical	O
staining	O
of	O
rectal	O
tumors	B
;	O
a	O
–	O
c	O
HCA2	O
,	O
d	O
–	O
f	O
HC10	O
expression	O
.	O

a	O
,	O
d	O
Expression	O
of	O
HLA	O
class	O
I	O
in	O
>	O
50	O
%	O
tumor	B
cells	O
;	O
b	O
,	O
e	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
<	O
50	O
%	O
tumor	B
cells	O
;	O
c	O
,	O
f	O
epithelial	O
cells	O
show	O
total	O
absence	O
for	O
HCA2	O
or	O
HC10	O
and	O
only	O
stromal	O
and	O
infiltrative	O
cells	O
show	O
positive	O
staining	O
for	O
HCA2	O
or	O
HC10	O
;	O
Original	O
magnification	O
×20	O
Analysis	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
tumors	B
Together	O
,	O
the	O
results	O
obtained	O
with	O
HCA2	O
and	O
HC10	O
are	O
expected	O
to	O
reflect	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
cancer	B
.	O

In	O
a	O
group	O
of	O
64	O
tumors	B
it	O
was	O
studied	O
whether	O
an	O
additional	O
staining	O
for	O
β2	O
m	O
would	O
better	O
define	O
HLA	O
class	O
I	O
expression	O
.	O

The	O
results	O
of	O
the	O
addition	O
of	O
β2	O
m	O
to	O
HCA2	O
and	O
HC10	O
were	O
comparable	O
to	O
those	O
obtained	O
with	O
HCA2	O
and	O
HC10	O
,	O
i.e.	O
only	O
1	O
of	O
64	O
tumors	B
was	O
differently	O
classified	O
.	O

Therefore	O
,	O
β2	O
m	O
was	O
not	O
scored	O
in	O
the	O
whole	O
cohort	O
and	O
HLA	O
class	O
I	O
expression	O
was	O
assessed	O
by	O
combining	O
HCA2	O
and	O
HC10	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	O
cells	O
(	O
further	O
referred	O
to	O
as	O
'	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
'	O
)	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
87	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

Only	O
3	O
(	O
0.6	O
%	O
)	O
irradiated	O
tumors	B
and	O
8	O
(	O
1.5	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
total	O
loss	O
of	O
HLA	O
class	O
I	O
(	O
negative	O
for	O
both	O
HCA2	O
and	O
HC10	O
)	O
.	O

Survival	O
results	O
of	O
patients	O
with	O
total	O
absence	O
of	O
HLA	O
class	O
I	O
on	O
tumor	B
cells	O
did	O
not	O
show	O
significant	O
difference	O
from	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

Therefore	O
,	O
these	O
groups	O
were	O
combined	O
and	O
will	O
be	O
further	O
referred	O
to	O
as	O
'	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
'	O
.	O

The	O
complete	O
results	O
are	O
shown	O
in	O
Table	O
2	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
-	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
,	O
indicating	O
that	O
irradiation	O
had	O
no	O
effect	O
on	O
HLA	O
class	O
I	O
expression	O
in	O
these	O
patients	O
.	O

Table	O
2Expression	O
of	O
HLA	O
class	O
I	O
in	O
rectal	O
cancer	B
using	O
HCA2	O
and	O
HC10	O
antibodiesHCA2HC10HLA	O
class	O
IHigh	O
(	O
N	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
N	O
(	O
%	O
)	O
IrradiatedHigh	O
(	O
N	O
)	O
27037406	O
(	O
85%	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
997070	O
(	O
15%	O
)	O
Non	O
-	O
irradiatedHigh	O
(	O
N	O
)	O
27732445	O
(	O
84%	O
)	O
Low	O
+	O
absence	O
(	O
N	O
)	O
1368787	O
(	O
16%	O
)	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
χ2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
χ2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	O
class	O
I	O
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	B
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O

Examples	O
of	O
Kaplan	O
–	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	B
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
–	O
d	O
)	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	B
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
have	O
a	O
better	O
overall	O
,	O
and	O
disease	B
free	O
survival	O
Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	B
free	O
survival	O
,	O
cancer	B
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Multivariate	O
analysis	O
Multivariate	O
analysis	O
was	O
performed	O
to	O
identify	O
factors	O
with	O
independent	O
prognostic	O
significance	O
and	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
.	O

Analyses	O
included	O
TNM	O
,	O
circumferential	O
margin	O
,	O
randomization	O
for	O
preoperative	O
radiotherapy	O
and	O
HLA	O
class	O
I	O
expression	O
(	O
low	B
vs.	I
high	I
HLA	I
class	I
I	I
positive	I
tumor	I
cells	I
)	O
(	O
Table	O
5	O
)	O
.	O

Advanced	O
pathological	O
(	O
TNM	O
)	O
stage	O
and	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margins	O
retained	O
their	O
strength	O
as	O
independent	O
prognostic	O
factors	O
in	O
these	O
survival	O
analyses	O
.	O

HLA	O
class	O
I	O
expression	O
showed	O
independent	O
prognostic	O
value	O
for	O
overall	O
survival	O
and	O
disease	B
-	O
free	O
survival	O
(	O
HR	O
:	O
1.3	O
,	O
P	O
=	O
0.042	O
and	O
HR	O
:	O
1.4	O
,	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
,	O
but	O
not	O
for	O
cancer	B
-	O
specific	O
survival	O
.	O

Table	O
5Multivariate	O
analysis	O
confirms	O
independent	O
better	O
overall	O
,	O
and	O
disease	B
free	O
survival	O
for	O
rectal	O
cancer	B
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
IOverall	O
survivalDisease	O
free	O
survivalCancer	O
specific	O
survivalHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueHLA	O
High10.04210.00610.653	O
Low1.3	O
(	O
1.0–1.6	O
)	O
1.4	O
(	O
1.1–1.8	O
)	O
1.1	O
(	O
0.8–1.5	O
)	O
Randomization	O
TME10.63210.21410.282	O
TME	O
+	O
RT1	O
(	O
0.8–1.2	O
)	O
0.9	O
(	O
0.7–1.1	O
)	O
1.1	O
(	O
0.9–1.5	O
)	O
TNM	O
I111	O
II2.2	O
(	O
1.7–3.0	O
)	O
<0.0012.1	O
(	O
1.6–2.8	O
)	O
<0.0013.5	O
(	O
2.0–6.1	O
)	O
<0.001	O
III3.1	O
(	O
2.4–4.1	O
)	O
<0.0013.1	O
(	O
2.3–4.0	O
)	O
<0.0019.0	O
(	O
5.4–14.9	O
)	O
<0.001	O
IV11.8	O
(	O
8.1–17.1	O
)	O
<0.001––50.3	O
(	O
28.5–89.1	O
)	O
<0.001CRM	O
Negative1<0.0011<0.0011<0.001	O
Positive1.3	O
(	O
1.1–1.5	O
)	O
1.8	O
(	O
1.4–2.2	O
)	O
1.3	O
(	O
1.1–1.5	O
)	O
Multivariate	O
analysis	O
for	O
cancer	B
specific	O
,	O
overall	O
and	O
disease	B
free	O
survival	O
was	O
performed	O
to	O
identify	O
factors	O
with	O
independent	O
prognostic	O
significance	O
and	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HR	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
shown	O
in	O
parentheses	O
.	O

HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
,	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
,	O
Radiotherapy	O
(	O
RT	O
)	O
;	O
circumferential	O
margin	O
(	O
CRM	O
)	O
;	O
P	O
value	O
is	O
based	O
on	O
Cox	O
'	O
regression	O
analyses	O
*	O
Statistical	O
significant	O
P	O
values	O
and	O
HR	O
are	O
in	O
bold	O

Case	O
presentation	O
In	O
November	O
2006	O
,	O
a	O
56-year	O
old	O
woman	O
(	O
III-1	O
in	O
pedigree	O
,	O
Figure	O
1	O
)	O
visited	O
our	O
clinic	O
for	O
genetic	O
counseling	O
because	O
she	O
was	O
worried	O
about	O
the	O
many	O
cases	O
of	O
cancer	B
that	O
had	O
occurred	O
in	O
her	O
family	O
.	O

The	O
direct	O
reason	O
for	O
her	O
visit	O
was	O
the	O
recent	O
death	O
of	O
her	O
39-year	O
old	O
son	O
(	O
IV-1	O
)	O
with	O
a	O
symptomatic	O
,	O
and	O
already	O
metastasized	B
,	O
rectal	O
adenocarcinoma	B
.	O

The	O
counselee	O
had	O
been	O
diagnosed	O
with	O
an	O
endometrial	O
and	O
a	O
sigmoid	O
carcinoma	B
at	O
age	O
53-	O
and	O
54-years	O
old	O
,	O
respectively	O
.	O

She	O
reported	O
her	O
overwhelming	O
family	O
history	O
,	O
which	O
easily	O
fulfilled	O
the	O
criteria	O
that	O
enable	O
selection	O
of	O
families	O
that	O
are	O
at	O
risk	O
for	O
Lynch	B
syndrome	I
(	O
Table	O
1	O
)	O
.	O

Subsequent	O
IHC	O
-	O
analysis	O
on	O
archival	O
tumor	B
material	O
of	O
her	O
sigmoid	O
carcinoma	B
demonstrated	O
abrogation	O
of	O
the	O
MSH2	O
and	O
MSH6	O
proteins	O
,	O
which	O
is	O
typically	O
associated	O
with	O
a	O
germline	O
MSH2	O
mutation	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
,	O
in	O
DNA	O
extracted	O
from	O
peripheral	O
lymphocytes	O
,	O
identified	O
an	O
entire	O
MSH2	O
gene	O
deletion	O
(	O
exons	O
1–16	O
)	O
and	O
confirmed	O
the	O
diagnosis	O
of	O
Lynch	B
syndrome	I
.	O

Pedigree	O
of	O
a	O
Lynch	B
syndrome	I
family	O
,	O
showing	O
organ	O
systems	O
and	O
age	O
of	O
diagnosis	O
,	O
see	O
legend	O
.	O

Year	O
,	O
year	O
of	O
diagnosis	O
/	O
diagnoses	O
;	O
asterisk	O
,	O
anamnestically	O
obtained	O
information	O
;	O
urinary	O
tract	O
,	O
urothelial	O
carcinoma	B
of	O
renal	O
pelvis	O
or	O
ureter	O
;	O
skin	O
,	O
keratoacanthoma	B
;	O
asc	O
.	O
,	O
ascending	O
colon	O
;	O
transv	O
.	O
,	O
transverse	O
colon	O
;	O
desc	O
.	O
,	O
descending	O
colon	O
.	O

In	O
retrospect	O
,	O
some	O
doctors	O
had	O
indeed	O
signaled	O
noteworthy	O
features	O
in	O
this	O
family	O
.	O

First	O
,	O
in	O
1979	O
,	O
a	O
gynecologist	O
who	O
was	O
treating	O
patient	O
II-6	O
consulted	O
a	O
colleague	O
about	O
the	O
very	O
early	O
onset	O
of	O
endometrial	O
carcinoma	B
.	O

His	O
colleague	O
reassured	O
him	O
at	O
that	O
time	O
that	O
the	O
age	O
at	O
presentation	O
,	O
41	O
years	O
old	O
,	O
was	O
not	O
in	O
fact	O
very	O
rare	O
.	O

Second	O
,	O
in	O
2005	O
,	O
a	O
gastroenterologist	O
spoke	O
of	O
possible	O
HNPCC	B
in	O
patient	O
III-2	O
,	O
who	O
was	O
diagnosed	O
with	O
carcinoma	B
of	O
the	O
papilla	O
of	O
Vater	O
after	O
she	O
had	O
developed	O
three	O
separate	O
colon	O
carcinomas	B
,	O
but	O
no	O
further	O
action	O
was	O
taken	O
.	O

Third	O
,	O
in	O
2006	O
,	O
an	O
oncologist	O
treating	O
patient	O
IV-1	O
suggested	O
MSI	O
testing	O
on	O
tumor	B
material	O
after	O
his	O
mother	O
(	O
III-1	O
)	O
had	O
expressed	O
her	O
concern	O
about	O
the	O
family	O
history	O
,	O
but	O
did	O
not	O
proceed	O
.	O

Discussion	O
This	O
family	O
is	O
a	O
fine	O
example	O
of	O
the	O
plethora	O
of	O
tumors	B
that	O
may	O
occur	O
in	O
Lynch	B
syndrome	I
and	O
demonstrates	O
why	O
the	O
term	O
Lynch	B
syndrome	I
is	O
preferred	O
nowadays	O
over	O
HNPCC	B
(	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
)	O
,	O
which	O
only	O
refers	O
to	O
CRC	B
.	O

The	O
organ	O
involvement	O
in	O
this	O
family	O
included	O
seven	O
organ	O
systems	O
:	O
colon	O
,	O
uterus	O
,	O
skin	O
,	O
stomach	O
,	O
urinary	O
tract	O
,	O
pancreas	O
and	O
hepatobiliary	O
system	O
.	O

The	O
manifestation	O
of	O
keratoacanthoma	B
in	O
this	O
family	O
enabled	O
a	O
sub	O
-	O
classification	O
to	O
Muir	B
Torre	I
syndrome	I
(	O
MTS	B
)	O
.	O

MTS	B
is	O
a	O
variant	O
of	O
Lynch	B
syndrome	I
and	O
germline	O
mutations	O
in	O
the	O
three	O
main	O
Lynch	B
syndrome	I
genes	O
(	O
MLH1	O
,	O
MSH2	O
and	O
MSH6	O
)	O
have	O
been	O
identified	O
in	O
MTS	B
families	O
[	O
7,8	O
]	O
.	O

Keratoacanthoma	B
should	O
be	O
regarded	O
as	O
one	O
of	O
the	O
tumors	B
that	O
lie	O
in	O
the	O
constellation	O
of	O
Lynch	B
syndrome	I
but	O
their	O
manifestation	O
could	O
depend	O
on	O
modifier	O
genes	O
and/or	O
environmental	O
factors	O
.	O

This	O
case	O
report	O
shows	O
a	O
considerable	O
delay	O
in	O
diagnosing	O
Lynch	B
syndrome	I
which	O
negatively	O
influenced	O
the	O
management	O
of	O
many	O
family	O
members	O
.	O

None	O
of	O
the	O
family	O
members	O
underwent	O
presymptomatic	O
screening	O
on	O
the	O
basis	O
of	O
the	O
family	O
history	O
,	O
while	O
clinical	O
surveillance	O
has	O
been	O
shown	O
to	O
decrease	O
mortality	O
in	O
Lynch	B
syndrome	I
families	O
[	O
9	O
]	O
.	O

Remarkably	O
,	O
in	O
none	O
of	O
the	O
medical	O
reports	O
we	O
obtained	O
was	O
a	O
family	O
history	O
reported	O
extending	O
further	O
than	O
first	O
-	O
degree	O
relatives	O
.	O

Conclusion	O
This	O
family	O
clearly	O
illustrates	O
a	O
lack	O
of	O
awareness	O
about	O
a	O
hereditary	O
tumor	B
syndrome	I
among	O
doctors	O
as	O
well	O
as	O
patients	O
.	O

In	O
general	O
,	O
it	O
is	O
prudent	O
to	O
be	O
aware	O
of	O
classic	O
hereditary	O
features	O
,	O
like	O
young	O
age	O
at	O
diagnosis	O
,	O
multiple	O
tumors	B
in	O
multiple	O
organs	O
and	O
a	O
positive	O
family	O
history	O
,	O
and	O
to	O
refer	O
suspected	O
cases	O
for	O
genetic	O
counseling	O
.	O

More	O
specifically	O
,	O
these	O
features	O
can	O
be	O
found	O
in	O
the	O
Amsterdam	O
and	O
Bethesda	O
criteria	O
(	O
Table	O
1	O
)	O
.	O

Subsequently	O
,	O
the	O
identification	O
of	O
at	O
-	O
risk	O
persons	O
will	O
optimize	O
the	O
timing	O
and	O
efficiency	O
that	O
surveillance	O
and	O
treatment	O
are	O
carried	O
out	O
.	O

The	O
DNA	O
sequence	O
of	O
each	O
microsatellite	O
in	O
the	O
tumor	B
was	O
compared	O
with	O
that	O
of	O
the	O
matched	O
normal	B
mucosa	O
.	O

It	O
was	O
considered	O
as	O
unstable	O
if	O
there	O
was	O
an	O
absence	O
,	O
shortening	O
or	O
prolongation	O
of	O
the	O
DNA	O
sequence	O
.	O

MSI	O
-	O
L	O
was	O
defined	O
as	O
1	O
unstable	O
microsatellite	O
out	O
of	O
5	O
,	O
while	O
MSI	O
-	O
H	O
was	O
defined	O
as	O
more	O
than	O
1	O
unstable	O
microsatellite	O
out	O
of	O
5	O
.	O

If	O
the	O
tumor	B
microsatellites	O
were	O
identical	O
to	O
those	O
of	O
the	O
normal	O
tissue	O
,	O
the	O
microsatellite	O
was	O
considered	O
as	O
stable	O
(	O
MSS	O
)	O
.	O

For	O
the	O
MSI	B
-	I
L	I
CRCs	B
,	O
BAT-40	O
and	O
MYCL	O
were	O
detected	O
.	O

If	O
either	O
of	O
these	O
two	O
markers	O
was	O
unstable	O
,	O
this	O
colorectal	O
sample	O
was	O
considered	O
as	O
MSI	O
-	O
H.	O
Immunohistochemical	O
staining	O
for	O
MSH2	O
,	O
MSH6	O
and	O
MLH1	O
on	O
TMAs	O
The	O
CRC	B
microarray	O
was	O
constructed	O
as	O
previously	O
described	O
[	O
8,9	O
]	O
.	O

Briefly	O
,	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
blocks	O
of	O
CRC	B
resections	O
were	O
cut	O
from	O
the	O
donor	O
block	O
and	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
(	O
HE	O
)	O
.	O

These	O
slides	O
were	O
used	O
to	O
guide	O
the	O
sampling	O
from	O
morphologically	O
representative	O
regions	O
of	O
the	O
tissues	O
.	O

A	O
tissue	O
array	O
instrument	O
(	O
Beecher	O
Instruments	O
,	O
Silver	O
Spring	O
,	O
MD	O
)	O
was	O
used	O
to	O
create	O
holes	O
in	O
a	O
recipient	O
paraffin	O
block	O
and	O
to	O
acquire	O
tissue	O
cores	O
from	O
the	O
donor	O
block	O
by	O
a	O
thin	O
-	O
walled	O
needle	O
with	O
an	O
inner	O
diameter	O
of	O
1.0	O
mm	O
,	O
held	O
in	O
an	O
X	O
-	O
Y	O
precision	O
guide	O
.	O

The	O
cylindrical	O
samples	O
were	O
retrieved	O
from	O
the	O
selected	O
regions	O
in	O
the	O
donors	O
and	O
extruded	O
directly	O
into	O
the	O
recipient	O
blocks	O
with	O
defined	O
array	O
coordinates	O
.	O

Three	O
cores	O
were	O
obtained	O
from	O
each	O
sample	O
.	O

After	O
the	O
construction	O
of	O
the	O
array	O
block	O
,	O
multiple	O
4-mm	O
thick	O
sections	O
were	O
cut	O
with	O
a	O
microtome	O
using	O
an	O
adhesive	O
-	O
coated	O
tape	O
sectioning	O
system	O
(	O
Instrumedics	O
,	O
Hackensack	O
,	O
NJ	O
)	O
.	O

In	O
our	O
analysis	O
the	O
rates	O
of	O
lost	O
cases	O
attributable	O
to	O
tissue	O
damage	O
were	O
less	O
than	O
5	O
%	O
for	O
the	O
different	O
markers	O
.	O

TMA	O
slides	O
were	O
stained	O
with	O
MLH1	O
antibodies	O
(	O
1:50	O
dilution	O
,	O
No.	O
sc-494	O
,	O
Santa	O
Cruz	O
,	O
Biotrade	O
Ltd	O
,	O
Shanghai	O
,	O
China	O
)	O
and	O
MSH2	O
(	O
1:100	O
dilution	O
,	O
No.	O
sc-581	O
,	O
Santa	O
Cruz	O
,	O
Biotrade	O
Ltd	O
,	O
Shanghai	O
,	O
China	O
)	O
.	O

IHC	O
staining	O
for	O
samples	O
on	O
the	O
tissue	O
microarray	O
was	O
carried	O
out	O
using	O
Envision	O
ready	O
-	O
to	O
-	O
use	O
methods	O
(	O
Dako	O
Diagnostics	O
,	O
Zug	O
,	O
Switzerland	O
)	O
.	O

Slides	O
were	O
deparaffinized	O
in	O
xylene	O
and	O
rehydrated	O
through	O
graded	O
concentrations	O
of	O
ethanol	O
to	O
distilled	O
water	O
,	O
and	O
endogenous	O
peroxidase	O
activity	O
was	O
blocked	O
by	O
incubation	O
with	O
30	O
mL	O
/	O
L	O
H2O2	O
in	O
methanol	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
sections	O
were	O
submitted	O
to	O
antigen	O
retrieval	O
in	O
a	O
pressure	O
cooker	O
containing	O
0.01	O
mmol	O
/	O
L	O
natrium	O
citricium	O
buffer	O
for	O
10	O
min	O
.	O

Slides	O
were	O
subsequently	O
incubated	O
in	O
100	O
mL	O
/	O
L	O
normal	O
goat	O
serum	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

Sections	O
were	O
permeabilized	O
in	O
PBS	O
-	O
Triton	O
and	O
incubated	O
overnight	O
with	O
primary	O
antibody	O
at	O
4	O
°	O
C	O
.	O

The	O
pathologist	O
and	O
technician	O
who	O
reviewed	O
the	O
immunostaining	O
of	O
the	O
tissue	O
samples	O
were	O
blinded	O
to	O
the	O
patient	O
's	O
information	O
.	O

Stained	O
slides	O
and	O
individual	O
cores	O
were	O
scored	O
as	O
either	O
positive	O
(	O
showing	O
nuclear	O
staining	O
in	O
at	O
least	O
some	O
tumor	B
cells	O
)	O
or	O
negative	O
.	O

Regarding	O
the	O
location	O
of	O
gene	O
mutations	O
,	O
we	O
found	O
that	O
3	O
patients	O
bore	O
mutations	O
in	O
exon	O
7	O
of	O
MSH2	O
,	O
2	O
had	O
mutations	O
in	O
exon	O
12	O
of	O
MSH2	O
,	O
1	O
had	O
a	O
mutation	O
in	O
exon	O
2	O
of	O
MSH6	O
,	O
and	O
2	O
had	O
mutations	O
in	O
exon	O
5	O
of	O
MSH6	O
.	O

No	O
MLH1	O
mutations	O
were	O
found	O
in	O
our	O
cohort	O
.	O

All	O
8	O
mutations	O
were	O
considered	O
pathogenic	O
mutations	O
.	O

The	O
mutation	O
of	O
C1886	O
A	O
>	O
G	O
,	O
C1668	O
C	O
>	O
T	O
was	O
reported	O
as	O
a	O
pathogenic	O
mutation	O
previously	O
[	O
22	O
-	O
25	O
]	O
.	O

However	O
,	O
the	O
other	O
six	O
mutations	O
have	O
not	O
been	O
reported	O
in	O
other	O
publications	O
and	O
are	O
likely	O
to	O
be	O
novel	O
mutations	O
.	O

We	O
also	O
attempted	O
to	O
screen	O
for	O
the	O
presence	O
of	O
all	O
these	O
mutations	O
in	O
50	O
randomly	O
selected	O
patients	O
in	O
the	O
MSS	B
group	O
and	O
in	O
50	O
normal	B
people	O
.	O

The	O
result	O
of	O
this	O
screen	O
was	O
negative	O
,	O
and	O
all	O
these	O
CRCs	B
with	O
mutations	O
stained	O
negatively	O
for	O
MSH2	O
or	O
/	O
and	O
MSH6	O
,	O
indicating	O
that	O
these	O
6	O
mutations	O
may	O
be	O
pathogenic	O
mutations	O
but	O
not	O
polymorphisms	O
.	O

In	O
terms	O
of	O
the	O
clinical	O
features	O
of	O
the	O
8	O
cases	O
with	O
mutations	O
,	O
only	O
1	O
conformed	O
to	O
the	O
Amsterdam	O
criteria	O
II	O
;	O
all	O
the	O
others	O
did	O
not	O
have	O
any	O
family	O
history	O
of	O
malignancy	O
.	O

Moreover	O
,	O
the	O
median	O
age	O
was	O
59	O
with	O
4	O
patients	O
that	O
were	O
older	O
than	O
60	O
years	O
old	O
.	O

One	O
limitation	O
of	O
this	O
study	O
is	O
that	O
it	O
is	O
a	O
single	O
-	O
center	O
study	O
with	O
a	O
relatively	O
small	O
sample	O
size	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
need	O
to	O
be	O
confirmed	O
by	O
a	O
well	O
designed	O
multi	O
-	O
center	O
study	O
,	O
which	O
is	O
one	O
of	O
our	O
ongoing	O
studies	O
in	O
China	O
.	O

Background	O
The	O
colon	O
is	O
composed	O
of	O
a	O
dynamic	O
and	O
self	O
-	O
renewing	O
epithelium	O
that	O
turns	O
over	O
every	O
three	O
to	O
five	O
days	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
at	O
the	O
base	O
of	O
the	O
crypt	O
,	O
variable	O
numbers	O
(	O
between	O
1	O
and	O
16	O
)	O
of	O
slowly	O
dividing	O
,	O
stationary	O
,	O
pluripotent	O
stem	O
cells	O
give	O
rise	O
to	O
more	O
rapidly	O
proliferating	O
,	O
transient	O
amplifying	O
cells	O
.	O

These	O
cells	O
differentiate	O
chiefly	O
into	O
post	O
-	O
mitotic	O
columnar	O
colonocytes	O
,	O
mucin	O
-	O
secreting	O
goblet	O
cells	O
,	O
and	O
enteroendocrine	O
cells	O
as	O
they	O
migrate	O
from	O
the	O
crypt	O
base	O
to	O
the	O
surface	O
where	O
they	O
are	O
sloughed	O
into	O
the	O
lumen	O
[	O
1	O
]	O
.	O

Several	O
signaling	O
pathways	O
,	O
notably	O
Wnt	O
,	O
Tgfβ	O
,	O
Bmp	O
,	O
Hedgehog	O
and	O
Notch	O
,	O
play	O
pivotal	O
roles	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
of	O
the	O
developing	O
and	O
adult	O
colon	O
[	O
2	O
]	O
.	O

Their	O
perturbation	O
,	O
via	O
mutation	O
or	O
epigenetic	O
modification	O
,	O
occurs	O
in	O
human	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
and	O
the	O
instillation	O
of	O
these	O
changes	O
via	O
genetic	O
engineering	O
in	O
mice	O
confers	O
a	O
correspondingly	O
high	O
risk	O
for	O
neoplasia	B
in	O
the	O
mouse	O
models	O
.	O

Moreover	O
,	O
tumor	B
cell	O
de	O
-	O
differentiation	O
correlates	O
with	O
key	O
tumor	B
features	O
,	O
such	O
as	O
tumor	B
progression	O
rates	O
,	O
invasiveness	O
,	O
drug	O
resistance	O
and	O
metastatic	O
potential	O
[	O
3	O
-	O
5	O
]	O
.	O

A	O
variety	O
of	O
scientific	O
and	O
organizational	O
obstacles	O
make	O
it	O
a	O
challenging	O
proposition	O
to	O
undertake	O
large	O
-	O
scale	O
comparisons	O
of	O
human	O
cancer	B
to	O
the	O
wide	O
range	O
of	O
genetically	O
engineered	O
mouse	O
models	O
.	O

To	O
evaluate	O
the	O
potential	O
of	O
this	O
approach	O
to	O
provide	O
integrated	O
views	O
of	O
the	O
molecular	O
basis	O
of	O
cancer	B
risk	O
,	O
tumor	B
development	O
and	O
malignant	B
progression	O
,	O
we	O
have	O
undertaken	O
a	O
comparative	O
analysis	O
of	O
a	O
variety	O
of	O
individually	O
developed	O
mouse	O
colon	O
tumor	B
models	O
(	O
reviewed	O
in	O
[	O
6,7	O
]	O
)	O
to	O
human	O
CRC	B
.	O

The	O
ApcMin	O
/	O
+	O
(	O
multiple	O
intestinal	O
neoplasia	O
)	O
mouse	O
model	O
harbors	O
a	O
germline	O
mutation	O
in	O
the	O
Apc	O
tumor	B
suppressor	O
gene	O
and	O
exhibits	O
multiple	O
tumors	B
in	O
the	O
small	O
intestine	O
and	O
colon	O
[	O
8	O
]	O
.	O

A	O
major	O
function	O
of	O
APC	O
is	O
to	O
regulate	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
as	O
part	O
of	O
a	O
β	O
-	O
catenin	O
degradation	O
complex	O
.	O

Loss	O
of	O
APC	O
results	O
in	O
a	O
failure	O
to	O
degrade	O
β	O
-	O
catenin	O
,	O
which	O
instead	O
enters	O
the	O
nucleus	O
to	O
act	O
as	O
a	O
transcriptional	O
co	O
-	O
activator	O
with	O
the	O
lymphoid	O
enhancer	O
factor	O
/	O
T	O
-	O
cell	O
factor	O
(	O
LEF	O
/	O
TCF	O
)	O
family	O
of	O
transcription	O
factors	O
[	O
9	O
]	O
.	O

The	O
localization	O
of	O
β	O
-	O
catenin	O
within	O
the	O
nucleus	O
indicates	O
activated	O
canonical	O
WNT	O
signaling	O
.	O

In	O
addition	O
to	O
germline	O
APC	O
mutations	O
that	O
occur	O
in	O
persons	O
with	O
familial	B
adenomatous	I
polyposis	I
coli	O
(	O
FAP	B
)	O
and	O
ApcMin	O
/	O
+	O
mice	O
,	O
loss	O
of	O
functional	O
APC	O
and	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
occurs	O
in	O
more	O
than	O
80	O
%	O
of	O
human	O
sporadic	O
CRCs	B
[	O
10	O
]	O
.	O

Similar	O
to	O
the	O
ApcMin	O
/	O
+	O
model	O
,	O
tumors	B
in	O
the	O
azoxymethane	O
(	O
AOM	O
)	O
carcinogen	O
model	O
,	O
which	O
occur	O
predominantly	O
in	O
the	O
colon	O
[	O
11	O
]	O
,	O
have	O
signaling	O
alterations	O
marked	O
by	O
activated	O
canonical	O
WNT	O
signaling	O
.	O

Results	O
Strategy	O
for	O
cross	O
-	O
species	O
analysis	O
Our	O
strategy	O
for	O
the	O
characterization	O
of	O
mouse	O
models	O
of	O
human	O
CRC	B
(	O
Figure	O
1	O
)	O
relies	O
on	O
gene	O
expression	O
differences	O
and	O
relative	O
patterning	O
across	O
a	O
range	O
of	O
mouse	O
CRC	B
models	O
,	O
normal	B
mouse	O
colon	O
developmental	O
stages	O
,	O
and	O
human	O
CRCs	B
.	O

Achieving	O
this	O
comparison	O
was	O
facilitated	O
by	O
the	O
use	O
of	O
reference	O
RNAs	O
from	O
whole	O
-	O
mouse	O
and	O
normal	B
adult	O
colon	O
reference	O
RNAs	O
for	O
both	O
mouse	O
and	O
human	O
measurements	O
.	O

Mouse	O
tumor	B
samples	O
were	O
profiled	O
on	O
cDNA	O
microarrays	O
using	O
the	O
embryonic	O
day	O
(	O
E	O
)	O
17.5	O
whole	O
mouse	O
reference	O
RNA	O
identical	O
to	O
that	O
used	O
previously	O
[	O
15	O
]	O
to	O
examine	O
embryonic	O
mouse	O
colon	O
gene	O
expression	O
dynamics	O
from	O
E13.5	O
to	O
E18.5	O
,	O
during	O
which	O
time	O
the	O
primitive	O
,	O
undifferentiated	O
,	O
pseudo	O
-	O
stratified	O
colonic	O
endoderm	O
becomes	O
a	O
differentiated	O
,	O
single	O
-	O
layered	O
epithelium	O
.	O

This	O
strategy	O
allowed	O
us	O
to	O
construct	O
a	O
gene	O
expression	O
database	O
of	O
mouse	O
colon	O
tumors	B
in	O
which	O
gene	O
expression	O
levels	O
of	O
the	O
tumors	B
could	O
be	O
referenced	O
,	O
ranked	O
,	O
and	O
statistically	O
compared	O
to	O
an	O
average	O
value	O
among	O
the	O
tumors	B
or	O
to	O
embryonic	O
or	O
adult	O
colon	O
gene	O
expression	O
levels	O
on	O
a	O
per	O
-	O
gene	O
basis	O
.	O

First	O
,	O
we	O
compared	O
the	O
four	O
models	O
with	O
each	O
other	O
,	O
then	O
to	O
mouse	O
colon	O
development	O
,	O
and	O
finally	O
to	O
human	O
CRCs	B
using	O
gene	O
ortholog	O
mapping	O
(	O
Figure	O
1	O
)	O
.	O

Stratification	O
of	O
murine	O
colon	O
tumor	B
models	O
by	O
localization	O
of	O
β	O
-	O
catenin	O
and	O
plan	O
for	O
analysis	O
.	O

Colon	O
tumors	B
from	O
four	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
CRC	B
were	O
subjected	O
to	O
microarray	O
gene	O
expression	O
profiling	O
.	O

The	O
gene	O
expression	O
profiles	O
from	O
the	O
different	O
mouse	O
model	O
tumors	B
were	O
compared	O
and	O
contrasted	O
to	O
each	O
other	O
,	O
as	O
well	O
as	O
to	O
those	O
from	O
embryonic	O
mouse	O
colon	O
development	O
and	O
100	O
human	O
CRCs	B
.	O

Mouse	O
colon	O
tumors	B
partition	O
into	O
classes	O
reflecting	O
differential	O
canonical	O
WNT	O
signaling	O
activity	O
To	O
discover	O
gene	O
expression	O
programs	O
underlying	O
differences	O
between	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
CRC	B
,	O
gene	O
expression	O
level	O
values	O
for	O
each	O
transcript	O
in	O
each	O
tumor	B
sample	O
was	O
set	O
to	O
its	O
ratio	O
relative	O
to	O
its	O
median	O
across	O
the	O
series	O
of	O
tumor	B
models	O
.	O

Using	O
non	O
-	O
parametric	O
statistical	O
analyses	O
,	O
1,798	O
cDNA	O
transcripts	O
were	O
identified	O
as	O
differentially	O
expressed	O
among	O
the	O
four	O
mouse	O
models	O
of	O
CRC	B
.	O

Five	O
major	O
gene	O
patterns	O
were	O
identified	O
using	O
K	O
-	O
means	O
clustering	O
(	O
clusters	O
C1-C5	O
;	O
Figure	O
2a	O
,	O
top	O
)	O
.	O

Genes	O
belonging	O
to	O
these	O
clusters	O
were	O
strongly	O
associated	O
with	O
annotated	O
gene	O
function	O
categories	O
(	O
see	O
Table	O
1	O
for	O
detailed	O
biological	O
descriptions	O
and	O
associations	O
)	O
.	O

For	O
example	O
,	O
cluster	O
C1	O
,	O
composed	O
of	O
transcripts	O
that	O
exhibited	O
lower	O
expression	O
in	O
Smad3-	O
/	O
-	O
tumors	B
and	O
higher	O
expression	O
in	O
AOM	O
,	O
ApcMin	O
/	O
+	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
,	O
contains	O
391	O
transcripts	O
,	O
including	O
Cdk4	O
,	O
Ctnnb1	O
,	O
Myc	O
,	O
Ezh2	O
,	O
Mcm2	O
and	O
Tcf3	O
.	O

Gene	O
list	O
over	O
-	O
representation	O
analysis	O
using	O
Ingenuity	O
Pathway	O
Analysis	O
applications	O
demonstrated	O
highly	O
significant	O
associations	O
to	O
cell	O
cycle	O
progression	O
,	O
replication	O
,	O
post	O
-	O
transcriptional	O
control	O
and	O
cancer	B
.	O

Similarly	O
,	O
cluster	O
C2	O
,	O
composed	O
of	O
663	O
transcripts	O
that	O
exhibited	O
high	O
expression	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
,	O
but	O
low	B
in	I
Smad3-	I
/	I
-	I
and	I
Tgfb1-	I
/	I
-	I
;	I
Rag2-	I
/	I
-	I
tumors	B
,	O
included	O
transcripts	O
for	O
contact	O
growth	O
inhibition	O
(	O
Metap1	O
,	O
Pcyox1	O
)	O
,	O
mitosis	O
(	O
Mif	O
,	O
Pik1	O
)	O
,	O
cell	O
cycle	O
progression	O
and	O
checkpoint	O
control	O
(	O
Id2	O
,	O
Ptp4A2	O
,	O
Tp53	O
)	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C11-C17	O
PS	O
,	O
ProbeSets	O
.	O

Human	O
CRCs	B
exhibit	O
gene	O
expression	O
profile	O
complexity	O
consistent	O
with	O
significant	O
tumor	B
subclasses	O
.	O

Genes	O
potentially	O
able	O
to	O
distinguish	O
cancer	B
subtypes	O
were	O
identified	O
from	O
Affymetrix	O
HG	O
-	O
U133	O
plus2	O
Genechip	O
expression	O
profiles	O
by	O
filtering	O
for	O
3,285	O
probe	O
sets	O
that	O
were	O
top	O
-	O
ranked	O
by	O
raw	O
expression	O
and	O
their	O
differential	O
regulation	O
in	O
at	O
least	O
10	O
out	O
of	O
100	O
human	O
colorectal	B
cancer	I
tumors	B
.	O

Coordinately	O
regulated	O
transcripts	O
and	O
similarly	O
behaving	O
samples	O
were	O
identified	O
via	O
hierarchical	O
tree	O
clustering	O
.	O

Seven	O
different	O
gene	O
clusters	O
(	O
C11	O
-	O
17	O
)	O
were	O
identified	O
that	O
distinguished	O
ten	O
or	O
more	O
tumors	B
from	O
the	O
other	O
tumors	B
.	O

Gene	O
clusters	O
were	O
found	O
to	O
be	O
highly	O
enriched	O
for	O
gene	O
functions	O
listed	O
in	O
Table	O
3	O
.	O

Data	O
were	O
processed	O
using	O
Robust	O
Microarray	O
Analysis	O
(	O
RMA	O
)	O
with	O
expression	O
value	O
ratios	O
depicted	O
as	O
the	O
relative	O
expression	O
per	O
probe	O
set	O
in	O
each	O
sample	O
relative	O
to	O
the	O
median	O
of	O
its	O
expression	O
across	O
the	O
100	O
CRCs	B
.	O

A	O
striking	O
heterogeneity	O
of	O
gene	O
expression	O
was	O
observed	O
,	O
including	O
metallothionein	O
genes	O
in	O
cluster	O
C15	O
previously	O
shown	O
to	O
be	O
predictive	O
of	O
microsatellite	O
instability	O
(	O
indicated	O
by	O
asterisk	O
)	O
,	O
and	O
C17	O
represented	O
by	O
734	O
probesets	O
rich	O
in	O
genes	O
associated	O
with	O
extracellular	O
matrix	O
and	O
connective	O
tissue	O
,	O
tumor	B
invasion	O
and	O
malignancy	B
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	B
,	O
human	O
CRC	B
.	O

Staging	O
:	O
nAC	O
,	O
normal	B
colon	O
;	O
Dukes	O
A	O
-	O
D	O
,	O
human	O
tumors	B
obtained	O
from	O
individuals	O
.	O

Clusters	O
C11-C17	O
labeled	O
to	O
the	O
right	O
of	O
the	O
heatmap	O
correspond	O
to	O
the	O
K	O
-	O
means	O
functional	O
clusters	O
listed	O
in	O
Table	O
3	O
.	O

To	O
evaluate	O
if	O
similar	O
sets	O
of	O
genes	O
are	O
systematically	O
activated	O
or	O
repressed	O
in	O
human	O
CRC	B
,	O
as	O
in	O
the	O
mouse	O
colon	O
tumors	B
,	O
we	O
undertook	O
two	O
procedures	O
to	O
align	O
the	O
data	O
.	O

First	O
,	O
gene	O
expression	O
values	O
for	O
the	O
mouse	O
and	O
human	O
tumors	B
were	O
separately	O
normalized	O
and	O
referenced	O
relative	O
to	O
their	O
respective	O
normal	B
adult	O
colon	O
controls	O
;	O
second	O
,	O
mouse	O
and	O
human	O
gene	O
identifiers	O
were	O
reduced	O
to	O
a	O
single	O
ortholog	O
gene	O
identifier	O
.	O

The	O
latter	O
is	O
a	O
somewhat	O
complex	O
procedure	O
that	O
requires	O
identifying	O
microarray	O
probes	O
from	O
each	O
platform	O
that	O
can	O
be	O
mapped	O
to	O
a	O
single	O
gene	O
ortholog	O
and	O
undertaking	O
a	O
procedure	O
to	O
aggregate	O
redundant	O
probes	O
within	O
a	O
platform	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
.	O

This	O
approach	O
allowed	O
the	O
identification	O
of	O
8,621	O
gene	O
transcripts	O
on	O
the	O
HG	O
-	O
U133	O
plus2	O
and	O
Vanderbilt	O
NIA	O
20	O
K	O
cDNA	O
arrays	O
for	O
which	O
relative	O
expression	O
values	O
could	O
be	O
mapped	O
for	O
nearly	O
all	O
mouse	O
and	O
human	O
samples	O
.	O

A	O
clustering	O
-	O
based	O
assessment	O
of	O
expression	O
across	O
the	O
whole	O
mouse	O
-	O
human	O
ortholog	O
gene	O
set	O
identified	O
a	O
large	O
number	O
of	O
transcripts	O
behaving	O
similarly	O
across	O
colon	O
tumors	B
,	O
many	O
irrespective	O
,	O
but	O
some	O
respective	O
of	O
species	O
.	O

Notably	O
,	O
the	O
great	O
majority	O
of	O
genes	O
over	O
-	O
expressed	O
in	O
all	O
tumors	O
were	O
also	O
over	O
-	O
expressed	O
during	O
colon	O
development	O
(	O
Figure	O
6a	O
)	O
.	O

To	O
evaluate	O
the	O
statistical	O
significance	O
of	O
this	O
pattern	O
,	O
we	O
used	O
a	O
Venn	O
overlap	O
filtering	O
strategy	O
and	O
Fisher	O
's	O
exact	O
test	O
analysis	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
2,212	O
ortholog	O
genes	O
over	O
-	O
expressed	O
in	O
at	O
least	O
10	O
%	O
of	O
the	O
human	O
cancers	B
relative	O
to	O
adult	O
colon	O
were	O
also	O
over	O
-	O
expressed	O
in	O
developing	O
colon	O
.	O

If	O
there	O
was	O
not	O
a	O
selection	O
for	O
developmental	O
genes	O
among	O
those	O
over	O
-	O
expressed	O
in	O
tumors	B
,	O
the	O
expected	O
overlap	O
would	O
be	O
(	O
2,718	O
/	O
8,621	O
)	O
×	O
2,212	O
=	O
697	O
transcripts	O
.	O

Using	O
Fisher	O
's	O
exact	O
test	O
for	O
the	O
significance	O
of	O
the	O
increased	O
overlap	O
of	O
1,080	O
versus	O
697	O
transcripts	O
is	O
p	O
<	O
1e-300	O
.	O

Similarly	O
,	O
genes	O
under	O
-	O
expressed	O
in	O
mouse	O
colon	O
development	O
and	O
human	O
CRCs	B
also	O
strongly	O
overlapped	O
(	O
Figure	O
6b	O
;	O
431	O
of	O
737	O
,	O
p	O
<	O
1e-76	O
)	O
.	O

This	O
result	O
is	O
significantly	O
greater	O
than	O
the	O
8	O
-	O
19	O
%	O
of	O
genes	O
that	O
were	O
estimated	O
to	O
be	O
over	O
-	O
expressed	O
in	O
human	O
colon	O
tumors	B
and	O
fetal	O
gut	O
morphogenesis	O
based	O
upon	O
a	O
computational	O
extrapolation	O
of	O
SAGE	O
data	O
[	O
27	O
]	O
.	O

Thus	O
,	O
our	O
findings	O
not	O
only	O
confirm	O
but	O
also	O
significantly	O
expand	O
and	O
experimentally	O
validate	O
the	O
previously	O
suggested	O
recapitulation	O
of	O
embryonic	O
signatures	O
by	O
human	O
CRCs	B
.	O

All	O
overlaps	O
between	O
tumor	B
expression	O
and	O
development	O
were	O
pooled	O
to	O
form	O
a	O
set	O
of	O
2,116	O
ortholog	O
gene	O
transcripts	O
.	O

This	O
was	O
subjected	O
to	O
hierarchical	O
tree	O
and	O
K	O
-	O
means	O
clustering	O
to	O
define	O
six	O
expression	O
clusters	O
,	O
C18-C23	O
(	O
Figure	O
6c	O
;	O
Table	O
4	O
)	O
.	O

These	O
clusters	O
provide	O
an	O
impressive	O
partitioning	O
of	O
groups	O
of	O
genes	O
associated	O
with	O
different	O
biological	O
functions	O
critical	O
for	O
colon	O
development	O
,	O
maturation	O
and	O
oncogenesis	B
.	O

Cluster	B
C22	I
(	I
860	I
transcripts	I
of	I
genes	I
strongly	I
expressed	I
both	I
developmentally	I
and	I
across	I
all	I
tumors	I
)	I
is	O
highly	O
enriched	O
with	O
genes	O
associated	O
with	O
cell	O
cycle	O
progression	O
,	O
replication	O
,	O
cancer	B
,	O
tumor	B
morphology	O
and	O
cellular	O
movement	O
.	O

Cluster	B
C18	I
(	I
258	I
transcripts	I
down	I
-	I
regulated	I
in	I
mouse	I
and	I
human	I
tumors	I
,	I
as	I
well	I
as	I
in	I
development	I
)	I
is	O
highly	O
enriched	O
in	O
genes	O
associated	O
with	O
digestive	O
tract	O
function	O
,	O
biochemical	O
and	O
lipid	O
metabolism	O
.	O

This	O
cluster	O
is	O
clearly	O
composed	O
of	O
genes	O
associated	O
with	O
the	O
mature	O
GI	O
tract	O
.	O

Thus	O
,	O
as	O
opposed	O
to	O
recapitulating	O
developmental	O
gene	O
activation	O
,	O
the	O
cluster	O
C18	O
pattern	O
indicates	O
a	O
corresponding	O
arrest	O
of	O
differentiation	O
in	O
both	O
mouse	O
and	O
human	O
tumors	B
.	O

Cluster	B
C23	I
(	I
142	I
transcripts	I
over	I
-	I
expressed	I
in	I
all	I
mouse	I
models	I
and	I
human	I
CRC	I
,	I
but	I
with	I
low	I
expression	I
in	I
development	I
)	I
maps	O
to	O
genes	O
highly	O
associated	O
with	O
the	O
disruption	O
of	O
basement	O
membranes	O
,	O
invasion	O
and	O
cell	O
cycle	O
progression	O
,	O
as	O
well	O
as	O
altered	O
transcriptional	O
control	O
.	O

Cluster	O
C21	O
(	O
313	O
transcripts	O
in	O
which	O
human	O
tumors	B
somewhat	O
variably	O
express	O
a	O
set	O
of	O
genes	O
that	O
are	O
rarely	O
expressed	O
by	O
the	O
mouse	O
tumors	B
)	O
is	O
remarkable	O
for	O
its	O
composition	O
of	O
genes	O
associated	O
with	O
cell	O
cycle	O
proliferation	O
,	O
tissue	O
disruption	O
and	O
angiogenesis	O
.	O

Thus	O
,	O
while	O
categorically	O
quite	O
similar	O
to	O
cluster	O
C23	O
,	O
the	O
genes	O
in	O
cluster	O
C21	O
represent	O
a	O
separately	O
regulated	O
module	O
that	O
is	O
enriched	O
for	O
genes	O
associated	O
with	O
invasion	O
.	O

Clusters	B
C21	I
and	I
C23	I
reveal	I
sets	I
of	I
genes	I
likely	I
involved	I
in	I
tumor	I
progression	I
.	O

Cluster	B
C22	I
(	I
with	I
genes	I
over	I
-	I
expressed	I
in	I
all	I
mouse	I
and	I
human	I
tumors	I
and	I
strongly	I
expressed	I
in	I
embryonic	I
colon	I
)	I
represents	O
a	O
group	O
of	O
genes	O
highly	O
correlated	O
with	O
transformation	O
.	O

The	O
top	O
-	O
ranked	O
transcription	O
factor	O
present	O
in	O
this	O
cluster	O
,	O
with	O
regulation	O
independent	O
of	O
β	O
-	O
catenin	O
localization	O
,	O
is	O
Myc	O
/	O
MYC	O
(	O
Figure	O
7b	O
)	O
.	O

Although	O
Myc	O
was	O
lower	O
in	O
expression	O
in	O
the	O
Smad3-	O
/	O
-	O
tumors	B
compared	O
to	O
tumors	B
from	O
the	O
other	O
three	O
models	O
,	O
it	O
was	O
elevated	O
in	O
all	O
four	O
models	O
relative	O
to	O
normal	B
adult	O
colon	O
.	O

Myc	O
/	O
MYC	O
was	O
over	O
-	O
expressed	O
in	O
all	O
mouse	O
and	O
human	O
tumors	B
as	O
well	O
as	O
in	O
development	O
.	O

This	O
contrasts	O
with	O
Sox4	O
,	O
which	O
is	O
unaltered	O
in	O
expression	O
in	O
the	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
but	O
is	O
up	O
-	O
regulated	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
relative	O
to	O
normal	B
adult	O
colon	O
(	O
Figure	O
7b	O
)	O
.	O

Myc	O
/	O
MYC	O
over	O
-	O
expression	O
may	O
be	O
independent	O
of	O
nuclear	O
β	O
-	O
catenin	O
status	O
.	O

Increased	O
Myc	O
/	O
MYC	O
expression	O
may	O
reflect	O
both	O
activation	O
of	O
canonical	O
Wnt	O
signaling	O
,	O
as	O
it	O
is	O
a	O
target	O
of	O
nuclear	O
β	O
-	O
catenin	O
/	O
TCF	O
[	O
28	O
]	O
,	O
and	O
deregulation	O
of	O
TGFβ	O
signaling	O
,	O
as	O
TGFβ1	O
is	O
known	O
to	O
repress	O
Myc	O
/	O
MYC	O
[	O
29	O
-	O
31	O
]	O
.	O

These	O
observations	O
suggest	O
a	O
fundamental	O
role	O
for	O
Myc	O
/	O
MYC	O
in	O
colonic	O
neoplasia	B
.	O

As	O
shown	O
in	O
Figure	O
2a	O
,	O
the	O
microarray	O
patterns	O
of	O
gene	O
expression	O
for	O
AOM	O
and	O
ApcMin	O
/	O
+	O
tumors	B
are	O
mirror	O
images	O
of	O
those	O
for	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
tumors	B
.	O

It	O
is	O
perhaps	O
not	O
surprising	O
that	O
combining	O
these	O
two	O
transcriptional	O
programs	O
results	O
in	O
increased	O
number	O
and	O
invasiveness	O
of	O
colonic	O
tumors	B
as	O
recently	O
reported	O
for	O
ApcMin	O
/	O
+	O
mice	O
crossed	O
to	O
Smad3-	O
/	O
-	O
mice	O
[	O
45	O
]	O
.	O

Moreover	O
,	O
combined	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
and	O
inhibition	O
of	O
TGFβ	O
signaling	O
also	O
results	O
in	O
more	O
advanced	O
intestinal	O
tumors	B
in	O
Apcdelta716	O
/	O
+	O
;	O
Smad4+	O
/	O
-	O
mice	O
[	O
46	O
]	O
,	O
and	O
intestine	O
-	O
specific	O
deletion	O
of	O
the	O
type	O
II	O
TGFβ	O
receptor	O
in	O
Apc1638N	O
/	O
wt	O
mice	O
[	O
47	O
]	O
.	O

The	O
findings	O
that	O
shared	O
over	O
-	O
expressed	O
signatures	O
are	O
identifiable	O
in	O
all	O
four	O
mouse	O
models	O
of	O
CRC	B
,	O
which	O
are	O
also	O
representative	O
of	O
the	O
majority	O
of	O
embryonic	O
colonic	O
over	O
-	O
expressed	O
signatures	O
,	O
and	O
that	O
these	O
signatures	O
are	O
also	O
present	O
in	O
all	O
human	O
CRCs	B
,	O
suggest	O
that	O
colon	O
tumors	B
may	O
arise	O
independently	O
of	O
canonical	O
WNT	O
signaling	O
status	O
.	O

A	O
likely	O
candidate	O
to	O
impart	O
this	O
oncogenic	O
signaling	O
is	O
Myc	O
,	O
which	O
is	O
an	O
embryonic	O
up	O
-	O
regulated	O
transcript	O
that	O
is	O
also	O
upregulated	O
in	O
all	O
human	O
CRCs	B
and	O
mouse	O
tumor	B
models	O
independently	O
of	O
nuclear	O
β	O
-	O
catenin	O
status	O
.	O

Embryology	O
provides	O
insight	O
into	O
the	O
biology	O
of	O
mouse	O
and	O
human	O
colon	O
tumors	B
It	O
has	O
long	O
been	O
suggested	O
that	O
cancer	B
represents	O
a	O
reversion	O
to	O
an	O
embryonic	O
state	O
,	O
partly	O
based	O
upon	O
the	O
observation	O
that	O
several	O
oncofetal	O
antigens	O
are	O
diagnostic	O
for	O
some	O
tumors	B
[	O
48,49	O
]	O
.	O

To	O
assess	O
the	O
embryology	O
-	O
related	O
aspects	O
of	O
tumorigenesis	B
and	O
tumor	B
progression	O
in	O
CRC	B
,	O
we	O
analyzed	O
and	O
compared	O
the	O
transcriptomes	O
of	O
normal	B
mouse	O
colon	O
development	O
and	O
models	O
of	O
CRC	B
.	O

Our	O
data	O
show	O
that	O
developmentally	O
regulated	O
genes	O
represent	O
approximately	O
56	O
%	O
of	O
mouse	O
tumor	B
signatures	O
,	O
and	O
that	O
the	O
tumor	B
signatures	O
from	O
the	O
four	O
mouse	O
models	O
recapitulate	O
approximately	O
85	O
%	O
of	O
developmentally	O
regulated	O
genes	O
.	O

There	O
are	O
at	O
least	O
two	O
regulatory	O
programs	O
that	O
determine	O
the	O
expression	O
of	O
developmental	O
genes	O
by	O
mouse	O
tumors	B
(	O
Figures	O
2	O
,	O
4	O
,	O
and	O
8)	O
.	O

The	O
simpler	O
program	O
is	O
evident	O
by	O
the	O
over	O
-	O
expression	O
of	O
the	O
earliest	O
genes	O
of	O
colon	O
development	O
by	O
the	O
nuclear	O
β	O
-	O
catenin	O
-	O
positive	O
models	O
.	O

The	O
more	O
subtle	O
program	O
could	O
be	O
detected	O
only	O
in	O
reference	O
to	O
adult	O
colon	O
and	O
is	O
highly	O
shared	O
by	O
nuclear	O
β	O
-	O
catenin	O
-	O
negative	O
models	O
.	O

This	O
program	O
,	O
though	O
modified	O
by	O
nuclear	O
β	O
-	O
catenin	O
status	O
,	O
is	O
represented	O
by	O
a	O
large	O
scale	O
over	O
-	O
expression	O
of	O
developmentally	O
expressed	O
genes	O
in	O
tumors	B
that	O
are	O
both	O
positive	O
and	O
negative	O
for	O
canonical	O
WNT	O
signaling	O
.	O

Genes	O
found	O
within	O
this	O
signature	O
have	O
a	O
large	O
overlap	O
with	O
those	O
present	O
in	O
the	O
colon	O
at	O
later	O
developmental	O
stages	O
(	O
E16.5-E18.5	O
)	O
.	O

An	O
integrated	O
view	O
of	O
colon	B
cancer	I
transcriptional	O
programs	O
provides	O
novel	O
insight	O
into	O
neoplasia	B
.	O

Murine	O
colon	O
tumor	B
adenomas	B
and	O
human	O
CRCs	B
both	O
show	O
adoption	O
and	O
dysregulation	O
of	O
signatures	O
tightly	O
controlled	O
during	O
embryonic	O
mouse	O
colon	O
development	O
.	O

The	O
use	O
of	O
etiologically	O
distinct	O
mouse	O
models	O
of	O
colon	B
cancer	I
allows	O
for	O
the	O
identification	O
of	O
models	O
that	O
resemble	O
different	O
stages	O
of	O
embryonic	O
mouse	O
colon	O
development	O
and	O
that	O
are	O
recapitulated	O
by	O
specific	O
tumor	B
types	O
.	O

(	O
a	O
)	O
All	O
tumors	B
exhibit	O
large	O
-	O
scale	O
activation	O
of	O
developmental	O
patterns	O
.	O

Nuclear	B
β	I
-	I
catenin	I
-	I
positive	I
(	O
ApcMin	O
/	O
+	O
and	O
AOM	O
)	O
tumors	B
map	O
more	O
strongly	O
to	O
early	O
development	O
stages	O
during	O
(	O
more	O
proliferative	O
,	O
less	O
differentiated	O
)	O
,	O
whereas	O
nuclear	B
β	I
-	I
catenin	I
-	I
negative	I
(	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
and	O
Smad3-	O
/	O
-	O
)	O
tumors	B
map	O
more	O
strongly	O
to	O
later	O
stages	O
consistent	O
with	O
increased	O
epithelial	O
differentiation	O
.	O

(	O
b	O
)	O
Overall	O
representation	O
of	O
the	O
relationship	O
of	O
mouse	O
colon	O
tumor	B
models	O
and	O
human	O
CRC	B
to	O
development	O
and	O
non	O
-	O
developmental	O
expression	O
patterns	O
.	O

Gene	O
expression	O
clusters	O
mapped	O
to	O
the	O
progression	O
of	O
adenomatous	O
and	O
carcinomatous	O
transformation	O
identified	O
in	O
Figures	O
5	O
and	O
6	O
are	O
shown	O
as	O
the	O
clusters	O
of	O
genes	O
whose	O
expression	O
is	O
either	O
gained	O
or	O
lost	O
associated	O
with	O
the	O
stage	O
of	O
progression	O
.	O

For	O
example	O
normal	B
development	O
could	O
be	O
considered	O
as	O
'	O
subverted	O
'	O
if	O
there	O
is	O
an	O
absence	O
of	O
expression	O
of	O
genes	O
normally	O
expressed	O
at	O
high	O
level	O
in	O
the	O
developing	O
colon	O
that	O
fail	O
to	O
be	O
expressed	O
in	O
tumors	B
(	O
for	O
example	O
,	O
C18	O
,	O
C19	O
)	O
,	O
or	O
that	O
are	O
activated	O
in	O
tumor	B
but	O
not	O
normally	O
expressed	O
in	O
development	O
(	O
C20	O
)	O
.	O

Upregulated	O
clusters	O
are	O
enriched	O
for	O
genes	O
with	O
known	O
oncogenic	O
functions	O
and	O
down	O
-	O
regulated	O
clusters	O
for	O
genes	O
associated	O
with	O
tumor	B
suppression	O
.	O

Both	O
mouse	O
colon	O
tumor	B
models	O
and	O
human	O
CRC	B
share	O
in	O
the	O
activation	O
of	O
embryonic	O
colon	O
expression	O
(	O
C22	O
)	O
,	O
or	O
partially	O
overlap	O
(	O
C23	O
,	O
dotted	O
lines	O
)	O
the	O
loss	O
or	O
repression	O
of	O
adult	O
differentiation	O
-	O
associated	O
genes	O
(	O
C19	O
)	O
,	O
and	O
the	O
loss	O
of	O
tumor	B
suppressor	O
genes	O
(	O
C18	O
)	O
.	O

Many	O
human	O
CRCs	B
also	O
lack	O
the	O
expression	O
of	O
additional	O
tumor	B
suppressor	O
programs	O
and	O
gain	O
the	O
expression	O
of	O
oncogenes	O
that	O
are	O
not	O
over	O
-	O
expressed	O
during	O
normal	B
developmental	O
morphogenesis	O
(	O
C21	O
)	O
.	O

How	O
do	O
genes	O
tightly	O
regulated	O
during	O
mouse	O
colon	O
development	O
become	O
activated	O
in	O
colon	O
tumors	B
?	O

While	O
activated	O
canonical	O
WNT	O
signaling	O
imparts	O
a	O
strong	O
influence	O
,	O
its	O
absence	O
in	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
and	O
Smad3-	O
/	O
-	O
tumors	B
,	O
as	O
determined	O
by	O
the	O
absence	O
of	O
nuclear	O
β	O
-	O
catenin	O
,	O
did	O
not	O
prevent	O
the	O
large	O
scale	O
activation	O
of	O
developmental	O
/	O
embryonic	O
gene	O
expression	O
.	O

One	O
mechanism	O
may	O
be	O
through	O
epigenetic	O
alterations	O
.	O

In	O
human	O
CRCs	B
,	O
these	O
types	O
of	O
alterations	O
in	O
gene	O
expression	O
programs	O
[	O
50	O
]	O
suggest	O
a	O
link	O
between	O
cellular	O
homeostasis	O
and	O
tumorigenesis	B
.	O

The	O
recruitment	O
of	O
histone	O
acetyltransferases	O
and	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
are	O
key	O
steps	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
during	O
normal	B
development	O
and	O
carcinogenesis	B
[	O
51	O
]	O
.	O

Induction	O
of	O
Hdac2	O
expression	O
occurs	O
in	O
82	O
%	O
of	O
human	O
CRCs	B
as	O
well	O
as	O
in	O
tumors	B
from	O
ApcMin	O
/	O
+	O
mice	O
[	O
19	O
]	O
.	O

Alternatively	O
,	O
common	O
regulatory	O
controls	O
may	O
operate	O
in	O
parallel	O
growth	O
and	O
differentiation	O
/	O
anti	O
-	O
diifferentiation	O
pathways	O
such	O
that	O
a	O
single	O
or	O
small	O
subset	O
of	O
regulators	O
,	O
such	O
as	O
MYC	O
or	O
one	O
or	O
more	O
micro	O
RNAs	O
,	O
may	O
be	O
responsible	O
for	O
the	O
control	O
of	O
multiple	O
pathways	O
.	O

Indeed	O
,	O
consistent	O
with	O
our	O
observation	O
of	O
nuclear	O
β	O
-	O
catenin	O
-	O
independent	O
activation	O
of	O
Myc	O
in	O
all	O
mouse	O
models	O
and	O
across	O
the	O
board	O
for	O
human	O
CRC	B
,	O
deletion	O
of	O
Myc	O
has	O
recently	O
been	O
demonstrated	O
to	O
completely	O
abrogate	O
nuclear	O
β	O
-	O
catenin	O
-	O
driven	O
small	O
bowel	O
oncogenesis	B
in	O
mouse	O
models	O
[	O
52	O
]	O
.	O

Comparative	O
analysis	O
reveals	O
underlying	O
development	O
-	O
related	O
signatures	O
in	O
human	O
CRCs	B
As	O
shown	O
in	O
Figure	O
5	O
,	O
considerable	O
and	O
intriguing	O
heterogeneity	O
of	O
human	O
CRC	B
is	O
observed	O
among	O
genes	O
highly	O
relevant	O
for	O
differential	O
malignant	B
behavior	O
.	O

However	O
,	O
employing	O
between	O
-	O
tumors	B
normalization	O
and	O
referencing	O
strategies	O
prevents	O
the	O
detection	O
of	O
gene	O
expression	O
patterns	O
that	O
are	O
shared	O
between	O
tumors	B
.	O

Using	O
the	O
adult	O
normal	B
colon	O
as	O
a	O
reference	O
,	O
as	O
shown	O
in	O
Figure	O
6	O
,	O
a	O
large	O
fraction	O
of	O
differential	O
gene	O
expression	O
relative	O
to	O
adult	O
colon	O
could	O
be	O
demonstrated	O
that	O
recapitulated	O
developmental	O
gene	O
expression	O
by	O
virtue	O
of	O
both	O
activating	O
embryonic	O
colon	O
gene	O
expression	O
and	O
failing	O
to	O
express	O
genes	O
associated	O
with	O
normal	B
colon	O
maturation	O
.	O

Within	O
these	O
developmentally	O
regulated	O
gene	O
sets	O
,	O
our	O
analyses	O
revealed	O
little	O
evidence	O
of	O
CRC	B
subsets	O
,	O
including	O
those	O
suggestive	O
of	O
nuclear	B
β	I
-	I
catenin	I
negative	I
tumors	B
that	O
might	O
approximate	O
the	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
signature	O
.	O

Our	O
inability	O
to	O
identify	O
distinct	O
subclasses	O
with	O
respect	O
to	O
developmental	O
genes	O
in	O
the	O
human	O
CRCs	B
is	O
perhaps	O
not	O
surprising	O
in	O
that	O
over	O
80	O
%	O
of	O
microsatellite	B
-	I
unstable	I
(	O
MSI+	B
)	O
CRCs	B
from	O
HNPCC	B
families	O
exhibit	O
nuclear	O
β	O
-	O
catenin	O
[	O
53	O
]	O
.	O

In	O
addition	O
,	O
within	O
the	O
developmental	O
genes	O
,	O
little	O
evidence	O
was	O
apparent	O
for	O
signatures	O
related	O
to	O
MSI+	B
tumors	B
,	O
often	O
associated	O
with	O
HNPCC	B
,	O
although	O
some	O
of	O
this	O
type	O
of	O
signature	O
was	O
perhaps	O
apparent	O
in	O
the	O
median	O
normalized	O
depiction	O
of	O
the	O
tumors	B
as	O
highlighted	O
in	O
Figure	O
5	O
.	O

Inter	O
-	O
organism	O
gene	O
ortholog	O
and	O
inter	O
-	O
platform	O
comparison	O
strategy	O
Pairs	O
of	O
human	O
and	O
mouse	O
ortholog	O
genes	O
(	O
12,693	O
)	O
were	O
curated	O
using	O
the	O
Mouse	O
Genome	O
Informatics	O
(	O
MGI	O
;	O
The	O
Jackson	O
Laboratory	O
)	O
[	O
61	O
]	O
and	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
Homologene	O
[	O
62	O
]	O
databases	O
.	O

Individual	O
microarray	O
elements	O
or	O
features	O
were	O
mapped	O
to	O
these	O
.	O

The	O
concatenated	O
human	O
and	O
mouse	O
RefSeq	O
IDs	O
was	O
used	O
as	O
the	O
composite	O
ID	O
for	O
the	O
orthologous	O
gene	O
pair	O
in	O
the	O
ortholog	O
genome	O
definition	O
.	O

NIA	O
/	O
Research	O
Genetics	O
mouse	O
cDNAs	O
were	O
mapped	O
to	O
human	O
orthologs	O
using	O
a	O
variety	O
of	O
resources	O
,	O
usually	O
via	O
the	O
Stanford	O
Online	O
Universal	O
Reference	O
resource	O
[	O
63	O
]	O
.	O

Gene	O
transcript	O
assignments	O
were	O
made	O
unique	O
by	O
choosing	O
the	O
longest	O
corresponding	O
transcript	O
.	O

To	O
map	O
the	O
Affymetrix	O
human	O
and	O
mouse	O
array	O
data	O
into	O
the	O
ortholog	O
genome	O
,	O
we	O
used	O
a	O
sequence	O
matching	O
approach	O
.	O

First	O
,	O
we	O
obtained	O
human	O
and	O
mouse	O
transcript	O
sequences	O
from	O
RefSeq	O
[	O
64	O
]	O
and	O
probe	O
sequences	O
from	O
the	O
manufacturer	O
's	O
website	O
[	O
65	O
]	O
.	O

Next	O
,	O
we	O
computed	O
all	O
perfect	O
probe	O
-	O
transcript	O
pairs	O
.	O

We	O
excluded	O
probes	O
that	O
matched	O
multiple	O
gene	O
symbols	O
but	O
accepted	O
probes	O
that	O
matched	O
multiple	O
transcripts	O
.	O

Probe	O
sets	O
were	O
assigned	O
to	O
represent	O
a	O
given	O
transcript	O
if	O
at	O
least	O
50	O
%	O
of	O
the	O
perfect	O
match	O
probes	O
of	O
the	O
probe	O
set	O
matched	O
to	O
that	O
transcript	O
.	O

The	O
newly	O
assigned	O
transcript	O
identifiers	O
were	O
then	O
used	O
to	O
map	O
probe	O
sets	O
to	O
ortholog	O
genes	O
.	O

Since	O
some	O
transcripts	O
have	O
multiple	O
probe	O
-	O
set	O
representations	O
on	O
both	O
the	O
Affymetrix	O
and	O
cDNA	O
microarrays	O
to	O
one	O
ortholog	O
identifier	O
,	O
we	O
employed	O
an	O
ad	O
hoc	O
strategy	O
to	O
use	O
the	O
average	O
of	O
those	O
probe	O
sets	O
or	O
cDNAs	O
that	O
exhibited	O
consistent	O
regulation	O
across	O
a	O
sample	O
series	O
.	O

In	O
such	O
cases	O
,	O
the	O
signals	O
of	O
the	O
regulated	O
probe	O
sets	O
that	O
were	O
interpreted	O
as	O
being	O
in	O
agreement	O
were	O
averaged	O
and	O
assigned	O
to	O
the	O
corresponding	O
ortholog	O
.	O

We	O
excluded	O
probe	O
sets	O
or	O
cDNAs	O
that	O
we	O
were	O
aware	O
corresponded	O
to	O
non	O
-	O
transcript	O
genomic	O
sequence	O
as	O
tested	O
using	O
BLAT	O
at	O
the	O
UCSC	O
Goldenpath	O
website	O
[	O
66	O
]	O
.	O

Mouse	O
-	O
human	O
RefSeq	O
gene	O
ortholog	O
assignments	O
can	O
be	O
found	O
at	O
GenomeTrafac	O
[	O
67,68	O
]	O
.	O

All	O
ortholog	O
assignments	O
and	O
cross	O
-	O
species	O
mapping	O
annotations	O
were	O
incorporated	O
into	O
annotations	O
associated	O
with	O
the	O
Affymetrix	O
HG	O
-	O
U133	O
plus2.0	O
genome	O
.	O

Gene	O
expression	O
ratios	O
obtained	O
for	O
the	O
mouse	O
samples	O
were	O
then	O
represented	O
as	O
expression	O
values	O
within	O
the	O
human	O
platform	O
for	O
all	O
of	O
the	O
probe	O
sets	O
that	O
mapped	O
to	O
the	O
corresponding	O
mouse	O
gene	O
ortholog	O
.	O

Data	O
for	O
the	O
primary	O
human	O
sample	O
series	O
,	O
as	O
well	O
as	O
the	O
combined	O
mouse	O
-	O
human	O
data	O
sets	O
,	O
are	O
available	O
in	O
the	O
Cincinnati	O
Children	O
's	O
Hospital	O
Medical	O
Center	O
microarray	O
data	O
server	O
[	O
69	O
]	O
in	O
the	O
HG	O
-	O
U133	O
genome	O
under	O
the	O
KaiserEtAl_2006	O
folders	O
(	O
'	O
guest	O
'	O
login	O
;	O
all	O
cross	O
-	O
platform	O
ortholog	O
gene	O
identifiers	O
are	O
contained	O
as	O
annotation	O
fields	O
within	O
the	O
HG	O
-	O
U133	O
genome	O
table	O
)	O
.	O

Statistical	O
and	O
data	O
visualization	O
approaches	O
Most	O
normalization	O
,	O
expression	O
-	O
level	O
referencing	O
,	O
statistical	O
comparisons	O
,	O
and	O
data	O
visualization	O
were	O
performed	O
using	O
GeneSpring	O
v7.0	O
(	O
Silicon	O
Genetics	O
-	O
Agilent	O
(	O
part	O
of	O
Agilent	O
Technologies	O
)	O
.	O

Fisher	O
's	O
exact	O
test	O
was	O
performed	O
online	O
at	O
the	O
MATFORSK	O
Fisher	O
's	O
Exact	O
Test	O
server	O
[	O
70	O
]	O
.	O

To	O
identify	O
differentially	O
expressed	O
features	O
between	O
two	O
or	O
more	O
classes	O
,	O
we	O
applied	O
GeneSpring	O
's	O
Wilcoxon	O
-	O
Mann	O
-	O
Whitney	O
or	O
the	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
respectively	O
.	O

For	O
three	O
or	O
more	O
classes	O
,	O
the	O
initial	O
non	O
-	O
parametric	O
test	O
was	O
followed	O
by	O
the	O
Student	O
-	O
Newman	O
-	O
Keuls	O
post	O
-	O
hoc	O
test	O
.	O

Results	O
from	O
the	O
primary	O
analyses	O
were	O
corrected	O
for	O
multiple	O
testing	O
effects	O
by	O
applying	O
Benjamini	O
and	O
Hochberg	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
correction	O
[	O
71	O
]	O
.	O

In	O
general	O
,	O
due	O
to	O
the	O
referencing	O
strategies	O
,	O
good	O
platform	O
technical	O
performances	O
,	O
and	O
moderately	O
low	O
within	O
-	O
group	O
biological	O
variation	O
of	O
gene	O
expression	O
,	O
stringent	O
cutoffs	O
could	O
be	O
used	O
,	O
that	O
is	O
,	O
the	O
FDR	O
level	O
of	O
significance	O
was	O
set	O
between	O
FDR	O
<	O
5.10	O
-	O
5	O
and	O
FDR	O
<	O
5.10	O
-	O
4	O
.	O

K	O
-	O
means	O
clustering	O
was	O
performed	O
using	O
the	O
GeneSpring	O
K	O
-	O
means	O
tool	O
and	O
the	O
Pearson	O
correlation	O
similarity	O
measure	O
.	O

Ontology	O
-	O
based	O
analysis	O
of	O
gene	O
cluster	O
-	O
associated	O
functional	O
correlates	O
Gene	O
expression	O
clusters	O
were	O
analyzed	O
for	O
the	O
occurrence	O
of	O
multiple	O
genes	O
involved	O
in	O
related	O
gene	O
function	O
categories	O
by	O
comparing	O
each	O
list	O
of	O
coordinately	O
regulated	O
clustered	O
genes	O
to	O
categories	O
within	O
Gene	O
Ontology	O
,	O
pathways	O
,	O
or	O
literature	O
-	O
based	O
gene	O
associations	O
using	O
GATACA	O
[	O
72	O
]	O
,	O
Ontoexpress	O
[	O
73	O
]	O
,	O
and	O
Ingenuity	O
Pathway	O
Analysis	O
,	O
version	O
3	O
(	O
IPA	O
,	O
Ingenuity	O
Systems	O
,	O
Redwood	O
City	O
,	O
CA	O
,	O
USA	O
)	O
[	O
74	O
]	O
.	O

To	O
do	O
this	O
,	O
each	O
cluster	O
indicated	O
in	O
Figures	O
2	O
,	O
4	O
,	O
5	O
,	O
6	O
and	O
8	O
was	O
converted	O
to	O
a	O
list	O
of	O
gene	O
identifiers	O
,	O
uploaded	O
to	O
the	O
application	O
,	O
and	O
examined	O
for	O
over	O
-	O
representation	O
of	O
multiple	O
genes	O
from	O
one	O
or	O
more	O
molecular	O
networks	O
,	O
or	O
functional	O
or	O
disease	B
associations	O
as	O
developed	O
from	O
literature	O
mining	O
.	O

Networks	O
of	O
these	O
focus	O
genes	O
were	O
algorithmically	O
generated	O
based	O
on	O
the	O
relationships	O
of	O
individual	O
genes	O
as	O
derived	O
from	O
literature	O
review	O
and	O
used	O
to	O
identify	O
the	O
biological	O
functions	O
and/or	O
associated	O
pathological	O
processes	O
most	O
significant	O
for	O
each	O
gene	O
cluster	O
.	O

Fisher	O
's	O
exact	O
test	O
was	O
used	O
to	O
calculate	O
a	O
p	O
value	O
estimating	O
the	O
probability	O
that	O
a	O
particular	O
functional	O
classification	O
or	O
category	O
of	O
genes	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
or	O
cluster	O
of	O
gene	O
expression	O
more	O
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O

For	O
each	O
cluster	O
,	O
only	O
the	O
top	O
significant	O
functional	O
classes	O
and	O
canonical	O
pathways	O
are	O
shown	O
.	O

Figure	O
7a	O
shows	O
a	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
and	O
an	O
associated	O
-	O
gene	O
network	O
that	O
was	O
a	O
top	O
-	O
ranked	O
association	O
of	O
the	O
clusters	O
that	O
exhibited	O
significant	O
over	O
-	O
expression	O
in	O
AOM	O
and	O
ApcMin	O
/	O
+	O
versus	O
Smad3-	O
/	O
-	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
mouse	O
models	O
.	O

Genes	O
or	O
gene	O
products	O
are	O
represented	O
as	O
nodes	O
,	O
and	O
biological	O
relationships	O
between	O
nodes	O
are	O
represented	O
as	O
edges	O
(	O
lines	O
)	O
.	O

All	O
edges	O
are	O
supported	O
by	O
at	O
least	O
one	O
literature	O
reference	O
from	O
a	O
manuscript	O
,	O
or	O
from	O
canonical	O
information	O
stored	O
in	O
the	O
Ingenuity	O
Pathways	O
Knowledge	O
Base	O
.	O

promoter	O
methylation	O
in	O
peripheral	O
blood	O
DNA	O
of	O
mutation	O
negative	O
familial	O
breast	B
cancer	I
patients	O
with	O
a	O
tumour	B
phenotype	O
Abstract	O
Introduction	O
Individuals	O
with	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
have	O
an	O
elevated	O
risk	O
of	O
developing	O
breast	B
cancer	I
,	O
and	O
often	O
display	O
characteristic	O
clinicopathological	O
features	O
.	O

We	O
hypothesised	O
that	O
inactivation	O
of	O
BRCA1	O
by	O
promoter	O
methylation	O
could	O
occur	O
as	O
a	O
germline	O
or	O
an	O
early	O
somatic	O
event	O
that	O
predisposes	O
to	O
breast	B
cancer	I
with	O
the	O
phenotype	O
normally	O
associated	O
with	O
BRCA1	O
germline	O
mutation	O
.	O

Methods	O
We	O
examined	O
seven	O
cases	O
from	O
breast	O
-	O
ovarian	B
cancer	I
families	O
with	O
tumours	B
that	O
showed	O
BRCA1-like	O
pathology	O
but	O
did	O
not	O
have	O
detectable	O
BRCA1	O
or	O
BRCA2	O
germline	O
mutations	O
present	O
.	O

Methylation	O
levels	O
were	O
tested	O
by	O
several	O
quantitative	O
techniques	O
including	O
MethyLight	O
,	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
and	O
a	O
newly	O
developed	O
digital	O
MS	O
-	O
HRM	O
assay	O
.	O

Results	O
In	O
one	O
patient	O
,	O
methylation	O
of	O
10	O
%	O
of	O
the	O
BRCA1	O
alleles	O
was	O
detected	O
in	O
the	O
peripheral	O
blood	O
DNA	O
,	O
consistent	O
with	O
20	O
%	O
of	O
cells	O
having	O
one	O
methylated	O
allele	O
.	O

Buccal	O
mucosa	O
DNA	O
from	O
this	O
individual	O
displayed	O
approximately	O
5	O
%	O
BRCA1	O
methylation	O
.	O

In	O
two	O
other	O
patients	O
,	O
methylation	O
of	O
BRCA1	O
was	O
detected	O
in	O
the	O
peripheral	O
blood	O
at	O
significantly	O
lower	O
but	O
still	O
readily	O
detectable	O
levels	O
(	O
approximately	O
1	O
%	O
)	O
.	O

Tumour	B
DNAs	O
from	O
these	O
three	O
patients	O
were	O
heavily	O
methylated	O
at	O
BRCA1	O
.	O

The	O
other	O
patients	O
had	O
no	O
detectable	O
BRCA1	O
methylation	O
in	O
their	O
peripheral	O
blood	O
.	O

One	O
of	O
seven	O
age	O
-	O
matched	O
controls	O
showed	O
extremely	O
low	O
levels	O
of	O
methylation	O
in	O
their	O
peripheral	O
blood	O
(	O
approximately	O
0.1	O
%	O
)	O
.	O

Conclusion	O
These	O
results	O
demonstrate	O
that	O
in	O
some	O
cases	O
of	O
breast	B
cancer	I
,	O
low	O
-	O
level	O
promoter	O
methylation	O
of	O
BRCA1	O
occurs	O
in	O
normal	B
tissues	O
of	O
the	O
body	O
and	O
is	O
associated	O
with	O
the	O
development	O
of	O
BRCA1-like	O
breast	B
cancer	I
.	O

Introduction	O
In	O
1994	O
,	O
BRCA1	O
was	O
identified	O
as	O
the	O
first	O
major	O
gene	O
associated	O
with	O
familial	O
breast	B
cancer	I
predisposition	O
[	O
1	O
]	O
.	O

Since	O
then	O
many	O
inactivating	O
mutations	O
in	O
BRCA1	O
have	O
been	O
identified	O
as	O
breast	B
cancer	I
predisposition	O
alleles	O
.	O

Breast	B
cancers	I
associated	O
with	O
BRCA1	O
mutations	O
often	O
show	O
characteristic	O
histological	O
features	O
including	O
high	O
grade	O
,	O
high	O
mitotic	O
count	O
,	O
solid	O
architecture	O
and	O
prominent	O
lymphocytic	O
infiltrates	O
,	O
all	O
features	O
resembling	O
so	O
-	O
called	O
medullary	O
cancer	B
[	O
2	O
-	O
4	O
]	O
.	O

BRCA1-associated	O
tumours	B
are	O
usually	O
negative	O
by	O
immunohistochemistry	O
for	O
the	O
oestrogen	O
receptor	O
(	O
ER	O
)	O
,	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
and	O
HER2	O
[	O
5	O
-	O
7	O
]	O
.	O

However	O
,	O
the	O
majority	O
of	O
breast	B
cancers	I
that	O
exhibit	O
a	O
BRCA1-like	O
phenotype	O
do	O
not	O
harbour	O
detectable	O
germline	O
mutations	O
in	O
BRCA1	O
.	O

Some	O
of	O
this	O
discordance	O
may	O
be	O
due	O
to	O
epigenetic	O
defects	O
in	O
breast	B
cancer	I
susceptibility	O
genes	O
such	O
as	O
BRCA1	O
contributing	O
to	O
breast	B
cancer	I
predisposition	O
.	O

Recent	O
reports	O
of	O
somatic	O
methylation	O
(	O
or	O
epimutations	O
)	O
affecting	O
an	O
allele	O
of	O
the	O
MLH1	O
gene	O
in	O
patients	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
indicate	O
inactivation	O
of	O
tumour	B
suppressor	O
genes	O
by	O
promoter	O
methylation	O
can	O
occur	O
early	O
in	O
development	O
or	O
possibly	O
in	O
the	O
germline	O
[	O
8	O
-	O
10	O
]	O
.	O

Allelic	O
methylation	O
is	O
functionally	O
equivalent	O
to	O
a	O
mutation	O
in	O
that	O
loss	O
of	O
activity	O
of	O
the	O
second	O
allele	O
arising	O
from	O
a	O
mutation	O
,	O
loss	O
of	O
heterozygosity	O
or	O
a	O
second	O
methylation	O
event	O
will	O
inactivate	O
the	O
gene	O
.	O

Methylation	O
of	O
the	O
BRCA1	O
promoter	O
has	O
been	O
shown	O
to	O
occur	O
in	O
approximately	O
20	O
%	O
of	O
breast	B
cancer	I
patients	O
[	O
11	O
-	O
14	O
]	O
.	O

Sporadic	O
tumours	B
with	O
BRCA1	O
promoter	O
methylation	O
have	O
been	O
reported	O
to	O
be	O
ER	B
and	I
PR	I
negative	I
[	O
13,14	O
]	O
,	O
or	O
to	O
display	O
similar	O
pathological	O
features	O
to	O
those	O
of	O
BRCA1-mutated	O
hereditary	O
breast	B
cancers	I
[	O
15	O
]	O
.	O

Furthermore	O
,	O
tumours	B
with	O
BRCA1	O
methylation	O
appear	O
to	O
have	O
similar	O
global	O
gene	O
expression	O
profiles	O
to	O
BRCA1	O
mutated	O
tumours	B
[	O
16	O
]	O
and	O
similar	O
genomic	O
copy	O
number	O
profiles	O
[	O
17	O
]	O
.	O

Other	O
authors	O
have	O
claimed	O
that	O
BRCA1	O
methylated	O
tumours	B
have	O
distinct	O
pathologies	O
to	O
those	O
seen	O
in	O
BRCA1	O
mutated	O
tumours	B
[	O
18	O
]	O
.	O

The	O
discrepancy	O
may	O
at	O
least	O
in	O
part	O
be	O
resolved	O
by	O
the	O
hypothesis	O
that	O
the	O
timing	O
of	O
BRCA1	O
methylation	O
will	O
influence	O
tumour	B
phenotype	O
;	O
the	O
earlier	O
in	O
tumorigenesis	O
methylation	O
occurs	O
,	O
the	O
greater	O
the	O
similarity	O
to	O
tumours	B
arising	O
from	O
germline	O
BRCA1	O
mutations	O
.	O

It	O
must	O
also	O
be	O
taken	O
into	O
consideration	O
that	O
while	O
most	O
tumours	B
arising	O
in	O
BRCA1	O
mutation	O
carriers	O
have	O
typical	O
pathology	O
,	O
a	O
sizeable	O
minority	O
do	O
not	O
.	O

We	O
hypothesised	O
that	O
some	O
individuals	O
are	O
predisposed	O
to	O
develop	O
breast	B
cancer	I
with	O
the	O
features	O
associated	O
with	O
BRCA1	O
mutations	O
because	O
they	O
carry	O
a	O
methylated	O
BRCA1	O
allele	O
in	O
their	O
somatic	O
tissues	O
.	O

In	O
digital	O
MS	O
-	O
HRM	O
,	O
bisulfite	O
modified	O
DNA	O
is	O
diluted	O
to	O
the	O
point	O
where	O
the	O
individual	O
PCR	O
reactions	O
contained	O
0	O
,	O
1	O
or	O
occasionally	O
2	O
amplifiable	O
templates	O
.	O

This	O
eliminates	O
the	O
problem	O
of	O
PCR	O
bias	O
where	O
unmethylated	O
or	O
methylated	O
templates	O
have	O
different	O
amplification	O
efficiencies	O
,	O
hence	O
skewing	O
the	O
actual	O
methylated	O
to	O
unmethylated	O
ratios	O
.	O

Multiple	O
replicates	O
of	O
the	O
diluted	O
sample	O
are	O
amplified	O
by	O
PCR	O
where	O
it	O
is	O
expected	O
that	O
many	O
reactions	O
will	O
not	O
amplify	O
because	O
of	O
the	O
absence	O
of	O
template	O
.	O

The	O
melting	O
profile	O
of	O
each	O
reaction	O
or	O
'	O
clone	O
'	O
is	O
then	O
used	O
to	O
determine	O
its	O
methylation	O
status	O
.	O

The	O
proportion	O
of	O
methylation	O
in	O
a	O
sample	O
can	O
be	O
readily	O
estimated	O
by	O
comparing	O
the	O
number	O
of	O
reactions	O
with	O
a	O
peak	O
with	O
elevated	O
melting	O
temperature	O
characteristic	O
of	O
methylation	O
,	O
over	O
those	O
with	O
an	O
lower	O
melting	O
temperature	O
unmethylated	O
peak	O
.	O

Digital	O
MS	O
-	O
HRM	O
was	O
performed	O
on	O
peripheral	O
blood	O
and	O
buccal	O
mucosal	O
DNA	O
from	O
KCF3	O
.	O

For	O
the	O
peripheral	O
blood	O
DNA	O
,	O
13	O
of	O
the	O
107	O
clones	O
had	O
a	O
methylated	O
peak	O
on	O
melting	O
analysis	O
(	O
Figure	O
3	O
)	O
,	O
equating	O
to	O
12	O
%	O
BRCA1	O
methylation	O
in	O
the	O
peripheral	O
blood	O
.	O

In	O
the	O
buccal	O
mucosa	O
,	O
4	O
of	O
the	O
69	O
clones	O
were	O
methylated	O
,	O
equating	O
to	O
6	O
%	O
methylation	O
.	O

These	O
results	O
confirmed	O
the	O
level	O
of	O
BRCA1	O
methylation	O
estimated	O
by	O
both	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
.	O

When	O
considered	O
at	O
a	O
cellular	O
rather	O
than	O
an	O
allelic	O
level	O
,	O
we	O
estimate	O
that	O
the	O
peripheral	O
blood	O
contains	O
approximately	O
25	O
%	O
of	O
cells	O
with	O
one	O
methylated	O
BRCA1	O
allele	O
and	O
that	O
the	O
buccal	O
mucosa	O
contains	O
approximately	O
10	O
%	O
methylated	O
cells	O
.	O

Digital	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
and	O
sequencing	O
for	O
KCF3	O
peripheral	O
blood	O
DNA	O
.	O

The	O
blue	O
curve	O
indicates	O
the	O
unmethylated	O
control	O
.	O

The	O
black	O
curve	O
indicates	O
the	O
methylated	O
control	O
.	O

The	O
green	O
curves	O
indicate	O
unmethylated	O
amplicons	O
.	O

The	O
red	O
curves	O
indicate	O
methylated	O
amplicons	O
.	O

Sequencing	O
for	O
the	O
unmethylated	O
and	O
methylated	O
controls	O
are	O
shown	O
above	O
the	O
digital	O
MS	O
-	O
HRM	O
results	O
.	O

Sequences	O
of	O
the	O
indicated	O
red	O
amplicons	O
(	O
lettered	O
)	O
are	O
shown	O
to	O
right	O
of	O
the	O
figure	O
where	O
the	O
letter	O
to	O
the	O
right	O
of	O
the	O
chromatograph	O
corresponds	O
to	O
the	O
curve	O
shown	O
.	O

Representative	O
methylated	O
and	O
unmethylated	O
clones	O
from	O
the	O
digital	O
MS	O
-	O
HRM	O
experiments	O
were	O
sequenced	O
to	O
confirm	O
the	O
methylation	O
status	O
(	O
Figure	O
3	O
)	O
.	O

A	O
stretch	O
of	O
22	O
bases	O
containing	O
four	O
CpG	O
sites	O
was	O
analysed	O
.	O

For	O
the	O
peripheral	O
blood	O
DNA	O
of	O
KCF3	O
(	O
Figure	O
3	O
)	O
,	O
four	O
of	O
the	O
six	O
methylated	O
clones	O
had	O
a	O
cytosine	O
present	O
at	O
all	O
four	O
CpGs	O
,	O
confirming	O
the	O
methylation	O
seen	O
by	O
other	O
methodologies	O
.	O

One	O
clone	O
had	O
cytosines	O
present	O
at	O
all	O
CpGs	O
sites	O
but	O
also	O
had	O
an	O
additional	O
cytosine	O
present	O
at	O
a	O
conversion	O
site	O
where	O
a	O
thymine	O
would	O
be	O
expected	O
,	O
preceding	O
a	O
CpG	O
site	O
.	O

The	O
other	O
non	O
-	O
CpG	O
cytosines	O
were	O
converted	O
indicating	O
that	O
this	O
corresponded	O
to	O
a	O
methylated	O
allele	O
.	O

For	O
one	O
other	O
clone	O
only	O
two	O
of	O
the	O
CpGs	O
were	O
methylated	O
but	O
this	O
may	O
have	O
been	O
due	O
to	O
incomplete	O
conversion	O
.	O

The	O
assay	O
conditions	O
used	O
in	O
this	O
study	O
could	O
not	O
distinguish	O
between	O
samples	O
with	O
pathogenic	O
BRCA1	O
mutations	O
and	O
those	O
with	O
pathogenic	O
BRCA2	O
mutations	O
.	O

Ionising	O
radiation	O
has	O
previously	O
been	O
show	O
to	O
separate	O
fibroblast	O
cells	O
which	O
carry	O
BRCA1	O
or	O
BRCA2	O
mutations	O
from	O
sporadic	O
cases	O
with	O
100	O
%	O
accuracy	O
[	O
31	O
]	O
,	O
but	O
our	O
experiment	O
differs	O
in	O
several	O
respects	O
.	O

We	O
compared	O
BRCA1	O
and	O
BRCA2	O
cases	O
to	O
familial	O
BRCAX	O
cases	O
as	O
an	O
appropriate	O
reference	O
group	O
for	O
familial	O
breast	O
cases	O
likely	O
to	O
be	O
identified	O
as	O
carriers	O
of	O
BRCA1	O
/	O
2	O
mutations	O
or	O
unclassified	O
variants	O
,	O
we	O
used	O
LCLs	O
instead	O
of	O
fibroblasts	O
,	O
we	O
selected	O
a	O
lower	O
IR	O
exposure	O
(	O
10Gy	O
vs	O
15Gy	O
)	O
,	O
and	O
we	O
chose	O
a	O
relatively	O
early	O
time	O
point	O
of	O
30	O
mins	O
after	O
exposure	O
to	O
IR	O
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
functional	O
differences	O
in	O
response	O
to	O
IR	O
between	O
the	O
BRCA1	O
,	O
BRCA2	O
and	O
BRCAX	O
cell	O
lines	O
.	O

Some	O
or	O
all	O
of	O
these	O
factors	O
may	O
explain	O
the	O
difference	O
in	O
the	O
ability	O
of	O
this	O
study	O
to	O
distinguish	O
BRCA1	O
from	O
BRCA2	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
DNA	O
damage	O
repair	O
.	O

However	O
,	O
differences	O
in	O
post	O
-	O
irradiation	O
response	O
between	O
BRCAX	O
individuals	O
and	O
BRCA1	O
/	O
2	O
mutation	O
carriers	O
are	O
supported	O
by	O
alternative	O
analysis	O
we	O
have	O
conducted	O
of	O
the	O
subset	O
of	O
genes	O
reported	O
to	O
be	O
involved	O
in	O
post	O
-	O
irradiation	O
response	O
,	O
comparing	O
mutation	O
-	O
negative	O
normal	B
female	O
controls	O
to	O
BRCAX	O
individuals	O
without	O
an	O
LCS	O
variant	O
,	O
or	O
to	O
BRCA1	O
or	O
BRCA2	O
truncating	O
mutation	O
carriers	O
.	O

Our	O
results	O
indicate	O
substantial	O
differences	O
in	O
radiation	O
response	O
between	O
normal	B
controls	O
and	O
the	O
patient	O
groups	O
,	O
and	O
also	O
considerable	O
differences	O
between	O
the	O
BRCAX	O
group	O
and	O
BRCA1	O
and	O
BRCA2	O
carriers	O
[	O
37	O
]	O
.	O

Alternative	O
IR	O
exposures	O
and/or	O
post	O
-	O
IR	O
timepoints	O
,	O
and	O
possibly	O
different	O
DNA	O
damaging	O
agents	O
,	O
should	O
be	O
considered	O
for	O
future	O
experiments	O
.	O

The	O
ultimate	O
aim	O
of	O
this	O
experiment	O
was	O
to	O
identify	O
array	O
profiles	O
that	O
would	O
be	O
useful	O
for	O
the	O
classification	O
of	O
unclassified	O
sequence	O
variants	O
of	O
BRCA1	O
or	O
BRCA2	O
.	O

In	O
the	O
clinical	O
setting	O
,	O
individuals	O
generally	O
present	O
with	O
full	O
sequencing	O
of	O
both	O
genes	O
,	O
and	O
presence	O
of	O
a	O
variant	O
in	O
one	O
gene	O
or	O
the	O
other	O
.	O

We	O
thus	O
assessed	O
the	O
ability	O
to	O
distinguish	O
BRCA1	O
or	O
BRCA2	O
,	O
separately	O
,	O
from	O
BRCAX	O
individuals	O
.	O

Importantly	O
,	O
since	O
most	O
unclassified	O
variants	O
are	O
predicted	O
to	O
cause	O
amino	O
acid	O
substitutions	O
,	O
we	O
also	O
assessed	O
the	O
relevance	O
of	O
mutation	O
effect	O
for	O
expression	O
profiles	O
.	O

We	O
found	O
that	O
the	O
genes	O
which	O
significantly	O
differed	O
between	O
BRCA1	O
or	O
BRCA2	O
and	O
BRCAX	O
LCLs	O
were	O
dependent	O
on	O
mutation	O
effect	O
.	O

Accordingly	O
,	O
the	O
SVM	O
prediction	O
for	O
each	O
mutation	O
effect	O
was	O
best	O
if	O
the	O
appropriate	O
gene	O
list	O
was	O
used	O
,	O
in	O
terms	O
of	O
both	O
accuracy	O
of	O
prediction	O
(	O
BRCA1	O
or	O
BRCA2	O
vs	O
BRCAX	O
)	O
and	O
confidence	O
in	O
the	O
classification	O
as	O
determined	O
by	O
the	O
distance	O
of	O
the	O
prediction	O
from	O
the	O
SVM	O
plane	O
.	O

Thus	O
we	O
strongly	O
urge	O
that	O
mutation	O
effect	O
is	O
taken	O
into	O
account	O
if	O
this	O
type	O
of	O
assay	O
is	O
to	O
be	O
developed	O
for	O
use	O
in	O
predicting	O
the	O
clinical	O
significance	O
of	O
BRCA1	O
/	O
2	O
variants	O
.	O

The	O
current	O
challenge	O
is	O
that	O
few	O
missense	O
variants	O
have	O
been	O
classified	O
with	O
respect	O
to	O
their	O
clinical	O
significance	O
,	O
with	O
the	O
only	O
23	O
individual	O
missense	O
variants	O
termed	O
clinically	O
important	O
by	O
BIC	O
,	O
17	O
in	O
BRCA1	O
and	O
six	O
in	O
BRCA2	O
.	O

Moreover	O
,	O
these	O
are	O
restricted	O
in	O
terms	O
of	O
the	O
domains	O
/	O
regions	O
in	O
which	O
they	O
occur	O
,	O
residing	O
in	O
the	O
BRCA1	O
start	O
site	O
(	O
n	O
=	O
2	O
)	O
,	O
ring	O
finger	O
(	O
n	O
=	O
4	O
)	O
or	O
transactivation	O
domains	O
(	O
n	O
=	O
11	O
)	O
,	O
and	O
the	O
BRCA2	O
CDK2	O
phosphorylation	O
site	O
(	O
n	O
=	O
3	O
)	O
or	O
at	O
one	O
codon	O
(	O
2336	O
,	O
n	O
=	O
3	O
)	O
in	O
a	O
region	O
of	O
unknown	O
function	O
.	O

It	O
will	O
thus	O
be	O
difficult	O
to	O
accrue	O
a	O
panel	O
of	O
known	O
pathogenic	O
missense	O
variants	O
for	O
use	O
in	O
such	O
predictive	O
assays	O
,	O
and	O
will	O
require	O
a	O
concerted	O
collaborative	O
effort	O
.	O

Assuming	O
sufficient	O
pathogenic	O
variants	O
are	O
identified	O
,	O
the	O
successful	O
execution	O
of	O
such	O
a	O
study	O
may	O
eventually	O
distinguish	O
missense	O
-	O
associated	O
gene	O
expression	O
patterns	O
that	O
are	O
generic	O
to	O
missense	O
mutations	O
,	O
and/or	O
those	O
that	O
are	O
specific	O
to	O
the	O
domain	O
location	O
of	O
missense	O
mutations	O
.	O

In	O
addition	O
,	O
a	O
possibly	O
greater	O
challenge	O
will	O
be	O
identifying	O
assay	O
conditions	O
(	O
cell	O
type	O
,	O
perturbation	O
,	O
time	O
-	O
point	O
etc	O
)	O
that	O
can	O
also	O
identify	O
gene	O
expression	O
differences	O
between	O
patients	O
with	O
rare	O
variants	O
of	O
low	O
clinical	O
significance	O
in	O
BRCA1	O
and/or	O
BRCA2	O
and	O
those	O
with	O
truly	O
high	O
-	O
risk	O
pathogenic	O
mutations	O
(	O
truncating	O
or	O
missense	O
)	O
in	O
these	O
genes	O
.	O

Our	O
study	O
,	O
using	O
conditions	O
that	O
were	O
not	O
optimal	O
for	O
separating	O
BRCA1	O
and	O
BRCA2	O
mutations	O
nevertheless	O
identified	O
gene	O
expression	O
differences	O
between	O
BRCA1	O
/	O
2	O
pathogenic	O
mutations	O
and	O
LCS	O
variants	O
,	O
suggesting	O
that	O
larger	O
sample	O
sizes	O
and	O
further	O
experimentation	O
may	O
identify	O
a	O
more	O
robust	O
gene	O
list	O
to	O
separate	O
pathogenic	O
mutations	O
,	O
variants	O
of	O
low	O
clinical	O
significance	O
,	O
and	O
individuals	O
with	O
no	O
sequence	O
alterations	O
in	O
BRCA1	O
/	O
2	O
.	O

27	O
LCLs	O
from	O
women	O
from	O
breast	B
cancer	I
families	O
that	O
have	O
tested	O
negative	O
for	O
pathogenic	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
(	O
BRCAX	O
)	O
after	O
complete	O
sequencing	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
gene	O
dosage	O
assay	O
(	O
MLPA	O
)	O
large	O
deletion	O
testing	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

Ten	O
samples	O
,	O
carried	O
either	O
BRCA1	O
or	O
BRCA2	O
sequence	O
germline	O
variants	O
considered	O
from	O
multifactorial	O
likelihood	O
classification	O
to	O
be	O
LCS	O
(	O
BRCA1	O
3582	O
G	O
>	O
C	O
D1155H	O
,	O
1605	O
C	O
>	O
T	O
R496C	O
,	O
5236	O
G	O
>	O
C	O
G1706A	O
(	O
2	O
samples	O
)	O
;	O
BRCA2	O
353	O
A	O
>	O
G	O
Y42C	O
,	O
2834	O
C	O
>	O
T	O
S869L	O
,	O
3031	O
G	O
>	O
A	O
D935N	O
(	O
3	O
samples	O
)	O
,	O
8795	O
A	O
>	O
C	O
E2856A	O
)	O
[	O
16	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
remaining	O
17	O
samples	O
carried	O
no	O
BRCA1	O
or	O
BRCA2	O
sequence	O
variants	O
other	O
than	O
common	O
polymorphisms	O
.	O

Gene	O
Expression	O
Profiling	O
LCLs	O
were	O
grown	O
in	O
RPMI	O
1640	O
media	O
with	O
15	O
%	O
fetal	O
bovine	O
serum	O
,	O
1	O
%	O
penicillin	O
-	O
streptomycin	O
and	O
1	O
%	O
L	O
-	O
glutamine	O
.	O

The	O
cell	O
number	O
was	O
normalised	O
and	O
fresh	O
medium	O
was	O
added	O
to	O
cells	O
24hr	O
prior	O
to	O
irradiation	O
with	O
10Gy	O
,	O
using	O
a	O
calibrated	O
Cs137	O
c	O
-	O
source	O
delivering	O
1	O
Gy	O
/	O
1.5	O
min	O
.	O

Total	O
RNA	O
was	O
harvested	O
30min	O
later	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Doncaster	O
,	O
VIC	O
)	O
.	O

The	O
Illumina	O
Totalprep	O
RNA	O
amplification	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
was	O
used	O
to	O
amplify	O
and	O
biotinylate	O
450ng	O
of	O
total	O
RNA	O
.	O

Biotinylated	O
RNA	O
was	O
hybridised	O
overnight	O
at	O
55	O
°	O
C	O
to	O
Illumina	O
Human-6	O
version	O
1	O
BeadChips	O
containing	O
>	O
46,000	O
probes	O
(	O
Illumina	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
microarrays	O
were	O
washed	O
,	O
stained	O
with	O
streptavidin	O
-	O
Cy3	O
,	O
and	O
then	O
scanned	O
with	O
an	O
Illumina	O
BeadArray	O
Scanner	O
.	O

Duplicate	O
arrays	O
were	O
performed	O
for	O
eight	O
cell	O
lines	O
across	O
the	O
different	O
groups	O
for	O
quality	O
control	O
purposes	O
,	O
with	O
duplicates	O
performed	O
on	O
different	O
days	O
.	O

All	O
duplicate	O
arrays	O
showed	O
highest	O
correlation	O
with	O
each	O
other	O
(	O
correlation	O
>	O
0.98	O
)	O
.	O

Duplicate	O
samples	O
were	O
not	O
included	O
in	O
analysis	O
.	O

Comparative	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
ten	O
genes	O
on	O
6–8	O
samples	O
,	O
using	O
GAPDH	O
to	O
normalise	O
all	O
data	O
,	O
and	O
the	O
comparative	O
cycle	O
threshold	O
method	O
for	O
analysis	O
.	O

Paired	O
student	O
t	O
tests	O
were	O
performed	O
to	O
determine	O
the	O
significance	O
of	O
gene	O
expression	O
changes	O
.	O

Expression	O
differences	O
were	O
validated	O
for	O
8	O
/	O
10	O
genes	O
tested	O
.	O

Data	O
Analysis	O
Raw	O
data	O
was	O
imported	O
into	O
Illumina	O
Beadstudio	O
and	O
then	O
exported	O
into	O
Genespring	O
v7.3	O
(	O
Agilent	O
Technologies	O
,	O
Forest	O
Hill	O
,	O
VIC	O
)	O
for	O
further	O
analysis	O
.	O

Data	O
was	O
normalised	O
(	O
per	O
chip	O
normalized	O
to	O
50th	O
percentile	O
and	O
per	O
gene	O
normalized	O
to	O
median	O
)	O
and	O
filtered	O
using	O
an	O
Illumina	O
detection	O
score	O
of	O
>	O
0.99	O
in	O
at	O
least	O
one	O
sample	O
,	O
which	O
yielded	O
20,874	O
probes	O
that	O
were	O
used	O
in	O
all	O
further	O
analyses	O
.	O

The	O
majority	O
of	O
these	O
probes	O
used	O
in	O
the	O
analysis	O
were	O
designed	O
by	O
Illumina	O
to	O
assay	O
the	O
curated	O
portion	O
of	O
the	O
NIH	O
Ref	O
sequence	O
database-16,923	O
were	O
present	O
in	O
the	O
Ref	O
sequence	O
database	O
,	O
comprising	O
65	O
%	O
of	O
all	O
Ref	O
sequence	O
-	O
listed	O
probes	O
on	O
the	O
array	O
.	O

Transcripts	O
which	O
had	O
a	O
>	O
2-fold	O
change	O
versus	O
the	O
mean	O
were	O
visualised	O
using	O
unsupervised	O
Hierarchical	O
Clustering	O
(	O
Figures	O
1	O
and	O
2	O
)	O
.	O

The	O
clustering	O
method	O
used	O
was	O
a	O
Pearson	O
correlation	O
similarity	O
measure	O
with	O
an	O
average	O
linkage	O
clustering	O
algorithm	O
.	O

Two	O
different	O
methods	O
were	O
used	O
to	O
classify	O
LCLs	O
based	O
on	O
mutation	O
status	O
:	O
(	O
1	O
)	O
A	O
multi	O
comparison	O
Gaussian	O
Process	O
Classifier	O
(	O
GPC	O
)	O
[	O
42	O
]	O
with	O
Leave	O
-	O
One	O
-	O
Out	O
cross	O
-	O
validation	O
to	O
determine	O
the	O
prediction	O
errors	O
,	O
as	O
previously	O
used	O
to	O
predict	O
BRCA1	O
/	O
BRCA2	O
mutation	O
status	O
of	O
irradiated	O
fibroblasts	O
[	O
31	O
]	O
;	O
(	O
2	O
)	O
A	O
linear	O
classification	O
method	O
commonly	O
used	O
for	O
classification	O
of	O
microarray	O
data	O
,	O
Support	O
Vector	O
Machines	O
(	O
SVM	O
)	O
[	O
43	O
]	O
with	O
Leave	O
-	O
One	O
-	O
Out	O
cross	O
validation	O
.	O

The	O
GPC	O
analysis	O
used	O
2031	O
genes	O
which	O
were	O
derived	O
from	O
a	O
t	O
-	O
test	O
to	O
select	O
the	O
genes	O
that	O
were	O
significantly	O
over	O
/	O
under	O
-	O
expressed	O
at	O
the	O
5	O
%	O
significance	O
,	O
while	O
the	O
SVM	O
used	O
genes	O
from	O
the	O
20,874	O
detected	O
probes	O
which	O
differed	O
between	O
groups	O
of	O
LCLs	O
using	O
a	O
t	O
-	O
test	O
p	O
of	O
0.05	O
.	O

All	O
resulting	O
gene	O
lists	O
are	O
available	O
as	O
supplementary	O
data	O
and	O
all	O
data	O
is	O
available	O
via	O
GEO	O
:	O
Accession	O
number	O
GSE10905	O
.	O

In	O
the	O
present	O
study	O
patients	O
included	O
in	O
the	O
Swedish	O
Polyposis	B
Registry	O
were	O
subjected	O
to	O
a	O
thorough	O
clinical	O
characterization	O
and	O
mutational	O
screening	O
of	O
the	O
APC	O
gene	O
including	O
screening	O
for	O
large	O
deletions	O
and	O
detection	O
of	O
low	O
-	O
frequency	O
alleles	O
caused	O
by	O
germline	O
mosaicism	O
.	O

Sixty	O
-	O
one	O
mutations	O
,	O
including	O
27	O
not	O
described	O
previously	O
,	O
are	O
reported	O
.	O

Among	O
the	O
characterized	O
mutations	O
are	O
elusive	O
changes	O
such	O
as	O
a	O
case	O
of	O
mosaicism	O
,	O
splicing	O
defects	O
,	O
and	O
a	O
mutation	O
in	O
APC	O
exon	O
1	O
which	O
is	O
the	O
most	O
5	O
'	O
APC	O
mutation	O
hitherto	O
reported	O
.	O

The	O
detection	O
of	O
reduced	O
APC	O
expression	O
in	O
one	O
family	O
is	O
also	O
described	O
.	O

A	O
combination	O
of	O
mutation	O
screening	O
techniques	O
was	O
used	O
to	O
achieve	O
as	O
high	O
a	O
mutation	O
-	O
detection	O
frequency	O
as	O
possible	O
.	O

Seven	O
of	O
the	O
identified	O
APC	O
mutations	O
were	O
large	O
deletions	O
,	O
ranging	O
from	O
a	O
deletion	O
of	O
86	O
bp	O
in	O
exon	O
15	O
to	O
a	O
deletion	O
of	O
the	O
whole	O
APC	O
gene	O
(	O
Figure	O
1C	O
)	O
.	O

Three	O
of	O
these	O
deletions	O
have	O
not	O
,	O
to	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
,	O
been	O
described	O
earlier	O
.	O

The	O
deletion	O
encompassing	O
APC	O
exon	O
4	O
in	O
patient	O
3765	O
,	O
c.423	O
-	O
1662_531	O
+	O
1825del3595	O
,	O
was	O
detected	O
by	O
RNA	O
-	O
based	O
PTT	O
with	O
subsequent	O
cDNA	O
sequencing	O
and	O
verified	O
by	O
long	O
-	O
range	O
PCR	O
on	O
genomic	O
DNA	O
.	O

We	O
could	O
not	O
detect	O
this	O
deletion	O
with	O
MLPA	O
even	O
though	O
a	O
probe	O
for	O
exon	O
4	O
is	O
included	O
in	O
the	O
MLPA	O
kit	O
(	O
see	O
the	O
discussion	O
)	O
.	O

Detection	O
of	O
the	O
large	O
deletion	O
in	O
patient	O
C591	O
,	O
encompassing	O
APC	O
exons	O
13	O
through	O
the	O
5	O
'	O
part	O
of	O
exon	O
15	O
,	O
was	O
carried	O
out	O
with	O
MLPA	O
.	O

The	O
deletion	O
in	O
patient	O
2136	O
was	O
identified	O
by	O
PTT	O
and	O
subsequent	O
DNA	O
sequencing	O
.	O

A	O
case	O
of	O
APC	O
mosaicism	O
Three	O
patients	O
(	O
C107	O
,	O
C257	O
,	O
and	O
C505	O
)	O
,	O
negative	O
for	O
mutations	O
in	O
APC	O
,	O
were	O
reported	O
as	O
de	O
novo	O
cases	O
with	O
no	O
known	O
family	O
history	O
of	O
FAP	B
.	O

These	O
patients	O
where	O
all	O
screened	O
for	O
APC	O
mutations	O
present	O
as	O
low	O
-	O
frequency	O
alleles	O
using	O
SSCP	O
/	O
HD	O
.	O

We	O
did	O
not	O
detect	O
any	O
signs	O
of	O
low	O
-	O
frequency	O
mutations	O
in	O
patients	O
C257	O
and	O
C505	O
.	O

However	O
,	O
in	O
patient	O
C107	O
,	O
aberrant	O
bands	O
,	O
possibly	O
originating	O
from	O
formation	O
of	O
heteroduplexes	O
,	O
was	O
detected	O
by	O
SSCP	O
/	O
HD	O
in	O
a	O
very	O
low	O
fraction	O
of	O
her	O
blood	O
lymphocytes	O
.	O

The	O
c.2700_2701delTC	O
mutation	O
,	O
which	O
results	O
in	O
frame	O
shift	O
at	O
codon	O
900	O
,	O
was	O
found	O
by	O
sequencing	O
of	O
the	O
aberrant	O
bands	O
excised	O
from	O
the	O
SSCP	O
/	O
HD	O
gel	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
mutation	O
was	O
detected	O
in	O
approximately	O
one	O
-	O
third	O
of	O
the	O
analyzed	O
tumor	B
-	O
derived	O
cells	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
by	O
DNA	O
sequencing	O
(	O
Figure	O
2B	O
)	O
.	O

The	O
mutation	O
was	O
not	O
detectable	O
at	O
all	O
in	O
the	O
sequence	O
determination	O
of	O
DNA	O
extracted	O
from	O
blood	O
lymphocytes	O
from	O
the	O
patient	O
(	O
Figure	O
2C	O
)	O
.	O

Detection	O
of	O
the	O
mosaic	O
c.2700_2701delTC	O
mutation	O
in	O
patient	O
C107	O
.	O

Nucleotide	O
2700	O
is	O
indicated	O
with	O
an	O
arrow	O
.	O

(	O
A	O
)	O
The	O
aberrant	O
bands	O
indicated	O
by	O
the	O
bracket	O
were	O
excised	O
from	O
the	O
SSCP	O
/	O
HD	O
gel	O
.	O

The	O
resulting	O
DNA	O
sequence	O
is	O
shown	O
to	O
the	O
right	O
.	O

(	O
B	O
)	O
DNA	O
sequence	O
from	O
DNA	O
extracted	O
from	O
tumor	B
-	O
derived	O
cells	O
from	O
the	O
patient	O
.	O

(	O
C	O
)	O
The	O
DNA	O
sequence	O
from	O
DNA	O
isolated	O
from	O
the	O
patient	O
's	O
blood	O
lymphocytes	O
.	O

Mutation	O
at	O
the	O
far	O
5'end	O
DNA	O
sequencing	O
of	O
APC	O
exon	O
1	O
in	O
patient	O
C157	O
revealed	O
the	O
c.70C	O
>	O
T	O
substitution	O
which	O
introduces	O
a	O
nonsense	O
mutation	O
in	O
codon	O
24	O
(	O
Figure	O
1	O
)	O
.	O

The	O
mutation	O
was	O
also	O
detectable	O
by	O
SSCP	O
/	O
HD	O
analysis	O
but	O
was	O
not	O
detectable	O
by	O
PTT	O
due	O
to	O
its	O
localization	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
PTT	O
fragment	O
.	O

However	O
,	O
indication	O
for	O
a	O
mutation	O
was	O
observed	O
as	O
lowered	O
intensity	O
of	O
the	O
full	O
-	O
length	O
fragment	O
.	O

Pedigree	O
presenting	O
a	O
part	O
of	O
family	O
1	O
of	O
the	O
Swedish	O
Polyposis	B
Registry	O
.	O

Family	O
members	O
where	O
positive	O
linkage	O
to	O
APC	O
has	O
been	O
confirmed	O
are	O
indicated	O
with	O
asterisks	O
.	O

A	O
case	O
of	O
APC	O
mosaicism	O
Screening	O
for	O
mosaic	O
mutations	O
in	O
the	O
three	O
APC-	B
and	I
MUTYH	I
-	I
negative	I
patients	O
with	O
de	O
novo	O
mutations	O
revealed	O
the	O
c.2700_2701delTC	O
mutation	O
in	O
patient	O
C107	O
.	O

This	O
mutation	O
was	O
detected	O
in	O
a	O
very	O
low	O
fraction	O
of	O
the	O
lymphocytes	O
and	O
was	O
only	O
detectable	O
using	O
the	O
SSCP	O
/	O
HD	O
analysis	O
(	O
Figure	O
2A	O
)	O
.	O

Owing	O
to	O
the	O
subtle	O
appearance	O
of	O
this	O
mutation	O
it	O
could	O
easily	O
have	O
been	O
overlooked	O
.	O

The	O
phenotype	O
of	O
patient	O
C107	O
does	O
not	O
fit	O
the	O
generally	O
accepted	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
AFAP	B
,	O
in	O
which	O
the	O
disease	B
-	O
causing	O
mutations	O
are	O
situated	O
either	O
in	O
the	O
5	O
'	O
or	O
3	O
'	O
regions	O
or	O
the	O
alternatively	O
spliced	O
part	O
of	O
exon	O
9	O
(	O
see	O
the	O
introduction	O
)	O
.	O

A	O
speculative	O
reason	O
for	O
the	O
attenuated	O
phenotype	O
could	O
be	O
that	O
the	O
patient	O
is	O
mosaic	O
in	O
the	O
epithelial	O
cells	O
of	O
the	O
colon	O
.	O

The	O
parents	O
of	O
patient	O
C107	O
of	O
age	O
73	O
and	O
80	O
years	O
as	O
well	O
as	O
her	O
three	O
children	O
,	O
age	O
31–40	O
years	O
,	O
were	O
free	O
of	O
polyps	B
.	O

No	O
CRC	B
has	O
been	O
diagnosed	O
on	O
either	O
the	O
maternal	O
or	O
paternal	O
side	O
of	O
the	O
family	O
.	O

The	O
mutation	O
was	O
not	O
detected	O
in	O
blood	O
samples	O
from	O
the	O
patient	O
's	O
parents	O
or	O
from	O
her	O
three	O
children	O
.	O

It	O
is	O
possible	O
that	O
either	O
gonadal	O
or	O
somatic	O
mosaicism	O
exists	O
in	O
patient	O
C107	O
.	O

APC	O
mutational	O
mosaicism	O
could	O
be	O
a	O
reason	O
for	O
the	O
quite	O
large	O
number	O
of	O
de	O
novo	O
or	O
sporadic	O
FAP	B
cases	O
that	O
exist	O
[	O
23	O
-	O
25,40	O
]	O
.	O

In	O
the	O
family	O
of	O
C107	O
the	O
mutation	O
has	O
not	O
been	O
passed	O
on	O
to	O
the	O
offspring	O
of	O
the	O
patient	O
and	O
,	O
thus	O
,	O
this	O
appears	O
to	O
be	O
a	O
sporadic	O
case	O
,	O
but	O
,	O
generally	O
,	O
the	O
existence	O
of	O
mosaicism	O
is	O
a	O
risk	O
of	O
error	O
in	O
predictive	O
diagnosis	O
in	O
FAP	B
/	O
AFAP	B
families	O
[	O
43	O
]	O
.	O

In	O
the	O
initial	O
stages	O
,	O
the	O
molecular	O
screening	O
procedure	O
of	O
FAP	B
/	O
AFAP	B
patients	O
uses	O
mainly	O
PCR	O
-	O
based	O
methods	O
for	O
analysis	O
of	O
the	O
APC	O
gene	O
in	O
DNA	O
from	O
isolated	O
blood	O
samples	O
.	O

Therefore	O
,	O
the	O
chances	O
of	O
detecting	O
pathogenic	O
low	O
-	O
frequency	O
APC	O
mutations	O
that	O
are	O
present	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
peripheral	O
blood	O
cells	O
or	O
only	O
in	O
the	O
colon	O
are	O
poor	O
.	O

Approximately	O
25	O
%	O
of	O
neurofibromatosis	B
type	I
2	I
(	O
NF2	B
)	O
patients	O
have	O
been	O
shown	O
to	O
be	O
cases	O
of	O
mosaicism	O
[	O
44	O
]	O
.	O

When	O
investigating	O
NF2	B
mutational	O
mosaicism	O
,	O
the	O
search	O
for	O
constitutional	O
mutations	O
is	O
preferably	O
carried	O
out	O
initially	O
in	O
tumor	B
cells	O
.	O

Detected	O
mutations	O
could	O
subsequently	O
be	O
verified	O
in	O
blood	O
leukocyte	O
samples	O
.	O

However	O
,	O
this	O
approach	O
would	O
not	O
be	O
applicable	O
for	O
FAP	B
mosaisicm	O
as	O
somatic	O
APC	O
mutations	O
are	O
frequently	O
found	O
in	O
tumors	B
.	O

Splice	O
-	O
site	O
affecting	O
mutations	O
Two	O
novel	O
germline	O
APC	O
mutations	O
that	O
introduce	O
different	O
cryptic	O
splice	O
sites	O
are	O
characterized	O
in	O
this	O
study	O
.	O

Both	O
mutations	O
result	O
in	O
the	O
aberrant	O
splicing	O
of	O
APC	O
exons	O
7	O
and	O
8	O
and	O
prematurely	O
truncated	O
APC	O
protein	O
,	O
and	O
both	O
are	O
defined	O
as	O
pathogenic	O
.	O

The	O
aberrant	O
splicing	O
identified	O
in	O
patient	O
C496	O
(	O
c.835	O
-	O
7	O
T	O
>	O
G	O
)	O
is	O
caused	O
by	O
an	O
introduction	O
of	O
a	O
new	O
active	O
splice	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
wildtype	O
AG	O
splice	O
site	O
of	O
intron	O
7	O
.	O

This	O
acceptor	O
site	O
is	O
apparently	O
preferred	O
by	O
the	O
splicing	O
machinery	O
,	O
as	O
shown	O
by	O
the	O
results	O
of	O
the	O
cDNA	O
sequencing	O
(	O
Figure	O
3	O
)	O
.	O

The	O
c.834	O
G	O
>	O
C	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
7	O
in	O
patient	O
C633	O
,	O
would	O
theoretically	O
introduce	O
a	O
missense	O
mutation	O
at	O
codon	O
278	O
.	O

However	O
,	O
as	O
demonstrated	O
by	O
the	O
cDNA	O
sequencing	O
results	O
(	O
Figure	O
4	O
)	O
the	O
mutation	O
leads	O
to	O
the	O
use	O
of	O
a	O
cryptic	O
splice	O
donor	O
site	O
11	O
bp	O
upstream	O
in	O
exon	O
7	O
.	O

This	O
real	O
outcome	O
of	O
the	O
mutation	O
would	O
easily	O
have	O
been	O
overlooked	O
unless	O
the	O
RNA	O
-	O
based	O
methods	O
had	O
been	O
used	O
.	O

Other	O
examples	O
of	O
aberrant	O
splicing	O
of	O
the	O
APC	O
gene	O
due	O
to	O
missense	O
mutations	O
have	O
recently	O
been	O
described	O
[	O
16	O
]	O
.	O

One	O
case	O
of	O
use	O
of	O
aberrant	O
splice	O
-	O
acceptor	O
site	O
of	O
APC	O
exon	O
8	O
has	O
been	O
reported	O
previously	O
in	O
a	O
patient	O
with	O
classical	O
polyposis	B
[	O
15	O
]	O
.	O

However	O
,	O
an	O
alternative	O
acceptor	O
splice	O
site	O
(	O
c.845	O
-	O
17A	O
>	O
G	O
)	O
in	O
intron	O
7	O
has	O
been	O
reported	O
from	O
a	O
patient	O
with	O
a	O
milder	O
phenotype	O
,	O
multiple	O
synchronous	O
colorectal	O
adenomas	B
[	O
45	O
]	O
.	O

Owing	O
to	O
the	O
fact	O
that	O
RNA	O
-	O
based	O
PTT	O
was	O
used	O
at	O
the	O
initial	O
stage	O
of	O
the	O
mutational	O
screening	O
,	O
detection	O
of	O
the	O
disease	B
-	O
causing	O
splice	O
-	O
site	O
mutations	O
was	O
straightforward	O
.	O

Sequencing	O
of	O
genomic	O
DNA	O
was	O
then	O
used	O
to	O
pinpoint	O
the	O
genetic	O
alteration	O
causing	O
the	O
aberrant	O
mRNA	O
sequence	O
that	O
was	O
visualized	O
in	O
the	O
PTT	O
experiments	O
.	O

The	O
use	O
of	O
both	O
DNA-	O
and	O
mRNA	O
-	O
based	O
methods	O
is	O
a	O
prerequisite	O
for	O
high	O
-	O
quality	O
investigation	O
of	O
splice	O
-	O
site	O
mutations	O
.	O

A	O
case	O
of	O
reduced	O
APC	O
expression	O
The	O
study	O
of	O
mRNA	O
levels	O
was	O
the	O
next	O
step	O
in	O
the	O
line	O
of	O
investigation	O
of	O
the	O
cause	O
of	O
disease	B
in	O
patients	O
with	O
no	O
detected	O
APC	O
mutation	O
.	O

Family	O
1	O
is	O
the	O
largest	O
kindred	O
in	O
the	O
Swedish	O
Polyposis	B
Registry	O
;	O
this	O
family	O
includes	O
150	O
individuals	O
of	O
whom	O
57	O
are	O
affected	B
by	O
the	O
disease	B
(	O
Figure	O
6	O
shows	O
part	O
of	O
the	O
pedigree	O
)	O
.	O

However	O
,	O
no	O
pathogenic	O
mutation	O
had	O
been	O
detected	O
after	O
screening	O
the	O
whole	O
coding	O
region	O
of	O
the	O
APC	O
gene	O
but	O
as	O
the	O
family	O
did	O
show	O
positive	O
linkage	O
to	O
the	O
APC	O
locus	O
we	O
decided	O
to	O
perform	O
expression	O
analyses	O
and	O
evidence	O
of	O
lowered	O
APC	O
expression	O
was	O
obtained	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
result	O
was	O
supported	O
by	O
the	O
indication	O
of	O
a	O
lower	O
expression	O
from	O
the	O
T	O
-	O
allele	O
from	O
analysis	O
of	O
the	O
APC	O
c.5465A	O
>	O
T	O
polymorphism	O
in	O
the	O
cDNA	O
sequencing	O
diagram	O
of	O
two	O
affected	B
family	O
members	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
search	O
for	O
mutations	O
in	O
the	O
DNA	O
sequence	O
of	O
the	O
APC	O
promoters	O
has	O
been	O
initiated	O
,	O
but	O
no	O
pathogenic	O
change	O
has	O
been	O
detected	O
to	O
this	O
date	O
.	O

The	O
possibility	O
of	O
the	O
pathogenic	O
change	O
being	O
epigenetic	O
will	O
have	O
to	O
be	O
investigated	O
further	O
.	O

Hypermethylation	O
of	O
CpG	O
sites	O
in	O
the	O
promoter	O
of	O
APC	O
has	O
been	O
reported	O
as	O
a	O
means	O
of	O
gene	O
silencing	O
in	O
colorectal	O
tumors	B
[	O
46	O
-	O
49	O
]	O
.	O

To	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
no	O
germ	O
-	O
line	O
inactivation	O
of	O
APC	O
caused	O
by	O
promoter	O
hypermethylation	O
has	O
been	O
reported	O
.	O

However	O
,	O
cases	O
of	O
pathogenic	O
germline	O
epimutations	O
have	O
been	O
identified	O
in	O
the	O
MLH1	O
gene	O
,	O
which	O
causes	O
hereditary	B
non	I
-	I
polyposis	I
CRC	B
[	O
50,51	O
]	O
.	O

Mutation	O
-	O
detection	O
frequency	O
The	O
61	O
different	O
APC	O
mutations	O
listed	O
in	O
Additional	O
file	O
2	O
were	O
identified	O
among	O
81	O
of	O
the	O
96	O
families	O
of	O
the	O
Swedish	O
Polyposis	B
Registry	O
that	O
were	O
screened	O
for	O
APC	O
mutations	O
.	O

Fifteen	O
of	O
the	O
cases	O
shown	O
to	O
be	O
APC	B
-	I
mutation	I
negative	I
where	O
all	O
subjected	O
to	O
mutational	O
screening	O
of	O
the	O
MUTYH	O
gene	O
and	O
six	O
of	O
them	O
were	O
shown	O
to	O
carry	O
biallelic	O
MUTYH	O
mutations	O
(	O
reported	O
in	O
Kanter	O
Smoler	O
et	O
al	O
[	O
31	O
]	O
)	O
.	O

The	O
overall	O
mutation	O
-	O
detection	O
rate	O
in	O
APC	O
and	O
MUTYH	O
among	O
the	O
families	O
in	O
our	O
study	O
was	O
thus	O
90	O
%	O
.	O

In	O
total	O
,	O
84	O
%	O
of	O
the	O
families	O
carried	O
APC	O
mutations	O
while	O
6	O
%	O
where	O
positive	O
for	O
biallelic	O
MUTYH	O
mutations	O
.	O

The	O
mutation	O
-	O
detection	O
rate	O
we	O
have	O
reached	O
in	O
this	O
study	O
is	O
notably	O
high	O
.	O

In	O
fact	O
,	O
a	O
disease	B
-	O
causing	O
mutation	O
was	O
detected	O
in	O
all	O
cases	O
who	O
presented	O
with	O
a	O
classical	O
FAP	B
phenotype	O
(	O
except	O
for	O
family	O
1	O
(	O
C152	O
)	O
,	O
where	O
we	O
have	O
clear	O
indications	O
for	O
inactivation	O
of	O
the	O
APC	O
transcription	O
)	O
.	O

The	O
mutation	O
-	O
negative	O
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	B
.	O

However	O
,	O
as	O
we	O
have	O
also	O
found	O
subtle	O
mutations	O
in	O
the	O
APC	O
gene	O
in	O
patients	O
with	O
attenuated	O
FAP	B
,	O
we	O
have	O
to	O
consider	O
inactivation	O
of	O
APC	O
to	O
be	O
responsible	O
for	O
some	O
of	O
these	O
FAP	B
cases	O
.	O

In	O
comparison	O
to	O
MLH1	O
and	O
MSH2	O
,	O
the	O
phenotype	O
of	O
MSH6	O
is	O
characterised	O
by	O
a	O
later	O
age	O
of	O
onset	O
of	O
CRC	B
,	O
incomplete	O
penetrance	O
,	O
and	O
a	O
higher	O
risk	O
and	O
later	O
age	O
of	O
onset	O
of	O
EC	B
in	O
female	O
MSH6	O
carriers15,21	O
.	O

MSH6	O
mutation	O
carriers	O
may	O
be	O
missed	O
amongst	O
analysis	O
of	O
HNPCC	B
families	O
if	O
the	O
Amsterdam	O
criteria	O
are	O
used	O
as	O
selection	O
criteria22	O
It	O
is	O
likely	O
that	O
MSH6	O
mutations	O
may	O
occur	O
at	O
a	O
higher	O
prevalence	O
in	O
a	O
cohort	O
of	O
EC	B
patients	O
in	O
comparison	O
to	O
HNPCC	B
cohorts	O
that	O
have	O
been	O
selected	O
by	O
the	O
Amsterdam	O
criteria	O
which	O
are	O
characteristic	O
of	O
HNPCC	B
families	O
with	O
a	O
mutation	O
in	O
MLH1	O
or	O
MSH2	O
.	O

A	O
few	O
studies	O
have	O
looked	O
at	O
the	O
prevalence	O
of	O
MSH6	O
mutations	O
in	O
EC	B
patients	O
with	O
estimates	O
between	O
1.7	O
%	O
of	O
patients	O
with	O
EC	B
less	O
than	O
50	O
years23	O
,	O
and	O
4.7	O
%	O
identified	O
in	O
EC	B
patients	O
un	O
-	O
selected	O
for	O
age	O
or	O
family	O
history24	O
.	O

In	O
this	O
study	O
we	O
sought	O
to	O
determine	O
the	O
prevalence	O
of	O
MSH6	O
mutations	O
in	O
our	O
Northern	O
Ireland	O
HNPCC	B
cohort	O
with	O
less	O
restrictive	O
inclusion	O
criteria	O
than	O
the	O
Amsterdam	O
II	O
criteria	O
,	O
in	O
an	O
attempt	O
to	O
include	O
as	O
many	O
MSH6	O
phenotype	O
families	O
as	O
possible	O
given	O
the	O
probable	O
later	O
onset	O
of	O
colon	B
cancers	I
;	O
and	O
also	O
determine	O
the	O
prevalence	O
of	O
mutations	O
in	O
an	O
unselected	O
cohort	O
of	O
EC	B
patients	O
.	O

All	O
DNA	O
was	O
or	O
had	O
been	O
extracted	O
by	O
the	O
Nucleic	O
Acid	O
Extraction	O
Centre	O
(	O
NAEC	O
)	O
,	O
Belfast	O
City	O
Hospital	O
,	O
and	O
stored	O
at	O
−80	O
°	O
C	O
.	O

Working	O
dilutions	O
in	O
X1	O
TE	O
were	O
made	O
at	O
5ng	O
/	O
μl	O
.	O

All	O
ten	O
exons	O
and	O
at	O
least	O
20	O
base	O
pair	O
(	O
bp	O
)	O
of	O
flanking	O
intronic	O
sequence	O
was	O
subject	O
to	O
direct	O
sequencing	O
analysis	O
.	O

PCR	O
products	O
for	O
nine	O
of	O
ten	O
exons	O
of	O
MSH6	O
were	O
obtained	O
using	O
Applied	O
Biosystems	O
VariantSEQr	O
™	O
Requencing	O
System	O
(	O
product	O
number	O
:	O
RSS000012234_02	O
)	O
.	O

All	O
reactions	O
were	O
carried	O
out	O
using	O
standard	O
reaction	O
mix	O
and	O
conditions	O
as	O
determined	O
by	O
ABI	O
.	O

Exon	O
1	O
primers	O
were	O
as	O
follows	O
:	O
1F	O
PCR	O
;	O
TCCGTCCGACAGAACGGTTG	O
,	O
1R	O
PCR	O
;	O
ATGCTCCAGACTCGACCCG	O
,	O
using	O
a	O
standard	O
25μl	O
reaction	O
mix	O
with	O
3.4μl	O
of	O
25	O
mm	O
MgCl2	O
and	O
0.4μl	O
of	O
5U	O
/	O
μl	O
Expand	O
DNA	O
polymerase	O
(	O
ABI	O
)	O
at	O
an	O
annealing	O
temperature	O
of	O
60	O
°	O
C	O
.	O

All	O
PCR	O
products	O
were	O
subject	O
to	O
clean	O
up	O
using	O
ExoSAPIT	O
®	O
�	O
to	O
remove	O
excess	O
primer	O
dimer	O
,	O
unincorporated	O
dNTPs	O
,	O
and	O
non	O
-	O
specific	O
DNA	O
products	O
.	O

Sequencing	O
reactions	O
were	O
carried	O
out	O
using	O
BigDye	O
®	O
terminator	O
Ready	O
Reaction	O
Mix	O
v1.1	O
from	O
ABI	O
®	O
,	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O

Additional	O
primers	O
were	O
required	O
to	O
sequence	O
exons	O
7	O
and	O
8	O
because	O
of	O
a	O
poly	O
T	O
at	O
the	O
5′	O
end	O
of	O
exon	O
7	O
,	O
which	O
resulted	O
in	O
slippage	O
during	O
the	O
sequencing	O
reaction	O
,	O
and	O
polymorphisms	O
situated	O
at	O
the	O
3′	O
,	O
(	O
c.3646	O
+	O
35_38delATCT	O
)	O
of	O
exon	O
7	O
,	O
and	O
5′	O
,	O
(	O
c.3647	O
−51_−35	O
del	O
17	O
)	O
,	O
and	O
3′	O
(	O
c.3802–42insT	O
)	O
end	O
of	O
exon	O
8	O
,	O
which	O
made	O
sequence	O
of	O
the	O
exons	O
unreadable	O
when	O
the	O
polymorphisms	O
were	O
present	O
in	O
the	O
heterozygous	O
state	O
.	O

Additional	O
sequencing	O
primers	O
for	O
exon	O
7	O
(	O
7F	O
Seq	O
;	O
TTGTGATTTTTTTTTTTTTAAG	O
,	O
7R	O
Seq	O
;	O
TAGTCTTCAAATGAGAAG	O
)	O
and	O
8	O
(	O
8F	O
Seq	O
;	O
GAGTTACTTCCTTATGCA	O
,	O
8R	O
Seq	O
;	O
GAAGTGCCCTCTCAAAAAACC	O
)	O
were	O
designed	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
by	O
the	O
Queen	O
's	O
University	O
Belfast	O
genomic	O
core	O
facility	O
on	O
an	O
ABI	O
3730	O
DNA	O
analyser	O
.	O

MLPA	O
Analysis	O
All	O
samples	O
were	O
subject	O
to	O
MLPA	O
analysis	O
using	O
SALSA	O
MLPA	O
KIT	O
POO8	O
MSH6	O
/	O
PMS2	O
from	O
MRC	O
-	O
Holland	O
.	O

Reaction	O
mix	O
and	O
conditions	O
are	O
as	O
determined	O
by	O
MRC	O
-	O
Holland	O
.	O

Electrophoresis	O
was	O
carried	O
on	O
an	O
ABI	O
3100	O
Avant	O
DNA	O
analyzer	O
using	O
a	O
GeneScan	O
™	O
-	O
500	O
ROX	O
™	O
size	O
standard	O
.	O

From	O
the	O
raw	O
data	O
generated	O
,	O
peak	O
heights	O
of	O
each	O
amplification	O
product	O
were	O
exported	O
to	O
Excel	O
worksheets	O
designed	O
by	O
Dr	O
Andrew	O
Wallace	O
,	O
National	O
Genetics	O
Reference	O
Laboratory	O
,	O
Manchester	O
,	O
so	O
that	O
the	O
result	O
of	O
each	O
sample	O
could	O
be	O
'	O
normalised	O
'	O
.	O

Statistical	O
Methods	O

The	O
cohort	O
sizes	O
necessary	O
to	O
obtain	O
estimates	O
with	O
adequate	O
precision	O
were	O
initially	O
calculated	O
using	O
a	O
Normal	O
approximation	O
to	O
the	O
binomial	O
sampling	O
distribution	O
provided	O
by	O
the	O
StatCalc	O
program	O
in	O
the	O
EpiInfo	O
package	O
(	O
)	O
.	O

The	O
Stata	O
package	O
(	O
)	O
was	O
used	O
to	O
give	O
the	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
(	O
Table	O
I	O
)	O
.	O

CONCLUSION	O
From	O
this	O
study	O
we	O
have	O
identified	O
the	O
minimum	O
prevalence	O
of	O
pathogenic	O
mutations	O
in	O
MSH6	O
to	O
be	O
higher	O
in	O
an	O
unselected	O
cohort	O
of	O
EC	B
patients	O
,	O
than	O
a	O
cohort	O
of	O
HNPCC	B
patients	O
who	O
have	O
been	O
selected	O
by	O
criteria	O
'	O
widened	O
'	O
from	O
the	O
traditional	O
Amsterdam	O
II	O
criteria	O
,	O
in	O
keeping	O
with	O
the	O
described	O
phenotype	O
of	O
MSH6	O
.	O

Unlike	O
the	O
other	O
more	O
common	O
MMR	O
genes	O
,	O
genomic	O
rearrangements	O
do	O
not	O
contribute	O
to	O
a	O
large	O
proportion	O
of	O
mutations	O
in	O
MSH6	O
.	O

HNPCC	B
families	O
may	O
not	O
be	O
identified	O
if	O
patients	O
present	O
with	O
HNPCC	B
associated	B
cancers	I
,	O
such	O
as	O
gynaecological	B
cancer	I
,	O
rather	O
than	O
the	O
more	O
commonly	O
recognised	O
phenotype	O
of	O
CRC	B
.	O

Clinicians	O
should	O
be	O
vigilant	O
to	O
this	O
possibility	O
when	O
presented	O
with	O
a	O
history	O
of	O
endometrial	B
cancer	I
in	O
young	O
women	O
.	O

Further	O
work	O
on	O
immunohistochemistry	O
of	O
possible	O
missense	O
variants	O
may	O
increase	O
the	O
true	O
frequency	O
of	O
mutations	O
in	O
MSH6	O
.	O

To	O
understand	O
more	O
precisely	O
the	O
mechanistic	O
roles	O
that	O
Mlh3	O
and	O
Pms2	O
play	O
in	O
GI	O
tumor	B
suppression	O
,	O
we	O
generated	O
Mlh3−	O
/	O
−;Apc1638N	O
(	O
MA	O
)	O
and	O
Mlh3−	O
/	O
−;Pms2−	O
/	O
−;Apc1638N	O
(	O
MPA	O
)	O
mice	O
.	O

We	O
show	O
that	O
in	O
vivo	O
Mlh3	O
mutations	O
significantly	O
increase	O
frameshift	O
mutation	O
rates	O
in	O
Apc	O
,	O
and	O
increase	O
GI	O
tumorigenesis	B
.	O

Unlike	O
typical	O
MSI	O
-	O
induced	O
mutations	O
,	O
Mlh3	O
deficiency	O
also	O
results	O
in	O
frameshift	O
mutations	O
in	O
non	O
-	O
repetitive	O
sequences	O
,	O
a	O
unique	O
mutational	O
signature	O
among	O
MMR	O
deficient	O
mice	O
found	O
only	O
in	O
Mlh3	B
deficient	I
mice	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
Pms2	O
in	O
SBR	O
,	O
combined	O
Mlh3	O
and	O
Pms2	O
mutations	O
proportionally	O
increase	O
point	O
mutations	O
and	O
show	O
a	O
sequence	O
preference	O
for	O
a	O
CpG	O
mutation	O
hotspot	O
also	O
previously	O
seen	O
in	O
Mlh1−	O
/	O
−	O
mice	O
.	O

Because	O
MPA	O
mutant	O
mice	O
also	O
have	O
significantly	O
increased	O
rates	O
of	O
GI	O
adenocarcinomas	B
vs.	O
Apc1638N	O
or	O
MA	O
mice	O
,	O
we	O
investigated	O
mechanisms	O
of	O
tumor	B
progression	O
.	O

Using	O
array	O
-	O
CGH	O
,	O
we	O
identified	O
a	O
recurrent	O
5-Mb	O
amplification	O
on	O
chromosome	O
12	O
in	O
GI	O
tumors	B
from	O
MPA	O
mice	O
.	O

We	O
defined	O
the	O
amplicon	O
critical	O
interval	O
and	O
demonstrated	O
that	O
it	O
contains	O
a	O
previously	O
uncharacterized	O
member	O
of	O
the	O
Transducin	O
enhancer	O
of	O
Split	O
(	O
TLE	O
)	O
/	O
Groucho	O
family	O
of	O
transcriptional	O
co	O
-	O
regulators	O
,	O
Tle6-like	O
,	O
that	O
contributes	O
to	O
tumor	B
progression	O
.	O

Tle6-like	O
overexpression	O
in	O
colon	B
cancer	I
cell	O
lines	O
increases	O
cell	O
proliferation	O
,	O
colony	O
-	O
formation	O
ability	O
,	O
cell	O
migration	O
and	O
xenograft	B
tumorigenicity	I
.	O

Human	O
TLE6D	O
,	O
an	O
alternatively	O
spliced	O
isoform	O
of	O
TLE6	O
,	O
with	O
a	O
domain	O
structure	O
similar	O
to	O
Tle6-like	O
,	O
has	O
functional	O
activity	O
similar	O
to	O
Tle6-like	O
.	O

Both	O
Tle6-like	O
and	O
TLE6D	O
interact	O
with	O
GI	O
tumor	B
suppressor	O
,	O
RUNX3	O
[	O
34	O
]	O
,	O
and	O
antagonize	O
RUNX3	O
gene	O
target	O
tranactivation	O
.	O

TLE6D	O
is	O
overexpressed	O
in	O
multiple	O
human	O
microsatellite	B
stable	I
(	O
MSS	O
)	O
and	O
microsatellite	B
unstable	I
(	O
MSI	O
-	O
H	O
)	O
CRCs	B
,	O
and	O
TLE6D	O
expression	O
levels	O
correlate	O
with	O
RUNX3	O
expression	O
levels	O
.	O

Collectively	O
,	O
these	O
findings	O
provide	O
important	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
through	O
which	O
MMR	B
-	I
deficiency	I
contributes	O
to	O
GI	O
tumorigenesis	B
and	O
implicate	O
a	O
novel	O
association	O
between	O
TLE6	O
isoforms	O
and	O
antagonism	O
of	O
RUNX	O
target	O
gene	O
expression	O
in	O
CRC	B
tumor	B
progression	O
.	O

RUNX	O
family	O
genes	O
regulate	O
lineage	O
and	O
stage	O
specific	O
gene	O
transcription	O
by	O
direct	O
binding	O
to	O
DNA	O
promoters	O
and	O
enhancer	O
elements	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Loss	O
of	O
Runx3	O
in	O
the	O
mouse	O
results	O
in	O
the	O
development	O
of	O
gastric	O
mucosal	O
hyperplasia	B
,	O
decreased	O
apoptosis	O
and	O
attenuated	O
TGF	O
-	O
β	O
anti	O
-	O
proliferative	O
signaling	O
.	O

Consistent	O
with	O
previous	O
observations	O
of	O
interactions	O
between	O
RUNX3	O
and	O
TLE	O
family	O
members	O
mediated	O
through	O
the	O
Runt	O
and	O
WD	O
repeat	O
domains	O
,	O
respectively	O
[	O
46	O
]	O
,	O
[	O
48	O
]	O
,	O
we	O
detected	O
an	O
interaction	O
between	O
RUNX3	O
and	O
Tle6-like	O
/	O
TLE6D	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
Tle6-like	O
/	O
TLE6D	O
antagonized	O
RUNX3	O
regulated	O
transcriptional	O
targets	O
.	O

However	O
,	O
while	O
these	O
experiments	O
show	O
an	O
association	O
between	O
RUNX3∶TLE6D	O
interactions	O
and	O
tumor	B
progression	O
,	O
they	O
do	O
not	O
demonstrate	O
mechanistically	O
the	O
functional	O
importance	O
of	O
this	O
interaction	O
in	O
accelerating	O
tumor	B
progression	O
.	O

Alternative	O
mRNA	O
splicing	O
allows	O
multiple	O
gene	O
products	O
to	O
be	O
produced	O
from	O
a	O
single	O
coding	O
sequence	O
,	O
and	O
through	O
this	O
mechanism	O
a	O
higher	O
diversity	O
of	O
mammalian	O
genes	O
is	O
generated	O
[	O
68	O
]	O
.	O

Several	O
distinct	O
TLE	O
/	O
Grg	O
gene	O
alternative	O
splice	O
forms	O
,	O
such	O
as	O
Grg-1s	O
,	O
QD	O
of	O
TLE4	O
,	O
and	O
Grg3b	O
[	O
42	O
]	O
,	O
[	O
69	O
]	O
,	O
[	O
70	O
]	O
,	O
have	O
been	O
reported	O
.	O

While	O
the	O
human	O
genome	O
does	O
not	O
encode	O
a	O
TLE6-LIKE	O
ortholog	O
,	O
a	O
structurally	O
equivalent	O
protein	O
,	O
TLE6D	O
,	O
is	O
generated	O
through	O
alternative	O
splicing	O
.	O

The	O
observation	O
that	O
GI	O
adenocarcinomas	B
from	O
both	O
humans	O
and	O
mice	O
use	O
two	O
very	O
distinct	O
mechanisms	O
to	O
amplify	O
Tle6-like	O
/	O
TLE6D	O
activity	O
suggests	O
a	O
strong	O
growth	O
advantage	O
and	O
selective	O
pressure	O
for	O
this	O
TLE	O
isoform	O
in	O
tumor	B
progression	O
.	O

Similarly	O
,	O
the	O
correlation	O
between	O
TLE6D	O
and	O
RUNX3	O
expression	O
in	O
human	O
CRC	B
suggests	O
a	O
model	O
whereby	O
RUNX3	O
inactivation	O
by	O
TLE6D	O
could	O
be	O
an	O
important	O
factor	O
driving	O
this	O
growth	O
advantage	O
in	O
both	O
MSI	B
-	I
H	I
and	O
MSS	B
CRC	B
.	O

Future	O
studies	O
will	O
be	O
required	O
to	O
understand	O
the	O
mechanistic	O
implications	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
in	O
CRC	B
progression	O
in	O
more	O
precise	O
detail	O
.	O

Materials	O
and	O
Methods	O
Mouse	O
Lines	O
and	O
Survival	O
Analyses	O
,	O
Tumor	B
Analysis	O
,	O
and	O
Apc	O
Mutation	O
Analysis	O
Wild	O
-	O
type	O
(	O
Wt	O
)	O
,	O
Pms2+	O
/	O
−	O
and	O
Mlh3+	O
/	O
−	O
mice	O
were	O
maintained	O
on	O
the	O
129	O
Sv	O
/	O
Ev	O
genetic	O
background	O
and	O
intercrossed	O
to	O
generate	O
Mlh3+	O
/	O
−;Pms2+	O
/	O
−	O
mice	O
as	O
described	O
before	O
[	O
13	O
]	O
.	O

Apc1638N	O
mice	O
were	O
backcrossed	O
four	O
times	O
to	O
129	O
Sv	O
/	O
Ev	O
and	O
subsequently	O
intercrossed	O
with	O
Mlh3+	O
/	O
−	O
;	O
Pms2+	O
/	O
−	O
to	O
generate	O
Mlh3−	O
/	O
−;Apc1638N	O
and	O
Mlh3−	O
/	O
−;Pms2−	O
/	O
−;Apc1638N	O
mice	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
were	O
generated	O
and	O
statistical	O
significance	O
between	O
genotypes	O
was	O
determined	O
using	O
the	O
Log	O
Rank	O
test	O
as	O
previously	O
performed	O
[	O
13	O
]	O
.	O

All	O
lines	O
of	O
mice	O
were	O
necropsied	O
when	O
they	O
became	O
morbid	O
or	O
moribund	O
.	O

Sacrificed	O
mice	O
were	O
surveyed	O
for	O
tumors	B
and	O
suspicious	O
masses	O
were	O
histology	O
analyzed	O
as	O
previously	O
performed	O
.	O

Statistical	O
analyses	O
of	O
tumor	B
onset	O
and	O
incidence	O
among	O
the	O
different	O
mouse	O
lines	O
were	O
performed	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
as	O
previously	O
described	O
[	O
23	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
,	O
[	O
35	O
]	O
,	O
[	O
71	O
]	O
,	O
[	O
72	O
]	O
,	O
[	O
73	O
]	O
,	O
[	O
74	O
]	O
,	O
[	O
75	O
]	O
,	O
[	O
76	O
]	O
.	O

Tumors	B
from	O
stomach	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
were	O
cut	O
into	O
two	O
parts	O
.	O

One	O
part	O
of	O
the	O
tumor	B
was	O
processed	O
for	O
histopathological	O
analysis	O
and	O
the	O
other	O
part	O
was	O
used	O
for	O
DNA	O
/	O
RNA	O
extractions	O
.	O

Genomic	O
DNA	O
samples	O
were	O
extracted	O
using	O
Puregene	O
DNA	O
Isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
and	O
subjected	O
to	O
mutational	O
analysis	O
of	O
Apc	O
gene	O
between	O
codons	O
677–1674	O
as	O
previously	O
described	O
[	O
33	O
]	O
.	O

Array	O
Comparative	O
Genomic	O
Hybridization	O
Analysis	O
Genomic	O
DNAs	O
were	O
isolated	O
from	O
tumor	B
tissue	O
and	O
tail	O
tissue	O
from	O
each	O
mouse	O
using	O
PUREGENE	O
DNA	O
Isolation	O
kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
.	O

DNAs	O
were	O
digested	O
with	O
DpnII	O
and	O
subsequently	O
purified	O
using	O
the	O
QIAquick	O
PCR	O
Purification	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
quality	O
of	O
the	O
DNA	O
samples	O
was	O
evaluated	O
using	O
the	O
Agilent	O
2100	O
BioAnalyzer	O
.	O

The	O
purified	O
fragmented	O
DNA	O
samples	O
were	O
random	O
-	O
prime	O
labeled	O
with	O
either	O
Cy5	O
or	O
Cy3	O
and	O
hybridized	O
as	O
previously	O
described	O
[	O
77	O
]	O
Briefly	O
,	O
for	O
each	O
labeling	O
reaction	O
,	O
2	O
µg	O
of	O
purified	O
digested	O
DNA	O
were	O
used	O
.	O

Each	O
sample	O
was	O
dye	O
-	O
swap	O
labeled	O
for	O
hybridization	O
to	O
mouse	O
70-mer	O
oligonucleotide	O
microarrays	O
(	O
Agilent	O
Technologies	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
containing	O
20,281	O
clones	O
.	O

After	O
hybridization	O
,	O
the	O
arrays	O
were	O
scanned	O
using	O
an	O
Agilent	O
Microarray	O
DNA	O
scanner	O
(	O
Agilent	O
Technologies	O
)	O
and	O
the	O
spot	O
intensity	O
was	O
extracted	O
from	O
slide	O
images	O
using	O
Agilent	O
Feature	O
Extraction	O
Software	O
7.0	O
.	O

The	O
data	O
were	O
further	O
analyzed	O
using	O
the	O
procedures	O
of	O
Automatic	O
Data	O
Analysis	O
Pipeline	O
(	O
ADAP	O
)	O
.	O

Only	O
spots	O
with	O
fluorescence	O
intensities	O
statistically	O
different	O
from	O
the	O
surrounding	O
background	O
(	O
P<0.001	O
)	O
were	O
considered	O
reliable	O
,	O
taking	O
up	O
>	O
85	O
%	O
of	O
total	O
spots	O
on	O
the	O
chip	O
.	O

For	O
further	O
analysis	O
the	O
fluorescence	O
intensity	O
values	O
of	O
reliable	O
spots	O
were	O
transformed	O
to	O
log2	O
.	O

To	O
minimize	O
the	O
effect	O
of	O
the	O
variations	O
,	O
the	O
log2	O
intensity	O
ratios	O
of	O
remaining	O
spots	O
were	O
subjected	O
to	O
normalization	O
by	O
Lowess	O
fitting	O
.	O

Gene	O
copy	O
number	O
changes	O
for	O
each	O
sample	O
was	O
calculated	O
by	O
taking	O
the	O
median	O
of	O
the	O
normalized	O
log2	O
intensity	O
ratios	O
of	O
dye	O
-	O
swapped	O
chip	O
experiments	O
for	O
the	O
corresponding	O
sample	O
.	O

The	O
gene	O
copy	O
numbers	O
were	O
ordered	O
along	O
chromosomes	O
by	O
the	O
map	O
positions	O
of	O
corresponding	O
genes	O
.	O

To	O
eliminate	O
systematic	O
noise	O
,	O
gene	O
copy	O
number	O
changes	O
(	O
log2Ratios	O
)	O
along	O
the	O
chromosomes	O
were	O
smoothed	O
by	O
taking	O
a	O
moving	O
median	O
of	O
symmetric	O
5-nearest	O
neighbors	O
,	O
followed	O
by	O
Lowess	O
fitting	O
(	O
f	O
=	O
0.2	O
)	O
.	O

The	O
mean	O
and	O
standard	O
deviation	O
(	O
SD	O
)	O
of	O
smoothed	O
log2Ratios	O
for	O
all	O
genes	O
in	O
all	O
the	O
samples	O
were	O
calculated	O
.	O

The	O
copy	O
number	O
profiles	O
of	O
at	O
least	O
5	O
consecutive	O
genes	O
that	O
deviated	O
significantly	O
above	O
mean+3SD	O
were	O
interpreted	O
as	O
regional	O
gains	O
,	O
below	O
mean-3SD	O
as	O
regional	O
losses	O
.	O

The	O
threshold	O
for	O
whole	O
chromosomal	O
gain	O
/	O
loss	O
was	O
mean±2SD	O
.	O

The	O
ideograms	O
of	O
chromosomal	O
aberrations	O
were	O
drawn	O
using	O
mapping	O
information	O
of	O
cytogenetic	O
bands	O
to	O
the	O
mouse	O
genome	O
(	O
NCBI	O
Mapview	O
Build	O
32	O
)	O
.	O

Given	O
the	O
above	O
unanticipated	O
characteristics	O
of	O
the	O
newly	O
discovered	O
mutations	O
—	O
especially	O
their	O
low	O
frequency	O
and	O
high	O
rate	O
of	O
heterozygosity	O
—	O
we	O
performed	O
an	O
initial	O
survey	O
to	O
characterize	O
the	O
epigenetic	O
status	O
of	O
genes	O
in	O
colon	B
cancer	I
on	O
a	O
genome	O
-	O
wide	O
level	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
an	O
expression	O
microarray	O
technique	O
to	O
characterize	O
the	O
spectrum	O
of	O
hypermethylated	O
genes	O
in	O
cancers	B
[	O
15	O
]	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
have	O
utilized	O
our	O
global	O
approach	O
to	O
comprehensively	O
compare	O
the	O
epigenetic	O
alteration	O
of	O
the	O
CAN	O
genes	O
in	O
both	O
breast	O
and	O
colon	B
cancers	I
,	O
and	O
included	O
analyses	O
in	O
the	O
specific	O
breast	B
cancer	I
lines	O
where	O
individual	O
mutations	O
were	O
identified	O
by	O
Sjoblom	O
et	O
al.	O
[	O
7	O
]	O
.	O

Genes	O
Targeted	O
by	O
Mutation	O
and	O
Hypermethylation	O
Common	O
Gene	O
Targets	O
of	O
Mutation	O
and	O
Hypermethylation	O
in	O
Breast	B
Cancer	I
MSP	O
and	O
RT	O
-	O
PCR	O
expression	O
analysis	O
of	O
selected	O
genes	O
.	O

Each	O
set	O
of	O
MSP	O
and	O
expression	O
analyses	O
are	O
labeled	O
with	O
the	O
corresponding	O
gene	O
name	O
.	O

U	O
denotes	O
the	O
unmethylated	O
band	O
,	O
and	O
M	O
denotes	O
the	O
methylated	O
band	O
.	O

In	O
vitro	O
methylated	O
DNA	O
(	O
IVD	O
)	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
methylation	O
.	O

cDNA	O
from	O
normal	B
breast	O
(	O
NB	O
)	O
and	O
normal	B
colon	O
(	O
NC	O
)	O
(	O
Figure	O
3	O
)	O
was	O
used	O
to	O
determine	O
the	O
expression	O
of	O
the	O
genes	O
in	O
normal	B
tissue	O
.	O

DKO	O
corresponds	O
to	O
DNMT	O
1	O
/	O
3b	O
double	O
knockout	O
HCT116	O
cells	O
.	O

All	O
RT	O
-	O
PCR	O
experiments	O
were	O
performed	O
in	O
parallel	O
without	O
reverse	O
transcriptase	O
as	O
a	O
control	O
,	O
and	O
in	O
all	O
cases	O
,	O
no	O
PCR	O
product	O
was	O
generated	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
control	O
experiment	O
performed	O
without	O
RT	O
for	O
normal	B
breast	O
is	O
shown	O
(	O
NB	O
no	O
RT	O
)	O
for	O
each	O
gene	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
for	O
all	O
cancer	B
lines	O
with	O
beta	O
-	O
actin	O
primers	O
to	O
control	O
for	O
the	O
amount	O
of	O
cDNA	O
(	O
Figure	O
3	O
,	O
bottom	O
)	O
.	O

Common	O
Gene	O
Targets	O
of	O
Mutation	O
and	O
Hypermethylation	O
in	O
Colon	B
Cancer	I
MSP	O
and	O
RT	O
-	O
PCR	O
expression	O
analysis	O
of	O
selected	O
genes	O
.	O

Each	O
set	O
of	O
MSP	O
and	O
expression	O
analyses	O
are	O
labeled	O
with	O
the	O
corresponding	O
gene	O
name	O
.	O

U	O
denotes	O
the	O
unmethylated	O
band	O
,	O
and	O
M	O
denotes	O
the	O
methylated	O
band	O
.	O

In	O
vitro	O
methylated	O
DNA	O
(	O
IVD	O
)	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
methylation	O
.	O

cDNA	O
from	O
normal	B
breast	O
(	O
NB	O
)	O
and	O
normal	B
colon	O
(	O
NC	O
)	O
was	O
used	O
to	O
determine	O
the	O
expression	O
of	O
the	O
genes	O
in	O
normal	B
tissue	O
.	O

DKO	O
corresponds	O
to	O
DNMT	O
1	O
/	O
3b	O
double	O
knockout	O
HCT116	O
cells	O
.	O

All	O
RT	O
-	O
PCR	O
experiments	O
were	O
performed	O
in	O
parallel	O
without	O
reverse	O
transcriptase	O
as	O
a	O
control	O
,	O
and	O
in	O
all	O
cases	O
,	O
no	O
PCR	O
product	O
was	O
generated	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
control	O
experiment	O
performed	O
without	O
RT	O
for	O
normal	B
colon	O
is	O
shown	O
(	O
NC	O
no	O
RT	O
)	O
for	O
each	O
gene	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
for	O
all	O
cancer	B
lines	O
with	O
beta	O
-	O
actin	O
primers	O
to	O
control	O
for	O
the	O
amount	O
of	O
cDNA	O
.	O

From	O
the	O
analysis	O
of	O
methylation	O
and	O
expression	O
status	O
of	O
the	O
36	O
common	O
target	O
genes	O
,	O
it	O
is	O
clear	O
that	O
,	O
although	O
hypermethylation	O
was	O
accompanied	O
by	O
loss	O
of	O
gene	O
expression	O
in	O
nearly	O
all	O
cases	O
,	O
loss	O
of	O
gene	O
expression	O
in	O
the	O
overlap	O
genes	O
can	O
occur	O
by	O
mechanisms	O
other	O
than	O
methylation	O
(	O
Table	O
S1	O
)	O
.	O

Potential	O
mechanisms	O
include	O
repressive	O
chromatin	O
modifications	O
,	O
mutational	O
changes	O
outside	O
the	O
coding	O
regions	O
that	O
destabilize	O
the	O
mRNA	O
,	O
or	O
coordinate	O
downregulation	O
of	O
relevant	O
pathways	O
.	O

For	O
example	O
,	O
p21	O
expression	O
is	O
frequently	O
decreased	O
in	O
tumors	B
with	O
inactivating	O
p53	O
mutations	O
[	O
25	O
]	O
.	O

To	O
confirm	O
our	O
MSP	O
results	O
,	O
we	O
analyzed	O
the	O
methylation	O
status	O
of	O
selected	O
genes	O
using	O
sequencing	O
of	O
bisulfite	O
-	O
treated	O
genomic	O
DNA	O
from	O
samples	O
that	O
were	O
used	O
in	O
the	O
MSP	O
studies	O
.	O

In	O
all	O
cases	O
,	O
bisulfite	O
sequencing	O
confirmed	O
the	O
results	O
obtained	O
with	O
MSP	O
(	O
Figure	O
4	O
)	O
.	O

For	O
another	O
control	O
,	O
we	O
also	O
studied	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
the	O
genes	O
in	O
a	O
derivative	O
of	O
HCT116	O
human	O
colon	B
cancer	I
cells	O
in	O
which	O
the	O
DNMT1	O
and	O
DNMT3b	O
DNA	O
methyltransferases	O
were	O
homozygously	O
deleted	O
(	O
DKO	O
cells	O
)	O
.	O

These	O
simultaneous	O
deletions	O
result	O
in	O
nearly	O
complete	O
lack	O
of	O
DNA	O
methylation	O
and	O
the	O
promoter	O
DNA	O
demethylation	O
and	O
re	O
-	O
expression	O
of	O
all	O
known	O
DNA	O
hypermethylated	O
genes	O
examined	O
in	O
these	O
cells	O
[	O
26	O
]	O
.	O

In	O
all	O
cases	O
,	O
the	O
loss	O
or	O
absence	O
of	O
methylation	O
at	O
the	O
promoter	O
regions	O
of	O
the	O
36	O
DNA	O
hypermethylated	O
loci	O
in	O
DKO	O
cells	O
was	O
associated	O
with	O
expression	O
of	O
these	O
genes	O
(	O
Figures	O
2	O
and	O
3	O
and	O
unpublished	O
data	O
)	O
.	O

Importantly	O
,	O
in	O
all	O
cases	O
,	O
these	O
36	O
overlap	O
genes	O
were	O
also	O
found	O
to	O
be	O
expressed	O
in	O
normal	B
colon	O
and	O
breast	O
tissue	O
(	O
Figures	O
2	O
and	O
3	O
and	O
Table	O
S1	O
)	O
.	O

The	O
above	O
data	O
may	O
be	O
particularly	O
significant	O
because	O
the	O
vast	O
majority	O
of	O
CAN	O
gene	O
mutations	O
identified	O
are	O
heterozygous	O
missense	O
mutations	O
.	O

It	O
is	O
possible	O
that	O
many	O
of	O
these	O
mutations	O
result	O
in	O
haploinsufficiency	O
or	O
cause	O
small	O
decreases	O
in	O
protein	O
or	O
transcript	O
abundance	O
that	O
may	O
be	O
functionally	O
meaningful	O
for	O
driving	O
tumorigenesis	O
.	O

Small	O
changes	O
in	O
expression	O
of	O
a	O
number	O
of	O
tumor	B
suppressor	O
genes	O
(	O
such	O
as	O
APC	O
,	O
SMAD4	O
,	O
MSH2	O
,	O
etc	O
.	O
)	O
have	O
now	O
been	O
well	O
described	O
to	O
have	O
tumorigenic	O
effects	O
[	O
8,29,30	O
]	O
.	O

Consistent	O
with	O
the	O
hemizygous	O
nature	O
of	O
the	O
mutations	O
,	O
it	O
seems	O
likely	O
that	O
DNA	O
methylation	O
deepens	O
the	O
haploinsufficiency	O
status	O
of	O
the	O
genes	O
when	O
both	O
changes	O
are	O
found	O
in	O
the	O
same	O
tumor	B
or	O
,	O
more	O
often	O
just	O
with	O
the	O
epigenetic	O
changes	O
alone	O
.	O

The	O
accompanying	O
loss	O
of	O
function	O
can	O
compound	O
,	O
and	O
thus	O
progressively	O
contribute	O
to	O
,	O
tumorigenesis	O
.	O

Functional	O
Associations	O
of	O
Common	O
Target	O
Genes	O
Next	O
,	O
we	O
analyzed	O
the	O
functional	O
associations	O
of	O
the	O
18	O
common	O
target	O
genes	O
that	O
demonstrate	O
cancer	B
-	O
specific	O
hypermethylation	O
.	O

We	O
utilized	O
Gene	O
Ontology	O
(	O
GO	O
)	O
classification	O
and	O
available	O
data	O
in	O
the	O
literature	O
to	O
describe	O
the	O
functional	O
associations	O
of	O
the	O
genes	O
(	O
Figure	O
8)	O
.	O

A	O
number	O
of	O
genes	O
are	O
involved	O
in	O
cell	O
adhesion	O
and	O
motility	O
and/or	O
signal	O
transduction	O
.	O

Examination	O
of	O
the	O
literature	O
revealed	O
that	O
at	O
least	O
six	O
of	O
these	O
genes	O
possess	O
known	O
tumor	O
suppressive	O
properties	O
,	O
defined	O
as	O
the	O
ability	O
to	O
modulate	O
known	O
tumor	B
suppressor	O
(	O
i.e.	O
,	O
p53	O
,	O
wnt	O
,	O
etc	O
.	O
)	O
function	O
or	O
inhibit	O
cancer	B
cell	O
growth	O
in	O
vitro	O
and/or	O
in	O
vivo	O
(	O
Figure	O
8)	O
.	O

We	O
then	O
determined	O
the	O
chromosomal	O
location	O
of	O
these	O
18	O
genes	O
.	O

We	O
compared	O
these	O
chromosomal	O
locations	O
to	O
those	O
that	O
have	O
been	O
shown	O
to	O
be	O
deleted	O
in	O
primary	O
human	O
tumors	B
in	O
the	O
literature	O
using	O
standard	O
genetic	O
mapping	O
or	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
.	O

Sixteen	O
out	O
of	O
18	O
(	O
89	O
%	O
,	O
next	O
to	O
last	O
panel	O
)	O
of	O
these	O
genes	O
map	O
to	O
loci	O
that	O
have	O
been	O
found	O
to	O
be	O
deleted	O
in	O
cancers	B
(	O
including	O
colon	O
,	O
breast	O
,	O
prostate	O
,	O
Wilm	B
's	I
tumor	I
,	O
hematopoietic	O
tumors	B
,	O
and	O
medulloblastoma	B
)	O
.	O

For	O
example	O
,	O
Yang	O
et	O
al.	O
demonstrated	O
that	O
19p13.3	O
,	O
the	O
location	O
of	O
APC2	O
,	O
is	O
a	O
common	O
site	O
of	O
LOH	O
or	O
deletion	O
in	O
breast	O
carcinoma	B
[	O
31	O
]	O
.	O

Similarly	O
,	O
SYNE1	O
localizes	O
to	O
6p25	O
,	O
a	O
location	O
that	O
is	O
subject	O
to	O
frequent	O
deletion	O
in	O
a	O
number	O
of	O
tumors	B
[	O
32,33	O
]	O
.	O

CHD5	O
is	O
a	O
well	O
-	O
documented	O
tumor	B
suppressor	O
gene	O
located	O
on	O
1p36	O
,	O
a	O
region	O
that	O
is	O
commonly	O
lost	O
in	O
malignancies	B
of	O
epithelial	O
,	O
neural	O
,	O
and	O
hematopoietic	O
origin	O
[	O
34	O
]	O
.	O

Referenced	O
data	O
are	O
summarized	O
in	O
Table	O
S4	O
.	O

Thus	O
,	O
the	O
18	O
genes	O
we	O
have	O
identified	O
are	O
genes	O
that	O
are	O
found	O
to	O
be	O
mutated	O
in	O
breast	O
and	O
colon	B
cancer	I
,	O
silenced	O
by	O
hypermethylation	O
in	O
these	O
tumors	B
,	O
and	O
reside	O
at	O
locations	O
subject	O
to	O
LOH	O
or	O
deletion	O
in	O
a	O
number	O
of	O
human	O
neoplasms	B
.	O

Statistical	O
Analyses	O
Unpaired	O
t	O
test	O
,	O
z	O
test	O
,	O
and	O
χ2	O
test	O
were	O
used	O
.	O

The	O
data	O
were	O
calculated	O
with	O
Statistica	O
6	O
(	O
StatSoft	O
,	O
Tulsa	O
,	O
OK	O
,	O
USA	O
)	O
.	O

Values	O
are	O
presented	O
as	O
arithmetrical	O
mean	O
±	O
SEM	O
.	O

The	O
present	O
study	O
describes	O
a	O
population	O
based	O
analysis	O
of	O
the	O
frequency	O
of	O
variants	O
of	O
unknown	O
significance	O
in	O
hMLH1	O
and	O
hMSH2	O
in	O
Danish	O
patients	O
with	O
sporadic	O
CRC	B
and	O
in	O
a	O
sub	O
-	O
cohort	O
of	O
controls	O
.	O

Some	O
of	O
the	O
variants	O
have	O
been	O
described	O
in	O
other	O
studies	O
,	O
and	O
some	O
are	O
,	O
to	O
our	O
knowledge	O
,	O
new	O
variants	O
unique	O
to	O
the	O
Danish	O
population	O
.	O

We	O
have	O
analyzed	O
the	O
allele	O
frequencies	O
of	O
29	O
variants	O
in	O
hMLH1	O
and	O
hMSH2	O
to	O
reveal	O
whether	O
they	O
cause	O
increased	O
susceptibility	O
to	O
sporadic	O
CRC	B
in	O
the	O
Danish	O
population	O
or	O
whether	O
they	O
are	O
private	O
variants	O
/	O
mutations	O
found	O
only	O
in	O
the	O
families	O
where	O
they	O
were	O
originally	O
identified	O
.	O

In	O
addition	O
to	O
the	O
29	O
variants	O
identified	O
in	O
Danish	O
individuals	O
,	O
six	O
variants	O
identified	O
in	O
other	O
Caucasian	O
populations	O
were	O
also	O
investigated	O
.	O

MLH1	O
and	O
MSH2	O
variants	O
*	O
identified	O
in	O
CRC	B
families	O
from	O
other	O
Caucasian	O
populations	O
than	O
the	O
Danish	O
Genotyping	O
using	O
Single	O
Base	O
Extension	O
(	O
SBE	O
)	O
-tag	O
arrays	O

Primer	O
design	O
The	O
multiplex	O
PCR	O
primers	O
were	O
designed	O
using	O
Oligo	O
6	O
[	O
22	O
]	O
.	O

The	O
PCR	O
products	O
were	O
between	O
100	O
and	O
450	O
bp	O
.	O

The	O
optimal	O
annealing	O
temperature	O
(	O
Ta	O
)	O
was	O
set	O
to	O
~50	O
°	O
C	O
,	O
the	O
GC	O
content	O
to	O
~40	O
%	O
and	O
the	O
primer	O
Tm	O
difference	O
to	O
≤1	O
.	O

The	O
single	O
base	O
extension	O
(	O
SBE	O
)	O
primers	O
contained	O
5	O
'	O
20-bp	O
'	O
tag	O
'	O
sequences	O
that	O
were	O
from	O
the	O
Affymetrix	O
GeneChip	O
®	O
Tag	O
Collection	O
.	O

The	O
gene	O
specific	O
part	O
of	O
the	O
SBE	O
primers	O
had	O
a	O
Tm	O
of	O
~50–60	O
°	O
C	O
(	O
calculated	O
using	O
PrimerExpress	O
2.0	O
)	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

The	O
tagged	O
SBE	O
primers	O
were	O
tested	O
for	O
major	O
hairpin	O
loop	O
formation	O
using	O
Oligo6	O
.	O

All	O
variants	O
were	O
typed	O
using	O
SBE	O
-	O
primers	O
for	O
both	O
DNA	O
strands	O
.	O

The	O
primers	O
were	O
synthesized	O
by	O
DNA	O
Technology	O
(	O
Aarhus	O
,	O
Denmark	O
)	O
.	O

The	O
multiplex	O
PCR	O
primer	O
and	O
the	O
SBE	O
primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Multiplex	O
PCR	O
The	O
multiplex	O
PCR	O
amplification	O
was	O
performed	O
with	O
6–9	O
primer	O
pairs	O
per	O
reaction	O
.	O

Twenty	O
ng	O
of	O
genomic	O
DNA	O
with	O
0.5	O
μl	O
Accuprime	O
™	O
DNA	O
polymerase	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
1	O
×	O
Accuprime	O
™	O
Buffer	O
I	O
,	O
and	O
0.08–1	O
μM	O
primers	O
was	O
amplified	O
in	O
25	O
μl	O
volumes	O
using	O
the	O
following	O
PCR	O
conditions	O
:	O
1	O
cycle	O
of	O
95	O
°	O
C	O
for	O
10	O
min	O
;	O
13	O
cycles	O
of	O
95	O
°	O
C	O
for	O
30	O
sec.	O
,	O
67	O
°	O
C	O
(	O
-1	O
°	O
C	O
/	O
cycle	O
)	O
for	O
45	O
sec.	O
and	O
72	O
°	O
C	O
for	O
45	O
sec.	O
;	O
20	O
cycles	O
of	O
95	O
°	O
C	O
for	O
30	O
sec.	O
,	O
55	O
°	O
C	O
for	O
45	O
sec.	O
and	O
72	O
°	O
C	O
for	O
45	O
sec.	O
;	O
1	O
cycle	O
of	O
72	O
°	O
C	O
for	O
10	O
min	O
.	O

A	O
subset	O
of	O
the	O
multiplex	O
PCR	O
products	O
were	O
analysed	O
on	O
a	O
2100	O
Bioanalyzer	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
to	O
test	O
the	O
performance	O
of	O
the	O
multiplex	O
PCR	O
.	O

The	O
multiplex	O
PCR	O
products	O
from	O
each	O
sample	O
were	O
pooled	O
for	O
further	O
analysis	O
.	O

Single	O
Base	O
Extension	O
(	O
SBE	O
)	O
reaction	O

The	O
pooled	O
PCR	O
products	O
from	O
each	O
sample	O
were	O
treated	O
with	O
Exonuclease	O
I	O
and	O
shrimp	O
alkaline	O
phosphatase	O
and	O
used	O
for	O
template	O
in	O
the	O
SBE	O
reaction	O
(	O
mini	O
-	O
sequencing	O
)	O
as	O
described	O
by	O
Lindross	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescent	O
labelled	O
ddNTP	O
were	O
Cyanine	O
5	O
(	O
Cy5	O
)	O
-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
®	O
-5-ddATP	O
and	O
R110-ddGTP	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

Preparation	O
of	O
microarrays	O
'	O
Anti	O
-	O
tag	O
'	O
oligonucleotides	O
complimentary	O
to	O
the	O
'	O
tag	O
'	O
sequences	O
of	O
the	O
SBE	O
primers	O
modified	O
with	O
NH2	O
groups	O
in	O
their	O
3	O
'	O
ends	O
,	O
and	O
containing	O
a	O
3'-spacer	O
of	O
15	O
T	O
residues	O
were	O
coupled	O
covalently	O
to	O
CodeLink	O
Activated	O
Slides	O
(	O
Amersham	O
Biosciences	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
according	O
to	O
manufacturer	O
instructions	O
.	O

The	O
only	O
exception	O
was	O
that	O
the	O
'	O
anti	O
-	O
tag	O
'	O
oligonucleotides	O
were	O
dissolved	O
in	O
150	O
mM	O
sodium	O
carbonate	O
buffer	O
,	O
pH	O
8.5	O
with	O
1	O
mM	O
betaine	O
at	O
a	O
concentration	O
of	O
20	O
μM.	O
The	O
oligonucleotides	O
were	O
printed	O
onto	O
the	O
slides	O
using	O
a	O
VersArray	O
ChipWriter	O
(	O
BioRad	O
,	O
Hercules	O
,	O
CA	O
)	O
with	O
3	O
Stealth	O
Micro	O
Spotting	O
Pins	O
(	O
TeleChem	O
International	O
Inc.	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Each	O
slide	O
consists	O
of	O
75	O
sub	O
-	O
arrays	O
with	O
13	O
×	O
12	O
spots	O
in	O
each	O
subarray	O
.	O

The	O
spots	O
were	O
130–150	O
μM	O
in	O
diameter	O
and	O
the	O
centre	O
-	O
to	O
-	O
centre	O
distance	O
between	O
two	O
spots	O
was	O
200	O
μM.	O
The	O
'	O
anti	O
-	O
tag	O
'	O
oligonucleotides	O
were	O
printed	O
in	O
duplicates	O
in	O
each	O
sub	O
-	O
array	O
.	O

The	O
spot	O
quality	O
was	O
tested	O
after	O
each	O
series	O
of	O
microarray	O
preparation	O
using	O
a	O
Cy3	O
labelled	O
random	O
oligonucleotide	O
hybridizing	O
to	O
all	O
spots	O
on	O
the	O
slide	O
independent	O
on	O
the	O
'	O
anti	O
-	O
tag	O
'	O
sequence	O
.	O

The	O
printed	O
slides	O
were	O
stored	O
at	O
room	O
temperature	O
until	O
use	O
.	O

Linkage	O
disequilibrium	O
(	O
LD	O
)	O
analysis	O
showed	O
high	O
LD	O
in	O
the	O
genomic	O
regions	O
covering	O
hMLH1	O
and	O
most	O
of	O
the	O
genomic	O
region	O
covering	O
hMSH2	O
in	O
the	O
Danish	O
population	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
variants	O
in	O
the	O
two	O
genes	O
in	O
general	O
are	O
not	O
associated	O
with	O
susceptibility	O
to	O
sporadic	O
CRC	B
in	O
a	O
Danish	O
population	O
.	O

The	O
age	O
of	O
the	O
cohort	O
of	O
cases	O
with	O
sporadic	O
CRC	B
is	O
relatively	O
young	O
(	O
mean	O
~58	O
years	O
)	O
compared	O
to	O
the	O
mean	O
age	O
of	O
onset	O
of	O
colorectal	O
CRC	B
in	O
the	O
general	O
Danish	O
population	O
(	O
mean	O
~70	O
years	O
)	O
[	O
49	O
]	O
.	O

Consequently	O
,	O
the	O
results	O
obtained	O
in	O
the	O
present	O
study	O
do	O
not	O
rule	O
out	O
that	O
variants	O
in	O
hMLH1	O
and	O
hMSH2	O
might	O
be	O
associated	O
with	O
sporadic	O
colorectal	B
cancer	I
at	O
an	O
older	O
age	O
.	O

However	O
,	O
generally	O
cancers	B
reflecting	O
an	O
inherited	O
susceptibility	O
seem	O
to	O
occur	O
in	O
a	O
relatively	O
young	O
age	O
.	O

Using	O
in	O
silico	O
analysis	O
several	O
of	O
the	O
analyzed	O
variants	O
were	O
predicted	O
to	O
either	O
abolish	O
or	O
introduce	O
ESEs	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
has	O
,	O
however	O
,	O
been	O
shown	O
that	O
only	O
a	O
minor	O
fraction	O
of	O
the	O
variants	O
predicted	O
to	O
change	O
ESEs	O
in	O
hMLH1	O
and	O
hMSH2	O
using	O
in	O
silico	O
analysis	O
do	O
indeed	O
change	O
the	O
pre	O
-	O
mRNA	O
splice	O
pattern	O
in	O
vivo	O
[	O
14,15	O
]	O
.	O

In	O
the	O
study	O
by	O
Auclair	O
et	O
al.	O
,	O
only	O
ESEs	O
at	O
or	O
close	O
to	O
5	O
'	O
splice	O
sites	O
were	O
found	O
to	O
cause	O
aberrant	O
splicing	O
.	O

None	O
of	O
the	O
variants	O
analysed	O
in	O
the	O
present	O
study	O
affected	O
5	O
'	O
splice	O
sites	O
.	O

Nevertheless	O
,	O
no	O
final	O
conclusions	O
regarding	O
splicing	O
can	O
be	O
drawn	O
from	O
the	O
in	O
silico	O
analyses	O
.	O

Twenty	O
two	O
variants	O
were	O
not	O
detected	O
in	O
the	O
sporadic	O
CRC	B
cases	O
and	O
in	O
the	O
sub	O
-	O
cohort	O
.	O

Among	O
those	O
were	O
the	O
six	O
variants	O
originally	O
identified	O
more	O
or	O
less	O
frequently	O
in	O
other	O
populations	O
(	O
Table	O
2	O
)	O
.	O

All	O
except	O
one	O
variant	O
(	O
c.380	O
A	O
>	O
G	O
,	O
p.	O

Asn127Ser	O
)	O
performed	O
very	O
well	O
in	O
the	O
SBE	O
-	O
tag	O
array	O
assay	O
.	O

This	O
rules	O
out	O
that	O
failure	O
in	O
detecting	O
the	O
variants	O
caused	O
their	O
absence	O
in	O
the	O
present	O
cohorts	O
.	O

Consequently	O
,	O
these	O
six	O
variants	O
are	O
not	O
polymorphic	O
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
variants	O
were	O
rare	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

They	O
were	O
only	O
detected	O
in	O
individuals	O
with	O
familiar	O
CRC	B
and	O
some	O
of	O
them	O
have	O
been	O
classified	O
as	O
pathogenic	O
mutations	O
or	O
neutral	O
variants	O
in	O
other	O
populations	O
(	O
see	O
Table	O
2	O
for	O
references	O
)	O
.	O

Four	O
rare	O
missense	O
variants	O
i.e.	O
hMLH1	O
c.1379	O
A	O
>	O
C	O
(	O
p.	O

Glu460Ala	O
)	O
and	O
c.1689	O
A	O
>	O
G	O
(	O
p.	O

Ile563Met	O
)	O
and	O
,	O
hMSH2	O
c.2062	O
A	O
>	O
G	O
(	O
p.	O

Met688Val	O
)	O
and	O
c.2542	O
G	O
>	O
T	O
(	O
p.	O

Ala848Ser	O
)	O
were	O
unclassified	O
and	O
have	O
to	O
our	O
knowledge	O
never	O
been	O
described	O
previously	O
neither	O
in	O
the	O
Danish	O
population	O
nor	O
in	O
other	O
populations	O
.	O

Other	O
disease	B
causing	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
families	O
harbouring	O
the	O
two	O
hMLH1	O
variants	O
changing	O
non	O
-	O
conserved	O
amino	O
acids	O
i.e.	O
pGlu460Ala	O
and	O
p.	O

Ile563Met	O
(	O
unpublished	O
results	O
)	O
consequently	O
,	O
these	O
variants	O
are	O
most	O
likely	O
neutral	O
and	O
not	O
involved	O
in	O
HNPCC	B
.	O

However	O
,	O
no	O
other	O
disease	B
causing	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
families	O
harbouring	O
the	O
hMSH2	O
variants	O
changing	O
conserved	O
amino	O
acids	O
i.e.	O
p.	O

Met688Val	O
and	O
p.	O

Ala848Ser	O
variants	O
.	O

Further	O
characterization	O
of	O
these	O
variants	O
such	O
as	O
functional	O
studies	O
and	O
segregations	O
analysis	O
are	O
needed	O
before	O
any	O
final	O
conclusion	O
can	O
be	O
drawn	O
regarding	O
their	O
pathogenicity	O
.	O

In	O
conclusion	O
,	O
high	O
penetrance	O
cancer	B
susceptibility	O
genes	O
involved	O
in	O
hereditary	O
syndromes	B
have	O
rarely	O
emerged	O
as	O
definitive	O
low	O
-	O
penetrance	O
genes	O
as	O
a	O
result	O
of	O
common	O
variants	O
increasing	O
disease	B
susceptibility	O
[	O
19	O
]	O
.	O

The	O
results	O
shown	O
in	O
the	O
present	O
study	O
demonstrate	O
that	O
the	O
high	O
-	O
penetrance	O
HNPCC	B
genes	O
hMLH1	O
and	O
hMSH2	O
also	O
do	O
not	O
appear	O
to	O
be	O
low	O
penetrance	O
genes	O
involved	O
in	O
sporadic	O
CRC	B
in	O
the	O
Danish	O
population	O
.	O

Design	O
considerations	O
in	O
a	O
sib	O
-	O
pair	O
study	O
of	O
linkage	O
for	O
susceptibility	O
loci	O
in	O
cancer	B
Abstract	O
Background	O
Modern	O
approaches	O
to	O
identifying	O
new	O
genes	O
associated	O
with	O
disease	B
allow	O
very	O
fine	O
analysis	O
of	O
associaton	O
and	O
can	O
be	O
performed	O
in	O
population	O
based	O
case	O
-	O
control	O
studies	O
.	O

However	O
,	O
the	O
sibpair	O
design	O
is	O
still	O
valuable	O
because	O
it	O
requires	O
few	O
assumptions	O
other	O
than	O
acceptably	O
high	O
penetrance	O
to	O
identify	O
genetic	O
loci	O
.	O

Methods	O
We	O
conducted	O
simulation	O
studies	O
to	O
assess	O
the	O
impact	O
of	O
design	O
factors	O
on	O
relative	O
efficiency	O
for	O
a	O
linkage	O
study	O
of	O
colorectal	B
cancer	I
.	O

We	O
considered	O
two	O
test	O
statistics	O
,	O
one	O
comparing	O
the	O
mean	O
IBD	O
probability	O
in	O
affected	B
pairs	O
to	O
its	O
null	O
value	O
of	O
0.5	O
,	O
and	O
one	O
comparing	O
the	O
mean	O
IBD	O
probabilities	O
between	O
affected	B
and	O
discordant	O
pairs	O
.	O

We	O
varied	O
numbers	O
of	O
parents	O
available	O
,	O
numbers	O
of	O
affected	B
and	O
unaffected	B
siblings	O
,	O
reconstructing	O
the	O
genotype	O
of	O
an	O
unavailable	O
affected	B
sibling	O
by	O
a	O
spouse	O
and	O
offspring	O
,	O
and	O
elimination	O
of	O
sibships	O
where	O
the	O
proband	O
carries	O
a	O
mutation	O
at	O
another	O
locus	O
.	O

Results	O
Power	O
and	O
efficiency	O
were	O
most	O
affected	O
by	O
the	O
number	O
of	O
affected	B
sibs	O
,	O
the	O
number	O
of	O
sib	O
pairs	O
genotyped	O
,	O
and	O
the	O
risk	O
attributable	O
to	O
linked	O
and	O
unlinked	O
loci	O
.	O

Genotyping	O
unaffected	B
siblings	O
added	O
little	O
power	O
for	O
low	O
penetrance	O
models	O
,	O
but	O
improved	O
validity	O
of	O
tests	O
when	O
there	O
was	O
genetic	O
heterogeneity	O
and	O
for	O
multipoint	O
testing	O
.	O

The	O
efficiency	O
of	O
the	O
concordant	O
-	O
only	O
test	O
was	O
nearly	O
always	O
better	O
than	O
the	O
concordant	O
-	O
discordant	O
test	O
.	O

Replacement	O
of	O
an	O
unavailable	O
affected	B
sibling	O
by	O
a	O
spouse	O
and	O
offspring	O
recovered	O
some	O
linkage	O
information	O
,	O
particularly	O
if	O
several	O
offspring	O
were	O
available	O
.	O

In	O
multipoint	O
analysis	O
,	O
the	O
concordant	O
-	O
only	O
test	O
was	O
showed	O
a	O
small	O
anticonservative	O
bias	O
at	O
5	O
cM	O
,	O
while	O
the	O
multipoint	O
concordant	O
-	O
discordant	O
test	O
was	O
generally	O
the	O
most	O
powerful	O
test	O
,	O
and	O
was	O
not	O
biased	O
away	O
from	O
the	O
null	O
at	O
5	O
cM.	O
Conclusion	O
Genotyping	O
parents	O
and	O
unaffected	B
siblings	O
is	O
useful	O
for	O
detecting	O
genotyping	O
errors	O
and	O
if	O
allele	O
frequencies	O
are	O
uncertain	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
an	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	B
and	O
unaffected	B
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

Methods	O
The	O
choice	O
of	O
sampling	O
schemes	O
for	O
a	O
colon	O
sibpair	O
study	O
requires	O
evaluation	O
,	O
as	O
several	O
different	O
options	O
exist	O
simultaneously	O
for	O
the	O
sampling	O
plan	O
(	O
how	O
many	O
families	O
and	O
which	O
relatives	O
to	O
sample	O
)	O
,	O
disease	B
model	O
(	O
penetrance	O
,	O
allele	O
frequency	O
,	O
etc	O
)	O
,	O
and	O
statistical	O
test	O
of	O
linkage	O
.	O

These	O
aspects	O
,	O
in	O
addition	O
to	O
the	O
method	O
of	O
generating	O
the	O
data	O
sets	O
for	O
the	O
simulations	O
comprise	O
the	O
methods	O
of	O
determining	O
an	O
optimal	O
design	O
strategy	O
for	O
a	O
colon	O
sibpair	O
study	O
.	O

In	O
our	O
analysis	O
of	O
design	O
issues	O
we	O
have	O
pursued	O
a	O
deterministic	O
simulation	O
approach	O
.	O

The	O
first	O
step	O
was	O
to	O
check	O
that	O
the	O
tests	O
we	O
considered	O
had	O
appropriate	O
size	O
,	O
using	O
extensive	O
simulations	O
.	O

For	O
those	O
tests	O
that	O
were	O
valid	O
,	O
we	O
then	O
performed	O
a	O
moderate	O
number	O
of	O
simulations	O
of	O
a	O
large	O
number	O
of	O
families	O
,	O
to	O
obtain	O
the	O
noncentrality	O
parameters	O
describing	O
the	O
behavior	O
of	O
each	O
design	O
configuration	O
and	O
test	O
.	O

We	O
were	O
then	O
able	O
to	O
compare	O
the	O
attributes	O
of	O
these	O
studies	O
across	O
the	O
different	O
design	O
configurations	O
genetic	O
models	O
and	O
tests	O
by	O
fitting	O
regression	O
models	O
,	O
as	O
further	O
described	O
below	O
.	O

Disease	B
Model	O
Parameter	O
Choices	O
Genetic	O
Heterogeneity	O
The	O
genetic	O
basis	O
of	O
many	O
complex	O
human	O
diseases	B
,	O
including	O
some	O
common	O
cancers	B
,	O
is	O
known	O
to	O
include	O
mutations	O
in	O
loci	O
that	O
confer	O
a	O
high	O
penetrance	O
to	O
carriers	O
.	O

In	O
order	O
to	O
minimize	O
the	O
impact	O
that	O
such	O
genetic	O
heterogeneity	O
may	O
have	O
on	O
the	O
statistical	O
efficiency	O
to	O
identify	O
novel	O
loci	O
,	O
gene	O
-	O
hunting	O
studies	O
are	O
often	O
restricted	O
to	O
those	O
cases	O
that	O
have	O
been	O
determined	O
not	O
to	O
be	O
related	O
to	O
any	O
known	O
susceptibility	O
locus	O
.	O

For	O
example	O
,	O
the	O
second	O
susceptibility	O
locus	O
for	O
breast	B
cancer	I
,	O
BRCA2	O
,	O
was	O
mapped	O
by	O
Wooster	O
et	O
al.	O
[	O
37	O
]	O
based	O
on	O
high	O
-	O
risk	O
families	O
for	O
whom	O
BRCA1	O
linkage	O
was	O
excluded	O
.	O

Genetic	O
syndromes	B
such	O
as	O
juvenile	B
polyposis	I
,	O
Peutz	B
-	I
Jeghers	I
syndrome	I
and	O
familial	B
adenomatous	I
polyposis	I
can	O
be	O
readily	O
eliminated	O
prior	O
to	O
sample	O
collection	O
on	O
the	O
basis	O
of	O
phenotypic	O
characteristics	O
.	O

However	O
,	O
mutations	O
in	O
mismatch	O
repair	O
(	O
MMR	O
)	O
loci	O
such	O
as	O
hMSH2	O
or	O
hMLH1	O
can	O
not	O
be	O
excluded	O
without	O
performing	O
molecular	O
studies	O
.	O

(	O
Measures	O
of	O
tumor	B
microsatellite	O
instability	O
or	O
immunohistochemistry	O
can	O
be	O
helpful	O
in	O
identifying	O
likely	O
carriers	O
,	O
but	O
are	O
neither	O
fully	O
sensitive	O
nor	O
specific	O
.	O
)	O

Estimating	O
the	O
proportion	O
of	O
affected	B
families	O
that	O
might	O
be	O
excluded	O
from	O
analysis	O
because	O
they	O
carry	O
MMR	O
mutations	O
is	O
difficult	O
.	O

Population	O
-	O
based	O
estimates	O
of	O
the	O
prevalence	O
of	O
germ	O
-	O
line	O
MMR	O
mutations	O
among	O
subjects	O
diagnosed	O
with	O
colorectal	B
cancer	I
vary	O
widely	O
even	O
within	O
populations	O
of	O
European	O
descent	O
[	O
38	O
-	O
41	O
]	O
,	O
and	O
only	O
a	O
few	O
estimates	O
are	O
available	O
for	O
other	O
ethnic	O
groups	O
[	O
42,43	O
]	O
.	O

Moreover	O
,	O
recruiting	O
from	O
high	O
-	O
risk	O
clinics	O
may	O
lead	O
to	O
disproportionate	O
over	O
-	O
representation	O
of	O
families	O
who	O
have	O
MMR	O
mutations	O
.	O

One	O
large	O
study	O
in	O
Finland	O
[	O
44	O
]	O
found	O
that	O
12	O
%	O
of	O
affected	B
sib	O
pairs	O
(	O
ASP	O
)	O
showed	O
MMR	O
defects	O
.	O

The	O
number	O
of	O
families	O
F	O
required	O
for	O
a	O
desired	O
level	O
of	O
power	O
sample	O
was	O
calculated	O
in	O
the	O
standard	O
way	O
[	O
59	O
]	O
by	O
solving	O
Zα+Z1−βF	O
=	O
ZsimFsim	O
for	O
F	O
,	O
where	O
Zα	O
and	O
Z1-β	O
are	O
the	O
quantiles	O
of	O
the	O
standard	O
normal	O
distribution	O
for	O
selected	O
values	O
of	O
α	O
and	O
β	O
,	O
and	O
Zsim	O
is	O
the	O
sample	O
mean	O
of	O
the	O
Z	O
-	O
scores	O
(	O
Zc	O
or	O
Zp	O
)	O
based	O
on	O
the	O
sample	O
size	O
Fsim	O
of	O
the	O
simulation	O
run	O
.	O

Comparison	O
of	O
Sampling	O
Strategies	O

The	O
relative	O
efficiency	O
and	O
absolute	O
power	O
comparisons	O
were	O
evaluated	O
over	O
a	O
range	O
of	O
assumptions	O
about	O
disease	B
allele	O
frequency	O
,	O
penetrance	O
,	O
and	O
heterogeneity	O
.	O

Summaries	O
are	O
provided	O
for	O
the	O
relative	O
efficiency	O
from	O
the	O
non	O
-	O
null	O
simulations	O
of	O
each	O
combination	O
of	O
parameters	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

Our	O
simulations	O
involved	O
the	O
manipulation	O
of	O
16	O
parameters	O
,	O
with	O
over	O
725,000	O
possible	O
combinations	O
arising	O
just	O
among	O
the	O
limited	O
set	O
of	O
settings	O
we	O
chose	O
for	O
each	O
parameter	O
.	O

In	O
practice	O
,	O
we	O
were	O
able	O
to	O
simulate	O
20	O
replicates	O
for	O
332	O
actual	O
parameter	O
combinations	O
.	O

In	O
order	O
to	O
assess	O
the	O
impact	O
of	O
each	O
variable	O
parameter	O
setting	O
on	O
the	O
power	O
and	O
efficiency	O
of	O
each	O
study	O
design	O
,	O
and	O
to	O
facilitate	O
generalization	O
of	O
our	O
results	O
to	O
other	O
similar	O
situations	O
that	O
we	O
did	O
not	O
specifically	O
simulate	O
,	O
we	O
constructed	O
linear	O
regression	O
models	O
of	O
the	O
square	O
root	O
of	O
the	O
per	O
-	O
family	O
contribution	O
to	O
the	O
noncentrality	O
parameter	O
(	O
Zsim	O
/	O
Fsim	O
)	O
and	O
ARE	O
estimates	O
resulting	O
from	O
each	O
simulation	O
as	O
a	O
function	O
of	O
the	O
simulation	O
parameters	O
.	O

Residuals	O
from	O
the	O
models	O
were	O
approximately	O
normally	O
distributed	O
,	O
and	O
scale	O
-	O
location	O
plots	O
did	O
not	O
suggest	O
the	O
data	O
were	O
heteroscedastic	O
.	O

We	O
evaluated	O
the	O
fit	O
of	O
alternative	O
regression	O
models	O
with	O
quadratic	O
,	O
inverse	O
,	O
or	O
logarithmic	O
transformations	O
of	O
both	O
the	O
predictor	O
and	O
outcome	O
variables	O
;	O
none	O
fit	O
the	O
observed	O
data	O
better	O
than	O
a	O
simple	O
linear	O
multiple	O
regression	O
model	O
.	O

The	O
proportion	O
of	O
variance	O
in	O
ZsimFsim	O
explained	O
by	O
the	O
linear	O
regression	O
(	O
R2	O
)	O
ranged	O
from	O
70–75	O
%	O
.	O

The	O
open	O
source	O
statistical	O
package	O
R	O
[	O
60	O
]	O
was	O
used	O
to	O
perform	O
all	O
regression	O
analyses	O
.	O

In	O
order	O
to	O
facilitate	O
interpretation	O
,	O
the	O
genetic	O
effects	O
(	O
baseline	O
disease	B
prevalence	O
,	O
allele	O
frequencies	O
,	O
and	O
relative	O
risks	O
of	O
the	O
linked	O
and	O
unlinked	O
loci	O
)	O
were	O
collapsed	O
into	O
""""	O
attributable	O
risks	O
""""	O
(	O
AR	O
)	O
for	O
the	O
linked	O
and	O
unlinked	O
loci	O
respectively	O
.	O

The	O
attributable	O
risk	O
is	O
the	O
proportion	O
of	O
the	O
total	O
disease	B
risk	O
attributable	O
to	O
variation	O
at	O
each	O
genetic	O
locus	O
.	O

The	O
fit	O
of	O
linear	O
regression	O
models	O
employing	O
the	O
two	O
AR	O
values	O
is	O
as	O
good	O
as	O
those	O
employing	O
the	O
five	O
original	O
terms	O
to	O
fit	O
the	O
data	O
,	O
using	O
the	O
Akaike	O
Information	O
Criterion	O
(	O
not	O
shown	O
;	O
[	O
61	O
]	O
)	O
.	O

Effect	O
of	O
design	O
and	O
population	O
parameters	O
or	O
non	O
-	O
centrality	O
parameters	O
Multiple	O
linear	O
regression	O
of	O
Z	O
/	O
F	O
on	O
simulation	O
parameters	O
.	O

aStandard	O
error	O
of	O
Estimate	O
;	O
bNumber	O
available	O
for	O
Zc	O
,	O
number	O
genotyped	O
for	O
Zp	O
;	O
cIndicator	O
variable	O
.	O

In	O
general	O
,	O
the	O
effects	O
on	O
power	O
of	O
changes	O
to	O
the	O
genetic	O
and	O
design	O
parameters	O
were	O
very	O
similar	O
for	O
the	O
discordant	O
test	O
.	O

Increasing	O
the	O
number	O
of	O
unaffected	B
sibs	O
typed	O
did	O
yield	O
a	O
small	O
increase	O
in	O
power	O
,	O
but	O
increasing	O
the	O
number	O
of	O
affected	B
sibs	O
,	O
parents	O
or	O
offspring	O
proxies	O
increased	O
power	O
by	O
a	O
larger	O
amount	O
,	O
even	O
with	O
the	O
discordant	O
pair	O
test	O
.	O

The	O
effect	O
of	O
experimental	O
screening	O
for	O
the	O
unlinked	O
syndrome	B
varied	O
substantially	O
depending	O
on	O
the	O
relative	O
magnitude	O
of	O
the	O
effects	O
of	O
the	O
unlinked	O
syndrome	B
:	O
if	O
the	O
unlinked	O
syndrome	B
had	O
an	O
attributable	O
risk	O
greater	O
than	O
or	O
equal	O
to	O
that	O
of	O
the	O
linked	O
syndrome	O
,	O
experimental	O
screening	O
resulted	O
in	O
a	O
large	O
increase	O
in	O
power	O
.	O

Otherwise	O
,	O
the	O
effect	O
of	O
experimental	O
screening	O
was	O
negligible	O
.	O

Power	O
for	O
a	O
given	O
sample	O
size	O
F	O
and	O
test	O
size	O
α	O
with	O
a	O
specified	O
combination	O
of	O
design	O
and	O
genetic	O
parameters	O
can	O
be	O
derived	O
from	O
the	O
regression	O
models	O
in	O
Table	O
5	O
by	O
first	O
obtaining	O
an	O
estimate	O
of	O
the	O
noncentrality	O
parameter	O
Z	O
/	O
F	O
from	O
the	O
appropriate	O
column	O
of	O
Table	O
4	O
,	O
multiplying	O
by	O
F	O
to	O
obtain	O
z^	O
,	O
and	O
then	O
solving	O
for	O
β	O
in	O
the	O
equation	O
below	O
:	O
β	O
=	O
Φ	O
(	O
Zα−z^	O
)	O
,	O
where	O
β	O
is	O
the	O
probability	O
of	O
Type	O
II	O
error	O
(	O
hence	O
power	O
is	O
1-β	O
)	O
and	O
Φ	O
(	O
z	O
)	O
is	O
the	O
cumulative	O
standard	O
normal	O
distribution	O
.	O

A	O
script	O
for	O
computing	O
the	O
predicted	O
power	O
for	O
any	O
particular	O
combination	O
of	O
these	O
parameters	O
,	O
using	O
the	O
statistical	O
languages	O
S	O
-	O
plus	O
or	O
R	O
is	O
also	O
available	O
from	O
the	O
website	O
[	O
65	O
]	O
.	O

Figures	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
show	O
estimated	O
power	O
of	O
the	O
Zc	O
test	O
for	O
varying	O
sample	O
sizes	O
given	O
several	O
values	O
of	O
AR	O
for	O
the	O
linked	O
and	O
unlinked	O
loci	O
,	O
recombination	O
fraction	O
(	O
θ	O
)	O
,	O
number	O
of	O
parents	O
genotyped	O
,	O
and	O
number	O
of	O
offspring	O
proxies	O
.	O

Except	O
as	O
noted	O
,	O
the	O
power	O
estimates	O
are	O
based	O
on	O
the	O
following	O
settings	O
of	O
the	O
genetic	O
and	O
design	O
parameters	O
:	O
two	O
total	O
affected	B
sibs	O
,	O
both	O
sampled	O
,	O
two	O
unaffected	B
sibs	O
(	O
not	O
sampled	O
)	O
,	O
no	O
parents	O
or	O
offspring	O
proxies	O
,	O
AR1	O
(	O
linked	O
locus	O
)	O
=	O
0.1	O
,	O
AR2	O
(	O
unlinked	O
locus	O
)	O
=	O
0.05	O
,	O
θ	O
=	O
0.05	O
,	O
and	O
no	O
screening	O
to	O
exclude	O
unlinked	O
families	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
attributable	O
risk	O
at	O
the	O
linked	O
locus	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
attributable	O
risk	O
at	O
the	O
unlinked	O
locus	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
recombination	O
fraction	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
number	O
of	O
typed	O
parents	O
on	O
estimated	O
power	O
.	O

Effect	O
of	O
varying	O
number	O
of	O
offspring	O
proxies	O
on	O
power	O
for	O
families	O
of	O
two	O
affected	B
siblings	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
numbers	O
of	O
offspring	O
proxies	O
(	O
1	O
or	O
2	O
)	O
on	O
estimated	O
power	O
,	O
families	O
with	O
two	O
affected	B
sibs	O
,	O
with	O
only	O
one	O
available	O
for	O
genotyping	O
(	O
1	O
or	O
2	O
)	O
,	O
compared	O
with	O
families	O
with	O
both	O
affected	B
sibs	O
available	O
for	O
genotyping	O
(	O
S	O
=	O
2	O
)	O
.	O

Effect	O
of	O
varying	O
number	O
of	O
offspring	O
proxies	O
on	O
power	O
for	O
families	O
of	O
three	O
affected	B
siblings	O
.	O

Effect	O
of	O
sample	O
size	O
and	O
varying	O
numbers	O
of	O
offspring	O
proxies	O
(	O
O	O
)	O
on	O
estimated	O
power	O
,	O
families	O
with	O
three	O
affected	B
sibs	O
,	O
with	O
only	O
two	O
available	O
for	O
genotyping	O
(	O
O	O
=	O
0	O
,	O
1	O
,	O
or	O
2	O
)	O
,	O
compared	O
with	O
families	O
with	O
all	O
three	O
affected	B
sibs	O
available	O
for	O
genotyping	O
(	O
S	O
=	O
3	O
)	O
.	O

Relative	O
Efficiency	O
of	O
Alternative	O
Designs	O
Because	O
the	O
power	O
of	O
the	O
discordant	O
test	O
was	O
rarely	O
much	O
greater	O
than	O
that	O
of	O
the	O
concordant	O
test	O
,	O
and	O
the	O
concordant	O
test	O
requires	O
genotyping	O
of	O
only	O
the	O
affected	B
sibs	O
,	O
the	O
ARE	O
of	O
the	O
concordant	O
test	O
was	O
always	O
greater	O
on	O
average	O
than	O
that	O
of	O
the	O
discordant	O
test	O
.	O

Nevertheless	O
,	O
we	O
were	O
interested	O
in	O
specific	O
combinations	O
of	O
design	O
and	O
genetic	O
parameters	O
that	O
might	O
have	O
resulted	O
in	O
better	O
relative	O
efficiency	O
for	O
the	O
discordant	O
test	O
.	O

Overall	O
,	O
the	O
ARE	O
for	O
the	O
discordant	O
test	O
was	O
larger	O
than	O
that	O
for	O
the	O
concordant	O
test	O
in	O
13	O
%	O
of	O
the	O
replications	O
.	O

We	O
used	O
a	O
logistic	O
regression	O
model	O
with	O
the	O
same	O
parameters	O
as	O
those	O
in	O
Tables	O
2	O
,	O
3	O
and	O
4	O
to	O
predict	O
the	O
probability	O
that	O
Zp	O
would	O
outperform	O
Zc	O
in	O
terms	O
of	O
relative	O
efficiency	O
(	O
not	O
shown	O
)	O
.	O

Only	O
under	O
circumstances	O
that	O
would	O
result	O
in	O
very	O
low	O
power	O
,	O
such	O
as	O
attributable	O
risks	O
for	O
the	O
unlinked	O
locus	O
more	O
than	O
twice	O
as	O
large	O
as	O
attributable	O
risks	O
for	O
the	O
linked	O
locus	O
,	O
or	O
recombination	O
fractions	O
>	O
0.1	O
,	O
was	O
Zp	O
predicted	O
to	O
outperform	O
Zc	O
in	O
our	O
simulated	O
sample	O
of	O
500	O
families	O
.	O

In	O
principle	O
,	O
including	O
genotype	O
data	O
from	O
unaffected	B
siblings	O
can	O
improve	O
the	O
ability	O
to	O
estimate	O
haplotypes	O
and	O
thereby	O
improve	O
power	O
when	O
multipoint	O
data	O
are	O
studied	O
.	O

Table	O
6	O
compares	O
estimates	O
of	O
Zc	O
and	O
Zp	O
for	O
a	O
selected	O
set	O
of	O
simulations	O
with	O
multipoint	O
Zm	O
scores	O
for	O
the	O
same	O
families	O
as	O
calculated	O
by	O
the	O
computer	O
program	O
Merlin	O
[	O
58	O
]	O
.	O

In	O
these	O
simulations	O
,	O
when	O
markers	O
were	O
spaced	O
no	O
closer	O
than	O
10	O
cM	O
from	O
one	O
another	O
,	O
as	O
is	O
usually	O
the	O
case	O
in	O
an	O
initial	O
genome	O
scan	O
,	O
we	O
observed	O
no	O
improvement	O
in	O
power	O
with	O
the	O
concordant	O
multipoint	O
statistic	O
,	O
but	O
an	O
improvement	O
in	O
power	O
with	O
the	O
discordant	O
test	O
.	O

When	O
markers	O
were	O
spaced	O
at	O
5	O
cM	O
intervals	O
,	O
however	O
,	O
the	O
power	O
of	O
both	O
multipoint	O
statistics	O
to	O
detect	O
linkage	O
exceeded	O
that	O
of	O
both	O
Zc	O
and	O
Zp	O
.	O

The	O
conservative	O
bias	O
of	O
Zmc	O
noted	O
in	O
Tables	O
2	O
and	O
3	O
appears	O
to	O
decrease	O
as	O
marker	O
intervals	O
become	O
smaller	O
.	O

To	O
test	O
this	O
,	O
we	O
conducted	O
additional	O
simulations	O
under	O
the	O
null	O
hypothesis	O
as	O
described	O
above	O
for	O
Tables	O
2	O
and	O
3	O
,	O
with	O
1000	O
repetitions	O
and	O
markers	O
spaced	O
at	O
5	O
,	O
10	O
,	O
and	O
20	O
cM.	O
The	O
magnitude	O
of	O
the	O
conservative	O
bias	O
in	O
Zmc	O
decreases	O
consistently	O
(	O
mean	O
Zmc	O
=	O
-0.58	O
at	O
20	O
cM	O
,	O
-0.23	O
at	O
10	O
cM	O
,	O
and	O
0.06	O
at	O
5	O
cM	O
)	O
as	O
marker	O
intervals	O
contract	O
,	O
becoming	O
significantly	O
anti	O
-	O
conservative	O
at	O
5	O
cM.	O

Discussion	O
In	O
studying	O
a	O
disease	B
like	O
colon	B
cancer	I
with	O
both	O
incomplete	O
penetrance	O
and	O
a	O
high	O
incidence	O
of	O
sporadics	O
,	O
prior	O
studies	O
have	O
shown	O
that	O
to	O
be	O
efficient	O
,	O
families	O
must	O
include	O
two	O
or	O
more	O
individuals	O
with	O
the	O
same	O
disease	B
from	O
whom	O
samples	O
can	O
be	O
obtained	O
.	O

The	O
practical	O
experience	O
of	O
many	O
investigators	O
suggests	O
that	O
once	O
an	O
initial	O
entree	O
is	O
gained	O
into	O
a	O
family	O
,	O
the	O
chances	O
of	O
enrolling	O
other	O
members	O
are	O
quite	O
high	O
.	O

Close	O
relatives	O
are	O
often	O
very	O
motivated	O
to	O
participate	O
in	O
research	O
into	O
a	O
disease	B
that	O
has	O
afflicted	O
their	O
family	O
,	O
especially	O
when	O
the	O
commitment	O
is	O
minimal	O
,	O
involving	O
only	O
a	O
blood	O
specimen	O
and	O
a	O
signed	O
consent	O
,	O
which	O
are	O
all	O
that	O
are	O
required	O
for	O
a	O
linkage	O
study	O
of	O
diseases	B
that	O
have	O
an	O
easily	O
established	O
phenotype	O
,	O
like	O
cancer	B
.	O

In	O
our	O
simulations	O
,	O
we	O
considered	O
inclusion	O
of	O
unaffected	B
sibs	O
and	O
the	O
use	O
of	O
spouse	O
and	O
offspring	O
to	O
replace	O
missing	O
affected	B
sibs	O
.	O

Including	O
unaffected	B
siblings	O
in	O
the	O
design	O
of	O
a	O
study	O
can	O
improve	O
the	O
power	O
to	O
detect	O
linkage	O
for	O
highly	O
-	O
penetrant	O
diseases	B
[	O
53,66	O
]	O
.	O

However	O
,	O
our	O
simulation	O
studies	O
demonstrate	O
that	O
for	O
the	O
model	O
-	O
free	O
linkage	O
tests	O
we	O
studied	O
,	O
for	O
low	O
penetrance	O
loci	O
,	O
and	O
with	O
no	O
genotyping	O
error	O
,	O
little	O
increase	O
in	O
power	O
can	O
be	O
gained	O
by	O
including	O
unaffected	B
siblings	O
in	O
the	O
design	O
of	O
a	O
sib	O
-	O
pair	O
study	O
of	O
a	O
late	O
onset	O
,	O
complex	O
disease	B
such	O
as	O
colorectal	B
cancer	I
.	O

The	O
inclusion	O
of	O
unaffected	B
siblings	O
can	O
be	O
useful	O
,	O
however	O
,	O
in	O
reducing	O
anti	O
-	O
conservative	O
biases	O
arising	O
from	O
heterogeneity	O
or	O
misspecification	O
of	O
marker	O
allele	O
frequencies	O
or	O
genotyping	O
errors	O
,	O
and	O
conservative	O
biases	O
arising	O
if	O
multipoint	O
statistics	O
are	O
used	O
with	O
an	O
insufficiently	O
dense	O
marker	O
set	O
.	O

Table	O
2	O
shows	O
that	O
,	O
with	O
markers	O
spaced	O
at	O
10	O
cM	O
intervals	O
,	O
Zmc	O
is	O
conservatively	O
biased	O
,	O
while	O
exhibiting	O
an	O
anticonservative	O
bias	O
in	O
Table	O
3	O
under	O
conditions	O
of	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
.	O

In	O
Table	O
6	O
,	O
Zmp	O
outperforms	O
with	O
markers	O
spaced	O
at	O
10	O
and	O
20	O
cM.	O
At	O
5	O
cM	O
,	O
Zmc	O
becomes	O
anticonservatively	O
biased	O
,	O
as	O
noted	O
above	O
.	O

It	O
may	O
be	O
useful	O
to	O
perform	O
simulations	O
to	O
assess	O
the	O
characteristics	O
of	O
the	O
tests	O
when	O
the	O
marker	O
spacing	O
decreases	O
,	O
as	O
would	O
be	O
possible	O
with	O
the	O
newer	O
SNP	O
array	O
-	O
based	O
platforms	O
.	O

Further	O
,	O
since	O
genome	O
-	O
wide	O
-	O
association	O
studies	O
do	O
not	O
utilize	O
the	O
full	O
power	O
of	O
the	O
sibpair	O
design	O
,	O
future	O
research	O
should	O
be	O
aimed	O
at	O
assessing	O
the	O
optimal	O
setting	O
for	O
relying	O
on	O
the	O
sibpair	O
design	O
,	O
as	O
it	O
is	O
premature	O
to	O
move	O
completely	O
away	O
from	O
this	O
study	O
design	O
[	O
15	O
]	O
.	O

If	O
a	O
secondary	O
goal	O
of	O
a	O
study	O
is	O
to	O
estimate	O
the	O
penetrance	O
,	O
then	O
unaffected	B
relatives	O
should	O
be	O
included	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
also	O
unaffected	B
siblings	O
could	O
help	O
in	O
evaluating	O
the	O
impact	O
of	O
environmental	O
factors	O
upon	O
disease	B
risk	O
.	O

Genotyping	O
errors	O
for	O
microsatellites	O
scans	O
are	O
currently	O
very	O
low	O
but	O
are	O
hard	O
to	O
assess	O
without	O
the	O
availability	O
of	O
parents	O
or	O
siblings	O
.	O

Our	O
findings	O
parallel	O
those	O
of	O
Holmans	O
et	O
al.	O
[	O
67	O
]	O
,	O
who	O
suggested	O
that	O
genotyping	O
affected	B
individuals	O
only	O
is	O
efficient	O
.	O

Crude	O
stratification	O
by	O
recruitment	O
center	O
is	O
unlikely	O
to	O
be	O
reliable	O
enough	O
for	O
controlling	O
population	O
heterogeneity	O
without	O
additional	O
adjustment	O
.	O

Stratification	O
by	O
ethnicity	O
is	O
generally	O
more	O
crucial	O
than	O
by	O
geography	O
,	O
although	O
both	O
factors	O
should	O
ideally	O
be	O
incorporated	O
.	O

However	O
,	O
collection	O
of	O
ethnicity	O
is	O
not	O
entirely	O
trivial	O
if	O
it	O
is	O
to	O
be	O
worthwhile	O
.	O

Although	O
various	O
coding	O
systems	O
have	O
been	O
established	O
by	O
different	O
agencies	O
,	O
no	O
consensus	O
has	O
been	O
established	O
regarding	O
the	O
level	O
of	O
detail	O
required	O
on	O
ethnicity	O
data	O
in	O
genetic	O
research	O
,	O
e.g.	O
category	O
distinctions	O
,	O
mixed	O
-	O
race	O
marriages	O
.	O

Mandal	O
et	O
al.	O
[	O
81	O
]	O
have	O
shown	O
that	O
marker	O
allele	O
frequencies	O
are	O
less	O
important	O
if	O
there	O
are	O
four	O
or	O
more	O
persons	O
per	O
family	O
,	O
especially	O
when	O
very	O
polymorphic	O
markers	O
are	O
used	O
.	O

When	O
the	O
parents	O
of	O
the	O
sibpair	O
have	O
been	O
genotyped	O
,	O
then	O
there	O
is	O
no	O
dependence	O
on	O
population	O
marker	O
allele	O
frequencies	O
and	O
no	O
source	O
of	O
bias	O
in	O
linkage	O
analysis	O
.	O

CpG	O
Island	O
Methylation	O
in	O
Familial	O
Colorectal	B
Cancer	I
Patients	O
Not	O
Fulfilling	O
the	O
Amsterdam	O
Criteria	O
Abstract	O
To	O
determine	O
the	O
role	O
of	O
methylation	O
in	O
colorectal	B
cancer	I
patients	O
with	O
a	O
family	B
history	I
,	O
we	O
enrolled	O
25	O
colorectal	B
cancer	I
patients	O
with	O
a	O
family	B
history	I
of	I
colorectal	I
cancer	I
but	O
without	O
a	O
mutation	O
in	O
the	O
hMLH1	O
and	O
hMSH2	O
genes	O
.	O

Thirty	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
were	O
included	O
as	O
control	O
.	O

The	O
methylation	O
status	O
of	O
COX2	O
,	O
MGMT	O
,	O
hMLH1	O
,	O
TIMP3	O
,	O
p16	O
,	O
and	O
MINT2	O
in	O
normal	B
mucosa	O
and	O
tumor	B
were	O
assessed	O
using	O
methylation	O
-	O
specific	O
PCR	O
.	O

In	O
patients	O
with	O
a	O
family	B
history	I
,	O
the	O
methylation	O
frequency	O
ranged	O
from	O
4.0	O
%	O
for	O
TIMP3	O
to	O
44.4	O
%	O
for	O
MGMT	O
,	O
whereas	O
,	O
in	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
,	O
it	O
ranged	O
from	O
6.7	O
%	O
for	O
TIMP3	O
to	O
50.0	O
%	O
for	O
p16	O
.	O

Nine	O
of	O
the	O
25	O
patients	O
with	O
family	B
history	I
(	O
36.0	O
%	O
)	O
were	O
classified	O
as	O
methylation	O
-	O
prone	O
,	O
and	O
nine	O
of	O
the	O
30	O
patients	O
with	O
sporadic	O
cancers	B
(	O
30.0	O
%	O
)	O
were	O
as	O
methylation	O
-	O
prone	O
,	O
making	O
their	O
methylation	O
indices	O
0.19	O
and	O
0.16	O
,	O
respectively	O
(	O
p=0.522	O
)	O
.	O

As	O
for	O
the	O
individual	O
genes	O
,	O
the	O
methylation	O
rate	O
of	O
MGMT	O
was	O
higher	O
in	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
(	O
44.0	O
%	O
vs.	O
13.0	O
%	O
,	O
p=0.016	O
)	O
,	O
whereas	O
the	O
methylation	O
rate	O
of	O
p16	O
was	O
higher	O
in	O
sporadic	O
colorectal	B
cancers	I
(	O
50.0	O
%	O
vs.	O
8.7	O
%	O
,	O
p=0.046	O
)	O
.	O

While	O
CpG	O
island	O
methylation	O
of	O
tumor	B
suppressor	O
genes	O
may	O
play	O
a	O
role	O
in	O
colorectal	O
carcinogenesis	O
,	O
the	O
genes	O
involved	O
may	O
be	O
different	O
between	O
tumors	B
of	O
patients	O
with	O
and	O
without	O
a	O
family	O
history	O
of	O
colorectal	B
cancer	I
.	O

RESULTS	O
Methylation	O
in	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
We	O
determined	O
CpG	O
island	O
methylation	O
at	O
six	O
loci	O
and	O
MSI	O
in	O
paired	O
normal	B
mucosa	O
and	O
tumor	B
tissue	O
from	O
25	O
colorectal	B
cancer	I
patients	O
with	O
family	B
history	I
.	O

Of	O
the	O
25	O
tumors	B
,	O
16	O
(	O
64.0	O
%	O
)	O
showed	O
promoter	O
methylation	O
of	O
at	O
least	O
one	O
gene	O
,	O
ranging	O
to	O
four	O
genes	O
.	O

Seven	O
tumors	B
showed	O
methylation	O
at	O
one	O
gene	O
,	O
seven	O
at	O
two	O
genes	O
,	O
one	O
at	O
three	O
genes	O
,	O
and	O
one	O
at	O
four	O
genes	O
.	O

In	O
contrast	O
,	O
of	O
the	O
25	O
samples	O
of	O
normal	B
colonic	O
mucosa	O
,	O
12	O
(	O
48.0	O
%	O
)	O
showed	O
promoter	O
methylation	O
:	O
eight	O
samples	O
at	O
one	O
gene	O
,	O
and	O
four	O
samples	O
at	O
two	O
genes	O
.	O

When	O
patients	O
with	O
a	O
family	B
history	I
were	O
categorized	O
as	O
having	O
0	O
-	O
1	O
(	O
MR	O
group	O
)	O
or	O
≥2	O
(	O
MP	O
group	O
)	O
methylated	O
loci	O
,	O
we	O
found	O
that	O
36.0	O
%	O
of	O
the	O
tumors	B
and	O
16.0	O
%	O
of	O
the	O
normal	B
mucosa	O
samples	O
could	O
be	O
categorized	O
as	O
MP	O
.	O

The	O
mean	O
methylation	O
index	O
(	O
the	O
number	O
of	O
methylated	O
loci	O
divided	O
by	O
the	O
total	O
number	O
of	O
tested	O
loci	O
)	O
was	O
0.11	O
(	O
0	O
-	O
0.33	O
)	O
in	O
normal	B
mucosa	O
and	O
0.19	O
(	O
0	O
-	O
0.66	O
)	O
in	O
tumors	B
(	O
p=0.078	O
)	O
.	O

A	O
high	O
proportion	O
of	O
tumors	B
(	O
44.0	O
%	O
)	O
were	O
methylated	O
at	O
the	O
MGMT	O
locus	O
,	O
whereas	O
20.0	O
%	O
,	O
20.0	O
%	O
,	O
and	O
16.0	O
%	O
were	O
methylated	O
at	O
the	O
COX2	O
,	O
hMLH1	O
,	O
and	O
MINT2	O
loci	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
only	O
8.0	O
%	O
of	O
p16	O
loci	O
and	O
4.0	O
%	O
of	O
TIMP3	O
loci	O
were	O
methylated	O
(	O
Fig.	O
2	O
)	O
.	O

We	O
found	O
that	O
the	O
COX2	O
,	O
MGMT	O
,	O
and	O
p16	O
loci	O
were	O
methylated	O
at	O
28.0	O
%	O
,	O
20.0	O
%	O
,	O
and	O
16.0	O
%	O
,	O
respectively	O
,	O
of	O
normal	B
mucosa	O
samples	O
of	O
patients	O
with	O
a	O
family	B
history	I
,	O
whereas	O
the	O
hMLH1	O
,	O
TIMP3	O
,	O
and	O
MINT2	O
loci	O
were	O
not	O
methylated	O
in	O
any	O
of	O
the	O
normal	B
mucosa	O
samples	O
.	O

The	O
frequency	O
of	O
methylation	O
of	O
the	O
COX2	O
and	O
p16	O
loci	O
was	O
higher	O
in	O
normal	B
mucosa	O
than	O
in	O
tumor	B
,	O
but	O
the	O
difference	O
did	O
not	O
reach	O
a	O
statistical	O
significance	O
.	O

Methylation	O
in	O
sporadic	O
colorectal	B
cancer	I
patients	O
We	O
also	O
assayed	O
CpG	O
island	O
methylation	O
at	O
these	O
six	O
loci	O
and	O
MSI	O
in	O
paired	O
tumors	B
and	O
normal	B
mucosa	O
from	O
30	O
patients	O
with	O
sporadic	O
colorectal	B
cancer	I
.	O

We	O
found	O
that	O
16	O
(	O
53.0	O
%	O
)	O
of	O
the	O
tumors	B
showed	O
promoter	O
methylation	O
of	O
at	O
least	O
one	O
gene	O
,	O
ranging	O
to	O
three	O
genes	O
.	O

Seven	O
tumors	B
showed	O
methylation	O
at	O
one	O
locus	O
,	O
six	O
at	O
two	O
loci	O
,	O
and	O
one	O
at	O
three	O
loci	O
.	O

In	O
contrast	O
,	O
only	O
7	O
(	O
23.0	O
%	O
)	O
of	O
the	O
normal	B
colonic	O
mucosa	O
samples	O
showed	O
promoter	O
methylation	O
,	O
each	O
at	O
one	O
gene	O
.	O

We	O
found	O
that	O
30.0	O
%	O
of	O
the	O
tumors	B
,	O
and	O
none	O
of	O
the	O
normal	B
mucosa	O
,	O
could	O
be	O
classified	O
as	O
MP	O
.	O

The	O
mean	O
methylation	O
index	O
was	O
0.04	O
(	O
0	O
-	O
0.17	O
)	O
in	O
normal	B
mucosa	O
and	O
0.16	O
(	O
0	O
-	O
0.5	O
)	O
in	O
tumors	B
(	O
p<0.001	O
)	O
.	O

Methylation	O
of	O
the	O
p16	O
locus	O
was	O
observed	O
in	O
a	O
high	O
proportion	O
(	O
33.3	O
%	O
)	O
of	O
sporadic	O
tumors	B
cases	O
,	O
whereas	O
methylation	O
of	O
the	O
COX2	O
,	O
MGMT	O
,	O
and	O
MINT2	O
loci	O
were	O
observed	O
in	O
20.0	O
%	O
,	O
13.3	O
%	O
,	O
and	O
13.3	O
%	O
,	O
respectively	O
,	O
of	O
these	O
tumors	B
.	O

In	O
contrast	O
,	O
only	O
6.7	O
%	O
of	O
tumors	B
were	O
methylated	O
at	O
the	O
TIMP3	O
promoter	O
(	O
Fig.	O
3	O
)	O
.	O

Methylation	O
of	O
the	O
p16	O
,	O
COX2	O
,	O
and	O
MGMT	O
loci	O
were	O
observed	O
in	O
13.3	O
%	O
,	O
6.7	O
%	O
,	O
and	O
3.4	O
%	O
,	O
respectively	O
,	O
of	O
the	O
normal	B
mucosa	O
samples	O
,	O
whereas	O
we	O
did	O
not	O
observe	O
methylation	O
of	O
the	O
hMLH1	O
,	O
TIMP3	O
,	O
and	O
MINT2	O
loci	O
in	O
any	O
of	O
these	O
tissues	O
.	O

Several	O
reports	O
have	O
described	O
an	O
association	O
between	O
the	O
methylation	O
status	O
of	O
multiple	O
genes	O
and	O
a	O
familial	O
tendency	O
to	O
colorectal	B
cancer	I
(	O
15	O
,	O
28	O
)	O
.	O

A	O
recent	O
large	O
study	O
,	O
however	O
,	O
found	O
no	O
evidence	O
that	O
patients	O
with	O
heavily	O
methylated	O
colorectal	B
cancers	I
were	O
more	O
likely	O
to	O
develop	O
a	O
second	O
malignancy	O
or	O
have	O
a	O
positive	O
family	B
history	I
of	I
cancer	I
(	O
29	O
)	O
.	O

Aberrant	O
methylation	O
may	O
result	O
from	O
an	O
inherited	O
defect	O
in	O
the	O
methylation	O
apparatus	O
.	O

In	O
this	O
study	O
,	O
considerable	O
proportions	O
of	O
cancer	B
in	O
both	O
groups	O
with	O
or	O
without	O
familial	O
history	O
of	O
colorectal	B
cancer	I
presented	O
the	O
methylated	O
genes	O
that	O
may	O
involved	O
in	O
carcinogenetic	O
pathways	O
.	O

It	O
still	O
remains	O
to	O
be	O
elucidated	O
whether	O
promoter	O
methylation	O
in	O
multiple	O
genes	O
is	O
one	O
of	O
main	O
mechanism	O
to	O
evoke	O
cancer	B
or	O
simple	O
bystander	O
.	O

However	O
,	O
our	O
results	O
confirm	O
that	O
CpG	O
island	O
promoter	O
methylation	O
may	O
be	O
a	O
universal	O
event	O
in	O
sporadic	O
or	O
familial	O
colorectal	B
cancer	I
,	O
and	O
is	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
for	O
'	O
second	O
hits	O
'	O
by	O
which	O
tumor	B
suppressor	O
genes	O
are	O
inactivated	O
.	O

Evidence	O
for	O
this	O
mechanism	O
in	O
familial	O
colorectal	B
cancers	I
was	O
previously	O
reported	O
in	O
studies	O
showing	O
aberrant	O
methylation	O
of	O
individual	O
genes	O
,	O
including	O
CDH1	O
,	O
VHL	O
,	O
and	O
hMLH1	O
,	O
in	O
hereditary	O
cancer	B
syndromes	I
(	O
30	O
-	O
32	O
)	O
.	O

Cancer	B
is	O
a	O
genetic	O
disease	B
.	O

Most	O
cancer	B
-	O
causing	O
mutations	O
are	O
somatic	O
,	O
occurring	O
in	O
the	O
affected	B
tissue	O
during	O
the	O
course	O
of	O
carcinogenesis	O
.	O

However	O
,	O
most	O
cancers	B
also	O
have	O
a	O
hereditary	O
component	O
,	O
caused	O
by	O
predisposing	O
mutations	O
that	O
affect	O
the	O
germline	O
,	O
are	O
heritable	O
,	O
contribute	O
to	O
the	O
initiation	O
of	O
carcinogenesis	O
,	O
and	O
influence	O
the	O
carcinogenesis	O
pathway	O
.	O

Although	O
hypermethylation	O
is	O
not	O
a	O
rare	O
event	O
,	O
either	O
in	O
sporadic	O
colorectal	B
cancers	I
or	O
in	O
colorectal	B
cancers	I
with	O
family	B
history	I
,	O
predisposing	O
germline	O
alterations	O
can	O
affect	O
detailed	O
aspects	O
of	O
methylation	O
.	O

Our	O
data	O
showed	O
two	O
of	O
the	O
genes	O
methylated	O
at	O
their	O
promoters	O
,	O
p16	O
and	O
MGMT	O
,	O
differ	O
according	O
to	O
the	O
tumor	B
type	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
methylation	O
of	O
p16	O
,	O
leading	O
to	O
its	O
loss	O
of	O
function	O
,	O
may	O
be	O
a	O
dominant	O
and	O
necessary	O
event	O
for	O
sporadic	O
colorectal	O
carcinogenesis	B
,	O
whereas	O
methylation	O
of	O
MGMT	O
may	O
be	O
dominant	O
and	O
necessary	O
in	O
colorectal	O
carcinogenesis	B
in	O
individuals	O
with	O
a	O
family	B
history	I
.	O

It	O
was	O
reported	O
that	O
the	O
frequency	O
and	O
pattern	O
of	O
gene	O
methylation	O
varied	O
between	O
HNPCC	B
syndrome	B
and	O
sporadic	O
adenomas	B
,	O
implying	O
differences	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
tumors	B
(	O
33	O
)	O
.	O

MGMT	O
has	O
been	O
considered	O
as	O
a	O
critical	O
step	O
of	O
genetic	O
instability	O
and	O
methylation	O
of	O
MGMT	O
are	O
proposed	O
to	O
show	O
a	O
distinctive	O
phenotype	O
of	O
MSI	B
-	I
L	I
or	O
mild	B
family	I
history	I
of	O
colorectal	B
cancer	I
(	O
34	O
,	O
35	O
)	O
.	O

The	O
present	O
study	O
also	O
showed	O
a	O
possibility	O
that	O
different	O
pathways	O
to	O
cancer	B
may	O
exit	O
according	O
to	O
the	O
molecular	O
background	O
and	O
some	O
subgroup	O
of	O
familial	O
colorectal	B
cancer	I
are	O
related	O
to	O
the	O
loss	O
of	O
function	O
of	O
MGMT	O
.	O

Thus	O
,	O
genes	O
selected	O
for	O
methylation	O
-	O
induced	O
functional	O
loss	O
may	O
differ	O
according	O
to	O
the	O
genetic	O
background	O
.	O

While	O
methylation	O
seems	O
to	O
be	O
a	O
universal	O
mechanism	O
by	O
which	O
gene	O
function	O
is	O
inactivated	O
,	O
the	O
germline	O
mutations	O
in	O
familial	O
tumors	B
confer	O
a	O
selective	O
advantage	O
for	O
their	O
tumorigenic	O
growth	O
,	O
but	O
other	O
genetic	O
and	O
epigenetic	O
lesions	O
are	O
also	O
necessary	O
.	O

Genetic	O
predisposition	O
to	O
CpG	O
island	O
methylation	O
may	O
be	O
a	O
modifying	O
factor	O
that	O
contributes	O
to	O
the	O
penetrance	O
of	O
HNPCC	B
.	O

Our	O
findings	O
thus	O
expand	O
these	O
early	O
observations	O
on	O
methylation	O
in	O
familial	O
colorectal	B
cancer	I
and	O
highlight	O
the	O
selective	O
advantage	O
of	O
epigenetic	O
gene	O
silencing	O
.	O

Impact	O
of	O
BRAF	O
,	O
MLH1	O
on	O
the	O
incidence	O
of	O
microsatellite	B
instability	I
high	I
colorectal	B
cancer	I
in	O
populations	O
based	O
study	O
Abstract	O
We	O
have	O
identified	O
an	O
alternative	O
pathway	O
of	O
tumorigenesis	B
in	O
sporadic	O
colon	B
cancer	I
,	O
involving	O
microsatellite	O
instability	O
due	O
to	O
mismatched	O
repair	O
methylation	O
,	O
which	O
may	O
be	O
driven	O
by	O
mutations	O
in	O
the	O
BRAF	O
gene	O
(	O
V600E	O
)	O
.	O

Colorectal	B
cancer	I
(	O
CRC	B
)	O
is	O
the	O
most	O
common	O
cancer	B
in	O
the	O
world	O
,	O
and	O
African	O
Americans	O
show	O
a	O
higher	O
incidence	O
than	O
other	O
populations	O
in	O
the	O
United	O
States	O
.	O

We	O
analyzed	O
sporadic	O
CRCs	B
in	O
Omani	O
(	O
of	O
African	O
origin	O
,	O
N	O
=	O
61	O
)	O
,	O
Iranian	O
(	O
of	O
Caucasian	O
origin	O
,	O
N	O
=	O
53	O
)	O
and	O
African	O
American	O
(	O
N	O
=	O
95	O
)	O
patients	O
for	O
microsatellite	O
instability	O
,	O
expression	O
status	O
of	O
mismatched	O
repair	O
genes	O
(	O
hMLH1	O
,	O
hMSH2	O
)	O
and	O
presence	O
of	O
the	O
BRAF	O
(	O
V600E	O
)	O
mutation	O
.	O

In	O
the	O
Omani	O
group	O
,	O
all	O
tumors	B
with	O
BRAF	O
mutations	O
were	O
located	O
in	O
the	O
left	O
side	O
of	O
the	O
colon	O
,	O
and	O
for	O
African	O
Americans	O
,	O
88	O
%	O
[	O
7	O
]	O
of	O
tumors	B
with	O
BRAF	O
mutations	O
were	O
found	O
in	O
the	O
right	O
side	O
of	O
the	O
colon	O
.	O

In	O
African	O
Americans	O
,	O
31	O
%	O
of	O
tumors	B
displayed	O
microsatellite	O
instability	O
at	O
two	O
or	O
more	O
markers	O
(	O
MSI	B
-	I
H	I
)	O
,	O
while	O
this	O
rate	O
was	O
26	O
%	O
and	O
13	O
%	O
for	O
tumors	B
in	O
the	O
Iranian	O
and	O
Omani	O
groups	O
,	O
respectively	O
.	O

A	O
majority	O
of	O
these	O
MSI	B
-	I
H	I
tumors	B
were	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
right	O
side	O
)	O
in	O
African	O
American	O
and	O
Iranian	O
subjects	O
,	O
whereas	O
most	O
were	O
located	O
in	O
the	O
distal	O
colon	O
(	O
left	O
side	O
)	O
in	O
Omani	O
subjects	O
.	O

Defects	O
in	O
hMLH1	O
gene	O
expression	O
were	O
found	O
in	O
77	O
%	O
of	O
MSI	B
-	I
H	I
tumors	B
in	O
both	O
African	O
Americans	O
and	O
Iranians	O
and	O
in	O
38	O
%	O
of	O
tumors	B
in	O
Omanis	O
.	O

BRAF	O
mutations	O
were	O
observed	O
in	O
all	O
subjects	O
:	O
10	O
%	O
of	O
tumors	B
in	O
African	O
Americans	O
(	O
8	O
/	O
82	O
)	O
,	O
2	O
%	O
of	O
tumors	B
in	O
Iranians	O
(	O
1	O
/	O
53	O
)	O
,	O
and	O
19	O
%	O
of	O
tumors	B
in	O
Omanis	O
(	O
11	O
/	O
59	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
CRC	B
occurs	O
at	O
a	O
younger	O
age	O
in	O
Omani	O
and	O
Iranian	O
patients	O
,	O
and	O
these	O
groups	O
showed	O
a	O
lower	O
occurrence	O
of	O
MSI	O
-	O
H	O
than	O
did	O
African	O
American	O
patients	O
.	O

Our	O
multivariate	O
model	O
suggests	O
an	O
important	O
and	O
significant	O
role	O
of	O
hMLH1	O
expression	O
and	O
BRAF	O
mutation	O
in	O
MSI	B
-	I
H	I
CRC	B
in	O
these	O
populations	O
.	O

The	O
high	O
occurrence	O
of	O
MSI	B
-	I
H	I
tumors	B
in	O
African	O
Americans	O
may	O
have	O
significant	O
implications	O
for	O
treatment	O
,	O
since	O
patients	O
with	O
MSI	B
-	I
H	I
lesions	B
display	O
a	O
different	O
response	O
to	O
chemotherapeutic	O
agents	O
such	O
as	O
5-fluorouracil	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
samples	O
from	O
two	O
different	O
populations	O
of	O
African	O
descent	O
(	O
African	O
American	O
and	O
Omani	O
)	O
and	O
a	O
Caucasian	O
population	O
(	O
Iranian	O
)	O
for	O
microsatellite	O
instability	O
and	O
BRAF	O
mutations	O
.	O

We	O
correlated	O
our	O
findings	O
with	O
the	O
silencing	O
of	O
genes	O
involved	O
in	O
DNA	O
MMR	O
.	O

We	O
evaluated	O
and	O
compared	O
the	O
demographic	O
and	O
clinicopathological	O
data	O
in	O
relation	O
to	O
molecular	O
alterations	O
in	O
specific	O
genes	O
(	O
BRAF	O
,	O
DNA	O
MMR	O
)	O
to	O
improve	O
our	O
understanding	O
of	O
colon	O
tumorgenesis	O
in	O
people	O
living	O
in	O
different	O
environments	O
.	O

Methods	O
Patients	O
A	O
total	O
of	O
95	O
African	O
American	O
CRC	B
patients	O
(	O
from	O
Howard	O
University	O
and	O
Johns	O
Hopkins	O
Hospital	O
between	O
1997	O
and	O
2004	O
;	O
self	O
-	O
identified	O
as	O
African	O
American	O
)	O
,	O
61	O
Omani	O
CRC	B
patients	O
(	O
from	O
the	O
two	O
tertiary	O
referral	O
hospitals	O
in	O
Oman	O
Sultan	O
Qaboos	O
University	O
Hospital	O
and	O
the	O
Royal	O
Hospital	O
between	O
2000	O
and	O
2004	O
who	O
underwent	O
surgical	O
resection	O
)	O
and	O
53	O
Iranian	O
CRC	B
patients	O
(	O
from	O
the	O
two	O
referral	O
hospitals	O
in	O
Shiraz	O
,	O
Iran	O
Namazi	O
Hospital	O
and	O
Saadi	O
Hospital	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
archival	O
tissue	O
was	O
collected	O
(	O
with	O
approval	O
from	O
all	O
above	O
sites	O
'	O
Institutional	O
Review	O
Boards	O
)	O
and	O
clinical	O
data	O
was	O
obtained	O
(	O
including	O
race	O
,	O
age	O
,	O
site	O
of	O
primary	O
tumor	B
,	O
mucin	O
production	O
and	O
tumor	B
differentiation	O
)	O
.	O

In	O
addition	O
,	O
the	O
family	O
history	O
of	O
cancer	B
was	O
analyzed	O
to	O
identify	O
those	O
pedigrees	O
that	O
met	O
either	O
the	O
Amsterdam	O
I	O
or	O
Amsterdam	O
II	O
criteria	O
for	O
HNPCC	B
.	O

The	O
study	O
was	O
performed	O
on	O
unselected	O
and	O
serially	O
collected	O
specimens	O
.	O

All	O
cases	O
underwent	O
surgery	O
within	O
the	O
given	O
collection	O
.	O

DNA	O
isolation	O
and	O
MSI	O
analysis	O
Archived	O
and	O
fresh	O
tumor	B
blocks	O
were	O
cut	O
into	O
5-μm	O
sections	O
on	O
Superfrost	O
slides	O
(	O
Fisher	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

The	O
tumor	B
and	O
normal	B
area	O
were	O
diagnosed	O
by	O
a	O
pathologist	O
using	O
the	O
H&E	O
matched	O
slide	O
and	O
microdissected	O
to	O
pinpoint	O
the	O
tumor	B
areas	O
as	O
well	O
as	O
normal	O
areas	O
from	O
at	O
least	O
two	O
slides	O
.	O

A	O
pinpoint	O
DNA	O
extraction	O
kit	O
was	O
used	O
as	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Zymo	O
Research	O
)	O
.	O

The	O
extracted	O
tumor	B
and	O
normal	B
matched	O
DNA	O
were	O
used	O
as	O
template	O
in	O
PCR	O
reactions	O
where	O
five	O
microsatellite	O
markers	O
(	O
Cancer	B
Research	O
58:5248–5257	O
,	O
1998;	O
[	O
21	O
]	O
;	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
and	O
D2S123	O
)	O
were	O
used	O
to	O
evaluate	O
MSI	O
status	O
.	O

PCR	O
products	O
were	O
analyzed	O
in	O
a	O
3130	O
ABI	O
GeneScan	O
.	O

Those	O
displaying	O
DNA	O
instability	O
at	O
only	O
one	O
of	O
the	O
markers	O
(	O
including	O
the	O
dinucleotides	O
)	O
were	O
labeled	O
MSI	O
-	O
L	O
,	O
those	O
displaying	O
instability	O
with	O
two	O
or	O
more	O
markers	O
were	O
labeled	O
MSI	O
-	O
H	O
,	O
and	O
those	O
displaying	O
no	O
instability	O
with	O
any	O
of	O
the	O
five	O
markers	O
tested	O
were	O
labeled	O
MSS	O
.	O

Due	O
to	O
unclear	O
characteristics	O
of	O
MSI	O
-	O
L	O
,	O
we	O
combined	O
MSS	O
and	O
MSI	O
-	O
L	O
as	O
one	O
group	O
(	O
non	O
-	O
MSI	O
-	O
H	O
)	O
.	O

Methylation	O
-	O
specific	O
PCR	O
The	O
presence	O
or	O
absence	O
of	O
hMLH1	O
and	O
p16	O
methylation	O
in	O
cancers	B
was	O
determined	O
by	O
comparing	O
the	O
signals	O
from	O
tumor	B
-	O
derived	O
tissues	O
with	O
those	O
from	O
normal	B
,	O
non	B
-	I
cancerous	I
tissues	O
,	O
as	O
previously	O
described	O
[	O
3,4	O
]	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
samples	O
using	O
a	O
Gentra	O
DNA	O
extraction	O
kit	O
(	O
Gentra	O
)	O
and	O
was	O
modified	O
using	O
DNA	O
modification	O
kits	O
as	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Zymo	O
Research	O
)	O
.	O

MSP	O
was	O
used	O
to	O
distinguish	O
unmethylated	O
from	O
methylated	O
alleles	O
,	O
based	O
on	O
sequence	O
alterations	O
produced	O
by	O
bisulfite	O
treatment	O
of	O
DNA	O
,	O
to	O
convert	O
unmethylated	O
cytosines	O
to	O
uracil	O
.	O

These	O
changes	O
are	O
identified	O
by	O
subsequent	O
PCR	O
using	O
primers	O
specific	O
to	O
the	O
methylated	O
(	O
unchanged	O
)	O
or	O
unmethylated	O
(	O
changed	O
)	O
DNA	O
.	O

Briefly	O
,	O
1	O
μg	O
of	O
genomic	O
DNA	O
was	O
denatured	O
by	O
treatment	O
with	O
NaOH	O
and	O
was	O
modified	O
by	O
the	O
addition	O
of	O
sodium	O
bisulfite	O
.	O

DNA	O
samples	O
were	O
purified	O
using	O
Wizard	O
DNA	O
purification	O
resin	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Promega	O
)	O
.	O

These	O
DNA	O
samples	O
were	O
again	O
treated	O
with	O
NaOH	O
,	O
then	O
precipitated	O
with	O
ethanol	O
and	O
resuspended	O
in	O
water	O
.	O

PCR	O
reactions	O
were	O
performed	O
using	O
the	O
primer	O
pairs	O
described	O
below	O
in	O
the	O
following	O
reaction	O
mix	O
:	O
10	O
×	O
PCR	O
buffer	O
[	O
16.6	O
mM	O
ammonium	O
sulfate	O
,	O
67	O
mM	O
Tris	O
(	O
pH	O
8.8	O
)	O
,	O
6.7	O
mM	O
MgCl2	O
,	O
and	O
10	O
mM	O
2-mercaptoethanol	O
]	O
,	O
dNTPs	O
(	O
each	O
at	O
1.25	O
mM	O
)	O
,	O
primers	O
(	O
50	O
pmol	O
each	O
per	O
reaction	O
)	O
,	O
and	O
bisulfite	O
-	O
modified	O
DNA	O
(	O
50	O
ng	O
)	O
in	O
a	O
final	O
volume	O
of	O
50	O
μl	O
.	O

Reactions	O
were	O
hot	O
-	O
started	O
at	O
95	O
°	O
C	O
for	O
5	O
min	O
,	O
after	O
which	O
1.25	O
units	O
of	O
Taq	O
polymerase	O
(	O
Life	O
Technologies	O
,	O
Inc.	O
)	O
were	O
added	O
.	O

Amplification	O
was	O
carried	O
out	O
in	O
an	O
Applied	O
Biosystem	O
temperature	O
cycler	O
for	O
40	O
cycles	O
(	O
30	O
sec	O
at	O
95	O
°	O
C	O
,	O
30	O
sec	O
at	O
59	O
°	O
C	O
then	O
30	O
sec	O
at	O
72	O
°	O
C	O
)	O
,	O
followed	O
by	O
a	O
final	O
4-min	O
extension	O
at	O
72	O
°	O
C	O
.	O

Two	O
sets	O
of	O
primers	O
were	O
used	O
simultaneously	O
to	O
check	O
for	O
methylated	O
or	O
unmethylated	O
CpG	O
islands	O
at	O
the	O
level	O
of	O
hMLH1	O
and	O
p16	O
promoters	O
.	O

The	O
primer	O
sequences	O
were	O
as	O
in	O
our	O
previous	O
study	O
[	O
4	O
]	O
.	O

Controls	O
for	O
methylated	O
and	O
unmethylated	O
DNA	O
were	O
DNA	O
from	O
the	O
SW48	O
colon	B
cancer	I
cell	O
line	O
and	O
normal	B
lymphocytes	O
,	O
respectively	O
.	O

Each	O
PCR	O
reaction	O
product	O
(	O
10	O
μl	O
)	O
was	O
directly	O
loaded	O
into	O
a	O
2	O
%	O
agarose	O
gel	O
,	O
which	O
was	O
later	O
stained	O
with	O
ethidium	O
bromide	O
to	O
allow	O
DNA	O
visualization	O
under	O
UV	O
illumination	O
.	O

The	O
presence	O
of	O
a	O
band	O
in	O
unmethylated	O
tumor	B
and	O
matched	O
normal	B
with	O
the	O
absence	O
of	O
a	O
methylation	O
band	O
in	O
the	O
tumor	B
was	O
defined	O
as	O
unmethylated	O
.	O

However	O
,	O
when	O
a	O
methylated	O
band	O
was	O
present	O
for	O
tumor	B
and	O
absent	O
for	O
the	O
normal	B
,	O
we	O
defined	O
the	O
sample	O
as	O
methylated	O
(	O
or	O
semi	O
-	O
methylated	O
if	O
both	O
unmethylated	O
or	O
methylated	O
bands	O
were	O
present	O
in	O
the	O
tumor	B
)	O
.	O

Multivariate	O
analysis	O
for	O
the	O
risk	O
factors	O
associated	O
with	O
MSI	O
-	O
H	O
occurrence	O
(	O
Model	O
including	O
single	O
term	O
and	O
interactions	O
effect	O
)	O
*	O
indicates	O
the	O
interaction	O
term	O
between	O
two	O
variables	O
.	O

Correlation	O
between	O
hMLH1	O
protein	O
expression	O
and	O
MSI	O
status	O
Expression	O
of	O
the	O
hMLH1	O
and	O
hMSH2	O
nuclear	O
proteins	O
was	O
examined	O
immunohistochemically	O
in	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
[	O
4	O
]	O
.	O

In	O
all	O
cases	O
,	O
non	O
-	O
neoplastic	O
cells	O
displayed	O
positive	O
nuclear	O
staining	O
for	O
both	O
hMLH1	O
and	O
hMSH2	O
.	O

The	O
nuclear	O
stained	O
slides	O
were	O
read	O
by	O
two	O
different	O
pathologists	O
,	O
and	O
normal	B
tissue	O
on	O
slides	O
where	O
no	O
primary	O
antibody	O
stained	O
was	O
used	O
as	O
negative	O
control	O
.	O

In	O
total	O
,	O
76	O
African	O
American	O
,	O
61	O
Omani	O
,	O
and	O
25	O
Iranian	O
cases	O
were	O
analyzed	O
.	O

Thirty	O
-	O
five	O
and	O
11	O
%	O
of	O
African	O
American	O
tumors	B
assayed	O
showed	O
loss	O
of	O
staining	O
for	O
hMLH1	O
and	O
hMSH2	O
,	O
respectively	O
.	O

Moreover	O
,	O
loss	O
of	O
hMLH1	O
and	O
hMSH2	O
staining	O
was	O
observed	O
in	O
77	O
%	O
and	O
5	O
%	O
of	O
MSI	B
-	I
H	I
African	O
American	O
tumors	B
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

The	O
loss	O
of	O
hMLH1	O
and	O
hMSH2	O
staining	O
was	O
observed	O
in	O
17	O
%	O
and	O
13	O
%	O
of	O
non	B
-	I
MSI	I
-	I
H	I
African	O
American	O
tumors	B
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

In	O
Omani	O
tumors	B
:	O
38	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
the	O
MSI	B
-	I
H	I
tumors	B
showed	O
absences	O
of	O
hMLH1	O
expression	O
(	O
Table	O
2	O
)	O
;	O
30	O
%	O
(	O
n	O
=	O
16	O
)	O
of	O
the	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
had	O
negative	O
hMLH1	O
.	O

Fifty	O
-	O
six	O
cases	O
of	O
Omani	O
patient	O
tested	O
for	O
the	O
presence	O
of	O
hMSH2	O
protein	O
by	O
immunohistochemical	O
staining	O
,	O
seven	O
Omani	O
cases	O
were	O
MSI	B
-	I
H.	I
In	O
Iranian	O
patients	O
,	O
77	O
%	O
[	O
10	O
]	O
of	O
the	O
MSI	B
-	I
H	I
tumors	B
were	O
negative	O
for	O
hMLH1	O
expression	O
(	O
Table	O
3	O
)	O
;	O
all	O
of	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
were	O
positive	B
for	I
hMLH1	I
expression	I
,	O
while	O
for	O
hMSH2	O
these	O
figures	O
were	O
8	O
%	O
[	O
1	O
]	O
and	O
0	O
,	O
respectively	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	O
expression	O
has	O
a	O
significant	O
preventive	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
0.13	O
(	O
0.04–0.41	O
)	O
;	O
p	O
<	O
0.0001	O
;	O
(	O
Table	O
4	O
)	O
)	O
.	O

Correlation	O
between	O
BRAF	O
mutation	O
and	O
MSI	O
status	O
Samples	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
a	O
point	O
mutation	O
that	O
frequently	O
occurs	O
in	O
the	O
oncogene	O
BRAF	O
leading	O
to	O
the	O
change	O
of	O
valine	O
to	O
glutamic	O
acid	O
at	O
position	O
600	O
of	O
the	O
BRAF	O
protein	O
.	O

In	O
all	O
samples	O
only	O
10	O
%	O
[	O
8	O
]	O
African	O
American	O
,	O
19	O
%	O
[	O
11	O
]	O
Omani	O
and	O
2	O
%	O
[	O
1	O
]	O
Iranian	O
samples	O
displayed	O
the	O
mutation	O
by	O
sequencing	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

In	O
the	O
MSI	B
-	I
H	I
group	O
,	O
the	O
BRAF	O
mutation	O
was	O
32	O
%	O
[	O
7	O
]	O
in	O
African	O
Americans	O
,	O
25	O
%	O
[	O
2	O
]	O
in	O
Omani	O
,	O
and	O
7	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
,	O
respectively	O
.	O

Eighteen	O
percent	O
and	O
2	O
%	O
of	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
carry	O
the	O
BRAF	O
mutation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
,	O
while	O
none	O
of	O
the	O
Iranians	O
carried	O
a	O
BRAF	O
mutation	O
in	O
this	O
group	O
.	O

A	O
BRAF	O
mutation	O
is	O
a	O
significant	O
risk	O
factor	O
for	O
MSI	O
-	O
H	O
occurrence	O
even	O
after	O
controlling	O
for	O
other	O
factors	O
in	O
the	O
multivariate	O
model	O
(	O
OR	O
=	O
12.11	O
(	O
2.82–52.03	O
)	O
;	O
p	O
=	O
0.001	O
;	O
(	O
Table	O
4	O
)	O
)	O
.	O

Discussion	O
DNA	O
MMR	O
gene	O
silencing	O
and/or	O
mutation	O
are	O
the	O
main	O
factors	O
leading	O
to	O
accumulation	O
of	O
mutations	O
within	O
genes	O
and	O
general	O
genome	O
instability	O
[	O
19	O
]	O
.	O

The	O
MSI	O
phenotype	O
resulting	O
from	O
such	O
alterations	O
is	O
one	O
of	O
the	O
early	O
events	O
leading	O
to	O
the	O
development	O
of	O
certain	O
cancers	B
.	O

It	O
occurs	O
in	O
patients	O
with	O
Lynch	B
syndrome	I
and	O
in	O
those	O
that	O
acquire	O
such	O
alterations	O
somatically	O
[	O
24	O
]	O
.	O

Another	O
event	O
occurring	O
in	O
adenoma	B
polyp	B
is	O
mutation	O
in	O
oncogenes	O
,	O
specifically	O
in	O
K	O
-	O
ras	O
and	O
BRAF	O
genes	O
in	O
the	O
case	O
of	O
colon	B
cancer	I
[	O
24	O
-	O
26	O
]	O
.	O

The	O
linkage	O
between	O
BRAF	O
mutations	O
and	O
MSI	O
was	O
previously	O
reported	O
[	O
27	O
-	O
30	O
]	O
.	O

In	O
general	O
,	O
Omani	O
people	O
have	O
a	O
mixed	O
Asian	O
and	O
African	O
ethnic	O
background	O
[	O
10	O
]	O
and	O
Iranians	O
are	O
of	O
Caucasian	O
ethnicity	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
African	O
Americans	O
,	O
Omanis	O
and	O
Iranians	O
,	O
the	O
MSI	B
phenotype	O
occurs	O
in	O
31	O
%	O
,	O
26	O
%	O
and	O
13	O
%	O
of	O
CRC	B
tumors	B
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
locations	O
of	O
the	O
tumors	B
in	O
African	O
Americans	O
and	O
Iranians	O
were	O
primarily	O
proximal	O
compared	O
to	O
distal	O
for	O
Omanis	O
;	O
and	O
BRAF	O
mutations	O
were	O
more	O
prevalent	O
in	O
Omanis	O
than	O
African	O
Americans	O
or	O
Iranians	O
(	O
19	O
%	O
,	O
10	O
%	O
and	O
2	O
%	O
,	O
respectively	O
)	O
.	O

While	O
the	O
MSI	B
phenotype	O
in	O
this	O
sample	O
of	O
African	O
Americans	O
is	O
less	O
than	O
we	O
previously	O
reported	O
(	O
43–45	O
%	O
)	O
,	O
[	O
3,4	O
]	O
it	O
appears	O
to	O
be	O
more	O
prevalent	O
in	O
African	O
Americans	O
than	O
in	O
others	O
and	O
still	O
high	O
in	O
the	O
general	O
US	O
population	O
[	O
31	O
-	O
33	O
]	O
.	O

The	O
current	O
sample	O
contained	O
more	O
African	O
Americans	O
and	O
more	O
right	O
-	O
sided	O
than	O
left	O
-	O
sided	O
tumors	B
.	O

The	O
MSI	B
phenotype	O
was	O
more	O
common	O
in	O
proximal	O
tumors	B
than	O
in	O
distal	O
ones	O
(	O
p	O
=	O
0.47	O
)	O
,	O
strengthening	O
earlier	O
findings	O
of	O
such	O
an	O
association	O
[	O
31	O
-	O
33	O
]	O
.	O

The	O
prevalence	O
of	O
MSI	B
-	I
H	I
tumors	B
indicates	O
the	O
importance	O
of	O
BRAF	O
mutations	O
,	O
particularly	O
in	O
the	O
African	O
Americans	O
,	O
since	O
they	O
represent	O
a	O
higher	O
mutation	O
profile	O
than	O
Iranians	O
and	O
Omanis	O
.	O

This	O
finding	O
suggests	O
that	O
,	O
at	O
least	O
within	O
the	O
MSI	B
-	I
H	I
group	O
of	O
patients	O
,	O
the	O
BRAF	O
V600E	O
mutation	O
in	O
exon	O
15	O
is	O
the	O
major	O
event	O
leading	O
to	O
tumor	B
development	O
.	O

In	O
addition	O
,	O
the	O
distal	O
location	O
of	O
Omani	O
MSI	B
-	I
H	I
tumors	B
may	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
presentation	O
of	O
the	O
disease	B
compared	O
to	O
proximal	O
ones	O
in	O
the	O
African	O
American	O
and	O
Iranian	O
populations	O
.	O

The	O
lower	O
frequency	O
of	O
MSI	B
-	I
H	I
tumors	B
observed	O
in	O
Omani	O
patients	O
could	O
be	O
related	O
to	O
the	O
higher	O
frequency	O
of	O
the	O
distal	O
location	O
.	O

This	O
needs	O
to	O
be	O
verified	O
in	O
a	O
larger	O
sample	O
size	O
.	O

The	O
absence	O
of	O
hMLH1	O
expression	O
was	O
more	O
pronounced	O
in	O
MSI	B
-	I
H	I
tumors	B
from	O
African	O
American	O
and	O
Iranian	O
patients	O
(	O
77	O
%	O
of	O
tumors	B
in	O
these	O
groups	O
showed	O
no	O
hMLH1	O
expression	O
)	O
.	O

However	O
,	O
for	O
Omanis	O
,	O
the	O
moderate	O
hMLH1expression	O
(	O
62	O
%	O
)	O
in	O
MSI	B
-	I
H	I
may	O
indicate	O
some	O
other	O
defects	O
in	O
the	O
component	O
of	O
base	O
excision	O
repair	O
(	O
Oxidative	O
DNA	O
damaged	O
markers	O
such	O
as	O
8-hydroxyguanosine	O
)	O
,	O
or	O
distinct	O
lymphangiogenic	O
phenotype	O
associated	O
with	O
MSI	O
other	O
than	O
in	O
mismatch	O
repair	O
genes	O
.	O

The	O
tumors	B
that	O
we	O
have	O
studied	O
included	O
MSI	B
-	I
H	I
tumors	B
that	O
were	O
negative	O
using	O
immunohistochemistry	O
for	O
hMLH1	O
.	O

This	O
incidence	O
is	O
less	O
than	O
compared	O
to	O
that	O
described	O
in	O
the	O
literature	O
(	O
77	O
%	O
[	O
34	O
]	O
)	O
,	O
although	O
the	O
numbers	O
described	O
are	O
small	O
.	O

Survival	O
of	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
patients	O
compared	O
with	O
sporadic	O
colorectal	B
cancer	I
patients	O
Abstract	O
Background	O
Patients	O
with	O
hereditary	B
non	I
-	I
poliposys	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
have	O
better	O
prognosis	O
than	O
sporadic	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

Aim	O
of	O
our	O
retrospective	O
study	O
was	O
to	O
compare	O
the	O
overall	O
survival	O
between	O
sporadic	O
CRC	B
and	O
HNPCC	B
patients	O
.	O

Methods	O
We	O
analyzed	O
a	O
cohort	O
of	O
40	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
HNPCC	B
cases	O
with	O
a	O
hospital	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	B
observed	O
during	O
the	O
period	O
1970–1993	O
.	O

In	O
15	O
HNPCC	B
patients	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	B
instability	I
.	O

Survival	O
rates	O
were	O
calculated	O
by	O
Kaplan	O
-	O
Meier	O
method	O
and	O
compared	O
with	O
log	O
rank	O
test	O
.	O

Results	O
The	O
median	O
age	O
at	O
diagnosis	O
of	O
the	O
primary	O
CRC	B
was	O
46.8	O
years	O
in	O
the	O
HNPCC	B
series	O
versus	O
61	O
years	O
in	O
sporadic	O
CRC	B
group	O
.	O

In	O
HNPCC	B
group	O
85	O
%	O
had	O
a	O
right	O
cancer	B
location	O
,	O
vs.	O
57	O
%	O
in	O
the	O
sporadic	O
cancer	B
group	O
.	O

In	O
the	O
sporadic	O
cancer	B
group	O
61.6	O
%	O
were	O
early	O
-	O
stages	O
cancer	B
(	O
Dukes	O
'	O
A	O
and	O
B	O
)	O
vs.	O
70	O
%	O
in	O
the	O
HNPCC	B
group	O
(	O
p	O
=	O
ns	O
)	O
.	O

The	O
crude	O
5-years	O
cumulative	O
survival	O
after	O
the	O
primary	O
CRC	B
was	O
94.2	O
%	O
in	O
HNPCC	B
patients	O
vs.	O
75.3	O
%	O
in	O
sporadic	O
cancer	B
patients	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
Our	O
results	O
show	O
that	O
overall	O
survival	O
of	O
colorectal	B
cancer	I
in	O
patients	O
with	O
HNPCC	B
is	O
better	O
than	O
sporadic	O
CRC	B
patients	O
.	O

The	O
different	O
outcome	O
probably	O
relates	O
to	O
the	O
specific	O
tumorigenesis	O
involving	O
DNA	O
mismatch	O
repair	O
dysfunction	O
.	O

Background	O
Colorectal	B
cancer	I
is	O
one	O
of	O
the	O
most	O
common	O
neoplasm	B
in	O
humans	O
[	O
1,2	O
]	O
.	O

It	O
's	O
known	O
that	O
a	O
definite	O
fraction	O
,	O
ranging	O
between	O
1	O
and	O
5	O
%	O
of	O
all	O
cases	O
of	O
colorectal	O
tumors	B
,	O
is	O
transmitted	O
from	O
one	O
generation	O
to	O
another	O
in	O
accordance	O
with	O
an	O
autosomal	O
dominant	O
model	O
;	O
this	O
is	O
the	O
case	O
of	O
Hereditary	B
Non	I
-	I
Polyposis	I
Colorectal	I
Cancer	I
(	O
HNPCC	B
)	O
and	O
of	O
Familial	B
Adenomatous	I
Polyposis	I
(	O
FAP	B
)	O
[	O
2	O
]	O
.	O

HNPCC	B
is	O
an	O
autosomal	O
dominant	O
disease	B
characterized	O
by	O
early	O
appearance	O
of	O
cancer	B
usually	O
of	O
the	O
right	O
colon	O
,	O
frequent	O
occurrence	O
of	O
multiple	O
lesions	B
(	O
both	O
synchronous	O
and	O
metachronous	O
)	O
and	O
a	O
striking	O
association	O
with	O
tumours	B
of	O
other	O
organs	O
,	O
in	O
particular	O
endometrium	O
,	O
urinary	O
tract	O
,	O
ovary	O
,	O
stomach	O
and	O
small	O
bowel	O
.	O

The	O
Amsterdam	O
criteria	O
,	O
currently	O
used	O
for	O
the	O
diagnosis	O
of	O
HNPCC	B
,	O
were	O
introduced	O
in	O
1989	O
to	O
provide	O
a	O
uniform	O
evaluation	O
of	O
familial	O
and	O
personal	O
history	O
.	O

They	O
were	O
revised	O
in	O
1999	O
and	O
included	O
various	O
extra	O
-	O
colonic	O
tumours	B
:	O
1	O
)	O
at	O
least	O
three	O
or	O
more	O
relatives	O
with	O
histological	O
verified	O
tumour	B
in	O
the	O
spectrum	O
of	O
HNPCC	B
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
)	O
at	O
least	O
two	O
generations	O
should	O
be	O
affected	O
;	O
3	O
)	O
one	O
or	O
more	O
tumours	B
diagnosed	O
when	O
under	O
the	O
age	O
of	O
50	O
years	O
;	O
4	O
)	O
FAP	B
should	O
be	O
excluded	O
[	O
3,4	O
]	O
.	O

Colorectal	O
tumours	B
with	O
microsatellite	B
instability	I
(	O
MSI	O
phenotype	O
)	O
have	O
mutations	O
in	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
and	O
in	O
particular	O
in	O
the	O
MSH2	O
and	O
MLH1	O
genes	O
,	O
respectively	O
found	O
on	O
chromosome	O
arms	O
2p	O
and	O
3p	O
[	O
5	O
-	O
9	O
]	O
.	O

These	O
mutations	O
lead	O
to	O
inactivation	O
of	O
the	O
genes	O
and	O
thus	O
to	O
a	O
defect	O
in	O
replication	O
/	O
repair	O
of	O
DNA	O
and	O
an	O
accumulation	O
in	O
the	O
cancer	B
cell	O
genome	O
of	O
ubiquitous	O
somatic	O
clonal	O
mutations	O
[	O
10	O
]	O
.	O

Constitutional	O
mutations	O
of	O
MMR	O
genes	O
are	O
found	O
in	O
50–70	O
%	O
of	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
and	O
in	O
the	O
Muir	B
-	I
Torre	I
syndrome	I
;	O
90	O
%	O
of	O
them	O
MLH1	B
and	I
MSH2	I
positive	I
[	O
11,12	O
]	O
.	O

A	O
certain	O
proportion	O
(	O
around	O
12–15	O
%	O
)	O
of	O
sporadic	O
colon	B
cancers	I
also	O
display	O
MSI	B
phenotype	O
[	O
13	O
-	O
17	O
]	O
.	O

Otherwise	O
,	O
MSI	O
seems	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
various	O
human	O
cancer	B
such	O
as	O
sporadic	O
endometrial	O
cancer	B
[	O
18	O
]	O
and	O
oral	O
squamous	O
cell	O
carcinoma	B
[	O
19	O
]	O
.	O

Colorectal	B
cancer	I
(	O
CRC	B
)	O
in	O
HNPCC	B
more	O
often	O
have	O
a	O
better	O
prognosis	O
than	O
in	O
sporadic	O
colorectal	O
carcinoma	B
[	O
3,4,20	O
-	O
22	O
]	O
,	O
but	O
it	O
has	O
been	O
unclear	O
whether	O
this	O
could	O
be	O
due	O
to	O
difference	O
in	O
stage	O
at	O
diagnosis	O
or	O
to	O
a	O
more	O
favourable	O
prognosis	O
of	O
cancer	B
in	O
HNPCC	B
and	O
FAP	B
.	O

The	O
aim	O
of	O
our	O
retrospective	O
study	O
was	O
to	O
compare	O
stage	O
and	O
overall	O
survival	O
between	O
patients	O
with	O
hereditary	O
and	O
sporadic	O
colorectal	B
cancer	I
patients	O
.	O

Conclusion	O
In	O
conclusion	O
,	O
our	O
findings	O
appear	O
to	O
confirm	O
previous	O
studies	O
[	O
30,31	O
]	O
which	O
detected	O
that	O
an	O
improved	O
survival	O
for	O
colon	B
cancer	I
in	O
HNPCC	B
,	O
compared	O
to	O
sporadic	O
CRC	B
,	O
usually	O
occur	O
.	O

In	O
fact	O
,	O
our	O
series	O
of	O
HNPCC	B
patients	O
reveals	O
a	O
marked	O
overall	O
survival	O
advantage	O
,	O
which	O
persisted	O
also	O
after	O
stratification	O
by	O
Dukes	O
'	O
stage	O
.	O

Therefore	O
,	O
survival	O
of	O
HNPCC	B
patients	O
not	O
always	O
depends	O
on	O
an	O
early	O
diagnosis	O
,	O
but	O
probably	O
also	O
on	O
distinct	O
biologic	O
features	O
.	O

In	O
this	O
context	O
,	O
MSI	O
mutation	O
pattern	O
plays	O
an	O
important	O
prognostic	O
role	O
since	O
colon	B
cancer	I
with	O
MSI	B
has	O
a	O
better	O
prognosis	O
than	O
tumours	B
without	O
MSI	O
.	O

A	O
large	O
series	O
of	O
HNPCC	B
should	O
be	O
examined	O
to	O
confirm	O
this	O
data	O
.	O

Furthermore	O
,	O
we	O
need	O
more	O
information	O
about	O
MSI	O
in	O
all	O
kind	O
of	O
colorectal	O
carcinomas	B
,	O
in	O
order	O
to	O
establish	O
postoperative	O
surveillance	O
thus	O
improving	O
patients	O
'	O
prognosis	O
and	O
allowing	O
clinicians	O
to	O
plan	O
more	O
accurate	O
and	O
targeted	O
therapy	O
.	O

Mutation	O
Rates	O
of	O
and	O
Coding	O
Microsatellites	O
in	O
Human	O
Cells	O
with	O
Defective	O
DNA	O
Mismatch	O
Repair	O
Abstract	O
Microsatellite	O
instability	O
promotes	O
colonic	O
tumorigenesis	O
through	O
generating	O
frameshift	O
mutations	O
at	O
coding	O
microsatellites	O
of	O
tumor	B
suppressor	O
genes	O
,	O
such	O
as	O
TGFBR2	O
and	O
ACVR2	O
.	O

As	O
a	O
consequence	O
,	O
signaling	O
through	O
these	O
TGFβ	O
family	O
receptors	O
is	O
abrogated	O
in	O
DNA	O
Mismatch	B
repair	I
(	I
MMR	I
)	I
-deficient	I
tumors	B
.	O

How	O
these	O
mutations	O
occur	O
in	O
real	O
time	O
and	O
mutational	O
rates	O
of	O
these	O
human	O
coding	O
sequences	O
have	O
not	O
previously	O
been	O
studied	O
.	O

We	O
utilized	O
cell	O
lines	O
with	O
different	O
MMR	O
deficiencies	O
(	O
hMLH1−	O
/	O
−	O
,	O
hMSH6−	O
/	O
−	O
,	O
hMSH3−	O
/	O
−	O
,	O
and	O
MMR	O
-	O
proficient	O
)	O
to	O
determine	O
mutation	O
rates	O
.	O

Plasmids	O
were	O
constructed	O
in	O
which	O
exon	O
3	O
of	O
TGFBR2	O
and	O
exon	O
10	O
of	O
ACVR2	O
were	O
cloned	O
+	O
1	O
bp	O
out	O
of	O
frame	O
,	O
immediately	O
after	O
the	O
translation	O
initiation	O
codon	O
of	O
an	O
enhanced	O
GFP	O
(	O
EGFP	O
)	O
gene	O
,	O
allowing	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
to	O
drive	O
EGFP	O
expression	O
.	O

Mutation	O
-	O
resistant	O
plasmids	O
were	O
constructed	O
by	O
interrupting	O
the	O
coding	O
microsatellite	O
sequences	O
,	O
preventing	O
frameshift	O
mutation	O
.	O

Stable	O
cell	O
lines	O
were	O
established	O
containing	O
portions	O
of	O
TGFBR2	O
and	O
ACVR2	O
,	O
and	O
nonfluorescent	O
cells	O
were	O
sorted	O
,	O
cultured	O
for	O
7–35	O
days	O
,	O
and	O
harvested	O
for	O
flow	O
cytometric	O
mutation	O
detection	O
and	O
DNA	O
sequencing	O
at	O
specific	O
time	O
points	O
.	O

DNA	O
sequencing	O
revealed	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
(	O
A9	O
in	O
TGFBR2	O
and	O
A7	O
in	O
ACVR2	O
)	O
in	O
the	O
fluorescent	O
cells	O
.	O

Two	O
distinct	O
fluorescent	O
populations	O
,	O
M1	O
(	O
dim	O
,	O
representing	O
heteroduplexes	O
)	O
and	O
M2	O
(	O
bright	O
,	O
representing	O
full	O
mutants	O
)	O
were	O
identified	O
,	O
with	O
the	O
M2	O
fraction	O
accumulating	O
over	O
time	O
.	O

hMLH1	O
deficiency	O
revealed	O
11	O
(	O
5.91	O
×	O
10−4	O
)	O
and	O
15	O
(	O
2.18	O
×	O
10−4	O
)	O
times	O
higher	O
mutation	O
rates	O
for	O
the	O
TGFBR2	O
and	O
ACVR2	O
microsatellites	O
compared	O
to	O
hMSH6	O
deficiency	O
,	O
respectively	O
.	O

The	O
mutation	O
rate	O
of	O
the	O
TGFBR2	O
microsatellite	O
was	O
∼3	O
times	O
higher	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
than	O
the	O
ACVR2	O
microsatellite	O
.	O

The	O
−1	O
bp	O
frameshift	O
mutation	O
rates	O
of	O
TGFBR2	O
and	O
ACVR2	O
microsatellite	O
sequences	O
are	O
dependent	O
upon	O
the	O
human	O
MMR	O
background	O
.	O

Colon	B
cancer	I
cell	O
models	O
highlight	O
the	O
relationship	O
between	O
defective	O
DNA	O
MMR	O
and	O
TGFBR2	O
and	O
ACVR2	O
frameshift	O
mutations	O
.	O

Both	O
genes	O
commonly	O
have	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
with	O
defective	O
MMR	O
.	O

Restoration	O
of	O
wild	O
type	O
(	O
WT	O
)	O
TGFBR2	O
and	O
ACVR2	O
by	O
chromosome	O
transfer	O
reveals	O
growth	O
suppression	O
in	O
the	O
cells	O
and	O
slower	O
growth	O
in	O
xenografts	O
in	O
nude	O
mice	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

Interestingly	O
,	O
HCT116+chr3	O
cells	O
,	O
which	O
have	O
two	O
mutant	O
hMLH1	O
and	O
two	O
mutant	O
TGFBR2	O
alleles	O
plus	O
one	O
WT	O
hMLH1	O
and	O
one	O
WT	O
TGFBR2	O
allele	O
,	O
express	O
∼33	O
%	O
WT	O
TGFBR2	O
mRNA	O
and	O
∼67	O
%	O
mutant	O
TGFBR2	O
mRNA	O
(	O
unpublished	O
data	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
HCT116+chr2	O
cells	O
,	O
which	O
have	O
two	O
mutant	O
hMLH1	O
and	O
two	O
mutant	O
ACVR2	O
alleles	O
plus	O
one	O
WT	O
ACVR2	O
allele	O
,	O
express	O
∼20	O
%	O
WT	O
ACVR2	O
mRNA	O
[	O
22	O
]	O
,	O
suggesting	O
a	O
slow	O
but	O
steady	O
mutation	O
of	O
the	O
transferred	O
ACVR2	O
allele	O
in	O
hMLH1	O
deficiency	O
.	O

Determining	O
mutation	O
rates	O
of	O
actual	O
human	O
coding	O
genes	O
in	O
human	O
MMR	O
deficiency	O
has	O
not	O
been	O
previously	O
performed	O
,	O
although	O
model	O
systems	O
using	O
noncoding	O
sequences	O
with	O
human	O
cell	O
and	O
yeast	O
MMR	O
systems	O
have	O
been	O
utilized	O
[	O
24	O
]	O
–	O
[	O
27	O
]	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
TGFBR2	O
and	O
ACVR2	O
frameshift	O
mutations	O
are	O
dependent	O
on	O
the	O
human	O
MMR	O
background	O
,	O
we	O
constructed	O
EGFP	O
plasmids	O
in	O
which	O
a	O
−1	O
bp	O
frameshift	O
mutation	O
at	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
was	O
detected	O
by	O
EGFP	O
expression	O
in	O
human	O
colon	B
cancer	I
cells	O
with	O
MMR	O
deficiency	O
.	O

With	O
this	O
new	O
cell	O
model	O
,	O
we	O
were	O
able	O
to	O
calculate	O
a	O
human	O
gene	O
mutation	O
rate	O
in	O
each	O
human	O
MMR	O
-	O
deficient	O
background	O
,	O
and	O
could	O
directly	O
compare	O
the	O
mutation	O
rate	O
between	O
TGFBR2	O
and	O
ACVR2	O
.	O

EGFP	O
expression	O
of	O
stably	O
transfected	O
HCT116	O
cell	O
lines	O
(	O
hMLH1−	O
/	O
−	O
)	O
containing	O
exon	O
3	O
of	O
TGFBR2	O
sequences	O
.	O

(	O
A	O
)	O
MR	O
TGFBR2	O
IF	O
cells	O
,	O
a	O
postive	O
control	O
,	O
showed	O
99	O
%	O
EGFP	O
expression	O
.	O

(	O
B	O
)	O
MR	O
TGFBR2	O
OF	O
cells	O
,	O
a	O
negative	O
control	O
,	O
showed	O
no	O
visible	O
fluorescence	O
.	O

(	O
C	O
)	O
TGFBR2	O
OF	O
cells	O
showed	O
1.22	O
%	O
net	O
fluorescence	O
.	O

Photomicrographs	O
of	O
stable	O
HCT116	O
cell	O
lines	O
are	O
representative	O
of	O
the	O
other	O
stable	O
cell	O
lines	O
containing	O
TGFBR2	O
exon	O
3	O
or	O
ACVR2	O
exon	O
10	O
sequences	O
.	O

Photomicrographs	O
in	O
top	O
panels	O
were	O
taken	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Zeiss	O
,	O
Germany	O
)	O
and	O
photomicrographs	O
in	O
bottom	O
panels	O
were	O
taken	O
with	O
a	O
light	O
microscope	O
of	O
the	O
identical	O
area	O
under	O
40	O
×	O
magnification	O
.	O

TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
coding	O
microsatellite	O
mutations	O
are	O
dependent	O
on	O
the	O
MMR	O
background	O
To	O
determine	O
mutation	O
frequencies	O
of	O
the	O
TGFBR2	O
and	O
ACVR2	O
coding	O
microsatellites	O
in	O
cells	O
with	O
different	O
MMR	O
backgrounds	O
(	O
Table	O
S1	O
)	O
,	O
nonfluorescent	O
cells	O
containing	O
either	O
MR	O
TGFBR2	O
OF	O
,	O
TGFBR2	O
OF	O
,	O
MR	O
ACVR2	O
OF	O
or	O
ACVR2	O
OF	O
were	O
sorted	O
and	O
exponentially	O
grown	O
for	O
7	O
to	O
35	O
days	O
.	O

At	O
specific	O
time	O
points	O
(	O
day	O
7	O
,	O
14	O
,	O
21	O
,	O
28	O
,	O
and/or	O
35	O
)	O
three	O
cultures	O
of	O
each	O
cell	O
line	O
were	O
analyzed	O
in	O
parallel	O
for	O
EGFP	O
expression	O
by	O
using	O
flow	O
cytometry	O
to	O
detect	O
−1	O
bp	O
frameshift	O
mutations	O
.	O

Three	O
different	O
populations	O
were	O
identified	O
according	O
to	O
their	O
EGFP	O
fluorescence	O
intensity	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
population	O
with	O
no	O
fluorescence	O
was	O
named	O
M0	O
,	O
the	O
population	O
with	O
low	O
fluorescence	O
M1	O
,	O
and	O
the	O
population	O
with	O
high	O
fluorescence	O
M2	O
.	O

EGFP	O
histograms	O
of	O
MR	O
TGFBR2	O
OF	O
and	O
TGFBR2	O
OF	O
cells	O
in	O
different	O
MMR	O
backgrounds	O
at	O
day	O
21	O
are	O
shown	O
in	O
Fig.	O
3E	O
,	O
in	O
which	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
showed	O
2	O
distinct	O
EGFP	O
cell	O
populations	O
,	O
M1	O
and	O
M2	O
.	O

M2	O
cells	O
from	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
showed	O
brighter	O
EGFP	O
expression	O
compared	O
to	O
M1	O
cells	O
(	O
Fig.	O
S1	O
)	O
.	O

Mutation	O
analysis	O
by	O
flow	O
cytometry	O
.	O

Nonfluorescent	O
cells	O
were	O
sorted	O
and	O
cells	O
were	O
exponentially	O
grown	O
for	O
7	O
to	O
35	O
days	O
.	O

At	O
specific	O
time	O
points	O
,	O
cells	O
were	O
harvested	O
,	O
and	O
200,000	O
cells	O
were	O
analyzed	O
for	O
EGFP	O
expression	O
(	O
identifying	O
a	O
−1	O
bp	O
mutation	O
)	O
by	O
flow	O
cytometry	O
.	O

For	O
example	O
,	O
with	O
hMLH1−	O
/	O
−	O
ACVR2	O
OF	O
cells	O
,	O
region	O
R1	O
,	O
R3	O
,	O
and	O
R2	O
were	O
set	O
according	O
to	O
(	O
A	O
)	O
cell	O
size	O
,	O
(	O
B	O
)	O
live	O
cells	O
,	O
and	O
(	O
C	O
)	O
fluorescence	O
.	O

Gated	O
R1	O
and	O
R3	O
(	O
live	O
cells	O
)	O
,	O
and	O
R2	O
were	O
analyzed	O
on	O
an	O
EGFP	O
histogram	O
(	O
D	O
)	O
and	O
two	O
distinct	O
EGFP	O
populations	O
were	O
plotted	O
.	O

The	O
population	O
displaying	O
no	O
fluorescence	O
was	O
designated	O
M0	O
,	O
the	O
population	O
with	O
dim	O
EGFP	O
expression	O
was	O
designated	O
M1	O
,	O
and	O
the	O
population	O
with	O
bright	O
EGFP	O
expression	O
was	O
designated	O
M2	O
.	O

(	O
E	O
)	O
EGFP	O
histograms	O
of	O
MR	O
TGFBR2	O
OF	O
and	O
TGFBR2	O
OF	O
cells	O
in	O
different	O
MMR	O
deficient	O
backgrounds	O
at	O
day	O
21	O
were	O
shown	O
as	O
representatives	O
of	O
mutation	O
analysis	O
.	O

Scaling	O
of	O
cell	O
counts	O
in	O
each	O
EGFP	O
histogram	O
is	O
different	O
for	O
each	O
MMR	O
background	O
.	O

Frameshift	O
mutation	O
at	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
in	O
different	O
human	O
MMR	O
deficient	O
backgrounds	O
.	O

Cells	O
from	O
the	O
M1	O
and/or	O
M2	O
populations	O
of	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
or	O
ACVR2	O
OF	O
cells	O
,	O
hMSH6−	O
/	O
−	O
TGFBR2	O
OF	O
or	O
ACVR2	O
OF	O
cells	O
,	O
and	O
hMSH3−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
were	O
sorted	O
and	O
cultured	O
.	O

DNA	O
from	O
each	O
cell	O
line	O
was	O
amplified	O
by	O
PCR	O
,	O
sub	O
-	O
cloned	O
and	O
all	O
single	O
cell	O
clones	O
were	O
individually	O
sequenced	O
to	O
assess	O
for	O
frameshift	O
mutation	O
of	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
.	O

Sequence	O
analysis	O
of	O
DNA	O
clones	O
from	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
revealed	O
mostly	O
1	O
bp	O
deletion	O
at	O
microsatellites	O
(	O
A9	O
for	O
TGFBR2	O
or	O
A7	O
for	O
ACVR2	O
)	O
,	O
shifting	O
the	O
EGFP	O
gene	O
into	O
the	O
reading	O
frame	O
and	O
leading	O
to	O
its	O
expression	O
(	O
A	O
)	O
.	O

Note	O
that	O
M2	O
clones	O
from	O
hMLH1−	O
/	O
−	O
TGFBR2	O
OF	O
cells	O
revealed	O
100	O
%	O
A9	O
/	O
T9	O
microsatellite	O
sequences	O
,	O
termed	O
a	O
""""	O
full	O
mutant	O
�	O
?	O
whereas	O
M1	O
clones	O
revealed	O
a	O
mixture	O
of	O
A10	O
/	O
T10	O
and	O
A9	O
/	O
T9	O
microsatellite	O
sequences	O
,	O
which	O
suggests	O
the	O
presence	O
of	O
an	O
A10	O
/	O
T9	O
heteroduplex	O
,	O
termed	O
an	O
""""	O
intermediate	O
mutant	O
�	O
?	O
(	O
B	O
)	O
.	O

To	O
determine	O
the	O
nature	O
of	O
the	O
mutations	O
observed	O
in	O
the	O
M1	O
population	O
,	O
we	O
analyzed	O
pooled	O
cells	O
as	O
well	O
as	O
single	O
cell	O
clones	O
.	O

In	O
pooled	O
samples	O
,	O
unlike	O
fully	O
mutant	O
sequences	O
observed	O
in	O
the	O
M2	O
populations	O
,	O
M1	O
population	O
sequences	O
often	O
revealed	O
two	O
overlapping	O
sequences	O
,	O
suggestive	O
of	O
heteroduplexes	O
(	O
A9	O
/	O
T10	O
in	O
TGFBR2	O
and	O
A7	O
/	O
T8	O
in	O
ACVR2	O
)	O
(	O
Fig.	O
5B	O
)	O
.	O

Single	O
cell	O
clones	O
revealed	O
the	O
presence	O
of	O
both	O
WT	O
and	O
−1	O
bp	O
frameshift	O
mutants	O
(	O
Fig.	O
5B	O
)	O
,	O
consistent	O
with	O
heteroduplexes	O
that	O
weakly	O
drive	O
EGFP	O
expression	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
hMLH1	O
deficiency	O
has	O
the	O
highest	O
susceptibility	O
for	O
frameshift	O
mutation	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
of	O
the	O
three	O
different	O
MMR	O
deficiencies	O
(	O
hMLH1−	O
/	O
−	O
,	O
hMSH6−	O
/	O
−	O
and	O
hMSH3−	O
/	O
−	O
)	O
.	O

In	O
addition	O
,	O
the	O
coding	O
microsatellite	O
of	O
TGFBR2	O
exon	O
3	O
has	O
a	O
higher	O
susceptibility	O
to	O
a	O
1	O
bp	O
frameshift	O
mutation	O
than	O
that	O
of	O
ACVR2	O
exon	O
10	O
in	O
hMLH1	O
,	O
hMSH6	O
,	O
(	O
and	O
hMSH3	O
)	O
deficiencies	O
.	O

The	O
frameshift	O
mutation	O
rates	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
are	O
dependent	O
on	O
the	O
MMR	O
background	O
The	O
M2	O
population	O
(	O
full	O
mutants	O
)	O
was	O
used	O
to	O
calculate	O
the	O
mutation	O
rates	O
at	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
by	O
the	O
""""	O
method	O
of	O
the	O
mean	O
�	O
?	O

[	O
28	O
]	O
(	O
Table	O
1	O
)	O
.	O

A	O
single	O
mutation	O
rate	O
was	O
calculated	O
by	O
taking	O
a	O
weighted	O
average	O
of	O
the	O
mutation	O
rates	O
at	O
the	O
different	O
time	O
points	O
,	O
the	O
weights	O
of	O
which	O
were	O
chosen	O
to	O
minimize	O
the	O
variance	O
of	O
the	O
estimate	O
as	O
previously	O
described	O
[	O
25	O
]	O
.	O

As	O
predicted	O
,	O
the	O
mutation	O
rate	O
at	O
the	O
microsatellite	O
of	O
TGFBR2	O
in	O
the	O
hMLH1−	O
/	O
−	O
background	O
was	O
highest	O
:	O
5.91	O
×	O
10−4±1.26	O
×	O
10−4	O
.	O

Mutation	O
at	O
the	O
A10	O
microsatellite	O
of	O
TGFBR2	O
is	O
∼3	O
times	O
more	O
frequent	O
than	O
mutation	O
at	O
the	O
A8	O
microsatellite	O
of	O
ACVR2	O
in	O
hMLH1	O
deficiency	O
(	O
P<0.01	O
)	O
.	O

In	O
addition	O
,	O
mutation	O
at	O
the	O
microsatellite	O
of	O
TGFBR2	O
is	O
∼4	O
times	O
higher	O
than	O
mutation	O
at	O
the	O
microsatellite	O
of	O
ACVR2	O
in	O
hMSH6	O
deficiency	O
.	O

Furthermore	O
,	O
mutations	O
at	O
the	O
microsatellites	O
of	O
TGFBR2	O
and	O
ACVR2	O
are	O
∼11–15	O
times	O
higher	O
in	O
hMLH1	O
deficiency	O
than	O
in	O
hMSH6	O
deficiency	O
(	O
P<0.01	O
)	O
.	O

Mutation	O
rates	O
from	O
hMSH3−	O
/	O
−	O
and	O
MMR	O
-	O
proficient	O
cell	O
lines	O
were	O
not	O
calculated	O
due	O
to	O
a	O
lack	O
of	O
net	O
fluorescent	O
M2	O
populations	O
.	O

These	O
data	O
confirm	O
that	O
hMLH1	O
deficiency	O
allows	O
a	O
higher	O
susceptibility	O
for	O
mutation	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
than	O
hMSH6	O
and	O
hMSH3	O
deficiencies	O
,	O
and	O
that	O
TGFBR2	O
exon	O
3	O
has	O
a	O
higher	O
susceptibility	O
to	O
mutation	O
at	O
its	O
coding	O
microsatellite	O
over	O
ACVR2	O
exon	O
10	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
.	O

As	O
we	O
hypothesized	O
,	O
the	O
mutational	O
frequencies	O
and	O
rates	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
microsatellites	O
are	O
dependent	O
on	O
the	O
MMR	O
deficient	O
background	O
with	O
hMLH1−	O
/	O
−>hMSH6−	O
/	O
−>hMSH3−	O
/	O
−.	O
As	O
TGFBR2	O
and	O
ACVR2	O
mutations	O
may	O
drive	O
the	O
pathogenesis	O
of	O
colorectal	B
cancers	I
,	O
our	O
human	O
data	O
is	O
consistent	O
with	O
the	O
virulence	O
of	O
tumor	B
formation	O
in	O
Lynch	B
syndrome	I
.	O

Patients	O
with	O
germline	O
mutation	O
in	O
hMLH1	O
may	O
present	O
with	O
cancer	B
at	O
younger	O
ages	O
compared	O
to	O
those	O
with	O
a	O
hMSH6	O
germline	O
mutation	O
[	O
29	O
]	O
.	O

Data	O
on	O
mutation	O
rates	O
for	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
(	O
Table	O
1	O
)	O
showed	O
similar	O
results	O
.	O

hMLH1−	O
/	O
−	O
TGFBR2	O
showed	O
the	O
highest	O
mutation	O
rate	O
at	O
its	O
coding	O
microsatellite	O
sequence	O
(	O
5.91	O
×	O
10−4	O
)	O
.	O

This	O
mutation	O
rate	O
is	O
similar	O
to	O
that	O
calculated	O
for	O
noncoding	O
(	O
CA	O
)	O
13	O
microsatellites	O
in	O
hMLH1−	O
/	O
−	O
cells	O
[	O
25	O
]	O
,	O
suggesting	O
that	O
this	O
coding	O
A10	O
and	O
the	O
noncoding	O
(	O
CA	O
)	O
13	O
microsatellites	O
are	O
equally	O
vulnerable	O
to	O
hMLH1	O
deficiency	O
.	O

The	O
mutation	O
rate	O
for	O
TGFBR2	O
was	O
3	O
fold	O
higher	O
than	O
that	O
for	O
ACVR2	O
in	O
both	O
hMLH1	O
(	O
5.91	O
×	O
10−4	O
)	O
and	O
hMSH6	O
(	O
0.54	O
×	O
10−4	O
)	O
deficiencies	O
.	O

The	O
rapid	O
rate	O
for	O
TGFBR2	O
mutation	O
with	O
MMR	O
deficiency	O
might	O
be	O
due	O
partly	O
to	O
TGFBR2	O
's	O
longer	O
polyadenine	O
tract	O
compared	O
to	O
ACVR2	O
,	O
as	O
longer	O
microsatellite	O
tracts	O
mutate	O
more	O
frequently	O
in	O
MMR	O
deficiency	O
[	O
7	O
]	O
.	O

In	O
the	O
case	O
of	O
ACVR2	O
exon	O
10	O
,	O
even	O
though	O
the	O
mutation	O
rate	O
is	O
slower	O
than	O
TGFBR2	O
exon	O
3	O
,	O
ultimately	O
fully	O
mutant	O
clones	O
accumulate	O
.	O

The	O
rapid	O
rate	O
for	O
TGFBR2	O
exon	O
3	O
mutation	O
is	O
probably	O
most	O
reflective	O
in	O
the	O
M1	O
population	O
,	O
as	O
there	O
is	O
a	O
rapid	O
heteroduplex	O
formation	O
particularly	O
in	O
hMLH1	O
deficiency	O
,	O
followed	O
by	O
full	O
mutation	O
.	O

In	O
ACVR2	O
exon	O
10	O
,	O
heteroduplex	O
formation	O
is	O
relatively	O
slower	O
.	O

With	O
both	O
TGFBR2	O
and	O
ACVR2	O
constructs	O
,	O
heteroduplex	O
formation	O
and	O
subsequent	O
full	O
mutation	O
are	O
slower	O
in	O
the	O
hMSH6−	O
/	O
−	O
background	O
compared	O
to	O
hMLH1−	O
/	O
−	O
background	O
.	O

It	O
has	O
been	O
shown	O
that	O
MSH6	O
and	O
MSH3	O
are	O
redundant	O
in	O
regard	O
to	O
frameshift	O
mutagenesis	O
in	O
a	O
yeast	O
model	O
[	O
30	O
]	O
,	O
which	O
supports	O
our	O
finding	O
that	O
hMSH6	O
and	O
hMSH3	O
defects	O
have	O
much	O
lower	O
frameshift	O
mutation	O
rates	O
than	O
the	O
hMLH1	O
defect	O
that	O
completely	O
eliminates	O
MMR	O
.	O

Lower	O
frameshift	O
mutation	O
rate	O
in	O
hMSH6	O
deficiency	O
would	O
logically	O
predict	O
a	O
lower	O
penetrance	O
in	O
Lynch	B
syndrome	I
for	O
which	O
no	O
germline	O
hMSH3	O
mutation	O
has	O
been	O
reported	O
.	O

In	O
summary	O
,	O
we	O
established	O
and	O
utilized	O
a	O
cell	O
model	O
in	O
which	O
actual	O
human	O
coding	O
microsatellite	O
sequences	O
of	O
TGFBR2	O
exon	O
3	O
and	O
ACVR2	O
exon	O
10	O
were	O
evaluated	O
in	O
real	O
time	O
for	O
frameshift	O
mutation	O
in	O
different	O
human	O
MMR	O
backgrounds	O
.	O

hMLH1	O
deficiency	O
confers	O
a	O
significantly	O
higher	O
mutation	O
rate	O
at	O
the	O
coding	O
microsatellites	O
of	O
TGFBR2	O
and	O
ACVR2	O
compared	O
to	O
hMSH6	O
and	O
hMSH3	O
deficiencies	O
.	O

In	O
addition	O
,	O
TGFBR2	O
mutates	O
at	O
a	O
higher	O
rate	O
than	O
ACVR2	O
in	O
both	O
hMLH1	O
and	O
hMSH6	O
deficiencies	O
.	O

These	O
bona	O
-	O
fide	O
human	O
genes	O
targeted	O
for	O
mutation	O
in	O
MMR	O
deficiency	O
mutate	O
at	O
differing	O
rates	O
,	O
and	O
lose	O
expression	O
of	O
their	O
encoded	O
proteins	O
in	O
colonic	O
neoplastic	O
cells	O
.	O

Understanding	O
these	O
targeted	O
genes	O
in	O
MMR	O
deficiency	O
has	O
implications	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
MSI	B
colorectal	O
tumors	B
.	O

Pedigree	O
for	O
Family	O
#	O
3	O
(	O
CRC	B
:	O
Colorectal	B
cancer	I
;	O
ESC	B
:	O
Oesophageal	B
cancer	I
;	O
LC	B
:	O
Lung	B
cancer	I
)	O
.	O

Of	O
the	O
17	O
CRC	B
patients	O
with	O
the	O
Lys618Ala	O
variant	O
,	O
two	O
had	O
MSI	B
(	O
11.8	O
%	O
)	O
,	O
one	O
in	O
the	O
familial	O
CRC	B
group	O
(	O
1	O
/	O
8	O
)	O
and	O
one	O
in	O
the	O
sporadic	O
CRC	B
group	O
(	O
1	O
/	O
9	O
)	O
.	O

The	O
MSI	B
-	I
positive	I
patient	O
from	O
the	O
familial	O
CRC	B
group	O
showed	O
loss	O
of	O
immunohistochemical	O
expression	O
of	O
MLH1	O
.	O

This	O
is	O
the	O
index	O
subject	O
(	O
II-3	O
)	O
for	O
the	O
third	O
family	O
(	O
Figure	O
4	O
)	O
and	O
no	O
hypermethylation	O
of	O
MLH1	O
gene	O
promoter	O
;	O
no	O
BRAF	O
p.	O

Val600Glu	O
mutation	O
were	O
detected	O
in	O
this	O
case	O
.	O

As	O
most	O
disease	O
pedigrees	O
are	O
small	O
,	O
it	O
is	O
difficult	O
to	O
obtain	O
a	O
sufficient	O
number	O
of	O
samples	O
from	O
affected	B
and	O
informative	O
unaffected	B
individuals	O
.	O

Moreover	O
,	O
LS	B
deleterious	O
variants	O
are	O
not	O
completely	O
penetrant	O
.	O

For	O
these	O
reasons	O
,	O
it	O
is	O
rarely	O
possible	O
to	O
categorize	O
variants	O
as	O
deleterious	O
based	O
on	O
segregation	O
alone	O
.	O

The	O
co	O
-	O
occurrence	O
of	O
another	O
known	O
deleterious	O
variant	O
reduces	O
the	O
likelihood	O
that	O
an	O
UV	O
is	O
truly	O
deleterious	O
,	O
especially	O
when	O
both	O
variants	O
are	O
located	O
in	O
trans	O
[	O
3	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
co	O
-	O
occurrence	O
of	O
a	O
deleterious	O
variant	O
in	O
one	O
of	O
the	O
LS	B
genes	O
with	O
the	O
p.	O

Lys618Ala	O
variant	O
has	O
been	O
observed	O
in	O
only	O
two	O
families	O
.	O

Liu	O
et	O
al	O
[	O
14	O
]	O
described	O
an	O
index	O
subject	O
from	O
a	O
LS	B
family	O
with	O
two	O
heterozygous	O
variants	O
(	O
c.546	O
-	O
2A	O
>	O
G	O
and	O
c.1852_1853AA	O
>	O
GC	O
)	O
;	O
only	O
the	O
former	O
segregated	O
with	O
LS	B
in	O
the	O
family	O
.	O

Similarly	O
,	O
Steinke	O
et	O
al	O
[	O
15	O
]	O
,	O
described	O
the	O
co	O
-	O
occurrence	O
of	O
the	O
p.	O

Lys618Ala	O
(	O
c.1852_1853AA	O
>	O
GC	O
)	O
variant	O
with	O
the	O
MSH6	O
p.	O

Arg1068X	O
(	O
c.3202C	O
>	O
T	O
)	O
deleterious	O
variant	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
coexistence	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
with	O
deleterious	O
variants	O
in	O
another	O
two	O
unrelated	O
LS	B
families	O
.	O

In	O
one	O
family	O
,	O
the	O
allele	O
distribution	O
of	O
the	O
pathogenic	O
and	O
unclassified	O
variant	O
was	O
in	O
trans	O
,	O
in	O
the	O
other	O
family	O
the	O
pathogenic	O
variant	O
was	O
detected	O
in	O
the	O
MSH6	O
gene	O
and	O
only	O
the	O
deleterious	O
variant	O
co	O
-	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
.	O

This	O
evidence	O
indicates	O
that	O
the	O
p.	O

Lys618Ala	O
variant	O
is	O
not	O
deleterious	O
.	O

The	O
molecular	O
hallmark	O
of	O
LS	B
tumours	B
is	O
an	O
MSI	B
phenotype	O
,	O
a	O
functional	O
consequence	O
of	O
MMR	O
deficiency	O
.	O

It	O
is	O
expected	O
that	O
the	O
putative	O
germ	O
-	O
line	O
mutation	O
responsible	O
for	O
LS	B
would	O
confer	O
the	O
MSI	B
phenotype	O
.	O

We	O
tested	O
the	O
MSI	O
status	O
of	O
17	O
tumours	B
from	O
p.	O

Lys618Ala	O
carriers	O
and	O
detected	O
only	O
two	O
cases	O
of	O
MSI	O
(	O
11.8	O
%	O
)	O
.	O

Taking	O
into	O
consideration	O
the	O
bias	O
caused	O
by	O
the	O
over	O
-	O
representation	O
of	O
Bethesda	O
Criteria	O
-	O
positive	O
tumours	B
in	O
this	O
subset	O
of	O
cases	O
(	O
8	O
/	O
17	O
)	O
,	O
the	O
MSI	O
frequency	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
unselected	O
CRC	B
group	O
[	O
7	O
]	O
.	O

This	O
is	O
further	O
proof	O
that	O
the	O
presence	O
of	O
this	O
variant	O
is	O
irrelevant	O
to	O
the	O
functional	O
inactivation	O
of	O
MLH1	O
in	O
CRC	B
patients	O
.	O

Nonetheless	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
this	O
variant	O
may	O
result	O
in	O
a	O
small	O
increase	O
in	O
susceptibility	O
to	O
CRC	B
or	O
adenomas	B
,	O
as	O
was	O
suggested	O
by	O
Fearnhead	O
et	O
al	O
[	O
16	O
]	O
.	O

Further	O
studies	O
with	O
appropriate	O
sample	O
sizes	O
are	O
required	O
to	O
address	O
the	O
low	O
penetrance	O
effect	O
of	O
this	O
variant	O
in	O
CRC	B
.	O

Finally	O
,	O
we	O
hypothesize	O
that	O
the	O
clinical	O
significance	O
of	O
a	O
genetic	O
variant	O
may	O
differ	O
according	O
to	O
genetic	O
background	O
.	O

Gene	O
functionality	O
may	O
be	O
the	O
net	O
result	O
of	O
the	O
effects	O
of	O
allelic	O
structures	O
and	O
their	O
interactions	O
with	O
environmental	O
factors	O
.	O

It	O
is	O
possible	O
that	O
low	O
-	O
penetrance	O
variants	O
behave	O
differently	O
in	O
different	O
populations	O
,	O
making	O
it	O
difficult	O
to	O
make	O
predictions	O
in	O
terms	O
of	O
conferred	O
risk	O
.	O

Conclusions	O
Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
and	O
others	O
indicate	O
that	O
the	O
c.1852_1853AA	O
>	O
GC	O
variant	O
should	O
be	O
considered	O
a	O
neutral	O
variant	O
for	O
LS	B
.	O

These	O
findings	O
have	O
considerable	O
relevance	O
for	O
the	O
clinical	O
management	O
of	O
CRC	B
probands	O
and	O
their	O
relatives	O
.	O

